uric acid and Gout
uric acid has been researched along with Gout in 4404 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Gout: Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess efficacy, safety, pharmacokinetics, and immunogenicity of pegloticase plus methotrexate (MTX) versus pegloticase plus placebo cotreatment for uncontrolled gout in a randomized, placebo-controlled, double-blind trial." | 9.69 | A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. ( Botson, JK; Chamberlain, J; Grewal, S; La, D; LaMoreaux, B; LoCicero, K; Majjhoo, A; Obermeyer, K; Ong, S; Parikh, N; Peterson, J; Saag, K; Sainati, S; Tesser, JRP; Verma, S; Weinblatt, ME; Xin, Y, 2023) |
| "To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of allopurinol using the 'start-low go-slow' dose approach." | 9.69 | Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. ( Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Haslett, J; Horne, A; Mihov, B; Stamp, L, 2023) |
| "To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) causes after treatment with febuxostat or allopurinol in patients with gout from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES) trial." | 9.51 | Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. ( Becker, MA; Borer, JS; Castillo, M; Gorelick, PB; Gunawardhana, L; Hunt, B; Saag, KG; Whelton, A; White, WB, 2022) |
| "The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion; however, the standard urate-lowering therapy (ULT) recommendation is first-line xanthine oxidase inhibitor (XOI), irrespective of the cause of hyperuricemia." | 9.51 | Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion. ( Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X, 2022) |
| "The present study compared the efficacy and safety of low-dose febuxostat versus allopurinol in chronic kidney disease (CKD) patients complicated with hyperuricemia (HUA)." | 9.51 | Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. ( Cao, B; Yang, N, 2022) |
| " One hundred and ninety-seven adults with gout and SUA levels ≥8 mg/dL were randomized to febuxostat or allopurinol in a 1:1 ratio for 36 weeks." | 9.51 | Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study. ( Borghi, C; Desideri, G; Gerritsen, M; Giannattasio, C; Nurmohamed, MT; Rajzer, M; Tausche, AK, 2022) |
| "Early allopurinol initiation during an acute gout flare did not lead to significant changes in time to resolution, flare recurrence, and inflammatory markers." | 9.51 | Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial. ( Manavathongchai, S; Pongsittisak, W; Satpanich, P, 2022) |
| "Gout is common in patients with heart failure (HF), and sodium-glucose cotransporter 2 inhibitors, a foundational treatment for HF, reduce uric acid levels." | 9.41 | Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. ( Butt, JH; Claggett, BL; de Boer, RA; Desai, AS; Docherty, KF; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Ponikowski, P; Sabatine, MS; Shah, SJ; Solomon, SD; Vaduganathan, M, 2023) |
| "Thirty-nine subjects with persistent hyperuricemia were randomized to receive curcumin (500-mg capsules twice daily, 20 subjects) or placebo (19 subjects)." | 9.41 | Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial. ( Asavatanabodee, P; Bupparenoo, P; Chaiamnuay, S; Narongroeknawin, P; Pakchotanon, R, 2021) |
| "To examine the efficacy and safety of pegloticase in combination with methotrexate (MTX) in patients with uncontrolled gout in an exploratory, open-label clinical trial (ClinicalTrials." | 9.41 | Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). ( Bennett, R; Botson, JK; Kenney, HM; LaMoreaux, B; Obermeyer, K; Peloso, PM; Peterson, J; Tesser, JRP; Weinblatt, ME, 2021) |
| "Our objective was to determine whether initiation of febuxostat during an acute gout flare prolongs the current episode." | 9.41 | Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial. ( Cui, X; Geng, H; Jia, E; Jiang, Y; Li, B; Ma, W; Qiu, X; Wei, J; Xiao, M; Xiao, Y; Xie, J; Yao, X; Zhang, J; Zhang, Y; Zhong, L, 2021) |
| " We evaluated the efficacy and safety of dotinurad versus febuxostat, a widely used drug in Japan, in hyperuricemic Japanese patients with or without gout." | 9.34 | A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. ( Furuno, K; Hosoya, T; Kanda, S, 2020) |
| "Dotinurad 2 mg was verified to have a non-inferior serum uric acid lowering effect compared with benzbromarone 50 mg, in Japanese hyperuricemic patients with or without gout." | 9.34 | Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020) |
| "Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout." | 9.34 | Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. ( De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Nuki, G; Perez-Ruiz, F; Ralston, SH; Robertson, M; Walters, M; Webster, J, 2020) |
| "To compare the efficacy and safety of low-dose febuxostat with low-dose benzbromarone in patients with primary gout, a randomized controlled, open-label trial was performed among male patients with primary gout for urate-lowering therapy (ULT) in a dedicated gout clinic in China." | 9.30 | Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. ( Cheng, X; Cui, L; He, Y; Ji, A; Li, C; Li, H; Liang, N; Ma, L; Sun, M; Sun, R; Sun, W; Wang, C; Wu, X; Xu, T; Xue, X; Yuan, X; Zhang, H, 2019) |
| "To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function." | 9.30 | Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019) |
| "To examine whether allopurinol dose escalation to achieve serum urate (SU) target can influence bone erosion or monosodium urate (MSU) crystal deposition, as measured by dual-energy computed tomography (DECT) in patients with gout." | 9.30 | Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial. ( Aati, O; Allan, J; Billington, K; Dalbeth, N; Doyle, A; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2019) |
| "To determine whether febuxostat with stepwise dose increase is as useful as colchicine prophylaxis in reducing gout flares during the initial introduction of urate-lowering therapy in patients with gout in comparison with febuxostat with no dose titration." | 9.27 | Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. ( Fujimori, S; Hidaka, Y; Ide, Y; Inoue, K; Kim, H; Sugimoto, M; Tamaki, S; Taniguchi, A; Yamamoto, T; Yamanaka, H, 2018) |
| " We did a post-hoc analysis of recorded on-study gout attacks and plasma uric acid concentrations according to treatment allocation." | 9.27 | Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. ( Ansquer, JC; Best, JD; Buizen, L; d'Emden, MC; Davis, TME; Feher, MD; Flack, J; Foucher, C; Gebski, V; Hedley, J; Jenkins, AJ; Keech, AC; Kesaniemi, YA; Li, L; McGill, N; Scott, RS; Sullivan, DR; Waldman, B, 2018) |
| "Gout patients do not routinely achieve optimal outcomes related in part to suboptimal administration of urate lowering therapy (ULT) including first-line xanthine oxidase inhibitors allopurinol or febuxostat." | 9.27 | Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial. ( Brittan, K; Brophy, M; Davis-Karim, A; Henrie, AM; Mikuls, TR; Neogi, T; Newcomb, J; O'Dell, JR; Palevsky, PM; Pillinger, MH; Pittman, D; Taylor, TH; Timilsina, S; Wu, H, 2018) |
| "The objective of the study was to evaluate the effect of lesinurad, a selective uric acid uptake inhibitor, alone and in combination with the xanthine oxidase inhibitor allopurinol, on serum uric acid and urinary urate excretion in patients with gout and hyperuricemia." | 9.27 | The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout. ( Baumgartner, S; Kerr, B; Manhard, K; Quart, B; Shen, Z; Yeh, LT, 2018) |
| "Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for treatment of hyperuricemia and gout." | 9.27 | Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout. ( Clauson, V; Gillen, M; Hall, J; Kankam, M; Lee, C; Liu, S; Miner, JN; Nguyen, M; Shen, Z; Walker, S; Wilson, D; Yang, X, 2018) |
| "Japanese male subjects aged 21-65 years with gout (n = 37) or asymptomatic hyperuricaemia (n = 35) and serum urate (sUA) ⩾8 mg/dl were randomized to febuxostat (10, 20, 40 mg) in combination with verinurad (2." | 9.27 | Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. ( Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X, 2018) |
| "The aim of this research work was to observe and analyze the efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia." | 9.27 | The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia. ( Wang, S, 2018) |
| "This multicenter, open-label study evaluated the efficacy and safety of long-term twice-daily oral topiroxostat administration in patients with or without gout." | 9.27 | Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout. ( Hosoya, T; Ishikawa, T; Ogawa, Y; Ohashi, T; Sakamoto, R, 2018) |
| "To examine the relationship among canakinumab, a monoclonal antibody targeting IL-1β; serum uric acid levels; and the incidence of gout attacks." | 9.27 | Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. ( Everett, BM; Glynn, RJ; Libby, P; MacFadyen, JG; Ridker, PM; Solomon, DH; Thuren, T, 2018) |
| " People with gout receiving at least creatinine clearance (CrCL)-based allopurinol dose for ≥1 month and SU ≥6 mg/dL were recruited." | 9.24 | A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. ( Barclay, ML; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017) |
| "To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12-month phase III trial in patients with tophaceous gout." | 9.24 | Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. ( Adler, S; Baumgartner, S; Bhakta, N; Dalbeth, N; Fung, M; Jones, G; Khanna, D; Kopicko, J; Perez-Ruiz, F; Storgard, C; Terkeltaub, R, 2017) |
| "There is little evidence guiding selection of nondiuretic, antihypertensive agents with a goal of lowering uric acid (SUA) and minimizing gout risk." | 9.24 | Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. ( Appel, LJ; Juraschek, SP; Miller, ER, 2017) |
| "In this double-blind, placebo-controlled study, 314 subjects with hyperuricemia (serum uric acid [UA] level of ≥7." | 9.24 | Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. ( Choi, HK; Dalbeth, N; Gunawardhana, L; Hunt, B; MacDonald, PA; Palmer, WE; Saag, KG; Thienel, U, 2017) |
| "Our objectives were to determine whether a change in serum uric acid (sUA) resulted in a corresponding change in the fractional excretion of uric acid (FEUA) and whether the renal response was different in patients with gout versus healthy subjects." | 9.24 | Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. ( Liu, S; Miner, JN; Perez-Ruiz, F, 2017) |
| "Lesinurad added to allopurinol demonstrated superior sUA lowering versus allopurinol-alone therapy and lesinurad 200 mg was generally well tolerated in patients with gout warranting additional therapy." | 9.24 | Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). ( Adler, S; Bardin, T; Baumgartner, S; Bhakta, N; Fung, M; Keenan, RT; Khanna, PP; Kopicko, J; So, A; Storgard, C, 2017) |
| "Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used in Japan for the treatment of hyperuricemic patients with or without gout." | 9.24 | Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. ( Hosoya, T; Ohashi, T; Sasaki, T, 2017) |
| " Cox proportional hazard ratio was used to compare the risk of CAD in gout patients taking allopurinol or/and benzbromarone with those taking neither drug." | 9.24 | Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study. ( Chiang, SJ; Daimon, M; Ho, Y; Lin, HC; Uang, YS; Wang, CH; Wang, LH, 2017) |
| "We aimed to assess the relative efficacy and safety of dotinurad (2 mg), benzbromarone (50 mg), and febuxostat (40 mg) in hyperuricemic patients with or without gout." | 9.22 | Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. ( Lee, YH; Song, GG, 2022) |
| "We aimed to assess the relative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout." | 9.22 | Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. ( Lee, YH; Song, GG, 2022) |
| "Increased serum uric acid (SUA) levels are commonly seen in patients with metabolic syndrome and are widely accepted as risk factors for hypertension, gout, non-alcoholic fatty liver disease, chronic kidney disease (CKD), and cardiovascular diseases." | 9.22 | Uric acid in metabolic syndrome: Does uric acid have a definitive role? ( Copur, S; Demiray, A; Kanbay, M, 2022) |
| "Uric acid (UA) is the final product of purine metabolism in the human body, and impaired purine metabolism can increase the uric acid in serum, finally resulting in hyperuricemia (HUA)." | 9.22 | Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights. ( Dong, B; Geng, Z; Mei, Y; Xu, L, 2022) |
| "This phase IIIB study compared the efficacy and safety of febuxostat and allopurinol in gout patients with or without tophi who were HLA-B*5801 negative." | 9.22 | Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. ( Chen, CJ; Chen, DY; Hsu, PN; Lai, JH; Lin, HY; Yu, KH, 2016) |
| "Control of serum uric acid (sUA) levels is very important during chemotherapy in patients with malignant tumors, as the risks of tumor lysis syndrome (TLS) and renal events are increased with increasing levels of sUA." | 9.22 | Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. ( Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T, 2016) |
| "In Japan, although topiroxostat, a selective xanthine oxidoreductase inhibitor, has been used for the treatment of patients with hyperuricemia including gout, no published randomized controlled studies evaluating the dose-dependent relationship with respect to the serum urate-lowering efficacy have been reported." | 9.22 | Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. ( Hashimoto, H; Hosoya, T; Ohashi, T; Sakamoto, R; Sasaki, T, 2016) |
| " Patients who had inadequate serum urate levels (a gout patient: serum urate level ≥416·4 μmol/L; an asymptomatic hyperuricemic patient with specific complications (urinary lithiasis, hypertension, hyperlipidemia and/or diabetes): serum urate level ≥475·8 μmol/L; and an asymptomatic hyperuricemic patient with no specific complications: serum urate level ≥535·3 μmol/L) were randomized to topiroxostat 120 mg/day or allopurinol 200 mg/day, with an equal allocation ratio, for 16 weeks." | 9.22 | Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. ( Hashimoto, H; Hosoya, T; Ogawa, Y; Ohashi, T; Sakamoto, R, 2016) |
| "To determine whether a pharmacist-staffed gout management program is more effective than usual care in achieving target serum uric acid (sUA) levels in gout patients." | 9.22 | A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial. ( Avins, A; Goldfien, R; Jacobson, A; Ng, M; Pressman, A, 2016) |
| "Excess body burden of uric acid promotes gout." | 9.22 | Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. ( Girardet, JL; Hagerty, DT; Hyndman, D; Iverson, C; Liu, S; Manhard, K; Miner, JN; Nanavati, P; Quart, B; Shen, Z; Tan, PK; Terkeltaub, R; Yeh, LT, 2016) |
| "Traditionally, allopurinol is not initiated during an acute gout attack to avoid prolonging the painful arthritis." | 9.20 | Does starting allopurinol prolong acute treated gout? A randomized clinical trial. ( Collamer, A; Higgs, J; Hill, EM; Sit, M; Sky, K, 2015) |
| "To compare the efficiency and safety of febuxostat with those of allopurinol in Chinese patients with gout and hyperuricemia." | 9.20 | A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. ( Chen, S; Ji, H; Ji, Q; Lin, J; Liu, B; Liu, H; Liu, P; Liu, X; Lu, Y; Ming, J; Peng, Y; Wang, J; Wang, Y; Xu, S; Zhang, Y, 2015) |
| "Allopurinol is the most widely prescribed serum uric acid-lowering therapy (ULT) in gout." | 9.20 | An open-label, 6-month study of allopurinol safety in gout: The LASSO study. ( Baumgartner, S; Becker, MA; Choi, HK; Cravets, M; Dalbeth, N; Fitz-Patrick, D; Storgard, C, 2015) |
| "We prospectively evaluated whether an effective 12-month uric acid-lowering therapy (ULT) with the available xanthine oxidase (XO) inhibitors allopurinol and febuxostat in patients with chronic tophaceous gout has an impact on oxidative stress and/or vascular function." | 9.19 | As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. ( Aringer, M; Bielitz, C; Christoph, M; Forkmann, M; Kopprasch, S; Richter, U; Tausche, AK; Wunderlich, C, 2014) |
| "Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout." | 9.19 | Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. ( Fujimori, S; Hara, S; Hisatome, I; Hosoya, T; Nomura, S; Ohno, I; Uchida, S; Yamamoto, T, 2014) |
| "Gout patients (n = 512) with serum uric acid (sUA) concentrations of at least 8." | 9.19 | An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. ( Bao, C; Du, H; Gu, J; Huang, A; Huang, X; Jiang, L; Li, J; Li, X; Li, Z; Liu, Y; Zhang, Y; Zhang, Z; Zhao, D; Zhu, P; Zuo, X, 2014) |
| "The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout." | 9.19 | Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. ( Baumgartner, S; Fleischmann, R; Hingorani, V; Kerr, B; Manhard, K; Miner, JN; Polvent, E; Quart, B; Shen, Z; Suster, M; Yeh, LT, 2014) |
| "The aims of this study were to establish whether, in patients with gout, MPO is released from neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol." | 9.19 | Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia. ( Drake, J; Forbes, LV; Kettle, AJ; Khalilova, IS; Stamp, LK; Turner, R; Zhang, M, 2014) |
| "To evaluate the efficacy and safety of IL-1 inhibitor rilonacept (IL-1 Trap) for gout flare (GF) prevention during initiation of uric acid-lowering therapy (ULT) with allopurinol in a multiregional phase 3 clinical trial." | 9.17 | Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. ( Evans, RR; Fouche, L; King-Davis, S; Luo, SF; Mitha, E; Schumacher, HR; Wang, J; Weinstein, SP; Yancopoulos, GD, 2013) |
| "Assess the impact of urate-lowering therapy on renal function in subjects with gout who were treated with febuxostat for ≤ 48 months." | 9.17 | Preservation of renal function during gout treatment with febuxostat: a quantitative study. ( Chefo, S; Gunawardhana, L; MacDonald, PA; Whelton, A, 2013) |
| "To compare the characteristics of female versus male gout patients and assess urate-lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout." | 9.16 | Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. ( Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA, 2012) |
| "0 mg/dL) gout subjects were enrolled in the 6-month, double-blind, randomized, comparative CONFIRMS trial and randomized, 1:1:1, to receive febuxostat, 40 mg or 80 mg, or allopurinol (200 mg or 300 mg based on renal function) once daily." | 9.16 | The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. ( Hunt, B; Jackson, RL; MacDonald, PA, 2012) |
| "To evaluate the efficacy and safety of the interleukin-1 inhibitor rilonacept (interleukin-1 Trap) for gout flare prevention during initiation of uric acid-lowering therapy (ULT)." | 9.16 | Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. ( Clower, J; Evans, RR; Jennings, W; Saag, KG; Schumacher, HR; Terkeltaub, R; Wang, J; Weinstein, SP; Yancopoulos, GD, 2012) |
| "To determine the efficacy and safety of increasing the allopurinol dose above the proposed creatinine clearance-based dose in patients with gout." | 9.15 | Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. ( Barclay, ML; Chapman, PT; Frampton, C; James, J; O'Donnell, JL; Stamp, LK; Zhang, M, 2011) |
| "To investigate the pharmacokinetic and pharmacodynamic interaction between probenecid and oxypurinol (the active metabolite of allopurinol) in patients with gout." | 9.15 | Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ( Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2011) |
| "Hyperuricemia of gout can arise due to either overproduction or underexcretion of uric acid." | 9.15 | Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. ( Goldfarb, DS; Gunawardhana, L; Hunt, B; MacDonald, PA, 2011) |
| "Febuxostat or allopurinol was administered to patients with hyperuricemia including gout for 8 weeks to compare the efficacy and safety of these drugs." | 9.15 | An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p ( Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011) |
| ": A multicenter study with randomized, placebo-controlled, double-blind, parallel-group comparison was carried out to evaluate the efficacy and safety of febuxostat in 103 patients with hyperuricemia (including patients with gout) in Japan." | 9.15 | Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "A multicenter study with randomized, placebo-controlled, double-blind, parallel, intergroup comparison was carried out to evaluate the dose-response relationship, efficacy, and safety of febuxostat in 202 patients with hyperuricemia (including patients with gout) in Japan." | 9.15 | Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "Febuxostat was administered to patients with hyperuricemia including gout in Japan to compare its efficacy and safety with those of allopurinol." | 9.15 | An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "In previous clinical studies of hyperuricemia including gout, although serum uric acid (sUA) levels reduced to 6." | 9.15 | Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. ( Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011) |
| "This 5-yr study assessed urate-lowering and clinical efficacy and safety of long-term febuxostat therapy in subjects with gout." | 9.14 | Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. ( Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009) |
| "The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8." | 9.14 | The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. ( Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF, 2010) |
| "To establish a benchmark for gout control using the proportion of patients with serum uric acid (SUA) < 0." | 9.14 | More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial. ( Arroll, B; Ben, C; Bennett, M; Dalbeth, N; Hettiarachchi, D; Shelling, G, 2009) |
| "To investigate the efficacy and tolerability of allopurinol as the first-choice antihyperuricaemic treatment for gout, and compare the efficacy and tolerability of benzbromarone and probenecid as second-choice treatment." | 9.14 | Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. ( Brouwers, JR; Delsing, J; Griep, EN; Hoekstra, M; Jansen, TL; Reinders, MK; van de Laar, MA; van Roon, EN, 2009) |
| "To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function." | 9.13 | Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. ( Becker, MA; Hunt, B; Joseph-Ridge, N; Lademacher, C; Macdonald, PA; Schumacher, HR; Streit, J; Wortmann, RL, 2008) |
| "To evaluate the major cardiovascular (CV) events of febuxostat compared to allopurinol for the treatment of gout or asymptomatic hyperuricemia." | 9.12 | The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis. ( Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T, 2021) |
| " Elevated uric acid levels are risk factors for gout, hypertension, and chronic kidney diseases." | 9.12 | Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. ( Kimura, Y; Kono, H; Tsukui, D, 2021) |
| "The description of gout dates back almost 5000 years, and scientific interest in uric acid increased when it was found to be involved in the pathogenesis of gout." | 9.12 | The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems. ( Agnoletti, D; Borghi, C; Cicero, AFG, 2021) |
| "Benzbromarone is effective in lowering uric acid levels and in reducing the number of acute attacks of gout in patients who have failed optimal treatment." | 9.11 | Benzbromarone therapy in management of refractory gout. ( Gow, P; Kumar, S; Ng, J, 2005) |
| "Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout." | 9.11 | Febuxostat compared with allopurinol in patients with hyperuricemia and gout. ( Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Streit, J; Wortmann, RL, 2005) |
| "To evaluate metformin efficacy and safety in patients with gout and insulin resistance (IR)." | 9.11 | [Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)]. ( Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Kudaeva, FM; Nasonov, EL; Tsapina, TN; Volkov, AV; Zilov, AV, 2005) |
| "To assess the short-term urate-lowering effect of fenofibrate in men on long-term allopurinol therapy for hyperuricaemia and gout." | 9.10 | Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. ( Ball, SG; Feher, MD; Hepburn, AL; Hogarth, MB; Kaye, SA, 2003) |
| "Uric acid overexcretion in patients with gout is frequently assessed by the measurement of 24 hour urinary uric acid excretion, which is cumbersome with ambulatory patients, and requires accurate timing and complete collection of the specimen." | 9.09 | Spot urine uric acid to creatinine ratio used in the estimation of uric acid excretion in primary gout. ( Hada, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 2001) |
| "It is known that chronic renal insufficiency (CRI) patients with gout may have subtle lead poisoning." | 9.09 | Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. ( Ho, HH; Lin, JL; Lin-Tan, DT; Yu, CC, 2001) |
| "To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout." | 9.08 | Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. ( Alonso-Ruiz, A; Calabozo, M; García-Erauskin, G; Herrero-Beites, A; Perez-Ruiz, F; Ruiz-Lucea, E, 1998) |
| "The objectives of this study were to establish if, and to what extent, benzbromarone affects allopurinol/oxypurinol kinetics, and to compare the uric acid lowering capabilities of Allomaron (allopurinol 100 mg plus benzbromarone 20 mg) with the effects of allopurinol alone in patients with confirmed gout." | 9.07 | The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. ( Groenewoud, G; Hundt, HK; Müller, FO; Schall, R; van der Merwe, JC; van Dyk, M, 1993) |
| "This study compared the effects of azapropazone and indomethacin plus allopurinol in the management of acute gout and hyperuricaemia." | 9.06 | Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. ( Davis, RH; Fraser, RC; Walker, FS, 1987) |
| "The antihyperuricemic properties of amflutizole were investigated in studies designed to determine its efficacy and mechanisms of action in individuals with gout and hyperuricemia." | 9.05 | Antihyperuricemic properties of amflutizole in gout. ( Fox, IH; Lightfoot, RW; Ridolfo, AS; Wortmann, RL, 1985) |
| "The effect of daily administration of a single 300-mg tablet of allopurinol on serum urate levels was compared with the effect of divided doses of the drug (100 mg three times a day) in an open-labeled crossover trial of 20 patients with hyperuricemia and gout." | 9.04 | Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. ( Elion, GB; Robin, JA; Rodnan, GP; Tolchin, SF, 1975) |
| "Gout is characterized by high serum uric acid (SUA) levels and arthritis." | 9.01 | Impact of bariatric surgery on serum uric acid levels and the incidence of gout-A meta-analysis. ( Kaushal, S; Koura, A; Lim, B; Oo, AM; Rao, J; Syn, N; Yeo, C; Yeo, D, 2019) |
| "Concerns about the cardiovascular safety of febuxostat lead to reconsideration of the place of febuxostat in the management of gout." | 9.01 | The role of febuxostat in gout. ( Bardin, T; Richette, P, 2019) |
| "Previous epidemiological investigations have evaluated the association between gout, serum uric acid levels, and obstructive sleep apnea syndrome (OSAS), but with inconsistent results." | 9.01 | A meta-analysis of the association between gout, serum uric acid level, and obstructive sleep apnea. ( Cheng, C; Liang, M; Min, M; Rizeq, FK; Shi, T; Sun, C; Sun, Y; Zhang, Y, 2019) |
| "We aimed to assess the relative efficacy and safety of once-daily administration of lesinurad in combination with xanthine oxidase inhibitor (XOI) in hyperuricemic patients with gout." | 9.01 | Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials . ( Lee, YH; Song, GG, 2019) |
| "This study aimed to examine whether the uric acid level or gout is causally associated with bone mineral density (BMD)." | 9.01 | Uric acid level, gout and bone mineral density: A Mendelian randomization study. ( Lee, YH; Song, GG, 2019) |
| " allopurinol was associated with the improved safety outcome and have comparable mortality and net clinical outcome in patients with hyperuricemia." | 9.01 | The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis. ( Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML, 2019) |
| "Gout develops in four stages beginning with an asymptomatic increase in blood levels of uric acid." | 8.98 | Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018) |
| "Gout and calcium pyrophosphate deposition disease (CPPD, pseudogout) are still the most frequent inflammatory arthritides in multimorbid elderly patients." | 8.98 | Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 1: Epidemiology and pathophysiology. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018) |
| "This was a pooled analysis of phase III trials on allopurinol and febuxostat, including 4101 patients with gout and hyperuricemia." | 8.95 | Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. ( Cimmino, MA; Cutolo, M; Perez-Ruiz, F, 2017) |
| "The research progress of puerarin and its derivatives in anti-inflammatory and anti-gout activities was reviewed in this paper." | 8.95 | [Research progress of puerarin and its derivatives on anti-inflammatory and anti-gout activities]. ( Li, XP; Ma, YC; Xing, ZH; Zhang, B; Zhang, MD, 2017) |
| "Lowering serum uric acid (SUA) levels can essentially cure gout; however, this is not widely practiced." | 8.95 | Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. ( Bolzani, A; Cheung, A; Choi, HK; Shiozawa, A; Szabo, SM, 2017) |
| "The aim of this study was to examine the associations of tea consumption with the serum uric acid (SUA) level, hyperuricemia (HU) and the risk of gout." | 8.95 | Is tea consumption associated with the serum uric acid level, hyperuricemia or the risk of gout? A systematic review and meta-analysis. ( Cui, Y; Deng, YH; Huang, YZ; Lei, GH; Li, LJ; Li, XA; Xie, X; Zeng, C; Zhang, Y, 2017) |
| "Recent evidence would indicate that high serum uric acid (SUA) levels can be a significant and independent risk factor for hypertension and cardiovascular diseases, such as ischemic heart disease and heart failure." | 8.93 | Uric acid lowering therapy in cardiovascular diseases. ( Iellamo, F; Romeo, F; Sposato, B; Volterrani, M, 2016) |
| " It is caused by factors that elevate the concentration of serum uric acid (sUA), leading to hyperuricemia (sUA >6." | 8.93 | Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL? ( Edwards, NL; Ruoff, G, 2016) |
| " Chondrocalcinosis is a radiographic entity characterized by deposits of calcium pyrophosphate crystals (CPP) within the fibrocartilage or hyalin cartilage." | 8.91 | [Gout and and calcium pyrophosphate crystal arthropathies: pathophysiology]. ( Albert, JD; Coiffier, G, 2015) |
| "Our review found low- to moderate-quality evidence indicating similar effects on withdrawals due to AEs and SAEs and incidence of acute gout attacks when allopurinol (100 to 600 mg daily) was compared with placebo, benzbromarone (100 to 200 mg daily) or febuxostat (80 mg daily)." | 8.90 | Allopurinol for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014) |
| "This study aims to compare the urate-lowering response rate of febuxostat and allopurinol in gout patient using a model-based meta-analysis." | 8.90 | [A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient]. ( Li, L; Lu, W; Sun, Y; Zhou, TY, 2014) |
| "To evaluate the safety and efficacy of febuxostat compared to allopurinol for the treatment of chronic gout." | 8.89 | A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. ( Ehteshami-Afshar, A; Faruque, LI; Homik, J; Tjosvold, L; Tonelli, M; Wiebe, N, 2013) |
| " Concordantly, recent studies have revived the controversy over the role of circulating uric acid, hyperuricemia, and gout as an independent prognostic factor for cardiovascular morbidity and mortality." | 8.89 | Chronic hyperuricemia, uric acid deposit and cardiovascular risk. ( Cheli, P; Del Pinto, R; Desideri, G; Di Giosia, P; Ferri, C; Ferri, L; Grassi, D; Properzi, G, 2013) |
| "Febuxostat has been approved for the treatment of hyperuricemia in patients with/without gout." | 8.89 | Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. ( Chen, S; Cheng, Q; Li, Q; Liu, L; Luo, T; Lv, Q; Mei, M; Yang, S; Ye, P; Zhang, W, 2013) |
| "Many patients with acute gout (11%-49%) have normal serum uric acid (SUA) levels." | 8.87 | Clinical inquiry. Are serum uric acid levels always elevated in acute gout? ( Fletcher, A; Leiszler, M; Poddar, S, 2011) |
| "Febuxostat, a nonpurine selective inhibitor of both the oxidized and reduced forms of xanthine oxidase, was approved in February 2009 by the US Food and Drug Administration for the management of hyperuricemia in adults with gout." | 8.85 | Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. ( Ernst, ME; Fravel, MA, 2009) |
| "Uric acid nephrolithiasis is typically found in individuals with a low urine pH and a normal concentration of urinary uric acid." | 8.84 | Uric acid nephrolithiasis. ( Bushinsky, DA; Liebman, SE; Taylor, JG, 2007) |
| "Impaired renal uric acid excretion is the major mechanism of hyperuricemia in patients with primary gout." | 8.84 | Control of renal uric acid excretion and gout. ( Kamatani, N; Taniguchi, A, 2008) |
| " Recently it has been identified that hypertension are frequently associated with myogenic hyperuricemia converted from overproduced hypoxanthine in the skeletal muscles." | 8.84 | [Idiopathic hyperuricemia with overproduction of uric acid]. ( Hisatome, I; Igawa, O; Mizuta, E, 2008) |
| "Although allopurinol has been available for approximately 50 years, hyperuricemia and its sequelae are not only prevalent, but the incidence and costs associated with this disorder continue to increase." | 8.82 | Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. ( Bomalaski, JS; Clark, MA, 2004) |
| "Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects." | 8.75 | Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1977) |
| "The occurrence of gout attacks at the start of uric acid lowering treatment worsens compliance." | 8.31 | A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout. ( Ghang, B; Jeong, W; Kim, J; Lee, J, 2023) |
| " Reducing uric acid and inhibiting inflammation are the focused areas of drug research and development on gout." | 8.31 | Rutin ameliorates gout via reducing XOD activity, inhibiting ROS production and NLRP3 inflammasome activation in quail. ( Huang, J; Li, Y; Lin, Z; Wang, Y; Wu, H; Zhang, B, 2023) |
| "Poor adherence to allopurinol among people with gout contributes to suboptimal gout management." | 8.31 | Optimizing adherence to allopurinol for gout: patients' perspectives. ( Aslani, P; Chan, JS; Coleshill, MJ; Day, RO; Michael, TJF; Spragg, JCJ; Stocker, SL, 2023) |
| " This research aimed to study the relation of ischemic cerebrovascular disease with benzbromarone use among persons with gout-related disorders." | 8.31 | The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan. ( Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS, 2023) |
| "Correlation influence factor analysis of gout patients' serum uric acid (SUA) levels, their examination fees, and various complications were explored." | 8.31 | Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross-sectional analysis. ( Dang, W; Liu, J; Wang, J; Xu, D; You, L; Zhao, L, 2023) |
| "To explore pro-inflammatory cytokines status in the tear fluid of patients with hyperuricemia and gout and its association with uric acid level." | 8.31 | Uric acid is independently associated with interleukin-1β levels in tear fluid of hyperuricemia and gout patients. ( Hu, X; Liu, C; Lu, H; Lu, T; Wu, M, 2023) |
| "Spontaneous serum uric acid (SUA) decrease has been found in many patients during acute gout attacks, but its mechanism remains unclear." | 8.31 | Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack. ( Cao, L; Du, X; Lin, C; Wan, W; Xu, R; Yang, X; Zhao, T; Zhou, M; Zhu, X; Zou, H, 2023) |
| "We investigated the appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors (XOIs) as first-line urate-lowering therapy (ULT) in patients with gout." | 8.31 | Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database. ( Kim, AR; Lee, SG; So, MW, 2023) |
| " It suppressed liver xanthine oxidase activity to decrease uric acid synthesis and modulated renal urate transporters to stimulate uric acid excretion, alleviating kidney damage caused by hyperuricemia." | 8.31 | Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters. ( An, J; Li, C; Li, Y; Lin, F; Ma, S; Wang, S; Xie, Y; Xu, L; Zhang, Y; Zhao, Y, 2023) |
| "Higher serum uric acid (SUA) can cause gout, which is principally characterized by arthritis due to monosodium urate crystal deposition in the lower extremities." | 8.31 | Association between serum uric acid levels and peripheral artery disease in Chinese adults with hypertension. ( Bao, H; Cheng, X; Han, F; Hu, F; Huang, X; Wang, T; Yu, C; Zhou, W; Zhu, L, 2023) |
| "To determine the risk of adverse events associated with colchicine or non-steroidal anti-inflammatory drug (NSAID) prophylaxis when initiating allopurinol for gout." | 8.31 | Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink. ( Bajpai, R; Clarson, LE; Forrester, H; Mallen, CD; Muller, S; Padmanabhan, N; Partington, RJ; Roddy, E; Whittle, R, 2023) |
| " Thus, we aimed to investigate diurnal variations in serum levels of UA and plasma levels of xanthine, hypoxanthine, and xanthine oxidoreductase (XOR) activity, which were measured at 18:00, 6:00, and 12:00 in male patients with coronary artery disease." | 8.31 | Diurnal Variations in Serum Uric Acid, Xanthine, and Xanthine Oxidoreductase Activity in Male Patients with Coronary Artery Disease. ( Hiki, M; Ishiwata, S; Kasai, T; Kato, T; Kuwabara, M; Matsumoto, H; Murase, T; Murata, A; Naito, R; Nakamura, T; Sato, A; Shimizu, M; Shitara, J; Suda, S; Yatsu, S, 2023) |
| "Achieving target serum uric acid (SUA) levels is important in gout management." | 8.31 | Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry. ( Ahn, JK; Choi, B; Choi, HJ; Choi, SR; Do, H; Kim, HO; Kim, JH; Kim, MJ; Kim, SH; Lee, CH; Lee, SG; Lee, SW; Moon, KW; Shin, K; Son, CN; Son, KM; Song, R, 2023) |
| " The averaged serum uric acid levels in patients with gout reduced after WMT (p = 0." | 8.12 | Effects of Washed Microbiota Transplantation on Serum Uric Acid Levels, Symptoms, and Intestinal Barrier Function in Patients with Acute and Recurrent Gout: A Pilot Study. ( Cai, JY; Deng, ZH; He, XX; Kong, LP; Wu, LH; Xia, HH; Xie, WR; Yang, XY; Zhang, R; Zheng, YM, 2022) |
| "Sixty-nine men with gout attending rheumatology clinics, all prescribed allopurinol for ≥ 6 months, completed the Intentional Non-Adherence Scale (INAS)." | 8.12 | Why Do Patients With Gout Not Take Allopurinol? ( Chalder, T; Dalbeth, N; Emad, Y; Petrie, KJ; Weinman, J, 2022) |
| "Characterized by an excessively increased uric acid (UA) level in serum, hyperuricemia induces gout and also poses a great threat to renal and cardiovascular systems." | 8.12 | Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing. ( Chai, S; Chai, X; Geng, WC; Guo, DS; Li, JJ; Wang, L; Wang, Y; Yu, H; Yue, YX; Zhang, Y, 2022) |
| " These physiological characteristics have promoted the study of poly-gallic acid (PGAL), a poly-oxidized form of gallic acid reported to be effective in in vitro models of inflammation." | 8.12 | Anti-inflammatory and Antioxidant Effect of Poly-gallic Acid (PGAL) in an In Vitro Model of Synovitis Induced by Monosodium Urate Crystals. ( Fernández-Torres, J; Gimeno, M; Luján-Juárez, IA; Martínez-Flores, K; Martínez-López, V; Montaño-Armendariz, N; Sánchez-Sánchez, R; Zamudio-Cuevas, Y, 2022) |
| " In this study, the xanthine oxidase (XO) inhibition and uric acid-lowering effect of corni fructus extract (CFE) were evaluated in mice with potassium oxonate-induced hyperuricemia." | 8.12 | Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia. ( Chen, C; Chen, FA; Chen, HC; Chiu, PY; Li, YL; Wang, CC, 2022) |
| " Ongoing research is examining the association of obesity, dietary patterns, and blood pressure (BP) with serum uric acid (sUA)." | 8.12 | Correlation of obesity, dietary patterns, and blood pressure with uric acid: data from the NHANES 2017-2018. ( Fan, GJ; Lin, YP; Lu, QY; Yao, J; Zhang, Y; Zhao, J, 2022) |
| "Pegloticase + methotrexate co-therapy was well-tolerated over 12 months, with sustained SU lowering, progressive gout flare reduction, and no new safety concerns." | 8.12 | A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an ( Bennett, R; Botson, JK; Chamberlain, J; Kenney, HM; LaMoreaux, B; Obermeyer, K; Peloso, PM; Peterson, J; Ramanathan, S; Song, Y; Tesser, JRP; Weinblatt, ME; Xin, Y; Zhao, L, 2022) |
| "Multiple observational studies have reported the close associations of obstructive sleep apnea (OSA) with serum uric acid (SUA) levels and gout." | 8.12 | Assessing the causal associations of obstructive sleep apnea with serum uric acid levels and gout: a bidirectional two-sample Mendelian randomization study. ( Cen, H; Ding, C; He, W; Huang, L; Jin, T; Ni, J; Xie, Y; Zeng, Z; Zhang, L, 2022) |
| "To investigate the efficacy and tolerability of febuxostat in gout patients on dialysis." | 8.02 | Efficacy and tolerability of febuxostat in gout patients on dialysis. ( Choi, SW; Choi, SY; Lee, S; Lim, DH; Oh, JS; So, MW, 2021) |
| "The objectives of our study were to compare the efficacy of febuxostat with allopurinol in Thai subjects with gout, as well as to determine the predictive factors of responsiveness to urate-lowering agents and to evaluate the safety of febuxostat in a real-world setting." | 8.02 | Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout. ( Jatuworapruk, K; Lertnawapan, R, 2021) |
| "This is a single-center, prospective cohort study conducted in one adult Arthritis Clinic at the University of the Philippines-Philippine General Hospital which included 138 patients with gout (1977 ACR criteria), SUA ≥ 6 mg/dl prior to ULT, initiated on ULT (allopurinol or febuxostat), with six months minimum follow-up and with SUA determination post-treatment." | 8.02 | Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines. ( Penserga, EG; Quilisadio, JEC; Salido, EO, 2021) |
| "The coexistence of calcium pyrophosphate dihydrate (CPPD) and monosodium urate monohydrate crystals in gouty tophi has rarely been reported." | 8.02 | Calcium Pyrophosphate Dihydrate Crystal Deposition in Gouty Tophi. ( Bardin, T; Bazin, D; Cohen-Solal, M; Ea, HK; Frochot, V; Gauffenic, A; Laredo, JD; Le, NH; Marty, C; Nguyen, QD; Olivier, O; Ostertag, A; Pham, NG; Richette, P, 2021) |
| "This study assessed factors associated with achieving target serum uric acid (sUA) level and occurrence of gouty arthritis in Japanese clinical practice." | 8.02 | Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021) |
| "In this nonrandomized, open-label, single-arm trial, we administered topiroxostat 40-160 mg/day to HFpEF patients with hyperuricemia or gout to achieve a target uric acid level of 6." | 8.02 | Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study. ( Asai, K; Koen, M; Kubota, Y; Shimizu, W; Wakita, M, 2021) |
| "Gout is a type of inflammatory arthritis caused by the deposition of monosodium uric acid (MSU) crystals in tissues." | 8.02 | Loganin Alleviates Gout Inflammation by Suppressing NLRP3 Inflammasome Activation and Mitochondrial Damage. ( Cho, YY; Choi, N; Jang, JH; Kang, HC; Lee, HS; Lee, JY; Yang, G, 2021) |
| "To investigate the incidence and potential risk factors for development of fenofibrate-associated nephrotoxicity in gout patients." | 8.02 | Effects of fenofibrate therapy on renal function in primary gout patients. ( Chen, Y; Cheng, X; Cui, L; Han, L; He, Y; Ji, A; Ji, X; Li, C; Li, H; Li, X; Liu, Z; Lu, J; Ma, L; Merriman, TR; Ren, W; Sun, W; Wang, C; Wang, X; Yuan, X; Zhang, H, 2021) |
| "The aim of this study was to identify the effects of melatonin on acute gouty inflammation and to investigate the underlying mechanisms." | 8.02 | Melatonin Alleviates Acute Gouty Inflammation In Vivo and In Vitro. ( Cao, L; Xiao, WZ; Zhao, L; Zhu, XX; Zou, HJ, 2021) |
| "In patients with gout, treating to target serum uric acid levels (sUA) of ≤6." | 8.02 | Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021) |
| "To analyse the antinociceptive interaction between quercetin (QUER) and diclofenac (DIC) in experimental arthritic gout-pain." | 8.02 | Quercetin decreases the antinociceptive effect of diclofenac in an arthritic gout-pain model in rats. ( Ángeles-López, GE; Aviles-Herrera, J; Bustamante-Marquina, A; Déciga-Campos, M; González-Trujano, ME; Navarrete-Vázquez, G; Ventura-Martínez, R, 2021) |
| " In this study, the differences between gout with cerebral infarction (gout+CI) and gout with coronary heart disease (gout+CHD) and related factors that affect serum uric acid (sUA) levels in gout+CI were investigated by a cross-sectional study." | 8.02 | Factors Influencing the Serum Uric Acid in Gout with Cerebral Infarction. ( Duan, L; Li, Y; Tian, Y; Yang, H, 2021) |
| "To assess factors associated with the ability to achieve and maintain target serum urate (SU) with allopurinol in patients with gout." | 7.96 | Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. ( Saag, KG; Singh, JA; Yang, S, 2020) |
| "Eucalyptol alleviates MSU-induced pain and inflammation via mechanisms possibly involving anti-oxidative effect." | 7.96 | Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis. ( Li, X; Li, Y; Liu, B; Tai, Y; Wang, C; Wang, P; Yin, C; Zheng, X, 2020) |
| " Our study was to discover different lipid levels of gout and asymptomatic hyperuricemia and the predictors of sUA (serum uric acid) levels." | 7.96 | The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study. ( Gu, J; Huang, Y; Jiang, Y; Li, X; Liang, J; Ou, J; Song, W; Wei, Q, 2020) |
| "The 24-hour uric acid excretion measurement is important in assessing disease status and helping to select the appropriate uric acid-lowering agent for patients with gout, however, it is inconvenient." | 7.96 | The Utility of the Random Urine Uric Acid-to-Creatinine Ratio for Patients with Gout Who Need Uricosuric Agents: Retrospective Cross-Sectional Study. ( Choi, ST; Kim, CH; Kim, SJ; Moon, SJ; Song, JS, 2020) |
| "Lifelong urate-lowering therapy (ULT) with xanthine oxidase inhibitors (XOIs), such as allopurinol and febuxostat, is the cornerstone of gout treatment." | 7.96 | Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study. ( Ahn, E; Kim, A; Kim, GT; Kim, Y; Lee, SG; So, MW, 2020) |
| "Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used for the management of hyperuricemic patients with or without gout in Japan." | 7.96 | Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study. ( Hashimoto, T; Ichikawa, K; Ishikawa, T; Kanno, Y; Maeda, T; Nakagawa, T; Sato, Y, 2020) |
| "To investigate the effects of serum uric acid (SUA) level and its fluctuation on renal dysfunction in gout patients." | 7.96 | Uric acid fluctuation had no effect on renal function among gout patients. ( Fu, Y; Mo, M; Shao, B; Shen, J; Shen, Y; Si, S; Wang, S; Wu, H; Xin, X; Yu, Y; Zhu, J, 2020) |
| "To assess the impact of allopurinol on diabetes in a retrospective cohort of Veterans' Affairs patients with gout." | 7.96 | Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study. ( Crittenden, DB; Greenberg, J; Pike, VC; Pillinger, MH; Qian, Y; Slobodnick, A; Toprover, M; Zhong, H, 2020) |
| " Herein we aimed to investigate whether procyanidin B2 (PCB2), a natural dietary compound, can suppress MSU crystals-stimulated gouty inflammation." | 7.96 | Management of Gout-associated MSU crystals-induced NLRP3 inflammasome activation by procyanidin B2: targeting IL-1β and Cathepsin B in macrophages. ( Jiang, M; Jiao, JY; Li, Y; Lian, LH; Lin, YC; Liu, J; Nan, JX; Piao, MH; Qiao, CY; Shang, Y; Sun, RH; Wu, YL; Ye, H; Zhan, ZY; Zhang, ZH, 2020) |
| "12 a week-long combined therapy of the allopurinol-reducing drug with the anti-inflammatory dose movalis prevents the exacerbation of the articular syndrome and improves the quality of life of patients with gout." | 7.96 | [Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout]. ( Gromova, MA; Kislyak, OA; Malysheva, NV; Tsurko, VV, 2020) |
| " Serum uric acid levels and estimated glomerular filtration rate (eGFR) of patients with gouty arthritis were collected at baseline and 1 year after febuxostat administration." | 7.96 | Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. ( Kim, JM; Kim, SH; Lee, SY; Son, CN, 2020) |
| "EATP lowered the serum uric acid level and increased the urine uric acid level through excretion, which is useful in the treatment of gout." | 7.91 | Therapeutic potential of ethyl acetate fraction of Tephrosia purpurea Linn. leaves in a rat model of gout. ( Nipate, SS; Yelmar, PS, 2019) |
| "Lesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI." | 7.91 | Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. ( Baumgartner, S; Goldfarb, DS; Jalal, D; Pillinger, M; Saag, KG; Schechter, BM; Terkeltaub, R; Valiyil, R; White, WB, 2019) |
| "To further explore the possibility of xanthine and hypoxanthine to be gout biomarkers as substitutes for uric acid." | 7.91 | Study on the diagnosis of gout with xanthine and hypoxanthine. ( Deng, B; Deng, M; Fei, X; Huang, Z; Wang, Y; Ye, L, 2019) |
| " The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 7.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
| "Gout patients with chronic kidney disease (CKD) accumulate the active allopurinol metabolite oxypurinol, suggesting that allopurinol may promote greater serum urate (sU) lowering in CKD patients." | 7.91 | Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function. ( Crittenden, DB; Fisher, MC; Keenan, RT; Krasnokutsky, S; Modjinou, DV; Oh, C; Pillinger, MH; Toprover, M, 2019) |
| " We investigated whether epigallocatechin-3-gallate (EGCG) suppresses the activation of the NLRP3 inflammasome, thereby effectively preventing gouty inflammation." | 7.91 | Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis. ( Cho, YY; Kang, HC; Lee, HE; Lee, HS; Lee, JY; Park, YB; Yang, G, 2019) |
| "To investigate the effects on hypercholesterolemia and hypertriglyceridemia in gouty patients receiving uric acid-lowering therapy (UALT)." | 7.91 | Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. ( Deng, JX; Jie, LG; Qu, Y; Wu, J; Yu, QH; Zhang, YP, 2019) |
| "In patients with gout, maintaining too low serum uric acid (SUA) level with urate-lowering therapy is a concern because uric acid is thought to be neuroprotective." | 7.88 | Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. ( Bardin, T; Debette, S; Latourte, A; Perez-Ruiz, F; Richette, P; Soumaré, A, 2018) |
| " The PKPD model was used to simulate mono and dual-ULT in gout patients with either under-excretion (lowered clearance) or overproduction of uric acid, with suboptimal adherence modelled as either a single drug holiday of increasing duration or doses taken at random." | 7.88 | Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout. ( Hill-McManus, D; Hughes, D; Lane, S; Marshall, S; Soto, E, 2018) |
| "Uric acid is best known for its role in gout-the most prevalent inflammatory arthritis in humans-that is also described as an unusual complication of anorexia nervosa (AN)." | 7.88 | Anorexia nervosa and uric acid beyond gout: An idea worth researching. ( Maas, J; Simeunovic Ostojic, M, 2018) |
| "The aetiology of gout is closely linked to the deposition of monosodium uric acid (MSU) crystals and the consequent activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome." | 7.88 | Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation. ( Cho, YY; Kang, HC; Lee, HE; Lee, HS; Lee, JY; Yang, G; Yeon, SH, 2018) |
| "This narrative review aims to highlight recent findings on the relation between uric acid level and cognitive decline or dementia." | 7.88 | Uric acid and cognitive decline: a double-edge sword? ( Bardin, T; Latourte, A; Richette, P, 2018) |
| "Numerous epidemiological studies have shown that male patients with uric acid nephrolithiasis outnumber female patients." | 7.88 | Mediators of the Effects of Gender on Uric Acid Nephrolithiasis: A Novel Application of Structural Equation Modeling. ( Chang, YY; Chen, HW; Chen, YC; Chou, YH; Li, CC; Wu, WJ; Yang, FM, 2018) |
| "A retrospective data analysis was performed within the UK Clinical Practice Research Datalink (1987-2014) among incident gout patients, aged ⩾40 years and starting allopurinol (n = 48 280)." | 7.88 | Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). ( Arts, ICW; Boonen, A; Burden, AM; de Vries, F; Scheepers, LEJM; Souverein, P; Spaetgens, B, 2018) |
| "To retrospectively analyze the efficacy and safety of febuxostat on gout patients with low serum uric acid level." | 7.88 | Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study. ( Chen, X; Gu, B; Li, C; Qian, K; Ren, Q; Shen, M; Su, D; Wang, X; Xu, W; Yang, L; Yuan, H; Zhang, J, 2018) |
| " SUA was downregulated during acute gouty arthritis, which might be associated with increased urinary excretion of uric acid." | 7.88 | Renal excretion is a cause of decreased serum uric acid during acute gout. ( Cao, L; Guo, M; Lv, X; Wan, W; Xue, Y; Zhao, T; Zheng, S; Zhu, X; Zou, H, 2018) |
| "Procyanidins significantly attenuated gout pain and suppressed ankle swelling." | 7.85 | Grape seed-derived procyanidins alleviate gout pain via NLRP3 inflammasome suppression. ( Fan, YX; Gui, X; Han, Y; Hu, L; Jiang, CY; Liu, BQ; Liu, HJ; Liu, WT; Pan, XX; Tang, YL, 2017) |
| "Studies have suggested a relationship between higher baseline serum uric acid (sUA) levels and an elevated risk of subsequent ischemic cardiovascular outcomes among acute coronary syndrome (ACS) patients; this relationship may be modified by a clinical history of gout and has not been studied in large patient cohorts." | 7.85 | An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. ( Akerblom, A; Clare, RM; Held, C; Hess, CN; James, S; Keenan, RT; Klein, AB; Mahaffey, KW; Pagidipati, NJ; Roe, MT; Tricoci, P; Wallentin, L; Wojdyla, D, 2017) |
| "Patient and provider factors, including allopurinol medication adherence, affect gout treatment outcomes." | 7.85 | Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management. ( Bendlin, KA; Coburn, BW; Meza, J; Mikuls, TR; Russell, CL; Sayles, H, 2017) |
| "Serum uric acid (sUA) levels are causally associated with the risk of gout flares." | 7.85 | Serum uric acid levels and the risk of flares among gout patients in a US managed care setting. ( Buysman, EK; Korrer, S; Shiozawa, A, 2017) |
| "We aimed to investigate the effects of febuxostat on IR and the expression of high-sensitivity C-reactive protein (hs-CRP) in patients with primary gout." | 7.85 | Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout. ( Li, Y; Lu, Y; Meng, J; Yuan, X, 2017) |
| "To evaluate and compare the safety and efficacy of three urate lowering agents: febuxostat, allopurinol, and benzbromarone, when used to treat Chinese gout patients." | 7.85 | A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study . ( Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J, 2017) |
| "The aim of this study was to evaluate relationships between serum uric acid (SUA) and newly emergent acute myocardial infarction (AMI), congestive heart failure (CHF), coronary artery disease (CAD), composite cardiovascular (CV) events (AMI, CHF, CAD), hypertension, hyperlipidemia, and renal disease in gout patients." | 7.85 | Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data. ( Bienen, EJ; Essex, MN; Hopps, M; Makinson, GT; Mardekian, J; Udall, M, 2017) |
| "A population analysis was conducted in nonmem using oxypurinol and urate plasma concentrations from 133 gout patients." | 7.83 | Predicting allopurinol response in patients with gout. ( Barclay, ML; Dalbeth, N; Duffull, SB; Merriman, TR; Stamp, LK; Wright, DF, 2016) |
| " Model flow based on guideline and real-world treatment paradigms incorporated gout flare, serum uric acid (sUA) testing, treatment titration, discontinuation, and adverse events, chronic kidney disease (CKD) incidence and progression, and type 2 diabetes mellitus (T2DM) incidence." | 7.83 | Febuxostat in the management of gout: a cost-effectiveness analysis. ( Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ, 2016) |
| "Psoriasis has been reported to be associated with raised serum uric acid levels and gout, and uric acid has been demonstrated to mediate inflammatory pathways via secretion of pro-inflammatory chemokines." | 7.83 | Psoriasis and uric acid: a population-based cross-sectional study. ( Lai, YC; Yew, YW, 2016) |
| "Gout is a chronic disease characterized by the deposition of urate crystals in the joints and throughout the body, caused by an excess burden of serum uric acid (sUA)." | 7.83 | The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective. ( Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ, 2016) |
| " Whether gout, the most common rheumatologic inflammatory arthritis, or its cause, elevated serum uric acid (SUA), is associated with VTE incidence is unknown." | 7.83 | Serum uric acid, gout, and venous thromboembolism: The atherosclerosis risk in communities study. ( Folsom, AR; Kubota, Y; McAdams-DeMarco, M, 2016) |
| "Benzbromarone provides useful urate-lowering efficacy and does not appear unsafe in patients with gout." | 7.83 | The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. ( Cathro, A; Corkill, M; Dalbeth, N; Frampton, C; Gardner, D; Grainger, R; Haslett, J; Kain, T; Kumar, R; Kumar, S; Metcalfe, S; Porter, D; Stamp, LK; Stebbings, S; Taylor, G; White, D; Wyeth, J, 2016) |
| "Gouty arthritis is caused by the deposition of uric acid crystals, which induce the activation of NOD-like receptor family, pyrin domain containing 3(NLRP3) inflammasome." | 7.83 | Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: a novel strategy to treat acute gout. ( Choi, JY; Jeong, S; Jung, Y; Kim, ND; Lee, HE; Lee, JY; Park, HH; Yang, G, 2016) |
| "There is very limited information on the association between arsenic and serum uric acid levels or gout." | 7.81 | Arsenic exposure, hyperuricemia, and gout in US adults. ( Fadrowski, JJ; Guallar, E; Kuo, CC; Lin, YS; Navas-Acien, A; Weaver, V, 2015) |
| "To identify modifiable patient and provider factors associated with allopurinol adherence and the achievement of a serum urate acid (SUA) goal in gout." | 7.81 | Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. ( Cheetham, TC; Coburn, BW; Curtis, JR; Mikuls, TR; Rashid, N; Saag, KG; Wu, YL, 2015) |
| "To quantify the risk of non-fatal acute myocardial infarction (AMI) among users of allopurinol." | 7.81 | Allopurinol use and risk of non-fatal acute myocardial infarction. ( Álvarez, A; Bryant, V; de Abajo, FJ; García-Poza, P; García-Rodríguez, LA; Gil, MJ; Rodríguez, A, 2015) |
| "To evaluate the cost-effectiveness of allopurinol versus febuxostat in adult patients with gout over a 5-year time period from a U." | 7.81 | Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. ( Bottorff, MB; Gandhi, PK; Gentry, WM; Ma, Q, 2015) |
| "Allopurinol is used as long-term therapy to reduce the occurrence of gout flares." | 7.81 | Allopurinol adherence among patients with gout: an Italian general practice database study. ( Antonioli, L; Blandizzi, C; Capogrosso-Sansone, A; Convertino, I; Cricelli, C; Cricelli, I; Fornai, M; Lapi, F; Mantarro, S; Montagnani, S; Pecchioli, S; Tuccori, M, 2015) |
| "Inefficient renal excretion of uric acid is the main pathophysiological mechanism for hyperuricemia in gout patients." | 7.81 | Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. ( Aniel-Quiroga, MA; Chinchilla, SP; Erauskin, GG; Herrero-Beites, AM; Merriman, T; Perez-Ruiz, F, 2015) |
| " Study patients had at least one medical claim with a diagnosis of gout, at least one filled prescription for febuxostat or allopurinol and at least one sUA measurement post-index prescription." | 7.81 | Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. ( Akhras, KS; Shiozawa, A; Singh, JA, 2015) |
| "Our objective was to evaluate data on the cost-effectiveness of febuxostat compared with standard clinical practice with allopurinol in patients with gout that was presented to the Scottish Medicines Consortium (SMC) in 2010." | 7.80 | Cost-effectiveness of febuxostat in chronic gout. ( Beard, SM; Nuki, G; Pearson, IV; von Scheele, BG, 2014) |
| "American College of Rheumatology and European League Against Rheumatism guidelines recommend colchicine to prevent gout flares in patients initiating and increasing uric acid–lowering therapy until serum uric acid is maintained at ≤6 mg/dl." | 7.80 | Evaluating appropriate use of prophylactic colchicine for gout flare prevention. ( George, M; Hussain, F; Pullman-Mooar, S; Schumacher, HR, 2014) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 7.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| "Hyperhomocysteinemia is one of the important factors of the cardiovascular disease, and gout is well known to be associated with cardiovascular disease." | 7.80 | Elevated serum homocysteine levels were not correlated with serum uric acid levels, but with decreased renal function in gouty patients. ( Choi, ST; Kim, JS; Song, JS, 2014) |
| "To assess the feasibility and diagnostic value of detecting uric acid depositing among patients with tophaceous gout using a dual energy CT based Gemstone spectral imaging (GSI) technology for qualitative analysis of uric acid." | 7.80 | Detection of uric acid depositing in tophaceous gout using a new dual energy spectral CT technology. ( Cai, J; Ding, Q; Li, X; Liu, B; Luo, L; Wang, J; Wang, W; Wang, X; Xia, L; Yu, Y; Zhang, C, 2014) |
| "Gout with uric acid underexcretion is associated with transporter gene SNP related mainly to tubular reabsorption, whereas uric acid normoexcretion is associated only with tubular secretion SNP." | 7.80 | Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. ( Bailén, R; Banegas, JR; de Miguel, E; Puig, JG; Torres, RJ, 2014) |
| "While the prevalence of gout was calculated by counting patients with this diagnosis hyperuricemia was inferred in patients taking allopurinol at hospital admission or discharge, on the assumption that this drug was only prescribed owing to the finding of high serum levels of uric acid." | 7.80 | Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. ( Conca, A; Corrao, S; Djade, CD; Franchi, C; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M, 2014) |
| "Probenecid is recommended as urate-lowering therapy (ULT) in patients with gout where xanthine oxidase inhibitors are ineffective, not tolerated, or contraindicated." | 7.79 | Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. ( Dalbeth, N; Gow, PJ; Pui, K, 2013) |
| "A loss-of-function mutation (Q141K, rs2231142) in the ATP-binding cassette, subfamily G, member 2 gene (ABCG2) has been shown to be associated with serum uric acid levels and gout in Asians, Europeans, and European and African Americans; however, less is known about these associations in other populations." | 7.79 | Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study. ( Best, LG; Brown-Gentry, KD; Cole, SA; Crawford, DC; Deelman, E; Fornage, M; Franceschini, N; Gaffo, AL; Glenn, KR; Heiss, G; Jenny, NS; Jorgensen, NW; Kao, WH; Kottgen, A; Li, Q; Liu, K; Matise, TC; North, KE; Spencer, KL; Umans, JG; Voruganti, VS; Zhang, L, 2013) |
| "Acute gout is associated with a decrease in serum uric acid (SUA) that is considered to be in response to acute inflammation but it may be a feature of gout itself." | 7.79 | The effect of the systemic inflammatory response, as provoked by elective orthopaedic surgery, on serum uric acid in patients without gout: a prospective study. ( Ashby, HL; Chugh, S; Deshpande, S; Ford, C; Gama, R; Razavi, C; Thomas, OL; Waldron, JL, 2013) |
| "Although hyperuricemia is suggested to increase allantoin production in both pro- and antioxidant manners, it remains undetermined whether it increases the serum concentration of allantoin." | 7.78 | Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients. ( Koga, M; Koyama, H; Kurajoh, M; Moriwaki, Y; Shoji, T; Sumida, C; Tsutsumi, Z; Yamamoto, A; Yamamoto, T, 2012) |
| "Allopurinol is the most commonly used urate-lowering therapy in gout." | 7.78 | Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. ( Dalbeth, N; Dockerty, JL; Drake, J; Frampton, C; Jones, PB; Stamp, LK; Taylor, WJ, 2012) |
| "In this hypothesis-generating study, gout patients who took colchicine had a significantly lower prevalence of MI and exhibited trends toward reduced all-cause mortality and lower CRP level versus those who did not take colchicine." | 7.78 | Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. ( Crittenden, DB; Cronstein, BN; Greenberg, JD; Keenan, RT; Lehmann, RA; Pillinger, MH; Schneck, L; Sedlis, SP; Shah, B, 2012) |
| "Blood lead levels in the range currently considered acceptable are associated with increased prevalence of gout and hyperuricemia." | 7.78 | Low-level lead exposure and the prevalence of gout: an observational study. ( Bhalla, V; Krishnan, E; Lingala, B, 2012) |
| " We present a case of tophaceous gout with uric acid levels that did not respond to prescription of very high doses of allopurinol or uricosuric agents." | 7.77 | Febuxostat efficacy in allopurinol-resistant tophaceous gout. ( Reid, G; Uh, M, 2011) |
| "Allopurinol, a purine base analog inhibitor of xanthine oxidase (XO) activity, remains the standard for pharmacologic urate-lowering management of gout." | 7.77 | Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. ( Chohan, S, 2011) |
| "The treatment of gout requires a lowering of serum urate (SU) levels, and allopurinol is the drug that is most commonly used for this purpose." | 7.77 | Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. ( Barclay, ML; Chapman, PT; Drake, J; Frampton, C; O'Donnell, JL; Stamp, LK; Zhang, M, 2011) |
| "Urate-lowering therapy (ULT), adjusted to achieve and maintain a serum uric acid (SUA) of <6 mg/dl, remains the standard of care for the chronic management of gout." | 7.77 | Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy. ( Gilliland, WR; Keith, MP, 2011) |
| "To identify factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol." | 7.77 | Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study. ( Kim, YG; Lee, CK; Lee, SG; So, MW; Yoo, B, 2011) |
| "We tested 16 million SNPs, identified through whole-genome sequencing of 457 Icelanders, for association with gout and serum uric acid levels." | 7.77 | Identification of low-frequency variants associated with gout and serum uric acid levels. ( Andreassen, OA; Besenbacher, S; Bjornsdottir, G; de Visser, MC; Eyjolfsson, GI; Geirsson, AJ; Gudbjartsson, DF; Gudjonsson, SA; Gylfason, A; Helgadottir, HT; Helgason, A; Hjartarson, E; Holm, H; Jonasdottir, A; Jonsdottir, I; Jonsson, H; Karason, A; Kiemeney, LA; Kong, A; Magnusson, G; Magnusson, OT; Masson, G; Olafsson, I; Pack, AI; Pedersen, JH; Rafnar, T; Saemundsdottir, J; Stefansson, H; Stefansson, K; Sulem, P; Thorsteinsdottir, U; Walters, GB; Zanon, C, 2011) |
| "Recent genome-wide association and functional studies have shown that the ABCG2 gene encodes for a urate transporter, and a common causal ABCG2 variant, rs2231142, leads to elevated uric acid levels and prevalent gout among Whites and Blacks." | 7.76 | The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people. ( Folsom, AR; Iso, H; Kitamura, A; Köttgen, A; Tanigawa, T; Yamagishi, K, 2010) |
| "Published evidence in the literature, regulatory status, and relative costs of colchicine and nonsteroidal anti-inflammatory drugs (NSAIDs) for prophylaxis of gouty flares during early urate-lowering therapy are reviewed." | 7.76 | Nonsteroidal anti-inflammatory drugs and colchicine to prevent gout flare during early urate-lowering therapy: perspectives on alternative therapies and costs. ( Peterson, DM, 2010) |
| "To assess the value of dual energy computed tomography (DECT) for the detection of uric acid (UA) deposition in patients with gout." | 7.76 | [Application of dual-energy computed tomography for detecting uric acid deposition in patients with gout]. ( Chen, Y; Jin, ZY; Liu, W; Sun, H; Wang, X; Xu, K; Xue, HD; Zeng, XJ; Zhang, YQ, 2010) |
| "In this article we describe a gouty caucasian male patient who had high levels of serum uric acid since 1970s." | 7.75 | Persistent normalization of serum levels of uric acid in a gouty patient after administration of cyproterone acetate. ( D'Angelo, S; Olivieri, I; Palazzi, C; Pennese, E, 2009) |
| "To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout." | 7.75 | Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. ( Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009) |
| "We examined the association between serum uric acid (SUA) level and the frequency, risk, and cost of gout flares among the elderly." | 7.75 | Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? ( Cahill, KE; Krishnan, E; Mody, RR; Patel, PA; Tang, J; Wu, EQ; Yu, AP, 2009) |
| "The aim of this prospective study was to evaluate results of metformin (MF) therapy during 1 year of uric acid (UA) metabolism and the clinical course of gout with insulin resistance (IR)." | 7.75 | [Effect of metformin on the clinical course of gout and insulin resistance]. ( Aleksandrova, EN; Barskova, VG; Eliseev, MS; Kudaeva, FM; Nasonov, EL; Nasonova, VA; Volkov, AV, 2009) |
| "Gout is well known to be produced by increased uric acid level in blood." | 7.75 | Calcium oxalate stone and gout. ( Marickar, YM, 2009) |
| "We identified three genetic loci associated with uric acid concentration and gout." | 7.74 | Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. ( Astor, BC; Benjamin, EJ; Boerwinkle, E; Coresh, J; Dehghan, A; Fox, CS; Hofman, A; Hwang, SJ; Kao, WL; Köttgen, A; Levy, D; Rivadeneira, F; van Duijn, CM; Witteman, JC; Yang, Q, 2008) |
| "2 mg/kg (monthly vs daily) in patients with tophaceous gout not treatable by allopurinol." | 7.74 | Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. ( Bardin, T; Brière, C; Hoenen-Clavert, V; Loeuille, D; Richette, P, 2007) |
| "To evaluate haemoglobin A1c (HbA1c), fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels in a nationally representative sample of men and women." | 7.74 | Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey. ( Choi, HK; Ford, ES, 2008) |
| "Cross-sectional studies indicate metabolic syndrome is a risk factor for elevated serum uric acid." | 7.74 | Impact of childhood metabolic syndrome components on the risk of elevated uric acid in adulthood: the Bogalusa Heart Study. ( Berenson, G; Chen, W; Menke, A; Muntner, P; Patel, DA; Srinivasan, S, 2008) |
| "We determined why calcium oxalate stones instead of uric acid stones form in some patients with gouty diathesis." | 7.73 | Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis. ( Moe, OW; Pak, CY; Peterson, RD; Poindexter, JR; Sakhaee, K, 2005) |
| "Patients with system lupus erythematosus, rheumatic arthritis, chronic active hepatitis and gout were found to have considerable hyperuricemia and be decreased in aminoacides content, which are the predecessors of purine." | 7.73 | [Hyperuricemia and disorders in content of amino acids-purine precursors in patients with autoimmune diseases and gout]. ( Anan'eva, MN; Dubiaga, VV; Nikolenko, IuI; Nikolenko, VIu; Shchukin, IN; Siniachenko, OV, 2005) |
| "Development of the acute and chronic inflammatory responses known as gout and pseudogout are associated with the deposition of monosodium urate (MSU) or calcium pyrophosphate dihydrate (CPPD) crystals, respectively, in joints and periarticular tissues." | 7.73 | Gout-associated uric acid crystals activate the NALP3 inflammasome. ( Martinon, F; Mayor, A; Pétrilli, V; Tardivel, A; Tschopp, J, 2006) |
| "Adherence to published allopurinol dosing guidelines led to suboptimal control of hyperuricemia in this population of patients with gout." | 7.73 | Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. ( Dalbeth, N; Gow, P; Kumar, S; Stamp, L, 2006) |
| "To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout." | 7.73 | Effect of fenofibrate in combination with urate lowering agents in patients with gout. ( Lee, CH; Lee, J; Lee, YH, 2006) |
| "The clinical manifestations of gout result from the formation and deposition of uric acid (UA) crystals." | 7.72 | Determination of uric acid in human saliva by capillary electrophoresis with electrochemical detection: potential application in fast diagnosis of gout. ( Chu, Q; Guan, Y; Ye, J, 2004) |
| "The effect of Tofu (bean curd) ingestion on uric acid metabolism was examined in 8 healthy and 10 gout subjects." | 7.70 | Effect of Tofu (bean curd) ingestion and on uric acid metabolism in healthy and gouty subjects. ( Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1998) |
| "To investigate the incidence of gout and the interaction between uric acid level and other risk factors in the development of gout." | 7.70 | The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. ( Chou, P; Lin, HY; Lin, KC, 2000) |
| " We examined the development of gout and an increased uric acid level in relation to lead, adjusting for other known risk factors." | 7.70 | Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. ( Hu, H; Kim, R; Liang, MH; Shadick, NA; Sparrow, D; Weiss, S, 2000) |
| "We compared gouty diathesis with uric acid versus calcium stones." | 7.69 | Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation. ( Adams-Huet, B; Khatchadourian, J; Pak, CY; Preminger, GM; Whitson, PA, 1995) |
| "Ten women with crystal-proved primary gout and normal serum creatinine levels (below 116 mmol/L) were studied while they were on a purine-restricted diet and taking no medications known to influence uric acid metabolism." | 7.69 | Purine metabolism in women with primary gout. ( de Miguel, E; Gil, AA; Mateos, FA; Miranda, ME; Pérez de Ayala, C; Puig, JG; Torres, RJ, 1994) |
| "Primary gout is characterized by increased plasma and decreased urinary concentrations of hypoxanthine, xanthine and uric acid." | 7.69 | Purine metabolism in patients with gout: the role of lead. ( Herrero, E; Mateos, FA; Miranda-Carús, E; Puig, JG; Ramos, T; Sanz, AG, 1997) |
| "Hyperuricemia and gout have been associated with cyclosporine A (CyA) therapy in transplant recipients." | 7.68 | Tophaceous gout in patients with renal transplants treated with cyclosporine A. ( Baethge, BA; Landreneau, MD; McDonald, JC; Work, J, 1993) |
| "Lasting normalisation of uric acid levels after treatment of patients with gout and hyperuricaemia with a combination of 300 mg allopurinol and 60 mg benzbromarone A total of 210 patients (163 men, 47 women) with gout and hyperuricaemia was treated for three months with daily doses of 300 mg allopurinol and 60 mg benzbromarone." | 7.68 | [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia]. ( Matzkies, F, 1992) |
| "To determine the frequency and characteristics of hyperuricemia and gouty arthritis among cyclosporine-treated heart transplant recipients." | 7.68 | Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. ( Burack, DA; Griffith, BP; Kahl, LE; Thompson, ME, 1992) |
| "We reviewed the clinical features and uric acid metabolism in 37 female patients with gout." | 7.68 | Female gout. Clinical spectrum and uric acid metabolism. ( Capitán, CF; de Miguel, E; Gijón, JB; Jiménez, ML; Mateos, FA; Michán, AD; Pérez de Ayala, C; Puig, JG, 1991) |
| "Ten patients with gout, hypertension, and mild to moderate renal insufficiency were studied for possible lead nephropathy by measuring stimulated urinary lead excretion." | 7.67 | Occult lead intoxication in patients with gout and kidney disease. ( Cecere, FA; Saylor, RP; Wright, LF, 1984) |
| "Sixteen hyperuricemic gouty patients were treated with diflunisal, a novel salicylate, 500 mg BID." | 7.67 | Hypouricemic action of diflunisal in gouty patients: in vitro and in vivo studies. ( Ambanelli, U; Ferraccioli, G; Spisni, A, 1984) |
| "The behavior of plasma and urine oxypurines (hypoxanthine and xanthine) and of uric acid has been studied in normal subjects and in gout patients." | 7.67 | [Analysis of uric acid and oxypurines in normal subjects and in gout patients]. ( Di Stefano, A; Leoncini, R; Marinello, E; Pizzichini, M; Porcelli, B; Taddeo, A, 1989) |
| "The clearance of uric acid, hypoxanthine and xanthine has been examined in gout patients and in normal subjects compared to creatinine, after a purine-free diet." | 7.67 | [Clearance of oxypurines in normal subjects and in gout patients subjected to a purine-free diet. Effects of allopurinol]. ( Di Stefano, A; Leoncini, R; Marinello, E; Pizzichini, M; Porcelli, B; Taddeo, A, 1989) |
| "The relationship between uric acid metabolism and lipid levels was analyzed in 148 male subjects with primary gout." | 7.67 | Relationship between hypertriglyceridemia and uric acid production in primary gout. ( Jiao, S; Kubo, M; Matsubara, K; Matsuzawa, Y; Takama, T; Tarui, S, 1989) |
| "Two members of a Spanish family were studied: an eight-year-old boy (Patient 1) with tophaceous gout, purine nucleotide and uric acid overproduction, and sensorineural deafness, and his 27-year-old mother (Patient 2), who had gout." | 7.67 | Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. ( Becker, MA; Jimenez, ML; Kim, M; Mateos, FA; Puig, JG; Simmonds, HA, 1988) |
| "A patient with coexistent Klinefelter's syndrome, systemic lupus erythematosus (SLE) and chronic tophaceous gouty arthritis developed allopurinol hypersensitivity." | 7.67 | Allopurinol hypersensitivity in a patient with coexistent systemic lupus erythematosus and tophaceous gout. ( Fam, AG; McDonald, J; Paton, T; Senn, J, 1988) |
| "The renal excretion of uric acid is usually diminished in primary gout with respect to increased serum urate levels." | 7.67 | Renal excretion of hypoxanthine and xanthine in primary gout. ( Jiménez, ML; Mateos, FA; Puig, JG; Ramos, TH, 1988) |
| "Uric acid concentration in the serum was investigated 3 times a day using the uricase method in 15 gout inpatients on a hypopurine diet with age- and sex-adjusted caloric content." | 7.67 | [Circadian rhythm of uric acid levels of the serum in gout]. ( Atanasov, NA; Karastanev, II; Kereziev, IK; Kuzmanova, SI; Solakov, PTs, 1987) |
| "In an open trial 15 patients with acute gout attacks were treated with Tolmetin." | 7.66 | [Treatment of acute gout attacks with tolmetin (author's transl)]. ( Gaismayer, K; Petera, P; Tausch, G, 1982) |
| "The incorporation of 15N-glycine into urinary uric acid was studied in three gouty patients, repeating a study carried out 13 to 27 years ago." | 7.66 | Long-term follow-up of incorporation of 15N from glycine into uric acid in gout. ( Roboz, J; Yu, TF, 1981) |
| "The results over 10 years in 200 patients (103 with gout and 97 with hyperuricaemia) treated with benzbromarone 75 - 120 mg/d are reported." | 7.66 | Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. ( Giudicelli, CP; Masbernard, A, 1981) |
| "We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin." | 7.66 | Indomethacin-induced hyperkalemia in three patients with gouty arthritis. ( Beckstrom, D; Findling, JW; Itskovitz, H; Kozin, F; Rawsthorne, L, 1980) |
| "A patient with intractable tophaceous gout and advanced renal failure responded favorably to treatment by long-term hemodialysis and administration of allopurinol." | 7.66 | Chronic gouty nephropathy treated by long-term hemodialysis and allopurinol. ( Johnson, WJ; O'Duffy, JD, 1979) |
| "Chronic lead nephtropathy, secondary gout (lead-gout) and porphyrinuria may develop after long lasting professional exposure to lead." | 7.65 | [Chronic lead poisoning: Lead gout with giant tophi on the skin, nephrophathy and porphyrinopathy]. ( Künzig, M; Orfanos, CE, 1975) |
| "Chickens genetically selected for high incidence of articular gout and hyperuricemia were used to determine the site of defective uric acid (UA) transport in gout." | 7.65 | Localization of renal tubular uric acid transport defect in gouty chickens. ( Quebbemann, AJ; Zmuda, MJ, 1975) |
| "THE CONCEPT OF AN ABNORMALITY OF GLUTAMINE METABOLISM IN PRIMARY GOUT WAS FIRST PROPOSED ON THE BASIS OF ISOTOPE DATA: when [(15)N]glycine was administered to gouty subjects, there was disproportionately great enrichment of N-(3 + 9) of uric acid, which derive from the amide-N of glutamine." | 7.65 | The kinetics of intramolecular distribution of 15N in uric acid after administration of (15N) glycine. A reappraisal of the significance of preferential labeling of N-(3+9) of uric acid in primary gout. ( Sperling, O; Starmer, CF; Wyngaarden, JB, 1973) |
| " Serum uric acid levels may rise slightly, but no clinical gout was seen in this study." | 7.64 | TREATMENT OF CONGESTIVE HEART FAILURE WITH TRIAMTERENE. ( FRIEDMAN, R; SCHUCHER, R; WENER, J, 1965) |
| "Adenine inhibited the de novo synthesis of purines in both normal and gouty man as shown by inhibition of the incorporation of glycine-(15)N into urinary uric acid without altering the incorporation of glycine-(15)N into urinary creatinine." | 7.64 | Suppression of glycine-15N incorporation into urinary uric acid by adenine-8-13C in normal and gouty subjects. ( Klinenberg, JR; Miller, J; Seegmiller, JE; Watts, RW, 1968) |
| " The MGH Acupuncture Sensation Scale and adverse events related to acupuncture will be measured after each treatment." | 7.30 | Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol. ( Chen, Z; Fang, MY; Huang, Y; Li, CN; Lin, FP; Liu, WH; Ma, Y; Tu, SH; Wang, B; Wang, Y; Xie, WX; Yu, LL; Zhang, RY; Zheng, CH, 2023) |
| "To determine the long-term use of and adherence to urate-lowering therapy (ULT), serum urate (SU) control, and self-reported flares in participants from a randomized controlled trial of allopurinol dose escalation, in order to achieve target SU concentration (< 0." | 7.11 | Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout. ( Coleman, GB; Dalbeth, N; Drake, J; Frampton, C; Haslett, J; Horne, AM; Stamp, LK; Su, I, 2022) |
| "Gout is a multifactorial metabolic and inflammatory disease that occurs when increased uric acid (UA) induce HU resulting in monosodium urate (MSU) crystal deposition in joints." | 7.01 | Uric acid en route to gout. ( Zhang, WZ, 2023) |
| " The primary endpoint was safety, assessed by adverse events (AE) and laboratory values." | 6.79 | Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. ( Evans, RR; King-Davis, S; Kivitz, A; Schumacher, HR; Sundy, JS; Weinstein, SP; Wu, R, 2014) |
| "Despite an increasing incidence of gout in older age patients with multiple metabolic and cardiovascular comorbidities, there are limited data addressing whether currently available urate-lowering therapy is comparably effective and safe in older (≥65 years of age) versus younger (<65 years of age) patients." | 6.76 | Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. ( Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, PA, 2011) |
| "Treatment with benzbromarone monotherapy (range: 100-200 mg/day; mean 138 mg/day) resulted in 92% of patients reaching target levels sUr | 6.73 | Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. ( Brouwers, JR; Houtman, PM; Jansen, TL; Reinders, MK; van Roon, EN, 2007) |
| "Treatment with febuxostat resulted in a significant reduction of sUA levels at all dosages." | 6.71 | Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. ( Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL, 2005) |
| "Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels." | 6.70 | Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001) |
| "The treatment of gout is based on several principles." | 6.58 | Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018) |
| "Gout is a clinical disorder that is characterized by the deposition of monosodium urate crystals (MSU) in joints and tendons, usually in the presence of prolonged hyperuricaemia." | 6.55 | Review of the ophthalmic manifestations of gout and uric acid crystal deposition. ( Ao, J; Casson, RJ; Goldblatt, F, 2017) |
| "Allopurinol is a safe option, slightly better than other ULDs." | 6.52 | Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. ( Carmona, L; Castrejon, I; Loza, E; Pérez-Ruiz, F; Rosario, MP; Toledano, E, 2015) |
| "Uric acid has a stimulating effect on the cerebral cortex, and this could have allowed humans, compared with other animals, to develop higher brain mass volume, better intellectual performances, and maybe evolutionary supremacy." | 6.52 | Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple". ( De Giorgi, A; Fabbian, F; Manfredini, R; Misurati, E; Pala, M; Parisi, C; Tiseo, R, 2015) |
| "Gout is one of the most common forms of arthritis." | 6.50 | Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout. ( Barclay, ML; Dalbeth, N; Merriman, TR; Roberts, RL; Singh, JA; Stamp, LK; Wright, DF, 2014) |
| "Uric acid is a waste product of purine catabolism." | 6.49 | Uric acid as a danger signal in gout and its comorbidities. ( Kataoka, H; Lai, JJ; Rock, KL, 2013) |
| "Uric acid has been identified as an endogenous adjuvant that drives immune responses in the absence of microbial stimulation." | 6.47 | The role of uric acid as an endogenous danger signal in immunity and inflammation. ( Ghaemi-Oskouie, F; Shi, Y, 2011) |
| "Uric acid is a weak acid that exists largely as MSU, the ionized form, in urate pool at physiologic pH." | 6.44 | [Physiology and dynamics of uric acid in hyperuricemia]. ( Nakamura, T; Takagi, K; Ueda, T, 2008) |
| "Dimethyl fumarate (DMF) has shown anti-inflammatory and antioxidant activities." | 5.91 | Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress. ( Cao, Y; Hu, Y; Jin, XF; Liu, Y; Zou, JM, 2023) |
| "Uric acid has antioxidant and neuroprotective properties." | 5.91 | [The influence of uric acid on the course of amyotrophic lateral sclerosis]. ( Areprintseva, DK; Kutlubaev, MA; Pervushina, EV, 2023) |
| "Uric acid (UA) is an important antioxidant that has been positively associated with muscle strength in older adults." | 5.91 | Association between serum uric acid and muscle strength in older adults with or without gout diagnosis: NHANES 2011-2014. ( de Oliveira, EP; Nahas, PC; Nehme, R, 2023) |
| "The gouty ulcers were not completely healed by Day 14 compared with those in the PBS controls." | 5.72 | Gout-associated uric acid crystals induce tophi ulcerations and impair wound healing in a novel gouty ulcer model. ( Bao, W; Cheng, X; Jia, C; Su, Y; Wang, P; Xue, Y; Yin, B, 2022) |
| "Melatonin (MLT) is a powerful endogenous anti-inflammatory agent and effective in reducing cellular damage." | 5.72 | Influence of Pinealectomy and Long-term Melatonin Administration on Inflammation and Oxidative Stress in Experimental Gouty Arthritis. ( Altinoz, E; Ballur, AFH; Bicer, Y; Demir, M; Elbe, H; Karayakali, M; Onal, MO; Yigitturk, G, 2022) |
| "Gout is a chronic disease caused by monosodium urate (MSU) crystal deposition in the joints and surrounding tissues." | 5.72 | Taxifolin blocks monosodium urate crystal-induced gouty inflammation by regulating phagocytosis and autophagy. ( Jiang, YJ; Lian, LH; Nan, JX; Piao, MH; Wang, H; Wu, YL, 2022) |
| "Gout is a painful form of inflammatory arthritis characterized by the deposition of monosodium urate (MSU) crystals in the joints." | 5.72 | The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model. ( Aganetti, M; Amaral, FA; Braga, AD; de Faria, AMC; de Oliveira, VLS; Galvão, I; Georgel, P; Martins, VD; Mastrippolito, D; Mendes, V; Muller, S; Rocha, V; Talamini, L; Verdot, C; Vieira, AT, 2022) |
| "To assess efficacy, safety, pharmacokinetics, and immunogenicity of pegloticase plus methotrexate (MTX) versus pegloticase plus placebo cotreatment for uncontrolled gout in a randomized, placebo-controlled, double-blind trial." | 5.69 | A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. ( Botson, JK; Chamberlain, J; Grewal, S; La, D; LaMoreaux, B; LoCicero, K; Majjhoo, A; Obermeyer, K; Ong, S; Parikh, N; Peterson, J; Saag, K; Sainati, S; Tesser, JRP; Verma, S; Weinblatt, ME; Xin, Y, 2023) |
| "No significant increase was noted in acute gout flare severity or duration among GA patients treated with early aggressive control of hyperuricemia using probenecid plus colchicine." | 5.69 | Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial. ( Chen, HC; Wei, JC; Yang, DH, 2023) |
| "To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of allopurinol using the 'start-low go-slow' dose approach." | 5.69 | Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. ( Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Haslett, J; Horne, A; Mihov, B; Stamp, L, 2023) |
| "This study aimed to investigate the efficacy and safety of tart cherry supplementary citrate (TaCCi) mixture on urine pH, serum urate (sUA), C-reactive protein (CRP), and gout flares in gout patients initiating urate-lowering therapy (ULT), in comparison to citrate mixture and sodium bicarbonate." | 5.69 | Efficacy and safety of tart cherry supplementary citrate mixture on gout patients: a prospective, randomized, controlled study. ( Cui, L; Dalbeth, N; Han, L; He, Y; Ji, A; Ji, X; Li, C; Li, X; Liu, Z; Sun, M; Sun, W; Wang, C; Wang, X; Wang, Z; Xue, X, 2023) |
| "Thus, hyperuricemia is associated with impaired endothelial function." | 5.62 | Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. ( Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB, 2021) |
| "Patients with hyperuricemia are among the high-risk group of postoperative gout attacks." | 5.62 | Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia. ( Fu, L; Liu, Y; Wen, J; Xu, C; Yan, T; Yang, H; You, Y; Yu, J; Zhan, D; Zhang, T, 2021) |
| "To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) causes after treatment with febuxostat or allopurinol in patients with gout from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES) trial." | 5.51 | Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. ( Becker, MA; Borer, JS; Castillo, M; Gorelick, PB; Gunawardhana, L; Hunt, B; Saag, KG; Whelton, A; White, WB, 2022) |
| "Calcium supplementation (770 mg/d from dairy or calcium citrate) reduced serum urate concentrations, suggesting that the gout-protective effect of low-fat dairy consumption is at least partly due to a urate-lowering effect of calcium." | 5.51 | Urate-lowering effect of calcium supplementation: Analyses of a randomized controlled trial. ( Alfenas, RCG; Alves, RDM; Bittencourt, JM; Cândido, FG; Freitas, DMO; Rocha, DMUP, 2022) |
| "The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion; however, the standard urate-lowering therapy (ULT) recommendation is first-line xanthine oxidase inhibitor (XOI), irrespective of the cause of hyperuricemia." | 5.51 | Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion. ( Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X, 2022) |
| "Allopurinol is a urate-lowering therapy used to treat patients with gout." | 5.51 | Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. ( Avery, AJ; Barr, RJ; Begg, AG; Duce, SL; Dumbleton, JS; Ford, I; Greenlaw, N; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; Pigazzani, F; Ritchie, LD; Rogers, A; Rooke, ED; Struthers, AD; Taggar, JS; Townend, JN; Walker, A; Wei, L, 2022) |
| "The present study compared the efficacy and safety of low-dose febuxostat versus allopurinol in chronic kidney disease (CKD) patients complicated with hyperuricemia (HUA)." | 5.51 | Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. ( Cao, B; Yang, N, 2022) |
| " One hundred and ninety-seven adults with gout and SUA levels ≥8 mg/dL were randomized to febuxostat or allopurinol in a 1:1 ratio for 36 weeks." | 5.51 | Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study. ( Borghi, C; Desideri, G; Gerritsen, M; Giannattasio, C; Nurmohamed, MT; Rajzer, M; Tausche, AK, 2022) |
| "Early allopurinol initiation during an acute gout flare did not lead to significant changes in time to resolution, flare recurrence, and inflammatory markers." | 5.51 | Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial. ( Manavathongchai, S; Pongsittisak, W; Satpanich, P, 2022) |
| "Gout is the most common inflammatory arthritis worldwide, and patients experience a heavy burden of cardiovascular and metabolic diseases." | 5.51 | mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? ( Broen, JCA; Jansen, M; Merriman, T; Ottria, A; Phipps-Green, A; Radstake, TRDJ; Schuiveling, M; van der Linden, M; van Lochem, E; Vazirpanah, N; Wichers, CGK; Zimmermann, M, 2019) |
| "Gout is a chronic disease associated with deposition of monosodium urate crystals and accompanied by diabetes, hypertension, and dyslipidemia." | 5.48 | Effect of fenofibrate on uric acid level in patients with gout. ( Choi, Y; Jung, JY; Kim, HA; Suh, CH; Yoon, D, 2018) |
| "Gout is a painful disorder which does not have an efficient delivery system for its treatment." | 5.46 | Oral delivery of allopurinol niosomes in treatment of gout in animal model. ( Kaithwas, G; Kanoujia, J; Parashar, P; Saraf, SA; Singh, N; Tripathi, CB, 2017) |
| "This network meta-analysis demonstrated an important absolute benefit of dotinurad 4 mg once daily to achieve target serum uric acid and low risk of adverse events for drug treatment of gout or hyperuricemia patients." | 5.41 | Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis. ( Chen, LR; Guo, Y; He, GH; Jiang, FF; Li, YJ; Qian, K; Wang, P; Yang, M; Yang, ZL; Yin, SJ, 2023) |
| " Gout is the most common inflammatory arthritis worldwide and starts with the crystallization of uric acid within the joints and soft tissues." | 5.41 | Amyloid A amyloidosis on medullary sponge kidney in a 28-year-old male with gout: A case report and literature review. ( Acikalin, MF; Kasifoglu, T; Yilmaz, F, 2023) |
| "Gout is common in patients with heart failure (HF), and sodium-glucose cotransporter 2 inhibitors, a foundational treatment for HF, reduce uric acid levels." | 5.41 | Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. ( Butt, JH; Claggett, BL; de Boer, RA; Desai, AS; Docherty, KF; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Ponikowski, P; Sabatine, MS; Shah, SJ; Solomon, SD; Vaduganathan, M, 2023) |
| "Theaflavins exert anti-gout effects by down regulating the gene and protein expression of glucose transporter 9 (GLUT9) and uric acid transporter 1 (URAT1), while upregulating the mRNA expression levels of organic anion transporter 1 (OAT1), organic cation transporter N1 (OCTN1), organic cation transporters 1/2 (Oct1/2), and organic anion transporter 2 (OAT2)." | 5.41 | Mechanisms of theaflavins against gout and strategies for improving the bioavailability. ( Chen, J; Gong, S; Hu, J; Li, X; Ma, L; Yu, H; Zheng, Y; Zheng, Z, 2023) |
| "Gout is a common inflammatory arthritis caused by increased serum uric acid levels." | 5.41 | The Chinese patent medicine Tongfengding capsule for gout in adults: a systematic review of safety and effectiveness. ( Hua, Q; Lin, Y; Liu, X; Luo, Y; Xia, A; Yang, Q; Zheng, K, 2023) |
| "Xanthine oxidase inhibitors such as allopurinol and febuxostat have been the mainstay urate-lowering therapy (ULT) for treating hyperuricaemia in patients with gout." | 5.41 | Mechanisms and rationale for uricase use in patients with gout. ( Lioté, F; Pérez-Ruiz, F; Schlesinger, N, 2023) |
| "Gout is a common inflammatory arthritis caused by persistently elevated uric acid levels." | 5.41 | Gout therapeutics and drug delivery. ( Boucetta, H; Chen, Z; He, W; Lai, Y; Li, X; Peng, X; Sosnik, A; Xie, B, 2023) |
| " This review article focuses on the relationship between uric acid and thirteen specific domains: transporters, genetic factors, diet, lifestyle, gout, diabetes mellitus, metabolic syndrome, atherosclerosis, hypertension, kidney diseases, cardiovascular diseases, neurological diseases, and malignancies." | 5.41 | Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases. ( Abe, K; Akashi, N; Aoki, Y; Fukuuchi, T; Hisatome, I; Ichida, K; Kurajoh, M; Kuwabara, M; Maruhashi, T; Miyata, H; Mizuta, E; Morikawa, N; Morita, M; Nishimiya, K; Ogino, K; Otani, N; Ouchi, M; Takada, T; Tanaka, A; Tanaka, Y; Tsutani, H, 2023) |
| "Thirty-nine subjects with persistent hyperuricemia were randomized to receive curcumin (500-mg capsules twice daily, 20 subjects) or placebo (19 subjects)." | 5.41 | Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial. ( Asavatanabodee, P; Bupparenoo, P; Chaiamnuay, S; Narongroeknawin, P; Pakchotanon, R, 2021) |
| "To examine the efficacy and safety of pegloticase in combination with methotrexate (MTX) in patients with uncontrolled gout in an exploratory, open-label clinical trial (ClinicalTrials." | 5.41 | Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). ( Bennett, R; Botson, JK; Kenney, HM; LaMoreaux, B; Obermeyer, K; Peloso, PM; Peterson, J; Tesser, JRP; Weinblatt, ME, 2021) |
| "Our objective was to determine whether initiation of febuxostat during an acute gout flare prolongs the current episode." | 5.41 | Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial. ( Cui, X; Geng, H; Jia, E; Jiang, Y; Li, B; Ma, W; Qiu, X; Wei, J; Xiao, M; Xiao, Y; Xie, J; Yao, X; Zhang, J; Zhang, Y; Zhong, L, 2021) |
| "Urate crystal gout arthritis and calcium pyrophosphate deposition disease (CPPD) are crystalline arthropathies seen in middle age to elderly patients, but are also seen in the active duty military population." | 5.41 | 20 Years of Radiographic Imaging: Crystalline Deposits Causing Severe Arthropathy and Erosions. ( Babb, S; Breighner, C; Goldstein, E; Mank, VMF; Meghpara, S; Roberts, J, 2023) |
| "Hip fractures were not significantly associated with UA." | 5.40 | Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study. ( Cawthon, PM; Lane, NE; Lay, YA; Lui, LY; Orwoll, E; Parimi, N; Wise, BL; Yao, W, 2014) |
| "Gout is a metabolic disorder associated with hyperuricemia resulting in the deposition of monosodium urate (MSU) crystals in joints and tissues." | 5.40 | Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation. ( Cao, L; Ding, G; Guo, CR; Huang, WZ; Meng, ZQ; Tang, ZH; Wang, KD; Wang, ZZ; Xiao, W; Yan, YX; Yang, ZL, 2014) |
| "Because refractory gout is associated with high oxidative stress in spite of high PUA, and profoundly depleting uric acid did not increase lipid or protein oxidation, we conclude that urate is not a major factor controlling oxidative stress in vivo." | 5.36 | Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. ( Ganson, NJ; Hershfield, MS; Jaggers, D; Kelly, SJ; Roberts, LJ; Santisteban, I; Scarlett, E; Sundy, JS, 2010) |
| "Dotinurad, a novel selective urate reabsorption inhibitor (SURI) that has a future potential for the treatment of hyperuricemia, reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1)." | 5.34 | Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 stu ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020) |
| "Dotinurad, a novel selective urate reabsorption inhibitor (SURI), reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1) for the treatment of hyperuricemia with or without gout." | 5.34 | Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020) |
| "Dotinurad at doses of 2-4-mg sufficiently reduced serum uric acid levels in hyperuricemic patients with or without gout, and its efficacy and safety were verified for long-term administration." | 5.34 | Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout. ( Fushimi, M; Hosoya, T; Ohashi, T; Okui, D; Sasaki, T, 2020) |
| " We evaluated the efficacy and safety of dotinurad versus febuxostat, a widely used drug in Japan, in hyperuricemic Japanese patients with or without gout." | 5.34 | A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. ( Furuno, K; Hosoya, T; Kanda, S, 2020) |
| "Dotinurad 2 mg was verified to have a non-inferior serum uric acid lowering effect compared with benzbromarone 50 mg, in Japanese hyperuricemic patients with or without gout." | 5.34 | Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020) |
| "Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout." | 5.34 | Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. ( De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Nuki, G; Perez-Ruiz, F; Ralston, SH; Robertson, M; Walters, M; Webster, J, 2020) |
| "Gout is a metabolic disorder that results in hyperuricemia and the deposition of positively birefringent monosodium urate crystals in various parts of the body." | 5.33 | Gout induced by intoxication of sodium bicarbonate in Korean native broilers. ( Ejaz, S; Kim, BS; Lim, CW, 2005) |
| "Episodes of gout are common in the setting of renal transplantation." | 5.31 | Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. ( Dittmer, I; Faire, B; Pilmore, HL, 2001) |
| "To compare the efficacy and safety of low-dose febuxostat with low-dose benzbromarone in patients with primary gout, a randomized controlled, open-label trial was performed among male patients with primary gout for urate-lowering therapy (ULT) in a dedicated gout clinic in China." | 5.30 | Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. ( Cheng, X; Cui, L; He, Y; Ji, A; Li, C; Li, H; Liang, N; Ma, L; Sun, M; Sun, R; Sun, W; Wang, C; Wu, X; Xu, T; Xue, X; Yuan, X; Zhang, H, 2019) |
| "To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function." | 5.30 | Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019) |
| "Lesinurad [Zurampic; 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)], a selective inhibitor of uric acid reabsorption transporters approved for the treatment of gout, is a racemate of two atropisomers." | 5.30 | Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers. ( Girardet, JL; Lee, CA; Miner, JN; Renner, M; Shen, Z; Wilson, DM; Yang, C; Zhou, D, 2019) |
| "We conducted a site-randomized trial (n=1463 patients) comparing a 1-year, pharmacist-led intervention to usual care in patients with gout initiating allopurinol." | 5.30 | Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. ( Cheetham, TC; Chen, L; Coburn, BW; Curtis, JR; Foster, PJ; Kerimian, A; Levy, GD; Low, KJ; Mikuls, TR; Rashid, N; Redden, DT; Saag, KG, 2019) |
| "URC102, a novel and potent inhibitor of human uric acid transporter 1 (hURAT1), is currently under clinical development to treat patients with gout." | 5.30 | URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers. ( Ahn, Y; Lee, H; Lee, HA; Onohara, M; Park, SI; Yoon, S; Yu, KS, 2019) |
| "To examine whether allopurinol dose escalation to achieve serum urate (SU) target can influence bone erosion or monosodium urate (MSU) crystal deposition, as measured by dual-energy computed tomography (DECT) in patients with gout." | 5.30 | Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial. ( Aati, O; Allan, J; Billington, K; Dalbeth, N; Doyle, A; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2019) |
| "Gout is an acute rheumatic disorder that occurs in connection with the deposition of monosodium urate (MSU) crystals in the joints." | 5.30 | Altered arachidonic acid metabolism in urate crystal induced inflammation. ( Duffin, KL; Gregory, SA; Isakson, PC; Margalit, A; Shaffer, AF, 1997) |
| "To determine whether febuxostat with stepwise dose increase is as useful as colchicine prophylaxis in reducing gout flares during the initial introduction of urate-lowering therapy in patients with gout in comparison with febuxostat with no dose titration." | 5.27 | Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. ( Fujimori, S; Hidaka, Y; Ide, Y; Inoue, K; Kim, H; Sugimoto, M; Tamaki, S; Taniguchi, A; Yamamoto, T; Yamanaka, H, 2018) |
| "6 years) with hyperuricemia (fasting serum uric acid ≥0." | 5.27 | Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II. ( Davis, TME; Davis, WA; Drinkwater, JJ; Keen, HI; Latkovic, E; Nossent, J, 2018) |
| " We did a post-hoc analysis of recorded on-study gout attacks and plasma uric acid concentrations according to treatment allocation." | 5.27 | Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. ( Ansquer, JC; Best, JD; Buizen, L; d'Emden, MC; Davis, TME; Feher, MD; Flack, J; Foucher, C; Gebski, V; Hedley, J; Jenkins, AJ; Keech, AC; Kesaniemi, YA; Li, L; McGill, N; Scott, RS; Sullivan, DR; Waldman, B, 2018) |
| "Gout patients do not routinely achieve optimal outcomes related in part to suboptimal administration of urate lowering therapy (ULT) including first-line xanthine oxidase inhibitors allopurinol or febuxostat." | 5.27 | Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial. ( Brittan, K; Brophy, M; Davis-Karim, A; Henrie, AM; Mikuls, TR; Neogi, T; Newcomb, J; O'Dell, JR; Palevsky, PM; Pillinger, MH; Pittman, D; Taylor, TH; Timilsina, S; Wu, H, 2018) |
| "The objective of the study was to evaluate the effect of lesinurad, a selective uric acid uptake inhibitor, alone and in combination with the xanthine oxidase inhibitor allopurinol, on serum uric acid and urinary urate excretion in patients with gout and hyperuricemia." | 5.27 | The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout. ( Baumgartner, S; Kerr, B; Manhard, K; Quart, B; Shen, Z; Yeh, LT, 2018) |
| "Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for treatment of hyperuricemia and gout." | 5.27 | Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout. ( Clauson, V; Gillen, M; Hall, J; Kankam, M; Lee, C; Liu, S; Miner, JN; Nguyen, M; Shen, Z; Walker, S; Wilson, D; Yang, X, 2018) |
| "Japanese male subjects aged 21-65 years with gout (n = 37) or asymptomatic hyperuricaemia (n = 35) and serum urate (sUA) ⩾8 mg/dl were randomized to febuxostat (10, 20, 40 mg) in combination with verinurad (2." | 5.27 | Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. ( Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X, 2018) |
| "To determine factors that predict inadequate serum urate (SU) lowering response in a randomized controlled trial of allopurinol dose escalation (DE) in gout." | 5.27 | Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. ( Barclay, M; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2018) |
| "The aim of this research work was to observe and analyze the efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia." | 5.27 | The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia. ( Wang, S, 2018) |
| "This multicenter, open-label study evaluated the efficacy and safety of long-term twice-daily oral topiroxostat administration in patients with or without gout." | 5.27 | Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout. ( Hosoya, T; Ishikawa, T; Ogawa, Y; Ohashi, T; Sakamoto, R, 2018) |
| "Gout is principally a disease of middle-aged men." | 5.26 | Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family. ( Cameron, JS; Dillon, MJ; Farebrother, DA; Pincott, JR; Simmons, HA; Warren, DJ, 1981) |
| " People with gout receiving at least creatinine clearance (CrCL)-based allopurinol dose for ≥1 month and SU ≥6 mg/dL were recruited." | 5.24 | A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. ( Barclay, ML; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017) |
| "To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12-month phase III trial in patients with tophaceous gout." | 5.24 | Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. ( Adler, S; Baumgartner, S; Bhakta, N; Dalbeth, N; Fung, M; Jones, G; Khanna, D; Kopicko, J; Perez-Ruiz, F; Storgard, C; Terkeltaub, R, 2017) |
| "There is little evidence guiding selection of nondiuretic, antihypertensive agents with a goal of lowering uric acid (SUA) and minimizing gout risk." | 5.24 | Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. ( Appel, LJ; Juraschek, SP; Miller, ER, 2017) |
| "To determine the long-term safety and efficacy of allopurinol dose escalation (DE) to achieve target serum urate (SU) in gout." | 5.24 | Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. ( Barclay, M; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017) |
| "In this double-blind, placebo-controlled study, 314 subjects with hyperuricemia (serum uric acid [UA] level of ≥7." | 5.24 | Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. ( Choi, HK; Dalbeth, N; Gunawardhana, L; Hunt, B; MacDonald, PA; Palmer, WE; Saag, KG; Thienel, U, 2017) |
| "The use of allopurinol in people with chronic kidney disease (CKD) remains one of the most controversial areas in gout management." | 5.24 | The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial. ( Barclay, M; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017) |
| "Our objectives were to determine whether a change in serum uric acid (sUA) resulted in a corresponding change in the fractional excretion of uric acid (FEUA) and whether the renal response was different in patients with gout versus healthy subjects." | 5.24 | Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. ( Liu, S; Miner, JN; Perez-Ruiz, F, 2017) |
| "Lesinurad added to allopurinol demonstrated superior sUA lowering versus allopurinol-alone therapy and lesinurad 200 mg was generally well tolerated in patients with gout warranting additional therapy." | 5.24 | Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). ( Adler, S; Bardin, T; Baumgartner, S; Bhakta, N; Fung, M; Keenan, RT; Khanna, PP; Kopicko, J; So, A; Storgard, C, 2017) |
| "Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used in Japan for the treatment of hyperuricemic patients with or without gout." | 5.24 | Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. ( Hosoya, T; Ohashi, T; Sasaki, T, 2017) |
| " Cox proportional hazard ratio was used to compare the risk of CAD in gout patients taking allopurinol or/and benzbromarone with those taking neither drug." | 5.24 | Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study. ( Chiang, SJ; Daimon, M; Ho, Y; Lin, HC; Uang, YS; Wang, CH; Wang, LH, 2017) |
| "In the double-blind, randomized, controlled trial, we aimed to evaluate the effects of compound tufuling oral liquid (CoTOL) on serum uric acid (sUA) levels and recurrence of acute gouty arthritis in intercritical and chronic gout treatment." | 5.24 | Hypouricemic and arthritis relapse-reducing effects of compound tufuling oral-liquid in intercritical and chronic gout: A double-blind, placebo-controlled, multicenter randomized trial. ( Fan, Y; Gao, X; Han, Y; Jing, X; Li, X; Li, Y; Sun, J; Tang, X; Wen, C; Wu, H; Xie, Z, 2017) |
| "Allopurinol has been universally successful in lowering the serum uric acid concentration and uric acid excretion to normal levels, while not significantly affecting the clearance of urate or other aspects of renal function." | 5.24 | The treatment of gout and disorders of uric acid metabolism with allopurinol. ( Houpt, JB; Ogryzlo, MA; Urowitz, MB; Weber, HM, 1966) |
| "We aimed to assess the relative efficacy and safety of dotinurad (2 mg), benzbromarone (50 mg), and febuxostat (40 mg) in hyperuricemic patients with or without gout." | 5.22 | Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. ( Lee, YH; Song, GG, 2022) |
| "We aimed to assess the relative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout." | 5.22 | Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. ( Lee, YH; Song, GG, 2022) |
| "Refractory, or uncontrolled, gout is a chronic, progressive, inflammatory arthropathy resulting from continued urate deposition after failed attempts to lower serum uric acid below the therapeutic threshold with oral urate-lowering therapies such as allopurinol and febuxostat." | 5.22 | Enhancing the Response Rate to Recombinant Uricases in Patients with Gout. ( LaMoreaux, B; Padnick-Silver, L; Schlesinger, N, 2022) |
| "Increased serum uric acid (SUA) levels are commonly seen in patients with metabolic syndrome and are widely accepted as risk factors for hypertension, gout, non-alcoholic fatty liver disease, chronic kidney disease (CKD), and cardiovascular diseases." | 5.22 | Uric acid in metabolic syndrome: Does uric acid have a definitive role? ( Copur, S; Demiray, A; Kanbay, M, 2022) |
| "We thoroughly searched five electronic resource databases for randomized controlled trials (RCTs) that compared the efficacy and safety of allopurinol versus conventional treatment or placebo for the treatment of patients with diabetes mellitus." | 5.22 | Effects of allopurinol on renal function in patients with diabetes: a systematic review and meta-analysis. ( Cai, Y; Liu, WJ; Liu, Y; Luo, Q; Tian, L; Zhao, Q, 2022) |
| "Uric acid (UA) is the final product of purine metabolism in the human body, and impaired purine metabolism can increase the uric acid in serum, finally resulting in hyperuricemia (HUA)." | 5.22 | Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights. ( Dong, B; Geng, Z; Mei, Y; Xu, L, 2022) |
| "Gout is well known as an inflammatory rheumatic disease presenting with arthritis and abnormal metabolism of uric acid." | 5.22 | Gout and Diet: A Comprehensive Review of Mechanisms and Management. ( Chen, S; Xu, H; Xu, Y; Yuan, M; Zhang, Y, 2022) |
| "Alcohol is recognized a risk factor for increased uric acid and gout flare." | 5.22 | The role of alcohol consumption in pathogenesis of gout. ( Nieradko-Iwanicka, B, 2022) |
| "This phase IIIB study compared the efficacy and safety of febuxostat and allopurinol in gout patients with or without tophi who were HLA-B*5801 negative." | 5.22 | Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. ( Chen, CJ; Chen, DY; Hsu, PN; Lai, JH; Lin, HY; Yu, KH, 2016) |
| "Control of serum uric acid (sUA) levels is very important during chemotherapy in patients with malignant tumors, as the risks of tumor lysis syndrome (TLS) and renal events are increased with increasing levels of sUA." | 5.22 | Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. ( Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T, 2016) |
| "In Japan, although topiroxostat, a selective xanthine oxidoreductase inhibitor, has been used for the treatment of patients with hyperuricemia including gout, no published randomized controlled studies evaluating the dose-dependent relationship with respect to the serum urate-lowering efficacy have been reported." | 5.22 | Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. ( Hashimoto, H; Hosoya, T; Ohashi, T; Sakamoto, R; Sasaki, T, 2016) |
| " Patients who had inadequate serum urate levels (a gout patient: serum urate level ≥416·4 μmol/L; an asymptomatic hyperuricemic patient with specific complications (urinary lithiasis, hypertension, hyperlipidemia and/or diabetes): serum urate level ≥475·8 μmol/L; and an asymptomatic hyperuricemic patient with no specific complications: serum urate level ≥535·3 μmol/L) were randomized to topiroxostat 120 mg/day or allopurinol 200 mg/day, with an equal allocation ratio, for 16 weeks." | 5.22 | Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. ( Hashimoto, H; Hosoya, T; Ogawa, Y; Ohashi, T; Sakamoto, R, 2016) |
| " This is a large pragmatic cluster-randomized trial designed to assess a highly automated, pharmacist-led intervention to optimize allopurinol treatment in gout." | 5.22 | Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study. ( Bridges, SL; Chang, JM; Cheetham, TC; Coburn, BW; Curtis, JR; Kerimian, A; Levy, GD; Low, KJ; Mikuls, TR; Rashid, N; Redden, DT; Saag, KG, 2016) |
| "Excess body burden of uric acid promotes gout." | 5.22 | Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. ( Girardet, JL; Hagerty, DT; Hyndman, D; Iverson, C; Liu, S; Manhard, K; Miner, JN; Nanavati, P; Quart, B; Shen, Z; Tan, PK; Terkeltaub, R; Yeh, LT, 2016) |
| "Traditionally, allopurinol is not initiated during an acute gout attack to avoid prolonging the painful arthritis." | 5.20 | Does starting allopurinol prolong acute treated gout? A randomized clinical trial. ( Collamer, A; Higgs, J; Hill, EM; Sit, M; Sky, K, 2015) |
| "To compare the efficiency and safety of febuxostat with those of allopurinol in Chinese patients with gout and hyperuricemia." | 5.20 | A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. ( Chen, S; Ji, H; Ji, Q; Lin, J; Liu, B; Liu, H; Liu, P; Liu, X; Lu, Y; Ming, J; Peng, Y; Wang, J; Wang, Y; Xu, S; Zhang, Y, 2015) |
| "Allopurinol is the most widely prescribed serum uric acid-lowering therapy (ULT) in gout." | 5.20 | An open-label, 6-month study of allopurinol safety in gout: The LASSO study. ( Baumgartner, S; Becker, MA; Choi, HK; Cravets, M; Dalbeth, N; Fitz-Patrick, D; Storgard, C, 2015) |
| "We prospectively evaluated whether an effective 12-month uric acid-lowering therapy (ULT) with the available xanthine oxidase (XO) inhibitors allopurinol and febuxostat in patients with chronic tophaceous gout has an impact on oxidative stress and/or vascular function." | 5.19 | As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. ( Aringer, M; Bielitz, C; Christoph, M; Forkmann, M; Kopprasch, S; Richter, U; Tausche, AK; Wunderlich, C, 2014) |
| "Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout." | 5.19 | Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. ( Fujimori, S; Hara, S; Hisatome, I; Hosoya, T; Nomura, S; Ohno, I; Uchida, S; Yamamoto, T, 2014) |
| "Gout patients (n = 512) with serum uric acid (sUA) concentrations of at least 8." | 5.19 | An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. ( Bao, C; Du, H; Gu, J; Huang, A; Huang, X; Jiang, L; Li, J; Li, X; Li, Z; Liu, Y; Zhang, Y; Zhang, Z; Zhao, D; Zhu, P; Zuo, X, 2014) |
| "The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout." | 5.19 | Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. ( Baumgartner, S; Fleischmann, R; Hingorani, V; Kerr, B; Manhard, K; Miner, JN; Polvent, E; Quart, B; Shen, Z; Suster, M; Yeh, LT, 2014) |
| "The aims of this study were to establish whether, in patients with gout, MPO is released from neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol." | 5.19 | Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia. ( Drake, J; Forbes, LV; Kettle, AJ; Khalilova, IS; Stamp, LK; Turner, R; Zhang, M, 2014) |
| "To evaluate the efficacy and safety of IL-1 inhibitor rilonacept (IL-1 Trap) for gout flare (GF) prevention during initiation of uric acid-lowering therapy (ULT) with allopurinol in a multiregional phase 3 clinical trial." | 5.17 | Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. ( Evans, RR; Fouche, L; King-Davis, S; Luo, SF; Mitha, E; Schumacher, HR; Wang, J; Weinstein, SP; Yancopoulos, GD, 2013) |
| "Assess the impact of urate-lowering therapy on renal function in subjects with gout who were treated with febuxostat for ≤ 48 months." | 5.17 | Preservation of renal function during gout treatment with febuxostat: a quantitative study. ( Chefo, S; Gunawardhana, L; MacDonald, PA; Whelton, A, 2013) |
| "To compare the characteristics of female versus male gout patients and assess urate-lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout." | 5.16 | Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. ( Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA, 2012) |
| "0 mg/dL) gout subjects were enrolled in the 6-month, double-blind, randomized, comparative CONFIRMS trial and randomized, 1:1:1, to receive febuxostat, 40 mg or 80 mg, or allopurinol (200 mg or 300 mg based on renal function) once daily." | 5.16 | The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. ( Hunt, B; Jackson, RL; MacDonald, PA, 2012) |
| "Twenty-three cases with gout receiving furosemide and allopurinol were recruited." | 5.16 | Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice. ( Barclay, ML; Chapman, PT; Drake, J; Frampton, C; O'Donnell, JL; Stamp, LK; Zhang, M, 2012) |
| "To evaluate the efficacy and safety of the interleukin-1 inhibitor rilonacept (interleukin-1 Trap) for gout flare prevention during initiation of uric acid-lowering therapy (ULT)." | 5.16 | Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. ( Clower, J; Evans, RR; Jennings, W; Saag, KG; Schumacher, HR; Terkeltaub, R; Wang, J; Weinstein, SP; Yancopoulos, GD, 2012) |
| "To determine the efficacy and safety of increasing the allopurinol dose above the proposed creatinine clearance-based dose in patients with gout." | 5.15 | Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. ( Barclay, ML; Chapman, PT; Frampton, C; James, J; O'Donnell, JL; Stamp, LK; Zhang, M, 2011) |
| "To investigate the pharmacokinetic and pharmacodynamic interaction between probenecid and oxypurinol (the active metabolite of allopurinol) in patients with gout." | 5.15 | Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ( Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2011) |
| "Hyperuricemia of gout can arise due to either overproduction or underexcretion of uric acid." | 5.15 | Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. ( Goldfarb, DS; Gunawardhana, L; Hunt, B; MacDonald, PA, 2011) |
| "Febuxostat or allopurinol was administered to patients with hyperuricemia including gout for 8 weeks to compare the efficacy and safety of these drugs." | 5.15 | An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p ( Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011) |
| ": A multicenter study with randomized, placebo-controlled, double-blind, parallel-group comparison was carried out to evaluate the efficacy and safety of febuxostat in 103 patients with hyperuricemia (including patients with gout) in Japan." | 5.15 | Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "A multicenter study with randomized, placebo-controlled, double-blind, parallel, intergroup comparison was carried out to evaluate the dose-response relationship, efficacy, and safety of febuxostat in 202 patients with hyperuricemia (including patients with gout) in Japan." | 5.15 | Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "Febuxostat was administered to patients with hyperuricemia including gout in Japan to compare its efficacy and safety with those of allopurinol." | 5.15 | An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "In previous clinical studies of hyperuricemia including gout, although serum uric acid (sUA) levels reduced to 6." | 5.15 | Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. ( Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011) |
| "Two replicate, randomized, double-blind, placebo-controlled trials (C0405 and C0406) were conducted between June 2006 and October 2007 at 56 rheumatology practices in the United States, Canada, and Mexico in patients with severe gout, allopurinol intolerance or refractoriness, and serum uric acid concentration of 8." | 5.15 | Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. ( Baraf, HS; Becker, MA; Edwards, NL; Gutierrez-Urena, SR; Hamburger, SA; Horowitz, Z; Huang, W; Lipsky, PE; Maroli, AN; Sundy, JS; Treadwell, EL; Vázquez-Mellado, J; Waltrip, RW; White, WB; Yood, RA, 2011) |
| "This 5-yr study assessed urate-lowering and clinical efficacy and safety of long-term febuxostat therapy in subjects with gout." | 5.14 | Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. ( Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009) |
| "Data collected from 2 randomized controlled clinical trials assessing the efficacy of etoricoxib or indomethacin for 7 days in acute gout were used to assess SU levels during acute gouty attacks." | 5.14 | Serum urate during acute gout. ( Norquist, JM; Schlesinger, N; Watson, DJ, 2009) |
| "The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8." | 5.14 | The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. ( Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF, 2010) |
| "To establish a benchmark for gout control using the proportion of patients with serum uric acid (SUA) < 0." | 5.14 | More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial. ( Arroll, B; Ben, C; Bennett, M; Dalbeth, N; Hettiarachchi, D; Shelling, G, 2009) |
| "Use of urate-lowering therapy (ULT), such as febuxostat or allopurinol, is recommended for the long-term management of hyperuricemia in patients with gout to reduce the incidence of acute flares." | 5.14 | Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. ( Hunt, B; Jackson, RL; Macdonald, PA; Wortmann, RL, 2010) |
| "To investigate the efficacy and tolerability of allopurinol as the first-choice antihyperuricaemic treatment for gout, and compare the efficacy and tolerability of benzbromarone and probenecid as second-choice treatment." | 5.14 | Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. ( Brouwers, JR; Delsing, J; Griep, EN; Hoekstra, M; Jansen, TL; Reinders, MK; van de Laar, MA; van Roon, EN, 2009) |
| "To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function." | 5.13 | Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. ( Becker, MA; Hunt, B; Joseph-Ridge, N; Lademacher, C; Macdonald, PA; Schumacher, HR; Streit, J; Wortmann, RL, 2008) |
| "Lower dosages of allopurinol are recommended to avoid toxicity in gout patients with impaired renal function." | 5.13 | Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. ( Angthararak, S; Panomvana, D; Sripradit, S, 2008) |
| "To evaluate the major cardiovascular (CV) events of febuxostat compared to allopurinol for the treatment of gout or asymptomatic hyperuricemia." | 5.12 | The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis. ( Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T, 2021) |
| " Elevated uric acid levels are risk factors for gout, hypertension, and chronic kidney diseases." | 5.12 | Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. ( Kimura, Y; Kono, H; Tsukui, D, 2021) |
| "This review aims to summarize recent evidence regarding the complex relationship between uric acid (UA), gout, and brain diseases." | 5.12 | Hyperuricemia, Gout, and the Brain-an Update. ( Dumurgier, J; Latourte, A; Paquet, C; Richette, P, 2021) |
| " Gout is a form of inflammatory arthritis which is characterized by an increase in the serum uric acid deposits in and around the joints of the extremities, the so called tophi." | 5.12 | Renal disorders in rheumatologic diseases: the spectrum is changing (part 2. Arthridides). ( Doria, A; Moroni, G; Ponticelli, C, 2021) |
| "To assess the efficacy and safety of the commonly used urate-lowering therapies (ULTs): febuxostat, allopurinol, and lesinurad in hyperuricemic patients with gout." | 5.12 | Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. ( Fan, M; Gu, J; Li, X; Liu, J; Schlesinger, N; Wu, X; Zhao, B, 2021) |
| "Uric acid, the end-product of purine metabolism in humans, is not only a cause of gout, but also may play roles in developing cardiovascular diseases such as hypertension, atrial fibrillation, chronic kidney disease, heart failure, coronary artery disease, and cardiovascular death." | 5.12 | Uric acid and cardiovascular disease: A clinical review. ( Kobayashi, Y; Node, K; Saito, Y; Tanaka, A, 2021) |
| "The treatment of gout with allopurinol is effective at reducing urate levels and the frequency of flares." | 5.12 | Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies. ( Hudson, M; Suissa, K; Suissa, S, 2021) |
| " It is noninferior to benzbromarone or febuxostat in reducing serum urate levels in hyperuricemic patients with or without gout." | 5.12 | Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. ( Hosoya, T; Ishikawa, T; Takahashi, T; Taniguchi, T, 2021) |
| "The description of gout dates back almost 5000 years, and scientific interest in uric acid increased when it was found to be involved in the pathogenesis of gout." | 5.12 | The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems. ( Agnoletti, D; Borghi, C; Cicero, AFG, 2021) |
| " Twenty-five patients with acute gout arthritis were randomized into two groups and treated over 5 days: group A, diclofenac 75 mg orally, twice a day; and group B, laser irradiation once a day." | 5.12 | Photobiomodulation of pain and inflammation in microcrystalline arthropathies: experimental and clinical results. ( Campana, V; Gavotto, A; Moya, M; Palma, J; Simes, J; Soriano, F; Soriano, M; Soriano, R; Spitale, L, 2006) |
| "Uric acid is a strong scavenger of reactive oxygen species, which are known to contribute to the development of atherosclerosis, while the incidence of atherosclerotic diseases is rather high in patients with gout." | 5.11 | Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy. ( Ka, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2004) |
| "72 cases of gouty renal damage were randomly divided into a treatment group of 42 cases and a control group of 30 cases to observe the therapeutic effects and the changes in 24-hour urinary protein content, blood creatinine, uric acid and urea nitrogen in blood before treatment and one month after treatment." | 5.11 | Clinical analysis for the acupuncture treatment in 42 cases of gouty renal damage. ( Ma, X, 2004) |
| "Benzbromarone is effective in lowering uric acid levels and in reducing the number of acute attacks of gout in patients who have failed optimal treatment." | 5.11 | Benzbromarone therapy in management of refractory gout. ( Gow, P; Kumar, S; Ng, J, 2005) |
| "Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout." | 5.11 | Febuxostat compared with allopurinol in patients with hyperuricemia and gout. ( Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Streit, J; Wortmann, RL, 2005) |
| "To evaluate metformin efficacy and safety in patients with gout and insulin resistance (IR)." | 5.11 | [Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)]. ( Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Kudaeva, FM; Nasonov, EL; Tsapina, TN; Volkov, AV; Zilov, AV, 2005) |
| "Sixty-three patients with crystal-confirmed tophaceous gout were treated with allopurinol, benzbromarone, or combined therapy to achieve serum uric acid levels less than the threshold for saturation of urate in tissues." | 5.10 | Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. ( Calabozo, M; Herrero-Beites, AM; Perez-Ruiz, F; Pijoan, JI; Ruibal, A, 2002) |
| "Chronic occupational exposure to lead is related to low urate excretion and a high incidence of gout in lead workers." | 5.10 | Environmental lead exposure and urate excretion in the general population. ( Ho, HH; Lin, JL; Tan, DT; Yu, CC, 2002) |
| "To assess the short-term urate-lowering effect of fenofibrate in men on long-term allopurinol therapy for hyperuricaemia and gout." | 5.10 | Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. ( Ball, SG; Feher, MD; Hepburn, AL; Hogarth, MB; Kaye, SA, 2003) |
| "We performed the present study to determine the degree of visceral fat accumulation and incidence of visceral fat obesity in 138 gout patients who were classified as overexcretion type (n = 53) and underexcretion type (n = 85) by their levels of uric acid clearance and urinary uric acid excretion." | 5.09 | Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout. ( Hada, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita , J; Yamamoto, T, 2001) |
| "To determine if lowering of serum uric acid (SUA) concentrations below 6 mg/dl or longer duration of lowered SUA will result in depletion of urate crystals from the knee joints and prevent further attacks of gout." | 5.09 | Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? ( Beutler, A; Clayburne, G; Eisner, E; Li-Yu, J; Rull, M; Schumacher, HR; Sieck, M, 2001) |
| "Uric acid overexcretion in patients with gout is frequently assessed by the measurement of 24 hour urinary uric acid excretion, which is cumbersome with ambulatory patients, and requires accurate timing and complete collection of the specimen." | 5.09 | Spot urine uric acid to creatinine ratio used in the estimation of uric acid excretion in primary gout. ( Hada, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 2001) |
| "It is known that chronic renal insufficiency (CRI) patients with gout may have subtle lead poisoning." | 5.09 | Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. ( Ho, HH; Lin, JL; Lin-Tan, DT; Yu, CC, 2001) |
| "To investigate whether allopurinol and benzbromarone affect the concentration of uridine in plasma, allopurinol or benzbromarone were administered to patients with gout for 3 to 6 months." | 5.08 | Effect of allopurinol and benzbromarone on the concentration of uridine in plasma. ( Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1997) |
| "The uric acid concentration in blood has been widely accepted as a diagnostic indicator of hyperuricemia and gout, and its assay method is well established." | 5.08 | Determination of uric acid in scalp hair for non-invasive evaluation of uricemic controls in hyperuricemia. ( Isaka, Y; Kobayashi, K; Morioka, Y; Tozawa, T, 1998) |
| "To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout." | 5.08 | Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. ( Alonso-Ruiz, A; Calabozo, M; García-Erauskin, G; Herrero-Beites, A; Perez-Ruiz, F; Ruiz-Lucea, E, 1998) |
| "The objectives of this study were to establish if, and to what extent, benzbromarone affects allopurinol/oxypurinol kinetics, and to compare the uric acid lowering capabilities of Allomaron (allopurinol 100 mg plus benzbromarone 20 mg) with the effects of allopurinol alone in patients with confirmed gout." | 5.07 | The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. ( Groenewoud, G; Hundt, HK; Müller, FO; Schall, R; van der Merwe, JC; van Dyk, M, 1993) |
| "Fifty patients with gout were randomly allocated to one of 2 groups receiving allopurinol, either continuously or for 2 months every year." | 5.06 | Intermittent control of hyperuricemia in the treatment of gout. ( Bull, PW; Scott, JT, 1989) |
| "This study compared the effects of azapropazone and indomethacin plus allopurinol in the management of acute gout and hyperuricaemia." | 5.06 | Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. ( Davis, RH; Fraser, RC; Walker, FS, 1987) |
| "Uric acid, the metabolic mediator of gout and urate renal stones, is associated with increased cardiovascular risk burden." | 5.05 | Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure. ( Borghi, C; Cosentino, E; Landolfo, M; Palazzuoli, A, 2020) |
| " Uric acid has anti-oxidant properties, but high levels predispose to gout and may play a role in metabolic syndrome." | 5.05 | Management of hyperuricemia in asymptomatic patients: A critical appraisal. ( Brucato, A; Carnovale, C; Cianci, F, 2020) |
| "Increased serum uric acid (SUA) levels cause gout and are associated with multiple diseases, including chronic kidney disease." | 5.05 | Polygenic analysis of the effect of common and low-frequency genetic variants on serum uric acid levels in Korean individuals. ( Chang, Y; Cho, SK; Kim, B; Kim, HL; Kim, HN; Kuo, PH; Myung, W; Ryu, S; Winkler, CA; Won, HH, 2020) |
| " While uric acid is usually discussed in the context of gout, hyperuricaemia is also associated with hypertension, chronic kidney disease, hypertriglyceridaemia, obesity, atherosclerotic heart disease, metabolic syndrome, and type 2 diabetes." | 5.05 | Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. ( Agabiti-Rosei, E; Borghi, C; Johnson, RJ; Kielstein, JT; Lurbe, E; Mancia, G; Redon, J; Stack, AG; Tsioufis, KP, 2020) |
| " Based on the patent literature of last five years, we can expect a burst of novel alternate compounds in the near future which could have the ability to reduce the uric acid level, by inhibiting XO enzyme in patients, which at the moment are striving hard to fight against the dreadful disease condition like gout." | 5.05 | Xanthine oxidase inhibitors: patent landscape and clinical development (2015-2020). ( Bedi, PMS; Sharma, S; Singh, H; Singh, JV, 2020) |
| "Hyperuricemia is a state in which the serum levels of uric acid are elevated." | 5.05 | Hyperuricemia, the heart, and the kidneys - to treat or not to treat? ( Bevc, S; Ekart, R; Hojs, R; Petreski, T, 2020) |
| " Here, we also review the clinical importance of altered ABCG2 expression and function in general drug metabolism, cancer multidrug resistance, and impaired uric acid excretion, leading to gout." | 5.05 | The ABCG2/BCRP transporter and its variants - from structure to pathology. ( Hegedűs, T; Homolya, L; Sarkadi, B, 2020) |
| "Uric acid, the end product of purine metabolism, plays a key role in the pathogenesis of gout and other disease processes." | 5.05 | Molecular Pathophysiology of Uric Acid Homeostasis. ( Estiverne, C; Mandal, AK; Mount, DB, 2020) |
| "The antihyperuricemic properties of amflutizole were investigated in studies designed to determine its efficacy and mechanisms of action in individuals with gout and hyperuricemia." | 5.05 | Antihyperuricemic properties of amflutizole in gout. ( Fox, IH; Lightfoot, RW; Ridolfo, AS; Wortmann, RL, 1985) |
| "Allopurinol was administered to seven patients with gout to compare the effects of three different methods of administration." | 5.04 | Single daily dose of allopurinol. ( Brewis, I; Ellis, RM; Scott, JT, 1975) |
| "The effect of daily administration of a single 300-mg tablet of allopurinol on serum urate levels was compared with the effect of divided doses of the drug (100 mg three times a day) in an open-labeled crossover trial of 20 patients with hyperuricemia and gout." | 5.04 | Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. ( Elion, GB; Robin, JA; Rodnan, GP; Tolchin, SF, 1975) |
| "Gout is characterized by high serum uric acid (SUA) levels and arthritis." | 5.01 | Impact of bariatric surgery on serum uric acid levels and the incidence of gout-A meta-analysis. ( Kaushal, S; Koura, A; Lim, B; Oo, AM; Rao, J; Syn, N; Yeo, C; Yeo, D, 2019) |
| "Gout is a systemic disease, characterized by the formation and deposition of crystals in tissues (mainly in and around the joints) of individuals with elevated serum uric acid levels." | 5.01 | Gout and arrhythmias: In search for causation beyond association. ( Angelidis, C; Deftereos, S; Giannopoulos, G, 2019) |
| "Efficacy was assessed by changes in serum urate (sUA), urinary uric acid, gout flare rates, and /or tophi." | 5.01 | Combination urate-lowering therapy in the treatment of gout: What is the evidence? ( Dalbeth, N; Perez-Ruiz, F, 2019) |
| "Advances in gout genetics have provided important molecular insights into disease pathogenesis, better characterized the pharmacogenetics of allopurinol, and raised the possibility of using genetic testing to provide personalized treatment for patients." | 5.01 | Genetic advances in gout: potential applications in clinical practice. ( Dalbeth, N; Merriman, TR; Tai, V, 2019) |
| "Pegloticase is a PEGylated uric acid specific enzyme indicated for the treatment of refractory gout." | 5.01 | Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature. ( Bessen, MY; Bessen, SY; Yung, CM, 2019) |
| "Concerns about the cardiovascular safety of febuxostat lead to reconsideration of the place of febuxostat in the management of gout." | 5.01 | The role of febuxostat in gout. ( Bardin, T; Richette, P, 2019) |
| "Gout is a disease characterized by abnormal metabolism of the uric acid, leading to undesired buildup of monosodium urate crystals affecting mainly the first metatarsal-phalangeal joint of the foot and less commonly other joints or the soft tissues of the body." | 5.01 | Rare Manifestation of Gout: Gouty Tophi in the Nose. ( IIliev, G; Ivanova, PP; Nedev, P; Popov, H, 2019) |
| " Cardioprotective benefits of allopurinol, a first-line agent for the treatment of gout, have been demonstrated to potentially prevent myocardial infarction, stroke, atrial fibrillation, and other cardiovascular diseases in observational studies in select populations." | 5.01 | Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy. ( Gupta, MK; Singh, JA, 2019) |
| "Previous epidemiological investigations have evaluated the association between gout, serum uric acid levels, and obstructive sleep apnea syndrome (OSAS), but with inconsistent results." | 5.01 | A meta-analysis of the association between gout, serum uric acid level, and obstructive sleep apnea. ( Cheng, C; Liang, M; Min, M; Rizeq, FK; Shi, T; Sun, C; Sun, Y; Zhang, Y, 2019) |
| "Purine metabolism in the circulatory system yields uric acid as its final oxidation product, which is believed to be linked to the development of gout and kidney stones." | 5.01 | Hyperuricemia and Cardiovascular Disease. ( Cheng, J; Huangfu, N; Wang, Y; Xu, Z; Zhang, D; Zhang, F; Zhang, S; Zhao, R; Zheng, W, 2019) |
| "We aimed to assess the relative efficacy and safety of once-daily administration of lesinurad in combination with xanthine oxidase inhibitor (XOI) in hyperuricemic patients with gout." | 5.01 | Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials . ( Lee, YH; Song, GG, 2019) |
| "This study aimed to examine whether the uric acid level or gout is causally associated with bone mineral density (BMD)." | 5.01 | Uric acid level, gout and bone mineral density: A Mendelian randomization study. ( Lee, YH; Song, GG, 2019) |
| " allopurinol was associated with the improved safety outcome and have comparable mortality and net clinical outcome in patients with hyperuricemia." | 5.01 | The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis. ( Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML, 2019) |
| "Lesinurad provides an additional option for people with gout unable to achieve target serum uric acid with XOI alone." | 4.98 | New urate-lowing therapies. ( Abhishek, A, 2018) |
| "Hyperuricemia (chronically elevated serum uric acid) is the main pathology underlying the development of gout, the most common inflammatory arthropathy." | 4.98 | ABCG2 as a therapeutic target candidate for gout. ( Fujita, K; Ichida, K, 2018) |
| "Gout develops in four stages beginning with an asymptomatic increase in blood levels of uric acid." | 4.98 | Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018) |
| "Gout and calcium pyrophosphate deposition disease (CPPD, pseudogout) are still the most frequent inflammatory arthritides in multimorbid elderly patients." | 4.98 | Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 1: Epidemiology and pathophysiology. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018) |
| " It arises through the deposition of uric acid crystals in joints as a result of hyperuricemia." | 4.95 | Treatment Options for Gout. ( Bleckwenn, M; Engel, B; Just, J; Weckbecker, K, 2017) |
| "Gout is a rheumatologic condition associated with elevated serum uric acid levels and deposition of monosodium urate crystals in joints and soft tissues." | 4.95 | Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares. ( Abazia, DT; Bridgeman, MB; Soskind, R, 2017) |
| "Gout is the most common form of inflammatory arthropathy and is caused by an excess of uric acid in the blood (hyperuricemia)." | 4.95 | Change gout: the need for a new approach. ( Punzi, L, 2017) |
| "This was a pooled analysis of phase III trials on allopurinol and febuxostat, including 4101 patients with gout and hyperuricemia." | 4.95 | Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. ( Cimmino, MA; Cutolo, M; Perez-Ruiz, F, 2017) |
| "The research progress of puerarin and its derivatives in anti-inflammatory and anti-gout activities was reviewed in this paper." | 4.95 | [Research progress of puerarin and its derivatives on anti-inflammatory and anti-gout activities]. ( Li, XP; Ma, YC; Xing, ZH; Zhang, B; Zhang, MD, 2017) |
| " In addition to education and a non-pharmacological management approach, urate-lowering therapy (ULT) should be considered from the first presentation of the disease, and serum uric acid (SUA) levels should be maintained at<6 mg/dL (360 µmol/L) and <5 mg/dL (300 µmol/L) in those with severe gout." | 4.95 | 2016 updated EULAR evidence-based recommendations for the management of gout. ( Bardin, T; Barskova, V; Becce, F; Castañeda-Sanabria, J; Coyfish, M; Doherty, M; Guillo, S; Jansen, TL; Janssens, H; Lioté, F; Mallen, C; Nuki, G; Pascual, E; Perez-Ruiz, F; Pimentao, J; Punzi, L; Pywell, T; Richette, P; So, A; Tausche, AK; Tubach, F; Uhlig, T; Zavada, J; Zhang, W, 2017) |
| "It appears that soluble uric acid has a much larger role to play than just being a risk factor for gout." | 4.95 | Factors modulating the inflammatory response in acute gouty arthritis. ( Cleophas, MC; Crişan, TO; Joosten, LA, 2017) |
| "[PubMed and Google Scholar databases] were search for all articles and trials published before 2016, using the key terms [hyperuricemia, gout, tophi, joint erosion, joint damage, treatment guidelines, American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), flare, comorbidity, epidemiology, adherence, serum uric acid (sUA), monosodium urate (MSU), <6 mg/dL, MSU crystal formation, as well as individual drug names and classes of treatments of interest (allopurinol, febuxostat, colchicine, non-steroidal anti-inflammatories (NSAIDs)]." | 4.95 | Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review. ( Keenan, RT, 2017) |
| "Lowering serum uric acid (SUA) levels can essentially cure gout; however, this is not widely practiced." | 4.95 | Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. ( Bolzani, A; Cheung, A; Choi, HK; Shiozawa, A; Szabo, SM, 2017) |
| "Recent evidence would indicate that high serum uric acid (SUA) levels can be a significant and independent risk factor for hypertension and cardiovascular diseases, such as ischemic heart disease and heart failure." | 4.93 | Uric acid lowering therapy in cardiovascular diseases. ( Iellamo, F; Romeo, F; Sposato, B; Volterrani, M, 2016) |
| "In patients with gout, serum uric acid (sUA) concentrations should be lowered at least below the target of 6 mg/dL (even below 5 mg/dL in patients with severe gout)." | 4.93 | Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. ( Borghi, C; Perez-Ruiz, F, 2016) |
| "Besides the well accepted need to treat hyperuricemia associated with gout, some large observational studies and small prospective therapeutic trials have suggested that treating asymptomatic hyperuricemia, especially by xanthine oxidase inhibition, the enzyme producing uric acid, could be beneficial for cardiovascular and renal risk prevention." | 4.93 | [HYPERURICEMIA AND POTENTIAL RISK OF CARDIOVASCULAR AND RENAL DISEASES]. ( Krzesinski, JM; Schils, R, 2016) |
| "Hyperuricemia (elevated serum uric acid) is prevalent, and an important mediator of gout, an increasingly common condition." | 4.93 | Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review. ( Jalal, DI, 2016) |
| " It is caused by factors that elevate the concentration of serum uric acid (sUA), leading to hyperuricemia (sUA >6." | 4.93 | Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL? ( Edwards, NL; Ruoff, G, 2016) |
| " In gout, inflammation arises from precipitation of uric acid in the form of needle-shaped monosodium urate crystals." | 4.91 | How neutrophil extracellular traps orchestrate the local immune response in gout. ( Hahn, J; Herrmann, M; Hoffmann, MH; Kienhöfer, D; Manger, B; Maueröder, C; Schauer, C; Schett, G, 2015) |
| "The goal of emerging therapies is to address the unsatisfactory control of serum uric acid in patients with symptomatic hyperuricemia such as those with gout, to provide better tolerability compared to traditional agents and minimize the risk of adverse events, especially in patients with comorbidities and the elderly." | 4.91 | Investigational drugs for hyperuricemia. ( Shahid, H; Singh, JA, 2015) |
| " Chondrocalcinosis is a radiographic entity characterized by deposits of calcium pyrophosphate crystals (CPP) within the fibrocartilage or hyalin cartilage." | 4.91 | [Gout and and calcium pyrophosphate crystal arthropathies: pathophysiology]. ( Albert, JD; Coiffier, G, 2015) |
| "In gouty patients, urate lowering therapies (ULTs) are recommended to bring serum uric acid (SUA) levels below 6." | 4.91 | Why focus on uric acid? ( Johnson, RJ, 2015) |
| " MSU nucleation was found to be increased by a number of factors, including sodium ions, uric acid binding antibodies, and synovial fluid or serum from patients with gout." | 4.91 | Factors influencing the crystallization of monosodium urate: a systematic literature review. ( Chhana, A; Dalbeth, N; Lee, G, 2015) |
| " Better understanding of the transporters URAT1 and ABCG2 in particular would appear to provide opportunities for more selective, better tolerated agents to increase the renal clearance of uric acid and thereby control hyperuricemia." | 4.90 | Uricosuric drugs: the once and future therapy for hyperuricemia? ( Bach, MH; Simkin, PA, 2014) |
| " The results of the meta-analysis showed that when gout had progressed to the stage of acute arthritis, there was no significant difference in clinical efficacy between Chinese herbal decoctions and traditional Western medicine, as indicated based on the following parameters: serum uric acid (standardized mean difference (SMD):0." | 4.90 | Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout. ( Chen, P; Cheng, D; Liu, L; Liu, X; Pettigrew, JC; Wu, Y; Yi, D; Zhang, Y; Zhou, L, 2014) |
| " The search terms were 'gout', 'gouty arthritis', 'hyperuricemia', 'uric acid', 'xanthine oxidase (XO) inhibitor', 'uricosuric', 'urate transporter 1(URAT1)' and 'glucose transporter 9 (GLUT9)'." | 4.90 | A review of phytotherapy of gout: perspective of new pharmacological treatments. ( Bochu, W; Ling, X, 2014) |
| " Most items showed a positive likelihood ratio (LR+) < 3, except for the following: response of arthritis to colchicine (LR+ 4." | 4.90 | Diagnostic value of clinical, laboratory, and imaging findings in patients with a clinical suspicion of gout: a systematic literature review. ( Andrès, M; Carmona, L; Falzon, L; Sivera, F; van der Heijde, DM, 2014) |
| "To systematically review the validity of serum uric acid (SUA) as a treatment target for patients with gout, and the clinimetric properties of the potential tools for monitoring these patients." | 4.90 | Treatment target and followup measures for patients with gout: a systematic literature review. ( Andrés, M; Carmona, L; Falzon, L; Sivera, F; van der Heijde, DM, 2014) |
| "Our review found low- to moderate-quality evidence indicating similar effects on withdrawals due to AEs and SAEs and incidence of acute gout attacks when allopurinol (100 to 600 mg daily) was compared with placebo, benzbromarone (100 to 200 mg daily) or febuxostat (80 mg daily)." | 4.90 | Allopurinol for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014) |
| "We considered all randomised controlled trials (RCTs) or quasi-randomised controlled trials (controlled clinical trials (CCTs)) that compared uricosuric medications (benzbromarone, probenecid or sulphinpyrazone) alone or in combination with another therapy (placebo or other active uric acid-lowering medication, or non-pharmacological treatment) in adults with chronic gout for inclusion." | 4.90 | Uricosuric medications for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014) |
| "This study aims to compare the urate-lowering response rate of febuxostat and allopurinol in gout patient using a model-based meta-analysis." | 4.90 | [A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient]. ( Li, L; Lu, W; Sun, Y; Zhou, TY, 2014) |
| " Twenty-five out of 41 trials, involving 23 different herbal prescriptions, found statistical significance in lowering serum uric acid level, and the overall effect from Chinese herbal medicine in inflammation relief is better than conventional therapies in 19 trials with 17 different prescriptions." | 4.89 | Chinese herbal medicine for gout: a systematic review of randomized clinical trials. ( Han, M; Li, XX; Liu, JP; Wang, YY, 2013) |
| "To evaluate the safety and efficacy of febuxostat compared to allopurinol for the treatment of chronic gout." | 4.89 | A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. ( Ehteshami-Afshar, A; Faruque, LI; Homik, J; Tjosvold, L; Tonelli, M; Wiebe, N, 2013) |
| "Traditionally, serum uric acid (SUA) has been implicated in acute gouty arthritis or chronic gouty arthropathy." | 4.89 | Hyperuricaemia: more than just a cause of gout? ( Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP, 2013) |
| " Concordantly, recent studies have revived the controversy over the role of circulating uric acid, hyperuricemia, and gout as an independent prognostic factor for cardiovascular morbidity and mortality." | 4.89 | Chronic hyperuricemia, uric acid deposit and cardiovascular risk. ( Cheli, P; Del Pinto, R; Desideri, G; Di Giosia, P; Ferri, C; Ferri, L; Grassi, D; Properzi, G, 2013) |
| "Febuxostat has been approved for the treatment of hyperuricemia in patients with/without gout." | 4.89 | Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. ( Chen, S; Cheng, Q; Li, Q; Liu, L; Luo, T; Lv, Q; Mei, M; Yang, S; Ye, P; Zhang, W, 2013) |
| "(a) To examine the latest information about renal tubular handling of uric acid, its genetic background and contribution to the causation of hyperuricemia." | 4.88 | Hyperuricemia, gout and the kidney. ( Gibson, T, 2012) |
| " The relationship between hyperuricemia and gout was first documented in the nineteenth century by Alfred Baring Garrod, who demonstrated deposits of uric acid crystals on a linen thread held dipped in acidified blood (the so-called "thread method")." | 4.88 | Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). ( Marson, P; Pasero, G, 2012) |
| "A number of epidemiological studies have reported an association between serum uric acid levels and a wide variety of high-risk conditions including hypertension, insulin resistance, and kidney and cerebro-cardiovascular disease." | 4.88 | Cardiovascular and renal effects of hyperuricaemia and gout. ( Leoncini, G; Pontremoli, R; Viazzi, F, 2012) |
| "Gout is a metabolic disorder of excess uric acid accumulation that manifests clinically as inflammatory arthritis, chronic arthropathy and the formation of deposits of uric acid known as tophi." | 4.88 | Pegloticase for treating refractory chronic gout. ( George, RL; Sundy, JS, 2012) |
| "In addition to its role as a metabolic waste product, uric acid has been proposed to be an important molecule with multiple functions in human physiologic and pathophysiologic processes and may be linked to human diseases beyond nephrolithiasis and gout." | 4.88 | Renal transport of uric acid: evolving concepts and uncertainties. ( Bobulescu, IA; Moe, OW, 2012) |
| "Gout is a metabolic disorder of purine metabolism and uric acid elimination." | 4.88 | Safety of urate-lowering therapies: managing the risks to gain the benefits. ( Keenan, RT, 2012) |
| "The approval of febuxostat, a non-purine-analogue inhibitor of xanthine oxidase, by the European Medicines Agency and the US Food and Drug Administration heralds a new era in the treatment of gout." | 4.87 | Gout therapeutics: new drugs for an old disease. ( Burns, CM; Wortmann, RL, 2011) |
| " Recent findings support the notion that the physiological function of ABCG2 is involved in the elimination of uric acid resulting in higher risk for developing gout in male patients harboring genetic variants." | 4.87 | In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). ( Kroemer, HK; Meyer zu Schwabedissen, HE, 2011) |
| " Identifying monosodium urate (MSU) and calcium pyrophosphate dehydrate (CPPD) crystals allows a quick and definitive diagnosis of both gout and CPPD arthritis, and remains the accepted gold standard." | 4.87 | Synovial fluid analysis for crystals. ( Andrés, M; Pascual, E; Sivera, F, 2011) |
| "Through the use of a systematic computer-based literature analysis, this pharmacoeconomic review evaluated costs, risks, and benefits of Colcrys (colchicine) compared with other treatments for gout in the US." | 4.87 | A new perspective on the pharmacoeconomics of colchicine. ( Davis, MW; Lauterio, TJ; Wertheimer, AI, 2011) |
| "In France, colchicine remains the standard treatment for the acute flare of gout." | 4.87 | [Treatment of gout]. ( Dubost, JJ; Mathieu, S; Soubrier, M, 2011) |
| "High uric acid (UA) levels can cause gout, urolithiasis and acute and chronic nephropathy, all of which are due to the deposit of urate crystals." | 4.87 | Is there anything good in uric acid? ( Alvarez-Lario, B; Macarrón-Vicente, J, 2011) |
| "Many patients with acute gout (11%-49%) have normal serum uric acid (SUA) levels." | 4.87 | Clinical inquiry. Are serum uric acid levels always elevated in acute gout? ( Fletcher, A; Leiszler, M; Poddar, S, 2011) |
| "During the past few decades, the mean serum uric acid levels and the prevalence of hyperuricemia in the general population appear to have increased." | 4.87 | The epidemiology of uric acid and fructose. ( Choi, HK; Rho, YH; Zhu, Y, 2011) |
| "Gout is a common metabolic disorder characterized by elevated uric acid leading to the formation and accumulation of uric acid crystals in synovial fluids." | 4.86 | Update on biology: uric acid and the activation of immune and inflammatory cells. ( Martinon, F, 2010) |
| "Uric acid crystals, the causative agent of gout, have recently gained widespread attention due to their role as a natural endogenous adjuvant." | 4.86 | Recent developments in immune activation by uric acid crystals. ( Chau, EM; Ng, G; Shi, Y, 2010) |
| " Chronic hyperuricemia (uric acid serum levels >6." | 4.86 | Crystal arthropathies: recognizing and treating "the gouch". ( Quillen, DM, 2010) |
| "Uric acid has historically been viewed as a purine metabolic waste product excreted by the kidney and gut that is relatively unimportant other than its penchant to crystallize in joints to cause the disease gout." | 4.85 | Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society? ( Benner, SA; Gabriela Sanchez-Lozada, L; Johnson, RJ; Mu, W; Nakagawa, T; Oliver, WJ; Rodriguez-Iturbe, B; Roncal, C; Sautin, YY, 2009) |
| " However, detection of SF monosodium urate and calcium pyrophosphate dihydrate crystals, even from un-inflamed joints during intercritical periods, allow a precise diagnosis of gout and of calcium pyrophosphate crystal-related arthritis." | 4.85 | Joint aspiration and injection and synovial fluid analysis. ( Courtney, P; Doherty, M, 2009) |
| "Elevated serum uric acid levels cause gout and are a risk factor for cardiovascular disease and diabetes." | 4.85 | Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. ( Adamski, J; Albrecht, E; Aulchenko, Y; Beckmann, JS; Bergmann, S; Bochud, M; Brown, M; Campbell, H; Caulfield, M; Connell, J; Doering, A; Dominiczak, A; Farrall, M; Gieger, C; Gyllensten, U; Homuth, G; Illig, T; Johansson, A; Johnson, T; Kolz, M; Lamina, C; Mangino, M; McCarthy, MI; Meitinger, T; Mooser, V; Munroe, P; Nagaraja, R; Nauck, M; Nyholt, DR; Peden, J; Peltonen, L; Perola, M; Pramstaller, P; Prokisch, H; Rudan, I; Salo, P; Salomaa, V; Samani, NJ; Sanna, S; Schlessinger, D; Spector, TD; Teumer, A; Uda, M; Vitart, V; Völker, U; Vollenweider, P; Völzke, H; Waeber, G; Wallace, C; Wang-Sattler, R; Waterworth, D; Watkins, H; Whitfield, JB; Wichmann, HE; Wilson, JF; Wright, AF, 2009) |
| "Gout is a common rheumatic disease in humans which is characterized by elevation in serum uric acid levels, and deposition of uric acid crystals in the joint." | 4.85 | Recent insights into the pathogenesis of hyperuricaemia and gout. ( Ralston, SH; Riches, PL; Wright, AF, 2009) |
| "Febuxostat, a nonpurine selective inhibitor of both the oxidized and reduced forms of xanthine oxidase, was approved in February 2009 by the US Food and Drug Administration for the management of hyperuricemia in adults with gout." | 4.85 | Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. ( Ernst, ME; Fravel, MA, 2009) |
| "*Febuxostat is an orally administered, non-purine, selective inhibitor of xanthine oxidase approved for the management of chronic hyperuricaemia in patients with gout." | 4.84 | Febuxostat. ( Hair, PI; Keating, GM; McCormack, PL, 2008) |
| " A rapid and massive raise of uric acid, during tumor lysis syndrome (TLS), and also a lower and chronic hyperuricemia, as in gout, mainly damage the kidney." | 4.84 | Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. ( Cammalleri, L; Malaguarnera, M, 2007) |
| "Uric acid nephrolithiasis is typically found in individuals with a low urine pH and a normal concentration of urinary uric acid." | 4.84 | Uric acid nephrolithiasis. ( Bushinsky, DA; Liebman, SE; Taylor, JG, 2007) |
| " While physicians have understood for at least a century that uric acid causes gout, we are now beginning to address the question of why hyperuricemia exists and the mechanisms by which uric acid acts to stimulate inflammation." | 4.84 | Hyperuricemia and gout: new insights into pathogenesis and treatment. ( Abeles, AM; Pillinger, MH; Rosenthal, P, 2007) |
| " Specifically, we review newly discovered mechanisms of uric acid-induced inflammation, uric acid's putative role as a "danger signal" in innate immunity, the possible link between hyperuricemia and cardiovascular disease, and evolutionary evidence suggesting that hyperuricemia conferred a survival advantage in primates (when the gene for uricase was lost) several million years ago." | 4.84 | Update on gout: pathophysiology and potential treatments. ( Abeles, AM; Cronstein, BN; Park, JY; Pillinger, MH, 2007) |
| "Impaired renal uric acid excretion is the major mechanism of hyperuricemia in patients with primary gout." | 4.84 | Control of renal uric acid excretion and gout. ( Kamatani, N; Taniguchi, A, 2008) |
| " Recently it has been identified that hypertension are frequently associated with myogenic hyperuricemia converted from overproduced hypoxanthine in the skeletal muscles." | 4.84 | [Idiopathic hyperuricemia with overproduction of uric acid]. ( Hisatome, I; Igawa, O; Mizuta, E, 2008) |
| " A syndrome of increased activity of PRPP synthetase, an X-linked dominant-inherited disorder, is one of the models of gout caused by increased production of uric acid." | 4.84 | [Increased activity of PRPP synthetase]. ( Iizasa, T, 2008) |
| "Urate lowering treatment is indicated in patients with recurrent acute attacks, tophi, gouty arthropathy, radiographic changes of gout, multiple joint involvement, or associated uric acid nephrolithiasis." | 4.84 | [Uricosuric agent]. ( Ohno, I, 2008) |
| "The association of elevated serum uric acid (hyperuricemia, gout) with the presence of classical coronary risk factors and coronary artery disease (CAD) or myocardial infarction (MI) has been analysed in many epidemiological studies." | 4.83 | [Is hyperuricemia a cardiovascular risk factor?]. ( Chizyński, K; Rózycka, M, 2006) |
| "Gout is a metabolic disorder in which there is either an increase in production or a decrease in excretion of uric acid leading to hyperuricemia." | 4.82 | Advanced imaging of gout. ( Gentili, A, 2003) |
| "Although allopurinol has been available for approximately 50 years, hyperuricemia and its sequelae are not only prevalent, but the incidence and costs associated with this disorder continue to increase." | 4.82 | Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. ( Bomalaski, JS; Clark, MA, 2004) |
| "Treatment of asymptomatic hyperuricemia is not necessary in most patients, unless perhaps they have very high levels of uric acid or are otherwise at risk of complications, such as those with a personal or strong family history of gout, urolithiasis, or uric acid nephropathy." | 4.81 | Asymptomatic hyperuricemia: to treat or not to treat. ( Dincer, AP; Dincer, HE; Levinson, DJ, 2002) |
| "Gout is a common disease arising due to abnormal purin metabolism and excessive accumulation of uric acid in the blood (hyperuricemia) and manifesting with attacks of acute gouty arthritis." | 4.81 | [Gout: current views. Stage oriented treatment]. ( Fedorova, NE; Grigor'eva, VD, 2002) |
| "Gout is a disease resulting from the deposition of urate crystals caused by the overproduction or underexcretion of uric acid." | 4.80 | Diagnosis and management of gout. ( Bross, MH; Pittman, JR, 1999) |
| " Calcium pyrophosphate deposition disease ("pseudogout") usually affects larger joints and often follows trauma, surgery, or ischemic heart disease." | 4.79 | Gout or 'pseudogout': how to differentiate crystal-induced arthropathies. ( Joseph, J; McGrath, H, 1995) |
| "A critical appraisal of the evidence commonly cited to support a link between high urate excretion and calcium oxalate (CaOx) urinary calculi is presented." | 4.79 | Urate and calcium oxalate stones: from repute to rhetoric to reality. ( Grover, PK; Ryall, RL, 1994) |
| "The proper diagnosis of gout and pseudogout (ie, calcium pyrophosphate dihydrate crystal deposition disease) leads to correct treatment." | 4.79 | Gout and 'pseudogout'. When are arthritic symptoms caused by crystal deposition? ( Beutler, A; Schumacher, HR, 1994) |
| "The molecular and biochemical aspects of purine nucleotide biosynthesis through de novo and salvage pathways, the production of uric acid, and their regulation mechanisms are reviewed for further understanding of hyperuricemia and gout." | 4.79 | [Metabolism of purine nucleotides and the production of uric acid]. ( Itakura, M; Yamaoka, T, 1996) |
| " PRS superactivity is an X-chromosome linked disorder, characterized by gout and uric acid overproduction resulting from accelerated synthesis of PRPP and purine nucleotides." | 4.79 | [PRPP synthetase superactivity]. ( Fujimori, S, 1996) |
| "Purine nucleotide degradation during ethanol catabolism, inhibition of renal excretion of urate by lactic acid, and high purine content of certain kinds of beverage are responsible for the elevation of serum uric acid level following alcohol drinking." | 4.79 | [Alcohol ingestion and hyperuricemia]. ( Yamanaka, H, 1996) |
| "A number of pharmacological agents can induce hyperuricaemia, and sometimes gout, usually by interfering with the renal tubular excretion of urate but also in some instances by increasing the formation of uric acid." | 4.78 | Drug-induced gout. ( Scott, JT, 1991) |
| "Gout is a clinical syndrome encompassing a group of metabolic diseases that are all characterized by abnormal uric acid metabolism." | 4.77 | Hyperuricemia and gout. ( German, DC; Holmes, EW, 1986) |
| "The therapy of gout is discussed taking into consideration the concomitant diseases occurring significantly frequently in patients with gout: Hypertension, uric acid-nephrolithiasis, hyperlipoproteinaemia, obesity, premature arteriosclerosis as well as diabetes mellitus." | 4.75 | [Therapy of gout]. ( Heidelmann, G; Thiele, P, 1977) |
| "Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects." | 4.75 | Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1977) |
| "Patients (n = 223) with gout taking allopurinol ≥300 mg daily attended a standardized gout assessment visit." | 4.31 | Predictors of Patient and Physician Assessments of Gout Control. ( Baumgartner, S; Choi, HK; Dalbeth, N; Frampton, C; Fung, M, 2023) |
| "Increased uric acid may have a protective effect in motor neuron diseases (MNDs)." | 4.31 | Prevalence of motor neuron diseases in gout patients: a nationwide population-based cohort study. ( Choi, H; Jun, JB; Kang, DR; Kim, JH; Kim, SH; Kwon, HS; Park, S; Park, Y, 2023) |
| "This study aimed to describe the incidence and prevalence of gout, describe the use of allopurinol among prevalent gout cases, and determine persistence with allopurinol and degree of compliance with treat-to-target recommendations before and after the publication of Swedish national guidelines in 2016." | 4.31 | Gout in Dalarna, Sweden - a population-based study of gout occurrence and compliance to treatment guidelines. ( Dehlin, M; Jacobsson, L; Sigurdardottir, V; Svärd, A, 2023) |
| "The occurrence of gout attacks at the start of uric acid lowering treatment worsens compliance." | 4.31 | A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout. ( Ghang, B; Jeong, W; Kim, J; Lee, J, 2023) |
| "Our findings linked normouricemic erosive gout to attenuated lubricin, with impaired control of cathepsin G activity, compounded by deleterious NLRP3 variants." | 4.31 | Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia. ( Cadzow, M; Campeau, A; Chhana, A; Dalbeth, N; Dambruoso, TJ; Elsaid, K; Elsayed, S; Ghassemian, M; Gonzalez, DJ; Höglund, J; Jay, GD; Karlsson, NG; Karsh, J; Liu-Bryan, R; Maltez, N; Merriman, TR; Miner, M; Phipps-Green, A; Qadri, M; Rossitto, LA; Schmidt, TA; Terkeltaub, R, 2023) |
| " Reducing uric acid and inhibiting inflammation are the focused areas of drug research and development on gout." | 4.31 | Rutin ameliorates gout via reducing XOD activity, inhibiting ROS production and NLRP3 inflammasome activation in quail. ( Huang, J; Li, Y; Lin, Z; Wang, Y; Wu, H; Zhang, B, 2023) |
| "Serial DECT scans from 32 people with gout were obtained over 2 years of allopurinol therapy, dose-escalated to serum urate of <0." | 4.31 | Changes in Tophus Composition During Urate-Lowering Therapy: A Dual-Energy Computed Tomography Study. ( Chen, L; Dalbeth, N; Doyle, AJ; Drake, J; Gamble, GD; Horne, A; Stamp, LK; Uhlig, T, 2023) |
| "Poor adherence to allopurinol among people with gout contributes to suboptimal gout management." | 4.31 | Optimizing adherence to allopurinol for gout: patients' perspectives. ( Aslani, P; Chan, JS; Coleshill, MJ; Day, RO; Michael, TJF; Spragg, JCJ; Stocker, SL, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common chronic disease that is related to high serum uric acid; however, the association between the frequency of gout flares and NAFLD risk remains unclear." | 4.31 | The risk of nonalcoholic fatty liver disease in gout patients with frequent flares: a retrospective cohort study. ( Chen, Y; Chi, J; Dong, B; Liu, C; Si, K; Wang, Y; Xu, L, 2023) |
| "This study aimed to explore the clinical characteristics of perioperative acute gout attacks in patients with varying uric acid levels undergoing orthopedic surgery, identify the risk factors for gout recurrence within the first postoperative year, and provide a disease prevention and diagnostic reference." | 4.31 | Acute gout attacks during the perioperative period and risk factors of recurrence after orthopedic surgery among untreated gout patients. ( Sun, X; Wang, H; Wang, W; Wu, Q; Yan, C; Zeng, H; Zhang, Z, 2023) |
| "In patients with gout receiving uric acid-lowering therapy, musculoskeletal ultrasound has the potential to observe changes in gout lesions." | 4.31 | Musculoskeletal Ultrasound in Monitoring the Efficacy of Gout: A Prospective Study Based on Tophus and Double Contour Sign ( Fan, Y; Gu, P; He, Y; Mou, X; Qing, Y; Tang, X; Yan, X; Yang, Q; Yuan, H; Yue, W, 2023) |
| " This research aimed to study the relation of ischemic cerebrovascular disease with benzbromarone use among persons with gout-related disorders." | 4.31 | The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan. ( Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS, 2023) |
| "Correlation influence factor analysis of gout patients' serum uric acid (SUA) levels, their examination fees, and various complications were explored." | 4.31 | Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross-sectional analysis. ( Dang, W; Liu, J; Wang, J; Xu, D; You, L; Zhao, L, 2023) |
| "Treatment of gout involves two basic approaches: reducing the serum uric acid mainly by xanthine oxidase inhibitors (XOIs) and alleviating the intensity of the accompanying acute arthritic inflammation using non-steroidal anti-inflammatory drugs (NSAIDs)." | 4.31 | Towards the Development of Dual Hypouricemic and Anti-inflammatory Candidates: Design, Synthesis, Stability Studies and Biological Evaluation of Some Mutual Ester Prodrugs of Febuxostat-NSAIDs. ( Abdel Moneim, AE; Daabees, HG; Elagawany, M; Rashad, AY; Rostom, SAF; Shahin, M, 2023) |
| "Spontaneous serum uric acid (SUA) decrease has been found in many patients during acute gout attacks, but its mechanism remains unclear." | 4.31 | Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack. ( Cao, L; Du, X; Lin, C; Wan, W; Xu, R; Yang, X; Zhao, T; Zhou, M; Zhu, X; Zou, H, 2023) |
| " A Mendelian randomization analysis of the association between caffeine-containing drinks and gout risk was conducted." | 4.31 | Exploring the mechanism underlying hyperuricemia using comprehensive research on multi-omics. ( Dai, Q; Fang, J; Li, B; Liu, H; Xie, R; Xu, Y, 2023) |
| " The volume of MSU crystals is associated with the improved SvdH erosion score based on CT images, regardless of serum uric acid level, demonstrating the potential of combining DECT and serum uric acid measurements in helping optimize the management of patients with gout." | 4.31 | Detailed analysis of the association between urate deposition and bone erosion in gout: a dual-energy computed tomography study. ( Deng, WM; Hung, YK; Jiang, GH; Wang, JY; Wang, W; Zhan, WF; Zheng, WY, 2023) |
| "Uric acid, the end product of purine degradation, causes hyperuricemia and gout, afflicting hundreds of millions of people." | 4.31 | Anaerobic purinolytic enzymes enable dietary purine clearance by engineered gut bacteria. ( Gao, L; Hu, Y; Ju, Y; Li, L; Li, P; Li, Z; Liu, D; Liu, S; Luo, Y; Tong, Y; Wang, J; Wang, Y; Wei, Y; Yu, H; Zhang, Y, 2023) |
| "Gout is a form of inflammatory arthritis that results from elevated serum uric acid levels and the deposition of urate crystals in multiple joints." | 4.31 | Development of a novel anti-inflammatory recombinant uricase with extended half-life for gout therapy. ( Fu, N; Li, Q; Quan, J; Zhang, Z, 2023) |
| "SIM0295, a novel inhibitor of human uric acid transporter 1 (hURAT1), is used to treat patients with gout and hyperuricemia." | 4.31 | Model Informed Development of SIM0295 in Patients with Gout and Hyperuricemia and Healthy Volunteers Using a Population Pharmacokinetics/ Pharmacodynamics Approach. ( Chen, Y; Huang, Q; Jiao, Z; Kim, JS; Shu, P; Wang, C; Xu, S; Yang, Y; Zhang, X, 2023) |
| "Pathophysiologic processes promoted by uric acid, including inflammation and oxidative stress, play a key role in the pathogenesis of several cardiovascular diseases." | 4.31 | [ANMCO statement: Uric acid and cardiovascular disease: evidence and therapeutic approach]. ( Aquilani, S; Castello, L; Colivicchi, F; Di Fusco, SA; Flori, M; Gabrielli, D; Gulizia, MM; Marino, G; Nardi, F; Oliva, F; Riccio, C, 2023) |
| " Uric acid (UA), a major risk factor for gout, has also been suggested to be a risk factor for CKD, but the efficacy of existing urate-lowering therapies for CKD is controversial." | 4.31 | GLUT9 as a potential drug target for chronic kidney disease: Drug target validation by a Mendelian randomization study. ( Fukui, K; Kamatani, N; Kamitsuji, S; Matsuo, A; Matsushita, M; Nishiu, J; Sasase, T; Ueda, M, 2023) |
| "Monosodium uric acid (MSU) crystal, the etiological agent of gout, has been shown to trigger innate immune responses via multiple pathways." | 4.31 | Clec12a inhibits MSU-induced immune activation through lipid raft expulsion. ( Li, S; Shi, Y; Song, D; Wang, W; Xia, T; Xu, Y; Yue, T, 2023) |
| "We investigated the appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors (XOIs) as first-line urate-lowering therapy (ULT) in patients with gout." | 4.31 | Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database. ( Kim, AR; Lee, SG; So, MW, 2023) |
| " It suppressed liver xanthine oxidase activity to decrease uric acid synthesis and modulated renal urate transporters to stimulate uric acid excretion, alleviating kidney damage caused by hyperuricemia." | 4.31 | Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters. ( An, J; Li, C; Li, Y; Lin, F; Ma, S; Wang, S; Xie, Y; Xu, L; Zhang, Y; Zhao, Y, 2023) |
| "Approximately 15% of US adults have circulating levels of uric acid above its solubility limit, which is causally linked to the disease gout." | 4.31 | A widely distributed gene cluster compensates for uricase loss in hominids. ( Augustijn, HE; Cabrera, AV; Chen, H; DeFeo, ME; Dodd, D; Ganesan, C; Gombar, S; Hou, BH; Huang, S; Jarman, JB; Liu, Y; Low, YS; Medema, MH; Meng, X; Pao, AC; Sekiba, K; van Wezel, G; Weakley, AM; Zhou, Z, 2023) |
| "Higher serum uric acid (SUA) can cause gout, which is principally characterized by arthritis due to monosodium urate crystal deposition in the lower extremities." | 4.31 | Association between serum uric acid levels and peripheral artery disease in Chinese adults with hypertension. ( Bao, H; Cheng, X; Han, F; Hu, F; Huang, X; Wang, T; Yu, C; Zhou, W; Zhu, L, 2023) |
| "This study aimed to examine the association of serum uric acid levels with incident cardiovascular disease and mortality in Korean adults without gout." | 4.31 | Uric Acid and Risk of Cardiovascular Disease and Mortality: A Longitudinal Cohort Study. ( Chang, TI; Kim, JY; Lim, H; Pak, H; Seo, C, 2023) |
| "To determine the risk of adverse events associated with colchicine or non-steroidal anti-inflammatory drug (NSAID) prophylaxis when initiating allopurinol for gout." | 4.31 | Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink. ( Bajpai, R; Clarson, LE; Forrester, H; Mallen, CD; Muller, S; Padmanabhan, N; Partington, RJ; Roddy, E; Whittle, R, 2023) |
| " Thus, we aimed to investigate diurnal variations in serum levels of UA and plasma levels of xanthine, hypoxanthine, and xanthine oxidoreductase (XOR) activity, which were measured at 18:00, 6:00, and 12:00 in male patients with coronary artery disease." | 4.31 | Diurnal Variations in Serum Uric Acid, Xanthine, and Xanthine Oxidoreductase Activity in Male Patients with Coronary Artery Disease. ( Hiki, M; Ishiwata, S; Kasai, T; Kato, T; Kuwabara, M; Matsumoto, H; Murase, T; Murata, A; Naito, R; Nakamura, T; Sato, A; Shimizu, M; Shitara, J; Suda, S; Yatsu, S, 2023) |
| "Hyperuricemia is a clinical disease characterized by a continuous increase in uric acid (UA) due to purine metabolism disorder." | 4.31 | Peptide NCTX15 derived from spider toxin gland effectively relieves hyperuricemia in mice. ( Bian, W; Fu, Z; Li, C; Liu, N; Liu, Y; Peng, Y; Ru, Z; Wang, Y; Wu, Y; Yang, X; Zhang, Y, 2023) |
| " Two definitions of hyperuricemia were used: capillary level equivalent to plasma uric acid level>360μmol/l (6mg/dl) and>420μmol/l (7mg/dl) and/or urate-lowering drug treatment for both thresholds." | 4.12 | Epidemiology of gout and hyperuricemia in New Caledonia. ( Bardin, T; Clerson, P; Magnat, E; Richette, P; Rouchon, B, 2022) |
| " The averaged serum uric acid levels in patients with gout reduced after WMT (p = 0." | 4.12 | Effects of Washed Microbiota Transplantation on Serum Uric Acid Levels, Symptoms, and Intestinal Barrier Function in Patients with Acute and Recurrent Gout: A Pilot Study. ( Cai, JY; Deng, ZH; He, XX; Kong, LP; Wu, LH; Xia, HH; Xie, WR; Yang, XY; Zhang, R; Zheng, YM, 2022) |
| "Lesinurad is a uricosuric agent for the treatment of hyperuricemia associated with gout, which was found lacking in efficacy and safety." | 4.12 | Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability. ( Ji, J; Liang, R; Liao, H; Liu, X; Pang, J; Shi, X; Tao, Y; Wu, T; Zhan, P; Zhang, J; Zhang, Z; Zhao, F; Zhao, T, 2022) |
| " Patients were aged ≥19 years; had CKD G3-G4; and used drugs including colchicine, allopurinol and febuxostat for hyperuricaemia or chronic gout during the period from April 2000 to October 2020." | 4.12 | Colchicine use and the risk of CKD progression: a multicentre nested case-control study. ( Chang, TI; Han, SH; Jhee, JH; Joo, YS; Kang, SW; Kim, HW; Kim, JY; Park, JT; Roh, YH; Yoo, TH; Yun, HR, 2022) |
| "Sixty-nine men with gout attending rheumatology clinics, all prescribed allopurinol for ≥ 6 months, completed the Intentional Non-Adherence Scale (INAS)." | 4.12 | Why Do Patients With Gout Not Take Allopurinol? ( Chalder, T; Dalbeth, N; Emad, Y; Petrie, KJ; Weinman, J, 2022) |
| "Six male patients with gout were treated with combined oral medication (febuxostat, 120 mg/d, and benzbromarone, 50 or 100 mg/d), aiming at a more rapid success of uric acid lowering treatment (ULT) compared to guideline suggestions." | 4.12 | Treating gout - can hypouricemia produced by moderate doses of combined oral treatment give early treatment success? Preliminary observations. ( Fairbanks, L; Gibson, T; Löffler, W, 2022) |
| "In gout, crystallization of uric acid in the form of monosodium urate (MSU) leads to a painful inflammatory response." | 4.12 | Natural antibodies and CRP drive anaphylatoxin production by urate crystals. ( Alberts, A; Brand, K; Hoffmeister, L; Klingberg, A; Neumann, K; Pich, A; Wessig, AK; Witte, T, 2022) |
| " Potential factors associated with reduced renal function including age, ethnicity, educational level, history of diabetes, hypertension, gout, hydronephrosis, serum uric acid level, and type of renal stone were evaluated using univariable and multivariable analyses." | 4.12 | Cardiovascular risk factors, ethnicity and infection stone are independent factors associated with reduced renal function in renal stone formers. ( Choy, SH; J R, S; Kamaruzaman, S; Lim, J; Malek, R; Md Yusoff, NA; Nagappan, P; Nyanatay, SA; Ong, TA; Sothilingam, S; Sundram, M; Toh, CC; Yeoh, WS, 2022) |
| "In the treat-to-target, tight control NOR-Gout study patients started ULT with escalating doses of allopurinol." | 4.12 | One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study. ( Haavardsholm, EA; Hammer, HB; Karoliussen, LF; Kvien, TK; Perez-Ruiz, F; Sexton, J; Uhlig, T, 2022) |
| "Characterized by an excessively increased uric acid (UA) level in serum, hyperuricemia induces gout and also poses a great threat to renal and cardiovascular systems." | 4.12 | Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing. ( Chai, S; Chai, X; Geng, WC; Guo, DS; Li, JJ; Wang, L; Wang, Y; Yu, H; Yue, YX; Zhang, Y, 2022) |
| " These physiological characteristics have promoted the study of poly-gallic acid (PGAL), a poly-oxidized form of gallic acid reported to be effective in in vitro models of inflammation." | 4.12 | Anti-inflammatory and Antioxidant Effect of Poly-gallic Acid (PGAL) in an In Vitro Model of Synovitis Induced by Monosodium Urate Crystals. ( Fernández-Torres, J; Gimeno, M; Luján-Juárez, IA; Martínez-Flores, K; Martínez-López, V; Montaño-Armendariz, N; Sánchez-Sánchez, R; Zamudio-Cuevas, Y, 2022) |
| "Gout is the most common form of inflammatory arthritis and is caused by deposition of monosodium urate crystals resulting from a high burden of uric acid (UA)." | 4.12 | Urate-lowering therapy for patients with gout on hemodialysis. ( Alkilany, R; Antonelli, M; Einstadter, D, 2022) |
| " the xanthine oxidase inhibitors allopurinol and febuxostat), traditional Chinese medicine has fewer side effects in the treatment of gout and can safely control serum uric acid and the level of inflammation." | 4.12 | Phytochemicals in traditional Chinese medicine can treat gout by regulating intestinal flora through inactivating NLRP3 and inhibiting XOD activity. ( Liu, ZB; Liu, ZQ; Sun, X; Wu, CJ; Zhang, LL; Zhang, T, 2022) |
| " In this study, the xanthine oxidase (XO) inhibition and uric acid-lowering effect of corni fructus extract (CFE) were evaluated in mice with potassium oxonate-induced hyperuricemia." | 4.12 | Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia. ( Chen, C; Chen, FA; Chen, HC; Chiu, PY; Li, YL; Wang, CC, 2022) |
| "The results obtained show that uric acid crystal detection using less invasive imaging methods in an animal model with birds and reptiles may expand gout diagnostics not only in veterinary medicine but also in human medicine and possibly replace arthrocentesis if a DF signal is detectable." | 4.12 | [X-Ray Dark-field radiography: Does this carry potential for diagnosing gout in exotic pets?] ( Andrejewski, J; Baumgartner, C; Braig, E; Herzen, J; Kimm, MA; Korbel, R; Pfeiffer, D; Roiser, N; Scholz, J, 2022) |
| "Sera of gout patients meeting the 2015 ACR/EULAR gout classification criteria (n = 20) and with hyperuricemia were studied at time zero and weeks 12 and 24 of febuxostat or allopurinol dose titration ULT." | 4.12 | Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes. ( Bittleman, D; Coras, R; Dadpey, B; Guma, M; Hamilton, B; Lauro, K; Liu-Bryan, R; Mikuls, TR; Quehenberger, O; Reilly, SM; Terkeltaub, R; Thorisdottir, H, 2022) |
| "Abnormal uric acid level result in the development of hyperuricemia and hallmark of various diseases, including renal injury, gout, cardiovascular disorders, and non-alcoholic fatty liver." | 4.12 | Anti-inflammatory potential of stevia residue extract against uric acid-associated renal injury in mice. ( Alharthi, F; Althobaiti, F; Chen, X; Mehmood, A; Murtaza, MA; Nadeem, M; Ranjha, MMAN; Shah, AA; Soliman, MM; Usman, M; Wang, C; Zhao, L, 2022) |
| " Ongoing research is examining the association of obesity, dietary patterns, and blood pressure (BP) with serum uric acid (sUA)." | 4.12 | Correlation of obesity, dietary patterns, and blood pressure with uric acid: data from the NHANES 2017-2018. ( Fan, GJ; Lin, YP; Lu, QY; Yao, J; Zhang, Y; Zhao, J, 2022) |
| "Pegloticase + methotrexate co-therapy was well-tolerated over 12 months, with sustained SU lowering, progressive gout flare reduction, and no new safety concerns." | 4.12 | A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an ( Bennett, R; Botson, JK; Chamberlain, J; Kenney, HM; LaMoreaux, B; Obermeyer, K; Peloso, PM; Peterson, J; Ramanathan, S; Song, Y; Tesser, JRP; Weinblatt, ME; Xin, Y; Zhao, L, 2022) |
| "Patients with hyperuricemia or gout or patients with high and low levels of serum uric acid may face poor outcomes of hip fractures." | 4.12 | The paradoxical relation between serum uric acid and outcomes of hip fracture in older patients after surgery: A 1-year follow-up study. ( Chu, Q; Fu, M; Liu, M; Sun, G; Wang, J; Yang, C; Zhang, Z, 2022) |
| " The language was used to formalize one- and two-drug titration of chronic and acute cases, and to perform retrospective analysis of the drug titration processes on 253 patients diagnosed of diabetes mellitus type 2 and treated with metformin, 321 patients treated of chonic heart failure with furosemide, 155 patients with hyperuricemia treated with allopurinol as initial drug and febuxostat as alternative drug, and 187 hyperuricemia patients with primary drug allopurinol and supplementary drug probenecid, in order to identify different types of drug titration deviations from standard DT methods." | 4.12 | Modelling and assessing one- and two-drug dose titrations. ( Alonso, JR; Kamišalić, A; Pečnik, Š; Riaño, D, 2022) |
| "Multiple observational studies have reported the close associations of obstructive sleep apnea (OSA) with serum uric acid (SUA) levels and gout." | 4.12 | Assessing the causal associations of obstructive sleep apnea with serum uric acid levels and gout: a bidirectional two-sample Mendelian randomization study. ( Cen, H; Ding, C; He, W; Huang, L; Jin, T; Ni, J; Xie, Y; Zeng, Z; Zhang, L, 2022) |
| " The frequency of gout attack and blood uric acid of patients 3 months after operation was lower than those before operation, and the differences were statistically significant." | 4.12 | Surgical Treatment of Hand and Foot Gout Stone and Influence Factors on Prognosis. ( Du, X; Jin, S; Qiu, X; Zhao, B; Zhao, W, 2022) |
| "Urate Transporter 1 (URAT1) plays a crucial role in uric acid transport, making it an attractive target for the treatment of gout and hyperuricemia." | 4.12 | Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors. ( Dong, Y; Gao, S; Liang, R; Liao, H; Liu, X; Pang, J; Qi, D; Shi, X; Wu, T; Zhan, P; Zhang, J; Zhang, X; Zhang, Z; Zhao, T, 2022) |
| "Gout is characterized by the deposition of monosodium urate crystals in patients with chronically elevated blood levels of uric acid." | 4.12 | Orthopaedic Management of Gout. ( Cohen-Rosenblum, AR; Guevara, ME; Hynes, KK; Somogyi, JR, 2022) |
| "Along with uric acid, which is the primary driving factor of gout, downstream inflammatory mediators have been shown to be involved in the pathogenesis of gouty arthritis flares." | 4.12 | Plasma adsorption in refractory chronic gouty arthritis flare: A case report. ( Cui, TJ; Lei, Y; Tang, C; Wang, XH; Zhang, XM; Zheng, ZH, 2022) |
| "Epidemiological evidence of the associations between metal exposure and gout-related outcomes (including serum uric acid [SUA], hyperuricemia and gout) is scarce." | 4.12 | Associations of metal exposure with hyperuricemia and gout in general adults. ( Hui, R; Shi, S; Wang, J; Xing, Y; Xu, J; Zhang, Y; Zhu, L; Zhu, X, 2022) |
| " The relationship between the uric acid metabolism target and the NLRP3 inflammasome may be the critical immune response between hyperuricemia and gouty arthritis." | 4.12 | Overnutrition-induced gout: An immune response to NLRP3 inflammasome dysregulation by XOD activity increased in quail. ( Huang, J; Li, Y; Lin, Z; Ren, Z; Wang, Y; Wu, H; Zhang, B, 2022) |
| "Pegloticase is an enzyme used to reduce serum uric acid levels in patients with chronic, treatment-refractory gout." | 4.02 | High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies. ( Frank, JE; Lai, SK; LaMoreaux, B; Li, Z; Livingston, EW; McSweeney, MD; Nyborg, AC; Talkington, AM; Yuan, H; Zhang, T, 2021) |
| "Self-reported gout or hyperuricemia and uric acid level." | 4.02 | Should we be more aware of gender aspects in hyperuricemia? Analysis of the population-based German health interview and examination survey for adults (DEGS1). ( Engel, B; Freitag, MH; Hoffmann, F; Jacobs, H, 2021) |
| "Our previous research showed that uric acid lowering therapy (ULT) for gout and hyperuricemia is being prescribed for pediatric patients even though these drugs have not been approved for use in children." | 4.02 | Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database. ( Honda, M; Horiuchi, H; Iijima, T; Ito, S; Murano, H; Nakajima, A; Torii, T; Yamanaka, H, 2021) |
| " Current data suggest that the mechanism of action of metformin contributes to the development of an anti-inflammatory effect, as well as a decrease in the level of uric acid, and its use can be potentially useful in patients with hyperuricemia and gout." | 4.02 | [Advantages of the use of metformin in patients with impaired uric acid metabolism]. ( Eliseev, MS; Nasonov, EL; Panevin, TS; Zhelyabina, OV, 2021) |
| "To investigate the efficacy and tolerability of febuxostat in gout patients on dialysis." | 4.02 | Efficacy and tolerability of febuxostat in gout patients on dialysis. ( Choi, SW; Choi, SY; Lee, S; Lim, DH; Oh, JS; So, MW, 2021) |
| "The objectives of our study were to compare the efficacy of febuxostat with allopurinol in Thai subjects with gout, as well as to determine the predictive factors of responsiveness to urate-lowering agents and to evaluate the safety of febuxostat in a real-world setting." | 4.02 | Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout. ( Jatuworapruk, K; Lertnawapan, R, 2021) |
| "This is a single-center, prospective cohort study conducted in one adult Arthritis Clinic at the University of the Philippines-Philippine General Hospital which included 138 patients with gout (1977 ACR criteria), SUA ≥ 6 mg/dl prior to ULT, initiated on ULT (allopurinol or febuxostat), with six months minimum follow-up and with SUA determination post-treatment." | 4.02 | Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines. ( Penserga, EG; Quilisadio, JEC; Salido, EO, 2021) |
| "The coexistence of calcium pyrophosphate dihydrate (CPPD) and monosodium urate monohydrate crystals in gouty tophi has rarely been reported." | 4.02 | Calcium Pyrophosphate Dihydrate Crystal Deposition in Gouty Tophi. ( Bardin, T; Bazin, D; Cohen-Solal, M; Ea, HK; Frochot, V; Gauffenic, A; Laredo, JD; Le, NH; Marty, C; Nguyen, QD; Olivier, O; Ostertag, A; Pham, NG; Richette, P, 2021) |
| "This study assessed factors associated with achieving target serum uric acid (sUA) level and occurrence of gouty arthritis in Japanese clinical practice." | 4.02 | Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021) |
| " Variables associated with the diagnosis of gout were as follows: serum uric acid > 350 μmol/L (OR 5." | 4.02 | External validation of Gout-calculator performance on a cohort of acute arthritis (SYNOLACTATE) sparing distal joints such as hallux and midfoot. A cross-sectional study of 170 patients. ( Albert, JD; Bendavid, C; Berthoud, O; Cadiou, S; Coiffier, G; Gougeon-Jolivet, A; Guggenbuhl, P; Robin, F, 2021) |
| " We used a case study of febuxostat versus allopurinol for the treatment of hyperuricemia in patients with gout." | 4.02 | Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design. ( Hill-McManus, D; Hughes, DA, 2021) |
| "Gout is present in one third of subjects with CKD but is usually an exclusion criterion in clinical trials investigating the role of uric acid in kidney disease." | 4.02 | Does gouty nephropathy exist, and is it more common than we think? ( Johnson, RJ; Piani, F, 2021) |
| "In this nonrandomized, open-label, single-arm trial, we administered topiroxostat 40-160 mg/day to HFpEF patients with hyperuricemia or gout to achieve a target uric acid level of 6." | 4.02 | Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study. ( Asai, K; Koen, M; Kubota, Y; Shimizu, W; Wakita, M, 2021) |
| "A high serum uric acid (SUA) concentration is associated with hyperuricemia (HUA) and gout." | 4.02 | Expression, localization and metabolic function of "resurrected" human urate oxidase in human hepatocytes. ( Chen, J; Duan, Y; Jiang, N, 2021) |
| "Gout is a type of inflammatory arthritis caused by the deposition of monosodium uric acid (MSU) crystals in tissues." | 4.02 | Loganin Alleviates Gout Inflammation by Suppressing NLRP3 Inflammasome Activation and Mitochondrial Damage. ( Cho, YY; Choi, N; Jang, JH; Kang, HC; Lee, HS; Lee, JY; Yang, G, 2021) |
| "To investigate the incidence and potential risk factors for development of fenofibrate-associated nephrotoxicity in gout patients." | 4.02 | Effects of fenofibrate therapy on renal function in primary gout patients. ( Chen, Y; Cheng, X; Cui, L; Han, L; He, Y; Ji, A; Ji, X; Li, C; Li, H; Li, X; Liu, Z; Lu, J; Ma, L; Merriman, TR; Ren, W; Sun, W; Wang, C; Wang, X; Yuan, X; Zhang, H, 2021) |
| "Uric acid has long been considered responsible for a single specific disease, namely gout." | 4.02 | The URRAH study. ( Carubbi, F; Del Pinto, R; Ferri, C; Pontremoli, R; Russo, E; Viazzi, F, 2021) |
| "Gout, caused by chronic elevation of serum uric acid levels, is the commonest form of inflammatory arthritis." | 4.02 | Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12. ( Higashino, T; Ichida, K; Inoue, I; Kawamura, Y; Matsuo, H; Morimoto, K; Nakaoka, H; Nakayama, A; Ooyama, H; Shigesawa, R; Shimizu, S; Shinomiya, N; Suzuki, H; Takada, T; Takeuchi, K; Toyoda, Y; Uchida, N, 2021) |
| "Gout is an autoinflammatory disease driven by interleukin-1 (IL-1) induction in response to uric acid crystals." | 4.02 | Cold-inducible RNA-binding protein (CIRP) potentiates uric acid-induced IL-1β production. ( Asano, T; Fujita, Y; Kawakami, A; Matsumoto, H; Matsuoka, N; Migita, K; Sato, S; Suzuki, E; Temmoku, J; Watanabe, H; Yago, T; Yashiro-Furuya, M, 2021) |
| "The aim of this study was to identify the effects of melatonin on acute gouty inflammation and to investigate the underlying mechanisms." | 4.02 | Melatonin Alleviates Acute Gouty Inflammation In Vivo and In Vitro. ( Cao, L; Xiao, WZ; Zhao, L; Zhu, XX; Zou, HJ, 2021) |
| "Abnormal blood uric acid (UA) levels can lead to its crystallization in the joints, consequently resulting in gout." | 4.02 | Highly permselective uric acid detection using kidney cell membrane-functionalized enzymatic biosensors. ( Jung, HG; Kim, I; Kim, YI; Lee, G; Lee, SW; Yoon, DS, 2021) |
| "In patients with gout, treating to target serum uric acid levels (sUA) of ≤6." | 4.02 | Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021) |
| "To analyse the antinociceptive interaction between quercetin (QUER) and diclofenac (DIC) in experimental arthritic gout-pain." | 4.02 | Quercetin decreases the antinociceptive effect of diclofenac in an arthritic gout-pain model in rats. ( Ángeles-López, GE; Aviles-Herrera, J; Bustamante-Marquina, A; Déciga-Campos, M; González-Trujano, ME; Navarrete-Vázquez, G; Ventura-Martínez, R, 2021) |
| " In this study, the differences between gout with cerebral infarction (gout+CI) and gout with coronary heart disease (gout+CHD) and related factors that affect serum uric acid (sUA) levels in gout+CI were investigated by a cross-sectional study." | 4.02 | Factors Influencing the Serum Uric Acid in Gout with Cerebral Infarction. ( Duan, L; Li, Y; Tian, Y; Yang, H, 2021) |
| "To assess factors associated with the ability to achieve and maintain target serum urate (SU) with allopurinol in patients with gout." | 3.96 | Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. ( Saag, KG; Singh, JA; Yang, S, 2020) |
| " We demonstrate continuous detection of temperature, respiration rate and low concentrations of uric acid and tyrosine, analytes associated with diseases such as gout and metabolic disorders." | 3.96 | A laser-engraved wearable sensor for sensitive detection of uric acid and tyrosine in sweat. ( Bo, X; Gao, W; Hsiai, TK; Kogan, A; Li, Z; Min, J; Pak, OS; Song, Y; Tu, J; Wang, M; Yang, Y; Zhang, H; Zhu, L, 2020) |
| "Eucalyptol alleviates MSU-induced pain and inflammation via mechanisms possibly involving anti-oxidative effect." | 3.96 | Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis. ( Li, X; Li, Y; Liu, B; Tai, Y; Wang, C; Wang, P; Yin, C; Zheng, X, 2020) |
| "Elevated blood uric acid (UA) levels have been positively associated with the severity of periodontitis." | 3.96 | Hyperuricemia as a potential plausible risk factor for periodontitis. ( Chen, ZY; Gao, J; Liang, ZJ; Ye, LW; Yu, T; Zhao, L, 2020) |
| " Hyperuricemia is the hallmark of developing gout and mostly caused by uric acid underexcretion." | 3.96 | The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort. ( Prom-Wormley, E; Roman, Y; Tiirikainen, M, 2020) |
| " Our study was to discover different lipid levels of gout and asymptomatic hyperuricemia and the predictors of sUA (serum uric acid) levels." | 3.96 | The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study. ( Gu, J; Huang, Y; Jiang, Y; Li, X; Liang, J; Ou, J; Song, W; Wei, Q, 2020) |
| "Staged operation for the treatment of giant gout stone on the first metatarsophalangeal joint of foot could correct joint deformity, restore shape of the first metatarsophalangeal joint, relieve pain of the affected foot, and beneficial for control content of serum uric acid, and has less complications." | 3.96 | [Clinical study of staging operation for large gouty stone on the first metatarsophalangeal joint]. ( Li, P; Wang, Y; Xu, SQ; Zhang, WJ; Zhang, Y, 2020) |
| "The 24-hour uric acid excretion measurement is important in assessing disease status and helping to select the appropriate uric acid-lowering agent for patients with gout, however, it is inconvenient." | 3.96 | The Utility of the Random Urine Uric Acid-to-Creatinine Ratio for Patients with Gout Who Need Uricosuric Agents: Retrospective Cross-Sectional Study. ( Choi, ST; Kim, CH; Kim, SJ; Moon, SJ; Song, JS, 2020) |
| " Included were all their patients receiving urate-lowering therapy (ULT), with a diagnostic code for gout or who had a serum uric acid (SUA) measurement." | 3.96 | Gout management in Swiss primary care - a retrospective observational study. ( di Gangi, S; Meier, R; Rosemann, T; Valeri, F; Zechmann, S, 2020) |
| "We conducted a cross-sectional Internet survey of people who visited the Gout and Uric Acid Education Society's website to assess patient/respondent perception of gout management goals." | 3.96 | Patient Perceptions of Gout Management Goals: A Cross-sectional Internet Survey. ( Edwards, NL; Singh, JA, 2020) |
| "Lifelong urate-lowering therapy (ULT) with xanthine oxidase inhibitors (XOIs), such as allopurinol and febuxostat, is the cornerstone of gout treatment." | 3.96 | Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study. ( Ahn, E; Kim, A; Kim, GT; Kim, Y; Lee, SG; So, MW, 2020) |
| "Excessive production of uric acid (UA) in blood may lead to gout, hyperuricaemia and kidney disorder; thus, a fast, simple and reliable biosensor is needed to routinely determine the UA concentration in blood without pretreatment." | 3.96 | Mobile healthcare system based on the combination of a lateral flow pad and smartphone for rapid detection of uric acid in whole blood. ( Chen, YT; Hsu, YP; Huang, CY; Li, NS; Pang, HH; Shiue, YL; Wei, KC; Yang, HW, 2020) |
| " The objective of the study is to investigate whether there is an association between concurrent serum levels of several PFAAs and gout, serum uric acid (SUA) or hyperuricemia in the U." | 3.96 | Perfluoroalkyl acids, hyperuricemia and gout in adults: Analyses of NHANES 2009-2014. ( Abadin, HG; Attanasio, R; Balluz, L; Buser, MC; Gehle, K; Murray, HE; Scinicariello, F, 2020) |
| "Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used for the management of hyperuricemic patients with or without gout in Japan." | 3.96 | Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study. ( Hashimoto, T; Ichikawa, K; Ishikawa, T; Kanno, Y; Maeda, T; Nakagawa, T; Sato, Y, 2020) |
| "To investigate the effects of serum uric acid (SUA) level and its fluctuation on renal dysfunction in gout patients." | 3.96 | Uric acid fluctuation had no effect on renal function among gout patients. ( Fu, Y; Mo, M; Shao, B; Shen, J; Shen, Y; Si, S; Wang, S; Wu, H; Xin, X; Yu, Y; Zhu, J, 2020) |
| "Macrophage activation by monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals mediates an interleukin (IL)-1β-dependent inflammation during gout and pseudo-gout flare, respectively." | 3.96 | Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages. ( Adimy, Y; Alzaid, F; Bardin, T; Campillo-Gimenez, L; Castelli, F; Cohen-Solal, M; Combes, C; Delvaux, A; Ea, HK; Fenaille, F; Lioté, F; Orliaguet, L; Prignon, A; Renaudin, F; Richette, P; Riveline, JP; Venteclef, N, 2020) |
| "To assess the impact of allopurinol on diabetes in a retrospective cohort of Veterans' Affairs patients with gout." | 3.96 | Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study. ( Crittenden, DB; Greenberg, J; Pike, VC; Pillinger, MH; Qian, Y; Slobodnick, A; Toprover, M; Zhong, H, 2020) |
| " Serum uric acid (UA) is a terminal metabolite of purine compound, while hyperuricemia (HU) and UA crystals are recognized causes of gout." | 3.96 | Association between hyperuricemia, gout, urate lowering therapy, and osteoarthritis: A protocol for a systematic review and meta-analysis. ( Chen, Y; Li, H; Li, X; Wang, Y; Yang, Z; Zhu, J, 2020) |
| " Herein we aimed to investigate whether procyanidin B2 (PCB2), a natural dietary compound, can suppress MSU crystals-stimulated gouty inflammation." | 3.96 | Management of Gout-associated MSU crystals-induced NLRP3 inflammasome activation by procyanidin B2: targeting IL-1β and Cathepsin B in macrophages. ( Jiang, M; Jiao, JY; Li, Y; Lian, LH; Lin, YC; Liu, J; Nan, JX; Piao, MH; Qiao, CY; Shang, Y; Sun, RH; Wu, YL; Ye, H; Zhan, ZY; Zhang, ZH, 2020) |
| " Outcomes were measured for prevalence, patient characteristics, treatment with uric acid lowering drugs for gout and asymptomatic hyperuricemia, and prevalence and incidence of gouty arthritis." | 3.96 | Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database. ( Honda, M; Horiuchi, H; Iijima, T; Ito, S; Murano, H; Nakajima, A; Torii, T; Yamanaka, H, 2020) |
| "Compared to hyperuricaemia model or acute gout model, the compound gout model showed little advantages of elevating serum uric acid, causing foot swelling and gout inflammation, while it caused more severe serum inflammation and gut microbiota dysbiosis." | 3.96 | Combined effects of MSU crystals injection and high fat-diet feeding on the establishment of a gout model in C57BL/6 mice. ( He, Z; Lin, X; Shao, T; Wang, M; Wen, C; Wen, X, 2020) |
| "12 a week-long combined therapy of the allopurinol-reducing drug with the anti-inflammatory dose movalis prevents the exacerbation of the articular syndrome and improves the quality of life of patients with gout." | 3.96 | [Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout]. ( Gromova, MA; Kislyak, OA; Malysheva, NV; Tsurko, VV, 2020) |
| " The best studied of these diseases is gout, in which crystallization of uric acid in the form of monosodium urate (MSU) mainly in synovial fluid of the joints leads to sterile inflammation." | 3.96 | Binding of Macrophage Receptor MARCO, LDL, and LDLR to Disease-Associated Crystalline Structures. ( Alberts, A; Brand, K; Hoffmeister, L; Klingberg, A; Neumann, K; Pich, A; Wessig, AK, 2020) |
| " Serum uric acid levels and estimated glomerular filtration rate (eGFR) of patients with gouty arthritis were collected at baseline and 1 year after febuxostat administration." | 3.96 | Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. ( Kim, JM; Kim, SH; Lee, SY; Son, CN, 2020) |
| "DECT scans of bilateral hands/wrists, feet/ankles, and knees were obtained on 153 patients with gout on allopurinol ≥300 mg daily for ≥3 months." | 3.96 | Radiologic evidence of symmetric and polyarticular monosodium urate crystal deposition in gout - A cluster pattern analysis of dual-energy CT. ( Baumgartner, S; Choi, HK; Dalbeth, N; Fung, M; Nicolaou, S; Simeone, FJ; Wei, J; Yokose, C; Zhang, Y, 2020) |
| "Elevated uric acid (UA) is a key risk factor for many disorders, including metabolic syndrome, gout and kidney stones." | 3.91 | A conserved role of the insulin-like signaling pathway in diet-dependent uric acid pathologies in Drosophila melanogaster. ( Beck, JN; Bose, N; Brackman, DJ; Chen, L; Chi, T; Giacomini, K; Hilsabeck, TA; Ho, S; Kahn, A; Kapahi, P; Killilea, DW; Lang, S; Sharma, A; Stoller, ML; Watson, MA; Wilson, KA, 2019) |
| "Altered corneal endothelial function was found in patients with gout when compared to healthy subjects and the alteration increased as gout duration and uric acid value increased." | 3.91 | Corneal Endothelial Morphology and Thickness Changes in Patients with Gout ( Atılgan, KG; Çağlayan, M; Göker, YŞ; Koç, M; Kösekahya, P; Tekin, K; Üçgül Atılgan, C, 2019) |
| "EATP lowered the serum uric acid level and increased the urine uric acid level through excretion, which is useful in the treatment of gout." | 3.91 | Therapeutic potential of ethyl acetate fraction of Tephrosia purpurea Linn. leaves in a rat model of gout. ( Nipate, SS; Yelmar, PS, 2019) |
| "Gout is caused by deposition of monosodium urate crystals in joints when plasma uric acid levels are chronically elevated beyond the saturation threshold, mostly due to renal underexcretion of uric acid." | 3.91 | Hyperuricemia and gout caused by missense mutation in d-lactate dehydrogenase. ( Birk, OS; Drabkin, M; Gurevich, E; Halperin, D; Kadir, R; Landau, D; Perez, Y; Wormser, O; Yogev, Y; Zalk, R; Zarivach, R; Zeller, L, 2019) |
| "Reduced renal clearance of uric acid is a major contributor to hyperuricemia." | 3.91 | Population-specific factors associated with fractional excretion of uric acid. ( Dalbeth, N; Merriman, TR; Narang, RK; Phipps-Green, A; Stamp, LK; Vincent, Z, 2019) |
| "To evaluate the corneal and tear film characteristics in patients with gout and compare these data with those of healthy subjects and to investigate the correlation of corneal densitometry with uric acid value and duration of disease." | 3.91 | Could corneal densitometry be used as a diagnostic and screening tool for ocular involvement in patients with gout? ( Atilgan, CU; Atilgan, KG; Ayli, D; Caglayan, M; Koc, M; Kosekahya, P; Tekin, K; Yilmazbas, P, 2019) |
| "Lesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI." | 3.91 | Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. ( Baumgartner, S; Goldfarb, DS; Jalal, D; Pillinger, M; Saag, KG; Schechter, BM; Terkeltaub, R; Valiyil, R; White, WB, 2019) |
| "Gout is experienced by approximately one in four adults treated with dialysis and two-thirds are prescribed allopurinol." | 3.91 | Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study. ( Chapman, PT; Frampton, C; Palmer, SC; Stamp, LK; Yeo, E, 2019) |
| "Circulating uric acid (UA) is an important biomarker, not only in the detection and management of gout, but also in assessing the risk of related comorbidity." | 3.91 | Antioxidant properties of citric acid interfere with the uricase-based measurement of circulating uric acid. ( Dover, SK; Duryee, MJ; Hollins, A; Hunter, CD; Mikuls, TR; Pirruccello, S; Real, KD; Ryan, EM; Sayles, H; Thiele, GM, 2019) |
| " Then serum urate (Sua), renal function, uric acid metabolism, and the prevalence of metabolic syndrome (Mets) were compared among these groups by the Tukey-Kramer test or Fisher's exact test." | 3.91 | Characteristics of gout patients according to the laterality of nephrolithiasis: A cross-sectional study using helical computed tomography. ( Hori, H; Shimizu, K; Shimizu, T; Umeyama, M, 2019) |
| " In the present study, we aimed to explore the relationship between TAK1 and gout as well as the effects of resveratrol on TAK1 activity and MSU crystal-induced inflammation." | 3.91 | Resveratrol attenuates the MSU crystal-induced inflammatory response through the inhibition of TAK1 activity. ( He, Y; Li, H; Ou, G; Ren, L; Yang, X; Zeng, M, 2019) |
| "Serum uric acid (SUA), hyperuricemia (HUA) and gout are complex traits with relatively high heritability." | 3.91 | Common variants in the ( Cheng, X; Li, C; Li, X; Li, Z; Shi, Y; Wang, C; Zhou, Z, 2019) |
| "To further explore the possibility of xanthine and hypoxanthine to be gout biomarkers as substitutes for uric acid." | 3.91 | Study on the diagnosis of gout with xanthine and hypoxanthine. ( Deng, B; Deng, M; Fei, X; Huang, Z; Wang, Y; Ye, L, 2019) |
| " The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 3.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
| " Of the 62% of q2w responders exhibiting persistent decreases in MAP, there were no significant differences in baseline age, sex, race, weight, body mass index, history of hypertension, hyperlipidemia, history of coronary artery disease, gout duration, MAP, serum urate, estimated glomerular filtration rate or urinary uric acid/creatinine ratio compared with those who did not lower MAP." | 3.91 | Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. ( Choi, HK; Johnson, RJ; Lipsky, PE; Yeo, AE, 2019) |
| "Gout patients with chronic kidney disease (CKD) accumulate the active allopurinol metabolite oxypurinol, suggesting that allopurinol may promote greater serum urate (sU) lowering in CKD patients." | 3.91 | Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function. ( Crittenden, DB; Fisher, MC; Keenan, RT; Krasnokutsky, S; Modjinou, DV; Oh, C; Pillinger, MH; Toprover, M, 2019) |
| "The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines." | 3.91 | Pharmacist-managed titration of urate-lowering therapy to streamline gout management. ( Bays, AM; Crawford, C; Huang, IJ; Liew, JW; Morcos, MB; Zuo, S, 2019) |
| " We investigated whether epigallocatechin-3-gallate (EGCG) suppresses the activation of the NLRP3 inflammasome, thereby effectively preventing gouty inflammation." | 3.91 | Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis. ( Cho, YY; Kang, HC; Lee, HE; Lee, HS; Lee, JY; Park, YB; Yang, G, 2019) |
| "Gout is a common metabolic disease in humans, and it is due to persistently elevated levels of uric acid in the blood." | 3.91 | Decreased Expression of CD14 in MSU-Mediated Inflammation May Be Associated with Spontaneous Remission of Acute Gout. ( Chen, J; Duan, L; Fu, Q; Li, Y; Luo, J; Shang, K; Wang, Y; Wei, Y, 2019) |
| "To investigate the effects on hypercholesterolemia and hypertriglyceridemia in gouty patients receiving uric acid-lowering therapy (UALT)." | 3.91 | Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. ( Deng, JX; Jie, LG; Qu, Y; Wu, J; Yu, QH; Zhang, YP, 2019) |
| "A study to evaluate the prevalence of uric acid (UA) nephrolithiasis with dual-energy CT (DECT) and explore the risk factors for kidney stones in primary gout patients." | 3.91 | Evaluation of the chemical composition of nephrolithiasis using dual-energy CT in Southern Chinese gout patients. ( Bashir, S; Cheng, ZY; Jiao, GL; Li, ZX; Zhou, SM; Zhou, Y, 2019) |
| "Adequate uric acid control before surgery could prevent the postsurgical gout flare." | 3.91 | Clinical characteristics and risk factors for gout flare during the postsurgical period. ( Jeon, CH; Jeong, H, 2019) |
| "In patients with gout, maintaining too low serum uric acid (SUA) level with urate-lowering therapy is a concern because uric acid is thought to be neuroprotective." | 3.88 | Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. ( Bardin, T; Debette, S; Latourte, A; Perez-Ruiz, F; Richette, P; Soumaré, A, 2018) |
| " The PKPD model was used to simulate mono and dual-ULT in gout patients with either under-excretion (lowered clearance) or overproduction of uric acid, with suboptimal adherence modelled as either a single drug holiday of increasing duration or doses taken at random." | 3.88 | Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout. ( Hill-McManus, D; Hughes, D; Lane, S; Marshall, S; Soto, E, 2018) |
| "Forty-seven clinically diagnosed gout patients and 50 subjects (serum uric acid < 7 mg/dL) as controls were included." | 3.88 | Ultrasonographic detection of double contour sign and hyperechoic aggregates for diagnosis of gout: two sites examination is as good as six sites examination. ( Bhadu, D; Das, SK; Dhakad, U; Sharma, M; Wakhlu, A, 2018) |
| "Uric acid is best known for its role in gout-the most prevalent inflammatory arthritis in humans-that is also described as an unusual complication of anorexia nervosa (AN)." | 3.88 | Anorexia nervosa and uric acid beyond gout: An idea worth researching. ( Maas, J; Simeunovic Ostojic, M, 2018) |
| "The aetiology of gout is closely linked to the deposition of monosodium uric acid (MSU) crystals and the consequent activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome." | 3.88 | Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation. ( Cho, YY; Kang, HC; Lee, HE; Lee, HS; Lee, JY; Yang, G; Yeon, SH, 2018) |
| "This narrative review aims to highlight recent findings on the relation between uric acid level and cognitive decline or dementia." | 3.88 | Uric acid and cognitive decline: a double-edge sword? ( Bardin, T; Latourte, A; Richette, P, 2018) |
| "Uric acid has been known since long ago for its implication in gout and in certain kinds of nephrolithiasis." | 3.88 | [Acid uric : key player in a recently recognized devastating nephropathy and in the development of chronic kidney disease.] ( Humbert, A; Stucker, F, 2018) |
| "Numerous epidemiological studies have shown that male patients with uric acid nephrolithiasis outnumber female patients." | 3.88 | Mediators of the Effects of Gender on Uric Acid Nephrolithiasis: A Novel Application of Structural Equation Modeling. ( Chang, YY; Chen, HW; Chen, YC; Chou, YH; Li, CC; Wu, WJ; Yang, FM, 2018) |
| " For each journal, articles relevant to gout and hyperuricaemia were identified by the search terms 'gout' and/or 'urate' and/or 'uric acid' using MEDLINE." | 3.88 | The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals. ( Bursill, D; Dalbeth, N; Taylor, WJ; Terkeltaub, R, 2018) |
| "The uric acid (UA) level in patients with gout is a key factor in disease management and is typically measured in the laboratory using plasma samples obtained after venous puncture." | 3.88 | Accuracy of the HumaSens ( Abrahamsson, A; Bardin, T; Clerson, P; Fabre, S; Gautier, JF; Hughes, G; Launay, JM; Miner, JN; Platt, A; Richette, P; Riveline, JP; Vidal-Trecan, T, 2018) |
| "Three SNPs, URAT1 rs11231825, GLUT9 rs16890979 and ABCG2 rs2231142, previously associated in our population with hyperuricemia and gout, were analyzed in 27 patients with HPRT deficiency treated with allopurinol for at least 5 years." | 3.88 | GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease. ( Puig, JG; Torres, RJ, 2018) |
| "A retrospective data analysis was performed within the UK Clinical Practice Research Datalink (1987-2014) among incident gout patients, aged ⩾40 years and starting allopurinol (n = 48 280)." | 3.88 | Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). ( Arts, ICW; Boonen, A; Burden, AM; de Vries, F; Scheepers, LEJM; Souverein, P; Spaetgens, B, 2018) |
| "There is evidence that uric acid may have antioxidant and neuroprotective effects and might therefore alter the risk for neurodegenerative diseases such as dementia." | 3.88 | Hyperuricemia and dementia - a case-control study. ( Broich, K; Engel, B; Gomm, W; Haenisch, B; Maier, W; Weckbecker, K, 2018) |
| "To retrospectively analyze the efficacy and safety of febuxostat on gout patients with low serum uric acid level." | 3.88 | Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study. ( Chen, X; Gu, B; Li, C; Qian, K; Ren, Q; Shen, M; Su, D; Wang, X; Xu, W; Yang, L; Yuan, H; Zhang, J, 2018) |
| " SUA was downregulated during acute gouty arthritis, which might be associated with increased urinary excretion of uric acid." | 3.88 | Renal excretion is a cause of decreased serum uric acid during acute gout. ( Cao, L; Guo, M; Lv, X; Wan, W; Xue, Y; Zhao, T; Zheng, S; Zhu, X; Zou, H, 2018) |
| "Dual urate-lowering therapy (ULT) with lesinurad in combination with either allopurinol or febuxostat is an option for patients with gout unsuccessfully treated on either monotherapy." | 3.88 | Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model. ( Hill-McManus, D; Hughes, D; Lane, S; Marshall, S; Soto, E, 2018) |
| " He was diagnosed as primary myelofibrosis and treated with interferon-α, together with urate acid-lowing therapy (febuxostat 60 mg once daily)." | 3.88 | [A case of gout secondary to primary myelofibrosis]. ( Hao, YJ; Ji, LL; Zhang, ZL, 2018) |
| "An association between ABCC4 and gout and fractional excretion of uric acid is consistent with the established role of MRP4 as a unidirectional renal uric acid efflux pump." | 3.85 | Population-Specific Resequencing Associates the ATP-Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men. ( Boocock, J; Cadzow, M; Choi, HK; Dalbeth, N; Dobbyn, A; Hindmarsh, JH; Mandal, AK; Merriman, TR; Mount, DB; Phipps-Green, AJ; Stahl, EA; Stamp, LK; Tanner, C; Topless, RK, 2017) |
| "Procyanidins significantly attenuated gout pain and suppressed ankle swelling." | 3.85 | Grape seed-derived procyanidins alleviate gout pain via NLRP3 inflammasome suppression. ( Fan, YX; Gui, X; Han, Y; Hu, L; Jiang, CY; Liu, BQ; Liu, HJ; Liu, WT; Pan, XX; Tang, YL, 2017) |
| "Gout is caused by elevated serum urate levels, which can be treated using inhibitors of the uric acid transporter, URAT1." | 3.85 | Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. ( Gunic, E; Liu, S; Miner, JN; Tan, PK, 2017) |
| "Studies have suggested a relationship between higher baseline serum uric acid (sUA) levels and an elevated risk of subsequent ischemic cardiovascular outcomes among acute coronary syndrome (ACS) patients; this relationship may be modified by a clinical history of gout and has not been studied in large patient cohorts." | 3.85 | An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. ( Akerblom, A; Clare, RM; Held, C; Hess, CN; James, S; Keenan, RT; Klein, AB; Mahaffey, KW; Pagidipati, NJ; Roe, MT; Tricoci, P; Wallentin, L; Wojdyla, D, 2017) |
| "Febuxostat has currently played pivotal role in the treatment of hyperuricemia, but there is little comprehensive information for the determinants of individual difference in efficacy of febuxostat." | 3.85 | Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy. ( Hira, D; Ikeda, Y; Katsube, Y; Koide, H; Minegaki, T; Morita, SY; Nishiguchi, K; Terada, T; Tsujimoto, M; Uzu, T, 2017) |
| "Gout is one of the most painful types of arthritis that arises when the body mounts an acute inflammatory reaction against a crystallized form of uric acid known as monosodium urate crystals (MSUs)." | 3.85 | S100A9 potentiates the activation of neutrophils by the etiological agent of gout, monosodium urate crystals. ( Fernandes, M; Lachhab, A; Marceau, F; Naccache, PH; Paré, G; Pelletier, M; Rousseau, LS; Tessier, P, 2017) |
| "Patient and provider factors, including allopurinol medication adherence, affect gout treatment outcomes." | 3.85 | Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management. ( Bendlin, KA; Coburn, BW; Meza, J; Mikuls, TR; Russell, CL; Sayles, H, 2017) |
| "There is poor adherence to recommended practice for dosing of colchicine in acute gout." | 3.85 | A survey of the assessment and management of gout in general practitioners and medical officers within the Illawarra Network, Australia. ( Riordan, J; Terrill, M, 2017) |
| "Adult gout patients were examined by serial ultrasonography after initiation of ULT with target serum uric acid (SUA) < 6 mg/dL." | 3.85 | Temporal evolution of urate crystal deposition over articular cartilage after successful urate-lowering therapy in patients with gout: An ultrasonographic perspective. ( Basu, K; Das, S; Ghosh, A; Ghosh, P; Goswami, RP; Lahiri, D, 2017) |
| "This study aimed to assess the sensitivity and specificity of ultrasonographic features of gout in intercritical and chronic stages and compared ultrasonographic features of gout between patients with persistent high serum uric acid (SUA) and patients with low SUA." | 3.85 | Sensitivity and specificity of ultrasonographic features of gout in intercritical and chronic phase. ( Basu, K; Das, S; Ghosh, A; Ghosh, P; Lahiri, D; Sinhamahapatra, P, 2017) |
| "ACP recommends that clinicians choose corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchicine to treat patients with acute gout." | 3.85 | Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. ( Barry, MJ; Boyd, C; Chow, RD; Denberg, TD; Forciea, MA; Harris, RP; Humphrey, LL; Kansagara, D; Qaseem, A; Vijan, S; Wilt, TJ, 2017) |
| "Arthritic gout is caused by joint inflammation triggered by the damaging effects of monosodium uric acid (MSU) crystal accumulation in the synovial space." | 3.85 | Macrophage-derived IL-1β enhances monosodium urate crystal-triggered NET formation. ( Rada, B; Sil, P; Surell, C; Wicklum, H, 2017) |
| "We aimed to investigate the effects of febuxostat on IR and the expression of high-sensitivity C-reactive protein (hs-CRP) in patients with primary gout." | 3.85 | Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout. ( Li, Y; Lu, Y; Meng, J; Yuan, X, 2017) |
| "To evaluate and compare the safety and efficacy of three urate lowering agents: febuxostat, allopurinol, and benzbromarone, when used to treat Chinese gout patients." | 3.85 | A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study . ( Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J, 2017) |
| "This study showed that DNI was an effective independent marker to differentiate between an acute gout attack and cellulitis at the crucial early phase irrespective of MSU crystal confirmation or serum uric acid concentration." | 3.85 | Delta neutrophil index contributes to the differential diagnosis between acute gout attack and cellulitis within 24 hours after hospitalization. ( Ha, YJ; Lee, SK; Lee, SW; Park, YB; Pyo, JY; Song, JJ, 2017) |
| "The aim of this study was to evaluate relationships between serum uric acid (SUA) and newly emergent acute myocardial infarction (AMI), congestive heart failure (CHF), coronary artery disease (CAD), composite cardiovascular (CV) events (AMI, CHF, CAD), hypertension, hyperlipidemia, and renal disease in gout patients." | 3.85 | Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data. ( Bienen, EJ; Essex, MN; Hopps, M; Makinson, GT; Mardekian, J; Udall, M, 2017) |
| " Colchicine, at low concentration (10 nM) achieved in gout flare prophylaxis dosing, promoted phosphorylation of AMPKα and macrophage M2 polarisation, and reduced activation of caspase-1 and release of IL-1β and CXCL1 by MSU crystals in BMDMs in vitro." | 3.83 | AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. ( Liu-Bryan, R; Terkeltaub, R; Viollet, B; Wang, Y, 2016) |
| "The purpose of this study is to investigate the effect of urate-lowering therapies (ULTs) on renal uric acid excretion in gout patients." | 3.83 | Influence of urate-lowering therapies on renal handling of uric acid. ( Chen, H; Ji, Z; Jiang, L; Ma, L; Wei, L; Yu, Q; Zhang, Z, 2016) |
| " Hyperuricemia was defined as a serum uric acid level >7 mg/dl for men and >6 mg/dl for women or allopurinol use." | 3.83 | Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. ( Bergamini, C; Bonora, E; Mantovani, A; Pernigo, M; Pichiri, I; Rigolon, R; Targher, G; Zoppini, G, 2016) |
| "A population analysis was conducted in nonmem using oxypurinol and urate plasma concentrations from 133 gout patients." | 3.83 | Predicting allopurinol response in patients with gout. ( Barclay, ML; Dalbeth, N; Duffull, SB; Merriman, TR; Stamp, LK; Wright, DF, 2016) |
| " Model flow based on guideline and real-world treatment paradigms incorporated gout flare, serum uric acid (sUA) testing, treatment titration, discontinuation, and adverse events, chronic kidney disease (CKD) incidence and progression, and type 2 diabetes mellitus (T2DM) incidence." | 3.83 | Febuxostat in the management of gout: a cost-effectiveness analysis. ( Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ, 2016) |
| "Psoriasis has been reported to be associated with raised serum uric acid levels and gout, and uric acid has been demonstrated to mediate inflammatory pathways via secretion of pro-inflammatory chemokines." | 3.83 | Psoriasis and uric acid: a population-based cross-sectional study. ( Lai, YC; Yew, YW, 2016) |
| "Anti-hyperuricemic effect was investigated using xanthine oxidase assay and uricosuric studies with rats in which hyperuricemia was induced by potassium oxonate and uric acid." | 3.83 | Effects of Pimenta pseudocaryophyllus extracts on gout: Anti-inflammatory activity and anti-hyperuricemic effect through xantine oxidase and uricosuric action. ( Antunes Saúde-Guimarães, D; Barros, CH; de Paula Michel Araújo, MC; Ferrari, FC; Lemos Lima, Rde C; Schimith Ferraz Filha, Z, 2016) |
| " The simple definition had similar performance to a SUGAR data-driven case definition with 5 weighted items: self-report, self-report of doctor diagnosis, colchicine use, urate-lowering therapy use, and hyperuricemia (sensitivity 87%, specificity 70%)." | 3.83 | Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. ( Brown, M; Cavagna, L; Chen, JH; Chou, YY; Cimmino, MA; da Rocha Castelar-Pinheiro, G; Dalbeth, N; Ea, HK; Eliseev, M; Fransen, J; Gerritsen, M; Jansen, TL; Janssen, M; Lin, C; Louthrenoo, W; McCarthy, G; Neogi, T; Perez-Ruiz, F; Schumacher, HR; Scire, CA; Sivera, F; Stamp, LK; Tausche, AK; Taylor, WJ; Uhlig, T; Vazquez-Mellado, J, 2016) |
| "To compare total and disease-specific health care expenditures by line of therapy in allopurinol and febuxostat initiators after diagnosis with gout and moderate-to-severe CKD." | 3.83 | Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease. ( Mitri, G; Schulman, KL; Tidwell, BA; Turpin, RS; Wittbrodt, ET, 2016) |
| "Gout is a chronic disease characterized by the deposition of urate crystals in the joints and throughout the body, caused by an excess burden of serum uric acid (sUA)." | 3.83 | The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective. ( Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ, 2016) |
| " Whether gout, the most common rheumatologic inflammatory arthritis, or its cause, elevated serum uric acid (SUA), is associated with VTE incidence is unknown." | 3.83 | Serum uric acid, gout, and venous thromboembolism: The atherosclerosis risk in communities study. ( Folsom, AR; Kubota, Y; McAdams-DeMarco, M, 2016) |
| "Benzbromarone provides useful urate-lowering efficacy and does not appear unsafe in patients with gout." | 3.83 | The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. ( Cathro, A; Corkill, M; Dalbeth, N; Frampton, C; Gardner, D; Grainger, R; Haslett, J; Kain, T; Kumar, R; Kumar, S; Metcalfe, S; Porter, D; Stamp, LK; Stebbings, S; Taylor, G; White, D; Wyeth, J, 2016) |
| "BACKGROUND Gout is characterized by deposition of uric acid crystals (monosodium urate) in tissues and fluids." | 3.83 | Tophaceous Gout in an Anorectic Patient Visualized by Dual Energy Computed Tomography (DECT). ( Christensen, HD; Hansen, IM; Morillon, MB; Sheta, HM, 2016) |
| "The aim of this study is to evaluate the diagnostic yield of dual-energy computed tomography (DECT) in detection of uric acid accumulation in joints or periarticular structures in patients suspected of having gout, in their intercritical period." | 3.83 | Dual-energy computed tomography as a diagnostic tool for gout during intercritical periods. ( Bogot, N; Breuer, GS; Nesher, G, 2016) |
| "Smoking has been found to be negatively correlated with serum uric acid levels by virtue of reduced production and increased consumption of endogenous antioxidant uric acid among smokers and has been reported to decrease incidence of gout." | 3.83 | Risk of acute gout among active smokers: data from nationwide inpatient sample. ( Donato, A; Karmacharya, P; Poudel, DR, 2016) |
| "Gout is caused by the overproduction of uric acid and the inefficient metabolism of dietary purines in humans." | 3.83 | Decrystallization of Crystals Using Gold "Nano-Bullets" and the Metal-Assisted and Microwave-Accelerated Decrystallization Technique. ( Aslan, K; Bonyi, E; Boone-Kukoyi, Z; Kioko, B; Lansiquot, C; Ozturk, B; Shortt, R; Thompson, N; Toker, S, 2016) |
| "Gouty arthritis is caused by the deposition of uric acid crystals, which induce the activation of NOD-like receptor family, pyrin domain containing 3(NLRP3) inflammasome." | 3.83 | Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: a novel strategy to treat acute gout. ( Choi, JY; Jeong, S; Jung, Y; Kim, ND; Lee, HE; Lee, JY; Park, HH; Yang, G, 2016) |
| "We report three Caucasian patients affected by gout and type 2 diabetes, who were treated with the recombinant nonglycosylated human interleukin-1 receptor antagonist anakinra (100 mg/day subcutaneously) after an unsatisfactory or incomplete response to urate-lowering therapy, colchicine, nonsteroidal anti-inflammatory drugs, and prednisone." | 3.81 | Anakinra treatment in patients with gout and type 2 diabetes. ( Bardelli, M; Cantarini, L; Galeazzi, M; Rigante, D; Vitale, A, 2015) |
| " The variables of the diagnostic rule (male sex, previous arthritis attack, onset <1 day, joint redness, involvement of the first MTP joint, hypertension or one or more cardiovascular disease, and serum uric acid >5." | 3.81 | The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. ( Fransen, J; Janssen, M; Janssens, HJ; Kienhorst, LB, 2015) |
| " In addition, we, for the first time, wanted to determine which concentrations of monosodium urate (MSU) in gout and calcium pyrophosphate (CP) in pseudogout are needed to detect or distinguish these soft tissue depositions with DECT." | 3.81 | Detection and characterization of crystal suspensions using single-source dual-energy computed tomography: a phantom model of crystal arthropathies. ( Ackermann, B; Blobel, J; Diekhoff, T; Hamm, B; Hermann, KG; Juran, R; Kiefer, T; Mews, J; Pilhofer, I; Stroux, A; Tsuyuki, M, 2015) |
| "There is very limited information on the association between arsenic and serum uric acid levels or gout." | 3.81 | Arsenic exposure, hyperuricemia, and gout in US adults. ( Fadrowski, JJ; Guallar, E; Kuo, CC; Lin, YS; Navas-Acien, A; Weaver, V, 2015) |
| "To identify modifiable patient and provider factors associated with allopurinol adherence and the achievement of a serum urate acid (SUA) goal in gout." | 3.81 | Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. ( Cheetham, TC; Coburn, BW; Curtis, JR; Mikuls, TR; Rashid, N; Saag, KG; Wu, YL, 2015) |
| "To quantify the risk of non-fatal acute myocardial infarction (AMI) among users of allopurinol." | 3.81 | Allopurinol use and risk of non-fatal acute myocardial infarction. ( Álvarez, A; Bryant, V; de Abajo, FJ; García-Poza, P; García-Rodríguez, LA; Gil, MJ; Rodríguez, A, 2015) |
| "To evaluate the cost-effectiveness of allopurinol versus febuxostat in adult patients with gout over a 5-year time period from a U." | 3.81 | Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. ( Bottorff, MB; Gandhi, PK; Gentry, WM; Ma, Q, 2015) |
| "Allopurinol is used as long-term therapy to reduce the occurrence of gout flares." | 3.81 | Allopurinol adherence among patients with gout: an Italian general practice database study. ( Antonioli, L; Blandizzi, C; Capogrosso-Sansone, A; Convertino, I; Cricelli, C; Cricelli, I; Fornai, M; Lapi, F; Mantarro, S; Montagnani, S; Pecchioli, S; Tuccori, M, 2015) |
| "Inefficient renal excretion of uric acid is the main pathophysiological mechanism for hyperuricemia in gout patients." | 3.81 | Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. ( Aniel-Quiroga, MA; Chinchilla, SP; Erauskin, GG; Herrero-Beites, AM; Merriman, T; Perez-Ruiz, F, 2015) |
| "The objective of the present work was to develop polymeric nanoparticles of uricase and aceclofenac (NSAID) and to incorporate them into gel, for delivering drugs to synovial joints, for effective treatment of Gout." | 3.81 | Urate crystal degradation for treatment of gout: a nanoparticulate combination therapy approach. ( Dwivedi, H; Kymonil, KM; Saraf, SA; Tiwari, S, 2015) |
| "Predicted by the core ingredient-target-pathway network, we collected 30 core ingredients in MSW and 25 inflammatory cytokines and uric acid synthetase or transporters, which are effective for gouty treatment through some related pathways." | 3.81 | A network pharmacology approach to determine active ingredients and rationality of herb combinations of Modified-Simiaowan for treatment of gout. ( Guochun, L; Shi, L; Xu, L; Yang, Y; Yin, L; Zhao, F, 2015) |
| "This study investigated the epidemiological evidence for a protective role of high serum concentration of uric acid, for which we used gout as a proxy, in the aetiology of MS, PD or MND." | 3.81 | Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies. ( Goldacre, MJ; Pakpoor, J; Ramagopalan, SV; Seminog, OO, 2015) |
| " Study patients had at least one medical claim with a diagnosis of gout, at least one filled prescription for febuxostat or allopurinol and at least one sUA measurement post-index prescription." | 3.81 | Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. ( Akhras, KS; Shiozawa, A; Singh, JA, 2015) |
| "Gout is a common inflammation disease resulting from an increase in serum uric acid." | 3.81 | Common Variants in LRP2 and COMT Genes Affect the Susceptibility of Gout in a Chinese Population. ( Dong, Z; He, H; Ji, H; Jin, L; Ma, Y; Pang, Y; Qian, Q; Wang, J; Wang, X; Xu, X; Yang, C; Yang, Y; Zhao, D; Zhou, J; Zou, H, 2015) |
| "Among the gouty patients, 36% refrain from the use of allopurinol, only 23% out of them require that its dose be adjusted to achieve the target level of UA." | 3.81 | [Time course of changes in the clinical manifestations of gout in men: data of a 7-year retrospective follow-up]. ( Barskova, VG; Denisov, IS; Eliseev, MS, 2015) |
| "Gout is managed poorly in Australian primary care, with low levels of allopurinol prescribing and serum urate testing." | 3.81 | An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. ( Dalbeth, N; Robinson, PC; Taylor, WJ, 2015) |
| "Gout is an acute inflammatory disease characterised by the presence of uric acid crystals in the joint." | 3.81 | Oral treatment with Bifidobacterium longum 51A reduced inflammation in a murine experimental model of gout. ( Amaral, FA; Galvão, I; Martins, FS; Nicoli, JR; Teixeira, MM; Vieira, AT, 2015) |
| "These data suggest that BMI influences serum urate and gout risk in response to chronic SSB intake, and renal tubular uric acid handling in response to an acute fructose load." | 3.81 | Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout. ( Dalbeth, N; Gamble, GD; Horne, A; House, ME; Merriman, TR; Phipps-Green, A; Stamp, LK, 2015) |
| "The main purpose of the present supplement, which is based on a symposium held in Bologna, 6-8 November 2014, is twofold: first of all, to reinforce the role of uric acid in the pathogenesis of gout and gout-related non-rheumatic diseases including renal involvement; second, to provide an updated review of the evidence supporting the relevant role of elevated uric acid as a risk factor for cardiovascular diseases." | 3.81 | The role of uric acid in the development of cardiovascular disease. ( Borghi, C, 2015) |
| "Using a Danish Register cohort of 86,039 adult new allopurinol users and propensity score matched controls, we found that gout requiring allopurinol prescription was associated with an increased fracture risk." | 3.81 | Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study. ( Abrahamsen, B; Bone, KW; Cooper, C; Dennison, EM; Harvey, NC; Rubin, KH; Schwarz, P, 2015) |
| "In a retrospective claims data study of enrollees in health plans affiliated with Optum, we evaluated patients from February 1, 2009, to May 31, 2012, with a gout diagnosis, a pharmacy claim for allopurinol or febuxostat, and at least 1 serum uric acid (SUA) result available during the follow-up period." | 3.81 | A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. ( Altan, A; Bancroft, T; Shiozawa, A; Singh, JA, 2015) |
| "Our objective was to evaluate data on the cost-effectiveness of febuxostat compared with standard clinical practice with allopurinol in patients with gout that was presented to the Scottish Medicines Consortium (SMC) in 2010." | 3.80 | Cost-effectiveness of febuxostat in chronic gout. ( Beard, SM; Nuki, G; Pearson, IV; von Scheele, BG, 2014) |
| "American College of Rheumatology and European League Against Rheumatism guidelines recommend colchicine to prevent gout flares in patients initiating and increasing uric acid–lowering therapy until serum uric acid is maintained at ≤6 mg/dl." | 3.80 | Evaluating appropriate use of prophylactic colchicine for gout flare prevention. ( George, M; Hussain, F; Pullman-Mooar, S; Schumacher, HR, 2014) |
| "Serum uric acid levels were not significantly different in the asymptomatic hyperuricaemia, gouty arthritis without tophi and gouty tophi groups." | 3.80 | The effects of gout on left atrial volume remodelling: a prospective echocardiographic study. ( Chang, PJ; Chang, ST; Chen, MC; Chung, CM; Hsiao, JF; Lin, CL; Lin, JC; Pan, KL, 2014) |
| " The pharmacist contacted each patient by phone, provided educational and dietary materials, and used a protocol that employs standard gout medications to achieve and maintain a serum uric acid (sUA) level of 6 mg/dL or less." | 3.80 | Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study. ( Avins, AL; Goldfien, RD; Hwe, A; Jacobson, A; Ng, MS; Pressman, A; Yip, G, 2014) |
| " riparia in reducing serum uric acid levels in a potassium oxonate-induced hyperuricemia mouse model." | 3.80 | Smilax riparia reduces hyperuricemia in mice as a potential treatment of gout. ( Anderson, S; Wu, XH; Yu, CH; Zhang, CF; Zhang, YW, 2014) |
| "The mean serum uric acid level of patients with gout in the practice had risen in comparison with a similar audit carried out in March 2009." | 3.80 | Management of gout in a South Auckland general practice. ( Arroll, B; Reaves, E, 2014) |
| "Febuxostat is recommended as 1 of 2 first-line urate-lowering therapies (ULT) for treating gout in the 2012 American College of Rheumatology Guidelines." | 3.80 | Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. ( Akhras, KS; Hatoum, H; Khanna, D; Khanna, P; Lin, SJ; Shiozawa, A, 2014) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 3.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| "Hyperhomocysteinemia is one of the important factors of the cardiovascular disease, and gout is well known to be associated with cardiovascular disease." | 3.80 | Elevated serum homocysteine levels were not correlated with serum uric acid levels, but with decreased renal function in gouty patients. ( Choi, ST; Kim, JS; Song, JS, 2014) |
| "Gout with uric acid underexcretion is associated with transporter gene SNP related mainly to tubular reabsorption, whereas uric acid normoexcretion is associated only with tubular secretion SNP." | 3.80 | Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. ( Bailén, R; Banegas, JR; de Miguel, E; Puig, JG; Torres, RJ, 2014) |
| "Among a renal transplant population with at least 1 year of follow-up, we included 27 patients with sustained hyperuricemia and 11 with normal serum uric acid (SUA) levels." | 3.80 | A pilot study on dual-energy computed tomography for detection of urate deposits in renal transplant patients with asymptomatic hyperuricemia. ( Alberú, J; Betanzos, JL; Criales-Vera, S; Hernández-Molina, G; Kimura-Hayama, E; Nicolaou, S; Rivera, Y; Rull-Gabayet, M, 2014) |
| " Increased serum uric acid level during this month had been reported in past studies of nongout patients." | 3.80 | The impact of Ramadan fast on patients with gout. ( Artul, S; Badarny, S; Habib, G; Hakim, G; Khazin, F; Khreish, M; Shehadeh, V, 2014) |
| "While the prevalence of gout was calculated by counting patients with this diagnosis hyperuricemia was inferred in patients taking allopurinol at hospital admission or discharge, on the assumption that this drug was only prescribed owing to the finding of high serum levels of uric acid." | 3.80 | Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. ( Conca, A; Corrao, S; Djade, CD; Franchi, C; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M, 2014) |
| "Probenecid is recommended as urate-lowering therapy (ULT) in patients with gout where xanthine oxidase inhibitors are ineffective, not tolerated, or contraindicated." | 3.79 | Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. ( Dalbeth, N; Gow, PJ; Pui, K, 2013) |
| " Hyperuricemia was defined as serum uric acid >6." | 3.79 | Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. ( Gelber, AC; Juraschek, SP; Kovell, LC; Miller, ER, 2013) |
| " Further evidences were collected about the role of diet in the non-pharmacological treatment of gout and the efficacy of oral corticosteroids and low-dose colchicine in the management of acute attacks." | 3.79 | Italian Society of Rheumatology recommendations for the management of gout. ( Bianchi, G; Borghi, C; Bortoluzzi, A; Cimmino, MA; D'Avola, GM; Desideri, G; Di Giacinto, G; Favero, M; Govoni, M; Grassi, W; Lombardi, A; Manara, M; Marangella, M; Matucci Cerinic, M; Medea, G; Minisola, G; Prevete, I; Punzi, L; Ramonda, R; Scirè, CA; Spadaro, A, 2013) |
| "A loss-of-function mutation (Q141K, rs2231142) in the ATP-binding cassette, subfamily G, member 2 gene (ABCG2) has been shown to be associated with serum uric acid levels and gout in Asians, Europeans, and European and African Americans; however, less is known about these associations in other populations." | 3.79 | Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study. ( Best, LG; Brown-Gentry, KD; Cole, SA; Crawford, DC; Deelman, E; Fornage, M; Franceschini, N; Gaffo, AL; Glenn, KR; Heiss, G; Jenny, NS; Jorgensen, NW; Kao, WH; Kottgen, A; Li, Q; Liu, K; Matise, TC; North, KE; Spencer, KL; Umans, JG; Voruganti, VS; Zhang, L, 2013) |
| "Gout and serum uric acid are associated with mortality but their simultaneous contributions have not been fully evaluated in the general population." | 3.79 | Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. ( Abdalla, AA; Casserly, LF; Cronin, CJ; Hanley, A; Hannigan, A; Hegarty, A; Kiernan, TJ; Murthy, BV; Nguyen, HT; Stack, AG, 2013) |
| "Gout is an abnormality in the body resulting in the accumulation of uric acid mainly in joints." | 3.79 | Enzyme-entrapped mesoporous silica for treatment of uric acid disorders. ( Chandra, MS; Krishnan, UM; Muthukoori, S; Narayanan, N; Sethuraman, S, 2013) |
| "Gout is a common disease caused by hyperuricemia, which shows elevated serum uric acid (SUA) levels." | 3.79 | Common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility. ( Chiba, T; Hamajima, N; Hishida, A; Ichida, K; Inoue, K; Kato, Y; Kawai, S; Matsuo, H; Nakamura, T; Nakashima, H; Nakayama, A; Ogata, H; Sakiyama, M; Sakurai, Y; Shimizu, S; Shimizu, T; Shinomiya, N; Takada, T; Takada, Y; Ushiyama, C; Wakai, K, 2013) |
| " Caspase-1, IL-1β, IL-18, and uric acid were measured in synovial fluid from 112 patients with gout and other arthritides, such as rheumatoid arthritis, osteoarthritis, and spondyloarthropathy." | 3.79 | Caspase-1 level in synovial fluid is high in patients with spondyloarthropathy but not in patients with gout. ( Bang, SY; Choi, CB; Jun, JB; Kim, JH; Kim, TH; Son, CN, 2013) |
| "Acute gout is associated with a decrease in serum uric acid (SUA) that is considered to be in response to acute inflammation but it may be a feature of gout itself." | 3.79 | The effect of the systemic inflammatory response, as provoked by elective orthopaedic surgery, on serum uric acid in patients without gout: a prospective study. ( Ashby, HL; Chugh, S; Deshpande, S; Ford, C; Gama, R; Razavi, C; Thomas, OL; Waldron, JL, 2013) |
| "The associations and gene-diet interactions involving VEGFR-2 gene polymorphisms and FD on uric acid provide new information on gout and hyperuricaemia risks in Malays." | 3.78 | Association and interaction effect between VEGF receptor-2 (VEGFR-2) gene polymorphisms and dietary pattern on blood uric acid in Malays and Indians. ( Hon, WM; Masaki, M; Roseline, YW; Shidoji, Y, 2012) |
| "Previous reports suggested that gout incidence increased with serum uric acid (sUA) level." | 3.78 | Gender-specific risk factors for incident gout: a prospective cohort study. ( Chen, JH; Chuang, SY; Pan, WH; Wu, YY; Yeh, WT, 2012) |
| "These were post hoc analyses of datasets from the Aspirin Myocardial Infarction Study, a 1:1 randomized, double-blind clinical trial, conducted from 1975 to 1979, that examined mortality rates following daily aspirin administration over three years in individuals with documented MI." | 3.78 | Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. ( Dabbous, O; Hariri, A; Krishnan, E; Lingala, B; Pandya, BJ, 2012) |
| "Several genome-wide association studies (GWASs) have reported associations between single nucleotide polymorphisms (SNPs) and uric acid concentrations or gout in a number of different ethnic populations." | 3.78 | Association between gout and polymorphisms in GCKR in male Han Chinese. ( Chu, N; Han, L; Li, C; Liu, S; Ma, X; Meng, D; Miao, Z; Wang, B; Wang, J; Zhang, K, 2012) |
| "Although hyperuricemia is suggested to increase allantoin production in both pro- and antioxidant manners, it remains undetermined whether it increases the serum concentration of allantoin." | 3.78 | Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients. ( Koga, M; Koyama, H; Kurajoh, M; Moriwaki, Y; Shoji, T; Sumida, C; Tsutsumi, Z; Yamamoto, A; Yamamoto, T, 2012) |
| "Allopurinol is the most commonly used urate-lowering therapy in gout." | 3.78 | Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. ( Dalbeth, N; Dockerty, JL; Drake, J; Frampton, C; Jones, PB; Stamp, LK; Taylor, WJ, 2012) |
| "In this hypothesis-generating study, gout patients who took colchicine had a significantly lower prevalence of MI and exhibited trends toward reduced all-cause mortality and lower CRP level versus those who did not take colchicine." | 3.78 | Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. ( Crittenden, DB; Cronstein, BN; Greenberg, JD; Keenan, RT; Lehmann, RA; Pillinger, MH; Schneck, L; Sedlis, SP; Shah, B, 2012) |
| "These findings demonstrate that mangiferin has the potential to be developed as a new therapeutic agent for the treatment of hyperuricemia and gout." | 3.78 | Reducing effect of mangiferin on serum uric acid levels in mice. ( Gao, L; Li, L; Lin, H; Liu, X; Lu, W; Niu, Y, 2012) |
| "Blood lead levels in the range currently considered acceptable are associated with increased prevalence of gout and hyperuricemia." | 3.78 | Low-level lead exposure and the prevalence of gout: an observational study. ( Bhalla, V; Krishnan, E; Lingala, B, 2012) |
| "We report the unusual case of a 63-year-old man with gout and coexisting pseudogout (calcium pyrophosphate dihydrate crystal deposition disease) affecting the same joint." | 3.77 | Gout and coexisting pseudogout in the knee joint. ( Huh, M; Kim, SJ; Seo, YJ; Yoo, JH; Yoo, Y; Yun, KH, 2011) |
| "In contrast to large GWA studies based on thousands of individuals and large meta-analyses combining GWAS results, we analyzed a small case/control sample for uric acid nephrolithiasis." | 3.77 | Application of a new method for GWAS in a related case/control sample with known pedigree structure: identification of new loci for nephrolithiasis. ( Bonerba, B; Caruso, MR; Casu, G; Casula, S; Concas, MP; Deiana, I; Forabosco, P; Maestrale, GB; Mele, C; Persico, I; Pirastu, M; Pistidda, P; Sassu, A; Thornton, T; Tore, S; Usai, P, 2011) |
| " As gout is characterized by elevated serum concentrations of uric acid, we investigated ADRB3 as a potential candidate for gout." | 3.77 | Positive correlation between Beta-3-Adrenergic Receptor (ADRB3) gene and gout in a Chinese male population. ( Chu, N; Han, L; Jia, Z; Li, C; Liu, S; Ma, X; Meng, D; Wang, B; Wang, J; Zhang, K; Zhoub, S, 2011) |
| " We present a case of tophaceous gout with uric acid levels that did not respond to prescription of very high doses of allopurinol or uricosuric agents." | 3.77 | Febuxostat efficacy in allopurinol-resistant tophaceous gout. ( Reid, G; Uh, M, 2011) |
| " This study investigated trends in uric acid levels, hyperuricemia and gout among adults in Taiwan from 1993-1996 to 2005-2008, using data collection from, Nutrition and health surveys in Taiwan (NAHSIT) conducted in 1993-1996 and 2005-2008." | 3.77 | Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. ( Chuang, SY; Hsieh, YT; Lee, SC; Pan, WH, 2011) |
| " Subjects were further categorized into 3 diagnostic groups: gout, asymptomatic hyperuricemia (no gout, serum uric acid [UA] ≥6." | 3.77 | Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. ( Gyftopoulos, S; Howard, RG; Pillinger, MH; Samuels, J; Swearingen, CJ; Thiele, RG, 2011) |
| "Allopurinol, a purine base analog inhibitor of xanthine oxidase (XO) activity, remains the standard for pharmacologic urate-lowering management of gout." | 3.77 | Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. ( Chohan, S, 2011) |
| "The treatment of gout requires a lowering of serum urate (SU) levels, and allopurinol is the drug that is most commonly used for this purpose." | 3.77 | Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. ( Barclay, ML; Chapman, PT; Drake, J; Frampton, C; O'Donnell, JL; Stamp, LK; Zhang, M, 2011) |
| "To study the prevalence of chronic kidney disease (CKD) and its impact on allopurinol dosing and uric acid control among patients with gout." | 3.77 | Chronic kidney disease in gout in a managed care setting. ( Dabbous, O; Fuldeore, MJ; Krishnan, E; Pandya, BJ; Riedel, AA; Zarotsky, V, 2011) |
| "Urate-lowering therapy (ULT), adjusted to achieve and maintain a serum uric acid (SUA) of <6 mg/dl, remains the standard of care for the chronic management of gout." | 3.77 | Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy. ( Gilliland, WR; Keith, MP, 2011) |
| "To identify factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol." | 3.77 | Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study. ( Kim, YG; Lee, CK; Lee, SG; So, MW; Yoo, B, 2011) |
| "To estimate the accuracy, sensitivity, specificity, and interobserver agreement of dual-energy computed tomography (CT) in detection of uric acid crystals in joints or periarticular structures in patients with arthralgia and patients suspected of having gout, with joint aspiration results as reference standard." | 3.77 | Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. ( Black, DF; Bongartz, T; Fletcher, JG; Glazebrook, KN; Guimarães, LS; Leng, S; Manek, NJ; McCollough, CH; Murthy, NS, 2011) |
| "Recent genome-wide association studies showed that serum uric acid (SUA) levels relate to ABCG2/BCRP gene, which locates in a gout-susceptibility locus revealed by a genome-wide linkage study." | 3.77 | ABCG2/BCRP dysfunction as a major cause of gout. ( Hosoya, T; Ichida, K; Matsuo, H; Nakamura, T; Nakayama, A; Shinomiya, N; Suzuki, H; Takada, T, 2011) |
| "High serum uric acid levels are associated with gout, atherosclerosis and cardiovascular disease." | 3.76 | Sex and age interaction with genetic association of atherogenic uric acid concentrations. ( Adams, TD; Brandstätter, A; Coassin, S; Hunt, SC; Kedenko, L; Kiechl, S; Kramer, F; Kronenberg, F; Lamina, C; Paulweber, B; Summerer, M; Willeit, J, 2010) |
| "These prospective data with long-term followup provide evidence that higher levels of serum uric acid increase the risk of gout in a graded manner among women, but the rate of increase is lower than that among men." | 3.76 | Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. ( Bhole, V; Choi, H; de Vera, M; Krishnan, E; Rahman, MM, 2010) |
| "Recent genome-wide association and functional studies have shown that the ABCG2 gene encodes for a urate transporter, and a common causal ABCG2 variant, rs2231142, leads to elevated uric acid levels and prevalent gout among Whites and Blacks." | 3.76 | The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people. ( Folsom, AR; Iso, H; Kitamura, A; Köttgen, A; Tanigawa, T; Yamagishi, K, 2010) |
| " We apply all the methods to GWAS of serum uric acid levels and gout with 550,000 single nucleotide polymorphisms in the Framingham Heart Study." | 3.76 | Analyze multivariate phenotypes in genetic association studies by combining univariate association tests. ( Fox, CS; Guo, CY; Wu, H; Yang, Q, 2010) |
| "To enable clinicians to initiate appropriate steps for long-term management of gout, including controlling acute exacerbations and pain and sustaining target serum uric acid (SUA) levels to control hyperuricemia as the underlying metabolic disorder." | 3.76 | The current state of care in gout: Addressing the need for better understanding of an ancient disease. ( Graser, E; Pope, RS; Zychowicz, ME, 2010) |
| "Fructose-rich beverages such as sugar-sweetened soda and orange juice can increase serum uric acid levels and, thus, the risk of gout, but prospective data on the relationship are limited." | 3.76 | Fructose-rich beverages and risk of gout in women. ( Choi, HK; Curhan, G; Willett, W, 2010) |
| "Published evidence in the literature, regulatory status, and relative costs of colchicine and nonsteroidal anti-inflammatory drugs (NSAIDs) for prophylaxis of gouty flares during early urate-lowering therapy are reviewed." | 3.76 | Nonsteroidal anti-inflammatory drugs and colchicine to prevent gout flare during early urate-lowering therapy: perspectives on alternative therapies and costs. ( Peterson, DM, 2010) |
| "To assess the value of dual energy computed tomography (DECT) for the detection of uric acid (UA) deposition in patients with gout." | 3.76 | [Application of dual-energy computed tomography for detecting uric acid deposition in patients with gout]. ( Chen, Y; Jin, ZY; Liu, W; Sun, H; Wang, X; Xu, K; Xue, HD; Zeng, XJ; Zhang, YQ, 2010) |
| "In a cohort of veterans with a diagnosis of gout prescribed allopurinol, colchicine or probenecid, quality of care was assessed by examining adherence to the following evidence-based recommendations: (1) whether patients starting a new allopurinol prescription (a) received continuous allopurinol, (b) received colchicine prophylaxis, (c) achieved the target uric acid level of | 3.75 | Opportunities for improving medication use and monitoring in gout. ( Asch, SM; Hodges, JS; Singh, JA, 2009) |
| "In this article we describe a gouty caucasian male patient who had high levels of serum uric acid since 1970s." | 3.75 | Persistent normalization of serum levels of uric acid in a gouty patient after administration of cyproterone acetate. ( D'Angelo, S; Olivieri, I; Palazzi, C; Pennese, E, 2009) |
| "To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout." | 3.75 | Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. ( Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009) |
| "We identified persons using two integrated delivery systems aged 18 years or older with a diagnosis of gout who initiated use of allopurinol, probenecid or sulfinpyrazone from 1 January 2000 to 30 June 2006." | 3.75 | Adherence with urate-lowering therapies for the treatment of gout. ( Andrade, SE; Briesacher, BA; Fouayzi, H; Harrold, LR; Ockene, IS; Raebel, MA; Yood, RA, 2009) |
| " Rosiglitazone was also administered to demonstrate whether improved insulin sensitivity would prevent high-purine diet induced renal injury and gouty-like lesions." | 3.75 | Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions. ( Gu, J; Li, C; Li, Y; Meng, D; Miao, Z; Wang, B; Wang, CY; Wang, J; Wang, L; Xing, X; Yan, S; Yuan, Y; Zhang, S, 2009) |
| "We examined the association between serum uric acid (SUA) level and the frequency, risk, and cost of gout flares among the elderly." | 3.75 | Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? ( Cahill, KE; Krishnan, E; Mody, RR; Patel, PA; Tang, J; Wu, EQ; Yu, AP, 2009) |
| " At moderate or high doses, an effect on any one marker may be absent or even the opposite of that observed at very high or excessive doses; examples include fasting plasma triglyceride, insulin sensitivity, and the putative marker uric acid." | 3.75 | Fructose ingestion: dose-dependent responses in health research. ( Livesey, G, 2009) |
| "To determine the association between allopurinol compliance and serum urate (sUA) level; and examine the association between sUA and gout-related healthcare costs in a large managed care population." | 3.75 | Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. ( Fuldeore, MJ; Halpern, R; Mikuls, TR; Mody, RR; Patel, PA, 2009) |
| "The aim of this prospective study was to evaluate results of metformin (MF) therapy during 1 year of uric acid (UA) metabolism and the clinical course of gout with insulin resistance (IR)." | 3.75 | [Effect of metformin on the clinical course of gout and insulin resistance]. ( Aleksandrova, EN; Barskova, VG; Eliseev, MS; Kudaeva, FM; Nasonov, EL; Nasonova, VA; Volkov, AV, 2009) |
| "Gout is well known to be produced by increased uric acid level in blood." | 3.75 | Calcium oxalate stone and gout. ( Marickar, YM, 2009) |
| "The name of Sir Alfred Baring Garrod is linked with the first detection of uric acid in blood and its accumulation in sufferers from gout as well as the formulation of the term rheumatoid arthritis." | 3.75 | [The High Priest of gout - Sir Alfred Baring Garrod (1819-1907)]. ( Keitel, W, 2009) |
| "Understanding how uric acid crystals provoke inflammation is crucial to improving our management of acute gout." | 3.74 | Gout in the spotlight. ( So, A, 2008) |
| " Conditions known to increase uric acid production (psoriasis, chronic bronchitis) and to decrease uric acid excretion (hypothyroidism, metabolic syndrome, and nephroangiosclerosis) may operate in a single patient, illustrating the dramatic clinical course of untreated gout." | 3.74 | An unusual patient with hypothyroidism, tophaceous gout, and marked joint destruction. ( Fraile, JM; Montoya, F; Puig, JG; Torres, RJ, 2008) |
| "We identified three genetic loci associated with uric acid concentration and gout." | 3.74 | Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. ( Astor, BC; Benjamin, EJ; Boerwinkle, E; Coresh, J; Dehghan, A; Fox, CS; Hofman, A; Hwang, SJ; Kao, WL; Köttgen, A; Levy, D; Rivadeneira, F; van Duijn, CM; Witteman, JC; Yang, Q, 2008) |
| "Our population-based data provide evidence for a protective effect of gout on the risk of PD and support the purported protective role of uric acid." | 3.74 | Gout and the risk of Parkinson's disease: a cohort study. ( Choi, H; De Vera, M; Gao, X; Kopec, J; Rahman, MM; Rankin, J, 2008) |
| "In 18 patients with monosodium urate (MSU) crystal proven gout, and after the initiation of successful serum uric acid (SUA)-lowering treatment, an arthrocentesis of the asymptomatic signal joint (11 knees, 7 first metatarsophalangeal joints) was performed every 3 months to obtain a synovial fluid (SF) sample." | 3.74 | Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. ( Pascual, E; Sivera, F, 2007) |
| "Using the Minneapolis Veterans Affairs electronic medical record system, we identified a cohort of veterans receiving medication to treat gout between January 1, 1999 and December 31, 2003, and evaluated 3 recently published evidence-based QIs for gout management: QI 1 = allopurinol dose <300 mg in gout patients with renal insufficiency, QI 2 = uric acid check within 6 months of starting a new allopurinol prescription, and QI 3 = complete blood count and creatine kinase check every 6 months for gout patients receiving prolonged colchicine therapy." | 3.74 | Quality of care for gout in the US needs improvement. ( Asch, SM; Hodges, JS; Singh, JA; Toscano, JP, 2007) |
| "2 mg/kg (monthly vs daily) in patients with tophaceous gout not treatable by allopurinol." | 3.74 | Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. ( Bardin, T; Brière, C; Hoenen-Clavert, V; Loeuille, D; Richette, P, 2007) |
| "Serum uric acid concentrations are correlated with gout and clinical entities such as cardiovascular disease and diabetes." | 3.74 | SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. ( Coassin, S; Döring, A; Fischer, G; Gieger, C; Gohlke, H; Henke, K; Illig, T; Klopp, N; Kronenberg, F; Mehta, D; Meisinger, C; Meitinger, T; Paulweber, B; Pfeufer, A; Prokisch, H; Rosskopf, D; Völzke, H; Wichmann, HE, 2008) |
| "For older adults with gout to (1) assess health care utilization and costs from a third-party payer perspective; (2) evaluate health care costs related to tophi; and (3) explore the relationship between elevated serum uric acid (UA) level, an indicator of disease control, and health care utilization." | 3.74 | Disease-related and all-cause health care costs of elderly patients with gout. ( Cahill, KE; Krishnan, E; Mody, RR; Patel, PA; Tang, J; Wu, EQ; Yu, AP, 2008) |
| "To evaluate haemoglobin A1c (HbA1c), fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels in a nationally representative sample of men and women." | 3.74 | Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey. ( Choi, HK; Ford, ES, 2008) |
| "Greater intakes of total vitamin C were significantly associated with lower serum uric acid concentrations, after adjustment for smoking, BMI, ethnicity, blood pressure, presence of gout, use of aspirin, and intake of energy, alcohol, dairy protein, fructose, meat, seafood and coffee." | 3.74 | Vitamin C intake and serum uric acid concentration in men. ( Ascherio, A; Choi, HK; Curhan, G; Forman, JP; Gao, X, 2008) |
| "Cross-sectional studies indicate metabolic syndrome is a risk factor for elevated serum uric acid." | 3.74 | Impact of childhood metabolic syndrome components on the risk of elevated uric acid in adulthood: the Bogalusa Heart Study. ( Berenson, G; Chen, W; Menke, A; Muntner, P; Patel, DA; Srinivasan, S, 2008) |
| " We evaluated the hypouricemic effect of propolis from China on hyperuricemia induced by the uricase inhibitor, oxonic acid (500 mg/kg p." | 3.73 | [Xanthine oxidase inhibitory activity and hypouricemia effect of propolis in rats]. ( Nishioka, N; Tsuji, T; Yoshizumi, K, 2005) |
| "Identification of monosodium urate (MSU) and calcium pyrophosphate dehydrate (CPPD) crystals in synovial fluid samples is diagnostic of gout and CPPD crystal related arthropathy." | 3.73 | Analysis for crystals in synovial fluid: training of the analysts results in high consistency. ( Frasquet, J; González-Salinas, J; Hernández-Aguado, I; Lumbreras, B; Pascual, E; Rodríguez, E, 2005) |
| "We determined why calcium oxalate stones instead of uric acid stones form in some patients with gouty diathesis." | 3.73 | Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis. ( Moe, OW; Pak, CY; Peterson, RD; Poindexter, JR; Sakhaee, K, 2005) |
| " In this article, we focus on the three common crystals and diseases: hydroxyapatite crystal deposition disease, calcium pyrophosphate dihydrate (CPPD) deposition disease, and monosodium urate crystals (gout)." | 3.73 | Cervical spine and crystal-associated diseases: imaging findings. ( Carlier, R; Chevrot, A; Drapé, JL; Feydy, A; Lioté, F, 2006) |
| "5), hypercalciuria-calcium greater than 200 mg, hyperoxaluria-oxalate greater than 45 mg, hyperuricosuria-uric acid greater than 600 mg, hypocitraturia-citrate less than 600 mg and purine gluttony-sulfate greater than 20 mg." | 3.73 | Ethnic background has minimal impact on the etiology of nephrolithiasis. ( Ekeruo, WO; Enemchukwu, CU; Maloney, ME; Preminger, GM; Springhart, WP; Young, MD, 2005) |
| "Patients with system lupus erythematosus, rheumatic arthritis, chronic active hepatitis and gout were found to have considerable hyperuricemia and be decreased in aminoacides content, which are the predecessors of purine." | 3.73 | [Hyperuricemia and disorders in content of amino acids-purine precursors in patients with autoimmune diseases and gout]. ( Anan'eva, MN; Dubiaga, VV; Nikolenko, IuI; Nikolenko, VIu; Shchukin, IN; Siniachenko, OV, 2005) |
| "Development of the acute and chronic inflammatory responses known as gout and pseudogout are associated with the deposition of monosodium urate (MSU) or calcium pyrophosphate dihydrate (CPPD) crystals, respectively, in joints and periarticular tissues." | 3.73 | Gout-associated uric acid crystals activate the NALP3 inflammasome. ( Martinon, F; Mayor, A; Pétrilli, V; Tardivel, A; Tschopp, J, 2006) |
| "The objectives of this study were to evaluate attainment of this target SUA among gout patients on allopurinol in a naturalistic setting and to assess its impact on gout flare risk." | 3.73 | Serum urate levels and gout flares: analysis from managed care data. ( Bakst, AW; Brewer, KK; Patel, PA; Sarawate, CA; Schumacher, HR; Yang, W, 2006) |
| " A diagnosis of gouty tophi was offered which was confirmed by histopathology and serum uric acid level." | 3.73 | FNAC of gouty tophi--a case report. ( Purohit, MB; Purohit, TM; Tandon, RK, 2006) |
| "Adherence to published allopurinol dosing guidelines led to suboptimal control of hyperuricemia in this population of patients with gout." | 3.73 | Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. ( Dalbeth, N; Gow, P; Kumar, S; Stamp, L, 2006) |
| "To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout." | 3.73 | Effect of fenofibrate in combination with urate lowering agents in patients with gout. ( Lee, CH; Lee, J; Lee, YH, 2006) |
| " Further antihyperuricemic-guided purification of the fraction afforded three lignans, phyllanthin (1), hypophyllanthin (2) and phyltetralin (3), of which 1 significantly reversed the plasma uric acid level of hyperuricemic animals to its normal level in a dose-dependent manner, comparable to that of allopurinol, benzbromarone and probenecid which are used clinically for the treatment of hyperuricemia and gout." | 3.73 | Antihyperuricemic lignans from the leaves of Phyllanthus niruri. ( Chan, KL; Murugaiyah, V, 2006) |
| "The plasma levels of lipoproteins, cholesterol, triglycerides and uric acid, and the renal excretion of uric acid were studied in 68 patients with gout and in another control group of 50 healthy subjects." | 3.72 | The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. ( Cardona, F; Collantes, E; Escudero, A; García-Fuentes, E; Soriguer, FJ; Tinahones, FJ, 2003) |
| "To test the hypothesis that stone-forming patients with type II diabetes (DM-II) have a high prevalence of uric acid (UA) stones and present with some of the biochemical features of gouty diathesis (GD)." | 3.72 | Biochemical profile of stone-forming patients with diabetes mellitus. ( Ekeruo, W; Moe, O; Pak, CY; Peterson, RD; Pietrow, P; Poindexter, JR; Preminger, GM; Sakhaee, K, 2003) |
| " Three individuals had markedly high plasma uric acid levels posthibernation; of these, two individuals died from extensive visceral gout and one recovered with fluid therapy." | 3.72 | A comparison between pre- and posthibernation morphometry, hematology, and blood chemistry in viperid snakes. ( Dutton, CJ; Taylor, P, 2003) |
| " The cardinal clinical features in individuals with the uromodulin mutation included hyperuricemia, decreased fractional excretion of uric acid, and chronic interstitial renal disease leading to end-stage renal disease (ESRD) in the fifth through seventh decade." | 3.72 | Clinical characterization of a family with a mutation in the uromodulin (Tamm-Horsfall glycoprotein) gene. ( Bleyer, AJ; Deterding, E; Ganier, D; Gorry, MC; Hart, TC; McBride, D; Sandhu, J; Satko, SG; Shihabi, Z; Weller, N; Woodard, AS; Xu, L; Zhu, H, 2003) |
| "Overactivity of phosphoribosylpyrophosphate synthetase (PRS) is an X chromosome-linked disorder of purine metabolism that is characterized by gout with uric acid overproduction and, in some families, neurodevelopmental impairment." | 3.72 | Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman. ( Ahmed, M; Becker, MA; García-Pavía, P; García-Puig, J; Rivero, M; Torres, RJ, 2003) |
| " Pure and mixed uric acid stones were strongly associated with a gouty diathesis, and vice versa." | 3.72 | Predictive value of kidney stone composition in the detection of metabolic abnormalities. ( Adams-Huet, B; Pak, CY; Pearle, MS; Poindexter, JR, 2003) |
| "In 99% of the cases, the underlying cause of gout is an inborn disorder of uric acid excretion." | 3.72 | [Avoid purine-rich foods, drink a lot, reduce weight. The most important recipes against hyperuricemia]. ( Benecke, M, 2003) |
| "Among 127 consenting patients, 81 with rheumatoid arthritis taking nonsteroidal antiinflammatory drugs (13 diclofenac, 20 naproxen) or disease modifying antirheumatic drugs (25 sulfasalazine, 23 methotrexate), 17 patients with polymyalgia rheumatica taking prednisone, and 29 patients with gout taking daily prophylactic colchicine (n = 12) or the uric acid lowering drugs allopurinol (10) or benzbromaron (7), 104 used their medication from a regular medication bottle fitted with a special cap containing microelectronics capable of recording time and date of opening and closing, defined as a medication event." | 3.72 | The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. ( de Klerk, E; Landewé, R; van der Linden, S; van der Tempel, H; van der Heijde, D, 2003) |
| "Anthropometric parameters, blood lipid spectrum, levels of glucose, uric acid (UA), immunoreactive insulin, HOMA index were studied in 55 male patients with gout (mean age 50." | 3.72 | [Insulin resistance syndrome in patients with gout and its influence on formation of clinical characteristics of the disease]. ( Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Nasonov, EL; Zilov, AV, 2004) |
| "The role of nitric oxide (NO) in the antinociceptive effect of indomethacin was assessed in the pain-induced functional impairment model in the rat (PIFIR model), a model of inflammatory and chronic pain similar to that observed in clinical gout." | 3.72 | Peripheral involvement of the nitric oxide-cGMP pathway in the indomethacin-induced antinociception in rat. ( Déciga-Campos, M; Díaz-Reval, MI; González-Trujano, ME; López-Muñoz, FJ; Ventura-Martínez, R, 2004) |
| "To determine whether the biochemical presentation and urinary physicochemical environment of patients with hyperuricosuria presenting with calcium stones (hyperuricosuric calcium urolithiasis [HUCU]) differs from those of patients with gouty diathesis (GD) or idiopathic uric acid urolithiasis." | 3.71 | Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. ( Koska, J; Pak, CY; Peterson, RD; Poindexter, JR; Sakhaee, K, 2002) |
| "To compare renal handling of uric acid in patients with primary gout with that of a control group." | 3.71 | Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. ( Calabozo, M; Erauskin, GG; Herrero-Beites, AM; Perez-Ruiz, F; Ruibal, A, 2002) |
| " Treatment with allopurinol results in a significant reduction in serum creatinine in patients with gout and in those with hyperuricemia and renal impairment." | 3.71 | Hyperuricemia, gout, and renal function after liver transplantation. ( Alexander, GJ; Gibbs, P; Gimson, AE; Neal, DA; Tom, BD, 2001) |
| ", anorexia nervosa and alcoholism, and the mechanisms by which increased uric acid level may be explained." | 3.70 | Tophaceous gout of the navicular bone as a cause of medial inflammatory tumor of the foot. ( Baldet, P; Blotman, F; Bonnel, F; Canovas, F; Leroux, JL; Medioni, D; Olive, P; Thomas, E, 1998) |
| "We measured serum concentrations of 1,25(OH)2-vitamin D3, 25(OH)-vitamin D3, parathyroid hormone (PTH), and uric acid in 114 male patients with primary gout and 51 normal male control subjects." | 3.70 | Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout. ( Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1998) |
| "We measured the serum concentrations of 1,25(OH)2-vitamin D3, 25(OH)-vitamin D3, parathyroid hormone (PTH) in 82 male patients with primary gout whose serum uric acid was significantly higher than that of 41 normal control male subjects (8." | 3.70 | Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout. ( Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1998) |
| "We studied 34 apparently healthy children and 2 propositi from kindreds with familial juvenile hyperuricaemic nephropathy (FJHN) - a disorder characterised by early onset, hyperuricaemia, gout, familial renal disease and a similarly low urate clearance relative to glomerular filtration rate (GFR) [fractional excretion of uric acid (FEur) 5." | 3.70 | Presymptomatic detection of familial juvenile hyperuricaemic nephropathy in children. ( Cameron, JS; Dalton, N; Haycock, GB; McBride, MB; Moro, F; Ogg, CS; Raman, GV; Rees, L; Rigden, S; Simmonds, HA; Van't Hoff, W, 1998) |
| " Alcohol consumption and central obesity were independent predictors of gout among hyperuricemic subjects irrespective of uric acid level." | 3.70 | Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. ( Chou, P; Lin, HY; Lin, KC, 2000) |
| "Accurate determination of serum and urinary uric acid concentrations is essential for the diagnosis and classification of gout according to uric acid metabolism derangement." | 3.70 | Effect of urine storage on urinary uric acid concentrations. ( Hada, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 2000) |
| "To investigate the incidence of gout and the interaction between uric acid level and other risk factors in the development of gout." | 3.70 | The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. ( Chou, P; Lin, HY; Lin, KC, 2000) |
| " We examined the development of gout and an increased uric acid level in relation to lead, adjusting for other known risk factors." | 3.70 | Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. ( Hu, H; Kim, R; Liang, MH; Shadick, NA; Sparrow, D; Weiss, S, 2000) |
| "Uric acid crystal was found in four patients pleural effusion and stones in two patients' spittle which were consist of monosodium urate (MSU)." | 3.70 | [Pleural effusion of gout]. ( Han, Y; Liu, L; Zhang, K, 2000) |
| " In this study, we show that the inflammatory microcrystals monosodium urate monohydrate (MSU) and calcium pyrophosphate dihydrate (CPPD), the major mediators of gout and pseudogout, differentially regulate the production of these two chemokines by human neutrophils." | 3.69 | Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. ( Hachicha, M; McColl, SR; Naccache, PH, 1995) |
| "We compared gouty diathesis with uric acid versus calcium stones." | 3.69 | Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation. ( Adams-Huet, B; Khatchadourian, J; Pak, CY; Preminger, GM; Whitson, PA, 1995) |
| " Accordingly, the glycosuria- and/or hyperglycemia-induced decrease in the biological half-life of oxypurinol must be considered in the administration of allopurinol to gouty patients with uncontrolled diabetes mellitus." | 3.69 | Effect of glucose infusion on the renal transport of purine bases and oxypurinol. ( Higashino, K; Moriwaki, Y; Suda, M; Takahashi, S; Yamamoto, T, 1995) |
| "Ten women with crystal-proved primary gout and normal serum creatinine levels (below 116 mmol/L) were studied while they were on a purine-restricted diet and taking no medications known to influence uric acid metabolism." | 3.69 | Purine metabolism in women with primary gout. ( de Miguel, E; Gil, AA; Mateos, FA; Miranda, ME; Pérez de Ayala, C; Puig, JG; Torres, RJ, 1994) |
| "Uricaemia-lowering treatment is indicated when hyperuricaemia is pronounced (90 mg/L or more) or when it is expressed by uric acid stones and/or gout." | 3.69 | [Hyperuricemia and gout: therapeutic indications]. ( Pawlotsky, Y, 1994) |
| " The 1977 ARA criteria for gout in a survey setting were used and serum uric acid was determined by a uricase method." | 3.69 | Gout is on the increase in New Zealand. ( Castle, B; Klemp, P; Robertson, MC; Stansfield, SA, 1997) |
| "Primary gout is characterized by increased plasma and decreased urinary concentrations of hypoxanthine, xanthine and uric acid." | 3.69 | Purine metabolism in patients with gout: the role of lead. ( Herrero, E; Mateos, FA; Miranda-Carús, E; Puig, JG; Ramos, T; Sanz, AG, 1997) |
| "We describe a patient with no history of gout and persistently normal serum uric acid concentrations in whom septic acute prepatellar bursitis was diagnosed initially, but empiric antibiotic therapy failed." | 3.69 | Prepatellar bursitis: a unique presentation of tophaceous gout in an normouricemic patient. ( Dawn, B; Walker, SE; Williams, JK, 1997) |
| "To determine whether the plasma level of uridine can be used to identify patients with gout, the plasma concentration of uridine was determined in patients with gout and normal subjects." | 3.69 | Is the plasma uridine level a marker of the overproduction of uric acid? ( Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1997) |
| "Uric acid in blood has been widely accepted as a reliable indicator of hyperuricemia and gout, and its assay method has been established." | 3.69 | [Determination of uric acid in scalp hair for non-invasive estimation of uricemic control in hyperuricemia]. ( Isaka, Y; Kobayashi, K; Morioka, Y; Tozawa, T, 1997) |
| "Increased serum urate concentrations in hereditary nephropathy associated with hyperuricemia and gout are due to severe impairment of uric acid excretion." | 3.68 | Hereditary nephropathy associated with hyperuricemia and gout. ( Calvin, TS; Gil, AA; Jiménez, ML; Mateos, FA; Miranda, ME; Picazo, ML; Puig, JG, 1993) |
| "Hyperuricemia and gout have been associated with cyclosporine A (CyA) therapy in transplant recipients." | 3.68 | Tophaceous gout in patients with renal transplants treated with cyclosporine A. ( Baethge, BA; Landreneau, MD; McDonald, JC; Work, J, 1993) |
| "The relation between creatinine and uric acid metabolism was analysed in 77 male patients with primary gout and 62 healthy male subjects." | 3.68 | Relation between creatinine and uric acid excretion. ( Nishida, Y, 1992) |
| "To determine the frequency and characteristics of hyperuricemia and gouty arthritis among cyclosporine-treated heart transplant recipients." | 3.68 | Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. ( Burack, DA; Griffith, BP; Kahl, LE; Thompson, ME, 1992) |
| "Synovial fluid (SF) samples, all containing monosodium urate crystals, obtained from 18 asymptomatic knees of 12 patients with gout, were serially analyzed before and one month after treatment with 1 mg/day of oral colchicine." | 3.68 | Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals. ( Castellano, JA; Pascual, E, 1992) |
| "Hypotheses concerning the development of uric acid and gouty nephropathy suggest that the initiating disease mechanism involves an interaction between uric acid or monosodium urate monohydrate (MSUM) crystals and renal tubular epithelial cells." | 3.68 | Ultrastructural studies of the reaction of urate crystals with a cultured renal tubular cell line. ( Axelsen, RA; Cross, M; Emmerson, BT; Osborne, JM, 1991) |
| "Effects of alminoprofen (AP), a non-steroidal anti-inflammatory agent, were investigated using several experimental gouty models." | 3.68 | [Effects of alminoprofen on sodium urate crystal-induced inflammation]. ( Hujiyoshi, T; Maeda, E; Uematsu, T, 1991) |
| " The three main types of crystal arthritis are monosodium urate (gout), calcium pyrophosphate dihydrate, and calcium phosphate (usually hydroxyapatite)." | 3.68 | Crystal arthritis: a clinician's view. ( Hall, S, 1991) |
| "The effect of serum and synovial fluid obtained from six healthy subjects and from 12 patients with gout, six with rheumatoid arthritis and 18 with calcium pyrophosphate dihydrate arthropathy (CPPD) on the rate of in vitro urate crystal formation was measured." | 3.68 | Evidence for a promoter of urate crystal formation in gouty synovial fluid. ( Dieppe, PA; McGill, NW, 1991) |
| "We reviewed the clinical features and uric acid metabolism in 37 female patients with gout." | 3.68 | Female gout. Clinical spectrum and uric acid metabolism. ( Capitán, CF; de Miguel, E; Gijón, JB; Jiménez, ML; Mateos, FA; Michán, AD; Pérez de Ayala, C; Puig, JG, 1991) |
| "The overactivity of PRPP synthetase is transmitted as a sex-linked abnormality, being characterized by uric acid overproduction and, in some patients, by muscular hypotonia, neurosensitive deafness and/or ataxia." | 3.68 | [Metabolism of purine nucleotides in the central nervous system in patients with phosphoribosylpyrophosphate synthetase hyperactivity and neurosensory deafness]. ( García Neito, V; García Puig, J; López Jiménez, M; Mateos Antón, F; Ramos Hernández, T; Sebastián Melián, J, 1990) |
| "Superactivity of phosphoribosylpyrophosphate (PRPP) synthetase is one of several hereditary enzyme abnormalities associated with gout and excessive uric acid excretion." | 3.67 | Diagnostic evaluation of phosphoribosylpyrophosphate synthetase activities in hemolysates. ( Becker, MA; Hecker, S; Losman, MJ; Woo, S, 1984) |
| "Ten patients with gout, hypertension, and mild to moderate renal insufficiency were studied for possible lead nephropathy by measuring stimulated urinary lead excretion." | 3.67 | Occult lead intoxication in patients with gout and kidney disease. ( Cecere, FA; Saylor, RP; Wright, LF, 1984) |
| "Sixteen hyperuricemic gouty patients were treated with diflunisal, a novel salicylate, 500 mg BID." | 3.67 | Hypouricemic action of diflunisal in gouty patients: in vitro and in vivo studies. ( Ambanelli, U; Ferraccioli, G; Spisni, A, 1984) |
| "The behavior of plasma and urine oxypurines (hypoxanthine and xanthine) and of uric acid has been studied in normal subjects and in gout patients." | 3.67 | [Analysis of uric acid and oxypurines in normal subjects and in gout patients]. ( Di Stefano, A; Leoncini, R; Marinello, E; Pizzichini, M; Porcelli, B; Taddeo, A, 1989) |
| "The clearance of uric acid, hypoxanthine and xanthine has been examined in gout patients and in normal subjects compared to creatinine, after a purine-free diet." | 3.67 | [Clearance of oxypurines in normal subjects and in gout patients subjected to a purine-free diet. Effects of allopurinol]. ( Di Stefano, A; Leoncini, R; Marinello, E; Pizzichini, M; Porcelli, B; Taddeo, A, 1989) |
| "To evaluate the frequency and the pathogenesis of hyperuricemia and gout during cyclosporine therapy, we studied renal-transplant recipients who were treated with either cyclosporine and prednisone (n = 129) or azathioprine and prednisone (n = 168)." | 3.67 | Cyclosporine-induced hyperuricemia and gout. ( Fox, IH; Lin, HY; McQuillan, MA; Palella, TD; Rocher, LL; Schmaltz, S, 1989) |
| "The relationship between uric acid metabolism and lipid levels was analyzed in 148 male subjects with primary gout." | 3.67 | Relationship between hypertriglyceridemia and uric acid production in primary gout. ( Jiao, S; Kubo, M; Matsubara, K; Matsuzawa, Y; Takama, T; Tarui, S, 1989) |
| "Two members of a Spanish family were studied: an eight-year-old boy (Patient 1) with tophaceous gout, purine nucleotide and uric acid overproduction, and sensorineural deafness, and his 27-year-old mother (Patient 2), who had gout." | 3.67 | Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. ( Becker, MA; Jimenez, ML; Kim, M; Mateos, FA; Puig, JG; Simmonds, HA, 1988) |
| "A patient with coexistent Klinefelter's syndrome, systemic lupus erythematosus (SLE) and chronic tophaceous gouty arthritis developed allopurinol hypersensitivity." | 3.67 | Allopurinol hypersensitivity in a patient with coexistent systemic lupus erythematosus and tophaceous gout. ( Fam, AG; McDonald, J; Paton, T; Senn, J, 1988) |
| "The renal excretion of uric acid is usually diminished in primary gout with respect to increased serum urate levels." | 3.67 | Renal excretion of hypoxanthine and xanthine in primary gout. ( Jiménez, ML; Mateos, FA; Puig, JG; Ramos, TH, 1988) |
| "20 patients with elevated serum uric acid levels and osteoarthritis of the hip or knee were given diflunisal 500 mg b." | 3.67 | [The uric acid-lowering effect of diflunisal]. ( Fasching, U, 1987) |
| "Similarity of the morphological picture of gouty nephropathy and primary glomerulonephritides in which purine antagonists turned out to be effective, a positive effect of azathioprine (Az) and 6-mercaptopurine (MP) on purine metabolism, and changes in immunity indices revealed in gout (hyperproduction of immunoglobulins and circulating immune complexes) necessitates the use of antimetabolites in combined therapy of gout patients with proteinuric and latent types of nephropathy." | 3.67 | [Substantiation and effectiveness of the use of purine antagonists in gouty nephropathy]. ( Diadyk, AI; Nikolenko, IuI; Shpilevaia, NI; Siniachenko, OV; Vasilenko, IV, 1987) |
| "It's reported that oral administration of fructose in normal and gouty patients causes a rise in serum uric acid (see "References": Stirpe et al." | 3.67 | [Evaluation of hyperuricemia caused by fructose in a status of altered uric acid metabolism]. ( Della Corte, E; Menghini, S, 1987) |
| "Uric acid concentration in the serum was investigated 3 times a day using the uricase method in 15 gout inpatients on a hypopurine diet with age- and sex-adjusted caloric content." | 3.67 | [Circadian rhythm of uric acid levels of the serum in gout]. ( Atanasov, NA; Karastanev, II; Kereziev, IK; Kuzmanova, SI; Solakov, PTs, 1987) |
| " Dispensary examinations of the patients resulted in a decrease in the level of uric acid and in the number of exacerbations of gouty arthritis, the reduction of the sizes of tophi or their disappearance." | 3.67 | [Rehabilitation of patients with gout during outpatient follow-up]. ( Akimova, TF; Ivanova, MM; Novoselova, TM; Tsurko, VV, 1987) |
| " Three of the four females showed impaired renal function and elevated serum uric acid levels, two of them suffered from recurrent gouty attacks." | 3.67 | [Secondary gout and pseudo-Bartter syndrome in females with laxative abuse]. ( Adam, O; Goebel, FD, 1987) |
| "The plasma concentrations of oxipurinol, the chief metabolite of allopurinol, were studied in 66 patients with gout in whom the dose of allopurinol varied between 100 and 400 mg per day." | 3.67 | Plasma oxipurinol concentrations during allopurinol therapy. ( Cross, M; Emmerson, BT; Gordon, RB; Thomson, DB, 1987) |
| "Gout is a disease linked to altered uric acid metabolism with increased uric acid concentration in the blood, the deposition of sodium urate crystals in certain tissues and abscesses." | 3.67 | [Arthropathies and nutrition: gout]. ( Milano, L, 1986) |
| "In a study designed to evaluate the radionuclide images in patients with gout, six (23%) of the 26 patients had clear evidence of Paget's disease of bone by technetium Tc 99m medronate imaging." | 3.67 | Paget's disease of bone in patients with gout. ( Hansell, JR; Lluberas-Acosta, G; Schumacher, HR, 1986) |
| "A family is described in which four members in three generations showed evidence of crystal deposition disease: two developed calcium pyrophosphate dihydrate (CPPD) crystal deposition, one calcific periarthritis, and one mixed crystal deposition disease (gout + chondrocalcinosis)." | 3.67 | Multiple microcrystal deposition within a family. ( Dieppe, PA; Doherty, M, 1985) |
| " Examples of calculating the risk for gout attack and of EPH gestosis, depending on serum uric acid level, is presented." | 3.67 | [Criteria for the selection and evaluation of diagnostic tests]. ( Keller, H, 1985) |
| " The association of arthritic disease and joint degeneration with the deposition of sodium urate crystals in gout and calcium pyrophosphate crystals in pseudogout (chondrocalcinosis) is clinically well established." | 3.67 | Apatite-type crystal deposition in arthritic cartilage. ( Ali, SY, 1985) |
| "1) is associated with gout and uric acid overproduction in affected hemizygous males." | 3.66 | Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate. ( Becker, MA; Itkin, P; Losman, MJ; Simkin, PA, 1982) |
| "Forty-seven patients with gout, 28 of whom had not previously been treated with allopurinol, and 25 normal subjects, were examined for 24-h urinary excretion of the most important adrenal steroid derivatives." | 3.66 | Hormonal aspects of human gout--excretion of adrenal hormone derivatives in gouty patients. ( Aleo, MF; Bianchi, E; Ferrari, S; Gregolini, L; Marcolongo, R; Marinello, E, 1983) |
| " The relationship between calcium oxalate (COX) crystals - implicated in the vasculitis of primary oxalosis - and immunologically mediated endothelial injury was also explored." | 3.66 | Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury. ( Boogaerts, MA; Hammerschmidt, DE; Jacob, HS; Roelant, C; Verwilghen, RL, 1983) |
| "In an open trial 15 patients with acute gout attacks were treated with Tolmetin." | 3.66 | [Treatment of acute gout attacks with tolmetin (author's transl)]. ( Gaismayer, K; Petera, P; Tausch, G, 1982) |
| "The incorporation of 15N-glycine into urinary uric acid was studied in three gouty patients, repeating a study carried out 13 to 27 years ago." | 3.66 | Long-term follow-up of incorporation of 15N from glycine into uric acid in gout. ( Roboz, J; Yu, TF, 1981) |
| "The results over 10 years in 200 patients (103 with gout and 97 with hyperuricaemia) treated with benzbromarone 75 - 120 mg/d are reported." | 3.66 | Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. ( Giudicelli, CP; Masbernard, A, 1981) |
| "Forty-nine patients with gout, many with hypertension and/or renal calculi, were given hydrochlorothiazide, furosemide, or ticrynafen." | 3.66 | Effects of diuretics on urate and calcium excretion. ( Berger, L; Kaung, C; Sarkozi, L; Yü, T, 1981) |
| " Drugs used for hyperuricemia and gout such as colchicine, allopurinol, probenecid, and sulphinpyrazone have not been implicated in affecting exercise performance." | 3.66 | Effects of exercise performance on drugs used in musculoskeletal disorders. ( Day, RO, 1981) |
| "Ten generations of selection for uricemia and articular gout have led to the development of the HUA line which is characterized by a threefold increase in plasma level of uric acid when compared to the control LUA line, even when fed diets containing normal levels of protein." | 3.66 | Hereditary uricemia and articular gout in chickens. ( Austic, RE; Cole, RK, 1980) |
| "Inherited enzyme deficiencies are found in a small proportion of patients with gout who produce an excess of uric acid." | 3.66 | Primary overproduction of urate caused by a partial deficiency of hypoxanthine-guanine phosphoribosyl transferase. ( Cassidy, M; Gregory, MC; Harley, EH, 1980) |
| "We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin." | 3.66 | Indomethacin-induced hyperkalemia in three patients with gouty arthritis. ( Beckstrom, D; Findling, JW; Itskovitz, H; Kozin, F; Rawsthorne, L, 1980) |
| " In 17 subjects with gout, blood uric acid levels were reduced by approximately 50%." | 3.66 | Tienilic acid: a single treatment for hyperuricaemia and hypertension? ( Gibson, T; Potter, CF; Rodgers, VA; Simmonds, HA, 1980) |
| "A patient with intractable tophaceous gout and advanced renal failure responded favorably to treatment by long-term hemodialysis and administration of allopurinol." | 3.66 | Chronic gouty nephropathy treated by long-term hemodialysis and allopurinol. ( Johnson, WJ; O'Duffy, JD, 1979) |
| "In most patients with primary gout hyperuricaemia results from a renal defect in tubular uric acid secretion." | 3.66 | Uricosuric therapy and urate solubility in blood and urine. ( Gröbner, W; Zöllner, N, 1979) |
| "After a short survey of the purine metabolism, excretion of uric acid, theories of gout and urate nephropathy methodical references are given for the estimation of excretion of uric acid, a normal region on test persons was established and compared with other authors." | 3.66 | [Diagnostic value of renal urate excretion]. ( Häntzschel, U; Költzsch, V, 1978) |
| " Synthesis of 14C-labelled N-formyl glycinamide ribonucleotide by lymphocytes was measured in healthy control subjects and patients with primary gout or hyperuricaemia secondary to renal failure, with or without allopurinol therapy." | 3.66 | Purine biosynthesis de novo by lymphocytes in gout. ( Brami, M; Chanard, J; Funck-Brentano, JL; Kamoun, P, 1978) |
| "Intrasynovial deposits of monourate crystals in the presence of serum hyperuricaemia, and calcium pyrophosphate dihydrate (CPPD) crystals, are responsible for gout and pseudogout respectively." | 3.66 | Crystal induced arthritis: gout and pseudogout. ( Webb, J, 1978) |
| " The color compensator allows differentiation between the monosodium urate crystals of gout and the crystals of pseudogout, or calcium pyrophosphate deposition disease." | 3.65 | An office technique for identifying crystal in synovial fluid. ( Wild, JH; Zvaifler, NJ, 1975) |
| "We have reported previously two siblings with gout and uric acid lithiasis associated with excessive purine production." | 3.65 | Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts. ( De Vries, A; Sperling, O; Zoref, E, 1975) |
| "In the majority of patients with gout and excessive uric acid production, underlying enzyme abnormalities have not been identified." | 3.65 | Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction. ( Becker, MA, 1976) |
| "A mutant feedback-resistant, physiologically superactive, phosphoribosylpyrophosphate (PP-ribose-P) synthetase was found in a family with purine overproduction, gout and uric acid lithiasis." | 3.65 | Superactivity of phosphoribosylpyrophosphate synthetase, due to feedback resistance, causing purine overproduction and gout. ( Boer, P; Brosh, S; de Vries, A; Sperling, O; Zoref, E, 1977) |
| "Chronic lead nephtropathy, secondary gout (lead-gout) and porphyrinuria may develop after long lasting professional exposure to lead." | 3.65 | [Chronic lead poisoning: Lead gout with giant tophi on the skin, nephrophathy and porphyrinopathy]. ( Künzig, M; Orfanos, CE, 1975) |
| " 91% have serum uric acid levels above the normal range and 61% present "hyperuricemia," according to "gouty risk" criteria." | 3.65 | [Occurrence of hyperuricemia in atrioventricular block. (Results of a study of 158 patients with isotopic pacemaker implantations)]. ( Gavelle, P; Laurens, P; Maurice, P, 1976) |
| "Plasma uric acid levels in 35 obese gouty and non-gouty subjects showed a highly significant mean fall of 0." | 3.65 | The effect of weight loss on plasma and urinary uric acid and lipid levels. ( Scott, JT; Sturge, RA, 1977) |
| "A case of recurrent, superficial phlebitis in the lower extremities, with raised blood uric acid levels, responsive to colchicine and to urate pool depletion, but unassociated with articular complaint is reported." | 3.65 | Recurrent gouty phlebitis without articular gout. ( Pasero, G, 1977) |
| "Dark red nodules that drained an opaque amber liquid developed on the extensor surfaces of both legs in a 69-year-old woman receiving furosemide and spironolactone for congestive heart failure." | 3.65 | Panniculitis of the legs with urate crystal deposition. ( Niemi, KM, 1977) |
| "The diagnosis of gout and pseudogout has traditionally been established by the identification, in synovial fluid, of monosodium urate and calcium pyrophosphate dihydrate crystals with compensated polarizing light microscopy." | 3.65 | Crystal deposition disease. Diagnosis by electron microscopy. ( Gorevic, P; Hoffstein, S; Honig, S; Weissmann, G, 1977) |
| "The prevalence of gout and the frequency distribution of serum uric acid (SUA) concentrations have been studied in four South African populations." | 3.65 | Rheumatic disorders in the South African Negro. Part IV. Gout and hyperuricaemia. ( Beighton, P; Solomon, L; Soskolne, CL; Sweet, MB, 1977) |
| " Such a synthesis was measured in 20 healthy controls, 24 patients with primary gout (11 on allopurinol therapy) and 26 patients with chronic renal failure and secondary hyperuricemia (8 on allopurinol therapy)." | 3.65 | [De novo purine biosynthesis. In vitro measurement in hyperuricemia (author's transl)]. ( Brami, M; Brunois, JP; Chanard, J; Funck-Brentano, JL; Kamoun, P; Pleau, JM, 1977) |
| " The drug is particularly useful in patients with chronic gouty arthritis and tophi, either refractory or allergic to probenecid, sulfinpyrazone, or allopurinol." | 3.65 | Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone. ( Yu, TF, 1976) |
| "Three patients with gout and seven with hyperuricaemia, previously untreated, took a single dose of 100 mg allopurinol and 20 mg benzbromaron (as a combined preparation) each morning." | 3.65 | [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)]. ( Berg, G; Matzkies, F, 1976) |
| "Chickens genetically selected for high incidence of articular gout and hyperuricemia were used to determine the site of defective uric acid (UA) transport in gout." | 3.65 | Localization of renal tubular uric acid transport defect in gouty chickens. ( Quebbemann, AJ; Zmuda, MJ, 1975) |
| " Calcium pyrophosphate crystals induced modest erythrocyte hemolysis, also, and time-course experiments showed a markedly different reaction curve from those produced by silica and urate." | 3.65 | Differential membranolytic effects of microcrystalline sodium urate and calcium pyrophosphate dihydrate. ( McCarty, DJ; Wallingford, WR, 1971) |
| "THE CONCEPT OF AN ABNORMALITY OF GLUTAMINE METABOLISM IN PRIMARY GOUT WAS FIRST PROPOSED ON THE BASIS OF ISOTOPE DATA: when [(15)N]glycine was administered to gouty subjects, there was disproportionately great enrichment of N-(3 + 9) of uric acid, which derive from the amide-N of glutamine." | 3.65 | The kinetics of intramolecular distribution of 15N in uric acid after administration of (15N) glycine. A reappraisal of the significance of preferential labeling of N-(3+9) of uric acid in primary gout. ( Sperling, O; Starmer, CF; Wyngaarden, JB, 1973) |
| "Certain gouty subjects with excessive de novo purine synthesis are deficient in hypoxanthineguanine phosphoribosyltransferase (HG-PRTase [EC 2." | 3.65 | Mechanism of excessive purine biosynthesis in hypoxanthine-guanine phosphoribosyltransferase deficiency. ( Sorensen, LB, 1970) |
| "Activity of hypoxanthine-guanine and adenine phosphoribosyl transferase enzymes has been assayed in erythrocytes from 10 normal adults, 37 subjects with gout, and 21 mentally retarded children with high and normal urinary uric acid:creatinine ratios." | 3.65 | Phosphoribosyl transferase activity in normal subjects, gout patients, and children with mental retardation. ( Davison, AN; Eyre, C; Scott, JT, 1971) |
| " Serum uric acid levels may rise slightly, but no clinical gout was seen in this study." | 3.64 | TREATMENT OF CONGESTIVE HEART FAILURE WITH TRIAMTERENE. ( FRIEDMAN, R; SCHUCHER, R; WENER, J, 1965) |
| "The characteristic phenomena of acute gouty arthritis are acute arthritis in a middle-aged male, associated with serum uric acid above 6 mg." | 3.63 | Diagnosis and treatment of gouty arthritis. ( TALBOTT, JH, 1953) |
| "Gout is triggered by high urate levels and causes inflammation, pain, and an impaired quality of life." | 3.30 | Immersion in Water Between 20-30 ( Chou, KR; Karwur, FF; Kurniasari, MD; Miao, NF; Rayanti, RE; Shen, CJ; Shih, YW; Tsai, HT; Yuliana, S, 2023) |
| " The incidence of adverse events was 50." | 3.30 | Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial. ( Lee, J; Min, J; Saag, KG; Shin, S; Terkeltaub, R, 2023) |
| " Most guidelines recommend using a lifelong continuation treat-to-target (T2T) strategy, in which ULT is dosed or combined until a serum urate target has been reached and maintained." | 3.30 | Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial. ( den Broeder, AA; den Broeder, N; Flendrie, M; Peeters, IR; Taylor, WJ; van Herwaarden, N, 2023) |
| " The MGH Acupuncture Sensation Scale and adverse events related to acupuncture will be measured after each treatment." | 3.30 | Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol. ( Chen, Z; Fang, MY; Huang, Y; Li, CN; Lin, FP; Liu, WH; Ma, Y; Tu, SH; Wang, B; Wang, Y; Xie, WX; Yu, LL; Zhang, RY; Zheng, CH, 2023) |
| "Uricosuric agents are the typical approach to the control of hyperuricemia; however, their use has been eclipsed by adverse reactions, and a safer uricosuric drug is badly needed." | 3.11 | Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study. ( Chen, Y; Di, X; Fan, L; Jin, Y; Li, X; Liu, R; Wang, Y; Wang, Z; Zheng, L; Zhou, Y, 2022) |
| "To determine the long-term use of and adherence to urate-lowering therapy (ULT), serum urate (SU) control, and self-reported flares in participants from a randomized controlled trial of allopurinol dose escalation, in order to achieve target SU concentration (< 0." | 3.11 | Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout. ( Coleman, GB; Dalbeth, N; Drake, J; Frampton, C; Haslett, J; Horne, AM; Stamp, LK; Su, I, 2022) |
| "Overweight and obesity are typical risk factors for the increased prevalence and incidence of gout." | 3.11 | The effects of aerobic exercise on body composition in overweight and obese patients with gout: a randomized, open-labeled, controlled trial. ( Geng, H; Jia, E; Liu, R; Ma, W; Wo, X; Yao, X; Zeng, Y; Zhan, Z; Zhang, J; Zhu, H, 2022) |
| "The prevalence of renal calculi in patients with gout is high." | 3.01 | Effect of alkalized urine on renal calculi in patients with gout: a protocol for a placebo-controlled, double-blinded randomized controlled trial. ( Geng, H; Jia, E; Lin, F; Liu, S; Wang, Y; Zhang, J; Zhong, L; Zhu, H, 2021) |
| "Gout is a painful chronic disease which disrupts work and family life and can lead to chronic joint damage." | 3.01 | Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol. ( Dalbeth, N; Goodyear-Smith, F; Grey, C; Heather, M; Lutui, H; Ofanoa, M; Ofanoa, SM; Tu'akoi, S; van der Werf, B, 2021) |
| "Gout is an autoinflammatory disease caused by the deposition of urate crystals." | 3.01 | Recent advances in gout drugs. ( Chen, R; Chi, X; Jiang, Z; Liu, Z; Shi, C; Xiu, S; Yi, C; Zhang, L; Zhou, Z, 2023) |
| "Hyperuricemia and gout are a group of disorders of purine metabolism." | 3.01 | The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics. ( Wu, X; You, C, 2023) |
| "If untreated, acute gout may eventually develop into chronic tophaceous gout characterized by tophi, chronic gouty synovitis, and structural joint damage, leading the crushing burden of treatment." | 3.01 | A review on gout: Looking back and looking ahead. ( Liu, W; Mo, Y; Tao, H; Wang, H, 2023) |
| "Gout is one of the most common noncommunicable diseases in Hong Kong." | 3.01 | The Hong Kong Society of Rheumatology consensus recommendations for the management of gout. ( Chan, JP; Cheung, TT; Ho, CT; So, H; Tsang, HH; Wong, PC; Yip, RM; Yu, CK, 2023) |
| "Gout is an autoimmune disease characterized by acute or chronic inflammation and damage to bone joints induced due to the precipitation of monosodium urate (MSU) crystals." | 3.01 | Immune and inflammatory mechanisms and therapeutic targets of gout: An update. ( Li, H; Liu, W; Peng, J; Wu, R; Wu, Y; Ye, Z; Zong, Z, 2023) |
| "Undertreated, gout can progress to palpable tophi and joint damage." | 3.01 | Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review. ( Terkeltaub, R, 2023) |
| "Gout is a multifactorial metabolic and inflammatory disease that occurs when increased uric acid (UA) induce HU resulting in monosodium urate (MSU) crystal deposition in joints." | 3.01 | Uric acid en route to gout. ( Zhang, WZ, 2023) |
| "Gout is characterized by hyperuricemia and the deposition of monosodium urate (MSU) crystals around joints." | 3.01 | Agents for the Treatment of Gout: Current Advances and Future Perspectives. ( Fan, Y; Liu, Y; Meng, Y; Qin, M; Wu, D; Zeng, X, 2023) |
| "KEY POINTS: • Gout flare recurrences were common within the first 3 months after starting urate-lowering therapy in gout patients." | 2.90 | Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare. ( Janssen, CA; Oude Voshaar, MAH; Ten Klooster, PM; van de Laar, MAFJ; Vonkeman, HE, 2019) |
| "Nurse-led gout care is efficacious and cost-effective compared with usual care." | 2.87 | Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. ( Abhishek, A; Ashton, D; Barclay, C; Doherty, M; Doherty, S; Duley, L; Hatton, R; Jenkins, W; Rees, F; Richardson, H; Sarmanova, A; Stevenson, M; Zhang, W, 2018) |
| "Allopurinol dosing has frequently been limited based on creatinine clearance (CrCL), resulting in failure to achieve target serum urate (SU)." | 2.87 | How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. ( Barclay, ML; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2018) |
| "Gout is increasing despite effective therapies to lower serum urate concentrations to 0." | 2.84 | Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol. ( Aung, E; Baysari, MT; Braithwaite, J; Buchbinder, R; Clay-Williams, R; Coiera, E; Day, RO; Frensham, LJ; Hunter, DJ; Laba, T; Lau, AYS; Li, L; McLachlan, A; McNeil, HP; Nguyen, AD; Pile, KD; Portek, I; Reath, J; Runciman, WB; Westbrook, JI; WIlliams, KM; Zwar, N, 2017) |
| "Gout is an auto-inflammatory disease driven by urate deposits with a second co-stimulatory factor evoking an (peri)arthritic fulminant inflammation often with a debute at night; inflammatory signals are enhanced via a NLRP3 pathway." | 2.82 | A historical journey of searching for uricosuric drugs. ( Jansen, TL; Matthijs, J; Tanja, G, 2022) |
| "Gout is a common hyperuricaemic metabolic condition that leads to painful inflammatory arthritis and a high comorbidity burden, especially cardiometabolic-renal (CMR) conditions, including hypertension, myocardial infarction, stroke, obesity, hyperlipidaemia, type 2 diabetes mellitus and chronic kidney disease." | 2.82 | Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. ( Choi, HK; McCormick, N; Yokose, C, 2022) |
| "Allopurinol is an agent of first choice for urate lowering therapy." | 2.82 | What's new on the front-line of gout pharmacotherapy? ( Blake, KEG; Saag, JL; Saag, KG, 2022) |
| "Gout is a systemic disease from which some patients develop numerous painful tophi that adversely affect quality of life and functionality." | 2.82 | Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response. ( Abdellatif, A; Albert, J; Amin, M; Baraf, HSB; Botson, JK; Edwards, NL; Freyne, B; Keenan, RT; Masri, KR; Peterson, J; Soloman, N; Strand, V; Yung, C, 2022) |
| "Gout is a common inflammatory arthritis caused by the deposition of sodium urate crystals in the joints." | 2.82 | The Role of the Intestine in the Development of Hyperuricemia. ( Chen, J; Liu, N; Yin, H, 2022) |
| "Gout is the most common inflammatory arthritis in the United States." | 2.82 | Management and Cure of Gouty Arthritis. ( Keller, SF; Mandell, BF, 2022) |
| "Gout is a common and potentially debilitating disease characterized by a painful inflammatory arthritis ("gout flare"), caused by the deposition of monosodium urate crystals in joints and surrounding tissues." | 2.82 | Emerging strategies for treating gout. ( Gaffo, AL; Huddleston, EM, 2022) |
| "In addition to traditional treatments for gout, novel therapies have been introduced in recent years." | 2.82 | Current state and prospects of gout treatment in Korea. ( Choi, ST; Park, EH; Song, JS, 2022) |
| "Gout is a common type of inflammatory arthritis characterized by the presence of monosodium urate crystals (MSU) in the joints." | 2.82 | Recent Insights Into the Role of Macrophages in Acute Gout. ( Liu, L; Liu, M; Shan, L; Xue, Y; Yu, Y; Zhao, L; Zhu, L, 2022) |
| "Gout is a chronic metabolic disease that seriously affects human health." | 2.82 | Susceptibility genes of hyperuricemia and gout. ( Nian, YL; You, CG, 2022) |
| "Gouty arthritis is a common inflammatory disease." | 2.82 | Role of microRNA alternation in the pathogenesis of gouty arthritis. ( Chen, B; Hong, S; Hu, Y; Li, L; Luo, Z; Wang, J; Wang, S; Wu, J; Xu, T; Yang, C; Yang, F; Yang, J; Yao, Y, 2022) |
| "Gout is a metabolic disorder, and one of the most common inflammatory arthritic conditions, caused by elevated serum urate (SU)." | 2.82 | Moving the Needle in Gout Management: The Role of Culture, Diet, Genetics, and Personalized Patient Care Practices. ( Roman, YM, 2022) |
| " All of the above RCTs showed that probiotics did not increase the incidence of adverse events." | 2.82 | Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials. ( Chen, H; Deng, Y; He, Q; Li, J; Liu, H; Xiang, W; Yang, K; Zeng, L; Zhu, X, 2022) |
| " Although dosing was otherwise well tolerated, two subjects experienced serious adverse events of acute kidney injury." | 2.82 | Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649. ( Dua, P; Gurrell, R; Kirby, S; Loudon, PT; Sudworth, M, 2016) |
| " ABT-639 demonstrated acceptable safety and pharmacokinetic profiles in human." | 2.80 | Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers. ( An, G; Awni, W; Duan, WR; Dutta, S; Liu, W; Nothaft, W, 2015) |
| "A modest dosage of vitamin C (500 mg/day) for 8 weeks had no clinically significant urate-lowering effects in patients with gout, despite the fact that plasma ascorbate levels increased." | 2.78 | Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial. ( Chapman, PT; Drake, JM; Frampton, C; O'Donnell, JL; Stamp, LK; Zhang, M, 2013) |
| "Hyperuricemia is associated with the presence and severity of obstructive sleep apnea (OSA)." | 2.78 | Serum urate levels are unchanged with continuous positive airway pressure therapy for obstructive sleep apnea: a randomized controlled trial. ( Prudon, B; Roddy, E; Stradling, JR; West, SD, 2013) |
| " Gout flares and IRs were the most frequently reported adverse events; these were least common in patients with a sustained urate-lowering response to treatment and those receiving biweekly treatment." | 2.78 | Long-term safety of pegloticase in chronic gout refractory to conventional treatment. ( Baraf, HS; Becker, MA; Dillon, A; Khanna, D; Ottery, FD; Sundy, JS; Vázquez-Mellado, J; Yood, RA, 2013) |
| "Hyperuricemia is the greatest risk factor for gout and is caused by an overproduction and/or inefficient renal clearance of urate." | 2.77 | Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. ( Day, RO; Graham, GG; Indraratna, PL; Jones, G; Kannangara, DR; Portek, I; Ramasamy, SN; Stocker, SL; Williams, KM, 2012) |
| "Despite an increasing incidence of gout in older age patients with multiple metabolic and cardiovascular comorbidities, there are limited data addressing whether currently available urate-lowering therapy is comparably effective and safe in older (≥65 years of age) versus younger (<65 years of age) patients." | 2.76 | Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. ( Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, PA, 2011) |
| "Forty-one patients were randomized to undergo 12-14 weeks of treatment with pegloticase at 1 of 4 dosage levels: 4 mg every 2 weeks, 8 mg every 2 weeks, 8 mg every 4 weeks, or 12 mg every 4 weeks." | 2.73 | Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. ( Baraf, HS; Barkhuizen, A; Becker, MA; Horowitz, Z; Huang, W; Maroli, AN; Moreland, LW; Sundy, JS; Waltrip, RW, 2008) |
| "Treatment with benzbromarone monotherapy (range: 100-200 mg/day; mean 138 mg/day) resulted in 92% of patients reaching target levels sUr | 2.73 | Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. ( Brouwers, JR; Houtman, PM; Jansen, TL; Reinders, MK; van Roon, EN, 2007) |
| " Maximum pUox was linearly related to the IV dose of PEG-uricase, the area under the curve (AUC) value increased linearly (up to a dose of 8 mg), and the pUox half-life was 6." | 2.73 | Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. ( Ganson, NJ; Hershfield, MS; Huang, W; Kelly, SJ; Rehrig, CD; Scarlett, EL; Sundy, JS, 2007) |
| "Recently, nephrolithiasis has been reported to be involved with renal manifestation of metabolic syndrome." | 2.73 | Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH. ( Inokuchi, T; Ka, T; Kobayashi, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2007) |
| " The dosing regimens to maintain uric acid levels below the therapeutic target of 6 mg/dL were then predicted by the model." | 2.73 | Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout. ( Alton, M; Huang, W; Marco, MD; Maroli, AN; Waltrip, RW; Wright, D; Yue, CS, 2008) |
| "Gout is a common form of inflammatory arthritis where urate crystals deposit in joints and surrounding tissues." | 2.72 | The Role of Advanced Imaging in Gout Management. ( Cao, H; Li, S; Liang, J; Lin, J; Wan, L; Xu, G, 2021) |
| "Gout is a common chronic disease with a high recurrence rate." | 2.72 | The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials. ( Li, Q; Tang, Y; Wang, D; Wang, M; Zhang, X, 2021) |
| "Gout is the most common form of inflammatory arthritis, and its incidence is highest in middle-aged and older patients." | 2.72 | Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity. ( Kumar, M; Manley, N; Mikuls, TR, 2021) |
| "Treatment with febuxostat resulted in a significant reduction of sUA levels at all dosages." | 2.71 | Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. ( Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL, 2005) |
| "Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels." | 2.70 | Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001) |
| "Gout is a chronic inflammatory disease caused by precipitation of urate crystals in the joints, kidneys, and urinary tract." | 2.66 | Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia. ( Kuriyama, S, 2020) |
| "Hyperuricemia is a strong precursor of gout, which deteriorates patients' health and quality of life." | 2.66 | Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials. ( Chang, SS; Lin, CH; Lin, SY; Lin, YJ; Wang, ST, 2020) |
| "Gout is a chronic disease due to the deposition of monosodium urate microcrystals in joints and tissues." | 2.66 | [Gout]. ( Bernard, A; Oehler, E; Pascart, T; Scuiller, A, 2020) |
| "Gout is the most common type of arthritis and is evoked by arousal of the inflammasome in the presence of urate crystals superponed on a dysmetabolism with urate accumulation." | 2.66 | Lessons and pitfalls from the 2020 Gout Clinical Practice Guideline presented in Atlanta at the ACR 2019. ( Jansen, TL; Janssen, M, 2020) |
| " Allopurinol, a urate synthesis inhibitor, is generally administered at a reduced dosage to patients with renal impairment." | 2.66 | Recent approaches to gout drug discovery: an update. ( Anzai, N; Hisatome, I; Kudo, H; Otani, N; Ouchi, M; Tsuruoka, S, 2020) |
| "Gout is a disease with acute and/or chronic inflammation and tissue damage induced by the precipitation of monosodium urate crystal (MSU) crystals in bone joints, kidneys, and subcutaneous sites." | 2.66 | Gout: a disease involved with complicated immunoinflammatory responses: a narrative review. ( Guo, C; Tian, Y; Wang, Q; Wu, M, 2020) |
| "Febuxostat had the best efficacy and safety results among the tested agents, and topiroxostat and allopurinol appeared to have fewer adverse events." | 2.66 | Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials. ( Lin, CJ; Lin, JY; Shi, Y; Sun, SS; Zhang, DH, 2020) |
| "Gout is the most common inflammatory arthritis and occurs when hyperuricaemia, sustained elevation of serum urate levels resulting in supersaturation of body tissues with urate, leads to the formation and deposition of monosodium urate crystals in and around the joints." | 2.66 | Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. ( Dehlin, M; Jacobsson, L; Roddy, E, 2020) |
| "Gout is now the commonest type of inflammatory arthritis despite availability of safe, effective and potentially 'curative' urate-lowering drugs." | 2.66 | Changing paradigms in the management of gout. ( Nuki, G; Riches, P, 2020) |
| "Gout is a disease in which the metabolic condition hyperuricemia leads to the formation of monosodium urate crystals, which provoke acute and chronic inflammatory responses through activation of the innate immune system." | 2.66 | Therapeutic approaches in the treatment of gout. ( Mandell, BF; Pillinger, MH, 2020) |
| "Gout is caused by monosodium urate crystal deposition in joints and tissues." | 2.66 | Gout: Rapid Evidence Review. ( Clebak, KT; Croad, JR; Morrison, A, 2020) |
| "Hyperuricemia is the key risk factor for gout and is considered a prerequisite for monosodium urate (MSU) crystal formation." | 2.66 | Pathophysiology of Gout. ( Dalbeth, N; Narang, RK, 2020) |
| " On the 5th and 6th day after beginning the treatment the dosage of 25 mg of Benzbromarone renders a morning value of 5,3 +/- 1,0 and an evening value of 5,0 +/- 0,9 mg/100 ml." | 2.64 | [Treatment of hyperuricemia using daily doses of 50 and 25mg of benzbromarone]. ( Berg, G; Matzkies, F; Minzlaff, R, 1977) |
| "Gout is a chronic disease caused by monosodium urate (MSU) crystal deposition." | 2.61 | Gout. ( Choi, HK; Dalbeth, N; Joosten, LAB; Khanna, PP; Matsuo, H; Perez-Ruiz, F; Stamp, LK, 2019) |
| "Gout is one of the most prevalent inflammatory rheumatic disease." | 2.61 | Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review. ( de Vries, R; Gerritsen, M; Heslinga, M; Nurmohamed, M; van Schaardenburg, D; Vedder, D; Walrabenstein, W, 2019) |
| " The main management issues are related to patient adherence, because gout patients have the lowest rate of medication possession ratio at 1 year, but they also include clinical inertia by physicians, meaning XOI dosage is not titrated according to regular serum uric acid level measurements for targeting serum uric acid levels for uncomplicated (6." | 2.61 | Gout: state of the art after a decade of developments. ( Lioté, F; Pascart, T, 2019) |
| "Despite many effective treatments for gout, its management remains a challenge internationally." | 2.61 | The Challenges of Approaching and Managing Gout. ( Fields, TR, 2019) |
| "Gout is associated with the risk of cardiovascular morbidity and mortality, but the biological relationship between the two remains uncertain." | 2.61 | Gout and cardiovascular disease: crystallized confusion. ( Abeles, AM; Pillinger, MH, 2019) |
| "This has been ascribed, in part, to haemodynamic changes, body weight reduction and several possible effects on myocardial, endothelial and tubulo-glomerular functions, as well as to reduced glucotoxicity." | 2.61 | Uric acid and the cardio-renal effects of SGLT2 inhibitors. ( Bailey, CJ, 2019) |
| "Older drugs for ULT like allopurinol are well studied and extensively described from typical adverse effects (mild skin rash) to unusual fatal reactions, while febuxostat seems to be overall well tolerated." | 2.61 | Safety and tolerability of available urate-lowering drugs: a critical review. ( Cicero, AF; Fogacci, F; Strilchuk, L, 2019) |
| "Gout is the most common type of inflammatory arthritis in adults with rising incidence and prevalence." | 2.58 | Gout Keratitis: A Case of Peripheral Ulcerative Keratitis Secondary to Gout With a Review of the Literature. ( Denisova, K; Lazzaro, DR; Mechel, E; Rizzuti, AE; Yazdanyar, A, 2018) |
| "Crystal arthritis is the most common type of inflammatory arthritis, and fractures contribute to significant morbidity and mortality, therefore, the relationship between the two is of clinical importance." | 2.58 | Crystalline arthropathy and bone health. ( Chang, I; Gazeley, D, 2018) |
| "Relapse of gout is common although delayed after discontinuation of ULT." | 2.58 | Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review. ( Beslon, V; Fournier, JP; Giraudeau, B; Maisonneuve, H; Maruani, A; Moreau, P, 2018) |
| "Evidence suggests that not treating gout to target in the long term is overall associated with worsening outcomes, such as flares, tophi and structural damage, which is associated to loss of quality of life and mortality." | 2.58 | Treat to target in gout. ( Dickson, AJ; Moreno-Lledó, A; Perez-Ruiz, F; Urionagüena, I, 2018) |
| "Gout is an inflammatory disease manifested by the deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons or soft tissues." | 2.58 | Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. ( Chen, DY; Chen, JH; Chen, SM; Chen, SY; Cheng, TT; Hsieh, SC; Hsieh, TY; Hsu, PF; Kuo, CF; Kuo, MC; Lam, HC; Lee, IT; Liang, TH; Lin, HY; Lin, SC; Tsai, WC; Tsai, WP; Tsay, GJ; Wei, JC; Yang, CH; Yu, KH, 2018) |
| "Despite being regarded as an easily-treatable disease, gout diagnosis and management can be challenging." | 2.58 | Change gout: how to deal with this "silently-developing killer" in everyday clinical practice. ( Borghi, C; Genderini, A; Grassi, W; Punzi, L; Rossi, C; Scirè, CA, 2018) |
| "Gout is the most common inflammatory arthritis and is increasing in relevance due to its rising prevalence and incidence." | 2.58 | Current status of ultrasound and dual-energy computed tomography in the evaluation of gout. ( Garner, HW; Wessell, DE, 2018) |
| "To review the extent of treatment success or failure with the xanthine oxidoreductase inhibitors allopurinol and febuxostat and indicate how the dosage of urate-lowering therapy (ULT) may be modified to increase the response in the majority of patients with gout." | 2.58 | Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout. ( Day, RO; Graham, GG; Kannangara, DRW; Stocker, SL, 2018) |
| "Examining therapies aimed at treating gout flares [anti-inflammatory action], bucillamine has some potential, but more data and Phase III studies are needed, to better understand its efficacy and safety." | 2.58 | Expert opinion on emerging urate-lowering therapies. ( Merriman, TR; Singh, JA; Stamp, LK, 2018) |
| " The use of allopurinol has been researched extensively and newer strategies for safer effective dosing are now recommended." | 2.58 | Gout - An update of aetiology, genetics, co-morbidities and management. ( Robinson, PC, 2018) |
| "The treatment of gout is based on several principles." | 2.58 | Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018) |
| " Genetic data may inform assessment of disease prognosis in individuals with hyperuricaemia or established gout, personalised lifestyle advice, selection and dosing of urate-lowering therapy, and prevention of serious medication adverse effects." | 2.55 | The genetics of gout: towards personalised medicine? ( Dalbeth, N; Merriman, TR; Stamp, LK, 2017) |
| "Gout is an inflammatory arthritis characterized by red, tender, hot and tumid joints." | 2.55 | The Immunological Basis in the Pathogenesis of Gout. ( Chen, J; Li, X; Qiao, Y; Wang, J; Wu, M; Yang, J, 2017) |
| "Gout is a common disease responsible for recurrent flares triggered by the deposition of monosodium urate crystals secondary to longstanding hyperuricaemia." | 2.55 | Current and future therapies for gout. ( Pascart, T; Richette, P, 2017) |
| "Gout is both an inflammatory and a metabolic disease." | 2.55 | Gout and Metabolic Syndrome: a Tangled Web. ( Krasnokutsky, S; Pillinger, MH; Thottam, GE, 2017) |
| " Two studies indicated dose-response relationship for sUA, achieving sUA target and gout attacks." | 2.55 | Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. ( Astrup, A; Bartels, EM; Bliddal, H; Carmona, L; Christensen, R; Gudbergsen, H; Henriksen, M; Knop, FK; Kristensen, LE; Nielsen, SM; Perez-Ruiz, F; Singh, JA; Taylor, WJ; Wæhrens, EE, 2017) |
| "Hyperuricemia has long been known to cause gout, and has recently been correlated with cardiovascular disease, hypertension, and renal disease." | 2.55 | The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies. ( Pontremoli, R, 2017) |
| "Gout is a clinical disorder that is characterized by the deposition of monosodium urate crystals (MSU) in joints and tendons, usually in the presence of prolonged hyperuricaemia." | 2.55 | Review of the ophthalmic manifestations of gout and uric acid crystal deposition. ( Ao, J; Casson, RJ; Goldblatt, F, 2017) |
| "Although gout is one of the most common forms of inflammatory arthritis, it has been relatively neglected until recently." | 2.55 | Major unanswered questions in the clinical gout field. ( Stamp, LK, 2017) |
| " Expert opinion: The initial dosage of allopurinol should be low, particularly in patients with renal impairment." | 2.55 | Allopurinol: insights from studies of dose-response relationships. ( Carland, JE; Day, RO; Graham, GG; Kannangara, DR; Stocker, SL; Williams, KM, 2017) |
| " Studies are needed in gout patients with chronic kidney disease and/or cardiovascular disease, so that escalation of dosing /combination of anti-inflammatory drugs needed to suppress gouty inflammation as well as escalation of dosing/combination of urate lowering drugs needed to achieve target serum urate level will lead to better understanding of gout treatment safety issues." | 2.55 | The safety of treatment options available for gout. ( Schlesinger, N, 2017) |
| "Gout affects the structure and function of the 1(st) MTP." | 2.53 | The first metatarsophalangeal joint in gout: a systematic review and meta-analysis. ( Dalbeth, N; Rome, K; Stewart, S; Vandal, AC, 2016) |
| "Flares of gout are often caused by large meals and high alcohol consumption." | 2.53 | [Nutritional therapy of gout]. ( Kiss, C; Nickolai, B, 2016) |
| "Gout is a true crystal deposition arthropathy caused by the precipitation of monosodium urate into joints and periarticular soft tissues." | 2.53 | Dual-Energy Computed Tomography of the Knee, Ankle, and Foot: Noninvasive Diagnosis of Gout and Quantification of Monosodium Urate in Tendons and Ligaments. ( Fishman, EK; Fritz, J; Fuld, MK; Henes, JC; Horger, MS, 2016) |
| "Gout is a common inflammatory arthritis among middle-aged men and postmenopausal women and can be a debilitating disease." | 2.53 | Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia. ( Schlesinger, N; Sharon, Y, 2016) |
| "The salient points include the need to treat gout to a serum urate target, the ability to start allopurinol during acute attacks, the need to treat with prophylactic anti-inflammatory drugs for adequate time periods, and the availability of a new urate-lowering drug on the Pharmaceutical Benefits Scheme (PBS)." | 2.53 | The management of gout: Much has changed. ( Robinson, PC; Stamp, LK, 2016) |
| "The prevalence of gout is rising and is likely attributed to several factors including increased incidence of comorbidities, lifestyle factors, and increased use of causative medications." | 2.53 | Gouty Arthritis: A Review of Acute Management and Prevention. ( Saseen, JJ; Wilson, L, 2016) |
| " Drug efficacy and safety, as outcomes, were measured by whether the target level of serum urate acid was achieved and whether any adverse events occurred, respectively." | 2.53 | Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. ( Gao, Y; Guo, Y; Li, D; Li, M; Li, S; Li, W; Sun, L; Wang, Y; Wei, F; Xu, W; Yang, H; Yang, X, 2016) |
| "Gout is the most common inflammatory arthritis in men over 40 years of age." | 2.53 | Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis. ( Christensen, R; Dalbeth, N; Fransen, J; Lassere, M; Morillon, MB; Singh, JA; Stamp, L; Taylor, W, 2016) |
| "This systematic review aims to summarise published evidence that assessed the management of gout in regard to the following: prescription of urate lowering therapy (ULT), monitoring of serum urate levels (sUA) and allopurinol dosing in patients with renal impairment, lifestyle advice and acute management of gout." | 2.52 | Management of gout in general practice--a systematic review. ( Jeyaruban, A; Larkins, S; Soden, M, 2015) |
| "Allopurinol is a safe option, slightly better than other ULDs." | 2.52 | Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. ( Carmona, L; Castrejon, I; Loza, E; Pérez-Ruiz, F; Rosario, MP; Toledano, E, 2015) |
| " Studies have identified the safe and effective dosing strategies for 'old' drugs such as allopurinol and colchicine." | 2.52 | Advances in pharmacotherapy for the treatment of gout. ( Dalbeth, N; Robinson, PC, 2015) |
| "Uric acid has a stimulating effect on the cerebral cortex, and this could have allowed humans, compared with other animals, to develop higher brain mass volume, better intellectual performances, and maybe evolutionary supremacy." | 2.52 | Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple". ( De Giorgi, A; Fabbian, F; Manfredini, R; Misurati, E; Pala, M; Parisi, C; Tiseo, R, 2015) |
| "Gout is one of the most common forms of arthritis and the prevalence is increasing." | 2.52 | Pharmacogenetic considerations in the treatment of gout. ( Roberts, RL; Stamp, LK, 2015) |
| "The pharmacological treatment of pain in CIA is strictly associated with the treatment of acute phases and flares of the disease, during which crystals trigger the inflammatory response." | 2.52 | Molecular mechanisms of pain in crystal-induced arthritis. ( Frallonardo, P; Galozzi, P; Lorenzin, M; Oliviero, F; Ortolan, A; Punzi, L; Ramonda, R; Scanu, A, 2015) |
| "Acute gout is an auto-inflammatory disease characterized by self-limiting inflammation in response to the deposition of monosodium urate (MSU) crystals in the joints or tissues." | 2.50 | Mechanisms of spontaneous resolution of acute gouty inflammation. ( Harper, JL; Steiger, S, 2014) |
| "Gout is a common crystal-induced arthritis, in which monosodium urate (MSU) crystals precipitate within joints and soft tissues and elicit an inflammatory response." | 2.50 | The crystallization of monosodium urate. ( Crittenden, DB; Martillo, MA; Nazzal, L, 2014) |
| "Gout is defined as an arthritic condition resulting from the deposition of monosodium urate (MSU) crystals in and/or around joints, following long-standing hyperuricemia." | 2.50 | Definition of hyperuricemia and gouty conditions. ( Bardin, T; Richette, P, 2014) |
| "Gout is the most common inflammatory arthritis worldwide." | 2.50 | Optimizing current treatment of gout. ( Doherty, M; Hui, M; Rees, F, 2014) |
| "Gout has been academically considered to be a step-up disease consisting of different stages: acute gout, intercritical gout, and chronic gout." | 2.50 | Clinical manifestations and diagnosis of gout. ( Castillo, E; Chinchilla, SP; Herrero-Beites, AM; Perez-Ruiz, F, 2014) |
| "Gout is a common inflammatory arthritis precipitated by an inflammatory reaction to urate crystals in the joint." | 2.50 | Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. ( Horsburgh, S; Robinson, PC, 2014) |
| "Gout is one of the most common forms of arthritis." | 2.50 | Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout. ( Barclay, ML; Dalbeth, N; Merriman, TR; Roberts, RL; Singh, JA; Stamp, LK; Wright, DF, 2014) |
| "Gout is increasingly seen in the elderly population, in large part due to physiological decline in renal function with age, and as a result of therapy for comorbidities, in particular the use of diuretic therapies for hypertension and congestive heart failure." | 2.50 | Urate-lowering therapy: current options and future prospects for elderly patients with gout. ( Chapman, PT; Stamp, LK, 2014) |
| "Gout is characterized by painful joint inflammation, most commonly in the first metatarsophalangeal joint, resulting from precipitation of monosodium urate crystals in a joint space." | 2.50 | Diagnosis, treatment, and prevention of gout. ( Hainer, BL; Matheson, E; Wilkes, RT, 2014) |
| "If tophaceous gout is suspected, alcohol fixation of the biopsy specimen is preferable, as it enables visualization of characteristic needle-shaped urate crystals." | 2.49 | Gouty tophi on the ear: a review. ( Chabra, I; Singh, R, 2013) |
| "Uric acid is a waste product of purine catabolism." | 2.49 | Uric acid as a danger signal in gout and its comorbidities. ( Kataoka, H; Lai, JJ; Rock, KL, 2013) |
| "Gout is a painful inflammatory arthritis associated with hyperuricemia, with a prevalence of almost 10 million in the USA." | 2.49 | The kidney in hyperuricemia and gout. ( Mount, DB, 2013) |
| "Gout is a prototype crystal-induced inflammatory disorder, characterized by neutrophil infiltration into inflamed joints." | 2.49 | Neutrophils, IL-1β, and gout: is there a link? ( Kambas, K; Mitroulis, I; Ritis, K, 2013) |
| "Gout is a growing health problem worldwide especially in affluent countries, such as Australia." | 2.48 | Systematic review of the prevalence of gout and hyperuricaemia in Australia. ( Merriman, TR; Robinson, PC; Taylor, WJ, 2012) |
| "Acute inflammation is the hallmark of the acute tissue reaction to crystals in both gout and pseudogout." | 2.48 | The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis). ( Busso, N; Ea, HK, 2012) |
| "Gout is a metabolic disease characterized by hyperuricemia and the deposition of monosodium urate (MSU) crystals in the joints and soft tissues, consisting of a self-limited acute phase characterized by recurrent attacks of synovitis and a chronic phase in which inflammatory and structural changes of the joints and periarticular tissues may lead to persistent symptoms." | 2.48 | Clinical features of gout. ( De Angelis, R; Grassi, W, 2012) |
| "Febuxostat is a novel non-purine, selective inhibitor of xanthine oxidase, metabolized and excreted by the liver, so no dose adjustment appears to be necessary in patients with mild-to-moderate renal impairment." | 2.48 | [Gout: an overview of available urate lowering therapies]. ( Richette, P, 2012) |
| "Gout is the most common inflammatory arthritis and one in which pathogenesis and risk factors are best understood." | 2.48 | Gout: why is this curable disease so seldom cured? ( Bardin, T; Doherty, M; Jansen, TL; Nuki, G; Pascual, E; Perez-Ruiz, F; Punzi, L; So, AK, 2012) |
| "Gout is probably one of the oldest diseases affecting men." | 2.48 | Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. ( Oliviero, F; Punzi, L; Ramonda, R; Scanu, A, 2012) |
| "Gout is a chronic, progressive inflammatory disease with intermittent arthritic flares, which should not be regarded as a minor inconvenience or nuisance." | 2.48 | The unwelcome visitor. ( Goh, LH; How, CH; Teng, GG; Tong, CY, 2012) |
| "Gout is a common and very painful inflammatory arthritis caused by hyperuricaemia." | 2.48 | The genetics of hyperuricaemia and gout. ( Choi, HK; Mount, DB; Reginato, AM; Yang, I, 2012) |
| "The new epidemic of gout is likely secondary in significant part to the rise in fructose consumption, as well as to the increase in obesity, the endurance of other dietary and non-dietary gout risk factors such as consumption of meat and alcohol, the continued use of culprit medications and potentially to the under-recognition of the benefits of certain foods and drinks (such as dairy products and coffee)." | 2.48 | A perspective on diet and gout. ( Kedar, E; Simkin, PA, 2012) |
| "Gout is a metabolic disorder of purine metabolism with primary manifestations of acute and chronic arthritis and tophus formation." | 2.48 | The rheumatology of gout. ( Sundy, JS, 2012) |
| "One of the limitations for successful treatment of gout is to consider it as an intermittent disease rather than a chronic inflammatory disease which, if improperly treated, leads to chronic clinical manifestations." | 2.48 | Evaluation and treatment of gout as a chronic disease. ( Herrero-Beites, AM; Perez-Ruiz, F, 2012) |
| "Gout and hyperuricemia have likewise been associated with the development of cardiovascular disease and metabolic syndrome." | 2.48 | The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. ( De Jesus, E; Rachabattula, S; Torralba, KD, 2012) |
| "Gout is not common in childhood compared with adulthood, and careful consideration of inborn errors of metabolism should be considered in these cases." | 2.47 | Gout and hyperuricemia in young people. ( Yamanaka, H, 2011) |
| "Uric acid has been identified as an endogenous adjuvant that drives immune responses in the absence of microbial stimulation." | 2.47 | The role of uric acid as an endogenous danger signal in immunity and inflammation. ( Ghaemi-Oskouie, F; Shi, Y, 2011) |
| " Allopurinol is the most commonly used ULT, but there is no consensus on dosing in renal impairment." | 2.47 | The challenges of gout management in the elderly. ( Jordan, S; Stamp, LK, 2011) |
| "Gout is frequently associated with the metabolic syndrome." | 2.47 | Diagnosis and treatment of gout in primary care. ( Conaghan, PG; Rakieh, C, 2011) |
| "Although classic gout is still most commonly seen, the disease can manifest as with a wide array of presentations." | 2.46 | Unusual clinical presentations of gout. ( Keenan, RT; Ning, TC, 2010) |
| "Hyperuricemia is considered to be a risk factor of not only gout but also renal and cardiovascular diseases, thus, it is important to use CCBs without adverse effect on uric acid metabolisms." | 2.46 | [Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers]. ( Hamada, T; Hisatome, I; Igawa, O; Mizuta, E; Shigemasa, C, 2010) |
| "Gout and hyperuricemia have long been suspected to be risk factors for cardiovascular disease." | 2.46 | Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? ( Keenan, RT; Shah, A, 2010) |
| "An acute attack of gout is a paradigm of acute sterile inflammation, as opposed to pyogenic inflammation." | 2.46 | Mechanisms of inflammation in gout. ( Busso, N; So, A, 2010) |
| "Over time, untreated or insufficiently treated gout may progress, with more frequent flares and formation of urate crystal deposits (tophi) and associated chronic, deforming arthritis (gouty arthropathy)." | 2.46 | What do I need to know about gout? ( Becker, MA; Ruoff, GE, 2010) |
| "Accumulating evidence suggests that hemiparesis exerts a protective effect against gout via the down-regulation of mechanical and neural modulators of inflammation in neurologically impaired extremities." | 2.46 | Polyarticular gout attacks following cerebrovascular accidents: is hemiparesis in fact protective? 2 cases and a review of the literature. ( Furer, V; Hsiao, SJ; Samuels, J; Vaynrub, M, 2010) |
| "Gout is the most common cause of inflammatory arthritis among men and postmenopausal women." | 2.46 | Gout: epitome of painful arthritis. ( VanItallie, TB, 2010) |
| "Gout is an acute inflammatory arthritis with the potency to fully destroy the integrity of the joint leading to severe disability." | 2.46 | Gout: a clinical syndrome illustrated and discussed. ( Bhansing, KJ; Janssen, M; Radstake, TR; van Bon, L, 2010) |
| "Gout is a true crystal deposition disease caused by formation of monosodium urate crystals in joints and other tissues." | 2.45 | New insights into the epidemiology of gout. ( Doherty, M, 2009) |
| "When treating gout one needs to treat acute attacks, and lower excess stores of uric acid to achieve dissolution of monosodium urate crystals through a long-term reduction of SU concentrations far beyond the threshold for saturation of urate and provide prophylaxis to prevent acute flares." | 2.45 | Gout--what are the treatment options? ( Dalbeth, N; Perez-Ruiz, F; Schlesinger, N, 2009) |
| "Gout is a disease caused by the deposition of monosodium urate monohydrate crystals." | 2.44 | Recent advances in crystal-induced acute inflammation. ( Akahoshi, T; Kitasato, H; Murakami, Y, 2007) |
| "Treatment of gout is usually considered after the first attack of arthritis, typically podagra." | 2.44 | Updates in the management of gout. ( Gilliland, WR; Keith, MP, 2007) |
| "Gout is the most common inflammatory arthropathy for men." | 2.44 | [Crystal-induced arthritis--old but important]. ( Aringer, M; Grässler, J; Winzer, M, 2007) |
| "There has been renewed interest in the treatment of gout with recent reported intervention studies of new agents such as etoricoxib, febuxostat and pegylated-uricase." | 2.44 | Assessment of outcome in clinical trials of gout--a review of current measures. ( Dalbeth, N; Grainger, R; Schumacher, HR; Singh, JA; Taylor, WJ, 2007) |
| "Novel therapies for gout have recently been developed which has prompted considerable efforts in defining the relevant outcomes for measurement in intervention trials of gout." | 2.44 | Establishing outcome domains for evaluating treatment of acute and chronic gout. ( Grainger, R; Taylor, WJ, 2008) |
| "Gout has been a recognized disease since the fifth century B." | 2.44 | [Historical review of gout and hyperuricemia investigations]. ( Nakamura, T, 2008) |
| "Uric acid is a weak acid that exists largely as MSU, the ionized form, in urate pool at physiologic pH." | 2.44 | [Physiology and dynamics of uric acid in hyperuricemia]. ( Nakamura, T; Takagi, K; Ueda, T, 2008) |
| "Urolithiasis is a clinically important complication of gout." | 2.44 | [Urolithiasis and nephropathy complicated with gout]. ( Shimizu, T, 2008) |
| "Gout is a crystal deposition disease." | 2.44 | [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia]. ( Fujimori, S, 2008) |
| "Thus, the treatment of hypertension and hyperlipidemia associated with hyperuricemia is also important." | 2.44 | [Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008) |
| "Gout is one of the best understood among the rheumatological disorders and one of the most satisfying to treat." | 2.43 | Diagnosis and management of gout: a rational approach. ( Suresh, E, 2005) |
| "Gout and calcium pyrophosphate deposition disease are two common causes of inflammatory joint disease." | 2.43 | An update on the treatment options for gout and calcium pyrophosphate deposition. ( Choy, G, 2005) |
| "Gout is one of the most readily manageable of the rheumatic diseases." | 2.43 | Understanding treatments for gout. ( Cannella, AC; Mikuls, TR, 2005) |
| "Future directions in the treatment of gout, in part guided by a better understanding of pathophysiology, are discussed." | 2.43 | Overview of hyperuricaemia and gout. ( Agudelo, C; Liu-Bryan, R; Masseoud, D; Rott, K, 2005) |
| "Gout is the most common inflammatory arthritis in men, affecting approximately 1-2% of adult men in Western countries." | 2.43 | Recent developments in diet and gout. ( Kavanaugh, A; Lee, SJ; Terkeltaub, RA, 2006) |
| "Hyperuricemia and gout are common conditions that have long been known to have a heritable component." | 2.43 | Genetic factors associated with gout and hyperuricemia. ( Bleyer, AJ; Hart, TC, 2006) |
| "Throughout history, gout has been associated with rich foods and excessive alcohol consumption." | 2.43 | A concise history of gout and hyperuricemia and their treatment. ( Nuki, G; Simkin, PA, 2006) |
| "Gouty arthritis is a characteristically intense acute inflammatory reaction that erupts in response to articular deposits of monosodium urate (MSU) crystals." | 2.43 | The inflammatory process of gout and its treatment. ( Cronstein, BN; Terkeltaub, R, 2006) |
| "Gout is a chronic metabolic disease caused by a disorder of the purine metabolism leading to hyperuricaemia." | 2.43 | Pathogenesis, clinical findings and management of acute and chronic gout. ( Cantatore, FP; Corrado, A; D'Onofrio, F; Melillo, N; Santoro, N, 2006) |
| "In most cases, gout is an easy disease to treat, but we do not have enough information about how to handle those few patients with "difficult" disease, and what we refer colloquially to as difficult gout has not been properly defined yet." | 2.42 | Gout. ( Pascual, E; Pedraz, T, 2004) |
| "Uric acid has profound beneficial effects since it scavenges potential harmful radicals in our body." | 2.42 | [Physiology and biochemistry of uric acid]. ( Hediger, MA, 2004) |
| "Gout is an inflammatory response to deposition of monosodium urate crystals in and around joints." | 2.41 | Clinical manifestations of gout and their management. ( Ryan, PF; van Doornum, S, 2000) |
| "Gout is a common form of arthritis, in which many of the risk factors, pathogenetic mechanisms, and clinical features have been recognized for years." | 2.41 | Gout: diagnosis, pathogenesis, and clinical manifestations. ( Agudelo, CA; Wise, CM, 2001) |
| "Gout is a condition characterized by the deposition of monosodium urate crystals in the joints or soft tissue." | 2.40 | Gout and hyperuricemia. ( Alloway, JA; Harris, MD; Siegel, LB, 1999) |
| "Hyperuricemia and gout are known to occur in patients receiving diuretic therapy." | 2.40 | Finger pad tophi. ( Chopra, KF; Grossman, ME; Schneiderman, P, 1999) |
| "Carpal tunnel syndrome is well known in gout (28 reported cases), and is secondary to gouty tenosynovitis." | 2.39 | [Double tunnel syndrome of the upper limb in tophaceous gout. Apropos of a case]. ( Jacoulet, P, 1994) |
| "Gout is a disease caused by deposits of sodium urate crystals in tissues." | 2.39 | [What remains of gout in 1993?]. ( Bourgeois, P; Rozenberg, S, 1994) |
| "Corticosteroids favour osteopenia which can be detected by measurement of bone density." | 2.39 | [Osteo-articular complications of heart transplantation]. ( Bourgeois, P; Rozenberg, S, 1995) |
| "Uric acid is a useful diagnostic tool as screening for most of purine metabolic disorders." | 2.39 | The importance of uric acid examination. ( Krijt, J; Schneiderka, P; Sebesta, I, 1994) |
| "Uric acid is one of the composition of urinary stones itself, but it has an activity of calcium oxalate stone formation." | 2.39 | [Hyperuricosuria and urolithiasis]. ( Koide, T, 1996) |
| "Tumor lysis syndrome is a critical illness characterized by massive tumor cell death leading to severe hyperuricemia, hyperphosphatemia, hypocalcemia, and acute renal failure after starting chemotherapy to cancers, especially lymphoproliferative malignancies." | 2.39 | [Hyperuricemia and the kidney]. ( Hikita, M; Hosoya, T; Ichida, K, 1996) |
| " Because of potential toxicity, colchicine should not be used to treat acute gout, but should be used in low dosage (0." | 2.38 | Prevention and management of gout. ( Hochberg, MC; Star, VL, 1993) |
| "Selective medical therapy of nephrolithiasis is highly effective in preventing new stone formation." | 2.38 | Renal calculi: pathogenesis, diagnosis, and medical therapy. ( Preminger, GM, 1992) |
| "Although typical gout is easily recognized and treated, several recent papers have addressed atypical presentations of gout, as well as other causes of podagra that might have been attributed previously to gout." | 2.38 | Gout and hyperuricemia. ( Agudelo, CA; Wise, CM, 1991) |
| "Gout is largely solved, both from diagnostic and therapeutic standpoints." | 2.37 | Crystal identification in human synovial fluids. Methods and interpretation. ( McCarty, DJ, 1988) |
| "Gout is a clinical syndrome with a limited range of manifestations arising as a result of the deposition of crystals of monosodium urate, the final product of purine metabolism in humans." | 2.37 | Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). ( Becker, MA, 1988) |
| "Acute gout is best treated with colchicine or indomethacin." | 2.36 | Hyperuricemia and gout. ( Sloan, RW, 1982) |
| " The ideal uricase inhibitor for induction of hyperuricemia would be one which is irreversible, noncompetitive, and relatively nontoxic, so that its activity would be independent of high levels of uric acid, and effective inhibition could be attained at low dosage levels." | 2.36 | Use of the uricase-inhibited rat as an animal model in toxicology. ( Nera, EA; Stavric, B, 1978) |
| "Gout is a painful and potentially crippling disorder." | 2.35 | The radiology of gout. Review article. ( Middlemiss, H; Watt, I, 1975) |
| "NAFLD was assessed using the Fibrosis-4 (Fib-4) index." | 1.91 | Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients. ( Lipsky, PE; Rustgi, VK; Schlesinger, N; Yeo, AE, 2023) |
| "Gout is a common chronic inflammatory disorder due to monosodium urate deposition, which results in severe inflammatory arthritis." | 1.91 | The disproportionately large contribution of the Māori and Pacific Islander community to the healthcare burden of gout in Western Sydney. ( Cai, K; Han, J; Lam, C; Manolios, N; Mitchell, J; Ng, BCK; Spencer, D; Wong, PKK, 2023) |
| " Moreover, the PRS also revealed a dose-response trend between AH rates and quartile scores." | 1.91 | Genetic contributions to female gout and hyperuricaemia using genome-wide association study and polygenic risk score analyses. ( Chang, JG; Chang, SJ; Chang, YS; Chen, YC; Chung, CC; Huang, CM; Lin, CY; Liu, TY; Tsai, FJ, 2023) |
| "Gout is a common crystal induced disease of high personal and social burden, characterised by severe arthritis and comorbidity if untreated." | 1.91 | Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia. ( Juhász, P; Kulin, A; Mózner, O; Nagy, K; Pálinkás, M; Poór, G; Rásonyi, R; Sarkadi, B; Szabó, E; Várady, G; Vörös, D; Zámbó, B, 2023) |
| "Chronic gout has an important impact on the daily life of patients and their families." | 1.91 | Living with gout. Experiences, impact and challenges of the disease. Qualitative study through focus groups. ( Díaz-Torné, C; Pou, MA; Pujol-Ribera, E; Rodríguez-Díez, B, 2023) |
| "Gout is a chronic disease caused by monosodium urate crystal deposition, typically affecting the big toe, midfoot, and ankle." | 1.91 | Gouty sacroiliitis: A case report of an often-overlooked cause of inflammatory back pain. ( Chen, SH; Guo, QH; Li, T; Lu, JG; Zheng, BL, 2023) |
| "Tophaceous gout is a common arthritis caused by the deposition of urate crystals and is related to limited joint function." | 1.91 | Interplay between fat, muscle, bone mass, and oteophytes and risk for tophaceous gout. ( Chen, YC; Hsu, CC; Hsu, CM; Huang, CC; Wu, RW, 2023) |
| "Gout is the most common inflammatory arthritis with an increasing prevalence and incidence across the globe." | 1.91 | Global status and trends in gout research from 2012 to 2021: a bibliometric and visual analysis. ( Han, Y; Li, W; Lin, Z; Wang, Y; Wu, H; Zhang, B, 2023) |
| "Gout is a chronic disease caused by monosodium urate crystal deposition." | 1.91 | Single-Cell Analysis in Blood Reveals Distinct Immune Cell Profiles in Gouty Arthritis. ( Chen, W; Chen, X; Gao, K; Huang, H; Huang, R; Mei, L; Wang, M; Wu, X; Yang, Z; Zhang, X, 2023) |
| "As pioglitazone is an insulin sens MSDC-itizer used for diabetes, its MPC inhibitory effect in diabetic individuals was investigated." | 1.91 | Inactivation of mitochondrial pyruvate carrier promotes NLRP3 inflammasome activation and gout development via metabolic reprogramming. ( Chen, CC; Chen, LC; Chen, YJ; Chien, WC; Chung, CH; Huang, CN; Huang, KY; Liao, NS; Lin, HA; Lin, HC; Lin, YY; Ojcius, DM; Shih, CT; Tsai, KJ; Wang, JY, 2023) |
| "Dimethyl fumarate (DMF) has shown anti-inflammatory and antioxidant activities." | 1.91 | Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress. ( Cao, Y; Hu, Y; Jin, XF; Liu, Y; Zou, JM, 2023) |
| "MSU-associated inflammation is majorly triggered by NOD-like receptor protein 3 (NLRP3) inflammasome that promotes interleukin (IL)-1β secretion." | 1.91 | Diallyl trisulfide inhibits monosodium urate-induced NLRP3 inflammasome activation via NOX3/4-dependent mitochondrial oxidative stress in RAW 264.7 and bone marrow-derived macrophages. ( Bang, E; Choi, YH; Hong, SH; Hwangbo, H; Ji, SY; Kim, DH; Kim, GY; Kim, MY; Lee, H; Park, C, 2023) |
| "Gout is considered uncommon among Black Africans." | 1.91 | Pattern of gout and its association with chronic kidney disease in Maiduguri, northeastern Nigeria. ( Adamu, AA; Sulaiman, MM; Yerima, A, 2023) |
| "Gout is associated with a higher risk of fracture; however, findings on the associations of hyperuricemia and urate-lowering therapy (ULT) with the risk of fracture have been inconsistent." | 1.91 | Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout. ( Choi, HK; Dalbeth, N; Lane, NE; Lei, G; Lyu, H; Wei, J; Wu, J; Zeng, C; Zhang, Y, 2023) |
| "Gout is the most common inflammatory rheumatic disease and elevated levels of serum urate (SU) are the main cause for its development." | 1.91 | Relationship between rs4349859 and rs116488202 polymorphisms close to MHC-I region and serum urate levels in patients with gout. ( Fernández-Torres, J; Martínez-Flores, K; Martínez-Nava, GA; Ruíz-Dávila, X; Sánchez-Sánchez, R; Zamudio-Cuevas, Y, 2023) |
| " We emulated a hypothetical trial comparing the rate of major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) among seven different strategies over 24 months." | 1.91 | Comparative Safety of Gout Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Clone-censor-weight Target Trial Emulation Approach. ( Desai, RJ; Glynn, RJ; Kim, SC; Liu, J; Solomon, DH; Yoshida, K, 2023) |
| "BACKGROUND Spinal gout is not so uncommon." | 1.91 | Unusual Cause of Cord Compression in a Patient with Chronic Lymphocytic Leukemia. ( Gebreselassie, KZ; Kligora, C; Ranic, LM; Valancius, D, 2023) |
| "Uric acid is an emerging biomarker for cardiovascular morbidity and mortality, but its association with all-cause mortality and ECG findings remains unestablished, specifically among older adults." | 1.91 | Sex specific serum uric acid levels are associated with ischemic changes on ECG and with 20-year all-cause mortality among older adults. ( Chetrit, A; Dankner, R; Goldman, A; Moshkovits, Y, 2023) |
| "In 2017 to 2018, gout affected 12." | 1.91 | Trends in Prevalence of Gout Among US Asian Adults, 2011-2018. ( Choi, HK; Hsu, J; Joshi, AD; Lin, K; Lu, N; McCormick, N; Merriman, T; Raffield, LM; Saag, K; Tanikella, S; Warner, E; Yokose, C; Zhang, Y, 2023) |
| "In Japan, hyperuricemia is on the rise." | 1.91 | Effect of Dietary Counseling on Patients with Asymptomatic Hyperuricemia. ( Akiyama, M; Arai, H; Asai, T; Kawakami, Y; Koike, R; Kondo, R; Onishi, M, 2023) |
| "Gout is an inflammatory arthritis initiated by the deposition of monosodium urate crystals (MSU) around the joints and surrounding tissues." | 1.91 | A wild rice-derived peptide R14 ameliorates monosodium urate crystals-induced IL-1β secretion through inhibition of NF-κB signaling and NLRP3 inflammasome activation. ( Chanjitwiriya, K; Charoenwutthikun, S; Kunthalert, D; Roytrakul, S, 2023) |
| "Gout is caused by monosodium urate (MSU) crystal deposition within joints." | 1.91 | Monosodium urate crystals alter the circadian clock in macrophages leading to loss of NLRP3 inflammasome repression: Implications for timing of the gout flare. ( Alhilali, M; Dalbeth, N; Jain, L; Popov, D; Poulsen, RC, 2023) |
| "Uric acid has antioxidant and neuroprotective properties." | 1.91 | [The influence of uric acid on the course of amyotrophic lateral sclerosis]. ( Areprintseva, DK; Kutlubaev, MA; Pervushina, EV, 2023) |
| "Gout is a common metabolic rheumatic disease, and there have been no reports on the serum levels of interleukin (IL)-41 in gout patients." | 1.91 | Potential clinical value of serum interleukin-41 levels in patients with acute gout. ( Li, M; Li, Y; Meng, S; Shi, S; Wu, X; Zhao, H; Zhou, Y, 2023) |
| "Gout is a common metabolic disorder characterized by deposits of monosodium urate monohydrate crystals (tophi) in soft tissue, triggering intense and acute arthritis with intolerable pain as well as articular and periarticular inflammation." | 1.91 | Identification of tophi in ultrasound imaging based on transfer learning and clinical practice. ( Chang, CC; Chang, CK; Lee, HY; Lin, KH; Lin, TM; Peng, SJ; Wu, BF, 2023) |
| " Logistic regression was used to estimate the association between hyperuricemia and nephrolithiasis, and a restricted cubic spline (RCS) model was used to explore the dose-response relationship between SUA and the risk of nephrolithiasis." | 1.91 | Asymptomatic hyperuricemia associated with increased risk of nephrolithiasis: a cross-sectional study. ( Cheng, N; Deng, H; Hou, Z; Li, Y; Meng, Q; Song, C; Sun, Y; Wang, Q; Yin, J; Zhang, J; Zhang, X, 2023) |
| "Gout is a metabolic disease resulting from the accumulation of monosodium urate (MSU) in joints, leading to crystal-induced arthritis." | 1.91 | [Recommendations for the diagnosis and treatment of gout in China]. ( Lin, H; Xu, D; Zhao, Y; Zhu, XX; Zou, HJ, 2023) |
| "The Gout Impact Scale (GIS), part of the Gout Assessment Questionnaire 2." | 1.91 | Reliability and Validity of the Korean Version of the Gout Impact Scale. ( Kim, JY; Kim, MJ; Lee, JJ; Moon, KW; Shin, K, 2023) |
| "Gout is the most common inflammatory arthritis and closely related to metabolic syndrome, leading to excruciating pain and the decline in quality of patients' life." | 1.91 | Metabolomic analysis for asymptomatic hyperuricemia and gout based on a combination of dried blood spot sampling and mass spectrometry technology. ( Liu, S; Liu, Y; Liu, Z; Wu, X, 2023) |
| "Gout is the most common inflammatory arthritis and is almost exclusively managed in primary care, however the course and severity of the condition is variable and poorly characterised." | 1.91 | Cohort study investigating gout flares and management in UK general practice. ( Finnikin, S; Mallen, CD; Roddy, E, 2023) |
| "Gout is associated with lifestyle, body mass index (BMI) and comorbidities, including dyslipidaemia." | 1.91 | Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study. ( Haavardsholm, EA; Hammer, HB; Karoliussen, LF; Kvien, TK; Sexton, J; Uhlig, T, 2023) |
| "And gout and hyperuricemia are also possible connection with cardiovascular disease and metabolic syndrome." | 1.72 | Triterpenoid acids from medicinal mushroom Inonotus obliquus (Chaga) alleviate hyperuricemia and inflammation in hyperuricemic mice: Possible inhibitory effects on xanthine oxidase activity. ( Dai, LJ; He, FX; Luo, LS; Wang, Y; Zhang, JL; Zhou, Q, 2022) |
| "The gouty ulcers were not completely healed by Day 14 compared with those in the PBS controls." | 1.72 | Gout-associated uric acid crystals induce tophi ulcerations and impair wound healing in a novel gouty ulcer model. ( Bao, W; Cheng, X; Jia, C; Su, Y; Wang, P; Xue, Y; Yin, B, 2022) |
| "Gout is the most common inflammatory arthritis, but was not considered in most COVID-19 and rheumatic diseases reports." | 1.72 | Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement. ( Burgos-Vargas, R; García-Maturano, JS; Gómez-Ruiz, C; Mosqueda-Gutiérrez, M; Peláez-Ballestas, I; Tafoya-Amado, A; Torres-Ordaz, DE; Vázquez-Mellado, A; Vázquez-Mellado, J, 2022) |
| "Melatonin (MLT) is a powerful endogenous anti-inflammatory agent and effective in reducing cellular damage." | 1.72 | Influence of Pinealectomy and Long-term Melatonin Administration on Inflammation and Oxidative Stress in Experimental Gouty Arthritis. ( Altinoz, E; Ballur, AFH; Bicer, Y; Demir, M; Elbe, H; Karayakali, M; Onal, MO; Yigitturk, G, 2022) |
| "The prevalence of nephrolithiasis, microhematuria, and proteinuria were 16." | 1.72 | Association of acidic urine pH with impaired renal function in primary gout patients: a Chinese population-based cross-sectional study. ( Chen, Y; Cui, L; Dalbeth, N; Feng, Z; He, Y; Ji, A; Ji, X; Li, C; Li, H; Li, X; Liu, Z; Lu, J; Merriman, TR; Mount, DB; Terkeltaub, R; Wang, X; Xu, Y; Xue, X, 2022) |
| "Pharmacological treatment of gout consists of treating acute flares with anti-inflammatory drugs and, if indicated, of urate lowering therapies (ULT)." | 1.72 | [Gout: an overview of diagnostics and treatment]. ( Flendrie, M; Jansen, TLTA; Janssen, M; Moses, A; Oude Voshaar, AMH; Peeters, IR; van Herwaarden, N, 2022) |
| "Our findings reinforce the need to treat gout early, before destruction of bone scaffold by extensive tophi, as MSU crystal dissolution by ULT may further weaken these areas and induce their collapse." | 1.72 | The shrinking toe sign in gout. ( Bardin, T; Bousson, V; Dalbeth, N; Do, MD; Ea, HK; Hieu, NL; Nguyen, QD; Resche-Rigon, M; Richette, P; Tran, KM, 2022) |
| "Recent studies showed that treatment of hyperuricemia did not affect the progression in chronic kidney disease (CKD) patients." | 1.72 | [Management of hyperuricemia in chronic kidney disease]. ( Auberson, M; Bonny, O; Livio, F; Schwotzer, N; So, A, 2022) |
| "Hyperuricemia was defined as a serum uric acid level of ≥7." | 1.72 | Association between serum uric acid and α-klotho protein levels in the middle-aged population. ( Choi, JY; Kim, D; Lee, HJ; Lee, J; Min, JY; Min, KB, 2022) |
| "Gout is usually found in patients with atrial fibrillation (AF)." | 1.72 | Kv1.5 channel mediates monosodium urate-induced activation of NLRP3 inflammasome in macrophages and arrhythmogenic effects of urate on cardiomyocytes. ( Higaki, K; Hisatome, I; Kurata, Y; Kuwabara, M; Lanaspa, MA; Li, P; Ninomiya, H; Shirayoshi, Y; Taufiq, F; Tsuneto, M, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) share common pathogenic mechanisms and risk factors." | 1.72 | The Negative Association Between NAFLD Severity and CKD in a Non-Diabetic Gouty Population. ( Chen, Y; Chi, J; Huang, Y; Lv, W; Wang, Y; Zhou, Y, 2022) |
| "Gout is a disease that manifests itself after decades of following a high-purine diet, with excessive alcohol consumption assumed to be one of the main contributors to the development of the disease." | 1.72 | The Relationship between Alcohol Consumption and Gout: A Mendelian Randomization Study. ( Chen, H; Chen, J; Fahira, A; Li, Z; Shi, Y; Syed, AAS; Yang, Q, 2022) |
| "Gout is the most common inflammatory arthritis in men with a rising incidence worldwide." | 1.72 | [Gout]. ( Tausche, AK, 2022) |
| "In the reverse direction analysis, genetic predisposition to both urate and gout were not associated with PA being investigated." | 1.72 | Genetically predicted physical activity is associated with lower serum urate concentrations. ( Chen, D; Guan, Y; Li, Y; Meng, L; Qian, Q; Wang, T; Wei, J, 2022) |
| "Gout is caused by deposition of monosodium urate (MSU) crystals." | 1.72 | Investigation on monosodium urate deposition in the first metatarsophalangeal joint and ankle of primary gout patients using dual-energy computed tomography. ( Nam, VT; Quoc, TAH; Tam, V, 2022) |
| "Gout is a common arthritis caused by deposition of monosodium urate crystals." | 1.72 | Natural Adrenocorticotropic Hormone (ACTH) Relieves Acute Inflammation in Gout Patients by Changing the Function of Macrophages. ( Cao, L; Liu, J; Wan, W; Xu, R; Xuan, D; Xue, Y; Yu, Y; Zhao, L; Zhao, T; Zou, H, 2022) |
| "Gout is the most common form of inflammatory arthritis in men." | 1.72 | Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions. ( Aung, E; Caillet, V; Coleshill, MJ; Cronin, P; Day, RO; Kannangara, DRW; Kouhkamari, M; Rodgers, A; Stocker, SL; Tam, K, 2022) |
| "Gout is a chronic disease caused by monosodium urate (MSU) crystal deposition in the joints and surrounding tissues." | 1.72 | Taxifolin blocks monosodium urate crystal-induced gouty inflammation by regulating phagocytosis and autophagy. ( Jiang, YJ; Lian, LH; Nan, JX; Piao, MH; Wang, H; Wu, YL, 2022) |
| "Gout is a common inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in individuals with hyperuricemia." | 1.72 | TET2-mutant clonal hematopoiesis and risk of gout. ( Agrawal, M; Bick, AG; Cunin, P; Ebert, BL; Gibson, CJ; Griffin, GK; Jaiswal, S; Kim, PG; Lin, AE; McConkey, M; Miller, PG; Natarajan, P; Neuberg, D; Nigrovic, PA; Niroula, A; Rao, DA; Schaefer, IM; Sekar, A; Shkolnik, V; Stone, RM; Uddin, MM; Weeks, LD; Wong, WJ, 2022) |
| "Hyperuricemia was associated with greater NLRP3 and gasdermin-D expression on human atheroma plaques in patients with peripheral artery disease." | 1.72 | Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia. ( Andrés, M; Argente-Del-Castillo, E; Mendieta, L; Miñano, A; Pascual, E; Trigueros, M, 2022) |
| "Gout is the most common cause of inflammatory arthritis in adults." | 1.72 | Monosodium urate deposition in the lumbosacral spine of patients with gout compared with non-gout controls: A dual-energy CT study. ( Becce, F; Fields, T; Mechlin, M; Oh, C; Pillinger, MH; Toprover, M, 2022) |
| "Gout is of unknown reason associated with cardiovascular disease." | 1.72 | Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study. ( Haavardsholm, EA; Hammer, HB; Jensen, G; Karoliussen, LF; Kvien, TK; Rollefstad, S; Semb, AG; Terslev, L; Uhlig, T, 2022) |
| "Gout is a self-limiting inflammatory arthritis mediated by the precipitation of monosodium urate (MSU) crystals that further activate the NLRP3 inflammasome and initiate a cascade of inflammatory events." | 1.72 | Monosodium urate crystals with controlled shape and aspect ratio for elucidating the pathological progress of acute gout. ( Chen, C; Fu, D; Ge, D; Guo, Y; Li, M; Liang, Z; Liu, Y; Sun, B; Wang, J; Yang, X; Zhang, L, 2022) |
| "Gout is an inflammatory joint disease caused by urate crystal deposition, which is associated with hyperuricemia." | 1.72 | Study on the interaction mechanism between luteoloside and xanthine oxidase by multi-spectroscopic and molecular docking methods. ( Cao, X; Chen, J; Cheng, Y; Liu, J; Pan, X; Wang, Y, 2022) |
| "Gout is a highly hereditary disease, but not all those carrying well-known risk variants have developing gout attack even in hyperuricemia status." | 1.72 | Polygenic risk score trend and new variants on chromosome 1 are associated with male gout in genome-wide association study. ( Chang, JG; Chang, SJ; Chang, YS; Chen, YC; Chung, CC; Huang, CM; Lin, CY; Liu, TY; Tsai, FJ, 2022) |
| "Gout is one of the most common inflammatory arthritis, where identification of MSU crystals in synovial fluid is a widely used diagnostic measure." | 1.72 | The Role of Ultrasound in Evaluating the Effect of Urate-lowering Drugs in Gout Patients. ( El Attar, EA; El-Mallah, R; Ibrahim, RA, 2022) |
| "Gout is a painful form of inflammatory arthritis characterized by the deposition of monosodium urate (MSU) crystals in the joints." | 1.72 | The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model. ( Aganetti, M; Amaral, FA; Braga, AD; de Faria, AMC; de Oliveira, VLS; Galvão, I; Georgel, P; Martins, VD; Mastrippolito, D; Mendes, V; Muller, S; Rocha, V; Talamini, L; Verdot, C; Vieira, AT, 2022) |
| "Gout is caused by elevated serum urate leading to the deposition of monosodium urate (MSU) crystals that can trigger episodes of acute inflammation." | 1.72 | Uricase-Deficient Larval Zebrafish with Elevated Urate Levels Demonstrate Suppressed Acute Inflammatory Response to Monosodium Urate Crystals and Prolonged Crystal Persistence. ( Astin, JW; Dalbeth, N; Hall, CJ; Linnerz, T; Rolland, L; Sung, YJ, 2022) |
| "Gout is a common inflammatory disease." | 1.72 | Lipoxin A4 attenuates MSU-crystal-induced NLRP3 inflammasome activation through suppressing Nrf2 thereby increasing TXNRD2. ( Chen, Y; Guo, X; Xia, H; Xu, L; You, CG; Zhao, M; Zhong, X; Zhou, Y, 2022) |
| "Hyperuricemia and gout have become gradually more common." | 1.72 | Associations between serum urate and telomere length and inflammation markers: Evidence from UK Biobank cohort. ( Cui, J; Lv, Z; Zhang, J, 2022) |
| "Meanwhile, untreated hyperuricemia was also suggested to lead to hypertension." | 1.72 | Increased Systolic Blood Pressure Mediates the Relationship Between Urate and Gout Risk in Indonesia: A Novel Application of a Partial Least Squares-Structural Equation Model. ( Dyah Kurniasari, M; Huruta, AD; Karwur, FF; Lin, YH; Rayanti, RE; Tsai, HT; Weng, SF, 2022) |
| "Gout is the most common form of inflammatory arthritis, caused by the deposition of monosodium urate (MSU) crystals in peripheral joints and tissue." | 1.62 | X-ray dark-field radiography for in situ gout diagnosis by means of an ex vivo animal study. ( Andrejewski, J; Birnbacher, L; Braig, EM; Busse, M; Herzen, J; Kimm, MA; Korbel, R; Petrich, C; Pfeiffer, D; Roiser, N; Sauter, A; Scholz, J, 2021) |
| "BACKGROUND Gout is a chronic disease characterized by deposition of monosodium urate crystals, typically manifesting as arthritis." | 1.62 | Gout Storm. ( Cardoso Nóbrega, V; Curcelli, EC; Junior, LAJ; Luiz da Silva, D; Martins, D; Matchil, NL; Okoshi, MP; Pacca, RL; Padovani de Toledo Moraes, M; Padovese, V; Pereira, FWL; Queiroz, DS; Silva, AM; Tonon, CR, 2021) |
| "Pretreatment with baricitinib, which blocks IL-6 receptor signaling, prevented MSU-induced cleaved caspase-1 or IL-1β induction in IL-6-primed neutrophils." | 1.62 | Uric acid-mediated inflammasome activation in IL-6 primed innate immune cells is regulated by baricitinib. ( Asano, T; Fujita, Y; Furuya, MY; Kawakami, A; Kozuru, H; Matsumoto, H; Matsuoka, N; Migita, K; Sato, S; Temmoku, J; Urano, T; Watanabe, H; Yatsuhashi, H, 2021) |
| " The lower risk of incident HTN after xanthine oxidase inhibitors exhibited a significant dose-response trend." | 1.62 | Urate-lowering therapy exerts protective effects against hypertension development in patients with gout. ( Hsu, CC; Hwu, CM; Li, HL; Lin, KH; Wei, JC; Yang, CC; Yen, FS, 2021) |
| "Gout is the most common inflammatory arthritis affecting 1." | 1.62 | Treat-to-Target urate-lowering therapy in primary gout patients: A real-world retrospective study at a dedicated gout clinic in China. ( Bai, XS; Cui, LL; He, YW; Li, CG; Li, XD; Qu, XJ; Sun, MS; Wang, C; Wang, M; Zhao, XD, 2021) |
| "Gout is the most common form of inflammatory arthritis in men, yet both patients and the public often do not recognise gout as a form of arthritis." | 1.62 | Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy? ( Aung, E; Carland, JE; Coleshill, MJ; Day, RO; Faasse, K; Stocker, S, 2021) |
| "Gout is a complex inflammatory arthritis affecting ~20% of people with an elevated serum urate level (hyperuricemia)." | 1.62 | Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects. ( Bixley, M; Cadzow, M; Choi, HK; Dalbeth, N; Guo, H; He, M; Hu, H; Li, C; Li, Z; Major, TJ; Markie, D; Merriman, TR; Phipps-Green, A; Shi, Y; Stamp, LK; Takei, R; Wei, WH, 2021) |
| "Gout was commonly observed in middle-aged men." | 1.62 | A Study of Metabolic Parameters in Patients with Gout: A Single Center Study from Nepal. ( Baral, R; Bhochhibhoya, M; Joshi, R; Lama, LD; Nakarmi, S; Vaidya, B, 2021) |
| "Thus, hyperuricemia is associated with impaired endothelial function." | 1.62 | Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. ( Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB, 2021) |
| "Gout is the most common inflammatory arthritis in adults." | 1.62 | Non-alcoholic fatty kidney disease (NAFKD): A novel disease that explains the etiology of hyperuricemia and gout in metabolic syndrome. ( Abrahim, M, 2021) |
| "Gout is a common metabolic disease with growing burden, caused by monosodium urate (MSU) microcrystal deposition." | 1.62 | Highly specific and label-free histological identification of microcrystals in fresh human gout tissues with stimulated Raman scattering. ( Ao, J; Chen, J; Hua, Y; Ji, M; Xu, H; Xue, Y; Yang, Y; Zhang, B; Zhu, X, 2021) |
| "Studies show that hyperuricemia is an element of the pathophysiology of many conditions." | 1.62 | How Are We Managing Patients with Hyperuricemia and Gout: A Cross Sectional Study Assessing Knowledge and Attitudes of Primary Care Physicians? ( Bozic, J; Rada, M; Rumboldt, M; Rumboldt, Z; Rusic, D; Tomicic, M; Zuzic Furlan, S, 2021) |
| "Gout is the most common inflammatory arthritis in men with a rising incidence worldwide." | 1.62 | [Gout]. ( Tausche, AK, 2021) |
| "In the reverse direction analysis, genetic predisposition to both urate and gout were not associated with T2D or any of 4 glycemic traits being investigated." | 1.62 | Genetic Predisposition to Type 2 Diabetes and Insulin Levels Is Positively Associated With Serum Urate Levels. ( Fan, J; Li, Y; Sun, L; Tse, LA; Yang, J; Zhu, J, 2021) |
| "Gout is often not adequately treated, and we aimed to apply urate lowering treatment (ULT) combined with individual information to achieve target serum urate (sUA) in clinical practice, and to identify predictors of achievement of this sUA target." | 1.62 | 12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target. ( Borgen, T; Haavardsholm, EA; Hammer, HB; Karoliussen, LF; Kvien, TK; Sexton, J; Uhlig, T, 2021) |
| "Patients with gout have an increased risk of urolithiasis and usually need urate-lowering therapy (ULT) for the prevention of disease progression." | 1.62 | Association of urate-lowering drugs with the risk of future urolithiasis in patients with gout: A population-based nested case-control study. ( Cheng-Chung Wei, J; Liu, CY; Wang, YH; Wu, SW; Yeh, CJ, 2021) |
| "Gout is a multifaceted inflammatory disease involving vascular impairments induced by hyperuricemia." | 1.62 | Gout-induced endothelial impairment: The role of SREBP2 transactivation of YAP. ( He, M; Li, X; Shi, W; Shyy, JY; Wang, L; Zhang, Y; Zhao, Y; Zhao, Z, 2021) |
| "Hyperuricemia is closely associated with insulin resistance syndrome (and its many cardiometabolic sequelae); however, whether they are causally related has long been debated." | 1.62 | Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization. ( Choi, HK; Leong, A; McCormick, N; Merriman, TR; Mount, DB; O'Connor, MJ; Yokose, C, 2021) |
| "Gout is an inflammatory disease triggered by deposition of monosodium urate (MSU) crystals in the joints, resulting in high neutrophil influx and pain." | 1.62 | CD300a contributes to the resolution of articular inflammation triggered by MSU crystals by controlling neutrophil apoptosis. ( Galvão, I; Levi-Schaffer, F; Queiroz-Junior, CM; Teixeira, MM; Valiate, BVS, 2021) |
| "Gout is a metabolically-related joint disease, characterized by recurrent episodic arthritis." | 1.62 | Non-pharmacological treatment of gout. ( Líška, D, 2021) |
| "• Enthesopathy is most frequently involved in the patellar insertion of the quadriceps tendon in gout." | 1.62 | Entheseal involvement of the lower extremities in gout: an ultrasonographic descriptive observational study. ( Cao, H; Liang, J; Lin, J; Xu, G; Yang, Y; Ye, Z; Zhu, G, 2021) |
| "Patients with hyperuricemia are among the high-risk group of postoperative gout attacks." | 1.62 | Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia. ( Fu, L; Liu, Y; Wen, J; Xu, C; Yan, T; Yang, H; You, Y; Yu, J; Zhan, D; Zhang, T, 2021) |
| "Comparative analysis with obesity, type 2 diabetes, ankylosing spondylitis and rheumatoid arthritis indicated that gout metagenomes were more similar to those of autoimmune than metabolic diseases." | 1.62 | Metagenomic analysis revealed the potential role of gut microbiome in gout. ( Bai, X; Chen, X; Chu, Y; Ding, F; Fang, X; Gao, Q; He, X; Huang, Q; Huang, R; Huang, Y; Jiang, Y; Li, J; Liang, L; Sun, S; Wang, M; Wang, P; Wang, Z; Wei, X; Wu, J; Wu, X; Xie, X; Yang, J; Yue, Z; Zhang, Y; Zhao, Y; Zhou, C, 2021) |
| "Gout is a recurrent and chronic form of arthritis caused by the deposition of monosodium urate (MSU) crystals in the joints." | 1.62 | Lower Temperatures Exacerbate NLRP3 Inflammasome Activation by Promoting Monosodium Urate Crystallization, Causing Gout. ( Ahn, H; Lee, G; Lee, GS, 2021) |
| "Gout has significant impact on the quality of life with over-utilisation of health resources." | 1.56 | Burden and management of gout in a multi-ethnic Asian cohort. ( Cheung, PP; Chua, CKT; Lim, AYN; Santosa, A; Teng, GG, 2020) |
| "Gout and hyperuricemia are common public health problem." | 1.56 | The prevalence of gout and hyperuricemia in middle-aged and elderly people in Tibet Autonomous Region, China: A preliminary study. ( Baima, Y; Gong, H; Lin, C; Lin, J; Liu, Q; Wang, Y; Zhang, Q, 2020) |
| "Currently, the treatment of gout mainly includes two basic methods: reducing uric acid and alleviating inflammation." | 1.56 | Development of novel NLRP3-XOD dual inhibitors for the treatment of gout. ( Ha, EH; Hu, Q; Li, H; Li, Z; Pang, J; Tian, S; Wang, W; Zhou, M, 2020) |
| "Gout is a common arthritis caused by monosodium urate crystals." | 1.56 | Contribution of Rare Variants of the ( Anzai, N; Hasegawa, T; Jutabha, P; Kawai, Y; Kojima, K; Matsuo, M; Misawa, K; Mishima, E; Nagasaki, M; Ouchi, M, 2020) |
| "Final diagnosis was FHL tendonitis secondary to gout proven by synovial fluid analysis." | 1.56 | Gout in the Flexor Hallucis Longus Tendon Mimicking Cellulitis: A Case Report. ( Ishimaru, N; Kanzawa, Y; Kinami, S; Ohnishi, J; Seto, H, 2020) |
| "Gout is increasing in prevalence despite effective pharmacotherapies." | 1.56 | Better outcomes for patients with gout. ( Aung, E; Coleshill, M; Day, R; Graham, G; Nguyen, A; Stocker, S, 2020) |
| "Gout is characterised by severe interleukin (IL)-1-mediated joint inflammation induced by monosodium urate crystals." | 1.56 | Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. ( Arts, P; Cavalli, G; Cleophas, MC; Crișan, TO; Dagna, L; Dalbeth, N; Dinarello, CA; Eisenmesser, EZ; Gilissen, C; Hindmarsh, JH; Hoischen, A; Jansen, TLTA; Janssen, M; Joosten, LA; Kim, S; Klück, V; Lelieveld, S; Merriman, TR; Netea, MG; Riches, P; Shaukat, A; Stamp, LK; Steehouwer, M; Tausche, AK; Van de Veerdonk, FL; van de Vorst, M; van Deuren, RC, 2020) |
| "Gout is the most common inflammatory arthritis and the worldwide incidence is increasing." | 1.56 | Identification of the urine and serum metabolomics signature of gout. ( Cao, S; Chen, Z; Gu, J; Huang, Y; Jiang, Y; Lv, Q; Ou, J; Qi, J; Qiu, M; Tu, L; Wei, Q; Wu, J; Xiao, M; Zhang, X, 2020) |
| "Gout is a painful form of inflammatory arthritis associated with several comorbidities, particularly cardiovascular disease." | 1.56 | Effect of tart cherry juice on risk of gout attacks: protocol for a randomised controlled trial. ( Barker, ME; Lamb, KL; Lynn, A; Russell, J, 2020) |
| "Gout is the typical feature of GAstrV infection in goslings." | 1.56 | Goose astrovirus infection affects uric acid production and excretion in goslings. ( Bao, E; Lv, Y; Wu, W; Xu, R, 2020) |
| "Hyperuricemia is a central risk factor for gout and increases the risk for other chronic diseases, including cardiometabolic disease, kidney disease, and hypertension." | 1.56 | High-Protein Diet Induces Hyperuricemia in a New Animal Model for Studying Human Gout. ( Dai, S; Guo, Y; Hong, F; Li, L; Liu, G; Pan, S; Qiao, X; Wang, J; Xie, X; Xu, P; Xue, T; Zhai, Y; Zheng, A, 2020) |
| " Further investigations are required to confirm the present results following multiple dosing with febuxostat." | 1.56 | A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects. ( Carland, JE; Day, RO; Graham, GG; Kamel, B; Liu, Z; Pile, KD; Stocker, SL; Williams, KM, 2020) |
| "Hyperuricemia and gout are common in patients with heart failure (HF) and are associated with poor outcomes." | 1.56 | Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. ( Andersson, K; Bjursell, M; Carnicelli, AP; Chiswell, K; Clare, R; Hedman, K; Lytle, B; Mentz, RJ; Pagidipati, N; Perl, S; Roe, MT; Vemulapalli, S, 2020) |
| "Gout is an inflammatory disease caused by monosodium urate (MSU) crystals." | 1.56 | In Vivo Transmigrated Human Neutrophils Are Highly Primed for Intracellular Radical Production Induced by Monosodium Urate Crystals. ( Björkman, L; Buck, A; Bylund, J; Christenson, K; Dahlstrand Rudin, A; Davidsson, L; Sanchez Klose, FP, 2020) |
| "Allopurinol treatment significantly reduced MAGE (4." | 1.56 | Blood glucose fluctuations detected by continuous glucose monitoring system in gout patients with normal glucose tolerance and the effect of urate-lowering therapy. ( Chen, Y; Dong, B; Lv, W; Mu, Z; Wang, F; Wang, J; Wang, W; Wang, Y; Wang, Z; Zhao, Y, 2020) |
| "Gout is a crystal associated arthritis caused by monosodium urate (MSU) accumulating in joint, and it belongs to metabolic rheumatic disease." | 1.56 | [Recommendations of diagnosis and treatment of gout in China]. ( Gu, JR; Xu, D; Zeng, XF; Zeng, XJ; Zhao, Y; Zhou, JG; Zhu, XX; Zou, HJ, 2020) |
| " The effect of uricosuric agents on the decrease in hospitalized stroke risk indicated a dose-response relationship." | 1.56 | Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout. ( Hsu, CC; Hwu, CM; Li, HL; Wei, JC; Yen, FS, 2020) |
| "Gout is an inflammatory arthritis caused by the phagocytosis of monosodium urate (MSU) crystal deposition in joints." | 1.56 | EPS8 regulates an NLRP3 inflammasome-independent caspase-1 activation pathway in monosodium urate crystal-treated RAW264.7 macrophages. ( Chuang, JP; Kao, CY; Lee, JC; Leu, TH; Ling, P; Maa, MC, 2020) |
| "Gout is a heterogeneous inflammatory disease with numerous clinical manifestations." | 1.56 | Development of a multivariable improvement measure for gout. ( Edwards, NL; Lipsky, PE; Schlesinger, N; Yeo, AE, 2020) |
| "Gout is a multisystem disease that may present in different ways." | 1.56 | A leg ulcer with hard, yellow projections. ( Azevedo, F; Baudrier, T; Cerejeira, A; Gomes, N; Lopes, JM; Moura, CS, 2020) |
| "Gout is the most prevalent inflammatory arthritis in adults." | 1.56 | Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study. ( Chung, YL; Fang, YJ; Lim, YP; Lin, CL, 2020) |
| "Gout is a serious medical, social and economic problem of today." | 1.56 | [INDICATORS OF GOUT INTERLAYKINS AND THERMOGRAPHY OF JOINTS ON THE BACKGROUND OF ENTEROSORBTION THERAPY]. ( Andreychyn, S; Hanberher, I; Korylchuk, N; Mudra, U, 2020) |
| "Nevertheless, gout is a "curable disease" by ULT, a treatment which in adequate doses may also have positive effect on several associated co-morbidities." | 1.56 | [Consequences of Gout and Hyperuricemia]. ( Bengtsson Boström, K; Dehlin, M; Forsblad d'Elia, H; Jacobsson, L; Kapetanovic, M; Sigurdardottir, V; Svärd, A; Wändell, P, 2020) |
| "Gout has a prevalence of 1." | 1.56 | [Gout - a common and well known disease]. ( Bengtsson Boström, K; Dehlin, M; Forsblad d'Elia, H; Jacobsson, L; Kapetanovic, M; Sigurdardottir, V; Svärd, A; Wändell, P, 2020) |
| "Gout was defined by the diagnosis codes in CDARS." | 1.56 | Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016. ( Cheung, BMY; Cheung, TT; Chung, MH; Lau, CS; Tsoi, MF, 2020) |
| "Patients with gout are at a higher risk of cardiovascular disease, which is associated with hyperlipidemia." | 1.56 | Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on ( Chung, YL; Fang, YJ; Li, JR; Lim, YP; Lin, CL; Su, CY; Tien, N; Wu, TY, 2020) |
| "Acute gout is an inflammatory response induced by monosodium urate (MSU) crystals." | 1.56 | HSP60 Regulates Monosodium Urate Crystal-Induced Inflammation by Activating the TLR4-NF- ( Gao, W; Huang, Q; Liu, J; Long, F; Mu, H; Qin, T; Ren, L; Tang, H; Zeng, M, 2020) |
| "Gout is a crystal-related arthropathy resulting from the deposition of monosodium urate." | 1.56 | Progress in Treatment of Gout Using Chinese and Western Medicine. ( Wang, X; Wang, YG, 2020) |
| "Although gout is the most common inflammatory arthritis, it is still frequently misdiagnosed." | 1.56 | 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. ( Bardin, T; Barskova, V; Becce, F; Castaneda, J; Coyfish, M; Doherty, M; Guillo, S; Jansen, T; Janssens, H; Lioté, F; Mallen, CD; Nuki, G; Pascual, E; Perez-Ruiz, F; Pimentao, J; Punzi, L; Pywell, A; Richette, P; So, AK; Tausche, AK; Tubach, F; Uhlig, T; Zavada, J; Zhang, W, 2020) |
| "Gout is common crystal arthritis that is often managed sub-optimally." | 1.56 | Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia. ( Bavanendrakumar, M; Robinson, PC, 2020) |
| "For instance, hypertension is found in 36-41% gout patients, and combined with metabolic syndrome it may reach 80%." | 1.51 | Role of immune system in development and progress of combined arterial hypertension and gout. ( Bychkov, ОА; Bychkova, NG; Bychkova, SA; Kondratiuk, VE; Morozova, ZV; Tarasiuk, AP, 2019) |
| "Curcumin treatment markedly inhibited the degradation of IκBα, the activation of NF-κB signaling pathway, and the expression levels of the NF-κB downstream inflammatory genes such as IL-1β, IL-6, TNF-α, COX-2, and PGE2 in the MSU-stimulated THP-1-derived macrophages." | 1.51 | Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of IκBα and blocking mitochondrial damage. ( Chen, B; Li, H; Ou, G; Ren, L; Yang, X; Zeng, M, 2019) |
| "The prevalence of gout has increased in recent decades." | 1.51 | Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout. ( Bellmann-Weiler, R; Feuchtner, G; Gruber, J; Halpern, EJ; Jaschke, W; Klauser, AS; Stofferin, H; Strobl, S; Weiss, G, 2019) |
| "Gout is a prevalent and incapacitating disease triggered by the deposition of monosodium urate (MSU) crystals in joints, which are also massively infiltrated by neutrophils." | 1.51 | Cytokine Production and NET Formation by Monosodium Urate-Activated Human Neutrophils Involves Early and Late Events, and Requires Upstream TAK1 and Syk. ( de Carvalho Oliveira, V; Dubois, CM; Isabel, M; Mayer, TZ; McDonald, PP; Sylvain-Prévost, S; Tatsiy, O, 2019) |
| "Gout is independently associated with increased risk of type 2 diabetes mellitus (T2DM)." | 1.51 | Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus. ( Chang, HW; Lan, YC; Lin, MH; Lin, YW; Wang, RY, 2019) |
| "Hyperuricemia was defined as having a serum urate level of >7." | 1.51 | Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. ( Chen-Xu, M; Choi, HK; Pillinger, MH; Rai, SK; Yokose, C, 2019) |
| "Gout was present in 6768 (4." | 1.51 | Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank. ( Cadzow, M; Dalbeth, N; Gamble, G; Merriman, TR; Narang, RK; Stamp, LK; Topless, R, 2019) |
| "Gout is a common inflammatory arthritis associated with adverse clinical outcomes." | 1.51 | Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study. ( Adeeb, F; Browne, LD; Fraser, AD; Kumar A U, A; Mohammed, E; Stack, AG, 2019) |
| "Gout is a disease driven solely by IL-1β secretion in response to monosodium urate (MSU) crystals which form during periods of hyperuricemia and thus presents an opportunity to study factors contributing to IL-1β secretion." | 1.51 | Secretion of IL-1β From Monocytes in Gout Is Redox Independent. ( Alberts, BM; Basnayake, K; Bruce, C; Davies, KA; Ghezzi, P; Mullen, LM, 2019) |
| "Gout is the most common inflammatory arthritis worldwide, and patients experience a heavy burden of cardiovascular and metabolic diseases." | 1.51 | mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? ( Broen, JCA; Jansen, M; Merriman, T; Ottria, A; Phipps-Green, A; Radstake, TRDJ; Schuiveling, M; van der Linden, M; van Lochem, E; Vazirpanah, N; Wichers, CGK; Zimmermann, M, 2019) |
| "Hyperuricemia was identified in 30." | 1.51 | Hyperuricemia and acute gout after laparoscopic sleeve gastrectomy. ( Katsogridaki, G; Magouliotis, D; Perivoliotis, K; Sioka, E; Tasiopoulou, V; Tzovaras, G; Zachari, E; Zacharoulis, D, 2019) |
| "Gout is one of the most common metabolic disorders in human." | 1.51 | Alpha2B-Adrenergic Receptor Regulates Neutrophil Recruitment in MSU-Induced Peritoneal Inflammation. ( Chen, J; Duan, L; Rao, X; Razavi, M; Tao, Y; Wei, Y; Zhong, J, 2019) |
| "Spinal gout is rarely encountered in clinical practice, is easily misdiagnosed, and often remains undiagnosed." | 1.51 | Diagnostic challenges of spinal gout: A case series. ( An, Q; Gu, R; Jiang, R; Ma, S; Zhao, J, 2019) |
| "Acute gout is an inflammatory response to MSU crystals." | 1.51 | Sirt1 ameliorates monosodium urate crystal-induced inflammation by altering macrophage polarization via the PI3K/Akt/STAT6 pathway. ( Liu, L; Xue, Y; Yu, Y; Zhao, T; Zhu, X; Zou, H, 2019) |
| "Gout was associated with higher risk of venous thromboembolism compared with controls (absolute rate 37." | 1.51 | Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy. ( Clarson, L; Mallen, C; Muller, S; Roddy, E; Sultan, AA; Whittle, R, 2019) |
| "People with gout are at an increased risk of readmission for heart failure and have longer hospital stays." | 1.51 | Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study. ( Doughty, RN; Drake, J; Frampton, C; Richards, AM; Stamp, LK; Troughton, RW, 2019) |
| "Thus, AE may be a potential treatment for hyperuricemia and gout." | 1.51 | Anti-hyperuricemic effect of Alpinia oxyphylla seed extract by enhancing uric acid excretion in the kidney. ( Kim, DS; Kim, JS; Lee, S; Lee, YS; Son, E; Sung, YY; Yuk, HJ, 2019) |
| "Gout is sterile joint inflammation triggered by the damaging effects of monosodium urate (MSU) crystals accumulation." | 1.51 | Downregulation of Transcription Factor T-Bet as a Protective Strategy in Monosodium Urate-Induced Gouty Inflammation. ( He, YL; Mi, QS; Yang, QB; Zhang, QB; Zhou, JG, 2019) |
| "Among treated gout patients, 76% were receiving allopurinol at a mean dose lower than 200mg/d, most without any further change of dose regimen over one year." | 1.48 | Persistent clinical inertia in gout in 2014: An observational French longitudinal patient database study. ( Flipo, RM; Hincapie, N; Lioté, F; Maravic, M; Pilet, S, 2018) |
| "2% were aware of first-line pharmacological management options; 28% answered the correct dosing regimen for colchicine." | 1.48 | A survey on the beliefs and knowledge of gout management in new medical graduates - New South Wales, Australia. ( Riordan, J; Terrill, M, 2018) |
| "Gout is a multifactorial disease characterized by acute inflammatory arthritis, and it is caused as a consequence of hyperuricemia." | 1.48 | A common variant of MAF/c-MAF, transcriptional factor gene in the kidney, is associated with gout susceptibility. ( Higashino, T; Hishida, A; Imaki, J; Kawaguchi, M; Komatsu, M; Matsuo, H; Nakashima, H; Nakatochi, M; Nakayama, A; Okada, Y; Ooyama, H; Sakiyama, M; Shimizu, S; Shinomiya, N; Tadokoro, S, 2018) |
| "His uric acid was 11 mg/dL despite maximal dosing of febuxostat." | 1.48 | Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease. ( Case, R; Jester, G; Wentworth, B, 2018) |
| "This is a cross-sectional study of untreated gout subjects (n = 34) and non-gout healthy controls (n = 64)." | 1.48 | Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein. ( Bang, D; Dektiarev, I; Guo, Y; Igel, TF; Katz, SD; Krasnokutsky, S; Pike, VC; Pillinger, MH; Romero, AG; Shah, B; Zhong, J, 2018) |
| "Gout is the most common inflammatory arthritis affecting men." | 1.48 | Blocking fatty acid-fueled mROS production within macrophages alleviates acute gouty inflammation. ( Ashimbayeva, E; Astin, JW; Britto, D; Crosier, KE; Crosier, PS; Dalbeth, N; Hall, CJ; Harper, JL; Lawrence, LM; Lieschke, GJ; Pool, B; Sanderson, LE; van der Kroef, M, 2018) |
| "Gout is a disabling and common arthritis with increasing prevalence." | 1.48 | [Gout - a treatable condition]. ( Gudbjornsson, B; Johannsdottir, GA; Jonsson, H; Palsson, O, 2018) |
| "Gout is an inflammatory arthritis characterized by abrupt self-limiting attacks of inflammation caused by precipitation of monosodium urate crystals (MSU) in the joint." | 1.48 | 4-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol is a potential agent for gout therapy as a dual inhibitor of XOD and NLRP3. ( Hu, Q; Li, S; Liu, W; Song, L; Zhou, M, 2018) |
| "Ethnicity and hypertension are predictive of gout risk, and the associations cannot be fully explained by serum urate." | 1.48 | Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities. ( Gaffo, AL; Los Campos, G; Merriman, TR; Reeves, M; Reynolds, RJ; Singh, JA; Sun, M; Vazquez, AI, 2018) |
| "Gout is a common inflammatory arthritis caused by the deposition of urate crystals within joints." | 1.48 | Pharmacophore modeling, molecular docking and molecular dynamics studies on natural products database to discover novel skeleton as non-purine xanthine oxidase inhibitors. ( Li, Y; Liu, X; Peng, J; Zhang, L; Zhou, Y; Zuo, Z, 2018) |
| "Gout is associated with higher cardiovascular risk that increases with disease severity." | 1.48 | The lack of association between the burden of monosodium urate crystals assessed with dual-energy computed tomography or ultrasonography with cardiovascular risk in the commonly high-risk gout patient. ( Budzik, JF; Capon, B; Ducoulombier, V; Godart, C; Grandjean, A; Houvenagel, E; Legrand, J; Luraschi, H; Motte, M; Namane, N; Norberciak, L; Pascart, T; Vandecandelaere, M, 2018) |
| "Gout is one of the most common inflammatory arthropathies, and the pathogenesis is well understood." | 1.48 | Chronic gout: Barriers to effective management. ( Arnold, MH; Rogenmoser, S, 2018) |
| "To examine whether gout is an independent risk factor for total joint replacement (TJR) and whether urate-lowering treatment (ULT) reduces this risk." | 1.48 | Urate-lowering treatment and risk of total joint replacement in patients with gout. ( Chen, JS; Chou, IJ; Doherty, M; Hsieh, AH; Kuo, CF; Luo, SF; See, LC; Yu, KH; Zhang, W, 2018) |
| "Gout is an inflammatory disease affecting multiple joints." | 1.48 | Plasma D-dimer is a Promising Indicator for the Treatment of Acute Gouty Attack. ( Chu, C; Lin, C; Song, P; Wu, Y; Xu, Q; Yang, Y, 2018) |
| "Hyperuricemia is the main risk factor for gout." | 1.48 | The benchmark dose estimation of reference levels of serum urate for gout. ( Chen, X; Cui, W; Ding, X; Duan, N; Jin, T; Wang, Z, 2018) |
| "Gout is one of the most common inflammatory arthritis in Malaysia." | 1.48 | Association of solute carrier family 2, member 9 (SLC2A9) genetic variant rs3733591 with gout in a Malay sample set. ( Amanda Jane, PG; Mahfudzah, A; Nazihah, MY; Tan, HL; Tony Richard, M; Wan Rohani, WT; Wan Syamimee, WG, 2018) |
| "Gout was associated with an increased risk of incident CKD (adjusted HR 1." | 1.48 | Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study. ( Belcher, J; Clarson, L; Mallen, CD; Muller, S; Roddy, E; Roughley, M; Sultan, AA; Whittle, R, 2018) |
| "Gout is a chronic disease associated with deposition of monosodium urate crystals and accompanied by diabetes, hypertension, and dyslipidemia." | 1.48 | Effect of fenofibrate on uric acid level in patients with gout. ( Choi, Y; Jung, JY; Kim, HA; Suh, CH; Yoon, D, 2018) |
| "Gout is a chronic disease, characterised by deposition of monosodium urate crystals in joints and tissues." | 1.48 | [A woman with a white skin lesion of her toe]. ( Hondebrink, LLC; Opstelten, W, 2018) |
| "Sensitivity and specificity were calculated by using the presence of monosodium urate (MSU) crystals in the synovial fluid or tissue aspirate as gold standard for gout diagnosis." | 1.46 | Performance of the 2015 American College of Rheumatology/European League Against Rheumatism gout classification criteria in Thai patients. ( Jatuworapruk, K; Lhakum, P; Louthrenoo, W; Pattamapaspong, N, 2017) |
| "2%) 19 patients received the recommended starting dosage of 100mg/day." | 1.46 | GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations. ( Delva, C; Ea, HK; Goossens, J; Guggenbuhl, P; Lambert, C; Lancrenon, S; Lanz, S; Lioté, F; Sahbane, S; Saraux, A, 2017) |
| "Tophaceous gout is painful and impairs quality of life." | 1.46 | Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking. ( Crittenden, DB; Gyftopoulos, S; Karis, E; Keenan, RT; Krasnokutsky, S; Lee, K; Modjinou, DV; Pike, VC; Pillinger, MH; Samuels, J, 2017) |
| "Gout is a chronic disease resulting from elevated serum urate (SU)." | 1.46 | Replication of Gout/Urate Concentrations GWAS Susceptibility Loci Associated with Gout in a Han Chinese Population. ( Chen, J; Cheng, X; Cui, L; Han, L; Hou, X; Ji, J; Jia, Z; Li, C; Li, X; Li, Z; Liu, T; Liu, Z; Lu, D; Lu, J; Ma, L; Mi, QS; Ren, W; Shi, Y; Wang, C; Wang, X; Xin, Y; Yu, Q; Yuan, X; Zhang, K; Zhou, Z, 2017) |
| "Management of gout is frequently suboptimal." | 1.46 | Management of Gout in a Hospital Setting: A Lost Opportunity. ( Chapman, PT; Frampton, C; O'Donnell, JL; Raja, R; Stamp, LK; Wright, S, 2017) |
| "Gout is the most common form of inflammatory arthritis in the United States." | 1.46 | My Treatment Approach to Gout. ( Aslam, F; Michet, C, 2017) |
| "Uric acid (UA) is an end product of purine metabolism by the enzyme xanthine oxidase (XOD)." | 1.46 | Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study. ( Chen, HM; Chen, MH; Chen, RJ; Chen, SJ; Chen, YL; Hsiao, CM; Wang, YJ; Wu, MD; Yech, YJ; Yuan, GF, 2017) |
| "Patients, who were treated for gout attack in two tertiary medical centers between January 2000 and April 2014, were divided into young (≤ 50 years), middle-aged, and elderly (> 65 years) groups." | 1.46 | Elderly Patients Exhibit Stronger Inflammatory Responses during Gout Attacks. ( Lee, EB; Lee, EY; Lee, GH; Lee, JH; Lee, WW; Park, JK; Shin, K; Song, YW; Yang, JA, 2017) |
| "Though efficacious and affordable treatments for gout are widely available, gout is still not well controlled in many countries of the world including China." | 1.46 | Adherence to gout management recommendations of Chinese patients. ( Fang, W; Sha, Y; Sheng, F; Zeng, X; Zhang, B, 2017) |
| "Gout is a disease characterized by the deposition of monosodium urate (MSU) crystals in the joints." | 1.46 | Dietary fiber and the short-chain fatty acid acetate promote resolution of neutrophilic inflammation in a model of gout in mice. ( Amaral, FA; Galvão, I; Garcia, CC; Macia, LM; Mackay, CR; Martins, FS; Sernaglia, ÉM; Sousa, LP; Tavares, LP; Teixeira, MM; Vieira, AT; Vinolo, MA, 2017) |
| "Gout was not associated with a risk of non-vertebral fracture." | 1.46 | Gout and the Risk of Non-vertebral Fracture. ( Curhan, GC; Kim, SC; Liu, J; Paik, JM; Solomon, DH, 2017) |
| "Gout is a chronic disease with a high burden of pain and inflammation." | 1.46 | Treat-to-target (T2T) recommendations for gout. ( Bardin, T; Braun, J; Cohen Solal, A; da Rocha Castelar-Pinheiro, G; Dalbeth, N; Doherty, M; Engel, B; Flader, C; Kay, J; Kiltz, U; Matsuoka, M; Perez-Ruiz, F; Saag, K; Smolen, J; So, A; Vazquez Mellado, J; Weisman, M; Westhoff, TH; Yamanaka, H, 2017) |
| "Gout is a self-limited inflammatory disease caused by deposition of monosodium urate (MSU) crystals in the joints." | 1.46 | Annexin A1 promotes timely resolution of inflammation in murine gout. ( Amaral, FA; Barroso, LC; Carneiro, FS; Costa, VV; Ferreira, TP; Galvão, I; Queiroz-Junior, CM; Silva, PM; Sousa, LP; Tavares, LP; Teixeira, MM; Vago, JP, 2017) |
| "Uric acid (UA) has been proven to directly cause mesangial cell (MC) proliferation with elusive mechanisms." | 1.46 | COX-2/mPGES-1/PGE2 cascade activation mediates uric acid-induced mesangial cell proliferation. ( Chen, Q; Ding, G; Gong, W; He, JC; Huang, S; Jia, Z; Li, S; Ruan, Y; Sun, Z; Xia, W; Yu, J; Zhang, A; Zhang, Y, 2017) |
| "Gout is a painful disorder which does not have an efficient delivery system for its treatment." | 1.46 | Oral delivery of allopurinol niosomes in treatment of gout in animal model. ( Kaithwas, G; Kanoujia, J; Parashar, P; Saraf, SA; Singh, N; Tripathi, CB, 2017) |
| "Gout is a common arthritis resulting from increased serum urate, and many loci have been identified that are associated with serum urate and gout." | 1.46 | Effects of multiple genetic loci on the pathogenesis from serum urate to gout. ( Dong, Z; He, H; Ji, H; Jiang, S; Jin, L; Li, Y; Ma, Y; Pang, Y; Wang, J; Wang, X; Wang, Y; Xu, X; Yang, C; Yang, Y; Zhao, D; Zhou, J; Zou, H, 2017) |
| "-Some of the reasons identified for poor adherence to anti-gout medications include the risk of flare of acute gout with the initiation of urate-lowering therapy (ULT), poor response to ULT and persistence of attacks of acute gout, suboptimal dosing of allopurinol therapy and intolerance of allopurinol." | 1.43 | Adherence and persistence to urate-lowering therapies in the Irish setting. ( Bennett, K; McGowan, B; Silke, C; Whelan, B, 2016) |
| "Gout is a chronic, extremely painful disease that is potentially curable when treated effectively." | 1.43 | Management of gout in the real world: current practice versus guideline recommendations. ( Baumgartner, S; Doghramji, PP; Fermer, S; Morlock, R; Wood, R, 2016) |
| " It remains to be seen whether allopurinol has a dose-response relationship with cardiovascular events at higher doses." | 1.43 | Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study. ( Hallas, J; Lindegaard, HM; Pottegård, A; Søltoft Larsen, K, 2016) |
| "Hyperuricaemia and gout are well-recognized complications of diuretic use." | 1.43 | Clinical and genetic features of diuretic-associated gout: a case-control study. ( Dalbeth, N; Franklin, C; Horne, A; Merriman, TR; Mitnala, S; Phipps-Green, A; Stamp, LK, 2016) |
| "Gout is associated with dyslipidaemia." | 1.43 | Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout. ( Dalbeth, N; Harrison, AA; Hill, C; Jansen, TL; Janssen, M; Jones, GT; Joosten, LA; Lester, S; Lioté, F; McCormick, SP; Merriman, TR; Phipps-Green, AJ; Radstake, TR; Rasheed, H; Riches, PL; Rischmueller, M; Smith, MD; So, A; Stamp, LK; Tausche, AK; Topless, R; van Rij, A, 2016) |
| "Gout is characterized by the monosodium urate monohydrate (MSU)-induced arthritis." | 1.43 | ALPK1 phosphorylates myosin IIA modulating TNF-α trafficking in gout flares. ( Chang, JG; Chen, CL; Chiang, SL; Huang, CM; Ko, AM; Ko, YC; Kuo, TM; Lee, CP; Liu, YF; Lu, CY; Ma, C; Tsai, EM, 2016) |
| "Gout is the most common inflammatory arthropathy of metabolic origin and it is characterized by intense inflammation, the underlying mechanisms of which are unknown." | 1.43 | Monosodium urate crystals induce oxidative stress in human synoviocytes. ( Camacho-Galindo, J; Cerna-Cortés, JF; Fernández-Torres, J; Gutierrez, M; Hernández-Díaz, C; Loissell-Baltazar, YA; López-Macay, A; López-Reyes, A; López-Villegas, EO; Martínez-Flores, K; Medina-Luna, D; Oliviero, F; Pineda, C; Santamaría-Olmedo, MG; Scanu, A; Zamudio-Cuevas, Y, 2016) |
| "Gout is a form of crystal arthropathy where monosodium urate (MSU) crystals deposit and elicit inflammation in a joint." | 1.43 | Wide-field imaging of birefringent synovial fluid crystals using lens-free polarized microscopy for gout diagnosis. ( Fitzgerald, J; Furst, D; Lee, SY; Ozcan, A; Zhang, Y, 2016) |
| "Gout was diagnosed according to the American College of Rheumatology criteria." | 1.43 | Usefulness of plain radiography for assessing hypouricemic treatment response in patients with tophaceous gout. ( Cheon, YH; Kim, HO; Kim, JE; Kim, JM; Kim, SH; Lee, SI; Lee, WS; Suh, YS; Yoo, WH, 2016) |
| "Gout is a systemic disorder characterized by hyperuricemia and recurrent arthritis, most involvement of ankles, midfoot joint and first metatarsophalangeal joint, with monosodium urate crystals deposition in synovial fluid and other tissues." | 1.43 | Miliarial gout: a rare presentation of extensive cutaneous tophi. ( Chiang, CP; Hung, TL; Wang, WM, 2016) |
| "Colchicine was more commonly used for attack prophylaxis than allopurinol." | 1.43 | The management of gout in different clinical specialties in Turkey: a patient-based survey. ( Balcı, MA; Balkarlı, A; Çobankara, V; Gök, K; Kaya, A; Kimyon, G; Kısacık, B; Küçük, A; Mercan, R; Onat, AM; Öztürk, MA; Pamuk, Ö; Şahin, Ş; Sayarlıoğlu, M; Şenel, S; Tezcan, ME; Tufan, A; Üreten, K; Yıldırım Çetin, G, 2016) |
| "Hyperuricemia is a common symptom in adult population." | 1.43 | Familial juvenile hyperuricemic nephropathy as rare cause of dialysis-dependent chronic kidney disease-a series of cases in two families. ( Adamczyk, P; Beck, B; Dyga, K; Kaminska-Pajak, KA; Szczepańska, M; Tkaczyk, M; Zaniew, M, 2016) |
| "Gout is the most common inflammatory arthritis in adults in the Western world." | 1.43 | Gout: will the "King of Diseases" be the first rheumatic disease to be cured? ( Singh, JA, 2016) |
| "Acute gout is a self-limiting inflammatory response to monosodium urate (MSU) crystals." | 1.43 | Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout. ( Liang, M; Liu, L; Wang, J; Xuan, D; Xue, Y; Yang, X; Zhang, J; Zhu, X; Zhu, Y; Zou, H, 2016) |
| "Differentiating gout, calcium pyrophosphate deposition disease (CPPD), and non-crystal-related inflammatory arthropathies (non-CRA) is essential but often clinically impossible." | 1.42 | Distinguishing gouty arthritis from calcium pyrophosphate disease and other arthritides. ( Bergner, R; Löffler, C; Löffler, U; Peters, L; Sattler, H; Uppenkamp, M, 2015) |
| "Twelve patients indicated that treatment of gout only encompasses treatment of the acute attack." | 1.42 | Health literacy in patients dealing with gout: a qualitative study. ( Boonen, A; de Vries, H; Hinsenveld, E; van Onna, M, 2015) |
| "Hyperuricemia is very common in industrialized countries and known to promote vascular smooth muscle cell proliferation." | 1.42 | Smaller caliber renal arteries are a novel feature of uromodulin-associated kidney disease. ( Adamczak, M; Blondin, D; Dekomien, G; Epplen, JT; Helmchen, U; Januszewicz, A; Januszewicz, M; Litwin, M; Matuszkiewicz-Rowińska, J; Michałowska, I; Prejbisz, A; Rump, LC; Sajnaga, D; Sellin, L; Szwench-Pietrasz, E; Więcek, A; Woznowski, M, 2015) |
| "Gout is a metabolic disorder that results in hyperuricemia and the deposition of positively birefringent monosodium urate crystals in various parts of the body." | 1.42 | Clinicopathologic characterization of visceral gout of various internal organs--a study of 2 cases from a venom and toxin research center. ( Fayyaz, AF; Kamyabi-Moghaddam, Z; Mokarizadeh, A; Nasoori, A; Pedram, B; Pirasteh, H; Shooshtari, MB, 2015) |
| "Gout was induced by the injection of MSU crystals into the knee joints of mice." | 1.42 | A Role for Gut Microbiota and the Metabolite-Sensing Receptor GPR43 in a Murine Model of Gout. ( Amaral, FA; Canesso, MC; De Leon, E; Galvão, I; Garcia, CC; Harper, JL; Macia, L; Mackay, CR; Martins, FS; Maslowski, KM; Nicoli, JR; Shim, D; Teixeira, MM; Vieira, AT, 2015) |
| "Gout is a disorder of purine metabolism that primarily occurs in adult males." | 1.42 | Treatment and prevention of gout. ( Ferrara, LR; Saccomano, SJ, 2015) |
| "Gout is a common clinical problem encountered by both general and specialist clinicians." | 1.42 | Update on the diagnosis and management of gout. ( Graf, SW; Ting, K; Whittle, SL, 2015) |
| "Gout is an inflammatory arthritis characterised by hyperuricemia, which, if poorly controlled, can lead to the development of tophi." | 1.42 | Ulcerated tophaceous gout. ( Filanovsky, MG; McNamara, MC; Sukhdeo, K, 2015) |
| "Gout is a consequence of an innate immune reaction to monosodium urate crystals deposited in joints." | 1.42 | Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares. ( Cadzow, M; Dalbeth, N; Flynn, TJ; Hindmarsh, JH; Jones, PB; Merriman, TR; Stamp, LK; Todd, AS; Topless, R; Walker, RJ, 2015) |
| "Gout is a potentially destructive inflammatory disorder occurring in the setting of hyperuricaemia and urate crystal deposition in tissue." | 1.42 | [Dual-energy computer tomography can be used for gout diagnostics]. ( Jørgensen, SH; Knudsen, ET; Rasmussen, C, 2015) |
| "Although gout is potentially curable with long-term urate lowering therapy, confusion about the details of urate measurement has contributed to suboptimal care." | 1.42 | Urate testing in gout: why, when and how. ( Arroll, B; Boswell, DR; Dalbeth, N; Gow, PJ; Lindsay, K; Stamp, LK; Te Karu, L; Winnard, D, 2015) |
| "Gout is a common metabolic disorder characterized by hyperuricemia and chronic inflammation." | 1.42 | Gout, not hyperuricemia alone, impairs left ventricular diastolic function. ( Chang, PJ; Chang, ST; Chen, MC; Chung, CM; Lin, CL; Lin, JC; Pan, KL, 2015) |
| "Gout is a metabolic disease, which is characterized by acute or chronic arthritis, and deposition of monosodium urate crystals in joint, bones, soft tissues, and kidneys." | 1.42 | Chronic tophaceous gout with unusual large tophi: case report. ( Abourazzak, FZ; Aradoini, N; Berrada, K; Harzy, T; Talbi, S, 2015) |
| " However, inadequate dosing and patient nonadherence or intolerance to therapy often lead to treatment failure." | 1.40 | CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. ( Bakris, GL; Doghramji, PP; Keenan, RT; Silber, SH, 2014) |
| "Gout is a common disease resulting from hyperuricemia which causes acute arthritis." | 1.40 | Common variant of leucine-rich repeat-containing 16A (LRRC16A) gene is associated with gout susceptibility. ( Chiba, T; Hamajima, N; Ichida, K; Inoue, H; Kanai, Y; Makino, T; Matsuo, H; Morita, E; Naito, M; Nakamura, T; Nakayama, A; Sakiyama, M; Sakurai, Y; Sato, J; Satoh, T; Shimizu, S; Shimizu, T; Shimono, K; Shinomiya, N; Suzuki, H; Takada, T; Takada, Y; Tatsukawa, S; Wakai, K, 2014) |
| "Hip fractures were not significantly associated with UA." | 1.40 | Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study. ( Cawthon, PM; Lane, NE; Lay, YA; Lui, LY; Orwoll, E; Parimi, N; Wise, BL; Yao, W, 2014) |
| "Gout is an important but certainly not an exclusive cause of arthritis of the first metatarsophalangeal joint." | 1.40 | Arthritis of the first metatarsophalangeal joint is not always gout: a prospective cohort study in primary care patients. ( Fransen, J; Janssen, M; Janssens, HJ; Kienhorst, LB; van de Lisdonk, EH, 2014) |
| "Gout was diagnosed at the last visit in 34 subjects; four in the normouricemia group and 30 in the hyperuricemia group (0." | 1.40 | The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort. ( Cohen, E; Duskin-Bitan, H; Garty, M; Goldberg, E; Krause, I; Levi, A; Shochat, T, 2014) |
| "Gout is characterized by an acute inflammatory reaction and the accumulation of neutrophils in response to monosodium urate (MSU) crystals." | 1.40 | Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. ( Bilyy, R; Frey, B; Harrer, T; Herrmann, M; Hoffmann, M; Holmdahl, R; Janko, C; Jeremic, I; Kienhöfer, D; Krenn, V; Lell, M; Manger, B; Munoz, LE; Naschberger, E; Rech, J; Schauer, C; Schett, G; Zhao, Y, 2014) |
| "Gout/hyperuricemia is a common multifactorial disease having typical environmental risks." | 1.40 | Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. ( Abe, J; Akashi, A; Chiba, T; Hosoya, T; Ichida, K; Kawai, S; Kawamura, Y; Matsuo, H; Nakamura, T; Nakaoka, H; Nakashima, H; Nakayama, A; Oikawa, Y; Okada, R; Sakiyama, M; Sakurai, Y; Shichijo, Y; Shimizu, S; Shinomiya, N; Suzuki, H; Takada, T; Takada, Y; Tamura, T; Wakai, K, 2014) |
| "Age of onset of gout has recently decreased; however, patients with early-onset gout remain uncommon, and relevant information is scant." | 1.40 | Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout. ( Chen, HY; Chung, WS; Lee, MC; Lu, CC; Wu, SK; Yeh, CJ, 2014) |
| "Gout is a metabolic disorder associated with hyperuricemia resulting in the deposition of monosodium urate (MSU) crystals in joints and tissues." | 1.40 | Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation. ( Cao, L; Ding, G; Guo, CR; Huang, WZ; Meng, ZQ; Tang, ZH; Wang, KD; Wang, ZZ; Xiao, W; Yan, YX; Yang, ZL, 2014) |
| "Gout affects 2." | 1.40 | Patients with gout can be cured in primary care. ( Doherty, M; Rees, F, 2014) |
| "Hyperuricemia is known to be a risk factor for incident type 2 diabetes mellitus, but the absolute magnitude of the association is not known." | 1.39 | Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. ( Akhras, KS; Krishnan, E; Liu, J; Marynchenko, M; Sharma, H; Shi, L; Tawk, R; Wu, EQ, 2013) |
| " Inappropriate dosing of medications in the setting of renal disease and lack of prophylaxis when initiating urate-lowering therapy (ULT) accounted for much of the lack of compliance with treatment recommendations." | 1.39 | Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. ( Firneno, C; Harrold, LR; Mazor, KM; Negron, A; Ogarek, J; Yood, RA, 2013) |
| "Gout is an ancient autoinflammatory disease that affects millions of people worldwide." | 1.39 | Transient receptor potential melastatin 2: a novel target for treatment of gout. ( Qiao, L; Zhai, Y; Zhong, Z, 2013) |
| "Infectious spondylodiscitis was first supposed due to the imaging of the spine although no pathogenic agent could be proved." | 1.39 | [< |
| "Most research in gout has concentrated on the proinflammatory mechanisms to explain the inflammation that is generated when leucocytes are in contact with monosodium urate crystals." | 1.39 | How to regulate neutrophils in gout. ( So, A, 2013) |
| "Gout is estimated to affect 1." | 1.39 | Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. ( Cottrell, E; Crabtree, V; Edwards, JJ; Roddy, E, 2013) |
| "Chronic tophaceous gout is treated with dietary control and medication." | 1.39 | Gout with auricular tophi following anti-tuberculosis treatment: a case report. ( Chang, HJ; Hsu, YC; Huang, SH; Wang, PC, 2013) |
| " On 48% of occasions, the time of allopurinol dosing was recorded, while just 79 (19%) blood samples were collected 6-9 hours postdosing, the time window used to establish the therapeutic range for oxypurinol." | 1.39 | An audit of a therapeutic drug monitoring service for allopurinol therapy. ( Day, RO; Graham, GG; Jones, G; Kannangara, DR; Ramasamy, SN; Ray, JE; Williams, KM, 2013) |
| "Gout has been recognized for centuries but is also a modern day scourge." | 1.38 | Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease. ( Bacani, AK; Bond, JR; Glazebrook, KN; Manek, NJ; McCollough, CH; Michet, CJ; Milks, J, 2012) |
| "Mean uric acid serum level was 281." | 1.38 | [Hyperuricemia in sickle cell disease in France]. ( Arlet, JB; Chatellier, G; Courbebaisse, M; de Montalembert, M; Pouchot, J; Prié, D; Ribeil, JA, 2012) |
| "Gout was induced by injecting MSU crystals into the joints of mice." | 1.38 | NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. ( Amaral, FA; Coelho, FM; Costa, VV; Cunha, FQ; Cunha, LD; Cunha, TM; Fagundes, CT; Peres, RS; Quesniaux, V; Ryffel, B; Sachs, D; Silveira, TN; Soriani, FM; Souza, DG; Tavares, LD; Teixeira, MM; Zamboni, DS, 2012) |
| "Incident gout was defined as self-reported onset of gout after baseline." | 1.38 | Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. ( Alonso, A; Baer, AN; Coresh, J; Gelber, AC; Maynard, JW; McAdams DeMarco, MA; Young, JH, 2012) |
| "The prevalence of gout has been increasing." | 1.38 | Evaluation of health care costs and utilization patterns for patients with gout. ( McBayne, T; Park, H; Prasla, K; Rascati, KL, 2012) |
| "Gout is a painful inflammatory arthropathy caused by crystallization of monosodium urate within the joints." | 1.38 | False-negative dual-energy computed tomography in a patient with acute gout. ( Glazebrook, KN; Ida, CM; Kakar, S; Laurini, JA; Leng, S; Moder, KG, 2012) |
| "Gout care is suboptimal because of lack of translation of knowledge into real-world practice, despite evidence-based guidelines." | 1.38 | Achieving treat to target in gout: a clinical practice improvement project. ( Lateef, A; Lau, TC; Lim, AY; Shen, L; Tan, CH; Teng, GG, 2012) |
| "Gout is a chronic, potentially debilitating condition characterized by an inflammatory process in the joints or periarticular tissues that results from the deposition of monosodium urate crystals." | 1.38 | Casebook consults: improving outcomes in gout (multimedia activity). ( Doghramji, PP; Mandell, BF; Pope, RS, 2012) |
| "ULT prescription and dosing are key modifiable factors associated with achieving SU target." | 1.38 | Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. ( Dalbeth, N; Horne, A; House, ME; McQueen, FM; Petrie, KJ; Taylor, WJ, 2012) |
| "The concept of 'treatment-failure gout' describes a unique population that has been either unable to tolerate allopurinol or who have not experienced normalization of serum urate levels on allopurinol." | 1.38 | Pegloticase and the patient with treatment-failure gout. ( Dave, AJ; Kelly, VM; Krishnan, E, 2012) |
| "Women who develop gout are more likely to be over the age of 50, have other comorbidities and be on diuretics." | 1.38 | Gout in women: differences in risk factors in young and older women. ( Gupta, R; Kumar, S; Suppiah, R, 2012) |
| "Gout is an ancient disease." | 1.38 | Management of gout: a 57-year-old man with a history of podagra, hyperuricemia, and mild renal insufficiency. ( Shmerling, RH, 2012) |
| "Insulin sensitivity was estimated using the homeostatic model assessment index (HOMA-B) for beta cell function and HOMA-IR for peripheral tissue IR." | 1.38 | Insulin resistance and metabolic syndrome in primary gout: relation to punched-out erosions. ( El-Fishawy, HS; Gheita, TA; Hussein, H; Nasrallah, MM, 2012) |
| "Gouty panniculitis is an unusual clinical manifestation of gout, characterized by the deposition of monosodium urate crystals in the lobular hypodermis." | 1.37 | Panniculitis: another clinical expression of gout. ( Espinoza, LR; Iglesias-Gamarra, A; Mejia, J; Ochoa, CD; Restrepo, JF; Rondon, F; Valderrama, V; Villaroya, N, 2011) |
| "Gout has not been described previously as a complication in cystic fibrosis (CF)." | 1.37 | Gout and hyperuricaemia in adults with cystic fibrosis. ( Brennan, A; Bright-Thomas, R; Helm, J; Horsley, A; Jones, A; Webb, K, 2011) |
| "Gout is increasing in prevalence throughout the world, particularly in developed countries." | 1.37 | Hyperuricaemia and gout. ( Shipley, M, 2011) |
| "Gout is an inflammatory-rheumatic disease characterized by an elevated serum urate concentration and recurrent flares, including painful, hot, red, and swollen joints and surrounding tissue." | 1.37 | Giant gouty tophi of the hand and wrist. ( Mittag, F; Wuenschel, M, 2011) |
| "The blood Cr level just reached the chronic renal failure level on the 26th day of the administration (about the 4th week), and obviously exceeded the renal failure level on the 41st day (about the 6th week)." | 1.37 | [Exploration on the establishment of animal models for gouty nephropathy complicated with chronic renal failure]. ( Meng, DM; Ren, W; Xing, RL, 2011) |
| "Asymptomatic hyperuricemia affects one in five adults in the general population and is associated with elevated cardiovascular risk." | 1.37 | [Contribution of the CoLaus study to decipher the determinants of serum uric acid]. ( Bochud, M; Vollenweider, P; Waeber, G, 2011) |
| "Gout is a prevalent inflammatory arthritis affecting 1-2% of adults characterized by activation of innate immune cells by monosodium urate (MSU) crystals resulting in the secretion of interleukin-1β (IL-1β)." | 1.37 | Neutrophil extracellular trap formation is associated with IL-1β and autophagy-related signaling in gout. ( Apostolidou, E; Boumpas, DT; Chrysanthopoulou, A; Drosos, GI; Kambas, K; Kourtzelis, I; Mitroulis, I; Ritis, K; Skendros, P, 2011) |
| "Gout is a common rheumatologic condition of recurrent polyarticular involvement." | 1.37 | Unknown: Multiple painful nodules - what is the diagnosis? Chronic tophaceous gout. ( Avhad, G; Dandale, A; Dhurat, R; Ghate, S, 2011) |
| "Published guidelines for the treatment of gout aim to improve the evidenced-based management of this disorder." | 1.36 | Adherence to treatment guidelines in two primary care populations with gout. ( Bottenberg, MM; Hegge, KA; Koenigsfeld, CF; Wall, GC, 2010) |
| "Asymptomatic hyperuricemia is not associated with suppressed neutrophil function." | 1.36 | Differences in MSU-induced superoxide responses by neutrophils from gout subjects compared to healthy controls and a role for environmental inflammatory cytokines and hyperuricemia in neutrophil function and survival. ( Grainger, R; Harper, JL; Harrison, A; Martin, WJ, 2010) |
| "Gout is commonly associated with obesity, arterial hypertension, diabetes, and dyslipidemia." | 1.36 | Metabolic syndrome characteristics in gout patients. ( de Miguel, ME; Fraile, JM; Lundelin, KJ; Martínez, P; Puig, JG; Torres, RJ; Vázquez, JJ, 2010) |
| " In addition, there was a dose-response relationship between SU and NAFLD in subjects with and without gout." | 1.36 | Gout and risk of non-alcoholic fatty liver disease. ( Chang, HC; Chen, HW; Chiu, CT; Hwang, JS; Ko, YS; Kuo, CF; Luo, SF; See, LC; Tseng, WY; Yu, KH, 2010) |
| "Uric acid was successfully extracted through the subjects' skin into the collection solution." | 1.36 | Non-invasive and transdermal measurement of blood uric acid level in human by electroporation and reverse iontophoresis. ( Chien, MY; Ching, CT; Huang, HH; Huang, HW; Huang, SY; Huang, W; Kuo, JF; Lai, LH; Lee, CK; Liu, CM; Liu, WH; Pan, HT; Shieh, HL; Sun, TP; Tsai, CL; Tseng, HH, 2010) |
| "Moreover, hyperuricemia is likely a risk factor for the development of diabetes mellitus." | 1.35 | Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. ( Chen, X; Chen, Y; Hu, J; Li, C; Miao, Z; Song, W; Sun, R; Wang, CY; Wang, F; Wang, Y; Wang, Z; Xu, F; Yan, S; Zhao, S, 2008) |
| "Gout is characterized by the deposition of monosodium urate crystals on the surface of the articular cartilage, within periarticular tissues, and within bone and skin." | 1.35 | Ultrasonography for diagnosing atypical gout. Two case reports. ( André, V; Berthelot, JM; Guillot, P; Le Goff, B; Maugars, Y, 2008) |
| "We documented 1215 new cases of type 2 diabetes." | 1.35 | Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. ( Choi, HK; De Vera, MA; Krishnan, E, 2008) |
| "Hyperuricemia is significantly predicted by anthropometric measure of SFT which is a simple clinical screening method along with creatinine levels." | 1.35 | Hyperuricemia and its related factors in an urban population, Izmir, Turkey. ( Akar, S; Akkoc, N; Birlik, M; Gurler, O; Onen, F; Pakoz, B; Sari, I; Sisman, AR, 2009) |
| "Gout is the most common autoinflammatory arthritis characterized by elevated serum urate and recurrent attacks of intra-articular crystal deposition of monosodium urate (MSU)." | 1.35 | NALP3 inflammasome functional polymorphisms and gout susceptibility. ( Li, CG; Meng, DM; Mi, QS; Miao, ZM; Wang, YG; Yan, SL; Zhao, SH; Zhou, L, 2009) |
| "Gout is an acute form of arthritis caused by the deposition of urate crystals, in which phagocytic cells and cytokines play a major pathogenic role." | 1.35 | Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. ( Capsoni, F; Catania, A; Ongari, AM; Reali, E, 2009) |
| "In the treatment of acute gout, 68." | 1.35 | A survey on the management of gout in Malaysia. ( Goh, EM; Gun, SC; Yeap, SS, 2009) |
| "The presence of crystals cannot exclude septic arthritis with certainty." | 1.34 | Does the presence of crystal arthritis rule out septic arthritis? ( Edlow, JA; McCauley, J; Nathanson, LA; Shah, K; Spear, J, 2007) |
| "Chronic gout and rheumatoid arthritis are common medical manifestations with debilitating effects on patients." | 1.34 | Tophaceous gout in a patient with rheumatoid arthritis. ( Baker, DL; Gilstrap, CA; Stroup, JS, 2007) |
| "Gout is the most common crystal-induced arthritis." | 1.33 | Intra-abdominal gout mimicking pelvic abscess. ( Chen, CH; Chen, CK; Pan, HB; Yang, CF; Yeh, LR, 2005) |
| "Gout is a metabolic disorder that results in hyperuricemia and the deposition of positively birefringent monosodium urate crystals in various parts of the body." | 1.33 | Gout induced by intoxication of sodium bicarbonate in Korean native broilers. ( Ejaz, S; Kim, BS; Lim, CW, 2005) |
| "As gout is very often primarily caused by a renal secretion disturbance of uric acid special diagnostics should be done." | 1.33 | [Hyperuricemia and gout: diagnosis and therapy]. ( Grässler, J; Richter, K; Roch, B; Schröder, HE; Tausche, AK; Unger, S; Wunderlich, C, 2006) |
| "Hyperuricemia and gout have shown an increase worldwide." | 1.33 | The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. ( Dong, Y; Gao, W; Nan, H; Qian, R; Qiao, Q; Tang, B; Tuomilehto, J, 2006) |
| "Hyperuricemia and gout are common complications in adult renal transplant recipients." | 1.33 | Hyperuricemia and gout following pediatric renal transplantation. ( Kemper, MJ; Neuhaus, TJ; Spartà, G, 2006) |
| "When treating acute gout in otherwise healthy patients, most physicians (77%) prefer oral colchicine, and in patients with renal impairment, about half of them (48%) choose corticosteroids or corticotropin as their first treatment." | 1.33 | The management of gout at an academic healthcare center in Beijing: a physician survey. ( Chen, LX; Fang, W; Li, M; Schumacher, HR; Zeng, X; Zhang, F, 2006) |
| "Furthermore, congestive heart failure is associated with impaired creatinine clearance and increased urea and urate, and osteoporosis and hip fractures are characterized by low albumin and cholesterol." | 1.32 | Association of biochemical values with morbidity in the elderly: a population-based Swedish study of persons aged 82 or more years. ( Berg, S; Evrin, PE; Johansson, B; McClearn, G; Nilsson, SE; Takkinen, S; Tryding, N, 2003) |
| "Hyperuricemia is the hallmark of severe gout with tophi formation." | 1.32 | [Rasburicase (Fasturtec)]. ( Frey, FJ; Gugger, M; Vogt, B, 2004) |
| "Thirteen patients with ESRD on intermittent haemodialysis treatment, six patients with chronic renal failure not yet on dialysis, and 15 age- and sex-matched healthy controls were examined." | 1.31 | Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients? ( Galle, PR; Himmelsbach, F; Märker-Hermann, E; Schreiner, O; Wandel, E, 2000) |
| " Allopurinol dosing guidelines and a therapeutic range for plasma oxypurinol levels have been published." | 1.31 | The optimal use of allopurinol: an audit of allopurinol use in South Auckland. ( Gow, P; Raill, B; Sharples, K; Stamp, L, 2000) |
| "In idiopathic uric acid nephrolithiasis, urinary pH and fractional excretion of urate are significantly lower than in control subjects, suggestive of defects in urinary acidification and urate excretion." | 1.31 | Biochemical profile of idiopathic uric acid nephrolithiasis. ( Frawley, WH; Pak, CY; Peterson, RD; Poindexter, JR; Sakhaee, K, 2001) |
| "We conclude that CPPD in pseudogout and monosodium urate in gout may not polarize in the routine H&E-stained sections." | 1.31 | Evaluation of crystals in formalin-fixed, paraffin-embedded tissue sections for the differential diagnosis of pseudogout, gout, and tumoral calcinosis. ( Basir, Z; Chivukula, M; Shidham, G; Shidham, V, 2001) |
| "Episodes of gout are common in the setting of renal transplantation." | 1.31 | Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. ( Dittmer, I; Faire, B; Pilmore, HL, 2001) |
| "Gout is an acute rheumatic disorder that occurs in connection with the deposition of monosodium urate (MSU) crystals in the joints." | 1.30 | Altered arachidonic acid metabolism in urate crystal induced inflammation. ( Duffin, KL; Gregory, SA; Isakson, PC; Margalit, A; Shaffer, AF, 1997) |
| "Cases of gout were identified from self-reporting of a doctor's diagnosis based on clinical criteria." | 1.30 | High prevalence of gout and related risk factors in Taiwan's Aborigines. ( Chang, FT; Chang, SJ; Chen, CJ; Cinkotai, FF; Ko, YC; Wang, TN, 1997) |
| "Gout is common disease with a worldwide distribution." | 1.30 | [Epidemiology, incidence and sex specific differences in primary gout]. ( Peichl, P, 1997) |
| "The uric acid level was 7." | 1.30 | The epidemiology of hyperuricaemia and gout in Taiwan aborigines. ( Chou, CT; Lai, JS, 1998) |
| "Gout was diagnosed in 106 of the 3517 patients seen from October 1989 through October 1993." | 1.29 | Gout in patients attending the rheumatology unit of Lomé Hospital. ( Mijiyawa, M, 1995) |
| " Urate-oxidase was given parenterally in a dosage of 1000 units per day, seven days a month." | 1.29 | Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. ( Borget, C; Bourgeois, P; Dorent, R; Koeger, AC; Roche, B; Rozenberg, S; Wrona, N, 1995) |
| "Gout is increasingly recognized in African populations, especially in urban centres." | 1.29 | Gout and hyperuricaemia. ( Darmawan, J; Lutalo, SK, 1995) |
| "A 20-day-old male infant presented with acute renal failure." | 1.29 | Lesch-Nyhan syndrome presenting with renal insufficiency in infancy and transient neonatal hypothyroidism. ( Hallett, RJ; Hull, RG; Jenkins, EA, 1994) |
| "Nine patients (43%) had a recurrence of tophi after an average period of 39." | 1.29 | Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. ( Breedveld, FC; van Lieshout-Zuidema, MF, 1993) |
| "We reviewed 5477 patients with urinary calculi who presented during the years from 1975 to 1993." | 1.29 | [An epidemiologic study on pathogenesis of uric acid urolithiasis]. ( Hikita, M; Hosoya, T; Ichida, K; Okabe, H; Saji, M; Sakai, O; Tabe, A, 1995) |
| "In addition, a single patient with von Gierke's disease showed a marked increase in the plasma activity of this enzyme, relative to that apparent in normal subjects." | 1.29 | Determination of human plasma xanthine oxidase activity by high-performance liquid chromatography. ( Higashino, K; Hiroishi, K; Moriwaki, Y; Nasako, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T, 1996) |
| "Gout is a common disease in the primary health care setting." | 1.28 | Gout. ( Feng, PH; Leong, KH, 1992) |
| "Subcutaneous fat necrosis is a well described, rare sequela of acute pancreatitis." | 1.28 | Subcutaneous pancreatic fat necrosis associated with acute arthritis. ( Naides, SJ; Niemann, TH; Saag, KG; Warner, CA, 1992) |
| "Dupuytren's disease is a relatively rare occurrence in a patient of the black race." | 1.28 | Dupuytren's contracture and gouty tophi in a black patient. ( Antoine, GA; LeFlore, I, 1991) |
| "The proteinuria was detected at age 10 and 6 years, respectively." | 1.28 | Underexcretory-type hyperuricemia, disproportionate to the reduced glomerular filtration rate, in two boys with mild proteinuria. ( Jojima, K; Kawakami, H; Matsuzaki, H; Murakami, T; Nakatsuka, K; Nohno, H, 1990) |
| "Pretreatment with colchicine, but not aspirin, indomethacin, allopurinol, or islet activating protein, abrogated the enhanced phospholipase A2 activities." | 1.28 | Monosodium urate crystals stimulate phospholipase A2 enzyme activities and the synthesis of a phospholipase A2-activating protein. ( Baker, DG; Bomalaski, JS; Brophy, LM; Clark, MA, 1990) |
| "In the patients with recurrent calcium nephrolithiasis and hypercalcinosis one should look for active impairment of uric acid metabolism which should be kept in mind when an antirecurrence treatment is planned." | 1.28 | [The effect of oral calcium loading on the serum concentrations and urinary excretion of uric acid in patients with recurrent calcium nephrolithiasis and hypercalciuria]. ( Ivanov, I; Tsachev, K, 1990) |
| "Gout was diagnosed through clinical history, physical examination and identification of monosodium urate crystals in the joint aspirate." | 1.28 | Polyarticular symmetric tophaceous joint inflammation as the initial presentation of gout. ( Verdile, VP; Vukmir, RB; Weiss, L, 1990) |
| "Gout is primarily a disease of middle-aged males and is unusual in females and adolescent males." | 1.28 | Precocious familial gout with reduced fractional urate clearance and normal purine enzymes. ( Calabrese, G; Cameron, JS; Davies, PM; Simmonds, HA, 1990) |
| "The coexistence of systemic lupus erythematosus and tophaceous gout is very rare." | 1.28 | A case of multiple urate deposition, without gouty attacks, in a patient with systemic lupus erythematosus. ( Kurita, Y; Numata, K; Ogawa, H; Tsuboi, R, 1989) |
| "Clinical gout was identified in 24% of patients with ADPKD; none of the patients with chronic renal failure of other etiologies had gout." | 1.28 | Hyperuricemia, gout, and autosomal dominant polycystic kidney disease. ( Lluberes, R; Martínez-Maldonado, M; Mejías, E; Navas, J, 1989) |
| "Obesity is common amongst the Maoris and accentuates their natural tendency to hyperuricaemia." | 1.27 | Hyperuricaemia, gout and kidney function in New Zealand Maori men. ( Bremner, K; Gibson, T; Hatfield, P; Robinson, G; Waterworth, R, 1984) |
| "Chronic tophaceous gout has become less common since the introduction of allopurinol and probenecid." | 1.27 | Mitral stenosis associated with valvular tophi. ( Callahan, JA; Edwards, WD; Ginsburg, WW; Scalapino, JN; Steckelberg, JM; Wooten, RS, 1984) |
| "31P-MRS could be used to diagnose fructose intolerance and to monitor the patients' compliance with a fructose-restricted diet." | 1.27 | Study of hereditary fructose intolerance by use of 31P magnetic resonance spectroscopy. ( Collins, JE; Herschkowitz, N; Leonard, JV; Oberhaensli, RD; Radda, GK; Rajagopalan, B; Schwarz, H; Taylor, DJ, 1987) |
| "Coexistent gout and systemic lupus erythematosus (SLE) have received increasing attention." | 1.27 | Gout and hyperuricaemia in systemic lupus erythematosus. ( Frocht, A; Leek, JC; Robbins, DL, 1987) |
| "Accordingly, one must treat the patient's gout as well as his various stages of the associated medical conditions, and each patient must be individualized." | 1.27 | Impact of associated medical conditions on clinical features of gout. ( Smith, H; Yu, TF, 1986) |
| "Obesity has to be considered a connecting link between both of them, and it is accelerating their genesis." | 1.26 | [Hallux rigidus arthrosis and gout]. ( Mertz, DP, 1982) |
| "It is shown that in osteoarthrosis the clinical characteristics vary from one joint group to another." | 1.26 | Heberden Oration 1981: epidemiology and the arthritides. ( Acheson, RM, 1982) |
| "Chondrocalcinosis was detected in knee radiographs of 8 of 138 gouty patients compared with none of 142 age matched nongouty normouricaemic controls (p less than 0." | 1.26 | Frequency of chondrocalcinosis of the knees in asymptomatic hyperuricaemia and rheumatoid arthritis: a controlled study. ( Hollingworth, P; Scott, JT; Williams, PL, 1982) |
| "Gout is principally a disease of middle-aged men." | 1.26 | Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family. ( Cameron, JS; Dillon, MJ; Farebrother, DA; Pincott, JR; Simmons, HA; Warren, DJ, 1981) |
| "Coronary heart disease is the leading cause of death in the gouty and nongouty population." | 1.26 | Changing trends of mortality in gout. ( Talbott, JH; Yü, T, 1980) |
| " A twice-daily regimen was considerably more effective than a single morning dosage in reduction of plasma urate, though both regimens were equally effective in antihypertensive potency." | 1.26 | Controlled inpatient study of tienilic acid in treatment of gout and hypertension. ( Reardon, JA; Scott, JT, 1980) |
| "Uric acid clearance was decreased to 3." | 1.26 | A case of gouty arthritis associated with Down's syndrome. ( Aikawa, T; Akaoka, I; Horiuchi, Y; Maruki, M; Mitamura, T; Nishida, Y; Nishizawa, T; Yokohari, R, 1976) |
| "The histological alterations in pseudogout were uniform, 2-4 rows of slightly pleomorphic synovial cells lined the inner surface of the joint capsule, sclerosing alterations were less frequent." | 1.26 | [Needle biopsy in gout and pseudogout (author's transl)]. ( Huth, F; Klein, W; Lenz, W, 1976) |
| "The management of gout has four phases: control of inflammation, diagnostic evaluation, education of the patient, and treatment for the hyperuricemia." | 1.26 | Management of gout. ( Simkin, PA, 1979) |
| "Eight of 36 untreated gouty men excreted acid at a rate more than three standard deviations above normal." | 1.26 | Uric acid excretion: quantitative assessment from spot, midmorning serum and urine samples. ( Hoover, PL; Paxson, CS; Simkin, PA; Wilson, WF, 1979) |
| "Hypertension was found in 18% of 65 patients with untreated gout, a lower prevalence than that previously reported." | 1.26 | Hypertension, renal function and gout. ( Gibson, T; Highton, J; Potter, CF; Simmonds, HA, 1979) |
| "Uric acid clearance was increased by benzbromarone from 3." | 1.26 | [The effect of benzbromaron in gout patients with limited kidney function]. ( Bresnik, W; Kuzmits, R; Müller, MM, 1979) |
| "Ticrynafen is an orally administered diuretic that is similar to the thiazides in its therapeutic actions, but unlike the thiazides, it increases urate excretion and lowers serum uric acid levels." | 1.26 | Evaluation of a new uricosuric diuretic--ticrynafen. ( Kosman, ME, 1979) |
| "A pheochromocytoma was found to be the cause of malignant hypertension, which had been present for many years." | 1.26 | [Juvenile gout with decreased activity of hypoxanthine-guanine-phosphoribosyl transferase and pheochromocytoma: partial persistence of tophi despite uric-acid reducing treatment for 12 years (author's transl)]. ( Goebel, FD; Gröbner, W; Ohlschlägel, G; Zöllner, N, 1978) |
| "The incidence of gout has increased in recent years." | 1.26 | [Gout - a surgical problem]. ( Flügel, M; Geldmacher, J, 1978) |
| "At the high dosage of 600 mg daily, the uric-acid reducing effect of allopurinol depends on the initial level of uric-acid concentration in the same manner as at the usual dosage of 300 mg daily, but is more marked at the entire hyperuricaemic concentration range of 65--71 mumol/l (11--12 mg/l)." | 1.26 | [Uric-acid reduction with high allopurinol dosages (author's transl)]. ( Loewer, H; Mertz, DP, 1979) |
| "Both renal calculi and tophi are frequent in female gout associated with blood dyscrasias." | 1.26 | Some unusual features of gouty arthritis in females. ( Yü, TF, 1977) |
| "Nearly 25% of all examined renal calculi contain uric acid, sodium acid urate or ammonium acid urate as constituents." | 1.26 | [Urate nephrolithiasis. Cause of consequence?]. ( Mertz, DP, 1976) |
| " The control of the hyperuricemia and gout has been satisfactorily accomplished in the Filipino patients with the long-term use of allopurinol, sometimes complemented with colchicine taken daily." | 1.25 | The Filipino and gout. ( Bayani-Sioson, PS; Torralba, TP, 1975) |
| "A nearly 72-old black male with sickle cell anemia suffered from heart failure, hypertension, chronic impaired kidney function with hyperuricemia and gout." | 1.25 | Long survival in sickle cell anemia. ( Huisman, TH; Sar, AV, 1975) |
| "The occurence of gout is questionable in this connection, relevant seems to be only the coincidence of psoriasis and gout." | 1.25 | [The simultaneous occurrence of psoriasis, sarcoidosis and gout. Report of 3 cases]. ( Eckes, L, 1975) |
| "Allopurinol has been universally successful in lowering the serum uric acid concentration and uric acid excretion to normal levels, while not significantly affecting the clearance of urate or other aspects of renal function." | 1.24 | The treatment of gout and disorders of uric acid metabolism with allopurinol. ( Houpt, JB; Ogryzlo, MA; Urowitz, MB; Weber, HM, 1966) |
Research
Studies (4,404)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1904 (43.23) | 18.7374 |
| 1990's | 285 (6.47) | 18.2507 |
| 2000's | 435 (9.88) | 29.6817 |
| 2010's | 1084 (24.61) | 24.3611 |
| 2020's | 696 (15.80) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ichida, K | 24 |
| Hosoyamada, M | 3 |
| Kimura, H | 1 |
| Takeda, M | 1 |
| Utsunomiya, Y | 1 |
| Hosoya, T | 32 |
| Endou, H | 5 |
| Talkington, AM | 1 |
| McSweeney, MD | 1 |
| Zhang, T | 3 |
| Li, Z | 16 |
| Nyborg, AC | 1 |
| LaMoreaux, B | 8 |
| Livingston, EW | 1 |
| Frank, JE | 1 |
| Yuan, H | 4 |
| Lai, SK | 1 |
| Adams, CD | 1 |
| Boutwell, BB | 1 |
| Wang, M | 11 |
| Zhang, Y | 38 |
| Zhang, M | 10 |
| Li, H | 18 |
| Wen, C | 4 |
| Zhao, T | 12 |
| Xie, Z | 3 |
| Sun, J | 4 |
| Riches, PL | 5 |
| Downie, L | 1 |
| Thomson, C | 1 |
| Luo, LS | 1 |
| Wang, Y | 53 |
| Dai, LJ | 1 |
| He, FX | 1 |
| Zhang, JL | 1 |
| Zhou, Q | 4 |
| Scholz, J | 3 |
| Roiser, N | 3 |
| Braig, EM | 2 |
| Petrich, C | 2 |
| Birnbacher, L | 1 |
| Andrejewski, J | 3 |
| Kimm, MA | 3 |
| Sauter, A | 2 |
| Busse, M | 2 |
| Korbel, R | 3 |
| Herzen, J | 3 |
| Pfeiffer, D | 3 |
| Jansen, TL | 29 |
| Tanja, G | 1 |
| Matthijs, J | 1 |
| Méndez-Salazar, EO | 2 |
| Martínez-Nava, GA | 4 |
| Ran, Z | 6 |
| Xue, X | 8 |
| Han, L | 8 |
| Terkeltaub, R | 35 |
| Merriman, TR | 67 |
| He, Y | 15 |
| Wang, C | 17 |
| Li, X | 31 |
| Liu, Z | 19 |
| Cui, L | 8 |
| Ji, A | 11 |
| Hu, S | 8 |
| Lu, J | 12 |
| Li, C | 29 |
| Bardin, T | 33 |
| Magnat, E | 1 |
| Clerson, P | 3 |
| Richette, P | 34 |
| Rouchon, B | 1 |
| Kojima, S | 2 |
| Uchiyama, K | 2 |
| Yokota, N | 2 |
| Tokutake, E | 2 |
| Wakasa, Y | 2 |
| Hiramitsu, S | 2 |
| Waki, M | 2 |
| Jinnouchi, H | 2 |
| Kakuda, H | 2 |
| Hayashi, T | 2 |
| Kawai, N | 2 |
| Sugawara, M | 3 |
| Mori, H | 2 |
| Tsujita, K | 2 |
| Matsui, K | 2 |
| Hisatome, I | 15 |
| Ohya, Y | 2 |
| Kimura, K | 2 |
| Saito, Y | 4 |
| Ogawa, H | 4 |
| Borghi, C | 14 |
| Fiorini, G | 1 |
| Zhou, GQ | 1 |
| Chen, G | 3 |
| Yang, J | 6 |
| Qin, WY | 1 |
| Ping, J | 1 |
| Wen, S | 1 |
| Arakawa, H | 1 |
| Tamai, I | 2 |
| Teng, MS | 1 |
| Wu, S | 2 |
| Hsu, LA | 1 |
| Chou, HH | 1 |
| Ko, YL | 1 |
| Engel, B | 4 |
| Hoffmann, F | 1 |
| Freitag, MH | 1 |
| Jacobs, H | 1 |
| Huang, Q | 4 |
| Wang, P | 8 |
| Liao, X | 1 |
| Lan, Z | 1 |
| Chen, L | 8 |
| Feng, J | 2 |
| Wang, F | 4 |
| Liu, P | 2 |
| Yue, X | 1 |
| Du, L | 1 |
| Zhao, Y | 10 |
| Yang, P | 1 |
| Luo, J | 2 |
| Zhu, Z | 3 |
| Hu, X | 2 |
| Cao, L | 11 |
| Lu, P | 1 |
| Sah, R | 1 |
| Lavine, K | 1 |
| Kim, B | 2 |
| Hu, H | 4 |
| Bao, W | 1 |
| Xue, Y | 13 |
| Cheng, X | 9 |
| Yin, B | 1 |
| Su, Y | 1 |
| Jia, C | 1 |
| Halperin Kuhns, VL | 3 |
| Woodward, OM | 8 |
| Jia, E | 8 |
| Zhu, H | 6 |
| Geng, H | 7 |
| Zhong, L | 4 |
| Liu, S | 11 |
| Lin, F | 3 |
| Zhang, J | 20 |
| Gaffo, AL | 9 |
| Saag, K | 7 |
| Doyle, AJ | 12 |
| Melnick, J | 1 |
| Horne, A | 28 |
| Foster, J | 1 |
| Mudano, A | 2 |
| Biggers-Clark, S | 1 |
| Redden, D | 1 |
| Dalbeth, N | 183 |
| Liu, W | 9 |
| Wu, YH | 1 |
| Xue, B | 1 |
| Jin, Y | 3 |
| Zhang, SM | 1 |
| Li, PH | 1 |
| Xie, Q | 2 |
| Wang, AH | 1 |
| Gao, JY | 1 |
| Cai, Y | 2 |
| Zhang, B | 12 |
| Liu, XY | 1 |
| Duan, R | 1 |
| Chabernaud Negrier, A | 1 |
| Taihi, L | 1 |
| Vicaut, E | 1 |
| Lioté, F | 24 |
| Ea, HK | 17 |
| Bousson, V | 3 |
| Leask, MP | 1 |
| Yu, CW | 1 |
| Wu, SC | 1 |
| Li, TH | 1 |
| Wei, JC | 6 |
| Sandoval-Plata, G | 5 |
| Nakafero, G | 4 |
| Chakravorty, M | 2 |
| Morgan, K | 5 |
| Abhishek, A | 16 |
| Singh, JA | 41 |
| Joseph, A | 1 |
| Baker, J | 1 |
| Richman, JS | 1 |
| Shaneyfelt, T | 1 |
| Saag, KG | 20 |
| Eisen, S | 1 |
| Stamp, LK | 81 |
| Farquhar, H | 1 |
| Lee, YH | 11 |
| Song, GG | 8 |
| Helm, M | 1 |
| Ng, B | 1 |
| Mogavero, A | 1 |
| Jatuworapruk, K | 11 |
| Grainger, R | 16 |
| Taylor, WJ | 41 |
| García-Maturano, JS | 1 |
| Torres-Ordaz, DE | 1 |
| Mosqueda-Gutiérrez, M | 1 |
| Gómez-Ruiz, C | 2 |
| Vázquez-Mellado, A | 1 |
| Tafoya-Amado, A | 1 |
| Peláez-Ballestas, I | 4 |
| Burgos-Vargas, R | 8 |
| Vázquez-Mellado, J | 18 |
| Kimura, Y | 1 |
| Tsukui, D | 1 |
| Kono, H | 6 |
| Morillon, MB | 6 |
| Christensen, R | 7 |
| Neogi, T | 23 |
| Kennedy, MA | 2 |
| Pedersen, BM | 2 |
| McCarthy, GM | 2 |
| Shea, B | 2 |
| Diaz-Torne, C | 10 |
| Tedeschi, SK | 2 |
| Gaffo, A | 6 |
| Nielsen, SM | 3 |
| Noerup, A | 1 |
| Simon, LS | 3 |
| Lassere, M | 4 |
| Tugwell, P | 2 |
| Gout Working Group, FTO | 1 |
| Martins, D | 1 |
| Tonon, CR | 1 |
| Pacca, RL | 1 |
| Matchil, NL | 1 |
| Junior, LAJ | 1 |
| Queiroz, DS | 1 |
| Pereira, FWL | 1 |
| Silva, AM | 1 |
| Padovese, V | 1 |
| Padovani de Toledo Moraes, M | 1 |
| Luiz da Silva, D | 1 |
| Cardoso Nóbrega, V | 1 |
| Curcelli, EC | 1 |
| Okoshi, MP | 1 |
| Xie, WR | 1 |
| Yang, XY | 1 |
| Deng, ZH | 1 |
| Zheng, YM | 1 |
| Zhang, R | 1 |
| Wu, LH | 1 |
| Cai, JY | 1 |
| Kong, LP | 1 |
| Xia, HH | 1 |
| He, XX | 1 |
| Tin, A | 6 |
| Schlosser, P | 1 |
| Matias-Garcia, PR | 1 |
| Thio, CHL | 2 |
| Joehanes, R | 1 |
| Liu, H | 5 |
| Yu, Z | 2 |
| Weihs, A | 1 |
| Hoppmann, A | 2 |
| Grundner-Culemann, F | 1 |
| Min, JL | 1 |
| Kuhns, VLH | 1 |
| Adeyemo, AA | 2 |
| Agyemang, C | 1 |
| Ärnlöv, J | 2 |
| Aziz, NA | 1 |
| Baccarelli, A | 1 |
| Bochud, M | 6 |
| Brenner, H | 1 |
| Bressler, J | 1 |
| Breteler, MMB | 1 |
| Carmeli, C | 1 |
| Chaker, L | 1 |
| Coresh, J | 12 |
| Corre, T | 2 |
| Correa, A | 1 |
| Cox, SR | 1 |
| Delgado, GE | 1 |
| Eckardt, KU | 3 |
| Ekici, AB | 2 |
| Endlich, K | 2 |
| Floyd, JS | 1 |
| Fraszczyk, E | 1 |
| Gao, X | 6 |
| Gelber, AC | 8 |
| Ghanbari, M | 1 |
| Ghasemi, S | 2 |
| Gieger, C | 6 |
| Greenland, P | 1 |
| Grove, ML | 2 |
| Harris, SE | 2 |
| Hemani, G | 1 |
| Henneman, P | 1 |
| Herder, C | 1 |
| Horvath, S | 1 |
| Hou, L | 1 |
| Hurme, MA | 1 |
| Hwang, SJ | 5 |
| Kardia, SLR | 1 |
| Kasela, S | 1 |
| Kleber, ME | 3 |
| Koenig, W | 2 |
| Kooner, JS | 3 |
| Kronenberg, F | 5 |
| Kühnel, B | 2 |
| Ladd-Acosta, C | 1 |
| Lehtimäki, T | 3 |
| Lind, L | 1 |
| Liu, D | 3 |
| Lloyd-Jones, DM | 1 |
| Lorkowski, S | 1 |
| Lu, AT | 1 |
| Marioni, RE | 1 |
| März, W | 3 |
| McCartney, DL | 1 |
| Meeks, KAC | 1 |
| Milani, L | 1 |
| Mishra, PP | 2 |
| Nauck, M | 5 |
| Nowak, C | 1 |
| Peters, A | 2 |
| Prokisch, H | 3 |
| Psaty, BM | 4 |
| Raitakari, OT | 2 |
| Ratliff, SM | 1 |
| Reiner, AP | 1 |
| Schöttker, B | 1 |
| Schwartz, J | 1 |
| Sedaghat, S | 2 |
| Smith, JA | 1 |
| Sotoodehnia, N | 1 |
| Stocker, HR | 1 |
| Stringhini, S | 1 |
| Sundström, J | 1 |
| Swenson, BR | 1 |
| van Meurs, JBJ | 1 |
| van Vliet-Ostaptchouk, JV | 1 |
| Venema, A | 1 |
| Völker, U | 3 |
| Winkelmann, J | 1 |
| Wolffenbuttel, BHR | 1 |
| Zhao, W | 2 |
| Zheng, Y | 3 |
| Loh, M | 1 |
| Snieder, H | 4 |
| Waldenberger, M | 4 |
| Levy, D | 2 |
| Akilesh, S | 1 |
| Susztak, K | 2 |
| Teumer, A | 5 |
| Köttgen, A | 15 |
| Chen, D | 2 |
| Xu, H | 5 |
| Sun, L | 3 |
| Li, Y | 36 |
| Wang, T | 8 |
| Patel, V | 1 |
| Dass, N | 1 |
| Peng, Z | 1 |
| Ding, YM | 1 |
| Pei, L | 2 |
| Yao, HH | 1 |
| Zhang, XW | 1 |
| Tang, SM | 1 |
| Liu, X | 15 |
| Li, B | 4 |
| Zhang, X | 15 |
| Mo, S | 1 |
| Liang, D | 1 |
| Zhu, J | 7 |
| Choi, HK | 39 |
| McCormick, N | 5 |
| Yokose, C | 8 |
| Honda, M | 2 |
| Horiuchi, H | 5 |
| Torii, T | 2 |
| Nakajima, A | 5 |
| Iijima, T | 2 |
| Murano, H | 2 |
| Yamanaka, H | 26 |
| Ito, S | 2 |
| Billington, K | 2 |
| Gamble, GD | 19 |
| Tan, P | 12 |
| Latto, K | 1 |
| Parshu Ram, T | 1 |
| Narang, R | 2 |
| Murdoch, R | 1 |
| Bursill, D | 4 |
| Mihov, B | 3 |
| Blake, KEG | 1 |
| Saag, JL | 1 |
| Ofanoa, M | 2 |
| Ofanoa, SM | 1 |
| Heather, M | 2 |
| Tu'akoi, S | 2 |
| Lutui, H | 2 |
| Grey, C | 2 |
| van der Werf, B | 1 |
| Goodyear-Smith, F | 2 |
| Chen, T | 1 |
| Ma, DL | 1 |
| Gutierrez, M | 7 |
| Sandoval, H | 1 |
| Bertolazzi, C | 1 |
| Soto-Fajardo, C | 1 |
| Tellez-Gastelum, RM | 1 |
| Reginato, AM | 4 |
| Clavijo-Cornejo, D | 1 |
| Yip, K | 2 |
| Berman, J | 1 |
| Anderson, IJ | 1 |
| Davis, AM | 1 |
| Jan, RH | 1 |
| Seifert, KD | 1 |
| Zohrabian, VM | 1 |
| Ikuta, I | 1 |
| Latourte, A | 8 |
| Dumurgier, J | 1 |
| Paquet, C | 1 |
| Rasmussen, C | 2 |
| Larsen, MB | 1 |
| Linauskas, A | 1 |
| Mikuls, TR | 18 |
| Soto, Q | 1 |
| Petro, A | 1 |
| Helget, L | 1 |
| Roul, P | 1 |
| Sayles, H | 4 |
| Cope, B | 1 |
| O'Dell, JR | 2 |
| England, BR | 1 |
| ElSayed, S | 4 |
| Jay, GD | 4 |
| Cabezas, R | 1 |
| Qadri, M | 4 |
| Schmidt, TA | 4 |
| Elsaid, KA | 1 |
| Zhao, L | 14 |
| Yang, X | 14 |
| Xu, R | 5 |
| Liu, J | 15 |
| Lin, C | 8 |
| Yu, Y | 7 |
| Xuan, D | 3 |
| Zhu, X | 14 |
| Liu, L | 12 |
| Hua, Y | 5 |
| Deng, C | 1 |
| Wan, W | 6 |
| Zou, H | 15 |
| Alhilali, M | 2 |
| Riordan, P | 1 |
| Chhana, A | 13 |
| McGlashan, S | 2 |
| Doyle, A | 4 |
| Andres, M | 18 |
| Khanna, P | 4 |
| Pascart, T | 15 |
| Budzik, JF | 9 |
| Ballur, AFH | 1 |
| Altinoz, E | 1 |
| Yigitturk, G | 1 |
| Onal, MO | 1 |
| Elbe, H | 1 |
| Bicer, Y | 1 |
| Karayakali, M | 1 |
| Demir, M | 1 |
| Xue, L | 1 |
| Chen, Y | 25 |
| Quan, F | 1 |
| Xiao, Y | 6 |
| Han, M | 2 |
| Jiang, Q | 1 |
| Lu, L | 1 |
| Mount, DB | 9 |
| Feng, Z | 1 |
| Xu, Y | 8 |
| Ji, X | 7 |
| Wang, X | 20 |
| Baffour, FI | 1 |
| Ferrero, A | 1 |
| Aird, GA | 1 |
| Powell, GM | 1 |
| Adkins, MC | 1 |
| Bekele, DI | 1 |
| Johnson, MP | 1 |
| Fletcher, JG | 2 |
| Glazebrook, KN | 5 |
| Tao, Y | 3 |
| Liao, H | 2 |
| Zhao, F | 2 |
| Liang, R | 2 |
| Shi, X | 4 |
| Zhang, Z | 11 |
| Ji, J | 2 |
| Wu, T | 3 |
| Pang, J | 4 |
| Zhan, P | 3 |
| van de Laar, CJ | 1 |
| Janssen, CA | 3 |
| Janssen, M | 24 |
| Oude Voshaar, MAH | 3 |
| Al, MJ | 1 |
| van de Laar, MAFJ | 3 |
| Barranco-Trabi, J | 1 |
| Mank, V | 1 |
| Minns, R | 1 |
| Ryan, C | 1 |
| Roberts, J | 3 |
| Yao, X | 3 |
| Xie, J | 4 |
| Jiang, Y | 12 |
| Qiu, X | 4 |
| Xiao, M | 6 |
| Tang, D | 2 |
| Wei, J | 9 |
| Li, S | 8 |
| Xu, G | 3 |
| Liang, J | 4 |
| Wan, L | 1 |
| Cao, H | 4 |
| Lin, J | 4 |
| Stewart, S | 7 |
| Phipps-Green, A | 21 |
| Wang, Z | 11 |
| Liu, R | 3 |
| Di, X | 1 |
| Zhou, Y | 7 |
| Fan, L | 1 |
| Zheng, L | 1 |
| Drosos, GC | 1 |
| Vedder, D | 2 |
| Houben, E | 1 |
| Boekel, L | 1 |
| Atzeni, F | 1 |
| Badreh, S | 1 |
| Boumpas, DT | 2 |
| Brodin, N | 1 |
| Bruce, IN | 1 |
| González-Gay, MÁ | 4 |
| Jacobsen, S | 1 |
| Kerekes, G | 1 |
| Marchiori, F | 1 |
| Mukhtyar, C | 1 |
| Ramos-Casals, M | 1 |
| Sattar, N | 1 |
| Schreiber, K | 1 |
| Sciascia, S | 1 |
| Svenungsson, E | 1 |
| Szekanecz, Z | 1 |
| Tausche, AK | 24 |
| Tyndall, A | 1 |
| van Halm, V | 1 |
| Voskuyl, A | 1 |
| Macfarlane, GJ | 1 |
| Ward, MM | 1 |
| Nurmohamed, MT | 2 |
| Tektonidou, MG | 1 |
| Peeters, IR | 2 |
| Oude Voshaar, AMH | 1 |
| Moses, A | 1 |
| Jansen, TLTA | 4 |
| Flendrie, M | 3 |
| van Herwaarden, N | 2 |
| Kim, HW | 1 |
| Joo, YS | 1 |
| Yun, HR | 1 |
| Kim, JY | 3 |
| Jhee, JH | 1 |
| Roh, YH | 1 |
| Park, JT | 1 |
| Chang, TI | 2 |
| Yoo, TH | 1 |
| Kang, SW | 1 |
| Han, SH | 1 |
| McPherson, M | 1 |
| Aslam, F | 3 |
| Botson, JK | 8 |
| Baraf, HSB | 2 |
| Keenan, RT | 15 |
| Albert, J | 1 |
| Masri, KR | 2 |
| Peterson, J | 6 |
| Yung, C | 1 |
| Freyne, B | 2 |
| Amin, M | 1 |
| Abdellatif, A | 2 |
| Soloman, N | 1 |
| Edwards, NL | 21 |
| Strand, V | 3 |
| Emad, Y | 1 |
| Weinman, J | 1 |
| Chalder, T | 1 |
| Petrie, KJ | 3 |
| Pérez Ruiz, F | 2 |
| Pérez Herrero, N | 1 |
| Gantes Pedraza, MÁ | 1 |
| Nguyen, QD | 3 |
| Hieu, NL | 1 |
| Tran, KM | 2 |
| Do, MD | 2 |
| Resche-Rigon, M | 2 |
| Te Kampe, R | 4 |
| Boonen, A | 10 |
| Jansen, T | 2 |
| de Vries, H | 3 |
| van Durme, C | 6 |
| Xu, N | 1 |
| Han, X | 3 |
| Huang, X | 3 |
| Zhu, W | 1 |
| Shen, M | 2 |
| Zhang, W | 16 |
| Jialin, C | 1 |
| Wei, M | 2 |
| Qiu, Z | 1 |
| Zeng, X | 6 |
| Schwotzer, N | 1 |
| Auberson, M | 1 |
| Livio, F | 1 |
| So, A | 15 |
| Bonny, O | 1 |
| Luo, L | 2 |
| Gan, R | 1 |
| Zeng, L | 4 |
| Yeo, AE | 6 |
| Lipsky, PE | 7 |
| Löffler, W | 4 |
| Fairbanks, L | 3 |
| Gibson, T | 17 |
| Siddiq, MAB | 1 |
| Rasker, JJ | 3 |
| Sun, M | 9 |
| Sun, W | 10 |
| Zhao, X | 1 |
| Qu, H | 1 |
| Zheng, G | 1 |
| Ma, L | 8 |
| Wang, J | 32 |
| Shi, Y | 13 |
| Fang, X | 2 |
| Chen, H | 10 |
| Cong, R | 1 |
| Song, Z | 2 |
| Chen, S | 6 |
| Liu, G | 2 |
| Liu, Y | 20 |
| Pang, X | 1 |
| Dong, F | 1 |
| Xing, W | 1 |
| Xu, X | 5 |
| Yin, H | 1 |
| Liu, N | 4 |
| Chen, J | 14 |
| Russell, MD | 2 |
| Nagra, D | 1 |
| Clarke, BD | 1 |
| Balachandran, S | 1 |
| Buazon, A | 1 |
| Boalch, A | 1 |
| Bechman, K | 1 |
| Adas, MA | 1 |
| Alveyn, EG | 1 |
| Rutherford, AI | 2 |
| Galloway, JB | 2 |
| Becce, F | 10 |
| Kumar, A | 1 |
| Wessig, AK | 2 |
| Hoffmeister, L | 2 |
| Klingberg, A | 2 |
| Alberts, A | 2 |
| Pich, A | 2 |
| Brand, K | 2 |
| Witte, T | 1 |
| Neumann, K | 2 |
| Christiansen, SN | 5 |
| Østergaard, M | 5 |
| Slot, O | 11 |
| Fana, V | 2 |
| Terslev, L | 7 |
| Türker, PF | 1 |
| Hoca, M | 1 |
| Özduran, G | 1 |
| Akçil Ok, M | 1 |
| Demir Çelebi, M | 1 |
| Filippou, G | 3 |
| Pacini, G | 2 |
| Sirotti, S | 2 |
| Zadory, M | 1 |
| Carboni, D | 1 |
| Damiani, A | 1 |
| Fiorentini, E | 1 |
| Cipolletta, E | 5 |
| Filippucci, E | 6 |
| Froehlich, JM | 1 |
| Sarzi Puttini, P | 1 |
| Schlesinger, N | 29 |
| Padnick-Silver, L | 2 |
| Rustgi, VK | 1 |
| Lee, HJ | 1 |
| Choi, JY | 2 |
| Lee, J | 7 |
| Kim, D | 1 |
| Min, JY | 1 |
| Min, KB | 1 |
| Phrintrakul, N | 1 |
| Wongthanee, A | 1 |
| Kasitanon, N | 2 |
| Louthrenoo, W | 8 |
| Li, P | 6 |
| Kurata, Y | 1 |
| Taufiq, F | 2 |
| Kuwabara, M | 8 |
| Ninomiya, H | 5 |
| Higaki, K | 1 |
| Tsuneto, M | 1 |
| Shirayoshi, Y | 1 |
| Lanaspa, MA | 3 |
| Huang, Y | 11 |
| Chi, J | 2 |
| Lv, W | 3 |
| Hilsabeck, TAU | 1 |
| Liu-Bryan, R | 10 |
| Guo, T | 1 |
| Wilson, KA | 2 |
| Bose, N | 2 |
| Raftery, D | 1 |
| Beck, JN | 2 |
| Lang, S | 2 |
| Jin, K | 1 |
| Nelson, CS | 1 |
| Oron, T | 1 |
| Stoller, M | 1 |
| Promislow, D | 1 |
| Brem, RB | 1 |
| Kapahi, P | 2 |
| Brunetti, L | 2 |
| Androulakis, IP | 1 |
| Elling, JM | 1 |
| van Eijk-Hustings, Y | 2 |
| Keller, SF | 1 |
| Mandell, BF | 11 |
| Sinnappah, KA | 1 |
| Stocker, SL | 13 |
| Chan, JS | 2 |
| Hughes, DA | 3 |
| Wright, DFB | 5 |
| Ramos, GK | 1 |
| Goldfarb, DS | 4 |
| Choy, SH | 1 |
| Nyanatay, SA | 1 |
| Sothilingam, S | 1 |
| Malek, R | 1 |
| J R, S | 1 |
| Toh, CC | 1 |
| Sundram, M | 1 |
| Md Yusoff, NA | 1 |
| Nagappan, P | 1 |
| Kamaruzaman, S | 1 |
| Yeoh, WS | 1 |
| Ong, TA | 1 |
| Lim, J | 1 |
| Lee, Y | 1 |
| Kim, N | 1 |
| Werlinger, P | 1 |
| Suh, DA | 1 |
| Lee, H | 4 |
| Cho, JH | 1 |
| Cheng, J | 2 |
| Uhlig, T | 18 |
| Karoliussen, LF | 8 |
| Sexton, J | 7 |
| Kvien, TK | 8 |
| Haavardsholm, EA | 8 |
| Perez-Ruiz, F | 55 |
| Hammer, HB | 8 |
| Schuh, A | 1 |
| Goyal, T | 1 |
| Schmidtmann, M | 1 |
| Koehl, P | 1 |
| Syed, AAS | 1 |
| Fahira, A | 1 |
| Yang, Q | 11 |
| Tse, JJ | 1 |
| Kondro, DA | 1 |
| Kuczynski, MT | 1 |
| Pauchard, Y | 1 |
| Veljkovic, A | 1 |
| Holdsworth, DW | 1 |
| Frasson, V | 1 |
| Manske, SL | 1 |
| MacMullan, P | 1 |
| Salat, P | 1 |
| Yu, H | 6 |
| Chai, S | 1 |
| Chai, X | 1 |
| Wang, L | 6 |
| Geng, WC | 1 |
| Li, JJ | 1 |
| Yue, YX | 1 |
| Guo, DS | 1 |
| Wu, ZD | 1 |
| Yang, XK | 1 |
| He, YS | 1 |
| Ni, J | 2 |
| Yin, KJ | 1 |
| Huang, JX | 1 |
| Feng, YT | 1 |
| Pan, HF | 1 |
| Pou, MA | 3 |
| Orfila, F | 1 |
| Pagonabarraga, J | 1 |
| Ferrer-Moret, S | 1 |
| Corominas, H | 2 |
| Zamudio-Cuevas, Y | 5 |
| Martínez-López, V | 1 |
| Luján-Juárez, IA | 1 |
| Montaño-Armendariz, N | 1 |
| Martínez-Flores, K | 5 |
| Fernández-Torres, J | 5 |
| Gimeno, M | 1 |
| Sánchez-Sánchez, R | 2 |
| Natsuko, PD | 1 |
| Laura, SC | 1 |
| Denise, CC | 1 |
| Lucio, VR | 1 |
| Carlos, AS | 1 |
| Fausto, SM | 1 |
| Ambar, LM | 1 |
| Copur, S | 1 |
| Demiray, A | 1 |
| Kanbay, M | 1 |
| Becker, MA | 35 |
| White, WB | 4 |
| Whelton, A | 3 |
| Borer, JS | 1 |
| Gorelick, PB | 1 |
| Hunt, B | 8 |
| Castillo, M | 2 |
| Gunawardhana, L | 7 |
| Chen, HW | 3 |
| Chen, YC | 5 |
| Lee, JT | 1 |
| Yang, FM | 2 |
| Kao, CY | 2 |
| Chou, YH | 3 |
| Chu, TY | 1 |
| Juan, YS | 1 |
| Wu, WJ | 3 |
| Alkilany, R | 2 |
| Einstadter, D | 2 |
| Antonelli, M | 2 |
| Yuan, X | 7 |
| Chen, R | 3 |
| Lin, X | 2 |
| Juraschek, SP | 7 |
| Gaziano, JM | 2 |
| Glynn, RJ | 5 |
| Gomelskaya, N | 1 |
| Bubes, VY | 1 |
| Buring, JE | 1 |
| Shmerling, RH | 3 |
| Sesso, HD | 1 |
| Weisshaar, S | 1 |
| Litschauer, B | 1 |
| Reichardt, B | 1 |
| Gruber, F | 1 |
| Leitner, S | 1 |
| Sibinovic, S | 1 |
| Kossmeier, M | 1 |
| Wolzt, M | 1 |
| Huddleston, EM | 1 |
| Ye, W | 1 |
| Zhu, Y | 6 |
| Chen, F | 3 |
| Wang, Q | 4 |
| Lv, X | 2 |
| Du, Z | 1 |
| Silva, CR | 4 |
| Saraiva, AL | 1 |
| Rossato, MF | 3 |
| Trevisan, G | 3 |
| Oliveira, SM | 4 |
| Guan, Y | 2 |
| Meng, L | 1 |
| Qian, Q | 2 |
| Cândido, FG | 1 |
| Alves, RDM | 1 |
| Freitas, DMO | 1 |
| Bittencourt, JM | 1 |
| Rocha, DMUP | 1 |
| Alfenas, RCG | 1 |
| Sahin, A | 1 |
| Kilic, K | 1 |
| Sakat, MS | 1 |
| Melikoglu, MA | 1 |
| Sarihan, K | 1 |
| Tam, V | 1 |
| Nam, VT | 1 |
| Quoc, TAH | 1 |
| Liu, ZQ | 1 |
| Sun, X | 6 |
| Liu, ZB | 1 |
| Zhang, LL | 1 |
| Wu, CJ | 1 |
| Ren, L | 5 |
| Li, Q | 6 |
| Zhan, X | 1 |
| Yang, R | 1 |
| Fang, Z | 1 |
| Liu, T | 5 |
| Wei, Z | 1 |
| Zhao, J | 3 |
| Lin, L | 1 |
| Mou, W | 1 |
| Dai, W | 1 |
| Bai, Z | 2 |
| Cao, J | 1 |
| Wong, PKK | 1 |
| Ng, BCK | 1 |
| Mitchell, J | 1 |
| Han, J | 1 |
| Lam, C | 1 |
| Spencer, D | 1 |
| Cai, K | 1 |
| Manolios, N | 1 |
| Coleshill, MJ | 5 |
| Day, RO | 16 |
| Tam, K | 1 |
| Kouhkamari, M | 1 |
| Caillet, V | 1 |
| Aung, E | 6 |
| Kannangara, DRW | 2 |
| Cronin, P | 1 |
| Rodgers, A | 1 |
| Li, R | 1 |
| Ren, W | 4 |
| Ning, C | 1 |
| Piao, MH | 2 |
| Wang, H | 8 |
| Jiang, YJ | 1 |
| Wu, YL | 5 |
| Nan, JX | 2 |
| Lian, LH | 2 |
| Agrawal, M | 1 |
| Niroula, A | 1 |
| Cunin, P | 1 |
| McConkey, M | 1 |
| Shkolnik, V | 1 |
| Kim, PG | 1 |
| Wong, WJ | 1 |
| Weeks, LD | 1 |
| Lin, AE | 1 |
| Miller, PG | 1 |
| Gibson, CJ | 1 |
| Sekar, A | 1 |
| Schaefer, IM | 1 |
| Neuberg, D | 1 |
| Stone, RM | 1 |
| Bick, AG | 1 |
| Uddin, MM | 1 |
| Griffin, GK | 1 |
| Jaiswal, S | 1 |
| Natarajan, P | 1 |
| Nigrovic, PA | 1 |
| Rao, DA | 1 |
| Ebert, BL | 1 |
| Mendieta, L | 1 |
| Argente-Del-Castillo, E | 1 |
| Trigueros, M | 1 |
| Miñano, A | 1 |
| Pascual, E | 33 |
| Van Demark, RE | 1 |
| Brown, J | 1 |
| Hayes, M | 2 |
| Smith, VJS | 1 |
| Yan, J | 1 |
| Wu, J | 9 |
| He, X | 2 |
| Kampe, RT | 1 |
| Hotea, I | 1 |
| Orji, OC | 1 |
| López-Domínguez, MB | 1 |
| Guetta-Baranes, T | 1 |
| Valdes, AM | 4 |
| Doherty, M | 32 |
| Hull, SD | 1 |
| Andersen, MW | 1 |
| Bengtsson, J | 1 |
| Skovgaard, N | 1 |
| Backe, MB | 1 |
| Pedersen, ML | 1 |
| Lin, CY | 2 |
| Chang, YS | 2 |
| Liu, TY | 2 |
| Huang, CM | 5 |
| Chung, CC | 2 |
| Tsai, FJ | 2 |
| Chang, JG | 4 |
| Chang, SJ | 6 |
| Fukuuchi, T | 3 |
| Itahashi, I | 1 |
| Takayanagi, F | 2 |
| Yamaoka, N | 2 |
| Kaneko, K | 3 |
| Avery, AJ | 2 |
| Mamas, M | 1 |
| Tata, LJ | 2 |
| Zhang, H | 17 |
| Coleman, GB | 1 |
| Frampton, C | 25 |
| Haslett, J | 3 |
| Drake, J | 17 |
| Su, I | 2 |
| Horne, AM | 2 |
| Wang, CC | 1 |
| Li, YL | 1 |
| Chiu, PY | 1 |
| Chen, C | 3 |
| Chen, HC | 2 |
| Chen, FA | 1 |
| Leung, N | 1 |
| Pillinger, MH | 21 |
| Toprover, M | 5 |
| Baumgartner, C | 1 |
| Braig, E | 1 |
| Yan, F | 2 |
| Qi, H | 1 |
| Yu, Q | 4 |
| Mechlin, M | 1 |
| Fields, T | 1 |
| Oh, C | 2 |
| Park, EH | 1 |
| Choi, ST | 5 |
| Song, JS | 4 |
| Akari, S | 1 |
| Nakamura, T | 25 |
| Furusawa, K | 1 |
| Miyazaki, Y | 1 |
| Kario, K | 1 |
| Topless, R | 11 |
| Noorbaloochi, S | 1 |
| Zhao, SS | 2 |
| Rajasundaram, S | 1 |
| Karhunen, V | 1 |
| Alam, U | 1 |
| Gill, D | 1 |
| Stauder, SK | 1 |
| Peloso, PM | 3 |
| Luo, Q | 1 |
| Zhao, Q | 3 |
| Tian, L | 1 |
| Liu, WJ | 1 |
| Rollefstad, S | 1 |
| Semb, AG | 1 |
| Jensen, G | 1 |
| Zhu, L | 6 |
| Liu, M | 3 |
| Shan, L | 2 |
| Galozzi, P | 4 |
| Oliviero, F | 9 |
| Scanu, A | 10 |
| Lorenzin, M | 4 |
| Ortolan, A | 4 |
| Favero, M | 3 |
| Doria, A | 3 |
| Ramonda, R | 8 |
| Guma, M | 1 |
| Dadpey, B | 1 |
| Coras, R | 1 |
| Hamilton, B | 1 |
| Quehenberger, O | 1 |
| Thorisdottir, H | 1 |
| Bittleman, D | 1 |
| Lauro, K | 1 |
| Reilly, SM | 1 |
| Vio, S | 1 |
| Gallo, M | 1 |
| Liang, Z | 1 |
| Li, M | 13 |
| Fu, D | 1 |
| Zhang, L | 9 |
| Guo, Y | 8 |
| Ge, D | 1 |
| Sun, B | 3 |
| Cao, W | 1 |
| Liang, F | 1 |
| Fang, Y | 1 |
| Cheng, Y | 2 |
| Pan, S | 2 |
| Pan, X | 1 |
| Cao, X | 1 |
| Mei, Y | 1 |
| Dong, B | 4 |
| Geng, Z | 1 |
| Xu, L | 8 |
| Di Battista, J | 2 |
| Grassi, W | 9 |
| Uchino, T | 1 |
| Motoki, N | 1 |
| Uchida, K | 1 |
| Asakura, H | 1 |
| Uno-Eder, K | 1 |
| Nomura, T | 1 |
| Tsukamoto, K | 1 |
| Nian, YL | 1 |
| You, CG | 2 |
| Mehmood, A | 1 |
| Althobaiti, F | 1 |
| Usman, M | 1 |
| Chen, X | 13 |
| Alharthi, F | 1 |
| Soliman, MM | 1 |
| Shah, AA | 1 |
| Murtaza, MA | 1 |
| Nadeem, M | 1 |
| Ranjha, MMAN | 1 |
| Ughi, N | 1 |
| Ariani, A | 2 |
| Raffeiner, B | 1 |
| Frallonardo, P | 2 |
| Hoxha, A | 1 |
| Parisi, S | 1 |
| Bortoluzzi, A | 2 |
| Ceccarelli, F | 1 |
| Lucchetti, R | 1 |
| Furini, F | 1 |
| Del Ross, T | 1 |
| Zanetti, A | 1 |
| Carrara, G | 2 |
| Scirè, CA | 7 |
| Yao, J | 1 |
| Lin, YP | 2 |
| Lu, QY | 1 |
| Fan, GJ | 1 |
| Pálinkás, M | 1 |
| Szabó, E | 1 |
| Kulin, A | 1 |
| Mózner, O | 1 |
| Rásonyi, R | 1 |
| Juhász, P | 1 |
| Nagy, K | 1 |
| Várady, G | 1 |
| Vörös, D | 1 |
| Zámbó, B | 1 |
| Sarkadi, B | 2 |
| Poór, G | 3 |
| Deng, JH | 1 |
| Zhong, GW | 1 |
| Zhang, JX | 1 |
| Ou, YN | 1 |
| Zhao, B | 3 |
| Fu, Y | 5 |
| Sheng, ZH | 1 |
| Gao, PY | 1 |
| Tan, L | 1 |
| Yu, JT | 1 |
| Yang, Y | 16 |
| Xian, W | 1 |
| Wu, D | 2 |
| Huo, Z | 1 |
| Hong, S | 4 |
| Xiao, H | 1 |
| Tesser, JRP | 3 |
| Bennett, R | 2 |
| Kenney, HM | 2 |
| Obermeyer, K | 4 |
| Song, Y | 3 |
| Xin, Y | 5 |
| Chamberlain, J | 3 |
| Ramanathan, S | 1 |
| Weinblatt, ME | 4 |
| Chu, Q | 2 |
| Yang, C | 12 |
| Fu, M | 1 |
| Sun, G | 1 |
| Luo, Z | 1 |
| Yang, F | 3 |
| Chen, B | 4 |
| Li, L | 13 |
| Yao, Y | 3 |
| Hu, Y | 5 |
| Wang, S | 8 |
| Xu, T | 2 |
| Li, YJ | 1 |
| Chen, LR | 1 |
| Yang, ZL | 2 |
| Jiang, FF | 1 |
| Qian, K | 2 |
| Yang, M | 6 |
| Yin, SJ | 1 |
| He, GH | 1 |
| Hammam, N | 1 |
| Li, J | 7 |
| Kay, J | 2 |
| Izadi, Z | 1 |
| Yazdany, J | 1 |
| Schmajuk, G | 1 |
| Lauffenburger, JC | 1 |
| Lu, Z | 1 |
| Mahesri, M | 1 |
| Kim, E | 1 |
| Tong, A | 1 |
| Kim, SC | 6 |
| Rodríguez-Díez, B | 1 |
| Pujol-Ribera, E | 1 |
| Wo, X | 1 |
| Zeng, Y | 1 |
| Ma, W | 4 |
| Zhan, Z | 1 |
| Yuan, M | 1 |
| Roman, YM | 1 |
| Parikh, N | 1 |
| Ong, S | 1 |
| La, D | 1 |
| LoCicero, K | 1 |
| Verma, S | 1 |
| Sainati, S | 1 |
| Grewal, S | 1 |
| Majjhoo, A | 1 |
| Riaño, D | 1 |
| Pečnik, Š | 1 |
| Alonso, JR | 1 |
| Kamišalić, A | 1 |
| Zhu, Q | 1 |
| Miao, Y | 1 |
| Bai, W | 1 |
| Yu, S | 1 |
| Guo, D | 1 |
| Sun, D | 2 |
| Zeng, F | 1 |
| Wang, W | 11 |
| Chen, Z | 4 |
| Shi, J | 2 |
| He, R | 1 |
| Ji, M | 2 |
| Mikhailidis, DP | 2 |
| Kouvari, M | 1 |
| Pangiotakos, DB | 1 |
| Zeng, Z | 1 |
| Jin, T | 3 |
| Huang, L | 1 |
| Xie, Y | 4 |
| He, W | 2 |
| Ding, C | 1 |
| Cen, H | 1 |
| Jiang, X | 3 |
| Deng, Y | 3 |
| Sun, F | 1 |
| Lin, P | 1 |
| Ma, Y | 7 |
| Cao, Y | 3 |
| Guo, QH | 1 |
| Lu, JG | 1 |
| Zheng, BL | 1 |
| Li, T | 2 |
| Chen, SH | 1 |
| Żyluk, A | 1 |
| Fliciński, F | 1 |
| Helget, LN | 1 |
| Sabolová, M | 1 |
| Kulma, M | 1 |
| Petříčková, D | 1 |
| Kletečková, K | 1 |
| Kouřimská, L | 1 |
| Du, X | 2 |
| Jin, S | 1 |
| Kurniasari, MD | 1 |
| Karwur, FF | 2 |
| Rayanti, RE | 2 |
| Shih, YW | 1 |
| Yuliana, S | 1 |
| Miao, NF | 1 |
| Chou, KR | 1 |
| Shen, CJ | 1 |
| Tsai, HT | 2 |
| Mackenzie, IS | 3 |
| Hawkey, CJ | 2 |
| Ford, I | 2 |
| Greenlaw, N | 1 |
| Pigazzani, F | 1 |
| Rogers, A | 1 |
| Struthers, AD | 2 |
| Begg, AG | 1 |
| Wei, L | 4 |
| Taggar, JS | 1 |
| Walker, A | 1 |
| Duce, SL | 1 |
| Barr, RJ | 1 |
| Dumbleton, JS | 1 |
| Rooke, ED | 1 |
| Townend, JN | 1 |
| Ritchie, LD | 1 |
| MacDonald, TM | 3 |
| He, Q | 1 |
| Yang, K | 1 |
| Xiang, W | 2 |
| Dong, Y | 2 |
| Gao, S | 3 |
| Qi, D | 1 |
| Fazlollahi, A | 1 |
| Zahmatyar, M | 1 |
| Alizadeh, H | 1 |
| Noori, M | 1 |
| Jafari, N | 1 |
| Nejadghaderi, SA | 1 |
| Sullman, MJM | 1 |
| Gharagozli, K | 1 |
| Kolahi, AA | 1 |
| Safiri, S | 1 |
| Mass, BB | 1 |
| Talevi, V | 1 |
| Hou, R | 1 |
| North, KE | 2 |
| Voruganti, VS | 2 |
| Tsai, YS | 2 |
| Ko, MY | 1 |
| Fung, M | 5 |
| Baumgartner, S | 13 |
| El-Mallah, R | 1 |
| Ibrahim, RA | 1 |
| El Attar, EA | 1 |
| Kwon, HS | 1 |
| Park, Y | 2 |
| Kim, JH | 5 |
| Kim, SH | 5 |
| Jun, JB | 3 |
| Park, S | 2 |
| Kang, DR | 1 |
| Choi, H | 6 |
| Miguel-Pérez, M | 1 |
| Coronel, L | 1 |
| Bong, D | 1 |
| Möller, I | 2 |
| Eliseev, MS | 7 |
| Panevin, TS | 1 |
| Zhelyabina, OV | 1 |
| Nasonov, EL | 6 |
| Sigurdardottir, V | 5 |
| Svärd, A | 5 |
| Jacobsson, L | 9 |
| Dehlin, M | 9 |
| Si, K | 2 |
| Wei, C | 1 |
| Hsu, CM | 1 |
| Hsu, CC | 3 |
| Wu, RW | 1 |
| Huang, CC | 1 |
| Sawada, S | 1 |
| Kajiyama, K | 1 |
| Shida, H | 1 |
| Kimura, R | 1 |
| Nakazato, Y | 1 |
| Iguchi, T | 1 |
| Oniyama, Y | 1 |
| Ishiguro, C | 1 |
| Uyama, Y | 1 |
| Kim, J | 1 |
| Ghang, B | 1 |
| Jeong, W | 1 |
| Shi, C | 1 |
| Zhou, Z | 7 |
| Chi, X | 1 |
| Xiu, S | 1 |
| Yi, C | 1 |
| Jiang, Z | 1 |
| Yilmaz, F | 1 |
| Acikalin, MF | 1 |
| Kasifoglu, T | 1 |
| Cohen-Rosenblum, AR | 1 |
| Somogyi, JR | 1 |
| Hynes, KK | 1 |
| Guevara, ME | 1 |
| Roddy, E | 21 |
| Ellis, B | 1 |
| Norton, S | 1 |
| Douiri, A | 1 |
| Gulliford, MC | 1 |
| Cope, AP | 1 |
| Satpanich, P | 4 |
| Robinson, PC | 14 |
| Hishe, HZ | 3 |
| Yang, N | 3 |
| Cao, B | 3 |
| Miyazaki, S | 3 |
| Hamada, T | 4 |
| Isoyama, T | 3 |
| Okada, S | 4 |
| Tomita, K | 4 |
| Endo, Y | 3 |
| Sugihara, S | 3 |
| Ogino, K | 5 |
| Yamamoto, K | 7 |
| Takenaka, A | 3 |
| Ul-Haq, A | 3 |
| Lee, KA | 3 |
| Seo, H | 3 |
| Kim, S | 4 |
| Jo, S | 3 |
| Ko, KM | 3 |
| Moon, SJ | 4 |
| Kim, YS | 3 |
| Choi, JR | 4 |
| Song, HY | 3 |
| Kim, HS | 4 |
| Zhao, LJ | 3 |
| Gao, HY | 3 |
| Gao, C | 3 |
| Li, XF | 3 |
| Elsaid, K | 3 |
| Rossitto, LA | 3 |
| Karsh, J | 3 |
| Miner, M | 3 |
| Cadzow, M | 16 |
| Dambruoso, TJ | 3 |
| Höglund, J | 3 |
| Ghassemian, M | 3 |
| Campeau, A | 3 |
| Maltez, N | 3 |
| Karlsson, NG | 3 |
| Gonzalez, DJ | 3 |
| Zhou, M | 7 |
| Liu, C | 7 |
| Qian, J | 3 |
| Hao, K | 3 |
| Jiang, C | 3 |
| Hu, Q | 6 |
| Xu, Q | 4 |
| Lin, CS | 3 |
| Galvão, I | 10 |
| Mastrippolito, D | 2 |
| Talamini, L | 2 |
| Aganetti, M | 2 |
| Rocha, V | 2 |
| Verdot, C | 2 |
| Mendes, V | 2 |
| de Oliveira, VLS | 2 |
| Braga, AD | 2 |
| Martins, VD | 2 |
| de Faria, AMC | 2 |
| Amaral, FA | 10 |
| Georgel, P | 3 |
| Vieira, AT | 5 |
| Muller, S | 7 |
| Lei, Y | 2 |
| Cui, TJ | 2 |
| Wang, XH | 2 |
| Zhang, XM | 2 |
| Tang, C | 3 |
| Zheng, ZH | 2 |
| Tu, Y | 2 |
| Du, J | 4 |
| Yu, D | 2 |
| He, P | 2 |
| Xu, J | 3 |
| Hui, R | 1 |
| Xing, Y | 1 |
| Shi, S | 2 |
| Jarraya, M | 1 |
| Roemer, F | 1 |
| Kwoh, CK | 1 |
| Guermazi, A | 1 |
| Linnerz, T | 1 |
| Sung, YJ | 1 |
| Rolland, L | 1 |
| Astin, JW | 2 |
| Hall, CJ | 2 |
| Saffarzadeh, M | 1 |
| Haydar, SMA | 1 |
| Shojania, K | 3 |
| Ouellette, H | 3 |
| Nicolaou, S | 8 |
| Murray, N | 1 |
| Wu, H | 10 |
| Ren, Z | 1 |
| Huang, J | 3 |
| Lin, Z | 3 |
| Zhong, X | 1 |
| Xia, H | 1 |
| Zhao, M | 2 |
| Guo, X | 2 |
| Schauer, C | 3 |
| Schoen, J | 1 |
| Lu, C | 1 |
| Herrmann, M | 5 |
| Lv, Z | 1 |
| Cui, J | 1 |
| Wang, JX | 1 |
| Fonseca, AC | 1 |
| Spragg, JCJ | 1 |
| Michael, TJF | 1 |
| Aslani, P | 1 |
| Tan, H | 1 |
| Zhang, S | 3 |
| Yang, DH | 1 |
| da Silva-Júnior, EF | 1 |
| Xu, S | 3 |
| Wu, X | 9 |
| You, C | 1 |
| Mirzaesmaeili, A | 1 |
| Zangiabadi, S | 1 |
| Raspanti, J | 1 |
| Akram, A | 1 |
| Inman, RD | 1 |
| Abdul-Sater, AA | 1 |
| Ohashi, Y | 1 |
| Toyoda, M | 1 |
| Saito, N | 1 |
| Koizumi, M | 1 |
| Kanai, G | 1 |
| Komaba, H | 1 |
| Kimura, M | 2 |
| Wada, T | 1 |
| Takahashi, H | 2 |
| Takahashi, Y | 1 |
| Ishida, N | 1 |
| Kakuta, T | 1 |
| Fukagawa, M | 1 |
| Min, J | 3 |
| Shin, S | 2 |
| Prest, M | 1 |
| Li, W | 3 |
| Han, Y | 5 |
| Yan, C | 1 |
| Wu, Q | 1 |
| Zeng, H | 1 |
| Wan, A | 1 |
| Luo, C | 1 |
| Tao, J | 1 |
| Zhong, H | 3 |
| Huang, Z | 2 |
| Zou, B | 1 |
| Zou, G | 1 |
| Xie, N | 1 |
| Liang, Y | 2 |
| Chen, W | 3 |
| Mei, L | 1 |
| Yang, Z | 3 |
| Gao, K | 1 |
| Huang, H | 2 |
| Huang, R | 2 |
| Chen, LC | 1 |
| Chen, YJ | 1 |
| Lin, HA | 1 |
| Chien, WC | 1 |
| Tsai, KJ | 1 |
| Chung, CH | 1 |
| Wang, JY | 2 |
| Chen, CC | 2 |
| Liao, NS | 1 |
| Shih, CT | 1 |
| Lin, YY | 1 |
| Huang, CN | 2 |
| Ojcius, DM | 1 |
| Huang, KY | 1 |
| Lin, HC | 2 |
| Fan, Y | 4 |
| Mou, X | 1 |
| Qing, Y | 1 |
| Yan, X | 2 |
| Tang, X | 3 |
| Yue, W | 1 |
| Gu, P | 1 |
| Wen, YF | 1 |
| Culhane-Pera, KA | 1 |
| Pergament, SL | 1 |
| Moua, Y | 1 |
| Vue, B | 1 |
| Yang, T | 1 |
| Lo, M | 1 |
| Knights, D | 1 |
| Straka, RJ | 1 |
| Xiao, C | 1 |
| Cui, H | 1 |
| Yan, P | 1 |
| Tang, M | 2 |
| Zou, Y | 2 |
| Alfredsson, L | 1 |
| Klareskog, L | 1 |
| Jin, XF | 1 |
| Zou, JM | 1 |
| Lai, SW | 4 |
| Liao, KF | 4 |
| Kuo, YH | 3 |
| Hwang, BF | 1 |
| Liu, CS | 1 |
| Kohagura, K | 1 |
| Kou, J | 1 |
| Dang, W | 2 |
| Xu, D | 5 |
| You, L | 1 |
| Zhu, F | 1 |
| Kim, MY | 1 |
| Bang, E | 1 |
| Hwangbo, H | 1 |
| Ji, SY | 1 |
| Kim, DH | 1 |
| Park, C | 1 |
| Hong, SH | 1 |
| Kim, GY | 1 |
| Choi, YH | 1 |
| Butt, JH | 1 |
| Docherty, KF | 1 |
| Claggett, BL | 1 |
| Desai, AS | 1 |
| Petersson, M | 1 |
| Langkilde, AM | 1 |
| de Boer, RA | 1 |
| Hernandez, AF | 1 |
| Inzucchi, SE | 1 |
| Kosiborod, MN | 1 |
| Køber, L | 1 |
| Lam, CSP | 1 |
| Martinez, FA | 1 |
| Ponikowski, P | 1 |
| Sabatine, MS | 1 |
| Shah, SJ | 1 |
| Vaduganathan, M | 1 |
| Jhund, PS | 1 |
| Solomon, SD | 1 |
| McMurray, JJV | 2 |
| Lekpa, FK | 1 |
| Bebey, FS | 1 |
| Bouallo, I | 1 |
| Njonnou, SRS | 1 |
| Luma, HN | 1 |
| Singwe-Ngandeu, M | 1 |
| Choukem, SP | 1 |
| Klück, V | 3 |
| Cabău, G | 1 |
| Mies, L | 1 |
| Bukkems, F | 1 |
| van Emst, L | 1 |
| Bakker, R | 1 |
| van Caam, A | 1 |
| Crişan, TO | 8 |
| Joosten, LAB | 6 |
| Teramura, S | 1 |
| Yamagishi, K | 2 |
| Umesawa, M | 1 |
| Hayama-Terada, M | 1 |
| Muraki, I | 1 |
| Maruyama, K | 1 |
| Tanaka, M | 1 |
| Kishida, R | 1 |
| Kihara, T | 1 |
| Takada, M | 1 |
| Ohira, T | 1 |
| Imano, H | 1 |
| Shimizu, Y | 1 |
| Sankai, T | 1 |
| Okada, T | 1 |
| Kitamura, A | 2 |
| Kiyama, M | 1 |
| Iso, H | 2 |
| Yerima, A | 1 |
| Sulaiman, MM | 1 |
| Adamu, AA | 1 |
| Kawada, T | 1 |
| Lane, NE | 2 |
| Lyu, H | 1 |
| Zeng, C | 2 |
| Lei, G | 1 |
| Provan, SA | 1 |
| Ruíz-Dávila, X | 1 |
| Yoshida, K | 1 |
| Desai, RJ | 2 |
| Solomon, DH | 5 |
| Gebreselassie, KZ | 1 |
| Valancius, D | 1 |
| Ranic, LM | 1 |
| Kligora, C | 1 |
| Nørup, A | 1 |
| Ellingsen, TJ | 1 |
| Wu, M | 6 |
| Lu, T | 1 |
| Lu, H | 1 |
| Gong, S | 1 |
| Zheng, Z | 1 |
| Hu, J | 2 |
| Moshkovits, Y | 1 |
| Goldman, A | 1 |
| Chetrit, A | 1 |
| Dankner, R | 1 |
| Ofanoa, S | 1 |
| Jansen, RM | 1 |
| Tao, H | 1 |
| Mo, Y | 1 |
| Yip, RM | 1 |
| Cheung, TT | 2 |
| So, H | 1 |
| Chan, JP | 1 |
| Ho, CT | 2 |
| Tsang, HH | 1 |
| Yu, CK | 1 |
| Wong, PC | 1 |
| Rashad, AY | 1 |
| Daabees, HG | 1 |
| Elagawany, M | 1 |
| Shahin, M | 1 |
| Abdel Moneim, AE | 1 |
| Rostom, SAF | 1 |
| Joshi, AD | 2 |
| Yu, B | 1 |
| Eliassen, AH | 1 |
| Curhan, GC | 2 |
| Raffield, LM | 3 |
| Bao, D | 1 |
| Lv, N | 1 |
| Duan, X | 1 |
| Zhao, MH | 1 |
| Hou, T | 1 |
| Dai, H | 2 |
| Hou, Y | 1 |
| Lin, H | 3 |
| Zhao, Z | 2 |
| Gu, Y | 1 |
| Zheng, J | 1 |
| Bi, Y | 1 |
| Ning, G | 1 |
| Xu, M | 1 |
| Wang, G | 3 |
| Zhuo, N | 2 |
| Yan, D | 1 |
| den Broeder, AA | 1 |
| den Broeder, N | 1 |
| Oberhofer, E | 1 |
| Lu, N | 4 |
| Tanikella, S | 1 |
| Lin, K | 1 |
| Warner, E | 1 |
| Merriman, T | 7 |
| Hsu, J | 1 |
| Xie, R | 1 |
| Dai, Q | 1 |
| Fang, J | 2 |
| Cherny, K | 1 |
| Marder, BA | 1 |
| Scandling, JD | 1 |
| Zheng, WY | 1 |
| Zhan, WF | 1 |
| Deng, WM | 1 |
| Hung, YK | 1 |
| Jiang, GH | 1 |
| Tong, Y | 1 |
| Wei, Y | 4 |
| Ju, Y | 1 |
| Gao, L | 3 |
| Luo, Y | 2 |
| Koike, R | 1 |
| Kawakami, Y | 1 |
| Kondo, R | 1 |
| Onishi, M | 1 |
| Akiyama, M | 3 |
| Asai, T | 1 |
| Arai, H | 1 |
| Fu, N | 1 |
| Quan, J | 1 |
| Shu, P | 1 |
| Kim, JS | 3 |
| Jiao, Z | 1 |
| Charoenwutthikun, S | 1 |
| Chanjitwiriya, K | 1 |
| Roytrakul, S | 1 |
| Kunthalert, D | 1 |
| Du, K | 1 |
| Mo, C | 1 |
| Dong, W | 1 |
| Wei, N | 1 |
| Zhong, W | 2 |
| You, Y | 2 |
| Di Fusco, SA | 1 |
| Castello, L | 1 |
| Marino, G | 1 |
| Flori, M | 1 |
| Aquilani, S | 1 |
| Riccio, C | 1 |
| Nardi, F | 1 |
| Gulizia, MM | 1 |
| Gabrielli, D | 1 |
| Oliva, F | 1 |
| Colivicchi, F | 1 |
| Kang, SH | 1 |
| Kim, BY | 1 |
| Son, EJ | 1 |
| Kim, GO | 1 |
| Do, JY | 1 |
| Popov, D | 1 |
| Jain, L | 1 |
| Poulsen, RC | 1 |
| Kwok, TSH | 2 |
| Kuriya, B | 1 |
| Hawker, G | 1 |
| Choy, G | 2 |
| Widdifield, J | 1 |
| Holbrook, HS | 1 |
| Calandruccio, JH | 1 |
| Meng, Y | 3 |
| Qi, Z | 1 |
| Niu, Y | 2 |
| Yuan, Z | 2 |
| He, G | 1 |
| Yu, M | 1 |
| Moon, KW | 4 |
| Kim, MJ | 5 |
| Shin, K | 4 |
| Ueda, M | 1 |
| Fukui, K | 1 |
| Kamatani, N | 22 |
| Kamitsuji, S | 1 |
| Matsuo, A | 1 |
| Sasase, T | 1 |
| Nishiu, J | 1 |
| Matsushita, M | 1 |
| Peng, J | 2 |
| Wu, Y | 4 |
| Ye, Z | 4 |
| Zong, Z | 1 |
| Wu, R | 2 |
| Kutlubaev, MA | 1 |
| Areprintseva, DK | 1 |
| Pervushina, EV | 1 |
| Song, D | 2 |
| Yue, T | 1 |
| Xia, T | 1 |
| Nehme, R | 1 |
| Nahas, PC | 1 |
| de Oliveira, EP | 1 |
| Kilimci, U | 1 |
| Uygun, DA | 1 |
| Bajad, S | 1 |
| Tanna, D | 1 |
| Durga Rao Yadavalli, JN | 1 |
| Gupta, R | 2 |
| Sheu, KL | 1 |
| Chen, SC | 1 |
| Zhang, Q | 6 |
| Li, N | 1 |
| Guo, R | 1 |
| Doğan, İ | 1 |
| Kor, A | 1 |
| Güven, SC | 1 |
| Fırat Oğuz, E | 1 |
| Başer, S | 1 |
| Atalar, E | 1 |
| Maraş, Y | 1 |
| Erel, Ö | 1 |
| Erten, Ş | 1 |
| So, MW | 4 |
| Kim, AR | 1 |
| Lee, SG | 4 |
| Meng, S | 1 |
| Zhao, H | 2 |
| Di, H | 1 |
| Yin, Y | 3 |
| Niessink, T | 1 |
| Giesen, T | 1 |
| Efdé, M | 1 |
| Comarniceanu, A | 1 |
| Otto, C | 1 |
| Hua, Q | 1 |
| Lin, Y | 1 |
| Zheng, K | 1 |
| Xia, A | 1 |
| Lv, L | 1 |
| Jiang, H | 1 |
| Zhou, X | 1 |
| Zeng, M | 4 |
| Ma, S | 2 |
| An, J | 1 |
| Grelska, A | 1 |
| Sharan, D | 1 |
| Light, SH | 1 |
| Wang, YY | 2 |
| Wang, N | 2 |
| Zhang, TJ | 1 |
| Jiang, YG | 1 |
| He, N | 2 |
| Zhao, GM | 1 |
| Wexler, DJ | 1 |
| Aviña-Zubieta, JA | 1 |
| De Vera, MA | 3 |
| Tong, J | 1 |
| Liao, Z | 1 |
| Jiang, M | 4 |
| Kannuthurai, V | 1 |
| Lin, TM | 1 |
| Lee, HY | 1 |
| Chang, CK | 1 |
| Lin, KH | 2 |
| Chang, CC | 1 |
| Wu, BF | 1 |
| Peng, SJ | 1 |
| Jarman, JB | 1 |
| Low, YS | 1 |
| Augustijn, HE | 1 |
| Huang, S | 4 |
| DeFeo, ME | 1 |
| Sekiba, K | 1 |
| Hou, BH | 1 |
| Meng, X | 3 |
| Weakley, AM | 1 |
| Cabrera, AV | 1 |
| van Wezel, G | 1 |
| Medema, MH | 1 |
| Ganesan, C | 1 |
| Pao, AC | 1 |
| Gombar, S | 1 |
| Dodd, D | 1 |
| Jia, Z | 5 |
| Dong, JF | 1 |
| Yan, WJ | 1 |
| Feng, XX | 1 |
| Li, LS | 1 |
| Cheng, W | 1 |
| Sun, CS | 1 |
| Li, CR | 1 |
| Deng, H | 1 |
| Cheng, N | 1 |
| Song, C | 1 |
| Sun, Y | 3 |
| Hou, Z | 2 |
| Yin, J | 1 |
| Meng, Q | 1 |
| Qin, H | 1 |
| Husain, H | 1 |
| Shah, V | 2 |
| Bankole, A | 1 |
| Martinez-Laguna, D | 1 |
| Estebanez, JL | 1 |
| Aivar, M | 1 |
| Gayarre, R | 1 |
| Conesa, A | 1 |
| Hoyo, J | 1 |
| Carbonell, C | 1 |
| Reyes, C | 1 |
| Zhu, XX | 3 |
| Zou, HJ | 3 |
| Stamp, L | 9 |
| Chapman, PT | 16 |
| Lee, JJ | 1 |
| Han, F | 1 |
| Yu, C | 1 |
| Hu, F | 1 |
| Zhou, W | 2 |
| Bao, H | 1 |
| Peng, X | 1 |
| Xie, B | 1 |
| Lai, Y | 1 |
| Sosnik, A | 1 |
| Boucetta, H | 1 |
| Castilla-Ojo, N | 1 |
| Turkson-Ocran, RA | 1 |
| Conlin, PR | 1 |
| Appel, LJ | 5 |
| Miller, ER | 6 |
| Wani, SK | 1 |
| Bhat, MDA | 1 |
| Malik, R | 1 |
| Seo, C | 1 |
| Pak, H | 1 |
| Lim, H | 1 |
| Gu, H | 1 |
| Qin, L | 1 |
| Zhao, D | 7 |
| Xue, W | 1 |
| Ai, Z | 1 |
| Xu, B | 1 |
| Peng, A | 1 |
| Calabuig, I | 3 |
| Marty-Ané, A | 2 |
| Norberciak, L | 7 |
| Legrand, J | 6 |
| Martínez-Sanchis, A | 1 |
| Bajpai, R | 1 |
| Forrester, H | 1 |
| Partington, RJ | 1 |
| Mallen, CD | 6 |
| Clarson, LE | 1 |
| Padmanabhan, N | 1 |
| Whittle, R | 3 |
| Zhang, WZ | 1 |
| Andres Cerezo, L | 1 |
| Navrátilová, A | 1 |
| Hulejová, H | 1 |
| Pavlíková, M | 3 |
| Závada, J | 4 |
| Pavelka, K | 6 |
| Šenolt, L | 1 |
| Stiburkova, B | 6 |
| Yamaguchi, A | 1 |
| Mukai, Y | 1 |
| Sakuma, T | 1 |
| Suganuma, Y | 1 |
| Furugen, A | 1 |
| Narumi, K | 1 |
| Kobayashi, M | 1 |
| Aoki, Y | 1 |
| Mizuta, E | 3 |
| Ouchi, M | 4 |
| Kurajoh, M | 2 |
| Maruhashi, T | 1 |
| Tanaka, A | 2 |
| Morikawa, N | 1 |
| Nishimiya, K | 1 |
| Akashi, N | 1 |
| Tanaka, Y | 2 |
| Otani, N | 3 |
| Morita, M | 1 |
| Miyata, H | 1 |
| Takada, T | 14 |
| Tsutani, H | 2 |
| Abe, K | 1 |
| Shimizu, M | 2 |
| Naito, R | 1 |
| Sato, A | 1 |
| Ishiwata, S | 1 |
| Yatsu, S | 1 |
| Shitara, J | 1 |
| Matsumoto, H | 3 |
| Murata, A | 1 |
| Kato, T | 1 |
| Suda, S | 1 |
| Hiki, M | 1 |
| Murase, T | 1 |
| Kasai, T | 1 |
| Yu, LL | 1 |
| Li, CN | 1 |
| Fang, MY | 1 |
| Wang, B | 4 |
| Lin, FP | 1 |
| Liu, WH | 2 |
| Tu, SH | 1 |
| Xie, WX | 1 |
| Zhang, RY | 1 |
| Zheng, CH | 1 |
| Qin, M | 1 |
| Nabrdalik, K | 1 |
| Lip, GYH | 1 |
| Laurent, V | 1 |
| Jauffret, C | 1 |
| Pacaud, A | 1 |
| Ducoulombier, V | 7 |
| Verdun, S | 1 |
| Hao, P | 1 |
| Ward, R | 1 |
| Tang, T | 1 |
| Luo, G | 1 |
| Xiang, C | 1 |
| An, S | 1 |
| Xu, TR | 1 |
| Bian, W | 1 |
| Peng, Y | 2 |
| Ru, Z | 1 |
| Fu, Z | 1 |
| Do, H | 1 |
| Choi, HJ | 2 |
| Choi, B | 1 |
| Son, CN | 4 |
| Choi, SR | 1 |
| Kim, HO | 2 |
| Song, R | 1 |
| Lee, SW | 5 |
| Ahn, JK | 1 |
| Lee, CH | 5 |
| Son, KM | 1 |
| Finnikin, S | 1 |
| Kvasnička, A | 1 |
| Friedecký, D | 1 |
| Brumarová, R | 1 |
| Pavelcová, K | 3 |
| Mašínová, J | 1 |
| Hasíková, L | 1 |
| Ješina, P | 1 |
| Li, D | 2 |
| Yuan, S | 1 |
| Ouyang, J | 1 |
| Lin, D | 1 |
| Quan, H | 2 |
| Fu, X | 1 |
| Mao, W | 1 |
| Bychkov, ОА | 1 |
| Kondratiuk, VE | 1 |
| Bychkova, NG | 1 |
| Morozova, ZV | 1 |
| Bychkova, SA | 1 |
| Tarasiuk, AP | 1 |
| Berrocal, V | 1 |
| An, L | 1 |
| Khanna, D | 9 |
| Hilsabeck, TA | 1 |
| Sharma, A | 1 |
| Brackman, DJ | 1 |
| Watson, MA | 1 |
| Killilea, DW | 1 |
| Ho, S | 1 |
| Kahn, A | 1 |
| Giacomini, K | 1 |
| Stoller, ML | 2 |
| Chi, T | 1 |
| Yang, S | 4 |
| Teramoto, K | 1 |
| Takeda, T | 1 |
| Matsumura, Y | 1 |
| Ohtahara, A | 2 |
| Kondoh, H | 1 |
| Barclay, M | 4 |
| Kwong, JS | 1 |
| Chung, SC | 1 |
| Shah, A | 2 |
| An, Z | 1 |
| Hemingway, H | 1 |
| Tian, H | 1 |
| Ou, G | 2 |
| Yeo, C | 1 |
| Kaushal, S | 1 |
| Lim, B | 1 |
| Syn, N | 1 |
| Oo, AM | 1 |
| Rao, J | 1 |
| Koura, A | 1 |
| Yeo, D | 1 |
| Fini, MA | 1 |
| Stenmark, KR | 1 |
| Ankli, B | 2 |
| Berger, CT | 2 |
| Haeni, N | 1 |
| Kyburz, D | 2 |
| Hügle, T | 2 |
| So, AK | 3 |
| Daikeler, T | 2 |
| Chapman, P | 3 |
| Hudson, B | 1 |
| Hamilton, G | 1 |
| Judd, A | 1 |
| Liang, N | 1 |
| Sun, R | 3 |
| Zhuo, Y | 1 |
| Cai, X | 1 |
| Kösekahya, P | 2 |
| Üçgül Atılgan, C | 1 |
| Atılgan, KG | 2 |
| Koç, M | 2 |
| Tekin, K | 2 |
| Çağlayan, M | 2 |
| Göker, YŞ | 1 |
| Gamala, M | 4 |
| Jacobs, JWG | 4 |
| Linn-Rasker, SF | 1 |
| Nix, M | 2 |
| Heggelman, BGF | 2 |
| Pasker-de Jong, PCM | 2 |
| van Laar, JM | 3 |
| Klaasen, R | 3 |
| Klauser, AS | 3 |
| Halpern, EJ | 2 |
| Strobl, S | 1 |
| Gruber, J | 3 |
| Feuchtner, G | 1 |
| Bellmann-Weiler, R | 1 |
| Weiss, G | 1 |
| Stofferin, H | 1 |
| Jaschke, W | 1 |
| Singh, AK | 1 |
| Haque, M | 1 |
| O'Sullivan, K | 1 |
| Chourasia, M | 1 |
| Ouseph, MM | 1 |
| Ahmed, S | 3 |
| Zhou, S | 1 |
| Zhong, Y | 1 |
| Yang, H | 5 |
| Nipate, SS | 1 |
| Yelmar, PS | 1 |
| Ha, YJ | 2 |
| Chung, SW | 1 |
| Lee, JH | 3 |
| Kang, EH | 2 |
| Lee, YJ | 2 |
| Song, YW | 3 |
| Chung, TT | 1 |
| Yu, KH | 6 |
| Kuo, CF | 5 |
| Luo, SF | 5 |
| Chiou, MJ | 1 |
| Lan, WC | 1 |
| Chen, JS | 2 |
| Tseng, WY | 3 |
| Hsieh, AH | 2 |
| Wang, LC | 1 |
| Khanna, PP | 5 |
| Matsuo, H | 17 |
| Collison, J | 1 |
| Marten, J | 1 |
| Wuttke, M | 1 |
| Kirsten, H | 1 |
| Sieber, KB | 1 |
| Qiu, C | 1 |
| Gorski, M | 1 |
| Giri, A | 1 |
| Sveinbjornsson, G | 1 |
| Chu, AY | 1 |
| O'Connor, LJ | 1 |
| Prins, B | 1 |
| Nutile, T | 2 |
| Noce, D | 1 |
| Cocca, M | 1 |
| van der Most, PJ | 1 |
| Horn, K | 1 |
| Fuchsberger, C | 1 |
| Afaq, S | 1 |
| Amin, N | 1 |
| Bakker, SJL | 1 |
| Bansal, N | 1 |
| Baptista, D | 1 |
| Bergmann, S | 2 |
| Biggs, ML | 1 |
| Biino, G | 1 |
| Boerwinkle, E | 5 |
| Bottinger, EP | 1 |
| Boutin, TS | 1 |
| Brumat, M | 1 |
| Burkhardt, R | 1 |
| Campana, E | 1 |
| Campbell, A | 1 |
| Campbell, H | 8 |
| Carroll, RJ | 1 |
| Catamo, E | 1 |
| Chambers, JC | 2 |
| Ciullo, M | 3 |
| Concas, MP | 2 |
| Cusi, D | 1 |
| Felicita, SC | 1 |
| de Borst, MH | 1 |
| De Grandi, A | 1 |
| de Mutsert, R | 1 |
| de Vries, APJ | 1 |
| Delgado, G | 1 |
| Demirkan, A | 2 |
| Devuyst, O | 4 |
| Dittrich, K | 1 |
| Ehret, G | 1 |
| Evans, MK | 2 |
| Gansevoort, RT | 1 |
| Gasparini, P | 3 |
| Giedraitis, V | 1 |
| Girotto, G | 1 |
| Gögele, M | 1 |
| Gordon, SD | 1 |
| Gudbjartsson, DF | 3 |
| Gudnason, V | 4 |
| Haller, T | 3 |
| Hamet, P | 1 |
| Harris, TB | 3 |
| Hayward, C | 4 |
| Hicks, AA | 3 |
| Hofer, E | 1 |
| Holm, H | 3 |
| Huang, W | 6 |
| Hutri-Kähönen, N | 1 |
| Ikram, MA | 1 |
| Lewis, RM | 2 |
| Ingelsson, E | 1 |
| Jakobsdottir, J | 1 |
| Jonsdottir, I | 2 |
| Jonsson, H | 3 |
| Joshi, PK | 1 |
| Josyula, NS | 1 |
| Jung, B | 1 |
| Kähönen, M | 2 |
| Kamatani, Y | 3 |
| Kanai, M | 2 |
| Kerr, SM | 1 |
| Kiess, W | 1 |
| Körner, A | 1 |
| Kovacs, P | 1 |
| Krämer, BK | 1 |
| Kubo, M | 6 |
| La Bianca, M | 1 |
| Lange, LA | 1 |
| Lehne, B | 1 |
| Loeffler, M | 1 |
| Loos, RJF | 1 |
| Lyytikäinen, LP | 1 |
| Magi, R | 2 |
| Mahajan, A | 1 |
| Martin, NG | 2 |
| Mascalzoni, D | 1 |
| Matsuda, K | 2 |
| Meisinger, C | 2 |
| Meitinger, T | 3 |
| Metspalu, A | 3 |
| Milaneschi, Y | 1 |
| O'Donnell, CJ | 2 |
| Wilson, OD | 1 |
| Mohlke, KL | 1 |
| Mononen, N | 1 |
| Montgomery, GW | 3 |
| Mook-Kanamori, DO | 1 |
| Müller-Nurasyid, M | 1 |
| Nadkarni, GN | 1 |
| Nalls, MA | 3 |
| Nikus, K | 1 |
| Ning, B | 1 |
| Nolte, IM | 3 |
| Noordam, R | 1 |
| O'Connell, JR | 1 |
| Olafsson, I | 2 |
| Padmanabhan, S | 1 |
| Penninx, BWJH | 1 |
| Perls, T | 1 |
| Pirastu, M | 4 |
| Pirastu, N | 3 |
| Pistis, G | 3 |
| Polasek, O | 4 |
| Ponte, B | 1 |
| Porteous, DJ | 1 |
| Poulain, T | 1 |
| Preuss, MH | 1 |
| Rabelink, TJ | 1 |
| Rettig, R | 1 |
| Rheinberger, M | 1 |
| Rice, KM | 1 |
| Rizzi, F | 1 |
| Robino, A | 1 |
| Rudan, I | 6 |
| Krajcoviechova, A | 1 |
| Cifkova, R | 1 |
| Rueedi, R | 1 |
| Ruggiero, D | 3 |
| Ryan, KA | 1 |
| Saba, Y | 1 |
| Salvi, E | 1 |
| Schmidt, H | 2 |
| Schmidt, R | 2 |
| Shaffer, CM | 1 |
| Smith, AV | 4 |
| Smith, BH | 1 |
| Spracklen, CN | 1 |
| Strauch, K | 3 |
| Stumvoll, M | 2 |
| Sulem, P | 3 |
| Tajuddin, SM | 1 |
| Teren, A | 1 |
| Thiery, J | 1 |
| Thorsteinsdottir, U | 3 |
| Toniolo, D | 3 |
| Tönjes, A | 2 |
| Tremblay, J | 1 |
| Uitterlinden, AG | 4 |
| Vaccargiu, S | 1 |
| van der Harst, P | 2 |
| van Duijn, CM | 5 |
| Verweij, N | 1 |
| Vollenweider, P | 5 |
| Waeber, G | 5 |
| Whitfield, JB | 3 |
| Wild, SH | 4 |
| Wilson, JF | 5 |
| Zonderman, AB | 2 |
| Wilson, JG | 1 |
| Pendergrass, SA | 1 |
| Ho, K | 1 |
| Parsa, A | 2 |
| Pramstaller, PP | 3 |
| Böger, CA | 1 |
| Butterworth, AS | 1 |
| Okada, Y | 6 |
| Edwards, TL | 1 |
| Stefansson, K | 3 |
| Scholz, M | 1 |
| Heid, IM | 1 |
| Hung, AM | 1 |
| Pattaro, C | 1 |
| Vitart, V | 5 |
| Drabkin, M | 1 |
| Yogev, Y | 1 |
| Zeller, L | 1 |
| Zarivach, R | 1 |
| Zalk, R | 1 |
| Halperin, D | 1 |
| Wormser, O | 1 |
| Gurevich, E | 1 |
| Landau, D | 1 |
| Kadir, R | 1 |
| Perez, Y | 1 |
| Birk, OS | 1 |
| Teh, CL | 1 |
| Cheong, YK | 1 |
| Wan, SA | 1 |
| Ling, GR | 1 |
| Fautrel, B | 1 |
| Belhassen, M | 1 |
| Hudry, C | 1 |
| Woronoff-Lemsi, MC | 1 |
| Levy-Bachelot, L | 1 |
| Van Ganse, E | 1 |
| Tubach, F | 3 |
| Stack, AG | 4 |
| Karra Gurunath, R | 1 |
| García de Yébenes, MJ | 1 |
| Carmona, L | 8 |
| Narang, RK | 5 |
| Vincent, Z | 1 |
| Palazzuoli, A | 1 |
| Landolfo, M | 2 |
| Cosentino, E | 1 |
| Sano, T | 3 |
| Sasaki, T | 6 |
| Fushimi, M | 4 |
| Ohashi, T | 8 |
| Kuriyama, S | 1 |
| Chua, CKT | 1 |
| Cheung, PP | 1 |
| Santosa, A | 2 |
| Lim, AYN | 2 |
| Teng, GG | 4 |
| Wilkinson, SL | 1 |
| Divers, SJ | 1 |
| Bo, X | 1 |
| Pak, OS | 1 |
| Tu, J | 1 |
| Kogan, A | 1 |
| Hsiai, TK | 1 |
| Gao, W | 4 |
| Yang, BY | 1 |
| Yu, HX | 1 |
| Song, XX | 1 |
| Higashino, T | 5 |
| Morimoto, K | 3 |
| Nakaoka, H | 5 |
| Toyoda, Y | 3 |
| Kawamura, Y | 8 |
| Shimizu, S | 12 |
| Hosomichi, K | 2 |
| Nakayama, A | 13 |
| Ooyama, K | 2 |
| Ooyama, H | 6 |
| Shimizu, T | 13 |
| Ueno, M | 1 |
| Ito, T | 2 |
| Tamura, T | 3 |
| Naito, M | 8 |
| Nakashima, H | 9 |
| Kawaguchi, M | 4 |
| Takao, M | 3 |
| Kawai, Y | 3 |
| Osada, N | 1 |
| Suzuki, H | 8 |
| Shinomiya, N | 13 |
| Inoue, I | 4 |
| Tallon, A | 1 |
| Jadhav, PP | 1 |
| Walrabenstein, W | 1 |
| Heslinga, M | 1 |
| de Vries, R | 1 |
| Nurmohamed, M | 1 |
| van Schaardenburg, D | 1 |
| Gerritsen, M | 5 |
| Parashar, P | 2 |
| Mazhar, I | 1 |
| Kanoujia, J | 2 |
| Yadav, A | 1 |
| Kumar, P | 2 |
| Saraf, SA | 3 |
| Saha, S | 1 |
| Shi, D | 2 |
| Chen, JY | 1 |
| Wu, HX | 2 |
| Zhou, QJ | 2 |
| Chen, HY | 2 |
| Lu, YF | 1 |
| Yu, RS | 2 |
| Guo, G | 1 |
| Dong, C | 1 |
| Yin, R | 3 |
| Zhao, R | 2 |
| Guo, J | 2 |
| Lu, G | 1 |
| Okui, D | 1 |
| Sumpter, NA | 3 |
| Reynolds, RJ | 6 |
| Yin, C | 2 |
| Liu, B | 7 |
| Zheng, X | 3 |
| Tai, Y | 2 |
| Duffull, SB | 2 |
| Gong, H | 1 |
| Liu, Q | 2 |
| Baima, Y | 1 |
| Ha, EH | 1 |
| Tian, S | 1 |
| Min, HK | 2 |
| Kim, HR | 1 |
| Leonardo, N | 1 |
| Lester, S | 2 |
| Whittle, S | 1 |
| Rischmueller, M | 2 |
| Brucato, A | 1 |
| Cianci, F | 1 |
| Carnovale, C | 1 |
| Lin, YJ | 1 |
| Lin, SY | 1 |
| Lin, CH | 2 |
| Wang, ST | 1 |
| Chang, SS | 1 |
| Furuno, K | 1 |
| Kanda, S | 1 |
| Boocock, J | 2 |
| Leask, M | 1 |
| Mandal, AK | 3 |
| Gosling, AL | 1 |
| Major, TJ | 8 |
| Horsfield, JA | 1 |
| Fadason, T | 1 |
| O'Sullivan, J | 1 |
| Stahl, EA | 3 |
| Zaidi, F | 1 |
| Gamble, GG | 1 |
| Riches, P | 4 |
| Kurreeman, F | 1 |
| Torres, RJ | 13 |
| Miner, JN | 12 |
| Dong, Z | 4 |
| Zhou, J | 6 |
| Jiang, S | 3 |
| He, H | 4 |
| Ji, H | 5 |
| Jin, L | 4 |
| Misawa, K | 1 |
| Hasegawa, T | 1 |
| Mishima, E | 1 |
| Jutabha, P | 2 |
| Kojima, K | 1 |
| Matsuo, M | 1 |
| Anzai, N | 7 |
| Nagasaki, M | 1 |
| Chen, ZY | 1 |
| Ye, LW | 1 |
| Liang, ZJ | 1 |
| Yu, T | 6 |
| Gao, J | 1 |
| Gamble, G | 5 |
| Phipps-Green, AJ | 9 |
| Tatsiy, O | 1 |
| Mayer, TZ | 1 |
| de Carvalho Oliveira, V | 1 |
| Sylvain-Prévost, S | 1 |
| Isabel, M | 1 |
| Dubois, CM | 1 |
| McDonald, PP | 1 |
| Xie, L | 1 |
| Feuchtner, GM | 1 |
| Ghoshhajra, B | 1 |
| Lianes, O | 1 |
| Nystad, TW | 1 |
| Røen, SA | 1 |
| Fevang, BS | 1 |
| Choi, SY | 1 |
| Choi, SW | 1 |
| Lee, S | 3 |
| Oh, JS | 3 |
| Lim, DH | 1 |
| Felten, R | 1 |
| Duret, PM | 1 |
| Gottenberg, JE | 1 |
| Spielmann, L | 1 |
| Messer, L | 1 |
| Lu, B | 1 |
| Lu, Q | 1 |
| Huang, B | 1 |
| Zheng, F | 1 |
| Ohnishi, J | 1 |
| Ishimaru, N | 1 |
| Seto, H | 1 |
| Kanzawa, Y | 1 |
| Kinami, S | 1 |
| Lu, X | 2 |
| Chi, H | 1 |
| Liao, E | 1 |
| Teng, D | 1 |
| Teng, X | 1 |
| Ba, J | 1 |
| He, L | 1 |
| Lai, X | 1 |
| Qin, G | 1 |
| Qin, Y | 1 |
| Shi, B | 1 |
| Sun, H | 3 |
| Tong, N | 1 |
| Zhang, JA | 1 |
| Yan, L | 1 |
| Yang, L | 2 |
| Zhu, M | 1 |
| Shan, Z | 1 |
| Teng, W | 1 |
| Day, R | 3 |
| Nguyen, A | 1 |
| Graham, G | 1 |
| Coleshill, M | 1 |
| Stocker, S | 2 |
| Mariotte, A | 1 |
| De Cauwer, A | 1 |
| Po, C | 1 |
| Abou-Faycal, C | 1 |
| Pichot, A | 1 |
| Paul, N | 1 |
| Aouadi, I | 1 |
| Carapito, R | 1 |
| Frisch, B | 1 |
| Macquin, C | 1 |
| Chatelus, E | 1 |
| Sibilia, J | 1 |
| Armspach, JP | 1 |
| Bahram, S | 1 |
| Roman, Y | 1 |
| Tiirikainen, M | 1 |
| Prom-Wormley, E | 1 |
| de Carvalho, RVH | 1 |
| Vago, JP | 2 |
| Silva, ALN | 1 |
| Carvalho, TG | 1 |
| Antunes, MM | 1 |
| Ribeiro, FM | 1 |
| Menezes, GB | 1 |
| Zamboni, DS | 2 |
| Sousa, LP | 4 |
| Teixeira, MM | 10 |
| van Deuren, RC | 1 |
| Cavalli, G | 1 |
| Shaukat, A | 1 |
| Arts, P | 1 |
| Cleophas, MC | 5 |
| Hindmarsh, JH | 4 |
| Steehouwer, M | 1 |
| Lelieveld, S | 1 |
| van de Vorst, M | 1 |
| Gilissen, C | 1 |
| Dagna, L | 1 |
| Van de Veerdonk, FL | 2 |
| Eisenmesser, EZ | 1 |
| Hoischen, A | 1 |
| Netea, MG | 5 |
| Dinarello, CA | 3 |
| Joosten, LA | 6 |
| Nguyen, AD | 3 |
| Robinson, P | 1 |
| Song, W | 2 |
| Ou, J | 2 |
| Wei, Q | 2 |
| Gu, J | 6 |
| Lv, Q | 3 |
| Tu, L | 1 |
| Qi, J | 1 |
| Qiu, M | 1 |
| Cao, S | 2 |
| Loh, K | 1 |
| Sharma, C | 1 |
| Keen, HI | 2 |
| Bavanendrakumar, M | 2 |
| Temmoku, J | 2 |
| Fujita, Y | 2 |
| Matsuoka, N | 2 |
| Urano, T | 1 |
| Furuya, MY | 1 |
| Asano, T | 2 |
| Sato, S | 3 |
| Watanabe, H | 2 |
| Kozuru, H | 1 |
| Yatsuhashi, H | 1 |
| Kawakami, A | 4 |
| Migita, K | 3 |
| Wrigley, R | 1 |
| Topless, RK | 4 |
| Harré Hindmarsh, J | 1 |
| Lawrence, A | 1 |
| Scott, S | 1 |
| Saparelli, F | 1 |
| Greville, G | 1 |
| Miller, A | 1 |
| Taylor, A | 1 |
| Gow, P | 7 |
| Lamb, KL | 1 |
| Lynn, A | 1 |
| Russell, J | 1 |
| Barker, ME | 1 |
| Pietsch, DEW | 1 |
| Kubler, P | 1 |
| Li, A | 1 |
| Zheng, S | 4 |
| Scuiller, A | 1 |
| Bernard, A | 1 |
| Oehler, E | 1 |
| Onuora, S | 1 |
| Xu, SQ | 1 |
| Zhang, WJ | 1 |
| Wu, W | 1 |
| Lv, Y | 3 |
| Bao, E | 1 |
| Kim, SJ | 2 |
| Kim, CH | 1 |
| Hong, F | 1 |
| Zheng, A | 1 |
| Xu, P | 2 |
| Xue, T | 1 |
| Dai, S | 1 |
| Xie, X | 3 |
| Qiao, X | 1 |
| Zhai, Y | 2 |
| Gustschin, A | 1 |
| Bodden, J | 1 |
| Meurer, F | 1 |
| Pfeiffer, F | 1 |
| Punzi, L | 18 |
| Medea, G | 2 |
| Kudo, H | 1 |
| Tsuruoka, S | 1 |
| Meier, R | 1 |
| di Gangi, S | 1 |
| Valeri, F | 1 |
| Rosemann, T | 1 |
| Zechmann, S | 1 |
| Jorge, A | 1 |
| D'Silva, K | 1 |
| Serling-Boyd, N | 1 |
| Matza, M | 1 |
| Nasrallah, M | 1 |
| Keller, S | 1 |
| Oza, A | 1 |
| Bolster, MB | 1 |
| Collier, D | 1 |
| Huang, YY | 1 |
| Gu, SW | 1 |
| Jiang, ZY | 1 |
| Yen, FS | 2 |
| Li, HL | 2 |
| Yang, CC | 1 |
| Hwu, CM | 2 |
| Tian, Y | 3 |
| Guo, C | 1 |
| Kamel, B | 3 |
| Graham, GG | 7 |
| Williams, KM | 7 |
| Carland, JE | 3 |
| Pile, KD | 2 |
| Carnicelli, AP | 1 |
| Clare, R | 1 |
| Chiswell, K | 1 |
| Lytle, B | 1 |
| Bjursell, M | 1 |
| Perl, S | 1 |
| Andersson, K | 1 |
| Hedman, K | 1 |
| Pagidipati, N | 1 |
| Vemulapalli, S | 1 |
| Roe, MT | 2 |
| Mentz, RJ | 1 |
| Keen, H | 3 |
| Bruyn, GAW | 1 |
| D'Agostino, MA | 1 |
| Sun, SS | 1 |
| Zhang, DH | 1 |
| Lin, CJ | 1 |
| Lin, JY | 1 |
| Hu, AM | 1 |
| Brown, JN | 1 |
| Bupparenoo, P | 1 |
| Pakchotanon, R | 1 |
| Narongroeknawin, P | 1 |
| Asavatanabodee, P | 1 |
| Chaiamnuay, S | 1 |
| Bai, XS | 1 |
| Zhao, XD | 1 |
| Cui, LL | 1 |
| He, YW | 1 |
| Li, XD | 1 |
| Qu, XJ | 1 |
| Sun, MS | 1 |
| Li, CG | 2 |
| Moulay Berkchi, J | 1 |
| Rkain, H | 1 |
| Benbrahim, L | 1 |
| Aktaou, S | 1 |
| Lazrak, N | 1 |
| Faiz, S | 1 |
| Ahid, S | 1 |
| Abouqal, R | 1 |
| Labzizi, S | 1 |
| Ouzeddoun, N | 1 |
| Oukerraj, L | 1 |
| Hmamouchi, I | 1 |
| Hajjaj-Hassouni, N | 1 |
| Allali, F | 1 |
| Kim, A | 1 |
| Kim, Y | 2 |
| Kim, GT | 1 |
| Ahn, E | 1 |
| Davidsson, L | 1 |
| Dahlstrand Rudin, A | 1 |
| Sanchez Klose, FP | 1 |
| Buck, A | 1 |
| Björkman, L | 1 |
| Christenson, K | 1 |
| Bylund, J | 1 |
| Li, NS | 1 |
| Chen, YT | 1 |
| Hsu, YP | 1 |
| Pang, HH | 1 |
| Huang, CY | 1 |
| Shiue, YL | 1 |
| Wei, KC | 1 |
| Yang, HW | 1 |
| Phang, KF | 1 |
| Low, BPL | 1 |
| Tan, PSH | 1 |
| Khong, ZW | 1 |
| Tay, SH | 1 |
| Mu, Z | 1 |
| Zeng, XJ | 3 |
| Gu, JR | 1 |
| Zhou, JG | 2 |
| Zeng, XF | 1 |
| Hoque, KM | 1 |
| Dixon, EE | 1 |
| Allan, J | 2 |
| Cho, SK | 1 |
| Myung, W | 1 |
| Chang, Y | 2 |
| Ryu, S | 1 |
| Kim, HN | 1 |
| Kim, HL | 1 |
| Kuo, PH | 1 |
| Winkler, CA | 1 |
| Won, HH | 1 |
| Chock, YP | 1 |
| Ross, JS | 1 |
| Suter, LG | 1 |
| Rhee, TG | 1 |
| Bansal, P | 1 |
| Virata, AR | 1 |
| Yin, S | 2 |
| Xie, C | 3 |
| Shu, L | 2 |
| Ponticelli, C | 1 |
| Moroni, G | 1 |
| Sullivan, JI | 1 |
| Tang, Y | 1 |
| Wang, D | 1 |
| Nuki, G | 14 |
| Arenas, MD | 1 |
| Soriano, R | 2 |
| Scinicariello, F | 1 |
| Buser, MC | 1 |
| Balluz, L | 1 |
| Gehle, K | 1 |
| Murray, HE | 1 |
| Abadin, HG | 1 |
| Attanasio, R | 1 |
| Chuang, JP | 1 |
| Lee, JC | 2 |
| Ling, P | 1 |
| Maa, MC | 2 |
| Leu, TH | 1 |
| Novikova, AM | 1 |
| Lertnawapan, R | 2 |
| Ishikawa, T | 3 |
| Maeda, T | 1 |
| Hashimoto, T | 1 |
| Nakagawa, T | 3 |
| Ichikawa, K | 1 |
| Sato, Y | 1 |
| Kanno, Y | 1 |
| Gomes, N | 1 |
| Cerejeira, A | 1 |
| Moura, CS | 1 |
| Lopes, JM | 1 |
| Baudrier, T | 1 |
| Azevedo, F | 1 |
| Tseng, CC | 1 |
| Wong, MC | 1 |
| Liao, WT | 1 |
| Chen, CJ | 4 |
| Lee, SC | 3 |
| Yen, JH | 1 |
| Fan, M | 1 |
| Faasse, K | 1 |
| Shen, J | 2 |
| Si, S | 1 |
| Mo, M | 1 |
| Xin, X | 1 |
| Shao, B | 1 |
| Shen, Y | 1 |
| Sung, KT | 1 |
| Lo, CI | 1 |
| Lai, YH | 1 |
| Tsai, JP | 1 |
| Yun, CH | 1 |
| Hsiao, CC | 1 |
| Kuo, JY | 1 |
| Hou, CJ | 1 |
| Hung, TC | 1 |
| Su, CH | 1 |
| Hung, CL | 1 |
| Yeh, HI | 1 |
| Sivera, F | 15 |
| Renaudin, F | 1 |
| Orliaguet, L | 1 |
| Castelli, F | 1 |
| Fenaille, F | 1 |
| Prignon, A | 1 |
| Alzaid, F | 1 |
| Combes, C | 1 |
| Delvaux, A | 1 |
| Adimy, Y | 1 |
| Cohen-Solal, M | 2 |
| Riveline, JP | 2 |
| Venteclef, N | 1 |
| Campillo-Gimenez, L | 1 |
| Quilisadio, JEC | 1 |
| Salido, EO | 1 |
| Penserga, EG | 1 |
| Rosas, G | 1 |
| Rahn, EJ | 2 |
| Agabiti-Rosei, E | 1 |
| Johnson, RJ | 13 |
| Kielstein, JT | 1 |
| Lurbe, E | 1 |
| Mancia, G | 2 |
| Redon, J | 1 |
| Tsioufis, KP | 1 |
| Watson, L | 3 |
| Belcher, J | 2 |
| Nicholls, E | 1 |
| Mallen, C | 3 |
| Fang, YJ | 2 |
| Chung, YL | 2 |
| Lin, CL | 6 |
| Lim, YP | 2 |
| Takei, R | 2 |
| Markie, D | 1 |
| Bixley, M | 1 |
| Guo, H | 2 |
| He, M | 2 |
| Wei, WH | 1 |
| Singh, JV | 1 |
| Bedi, PMS | 1 |
| Singh, H | 1 |
| Sharma, S | 1 |
| Vaidya, B | 1 |
| Baral, R | 1 |
| Lama, LD | 1 |
| Joshi, R | 1 |
| Bhochhibhoya, M | 1 |
| Nakarmi, S | 1 |
| Guan, J | 1 |
| Huang, XQ | 1 |
| Dong, JL | 1 |
| Lu, HM | 1 |
| Lin, YW | 2 |
| Yi, ZB | 1 |
| Wu, LM | 1 |
| Huang, YM | 1 |
| Lan, T | 1 |
| Mudra, U | 1 |
| Andreychyn, S | 1 |
| Hanberher, I | 1 |
| Korylchuk, N | 1 |
| Baidurin, S | 1 |
| Bekenova, F | 1 |
| Nakysh, A | 1 |
| Akhmetzhanova, S | 1 |
| Abai, G | 1 |
| Kapetanovic, M | 4 |
| Bengtsson Boström, K | 3 |
| Wändell, P | 3 |
| Forsblad d'Elia, H | 2 |
| Bergsten, U | 2 |
| Slobodnick, A | 1 |
| Greenberg, J | 1 |
| Crittenden, DB | 5 |
| Pike, VC | 3 |
| Qian, Y | 2 |
| Zou, Z | 2 |
| Tsoi, MF | 1 |
| Chung, MH | 1 |
| Cheung, BMY | 1 |
| Lau, CS | 1 |
| Sakaguchi, S | 1 |
| Le, NH | 2 |
| Letavernier, E | 1 |
| Correas, JM | 1 |
| Gauffenic, A | 1 |
| Pham, NG | 1 |
| Olivier, O | 1 |
| Frochot, V | 1 |
| Bazin, D | 1 |
| Marty, C | 1 |
| Ostertag, A | 1 |
| Laredo, JD | 1 |
| Bodofsky, S | 1 |
| Thomas, TJ | 1 |
| Müller, FC | 2 |
| Møller, JM | 1 |
| Børgesen, HF | 1 |
| Gosvig, KK | 1 |
| Checa, A | 4 |
| Pyne, L | 1 |
| Walsh, M | 2 |
| Miller, HN | 1 |
| Charleston, J | 2 |
| Wu, B | 2 |
| Gleason, K | 1 |
| White, K | 2 |
| Dennison Himmelfarb, CR | 1 |
| Ford, DE | 1 |
| Plante, TB | 1 |
| Ton, J | 1 |
| Kolber, MR | 1 |
| Pooni, RS | 1 |
| Corbett, R | 1 |
| Koto, R | 2 |
| Chui, CSK | 1 |
| Choi, AKY | 1 |
| Lam, MMY | 1 |
| Kwan, TH | 1 |
| Li, OC | 1 |
| Leng, Y | 1 |
| Chow, DLY | 1 |
| Liu, F | 2 |
| Hu, Z | 1 |
| Guo, K | 1 |
| Min, JZ | 1 |
| Petreski, T | 1 |
| Ekart, R | 1 |
| Hojs, R | 1 |
| Bevc, S | 1 |
| Ebstein, E | 1 |
| Forien, M | 1 |
| Norkuviene, E | 2 |
| Mouterde, G | 1 |
| Daien, C | 1 |
| Brière, C | 2 |
| Petraitis, M | 2 |
| Ora, J | 1 |
| Dieudé, P | 2 |
| Ottaviani, S | 2 |
| Taylor, W | 4 |
| Qiao, CY | 1 |
| Shang, Y | 2 |
| Zhan, ZY | 1 |
| Ye, H | 1 |
| Lin, YC | 1 |
| Jiao, JY | 1 |
| Sun, RH | 1 |
| Zhang, ZH | 1 |
| Homolya, L | 1 |
| Hegedűs, T | 1 |
| Takakubo, Y | 1 |
| Imamura, Y | 1 |
| Tezuka, H | 1 |
| Naganuma, Y | 1 |
| Ito, J | 1 |
| Oki, H | 1 |
| Sasaki, A | 1 |
| Sasaki, K | 1 |
| Konta, T | 1 |
| Takagi, M | 1 |
| Murayama, M | 1 |
| Nishida, M | 1 |
| Kudo, Y | 1 |
| Deguchi, T | 1 |
| Marukawa, K | 1 |
| Fujieda, Y | 1 |
| Abe, N | 1 |
| Kato, M | 1 |
| Shibuya, H | 1 |
| Matsuno, Y | 1 |
| Atsumi, T | 1 |
| Lukkunaprasit, T | 1 |
| Rattanasiri, S | 1 |
| Turongkaravee, S | 1 |
| Suvannang, N | 1 |
| Ingsathit, A | 1 |
| Attia, J | 2 |
| Thakkinstian, A | 1 |
| Yu, X | 1 |
| Zeng, P | 1 |
| Robin, F | 1 |
| Berthoud, O | 1 |
| Albert, JD | 2 |
| Cadiou, S | 1 |
| Gougeon-Jolivet, A | 1 |
| Bendavid, C | 1 |
| Guggenbuhl, P | 2 |
| Coiffier, G | 2 |
| Clebak, KT | 1 |
| Morrison, A | 1 |
| Croad, JR | 1 |
| Shao, T | 1 |
| Wen, X | 1 |
| He, Z | 1 |
| Meyer, MM | 1 |
| Marks, LA | 1 |
| Hallas, J | 3 |
| Webster, J | 1 |
| Ralston, SH | 3 |
| Walters, M | 1 |
| Robertson, M | 1 |
| De Caterina, R | 1 |
| Findlay, E | 1 |
| Meng, B | 1 |
| Shou, Q | 1 |
| Shao, X | 1 |
| Zhou, H | 2 |
| Mi, W | 1 |
| Wu, TY | 1 |
| Su, CY | 1 |
| Li, JR | 1 |
| Tien, N | 1 |
| Chen, SK | 1 |
| Hill-McManus, D | 4 |
| Miake, J | 1 |
| Mahati, E | 1 |
| Maharani, N | 1 |
| Utami, SB | 1 |
| Bahrudin, U | 1 |
| Gromova, MA | 1 |
| Tsurko, VV | 4 |
| Kislyak, OA | 1 |
| Malysheva, NV | 1 |
| Kang, L | 2 |
| Hu, P | 2 |
| Abrahim, M | 1 |
| Node, K | 1 |
| Kobayashi, Y | 2 |
| Köttgen, M | 3 |
| Piani, F | 1 |
| Premachandra, KH | 1 |
| Roberts, DM | 1 |
| Cui, X | 1 |
| Houvenagel, E | 5 |
| Desideri, G | 5 |
| Rajzer, M | 1 |
| Giannattasio, C | 1 |
| Wakita, M | 1 |
| Asai, K | 1 |
| Kubota, Y | 2 |
| Koen, M | 1 |
| Shimizu, W | 1 |
| Mu, H | 1 |
| Qin, T | 1 |
| Long, F | 1 |
| Tang, H | 1 |
| Morgan, SL | 1 |
| Duan, Y | 1 |
| Jiang, N | 1 |
| Xu, VYY | 1 |
| Lake, SL | 1 |
| Ahn, SJ | 1 |
| Zhang, D | 2 |
| Levine, BD | 1 |
| Pool, B | 15 |
| Ranganath, VK | 1 |
| Benhaim, P | 1 |
| Nelson, SD | 1 |
| Hsieh, SS | 1 |
| FitzGerald, JD | 2 |
| Ao, J | 2 |
| Vernerová, A | 1 |
| Kujovská Krčmová, L | 1 |
| Melichar, B | 1 |
| Švec, F | 1 |
| Døssing, A | 1 |
| Bliddal, H | 2 |
| Boesen, M | 1 |
| Rai, SK | 3 |
| Carson, KA | 1 |
| Zuzic Furlan, S | 1 |
| Rusic, D | 1 |
| Bozic, J | 1 |
| Rumboldt, M | 1 |
| Rumboldt, Z | 2 |
| Rada, M | 1 |
| Tomicic, M | 1 |
| Ventura-Ríos, L | 3 |
| Rodríguez-Henríquez, P | 2 |
| Pineda, C | 8 |
| Franco-Cendejas, R | 1 |
| Lozada-Pérez, CA | 1 |
| Albert, JA | 1 |
| Irvin, MR | 1 |
| Bridges, SL | 4 |
| Kim, H | 3 |
| Arnett, DK | 1 |
| Lupi, AS | 1 |
| Vazquez, AI | 3 |
| Suissa, S | 1 |
| Suissa, K | 1 |
| Hudson, M | 1 |
| Topless, RKG | 1 |
| Florez, JC | 1 |
| Hirschhorn, JN | 1 |
| Wilcox, PL | 1 |
| Cole, JB | 1 |
| Choi, N | 1 |
| Yang, G | 4 |
| Jang, JH | 1 |
| Kang, HC | 3 |
| Cho, YY | 3 |
| Lee, HS | 4 |
| Lee, JY | 4 |
| Estiverne, C | 1 |
| Oh, YJ | 1 |
| Jeong, JH | 1 |
| Choi, SJ | 4 |
| Ahn, SM | 1 |
| Kim, YG | 4 |
| Lee, CK | 4 |
| Yoo, B | 3 |
| Del Pinto, R | 2 |
| Viazzi, F | 2 |
| Pontremoli, R | 4 |
| Ferri, C | 3 |
| Carubbi, F | 1 |
| Russo, E | 1 |
| Fan, J | 1 |
| Tse, LA | 1 |
| Lefebvre, A | 1 |
| Calhoun, DA | 1 |
| Oparil, S | 1 |
| Dudenbostel, T | 1 |
| Feig, DI | 1 |
| Redden, DT | 3 |
| Muntner, P | 2 |
| Foster, PJ | 2 |
| Biggers-Clark, SR | 1 |
| Sattui, SE | 1 |
| Saddekni, MB | 1 |
| Borgen, T | 1 |
| Jin, Z | 2 |
| Mackie, SL | 1 |
| Mao, Y | 2 |
| Wan, Z | 1 |
| Song, L | 2 |
| Hu, L | 2 |
| Lei, X | 2 |
| Xie, XQ | 1 |
| Geng, Y | 1 |
| Guan, Q | 1 |
| Ren, Y | 1 |
| Guo, L | 1 |
| Lu, ZM | 1 |
| Shi, JS | 1 |
| Xu, ZH | 1 |
| Uchida, N | 1 |
| Shigesawa, R | 1 |
| Takeuchi, K | 1 |
| Mank, VMF | 1 |
| Goldstein, E | 1 |
| Babb, S | 1 |
| Meghpara, S | 1 |
| Breighner, C | 1 |
| Salavastru, C | 1 |
| Copaci, FI | 1 |
| Vrinceanu, D | 1 |
| Sendrea, AM | 1 |
| Tiplica, GS | 1 |
| Ortiz, MA | 1 |
| Garcia-Guillen, A | 1 |
| Jeria-Navarro, S | 1 |
| Sainz, L | 1 |
| Fernandez-Sanchez, S | 1 |
| Vidal, S | 1 |
| Mikhailichenko, N | 1 |
| Wang, YH | 2 |
| Lai, TJ | 1 |
| Nieradko-Iwanicka, B | 1 |
| Borelli, CM | 1 |
| Doherty, BT | 1 |
| Yago, T | 1 |
| Yashiro-Furuya, M | 1 |
| Suzuki, E | 1 |
| Wu, SW | 1 |
| Liu, CY | 1 |
| Yeh, CJ | 3 |
| Cheng-Chung Wei, J | 1 |
| Takahashi, T | 1 |
| Taniguchi, T | 1 |
| Lee, LE | 1 |
| Kim, JE | 2 |
| Lee, SJ | 2 |
| Yoon, S | 2 |
| Kang, H | 1 |
| Song, JJ | 3 |
| Shi, W | 1 |
| Shyy, JY | 1 |
| O'Connor, MJ | 1 |
| Leong, A | 1 |
| Valiate, BVS | 1 |
| Queiroz-Junior, CM | 3 |
| Levi-Schaffer, F | 1 |
| Calvo-Aranda, E | 1 |
| Sanchez-Aranda, FM | 1 |
| Casimiro-Soriguer, CS | 1 |
| Dopazo, J | 1 |
| Çubuk, C | 1 |
| Francisco-Balderas, A | 1 |
| Lozada-Pérez, C | 1 |
| Sánchez-González, A | 1 |
| Silveira, LH | 2 |
| Burguete-García, AI | 1 |
| Orbe-Orihuela, C | 1 |
| Lagunas-Martínez, A | 1 |
| Vazquez-Gomez, A | 1 |
| López-Reyes, A | 3 |
| Palacios-González, B | 1 |
| Xiao, WZ | 1 |
| Bindoli, S | 1 |
| Luisetto, R | 3 |
| Sfriso, P | 3 |
| Líška, D | 1 |
| Diez-Lopez, C | 1 |
| Perez-Contreras, J | 1 |
| Yue, H | 1 |
| Ou, Y | 1 |
| Liang, S | 1 |
| Deng, W | 1 |
| Zhang, C | 3 |
| Hua, L | 1 |
| Hu, W | 1 |
| Sun, P | 1 |
| Kumar, M | 1 |
| Manley, N | 1 |
| Kim, I | 1 |
| Kim, YI | 1 |
| Jung, HG | 1 |
| Lee, G | 3 |
| Yoon, DS | 1 |
| Shang, J | 1 |
| Li, XH | 1 |
| Lu, SQ | 1 |
| Li, LL | 1 |
| Zhu, C | 1 |
| Zhu, G | 1 |
| Nguyen, HT | 2 |
| Vu, TY | 1 |
| Dakal, TC | 1 |
| Dhabhai, B | 1 |
| Nguyen, XHQ | 1 |
| Tatipamula, VB | 1 |
| Carpentier, P | 1 |
| Luraschi, H | 4 |
| Verclytte, S | 1 |
| Ventura-Martínez, R | 2 |
| Déciga-Campos, M | 2 |
| Bustamante-Marquina, A | 1 |
| Ángeles-López, GE | 1 |
| Aviles-Herrera, J | 1 |
| González-Trujano, ME | 2 |
| Navarrete-Vázquez, G | 1 |
| Di Carlo, M | 2 |
| Di Matteo, A | 1 |
| Salaffi, F | 3 |
| Eskild, T | 1 |
| Agnoletti, D | 1 |
| Cicero, AFG | 1 |
| Khanna, I | 1 |
| Pietro, R | 1 |
| Ali, Y | 1 |
| Song, H | 1 |
| Man, S | 1 |
| Hanvivadhanakul, P | 2 |
| Towiwat, P | 4 |
| Shi, L | 4 |
| Xu, C | 1 |
| Wen, J | 1 |
| Zhan, D | 1 |
| Yu, J | 2 |
| Fu, L | 1 |
| Yan, T | 1 |
| Badii, M | 1 |
| Gaal, OI | 1 |
| Davar, R | 1 |
| Habibi, E | 1 |
| Keating, ST | 1 |
| Novakovic, B | 2 |
| Helsen, MM | 1 |
| Macartney-Coxson, D | 1 |
| Stunnenberg, HG | 2 |
| Noori, S | 1 |
| Mirzababaei, A | 1 |
| Amini, MR | 1 |
| Clark, CCT | 1 |
| Mirzaei, K | 1 |
| Duan, L | 3 |
| Dyah Kurniasari, M | 1 |
| Huruta, AD | 1 |
| Lin, YH | 1 |
| Weng, SF | 1 |
| Chu, Y | 1 |
| Sun, S | 1 |
| Gao, Q | 1 |
| Liang, L | 1 |
| Zhou, C | 1 |
| Ding, F | 1 |
| Bai, X | 1 |
| Wei, X | 1 |
| Yue, Z | 1 |
| Zhong, CS | 1 |
| Zeng, B | 1 |
| Qiu, JH | 1 |
| Xu, LH | 1 |
| Zhong, MY | 1 |
| Huang, YT | 1 |
| Liu, SY | 1 |
| Zha, QB | 1 |
| Hu, B | 1 |
| Ou-Yang, DY | 1 |
| He, XH | 1 |
| Pongsittisak, W | 1 |
| Manavathongchai, S | 1 |
| Handa, R | 1 |
| Malaviya, AN | 3 |
| Ahn, H | 1 |
| Lee, GS | 1 |
| Barclay, ML | 7 |
| Cochrane, E | 1 |
| Harper, R | 1 |
| Lhakum, P | 1 |
| Pattamapaspong, N | 1 |
| Tanner, C | 1 |
| Dobbyn, A | 1 |
| Liu, HJ | 1 |
| Pan, XX | 1 |
| Liu, BQ | 1 |
| Gui, X | 1 |
| Jiang, CY | 1 |
| Fan, YX | 1 |
| Tang, YL | 1 |
| Liu, WT | 1 |
| Tan, PK | 3 |
| Gunic, E | 1 |
| Goossens, J | 1 |
| Lancrenon, S | 1 |
| Lanz, S | 1 |
| Lambert, C | 1 |
| Saraux, A | 1 |
| Delva, C | 1 |
| Sahbane, S | 1 |
| Boumans, D | 1 |
| Hettema, ME | 1 |
| Vonkeman, HE | 4 |
| Maatman, RG | 1 |
| van de Laar, MA | 5 |
| Deeks, ED | 1 |
| Janssens, HJEM | 4 |
| Fransen, J | 12 |
| Schumacher, HR | 53 |
| Just, J | 1 |
| Bleckwenn, M | 1 |
| Weckbecker, K | 2 |
| Pagidipati, NJ | 1 |
| Hess, CN | 1 |
| Clare, RM | 1 |
| Akerblom, A | 1 |
| Tricoci, P | 1 |
| Wojdyla, D | 1 |
| James, S | 1 |
| Held, C | 1 |
| Mahaffey, KW | 1 |
| Klein, AB | 2 |
| Wallentin, L | 1 |
| Vargas-Santos, AB | 2 |
| Koide, H | 1 |
| Hira, D | 1 |
| Tsujimoto, M | 1 |
| Katsube, Y | 1 |
| Minegaki, T | 1 |
| Uzu, T | 1 |
| Ikeda, Y | 2 |
| Morita, SY | 1 |
| Nishiguchi, K | 1 |
| Terada, T | 1 |
| Maravic, M | 1 |
| Hincapie, N | 1 |
| Pilet, S | 1 |
| Flipo, RM | 2 |
| Gao, Z | 1 |
| Lü, K | 1 |
| Cleophas, MCP | 1 |
| Erler, K | 1 |
| Lu, CC | 2 |
| Wu, SK | 2 |
| Chung, WS | 2 |
| Lin, LH | 1 |
| Hung, TW | 1 |
| La-Crette, J | 1 |
| Jenkins, W | 4 |
| Fernandes, G | 1 |
| Bangalore, S | 1 |
| Morlock, R | 4 |
| Terrill, M | 2 |
| Riordan, J | 2 |
| Fisher, MC | 3 |
| Rousseau, LS | 1 |
| Paré, G | 3 |
| Lachhab, A | 1 |
| Naccache, PH | 9 |
| Marceau, F | 1 |
| Tessier, P | 2 |
| Pelletier, M | 1 |
| Fernandes, M | 2 |
| Fu, T | 2 |
| Gu, Z | 2 |
| Shields, GE | 1 |
| Timofeeva, M | 2 |
| Tzoulaki, I | 2 |
| Tsilidis, KK | 1 |
| Ioannidis, JP | 1 |
| Theodoratou, E | 5 |
| Jones, G | 4 |
| Kopicko, J | 2 |
| Bhakta, N | 2 |
| Adler, S | 2 |
| Storgard, C | 4 |
| Apanaviciene, I | 1 |
| Virviciute, D | 1 |
| Baranauskaite, A | 1 |
| Modjinou, DV | 2 |
| Krasnokutsky, S | 5 |
| Gyftopoulos, S | 2 |
| Karis, E | 1 |
| Lee, K | 1 |
| Samuels, J | 3 |
| Qiao, Y | 1 |
| Hou, X | 1 |
| Lu, D | 1 |
| Zhang, K | 4 |
| Mi, QS | 3 |
| Habib, G | 2 |
| Rashid, I | 1 |
| Otter, S | 1 |
| Kumar, S | 5 |
| Rome, K | 4 |
| Soskind, R | 1 |
| Abazia, DT | 1 |
| Bridgeman, MB | 1 |
| Rasheed, H | 3 |
| Rech, HJ | 1 |
| Cavallaro, A | 4 |
| Wijkström, J | 1 |
| Söderberg, M | 1 |
| Wernerson, A | 1 |
| Dong, A | 1 |
| Bai, Y | 1 |
| Zuo, C | 1 |
| Grandjean, A | 3 |
| Motte, M | 3 |
| Vandecandelaere, M | 3 |
| Godart, C | 3 |
| Namane, N | 3 |
| Pyo, JY | 2 |
| Kim, DS | 2 |
| Jung, SM | 1 |
| Park, YB | 5 |
| Soumaré, A | 2 |
| Debette, S | 2 |
| Wright, S | 1 |
| O'Donnell, JL | 5 |
| Raja, R | 1 |
| Michet, C | 1 |
| Hirschmann, A | 1 |
| Manigold, T | 1 |
| Coburn, BW | 5 |
| Bendlin, KA | 2 |
| Meza, J | 1 |
| Russell, CL | 1 |
| Kim, JW | 1 |
| Kwak, SG | 1 |
| Park, SH | 4 |
| Thottam, GE | 1 |
| Bartels, EM | 1 |
| Henriksen, M | 1 |
| Wæhrens, EE | 1 |
| Gudbergsen, H | 1 |
| Astrup, A | 1 |
| Knop, FK | 1 |
| Kristensen, LE | 1 |
| Soto, E | 3 |
| Marshall, S | 3 |
| Lane, S | 2 |
| Hughes, D | 2 |
| Dai, J | 1 |
| Duan, S | 1 |
| Chen, RJ | 1 |
| Chen, MH | 2 |
| Chen, YL | 1 |
| Hsiao, CM | 1 |
| Chen, HM | 1 |
| Chen, SJ | 1 |
| Wu, MD | 1 |
| Yech, YJ | 1 |
| Yuan, GF | 1 |
| Wang, YJ | 1 |
| Zoccali, C | 1 |
| Bollen, SM | 1 |
| Rutten, MJCM | 1 |
| Palmer, WE | 1 |
| MacDonald, PA | 15 |
| Thienel, U | 1 |
| Cutolo, M | 2 |
| Cimmino, MA | 7 |
| Frensham, LJ | 1 |
| Baysari, MT | 2 |
| Lau, AYS | 1 |
| Zwar, N | 1 |
| Reath, J | 1 |
| Laba, T | 1 |
| McLachlan, A | 1 |
| Runciman, WB | 1 |
| Buchbinder, R | 5 |
| Clay-Williams, R | 1 |
| Coiera, E | 1 |
| Braithwaite, J | 1 |
| McNeil, HP | 1 |
| Hunter, DJ | 1 |
| Portek, I | 2 |
| Westbrook, JI | 1 |
| Yazdanyar, A | 1 |
| Rizzuti, AE | 1 |
| Mechel, E | 1 |
| Denisova, K | 1 |
| Lazzaro, DR | 1 |
| Sakiyama, M | 9 |
| Tadokoro, S | 1 |
| Komatsu, M | 1 |
| Hishida, A | 5 |
| Nakatochi, M | 3 |
| Imaki, J | 1 |
| Tamaki, S | 1 |
| Ide, Y | 1 |
| Inoue, K | 3 |
| Sugimoto, M | 1 |
| Hidaka, Y | 3 |
| Taniguchi, A | 8 |
| Fujimori, S | 14 |
| Yamamoto, T | 33 |
| Yang, JA | 1 |
| Lee, GH | 1 |
| Lee, WW | 1 |
| Lee, EY | 2 |
| Lee, EB | 2 |
| Park, JK | 1 |
| Panova, E | 1 |
| Sheng, F | 1 |
| Fang, W | 2 |
| Sha, Y | 1 |
| Cleveland, J | 1 |
| Hasan, MM | 1 |
| Mahmood, ZA | 1 |
| Chang, I | 1 |
| Gazeley, D | 1 |
| Beslon, V | 1 |
| Moreau, P | 1 |
| Maruani, A | 1 |
| Maisonneuve, H | 1 |
| Giraudeau, B | 1 |
| Fournier, JP | 1 |
| Bhadu, D | 1 |
| Das, SK | 1 |
| Wakhlu, A | 1 |
| Dhakad, U | 1 |
| Sharma, M | 1 |
| Xing, ZH | 1 |
| Ma, YC | 1 |
| Li, XP | 1 |
| Zhang, MD | 1 |
| Fujita, K | 2 |
| Moreno-Lledó, A | 1 |
| Urionagüena, I | 2 |
| Dickson, AJ | 1 |
| Jhang, JJ | 2 |
| Lin, JH | 1 |
| Yen, GC | 2 |
| Simeunovic Ostojic, M | 1 |
| Maas, J | 1 |
| Marcotti, A | 1 |
| Miralles, A | 1 |
| Dominguez, E | 1 |
| Gomis, A | 1 |
| Belmonte, C | 1 |
| de la Peña, E | 1 |
| Yeon, SH | 1 |
| Lee, HE | 3 |
| Brenner, JE | 1 |
| Foster, WJ | 1 |
| Chen, DY | 2 |
| Chen, JH | 5 |
| Chen, SY | 2 |
| Chen, SM | 2 |
| Cheng, TT | 1 |
| Hsieh, SC | 1 |
| Hsieh, TY | 1 |
| Hsu, PF | 1 |
| Kuo, MC | 1 |
| Lam, HC | 1 |
| Lee, IT | 1 |
| Liang, TH | 1 |
| Lin, HY | 7 |
| Lin, SC | 1 |
| Tsai, WP | 1 |
| Tsay, GJ | 1 |
| Yang, CH | 1 |
| Tsai, WC | 1 |
| Chatfield, SM | 2 |
| Grebe, K | 1 |
| Whitehead, LW | 1 |
| Rogers, KL | 1 |
| Nebl, T | 1 |
| Murphy, JM | 2 |
| Wicks, IP | 2 |
| Linn-Rasker, SP | 1 |
| Case, R | 1 |
| Wentworth, B | 1 |
| Jester, G | 1 |
| Tang, SCW | 1 |
| Fanning, N | 1 |
| Spiliopoulou, A | 1 |
| Wei, WQ | 1 |
| Gifford, A | 1 |
| Shen, X | 1 |
| Varley, T | 1 |
| McKeigue, P | 1 |
| Wright, AF | 7 |
| Joshi, P | 1 |
| Denny, JC | 1 |
| Yuan, Y | 3 |
| Xiang, X | 1 |
| Yuan, TL | 1 |
| Qiu, L | 1 |
| Luo, YB | 1 |
| Packham, J | 1 |
| Obrenovic, K | 1 |
| Rivett, A | 1 |
| Ledingham, JM | 1 |
| Donovan, P | 1 |
| Romero, AG | 1 |
| Bang, D | 1 |
| Shah, B | 2 |
| Igel, TF | 1 |
| Dektiarev, I | 1 |
| Zhong, J | 2 |
| Katz, SD | 1 |
| Ran, B | 1 |
| Estevez-Garcia, IO | 1 |
| Gallegos-Nava, S | 1 |
| Vera-Pérez, E | 1 |
| Vancini, G | 1 |
| Hernández-Díaz, C | 4 |
| Sánchez-Muñoz, F | 1 |
| Ballinas-Verdugo, MA | 1 |
| Castillo-Martínez, D | 1 |
| Amezcua-Guerra, LM | 1 |
| Heppner, HJ | 1 |
| Humbert, A | 1 |
| Stucker, F | 1 |
| Miao, M | 1 |
| Davis, WA | 1 |
| Latkovic, E | 1 |
| Drinkwater, JJ | 1 |
| Nossent, J | 1 |
| Davis, TME | 2 |
| Franklin, JM | 1 |
| Spoendlin-Allen, J | 1 |
| Danaei, G | 1 |
| Lee, CA | 2 |
| Shen, Z | 7 |
| Wilson, DM | 2 |
| Ostertag, TM | 1 |
| Girardet, JL | 3 |
| Hall, J | 3 |
| Gillen, M | 3 |
| Larsson, SC | 2 |
| Carlström, M | 1 |
| Waldman, B | 1 |
| Ansquer, JC | 1 |
| Sullivan, DR | 1 |
| Jenkins, AJ | 1 |
| McGill, N | 2 |
| Buizen, L | 1 |
| Best, JD | 1 |
| Feher, MD | 4 |
| Foucher, C | 1 |
| Kesaniemi, YA | 1 |
| Flack, J | 1 |
| d'Emden, MC | 1 |
| Scott, RS | 1 |
| Hedley, J | 1 |
| Gebski, V | 1 |
| Keech, AC | 1 |
| Pang, Y | 3 |
| Kuehn, BM | 1 |
| Alvarez-Hernández, E | 2 |
| García-Méndez, S | 1 |
| Pascual-Ramos, V | 1 |
| Rull-Gabayet, M | 2 |
| Rossi, C | 1 |
| Genderini, A | 1 |
| Ding, X | 2 |
| Atilgan, CU | 1 |
| Ayli, D | 1 |
| Yilmazbas, P | 1 |
| Ranieri, L | 2 |
| Contero, C | 1 |
| Peral, ML | 1 |
| Zapater, P | 1 |
| Sanderson, LE | 1 |
| Lawrence, LM | 1 |
| van der Kroef, M | 1 |
| Ashimbayeva, E | 1 |
| Britto, D | 1 |
| Harper, JL | 9 |
| Lieschke, GJ | 1 |
| Crosier, KE | 1 |
| Crosier, PS | 1 |
| Timilsina, S | 1 |
| Brittan, K | 1 |
| Brophy, M | 1 |
| Davis-Karim, A | 1 |
| Henrie, AM | 1 |
| Newcomb, J | 1 |
| Palevsky, PM | 1 |
| Pittman, D | 1 |
| Taylor, TH | 1 |
| Johannsdottir, GA | 1 |
| Palsson, O | 1 |
| Gudbjornsson, B | 1 |
| Zhang, G | 1 |
| Cui, Y | 2 |
| Chin, CY | 1 |
| Ho, LJ | 1 |
| Lai, JH | 2 |
| Disveld, IJM | 2 |
| Rongen, GA | 2 |
| Kienhorst, LBE | 2 |
| Zoakman, S | 2 |
| Li, CC | 1 |
| Chang, YY | 1 |
| McHugh, J | 1 |
| Fabre, S | 1 |
| Launay, JM | 1 |
| Gautier, JF | 1 |
| Vidal-Trecan, T | 1 |
| Platt, A | 1 |
| Abrahamsson, A | 1 |
| Hughes, G | 1 |
| Reeves, M | 1 |
| Los Campos, G | 1 |
| Garner, HW | 1 |
| Wessell, DE | 1 |
| Yeh, LT | 3 |
| Kerr, B | 2 |
| Manhard, K | 3 |
| Quart, B | 3 |
| Kankam, M | 1 |
| Lee, C | 2 |
| Walker, S | 1 |
| Clauson, V | 1 |
| Wilson, D | 2 |
| Nguyen, M | 1 |
| Lin, CT | 1 |
| Harrold, LR | 6 |
| McCarthy, G | 10 |
| Kumar, N | 1 |
| da Rocha Castelar-Pinheiro, G | 4 |
| Biernat-Kaluza, E | 1 |
| Rosenthal, A | 1 |
| Hershfield, MS | 7 |
| Czegley, C | 1 |
| Zuo, Z | 1 |
| Capon, B | 2 |
| Drivelegka, P | 1 |
| Jacobsson, LTH | 2 |
| Shiramoto, M | 1 |
| Yamamoto, A | 4 |
| Ito, Y | 2 |
| Puig, JG | 22 |
| Scheepers, LEJM | 2 |
| Burden, AM | 1 |
| Arts, ICW | 1 |
| Spaetgens, B | 3 |
| Souverein, P | 1 |
| de Vries, F | 1 |
| Ma, A | 1 |
| Giannopoulos, G | 1 |
| Angelidis, C | 1 |
| Deftereos, S | 1 |
| Xie, W | 1 |
| Zhou, R | 1 |
| Hu, C | 1 |
| Lu, S | 1 |
| Chai, Y | 1 |
| Rogenmoser, S | 1 |
| Arnold, MH | 1 |
| Hutton, J | 1 |
| Fatima, T | 3 |
| Kupfer, S | 1 |
| Winklhofer, S | 1 |
| Becker, AS | 1 |
| Distler, O | 1 |
| Chung, CB | 2 |
| Alkadhi, H | 2 |
| Finkenstaedt, T | 1 |
| Black-Maier, E | 1 |
| Daubert, JP | 1 |
| Chou, IJ | 1 |
| See, LC | 2 |
| Yagnik, D | 1 |
| Hills, F | 1 |
| Kisfalvi, K | 1 |
| Burgess, S | 1 |
| Michaëlsson, K | 1 |
| Reuss-Borst, M | 1 |
| McKinney, C | 1 |
| Iverson, C | 2 |
| Schechter, BM | 1 |
| Valiyil, R | 1 |
| Jalal, D | 1 |
| Pillinger, M | 1 |
| Doghramji, PP | 4 |
| Chu, C | 1 |
| Song, P | 1 |
| Duan, N | 1 |
| Cui, W | 1 |
| Kapetanovic, MC | 1 |
| Nilsson, P | 1 |
| Turesson, C | 1 |
| Englund, M | 1 |
| Gomm, W | 1 |
| Broich, K | 1 |
| Maier, W | 1 |
| Haenisch, B | 1 |
| Fernandes, MJ | 2 |
| Jing, J | 1 |
| Sitter, T | 1 |
| Schaeffner, E | 1 |
| Schultheiss, UT | 1 |
| Xu, W | 2 |
| Gu, B | 1 |
| Ren, Q | 1 |
| Su, D | 1 |
| Callon, KE | 5 |
| Tay, ML | 1 |
| Musson, D | 1 |
| Naot, D | 6 |
| Cornish, J | 11 |
| Ogawa, Y | 2 |
| Sakamoto, R | 3 |
| Calvo Aranda, E | 1 |
| Gonzalez Martin, J | 1 |
| Abdelkader Abu-Sneimeh, A | 1 |
| Carrion, O | 1 |
| Sainz, F | 1 |
| Garcia de la Peña, P | 1 |
| Zhang, P | 1 |
| Ashcroft, JA | 1 |
| MacFadyen, JG | 1 |
| Libby, P | 1 |
| Thuren, T | 1 |
| Everett, BM | 1 |
| Ridker, PM | 3 |
| Ebrahimpour-Koujan, S | 1 |
| Saneei, P | 1 |
| Larijani, B | 1 |
| Esmaillzadeh, A | 1 |
| Yu, XN | 1 |
| Wu, HY | 1 |
| Deng, YP | 1 |
| Zhuang, GT | 1 |
| Tan, BH | 1 |
| Huang, YZ | 2 |
| Tang, SY | 1 |
| Tu, X | 1 |
| Jordan, JB | 1 |
| Zhong, S | 2 |
| Tognetti, L | 1 |
| Cinotti, E | 1 |
| Fiorani, D | 1 |
| Rubegni, P | 1 |
| Perrot, JL | 1 |
| Bhattacharyya, S | 1 |
| Macklin, EA | 1 |
| Schwarzschild, MA | 2 |
| Perez-Gomez, MV | 1 |
| Bartsch, LA | 1 |
| Ortiz, A | 1 |
| Montenegro, MF | 1 |
| Lundberg, JO | 1 |
| Weitzberg, E | 1 |
| Richardson, H | 1 |
| Sarmanova, A | 1 |
| Ashton, D | 1 |
| Barclay, C | 1 |
| Doherty, S | 1 |
| Duley, L | 1 |
| Hatton, R | 1 |
| Rees, F | 4 |
| Stevenson, M | 1 |
| Guo, M | 1 |
| Saigal, R | 1 |
| Goyal, LK | 1 |
| Jain, DK | 1 |
| Wan Rohani, WT | 1 |
| Mahfudzah, A | 1 |
| Nazihah, MY | 1 |
| Tan, HL | 1 |
| Wan Syamimee, WG | 1 |
| Amanda Jane, PG | 1 |
| Tony Richard, M | 1 |
| Tecer, D | 1 |
| Yardımcı, GK | 1 |
| Sari, A | 1 |
| Babaoglu, H | 1 |
| Alammari, YM | 1 |
| Gheta, D | 1 |
| Flood, RM | 1 |
| Boran, G | 1 |
| Kane, DJ | 1 |
| Mullan, RH | 1 |
| Bouaziz, W | 1 |
| Rekik, MA | 1 |
| Guidara, AR | 1 |
| Keskes, H | 1 |
| Roughley, M | 1 |
| Sultan, AA | 2 |
| Clarson, L | 2 |
| Chavarriaga, J | 1 |
| Ocampo, M | 1 |
| Fakih, N | 1 |
| Silva Herrera, J | 1 |
| Lee, CP | 5 |
| Huang, YN | 1 |
| Nithiyanantham, S | 1 |
| Ko, YC | 8 |
| Latif, ZP | 1 |
| Jung, JY | 1 |
| Choi, Y | 1 |
| Suh, CH | 3 |
| Yoon, D | 1 |
| Kim, HA | 2 |
| Yeo, E | 1 |
| Palmer, SC | 1 |
| Zhou, D | 2 |
| Renner, M | 1 |
| Ryan, EM | 1 |
| Duryee, MJ | 1 |
| Hollins, A | 1 |
| Dover, SK | 1 |
| Pirruccello, S | 1 |
| Real, KD | 1 |
| Hunter, CD | 1 |
| Thiele, GM | 1 |
| Fields, TR | 3 |
| Tiku, A | 1 |
| Badve, SV | 1 |
| Johnson, DW | 1 |
| Hori, H | 1 |
| Umeyama, M | 1 |
| Shimizu, K | 1 |
| Hondebrink, LLC | 1 |
| Opstelten, W | 2 |
| Cheetham, TC | 4 |
| Levy, GD | 3 |
| Rashid, N | 4 |
| Kerimian, A | 2 |
| Low, KJ | 2 |
| Curtis, JR | 3 |
| Ji, LL | 1 |
| Hao, YJ | 1 |
| Zhang, ZL | 1 |
| Tai, V | 1 |
| Bessen, SY | 1 |
| Bessen, MY | 1 |
| Yung, CM | 1 |
| Abeles, AM | 3 |
| Chang, HW | 1 |
| Lin, MH | 1 |
| Lan, YC | 1 |
| Wang, RY | 1 |
| Chen-Xu, M | 1 |
| Duong, NT | 1 |
| Ngoc, NT | 1 |
| Thang, NTM | 1 |
| Phuong, BTH | 1 |
| Nga, NT | 1 |
| Tinh, ND | 1 |
| Quynh, DH | 1 |
| Ton, ND | 1 |
| Hai, NV | 1 |
| Katayama, A | 1 |
| Yokokawa, H | 1 |
| Fukuda, H | 1 |
| Ono, Y | 1 |
| Isonuma, H | 1 |
| Hisaoka, T | 1 |
| Naito, T | 1 |
| Kiyani, MM | 1 |
| Sohail, MF | 1 |
| Shahnaz, G | 1 |
| Rehman, H | 1 |
| Akhtar, MF | 1 |
| Nawaz, I | 1 |
| Mahmood, T | 1 |
| Manzoor, M | 1 |
| Bokhari, SAI | 1 |
| Wang, YG | 2 |
| Mohammed, E | 1 |
| Browne, LD | 1 |
| Kumar A U, A | 1 |
| Adeeb, F | 1 |
| Fraser, AD | 1 |
| Lee, JS | 2 |
| Kwon, OC | 1 |
| Anderson, NG | 1 |
| Rajeswari, M | 1 |
| Polson, M | 1 |
| Guyen, O | 1 |
| Viry, A | 1 |
| Choi, C | 1 |
| Kirkbride, TE | 1 |
| Raja, AY | 1 |
| IIliev, G | 1 |
| Ivanova, PP | 1 |
| Nedev, P | 1 |
| Popov, H | 1 |
| Alberts, BM | 1 |
| Bruce, C | 1 |
| Basnayake, K | 1 |
| Ghezzi, P | 1 |
| Davies, KA | 1 |
| Mullen, LM | 1 |
| Bailey, CJ | 1 |
| Deng, M | 1 |
| Deng, B | 1 |
| Ye, L | 1 |
| Fei, X | 1 |
| Vazirpanah, N | 1 |
| Ottria, A | 1 |
| van der Linden, M | 1 |
| Wichers, CGK | 1 |
| Schuiveling, M | 1 |
| van Lochem, E | 1 |
| Zimmermann, M | 1 |
| Jansen, M | 1 |
| Radstake, TRDJ | 1 |
| Broen, JCA | 1 |
| Katsogridaki, G | 1 |
| Tzovaras, G | 1 |
| Sioka, E | 1 |
| Perivoliotis, K | 1 |
| Zachari, E | 1 |
| Magouliotis, D | 1 |
| Tasiopoulou, V | 1 |
| Zacharoulis, D | 1 |
| Gupta, MK | 1 |
| Vanquaethem, H | 1 |
| Biale, L | 1 |
| Thierry, C | 1 |
| Lee, SH | 3 |
| Park, G | 1 |
| Oh, SM | 1 |
| Oh, DS | 1 |
| Narkiewicz, K | 1 |
| Chen, SL | 1 |
| Chen, JR | 1 |
| Yang, SW | 1 |
| Ehlers, PF | 1 |
| Mihara, K | 1 |
| Shi, T | 1 |
| Min, M | 1 |
| Sun, C | 2 |
| Cheng, C | 1 |
| Liang, M | 2 |
| Rizeq, FK | 1 |
| Strilchuk, L | 1 |
| Fogacci, F | 1 |
| Cicero, AF | 1 |
| Landgren, AJ | 1 |
| Razavi, M | 1 |
| Rao, X | 1 |
| Lee, SY | 3 |
| Kim, JM | 2 |
| Huangfu, N | 1 |
| Xu, Z | 1 |
| Zhang, F | 2 |
| Zheng, W | 1 |
| Schulz, M | 1 |
| McLachlan, AJ | 2 |
| Ichihara, S | 2 |
| Ikezaki, H | 1 |
| Furusyo, N | 1 |
| Hirata, M | 3 |
| Okada, R | 3 |
| Kawai, S | 3 |
| Nishida, Y | 6 |
| Shimanoe, C | 1 |
| Ibusuki, R | 2 |
| Takezaki, T | 2 |
| Nakajima, M | 2 |
| Ozaki, E | 1 |
| Matsui, D | 1 |
| Nishiyama, T | 2 |
| Suzuki, S | 1 |
| Takashima, N | 1 |
| Kita, Y | 1 |
| Endoh, K | 1 |
| Kuriki, K | 1 |
| Uemura, H | 2 |
| Arisawa, K | 2 |
| Oze, I | 1 |
| Matsuo, K | 1 |
| Nakamura, Y | 3 |
| Mikami, H | 1 |
| Kato, N | 1 |
| Murakami, Y | 2 |
| Matsubara, T | 1 |
| Yokota, M | 2 |
| Wakai, K | 5 |
| Mančíková, A | 1 |
| Krylov, V | 1 |
| Bohatá, J | 1 |
| Liang, G | 1 |
| Nie, Y | 1 |
| Zeng, S | 1 |
| Liang, C | 1 |
| Xiao, D | 1 |
| Zhan, S | 1 |
| Zheng, Q | 1 |
| Jiang, R | 1 |
| An, Q | 1 |
| Gu, R | 1 |
| Yu, SH | 1 |
| Kim, MK | 1 |
| Akther, M | 1 |
| Han, JH | 1 |
| Kim, TY | 1 |
| Jiang, J | 1 |
| Kang, TB | 1 |
| Lee, KH | 1 |
| Ten Klooster, PM | 2 |
| Alvarado-de la Barrera, C | 1 |
| López-López, CO | 1 |
| Lee, HA | 1 |
| Yu, KS | 1 |
| Park, SI | 1 |
| Onohara, M | 1 |
| Ahn, Y | 1 |
| Deprouw, C | 1 |
| Guignot, M | 1 |
| Bougeois-Sarran, C | 2 |
| Coblentz-Baumann, L | 1 |
| Sing, K | 1 |
| Berg, K | 1 |
| Virdis, A | 1 |
| Aati, O | 11 |
| El-Tantawy, WH | 1 |
| Zavisanos, A | 1 |
| Hasenstein, T | 1 |
| Meyr, AJ | 1 |
| Huang, IJ | 1 |
| Liew, JW | 1 |
| Morcos, MB | 1 |
| Zuo, S | 1 |
| Crawford, C | 1 |
| Bays, AM | 1 |
| Trost, JR | 1 |
| Konstantinov, KN | 1 |
| Doughty, RN | 1 |
| Troughton, RW | 1 |
| Richards, AM | 1 |
| Barskova, V | 3 |
| Castaneda, J | 1 |
| Coyfish, M | 2 |
| Guillo, S | 2 |
| Janssens, H | 2 |
| Pimentao, J | 3 |
| Pywell, A | 1 |
| Lee, YS | 1 |
| Sung, YY | 1 |
| Yuk, HJ | 1 |
| Son, E | 1 |
| Cho, H | 1 |
| Rashidi, M | 1 |
| Simpson, DS | 1 |
| Hempel, A | 1 |
| Frank, D | 1 |
| Petrie, E | 1 |
| Vince, A | 1 |
| Feltham, R | 1 |
| Murphy, J | 1 |
| Salvesen, GS | 1 |
| Vince, JE | 1 |
| Cheng, KW | 1 |
| Yan, M | 1 |
| Ma, X | 4 |
| Yang, QB | 1 |
| He, YL | 1 |
| Zhang, QB | 1 |
| Nagase, M | 2 |
| Shirahama, Y | 1 |
| Shimoshikiryo, I | 1 |
| Katsuura-Kamano, S | 1 |
| Hara, M | 1 |
| Iwasawa, S | 1 |
| Ohnaka, K | 1 |
| Saitoh, T | 1 |
| Takahashi, A | 2 |
| Tanaka, K | 1 |
| Braun, J | 2 |
| Kiltz, U | 2 |
| Choi, A | 1 |
| Gao, R | 1 |
| Munro, J | 2 |
| Ferrari, AJL | 1 |
| Corrêa Fernandes, AR | 1 |
| De Almeida Agustinelli, R | 1 |
| Seike, H | 1 |
| De Ávila Fernandes, E | 1 |
| Fu, Q | 1 |
| Shang, K | 1 |
| Zhang, YP | 1 |
| Qu, Y | 1 |
| Jie, LG | 1 |
| Deng, JX | 1 |
| Yu, QH | 1 |
| Li, ZX | 1 |
| Jiao, GL | 1 |
| Zhou, SM | 1 |
| Cheng, ZY | 1 |
| Bashir, S | 1 |
| Zeitoun, D | 1 |
| Sverzut, JM | 1 |
| Jeong, H | 1 |
| Jeon, CH | 1 |
| Ellmann, H | 1 |
| Bayat, S | 3 |
| Araujo, E | 2 |
| Manger, B | 6 |
| Kleyer, A | 1 |
| Lell, M | 4 |
| Schenker, H | 1 |
| Simon, D | 1 |
| Tascilar, K | 1 |
| Schett, G | 6 |
| Rech, J | 4 |
| Jakše, B | 2 |
| Pajek, M | 1 |
| Pajek, J | 1 |
| Qi, X | 1 |
| Jin, H | 1 |
| Simeone, FJ | 1 |
| Liu, CW | 1 |
| Chang, WC | 3 |
| Lee, CC | 1 |
| Shau, WY | 1 |
| Hsu, FS | 1 |
| Wang, ML | 1 |
| Chen, TC | 1 |
| Lo, C | 1 |
| Hwang, JJ | 1 |
| Inaba, S | 1 |
| Sautin, Y | 1 |
| Garcia, GE | 1 |
| Schernhammer, E | 1 |
| Qiu, J | 1 |
| Wermuth, L | 1 |
| Lassen, CF | 1 |
| Friis, S | 1 |
| Ritz, B | 1 |
| Pui, K | 1 |
| Gow, PJ | 3 |
| Kovell, LC | 2 |
| Mitha, E | 1 |
| Fouche, L | 1 |
| Weinstein, SP | 3 |
| Yancopoulos, GD | 2 |
| King-Davis, S | 2 |
| Evans, RR | 3 |
| Bray, GA | 1 |
| Di Geso, L | 2 |
| Rovisco, J | 1 |
| dos Santos, RM | 1 |
| Hoffmeister, C | 3 |
| Ferreira, J | 3 |
| Assreuy, J | 1 |
| Manara, M | 2 |
| Prevete, I | 1 |
| Bianchi, G | 1 |
| D'Avola, GM | 1 |
| Di Giacinto, G | 1 |
| Govoni, M | 3 |
| Lombardi, A | 2 |
| Marangella, M | 1 |
| Matucci Cerinic, M | 1 |
| Spadaro, A | 1 |
| Minisola, G | 2 |
| Spencer, KL | 1 |
| Jorgensen, NW | 1 |
| Fornage, M | 2 |
| Best, LG | 1 |
| Brown-Gentry, KD | 1 |
| Cole, SA | 1 |
| Crawford, DC | 1 |
| Deelman, E | 1 |
| Franceschini, N | 1 |
| Glenn, KR | 1 |
| Heiss, G | 1 |
| Jenny, NS | 1 |
| Liu, K | 3 |
| Matise, TC | 1 |
| Umans, JG | 1 |
| Kao, WH | 4 |
| Hanley, A | 1 |
| Casserly, LF | 1 |
| Cronin, CJ | 1 |
| Abdalla, AA | 1 |
| Kiernan, TJ | 1 |
| Murthy, BV | 1 |
| Hegarty, A | 1 |
| Hannigan, A | 1 |
| Ko, AM | 5 |
| Tu, HP | 4 |
| Liu, TT | 1 |
| Yuo, CY | 1 |
| Chiang, SL | 4 |
| Liu, YF | 2 |
| Chang, CM | 1 |
| Tsai, SF | 1 |
| Krishnan, E | 14 |
| Akhras, KS | 4 |
| Sharma, H | 2 |
| Marynchenko, M | 2 |
| Wu, EQ | 3 |
| Tawk, R | 1 |
| Mazor, KM | 1 |
| Negron, A | 1 |
| Ogarek, J | 1 |
| Firneno, C | 1 |
| Yood, RA | 9 |
| Fornaciari, G | 1 |
| Giuffra, V | 1 |
| Li, XX | 1 |
| Liu, JP | 1 |
| Yip, S | 1 |
| Murphy, R | 1 |
| Wu, E | 1 |
| Tawk, RH | 1 |
| Drake, JM | 2 |
| Naredo, E | 1 |
| Uson, J | 1 |
| Jiménez-Palop, M | 1 |
| Martínez, A | 3 |
| Vicente, E | 1 |
| Brito, E | 1 |
| Rodríguez, A | 2 |
| Cornejo, FJ | 1 |
| Castañeda, S | 1 |
| Martínez, MJ | 1 |
| Sanz, J | 1 |
| Batlle-Gualda, E | 2 |
| Garrido, J | 1 |
| Beard, SM | 1 |
| von Scheele, BG | 1 |
| Pearson, IV | 1 |
| Urano, W | 3 |
| Inoue, E | 1 |
| Sekita, C | 1 |
| Ichikawa, N | 1 |
| Koseki, Y | 1 |
| Kemter, E | 1 |
| Prueckl, P | 1 |
| Sklenak, S | 1 |
| Rathkolb, B | 1 |
| Habermann, FA | 1 |
| Hans, W | 1 |
| Gailus-Durner, V | 1 |
| Fuchs, H | 1 |
| Hrabě de Angelis, M | 1 |
| Wolf, E | 1 |
| Aigner, B | 1 |
| Wanke, R | 1 |
| Muthukoori, S | 1 |
| Narayanan, N | 1 |
| Chandra, MS | 1 |
| Sethuraman, S | 1 |
| Krishnan, UM | 1 |
| McQueen, FM | 20 |
| Sundy, J | 1 |
| Baraf, HS | 8 |
| Gagné, V | 1 |
| Marois, L | 2 |
| Levesque, JM | 1 |
| Galarneau, H | 1 |
| Lahoud, MH | 1 |
| Caminschi, I | 1 |
| Miyaji, T | 2 |
| Kawasaki, T | 1 |
| Togawa, N | 1 |
| Omote, H | 2 |
| Moriyama, Y | 4 |
| Yeter, KC | 1 |
| Ortiz, EC | 1 |
| Arkfeld, DG | 1 |
| Ogata, H | 2 |
| Takada, Y | 4 |
| Chiba, T | 6 |
| Ushiyama, C | 1 |
| Hamajima, N | 4 |
| Sakurai, Y | 5 |
| Kato, Y | 2 |
| Zhong, Z | 1 |
| Qiao, L | 1 |
| Bang, SY | 1 |
| Choi, CB | 1 |
| Kim, TH | 1 |
| Dünkel, J | 1 |
| Oestmann, A | 1 |
| Jonczy, M | 1 |
| Christoph, M | 1 |
| Forkmann, M | 1 |
| Richter, U | 1 |
| Kopprasch, S | 2 |
| Bielitz, C | 1 |
| Aringer, M | 6 |
| Wunderlich, C | 3 |
| Batt, C | 1 |
| Black, MA | 1 |
| Merriman, ME | 2 |
| Harrison, A | 2 |
| Highton, J | 3 |
| Jones, P | 1 |
| Voshaar, MA | 1 |
| Bode, C | 1 |
| Prudon, B | 1 |
| Stradling, JR | 1 |
| West, SD | 1 |
| Mulay, SR | 1 |
| Evan, A | 1 |
| Anders, HJ | 1 |
| Nasi, S | 1 |
| Silva, MA | 1 |
| Guerra, GP | 2 |
| Dray, M | 2 |
| Pitto, R | 1 |
| Bentley, J | 1 |
| Chabra, I | 1 |
| Singh, R | 1 |
| Herrero-Beites, AM | 12 |
| Cottrell, E | 1 |
| Crabtree, V | 1 |
| Edwards, JJ | 1 |
| Chen, P | 3 |
| White, M | 1 |
| Barratt-Boyes, C | 1 |
| Orr-Walker, B | 1 |
| Chang, HJ | 1 |
| Wang, PC | 1 |
| Hsu, YC | 3 |
| Huang, SH | 1 |
| Kannangara, DR | 4 |
| Ramasamy, SN | 2 |
| Ray, JE | 1 |
| Bakris, GL | 1 |
| Silber, SH | 1 |
| Nagoba, BS | 1 |
| Punpale, A | 1 |
| Poddar, A | 1 |
| Suryawanshi, NM | 1 |
| Swami, GA | 1 |
| Selkar, SP | 1 |
| Hollis-Moffatt, JE | 1 |
| Franklin, C | 5 |
| Jones, PB | 3 |
| White, DH | 1 |
| Rajan, A | 1 |
| Kalluru, R | 3 |
| Gutierrez-Urena, SR | 2 |
| Treadwell, EL | 2 |
| Rehrig, CD | 2 |
| Ottery, FD | 3 |
| Sundy, JS | 15 |
| Morita, E | 2 |
| Inoue, H | 2 |
| Tatsukawa, S | 2 |
| Sato, J | 1 |
| Shimono, K | 1 |
| Makino, T | 1 |
| Satoh, T | 2 |
| Kanai, Y | 4 |
| Gruaz, L | 3 |
| Burger, D | 3 |
| Faruque, LI | 1 |
| Ehteshami-Afshar, A | 1 |
| Wiebe, N | 1 |
| Tjosvold, L | 1 |
| Homik, J | 1 |
| Tonelli, M | 1 |
| Doucet, BP | 1 |
| Jegatheesan, D | 1 |
| Burke, J | 1 |
| Maynard, JW | 4 |
| McAdams-DeMarco, MA | 4 |
| Law, A | 2 |
| Kao, L | 1 |
| Baer, AN | 5 |
| Mallinson, PI | 2 |
| Reagan, AC | 1 |
| Coupal, T | 1 |
| Munk, PL | 3 |
| Steiger, S | 3 |
| Parimi, N | 1 |
| Lui, LY | 1 |
| Wise, BL | 1 |
| Yao, W | 1 |
| Lay, YA | 1 |
| Cawthon, PM | 1 |
| Orwoll, E | 1 |
| Martillo, MA | 1 |
| Nazzal, L | 1 |
| House, ME | 9 |
| George, M | 1 |
| Pullman-Mooar, S | 1 |
| Hussain, F | 1 |
| Stumpf, J | 1 |
| Toniolo, M | 1 |
| Haller, C | 1 |
| Pan, KL | 3 |
| Lin, JC | 3 |
| Chen, MC | 3 |
| Chang, PJ | 2 |
| Hsiao, JF | 1 |
| Chang, ST | 3 |
| Chung, CM | 3 |
| Goldfien, RD | 1 |
| Ng, MS | 1 |
| Yip, G | 1 |
| Hwe, A | 1 |
| Jacobson, A | 2 |
| Pressman, A | 2 |
| Avins, AL | 1 |
| Akkus, O | 2 |
| Bach, MH | 1 |
| Simkin, PA | 24 |
| Ohno, I | 2 |
| Nomura, S | 1 |
| Uchida, S | 2 |
| Hara, S | 2 |
| Chinchilla, SP | 4 |
| Zhou, L | 2 |
| Pettigrew, JC | 1 |
| Cheng, D | 1 |
| Yi, D | 1 |
| Wu, XH | 1 |
| Yu, CH | 1 |
| Zhang, CF | 1 |
| Anderson, S | 1 |
| Zhang, YW | 1 |
| Du, H | 2 |
| Jiang, L | 2 |
| Zuo, X | 1 |
| Zhu, P | 1 |
| Huang, A | 1 |
| Bao, C | 1 |
| Kienhorst, LB | 3 |
| Janssens, HJ | 4 |
| van de Lisdonk, EH | 1 |
| Holzinger, D | 1 |
| Nippe, N | 1 |
| Vogl, T | 2 |
| Marketon, K | 1 |
| Mysore, V | 1 |
| Weinhage, T | 1 |
| Baeten, D | 1 |
| Ives, A | 1 |
| Busso, N | 5 |
| Foell, D | 1 |
| Bas, S | 1 |
| Gabay, C | 1 |
| Roth, J | 1 |
| Purvis, L | 2 |
| Stewart, A | 2 |
| Merriman, M | 2 |
| Fleischmann, R | 1 |
| Suster, M | 1 |
| Polvent, E | 1 |
| Hingorani, V | 1 |
| Lamers-Karnebeek, FB | 1 |
| Van Riel, PL | 2 |
| Duskin-Bitan, H | 1 |
| Cohen, E | 1 |
| Goldberg, E | 1 |
| Shochat, T | 1 |
| Levi, A | 1 |
| Garty, M | 1 |
| Krause, I | 1 |
| Roseline, YW | 1 |
| Shidoji, Y | 1 |
| Hon, WM | 1 |
| Masaki, M | 1 |
| Hui, M | 1 |
| Huppertz, A | 1 |
| Hermann, KG | 2 |
| Diekhoff, T | 2 |
| Wagner, M | 2 |
| Hamm, B | 2 |
| Schmidt, WA | 1 |
| Saar, J | 1 |
| Kirch, W | 1 |
| Reaves, E | 1 |
| Arroll, B | 4 |
| Olazagasti, J | 1 |
| Wang, AS | 1 |
| Isseroff, R | 1 |
| Bongartz, T | 3 |
| Kavros, SJ | 1 |
| Murthy, NS | 2 |
| Merry, SP | 1 |
| Franz, WB | 1 |
| Michet, CJ | 2 |
| Veetil, BM | 1 |
| Davis, JM | 1 |
| Mason, TG | 1 |
| Warrington, KJ | 1 |
| Ytterberg, SR | 1 |
| Matteson, EL | 1 |
| Crowson, CS | 1 |
| Leng, S | 3 |
| McCollough, CH | 3 |
| Hatoum, H | 1 |
| Lin, SJ | 1 |
| Shiozawa, A | 8 |
| Marcotte, G | 1 |
| Rai, S | 1 |
| Galo, JS | 1 |
| Bhole, V | 2 |
| Castillo, E | 1 |
| Coleman, B | 1 |
| Bennett, M | 2 |
| Wolfenden, TP | 1 |
| Jackson, J | 1 |
| Vitale, A | 1 |
| Cantarini, L | 1 |
| Rigante, D | 1 |
| Bardelli, M | 1 |
| Galeazzi, M | 1 |
| Robier, C | 2 |
| Stettin, M | 1 |
| Quehenberger, F | 2 |
| Neubauer, M | 3 |
| Ray, K | 1 |
| Berendsen, D | 3 |
| Janssen, MC | 1 |
| Janko, C | 2 |
| Munoz, LE | 2 |
| Kienhöfer, D | 2 |
| Frey, B | 1 |
| Naschberger, E | 1 |
| Holmdahl, R | 1 |
| Krenn, V | 1 |
| Harrer, T | 1 |
| Jeremic, I | 1 |
| Bilyy, R | 1 |
| Hoffmann, M | 1 |
| Ling, X | 1 |
| Bochu, W | 1 |
| Carter, JD | 1 |
| Patelli, M | 1 |
| Anderson, SR | 1 |
| Prakash, N | 1 |
| Rodriquez, EJ | 1 |
| Bateman, H | 1 |
| Sterrett, A | 1 |
| Valeriano, J | 1 |
| Ricca, LR | 1 |
| Akram, M | 1 |
| Usmanghani, K | 1 |
| Ahmed, I | 1 |
| Azhar, I | 1 |
| Hamid, A | 1 |
| Cavagna, L | 4 |
| Liu, LM | 1 |
| Cheng, SF | 1 |
| Shieh, PC | 1 |
| Chen, JJ | 1 |
| Kuo, SC | 2 |
| Kuo, DH | 1 |
| Huang, LJ | 1 |
| Way, TD | 1 |
| Joo, K | 1 |
| Kwon, SR | 1 |
| Lim, MJ | 1 |
| Jung, KH | 1 |
| Joo, H | 1 |
| Park, W | 1 |
| Castaldo, G | 1 |
| Mussap, M | 1 |
| Testa, A | 1 |
| Horsburgh, S | 1 |
| Turner, R | 2 |
| Khalilova, IS | 1 |
| Forbes, LV | 1 |
| Kettle, AJ | 1 |
| Oikawa, Y | 1 |
| Abe, J | 2 |
| Shichijo, Y | 1 |
| Akashi, A | 1 |
| Füessl, HS | 5 |
| Ogdie, A | 4 |
| Weatherall, M | 1 |
| Oderda, GM | 1 |
| Hess, K | 1 |
| Brixner, DI | 1 |
| Feehan, M | 1 |
| Akhras, K | 1 |
| Roberts, RL | 3 |
| Wright, DF | 2 |
| Xu, JX | 1 |
| Bailén, R | 2 |
| González Senac, NM | 1 |
| López, MM | 1 |
| Llena, ML | 1 |
| Migoya, M | 1 |
| Rodríguez, MT | 1 |
| de Miguel, E | 9 |
| Mireku, KA | 1 |
| Burgy, JR | 1 |
| Davis, LS | 1 |
| Kivitz, A | 1 |
| Cai, J | 1 |
| Xia, L | 1 |
| Ding, Q | 1 |
| Lee, MC | 1 |
| Cheng, YT | 1 |
| Ho, CY | 1 |
| Siegert, RJ | 1 |
| Banegas, JR | 1 |
| Kimura-Hayama, E | 1 |
| Criales-Vera, S | 1 |
| Betanzos, JL | 1 |
| Rivera, Y | 1 |
| Alberú, J | 1 |
| Hernández-Molina, G | 1 |
| Yoon, BY | 1 |
| Joo, HY | 1 |
| Shin, KC | 1 |
| Baek, HJ | 1 |
| Sorensen, LB | 17 |
| Falzon, L | 3 |
| van der Heijde, DM | 3 |
| Kydd, AS | 4 |
| Seth, R | 3 |
| Edwards, CJ | 4 |
| Bombardier, C | 4 |
| Altaf, S | 2 |
| Jones, GT | 2 |
| van Rij, AM | 1 |
| White, D | 4 |
| Jeyaruban, A | 1 |
| Larkins, S | 1 |
| Soden, M | 1 |
| Agilli, M | 1 |
| Aydin, FN | 1 |
| Cayci, T | 1 |
| Kurt, YG | 1 |
| Hsu, JT | 1 |
| Nagamori, S | 1 |
| Taketani, Y | 1 |
| Suma, S | 2 |
| Oda, T | 1 |
| Kumagai, H | 1 |
| Orlowsky, EW | 1 |
| Stabler, TV | 1 |
| Montell, E | 1 |
| Vergés, J | 1 |
| Kraus, VB | 1 |
| Wangkaew, S | 1 |
| Hongsongkiat, S | 1 |
| Tanasombat, C | 1 |
| Sukittawut, W | 1 |
| Badarny, S | 1 |
| Khreish, M | 1 |
| Khazin, F | 1 |
| Shehadeh, V | 1 |
| Hakim, G | 1 |
| Artul, S | 1 |
| Inani, K | 1 |
| Mernissi, F | 1 |
| Sriranganathan, MK | 1 |
| Vinik, O | 1 |
| Kiefer, T | 1 |
| Stroux, A | 1 |
| Pilhofer, I | 1 |
| Juran, R | 1 |
| Mews, J | 1 |
| Blobel, J | 1 |
| Tsuyuki, M | 1 |
| Ackermann, B | 1 |
| Funck, V | 1 |
| Tonello, R | 1 |
| Pesquero, JB | 1 |
| Bader, M | 1 |
| Oliveira, MS | 1 |
| McDougall, JJ | 1 |
| Brown, M | 4 |
| Eliseev, M | 3 |
| Scire, C | 1 |
| Chou, YY | 3 |
| Cimmino, M | 1 |
| Viollet, B | 1 |
| Ji, Z | 1 |
| Němec, P | 1 |
| Meng, ZQ | 1 |
| Tang, ZH | 1 |
| Yan, YX | 1 |
| Guo, CR | 1 |
| Ding, G | 2 |
| Huang, WZ | 1 |
| Wang, ZZ | 1 |
| Wang, KD | 1 |
| Xiao, W | 1 |
| Löffler, C | 1 |
| Sattler, H | 1 |
| Peters, L | 1 |
| Löffler, U | 1 |
| Uppenkamp, M | 1 |
| Bergner, R | 1 |
| McGowan, B | 1 |
| Bennett, K | 1 |
| Silke, C | 1 |
| Whelan, B | 2 |
| Franchi, C | 1 |
| Salerno, F | 1 |
| Conca, A | 1 |
| Djade, CD | 1 |
| Tettamanti, M | 1 |
| Pasina, L | 1 |
| Corrao, S | 1 |
| Marengoni, A | 1 |
| Marcucci, M | 1 |
| Mannucci, PM | 1 |
| Nobili, A | 1 |
| Mead, T | 1 |
| Arabindoo, K | 1 |
| Smith, B | 1 |
| Lund-Iversen, M | 1 |
| Holland, R | 1 |
| McGill, NW | 6 |
| Kuo, CC | 1 |
| Weaver, V | 1 |
| Fadrowski, JJ | 1 |
| Lin, YS | 1 |
| Guallar, E | 1 |
| Navas-Acien, A | 1 |
| van Onna, M | 1 |
| Hinsenveld, E | 1 |
| Castrejon, I | 1 |
| Toledano, E | 1 |
| Rosario, MP | 1 |
| Loza, E | 1 |
| Gill, G | 1 |
| Aubrun, A | 1 |
| Palazzo, E | 1 |
| Meyer, O | 1 |
| de Abajo, FJ | 1 |
| Gil, MJ | 1 |
| García-Poza, P | 1 |
| Álvarez, A | 1 |
| Bryant, V | 1 |
| García-Rodríguez, LA | 1 |
| An, G | 1 |
| Duan, WR | 1 |
| Nothaft, W | 1 |
| Awni, W | 1 |
| Dutta, S | 1 |
| Hainer, BL | 1 |
| Matheson, E | 1 |
| Wilkes, RT | 1 |
| Davies, MJ | 1 |
| Trujillo, A | 1 |
| Vijapurkar, U | 1 |
| Damaraju, CV | 1 |
| Meininger, G | 1 |
| Pisetsky, DS | 1 |
| Das, A | 1 |
| Savant, SS | 1 |
| Mandal, RK | 1 |
| Hassan, S | 1 |
| Kodithuwakku, ND | 1 |
| Feng, YD | 1 |
| Zhang, YY | 1 |
| Pan, M | 1 |
| Fang, WR | 1 |
| Li, YM | 1 |
| Gandhi, PK | 1 |
| Gentry, WM | 1 |
| Ma, Q | 1 |
| Bottorff, MB | 1 |
| Vela, P | 4 |
| Durcan, L | 1 |
| Lawrence Edwards, N | 1 |
| Shaw, OM | 1 |
| Danjoh, I | 1 |
| Terashige, S | 1 |
| Yin, G | 1 |
| Tokumasu, A | 1 |
| Onoue, H | 1 |
| Iwaya, K | 1 |
| Oosting, M | 1 |
| Lemmers, H | 1 |
| Toenhake-Dijkstra, H | 1 |
| Moilanen, LJ | 1 |
| Hämäläinen, M | 1 |
| Lehtimäki, L | 1 |
| Nieminen, RM | 1 |
| Moilanen, E | 1 |
| Prejbisz, A | 1 |
| Sellin, L | 1 |
| Szwench-Pietrasz, E | 1 |
| Woznowski, M | 1 |
| Michałowska, I | 1 |
| Blondin, D | 1 |
| Sajnaga, D | 1 |
| Epplen, JT | 1 |
| Litwin, M | 1 |
| Dekomien, G | 1 |
| Januszewicz, M | 1 |
| Helmchen, U | 1 |
| Matuszkiewicz-Rowińska, J | 1 |
| Adamczak, M | 1 |
| Więcek, A | 1 |
| Januszewicz, A | 1 |
| Rump, LC | 1 |
| Mantarro, S | 1 |
| Capogrosso-Sansone, A | 1 |
| Tuccori, M | 1 |
| Blandizzi, C | 1 |
| Montagnani, S | 1 |
| Convertino, I | 1 |
| Antonioli, L | 1 |
| Fornai, M | 1 |
| Cricelli, I | 1 |
| Pecchioli, S | 1 |
| Cricelli, C | 1 |
| Lapi, F | 1 |
| Greenberg, KI | 1 |
| Grams, ME | 1 |
| Flipo, RN | 1 |
| Patrikos, DK | 1 |
| De Giorgi, A | 1 |
| Fabbian, F | 1 |
| Pala, M | 1 |
| Tiseo, R | 1 |
| Parisi, C | 1 |
| Misurati, E | 1 |
| Manfredini, R | 1 |
| Aniel-Quiroga, MA | 2 |
| Erauskin, GG | 2 |
| Tiwari, S | 1 |
| Dwivedi, H | 1 |
| Kymonil, KM | 1 |
| Hill, EM | 1 |
| Sky, K | 1 |
| Sit, M | 1 |
| Collamer, A | 1 |
| Higgs, J | 1 |
| Huffman, JE | 1 |
| Albrecht, E | 3 |
| Mangino, M | 3 |
| Kapur, K | 1 |
| Johnson, T | 2 |
| Kutalik, Z | 2 |
| Lopez, LM | 2 |
| Salo, P | 3 |
| Goel, A | 2 |
| Tanaka, T | 3 |
| Dehghan, A | 4 |
| Malerba, G | 2 |
| Portas, L | 2 |
| Boteva, L | 1 |
| Navarro, P | 2 |
| Johansson, A | 3 |
| Esko, T | 2 |
| Peden, JF | 2 |
| Murgia, F | 2 |
| Tenesa, A | 4 |
| Mihailov, E | 1 |
| Grotevendt, A | 2 |
| Gislason, GK | 2 |
| D'Adamo, P | 2 |
| Ulivi, S | 2 |
| Campbell, S | 4 |
| Kolcic, I | 3 |
| Fisher, K | 1 |
| Viigimaa, M | 2 |
| Metter, JE | 2 |
| Masciullo, C | 1 |
| Trabetti, E | 2 |
| Bombieri, C | 1 |
| Sorice, R | 2 |
| Döring, A | 3 |
| Reischl, E | 1 |
| Hofman, A | 4 |
| Wichmann, HE | 4 |
| Davies, G | 2 |
| Gow, AJ | 2 |
| Smit, JH | 2 |
| Kirin, M | 2 |
| Nagaraja, R | 3 |
| Schurmann, C | 2 |
| Budde, K | 2 |
| Farrington, SM | 3 |
| Jula, A | 2 |
| Salomaa, V | 3 |
| Sala, C | 2 |
| Hengstenberg, C | 4 |
| Burnier, M | 3 |
| Klopp, N | 3 |
| Kloiber, S | 2 |
| Schipf, S | 2 |
| Ripatti, S | 2 |
| Cabras, S | 1 |
| Soranzo, N | 2 |
| Homuth, G | 2 |
| Munroe, PB | 2 |
| Hastie, N | 2 |
| Cabrera, C | 1 |
| Haley, C | 1 |
| Franco, OH | 1 |
| Penninx, BW | 2 |
| Ferrucci, L | 2 |
| Gambaro, G | 2 |
| Deary, IJ | 2 |
| Dunlop, MG | 3 |
| Gyllensten, U | 3 |
| Spector, TD | 3 |
| Watkins, H | 3 |
| Perola, M | 3 |
| Caulfield, M | 3 |
| Völzke, H | 4 |
| Guochun, L | 1 |
| Yin, L | 1 |
| Reid, G | 4 |
| Kennedy, NJ | 1 |
| Healy, PJ | 1 |
| Harrison, AA | 4 |
| Pakpoor, J | 1 |
| Seminog, OO | 1 |
| Ramagopalan, SV | 1 |
| Goldacre, MJ | 1 |
| Nasoori, A | 1 |
| Pedram, B | 1 |
| Kamyabi-Moghaddam, Z | 1 |
| Mokarizadeh, A | 1 |
| Pirasteh, H | 1 |
| Fayyaz, AF | 1 |
| Shooshtari, MB | 1 |
| Gupta, S | 2 |
| Yui, JC | 1 |
| Fitzhugh, CD | 1 |
| Clark, C | 1 |
| Siddiqui, S | 1 |
| Conrey, AK | 1 |
| Kato, GJ | 1 |
| Minniti, CP | 1 |
| Galassi, FM | 1 |
| Macia, L | 1 |
| Martins, FS | 3 |
| Canesso, MC | 1 |
| Garcia, CC | 2 |
| Maslowski, KM | 1 |
| De Leon, E | 1 |
| Shim, D | 1 |
| Nicoli, JR | 2 |
| Mackay, CR | 2 |
| Zhou, TY | 1 |
| Lu, W | 2 |
| Eijgelaar, RS | 1 |
| Radstake, TR | 3 |
| Bruderer, SG | 1 |
| Bodmer, M | 1 |
| Jick, SS | 1 |
| Meier, CR | 1 |
| Zykova, SN | 1 |
| Storhaug, HM | 1 |
| Toft, I | 1 |
| Chadban, SJ | 1 |
| Jenssen, TG | 1 |
| White, SL | 1 |
| Zhang, N | 1 |
| Li, G | 3 |
| Zheng, C | 1 |
| Koblick, R | 1 |
| Maueröder, C | 1 |
| Hahn, J | 3 |
| Hoffmann, MH | 1 |
| Ming, J | 1 |
| Lu, Y | 2 |
| Ji, Q | 1 |
| Yu, YK | 1 |
| Yu, F | 1 |
| Ye, C | 1 |
| Shen, GF | 1 |
| Lei, XM | 1 |
| Zhang, ST | 1 |
| Hu, SX | 1 |
| Shahid, H | 1 |
| Stasinopoulou, K | 1 |
| Li, ZG | 1 |
| Montagna, P | 1 |
| Brizzolara, R | 1 |
| Ferrone, C | 1 |
| Paolino, S | 1 |
| Barskova, VG | 6 |
| Denisov, IS | 1 |
| Saccomano, SJ | 1 |
| Ferrara, LR | 1 |
| Ting, K | 2 |
| Graf, SW | 2 |
| Whittle, SL | 2 |
| Mantovani, A | 1 |
| Rigolon, R | 1 |
| Pichiri, I | 1 |
| Pernigo, M | 1 |
| Bergamini, C | 1 |
| Zoppini, G | 1 |
| Bonora, E | 1 |
| Targher, G | 1 |
| Vanheule, V | 1 |
| Janssens, R | 1 |
| Boff, D | 1 |
| Kitic, N | 1 |
| Berghmans, N | 1 |
| Ronsse, I | 1 |
| Kungl, AJ | 1 |
| Van Damme, J | 1 |
| Proost, P | 1 |
| Mortier, A | 1 |
| Fitz-Patrick, D | 1 |
| Cravets, M | 1 |
| Filanovsky, MG | 1 |
| Sukhdeo, K | 1 |
| McNamara, MC | 1 |
| Flynn, TJ | 2 |
| Todd, AS | 1 |
| Walker, RJ | 1 |
| Baek, S | 1 |
| Lee, DG | 1 |
| Kim, EK | 1 |
| Cho, ML | 1 |
| Kwok, SK | 1 |
| Ju, JH | 1 |
| Jørgensen, SH | 1 |
| Knudsen, ET | 1 |
| Atxotegi, J | 1 |
| Agarwaal, A | 1 |
| Green, L | 1 |
| Thiagarajan, P | 1 |
| Naden, RP | 1 |
| Vaquez-Mellado, J | 1 |
| Yarows, SA | 1 |
| Winnard, D | 1 |
| Boswell, DR | 1 |
| Te Karu, L | 2 |
| Lindsay, K | 2 |
| Addadi, L | 3 |
| Volterrani, M | 1 |
| Iellamo, F | 1 |
| Sposato, B | 1 |
| Romeo, F | 1 |
| de Lautour, H | 1 |
| Adebajo, A | 1 |
| Alten, R | 1 |
| da Rocha Castelar Pinheiro, G | 1 |
| Helliwell, P | 1 |
| Kerr, G | 1 |
| Kavanaugh, A | 2 |
| Ralph Schumacher, H | 1 |
| van de Laar, M | 1 |
| Srinivasasainagendra, V | 1 |
| Klimentidis, YC | 1 |
| Allison, DB | 1 |
| Lan, B | 1 |
| Jiri, M | 1 |
| Feng, T | 2 |
| Bastos, LF | 1 |
| Oliveira, TH | 1 |
| Dias, AC | 2 |
| Oliveira, VL | 1 |
| Tavares, LD | 3 |
| Costa, VV | 4 |
| Soriani, FM | 2 |
| Szymkowski, DE | 1 |
| Ryffel, B | 2 |
| Souza, DG | 3 |
| Daoussis, D | 1 |
| Karamessini, M | 1 |
| Chroni, E | 1 |
| Kraniotis, P | 1 |
| Kim, SK | 4 |
| Choe, JY | 4 |
| Park, KY | 3 |
| Feng, X | 1 |
| Sapsford, M | 2 |
| Petsch, C | 2 |
| Dennison, EM | 1 |
| Rubin, KH | 1 |
| Schwarz, P | 1 |
| Harvey, NC | 1 |
| Bone, KW | 1 |
| Cooper, C | 1 |
| Abrahamsen, B | 1 |
| Müller-Ladner, U | 2 |
| Larsen, KS | 1 |
| Pottegård, A | 2 |
| Lindegaard, H | 1 |
| Smolen, LJ | 2 |
| Gahn, JC | 2 |
| Mitri, G | 3 |
| Altan, A | 1 |
| Bancroft, T | 1 |
| Fermer, S | 2 |
| Wood, R | 2 |
| Lai, YC | 1 |
| Yew, YW | 1 |
| Lessing, JN | 1 |
| Mathias, PC | 1 |
| Pierce, RG | 1 |
| Gao, H | 1 |
| Burke, BT | 1 |
| Grams, M | 1 |
| Deng, J | 1 |
| Lin, W | 1 |
| Yin, Z | 1 |
| Yao, C | 1 |
| Araujo, EG | 2 |
| Englbrecht, M | 1 |
| Hueber, AJ | 1 |
| Metzger, SC | 1 |
| Koehm, M | 1 |
| Wichmann, JL | 1 |
| Buettner, S | 1 |
| Scholtz, JE | 1 |
| Beeres, M | 1 |
| Kerl, JM | 1 |
| Albrecht, MH | 1 |
| Hammerstingl, R | 1 |
| Vogl, TJ | 1 |
| Bauer, RW | 1 |
| Søltoft Larsen, K | 1 |
| Lindegaard, HM | 1 |
| Gill, TK | 1 |
| Tucker, GR | 1 |
| Hill, CL | 1 |
| Hsu, PN | 1 |
| Ferrari, FC | 1 |
| Lemos Lima, Rde C | 1 |
| Schimith Ferraz Filha, Z | 1 |
| Barros, CH | 1 |
| de Paula Michel Araújo, MC | 1 |
| Antunes Saúde-Guimarães, D | 1 |
| Hentzen, KS | 1 |
| Hrdy, MM | 1 |
| Wallace, MC | 1 |
| Qu, J | 1 |
| Zhan, Y | 1 |
| Viroli, C | 1 |
| Montecucco, C | 1 |
| Matucci-Cerinic, M | 1 |
| Guo, Z | 1 |
| Ang, KY | 1 |
| Hou, Q | 1 |
| Su, X | 1 |
| Qiao, J | 1 |
| Koh, E | 1 |
| Danliang, H | 1 |
| Lee, YK | 1 |
| Vandal, AC | 3 |
| Rodrigues, IP | 1 |
| Reis, AC | 1 |
| Ribeiro Oliveira, RD | 1 |
| Louzada-Junior, P | 1 |
| Leng, L | 1 |
| Bucala, R | 1 |
| Bozza, MT | 1 |
| Venkat-Raman, G | 1 |
| Gast, C | 1 |
| Marinaki, A | 2 |
| Aradoini, N | 1 |
| Talbi, S | 1 |
| Berrada, K | 1 |
| Abourazzak, FZ | 1 |
| Harzy, T | 1 |
| Kurano, T | 1 |
| Thakur, UJ | 1 |
| Thawait, GK | 1 |
| Fuld, MK | 2 |
| McAdams-DeMarco, M | 2 |
| Fishman, EK | 2 |
| Carrino, JA | 1 |
| Pustjens, T | 1 |
| van der Linden, S | 2 |
| Kim, HJ | 1 |
| Ahn, HS | 1 |
| Park, EJ | 1 |
| Yim, SY | 1 |
| Ren, YC | 1 |
| Jin, TB | 1 |
| Sun, XD | 1 |
| Geng, TT | 1 |
| Zhang, MX | 1 |
| Kang, LL | 1 |
| Sylvester, JE | 1 |
| Leggit, JC | 1 |
| Shah, N | 1 |
| Fernandes, A | 1 |
| Faria, MT | 1 |
| Oliveira, A | 1 |
| Vieira, T | 1 |
| Pereira, J | 1 |
| Ruan, S | 1 |
| Carr, A | 1 |
| Bäurle, A | 1 |
| Sun, N | 1 |
| Wu, L | 1 |
| Di, Y | 1 |
| Mitnala, S | 1 |
| Hopfer, H | 1 |
| Mayr, M | 2 |
| Nickolai, B | 1 |
| Kiss, C | 1 |
| Goldblatt, F | 1 |
| Casson, RJ | 1 |
| Tamura, K | 1 |
| Kiguchi, T | 1 |
| Okamoto, M | 1 |
| Kaneko, M | 2 |
| Maemondo, M | 1 |
| Gemba, K | 1 |
| Fujimaki, K | 1 |
| Kirito, K | 1 |
| Goto, T | 1 |
| Fujisaki, T | 1 |
| Takeda, K | 1 |
| Ueda, T | 10 |
| Wittbrodt, ET | 1 |
| Turpin, RS | 1 |
| Tidwell, BA | 1 |
| Schulman, KL | 1 |
| Ramachandran, S | 1 |
| Fritz, J | 1 |
| Henes, JC | 1 |
| Horger, MS | 1 |
| Hashimoto, H | 2 |
| Smith, MD | 1 |
| Hill, C | 1 |
| van Rij, A | 1 |
| McCormick, SP | 1 |
| Dua, P | 1 |
| Gurrell, R | 1 |
| Kirby, S | 1 |
| Sudworth, M | 1 |
| Loudon, PT | 1 |
| Hyndman, D | 2 |
| Ahmad, Z | 1 |
| Gupta, AK | 1 |
| Sharma, R | 1 |
| Bhalla, AS | 1 |
| Kumar, U | 1 |
| Sreenivas, V | 1 |
| Sharon, Y | 1 |
| Ma, C | 1 |
| Lu, CY | 1 |
| Kuo, TM | 2 |
| Chen, CL | 2 |
| Tsai, EM | 1 |
| Loissell-Baltazar, YA | 1 |
| Medina-Luna, D | 1 |
| López-Macay, A | 1 |
| Camacho-Galindo, J | 1 |
| Santamaría-Olmedo, MG | 1 |
| López-Villegas, EO | 1 |
| Cerna-Cortés, JF | 1 |
| Mome, R | 1 |
| Bakinde, N | 1 |
| Filiopoulos, V | 1 |
| Hadjiyannakos, D | 1 |
| Vlassopoulos, D | 1 |
| Sircar, D | 1 |
| Wallace, AB | 1 |
| Johnson, W | 1 |
| Sánchez-Bringas, G | 1 |
| Reginato, A | 2 |
| Alva, M | 1 |
| Audisio, M | 1 |
| Bertoli, A | 1 |
| Cazenave, T | 1 |
| Mora, C | 1 |
| Py, G | 1 |
| Sedano, O | 1 |
| Solano, C | 1 |
| Richardson, JC | 1 |
| Liddle, J | 1 |
| Hider, S | 1 |
| Prinjha, S | 1 |
| Ziebland, S | 1 |
| Quilis, N | 1 |
| Gil, S | 1 |
| Petru, L | 1 |
| Sebesta, I | 5 |
| Wilson, L | 1 |
| Saseen, JJ | 1 |
| Stiefelhagen, P | 2 |
| Folsom, AR | 2 |
| Schils, R | 1 |
| Krzesinski, JM | 1 |
| Goldfien, R | 1 |
| Ng, M | 1 |
| Avins, A | 1 |
| Farrar, JE | 1 |
| Gaucher, EA | 1 |
| Furst, D | 1 |
| Fitzgerald, J | 2 |
| Ozcan, A | 1 |
| Jimenez-Liñan, LM | 1 |
| Edwards, L | 2 |
| Gardner, D | 1 |
| Stebbings, S | 1 |
| Taylor, G | 1 |
| Kumar, R | 1 |
| Kain, T | 1 |
| Porter, D | 1 |
| Corkill, M | 1 |
| Cathro, A | 1 |
| Metcalfe, S | 1 |
| Wyeth, J | 1 |
| Robbins, RC | 1 |
| Edison, JD | 1 |
| Hedrich, C | 1 |
| Christensen, HD | 1 |
| Sheta, HM | 1 |
| Hansen, IM | 1 |
| Feltelius, N | 1 |
| Chang, JM | 1 |
| Das Gupta, E | 1 |
| Sakthiswary, R | 1 |
| Lee, SL | 1 |
| Wong, SF | 1 |
| Hussein, H | 2 |
| Gun, SC | 2 |
| Castañeda-Sanabria, J | 1 |
| Pywell, T | 1 |
| Breuer, GS | 1 |
| Bogot, N | 1 |
| Nesher, G | 1 |
| Jalal, DI | 1 |
| Humphrey, C | 1 |
| Hulme, R | 1 |
| Das, S | 2 |
| Goswami, RP | 1 |
| Ghosh, A | 2 |
| Ghosh, P | 2 |
| Lahiri, D | 2 |
| Basu, K | 2 |
| Macia, LM | 1 |
| Sernaglia, ÉM | 1 |
| Vinolo, MA | 1 |
| Tavares, LP | 2 |
| Ben Salem, C | 1 |
| Slim, R | 1 |
| Fathallah, N | 1 |
| Hmouda, H | 1 |
| Bianucci, R | 1 |
| Perciaccante, A | 1 |
| Appenzeller, O | 1 |
| Suh, YS | 1 |
| Cheon, YH | 1 |
| Lee, WS | 1 |
| Yoo, WH | 1 |
| Lee, SI | 1 |
| Sinhamahapatra, P | 1 |
| Paik, JM | 1 |
| Chia, FL | 1 |
| Lee, SS | 2 |
| Oh, DH | 1 |
| Park, DJ | 1 |
| Chae, SC | 1 |
| Yun, KJ | 1 |
| Chung, WT | 1 |
| Ruoff, G | 1 |
| Castelar, G | 1 |
| Singh, J | 2 |
| Wei, F | 1 |
| Gao, Y | 1 |
| Kumar, B | 1 |
| Lenert, P | 1 |
| Allen, B | 1 |
| Miranda, R | 1 |
| Poudel, DR | 1 |
| Karmacharya, P | 1 |
| Donato, A | 1 |
| Smolen, J | 1 |
| Cohen Solal, A | 1 |
| Flader, C | 1 |
| Matsuoka, M | 1 |
| Vazquez Mellado, J | 1 |
| Weisman, M | 1 |
| Westhoff, TH | 1 |
| Buysman, EK | 1 |
| Korrer, S | 1 |
| Hung, TL | 1 |
| Wang, WM | 1 |
| Chiang, CP | 1 |
| Nanavati, P | 1 |
| Hagerty, DT | 1 |
| Öztürk, MA | 1 |
| Mercan, R | 1 |
| Gök, K | 1 |
| Onat, AM | 1 |
| Kısacık, B | 1 |
| Kimyon, G | 1 |
| Balkarlı, A | 1 |
| Kaya, A | 1 |
| Çobankara, V | 1 |
| Balcı, MA | 1 |
| Pamuk, Ö | 1 |
| Yıldırım Çetin, G | 1 |
| Sayarlıoğlu, M | 1 |
| Şenel, S | 1 |
| Tezcan, ME | 1 |
| Küçük, A | 1 |
| Üreten, K | 1 |
| Şahin, Ş | 1 |
| Tufan, A | 1 |
| Jung, JH | 1 |
| Ji, JD | 1 |
| Seo, YH | 1 |
| Kissin, EY | 1 |
| Cagnotto, G | 1 |
| Lima Gomes Ochtrop, M | 1 |
| Lazovskis, J | 1 |
| Thompson, N | 1 |
| Boone-Kukoyi, Z | 1 |
| Shortt, R | 1 |
| Lansiquot, C | 1 |
| Kioko, B | 1 |
| Bonyi, E | 1 |
| Toker, S | 1 |
| Ozturk, B | 1 |
| Aslan, K | 1 |
| Kaminska-Pajak, KA | 1 |
| Dyga, K | 1 |
| Adamczyk, P | 1 |
| Szczepańska, M | 1 |
| Zaniew, M | 1 |
| Beck, B | 1 |
| Tkaczyk, M | 1 |
| Carroll, MB | 1 |
| Smith, DM | 1 |
| Shaak, TL | 1 |
| Qaseem, A | 2 |
| McLean, RM | 1 |
| Starkey, M | 1 |
| Forciea, MA | 2 |
| Denberg, TD | 2 |
| Barry, MJ | 2 |
| Boyd, C | 2 |
| Chow, RD | 2 |
| Fitterman, N | 1 |
| Humphrey, LL | 2 |
| Kansagara, D | 2 |
| Manaker, S | 1 |
| Vijan, S | 2 |
| Wilt, TJ | 2 |
| Newberry, SJ | 1 |
| Motala, A | 1 |
| Booth, M | 1 |
| Maglione, MA | 1 |
| Han, D | 1 |
| Tariq, A | 1 |
| O'Hanlon, CE | 1 |
| Shanman, R | 1 |
| Dudley, W | 1 |
| Shekelle, PG | 1 |
| Harris, RP | 1 |
| Knight, J | 2 |
| Sil, P | 2 |
| Wicklum, H | 1 |
| Surell, C | 1 |
| Rada, B | 2 |
| Coupal, TM | 1 |
| McLaughlin, PD | 1 |
| Ouellette, HA | 1 |
| Meng, J | 1 |
| Hughes, JC | 1 |
| Wallace, JL | 1 |
| Bryant, CL | 1 |
| Salvig, BE | 1 |
| Fourakre, TN | 1 |
| Stone, WJ | 1 |
| El-Zawawy, H | 1 |
| Hayes, CP | 1 |
| Reaves, BJ | 1 |
| Breen, P | 1 |
| Quinn, S | 1 |
| Sokolove, J | 1 |
| Beltrán, LM | 1 |
| Mejía-Chew, C | 1 |
| Tevar, D | 1 |
| Webers, C | 1 |
| Tran-Duy, A | 1 |
| Schoonbrood, T | 1 |
| Jutkowitz, E | 1 |
| Dubreuil, M | 1 |
| Kuntz, KM | 1 |
| Thiele, RG | 5 |
| Kim, ND | 1 |
| Jeong, S | 1 |
| Jung, Y | 1 |
| Park, HH | 1 |
| Su, J | 1 |
| Zhou, T | 1 |
| Tian, J | 1 |
| Vincent, ZL | 1 |
| House, M | 2 |
| Kulasegaran, T | 1 |
| Barroso, LC | 1 |
| Carneiro, FS | 1 |
| Ferreira, TP | 1 |
| Silva, PM | 1 |
| Lusco, MA | 1 |
| Fogo, AB | 2 |
| Najafian, B | 1 |
| Alpers, CE | 1 |
| Min-Shan Ko, A | 1 |
| Wang, SJ | 4 |
| Sun, Z | 1 |
| Ruan, Y | 1 |
| Chen, Q | 1 |
| Gong, W | 1 |
| Xia, W | 1 |
| He, JC | 1 |
| Zhang, A | 1 |
| Wallace, M | 1 |
| Singh, N | 1 |
| Tripathi, CB | 1 |
| Kaithwas, G | 1 |
| Maglio, C | 1 |
| Peltonen, M | 1 |
| Neovius, M | 1 |
| Jacobson, P | 1 |
| Rudin, A | 1 |
| Carlsson, LM | 1 |
| Westerfield, KL | 1 |
| Mounsey, A | 1 |
| Nashelsky, J | 1 |
| Lee, SK | 4 |
| Szabo, SM | 1 |
| Bolzani, A | 1 |
| Cheung, A | 1 |
| Daimon, M | 1 |
| Wang, CH | 1 |
| Ho, Y | 1 |
| Uang, YS | 1 |
| Chiang, SJ | 1 |
| Wang, LH | 1 |
| Corbett, EJM | 1 |
| Pentony, P | 1 |
| Schlee, S | 3 |
| Bollheimer, LC | 3 |
| Bertsch, T | 3 |
| Sieber, CC | 3 |
| Härle, P | 3 |
| Li, XA | 1 |
| Li, LJ | 1 |
| Deng, YH | 1 |
| Lei, GH | 1 |
| Essex, MN | 1 |
| Hopps, M | 1 |
| Bienen, EJ | 1 |
| Udall, M | 1 |
| Mardekian, J | 1 |
| Makinson, GT | 1 |
| Goldberg, EL | 1 |
| Asher, JL | 1 |
| Molony, RD | 1 |
| Shaw, AC | 1 |
| Zeiss, CJ | 1 |
| Morozova-Roche, LA | 1 |
| Herzog, RI | 1 |
| Iwasaki, A | 1 |
| Dixit, VD | 1 |
| Pennick, KE | 1 |
| Holicky, RA | 1 |
| Wilkerson, MJ | 1 |
| Jing, X | 1 |
| Smith, T | 2 |
| Nicolson, B | 1 |
| Clark, B | 2 |
| Callon, K | 2 |
| Haskard, DO | 4 |
| Reid, IR | 2 |
| Popa-Nita, O | 3 |
| Fontenot, A | 1 |
| Harris, P | 1 |
| Macasa, A | 1 |
| Menon, Y | 1 |
| Quinet, R | 1 |
| Angeles, RM | 1 |
| Gong, Y | 1 |
| Iwasaki, Y | 1 |
| Kano, O | 1 |
| Ikeda, K | 1 |
| Schlesinger, I | 1 |
| Montoya, F | 1 |
| Fraile, JM | 3 |
| Le, MT | 1 |
| Shafiu, M | 1 |
| Mu, W | 2 |
| Owens, D | 1 |
| Reinders, MK | 3 |
| Haagsma, C | 1 |
| van Roon, EN | 3 |
| Delsing, J | 2 |
| Brouwers, JR | 3 |
| Miao, Z | 3 |
| Zhao, S | 1 |
| Xu, F | 1 |
| Yan, S | 2 |
| Wang, CY | 2 |
| Sautin, YY | 1 |
| Oliver, WJ | 1 |
| Roncal, C | 1 |
| Gabriela Sanchez-Lozada, L | 1 |
| Rodriguez-Iturbe, B | 1 |
| Benner, SA | 1 |
| Le Goff, B | 1 |
| Berthelot, JM | 1 |
| André, V | 1 |
| Guillot, P | 1 |
| Maugars, Y | 1 |
| Song, EF | 1 |
| Xiang, Q | 1 |
| Ren, KM | 1 |
| Hu, JC | 1 |
| Wu, F | 1 |
| Gong, MF | 1 |
| Bi, HM | 1 |
| Hodges, JS | 2 |
| Asch, SM | 2 |
| Gregory, K | 1 |
| Sheehan, T | 1 |
| Chen, LX | 5 |
| Hair, PI | 1 |
| McCormack, PL | 1 |
| Keating, GM | 1 |
| Barkhuizen, A | 1 |
| Moreland, LW | 2 |
| Waltrip, RW | 6 |
| Maroli, AN | 4 |
| Horowitz, Z | 2 |
| Abrams, B | 3 |
| Dore, RK | 1 |
| Weaver, AL | 1 |
| Cheh, MA | 1 |
| Kennison, RH | 1 |
| Graessler, J | 3 |
| Kao, WL | 1 |
| Rivadeneira, F | 3 |
| Astor, BC | 1 |
| Benjamin, EJ | 1 |
| Witteman, JC | 3 |
| Fox, CS | 5 |
| Riddell, CM | 1 |
| Elliott, M | 1 |
| Cairns, AP | 1 |
| ROBINSON, WD | 3 |
| CONN, JW | 1 |
| Matsumoto, AK | 1 |
| De Vera, M | 2 |
| Rahman, MM | 2 |
| Rankin, J | 1 |
| Kopec, J | 1 |
| Wortmann, RL | 9 |
| Streit, J | 3 |
| Lademacher, C | 4 |
| Joseph-Ridge, N | 4 |
| Thissen, CA | 1 |
| Frank, J | 1 |
| Lucker, GP | 1 |
| Palazzi, C | 1 |
| D'Angelo, S | 1 |
| Pennese, E | 1 |
| Olivieri, I | 1 |
| Sari, I | 1 |
| Akar, S | 1 |
| Pakoz, B | 1 |
| Sisman, AR | 1 |
| Gurler, O | 1 |
| Birlik, M | 1 |
| Onen, F | 1 |
| Akkoc, N | 1 |
| Al-Arfaj, AM | 1 |
| Eftekhari, A | 1 |
| Miao, ZM | 1 |
| Zhao, SH | 1 |
| Yan, SL | 1 |
| Meng, DM | 2 |
| Martin, WJ | 3 |
| Walton, M | 1 |
| Harper, J | 1 |
| Malik, A | 1 |
| Dinnella, JE | 1 |
| Clayburne, GM | 1 |
| Lloyd, E | 3 |
| Shulten, P | 1 |
| Thomas, J | 4 |
| Miller, M | 1 |
| Smith, M | 2 |
| Ahern, M | 1 |
| Kanevets, U | 1 |
| Sharma, K | 1 |
| Dresser, K | 1 |
| Titov, VN | 1 |
| Dmitriev, VA | 1 |
| Oshchepkova, EV | 1 |
| Curhan, G | 4 |
| Traynor, K | 1 |
| Guan, M | 2 |
| Kong, N | 1 |
| Andrade, SE | 3 |
| Briesacher, BA | 1 |
| Raebel, MA | 3 |
| Fouayzi, H | 2 |
| Ockene, IS | 2 |
| Xing, X | 1 |
| Meng, D | 3 |
| Chohan, S | 4 |
| Marasini, B | 1 |
| Massarotti, M | 1 |
| Haggins, DG | 1 |
| York, RH | 1 |
| Yeni, YN | 1 |
| Norquist, JM | 1 |
| Watson, DJ | 1 |
| Patel, PA | 4 |
| Mody, RR | 3 |
| Yu, AP | 2 |
| Cahill, KE | 2 |
| Tang, J | 3 |
| Livesey, G | 1 |
| Courtney, P | 1 |
| Weaver, J | 1 |
| Somani, N | 1 |
| Bauer, TW | 1 |
| Piliang, M | 1 |
| Slobodin, G | 1 |
| Lurie, M | 1 |
| Rosner, I | 1 |
| Odeh, M | 1 |
| Rozenbaum, M | 1 |
| Halpern, R | 1 |
| Fuldeore, MJ | 2 |
| Kolz, M | 1 |
| Sanna, S | 2 |
| Wallace, C | 1 |
| Farrall, M | 1 |
| Nyholt, DR | 1 |
| Aulchenko, Y | 1 |
| Beckmann, JS | 1 |
| Connell, J | 1 |
| Dominiczak, A | 1 |
| Lamina, C | 2 |
| McCarthy, MI | 1 |
| Mooser, V | 1 |
| Munroe, P | 1 |
| Peden, J | 1 |
| Samani, NJ | 2 |
| Schlessinger, D | 1 |
| Uda, M | 1 |
| Waterworth, D | 1 |
| Wang-Sattler, R | 1 |
| Adamski, J | 1 |
| Pramstaller, P | 1 |
| Doering, A | 1 |
| Peltonen, L | 1 |
| Illig, T | 3 |
| Guggino, WB | 1 |
| Hughes, T | 1 |
| Penna, KJ | 1 |
| Zelman, D | 1 |
| Scavulli, J | 1 |
| Wall, GC | 1 |
| Koenigsfeld, CF | 1 |
| Hegge, KA | 1 |
| Bottenberg, MM | 1 |
| Berger, JS | 1 |
| Weinik, MM | 1 |
| Nygaard, HB | 1 |
| Shenoi, S | 1 |
| Shukla, S | 1 |
| Hayman, S | 1 |
| Marcason, W | 1 |
| Kudaeva, FM | 2 |
| Aleksandrova, EN | 1 |
| Volkov, AV | 2 |
| Nasonova, VA | 2 |
| Gracey, E | 1 |
| MacGibbon, A | 1 |
| Palmano, K | 2 |
| Marickar, YM | 1 |
| McMahan, Z | 1 |
| Patel, PC | 1 |
| Markham, DW | 1 |
| Drazner, MH | 1 |
| Mammen, PP | 1 |
| Capsoni, F | 1 |
| Ongari, AM | 1 |
| Reali, E | 1 |
| Catania, A | 1 |
| Evans, R | 2 |
| MacDonald, P | 2 |
| McQueen, F | 1 |
| Winzer, M | 2 |
| Ka, T | 5 |
| Inokuchi, T | 3 |
| Tamada, D | 1 |
| Suda, M | 2 |
| Tsutsumi, Z | 20 |
| Okuda, C | 1 |
| Takahashi, S | 20 |
| Moriwaki, Y | 22 |
| Artmann, A | 1 |
| Ratzenböck, M | 1 |
| Noszian, I | 1 |
| Trieb, K | 1 |
| Stark, K | 2 |
| Reinhard, W | 2 |
| Grassl, M | 1 |
| Erdmann, J | 2 |
| Schunkert, H | 2 |
| Lea, RA | 1 |
| Chiang, HC | 1 |
| Wang, TN | 3 |
| Huang, MC | 1 |
| Ou, TT | 1 |
| Lin, GT | 1 |
| Wiesner, T | 1 |
| Fried, I | 1 |
| Keitel, W | 3 |
| Khitrik, NM | 1 |
| Didkovskiĭ, NA | 1 |
| Malashenkova, IK | 1 |
| Egorov, IV | 2 |
| Selvi, E | 1 |
| Friedman, JH | 1 |
| Sachs, L | 1 |
| Batra, KL | 1 |
| Zimmermann, B | 1 |
| McClory, J | 1 |
| Said, N | 1 |
| Kobayashi, S | 1 |
| Okamoto, H | 1 |
| Momohara, S | 1 |
| Tomatsu, T | 1 |
| Bacani, AK | 1 |
| Bond, JR | 1 |
| Milks, J | 1 |
| Manek, NJ | 2 |
| Ning, TC | 1 |
| Igawa, O | 4 |
| Shigemasa, C | 2 |
| Brandstätter, A | 1 |
| Kiechl, S | 1 |
| Hunt, SC | 1 |
| Coassin, S | 2 |
| Paulweber, B | 2 |
| Kramer, F | 1 |
| Summerer, M | 1 |
| Willeit, J | 1 |
| Kedenko, L | 1 |
| Adams, TD | 1 |
| Briesacher, B | 1 |
| Ernst, ME | 1 |
| Fravel, MA | 1 |
| Pozzuoli, A | 1 |
| Frezzato, F | 1 |
| Agostini, C | 1 |
| Schorn, C | 1 |
| Strysio, M | 1 |
| Kortan, N | 1 |
| Roebuck, J | 1 |
| Law, YY | 1 |
| Lue, KH | 1 |
| Lu, KH | 1 |
| Hu, QH | 1 |
| Jiao, RQ | 1 |
| Lv, YZ | 1 |
| Kong, LD | 1 |
| Espinoza, LR | 2 |
| Wells, AF | 1 |
| Yeap, SS | 1 |
| Goh, EM | 1 |
| Tanigawa, T | 1 |
| Martinon, F | 2 |
| Nowatzky, J | 1 |
| Howard, R | 1 |
| Alonso, A | 2 |
| Sovell, KA | 1 |
| Mascitelli, L | 1 |
| Pezzetta, F | 1 |
| Goldstein, MR | 1 |
| Ostović, KT | 1 |
| Kaić, G | 1 |
| Ostović, I | 1 |
| Skoro, M | 1 |
| Novak, NP | 1 |
| Morović-Vergles, J | 1 |
| Perry, ME | 2 |
| Madhok, R | 1 |
| Simon, HB | 2 |
| Regule, D | 1 |
| Wong, S | 1 |
| Mason, B | 1 |
| Sarma, P | 1 |
| Das, D | 1 |
| Deka, P | 1 |
| Deka, AC | 1 |
| Ng, G | 1 |
| Chau, EM | 1 |
| Hernandez-Baldizon, S | 1 |
| Carotti, M | 1 |
| Ciapetti, A | 1 |
| Akkara Veetil, BM | 1 |
| Pile, JC | 1 |
| Thorens, B | 1 |
| Ruoff, GE | 1 |
| de Miguel, ME | 1 |
| Martínez, P | 2 |
| Lundelin, KJ | 1 |
| Vázquez, JJ | 3 |
| Hernández Cuevas, C | 1 |
| Hernández Roque, L | 1 |
| Terán, L | 1 |
| Espinoza, J | 1 |
| Esquivel-Valerio, JA | 1 |
| Goycochea-Robles, MV | 1 |
| Aceves, FJ | 1 |
| Bernard, AG | 1 |
| Ventura, L | 1 |
| Shumsky, C | 1 |
| Hernández Garduño, A | 1 |
| Chiu, CT | 1 |
| Ko, YS | 1 |
| Hwang, JS | 1 |
| Chang, HC | 1 |
| Iharada, M | 1 |
| Fujimoto, T | 1 |
| Hiasa, M | 1 |
| Guo, CY | 1 |
| Roberts, LJ | 1 |
| Ganson, NJ | 3 |
| Kelly, SJ | 4 |
| Santisteban, I | 1 |
| Scarlett, E | 2 |
| Jaggers, D | 1 |
| Indridason, OS | 1 |
| Thorleifsson, G | 1 |
| Edvardsson, V | 1 |
| de Vegt, F | 1 |
| d'Ancona, FC | 1 |
| den Heijer, M | 1 |
| Wetzels, JF | 1 |
| Franzson, L | 1 |
| Rafnar, T | 2 |
| Kristjansson, K | 1 |
| Bjornsdottir, US | 1 |
| Eyjolfsson, GI | 2 |
| Kiemeney, LA | 2 |
| Kong, A | 2 |
| Palsson, R | 1 |
| Hsiao, SJ | 1 |
| Vaynrub, M | 1 |
| Furer, V | 1 |
| Hettiarachchi, D | 1 |
| Ben, C | 1 |
| Shelling, G | 1 |
| Tabara, Y | 1 |
| Kohara, K | 1 |
| Kawamoto, R | 1 |
| Hiura, Y | 1 |
| Nishimura, K | 1 |
| Morisaki, T | 1 |
| Kokubo, Y | 1 |
| Okamura, T | 1 |
| Tomoike, H | 1 |
| Iwai, N | 1 |
| Miki, T | 1 |
| Burns, CM | 1 |
| Ochoa, CD | 1 |
| Valderrama, V | 1 |
| Mejia, J | 1 |
| Rondon, F | 1 |
| Villaroya, N | 1 |
| Restrepo, JF | 1 |
| Iglesias-Gamarra, A | 1 |
| Lebedeva, MV | 2 |
| Stakhova, TIu | 1 |
| Zaĭtseva, LI | 1 |
| Selivanova, OIu | 1 |
| Severova, MM | 1 |
| Yoo, Y | 1 |
| Seo, YJ | 1 |
| Huh, M | 1 |
| Yoo, JH | 1 |
| Yun, KH | 1 |
| Kitamura, K | 1 |
| Kaneko, S | 1 |
| Yan, K | 1 |
| Yamada, H | 1 |
| Shimada, H | 1 |
| Kimura, T | 1 |
| Katada, T | 1 |
| Fukutomi, T | 1 |
| Seki, G | 1 |
| Fujita, T | 3 |
| Yamada, A | 1 |
| Wempe, MF | 1 |
| Sakurai, H | 1 |
| VanItallie, TB | 1 |
| Panzner, I | 2 |
| Aust, D | 1 |
| Bhansing, KJ | 1 |
| van Bon, L | 1 |
| Handler, J | 1 |
| Glazer, NL | 1 |
| Chasman, DI | 2 |
| Aspelund, T | 1 |
| Eiriksdottir, G | 1 |
| Launer, L | 1 |
| Nalls, M | 1 |
| Hernandez, D | 1 |
| Arking, DE | 1 |
| Linda Kao, WH | 1 |
| Chonchol, M | 1 |
| Haritunians, T | 1 |
| Lumley, T | 1 |
| Shlipak, M | 1 |
| Larson, MG | 1 |
| Upadhyay, A | 1 |
| Stricker, B | 1 |
| Parker, AN | 1 |
| Siscovick, DS | 2 |
| Cipriani, S | 1 |
| Rainer, F | 1 |
| Piret, SE | 1 |
| Danoy, P | 1 |
| Dahan, K | 2 |
| Reed, AA | 1 |
| Pryce, K | 1 |
| Wong, W | 1 |
| Müller, T | 1 |
| Kotanko, P | 1 |
| Lhotta, K | 2 |
| Brown, MA | 2 |
| Thakker, RV | 1 |
| FIESSINGER, N | 1 |
| Quillen, DM | 1 |
| Zychowicz, ME | 1 |
| Pope, RS | 2 |
| Graser, E | 1 |
| Jordan, S | 2 |
| Willett, W | 1 |
| Cayley, WE | 1 |
| Meyer zu Schwabedissen, HE | 1 |
| Kroemer, HK | 1 |
| Pu, J | 1 |
| Bu, Y | 1 |
| Liao, F | 1 |
| Harris, DJ | 1 |
| Kuritzky, L | 1 |
| Panchal, R | 1 |
| Peterson, DM | 1 |
| Flemmig, J | 1 |
| Kuchta, K | 1 |
| Arnhold, J | 1 |
| Rauwald, HW | 1 |
| Maranian, P | 1 |
| Yu, JW | 1 |
| Yang, TG | 1 |
| Diao, WX | 1 |
| Cai, XQ | 1 |
| Hu, DL | 1 |
| Chen, CQ | 1 |
| Chen, ZX | 1 |
| Widerøe, TE | 1 |
| Wijnands, JM | 1 |
| Arts, IC | 1 |
| Dagnelie, PC | 1 |
| Stehouwer, CD | 1 |
| Ching, CT | 1 |
| Sun, TP | 1 |
| Tsai, CL | 1 |
| Huang, HH | 1 |
| Kuo, JF | 1 |
| Lai, LH | 1 |
| Chien, MY | 1 |
| Tseng, HH | 1 |
| Pan, HT | 1 |
| Huang, SY | 1 |
| Shieh, HL | 1 |
| Liu, CM | 1 |
| Huang, HW | 1 |
| Xue, HD | 1 |
| Zhang, YQ | 1 |
| Xu, K | 1 |
| Jin, ZY | 1 |
| Ghaemi-Oskouie, F | 1 |
| Cohen, MG | 1 |
| Akl, KF | 1 |
| James, J | 1 |
| Tore, S | 2 |
| Casula, S | 1 |
| Casu, G | 1 |
| Pistidda, P | 1 |
| Persico, I | 2 |
| Sassu, A | 1 |
| Maestrale, GB | 1 |
| Mele, C | 1 |
| Caruso, MR | 1 |
| Bonerba, B | 1 |
| Usai, P | 1 |
| Deiana, I | 1 |
| Thornton, T | 1 |
| Forabosco, P | 1 |
| Zhoub, S | 1 |
| Chu, N | 2 |
| Charles, BA | 1 |
| Shriner, D | 2 |
| Doumatey, A | 1 |
| Herbert, A | 1 |
| Gerry, NP | 1 |
| Christman, MF | 1 |
| Adeyemo, A | 1 |
| Rotimi, CN | 2 |
| Kessenich, CR | 1 |
| Jackson, RL | 3 |
| Keller, DL | 1 |
| Wertheimer, AI | 1 |
| Davis, MW | 1 |
| Lauterio, TJ | 1 |
| Dubost, JJ | 1 |
| Mathieu, S | 1 |
| Soubrier, M | 1 |
| Allaeys, I | 1 |
| Rusu, D | 1 |
| Picard, S | 1 |
| Pouliot, M | 1 |
| Borgeat, P | 1 |
| Poubelle, PE | 1 |
| GUTMAN, AB | 35 |
| YÜ, TF | 39 |
| Tirado-González, M | 1 |
| González-Serva, A | 1 |
| Shaw, O | 1 |
| Messerli, FH | 1 |
| Makani, H | 1 |
| Halpern, D | 1 |
| Zhang, LY | 1 |
| Wittköpper, K | 1 |
| Emons, J | 1 |
| El-Armouche, A | 1 |
| Shen, L | 2 |
| Ji, HF | 1 |
| Uh, M | 1 |
| Watson, M | 1 |
| Wong, H | 1 |
| Chun, W | 1 |
| Naoyuki, K | 4 |
| Tatsuo, H | 4 |
| Hada, T | 11 |
| Kohri, K | 5 |
| Matsuzawa, Y | 6 |
| Shin, F | 3 |
| Toshikazu, H | 3 |
| Kenjiro, K | 3 |
| Toshitaka, N | 3 |
| Takanori, U | 3 |
| Tetsuya, Y | 3 |
| Hisashi, Y | 3 |
| Yuji, M | 3 |
| Chuang, SY | 2 |
| Hsieh, YT | 1 |
| Pan, WH | 3 |
| Howard, RG | 1 |
| Swearingen, CJ | 1 |
| Horsley, A | 1 |
| Helm, J | 1 |
| Brennan, A | 1 |
| Bright-Thomas, R | 1 |
| Webb, K | 1 |
| Jones, A | 1 |
| Boers, M | 1 |
| Maksymowych, WP | 1 |
| Yeh, WT | 2 |
| Wu, YY | 1 |
| Liu, CT | 1 |
| Semmo, M | 1 |
| Akylbekova, EL | 1 |
| Wyatt, SB | 1 |
| Palmer, C | 1 |
| Reilly, M | 1 |
| Shlipak, MG | 1 |
| Siscovick, D | 1 |
| Flessner, MF | 1 |
| Cupples, LA | 1 |
| Riedel, AA | 1 |
| Zarotsky, V | 1 |
| Pandya, BJ | 2 |
| Dabbous, O | 2 |
| Chiou, SJ | 1 |
| Kriegsmann, J | 1 |
| Lange, U | 1 |
| Hamburger, SA | 1 |
| Messina, M | 1 |
| Messina, VL | 1 |
| Chan, P | 1 |
| Keith, MP | 2 |
| Gilliland, WR | 2 |
| Bollée, G | 1 |
| Flamant, M | 1 |
| Morinière, V | 1 |
| Pawtowski, A | 1 |
| Heidet, L | 1 |
| Lacombe, D | 1 |
| Pirson, Y | 1 |
| Antignac, C | 2 |
| Knebelmann, B | 1 |
| Tardella, M | 1 |
| Arlet, JB | 1 |
| Ribeil, JA | 1 |
| Chatellier, G | 1 |
| Pouchot, J | 1 |
| de Montalembert, M | 1 |
| Prié, D | 1 |
| Courbebaisse, M | 1 |
| Alvarez-Lario, B | 1 |
| Macarrón-Vicente, J | 1 |
| Guimarães, LS | 1 |
| Black, DF | 1 |
| Yébenes, MJ | 1 |
| Ureña, I | 1 |
| Adenwalla, HN | 1 |
| O'Connor, CR | 1 |
| Shipley, M | 1 |
| Sachs, D | 1 |
| Coelho, FM | 1 |
| Fagundes, CT | 1 |
| Silveira, TN | 1 |
| Cunha, LD | 1 |
| Quesniaux, V | 1 |
| Peres, RS | 1 |
| Cunha, TM | 1 |
| Cunha, FQ | 1 |
| Policarpio-Nicolas, ML | 1 |
| Valente, PT | 1 |
| Leiszler, M | 1 |
| Poddar, S | 1 |
| Fletcher, A | 1 |
| Walters, GB | 1 |
| Helgadottir, HT | 1 |
| Helgason, A | 1 |
| Gudjonsson, SA | 1 |
| Zanon, C | 1 |
| Besenbacher, S | 1 |
| Bjornsdottir, G | 1 |
| Magnusson, OT | 1 |
| Magnusson, G | 1 |
| Hjartarson, E | 1 |
| Saemundsdottir, J | 1 |
| Gylfason, A | 1 |
| Jonasdottir, A | 1 |
| Karason, A | 1 |
| Stefansson, H | 1 |
| Andreassen, OA | 1 |
| Pedersen, JH | 1 |
| Pack, AI | 1 |
| de Visser, MC | 1 |
| Geirsson, AJ | 1 |
| Masson, G | 1 |
| Rho, YH | 1 |
| Herbert, JD | 1 |
| Coulson, JO | 1 |
| Coulson, TD | 1 |
| McAdams DeMarco, MA | 1 |
| Young, JH | 1 |
| Mittag, F | 1 |
| Wuenschel, M | 1 |
| Chefo, S | 2 |
| Chales, G | 1 |
| Xing, RL | 1 |
| Uratsuji, H | 1 |
| Tada, Y | 1 |
| Kawashima, T | 1 |
| Kamata, M | 1 |
| Hau, CS | 1 |
| Asano, Y | 1 |
| Sugaya, M | 1 |
| Kadono, T | 1 |
| Asahina, A | 1 |
| Tamaki, K | 1 |
| Yashio, K | 1 |
| Katayama, Y | 1 |
| Takashima, T | 1 |
| Ishiguro, N | 1 |
| Doi, H | 1 |
| Suzuki, M | 1 |
| Wada, Y | 3 |
| Watanabe, Y | 1 |
| Gao, A | 1 |
| Mitroulis, I | 2 |
| Kambas, K | 2 |
| Chrysanthopoulou, A | 1 |
| Skendros, P | 1 |
| Apostolidou, E | 1 |
| Kourtzelis, I | 1 |
| Drosos, GI | 1 |
| Ritis, K | 2 |
| Suresh, E | 2 |
| Das, P | 1 |
| Jin, M | 1 |
| Yang, I | 2 |
| Luo, JJ | 1 |
| Yang, XF | 1 |
| Frediani, B | 1 |
| Delle Sedie, A | 1 |
| Bombardieri, S | 1 |
| Iagnocco, A | 1 |
| Valesini, G | 1 |
| Avhad, G | 1 |
| Dandale, A | 1 |
| Ghate, S | 1 |
| Dhurat, R | 1 |
| Lingala, B | 2 |
| Hariri, A | 1 |
| Rakieh, C | 1 |
| Conaghan, PG | 1 |
| Marson, P | 1 |
| Pasero, G | 4 |
| De Angelis, R | 2 |
| Leoncini, G | 1 |
| Lipkowitz, MS | 1 |
| Park, H | 1 |
| Rascati, KL | 1 |
| Prasla, K | 1 |
| McBayne, T | 1 |
| Burns, LC | 1 |
| Koenig, N | 1 |
| Abufayyah, M | 1 |
| Law, G | 1 |
| Hu, M | 1 |
| Tomlinson, B | 1 |
| Kakar, S | 1 |
| Ida, CM | 1 |
| Laurini, JA | 1 |
| Moder, KG | 1 |
| Koyama, H | 1 |
| Shoji, T | 1 |
| Sumida, C | 1 |
| Koga, M | 1 |
| Dockerty, JL | 1 |
| Shin, J | 1 |
| Kong, M | 1 |
| Li, WM | 1 |
| Huang, SP | 1 |
| Tsai, CC | 1 |
| Chang, AW | 1 |
| Lin, YL | 1 |
| Clower, J | 1 |
| Jennings, W | 1 |
| Koga, T | 1 |
| Satomura, K | 1 |
| Izumi, M | 1 |
| Torigoshi, T | 1 |
| Maeda, Y | 1 |
| Izumi, Y | 1 |
| Jiuchi, Y | 1 |
| Miyashita, T | 1 |
| Yamasaki, S | 1 |
| Aiba, Y | 1 |
| Komori, A | 1 |
| Nakamura, M | 1 |
| Motokawa, S | 1 |
| Ishibashi, H | 1 |
| Kushnarenko, NN | 1 |
| Govorin, AV | 1 |
| Shcherbakova, OA | 1 |
| Sotnikova, SG | 1 |
| Ivanitskaia, OV | 1 |
| Kotz, J | 1 |
| Hofmann, F | 1 |
| Forsythe, A | 1 |
| Lehmann, RA | 1 |
| Schneck, L | 1 |
| Greenberg, JD | 1 |
| Cronstein, BN | 3 |
| Sedlis, SP | 1 |
| Zgaga, L | 2 |
| Kyle, J | 1 |
| Agakov, F | 1 |
| Walker, M | 1 |
| McNeill, G | 1 |
| Kunitskaia, NA | 1 |
| Ar'ev, AL | 1 |
| He, J | 1 |
| Peng, DQ | 1 |
| Kao, LW | 1 |
| Mylona, EE | 1 |
| Mouktaroudi, M | 1 |
| Makri, S | 1 |
| Pistiki, A | 1 |
| Georgitsi, M | 1 |
| Savva, A | 1 |
| van der Meer, JW | 1 |
| Giamarellos-Bourboulis, EJ | 1 |
| Lim, AY | 1 |
| Tan, CH | 1 |
| Lateef, A | 1 |
| Lau, TC | 1 |
| George, RL | 1 |
| Indraratna, PL | 1 |
| Bhalla, V | 1 |
| Hou, CW | 1 |
| Lee, YC | 1 |
| Hung, HF | 1 |
| Fu, HW | 1 |
| Jeng, KC | 1 |
| Yu, P | 1 |
| Di, D | 1 |
| Xue, R | 1 |
| Cao, G | 1 |
| Pan, Z | 1 |
| Gong, C | 1 |
| Tong, CY | 1 |
| How, CH | 1 |
| Goh, LH | 1 |
| Rock, KL | 2 |
| Kataoka, H | 1 |
| Lai, JJ | 1 |
| Conway, R | 1 |
| Coughlan, RJ | 1 |
| Carey, JJ | 1 |
| Krüger, K | 1 |
| Ordóñez, S | 1 |
| Reeves, Q | 1 |
| Katsiki, N | 1 |
| Karagiannis, A | 1 |
| Athyros, VG | 1 |
| Yee, J | 1 |
| Bleyer, AJ | 3 |
| Kmoch, S | 2 |
| Bobulescu, IA | 1 |
| Moe, OW | 2 |
| Kedar, E | 1 |
| Mehta, TH | 1 |
| Murea, M | 1 |
| Dave, AJ | 1 |
| Kelly, VM | 1 |
| Yakut, S | 1 |
| Cetin, Z | 1 |
| Arman, M | 1 |
| Akbas, H | 1 |
| Manguoglu, AE | 1 |
| Luleci, G | 1 |
| Zochling, J | 1 |
| Dillon, A | 1 |
| Suppiah, R | 1 |
| Grassi, D | 1 |
| Ferri, L | 1 |
| Di Giosia, P | 1 |
| Cheli, P | 1 |
| Properzi, G | 1 |
| Rivard, C | 1 |
| Pluta, RM | 1 |
| Burke, AE | 1 |
| Livingston, EH | 1 |
| McLaughlin, RJ | 1 |
| Yilmaz, S | 1 |
| Celik, G | 1 |
| Gündogdu, A | 1 |
| Choi, CM | 1 |
| Lew, BL | 1 |
| Sim, WY | 1 |
| Garay, R | 1 |
| Torralba, KD | 1 |
| De Jesus, E | 1 |
| Rachabattula, S | 1 |
| Gheita, TA | 1 |
| El-Fishawy, HS | 1 |
| Nasrallah, MM | 1 |
| Waldron, JL | 1 |
| Ashby, HL | 1 |
| Razavi, C | 1 |
| Thomas, OL | 1 |
| Chugh, S | 1 |
| Deshpande, S | 1 |
| Ford, C | 1 |
| Gama, R | 1 |
| Krumsiek, J | 1 |
| Hundertmark, C | 1 |
| O'Seaghdha, CM | 1 |
| Johnson, AD | 1 |
| Struchalin, M | 1 |
| Middelberg, RP | 1 |
| Brown, MJ | 1 |
| Zemunik, T | 1 |
| Huffman, J | 1 |
| Yengo, L | 1 |
| Zhao, JH | 1 |
| Feitosa, MF | 1 |
| Bakker, SJ | 1 |
| Steri, M | 1 |
| Lagou, V | 1 |
| Rose, LM | 1 |
| Müller, C | 1 |
| Oldmeadow, C | 1 |
| Putku, M | 1 |
| Czamara, D | 1 |
| Kraft, P | 1 |
| Frogheri, L | 1 |
| Thun, GA | 1 |
| Launer, LJ | 1 |
| McArdle, P | 1 |
| Shuldiner, AR | 1 |
| Schallert, M | 1 |
| Jacobs, DR | 1 |
| Rotter, JI | 1 |
| Balkau, B | 1 |
| Froguel, P | 1 |
| Salumets, A | 1 |
| Khaw, KT | 1 |
| Langenberg, C | 1 |
| Wareham, NJ | 1 |
| Isaacs, A | 1 |
| Kraja, A | 1 |
| Wild, PS | 1 |
| Scott, RJ | 1 |
| Holliday, EG | 1 |
| Org, E | 1 |
| Bandinelli, S | 1 |
| Lupo, A | 1 |
| Lattka, E | 1 |
| Theis, F | 1 |
| Bruinenberg, M | 1 |
| Stolk, RP | 1 |
| Winkelmann, BR | 1 |
| Boehm, BO | 1 |
| Lucae, S | 1 |
| Mudgal, P | 1 |
| Plenge, RM | 1 |
| Mateo Leach, I | 1 |
| van Gilst, WH | 1 |
| Ongen, H | 1 |
| Imboden, M | 1 |
| von Eckardstein, A | 1 |
| Cucca, F | 1 |
| Piras, MG | 1 |
| Ernst, F | 1 |
| Prokopenko, I | 1 |
| Shin, SY | 1 |
| Viikari, J | 1 |
| Nelson, CP | 1 |
| Meschia, JF | 1 |
| Sharma, P | 2 |
| Singleton, AB | 1 |
| Zeller, T | 1 |
| Laan, M | 1 |
| Hillege, HL | 1 |
| Probst-Hensch, NM | 1 |
| Bouatia-Naji, N | 1 |
| Loos, RJ | 1 |
| Borecki, IB | 1 |
| Wolffenbuttel, BH | 1 |
| Navis, G | 1 |
| Raitakari, O | 1 |
| Meltzer, M | 1 |
| Martínez-Indart, L | 1 |
| Pijoan, JI | 3 |
| Hsu, SN | 1 |
| Chiu, SK | 1 |
| Ye, P | 1 |
| Cheng, Q | 1 |
| Mei, M | 1 |
| Luo, T | 1 |
| Russell, E | 1 |
| Schiltz, C | 2 |
| Prudhommeaux, F | 2 |
| Meunier, A | 1 |
| Champy, R | 2 |
| Callebert, J | 1 |
| Abdelrahman, M | 1 |
| Rafi, A | 1 |
| Ghacha, R | 1 |
| Youmbissi, JT | 1 |
| Qayyum, T | 1 |
| Karkar, A | 1 |
| Spieker, LE | 1 |
| Ruschitzka, FT | 1 |
| Lüscher, TF | 1 |
| Noll, G | 1 |
| Isomäki, H | 4 |
| Dincer, HE | 1 |
| Dincer, AP | 1 |
| Levinson, DJ | 5 |
| Akkasilpa, S | 2 |
| Deesomchok, U | 2 |
| Calabozo, M | 5 |
| Ruibal, A | 2 |
| Fukuchi, M | 1 |
| Shekarriz, B | 1 |
| Ziegler, E | 1 |
| Ohta, H | 2 |
| Pak, CY | 6 |
| Poindexter, JR | 5 |
| Peterson, RD | 4 |
| Koska, J | 1 |
| Sakhaee, K | 4 |
| Lin, JL | 2 |
| Tan, DT | 1 |
| Ho, HH | 3 |
| Yu, CC | 2 |
| Sorensen, CM | 1 |
| Chandhoke, PS | 1 |
| Park, YS | 2 |
| Yoon, SJ | 1 |
| Wakefield, RJ | 1 |
| Emery, P | 1 |
| Pease, C | 1 |
| Hepburn, AL | 3 |
| Hogarth, MB | 1 |
| Ball, SG | 1 |
| Kaye, SA | 2 |
| Cardona, F | 1 |
| Tinahones, FJ | 1 |
| Collantes, E | 1 |
| Escudero, A | 1 |
| García-Fuentes, E | 1 |
| Soriguer, FJ | 1 |
| Nakajima, H | 1 |
| Iwatani, M | 4 |
| Yamanouchi, T | 7 |
| Matsumoto, Y | 1 |
| Mineo, I | 2 |
| Nakagawa, C | 1 |
| Tarui, S | 4 |
| Yoshio, N | 1 |
| Moe, O | 1 |
| Preminger, GM | 4 |
| Pietrow, P | 1 |
| Ekeruo, W | 1 |
| Moyer, RA | 1 |
| John, DS | 1 |
| Dutton, CJ | 1 |
| Taylor, P | 1 |
| Woodard, AS | 1 |
| Shihabi, Z | 1 |
| Sandhu, J | 1 |
| Satko, SG | 1 |
| Weller, N | 1 |
| Deterding, E | 1 |
| McBride, D | 1 |
| Gorry, MC | 1 |
| Ganier, D | 1 |
| Hart, TC | 2 |
| Huang, CT | 1 |
| Chen, ML | 1 |
| Huang, LL | 1 |
| Mao, IF | 1 |
| Nitti, F | 1 |
| Fumagalli, M | 1 |
| Incorvaia, C | 1 |
| García-Pavía, P | 1 |
| Rivero, M | 1 |
| Ahmed, M | 1 |
| García-Puig, J | 2 |
| Adams-Huet, B | 2 |
| Pearle, MS | 1 |
| Lien, LC | 1 |
| SEIFERT, P | 1 |
| WEISS, TE | 3 |
| MULLER, AF | 4 |
| BAUER, W | 2 |
| BENEDICT, JD | 6 |
| BIEN, EJ | 5 |
| STETTEN, D | 8 |
| TALBOTT, JH | 16 |
| BISHOP, C | 9 |
| BEECHER, L | 1 |
| BOLLIGER, A | 2 |
| GROSS, R | 2 |
| BALLABIO, CB | 3 |
| AMIRA, A | 1 |
| DIOGUARDI, N | 1 |
| WASSERMAN, LR | 1 |
| LASTER, L | 6 |
| HOFFMAN, WS | 2 |
| SIROTA, JH | 2 |
| MARSON, FG | 4 |
| MASON, RM | 2 |
| BONELLI, M | 1 |
| BUCHBORN, E | 1 |
| WENK, M | 1 |
| BEYER, A | 1 |
| RANDOLPH, V | 1 |
| BUZARD, JA | 1 |
| ZUMOFF, B | 1 |
| ZUCKER, M | 1 |
| CANOA, E | 2 |
| CIFUENTES DELATTE, L | 2 |
| HAUGE, M | 1 |
| HARVALD, B | 1 |
| PATON, BC | 1 |
| CHENKIN, T | 1 |
| BURNS, JJ | 1 |
| BRODIE, BB | 1 |
| CIRLA, E | 1 |
| MOORE, CB | 1 |
| POMMATAU, E | 1 |
| WYNGAARDEN, JB | 16 |
| Jeune, M | 1 |
| Charrat, A | 1 |
| Bertrand, J | 1 |
| VIOLA, PL | 1 |
| COODLEY, E | 1 |
| BLAIR, AE | 1 |
| HILLEY, L | 1 |
| BACRI, J | 1 |
| SEEGMILLER, JE | 42 |
| LIDDLE, LV | 1 |
| LACAPERE, J | 1 |
| OREN, BG | 1 |
| RICH, M | 1 |
| BELLE, MS | 1 |
| GOLDTHWAIT, JC | 1 |
| BUTLER, CF | 1 |
| STILLMAN, JS | 1 |
| BARBIERI, P | 2 |
| FUOCO, L | 1 |
| RUSCONI, A | 1 |
| SALA, G | 1 |
| BLACK, H | 1 |
| YALOW, RS | 1 |
| BERSON, SA | 1 |
| BLATT, IM | 1 |
| MIKKELSEN, WM | 12 |
| DENNING, RM | 1 |
| GOLDSMITH, LI | 1 |
| BLAHOS, J | 2 |
| LAVICKA, J | 3 |
| ATSMON, A | 1 |
| DE VRIES, A | 14 |
| LAZEBNIK, J | 2 |
| SALINGER, H | 1 |
| ARONOFF, A | 1 |
| BARKUM, H | 1 |
| BARCELO, P | 9 |
| PUIG MUSET, P | 1 |
| SANS SOLA, L | 2 |
| BECKER, JH | 1 |
| BECKETT, AG | 1 |
| LEWIS, JG | 1 |
| FREEMAN, RB | 1 |
| DUNCAN, GG | 4 |
| GRAYZEL, AI | 2 |
| LIDDLE, L | 1 |
| MUGLER, A | 9 |
| MCCARTY, DJ | 22 |
| HOLLANDER, JL | 2 |
| VILLA, L | 1 |
| LOVE, E | 1 |
| KERSLEY, GD | 8 |
| GIBBS, AR | 1 |
| VACHTENHEIM, J | 3 |
| SVOJITKA, J | 1 |
| YU, FT | 1 |
| ADLER, M | 1 |
| JAVITT, NB | 1 |
| SISON, AB | 1 |
| REYES, MG | 1 |
| GUTIERREZ, MT | 1 |
| SNODELL, FE | 1 |
| THOMPSON, GR | 4 |
| DUFF, IF | 4 |
| GALINDEZ, H | 1 |
| VIOLLE, PL | 1 |
| HOWELL, RR | 8 |
| EANES, ED | 1 |
| ITSKOVITZ, HD | 1 |
| SELLERS, AM | 1 |
| HOLLANDER, E | 7 |
| ATTALI, P | 1 |
| PRUNIER, P | 1 |
| SUTTENFIELD, FD | 1 |
| REUBI, F | 1 |
| VORBURGER, C | 1 |
| WALLACE, SL | 7 |
| BERNSTEIN, D | 2 |
| YU, TS | 1 |
| BERGER, L | 6 |
| ZVAIFLER, NJ | 2 |
| PEKIN, TJ | 1 |
| ZELMAN, S | 1 |
| COMMANDRE, F | 1 |
| LAPEYRE, L | 1 |
| BERNET, C | 1 |
| BARALIS, G | 1 |
| PRUVOST, JY | 1 |
| DELBARRE, F | 25 |
| PERLES, L | 1 |
| MARTINE AU, J | 1 |
| LEPROVOST, J | 1 |
| RICCIONI, N | 1 |
| DUNCAN, H | 2 |
| WAKIM, KG | 1 |
| WARD, LE | 4 |
| NUGENT, CA | 4 |
| MACDIARMID, WD | 2 |
| TYLER, FH | 3 |
| SERRE, H | 4 |
| SIMON, L | 3 |
| CLAUSTRE, J | 3 |
| JOCSON, CT | 1 |
| PERET RIERA, J | 1 |
| MURIACH, V | 1 |
| BALAGUER VINTRO, I | 1 |
| MARTEL, W | 2 |
| RAKIC, MT | 3 |
| HAYES, JT | 1 |
| AYVAZIAN, JH | 1 |
| AYVAZIAN, IF | 1 |
| MUSTARD, JF | 1 |
| MURPHY, EA | 1 |
| OGRYZLO, MA | 5 |
| SMYTHE, HA | 1 |
| BORRACHERO, J | 2 |
| MADRID, J | 1 |
| ROSE, BS | 5 |
| PRIOR, IA | 8 |
| YUE, TF | 2 |
| FRANCOMANERA, R | 1 |
| AUSCHER, C | 19 |
| VERDU, R | 1 |
| YEARWOOD, HM | 1 |
| BAKER, OA | 1 |
| WILLIAMSON, CI | 1 |
| BEETHAM, WP | 1 |
| LABOUCHE, F | 1 |
| DULUC, J | 1 |
| BARREAU, J | 1 |
| THOMAS, E | 3 |
| SCOTT, JT | 54 |
| DIXON, AS | 1 |
| BYWATERS, EG | 2 |
| DAVIDSON, F | 2 |
| FOX, SL | 1 |
| AGNOLETTO, A | 1 |
| CARNELUTTI, M | 1 |
| CONTI, M | 1 |
| FOA, V | 1 |
| ROSENTHAL, IM | 1 |
| GABALLAH, S | 1 |
| RAFELSON, ME | 1 |
| ITO, H | 1 |
| OKAZAKI, M | 1 |
| AKAOKA, I | 10 |
| KOYAMA, S | 1 |
| BRILL, JM | 2 |
| KELLGREN, JH | 1 |
| DENMAN, AM | 1 |
| SZUR, L | 1 |
| ANSELL, BM | 1 |
| MCKECHNIE, JK | 1 |
| FELDMAN, EB | 4 |
| RICHET, G | 4 |
| ALBAHARY, C | 1 |
| ARDAILLOU, R | 2 |
| SULTAN, C | 1 |
| MOREL-MAROGER, A | 1 |
| SIMPSON, FO | 1 |
| WAAL, HJ | 1 |
| LESCH, M | 2 |
| NYHAN, WL | 5 |
| CANER, JE | 1 |
| DECKER, JL | 4 |
| GASPARDY, G | 1 |
| SCHULHOF, O | 1 |
| VIDA, M | 1 |
| RYCKEWAERT, A | 16 |
| KAHN, MF | 3 |
| FRENEAUX, B | 1 |
| DE SEZE, S | 9 |
| ICHISEKI, H | 1 |
| ARAI, K | 1 |
| REUTTER, F | 2 |
| SCHAUB, F | 1 |
| GRAVANO, L | 1 |
| MEYER, JS | 1 |
| KYPROS, GP | 1 |
| GILROY, J | 1 |
| AMAKO, T | 1 |
| YAMAMOTO, M | 2 |
| ODA, H | 2 |
| FUJIKI, A | 1 |
| HOLLOWAY, VP | 5 |
| FISHBACK, DB | 1 |
| CASTOR, LH | 1 |
| HANSEN, OE | 3 |
| TVETER, KJ | 1 |
| LIUM, O | 1 |
| PAKULA, A | 1 |
| BARTON, EM | 1 |
| DEDMON, RE | 1 |
| SUNDSTROM, WR | 1 |
| SANSSOLA, YL | 1 |
| PADOVA, J | 1 |
| PATCHEFSKY, A | 1 |
| ONESTI, G | 1 |
| FALUDI, G | 1 |
| BENDERSKY, G | 1 |
| ISHMAEL, WK | 1 |
| OWENS, JN | 1 |
| PAYNE, RW | 1 |
| HONICK, MD | 1 |
| BERKOWITZ, D | 1 |
| ANICHINI, M | 1 |
| GARGANO, N | 1 |
| BARTORELLI, C | 1 |
| VIX, VA | 1 |
| TREADWELL, B | 1 |
| LAURENT, TC | 1 |
| REAH, TG | 1 |
| FUJIKI, T | 1 |
| ROBECCHI, A | 1 |
| KUZELL, WC | 2 |
| GLOVER, RP | 2 |
| GIBBS, JO | 1 |
| BLAU, RA | 1 |
| HALL, AP | 5 |
| BOURSIER, B | 1 |
| MIGNON, F | 1 |
| VALKENBURG, HA | 3 |
| DAVIDSON, RT | 2 |
| ENGELS, JP | 1 |
| NEEL, JV | 2 |
| KOELBEL, F | 1 |
| GREGOROVA, I | 1 |
| SONKA, J | 1 |
| WENER, J | 1 |
| SCHUCHER, R | 1 |
| FRIEDMAN, R | 1 |
| HELLER, H | 1 |
| ALVSAKER, JO | 10 |
| DUARTE, CG | 1 |
| BLAND, JH | 1 |
| KELLERMEYER, RW | 3 |
| BRECKENRIDGE, RT | 1 |
| SANCHEZMDEL, C | 1 |
| MONTERO, M | 1 |
| BERMEJILLO, F | 1 |
| PAKPOY, RK | 1 |
| KLINENBERG, JR | 23 |
| GOLDFINGER, SE | 4 |
| MALAWISTA, SE | 5 |
| KAPLAN, D | 3 |
| HALBERSTAM, D | 2 |
| GONICK, HC | 3 |
| RUBINI, ME | 1 |
| GLEASON, IO | 1 |
| SOMMERS, SC | 1 |
| FREUDWEILER, M | 1 |
| BUCHANAN, WW | 2 |
| DUNCAN, TG | 3 |
| SCHLESS, GL | 2 |
| CRISTOFORI, FC | 2 |
| RINGOIR, S | 1 |
| RIVERA, JV | 1 |
| MARTINEZ MALDONADO, M | 1 |
| RAMIREZDEARELLANO, GA | 1 |
| EHRLICH, L | 1 |
| GATTER, RA | 1 |
| HOGAN, JM | 1 |
| KOLLER, F | 1 |
| CURREY, HL | 1 |
| SWETTENHAM, KV | 1 |
| RIBI, A | 1 |
| VELAYOS, EE | 1 |
| SMYTH, CJ | 4 |
| DODGE, HJ | 4 |
| VALKENBURG, H | 1 |
| GAST, LF | 3 |
| BRECKENRIDGE, A | 1 |
| METCALFE-GIBSON, A | 1 |
| MCCORMICK, EW | 1 |
| BLOCH, R | 1 |
| VOGT, R | 1 |
| RAND, R | 2 |
| PASCALE, LR | 1 |
| DUBIN, A | 1 |
| BRONSKY, D | 1 |
| ALLEN, GE | 1 |
| ROGERS, FB | 1 |
| LANSBURY, J | 1 |
| BUZARD, J | 1 |
| PERNET, JL | 1 |
| PERNET, A | 1 |
| FRIEDRICH, S | 1 |
| LANE, M | 1 |
| KEMPER, JW | 1 |
| LAUDAT, MH | 1 |
| LAGRUE, G | 7 |
| MILLIEZ, P | 1 |
| MASONI, A | 1 |
| TOMASI, AM | 1 |
| ANTONIOLI, G | 1 |
| MORRIS, JB | 1 |
| POPERT, AJ | 1 |
| HEWITT, JV | 1 |
| Benecke, M | 1 |
| Enomoto, A | 2 |
| Niwa, T | 1 |
| Gentili, A | 1 |
| Darmawan, J | 3 |
| Nuralim, H | 1 |
| de Klerk, E | 1 |
| van der Heijde, D | 1 |
| Landewé, R | 1 |
| van der Tempel, H | 1 |
| van der Linden, S | 1 |
| Terkeltaub, RA | 9 |
| Lunam, CA | 1 |
| Gentle, MJ | 2 |
| Nilsson, SE | 1 |
| Takkinen, S | 1 |
| Tryding, N | 1 |
| Evrin, PE | 1 |
| Berg, S | 1 |
| McClearn, G | 1 |
| Johansson, B | 1 |
| Oaks, JL | 1 |
| Gilbert, M | 1 |
| Virani, MZ | 1 |
| Watson, RT | 1 |
| Meteyer, CU | 1 |
| Rideout, BA | 2 |
| Shivaprasad, HL | 1 |
| Chaudhry, MJ | 1 |
| Arshad, M | 1 |
| Mahmood, S | 1 |
| Ali, A | 1 |
| Khan, AA | 1 |
| Meyers, OL | 3 |
| Cassim, B | 1 |
| Mody, GM | 2 |
| BRAMIGK, F | 1 |
| GARNER, W | 1 |
| BENE, E | 2 |
| MANDEL, L | 1 |
| NORCROSS, BM | 1 |
| LOCKIE, LM | 1 |
| ROCHE, M | 2 |
| IZAR, G | 1 |
| Casimire-Etzioni, AL | 1 |
| Wellehan, JF | 1 |
| Embury, JE | 1 |
| Terrell, SP | 1 |
| Raskin, RE | 1 |
| Zeng, QY | 1 |
| Pedraz, T | 1 |
| Bomalaski, JS | 4 |
| Clark, MA | 2 |
| Iakunina, IA | 3 |
| Zilov, AV | 2 |
| Il'inykh, EV | 2 |
| Snaith, M | 2 |
| Leclercq, P | 1 |
| Malaise, MG | 1 |
| López Jiménez, M | 5 |
| García Puig, J | 6 |
| Zakharova, MM | 1 |
| Karateev, AE | 1 |
| Fedorova, AA | 1 |
| Bieber, JD | 1 |
| Tramontini, N | 1 |
| Huber, C | 1 |
| Kilgore, KS | 1 |
| FORSHAM, PH | 2 |
| FRIEDMAN, M | 1 |
| BYERS, SO | 1 |
| ORSTROM, A | 1 |
| ORSTROM, M | 1 |
| SOLOWAY, S | 1 |
| Proffitt, F | 1 |
| Bagla, P | 1 |
| Aslam, N | 1 |
| Lo, S | 1 |
| McNab, I | 1 |
| Hediger, MA | 2 |
| Vock, P | 1 |
| Bonel, H | 1 |
| Villiger, PM | 1 |
| Vogt, B | 1 |
| Gugger, M | 1 |
| Frey, FJ | 1 |
| Díaz-Reval, MI | 1 |
| López-Muñoz, FJ | 1 |
| Osiri, M | 1 |
| Avihingsanon, Y | 1 |
| Kodali, VR | 1 |
| Dunn, NA | 1 |
| Ye, J | 1 |
| Yoshizumi, K | 1 |
| Nishioka, N | 2 |
| Tsuji, T | 1 |
| Palo, WA | 3 |
| Eustace, D | 2 |
| Vernillet, L | 1 |
| Lumbreras, B | 1 |
| Frasquet, J | 1 |
| González-Salinas, J | 1 |
| Rodríguez, E | 2 |
| Hernández-Aguado, I | 1 |
| Chen, CH | 1 |
| Chen, CK | 2 |
| Yeh, LR | 1 |
| Pan, HB | 2 |
| Yang, CF | 2 |
| Kostrzewa-Zabłocka, E | 1 |
| Pritzker, K | 1 |
| Firestein, GS | 1 |
| Kolyvanos Naumann, U | 1 |
| Suter, PM | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| Feydy, A | 1 |
| Carlier, R | 1 |
| Chevrot, A | 1 |
| Drapé, JL | 1 |
| Ejaz, S | 1 |
| Kim, BS | 1 |
| Lim, CW | 1 |
| Fam, AG | 6 |
| Melloni, P | 1 |
| Valls, R | 1 |
| Yuguero, M | 1 |
| Larrosa, M | 1 |
| Hung, JY | 1 |
| Wu, SS | 1 |
| Maloney, ME | 1 |
| Springhart, WP | 1 |
| Ekeruo, WO | 1 |
| Young, MD | 1 |
| Enemchukwu, CU | 1 |
| Yang, YH | 1 |
| Quiceno, GA | 1 |
| Cush, JJ | 1 |
| Ng, J | 1 |
| Wong, ML | 1 |
| Yamanaka, M | 1 |
| Nikolenko, IuI | 4 |
| Siniachenko, OV | 7 |
| Anan'eva, MN | 1 |
| Nikolenko, VIu | 1 |
| Dubiaga, VV | 1 |
| Shchukin, IN | 1 |
| Garcia-Porrua, C | 1 |
| Canedo, C | 1 |
| Argueso, R | 1 |
| Cannella, AC | 1 |
| Huang, GS | 1 |
| Chang, DM | 1 |
| Kao, HW | 1 |
| Chen, CY | 1 |
| Huang, K | 1 |
| Masseoud, D | 1 |
| Rott, K | 1 |
| Agudelo, C | 1 |
| Espejo-Baena, A | 1 |
| Coretti, SM | 1 |
| Fernandez, JM | 1 |
| Garcia-Herrera, JM | 1 |
| Del Pino, JR | 1 |
| Pétrilli, V | 1 |
| Mayor, A | 1 |
| Tardivel, A | 1 |
| Tschopp, J | 2 |
| van den Berge, M | 1 |
| Vrugt, B | 1 |
| Holt, C | 1 |
| Smit, CJ | 1 |
| Hoogenberg, K | 1 |
| Bernad, B | 1 |
| Narvaez, J | 1 |
| Diez-Garcia, M | 1 |
| Valverde, J | 1 |
| Coassin, M | 1 |
| Piovanetti, O | 1 |
| Stark, WJ | 1 |
| Green, WR | 1 |
| Tsapina, TN | 1 |
| Rozin, AP | 1 |
| Braun-Moscovici, Y | 1 |
| Balbir-Gurman, A | 1 |
| Unger, S | 2 |
| Richter, K | 1 |
| Grässler, J | 2 |
| Roch, B | 1 |
| Schröder, HE | 10 |
| Sarawate, CA | 1 |
| Yang, W | 1 |
| Brewer, KK | 1 |
| Bakst, AW | 1 |
| Purohit, MB | 1 |
| Purohit, TM | 1 |
| Tandon, RK | 1 |
| Davis, J | 1 |
| Fuller, J | 1 |
| Chan, KA | 1 |
| Roblin, D | 1 |
| Von Worley, A | 1 |
| Platt, R | 1 |
| Bornstein, SR | 1 |
| Soriano, F | 1 |
| Campana, V | 1 |
| Moya, M | 1 |
| Gavotto, A | 1 |
| Simes, J | 1 |
| Soriano, M | 1 |
| Spitale, L | 1 |
| Palma, J | 1 |
| Conaghan, P | 1 |
| Gerster, J | 1 |
| Jacobs, J | 1 |
| Leeb, B | 1 |
| Netter, P | 2 |
| Pignone, A | 1 |
| Zimmermann-Gòrska, I | 3 |
| Kwon, CY | 1 |
| Zandi-Nejad, K | 1 |
| Nan, H | 1 |
| Qiao, Q | 1 |
| Tang, B | 1 |
| Qian, R | 1 |
| Tuomilehto, J | 1 |
| Ordi, J | 1 |
| Alonso, PL | 1 |
| de Zulueta, J | 1 |
| Esteban, J | 1 |
| Velasco, M | 1 |
| Mas, E | 1 |
| Campo, E | 1 |
| Fernández, PL | 1 |
| Hearn, A | 1 |
| Fitzgerald, K | 1 |
| Golenbock, D | 1 |
| Reed, G | 1 |
| Akira, S | 1 |
| Shima, Y | 1 |
| Teruya, K | 1 |
| Rao, S | 1 |
| Gupta, K | 1 |
| Arora, R | 1 |
| Arulselvi, S | 1 |
| Spartà, G | 1 |
| Kemper, MJ | 1 |
| Neuhaus, TJ | 1 |
| Murugaiyah, V | 1 |
| Chan, KL | 1 |
| Pohar, S | 1 |
| Murphy, G | 1 |
| Gersch, MS | 1 |
| Rose, DM | 1 |
| Sydlaske, AD | 1 |
| Agha-Babakhani, A | 1 |
| Johnson, K | 1 |
| Moore, DF | 1 |
| Sun, JD | 1 |
| Chizyński, K | 1 |
| Rózycka, M | 1 |
| Caldas, CA | 1 |
| Fuller, R | 1 |
| Scott, P | 1 |
| Ma, H | 1 |
| Viriyakosol, S | 1 |
| Croft, JD | 1 |
| Corrado, A | 1 |
| D'Onofrio, F | 1 |
| Santoro, N | 1 |
| Melillo, N | 1 |
| Cantatore, FP | 1 |
| Shah, K | 1 |
| Spear, J | 1 |
| Nathanson, LA | 1 |
| McCauley, J | 1 |
| Edlow, JA | 1 |
| Akahoshi, T | 1 |
| Kitasato, H | 1 |
| Houtman, PM | 1 |
| Scarlett, EL | 1 |
| Wise, CM | 4 |
| Jacobs, JW | 4 |
| Bijlsma, JW | 4 |
| Cammalleri, L | 1 |
| Malaguarnera, M | 1 |
| Martínez-Villén, G | 1 |
| Canales, V | 1 |
| Hernández-Rossi, A | 1 |
| Herrera, A | 1 |
| Toscano, JP | 1 |
| Liebman, SE | 1 |
| Taylor, JG | 1 |
| Bushinsky, DA | 1 |
| Rollet-Labelle, E | 1 |
| Thibault, N | 1 |
| Gilbert, C | 2 |
| Bourgoin, SG | 2 |
| Spackey, J | 1 |
| Demos, TC | 1 |
| Lomasney, LM | 1 |
| Kobayashi, T | 1 |
| Dahiya, A | 1 |
| Leach, J | 1 |
| Levy, H | 1 |
| De Leonardis, F | 1 |
| Colina, M | 1 |
| Bruschi, M | 1 |
| Trotta, F | 1 |
| Martin, I | 1 |
| Canteli, B | 1 |
| Alvarado-Romano, V | 1 |
| Jiménez-Vaca, AL | 1 |
| Pozo-Molina, G | 1 |
| Cuevas-Covarrubias, SA | 1 |
| Johnson, TR | 1 |
| Weckbach, S | 1 |
| Kellner, H | 1 |
| Reiser, MF | 1 |
| Becker, CR | 1 |
| Alderman, MH | 1 |
| Kutzing, MK | 1 |
| Firestein, BL | 1 |
| Grusch, B | 1 |
| Rintelen, B | 1 |
| Leeb, BF | 1 |
| Hoenen-Clavert, V | 1 |
| Loeuille, D | 1 |
| Pope, RM | 1 |
| Bellini, LP | 1 |
| Rosenthal, P | 1 |
| Jerome, JT | 1 |
| Sankaran, B | 1 |
| Thirumagal, K | 1 |
| Annemans, L | 1 |
| Spaepen, E | 1 |
| Gaskin, M | 1 |
| Bonnemaire, M | 1 |
| Malier, V | 1 |
| Gilbert, T | 1 |
| COTTERMAN, CW | 1 |
| FREYBERG, RH | 1 |
| WOLFSON, WQ | 1 |
| HUNT, HD | 1 |
| Park, JY | 1 |
| Baker, DL | 1 |
| Stroup, JS | 1 |
| Gilstrap, CA | 1 |
| Sturrock, RD | 1 |
| Phelps, P | 6 |
| Griep, EN | 1 |
| Hoekstra, M | 1 |
| Marie, I | 1 |
| Parrad, M | 1 |
| Lahaxe, L | 1 |
| Levesque, H | 1 |
| Houdent, C | 1 |
| Earl, SC | 1 |
| Hull, R | 1 |
| Kasifoglue, T | 1 |
| Cansu, D | 1 |
| Korkmaz, C | 1 |
| Mehta, D | 1 |
| Gohlke, H | 1 |
| Fischer, G | 1 |
| Henke, K | 1 |
| Pfeufer, A | 1 |
| Rosskopf, D | 1 |
| Gray, NK | 1 |
| Floyd, J | 1 |
| Palmer, CN | 1 |
| Knott, SA | 1 |
| Shu, X | 1 |
| Janicijevic, B | 1 |
| Smolej-Narancic, N | 1 |
| Gorgoni, B | 1 |
| Morgan, J | 1 |
| Biloglav, Z | 1 |
| Barac-Lauc, L | 1 |
| Pericic, M | 1 |
| Klaric, IM | 1 |
| Skaric-Juric, T | 1 |
| Richardson, WA | 1 |
| Hohenstein, P | 1 |
| Kimber, CH | 1 |
| Donnelly, LA | 1 |
| Fairbanks, LD | 2 |
| McKeigue, PM | 1 |
| Morris, AD | 1 |
| Rudan, P | 1 |
| Hastie, ND | 1 |
| Proctor, PH | 1 |
| Ford, ES | 1 |
| Neureuther, K | 1 |
| Wiedmann, S | 1 |
| Sedlacek, K | 1 |
| Baessler, A | 1 |
| Fischer, M | 2 |
| Weber, S | 1 |
| Kaess, B | 1 |
| Hollowell, M | 1 |
| Thompson, LD | 1 |
| Pantanowitz, L | 1 |
| Takagi, K | 2 |
| Iizasa, T | 1 |
| Yue, CS | 1 |
| Alton, M | 1 |
| Wright, D | 1 |
| Marco, MD | 1 |
| Panomvana, D | 1 |
| Sripradit, S | 1 |
| Angthararak, S | 1 |
| Forman, JP | 1 |
| Ascherio, A | 1 |
| Srinivasan, S | 1 |
| Menke, A | 1 |
| Patel, DA | 1 |
| Berenson, G | 1 |
| Tanabe, Y | 2 |
| Schulze, H | 1 |
| Meier, MS | 1 |
| Barry, PE | 1 |
| Dawber, TR | 1 |
| McNamara, PM | 1 |
| Maclachlan, MJ | 1 |
| Rodnan, GP | 6 |
| Blechman, WJ | 1 |
| Rosenberg, DG | 1 |
| Hilf, P | 1 |
| Ask-Upmark, E | 1 |
| Melmon, KL | 1 |
| Webster, ME | 2 |
| Healey, LA | 8 |
| Skeith, MD | 1 |
| Bayani-Sioson, PS | 2 |
| Emmerson, BT | 36 |
| Wilson, JD | 1 |
| Simmonds, HA | 30 |
| North, JD | 2 |
| Zöllner, N | 26 |
| Schattenkirchner, M | 5 |
| Jakovcic, S | 1 |
| Benedek, TG | 2 |
| Jeremy, R | 3 |
| Cottet, J | 2 |
| Vittu, C | 1 |
| Bourde, CH | 1 |
| Saker, BM | 1 |
| Tofler, OB | 1 |
| Burvill, MJ | 1 |
| Reilly, KA | 1 |
| Benke, PJ | 2 |
| Lampe, WT | 1 |
| Krawczyński, J | 1 |
| Zulawnik, W | 1 |
| Drewnowska, I | 1 |
| Orndahl, G | 3 |
| Chase, PH | 1 |
| Ellman, A | 1 |
| Martin, JH | 1 |
| Gordon, M | 1 |
| Wallace, R | 1 |
| Nissen, NI | 1 |
| Paikin, H | 1 |
| Marie, J | 1 |
| Royer, P | 2 |
| Rappaport, R | 1 |
| Dimopoulos, C | 1 |
| Chinaris, L | 1 |
| Polić, V | 1 |
| Sigaher, V | 1 |
| Verger, D | 1 |
| Leroux-Robert, C | 2 |
| Ganter, P | 1 |
| Inagaki, K | 3 |
| Bufalari, A | 1 |
| Meloni, G | 1 |
| Aignan, M | 1 |
| Fournout, J | 1 |
| Fabre, P | 1 |
| Lagarde, G | 1 |
| Duff, GW | 3 |
| Atkins, E | 2 |
| Higson, FK | 1 |
| Jones, OT | 1 |
| Fox, IH | 18 |
| McMillan, RM | 2 |
| Vater, CA | 2 |
| Hasselbacher, P | 4 |
| Harris, ED | 2 |
| Rae, SA | 1 |
| Davidson, EM | 1 |
| Smith, MJ | 2 |
| Sanwald, R | 1 |
| Ullman, B | 2 |
| Yip, LC | 1 |
| Balis, ME | 3 |
| Ward, PC | 1 |
| Weinberger, A | 9 |
| Pinkhas, J | 4 |
| Hankiewicz, J | 1 |
| Losman, MJ | 2 |
| Itkin, P | 1 |
| Wisner, DE | 1 |
| Gutensohn, W | 1 |
| Akizuki, M | 1 |
| Yoshida, S | 1 |
| Gregolini, L | 1 |
| Ferrari, S | 1 |
| Marcolongo, R | 15 |
| Aleo, MF | 2 |
| Marinello, E | 9 |
| Bianchi, E | 1 |
| Ciompi, ML | 1 |
| Bazzichi, LM | 1 |
| Bertolucci, D | 1 |
| Mazzoni, MR | 1 |
| Mencacci, S | 1 |
| Macchia, D | 1 |
| Mariani, G | 3 |
| Tirri, G | 2 |
| La Montagna, G | 1 |
| Tirri, R | 1 |
| Dieppe, PA | 6 |
| Whicher, JT | 1 |
| Walters, G | 1 |
| Nakonechny, DS | 1 |
| Sailer, D | 4 |
| Paul, H | 1 |
| Papadimitriou, GM | 1 |
| Hardwell, TR | 1 |
| Braven, J | 1 |
| Shaw, S | 2 |
| Whittaker, M | 1 |
| Watt, I | 2 |
| Wall, B | 1 |
| Agudelo, CA | 13 |
| Tesser, JR | 1 |
| Mountz, J | 1 |
| Holt, D | 1 |
| Turner, RA | 3 |
| de Médicis, R | 3 |
| Lussier, A | 3 |
| Kahan, A | 1 |
| Tétreault, L | 1 |
| Carcassi, A | 10 |
| Galli, M | 1 |
| Boschi, S | 3 |
| Di Cairano, G | 1 |
| Hecker, S | 1 |
| Woo, S | 1 |
| Jacobs, RP | 1 |
| Porter, GA | 1 |
| Johnson, FN | 1 |
| Amdisen, A | 1 |
| Reynolds, MD | 1 |
| Valasco Domínguez, E | 1 |
| García Velasco, F | 1 |
| Arranz Velasco, JL | 1 |
| Sanz Cantalapiedra, R | 1 |
| Barrio Arredondo, MT | 1 |
| del Pozo Pérez, MA | 1 |
| Gröbner, W | 17 |
| Foley, RJ | 1 |
| Weinman, EJ | 3 |
| Kagami, T | 3 |
| Ginsberg, MH | 2 |
| Nys, Y | 1 |
| Rzasa, J | 1 |
| McFarland, DC | 1 |
| Coon, CN | 1 |
| Reynolds, PP | 1 |
| Knapp, MJ | 1 |
| Holmes, EW | 5 |
| Wilson, JM | 1 |
| Kelley, WN | 25 |
| Wright, LF | 1 |
| Saylor, RP | 1 |
| Cecere, FA | 1 |
| Loré, F | 1 |
| Manasse, G | 1 |
| Macrí, P | 4 |
| Pisani, M | 1 |
| Altman, RD | 1 |
| Newman, JH | 1 |
| Diadyk, AI | 6 |
| Vasilenko, IV | 4 |
| Yarom, A | 1 |
| Rennebohm, RM | 1 |
| Strife, F | 1 |
| Levinson, JE | 1 |
| Sharpe, CR | 1 |
| Kennedy, TD | 1 |
| Higgens, CS | 2 |
| Woodrow, DF | 1 |
| Williamson, PJ | 1 |
| Ene, MD | 1 |
| Roberts, CJ | 1 |
| Waterworth, R | 2 |
| Hatfield, P | 2 |
| Robinson, G | 2 |
| Bremner, K | 2 |
| Palella, TD | 4 |
| Barats, IS | 2 |
| Antommattei, O | 1 |
| Reginato, AJ | 1 |
| Clayburne, G | 2 |
| Levy, A | 1 |
| Salamon, F | 1 |
| Mertz, DP | 44 |
| Eichhorn, R | 1 |
| Ferraccioli, G | 1 |
| Spisni, A | 1 |
| Ambanelli, U | 1 |
| Dumas, JR | 1 |
| Kolba, KS | 1 |
| Harlay, A | 2 |
| Chayen, J | 2 |
| Maidment, CG | 1 |
| Greaves, MF | 1 |
| Black, AJ | 1 |
| Stĕpán, J | 4 |
| Cáp, F | 2 |
| Fiddis, RW | 1 |
| Vlachos, N | 1 |
| Calvert, PD | 1 |
| Sváb, V | 2 |
| Kolár, J | 1 |
| Susta, A | 1 |
| Turpin, G | 1 |
| Kuntz, D | 9 |
| Boogaerts, MA | 1 |
| Hammerschmidt, DE | 1 |
| Roelant, C | 1 |
| Verwilghen, RL | 1 |
| Jacob, HS | 1 |
| Earll, JM | 1 |
| Saavedra, M | 1 |
| Yu, CF | 2 |
| Garman, RH | 1 |
| Nuzzi, MJ | 1 |
| Geraci, JN | 1 |
| Bueno Jiménez, C | 3 |
| Gil Micharet, MS | 3 |
| Grau Linares, V | 3 |
| Pérez Miranda, M | 3 |
| Sugai, M | 1 |
| Gertner, E | 1 |
| Lewis, A | 1 |
| Cats, A | 2 |
| van Romunde, LK | 1 |
| Pauri, A | 1 |
| Thomas, AL | 1 |
| Majoos, FL | 1 |
| Pompucci, G | 4 |
| D'Amato, MS | 2 |
| Tiitinen, S | 1 |
| Nissilä, M | 1 |
| Ruutsalo, HM | 1 |
| Armstrong, RD | 1 |
| Rodgers, AV | 4 |
| Panetti, M | 1 |
| Pisko, E | 1 |
| Morawska, Z | 1 |
| Makulska, I | 1 |
| Morawska, A | 1 |
| Spaccarelli, A | 1 |
| Giacomello, A | 4 |
| Sorgi, ML | 3 |
| Zoppini, A | 4 |
| Roboz, J | 2 |
| Darlington, LG | 6 |
| Hollingworth, P | 3 |
| Burry, HC | 2 |
| Mondillo, S | 1 |
| Huston, GJ | 1 |
| Webster, DR | 1 |
| Mateos, F | 3 |
| Muñoz, A | 1 |
| Gaspar, G | 1 |
| Ramos, T | 3 |
| Gijón Baños, J | 1 |
| Toseland, P | 2 |
| Faller, J | 2 |
| Bayliss, R | 1 |
| Clarke, C | 1 |
| Whitehead, TP | 1 |
| Whitfield, AG | 1 |
| Scalapino, JN | 1 |
| Edwards, WD | 1 |
| Steckelberg, JM | 1 |
| Wooten, RS | 1 |
| Callahan, JA | 1 |
| Ginsburg, WW | 1 |
| Rotés Querol, J | 1 |
| Naidoo, PD | 1 |
| MacDermot, KD | 1 |
| Allsop, J | 1 |
| Watts, RW | 9 |
| Russell, IJ | 2 |
| Mansen, C | 1 |
| Kolb, LM | 1 |
| Kolb, WP | 1 |
| Hirai, A | 2 |
| Kumagai, A | 3 |
| Chodorowski, Z | 3 |
| Batuman, V | 1 |
| Maesaka, JK | 1 |
| Haddad, B | 1 |
| Tepper, E | 1 |
| Landy, E | 1 |
| Wedeen, RP | 1 |
| Vigo, P | 1 |
| Ortolani, S | 1 |
| Soldati, L | 1 |
| Girardello, R | 1 |
| Fleischmann, L | 1 |
| Polli, EE | 1 |
| Leaney, BJ | 1 |
| Calvert, JM | 1 |
| Schindel, B | 1 |
| Liberman, UA | 3 |
| Sperling, O | 13 |
| Leumann, EP | 1 |
| Wegmann, W | 1 |
| Abramson, SB | 1 |
| Weissmann, G | 4 |
| Kaplan, AP | 1 |
| Ghebrehiwet, B | 1 |
| Matzkies, F | 13 |
| Gerster, JC | 3 |
| Papaioannou, C | 1 |
| McDuffie, FC | 1 |
| MacIntyre, S | 1 |
| Kushner, I | 2 |
| Jaworski, RC | 1 |
| Gibson, M | 1 |
| Horváth, G | 1 |
| Niepel, G | 1 |
| Boss, GR | 2 |
| Ragsdale, RA | 1 |
| Zettner, A | 1 |
| Beck, LH | 2 |
| Khachadurian, AK | 1 |
| Feng, RJ | 1 |
| Wormsted, MA | 1 |
| Cohen, MB | 1 |
| Martin, DW | 1 |
| Fellström, B | 1 |
| Prior, L | 1 |
| Reinhardt, K | 1 |
| Kawenoki-Minc, E | 14 |
| Brzozowska-Jurkowska, AM | 3 |
| Arkhipov, VE | 1 |
| Borisov, IA | 1 |
| Sura, VV | 1 |
| Kawaguchi, Y | 1 |
| Shirasawa, K | 1 |
| Yotsumoto, S | 1 |
| Nagahara, S | 1 |
| Zalokar, J | 3 |
| Lellouch, J | 3 |
| Claude, JR | 3 |
| Potter, C | 2 |
| Rogers, V | 2 |
| Vitali, C | 2 |
| Clerico, A | 2 |
| Riente, L | 2 |
| Molea, N | 1 |
| Pilo, A | 2 |
| Bianchi, R | 2 |
| Bluestone, R | 16 |
| Klinenberg, J | 3 |
| Lee, IK | 1 |
| Ferber, H | 1 |
| Bader, U | 1 |
| Mamasaliev, NS | 1 |
| Tursunov, SIu | 1 |
| Nabieva, AF | 1 |
| Pritchard, MH | 1 |
| Berni, G | 1 |
| Lagi, A | 1 |
| Francois, C | 1 |
| Pikhlak, EG | 1 |
| Piliaev, VG | 3 |
| Sloan, RW | 1 |
| Rapado, A | 7 |
| Dorn, M | 1 |
| King, DF | 1 |
| King, LA | 1 |
| Gerber, NJ | 1 |
| Schorn, D | 1 |
| Rouault, T | 1 |
| Caldwell, DS | 1 |
| Martin, SM | 1 |
| Gastwirth, CM | 1 |
| Petera, P | 1 |
| Gaismayer, K | 1 |
| Tausch, G | 2 |
| Dewes, W | 1 |
| Bach, D | 1 |
| Zilliken, F | 1 |
| Schneeberger, W | 1 |
| Kraines, JL | 1 |
| Ellman, MH | 1 |
| Lundquist, CD | 1 |
| Aronson, IK | 1 |
| Henderson, TW | 1 |
| Skosey, JL | 1 |
| Solomon, LM | 1 |
| Dennstedt, FE | 1 |
| Weilbaecher, DG | 1 |
| Kolb, S | 1 |
| König, HJ | 2 |
| Sensi, S | 1 |
| Gisser, SD | 1 |
| Kletter, I | 1 |
| Slack, J | 2 |
| Colton, RS | 3 |
| Acheson, RM | 3 |
| Williams, PL | 1 |
| Gordon, RB | 6 |
| Counsilman, AC | 1 |
| Cross, SM | 1 |
| Akizuki, S | 1 |
| Schoenberg, O | 1 |
| David, M | 1 |
| Feuerman, EI | 1 |
| Schoenberg, A | 1 |
| Myrhed, M | 1 |
| Stark, TW | 1 |
| Hirokawa, RH | 1 |
| Naveau, B | 1 |
| Thiele, P | 12 |
| Heidelmann, G | 14 |
| Häntzschel, H | 3 |
| Reinelt, D | 2 |
| Otto, W | 4 |
| Heuckenkamp, PU | 3 |
| Mikulíková, D | 2 |
| Trnavský, K | 3 |
| Mituszova, M | 3 |
| Horwitz, LR | 1 |
| Liebman, JA | 1 |
| Cavolo, DJ | 1 |
| Kalmár, L | 1 |
| Ablonczy, E | 1 |
| Müzes, G | 1 |
| Neumark, T | 1 |
| Répay, I | 1 |
| Gergely, P | 1 |
| Zechner, O | 1 |
| Pflüger, H | 1 |
| Scheiber, V | 1 |
| Templeton, JS | 1 |
| Vukotić, D | 3 |
| Berndt, H | 1 |
| Vitić, J | 1 |
| Nikolić, V | 1 |
| Pilipović, N | 1 |
| Jechová, D | 1 |
| Smeralová, V | 1 |
| Fiechtner, JJ | 2 |
| Masbernard, A | 2 |
| Giudicelli, CP | 1 |
| Baiatova, KV | 1 |
| Sankalé, M | 1 |
| Muñez-Sanz, A | 1 |
| Sarkozi, L | 1 |
| Kaung, C | 3 |
| Dunky, A | 1 |
| Nitsche, V | 1 |
| Eberl, R | 4 |
| Grabner, W | 2 |
| Worlicek, H | 1 |
| Fay, R | 1 |
| Bollet, AJ | 1 |
| Beenken, O | 1 |
| Kopperschläger, G | 1 |
| Pietruschka, WD | 1 |
| Weinhold, D | 1 |
| Fraser, KJ | 1 |
| Duffy, WB | 1 |
| Senekjian, HO | 1 |
| Knight, TF | 1 |
| Akimova, TF | 2 |
| Novoselova, TM | 2 |
| Aliab'eva, AP | 1 |
| Warren, DJ | 3 |
| Naik, RB | 1 |
| Müller, M | 1 |
| Kuzmits, R | 2 |
| Frassine, I | 1 |
| Lorant, P | 1 |
| Tak, HK | 2 |
| Wilcox, WR | 4 |
| Cooper, SM | 2 |
| Farebrother, DA | 2 |
| Pincott, JR | 1 |
| Simmons, HA | 1 |
| Dillon, MJ | 1 |
| Cameron, JS | 13 |
| Hägeli, S | 1 |
| Burke, C | 1 |
| Scholer, A | 1 |
| Linnane, JW | 1 |
| Burry, AF | 1 |
| Counts, GB | 1 |
| Treadway, WJ | 1 |
| Holt, DA | 1 |
| Pegram, RA | 1 |
| Wyatt, RD | 1 |
| Klarica, J | 3 |
| Guzmán, L | 1 |
| Weryńska-Przybylska, J | 5 |
| Eyman, E | 9 |
| Frackiewicz, A | 1 |
| Mikołajew, M | 1 |
| Pilichowska, I | 1 |
| Stachurska, J | 1 |
| Szymańska, M | 1 |
| Glaser, B | 1 |
| Abeles, M | 2 |
| Fessel, WJ | 6 |
| Jessee, EF | 1 |
| Toone, E | 2 |
| Owen, DS | 3 |
| Irby, R | 3 |
| Lamphier, TA | 1 |
| Fenner, H | 1 |
| Miskew, DB | 1 |
| Goldflies, ML | 1 |
| Verheggen, T | 1 |
| Mikkers, F | 1 |
| Everaerts, F | 1 |
| Oerlemans, F | 1 |
| De Bruyn, C | 1 |
| Oehler, G | 1 |
| Lasch, HG | 1 |
| Jelke, K | 1 |
| Krause, G | 1 |
| Jüttner, A | 1 |
| Angar, T | 1 |
| Grosse-Kielisch, C | 1 |
| Bach, GL | 1 |
| Cole, RK | 4 |
| Austic, RE | 4 |
| Cassidy, M | 1 |
| Gregory, MC | 1 |
| Harley, EH | 1 |
| Astapenko, MG | 2 |
| Mikanagi, K | 9 |
| Kawai, K | 1 |
| Itakura, M | 3 |
| Koide, Y | 1 |
| Kugai, N | 1 |
| Kimura, S | 1 |
| Yamashita, K | 1 |
| Ogata, E | 2 |
| Murray, JB | 1 |
| Findling, JW | 1 |
| Beckstrom, D | 1 |
| Rawsthorne, L | 1 |
| Kozin, F | 1 |
| Itskovitz, H | 1 |
| Young, D | 1 |
| Nishioka, K | 8 |
| Gleadle, RI | 1 |
| Chiaroni, G | 1 |
| Potter, CF | 3 |
| Jarvik, ME | 1 |
| Trubnikov, VF | 1 |
| Egorov, VP | 1 |
| Reardon, JA | 1 |
| Rodgers, VA | 1 |
| Sorensen, LF | 1 |
| Reif, MC | 1 |
| Constantiner, A | 1 |
| Levitt, MF | 1 |
| Sforza, GR | 1 |
| Della Fazia, L | 1 |
| Masciangelo, F | 1 |
| Morozzi, G | 3 |
| Lo Cosmo, C | 1 |
| Famaey, JP | 2 |
| Jackson, L | 2 |
| Taylor, R | 1 |
| Faaiuso, S | 1 |
| Ainuu, SP | 1 |
| Whitehouse, S | 2 |
| Zimmet, P | 1 |
| Heinrich, JJ | 2 |
| Ben Hmida, M | 2 |
| Hachicha, J | 1 |
| Bahloul, Z | 1 |
| Kaddour, N | 1 |
| Kharrat, M | 1 |
| Jarraya, F | 1 |
| Jarraya, A | 1 |
| Hachicha, M | 1 |
| McColl, SR | 1 |
| Jacoulet, P | 1 |
| Jovaní, V | 1 |
| Eastmond, CJ | 1 |
| Garton, M | 1 |
| Robins, S | 1 |
| Riddoch, S | 1 |
| Khatchadourian, J | 1 |
| Whitson, PA | 1 |
| Mijiyawa, M | 1 |
| Akaoka, Y | 1 |
| Rozenberg, S | 3 |
| Roche, B | 1 |
| Dorent, R | 1 |
| Koeger, AC | 1 |
| Borget, C | 1 |
| Wrona, N | 1 |
| Bourgeois, P | 3 |
| McBride, MB | 7 |
| Hatfield, PJ | 3 |
| Graham, R | 2 |
| McCaskey, J | 2 |
| Jackson, M | 2 |
| Quaratino, CP | 2 |
| Rucci, C | 1 |
| Ciaglia, P | 1 |
| Porcelli, B | 3 |
| Vannoni, D | 1 |
| Leoncini, R | 3 |
| Pizzichini, M | 3 |
| Pagani, R | 1 |
| Hakoda, M | 2 |
| Terai, C | 2 |
| Kawaguchi, R | 1 |
| Kashiwazaki, S | 3 |
| Mateos, FA | 13 |
| Miranda, ME | 3 |
| Pérez de Ayala, C | 3 |
| Gil, A | 2 |
| Krijt, J | 2 |
| Maly, J | 1 |
| Higashino, K | 12 |
| Nasako, Y | 3 |
| Hiroishi, K | 3 |
| Gresser, U | 4 |
| Gathof, BS | 1 |
| Gross, M | 2 |
| Yamakita, J | 9 |
| Star, VL | 1 |
| Hochberg, MC | 1 |
| Bagatin, J | 1 |
| Simunić, M | 1 |
| Sardelić, S | 1 |
| Pritzker, KP | 2 |
| Bassett, JE | 1 |
| Lee, QP | 1 |
| O'Reilly, S | 1 |
| Joseph, J | 1 |
| McGrath, H | 1 |
| Lutalo, SK | 2 |
| Jajić, I | 2 |
| Youssef, P | 1 |
| Brama, T | 1 |
| York, H | 1 |
| Pickard, P | 1 |
| Stewart, P | 1 |
| Grover, PK | 2 |
| Ryall, RL | 2 |
| Peterseim, U | 1 |
| von Gizycki-Nienhaus, B | 1 |
| Meurer, M | 1 |
| Reiter, L | 1 |
| Edmonds, J | 1 |
| Snaith, ML | 5 |
| Chou, P | 3 |
| Soong, LN | 1 |
| Gil, AA | 3 |
| Ghio, AJ | 1 |
| Kennedy, TP | 1 |
| Rao, G | 1 |
| Cooke, CL | 1 |
| Miller, MJ | 1 |
| Hoidal, JR | 2 |
| Komoriya, K | 1 |
| Osada, Y | 1 |
| Hasegawa, M | 1 |
| Kondo, S | 1 |
| Couch, RC | 1 |
| Griffin, TB | 1 |
| Matsubara, C | 1 |
| Yokoi, Y | 1 |
| Nakamichi, N | 1 |
| Takamura, K | 1 |
| Mukhin, NA | 1 |
| Balkarov, IM | 7 |
| Maksimov, NA | 3 |
| Jenkins, EA | 1 |
| Hallett, RJ | 1 |
| Hull, RG | 1 |
| Pawlotsky, Y | 1 |
| Gonzalez, EB | 2 |
| Miller, SB | 1 |
| Yasuhara, K | 1 |
| Tomita, Y | 1 |
| Takayama, A | 1 |
| Fujikawa, H | 1 |
| Otake, Y | 1 |
| Takahashi, K | 1 |
| Ortiz-Bravo, E | 2 |
| Sieck, MS | 1 |
| van Lieshout-Zuidema, MF | 1 |
| Breedveld, FC | 1 |
| Kanbe, K | 1 |
| Kobuna, Y | 1 |
| Beutler, A | 3 |
| Jacobs, F | 1 |
| Hurault de Ligny, B | 1 |
| Le Goff, C | 1 |
| Ryckelynck, JP | 1 |
| Michelsen, A | 1 |
| Picazo, ML | 1 |
| Jiménez, ML | 7 |
| Calvin, TS | 1 |
| Müller, FO | 1 |
| Schall, R | 1 |
| Groenewoud, G | 1 |
| Hundt, HK | 1 |
| van der Merwe, JC | 1 |
| van Dyk, M | 1 |
| Moro, F | 4 |
| Jinnai, K | 1 |
| Kono, N | 2 |
| Yamamoto, Y | 1 |
| Kanda, F | 1 |
| Ohno, S | 1 |
| Tsutsumi, M | 1 |
| Yamada, Y | 2 |
| Kawachi, M | 2 |
| Donegan, CF | 1 |
| Berman, P | 1 |
| Baethge, BA | 1 |
| Work, J | 1 |
| Landreneau, MD | 1 |
| McDonald, JC | 1 |
| Veerapen, K | 1 |
| van Linthoudt, D | 1 |
| Neilson, EG | 1 |
| Boyd, RE | 1 |
| Domoto, K | 1 |
| Okabe, H | 1 |
| Tabe, A | 1 |
| Saji, M | 1 |
| Hikita, M | 2 |
| Sakai, O | 2 |
| van Vugt, RM | 1 |
| Wang, HC | 1 |
| Tsai, MD | 1 |
| Jamar, F | 1 |
| Schofield, JB | 1 |
| Peters, AM | 1 |
| Binns, RM | 1 |
| Herbelin, A | 1 |
| Georgadze, ZO | 1 |
| Balabolkin, MI | 1 |
| Mamaeva, GG | 1 |
| Liudina, LI | 1 |
| Mishchenko, BP | 1 |
| Arbuzova, MI | 1 |
| Holland, NW | 1 |
| Jost, D | 1 |
| Duprez, TP | 1 |
| Malghem, J | 1 |
| Vande Berg, BC | 1 |
| Noel, HM | 1 |
| Munting, EA | 1 |
| Maldague, BE | 1 |
| Lukicheva, TI | 1 |
| Aleksandrovskaia, TN | 1 |
| Oleĭnikova, EB | 1 |
| Kozlova, VG | 1 |
| Shovskaia, TN | 1 |
| Zonana-Nacach, A | 1 |
| Alarcón, GS | 1 |
| Daniel, WW | 1 |
| Corr, SA | 1 |
| Seaton, K | 1 |
| Popp, JD | 1 |
| Bidgood, WD | 1 |
| Reber, P | 1 |
| Crevoisier, X | 1 |
| Noesberger, B | 1 |
| Kosaka, H | 1 |
| Ohtahara, K | 1 |
| Tsuboi, M | 1 |
| Manabe, I | 1 |
| Sawaguchi, M | 1 |
| Fujimoto, Y | 1 |
| Yoshida, A | 1 |
| Takeda, A | 1 |
| Schneiderka, P | 1 |
| Asplin, JR | 1 |
| al Ali, N | 1 |
| Iglesias, A | 1 |
| Londono, JC | 1 |
| Saaibi, DL | 1 |
| Peña, M | 1 |
| Lizarazo, H | 1 |
| Yamaoka, T | 1 |
| Tatibana, M | 1 |
| Koide, T | 1 |
| Wrenger, E | 1 |
| Bahlmann, J | 1 |
| Floege, J | 2 |
| Klemp, P | 1 |
| Stansfield, SA | 1 |
| Castle, B | 1 |
| Robertson, MC | 1 |
| Eulderink, F | 1 |
| Postma, T | 1 |
| Miranda-Carús, E | 1 |
| Sanz, AG | 1 |
| Herrero, E | 1 |
| Hoffman, GS | 1 |
| al-Ali, N | 1 |
| al-Sughayer, A | 1 |
| Umamaheswaran, I | 1 |
| al-Gaurer, S | 1 |
| Hussain, AA | 1 |
| Kundu, AK | 1 |
| Dawn, B | 1 |
| Williams, JK | 1 |
| Walker, SE | 1 |
| Margalit, A | 2 |
| Duffin, KL | 1 |
| Shaffer, AF | 1 |
| Gregory, SA | 1 |
| Isakson, PC | 2 |
| Chang, FT | 2 |
| Cinkotai, FF | 1 |
| Gurwitz, JH | 1 |
| Kalish, SC | 1 |
| Bohn, RL | 1 |
| Monane, M | 1 |
| Mogun, H | 1 |
| Avorn, J | 1 |
| Nickeleit, V | 1 |
| Mihatsch, MJ | 1 |
| Getting, SJ | 1 |
| Flower, RJ | 1 |
| Parente, L | 1 |
| Woliztky, BA | 1 |
| Martins, MA | 1 |
| Perretti, M | 1 |
| Chaoui, A | 1 |
| Garcia, J | 1 |
| Kurt, AM | 1 |
| Toda, K | 1 |
| Goriki, K | 1 |
| Ochiai, M | 1 |
| Tokunou, H | 1 |
| Uehara, S | 1 |
| Okusaki, K | 1 |
| Kobayashi, K | 2 |
| Morioka, Y | 2 |
| Isaka, Y | 2 |
| Tozawa, T | 2 |
| Curto, R | 1 |
| Voit, EO | 1 |
| Cascante, M | 1 |
| Peichl, P | 1 |
| Pöllmann, G | 1 |
| Kullich, W | 3 |
| Klein, G | 5 |
| Logan, JA | 1 |
| Morrison, E | 1 |
| McGill, PE | 1 |
| Olive, P | 1 |
| Canovas, F | 1 |
| Medioni, D | 1 |
| Leroux, JL | 1 |
| Baldet, P | 1 |
| Bonnel, F | 1 |
| Blotman, F | 1 |
| Walter-Sack, I | 4 |
| de Vries, JX | 1 |
| Chou, CT | 1 |
| Lai, JS | 1 |
| Ushijima, K | 1 |
| Sancho, T | 1 |
| Buño, A | 1 |
| Togashi, R | 1 |
| Dan, T | 1 |
| Grahame, R | 9 |
| Marsh, FP | 1 |
| Page, T | 1 |
| Coleman, M | 1 |
| Darby, AJ | 1 |
| Harness, NF | 1 |
| Pritchard, MS | 1 |
| Stavrou, C | 1 |
| Pierides, A | 1 |
| Zouvani, I | 1 |
| Kyriacou, K | 1 |
| Neophytou, P | 1 |
| Christodoulou, K | 1 |
| Deltas, CC | 1 |
| von Essen, R | 2 |
| Hölttä, AM | 2 |
| Pikkarainen, R | 1 |
| Lloyd, A | 1 |
| Burchett, I | 1 |
| Alonso-Ruiz, A | 2 |
| Duruelo, J | 1 |
| Khattak, FH | 1 |
| Morris, IM | 1 |
| Harris, K | 1 |
| Owen-Smith, B | 1 |
| Quiney, J | 1 |
| Read, J | 1 |
| Sgonc, R | 1 |
| Fend, F | 1 |
| König, P | 1 |
| Rigden, S | 1 |
| Haycock, GB | 1 |
| Dalton, N | 1 |
| Van't Hoff, W | 1 |
| Rees, L | 1 |
| Raman, GV | 1 |
| Ogg, CS | 4 |
| Beutler, AM | 1 |
| Decaux, G | 1 |
| Soupart, A | 1 |
| Musch, W | 1 |
| Hannotier, P | 1 |
| Prospert, F | 1 |
| Emmerson, B | 1 |
| Herrero-Beites, A | 1 |
| García-Erauskin, G | 2 |
| Ruiz-Lucea, E | 1 |
| Marcil, J | 1 |
| Harbour, D | 1 |
| Houle, MG | 1 |
| Bourgoin, S | 1 |
| Vague, J | 1 |
| Cuan, A | 1 |
| Magaña, M | 1 |
| Cazarín, J | 1 |
| Pacheco-Tena, C | 1 |
| Kivlighn, SD | 1 |
| Suga, S | 1 |
| Chazerain, P | 2 |
| Ziza, JM | 2 |
| Harris, MD | 1 |
| Siegel, LB | 1 |
| Alloway, JA | 1 |
| Barynov, EF | 1 |
| Syniachenko, OV | 1 |
| Hryn', VK | 1 |
| Bondarenko, NM | 1 |
| Barynova, ME | 1 |
| Pittman, JR | 1 |
| Bross, MH | 1 |
| Dieppe, P | 5 |
| Swan, A | 2 |
| Nakanishi, N | 1 |
| Suzuki, K | 1 |
| Kawashimo, H | 1 |
| Nakamura, K | 1 |
| Tatara, K | 1 |
| Aboulafia, AJ | 1 |
| Prickett, B | 1 |
| Giltman, L | 1 |
| Hayashi, H | 1 |
| Nagasaka, S | 1 |
| Ishikawa, S | 1 |
| Rokkaku, K | 1 |
| Saito, T | 2 |
| Kusaka, I | 1 |
| Higashiyama, M | 1 |
| Kubota, K | 1 |
| Murakami, T | 2 |
| Sanders, KA | 1 |
| Huecksteadt, T | 1 |
| Sturrock, AB | 1 |
| Bruin-Weller, MS | 1 |
| Van Vloten, WA | 1 |
| Van Velde, JI | 1 |
| Perkins, P | 1 |
| Jones, AC | 1 |
| Wyndham, M | 1 |
| Baker, DG | 3 |
| Chopra, KF | 1 |
| Schneiderman, P | 1 |
| Grossman, ME | 1 |
| Rosas, J | 1 |
| Zoref-Shani, E | 1 |
| Feinstein, S | 1 |
| Frishberg, Y | 1 |
| Bromberg, Y | 1 |
| Hauser, SD | 1 |
| Wasada, T | 1 |
| Iwamoto, Y | 1 |
| Moritani, M | 1 |
| Takeuchi, F | 2 |
| Clive, DM | 1 |
| Majewski, J | 1 |
| Ott, J | 1 |
| Shidham, V | 2 |
| Shidham, G | 2 |
| Lin, KC | 2 |
| Ellis, S | 1 |
| Isenberg, D | 1 |
| Song, J | 1 |
| Lee, WK | 1 |
| Schreiner, O | 1 |
| Wandel, E | 1 |
| Himmelsbach, F | 1 |
| Galle, PR | 1 |
| Märker-Hermann, E | 1 |
| Johnson, JR | 1 |
| Dessein, PH | 1 |
| Shipton, EA | 1 |
| Stanwix, AE | 1 |
| Joffe, BI | 1 |
| Ramokgadi, J | 1 |
| van Doornum, S | 1 |
| Ryan, PF | 1 |
| Yuan, SC | 1 |
| Wang, CJ | 1 |
| Kuo, HW | 1 |
| Hsieh, YS | 1 |
| Mader, R | 1 |
| Shadick, NA | 1 |
| Kim, R | 1 |
| Weiss, S | 1 |
| Liang, MH | 2 |
| Sparrow, D | 1 |
| Yeh, L | 1 |
| Lai, PH | 1 |
| Liang, HL | 1 |
| Resnick, D | 1 |
| Jinnah, HA | 1 |
| De Gregorio, L | 1 |
| Harris, JC | 1 |
| O'Neill, JP | 1 |
| Tatsuno, I | 1 |
| Sharples, K | 1 |
| Raill, B | 1 |
| Dudler, J | 1 |
| Weinzweig, J | 1 |
| Fletcher, JW | 1 |
| Linburg, RM | 1 |
| Landis, RC | 1 |
| Al-Arfaj, AS | 1 |
| Yamakita , J | 1 |
| Ishibuchi, S | 1 |
| Morimoto, H | 1 |
| Oe, T | 1 |
| Ikebe, T | 1 |
| Fukunari, A | 1 |
| Kamezawa, M | 1 |
| Yamada, I | 1 |
| Naka, Y | 1 |
| Li-Yu, J | 1 |
| Sieck, M | 1 |
| Rull, M | 1 |
| Eisner, E | 1 |
| Delnomdedieu, M | 1 |
| Oliverio, MI | 1 |
| Williams, LD | 1 |
| Saifer, MGP | 1 |
| Sherman, MR | 1 |
| Coffman, TM | 1 |
| Johnson, GA | 1 |
| Schumacher , HR | 1 |
| Sancho Bueso, T | 1 |
| Bol, P | 1 |
| Lin-Tan, DT | 1 |
| Monev, SD | 1 |
| Chang, HY | 1 |
| Tsai, KS | 1 |
| Frawley, WH | 1 |
| Habermann, W | 1 |
| Kiesler, K | 1 |
| Eherer, A | 1 |
| Beham, A | 1 |
| Friedrich, G | 1 |
| Chivukula, M | 1 |
| Basir, Z | 1 |
| Badilla, A | 1 |
| Rojas, C | 1 |
| Shcherbak, AV | 1 |
| Kozlovskaia, LV | 1 |
| Podorol'skaia, LV | 1 |
| Gindis, AA | 1 |
| Stein, M | 1 |
| Shen, ML | 1 |
| Desaulniers, P | 1 |
| Würzner, G | 1 |
| Chiolero, A | 1 |
| Maillard, M | 1 |
| Fallab-Stubi, CL | 1 |
| Brunner, HR | 1 |
| Sturm, E | 1 |
| Scolari, F | 1 |
| Viola, BF | 1 |
| Prati, E | 1 |
| Ghiggeri, GM | 1 |
| Caridi, G | 1 |
| Amoroso, A | 1 |
| Casari, G | 1 |
| Maiorca, R | 1 |
| Neal, DA | 1 |
| Tom, BD | 1 |
| Gimson, AE | 1 |
| Gibbs, P | 1 |
| Alexander, GJ | 1 |
| Pilmore, HL | 1 |
| Faire, B | 1 |
| Dittmer, I | 1 |
| Aupperle, K | 1 |
| Liberopoulos, E | 1 |
| Christides, D | 1 |
| Elisaf, M | 1 |
| Fedorova, NE | 1 |
| Grigor'eva, VD | 1 |
| Boye, T | 1 |
| Guennoc, B | 1 |
| Carsuzaa, F | 1 |
| Weselman, KO | 1 |
| Tsai, LY | 1 |
| Gálvez, J | 1 |
| Sáiz, E | 1 |
| Linares, LF | 1 |
| Climent, A | 1 |
| Marras, C | 1 |
| Pina, MF | 1 |
| Castellón, P | 1 |
| Amer, H | 1 |
| Zaloga, B | 1 |
| Hughes, JL | 1 |
| Hoda, RS | 1 |
| Neto, M | 1 |
| Pilloff, B | 1 |
| Simon, J | 1 |
| Musil, J | 1 |
| Hannan, SF | 1 |
| Potter, CS | 1 |
| Crute, CM | 1 |
| Pinto, B | 2 |
| Rocha, E | 2 |
| Brien, G | 1 |
| Bick, C | 1 |
| Gremske, D | 1 |
| Winocour, PD | 2 |
| Turner, MR | 1 |
| Taylor, TG | 2 |
| Munday, KA | 2 |
| Hers, HG | 1 |
| Van Den Berghe, G | 2 |
| Bogner, G | 1 |
| Tilscher, H | 1 |
| Nishizawa, T | 5 |
| Maruki, M | 1 |
| Aikawa, T | 1 |
| Mitamura, T | 1 |
| Yokohari, R | 1 |
| Horiuchi, Y | 1 |
| Henninces, D | 1 |
| Anisimov, VE | 1 |
| Raivio, KO | 1 |
| Becker, 7A | 1 |
| Meyer, LJ | 4 |
| Greene, ML | 6 |
| Wild, JH | 1 |
| Hohneck, A | 1 |
| Griebsch, A | 7 |
| Korfmacher, I | 2 |
| Zoref, E | 3 |
| Lenz, W | 1 |
| Klein, W | 1 |
| Huth, F | 1 |
| Loizzi, P | 2 |
| Terlizzi, N | 1 |
| Micheli, V | 2 |
| Boer, P | 1 |
| Brosh, S | 1 |
| Kippen, I | 7 |
| Pollet, J | 1 |
| Galliot, M | 1 |
| Khalaf, AA | 1 |
| Riario-Sforza, G | 4 |
| Sales, LM | 1 |
| Pallalardo, A | 1 |
| Gancitano, A | 1 |
| Krupar, V | 2 |
| Rieselbach, RE | 4 |
| Berg, G | 7 |
| Minzlaff, R | 1 |
| Hauss, J | 1 |
| Schönleben, K | 1 |
| Hrubesch, M | 1 |
| Schmidt, E | 1 |
| Müller, KM | 1 |
| Sany, J | 1 |
| Rosenberg, F | 1 |
| Bataille, R | 1 |
| Heel, RC | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Schräpler, P | 2 |
| Schulz, E | 2 |
| Kleinschmidt, A | 1 |
| Schettler, G | 1 |
| Stavric, B | 1 |
| Nera, EA | 1 |
| Mangini, RJ | 2 |
| Peitzman, SJ | 1 |
| Fernandez, PC | 1 |
| Bodison, W | 1 |
| Ellis, I | 1 |
| Dorhout Mees, DJ | 1 |
| Dzhen-gu, K | 1 |
| Serry, MM | 1 |
| Gall, EP | 1 |
| Westberg, NG | 1 |
| Rosén, E | 1 |
| Waldenström, J | 1 |
| Korom, I | 1 |
| Szabó, L | 1 |
| László, A | 1 |
| Dallmann, L | 1 |
| Ormos, J | 1 |
| Kilbourn, K | 1 |
| Horner, I | 1 |
| Böhmer, R | 2 |
| Molina, J | 1 |
| Hoover, PL | 1 |
| Paxson, CS | 1 |
| Wilson, WF | 1 |
| Payne, RB | 1 |
| Johnson, WJ | 1 |
| O'Duffy, JD | 2 |
| Krey, PR | 1 |
| Bailen, DA | 1 |
| Wolfram, G | 9 |
| Fusani, L | 1 |
| King, RS | 1 |
| Wichman, BA | 1 |
| Morton, NE | 1 |
| Canoso, JJ | 2 |
| Warnock, DG | 1 |
| Zacharias, F | 1 |
| Sergent, JS | 1 |
| Dansereau, JY | 1 |
| Ménard, HA | 1 |
| Dorph, DJ | 1 |
| Smith, H | 2 |
| Bresnik, W | 3 |
| Müller, MM | 4 |
| Kosman, ME | 1 |
| Murphy, JE | 1 |
| Barsom, S | 1 |
| Green, EJ | 1 |
| Dilworth, JH | 1 |
| Levitin, PM | 1 |
| Urman, JD | 1 |
| Ballou, SP | 1 |
| Khan, MA | 1 |
| Harris, JW | 1 |
| Lowenthal, MN | 1 |
| Dymond, ID | 1 |
| Flouvier, B | 1 |
| Devulder, B | 1 |
| Heyden, S | 4 |
| Romanoff, NR | 1 |
| Rubinow, A | 1 |
| Spark, EC | 1 |
| Kozhevnikov, EM | 1 |
| Voĭtov, LI | 1 |
| Efimova, MN | 1 |
| Samokhina, RF | 1 |
| Zahn, CE | 1 |
| Nyburg, SC | 1 |
| Luk, SC | 1 |
| Houpt, JB | 3 |
| Häntzschel, U | 1 |
| Költzsch, V | 1 |
| Fries, JF | 1 |
| Zimmet, PZ | 1 |
| Thoma, K | 1 |
| Perricone, E | 1 |
| Brandt, KD | 2 |
| Kamoun, P | 2 |
| Chanard, J | 2 |
| Brami, M | 2 |
| Funck-Brentano, JL | 2 |
| Goebel, FD | 3 |
| Ohlschlägel, G | 1 |
| Lang, F | 1 |
| Greger, R | 1 |
| Silbernagel, H | 1 |
| Günther, R | 8 |
| Deetjen, P | 2 |
| Remmele, W | 1 |
| Meyer, R | 1 |
| Gnauck, H | 1 |
| Bettendorf, U | 1 |
| Kanzler, G | 1 |
| Hevia, P | 2 |
| Shaffer, RH | 1 |
| Peterson, DW | 1 |
| Clifford, AJ | 2 |
| Sůnová, J | 1 |
| Flügel, M | 1 |
| Geldmacher, J | 1 |
| Sundaram, PV | 1 |
| Igloi, MP | 1 |
| Wassermann, R | 1 |
| Hinsch, W | 1 |
| Wongsurawat, V | 1 |
| Wongsurawat, N | 1 |
| Badley, EM | 1 |
| Meyrick, JS | 1 |
| Wood, PH | 1 |
| Masuda, T | 1 |
| Abgarowicz, T | 1 |
| Brzozowska-Jurkowska, M | 1 |
| Webb, J | 1 |
| Lindsley, HB | 1 |
| Kästner, P | 1 |
| Schäfer, W | 1 |
| Brauer, GW | 1 |
| Weiss, JJ | 1 |
| Goldman, RT | 1 |
| Rigg, GA | 1 |
| Campbell, BC | 1 |
| Moore, MR | 2 |
| Goldberg, A | 1 |
| Hernandez, LA | 1 |
| Dick, WC | 1 |
| Gioffrè, W | 1 |
| Brandi, L | 1 |
| Pallassini, A | 1 |
| Faure, G | 1 |
| Pusevski, A | 1 |
| Berg, H | 2 |
| Steele, TH | 5 |
| Loewer, H | 2 |
| Morin, C | 1 |
| Bernier, J | 1 |
| Johnson, LA | 1 |
| Mähr, G | 1 |
| Krízek, V | 6 |
| Nebout, T | 1 |
| Kazandjian, M | 1 |
| Haslock, I | 1 |
| Wright, V | 1 |
| Chamney, B | 1 |
| Middlemiss, H | 1 |
| Orfanos, CE | 1 |
| Künzig, M | 1 |
| Bröll, H | 1 |
| Sochor, H | 1 |
| Babucke, G | 4 |
| Sagebiel, L | 1 |
| Laurens, P | 1 |
| Gavelle, P | 1 |
| Maurice, P | 1 |
| McCarthy, DJ | 1 |
| Coomes, EN | 1 |
| Haeckel, R | 1 |
| de Gèry, A | 13 |
| Pasquier, C | 3 |
| Novak, A | 1 |
| Knesl, E | 1 |
| Kaiser, E | 1 |
| Campion, DS | 2 |
| Olsen, RW | 1 |
| Caughey, D | 1 |
| Stuhlsatz, HW | 1 |
| Enzensberger, W | 1 |
| Greiling, H | 3 |
| Jacobs, D | 2 |
| Frank, O | 5 |
| Sturge, RA | 1 |
| Marcellan, FJ | 1 |
| Robinson, H | 1 |
| Masi, AT | 1 |
| Castrillo, JM | 1 |
| Niemi, KM | 1 |
| Appelboom, T | 1 |
| Honig, S | 1 |
| Gorevic, P | 1 |
| Hoffstein, S | 1 |
| Rosenthal, M | 1 |
| Beighton, P | 2 |
| Solomon, L | 3 |
| Soskolne, CL | 2 |
| Sweet, MB | 1 |
| Brzozowska, AM | 1 |
| Pleau, JM | 1 |
| Brunois, JP | 1 |
| Tofuku, Y | 4 |
| Kuroda, M | 2 |
| Takeda, R | 1 |
| Barr, GD | 1 |
| Waisman, J | 6 |
| Erzsébet, H | 1 |
| István, H | 1 |
| Wolff, G | 1 |
| Tobiasch, V | 1 |
| Eder, M | 1 |
| Singer, P | 1 |
| Tuner, MR | 1 |
| Neuwirth, R | 1 |
| Reynolds, AF | 1 |
| Wyler, AR | 1 |
| Norris, HT | 1 |
| Gascon, J | 1 |
| Jaross, W | 1 |
| Szmigiel, Z | 1 |
| Pawlicka, G | 1 |
| Sowa, M | 1 |
| Glynn, JJ | 1 |
| Clayton, ML | 1 |
| Shenoy, TS | 1 |
| de Graciansky, P | 1 |
| Larrégue, M | 1 |
| Martinet, C | 1 |
| Lemaire, V | 1 |
| Klemens, UH | 1 |
| von Löwis of Menar, P | 1 |
| Bartolozzi, G | 1 |
| Bernini, G | 1 |
| Marianelli, L | 1 |
| Nassi, P | 1 |
| Thompson, L | 2 |
| Hiisi-Brummer, L | 1 |
| Yolken, RH | 1 |
| Miller, DR | 1 |
| Morley, CJ | 1 |
| Houston, IB | 1 |
| Morris-Jones, P | 1 |
| Synková, J | 1 |
| Brátová, M | 1 |
| Groh, J | 1 |
| Dítĕ, P | 1 |
| Warembourg, H | 1 |
| Stalnikiewicz, G | 1 |
| Ravera, R | 1 |
| Potaux, L | 1 |
| Aparicio, M | 1 |
| Maurel, C | 1 |
| Ruedas, ME | 1 |
| Martin-Dupont, Cl | 1 |
| Brewis, I | 1 |
| Ellis, RM | 1 |
| Row, PG | 1 |
| Gottlieb, N | 1 |
| Grendelmeier, P | 1 |
| Marshall, LL | 1 |
| Uccella, R | 1 |
| Torralba, TP | 1 |
| Brewis, ID | 1 |
| Loebl, WY | 3 |
| Al-Hujaj, M | 3 |
| Schonthal, H | 3 |
| Sar, AV | 1 |
| Huisman, TH | 1 |
| Ibrahim, SA | 1 |
| Blécourt, JJ | 1 |
| Ferretti, PG | 1 |
| Marchini, L | 1 |
| Africa, A | 1 |
| Passeri, M | 1 |
| Meyer, WJ | 1 |
| Gill, JR | 1 |
| Bartter, FC | 1 |
| Sosovec, V | 1 |
| Nicholson, G | 1 |
| Yonezawa, H | 2 |
| Naito, H | 1 |
| Robin, JA | 2 |
| Tolchin, SF | 2 |
| Elion, GB | 4 |
| Keller, H | 3 |
| Lequesne, M | 1 |
| Bensasson, M | 1 |
| Dwosh, IL | 1 |
| Marchant, PJ | 1 |
| Lacroix, S | 1 |
| Omura, S | 1 |
| Wyhofsky, V | 1 |
| Mwasi, LM | 1 |
| Stanhope, JM | 1 |
| Mielants, H | 3 |
| Veys, EM | 3 |
| DeBussere, A | 1 |
| van der Jeught, J | 1 |
| Sinclair, DS | 1 |
| Schirmeister, J | 1 |
| Ooi, Y | 1 |
| Hara, I | 1 |
| Iwao, T | 1 |
| Zmuda, MJ | 1 |
| Quebbemann, AJ | 1 |
| Eckes, L | 1 |
| Barlattani, M | 1 |
| Messina, B | 2 |
| Gallen, S | 1 |
| Erill, S | 1 |
| Laporte, J | 1 |
| Mandel, NS | 2 |
| Mandel, GS | 2 |
| Siegenthaler-Zuber, G | 1 |
| De Biasio, R | 1 |
| Alth, G | 1 |
| Ogris, E | 1 |
| Müller, G | 1 |
| Judák, A | 2 |
| Gyódi, E | 1 |
| Stenszky, V | 1 |
| Leong, KH | 1 |
| Feng, PH | 1 |
| Delaney, V | 1 |
| Sumrani, N | 1 |
| Daskalakis, P | 1 |
| Hong, JH | 1 |
| Sommer, BG | 1 |
| Rühle, H | 1 |
| Roselló Pardo, R | 1 |
| Rodríguez Ruiz, T | 1 |
| Graff, SN | 1 |
| Seiler, JG | 1 |
| Jupiter, JB | 1 |
| Low, LL | 1 |
| Cervantes, AG | 1 |
| Melcher, WL | 1 |
| Culora, G | 1 |
| Gallagher, PJ | 1 |
| Muirden, KD | 1 |
| Wigley, RD | 1 |
| Ford, TC | 1 |
| Peters, TD | 1 |
| Ball, GV | 3 |
| Burack, DA | 1 |
| Griffith, BP | 1 |
| Thompson, ME | 1 |
| Kahl, LE | 1 |
| Kawagoe, Y | 1 |
| Kaneko, N | 1 |
| Kimata, S | 1 |
| Hosoda, S | 1 |
| Wernick, R | 1 |
| Winkler, C | 1 |
| Adam, RF | 1 |
| Loynes, RD | 1 |
| Kam, M | 1 |
| Perl-Treves, D | 2 |
| Caspi, D | 1 |
| Castellano, JA | 1 |
| Niemann, TH | 1 |
| Warner, CA | 1 |
| Naides, SJ | 1 |
| Roessler, BJ | 1 |
| Golovoy, N | 1 |
| Heidler, S | 1 |
| Paulsen, TP | 1 |
| Cross, M | 3 |
| Osborne, JM | 1 |
| Axelsen, RA | 1 |
| Maeda, E | 1 |
| Hujiyoshi, T | 1 |
| Uematsu, T | 1 |
| Raman, V | 1 |
| Chantler, C | 3 |
| Duley, JA | 2 |
| Miranda Carús, ME | 1 |
| Luz Picazo, M | 1 |
| Ortíz Vázquez, J | 1 |
| Sorghi, ML | 1 |
| Savini, F | 1 |
| Sönmez, G | 1 |
| Mert, N | 1 |
| Hall, S | 1 |
| Bagriĭ, EA | 1 |
| Davies, PM | 2 |
| Dyer, CA | 1 |
| Martin, J | 1 |
| Curtiss, LK | 1 |
| LeFlore, I | 1 |
| Antoine, GA | 1 |
| Marshall, VR | 1 |
| di Giovine, FS | 1 |
| Thornton, E | 1 |
| Michán, AD | 1 |
| Capitán, CF | 1 |
| Gijón, JB | 1 |
| Stankovíc, A | 1 |
| Front, P | 1 |
| Barbara, A | 1 |
| Mitrovíc, DR | 1 |
| Wolfe, F | 1 |
| Sterling, LP | 1 |
| Matsushima, M | 1 |
| Noto, M | 1 |
| Kawakami, H | 1 |
| Nakatsuka, K | 1 |
| Jojima, K | 1 |
| Nohno, H | 1 |
| Matsuzaki, H | 1 |
| Keller, C | 2 |
| Lathan, HH | 1 |
| Fabian, K | 1 |
| Kämpfe, U | 1 |
| Dixon, RM | 2 |
| Kemp, GJ | 2 |
| Angus, PW | 2 |
| McAlindon, TE | 2 |
| Rajagopalan, B | 3 |
| Radda, GK | 3 |
| Mateos Antón, F | 2 |
| Ramos Hernández, T | 1 |
| Sebastián Melián, J | 1 |
| García Neito, V | 1 |
| Hess, B | 1 |
| Binswanger, U | 1 |
| Roubenoff, R | 1 |
| Schwandt, P | 3 |
| Brophy, LM | 1 |
| Imanishi, M | 1 |
| Ikegami, M | 1 |
| Ishii, T | 1 |
| Nishioka, T | 1 |
| Uemura, T | 1 |
| Kunikata, S | 1 |
| Kanda, H | 1 |
| Matsuura, T | 1 |
| Akiyama, T | 1 |
| Kurita, T | 1 |
| Foreman, JW | 1 |
| Yudkoff, M | 1 |
| Loenen, HM | 1 |
| Eshuis, H | 1 |
| Löwik, MR | 1 |
| Schouten, EG | 1 |
| Hulshof, KF | 1 |
| Odink, J | 1 |
| Kok, FJ | 1 |
| Kamilli, I | 1 |
| Ivanov, I | 1 |
| Tsachev, K | 1 |
| Gathof, B | 1 |
| Vukmir, RB | 1 |
| Weiss, L | 1 |
| Verdile, VP | 1 |
| Safir, A | 1 |
| Dunn, SN | 1 |
| Martin, RG | 1 |
| Tate, GW | 1 |
| Mincey, GJ | 1 |
| Deray, G | 1 |
| Assogba, U | 1 |
| Le Hoang, P | 1 |
| Brillet, G | 1 |
| Baumelou, B | 1 |
| Jacobs, C | 1 |
| Borghi, L | 1 |
| Ferretti, PP | 1 |
| Elia, GF | 1 |
| Amato, F | 1 |
| Melloni, E | 1 |
| Trapassi, MR | 1 |
| Novarini, A | 1 |
| Horowitz, MD | 1 |
| Abbey, L | 1 |
| Sirota, DK | 1 |
| Spiera, H | 1 |
| Hall, IH | 1 |
| Scoville, JP | 1 |
| Reynolds, DJ | 1 |
| Simlot, R | 1 |
| Duncan, P | 1 |
| Landau, A | 1 |
| Reese, DJ | 1 |
| Blumenthal, DR | 1 |
| Chin, NW | 1 |
| Calabrese, G | 1 |
| Ballhaus, S | 1 |
| Mees, K | 1 |
| Guerne, PA | 1 |
| Zuraw, B | 1 |
| Lotz, M | 1 |
| Axelsen, R | 1 |
| Riccieri, V | 1 |
| Salerno, C | 1 |
| Anna, T | 1 |
| Gabriella, M | 1 |
| Roberto, M | 2 |
| González, AA | 1 |
| Casas, E | 2 |
| Capitán, MC | 2 |
| Bull, PW | 2 |
| Rocher, LL | 2 |
| McQuillan, MA | 2 |
| Di Stefano, A | 2 |
| Taddeo, A | 3 |
| Stiefel, M | 1 |
| Verberckmoes, R | 1 |
| Ritz, E | 1 |
| Schmaltz, S | 1 |
| Richter, WO | 1 |
| Konrád, K | 1 |
| Costantini, AV | 1 |
| Ferreira, A | 1 |
| Silva Júnior, BA | 1 |
| Braga, FM | 1 |
| Gargiulo, NM | 1 |
| Stávale, JN | 1 |
| Kurita, Y | 1 |
| Tsuboi, R | 2 |
| Numata, K | 1 |
| Matsubara, K | 1 |
| Jiao, S | 1 |
| Takama, T | 1 |
| Ulreich, A | 2 |
| González Sanz, A | 1 |
| Calabria, AA | 3 |
| Lalumera, M | 2 |
| Gerli, R | 1 |
| Alessandrini, C | 2 |
| Cavallo, G | 3 |
| Halverson, PB | 1 |
| Kim, M | 1 |
| Zhovnirenko, LP | 1 |
| Gostishcheva, IA | 1 |
| Tiller, DJ | 1 |
| Hall, BM | 1 |
| Horvarth, JS | 1 |
| Duggin, GG | 1 |
| Thompson, JF | 1 |
| Sheil, AG | 1 |
| D'Ubaldo, F | 1 |
| Petrini, G | 1 |
| Campagna, S | 1 |
| Oberhaensli, RD | 1 |
| Taylor, DJ | 1 |
| Collins, JE | 1 |
| Leonard, JV | 1 |
| Schwarz, H | 1 |
| Herschkowitz, N | 1 |
| Palmer, DG | 2 |
| Hessian, PA | 1 |
| Mejías, E | 1 |
| Navas, J | 1 |
| Lluberes, R | 1 |
| Martínez-Maldonado, M | 3 |
| Varshavskiĭ, VA | 1 |
| Pal'tsev, MA | 1 |
| Poliantseva, LR | 1 |
| Cheung, HS | 1 |
| Parrini, E | 1 |
| Bacarelli, MR | 1 |
| Mazzullo, G | 1 |
| Rosen, MS | 1 |
| Cherian, PV | 2 |
| Pascual Gómez, E | 1 |
| Campion, G | 1 |
| Singer, JZ | 1 |
| Campbell, SM | 1 |
| Gores, PF | 1 |
| Fryd, DS | 1 |
| Sutherland, DE | 1 |
| Najarian, JS | 1 |
| Simmons, RL | 1 |
| Price, CP | 1 |
| James, DR | 1 |
| German, DC | 2 |
| Welby, TJ | 1 |
| Ostbye, T | 1 |
| Salmond, CE | 1 |
| Stokes, YM | 1 |
| Khan, MS | 1 |
| Akhtar, P | 1 |
| Majeed, A | 1 |
| Derus, CL | 1 |
| Bowman, B | 1 |
| Bengoa, JM | 1 |
| Sitrin, MD | 1 |
| Akaoka, L | 1 |
| McDonald, J | 1 |
| Paton, T | 1 |
| Senn, J | 1 |
| Ramos, TH | 1 |
| Aoyagi, Y | 1 |
| Kamimura, T | 1 |
| Ichida, F | 1 |
| González Buitrago, JM | 1 |
| Arroyo, A | 1 |
| Vega, L | 1 |
| García Fernández, N | 1 |
| De la Rua, A | 1 |
| Navajo, JA | 1 |
| Martínez-Cordero, E | 2 |
| Bessudo-Babani, A | 1 |
| Treviño Pérez, SC | 1 |
| Guillermo-Grajales, E | 1 |
| Benabe, JE | 1 |
| Jósfay, J | 1 |
| Ludányi, E | 1 |
| West, C | 2 |
| Carpenter, BJ | 1 |
| Hakala, TR | 1 |
| Misz, I | 1 |
| Vizi, F | 1 |
| Ikeda, H | 3 |
| Miyahara, T | 3 |
| Fraser, RC | 1 |
| Davis, RH | 1 |
| Walker, FS | 1 |
| Coderre, TJ | 1 |
| Wall, PD | 1 |
| Hara, N | 1 |
| Kiyokawa, H | 1 |
| Himeno, S | 1 |
| Miyazaki, T | 1 |
| Popova, IuP | 2 |
| Ogura, Y | 1 |
| Mimura, N | 2 |
| Serniak, PS | 1 |
| Kobets, VG | 1 |
| Collado, A | 1 |
| Kanterewicz, E | 1 |
| Sanmartí, R | 1 |
| Alba, R | 1 |
| Brancós, MA | 1 |
| Rotés-Querol, J | 1 |
| Fasching, U | 1 |
| Broulik, PD | 1 |
| Stĕpán, JJ | 1 |
| Pacovský, V | 1 |
| Colling, M | 1 |
| Matulis, AA | 1 |
| Bareĭkene, IP | 1 |
| Venalis, AI | 1 |
| Shpilevaia, NI | 1 |
| Krapac, L | 1 |
| Gross, BD | 1 |
| Williams, RB | 1 |
| DiCosimo, CJ | 1 |
| Williams, SV | 1 |
| Bośmanský, K | 3 |
| Ondrasík, M | 2 |
| Faragher, RI | 1 |
| Caelli, DJ | 1 |
| Menghini, S | 1 |
| Della Corte, E | 2 |
| Golovanova, OE | 1 |
| Reznikov, IuP | 1 |
| Pankrat'ev, LM | 1 |
| Pennes, DR | 1 |
| Dong, SQ | 1 |
| Soliev, TS | 1 |
| Thiehle, P | 1 |
| Solakov, PTs | 1 |
| Atanasov, NA | 1 |
| Karastanev, II | 1 |
| Kereziev, IK | 1 |
| Kuzmanova, SI | 1 |
| Ivanova, MM | 1 |
| Hazelton, RA | 1 |
| Whyte, IM | 1 |
| Dykman, D | 1 |
| Simon, EE | 1 |
| Frocht, A | 1 |
| Leek, JC | 1 |
| Robbins, DL | 1 |
| Garyfallos, A | 1 |
| Magoula, I | 1 |
| Tsapas, G | 1 |
| Mohanaruban, K | 1 |
| Joglekar, M | 1 |
| Swift, CG | 1 |
| Tomlinson, K | 1 |
| Ortman, BL | 1 |
| Pack, LL | 1 |
| Adam, O | 1 |
| Bergman, HD | 1 |
| Filippova, VG | 1 |
| Popova, LA | 1 |
| Chekova, VV | 1 |
| L'vova, GN | 1 |
| Vasil'eva, IM | 1 |
| Thomson, DB | 1 |
| Lianga, J | 1 |
| Waslen, GD | 1 |
| Penney, CJ | 1 |
| Alessandri, C | 1 |
| Violi, F | 1 |
| Bonavita, MS | 1 |
| Barreira-Mercado, E | 1 |
| Katona, G | 1 |
| Milano, L | 1 |
| Kummer, H | 1 |
| Fleckenstein, JL | 1 |
| Herrero, EH | 1 |
| Arnalich, FF | 1 |
| Fioravanti, A | 1 |
| Renieri, A | 1 |
| Vacha, J | 2 |
| Kohoutova, B | 2 |
| Bergström, G | 1 |
| Bjelle, A | 1 |
| Sundh, V | 1 |
| Svanborg, A | 1 |
| Hoyt, RE | 1 |
| Gordon, TP | 2 |
| Roberts-Thomson, PJ | 2 |
| Porst, H | 1 |
| Liebscher, K | 1 |
| Gocheva, V | 1 |
| Atanasova, P | 1 |
| Strader, KW | 1 |
| Lally, EV | 1 |
| Ho, G | 1 |
| Kaplan, SR | 1 |
| Lluberas-Acosta, G | 1 |
| Hansell, JR | 1 |
| Taneda, A | 1 |
| Conthe Gutiérrez, P | 1 |
| Monteagudo, FS | 2 |
| Lluberas, G | 1 |
| Dong, DC | 1 |
| Li, ZC | 1 |
| Fu, XL | 1 |
| Woods, HF | 1 |
| Bax, ND | 1 |
| Jackson, PR | 1 |
| ter Borg, EJ | 1 |
| Pechán, I | 1 |
| Bosák, V | 1 |
| Gerová, Z | 1 |
| Tvarozková, Z | 1 |
| Campion, EW | 1 |
| DeLabry, LO | 1 |
| van Soesbergen, RM | 1 |
| Matricali, B | 1 |
| Mahapatro, RC | 1 |
| Sylvia, LC | 1 |
| Becker, SM | 1 |
| Bodem, H | 1 |
| Moxley, G | 1 |
| Ruddy, S | 1 |
| Zoppi, A | 1 |
| Fogari, R | 1 |
| Corradi, L | 1 |
| Finardi, G | 1 |
| Rundles, RW | 3 |
| Frantsova, Zh | 1 |
| Ridolfo, AS | 1 |
| Lightfoot, RW | 2 |
| Varga, J | 1 |
| Giampaolo, C | 1 |
| Goldenberg, DL | 1 |
| Tsujimoto, F | 1 |
| Tada, S | 1 |
| Schlapbach, P | 1 |
| Lo, B | 1 |
| Hankin, FM | 1 |
| Mayhew, DE | 1 |
| Coapman, RA | 1 |
| Snedden, M | 1 |
| Schneider, LH | 1 |
| Moore, JR | 1 |
| Weiland, AJ | 1 |
| Littman, BH | 1 |
| O'Connor, JP | 1 |
| Macfarlane, DG | 1 |
| Mank, H | 1 |
| Mende, T | 1 |
| Ahern, MJ | 1 |
| Reid, C | 1 |
| John, D | 1 |
| DeBruyne, S | 1 |
| Dwosh, I | 1 |
| Marliss, EB | 1 |
| Gawoski, JM | 1 |
| Balogh, K | 1 |
| Landis, WJ | 1 |
| Wordsworth, BP | 1 |
| Mowat, AG | 1 |
| Matsushige, H | 1 |
| Gotcheva, V | 1 |
| Atanassova, P | 1 |
| Todorova, L | 1 |
| Astrug, A | 1 |
| Dimitrov, T | 1 |
| Heidland, A | 1 |
| Hörl, WH | 1 |
| Schaefer, RM | 1 |
| Teschner, M | 1 |
| Weipert, J | 1 |
| Heidbreder, E | 1 |
| Buzzone, G | 1 |
| Sambataro, A | 1 |
| Camarda, G | 1 |
| Castiglione, F | 1 |
| Schillaci, W | 1 |
| Balsamo, S | 1 |
| Verde, F | 1 |
| Borade, VB | 1 |
| Kakrani, AL | 1 |
| Ahaley, SK | 1 |
| Ruiz, M | 1 |
| Furió Bacete, V | 1 |
| Juárez Centeno, D | 1 |
| Khalifa, P | 1 |
| Sereni, D | 1 |
| Boissonnas, A | 1 |
| Cremer, GA | 1 |
| Laroche, C | 2 |
| Ali, SY | 1 |
| Loginova, TK | 1 |
| Ershov, IuA | 1 |
| Stirpe, F | 1 |
| Bonetti, E | 1 |
| Abbondanza, A | 1 |
| Abbati, A | 1 |
| De Stefano, F | 1 |
| Mazurkiewicz, M | 1 |
| Seniów, A | 1 |
| Wachnik, Z | 1 |
| Sletten, K | 1 |
| Aakesson, I | 1 |
| Casey, AE | 1 |
| Gilbert, F | 1 |
| Ratliff, CR | 1 |
| Downey, EL | 1 |
| Elbrechter, J | 1 |
| Nicholls, A | 1 |
| Dobiás, J | 1 |
| Yamamura, Y | 2 |
| Katsunuma, N | 1 |
| Kawano, H | 2 |
| Becher, H | 1 |
| Mecke, D | 1 |
| Kleinen, R | 1 |
| Jensen, J | 1 |
| Blankenhorn, DH | 1 |
| Kornerup, V | 1 |
| Harvey, HP | 1 |
| Finn, R | 1 |
| Tweedie, MC | 1 |
| Jones, PO | 1 |
| Hall, SM | 1 |
| Dinsdale, OF | 1 |
| Bourdillon, RE | 1 |
| Perheentupa, J | 1 |
| Raivio, K | 1 |
| Harvey, WC | 1 |
| Scull, E | 1 |
| Leroy, EC | 1 |
| Kagen, LJ | 1 |
| Sandson, J | 1 |
| Gieseking, R | 1 |
| Barth, WF | 1 |
| Carmena, R | 1 |
| Fruhmann, G | 1 |
| Fritz, H | 2 |
| Bergstermann, H | 1 |
| Lozano-Tonkin, C | 1 |
| Kallie, RN | 3 |
| D'Aeth, R | 1 |
| Dowdle, EB | 1 |
| Joubert, SM | 3 |
| Casey, JH | 1 |
| Hoffman, MM | 1 |
| Solomon, S | 1 |
| Kölle, G | 1 |
| Maldyk, E | 3 |
| Polowiec, Z | 2 |
| Wagner, T | 2 |
| Sparagana, M | 1 |
| Phillips, G | 1 |
| Holzmann, H | 3 |
| Hoede, N | 1 |
| Morsches, B | 2 |
| Pasero, GP | 1 |
| Ciompi, MI | 1 |
| Ostendorp, U | 1 |
| Cayla, J | 2 |
| Rondier, J | 3 |
| Perreau, C | 1 |
| Zsernaviczky, J | 1 |
| von Torklus, D | 1 |
| Wilke, H | 1 |
| Frahm, H | 1 |
| Bach, JF | 1 |
| Bach, MA | 1 |
| Dardenne, M | 1 |
| Berlyne, GM | 1 |
| Shaw, AB | 1 |
| Nilwarangkur, S | 1 |
| Nivet, M | 1 |
| Marcovici, J | 1 |
| Compagnon, P | 1 |
| Laruelle, P | 1 |
| Rosenbloom, FM | 4 |
| Henderson, JF | 3 |
| Braun, S | 1 |
| Saint-Georges-Chaumet, F | 1 |
| Amor, B | 5 |
| Foglierini, J | 2 |
| Larrieu, F | 1 |
| Frugier, JC | 1 |
| Brouilhet, H | 5 |
| Olivier, JL | 2 |
| Rose, A | 1 |
| Solnica, J | 3 |
| Mitrovic, D | 2 |
| Massé, C | 1 |
| Jurmand, SH | 1 |
| Caroit, M | 2 |
| Durieu, J | 1 |
| Guérin, C | 1 |
| Dreyfus, P | 2 |
| Six, B | 2 |
| Forette, B | 2 |
| Kahn, CB | 1 |
| Wallingford, WR | 1 |
| Meyskens, FL | 1 |
| Williams, HE | 1 |
| Schilling, F | 2 |
| Freeman, D | 1 |
| Eilam, G | 1 |
| Hunt, RD | 1 |
| Garcia, FG | 1 |
| Walsh, RJ | 1 |
| Cottin, S | 1 |
| Prost, A | 4 |
| Rita, GA | 1 |
| Newcombe, DS | 2 |
| Wood, AW | 1 |
| Naff, GB | 2 |
| Byers, PH | 2 |
| MacCarty, DJ | 1 |
| Silcox, DC | 2 |
| Starmer, CF | 2 |
| de Weerdt, A | 2 |
| Catto, M | 1 |
| Kostel, PJ | 1 |
| Johnson, MG | 1 |
| Rosenweig, S | 1 |
| Switzer, RL | 1 |
| Gershon, SL | 1 |
| McLaughlin, RE | 1 |
| Davis, JS | 1 |
| Webb, FW | 1 |
| Roux, H | 3 |
| Shirahama, T | 1 |
| Cohen, AS | 1 |
| Pentikäinen, P | 1 |
| Frank, W | 1 |
| Petroni, D | 1 |
| Leńko, J | 1 |
| Ferguson, RH | 2 |
| Worthington, JW | 2 |
| Fallet, GH | 1 |
| Lechi, A | 1 |
| Covi, G | 1 |
| Pedrolli, E | 1 |
| D'Andrea, F | 1 |
| Lechi, C | 1 |
| Mengoli, C | 1 |
| Sguizzato, G | 1 |
| Cadenhead, A | 2 |
| Dean, BM | 2 |
| Riley, MJ | 1 |
| Fuss, M | 1 |
| Van Landuyt, P | 1 |
| Weiser, M | 1 |
| Fontinoy, N | 1 |
| Hasslacher, C | 1 |
| Wahl, P | 1 |
| Vollmar, J | 1 |
| Pérez Cano, R | 1 |
| Yánez Polo, MA | 1 |
| Melero Bellido, M | 1 |
| Casimiro Soringuer, F | 1 |
| Causse Prado, M | 1 |
| Muñóz González, J | 1 |
| Allwright, GT | 1 |
| Diamond, HS | 3 |
| Carter, AC | 3 |
| Tondreau, NE | 1 |
| Hirose, K | 1 |
| Debolini, A | 1 |
| Fontenaille, C | 3 |
| Guiheneuc, P | 3 |
| Heron, B | 3 |
| Lucas, J | 2 |
| Campion, D | 2 |
| Whitehouse, M | 2 |
| Emmrich, R | 1 |
| Gluck, FB | 1 |
| Wellmann, KF | 1 |
| Volk, BW | 1 |
| Doerr, W | 1 |
| Lasaroff, N | 1 |
| Réthyly, E | 1 |
| Pálfy, A | 1 |
| Tanaka, H | 1 |
| Sato, T | 1 |
| Mundy, GR | 1 |
| Fleckenstein, L | 1 |
| Mazzullo, JM | 1 |
| Sundaresan, PR | 1 |
| Weintraub, M | 1 |
| Lasagna, L | 1 |
| Johnson, ES | 2 |
| Hollander, IJ | 1 |
| Kościańska, J | 1 |
| Blacket, RB | 1 |
| Leelarthaepin, B | 1 |
| Palmer, AJ | 1 |
| Woodhill, JM | 1 |
| Whitehouse, MW | 4 |
| Schlosstein, L | 2 |
| Richmond, DE | 1 |
| Moskowitz, RW | 1 |
| Garcia, F | 1 |
| Carrozzo, M | 1 |
| Pipitone, V | 1 |
| Tidl, G | 1 |
| Rastegar, A | 2 |
| Thier, SO | 3 |
| Swales, JD | 1 |
| Kopstein, J | 1 |
| Wrong, OM | 1 |
| Asch, L | 2 |
| Villiaumey, J | 1 |
| Larget-Piet, B | 1 |
| Rotterdam, M | 1 |
| Cristol, R | 1 |
| Loeper, J | 1 |
| Buchanan, KD | 2 |
| Boine, L | 1 |
| Stamler, J | 1 |
| Swiderska-Kulikowa, B | 1 |
| Jelińska, S | 1 |
| Caraway, WT | 1 |
| Holmes, E | 1 |
| Escher, M | 1 |
| Boyle, JA | 4 |
| Semple, PF | 1 |
| Laszlo, J | 1 |
| Kilani, C | 1 |
| Saporta, L | 2 |
| Suzuki, Y | 1 |
| de Haas, WH | 1 |
| Ramsdell, CM | 2 |
| Postlethwaite, AE | 3 |
| Kröpelin, T | 1 |
| Brogard, JM | 2 |
| Coumaros, D | 1 |
| Franckhauser, J | 1 |
| Stahl, A | 2 |
| Stahl, J | 1 |
| Sopata, I | 2 |
| Hofmeister, F | 1 |
| Brandt, H | 1 |
| Deák, J | 1 |
| Lukes, J | 1 |
| Kazandjan, M | 1 |
| Urbánek, T | 2 |
| Hüttl, S | 2 |
| Hüttlová, O | 2 |
| Srámek, F | 2 |
| Stein, G | 1 |
| Schneider, V | 3 |
| Mikus, F | 1 |
| Vojtisek, O | 1 |
| Kanková, D | 1 |
| Jorda, V | 1 |
| Vykydal, M | 2 |
| Pegrimová, E | 2 |
| Bouvenot, G | 1 |
| Mosora, M | 1 |
| Boloşiu, H | 1 |
| Scott, WA | 1 |
| Robinson, RG | 1 |
| Corrigan, AB | 1 |
| Hayashi, TT | 1 |
| Gillo, D | 1 |
| Turner, JH | 1 |
| Zieliński, Z | 1 |
| Vovan, L | 2 |
| Dutertre, P | 2 |
| Serratrice, G | 2 |
| Recordier, AM | 2 |
| Royer, R | 4 |
| Boulange, M | 1 |
| Maling, HM | 1 |
| Zweig, MH | 1 |
| Williams, MA | 1 |
| Anderson, W | 1 |
| Hagen, K | 1 |
| Mahrenholz, U | 1 |
| Green, H | 1 |
| Ishii, K | 1 |
| Klabusay, L | 1 |
| Raska, P | 1 |
| Duda, V | 1 |
| Bachmann, K | 1 |
| Bergner, D | 1 |
| Bornhofen, E | 1 |
| Stürzenhofecker, P | 1 |
| Kunev, K | 1 |
| Katranushkov, I | 1 |
| Denninger, K | 1 |
| Ravera, M | 5 |
| Spaziante, B | 1 |
| Chini, V | 1 |
| Frankhauser, J | 1 |
| Ward, PA | 1 |
| Hood, B | 4 |
| Olander, R | 4 |
| Bluhm, GB | 2 |
| Riddle, JM | 2 |
| Alarcón-Segovia, DA | 1 |
| Cetina, JA | 1 |
| Díaz-Jouanen, E | 1 |
| Simon, KH | 1 |
| Terhorst, B | 1 |
| Bastian, HP | 1 |
| Siegelaub, AB | 1 |
| de Grey, A | 1 |
| Danchot, J | 1 |
| Kayembe, D | 1 |
| Sigg-Farner, C | 1 |
| Deplaen, JL | 1 |
| Sweet, B | 1 |
| Percy, JS | 1 |
| Starmer, F | 1 |
| Katz, JL | 1 |
| Weiner, H | 1 |
| Gutman, A | 1 |
| Schlosstein, LH | 1 |
| Paulus, HE | 2 |
| Litvak, J | 1 |
| Briney, W | 1 |
| Geerdink, RA | 1 |
| de Vries, WH | 1 |
| Willemse, J | 1 |
| Oei, TL | 1 |
| de Bruyn, CH | 1 |
| Fleischmann, V | 1 |
| Adadevoh, BK | 1 |
| Martin, E | 1 |
| Ody, B | 1 |
| Bennett, RM | 1 |
| Chait, A | 1 |
| Lewis, B | 2 |
| Tcherdakoff, P | 3 |
| Backmann, L | 4 |
| Olin, JS | 1 |
| Devenyi, P | 1 |
| Weldon, KL | 1 |
| Rubens-Duval, A | 1 |
| Malhotra, KK | 1 |
| Kathpalia, SC | 1 |
| Goulatia, RK | 1 |
| Butturini, U | 2 |
| Herzberg, L | 1 |
| Mincu, I | 1 |
| Navas, P | 1 |
| Grasset, D | 1 |
| Helm, E | 1 |
| Koçak, N | 1 |
| Tunali, A | 1 |
| Ozdoğan, E | 1 |
| Tuna, S | 1 |
| Mituszova, L | 1 |
| Erdély, E | 1 |
| Bényai, B | 1 |
| Basu, TK | 1 |
| Stein, RM | 1 |
| Peavy, PW | 1 |
| Franco, DJ | 1 |
| Gibson, TJ | 1 |
| Franck, WA | 2 |
| Bress, NM | 2 |
| Singer, FR | 1 |
| Krane, SM | 2 |
| Coe, F | 1 |
| Jacobelli, S | 1 |
| Reiss, E | 1 |
| Genant, H | 1 |
| Ellman, M | 1 |
| Hadler, NM | 1 |
| Robinson, DR | 1 |
| Muszkowska-Penson, J | 1 |
| Stolarczyk, J | 1 |
| Chang, GN | 1 |
| Fam, A | 1 |
| Little, AH | 1 |
| Malkin, A | 1 |
| Machtey, I | 1 |
| Meer, A | 1 |
| Goldberg, LS | 1 |
| Rosenfeld, JB | 1 |
| Mercier, N | 1 |
| Bartel, AG | 1 |
| Blétry, O | 1 |
| Cartier, P | 4 |
| Hamet, M | 3 |
| Clauvel, JP | 1 |
| Koperska, M | 1 |
| Jezewska, MM | 1 |
| Wessler, S | 1 |
| Avioli, LV | 1 |
| Fluur, E | 1 |
| Haverling, M | 1 |
| Molin, C | 1 |
| Christian, CL | 1 |
| Butler, VP | 1 |
| Hamerman, D | 1 |
| Larson, CB | 1 |
| Pearson, CM | 1 |
| Symthe, HA | 1 |
| Taranta, A | 1 |
| Tomasi, TB | 1 |
| Weinberger, HJ | 1 |
| Miyahara, M | 1 |
| Fujise, Y | 1 |
| Hoshikawa, K | 1 |
| Nakagawa, K | 1 |
| Bäumer, A | 4 |
| Susić, D | 1 |
| Reese, GM | 1 |
| Vogler, WR | 2 |
| Drane, JW | 1 |
| Rouques, C | 1 |
| Paolaggi, F | 4 |
| Mertz, P | 1 |
| Strohmeyer, G | 2 |
| Douglas, G | 1 |
| Thompson, M | 1 |
| Larmon, WA | 1 |
| Pollard, AC | 1 |
| Shelp, WD | 1 |
| Kaplan, G | 1 |
| Balasubramaniam, P | 1 |
| Silva, JF | 1 |
| Harvengt, C | 1 |
| Lavenne, F | 1 |
| Galmiche, P | 1 |
| Mizon, JP | 1 |
| Plaquet, R | 1 |
| Gentit, F | 1 |
| Quiret, JC | 1 |
| Gottesbüren, H | 1 |
| Brown, CH | 1 |
| Stashick, E | 1 |
| Carbone, PP | 1 |
| Radi, I | 1 |
| Frayha, RA | 1 |
| French, JG | 1 |
| Kjelsberg, MO | 1 |
| Schull, WJ | 1 |
| Glynn, LE | 1 |
| Delbarre, MF | 1 |
| Henrard, JC | 1 |
| Puel, M | 2 |
| Aldo, C | 1 |
| Sunder, JH | 1 |
| Kantor, TG | 1 |
| Krenitsky, TA | 1 |
| Dancis, J | 1 |
| Silvers, DN | 1 |
| Mogrovejo Velarde, A | 1 |
| Figueiredo, G | 1 |
| Salvatella Viñals, J | 1 |
| Barnes, CG | 1 |
| Falls, WF | 1 |
| Kramer, HJ | 1 |
| Lu, E | 1 |
| Herrick, N | 1 |
| Vinstein, AL | 1 |
| Cockerill, EM | 1 |
| Masszi, J | 1 |
| Horváth, A | 1 |
| Mecher, T | 1 |
| Kulcsár, G | 1 |
| O'Sullivan, JB | 1 |
| Beardmore, TD | 2 |
| Cashman, JS | 1 |
| Tobias, PV | 1 |
| Shaw, AH | 1 |
| Cafiero, M | 1 |
| Buono, G | 1 |
| Sensale, P | 1 |
| Diamond, H | 1 |
| Wiedemann, E | 1 |
| Rose, HG | 1 |
| Schwartz, E | 1 |
| Honda, H | 1 |
| Gindin, RA | 1 |
| Henninges, D | 4 |
| Schwoerer, P | 1 |
| Rückert, KH | 1 |
| Chowanetz, W | 1 |
| Leo, W | 1 |
| Dabrowski, W | 1 |
| Maeder, HU | 1 |
| Gietka, J | 1 |
| Sulek, K | 1 |
| Marion, RB | 1 |
| Alperin, JE | 1 |
| Maloney, WH | 1 |
| Cassagrande, PA | 1 |
| Towson, J | 1 |
| Guilbaud, J | 1 |
| Droniou, J | 1 |
| Treadwell, BL | 1 |
| Chalmers, RA | 2 |
| Bitensky, L | 1 |
| Balasse-Ketelbant, P | 1 |
| Horacio Day, J | 1 |
| Addae, SK | 1 |
| Konotey-Ahulu, FI | 1 |
| Hoshino, T | 1 |
| Tsutsui, K | 1 |
| Minegishi, T | 1 |
| Murata, H | 1 |
| Shibata, K | 1 |
| Nikolov, GS | 1 |
| Tellkamp, F | 3 |
| Feuerstein, C | 1 |
| Alexopoulos, J | 1 |
| Schmidt, K | 1 |
| Engelhardt, K | 1 |
| Jonas, S | 1 |
| Snedden, W | 2 |
| Parker, RB | 1 |
| Hajzok, O | 1 |
| Hajzoková, M | 1 |
| Thorpe, JJ | 1 |
| Daley, JM | 1 |
| Varricchio, M | 1 |
| Russo, R | 1 |
| Gentile, S | 1 |
| Ugo, C | 2 |
| Louyot, P | 2 |
| Pourel, J | 1 |
| Gaucher, A | 2 |
| Montet, Y | 1 |
| Cammeo, F | 1 |
| Traina, GC | 1 |
| Olmi, R | 1 |
| De Vecchis, L | 1 |
| Soria, C | 1 |
| Guerin, B | 1 |
| Coscelli, C | 1 |
| Palmari, V | 1 |
| Vargazon, B | 1 |
| Pecenko, M | 1 |
| Alepa, FP | 1 |
| Frazier, PD | 1 |
| Smith, EE | 1 |
| Kurlander, GJ | 1 |
| Powell, RC | 1 |
| Bowie, EA | 1 |
| Jakubowska, D | 1 |
| Ziólkiewicz, Z | 1 |
| Kleinman, HZ | 1 |
| Ewbank, RL | 1 |
| Benedetti, A | 3 |
| Bucciante, G | 1 |
| Cattano, G | 1 |
| Nardini, A | 3 |
| Neubaur, J | 1 |
| Willms, B | 1 |
| Söling, HD | 1 |
| Creutzfeldt, W | 1 |
| Woodbury, JF | 1 |
| Mehta, DM | 1 |
| Morse, WI | 1 |
| Preger, L | 1 |
| Sanders, GW | 1 |
| Gold, RH | 1 |
| Steinbach, HL | 1 |
| Pitman, P | 1 |
| Falk, S | 1 |
| Bronstein, LH | 1 |
| Berger, AR | 1 |
| Hutchison, JC | 1 |
| Wilkinson, WH | 1 |
| McMahon, FG | 1 |
| Helbig, W | 1 |
| Findeisen, B | 1 |
| Mirosch, W | 1 |
| Douglas, JB | 1 |
| Emmrich, P | 1 |
| Gerbaux, JO | 1 |
| Rodhain, J | 1 |
| Morgenroth, K | 1 |
| Backmann, R | 1 |
| Mello, A | 1 |
| Mello, NR | 1 |
| Josef, H | 1 |
| Cossermelli, W | 1 |
| Debes, AC | 1 |
| Kopersztych, S | 1 |
| Brunelli, E | 1 |
| Klotz, H | 1 |
| Prohaska, E | 1 |
| Salmhofer, H | 1 |
| Schmid, L | 1 |
| Hiroata, R | 1 |
| Nomura, Y | 1 |
| Aibara, K | 1 |
| Miyaki, K | 1 |
| Dry, J | 3 |
| Seebach, LM | 1 |
| Jackman, AE | 1 |
| Barnhart, MI | 1 |
| Caraceni, C | 1 |
| Marugo, M | 3 |
| Scopinaro, N | 2 |
| Minuto, F | 2 |
| Busonera, G | 2 |
| Rail, GA | 1 |
| Bergstresser, P | 1 |
| Weed, CL | 1 |
| Isomäki, HA | 1 |
| Takkunen, H | 1 |
| Kastner, C | 1 |
| Canlorbe, P | 1 |
| Busuttil, R | 1 |
| Knapp, E | 5 |
| Hohenegger, M | 1 |
| Khachadurian, A | 1 |
| Gospodinoff, L | 1 |
| Salvini, S | 1 |
| Bourde, C | 4 |
| Boyce, WH | 1 |
| Bayeli, PF | 1 |
| Montagnani, M | 1 |
| Labrune, B | 1 |
| Bonnenfant, F | 1 |
| Ribierre, M | 1 |
| Mallet, R | 1 |
| Virtanen, KS | 1 |
| Halonen, PI | 1 |
| Ripault, J | 1 |
| Benoist, M | 1 |
| Nguyen-Huy, D | 1 |
| Bloch-Michel, H | 1 |
| Carnovale, M | 2 |
| Baccarini, V | 2 |
| Martina, GD | 1 |
| Schwarczmann, P | 2 |
| Lejeune, E | 3 |
| Tolot, F | 1 |
| Meunier, P | 4 |
| van Bogaert, P | 1 |
| Santamaria, A | 2 |
| Schatanoff, J | 1 |
| Bosco, JS | 1 |
| Greenleaf, JE | 1 |
| Kaye, RL | 1 |
| Averkin, EG | 1 |
| Kogut, MD | 1 |
| Donnell, GN | 1 |
| Sweetman, L | 3 |
| Glueck, CJ | 1 |
| Fujimoto, WY | 1 |
| Mérillon, H | 1 |
| Camus, JP | 1 |
| Laveant-Hébrard, C | 1 |
| Frank, M | 4 |
| Tkach, S | 1 |
| Cagli, V | 1 |
| Ruotolo, V | 1 |
| Bossini, A | 1 |
| Bologna, E | 1 |
| Boettcher, WG | 1 |
| Bonfiglio, M | 1 |
| Hamilton, HH | 1 |
| Sheets, RF | 1 |
| Smith, K | 1 |
| Thomson, AE | 1 |
| Denko, CW | 1 |
| Robert D'Eshougues, J | 1 |
| Sfikakis, P | 2 |
| Taddeucci, E | 1 |
| Terreni, F | 1 |
| De Moro, ER | 1 |
| De Dahinten, NM | 1 |
| Katz, WA | 2 |
| Schubert, M | 1 |
| Carrel, JL | 1 |
| Carrel, JM | 1 |
| Davidson, DM | 1 |
| Coutts, A | 1 |
| Calabro, JJ | 1 |
| Kitamura, M | 1 |
| Nakayama, T | 1 |
| Narasaki, K | 1 |
| Okazaki, T | 1 |
| Yoshimura, T | 2 |
| Ueda, Y | 1 |
| Kagawa, K | 1 |
| Ravault, PP | 2 |
| Vignon, G | 5 |
| Bouvier, M | 3 |
| Queneau, P | 1 |
| Coste, F | 1 |
| Healy, LA | 1 |
| Jolley, RL | 1 |
| Scott, CD | 1 |
| Weilerstein, R | 1 |
| Del Regno, F | 1 |
| Capobianco, G | 1 |
| Lloyd-Mostyn, RH | 1 |
| Lord, PS | 1 |
| Glover, R | 1 |
| Gilliland, IC | 1 |
| Chow, DC | 1 |
| Kawahara, FS | 1 |
| Saunders, T | 1 |
| Fink, JK | 1 |
| Biagi, RW | 1 |
| Bapat, BN | 1 |
| Barreca, T | 2 |
| Ophir, R | 1 |
| Adam, A | 1 |
| Prasse, D | 1 |
| Klöpfer-Zaar, M | 2 |
| Houli, J | 1 |
| Sabah, D | 1 |
| Krapp, R | 1 |
| Gärtner, A | 1 |
| Schneider, HJ | 1 |
| Tscharnke, J | 1 |
| Rolle, E | 1 |
| Chapuy, P | 1 |
| Megard, M | 1 |
| Chatin, B | 1 |
| Sulzberger, I | 1 |
| Klöpfer, M | 1 |
| Zimmerman, WJ | 1 |
| Heinz, K | 1 |
| Schabel, F | 1 |
| Zaar, I | 1 |
| Thieme, G | 1 |
| Scheier, CA | 1 |
| Ménard, J | 2 |
| Tachon, G | 1 |
| Eyre, C | 1 |
| Davison, AN | 1 |
| Gorden, P | 1 |
| Robertson, GL | 1 |
| Van Goor, W | 1 |
| Kooiker, CJ | 1 |
| Mees, EJ | 1 |
| Gresham, GE | 1 |
| Keller, MD | 1 |
| Parker, RA | 1 |
| Van Peenen, HJ | 1 |
| Knowles, BR | 1 |
| Mervart, I | 1 |
| Platzbecker, H | 1 |
| Lange, A | 1 |
| Böhme, A | 2 |
| Wiegleb, C | 1 |
| Dörner, K | 1 |
| Manzke, H | 1 |
| Tremel, R | 1 |
| Pohl, W | 1 |
| Rastogi, SP | 1 |
| Volans, G | 1 |
| Elliott, RW | 1 |
| Eccleston, DW | 1 |
| Ashcroft, R | 1 |
| Webster, D | 1 |
| Kerr, DN | 1 |
| Kato, H | 1 |
| Russell, WJ | 1 |
| Uda, Y | 1 |
| Hamilton, HB | 1 |
| Kawamoto, S | 1 |
| Johnson, KG | 1 |
| Herbst, M | 2 |
| Gebhardt, R | 1 |
| Lührs, M | 1 |
| Fritze, E | 1 |
| Kallweit, C | 1 |
| Müller, HO | 1 |
| Südhof, H | 1 |
| Clausen, JE | 1 |
| Klimov, AN | 1 |
| Sil'vestrov, VP | 1 |
| Sigareva, VM | 1 |
| Ban'kovskaia, EB | 1 |
| Nyfos, L | 1 |
| Rapado Errazti, A | 2 |
| Mardomingo Varela, P | 1 |
| Rubio Caballero, M | 1 |
| Giovannelli, G | 1 |
| Gragnoli, G | 1 |
| Pupillo, A | 1 |
| Sternon, J | 1 |
| Kocheleff, P | 1 |
| Couturier, E | 1 |
| Balasse, E | 1 |
| Vanden Abeele, P | 1 |
| Terjung, E | 1 |
| Stĕpánek, P | 2 |
| Sadílek, L | 1 |
| Müller, GW | 2 |
| Gutschmidt, HJ | 1 |
| Lenoch, F | 2 |
| Sobĕslavský, C | 1 |
| Carpenter, DG | 1 |
| Carter, CH | 1 |
| Hoefnagel, D | 1 |
| Kissel, P | 3 |
| Lamarche, M | 2 |
| Miller, J | 2 |
| Barlow, KA | 2 |
| Haslam, RM | 1 |
| Pardo, V | 1 |
| Perez-Stable, E | 1 |
| Fisher, ER | 1 |
| Himes, DS | 1 |
| Schindera, F | 2 |
| Plante, GE | 1 |
| Durivage, J | 1 |
| Lemieux, G | 1 |
| Michotte, JL | 1 |
| Burtonboy, G | 1 |
| Shreeve, WW | 1 |
| Munsat, TL | 1 |
| Carell, RE | 1 |
| Menkes, J | 1 |
| Ostberg, Y | 1 |
| Hitchings, GH | 1 |
| Becker, MH | 1 |
| Wallin, JK | 1 |
| Grígel, M | 1 |
| Kacina, F | 1 |
| Kokles, M | 1 |
| Cagán, S | 1 |
| Schilling, A | 1 |
| Slansky, HH | 1 |
| Kubara, T | 1 |
| Catlett, GF | 1 |
| Kidera, GJ | 1 |
| Riccitelli, ML | 1 |
| Boyett, JD | 1 |
| Furtado, VD | 1 |
| Schmidt, FH | 1 |
| Arnot, R | 1 |
| Glass, HI | 3 |
| Kaufman, JM | 1 |
| Myers, AR | 1 |
| Epstein, FH | 1 |
| Toone, EC | 1 |
| Highton, TC | 1 |
| Malamos, B | 1 |
| Tsekos, G | 1 |
| Tasiopoulos, T | 1 |
| Siller, K | 2 |
| Hunder, GG | 1 |
| Bickel, WH | 1 |
| Steele, AD | 1 |
| Gold, MS | 1 |
| Williams, JC | 1 |
| Spivack, M | 1 |
| Grann, V | 1 |
| Howorth, PJ | 1 |
| Zilva, JF | 1 |
| Bernheim, C | 1 |
| Bibus, B | 1 |
| Misgeld, V | 1 |
| Kotzaurek, R | 1 |
| Hueber, EF | 1 |
| Kemilä, S | 1 |
| Pecherstorfer, M | 2 |
| Callies, R | 1 |
| Jordan, H | 1 |
| Griendl, W | 1 |
| Kalb, R | 1 |
| Koch, G | 1 |
| Schlosser, GA | 1 |
| Doumerg, C | 1 |
| Zaunbauer, W | 1 |
| Sobti, P | 1 |
| Bhasin, RC | 1 |
| Morioka, S | 2 |
| Bianco, G | 2 |
| Gilles, DC | 1 |
| Arnot, RN | 2 |
| Ben Hameid, SS | 1 |
| Krömer, H | 1 |
| Sjöberg, KH | 3 |
| Killen, BU | 1 |
| Moesmann, G | 1 |
| Strejcek, J | 1 |
| Kucerová, L | 1 |
| Moore, RY | 1 |
| Pokorný, M | 1 |
| Resl, V | 1 |
| Zucchelli, P | 1 |
| Sasdelli, M | 1 |
| Fusaroli, M | 1 |
| Salvatierra, D | 1 |
| De la Higuera, J | 1 |
| Pérez Gálvez, M | 1 |
| Solnica, F | 1 |
| Vindel, J | 1 |
| Lira, MA | 1 |
| Fraga Filho, C | 1 |
| de Aguiar, JA | 1 |
| Kovach, RD | 1 |
| Rabussier, H | 1 |
| Desgrez, P | 1 |
| Fossati, P | 1 |
| Lefebvre, J | 1 |
| Decoulx, M | 1 |
| Peltier, JM | 1 |
| Linquette, M | 1 |
| Chirone, E | 1 |
| Kikutani, T | 1 |
| Muranaka, M | 1 |
| Scherbel, AL | 1 |
| Di Paolo, N | 1 |
| Lunghetti, R | 1 |
| Bravi, A | 1 |
| Steel, K | 1 |
| Boggiano, C | 1 |
| Shorthouse, PH | 1 |
| Chattapadhyay, K | 1 |
| Friedland, M | 1 |
| Ehrlich, GE | 1 |
| Streiker, FB | 1 |
| Godfrey, RG | 1 |
| Rankin, TJ | 1 |
| James, JA | 1 |
| Teberg, AJ | 1 |
| Nelson, LG | 1 |
| Komatsu, T | 1 |
| McKiddie, M | 1 |
| Jasani MK GRAY, HW | 1 |
| Jackson, IM | 1 |
| Champion, D | 1 |
| Antila, V | 1 |
| Elsilä, M | 1 |
| Teisberg, P | 1 |
| Dihlmann, W | 1 |
| Fernholz, HJ | 1 |
| Pagliara, AS | 1 |
| Goodman, AD | 1 |
| Altus, RE | 1 |
| Chaloupková, E | 1 |
| Anumonye, A | 1 |
| Dobson, JW | 1 |
| Oppenheim, S | 1 |
| Sutherland, JS | 1 |
| Flückiger, P | 1 |
| Runcie, J | 1 |
| Thomson, TJ | 1 |
| Sass, JK | 1 |
| Itabashi, HH | 1 |
| Dexter, RA | 1 |
| Ruitton, P | 1 |
| Volle, L | 1 |
| Bertrand, JN | 1 |
| Reeves, B | 1 |
| Trevaks, G | 1 |
| Lovell, RR | 1 |
| Iglesias, EJ | 1 |
| Kotler, A | 1 |
| Blumberg, BS | 1 |
| Wyncaarden, JB | 1 |
| Sokoloff, L | 1 |
| Lieber, CS | 1 |
| Drenick, EJ | 1 |
| Allen, DJ | 1 |
| Milosovich, G | 1 |
| Mattocks, AM | 1 |
| Sarre, H | 1 |
| Lapidus, PW | 1 |
| Guidotti, FP | 1 |
| Benoit, P | 1 |
| Ginsbourger, R | 1 |
| Ryan, JA | 1 |
| Goy, P | 1 |
| Spanio, L | 1 |
| De Battisti, C | 1 |
| Garrod, PR | 1 |
| McSwiney, RR | 1 |
| Bold, AM | 1 |
| Newton, DR | 1 |
| Rosenthale, ME | 1 |
| Kassarich, J | 1 |
| Schneider, F | 1 |
| Urowitz, MB | 2 |
| Weber, HM | 2 |
| Krakoff, IH | 1 |
| Turrian, H | 1 |
| Maier, C | 1 |
| Burch, TA | 1 |
| O'Brien, WM | 1 |
| Need, R | 1 |
| Kurland, LT | 1 |
| Maher, FT | 1 |
| Humphreys, DM | 1 |
| Eisen, V | 1 |
| Milne, MD | 1 |
| Bremner, JM | 1 |
| Lawrence, JS | 1 |
| Goldfarb, E | 1 |
| Podevin, R | 1 |
| Amiel, C | 1 |
| Strottman, MP | 1 |
| Brooks, GW | 1 |
| Mueller, E | 1 |
| Whitehouse, FW | 1 |
| Cleary, WJ | 1 |
| Bartels, EC | 1 |
| Levin, NW | 1 |
| Abrahams, OL | 1 |
| Rajan, KT | 1 |
| Moore, JD | 1 |
| Breitenbach, RP | 1 |
| Boland, EW | 1 |
| Binder, E | 1 |
| Munck, A | 1 |
| Chériè Lignière, G | 1 |
| Menozzi, M | 1 |
| Necchi Della Silva, A | 1 |
| Heise, GW | 1 |
| Bukhtoiarova, FG | 1 |
| Malova, MN | 1 |
| Linkin, SM | 1 |
| Boĭchenko, LM | 1 |
Clinical Trials (80)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Comparative Trial on the Effect of Febuxostat in Preventing Cerebral and Cardiorenovascular Events in Patients With Hyperuricemia[NCT01984749] | 1,000 participants (Anticipated) | Interventional | 2013-11-30 | Active, not recruiting | |||
| STorytelling to Improve DiseasE Outcomes in GoUT: The STRIDE-GO Study[NCT02741700] | 306 participants (Actual) | Interventional | 2017-05-31 | Completed | |||
| A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA® (Pegloticase) (MIRROR Open-Label [OL])[NCT03635957] | Phase 4 | 14 participants (Actual) | Interventional | 2018-09-26 | Completed | ||
| A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities[NCT01101035] | Phase 3 | 6,198 participants (Actual) | Interventional | 2010-04-23 | Completed | ||
| Physicians' Health Study II: Trial of Vitamins in the Chemoprevention of Cancer, CVD, and Eye Disease[NCT00270647] | 14,641 participants (Actual) | Interventional | 1997-07-31 | Completed | |||
| A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor[NCT01508702] | Phase 3 | 214 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)[NCT01391325] | Phase 4 | 1,735 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to[NCT01510158] | Phase 3 | 607 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects With Tophaceou[NCT01510769] | Phase 3 | 330 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response t[NCT01493531] | Phase 3 | 610 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Diagnostic Value of DECT Scan Compared to Diagnostic Needle Aspiration[NCT03038386] | 100 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | |||
| Exploratory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIa) Study)[NCT02344862] | Phase 2 | 80 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Confirmatory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIb) Study)[NCT02416167] | Phase 2 | 200 participants (Anticipated) | Interventional | 2015-05-31 | Completed | ||
| Official Title: Safety and Efficacy Evaluation Study of FYU-981 Long-term Administration for Hyperuricemia With or Without Gout (Phase III Study)[NCT03006445] | Phase 3 | 330 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)[NCT03100318] | Phase 3 | 201 participants (Actual) | Interventional | 2017-04-01 | Completed | ||
| The Effect of Tart Cherry Juice on Risk of Gout Attacks: a Randomised Controlled Trial[NCT03621215] | 120 participants (Anticipated) | Interventional | 2019-07-15 | Active, not recruiting | |||
| A Three Arms, Randomized, Double-blind Controlled Trial of the Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia[NCT06084585] | 180 participants (Anticipated) | Interventional | 2023-10-23 | Recruiting | |||
| Dietary Approaches to Stop Hypertension (DASH) Diet Effects on Serum Uric Acid (SUA) in Adults With Hyperuricemia and Gout[NCT03569020] | 43 participants (Actual) | Interventional | 2018-08-07 | Completed | |||
| University of Alabama at Birmingham CORT Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure[NCT02038179] | Phase 2/Phase 3 | 99 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Pragmatic, Randomized, Multicenter, Double-blind, Controlled, Clinical Trial of Prednisolone Versus Colchicine for Acute Gout in Primary Care[NCT05698680] | Phase 4 | 314 participants (Anticipated) | Interventional | 2023-01-18 | Recruiting | ||
| Prospective Study of the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders[NCT06092346] | 999 participants (Anticipated) | Observational | 2024-01-03 | Recruiting | |||
| Serum Uric Acid Levels and Initial Presentation of Cardiovascular Diseases: a CALIBER Study[NCT03425305] | 180,000 participants (Actual) | Observational | 1998-01-31 | Active, not recruiting | |||
| African American Study of Kidney Disease and Hypertension ABPM Pilot Study[NCT00582777] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout[NCT01078389] | Phase 2 | 314 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept[NCT04012294] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-08-30 | Recruiting | ||
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| CSP #594 - Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat[NCT02579096] | Phase 4 | 950 participants (Actual) | Interventional | 2017-03-06 | Completed | ||
| A Phase 2a, Randomized, Open-Label, Single-Site Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to RDEA3170 Administered Alone and Febuxostat Administered Alone, Respectively in Jap[NCT02317861] | Phase 1/Phase 2 | 110 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout[NCT02139046] | Phase 3 | 1,790 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP[NCT01327846] | Phase 3 | 10,066 participants (Actual) | Interventional | 2011-04-11 | Completed | ||
| Arthritis Research UK Gout Treatment Trial. Phase 2: Two Year Randomised Controlled Trial of a Nurse Led Package of Care[NCT01477346] | 517 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Effect of a Cold Water Immersion (CWI) on Pain in People With Gouty Arthritis: A Community Based Randomized Controlled Trial[NCT04587544] | 76 participants (Actual) | Interventional | 2019-07-01 | Completed | |||
| A Novel Centralized 'Virtual' Gout Clinic for Chronic Gout Management (NIAMS :CoRT)[NCT02790463] | 1,463 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| Novel Complex Radiodiagnostics of Peripherial Arthropathies[NCT05657847] | 500 participants (Anticipated) | Observational | 2022-03-07 | Recruiting | |||
| A Phase I, Placebo-controlled, Randomized, Double Blind, Single or Multiple Dose Study of URC102 in Healthy Male Volunteers of Korean and Caucasian to Assess Safety, Pharmacokinetics and Pharmacodynamics[NCT01953497] | Phase 1 | 81 participants (Actual) | Interventional | 2013-05-23 | Completed | ||
| A Phase I, Placebo-controlled, Randomized, Double Blind, Dose-escalation Study to Assess the Safety and Pharmacokinetic and Pharmacodynamic Characteristics of Repeated-dose URC102 in Healthy Korean Adult Males[NCT02524678] | Phase 1 | 21 participants (Actual) | Interventional | 2015-08-05 | Completed | ||
| Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout[NCT00325195] | Phase 3 | 225 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout[NCT01356498] | Phase 3 | 151 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy[NCT00958438] | Phase 3 | 248 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Assessing Patients With Suspected Stress or Insufficiency Fracture of the Lower Extremity With Photon-Counting-Computed-Tomography[NCT06024798] | 50 participants (Anticipated) | Observational [Patient Registry] | 2023-09-30 | Not yet recruiting | |||
| Comparison of the Ease of Swallowability of B/F/TAF Placebo Compared to DTG/ABC/3TC Placebo[NCT04600687] | 50 participants (Actual) | Interventional | 2018-11-06 | Completed | |||
| Assessing the Role of the NLRP3 Inflammasome in Driving Inflammation in Affected Joints of Patients With Intercritical Gout[NCT04125459] | 8 participants (Anticipated) | Observational | 2020-01-22 | Active, not recruiting | |||
| Value of Uric Acid as Early Predictor of Lupus Nephritis in Assiut University Hospital[NCT05402735] | 100 participants (Anticipated) | Observational | 2022-06-15 | Recruiting | |||
| A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate- Lowering Therapy[NCT00856206] | Phase 3 | 1,315 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| A Phase 3, Randomized, Multicenter, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout[NCT02082769] | Phase 3 | 504 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| A Structured Nurse Led Patient Management Programme to Improve Outcomes in Gout: A Randomized Controlled Trial[NCT03345186] | 56 participants (Anticipated) | Interventional | 2019-04-01 | Active, not recruiting | |||
| Effects of Bariatric Surgery in Swedish Obese Subjects[NCT01479452] | 4,047 participants (Actual) | Interventional | 1987-01-31 | Completed | |||
| Keto-diet for Intubated Critical Care COVID-19 (KICC-COVID19)[NCT04358835] | 0 participants (Actual) | Interventional | 2020-09-01 | Withdrawn (stopped due to Study did not begin enrollment, multiple competing studies at same institution) | |||
| A Phase II Study of Multiple Doses of Intravenous Puricase in Subjects With Hyperuricemia and Refractory Gout[NCT00080210] | Phase 2 | 40 participants | Interventional | 2004-03-31 | Completed | ||
| A Phase 3, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout.[NCT00174915] | Phase 3 | 1,072 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Novel Methods for Ascertainment of Gout Flares -A Pilot Study[NCT02855437] | 44 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| Phase II, Open-Label Study, to Assess the Long-Term Safety of Oral TMX-67 in Subjects With Gout[NCT00174941] | Phase 2 | 116 participants (Actual) | Interventional | 2001-03-31 | Completed | ||
| A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout[NCT00175019] | Phase 3 | 1,086 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Postprandial Modulation of HDL Metabolism[NCT01803594] | 18 participants (Actual) | Interventional | 2012-08-31 | Completed | |||
| Effects of Dairy Fat on Postprandial Inflammation- Phase 1[NCT01811329] | 38 participants (Actual) | Interventional | 2013-08-01 | Active, not recruiting | |||
| A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.[NCT00430248] | Phase 3 | 2,269 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Allopurinol Versus Febuxostat: A New Approach for Management of Hepatic Steatosis in Metabolic-Associated Fatty Liver Disease[NCT05474560] | Phase 4 | 90 participants (Actual) | Interventional | 2022-01-01 | Completed | ||
| A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout[NCT00111657] | Phase 2 | 30 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout[NCT00102440] | Phase 3 | 760 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Phase II, Dose-Response, Safety and Efficacy Study of Oral TMX-67 in Subjects With Gout.[NCT00174967] | Phase 2 | 153 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| Study Protocol for a Prospective Observational Study Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation[NCT04017806] | 60 participants (Anticipated) | Observational | 2018-09-19 | Recruiting | |||
| Observational Study of the Use of KRYSTEXXA® (Pegloticase) in Adult Hyperuricemic Patients With Gout Refractory to Conventional Therapy[NCT01466166] | 188 participants (Actual) | Observational | 2011-11-15 | Completed | |||
| ACTH vs Betamethasone for the Treatment of Acute Gout in Hospitalized Patients: A Randomized, Open Label, Comparative Study[NCT04306653] | 60 participants (Anticipated) | Interventional | 2018-01-05 | Recruiting | |||
| A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy[NCT00829829] | Phase 3 | 241 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Effectiveness of Colchicine Among Patients With COVID-19 Infection[NCT04867226] | Phase 2 | 100 participants (Actual) | Interventional | 2021-05-08 | Completed | ||
| Alternative Haemodiafiltration in Summer Season for Chronic Kidney Disease Patients[NCT05861219] | 100 participants (Anticipated) | Interventional | 2023-06-21 | Not yet recruiting | |||
| Using of the Skin as a Third Spare Kidney for Patients With Chronic Renal Failure[NCT03810989] | 86 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | |||
| Apple Cider Vinegar for the Prevention of Urinary Lithiasis (APUL)[NCT04073719] | 50 participants (Anticipated) | Interventional | 2019-09-01 | Not yet recruiting | |||
| Observational Study to Determine the Effect of Wearing of White Coat on Patient Satisfaction in Indian Out Patient Department (OPD) Setting[NCT02669355] | 123 participants (Actual) | Observational | 2015-10-31 | Completed | |||
| A Study to Assess a Direct Physical Measurement Method for Evaluation of Tophus Nodules in Subjects With Gout.[NCT00175006] | 13 participants (Actual) | Observational | 2002-11-30 | Completed | |||
| Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145] | Phase 3 | 80 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)[NCT02783469] | 1,915 participants (Actual) | Observational | 2004-10-31 | Completed | |||
| Febuxostat (Zurig) Efficacy & Safety Trial in Comparison With Allopurinol in Hyperuricemic Subjects With or Without Gout[NCT02600780] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| The Bogalusa Heart Study[NCT00005129] | 11,737 participants (Actual) | Observational | 1972-06-30 | Active, not recruiting | |||
| Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397] | Phase 4 | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| Nitrite Supplementation to Mitigate Fatigability and Increase Function in Long COVID Patients[NCT05618574] | Phase 3 | 40 participants (Anticipated) | Interventional | 2023-12-01 | Recruiting | ||
| [NCT00000482] | Phase 3 | 0 participants | Interventional | 1965-04-30 | Completed | ||
| Do Different Methods of Educating Patients Regarding Fluid Intake Reduce Kidney Stone Risks?[NCT01928108] | 10 participants (Actual) | Observational | 2013-07-31 | Completed | |||
| Does Potassium Citrate Supplementation Reduce Stone Recurrence in Calcium Phosphate Stone Formers With Risk Factors?[NCT01980004] | Phase 2 | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to closure due to failure to recruit any patients that met study criteria) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Gout Flares
Participant-reported total number of gout flares in the last 1 month (NCT02741700)
Timeframe: 12 months
| Intervention | Self-reported gout flares in 1 month (Mean) |
|---|---|
| Gout Storytelling Video | 0.74 |
| Video About Management of Another Chronic Condition | 0.99 |
Patient Satisfaction
Patient satisfaction with medication on the patient questionnaire (SATMED composite score), range 0-100. The SATMED-Q contains 17 items, each scored on a 5-point Likert scale. The total composite score ranges between 0 and 68. The score was converted to a percentage as recommended (=(raw score*100)/68); higher score = more satisfaction with medication. (NCT02741700)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Gout Storytelling Video | 62.16 |
| Video About Management of Another Chronic Condition | 67.43 |
Target Serum Urate
Serum urate with absolute value in mg/dl, as indirect measures of better ULT adherence and important gout outcomes (NCT02741700)
Timeframe: 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| Gout Storytelling Video | 5.94 |
| Video About Management of Another Chronic Condition | 5.72 |
Medication Adherence
ULT adherence, directly measured by using MEMS (Medication Event Monitoring System) Caps at 3, 6, and 9 months (assess intervention's effect) and 12 months (assess the durability of effect) (NCT02741700)
Timeframe: 3, 6, 9, and 12 months
| Intervention | percentage of days ULT was taken (Mean) | |||
|---|---|---|---|---|
| MEMSCap™ ULT MPR at 3-months | MEMSCap™ ULT MPR at 6-months | MEMSCap™ ULT MPR at 9-months | MEMSCap™ ULT MPR at 12-months | |
| Gout Storytelling Video | 72.61 | 68.52 | 65.85 | 60.54 |
| Video About Management of Another Chronic Condition | 70.12 | 69.33 | 67.32 | 63.82 |
Percentage of Serum Uric Acid (sUA < 5 mg/dL) Overall Responders
Serum uric acid (sUA < 5 mg/dL) overall responders are defined as participants achieving and maintaining sUA < 5 mg/dL for at least 80% of the time during Month 3 and Month 6 (Weeks 10, 12, 14, 20, 22, and 24) combined. Participants with more than one sUA result in Month 3 and Month 6 are considered responders if a participant's weighted proportion of hours that sUA is < 6 mg/dL is greater than or equal to 80%. Participants with the proportion of hours less than 80% are counted as non-responders. Participants with only one value in Month 3 and Month 6 are considered overall responders if they are considered responders in both Month 3 and Month 6. (NCT03635957)
Timeframe: Month 3 and Month 6 combined (Weeks 10, 12, 14, 20, 22, and 24)
| Intervention | percentage of participants (Number) |
|---|---|
| Pegloticase With Methotrexate (MTX) | 78.6 |
Percentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 3
Serum uric acid (sUA < 5 mg/dL) responders are defined as participants achieving and maintaining sUA < 5 mg/dL for at least 80% of the time during Month 3. Month 3 includes pre-infusion and post-infusion sUA assessments at Week 10, pre-infusion and post-infusion sUA assessments at Week 12, pre-infusion assessments at Week 14, and unscheduled assessments between Week 10 and Week 14 pre-infusion. (NCT03635957)
Timeframe: Month 3 (Weeks 10, 12, and 14)
| Intervention | percentage of participants (Number) |
|---|---|
| Pegloticase With Methotrexate (MTX) | 78.6 |
Percentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 6
Serum uric acid (sUA < 5 mg/dL) responders are defined as participants achieving and maintaining sUA < 5 mg/dL for at least 80% of the time during Month 6. Month 6 includes pre-infusion and post-infusion sUA assessments at Week 20, pre-infusion and post-infusion sUA assessments at Week 22, pre-infusion assessments at Week 24, and unscheduled sUA assessments between Week 20 and Week 24. (NCT03635957)
Timeframe: Month 6 (Weeks 20, 22, and 24)
| Intervention | percentage of participants (Number) |
|---|---|
| Pegloticase With Methotrexate (MTX) | 78.6 |
Percentage of Serum Uric Acid (sUA < 6 mg/dL) Overall Responders
Serum uric acid (sUA < 6 mg/dL) overall responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 3 and Month 6 (Weeks 10, 12, 14, 20, 22, and 24) combined. Participants with more than one sUA result in Month 3 and Month 6 are considered responders if a participant's weighted proportion of hours that sUA is < 6 mg/dL is greater than or equal to 80%. Participants with the proportion of hours less than 80% are counted as non-responders. Participants with only one value in Month 3 and Month 6 are considered overall responders if they are considered responders in both Month 3 and Month 6. (NCT03635957)
Timeframe: Month 3 and Month 6 combined (Weeks 10, 12, 14, 20, 22, and 24)
| Intervention | percentage of participants (Number) |
|---|---|
| Pegloticase With Methotrexate (MTX) | 78.6 |
Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 3
Serum uric acid (sUA < 6 mg/dL) responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 3 (Weeks 10, 12, and 14). Month 3 includes pre-infusion and post-infusion sUA assessments at Week 10, pre-infusion and post-infusion sUA assessments at Week 12, pre-infusion assessments at Week 14, and unscheduled assessments between Week 10 and Week 14 pre-infusion. (NCT03635957)
Timeframe: Month 3 (Weeks 10, 12, and 14)
| Intervention | percentage of participants (Number) |
|---|---|
| Pegloticase With Methotrexate (MTX) | 78.6 |
Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 6
Serum uric acid (sUA < 6 mg/dL) responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 6 (Weeks 20, 22, and 24). Month 6 includes pre-infusion and post-infusion sUA assessments at Week 20, pre-infusion and post-infusion sUA assessments at Week 22, pre-infusion assessments at Week 24, and unscheduled sUA assessments between Week 20 and Week 24. (NCT03635957)
Timeframe: Month 6 (Weeks 20, 22, and 24)
| Intervention | percentage of participants (Number) |
|---|---|
| Pegloticase With Methotrexate (MTX) | 78.6 |
Mean Change in sUA From Pegloticase Baseline to Weeks 14, 24, 36, 52
The mean change from baseline is based on observed values in participants remaining on treatment at given time point. For sUA values less than the lower limit of detection (up to 1.5 mg/dL), 0 is used in the analysis. (NCT03635957)
Timeframe: Baseline (defined as the last measurement taken prior to the first infusion of pegloticase in the pegloticase + IMM period), Pre- and Post-Infusion at Weeks 14, 24, 36 and Week 52
| Intervention | mg/dL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Change at Week 14 - pre-infusion | Change at Week 14 - post-infusion | Change at Week 24 - pre-infusion | Change at Week 24 - post-infusion | Change at Week 36 - pre-infusion | Change at Week 36 - post-infusion | Change at Week 52 | |
| Pegloticase With Methotrexate (MTX) | -9.27 | -9.31 | -9.27 | -9.48 | -8.13 | -9.41 | -8.15 |
Percentage of Participants With Antiplatelet Trialists' Collaborative (APTC) Event
APTC events were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 9.6 |
| Allopurinol | 8.8 |
Percentage of Participants With Cardiovascular (CV) Death
Events were adjudicated by an independent cardiovascular endpoints committee as CV death. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 4.3 |
| Allopurinol | 3.2 |
Percentage of Participants With Non-fatal Myocardial Infarction (MI)
Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal MI. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 3.6 |
| Allopurinol | 3.8 |
Percentage of Participants With Non-fatal Stroke
Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal stroke. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 2.3 |
| Allopurinol | 2.3 |
Percentage of Participants With Primary MACE Composite (Final Analysis)
Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 10.8 |
| Allopurinol | 10.4 |
Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)
Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 8.0 |
| Allopurinol | 8.0 |
Percentage of Participants With Unstable Angina With Urgent Coronary Revascularization
Events were adjudicated by an independent cardiovascular endpoints committee as unstable angina with urgent coronary revascularization. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 1.6 |
| Allopurinol | 1.8 |
Number of Subjects With an sUA Level That is < 6.0 mg/dL
(NCT01508702)
Timeframe: 6 months
| Intervention | Number of Subjects (Number) |
|---|---|
| Lesinurad 400 mg | 32 |
| Placebo | 2 |
Incidence of Gout Flares
Proportion of subjects who experienced at least one gout flare requiring treatment during the study. (NCT01391325)
Timeframe: Every month for 6 months.
| Intervention | percentage of subjects (Number) |
|---|---|
| Allopurinol | 33.4 |
Proportion of Subjects With Serum Urate (sUA) Less Than 6.0 mg/dL
Proportion of subjects with serum urate (sUA) less than 6.0 mg/dL at Month 6 using Last Observation Carried Forward (LOCF) for subjects with missing values at Month 6. (NCT01391325)
Timeframe: Month 6
| Intervention | percentage of subjects (Number) |
|---|---|
| Allopurinol | 43.4 |
Safety of Allopurinol
Proportion of subjects who experienced at least one Treatment Emergent Adverse Event (TEAE) during the study. (NCT01391325)
Timeframe: Every month for 6 months.
| Intervention | percentage of subjects (Number) |
|---|---|
| Allopurinol | 55.1 |
Mean Change From Baseline to Month 6 in SF-36 PCS+MCS
The SF-36 is a short-form health survey with 36 questions that yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical (PCS) and mental health (MCS) summary. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability. The component scores (PCS and MCS) are norm-based to a standard population with a mean of 50 and a standard deviation of 10. (NCT01391325)
Timeframe: Month 6
| Intervention | units on a scale (Mean) | |
|---|---|---|
| SF-36 Physical Component Summary | SF-36 Mental Health Component Summary | |
| Allopurinol | 3.88 | 0.71 |
Gout Flares
Mean rate of gout flares requiring treatment for the 6-month period from the end of Month 6 to the end of Month 12 (NCT01510158)
Timeframe: 12 Months
| Intervention | Gout Flares (Mean) |
|---|---|
| Lesinurad 200 mg + Allopurinol | .60 |
| Lesinurad 400 mg + Allopurinol | .50 |
| Placebo + Allopurinol | .60 |
Proportion of Subjects With an sUA Level That is < 6.0 mg/dL
(NCT01510158)
Timeframe: 6 Months, analysis after all subjects complete 12 months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0.542 |
| Lesinurad 400 mg + Allopurinol | 0.592 |
| Placebo + Allopurinol | 0.279 |
Tophus
Proportion of subjects with ≥ 1 target tophus at Baseline who experience complete resolution of at least 1 target tophus by Month 12 (NCT01510158)
Timeframe: 12 Months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0 |
| Lesinurad 400 mg + Allopurinol | 0.211 |
| Placebo + Allopurinol | 0.294 |
Complete or Partial Response of at Least One Tophus
Proportion of subjects with a best tophus response on at least 1 target tophus of complete (disappearance of at least 1 target tophus) or partial (≥ 50% decrease in the area of at least 1 target tophus) resolution by Month 12 (NCT01510769)
Timeframe: 12 Months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Febuxostat 80 mg | 0.566 |
| Lesinurad 400 mg + Febuxostat 80 mg | 0.587 |
| Placebo + Febuxostat 80 mg | 0.505 |
Complete Resolution of at Least One Target Tophus
Proportion of subjects who experience complete resolution of at least 1 target tophus by Month 12 (NCT01510769)
Timeframe: 12 Months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Febuxostat 80 mg | 0.255 |
| Lesinurad 400 mg + Febuxostat 80 mg | 0.303 |
| Placebo + Febuxostat 80 mg | 0.211 |
Quality of Life
Proportion of subjects with an improvement from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) of at least 0.25 at Month 12. The HAQ-DI assesses a patient's level of functional ability with items scores ranging from 0-3 with 0 being the least disability. (NCT01510769)
Timeframe: 12 Months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Febuxostat 80 mg | 0.442 |
| Lesinurad 400 mg + Febuxostat 80 mg | 0.333 |
| Placebo + Febuxostat 80 mg | 0.525 |
Subjects With a Serum Urate (sUA) Level That is < 5.0 mg/dL by Month 6
Proportion of subjects with an sUA level that is < 5.0 mg/dL by Month 6 (NCT01510769)
Timeframe: 6 months, analysis after all subjects complete 12 months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Febuxostat 80 mg | 0.566 |
| Lesinurad 400 mg + Febuxostat 80 mg | 0.761 |
| Placebo + Febuxostat 80 mg | 0.468 |
Gout Flares
Mean rate of gout flares requiring treatment for the 6-month period from the end of Month 6 to the end of Month 12. (NCT01493531)
Timeframe: 12 Months
| Intervention | Gout Flares (Mean) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0.7 |
| Lesinurad 400 mg + Allopurinol | 0.8 |
| Placebo + Allopurinol | 0.9 |
Subjects With ≥ 1 Target Tophus at Baseline Who Experience Complete Resolution of at Least 1 Target Tophus by Month 12
Proportion of subjects with ≥ 1 target tophus at Baseline who experience complete resolution of at least 1 target tophus by Month 12 (NCT01493531)
Timeframe: 12 months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0.314 |
| Lesinurad 400 mg + Allopurinol | 0.276 |
| Placebo + Allopurinol | 0.333 |
Subjects With a Serum Urate (sUA) < 6.0 mg/dL by Month 6.
Proportion of subjects with an sUA level that is < 6.0 mg/dL by Month 6. (NCT01493531)
Timeframe: 6 months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0.554 |
| Lesinurad 400 mg + Allopurinol | 0.665 |
| Placebo + Allopurinol | 0.233 |
Uric Acid Level
Measured in serum (NCT03569020)
Timeframe: At 4-weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Dietitian-Directed Diet | 7.67 |
| Self-Directed Diet | 8.03 |
Uric Acid Level
Measured in serum (NCT03569020)
Timeframe: At 8-weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Dietitian-Directed Diet | 7.75 |
| Self-Directed Diet | 7.98 |
Uric Acid Level
Measured in serum (NCT03569020)
Timeframe: Baseline
| Intervention | mg/dL (Mean) |
|---|---|
| Dietitian-Directed Diet Then Self-Directed Diet | 8.23 |
| Self-Directed Diet Then Dietitian-Directed Diet | 8.03 |
Body Mass Index (kg/m^2)
Derived from baseline height, and serial weight measurements (NCT03569020)
Timeframe: Baseline, 4-weeks, 8-weeks
| Intervention | kg/m^2 (Mean) | ||
|---|---|---|---|
| Baseline | Period 1 | Period 2 | |
| Dietitian-Directed Diet Then Self-Directed Diet | 33.4 | 33.0 | 33.6 |
| Self-Directed Diet Then Dietitian-Directed Diet | 33.5 | 33.6 | 33.5 |
Diastolic Blood Pressure (mm Hg)
(NCT03569020)
Timeframe: At baseline, 4-weeks, 8-weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Period 1 | Period 2 | |
| Dietitian-Directed Diet Then Self-Directed Diet | 74.9 | 76.1 | 77.3 |
| Self-Directed Diet Then Dietitian-Directed Diet | 72.6 | 75.0 | 74.0 |
Fasting Blood Glucose (mg/dL)
Measured in serum (NCT03569020)
Timeframe: Baseline, 4-weeks, 8-weeks
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period 1 | Period 2 | |
| Dietitian-Directed Diet Then Self-Directed Diet | 93.0 | 96.5 | 97.1 |
| Self-Directed Diet Then Dietitian-Directed Diet | 103.0 | 103.2 | 97.6 |
Low Density Lipoprotein Cholesterol (mg/dL)
Measured in serum (NCT03569020)
Timeframe: Baseline, 4-weeks, 8-weeks
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period 1 | Period 2 | |
| Dietitian-Directed Diet Then Self-Directed Diet | 109.0 | 105.3 | 107.5 |
| Self-Directed Diet Then Dietitian-Directed Diet | 115.5 | 113.4 | 105.5 |
Systolic Blood Pressure (mm Hg)
(NCT03569020)
Timeframe: Baseline, 4-weeks, 8-weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Period 1 (4-weeks) | Period 2 (8-weeks) | |
| Dietitian-Directed Diet Then Self-Directed Diet | 125.0 | 126.4 | 129.4 |
| Self-Directed Diet Then Dietitian-Directed Diet | 123.5 | 123.7 | 124.8 |
Change in Flow-mediated Arterial Vasodilation
Compare endothelial function as indexed by flow-mediated arterial vasodilation (FMD) within each phase of treatment (allopurinol 300 mg/day PO or placebo). Percent (%) change in FMD is calculated by comparing FMD (%) at the end of each treatment phase to pre-treatment values. (NCT02038179)
Timeframe: 4 weeks (pre-treatment vs. post-treatment FMD Values (%))
| Intervention | percent change (Mean) |
|---|---|
| Allopurinol Phase | 2.5 |
| Placebo Phase | -0.1 |
Change in Serum Levels of High Sensitivity C-reactive Protein
Serum level of high sensitivity C-reactive protein will be reported as a change during treatment phase (allopurinol 300 mg/day PO or placebo). Change in serum level of C-reactive protein is calculated by comparing serum values at the end of each treatment phase to pre-treatment levels. (NCT02038179)
Timeframe: 4 weeks (pre-treatment vs. post-treatment serum levels)
| Intervention | mg/L (Mean) |
|---|---|
| Allopurinol Phase | 0.6 |
| Placebo Phase | 0.8 |
Change in Systolic Blood Pressure (SBP)
Compare systolic blood pressure (SBP) captured by wearing a 24 hour ambulatory blood pressure monitor during each phase of treatment (allopurinol 300 mg/day PO or placebo). Change in systolic blood pressure is calculated by comparing SBP at the end of each treatment phase to pre-treatment values. (NCT02038179)
Timeframe: 4 weeks (pre-treatment vs. post-treatment SBP)
| Intervention | mm Hg (Mean) |
|---|---|
| Allopurinol Phase | -1.39 |
| Placebo Phase | -1.06 |
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint
The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of this single joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst). Individual erosion scores were summed to a maximum erosion score of 5 for joints in the hands and 10 for joints in the feet. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 24 | |
| Febuxostat 40 mg or 80 mg | 0.16 | 0.01 |
| Placebo | 0.11 | 0.01 |
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Scores From Full Hands and Feet Radiographs
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 24 (n=78,74) | |
| Febuxostat 40 mg or 80 mg | 0.36 | 0.17 |
| Placebo | 0.17 | 0.11 |
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Score of the Single Affected Joint
The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of the single affected joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) and Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst). The Erosion Score and the JSN Score were summed for the Total Score. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 24(n=81,76) | |
| Febuxostat 40 mg or 80 mg | 0.85 | 0.00 |
| Placebo | 0.77 | 0.05 |
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Scores From Full Hands and Feet Radiographs
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst) for a total JSN score range of 0 to 208. The Erosion Score and the JSN Score were combined for a total possible score of 0 to 528. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 24 (n=78,74) | |
| Febuxostat 40 mg or 80 mg | 4.98 | 0.31 |
| Placebo | 4.56 | 0.29 |
Mean Change From Baseline to Month 24 in the Rheumatoid Arthritis MRI Scoring System (RAMRIS) Score of the Single Affected Joint
The single affected joint was defined as the joint with the history of the first acute gout flare. Magnetic Resonance Imaging (MRI) was evaluated using the Rheumatoid Arthritis MRI Score (RAMRIS). Bone erosion in the proximal and distal location were each assessed in the affected joint using an 11-point scale where 0=no erosion (best) to 10=91-100% bone eroded (worst) for a bone erosion score range of 0 to 20. Bone marrow edema in the proximal and distal location were each assessed using a 4-point scale where 0=no edema (best) to 3=67-100% edema (worst) for a bone marrow edema (BME) score range of 0 to 6. Synovitis was assessed in the affected joint using a 4-point scale where 0=normal (best) to 3=severe (worst). Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Synovitis:Baseline (BL)(n=82,76) | Synovitis:Change from Baseline (n=75,67) | Erosion (Distal+Proximal):Baseline (n=84,77) | Erosion (Distal+Proximal):Change from BL(n=79,69) | Edema (Distal+Proximal):Baseline (BL) (n=81,75) | Edema (Distal+Proximal):Change from BL(n=77,66) | |
| Febuxostat 40 mg or 80 mg | 1.29 | -0.43 | 1.63 | -0.01 | 0.73 | -0.36 |
| Placebo | 1.09 | -0.07 | 1.48 | 0.04 | 0.51 | -0.10 |
All-Cause Death
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
Exploratory Hierarchical Composite Endpoint
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of Days Alive and Out of the Hospital During the 30 Days Following Randomization
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of Days Alive, Out of the Intensive Care Unit, Free of Mechanical Ventilation/Extracorporeal Membrane Oxygenation, or Maximal Available Respiratory Support in the 30 Days Following Randomization
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
Primary Hierarchical Composite Endpoint
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
Secondary Hierarchical Composite Endpoint
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
Seven-category Ordinal Scale
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3
"Participants were defined as flaring in Phase 3 if they:~-1) met 3 of 4 following participant-reported criteria:~a) warm joint(s)~b) swollen joint(s)~c) pain (>3) at rest on a scale of 0-10 (10 being the worst pain)~d) self-identified gout flare~OR~-2) reported use of medications to treat flare" (NCT02579096)
Timeframe: Phase III of the study (weeks 49-72 of study duration)
| Intervention | Participants (Count of Participants) |
|---|---|
| Allopurinol / Sham Comparator (Febuxostat) | 135 |
| Febuxostat / Sham Comparator (Allopurinol) | 165 |
Percentage of Participants With at Least One Gout Flare Requiring Treatment
"A participant was considered to have a gout flare if the following criteria were met:~Participant-reported acute particular pain typical of a gout attack that was deemed by participant and/or investigator to require treatment and was treated with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids, Participant experienced at least 3 or more of: 1) Joint swelling, 2) Redness, 3) Tenderness, 4) Pain, Participant experienced at least one or more of: 1) Rapid onset of pain, 2) Decreased range of motion, 3) Joint warmth, 4) Other symptoms similar to a prior gout flare." (NCT02139046)
Timeframe: Baseline to Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 20.7 |
| Febuxostat IR 40 mg | 21.0 |
| Febuxostat XR 40 mg | 22.8 |
| Febuxostat IR 80 mg | 27.2 |
| Febuxostat XR 80 mg | 26.6 |
Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3
(NCT02139046)
Timeframe: Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.3 |
| Febuxostat IR 40 mg | 15.7 |
| Febuxostat XR 40 mg | 25.9 |
| Febuxostat IR 80 mg | 42.6 |
| Febuxostat XR 80 mg | 50.1 |
Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3
(NCT02139046)
Timeframe: Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.6 |
| Febuxostat IR 40 mg | 40.3 |
| Febuxostat XR 40 mg | 48.2 |
| Febuxostat IR 80 mg | 57.7 |
| Febuxostat XR 80 mg | 61.1 |
Core Phase All-cause Mortality
Number of participant deaths (NCT01327846)
Timeframe: From randomization, to end of treatment plus 30 days, up to approximately 6 years
| Intervention | Participants (Number) |
|---|---|
| Group I | 239 |
| Group II | 238 |
| Group III | 228 |
| Group IV | 375 |
Core Phase All-cause Mortality, Non-fatal MI, or Non-fatal Stroke
Occurrence of the composite endpoint consisting of all-cause mortality, non-fatal IM, or non-fatal stroke (NCT01327846)
Timeframe: From randomization, to end of treatment plus 30 days, up to approximately 6 years
| Intervention | Participants (Number) |
|---|---|
| Group I | 403 |
| Group II | 395 |
| Group III | 394 |
| Group IV | 661 |
Patients With Core Phase New Onset Type 2 Diabetes Among Patients With Pre-diabetes at Randomization
Time to CEC confirmed new onset of type 2 diabetes among those with pre-diabetes at randomization (i.e. excluding those that are normoglycemic at baseline) (NCT01327846)
Timeframe: From randomization up to approximately 6 years
| Intervention | Participants (Number) |
|---|---|
| Group I | 169 |
| Group II | 171 |
| Group III | 161 |
| Group IV | 246 |
Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its Components
"Time to occurrence of CEC (Cardiovascular clinical events adjudication committee) confirmed MACE, which was a composite endpoint consisting of CEC confirmed CV death, CEC confirmed non-fatal MI,or CEC confirmed non-fatal stroke. Patients with the CEC adjudicated reason for death of Unknown were counted as CV (cardiovascular) death." (NCT01327846)
Timeframe: From randomization, to end of treatment plus 30 days, up to approximately 6 years
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| MACE | CV death | MI (fatal and non-fatal) | MI (non-fatal) | Stroke (fatal and non-fatal) | Stroke (non-fatal) | |
| Group I | 322 | 151 | 174 | 171 | 51 | 51 |
| Group II | 320 | 144 | 159 | 158 | 63 | 63 |
| Group III | 313 | 137 | 169 | 168 | 58 | 58 |
| Group IV | 535 | 235 | 292 | 291 | 92 | 91 |
Patients With Core Phase CEC Confirmed CV Death, Non-fatal MI, Non-fatal Stroke, or Hospitalization for Unstable Angina Requiring Unplanned Revascularization
"Occurrence of the composite cardiovascular endpoint consisting of cardiovascular death, non-fatal MI, non-fatal stroke or hospitalization for unstable angina requiring unplanned revascularization.~MACE includes CV death, non-fatal MI and non-fatal stroke. CEC = Clinical Endpoints Committee" (NCT01327846)
Timeframe: From randomization, to end of treatment pus 30 days, up to approximately 6 years
| Intervention | Participants (Number) | |
|---|---|---|
| MACE or unstable angina | Unstable angina | |
| Group I | 348 | 34 |
| Group II | 352 | 38 |
| Group III | 344 | 38 |
| Group IV | 601 | 85 |
Summary of Adverse Events (Core Phase)
Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring during the double-blind Core phase of the study. AEs/SAEs are any signs or symptoms that occur during the study treatment. (NCT01327846)
Timeframe: From randomization, to end of treatment plus 30 days, up to approximately 6 years
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Patients with at least one AE | AEs suspected to be related tostudy drug | Patients with at least one SAE | Discontinued due to SAEs | Discontinued due to non-seriousAEs | AEs leading to study treatmentinterruption | |
| Group I | 1987 | 355 | 836 | 135 | 40 | 268 |
| Group II | 1970 | 350 | 812 | 130 | 34 | 270 |
| Group III | 1872 | 267 | 741 | 117 | 26 | 228 |
| Group IV | 2915 | 474 | 1204 | 198 | 47 | 399 |
Summary of Adverse Events (Extension Phase)
Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring during the Extension phase of the study. AEs/SAEs are any signs or symptoms that occur during the study treatment. (NCT01327846)
Timeframe: From start of Extension phase, to end of treatment plus 30 days, up to approximately 2 years
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Patients with at least one AE | AEs suspected to be related tostudy drug | Patients with at least one SAE | Discontinued due to SAEs | Discontinued due to non-seriousAEs | AEs leading to study treatmentinterruption | |
| Group I | 788 | 40 | 310 | 67 | 8 | 59 |
| Group II | 845 | 34 | 326 | 71 | 6 | 72 |
| Group III | 793 | 43 | 322 | 71 | 12 | 62 |
| Group IV | 1250 | 65 | 465 | 98 | 8 | 100 |
Adherence to Medication
Adherence to prescribed medication (NCT02790463)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care | 250 |
| Intervention | 341 |
sUA < 6.0 mg/dl at 1 Year
Achievement of serum uric acid (sUA) < 6.0 mg/dl at 1 year (NCT02790463)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care | 117 |
| Intervention | 204 |
Change in Number of Swollen Joints
Change from Baseline to Month 6 (or last observation carried forward)in number of swollen joints per subject. Values were inputed using last observation carried forward analysis for subjects who did not complete the studies. (NCT00325195)
Timeframe: Baseline and Final Visit (Month 6 or LOCF)
| Intervention | Swollen joints (Mean) |
|---|---|
| q2 Wks | -5.5 |
| q4 Wks | -5.1 |
| Placebo | -2.6 |
Change in Number of Tender Joints
Change from Baseline to Month 6 (or last observation carried forward) in number of tender joints per participant (NCT00325195)
Timeframe: Baseline and Final Visit (Month 6 or LOCF)
| Intervention | Tender joints (Mean) |
|---|---|
| q2 Wks | -7.4 |
| q4 Wks | -6.1 |
| Placebo | -1.2 |
Plasma Uric Acid (PUA) Responder
PUA Responder was defined as a participant who achieved and maintained plasma uric acid concentrations < 6 mg/dL for at least 80% of the time during months 3 and 6 combined. Participants who withdrew from the study before month 6 were considered non-responders. (NCT00325195)
Timeframe: Months 3 and 6
| Intervention | Participants (Number) |
|---|---|
| q2 Wks | 36 |
| q4 Wks | 29 |
| Placebo | 0 |
Reduction in Tophus Burden
percentage of tophaceous subjects who demonstrated a complete resolution (100 % decrease in measured area or complete disappearance)of at least one tophus in the absence of other tophus progression or new tophi, as assessed by a blinded Central Reader using standardized digital photographs and image analysis software. (NCT00325195)
Timeframe: Baseline and Final Visit (6 months or LOCF)
| Intervention | Percent subjects with resolved tophus (Number) |
|---|---|
| q2 Wks | 40 |
| q4 Wks | 21 |
| Placebo | 7 |
Change in Patient Reported Outcomes of Pain, Physical Function and Quality of Life
Health Assessment Questionnaire(HAQ: VAS pain scale where 0 (no pain)-100 (severe pain); HAQ disability index (HAQ-DI) on a scale from 0(no disability) to 3 (completely disabled), and a unit change of > or =0.22 is considerd a mimimal clinically important difference(MCID). SF-36 Physical Component Summary Score (SF36-PCS), a composite score where 0 is the worst score and 100 the best possible, and where a change of > or =2.5 units in the PCS is considered a MCID. (NCT00325195)
Timeframe: Baseline to Final Visit (Month 6 or LOCF)
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| HAQ-VAS Pain | HAQ-DI | SF-36 PCS | |
| Placebo | 1.4 | 0.0 | -0.3 |
| q2 Wks | -11.4 | -0.22 | 4.4 |
| q4 Wks | -6.9 | -0.20 | 4.9 |
Percentage of Subjects With Gout Flare Per 3-month Period
Percent of participants reporting a gout flare during Months 1-3 and Months 4-6. Denominator during the respective period was based upon number of participants during that period. (NCT00325195)
Timeframe: Months 1-3 and Months 4-6
| Intervention | Percent subjects reporting flares (Number) | |
|---|---|---|
| Months 1-3 | Months 4-6 | |
| Placebo | 54 | 67 |
| q2 Wks | 75 | 41 |
| q4 Wks | 81 | 56 |
Gout Flare Frequency
The the mean number of flares per subject (flare frequency)was assessed over 3-month periods for up to 2 years of treatment (NCT01356498)
Timeframe: Up to 2 years
| Intervention | Flares (Mean) | |||||
|---|---|---|---|---|---|---|
| Months 1-3 | Months 4-6 | Months 7-9 | Months 10-12 | Months 16-18 | Months 22-24 | |
| Placebo in RCT, q2 in OLE | 2.3 | 1.3 | 1.2 | 0.6 | 0.2 | 0.4 |
| Placebo in RCT, q4 in OLE | 1.5 | 0.8 | 0.4 | 0.4 | 0.4 | 0.7 |
| q2 RCT, Non-responder | 0.6 | 1.0 | 0.6 | 0.9 | 0.7 | 0.3 |
| q2 RCT, Responder | 0.4 | 0.4 | 0.0 | 0.1 | 0.1 | 0.1 |
| q4 RCT Non-responder | 1.3 | 0.8 | 0.6 | 0.9 | 0.6 | 0.6 |
| q4 RCT, Responder | 0.8 | 0.7 | 0.3 | 0.2 | .3 | 0.1 |
Gout Flare Incidence
Percentage of participants remaining in the study during the specified interval who experienced a gout flare during this interval. (NCT01356498)
Timeframe: Assessed in 3-month intervals up to 2 years
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Months 1-3 | Months 4-6 | Months 7-9 | Months 10-12 | Months 16-18 | Months 22-24 | |
| Placebo in RCT, q2 in OLE | 65.2 | 45.0 | 43.8 | 28.6 | 18.2 | 27.3 |
| Placebo in RCT, q4 in OLE | 68.8 | 38.5 | 22.2 | 28.6 | 20.0 | 33.3 |
| q2 RCT, Non-responder | 45.5 | 35.0 | 27.8 | 47.1 | 33.3 | 25.0 |
| q2 RCT, Responder | 25.7 | 23.5 | 3.0 | 9.4 | 6.5 | 3.4 |
| q4 RCT Non-responder | 67.9 | 50.0 | 42.9 | 45.0 | 38.9 | 55.6 |
| q4 RCT, Responder | 56.0 | 40.0 | 24.0 | 16.7 | 25.0 | 5.3 |
Patient Reported Outcome: SF-36 Physical Component Summary Score
"SF-36 is the Medical Outcomes Survey Short Form-36, a 36-item self-reported questionnaire which assesses health-related limitations in 8 dimensions. The Physical Component Summary Score (PCS) is a composite summary score derived from the dimensions related to physical functioning outcomes: Physical Function, Role Physical, General Health and Bodily Pain (each with a 0 to 100 scale where 0=worst, 100=best).~The Summary Score is constructed as a T-score with a mean of 50 and standard deviation of 10, where higher scores indicate a better health status." (NCT01356498)
Timeframe: RCT Week 25; OLE Week 25; OLE Week 53, OLE Week 77, OLE Week 101
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline value (pre-pegloticase) | Final Visit value (LOCF) | |
| Placebo in RCT, q2 in OLE | 27.55 | 30.34 |
| Placebo in RCT, q4 in OLE | 36.2 | 38.8 |
| q2 RCT, Non-responder | 33.71 | 37.68 |
| q2 RCT, Responder | 34.92 | 40.40 |
| q4 RCT Responder | 34.11 | 40.82 |
| q4 RCT, Non-responder | 32.8 | 34.76 |
Tophus Response
Target tophi evaluated during the randomized, controlled study were followed for response at 3, 6, 12, 18 and 24 months in this open-label extention study. Results from each participant's final assessment on drug are reported (as last observation carried forward). Complete response=complete disappearance of at least one tophus with no new or worsening tophus. Partial Response=a 50% or more decrease in at least one tophus with no new or worsening tophus. (NCT01356498)
Timeframe: Up to 2 years
| Intervention | participants (Number) | |
|---|---|---|
| Complete Response | Partial Response | |
| Placebo in RCT, q2 in OLE | 10 | 3 |
| Placebo in RCT, q4 in OLE | 3 | 1 |
| q2 RCT, Non-responder | 4 | 4 |
| q2 RCT, Responder | 19 | 4 |
| q4 RCT Non-responder | 7 | 2 |
| q4 RCT, Responder | 13 | 0 |
Uric Acid (mg/dL)
Uric acid measured at 3 month-intervals (NCT01356498)
Timeframe: Week 13, Week 25, Week 53, Week 101
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| OLE Week 13 | OLE Week 25 | OLE Week 53 | OLE Week 101 | |
| Placebo in RCT, q2 in OLE | 5.06 | 4.69 | 2.7 | 4.29 |
| Placebo in RCT, q4 in OLE | 8.08 | 8.09 | 6.45 | 8.5 |
| q2 RCT, Non-responder | 9.76 | 8.89 | 9.18 | 7.7 |
| q2 RCT, Responder | 1.33 | 1.4 | 0.87 | 0.84 |
| q4 RCT Non-responder | 9.66 | 9.94 | 9.59 | 9.42 |
| q4 RCT, Responder | 1.91 | 1.95 | 1.55 | 1.47 |
Number of Gout Flare Days Per Participant From Day 1 to Day 113 (Week 16)
Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain, and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flare days per participant was reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)
| Intervention | Gout flare days (Mean) |
|---|---|
| Placebo | 11.7 |
| Rilonacept 80 mg | 4.30 |
| Rilonacept 160 mg | 1.86 |
Number of Gout Flare Days With Participant's Pain Score of 5 or More (From Daily Diary) Per Participant From Day 1 to Day 113 (Week 16)
Participants were asked to complete a telephone diary by calling the IVRS daily beginning at the baseline visit (Day 1) through the follow-up visit (Day 141) and reported their general well-being, gout symptoms, and weekly study drug administrations. At the onset of pain from a gout flare, participants were to answer additional diary questions regarding their gout flare and had to continue daily flare assessments until they reported the flare had ended. If a flare occurred just prior to the follow-up visit (Day 141), participants were to continue completing the daily diary until the flare resolved. Gout flare pain was assessed on a scale from 0 to 10 (with 0=no pain and 10=severe pain) within the past 24 hours. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)
| Intervention | Gout flare days (Mean) |
|---|---|
| Placebo | 4.28 |
| Rilonacept 80 mg | 1.67 |
| Rilonacept 160 mg | 0.88 |
Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16)
Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flares per participant was reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)
| Intervention | Gout flares (Mean) |
|---|---|
| Placebo | 1.23 |
| Rilonacept 80 mg | 0.35 |
| Rilonacept 160 mg | 0.34 |
Number of Modified Gout Flares Per Participant From Day 1 to Day 113 (Week 16)
Modified gout flare was defined using modified definition of a gout flare as participant-reported articular pain typical of a gout attack that was deemed to require treatment with anti-inflammatory therapy. Number of modified gout flares per participant were reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)
| Intervention | Gout flares (Mean) |
|---|---|
| Placebo | 1.51 |
| Rilonacept 80 mg | 0.62 |
| Rilonacept 160 mg | 0.48 |
Percentage of Participants With at Least One Flare From Day 1 to Day 113 (Week 16)
Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain; and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least one gout flare was reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 56.1 |
| Rilonacept 80 mg | 25.6 |
| Rilonacept 160 mg | 20.5 |
Percentage of Participants With at Least Two Flares From Day 1 to Day 113 (Week 16)
Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain, and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least two gout flares was reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 32.9 |
| Rilonacept 80 mg | 8.5 |
| Rilonacept 160 mg | 6.0 |
Number of Gout Flare Days Per Participant From Day 1 to Day 112 (Week 16)
A gout flare was defined as participant reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flares per participant was reported for this outcome measure. Flare days were counted up to Week 16, regardless of whether or not the flares occurred during the treatment period. (NCT00856206)
Timeframe: Day 1 to Day 112 (Week 16)
| Intervention | Gout flare Days (Mean) |
|---|---|
| Placebo | 7.66 |
| Rilonacept 160 mg | 2.66 |
Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16)
A gout flare was defined as participant reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flares per participant was reported for this outcome measure. For drop-outs, only flares occurred before Day 112 were counted, regardless whether the flares occurred during the treatment period or not. (NCT00856206)
Timeframe: Day 1 to Day 112 (Week 16)
| Intervention | Gout flares (Mean) |
|---|---|
| Placebo | 1.73 |
| Rilonacept 160 mg | 0.51 |
Percentage of Participants With at Least One Flare From Day 1 to Day 112 (Week 16)
A gout flare was defined as participant reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least one gout flare was reported for this outcome measure. For drop-outs, only flares occurred before Day 112 were counted, regardless whether the flares occurred during the treatment period or not. (NCT00856206)
Timeframe: Day 1 to Day 112 (Week 16)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 51.1 |
| Rilonacept 160 mg | 25.7 |
Percentage of Participants With at Least Two Flares From Day 1 to Day 112 (Week 16)
A gout flare was defined as participant reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least two gout flare was reported for this outcome measure. For drop-outs, only flares occurred before Day 112 were counted, regardless whether the flares occurred during the treatment period or not. (NCT00856206)
Timeframe: Day 1 to Day 112 (Week 16)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 34.7 |
| Rilonacept 160 mg | 11.7 |
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the administration of first dose of study drug up to 35 days after the last dose of study drug). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. (NCT00856206)
Timeframe: Baseline up to Week 20
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| With at least 1 TEAE | With TEAEs related to study drug | With serious TEAEs | With TEAEs resulting in drug withdrawal | With serious TEAEs resulting in drug withdrawal | With TEAEs leading to study discontinuation | With serious TEAE leading to study discontinuation | Treatment emergent deaths | |
| Placebo | 59.1 | 13.0 | 3.9 | 3.3 | 1.8 | 3.0 | 1.5 | 0.3 |
| Rilonacept 160 mg | 66.6 | 27.5 | 3.1 | 5.0 | 1.1 | 4.7 | 1.0 | 0.2 |
Absolute Change in the Serum Urate Level at the Final Visit Relative to Baseline
(NCT02082769)
Timeframe: Baseline and Final Visit (up to 26 weeks)
| Intervention | umol/l (Mean) |
|---|---|
| Febuxostat 40 mg QD | 182.2 |
| Febuxostat 80 mg QD | 216.0 |
| Allopurinol 100mg QD | 170.4 |
Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL)
(NCT02082769)
Timeframe: Last 3 visits (any last 3 visits up to week 26)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat 40 mg QD | 22.5 |
| Febuxostat 80 mg QD | 33.5 |
| Allopurinol 100mg QD | 17.0 |
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit
(NCT02082769)
Timeframe: Final Visit (up to 26 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat 40 mg QD | 45.0 |
| Febuxostat 80 mg QD | 58.9 |
| Allopurinol 100mg QD | 34.6 |
Change in the Total Number of Tophi at Final Visit in the Subset of Subjects With Palpable Tophi at the Screening Visit
Change in number of tophi/subject was calculated for the subset of subjects with palpable tophi at the Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Final Visit (up to 28 weeks)
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Febuxostat 240 mg QD | 0.0 |
| Allopurinol QD | 0.0 |
| Placebo QD | 0.0 |
Change in the Total Number of Tophi at Week 28 in the Subset of Subjects With Palpable Tophi at the Screening Visit.
Change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were not palpable at the Week 28 visit, the total count was assumed to be 0. (NCT00174915)
Timeframe: Baseline and Week 28
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Febuxostat 240 mg QD | 0.0 |
| Allopurinol QD | 0.0 |
| Placebo QD | 0.0 |
Percent Change From Baseline in Serum Urate Levels at Final Visit
The percent change in serum urate from baseline to the Final visit was summarized. The percent change in serum urate was calculated as [(Final visit - baseline levels)/baseline]*100. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Baseline and Final Visit (up to 28 weeks)
| Intervention | Percent change (Mean) |
|---|---|
| Febuxostat 80 mg QD | -45.2 |
| Febuxostat 120 mg QD | -51.9 |
| Febuxostat 240 mg QD | -66.3 |
| Allopurinol QD | -33.7 |
| Placebo QD | -3.0 |
Percent Change From Baseline in Serum Urate Levels at Week 28.
Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(Week 28 - baseline levels)/baseline]*100 and summarized. (NCT00174915)
Timeframe: Baseline and Week 28
| Intervention | Percent change (Mean) |
|---|---|
| Febuxostat 80 mg QD | -47.6 |
| Febuxostat 120 mg QD | -54.9 |
| Febuxostat 240 mg QD | -67.8 |
| Allopurinol QD | -34.4 |
| Placebo QD | -3.6 |
Percent Change in Primary Tophus Size at Final Visit, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.
Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Baseline and Final Visit (up to 28 weeks)
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -33.8 |
| Febuxostat 120 mg QD | -42.4 |
| Febuxostat 240 mg QD | -47.0 |
| Allopurinol QD | -22.6 |
| Placebo QD | -40.3 |
Percent Change in Primary Tophus Size at Week 28, as Determined by Physical Measurement in the Subset of Subjects With Palpable Tophi at the Screening Visit.
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero. (NCT00174915)
Timeframe: Baseline and Week 28
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -45.6 |
| Febuxostat 120 mg QD | -54.2 |
| Febuxostat 240 mg QD | -53.2 |
| Allopurinol QD | -31.5 |
| Placebo QD | -52.0 |
Percentage of Subjects Requiring Treatment for a Gout Flare Between Weeks 8 and 28 of the Double-Blind Treatment Period.
Percentage of subjects requiring treatment for a gout flare between Weeks 8 and 28 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once. (NCT00174915)
Timeframe: Weeks 8 through 28
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 55 |
| Febuxostat 120 mg QD | 54 |
| Febuxostat 240 mg QD | 57 |
| Allopurinol QD | 46 |
| Placebo QD | 52 |
Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL).
Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject. (NCT00174915)
Timeframe: Last 3 visits (any last 3 visits up to week 28)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 48 |
| Febuxostat 120 mg QD | 65 |
| Febuxostat 240 mg QD | 69 |
| Allopurinol QD | 22 |
| Placebo QD | 0 |
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit
The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected and may have differed by subject. (NCT00174915)
Timeframe: Final Visit (up to 28 weeks).
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 72 |
| Febuxostat 120 mg QD | 79 |
| Febuxostat 240 mg QD | 92 |
| Allopurinol QD | 39 |
| Placebo QD | 1 |
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Week 28
Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 28 visit was summarized. (NCT00174915)
Timeframe: Week 28
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 76 |
| Febuxostat 120 mg QD | 87 |
| Febuxostat 240 mg QD | 94 |
| Allopurinol QD | 41 |
| Placebo QD | 1 |
Feasibility of Using IVR vs. RheumPRO to Report Gout Flares
Feasibility ----Assessed by the percentage of participants completing answer IRV/RheumPRO queries. (NCT02855437)
Timeframe: 6 months
| Intervention | percentage of weekly response (Mean) |
|---|---|
| Interactive Voice Response | 81 |
| RheumPro Smartphone Application | 80 |
Preference IVR vs RheumPRO
Percentage of total study population preferring IVR vs. RheumPRO (NCT02855437)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Interactive Voice Response | 3 |
| RheumPro Smartphone Application | 28 |
Percent Change in Serum Urate Levels From Baseline at Final Visit.
The percent change in serum urate from baseline to the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00174941)
Timeframe: Baseline and Last Visit on treatment (up to 66 months).
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -49.2 |
| Febuxostat 80 mg QD | -47.1 |
| Febuxostat 120 mg QD | -50.7 |
| Total Febuxostat | -48.1 |
Percent Change in Serum Urate Levels From Baseline at Month 12 Visit.
Serum urate values were obtained at the Month 12 visit. The percent change in serum urate from baseline to the Month 12 visit was summarized. (NCT00174941)
Timeframe: Baseline and Month 12
| Intervention | percentage of subjects (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.0 |
| Febuxostat 80 mg QD | -49.7 |
| Febuxostat 120 mg QD | -49.3 |
| Total Febuxostat | -48.3 |
Percent Change in Serum Urate Levels From Baseline at Month 18 Visit.
Serum urate values were obtained at the Month 18 visit. The percent change in serum urate from baseline to the Month 18 visit was summarized. (NCT00174941)
Timeframe: Baseline and Month 18
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.5 |
| Febuxostat 80 mg QD | -48.7 |
| Febuxostat 120 mg QD | -39.5 |
| Total Febuxostat | -45.4 |
Percent Change in Serum Urate Levels From Baseline at Month 24 Visit.
Serum urate values were obtained at the Month 24 visit. The percent change in serum urate from baseline to the Month 24 visit was summarized. (NCT00174941)
Timeframe: Baseline and Month 24
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -38.9 |
| Febuxostat 80 mg QD | -46.7 |
| Febuxostat 120 mg QD | -54.7 |
| Total Febuxostat | -47.3 |
Percent Change in Serum Urate Levels From Baseline at Month 36 Visit.
Serum urate values were obtained at the Month 36 visit. The percent change in serum urate from baseline to the Month 36 visit was summarized. (NCT00174941)
Timeframe: Baseline and Month 36
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -43.0 |
| Febuxostat 80 mg QD | -46.9 |
| Febuxostat 120 mg QD | -56.4 |
| Total Febuxostat | -48.4 |
Percent Change in Serum Urate Levels From Baseline at Month 48 Visit.
Serum urate values were obtained at the Month 48 visit. The percent change in serum urate from baseline to the Month 48 visit was summarized. (NCT00174941)
Timeframe: Baseline and Month 48
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -50.0 |
| Febuxostat 80 mg QD | -50.3 |
| Febuxostat 120 mg QD | -53.8 |
| Total Febuxostat | -51.1 |
Percent Change in Serum Urate Levels From Baseline at Month 6 Visit.
Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized. (NCT00174941)
Timeframe: Baseline and Month 6
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.9 |
| Febuxostat 80 mg QD | -50.6 |
| Febuxostat 120 mg QD | -47.6 |
| Total Febuxostat | -48.3 |
Percent Change in Serum Urate Levels From Baseline at Month 60 Visit.
The secondary outcome was the mean percent change from baseline to Month 60 visit as assessed by serum urate levels collected at baseline and at the Month 60 visit by dose at observation. (NCT00174941)
Timeframe: Baseline and Month 60
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -45.5 |
| Febuxostat 80 mg QD | -51.1 |
| Febuxostat 120 mg QD | -59.0 |
| Total Febuxostat | -52.0 |
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Final Visit.
The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00174941)
Timeframe: Last Visit on treatment (up to 66 months).
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 100 |
| Febuxostat 80 mg QD | 82 |
| Febuxostat 120 mg QD | 81 |
| Total Febuxostat | 83 |
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit.
Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 12 visit was summarized. (NCT00174941)
Timeframe: Month 12
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 57 |
| Febuxostat 80 mg QD | 85 |
| Febuxostat 120 mg QD | 67 |
| Total Febuxostat | 79 |
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit.
Serum urate values were obtained at the Month 18 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 18 visit was summarized. (NCT00174941)
Timeframe: Month 18
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 50 |
| Febuxostat 80 mg QD | 82 |
| Febuxostat 120 mg QD | 57 |
| Total Febuxostat | 74 |
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit.
Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 24 visit was summarized. (NCT00174941)
Timeframe: Month 24
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 63 |
| Febuxostat 80 mg QD | 76 |
| Febuxostat 120 mg QD | 92 |
| Total Febuxostat | 77 |
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 36 Visit.
Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 36 visit was summarized. (NCT00174941)
Timeframe: Month 36
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 67 |
| Febuxostat 80 mg QD | 84 |
| Febuxostat 120 mg QD | 92 |
| Total Febuxostat | 84 |
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 48 Visit.
Serum urate values were obtained at the Month 48 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 48 visit was summarized. (NCT00174941)
Timeframe: Month 48
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 83 |
| Febuxostat 80 mg QD | 92 |
| Febuxostat 120 mg QD | 85 |
| Total Febuxostat | 90 |
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit.
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 6 visit was summarized. (NCT00174941)
Timeframe: Month 6
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 50 |
| Febuxostat 80 mg QD | 93 |
| Febuxostat 120 mg QD | 65 |
| Total Febuxostat | 82 |
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 60 Visit.
Serum urate values were obtained at the Month 60 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 60 visit was summarized. (NCT00174941)
Timeframe: Month 60
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 100 |
| Febuxostat 80 mg QD | 93 |
| Febuxostat 120 mg QD | 91 |
| Total Febuxostat | 93 |
Percent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline.
The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and final visit. The percent change from baseline in primary tophus size to the final visit was summarized. (NCT00175019)
Timeframe: Final Visit (up to 40 months).
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -96 |
| Febuxostat 120 mg QD | -84 |
| Allopurinol QD | -67 |
Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline.
The area of the primary tophus was calculated based on the length and width of the tophus measured at the Month 12 visit. The percent change from baseline in primary tophus size to the Month 12 visit was summarized. (NCT00175019)
Timeframe: Month 12
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -82 |
| Febuxostat 120 mg QD | -79 |
| Allopurinol QD | -56 |
Percent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline.
The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 24 visit. The percent change from baseline in primary tophus size to the Month 24 visit was summarized. (NCT00175019)
Timeframe: Month 24
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -100 |
| Febuxostat 120 mg QD | -96 |
| Allopurinol QD | -87 |
Percent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline.
The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 36 visit. The percent change from baseline in primary tophus size to the Month 36 visit was summarized. (NCT00175019)
Timeframe: Month 36
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -83 |
Percent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit.
The number of tophi were counted at baseline and final visits. The percent change from baseline in the number of tophi to the final visit was summarized. (NCT00175019)
Timeframe: Final Visit (up to 40 months).
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -59.9 |
| Febuxostat 120 mg QD | -58.3 |
| Allopurinol QD | -48.7 |
Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment.
The percent change in serum urate from baseline to the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment. (NCT00175019)
Timeframe: Last Visit on treatment (up to 40 months).
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -46.69 |
| Febuxostat 120 mg QD | -52.99 |
| Allopurinol QD | -32.17 |
Percentage of Subjects Requiring Treatment for Gout Flare After Month 12.
The percentage of subjects requiring treatment for gout flare after the first 12 months of final stable treatment was summarized. (NCT00175019)
Timeframe: After Month 12 to Final Visit
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 15.3 |
| Febuxostat 120 mg QD | 19.8 |
| Allopurinol QD | 23.2 |
Percentage of Subjects Requiring Treatment for Gout Flare up to Month 12.
The percentage of subjects requiring treatment for gout flare during the first twelve months of final stable treatment was summarized. (NCT00175019)
Timeframe: Month 12
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 29.4 |
| Febuxostat 120 mg QD | 42.5 |
| Allopurinol QD | 28.3 |
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment.
The percentage of subjects whose serum urate was <6.0 mg/dL at the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment. (NCT00175019)
Timeframe: Last Visit on treatment (up to 40 months).
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 70.8 |
| Febuxostat 120 mg QD | 82.0 |
| Allopurinol QD | 32.6 |
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1.
Serum urate values were obtained at the Month 1 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 1 visit was summarized. (NCT00175019)
Timeframe: Month 1
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 80.8 |
| Febuxostat 120 mg QD | 87.0 |
| Allopurinol QD | 46.0 |
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12.
Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 12 visit was summarized. (NCT00175019)
Timeframe: Month 12
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 88.9 |
| Febuxostat 120 mg QD | 86.3 |
| Allopurinol QD | 82.2 |
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24.
Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 24 visit was summarized. (NCT00175019)
Timeframe: Month 24
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 89.3 |
| Febuxostat 120 mg QD | 87.2 |
| Allopurinol QD | 78.6 |
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36.
Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 36 visit was summarized. (NCT00175019)
Timeframe: Month 36
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 90.8 |
| Febuxostat 120 mg QD | 91.5 |
| Allopurinol QD | 90.0 |
Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.
The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Baseline and Last Visit on treatment (up to 6 months)
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -33.1 |
| Febuxostat 80 mg QD | -40.6 |
| Allopurinol 200 mg or 300 mg QD | -31.3 |
Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.
Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 2
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.1 |
| Febuxostat 80 mg QD | -44.5 |
| Allopurinol 200 mg or 300 mg QD | -33.8 |
Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit
Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 4
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -34.9 |
| Febuxostat 80 mg QD | -45.5 |
| Allopurinol 200 mg or 300 mg QD | -34.5 |
Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.
Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 6
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.6 |
| Febuxostat 80 mg QD | -45.1 |
| Allopurinol 200 mg or 300 mg QD | -34.4 |
Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is <6.0 mg/dl
The percentage of subjects with mild-to-moderate renal impairment whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 49.7 |
| Febuxostat 80 mg QD | 71.6 |
| Allopurinol 200 mg or 300 mg QD | 42.3 |
Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.
The percentage of subjects whose serum urate level was <6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 45.2 |
| Febuxostat 80 mg QD | 67.1 |
| Allopurinol 200 mg or 300 mg QD | 42.1 |
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Final Visit
The percentage of subjects whose serum urate level was <4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 2.5 |
| Febuxostat 80 mg QD | 17.5 |
| Allopurinol 200 mg or 300 mg QD | 1.5 |
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 2 Visit
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 2.1 |
| Febuxostat 80 mg QD | 17.5 |
| Allopurinol 200 mg or 300 mg QD | 1.5 |
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 4 Visit
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 2.0 |
| Febuxostat 80 mg QD | 18.6 |
| Allopurinol 200 mg or 300 mg QD | 1.4 |
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 6 Visit
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 3.1 |
| Febuxostat 80 mg QD | 20.3 |
| Allopurinol 200 mg or 300 mg QD | 1.8 |
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Final Visit.
The percentage of subjects whose serum urate level was <5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 16.5 |
| Febuxostat 80 mg QD | 44.0 |
| Allopurinol 200 mg or 300 mg QD | 13.2 |
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 2 Visit.
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 15.4 |
| Febuxostat 80 mg QD | 45.9 |
| Allopurinol 200 mg or 300 mg QD | 11.7 |
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 4 Visit.
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 15.0 |
| Febuxostat 80 mg QD | 51.6 |
| Allopurinol 200 mg or 300 mg QD | 13.5 |
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 6 Visit.
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 19.3 |
| Febuxostat 80 mg QD | 49.7 |
| Allopurinol 200 mg or 300 mg QD | 14.8 |
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 2 Visit.
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 49.1 |
| Febuxostat 80 mg QD | 74.1 |
| Allopurinol 200 mg or 300 mg QD | 43.2 |
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 4 Visit.
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 47.1 |
| Febuxostat 80 mg QD | 75.2 |
| Allopurinol 200 mg or 300 mg QD | 45.5 |
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 6 Visit.
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat 40 mg QD | 48.9 |
| Febuxostat 80 mg QD | 75.3 |
| Allopurinol 200 mg or 300 mg QD | 46.6 |
Development of Antibodies to PEG-uricase
Number of patients who developed antibodies to PEG-uricase (NCT00111657)
Timeframe: baseline, then prior to infusions and 7 wks after last infusion
| Intervention | participants (Number) |
|---|---|
| Pegloticase | 15 |
Infusion 1: Maximum Concentration (Cmax) Value
The highest drug concentration in the blood after the first infusion of study drug. (NCT00111657)
Timeframe: 2 hours
| Intervention | mU/mL (Mean) |
|---|---|
| Single Arm - Pegloticase | 25.6 |
Infusion 1: Minimum Concentration (Cmin)
The lowest drug concentration in the blood after the first infusion of study drug. (NCT00111657)
Timeframe: 21 days after the infusion
| Intervention | mU/mL (Mean) |
|---|---|
| Single Arm - Pegloticase | 4.9 |
Reduction in Plasma Uric Acid to Less Than 6 mg/dL.
(NCT00111657)
Timeframe: Baseline to Day 105
| Intervention | Participants (Number) |
|---|---|
| Single Arm | 17 |
Clinical Response: Number of Swollen and Tender Joints
Count of tenderness and swelling of 68 joints (NCT00111657)
Timeframe: Basline and day 134
| Intervention | joints (Median) | |||
|---|---|---|---|---|
| Number of Tender joints at baseline | Number of Tender joints at day 134 | Number of Swollen jonts at baseline | Number of Swollen jonts at day 134 | |
| Pegloticase | 13 | 2 | 9 | 6 |
Change From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening.
Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Allopurinol 300 mg QD | 0.0 |
Change From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening.
The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 28
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Allopurinol 300 mg QD | 0.0 |
Change From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening.
The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 52
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | -1.0 |
| Allopurinol 300 mg QD | 0.0 |
Percent Change From Baseline in Serum Urate Levels at Final Visit
The percent change in serum urate from baseline to the Final visit was calculated as [(Final Visit - baseline levels/baseline)]*100 and summarized. The Final visit was the last visit with a serum urate value. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -44.7 |
| Febuxostat 120 mg QD | -51.5 |
| Allopurinol 300 mg QD | -33.0 |
Percent Change From Baseline in Serum Urate Levels at Week 28.
Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(week 28 - baseline levels/baseline)]*100 and summarized. (NCT00102440)
Timeframe: Baseline and Week 28
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -46.3 |
| Febuxostat 120 mg QD | -53.5 |
| Allopurinol 300 mg QD | -34.8 |
Percent Change From Baseline in Serum Urate Levels at Week 52.
Serum urate values were obtained at the Week 52 visit. The percent change in serum urate was calculated as [(week 52 - baseline levels/baseline)]*100 and summarized. (NCT00102440)
Timeframe: Baseline and Week 52
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -47.7 |
| Febuxostat 120 mg QD | -53.0 |
| Allopurinol 300 mg QD | -34.8 |
Percent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.
Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -51.7 |
| Febuxostat 120 mg QD | -43.8 |
| Allopurinol 300 mg QD | -39.6 |
Percent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 28
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -29.5 |
| Febuxostat 120 mg QD | -49.5 |
| Allopurinol 300 mg QD | -28.6 |
Percent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 52 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 52
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -83.4 |
| Febuxostat 120 mg QD | -65.5 |
| Allopurinol 300 mg QD | -49.7 |
Percentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52.
The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once. (NCT00102440)
Timeframe: Weeks 8 through 52
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 64 |
| Febuxostat 120 mg QD | 70 |
| Allopurinol 300 mg QD | 64 |
Percentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit
The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Final Visit (up to 52 weeks)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 74 |
| Febuxostat 120 mg QD | 80 |
| Allopurinol 300 mg QD | 36 |
Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit
Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 28 visit was summarized. (NCT00102440)
Timeframe: Week 28
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 72 |
| Febuxostat 120 mg QD | 82 |
| Allopurinol 300 mg QD | 42 |
Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit
Serum urate values were obtained at the Week 52 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 52 visit was summarized. (NCT00102440)
Timeframe: Week 52
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 81 |
| Febuxostat 120 mg QD | 82 |
| Allopurinol 300 mg QD | 39 |
Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL)
Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject. (NCT00102440)
Timeframe: Last 3 Visits (up to 52 weeks)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 53 |
| Febuxostat 120 mg QD | 62 |
| Allopurinol 300 mg QD | 21 |
Maximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period.
Serum urate values were obtained at the Day 7, 14, 21,and 28 visits. The maximum percent change in serum urate levels obtained at any visit was summarized. (NCT00174967)
Timeframe: Baseline and Any visit (Day 7, 14, 21,or 28)
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | 42.5 |
| Febuxostat 80 mg QD | 49.2 |
| Febuxostat 120 mg QD | 62.8 |
| Placebo QD | 10.0 |
Percent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28.
24-hour urine uric acid levels were obtained at the Day 28 visit. The percent change in 24-hour urine uric acid level from baseline to the Day 28 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 28.
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -43.6 |
| Febuxostat 80 mg QD | -46.5 |
| Febuxostat 120 mg QD | -45.7 |
| Placebo QD | 5.9 |
Percent Change in Serum Urate Levels From Baseline to the Day 14 Visit.
Serum urate values were obtained at the Day 14 visit. The percent change in serum urate from baseline to the Day 14 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 14.
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -37.1 |
| Febuxostat 80 mg QD | -41.8 |
| Febuxostat 120 mg QD | -56.9 |
| Placebo QD | 1.62 |
Percent Change in Serum Urate Levels From Baseline to the Day 21 Visit
Serum urate values were obtained at the Day 21 visit. The percent change in serum urate from baseline to the Day 21 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 21.
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -37.3 |
| Febuxostat 80 mg QD | -43.9 |
| Febuxostat 120 mg QD | -59.4 |
| Placebo QD | -0.57 |
Percent Change in Serum Urate Levels From Baseline to the Day 28 Visit.
Serum urate values were obtained at the Day 28 visit. The percent change in serum urate from baseline to the Day 28 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 28.
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -36.6 |
| Febuxostat 80 mg QD | -44.3 |
| Febuxostat 120 mg QD | -59.1 |
| Placebo QD | -2.2 |
Percent Change in Serum Urate Levels From Baseline to the Day 7 Visit.
Serum urate values were obtained at the Day 7 visit. The percent change in serum urate from baseline to the Day 7 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 7.
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.0 |
| Febuxostat 80 mg QD | -39.2 |
| Febuxostat 120 mg QD | -53.44 |
| Placebo QD | 0.71 |
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 14 Visit.
Serum urate values were obtained at the Day 14 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 14 visit was summarized. (NCT00174967)
Timeframe: Day 14.
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 56 |
| Febuxostat 80 mg QD | 68 |
| Febuxostat 120 mg QD | 94 |
| Placebo QD | 0 |
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 21 Visit.
Serum urate values were obtained at the Day 21 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 21 visit was summarized. (NCT00174967)
Timeframe: Day 21.
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 59 |
| Febuxostat 80 mg QD | 76 |
| Febuxostat 120 mg QD | 97 |
| Placebo QD | 0 |
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 7 Visit.
Serum urate values were obtained at the Day 7 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 7 visit was summarized. (NCT00174967)
Timeframe: Day 7.
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 50 |
| Febuxostat 80 mg QD | 59 |
| Febuxostat 120 mg QD | 91 |
| Placebo QD | 3 |
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit.
Serum urate values were obtained at the Day 28 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 28 visit was summarized. (NCT00174967)
Timeframe: Day 28.
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 56 |
| Febuxostat 80 mg QD | 76 |
| Febuxostat 120 mg QD | 94 |
| Placebo QD | 0 |
Number of Participants With Anaphylaxis
"Anaphylaxis was defined using the National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network (NIAID/FAAN) criteria: Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives; pruritus or flushing; swollen lips, tongue, or uvula), and at least 1 of the following:~Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia).~Reduced blood pressure (i.e., systolic blood pressure < 90 mm Hg or greater than 30% decrease from that patient's baseline) or associated symptoms of end-organ failure (e.g., hypotonia [collapse], syncope, incontinence)." (NCT01466166)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Pegloticase | 5 |
Number of Participants With Immune Complex-related Events
Immune complex-related events were defined as any presumptive immune complex-related disorders that were confirmed by an appropriate investigation of the event and of complement markers (C3 and C4 levels). Clinical manifestations could have included skin rash, arthralgia, arthritis, proteinuria, serum sickness, and cryoglobulinemia. (NCT01466166)
Timeframe: From first dose of study drug to the end of the 12-week follow-up period (63 weeks).
| Intervention | Participants (Count of Participants) |
|---|---|
| Pegloticase | 3 |
Number of Participants With Infusion Reactions
Infusion reactions were defined as adverse events (AEs) or clusters of events, not attributable to another cause that occurred during or within 2 hours after the infusion of pegloticase. Any other case that occurred outside of the 2-hour window was categorized per Investigator discretion. (NCT01466166)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Pegloticase | 42 |
Change From Baseline in Number of Gout Flares
The number of gout flares occurring in the 2 weeks prior to each visit. Baseline number of flares was calculated as the average number of flares that occurred in the 6-month baseline period divided by 12 weeks. (NCT01466166)
Timeframe: Baseline, week 24 and week 48
| Intervention | flares (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| Pegloticase | -0.83 | -1.00 |
Number of Palpable Tophi Over Time
Gout tophi are nodular deposits of urate crystals and inflammatory cells in joints, soft tissues, bones, and in some organs. (NCT01466166)
Timeframe: Baseline and weeks 24 and 52
| Intervention | tophi (Mean) | ||
|---|---|---|---|
| Baseline | Week 24 | Week 52 | |
| Pegloticase | 13.58 | 5.70 | 3.68 |
Number of Swollen Joints Over Time
(NCT01466166)
Timeframe: Baseline and weeks 24 and 52
| Intervention | swollen joints (Mean) | ||
|---|---|---|---|
| Baseline | Week 24 | Week 52 | |
| Pegloticase | 8.60 | 4.05 | 1.46 |
Number of Tender Joints Over Time
(NCT01466166)
Timeframe: Baseline and weeks 24 and 52
| Intervention | tender joints (Mean) | ||
|---|---|---|---|
| Baseline | Week 24 | Week 52 | |
| Pegloticase | 9.33 | 2.38 | 0.79 |
Percentage of Participants With Normalization of Serum Uric Acid at Week 24 and Week 52
Normalization of serum uric acid was defined as serum uric acid value less than 6 mg/dL. (NCT01466166)
Timeframe: Week 24 and week 52
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 24 | Week 52 | |
| Pegloticase | 27.7 | 12.2 |
Number of Gout Flare Days Per Participant From Day 1 to Day 112 (Week 16)
Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain, and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flare days per participant was reported for this outcome measure. (NCT00829829)
Timeframe: Day 1 to Day 112 (Week 16)
| Intervention | Gout flare Days (Mean) |
|---|---|
| Placebo | 5.52 |
| Rilonacept 80 mg | 2.36 |
| Rilonacept 160 mg | 0.98 |
Number of Gout Flare Days With Participant's Pain Score of 5 or More (From Daily Diary) Per Participant From Day 1 to Day 112 (Week 16)
Participants were asked to complete a telephone diary by calling the IVRS daily beginning at the baseline visit (Day 1) through the follow-up visit (Day 141) and reported their general well-being, gout symptoms, and weekly study drug administrations. At the onset of pain from a gout flare, participants were to answer additional diary questions regarding their gout flare and had to continue daily flare assessments until they reported the flare had ended. If a flare occurred just prior to the follow-up visit (Day 141), participants were to continue completing the daily diary until the flare resolved. Gout flare pain was assessed on a scale from 0 to 10 (with 0=no pain and 10=severe pain) within the past 24 hours. (NCT00829829)
Timeframe: Day 1 to Day 112 (Week 16)
| Intervention | Gout flare days (Mean) |
|---|---|
| Placebo | 2.13 |
| Rilonacept 80 mg | 0.85 |
| Rilonacept 160 mg | 0.35 |
Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16)
A gout flare was defined as participant reported acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flares per participant was reported for this outcome measure. For drop-outs, only flares occurred before Day 112 were counted, regardless whether the flares occurred during the treatment period or not. (NCT00829829)
Timeframe: Day 1 to Day 112 (Week 16)
| Intervention | Number of Gout flares per participant (Mean) |
|---|---|
| Placebo | 1.06 |
| Rilonacept 80 mg | 0.29 |
| Rilonacept 160 mg | 0.21 |
Number of Modified Gout Flares Per Participant From Day 1 to Day 112 (Week 16)
Modified gout flare was defined using modified definition of a gout flare as participant-reported articular pain typical of a gout attack that was deemed to require treatment with anti-inflammatory therapy. Number of modified gout flares per participant were reported for this outcome measure. (NCT00829829)
Timeframe: Day 1 to Day 112 (Week 16)
| Intervention | modified gout flares (Mean) |
|---|---|
| Placebo | 1.19 |
| Rilonacept 80 mg | 0.40 |
| Rilonacept 160 mg | 0.28 |
Percentage of Participants With at Least One Gout Flare From Day 1 to Day 112 (Week 16)
Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain; and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least one gout flare was reported for this outcome measure. (NCT00829829)
Timeframe: Day 1 to Day 112 (Week 16)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 46.8 |
| Rilonacept 80 mg | 18.8 |
| Rilonacept 160 mg | 16.3 |
Percentage of Participants With at Least Two Gout Flares From Day 1 to Day 112 (Week 16)
Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain, and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least two gout flares was reported for this outcome measure. (NCT00829829)
Timeframe: Day 1 to Day 112 (Week 16)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 31.6 |
| Rilonacept 80 mg | 5.0 |
| Rilonacept 160 mg | 3.8 |
Average Percent Difference in Area Between Raters
Each rater measured length and width (mm) of the tophus at 2 visits separated by no more than 10 days. Area of the tophus was summarized using the average percent difference, calculated as the absolute difference of Raters 1 and 2 divided by the average of Raters 1 and 2 for the same tophus, pooled across visits. (NCT00175006)
Timeframe: Visit 1 (Day 1 ) and Visit 2 (Day 6-11)
| Intervention | mm² (Mean) |
|---|---|
| Average Percent Difference | |
| Tophi Participants | 32 |
Average Percent Difference in Area Between Visits
The rater measured length and width (mm) of the tophus at 2 visits separated by no more than 10 days. Area of the tophus was summarized using average percent difference, calculated as absolute difference of Visits 1 and 2 divided by the average of Visits 1 and 2 for the same tophus, pooled across raters. (NCT00175006)
Timeframe: Visit 1 (Day 1) and Visit 2 (Days 6-11)
| Intervention | mm² (Mean) |
|---|---|
| Average Percent Difference | |
| Tophi Participants | 29 |
Reviews
755 reviews available for uric acid and Gout
| Article | Year |
|---|---|
The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Tr | 2021 |
A historical journey of searching for uricosuric drugs.
Topics: Aged; Gout; Humans; Hyperuricemia; Pharmaceutical Preparations; Uric Acid; Uricosuric Agents | 2022 |
Uric acid extrarenal excretion: the gut microbiome as an evident yet understated factor in gout development.
Topics: Gastrointestinal Microbiome; Gout; Humans; Risk Factors; Uric Acid | 2022 |
Urate transport in health and disease.
Topics: Gout; Humans; Hyperuricemia; Organic Cation Transport Proteins; Uric Acid | 2021 |
The genetic basis of urate control and gout: Insights into molecular pathogenesis from follow-up study of genome-wide association study loci.
Topics: Aldehyde Dehydrogenase, Mitochondrial; Follow-Up Studies; Genetic Predisposition to Disease; Genome- | 2021 |
Treatment advances in gout.
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 2021 |
Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
Topics: Benzbromarone; Benzothiazoles; Febuxostat; Gout; Gout Suppressants; Humans; Network Meta-Analysis; R | 2022 |
Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis.
Topics: Animals; Atherosclerosis; Comorbidity; Diabetes Mellitus, Type 2; Gout; Humans; Hypertension; Hyperu | 2021 |
Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group.
Topics: Biomarkers; Gout; Gout Suppressants; Humans; Outcome Assessment, Health Care; Treatment Outcome; Uri | 2021 |
Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
Topics: Gout; Gout Suppressants; Humans; Network Meta-Analysis; Nitriles; Pyridines; Randomized Controlled T | 2022 |
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care.
Topics: Adult; Comorbidity; Diabetes Mellitus, Type 2; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric | 2022 |
What's new on the front-line of gout pharmacotherapy?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Quality of Life; Uric Acid | 2022 |
Update of the current role of ultrasound in asymptomatic hyperuricemia. A systematic literature review.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Ultrasonography; Uric Acid | 2022 |
Hyperuricemia, Gout, and the Brain-an Update.
Topics: Brain; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2021 |
Dual-energy computed tomography in crystalline arthritis: knowns and unknowns.
Topics: Calcium Pyrophosphate; Gout; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid | 2022 |
The effect of initiation of urate-lowering treatment during a gout flare on the current episode: a meta-analysis of randomized controlled trials.
Topics: Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid | 2022 |
The Role of Advanced Imaging in Gout Management.
Topics: Biomarkers; Diagnostic Imaging; Disease Management; Disease Susceptibility; Gout; Humans; Hyperurice | 2021 |
Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.
Topics: Expert Testimony; Gout; Gout Suppressants; Humans; Immunologic Factors; Immunomodulation; Polyethyle | 2022 |
Gout. What's up doc?
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Spain; Uric Acid | 2022 |
Clinical features of gout in adult patients with type Ia glycogen storage disease: a single-centre retrospective study and a review of literature.
Topics: Adolescent; Adult; Child; Female; Glycogen Storage Disease; Gout; Humans; Retrospective Studies; Sym | 2022 |
The chemistry, processing, and preclinical anti-hyperuricemia potential of tea: a comprehensive review.
Topics: Gout; Humans; Hyperuricemia; Polyphenols; Tea; Uric Acid | 2023 |
The Role of the Intestine in the Development of Hyperuricemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gout; Humans; Hyperuricemia; Intestines; Ne | 2022 |
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout.
Topics: Allopurinol; Antibodies; Gout; Gout Suppressants; Humans; Urate Oxidase; Uric Acid | 2022 |
Does seasonality of the microbiota contribute to the seasonality of acute gout flare?
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Hyperuricemia; Microbiota; Symptom Flare Up; Uric | 2022 |
Management and Cure of Gouty Arthritis.
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2022 |
Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: a systematic review.
Topics: Gout; Humans; Medication Adherence; Telephone; Text Messaging; Uric Acid | 2022 |
Update on Uric Acid and the Kidney.
Topics: Allopurinol; Female; Gout; Gout Suppressants; Humans; Kidney; Male; Parkinson Disease; Renal Insuffi | 2022 |
Environmental factors and risk of gout.
Topics: Gout; Humans; Inflammation; Uric Acid | 2022 |
Uric acid in metabolic syndrome: Does uric acid have a definitive role?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2022 |
Emerging strategies for treating gout.
Topics: Colchicine; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2022 |
Erosive Tophaceous Gouty Arthropathy of the Hand: A Case Report.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Skin Abnormalities; Uric Acid | 2022 |
Effect modification by contextual factors of urate-lowering therapy on serum urate in people with gout: A systematic review with meta-regression analysis.
Topics: Gout; Gout Suppressants; Humans; Regression Analysis; Uric Acid | 2022 |
Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.
Topics: Aspirin; Gout; Humans; Hyperuricemia; Off-Label Use; Uric Acid | 2022 |
Current state and prospects of gout treatment in Korea.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Republic of Korea; Uric Acid | 2022 |
Dual-Energy Computed Tomography Has Additional Prognostic Value Over Clinical Measures in Gout Including Tophi: A Systematic Literature Review.
Topics: Arthritis, Gouty; Gout; Humans; Prognosis; Prospective Studies; Reproducibility of Results; Tomograp | 2022 |
Effects of allopurinol on renal function in patients with diabetes: a systematic review and meta-analysis.
Topics: Allopurinol; Diabetes Mellitus; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Uric Acid | 2022 |
Recent Insights Into the Role of Macrophages in Acute Gout.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Gout; Macrophages; Mice; TRPV Cation Channels; | 2022 |
When underlying biology threatens the randomization principle - initial gout flares of urate-lowering therapy.
Topics: Biology; Gout; Gout Suppressants; Humans; Random Allocation; Randomized Controlled Trials as Topic; | 2022 |
Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights.
Topics: Endothelial Cells; Gout; Humans; Hyperuricemia; Inflammation; Renal Insufficiency, Chronic; Uric Aci | 2022 |
Susceptibility genes of hyperuricemia and gout.
Topics: Gout; Humans; Hyperuricemia; Mutation; Risk Factors; Uric Acid | 2022 |
Critical appraisal of serum urate targets in the management of gout.
Topics: Gout; Gout Suppressants; Humans; Rheumatology; Uric Acid | 2022 |
Role of microRNA alternation in the pathogenesis of gouty arthritis.
Topics: Arthritis, Gouty; Gout; Humans; MicroRNAs; Uric Acid | 2022 |
Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Probenecid; Randomized Contro | 2023 |
Gout and Diet: A Comprehensive Review of Mechanisms and Management.
Topics: Arthritis, Gouty; Diet; Gout; Humans; Inflammation; Uric Acid | 2022 |
Moving the Needle in Gout Management: The Role of Culture, Diet, Genetics, and Personalized Patient Care Practices.
Topics: Aged; Diet; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Care; Reproducibility of Results | 2022 |
Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.
Topics: Arthritis, Rheumatoid; Bone Diseases, Metabolic; Chronic Disease; Dietary Supplements; Gout; Humans; | 2022 |
Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis.
Topics: Antioxidants; Case-Control Studies; Female; Gout; Humans; Male; Parkinson Disease; Uric Acid | 2022 |
Novel Insights into the Effects of Genetic Variants on Serum Urate Response to an Acute Fructose Challenge: A Pilot Study.
Topics: Adult; Fructose; Gout; Humans; Hyperuricemia; Male; Middle Aged; Pilot Projects; Risk Factors; Uric | 2022 |
Recent advances in gout drugs.
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 2023 |
Amyloid A amyloidosis on medullary sponge kidney in a 28-year-old male with gout: A case report and literature review.
Topics: Adult; Amyloidosis; Gout; Humans; Kidney; Kidney Diseases; Male; Medullary Sponge Kidney; Uric Acid | 2023 |
Crystal arthropathies and osteoarthritis-where is the link?
Topics: Calcinosis; Crystal Arthropathies; Gout; Humans; Inflammation; Osteoarthritis; Uric Acid | 2023 |
Novel perception of neutrophil extracellular traps in gouty inflammation.
Topics: Extracellular Traps; Gout; Humans; Inflammation; Neutrophils; Perception; Uric Acid | 2023 |
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present).
Topics: Gout; Humans; Hyperuricemia; Organic Anion Transporters; Organic Cation Transport Proteins; Patents | 2022 |
The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics.
Topics: Biomarkers; Gout; Humans; Hyperuricemia; Proteomics; Uric Acid | 2023 |
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER.
Topics: Aged; Colchicine; Gout; Heart Failure; Humans; Male; Stroke Volume; Uric Acid; Ventricular Function, | 2023 |
Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set.
Topics: Gout; Humans; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Systematic Rev | 2023 |
Mechanisms of theaflavins against gout and strategies for improving the bioavailability.
Topics: Animals; Biological Availability; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2023 |
Interventions designed to improve uptake of allopurinol for gout treatment in Aotearoa New Zealand: a scoping review.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; New Zealand; Quality of Life; Uric Acid | 2023 |
A review on gout: Looking back and looking ahead.
Topics: Arthritis, Gouty; Extracellular Traps; Glucose Transport Proteins, Facilitative; Gout; Humans; Infla | 2023 |
The Hong Kong Society of Rheumatology consensus recommendations for the management of gout.
Topics: Consensus; Gout; Gout Suppressants; Hong Kong; Humans; Hyperuricemia; Rheumatology; Uric Acid | 2023 |
Efficacy of initiating urate-lowering therapy during an acute gout episode: a meta-analysis.
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Pain; Uric Acid | 2023 |
Management of Gout in the Hand and Wrist.
Topics: Adult; Gout; Humans; Hyperuricemia; Upper Extremity; Uric Acid; Wrist | 2023 |
Immune and inflammatory mechanisms and therapeutic targets of gout: An update.
Topics: Animals; Arthritis, Gouty; Cytokines; Gout; Inflammasomes; Inflammation; Macrophages; Uric Acid | 2023 |
The Chinese patent medicine Tongfengding capsule for gout in adults: a systematic review of safety and effectiveness.
Topics: Adult; Capsules; Gout; Humans; Interleukin-8; Nonprescription Drugs; Randomized Controlled Trials as | 2023 |
Analysis of Metabolites in Gout: A Systematic Review and Meta-Analysis.
Topics: Creatinine; Gout; Humans; Hypoxanthine; Uric Acid; Xanthine | 2023 |
Management of Patients with Gout and Kidney Disease: A Review of Available Therapies and Common Missteps.
Topics: Colchicine; Gout; Humans; Quality of Life; Renal Insufficiency, Chronic; Uric Acid | 2023 |
Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research.
Topics: Gout; Humans; Joints; Osteoarthritis; Uric Acid | 2023 |
Mechanisms and rationale for uricase use in patients with gout.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Hyperuricemia; Quality of Life; Urate Oxidase; Uric Ac | 2023 |
Gout therapeutics and drug delivery.
Topics: Drug Delivery Systems; Gout; Humans; Hyperuricemia; Quality of Life; Uric Acid | 2023 |
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
Topics: Diabetes Mellitus, Type 2; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up; Uric Ac | 2023 |
Uric acid en route to gout.
Topics: Gout; Humans; Hyperuricemia; Symptom Flare Up; Uric Acid | 2023 |
Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases.
Topics: Diet; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2023 |
Agents for the Treatment of Gout: Current Advances and Future Perspectives.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Xanthine Oxidase | 2023 |
The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Inflammation; Uric Acid | 2023 |
Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements.
Topics: Consensus; Gout; Gout Suppressants; Humans; Hyperuricemia; Practice Guidelines as Topic; Uric Acid | 2019 |
Impact of bariatric surgery on serum uric acid levels and the incidence of gout-A meta-analysis.
Topics: Adolescent; Adult; Bariatric Surgery; Body Mass Index; Female; Gout; Humans; Male; MEDLINE; Middle A | 2019 |
Gout.
Topics: Adrenal Cortex Hormones; Gout; Gout Suppressants; Humans; Risk Factors; Uric Acid | 2019 |
Gout.
Topics: Gout; Gout Suppressants; Humans; Patient Care Management; Risk Reduction Behavior; Uric Acid | 2019 |
Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Disease Progression; Gout; Gout Su | 2020 |
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Benzothiazoles; Drug Interactions; Febuxosta | 2020 |
Clinical Management of Reptile Renal Disease.
Topics: Animals; Gout; Kidney; Kidney Diseases; Reptiles; Uric Acid | 2020 |
A novel mutation in gene of PRPS1 in a young Chinese woman with X-linked gout: a case report and review of the literature.
Topics: Asian People; Female; Genes, X-Linked; Gout; Humans; Hyperuricemia; Mutation, Missense; Purine-Pyrim | 2020 |
How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials.
Topics: Female; Gout; Gout Suppressants; Humans; Male; Randomized Controlled Trials as Topic; Symptom Flare | 2020 |
Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Dietary Supplement | 2019 |
Beyond urate lowering: Analgesic and anti-inflammatory properties of allopurinol.
Topics: Allopurinol; Analgesics; Anti-Inflammatory Agents; Enzyme Inhibitors; Free Radical Scavengers; Gout; | 2020 |
Comorbidities in gout and hyperuricemia: causality or epiphenomena?
Topics: Cardiovascular Diseases; Comorbidity; Gout; Humans; Hyperuricemia; Prevalence; Renal Insufficiency, | 2020 |
Management of hyperuricemia in asymptomatic patients: A critical appraisal.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2020 |
Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
Topics: Bayes Theorem; Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Quality of Lif | 2020 |
At the crossroads of gout and psoriatic arthritis: "psout".
Topics: Arthritis, Psoriatic; Comorbidity; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2020 |
[Gout].
Topics: Chronic Disease; Diagnosis, Differential; Gout; Humans; Hyperuricemia; Prevalence; Risk Factors; Uri | 2020 |
Lessons and pitfalls from the 2020 Gout Clinical Practice Guideline presented in Atlanta at the ACR 2019.
Topics: Gout; Gout Suppressants; Guideline Adherence; Humans; Practice Guidelines as Topic; Rheumatology; So | 2020 |
Recent approaches to gout drug discovery: an update.
Topics: Allopurinol; Arthritis, Gouty; Drug Discovery; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric | 2020 |
Gout: a disease involved with complicated immunoinflammatory responses: a narrative review.
Topics: Animals; Cytokines; Gout; Humans; Inflammasomes; Interleukin-1beta; Neutrophils; Uric Acid | 2020 |
Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta | 2020 |
Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2020 |
Polygenic analysis of the effect of common and low-frequency genetic variants on serum uric acid levels in Korean individuals.
Topics: Adult; Aldehyde Dehydrogenase, Mitochondrial; Asian People; Chromosomes, Human, Pair 12; Female; Gen | 2020 |
Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.
Topics: Adult; Aged; Case-Control Studies; Comorbidity; Ethnicity; Female; Gout; Gout Suppressants; Humans; | 2020 |
Renal disorders in rheumatologic diseases: the spectrum is changing (part 2. Arthridides).
Topics: Arthritis, Rheumatoid; Chronic Disease; Gout; Humans; Kidney Calculi; Uric Acid | 2021 |
The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials.
Topics: Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid | 2021 |
Changing paradigms in the management of gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid | 2020 |
The biology of urate.
Topics: Gout; Humans; Hyperuricemia; Kidney; Organic Anion Transporters; Uric Acid | 2020 |
Therapeutic approaches in the treatment of gout.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Mal | 2020 |
Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Aci | 2021 |
Gout: Where Is the Weak Link?
Topics: Gout; Gout Suppressants; Humans; Inflammation; Uric Acid | 2020 |
Cardiovascular safety risks associated with gout treatments.
Topics: Allopurinol; Animals; Cardiovascular Diseases; Colchicine; Gout; Gout Suppressants; Heart Disease Ri | 2020 |
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.
Topics: Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2020 |
Xanthine oxidase inhibitors: patent landscape and clinical development (2015-2020).
Topics: Animals; Drug Development; Enzyme Inhibitors; Gout; Humans; Hyperuricemia; Patents as Topic; Reactiv | 2020 |
Advances in our understanding of gout as an auto-inflammatory disease.
Topics: Comorbidity; Gout; Humans; Hyperuricemia; Inflammation; Uric Acid | 2020 |
Hyperuricemia, the heart, and the kidneys - to treat or not to treat?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Kidney; Myocardium; Renal Insufficiency, Chron | 2020 |
The ABCG2/BCRP transporter and its variants - from structure to pathology.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Neoplasm; Endopla | 2020 |
The association between genetic polymorphisms in ABCG2 and SLC2A9 and urate: an updated systematic review and meta-analysis.
Topics: Alleles; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; Female; Gene Express | 2020 |
Gout: Rapid Evidence Review.
Topics: Adrenal Cortex Hormones; Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Obesi | 2020 |
Clinical implications of synovial fluid specimen handling for crystal associated arthritides: A systematic review.
Topics: Calcium Pyrophosphate; Crystal Arthropathies; Crystallization; Edetic Acid; Gout; Humans; Predictive | 2021 |
Uric acid and cardiovascular disease: A clinical review.
Topics: Cardiovascular Diseases; Gout; Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Acid | 2021 |
Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2021 |
Non-invasive determination of uric acid in human saliva in the diagnosis of serious disorders.
Topics: Biomarkers; Gout; Humans; Hyperuricemia; Saliva; Uric Acid | 2021 |
The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review.
Topics: Azathioprine; Gout; Gout Suppressants; Humans; Immunologic Factors; Polyethylene Glycols; Urate Oxid | 2021 |
Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies.
Topics: Allopurinol; Bias; Cause of Death; Gout; Gout Suppressants; Humans; Hyperuricemia; Mortality; Observ | 2021 |
Molecular Pathophysiology of Uric Acid Homeostasis.
Topics: Genome-Wide Association Study; Gout; Homeostasis; Humans; Organic Anion Transporters; Uric Acid | 2020 |
Pathophysiology of Gout.
Topics: Cytokines; Gout; Humans; Hyperuricemia; Uric Acid | 2020 |
20 Years of Radiographic Imaging: Crystalline Deposits Causing Severe Arthropathy and Erosions.
Topics: Aged; Calcium Pyrophosphate; Chondrocalcinosis; Female; Gout; Humans; Joint Diseases; Middle Aged; O | 2023 |
Tophaceous Gout - When the Skin Comes First.
Topics: Gout; Humans; Quality of Life; Skin; Uric Acid | 2020 |
The role of alcohol consumption in pathogenesis of gout.
Topics: Alcohol Drinking; Alcoholic Beverages; Beer; Ethanol; Gout; Humans; Hyperuricemia; Symptom Flare Up; | 2022 |
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
Topics: Benzothiazoles; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Uricosuric Ag | 2021 |
Regulation of crystal induced inflammation: current understandings and clinical implications.
Topics: Gout; Humans; Inflammasomes; Inflammation; Interleukin-1beta; Macrophages; Uric Acid | 2021 |
Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity.
Topics: Aged; Comorbidity; Gout; Gout Suppressants; Humans; Middle Aged; Symptom Flare Up; Uric Acid | 2021 |
An update of genetics, co-morbidities and management of hyperuricaemia.
Topics: Cardiovascular Diseases; Comorbidity; Genome-Wide Association Study; Gout; Humans; Hyperuricemia; Re | 2021 |
Global patterns of treat-to-serum urate target care for gout: Systematic review and meta-analysis.
Topics: Gout; Gout Suppressants; Humans; Research Design; Rheumatology; Uric Acid | 2021 |
The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems.
Topics: Gout; Humans; Hyperuricemia; Kidney; Radiopharmaceuticals; Uric Acid | 2021 |
What Has Dual Energy CT Taught Us About Gout?
Topics: Gout; Humans; Joints; Tomography, X-Ray Computed; Ultrasonography; Uric Acid | 2021 |
Effect of orlistat on serum uric acid level in adults: A systematic review and meta-analysis of randomised controlled trials.
Topics: Adult; Gout; Humans; Hyperuricemia; Orlistat; Randomized Controlled Trials as Topic; Uric Acid; Weig | 2021 |
Lesinurad: A Review in Hyperuricaemia of Gout.
Topics: Adult; Allopurinol; Drug Therapy, Combination; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuri | 2017 |
Treatment Options for Gout.
Topics: Adult; Germany; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2017 |
Value and Progress of Ultrasound in Diagnosis and Treatment of Hyperuricemia.
Topics: Arthritis, Gouty; Carotid Artery Diseases; Gout; Humans; Hyperuricemia; Kidney; Non-alcoholic Fatty | 2017 |
The genetics of gout: towards personalised medicine?
Topics: Allopurinol; Genome-Wide Association Study; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Sty | 2017 |
Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies.
Topics: Biomarkers; Gout; Humans; Mendelian Randomization Analysis; Nephrolithiasis; Observational Studies a | 2017 |
The Immunological Basis in the Pathogenesis of Gout.
Topics: Adaptive Immunity; Animals; Disease Susceptibility; Gout; Humans; Immunity, Cellular; Immunity, Humo | 2017 |
Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Gout Suppressant | 2017 |
Change gout: the need for a new approach.
Topics: Biomarkers; Body Mass Index; Cardiovascular Diseases; Diet Therapy; Disease Progression; Evidence-Ba | 2017 |
[Dual-energy computed tomography diagnostics for gout].
Topics: Crystallization; Follow-Up Studies; Gout; Humans; Joints; Prognosis; Tomography, X-Ray Computed; Uri | 2017 |
Current and future therapies for gout.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Practice Guidelines as Topic; Uric Acid | 2017 |
Gout and Metabolic Syndrome: a Tangled Web.
Topics: Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Gout; Humans; Hyperlipide | 2017 |
Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.
Topics: Bariatric Surgery; Diet Therapy; Diuretics; Exercise Therapy; Female; Gout; Humans; Hypoglycemic Age | 2017 |
The challenge of Mendelian randomization approach.
Topics: Cardiovascular Diseases; Disease Progression; Gout; Humans; Kidney Diseases; Randomized Controlled T | 2017 |
The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies.
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Kidney Diseas | 2017 |
Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Topics: Adult; Allopurinol; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Febuxostat; Female; Gout | 2017 |
Gout Keratitis: A Case of Peripheral Ulcerative Keratitis Secondary to Gout With a Review of the Literature.
Topics: Adult; Corneal Stroma; Corneal Ulcer; Gout; Humans; Male; Uric Acid | 2018 |
Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.
Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Patien | 2017 |
Crystalline arthropathy and bone health.
Topics: Bone and Bones; Bone Density; Chondrocalcinosis; Crystal Arthropathies; Fractures, Bone; Gout; Human | 2018 |
Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
Topics: Clinical Trials as Topic; Gout; Gout Suppressants; Humans; Observational Studies as Topic; Recurrenc | 2018 |
[Research progress of puerarin and its derivatives on anti-inflammatory and anti-gout activities].
Topics: Anti-Inflammatory Agents; Gout; Gout Suppressants; Humans; Isoflavones; Uric Acid; Xanthine Oxidase | 2017 |
New urate-lowing therapies.
Topics: Acetamides; Drug Interactions; Enzyme Inhibitors; Gout; Gout Suppressants; Humans; Phenylacetates; P | 2018 |
ABCG2 as a therapeutic target candidate for gout.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Design; Gout; Gout Suppressan | 2018 |
Cardiac and renal protective effects of urate-lowering therapy.
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Treat to target in gout.
Topics: Disease Management; Gout; Gout Suppressants; Humans; Uric Acid | 2018 |
Novel uricosurics.
Topics: Disease Management; Gout; Gout Suppressants; Humans; Uric Acid | 2018 |
Beneficial Properties of Phytochemicals on NLRP3 Inflammasome-Mediated Gout and Complication.
Topics: Animals; Antioxidants; Crystallization; Diet; Flavonoids; Gout; Humans; Inflammasomes; Interleukin-1 | 2018 |
Retinal complications of gout: a case report and review of the literature.
Topics: Anterior Eye Segment; Fluorescein Angiography; Fundus Oculi; Gout; Humans; Macula Lutea; Male; Middl | 2018 |
Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
Topics: Biomarkers; Comorbidity; Consensus; Down-Regulation; Gout; Gout Suppressants; Humans; Hyperuricemia; | 2018 |
Gout: A Disease of Kings.
Topics: Glucose Transport Proteins, Facilitative; Gout; History, 19th Century; History, 20th Century; Histor | 2018 |
An association of smoking with serum urate and gout: A health paradox.
Topics: Gout; Humans; Hyperuricemia; Risk; Smoking; Uric Acid | 2018 |
[Progress on diagnosis and treatment of tophus].
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Uric Acid | 2017 |
What Is the Evidence for Treat-to-Target Serum Urate in Gout?
Topics: Dose-Response Relationship, Drug; Drug Monitoring; Evidence-Based Medicine; Gout; Gout Suppressants; | 2018 |
Gout: state of the art after a decade of developments.
Topics: Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Xant | 2019 |
Change gout: how to deal with this "silently-developing killer" in everyday clinical practice.
Topics: Gout; Humans; Male; Uric Acid; Uricosuric Agents | 2018 |
Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.
Topics: Biomarkers; Clinical Trials as Topic; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2018 |
Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Gout; Gout Suppressants; Humans; Longitudinal Studies; | 2018 |
Investigational drugs for hyperuricemia, an update on recent developments.
Topics: Animals; Drug Design; Drugs, Investigational; Gout; Gout Suppressants; Humans; Hyperuricemia; Medica | 2018 |
Current status of ultrasound and dual-energy computed tomography in the evaluation of gout.
Topics: Arthritis, Gouty; Gout; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid | 2018 |
An update on the genetics of hyperuricaemia and gout.
Topics: Animals; Disease Progression; Genetic Predisposition to Disease; Genetic Variation; Genome-Wide Asso | 2018 |
Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
Topics: Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2018 |
Gout and arrhythmias: In search for causation beyond association.
Topics: Ablation Techniques; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biomarkers; Gout; Gout Suppressan | 2019 |
Combination urate-lowering therapy in the treatment of gout: What is the evidence?
Topics: Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2019 |
[Update on Gout and Calcium pyrophosphate deposition (CPPD)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chondrocalcinosis; Colchicine; Diagnostic Imaging; Glucocor | 2018 |
The Role of Inhibitory Receptors in Monosodium Urate Crystal-Induced Inflammation.
Topics: Animals; Costimulatory and Inhibitory T-Cell Receptors; Disease Susceptibility; Gout; Humans; Immuno | 2018 |
Expert opinion on emerging urate-lowering therapies.
Topics: Anti-Inflammatory Agents; Drug Design; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2018 |
Consumption of sugar sweetened beverages and dietary fructose in relation to risk of gout and hyperuricemia: a systematic review and meta-analysis.
Topics: Fructose; Gout; Humans; Hyperuricemia; Sugar-Sweetened Beverages; Uric Acid | 2020 |
Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts.
Topics: Cohort Studies; Cross-Sectional Studies; Diet; Genetic Predisposition to Disease; Gout; Humans; Unit | 2018 |
Gout - An update of aetiology, genetics, co-morbidities and management.
Topics: Allopurinol; Chronic Disease; Comorbidity; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperu | 2018 |
The Challenges of Approaching and Managing Gout.
Topics: Acetamides; Allopurinol; Antibodies, Monoclonal, Humanized; Colchicine; Diet Therapy; Febuxostat; Go | 2019 |
Genetic advances in gout: potential applications in clinical practice.
Topics: Allopurinol; Disease Progression; Genome-Wide Association Study; Gout; Gout Suppressants; HLA-B Anti | 2019 |
Patient perspectives in gout: a review.
Topics: Biomarkers; Gout; Gout Suppressants; Humans; Medication Adherence; Quality Improvement; Uric Acid | 2019 |
Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature.
Topics: Adult; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Immunosuppressive Agents; Male; M | 2019 |
The role of febuxostat in gout.
Topics: Biomarkers; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid | 2019 |
Gout and cardiovascular disease: crystallized confusion.
Topics: Biomarkers; Cardiovascular Diseases; Colchicine; Global Health; Gout; Gout Suppressants; Humans; Mor | 2019 |
Rare Manifestation of Gout: Gouty Tophi in the Nose.
Topics: Allopurinol; Biopsy, Needle; Gout; Humans; Immunohistochemistry; Male; Middle Aged; Nasal Cavity; Na | 2019 |
Uric acid and the cardio-renal effects of SGLT2 inhibitors.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gout; Heart; Humans; Hypoglycemic Agents; Kidney | 2019 |
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Topics: Allopurinol; Anti-Inflammatory Agents; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppr | 2019 |
Painless gouty tophus in the nasal bridge: A case report and literature review.
Topics: Aged; Arthritis, Gouty; Biopsy, Fine-Needle; C-Reactive Protein; Colchicine; Febuxostat; Gout; Gout | 2019 |
A meta-analysis of the association between gout, serum uric acid level, and obstructive sleep apnea.
Topics: Adult; Aged; Biomarkers; Body Mass Index; Brazil; Correlation of Data; Disease Susceptibility; Femal | 2019 |
Safety and tolerability of available urate-lowering drugs: a critical review.
Topics: Enzyme Inhibitors; Gout; Gout Suppressants; Humans; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2019 |
The anatomical pathology of gout: a systematic literature review.
Topics: Gout; Humans; Kidney; Musculoskeletal System; Skin; Uric Acid | 2019 |
Hyperuricemia and Cardiovascular Disease.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2019 |
Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials
.
Topics: Bayes Theorem; Drug Therapy, Combination; Gout; Humans; Network Meta-Analysis; Randomized Controlled | 2019 |
Genome-wide meta-analysis identifies multiple novel loci associated with serum uric acid levels in Japanese individuals.
Topics: Alleles; Computational Biology; Genetic Predisposition to Disease; Genome-Wide Association Study; Ge | 2019 |
The effects of fruit consumption in patients with hyperuricaemia or gout.
Topics: Ascorbic Acid; Dietary Fiber; Fructose; Fruit; Fruit and Vegetable Juices; Gout; Humans; Hyperuricem | 2019 |
The diagnostic performance of dual energy CT for diagnosing gout: a systematic literature review and meta-analysis.
Topics: Gout; Humans; Joints; Sensitivity and Specificity; Tomography, X-Ray Computed; Uric Acid | 2019 |
Natural products for the management of hyperuricaemia and gout: a review.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Asteraceae; Biological Products; Double-Blind M | 2021 |
Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout.
Topics: Adult; Aldehyde Dehydrogenase, Mitochondrial; Asymptomatic Diseases; ATP Binding Cassette Transporte | 2019 |
Uric acid level, gout and bone mineral density: A Mendelian randomization study.
Topics: Bone Density; Causality; Femur Neck; Gout; Humans; Hyperuricemia; Lumbar Vertebrae; Mendelian Random | 2019 |
Uric Acid and Plant-Based Nutrition.
Topics: Biomarkers; Diet, Healthy; Diet, Vegetarian; Gout; Humans; Hyperuricemia; Nutritive Value; Protectiv | 2019 |
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Topics: Aged; Allopurinol; Asymptomatic Diseases; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; G | 2019 |
Energy and fructose from beverages sweetened with sugar or high-fructose corn syrup pose a health risk for some people.
Topics: Beverages; Diabetes Mellitus; Diet; Dietary Sucrose; Fatty Liver; Fructose; Glucose; Gout; Humans; L | 2013 |
New classification criteria for gout: a framework for progress.
Topics: Crystallization; Gout; Humans; Rheumatology; Sensitivity and Specificity; Uric Acid | 2013 |
Serum uric acid and gout: from the past to molecular biology.
Topics: Gout; Humans; Risk Factors; Uric Acid | 2013 |
Chinese herbal medicine for gout: a systematic review of randomized clinical trials.
Topics: Drugs, Chinese Herbal; Gout; Humans; Inflammation; Medicine, Chinese Traditional; Pain Management; P | 2013 |
Type 1 sodium-dependent phosphate transporter acts as a membrane potential-driven urate exporter.
Topics: Amino Acid Sequence; Animals; Gout; Humans; Membrane Potentials; Molecular Sequence Data; Polymorphi | 2013 |
Treatment of hyperuricaemia and gout.
Topics: Biological Products; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2013 |
Systematic review of the prevalence of gout and hyperuricaemia in Australia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Australia; Blood Donors; Child; Europe; Female; Gout; Hu | 2012 |
Gouty tophi on the ear: a review.
Topics: Biopsy; Diagnosis, Differential; Ear Diseases; Ear, External; Ethanol; Gout; Humans; Uric Acid | 2013 |
Association of the lipoprotein receptor-related protein 2 gene with gout and non-additive interaction with alcohol consumption.
Topics: Adaptor Proteins, Signal Transducing; Alcohol Drinking; Carrier Proteins; Female; Genetic Predisposi | 2013 |
A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcom | 2013 |
The distribution of urate deposition within the extremities in gout: a review of 148 dual-energy CT cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Extremities; Female; Gout; Humans; Male; Mid | 2014 |
Mechanisms of spontaneous resolution of acute gouty inflammation.
Topics: Arthritis, Gouty; Cytokines; Gout; Humans; Inflammation; Joints; Macrophages; Neutrophils; Remission | 2014 |
The crystallization of monosodium urate.
Topics: Cartilage, Articular; Chemistry, Physical; Crystallization; Gout; Humans; Hyperuricemia; Immunity, H | 2014 |
[New aspects of diagnosis and therapy of gout].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Diagnosis, Differential | 2013 |
Definition of hyperuricemia and gouty conditions.
Topics: Cardiovascular Diseases; Crystallization; Female; Gout; Humans; Hyperuricemia; Male; Risk Factors; U | 2014 |
Uricosuric drugs: the once and future therapy for hyperuricemia?
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Drug Dis | 2014 |
Canakinumab for gout: a specific, patient-profiled indication.
Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as | 2014 |
Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout.
Topics: Adult; Aged; Databases, Bibliographic; Drugs, Chinese Herbal; Gout; Gout Suppressants; Humans; Medic | 2014 |
Gout.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Colchicine; Comorbidi | 2013 |
Optimizing current treatment of gout.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Humans; Uric Aci | 2014 |
Multiple firm nodules and tender, indurated plaques.
Topics: Adult; Allopurinol; Biopsy, Needle; Diagnosis, Differential; Follow-Up Studies; Gout; Humans; Immuno | 2014 |
Medication adherence in gout: a systematic review.
Topics: Biomarkers; Gout; Gout Suppressants; Humans; Medication Adherence; Multivariate Analysis; Risk Facto | 2014 |
Clinical manifestations and diagnosis of gout.
Topics: Asymptomatic Diseases; Chronic Disease; Disease Progression; Gout; Humans; Hyperuricemia; Uric Acid | 2014 |
Structural joint damage in gout.
Topics: Bone Remodeling; Cartilage; Gout; Gout Suppressants; Humans; Hyperuricemia; Joints; Osteoblasts; Ost | 2014 |
The genetic basis of gout.
Topics: Gene-Environment Interaction; Genome-Wide Association Study; Glycolysis; Gout; Humans; Hyperuricemia | 2014 |
Prophylaxis for acute gout flares after initiation of urate-lowering therapy.
Topics: Acute Disease; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2014 |
A review of phytotherapy of gout: perspective of new pharmacological treatments.
Topics: Animals; Anti-Inflammatory Agents; Gout; Humans; Hyperuricemia; Phytotherapy; Plants, Medicinal; Uri | 2014 |
The emerging role of biotechnological drugs in the treatment of gout.
Topics: Biotechnology; Cytokines; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Recombinant Protein | 2014 |
Is it time to revise the normal range of serum uric acid levels?
Topics: Age Factors; Biomarkers; Female; Gout; Healthy Volunteers; Humans; Hyperuricemia; Male; Predictive V | 2014 |
Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Colchicine; Gout; Gout Suppressants; Humans; Hype | 2014 |
Imaging modalities for the classification of gout: systematic literature review and meta-analysis.
Topics: Gout; Humans; Magnetic Resonance Imaging; Tomography, X-Ray Computed; Ultrasonography; Uric Acid | 2015 |
Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.
Topics: Allopurinol; Biomarkers; Dose-Response Relationship, Drug; Gout; Gout Suppressants; Humans; Patient | 2014 |
Diagnostic value of clinical, laboratory, and imaging findings in patients with a clinical suspicion of gout: a systematic literature review.
Topics: Arthritis; Colchicine; Diagnostic Imaging; Gout; Gout Suppressants; Humans; Radiography; Sensitivity | 2014 |
Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews.
Topics: Gout; Humans; Treatment Outcome; Uric Acid; Uricosuric Agents | 2014 |
Treatment target and followup measures for patients with gout: a systematic literature review.
Topics: Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2014 |
Twenty-eight loci that influence serum urate levels: analysis of association with gout.
Topics: AMP-Activated Protein Kinases; Basic-Leucine Zipper Transcription Factors; Carrier Proteins; Case-Co | 2016 |
Management of gout in general practice--a systematic review.
Topics: Disease Management; General Practice; Gout; Gout Suppressants; Humans; Life Style; Uric Acid | 2015 |
Urate-lowering therapy: current options and future prospects for elderly patients with gout.
Topics: Aged; Gout; Gout Suppressants; Humans; Uric Acid | 2014 |
Allopurinol for chronic gout.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans | 2014 |
Interventions for tophi in gout.
Topics: Gout; Humans; Polyethylene Glycols; Randomized Controlled Trials as Topic; Urate Oxidase; Uric Acid | 2014 |
[Gout and cardiovascular risk].
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2014 |
Uricosuric medications for chronic gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Chronic Disease; Controlled Clinical Trials as Topic; Femal | 2014 |
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
Topics: Aged; Chronic Disease; Clinical Trials, Phase III as Topic; Cluster Analysis; Dose-Response Relation | 2014 |
Managing gout: there's more we can do.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Age Distribution; Aged; Allopurinol; Anti-Inflammator | 2014 |
Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
Topics: Allopurinol; Biomarkers; Down-Regulation; Gout; Gout Suppressants; Humans; Hyperuricemia; Odds Ratio | 2015 |
A review of uric acid, crystal deposition disease, and gout.
Topics: Early Diagnosis; Early Medical Intervention; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Ac | 2015 |
Advances in pharmacotherapy for the treatment of gout.
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclona | 2015 |
Diagnosis, treatment, and prevention of gout.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Diet Therapy; Disease Management; | 2014 |
Gout nodulosis: report of a rare case and brief review.
Topics: Chronic Disease; Dermis; Foot Diseases; Gout; Humans; Male; Middle Aged; Subcutaneous Tissue; Uric A | 2015 |
Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group.
Topics: Absorptiometry, Photon; Consensus Development Conferences as Topic; Diagnostic Imaging; Female; Gout | 2015 |
Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple".
Topics: Animals; Antioxidants; Cardiovascular Diseases; Cognition; Female; Gout; Humans; Hyperuricemia; Male | 2015 |
The gouty tophus: a review.
Topics: Disease Progression; Gout; Gout Suppressants; Humans; Quality of Life; Treatment Outcome; Uric Acid | 2015 |
Modulation of genetic associations with serum urate levels by body-mass-index in humans.
Topics: Antigens, Nuclear; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Tra | 2015 |
Pharmacogenetic considerations in the treatment of gout.
Topics: Allopurinol; Gout; HLA-B Antigens; Humans; Pharmacogenetics; Treatment Outcome; Uric Acid | 2015 |
[A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Uric Acid | 2014 |
Sugar-sweetened beverages, urate, gout and genetic interaction.
Topics: Beverages; Dietary Sucrose; Gene-Environment Interaction; Gout; Humans; Native Hawaiian or Other Pac | 2014 |
How neutrophil extracellular traps orchestrate the local immune response in gout.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Extracellular Traps; Gout; Humans; Inflam | 2015 |
[Serum uric acid reference values: clinical nonsense as a measure of quality].
Topics: Allopurinol; Gout; Humans; Male; Medication Adherence; Middle Aged; Quality Indicators, Health Care; | 2015 |
Investigational drugs for hyperuricemia.
Topics: Aged; Animals; Drug Design; Drugs, Investigational; Gout; Gout Suppressants; Humans; Hyperuricemia; | 2015 |
The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout.
Topics: Animals; Ascorbic Acid; Coffee; Culture; Diet; Ethanol; Feeding Behavior; Female; Global Health; Gou | 2015 |
Rational pharmacotherapy (RPT) in goutology: Define the serum uric acid target & treat-to-target patient cohort and review on urate lowering therapy (ULT) applying synthetic drugs.
Topics: Gout; Humans; Treatment Outcome; Uric Acid; Uricosuric Agents | 2015 |
ABCG2: the molecular mechanisms of urate secretion and gout.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Gout; Hu | 2015 |
[Gout and and calcium pyrophosphate crystal arthropathies: pathophysiology].
Topics: Acute Disease; Calcium Pyrophosphate; Chondrocalcinosis; Gout; Humans; Uric Acid | 2015 |
Molecular mechanisms of pain in crystal-induced arthritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Calcium Pyrophosphate; Chondrocalc | 2015 |
2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Topics: Arthralgia; Europe; Gout; Humans; Synovial Fluid; United States; Uric Acid | 2015 |
Mechanisms of crystal formation in gout-a structural approach.
Topics: Crystallization; Gout; Humans; Uric Acid | 2015 |
Uric acid lowering therapy in cardiovascular diseases.
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatmen | 2016 |
Association analysis of the beta-3 adrenergic receptor Trp64Arg (rs4994) polymorphism with urate and gout.
Topics: Biomarkers; Case-Control Studies; Gene Frequency; Genetic Association Studies; Genetic Predispositio | 2016 |
Why focus on uric acid?
Topics: Animals; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; Risk Fact | 2015 |
The management of hyperuricemia with urate deposition.
Topics: Diet; Gout; Humans; Hyperuricemia; Obesity; Overweight; Uric Acid | 2015 |
Factors influencing the crystallization of monosodium urate: a systematic literature review.
Topics: Animals; Antibodies; Connective Tissue; Crystallization; Gout; Humans; Hydrogen-Ion Concentration; P | 2015 |
The first metatarsophalangeal joint in gout: a systematic review and meta-analysis.
Topics: Gout; Humans; Metatarsophalangeal Joint; Osteoarthritis; Uric Acid | 2016 |
From juvenile hyperuricaemia to dysfunctional uromodulin: an ongoing metamorphosis.
Topics: Adolescent; Chromosomes, Human, Pair 16; DNA Mutational Analysis; Exons; Gout; Hepatocyte Nuclear Fa | 2016 |
Effects of coffee consumption on serum uric acid: systematic review and meta-analysis.
Topics: Coffee; Female; Gout; Humans; Hyperuricemia; Male; Sex Factors; Uric Acid | 2016 |
[Studies on association between nonalcoholic fatty liver disease and hyperuricemia: current status and future prospects].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Non-alcoholic Fatty | 2016 |
[Uric acid, kidney disease and nephrolithiasis].
Topics: Acid-Base Equilibrium; Gout; Humans; Hyperuricemia; Insulin Resistance; Kidney; Nephrolithiasis; Ren | 2016 |
[Nutritional therapy of gout].
Topics: Alcohol Drinking; Combined Modality Therapy; Diet, Mediterranean; Feeding Behavior; Gout; Humans; Nu | 2016 |
Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2016 |
Review of the ophthalmic manifestations of gout and uric acid crystal deposition.
Topics: Eye Diseases; Gout; Humans; Hyperuricemia; Uric Acid | 2017 |
Dual-Energy Computed Tomography of the Knee, Ankle, and Foot: Noninvasive Diagnosis of Gout and Quantification of Monosodium Urate in Tendons and Ligaments.
Topics: Ankle Joint; Foot; Gout; Humans; Knee Joint; Ligaments, Articular; Radiography, Dual-Energy Scanned | 2016 |
Urate Handling in the Human Body.
Topics: Gout; Humans; Hyperuricemia; Intestinal Mucosa; Kidney; Kidney Tubules; Organic Anion Transporters; | 2016 |
Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia.
Topics: Eye Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid; Uveitis | 2016 |
The management of gout: Much has changed.
Topics: Gout; Gout Suppressants; Humans; Patient Education as Topic; Uric Acid | 2016 |
Gouty Arthritis: A Review of Acute Management and Prevention.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Gout | 2016 |
[HYPERURICEMIA AND POTENTIAL RISK OF CARDIOVASCULAR AND RENAL DISEASES].
Topics: Aged; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male | 2016 |
Review: Gout: A Roadmap to Approaches for Improving Global Outcomes.
Topics: Comorbidity; Disease Management; Global Health; Gout; Gout Suppressants; Humans; Hyperuricemia; Magn | 2017 |
[Inflammasome and gout].
Topics: Antibodies, Monoclonal; Arthritis, Rheumatoid; Cytokines; Evidence-Based Medicine; Gout; Gout Suppre | 2016 |
2016 updated EULAR evidence-based recommendations for the management of gout.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Delphi Technique; Directive Counse | 2017 |
Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review.
Topics: Gout; Humans; Hyperuricemia; Kidney; Kidney Diseases; Uric Acid | 2016 |
Drug-induced hyperuricaemia and gout.
Topics: Androgens; Antitubercular Agents; Aspirin; Carbohydrates; Cytotoxins; Diuretics; Gout; Humans; Hyper | 2017 |
Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?
Topics: Disease Management; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Compliance; Uric Acid | 2016 |
Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Odds Ratio; Probability; Rand | 2016 |
Gout and African Americans: Reducing disparities.
Topics: Black or African American; Gout; Gout Suppressants; Healthcare Disparities; Humans; Medication Thera | 2016 |
Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis.
Topics: Biomarkers; Gout; Humans; Reproducibility of Results; Research Design; Systematic Reviews as Topic; | 2016 |
Xanthine oxidoreductase and its inhibitors: relevance for gout.
Topics: Allopurinol; Animals; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hypoxanthine; | 2016 |
Diagnosis of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline.
Topics: Algorithms; Gout; Humans; Practice Guidelines as Topic; Reference Standards; Sensitivity and Specifi | 2017 |
Dual-Energy CT for the Musculoskeletal System.
Topics: Adult; Aged; Arthrography; Artifacts; Bone Density; Bone Marrow Diseases; Collagen; Edema; Female; G | 2016 |
Update on Crystal-Induced Arthritides.
Topics: Aged; Global Health; Gout; Humans; Morbidity; Prevalence; Uric Acid | 2017 |
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Hu | 2017 |
Allopurinol: insights from studies of dose-response relationships.
Topics: Allopurinol; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressants; Humans; Hyperuricemi | 2017 |
Imaging of gout: New tools and biomarkers?
Topics: Biomarkers; Gout; Humans; Uric Acid | 2016 |
Factors modulating the inflammatory response in acute gouty arthritis.
Topics: Arthritis, Gouty; Autophagy; Gastrointestinal Microbiome; Gout; Humans; Hyperuricemia; Inflammasomes | 2017 |
Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
Topics: Chronic Disease; Comorbidity; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Compliance; Pr | 2017 |
The safety of treatment options available for gout.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents; Chronic Disease; Comorbidity; Gout; Gout Suppressants | 2017 |
Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review.
Topics: Gout; Humans; Incidence; Recurrence; Risk; Uric Acid | 2017 |
Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics.
Topics: Aged; Arthritis; Calcium; Calcium Pyrophosphate; Chondrocalcinosis; Diagnosis, Differential; Gout; H | 2018 |
Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 1: Epidemiology and pathophysiology.
Topics: Aged; Aged, 80 and over; Calcium; Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Crys | 2018 |
Is tea consumption associated with the serum uric acid level, hyperuricemia or the risk of gout? A systematic review and meta-analysis.
Topics: Gout; Humans; Hyperuricemia; Observational Studies as Topic; Tea; Uric Acid | 2017 |
Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.
Topics: Aged; Arthritis; Calcium; Calcium Pyrophosphate; Gout; Gout Suppressants; Humans; Uric Acid | 2018 |
SLC2A9--a fructose transporter identified as a novel uric acid transporter.
Topics: Animals; Female; Fructose; Glucose Transport Proteins, Facilitative; Gout; Homeostasis; Humans; Hype | 2008 |
Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society?
Topics: Animals; Antioxidants; Ascorbic Acid; Blood Pressure; Evolution, Molecular; Fasting; Fructose; Gout; | 2009 |
Febuxostat.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Molecular Structur | 2008 |
The pathogenesis of gout.
Topics: Gout; Humans; Prognosis; Risk Factors; Synovial Membrane; Uric Acid | 2008 |
Clinical manifestations of hyperuricemia and gout.
Topics: Diagnosis, Differential; Gout; Humans; Hyperuricemia; Uric Acid | 2008 |
The gout diagnosis.
Topics: Biomarkers; Diagnosis, Differential; Gout; Humans; Physical Examination; Uric Acid | 2008 |
Gout: an evidence-based review.
Topics: Anti-Inflammatory Agents; Evidence-Based Medicine; Gout; Gout Suppressants; Humans; Uric Acid | 2008 |
Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.
Topics: Bone Resorption; Crystallization; Glucose Transport Proteins, Facilitative; Gout; Gout Suppressants; | 2009 |
Quality of life and quality of care for patients with gout.
Topics: Allopurinol; Delivery of Health Care; Disability Evaluation; Female; Gout; Gout Suppressants; Health | 2009 |
Reassessing serum urate targets in the management of refractory gout: can you go too low?
Topics: Crystallization; Gout; Gout Suppressants; Humans; Oxidative Stress; Uric Acid | 2009 |
Update on emerging urate-lowering therapies.
Topics: Allopurinol; Drug Discovery; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Polyeth | 2009 |
Joint aspiration and injection and synovial fluid analysis.
Topics: Adrenal Cortex Hormones; Calcium Pyrophosphate; Crystallization; Gout; Humans; Injections, Intra-Art | 2009 |
New insights into the epidemiology of gout.
Topics: Acute Disease; Diagnosis, Differential; Gout; Humans; Risk Factors; Uric Acid | 2009 |
Gout--what are the treatment options?
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anti-Inflammatory Agents, Non-Steroidal; Colch | 2009 |
Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations.
Topics: Female; Genetic Variation; Genome-Wide Association Study; Gout; Humans; Male; Uric Acid | 2009 |
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Uric Acid | 2009 |
Recent insights into the pathogenesis of hyperuricaemia and gout.
Topics: Animals; Genetic Predisposition to Disease; Genome-Wide Association Study; Gout; Humans; Hyperuricem | 2009 |
Crystal-induced neutrophil activation.
Topics: Animals; Crystallization; Gout; Humans; Neutrophil Activation; Signal Transduction; Uric Acid | 2010 |
Medical implications of hyperuricemia.
Topics: Animals; Cardiovascular Diseases; Gout; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabo | 2009 |
Gout in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnostic Errors; Female; Gout; Gout Suppressants; Humans; | 2009 |
Unusual clinical presentations of gout.
Topics: Aged; Diagnosis, Differential; Gout; Humans; Uric Acid | 2010 |
[Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers].
Topics: Anaerobiosis; Calcium Channel Blockers; Cardiovascular Diseases; Depression, Chemical; Gout; Humans; | 2010 |
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Topics: Allopurinol; Biotransformation; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibito | 2009 |
Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout.
Topics: Atherosclerosis; Gout; Humans; Hyperuricemia; Inflammasomes; Lipid Metabolism; Lipids; Oxidative Str | 2010 |
Diagnosing and treating gout: a review to aid primary care physicians.
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Gou | 2010 |
Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?
Topics: Animals; Antioxidants; Cardiovascular Diseases; Cells, Cultured; Clinical Trials as Topic; Comorbidi | 2010 |
Update on biology: uric acid and the activation of immune and inflammatory cells.
Topics: Acute Disease; Crystallization; Gout; Humans; Immune System; Immunity, Innate; Inflammation; Inflamm | 2010 |
The role of uric acid and other crystals in osteoarthritis.
Topics: Calcium Pyrophosphate; Crystallization; Gout; Humans; Joints; Osteoarthritis; Uric Acid | 2010 |
Gout, hyperuricemia, and Parkinson's disease: a protective effect?
Topics: Aged; Biomarkers; Clinical Trials as Topic; Comorbidity; Female; Gout; Humans; Hyperuricemia; Male; | 2010 |
Mechanisms of inflammation in gout.
Topics: Acute Disease; Animals; Carrier Proteins; Chemotaxis, Leukocyte; Crystallization; Disease Models, An | 2010 |
An update on inflammatory arthropathies including pharmacologic management and preoperative considerations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Diagnosis, Differential; Foot Diseases; Foot Joi | 2010 |
Recent developments in immune activation by uric acid crystals.
Topics: Animals; Crystallization; Gout; Humans; Immunity, Innate; Uric Acid | 2010 |
Uric acid transport and disease.
Topics: Animals; Biological Transport; Glucose Transport Proteins, Facilitative; Gout; Humans; Hypertension; | 2010 |
What do I need to know about gout?
Topics: Clinical Competence; Female; Gout; Gout Suppressants; Humans; Male; Morbidity; Physicians, Family; R | 2010 |
Management of gout: beyond allopurinol.
Topics: Allopurinol; Animals; Biomarkers; Disease Management; Gout; Humans; Uric Acid | 2010 |
Polyarticular gout attacks following cerebrovascular accidents: is hemiparesis in fact protective? 2 cases and a review of the literature.
Topics: Central Nervous System; Gout; Humans; Male; Middle Aged; Paresis; Rheumatic Diseases; Stroke; Thromb | 2010 |
Gout therapeutics: new drugs for an old disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Drug Administra | 2011 |
Gout: epitome of painful arthritis.
Topics: Arthritis; Female; Gout; Humans; Hyperuricemia; Immunity, Innate; Male; Pain; Uric Acid | 2010 |
Gout: a clinical syndrome illustrated and discussed.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2010 |
Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors.
Topics: Cardiovascular Diseases; Coronary Disease; Female; Genetic Loci; Genome-Wide Association Study; Gout | 2010 |
Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis.
Topics: Biomarkers; Gout; Humans; Oxidative Stress; Parkinson Disease; Prognosis; Risk Factors; Urate Oxidas | 2010 |
Crystal arthropathies: recognizing and treating "the gouch".
Topics: Allopurinol; Antimetabolites; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Huma | 2010 |
Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers.
Topics: Biomarkers; Chronic Disease; Endpoint Determination; Female; Gout; Humans; Male; Predictive Value of | 2011 |
In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding | 2011 |
[Molecular mechanism of renal urate transport: urate transporters as novel targets for drug development].
Topics: Animals; Biological Transport; Drug Design; Gout; Humans; Hyperuricemia; Kidney; Kidney Glomerulus; | 2010 |
Gout and hyperuricemia in young people.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Gout; Humans; Hyperuricemia; Middle Aged; U | 2011 |
The role of uric acid as an endogenous danger signal in immunity and inflammation.
Topics: Adjuvants, Immunologic; Animals; Autoimmunity; Carrier Proteins; Crystallization; Disease Models, An | 2011 |
Synovial fluid analysis for crystals.
Topics: Calcium Pyrophosphate; Chondrocalcinosis; Gout; Humans; Synovial Fluid; Uric Acid | 2011 |
Clinical practice. Gout.
Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Gout; Gout Suppressants; Humans; Hyperuricemia; M | 2011 |
Pegloticase (krystexxa) for treatment of refractory gout.
Topics: Animals; Clinical Trials as Topic; Enzymes, Immobilized; Gout; Humans; Polyethylene Glycols; Treatme | 2011 |
A new perspective on the pharmacoeconomics of colchicine.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Chronic Disease; Colchicine; Costs and Cos | 2011 |
[Treatment of gout].
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxosta | 2011 |
Uric acid metabolism in normal man and in primary gout.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Inosine Monophosphate; Male; Quaternary Ammonium Comp | 1965 |
[Febuxostat].
Topics: Allopurinol; Enzyme Activation; Febuxostat; Gout; Gout Suppressants; Humans; Randomized Controlled T | 2011 |
A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Primary Health Care; Thiazoles; Treatmen | 2011 |
Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele.
Topics: Adult; Aged; Animals; Black or African American; CHO Cells; Cricetinae; Female; Genetic Loci; Geneti | 2011 |
The challenges of gout management in the elderly.
Topics: Aged; Aging; Gout; Humans; Uric Acid | 2011 |
[Gout - regardless of therapeutic options a "forgotten" disease].
Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Cytokines; Europe; Febuxost | 2011 |
Soyfoods, hyperuricemia and gout: a review of the epidemiologic and clinical data.
Topics: Asia; Attitude of Health Personnel; Diet; Gout; Humans; Hyperuricemia; Prevalence; Risk Factors; Soy | 2011 |
Is there anything good in uric acid?
Topics: Age Factors; Brain Diseases; Cardiovascular Diseases; Female; Gout; Humans; Hypertension; Hyperurice | 2011 |
Clinical inquiry. Are serum uric acid levels always elevated in acute gout?
Topics: Acute Disease; Allopurinol; Arthritis, Gouty; Biomarkers; Gout; Gout Suppressants; Humans; Hyperuric | 2011 |
The epidemiology of uric acid and fructose.
Topics: Adult; Aged; Aged, 80 and over; Beverages; Diabetes Mellitus; Female; Fructose; Gout; Humans; Hyperu | 2011 |
Hyperuricemia, gout and the kidney.
Topics: Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; Uric Acid | 2012 |
Recent advances in management of gout.
Topics: Adrenal Cortex Hormones; Alcohol Drinking; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2012 |
Uric acid, hyperuricemia and vascular diseases.
Topics: Coronary Disease; Gout; Humans; Hypertension; Hyperuricemia; Inflammasomes; Inflammation; Metabolic | 2012 |
Diagnosis and treatment of gout in primary care.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Gout; Gout Suppressants; Humans; Primary Healt | 2011 |
Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis).
Topics: Arthritis, Gouty; Biomarkers; Chondrocalcinosis; Crystallization; Gout; History, 19th Century; Histo | 2012 |
Metabolism of crystals within the joint.
Topics: Arthritis, Gouty; Biomarkers; Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Chondroc | 2012 |
The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis).
Topics: Apoptosis; Arthritis, Gouty; Biomarkers; Calcium Phosphates; Carrier Proteins; Chondrocalcinosis; En | 2012 |
Clinical features of gout.
Topics: Acute Disease; Arthritis, Gouty; Biomarkers; Chronic Disease; Crystallization; Diagnosis, Differenti | 2012 |
Cardiovascular and renal effects of hyperuricaemia and gout.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Complications; Disease Progression; Evidence-Based Med | 2012 |
[Urate exporter gene ABCG 2/BCRP and gout risk].
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Gout; Hy | 2011 |
Regulation of uric acid excretion by the kidney.
Topics: Gout; Humans; Hyperuricemia; Kidney; Organic Anion Transporters; Organic Cation Transport Proteins; | 2012 |
Gout measures: Gout Assessment Questionnaire (GAQ, GAQ2.0), and physical measurement of tophi.
Topics: Gout; Humans; Physical Examination; Reproducibility of Results; Severity of Illness Index; Surveys a | 2011 |
Pathway analysis of genome-wide association studies on uric acid concentrations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Genome-Wide Association Study; Gout; Humans; Male; Metab | 2012 |
[Renal affection in gout].
Topics: Creatinine; Gout; Humans; Hyperuricemia; Insulin Resistance; Kidney Diseases; Kidney Glomerulus; Pro | 2012 |
[Gout: an overview of available urate lowering therapies].
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Guidelines as Topic; Humans; Or | 2012 |
Pegloticase for treating refractory chronic gout.
Topics: Animals; Biomarkers; Chronic Disease; Drug Interactions; Evidence-Based Medicine; Gout; Gout Suppres | 2012 |
Gout: why is this curable disease so seldom cured?
Topics: Attitude to Health; Chronic Disease; Disease Management; Drug Utilization; Gout; Humans; Life Style; | 2012 |
Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets.
Topics: Animals; Gout; Hereditary Autoinflammatory Diseases; Humans; Hyperuricemia; Uric Acid | 2012 |
The unwelcome visitor.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colchicine | 2012 |
Uric acid as a danger signal in gout and its comorbidities.
Topics: Biomarkers; Cardiovascular Diseases; Comorbidity; Crystallization; Diabetes Mellitus; Gout; Humans; | 2013 |
The genetics of hyperuricaemia and gout.
Topics: Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transport | 2012 |
Hyperuricaemia: more than just a cause of gout?
Topics: Animals; Biomarkers; Cardiovascular Diseases; Female; Gout; Humans; Hyperuricemia; Inflammation; Kid | 2013 |
Renal transport of uric acid: evolving concepts and uncertainties.
Topics: Biological Transport; Glucose Transport Proteins, Facilitative; Gout; Humans; Hyperuricemia; Kidney; | 2012 |
A perspective on diet and gout.
Topics: Diet; Fructose; Gout; Humans; Hyperuricemia; Purines; Risk Factors; Uric Acid | 2012 |
Genetic disorders resulting in hyper- or hypouricemia.
Topics: Gout; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Renal Tubular Transport, Inborn Errors; U | 2012 |
The rheumatology of gout.
Topics: Gout; Gout Suppressants; Humans; Kidney Failure, Chronic; Uric Acid | 2012 |
Uric acid stones and hyperuricosuria.
Topics: Enzyme Inhibitors; Gout; Humans; Hydrogen-Ion Concentration; Risk Factors; Uric Acid; Urolithiasis; | 2012 |
Advanced kidney failure and hyperuricemia.
Topics: Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; Renal Dialysis; Uric Acid | 2012 |
Evaluation and treatment of gout as a chronic disease.
Topics: Arthritis, Gouty; Chronic Disease; Disease Progression; Evaluation Studies as Topic; Febuxostat; Fem | 2012 |
Safety of urate-lowering therapies: managing the risks to gain the benefits.
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; | 2012 |
The accuracy of methods for urate crystal detection in synovial fluid and the effect of sample handling: a systematic review.
Topics: Chemistry, Clinical; Crystallization; Gout; Humans; Reproducibility of Results; Specimen Handling; S | 2013 |
Update on gout 2012.
Topics: Disease Management; Gout; Gout Suppressants; Humans; Hyperuricemia; Tomography, X-Ray Computed; Ultr | 2012 |
Chronic hyperuricemia, uric acid deposit and cardiovascular risk.
Topics: Cardiovascular Diseases; Chronic Disease; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2013 |
Novel drug discovery strategies for gout.
Topics: Drug Discovery; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Uric Acid; Uricosuric Agents; | 2013 |
The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions.
Topics: Animals; Diet; Gout; Humans; Hyperuricemia; Organic Anion Transporters; Risk Factors; Uric Acid | 2012 |
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations.
Topics: Analysis of Variance; Gene Frequency; Genetic Loci; Genome-Wide Association Study; Glucose; Gout; Hu | 2013 |
Dual-energy computed tomography for gout diagnosis and management.
Topics: Arthritis, Gouty; Drug Monitoring; Gout; Gout Suppressants; Humans; Tomography, X-Ray Computed; Uric | 2013 |
The kidney in hyperuricemia and gout.
Topics: Animals; Gout; Homeostasis; Humans; Hyperuricemia; Kidney; Kidney Diseases; Prognosis; Uric Acid | 2013 |
Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trial | 2013 |
Neutrophils, IL-1β, and gout: is there a link?
Topics: Animals; Apoptosis; Gout; Humans; Interleukin-1beta; Intracellular Space; Neutrophil Activation; Neu | 2013 |
The management of hyperuricemia and gout in patients with heart failure.
Topics: Cardiovascular Agents; Comorbidity; Gout; Gout Suppressants; Heart Failure; Humans; Risk Factors; Ur | 2002 |
Asymptomatic hyperuricemia: to treat or not to treat.
Topics: Age Factors; Allopurinol; Cardiovascular Diseases; Clinical Trials as Topic; Gout; Gout Suppressants | 2002 |
Uric acid nephrolithiasis: current concepts and controversies.
Topics: Cross-Sectional Studies; Gout; Humans; Hydrogen-Ion Concentration; Incidence; Kidney Calculi; Potass | 2002 |
Hyperuricosuric calcium nephrolithiasis.
Topics: Allopurinol; Calcium Oxalate; Citrates; Female; Gout; Gout Suppressants; Humans; Kidney Calculi; Lit | 2002 |
[Mode of existence and dynamics of uric acid in blood].
Topics: Animals; Gout; Humans; Hyperuricemia; Uric Acid | 2003 |
[Influence of sex and age on serum uric acid level].
Topics: Age Factors; Estrogens; Female; Gout; Humans; Hyperuricemia; Male; Sex Factors; Uric Acid | 2003 |
[Effect of foods on serum uric acid level].
Topics: Diet; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Drinking; Food; Food Analysis; Gout; Hu | 2003 |
[Effect of ethanol on uric acid level].
Topics: Acetaldehyde; Animals; Erythrocytes; Ethanol; Gout; Humans; Hyperuricemia; Purines; Pyrazinamide; Ur | 2003 |
[Definition and determination of serum uric acid level].
Topics: Biomarkers; Blood Chemical Analysis; Gout; Humans; Hyperuricemia; Practice Guidelines as Topic; Refe | 2003 |
[Exercise therapy for hyperuricemia].
Topics: Anaerobic Threshold; Exercise; Exercise Therapy; Gout; Humans; Hyperuricemia; Purine Nucleotides; Ur | 2003 |
[Diet therapy for management of hyperuricemia and gout].
Topics: Adult; Alcoholic Beverages; Diet, Reducing; Gout; Humans; Hyperuricemia; Male; Obesity; Purines; Tem | 2003 |
[Tophaceous gout].
Topics: Bone and Bones; Diagnosis, Differential; Gout; Humans; Joints; Macrophages; Magnetic Resonance Imagi | 2003 |
[Gouty kidney].
Topics: Animals; Diet; Gout; Humans; Hyperuricemia; Kidney Diseases; Sodium Bicarbonate; Tartrates; Uric Aci | 2003 |
[Sleep apnea syndrome].
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Life Style; Sleep Apnea Syndromes; Uric Acid | 2003 |
[Idiopathic retroperitoneal fibrosis and hyperuricemia].
Topics: Gout; Humans; Hyperuricemia; Male; Middle Aged; Prednisolone; Receptors, Interleukin-2; Retroperiton | 2003 |
[Blood antioxidant capacity in gout].
Topics: Allopurinol; Animals; Antioxidants; Arteriosclerosis; Enzyme Inhibitors; Free Radical Scavengers; Go | 2003 |
[Interleukin 6 deduces serum urate concentration].
Topics: Clinical Trials as Topic; Gout; Humans; Inflammation Mediators; Interleukin-6; Recombinant Proteins; | 2003 |
[DISEASES OF THE METABOLISM OF PURINES AND PYRIMIDINES].
Topics: Gout; Humans; Metabolic Diseases; Orotic Acid; Purines; Pyrimidines; Uric Acid; Urine; Xanthines | 1963 |
ACUTE GOUT--UNSOLVED.
Topics: Arthritis; Colchicine; Gout; Humans; Uric Acid; Uricosuric Agents | 1963 |
[HYPERURICEMIA AND ATHEROSCLEROSIS].
Topics: Arteriosclerosis; Atherosclerosis; Blood; Cerebrovascular Disorders; Coronary Disease; Gout; Humans; | 1964 |
[THE GOUTY KIDNEY--PATHOGENESIS OF HYPERURICEMIA AND PATHOGENIC ROLE OF THE KIDNEY].
Topics: Blood; Gout; Humans; Hyperuricemia; Kidney; Kidney Diseases; Uric Acid | 1963 |
RECENT ADVANCES IN STUDY OF URIC ACID METABOLISM AND GOUT.
Topics: Gout; Humans; Metabolism; Uric Acid | 1965 |
Advanced imaging of gout.
Topics: Gout; Humans; Magnetic Resonance Imaging; Tomography, X-Ray Computed; Uric Acid | 2003 |
Hyperuricaemia and gout: clinical guideline 2003.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Child; Colchicine; Female; Gout; Gout Suppress | 2003 |
Gout.
Topics: Crystallization; Feeding Behavior; Gout; Gout Suppressants; Humans; Joints; Uric Acid | 2004 |
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Topics: Allopurinol; Amlodipine; Clinical Trials as Topic; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hype | 2004 |
[Gout].
Topics: Arthritis, Infectious; Comorbidity; Diagnosis, Differential; Gout; Gout Suppressants; Humans; Progno | 2004 |
[Uratic gout].
Topics: Arthritis, Gouty; Diet; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2004 |
Gout: on the brink of novel therapeutic options for an ancient disease.
Topics: Acute Disease; Benzothiadiazines; Diuretics; Female; Gout; Humans; Hypertension; Hyperuricemia; Kidn | 2004 |
Gouty flexor tenosynovitis mimicking infection: a case report emphasising the value of ultrasound in diagnosis.
Topics: Adult; Colchicine; Female; Fingers; Follow-Up Studies; Gout; Humans; Pain Measurement; Risk Assessme | 2004 |
[Physiology and biochemistry of uric acid].
Topics: Animals; Birds; Carrier Proteins; Glomerular Filtration Rate; Gout; Humans; Kidney Calculi; Organic | 2004 |
[Uric acid and diabetes mellitus].
Topics: Diabetes Mellitus; Diabetic Nephropathies; Gout; Humans; Uric Acid | 2004 |
Recent advances in the management of gout and hyperuricemia.
Topics: Gout; Humans; Hyperuricemia; Treatment Outcome; Uric Acid; Uricosuric Agents | 2005 |
[Hyperuricemia/gout. Main symptoms of arthropathy. Severe acute joint pain, redness, inflammation].
Topics: Allopurinol; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diagnosis, Dif | 2005 |
Gout: excess calories, purines, and alcohol intake and beyond. Response to a urate-lowering diet.
Topics: Alcohol Drinking; Dietary Proteins; Energy Intake; Gout; Humans; Purines; Uric Acid | 2005 |
Iatrogenic rheumatic syndromes in the elderly.
Topics: Aged; Arthralgia; Colchicine; Connective Tissue Diseases; Gout; Gout Suppressants; Humans; Hydroxyme | 2005 |
Renal urate handling: clinical relevance of recent advances.
Topics: Animals; Biological Transport; Carrier Proteins; Gout; Humans; Hyperuricemia; Kidney Tubules; Mutati | 2005 |
Diagnosis and management of gout: a rational approach.
Topics: Acute Disease; Chronic Disease; Crystallization; Diagnosis, Differential; Gout; Humans; Hyperuricemi | 2005 |
Pathogenesis of gout.
Topics: Cardiovascular Diseases; Crystallization; Diet; Gout; Humans; Hyperuricemia; Inflammation; Insulin R | 2005 |
An update on the treatment options for gout and calcium pyrophosphate deposition.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Allopurinol; Animals; Anti-Inflammatory Agents | 2005 |
Understanding treatments for gout.
Topics: Acute Disease; Adrenal Cortex Hormones; Behavior Therapy; Chronic Disease; Colchicine; Female; Gout; | 2005 |
Diagnosis of gout: clinical, laboratory, and radiologic findings.
Topics: Acute Disease; Adult; Age Factors; Aged; Arthrography; Chondrocalcinosis; Diagnosis, Differential; F | 2005 |
Overview of hyperuricaemia and gout.
Topics: Antioxidants; Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Prevalence; Uric Acid | 2005 |
Current trends in crystal identification.
Topics: Calcinosis; Calcium Phosphates; Diagnostic Errors; False Positive Reactions; Gout; Humans; Joints; O | 2006 |
Recent developments in diet and gout.
Topics: Beer; Feeding Behavior; Female; Food, Formulated; Gout; Humans; Insulin Resistance; Male; Metabolic | 2006 |
New insights into gout epidemiology.
Topics: Cardiovascular Diseases; Comorbidity; Feeding Behavior; Female; Gout; Humans; Male; Prevalence; Risk | 2006 |
[Hyperuricemic nephropathy: Pathogenesis, pathophysiology, and therapy].
Topics: DNA-Binding Proteins; Gout; Hepatocyte Nuclear Factor 1-beta; Humans; Hyperuricemia; Kidney Diseases | 2006 |
Genetic factors associated with gout and hyperuricemia.
Topics: Blood Group Antigens; Genetic Markers; Genetic Predisposition to Disease; Gout; Humans; Hyperuricemi | 2006 |
EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Topics: Advisory Committees; Biomedical Research; Comorbidity; Delphi Technique; Evidence-Based Medicine; Go | 2006 |
Gout: update on some pathogenic and clinical aspects.
Topics: Crystallization; Gout; Humans; Inflammation; Joints; Magnetic Resonance Imaging; Uric Acid | 2006 |
Renal urate transport.
Topics: Animals; Biological Transport, Active; Carrier Proteins; Gout; Humans; Kidney Tubules, Proximal; Org | 2006 |
A concise history of gout and hyperuricemia and their treatment.
Topics: Arthritis, Gouty; Gout; History, 19th Century; History, Ancient; Humans; Hyperuricemia; Politics; Un | 2006 |
The inflammatory process of gout and its treatment.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Clinical Trials | 2006 |
Uric acid and the immune response.
Topics: Gout; Humans; Immunity, Active; Immunity, Innate; Uric Acid | 2006 |
[Is hyperuricemia a cardiovascular risk factor?].
Topics: Cardiovascular Diseases; Comorbidity; Female; Gout; Humans; Hyperuricemia; Obesity; Risk Factors; Se | 2006 |
Gout in 2006: the perfect storm.
Topics: Global Health; Gout; Gout Suppressants; Humans; Morbidity; Prognosis; Uric Acid | 2006 |
Pathogenesis, clinical findings and management of acute and chronic gout.
Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Co | 2006 |
Therapeutic advances in gout.
Topics: Allopurinol; Feeding Behavior; Gout; Humans; Metabolic Syndrome; Risk Reduction Behavior; Uric Acid; | 2007 |
Recent advances in crystal-induced acute inflammation.
Topics: Acute Disease; Carrier Proteins; Gout; Humans; Immunity, Innate; Inflammation; Interleukin-1beta; Me | 2007 |
Updates in the management of gout.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Ster | 2007 |
Crystal-associated arthritis in the elderly.
Topics: Aged; Allopurinol; Arthritis; Arthritis, Gouty; Calcium Pyrophosphate; Chondrocalcinosis; Comorbidit | 2007 |
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2007 |
Recent developments in crystal-induced inflammation pathogenesis and management.
Topics: Chondrocalcinosis; Evidence-Based Medicine; Gout; Humans; Inflammation; Uric Acid | 2007 |
Uric acid nephrolithiasis.
Topics: Diabetes Complications; Gout; Humans; Nephrolithiasis; Uric Acid; Urine | 2007 |
Uricase and other novel agents for the management of patients with treatment-failure gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Rec | 2007 |
[Crystal-induced arthritis--old but important].
Topics: Anti-Inflammatory Agents; Gout; Gout Suppressants; Humans; Uric Acid | 2007 |
Assessment of outcome in clinical trials of gout--a review of current measures.
Topics: Arthritis, Gouty; Female; Gout; Humans; Male; Pain Measurement; Prognosis; Randomized Controlled Tri | 2007 |
Elderly-onset gout: a review.
Topics: Age Factors; Aged; Aged, 80 and over; Diuretics; Female; Gout; Humans; Immunosuppressive Agents; Inc | 2007 |
Why is gout so poorly managed?
Topics: Arthritis, Rheumatoid; Attitude of Health Personnel; Family Practice; Gout; Humans; Joints; Uric Aci | 2007 |
Altered uric acid levels and disease states.
Topics: Animals; Cardiovascular Diseases; Gout; Humans; Hypertension; Hyperuricemia; Inflammation; Kidney Di | 2008 |
The role of interleukin-1 and the inflammasome in gout: implications for therapy.
Topics: Animals; Arthritis, Gouty; Carrier Proteins; Colchicine; Gout; Gout Suppressants; Humans; Hyperurice | 2007 |
Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?
Topics: Allopurinol; Gout; Humans; Treatment Outcome; Uric Acid | 2007 |
Hyperuricemia and gout: new insights into pathogenesis and treatment.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; G | 2007 |
Update on gout: pathophysiology and potential treatments.
Topics: Animals; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Immu | 2007 |
Gout is a risk factor for cardiovascular disease.
Topics: Acute Disease; Algorithms; Cardiovascular Diseases; Gout; Harm Reduction; Humans; Recurrence; Risk A | 2007 |
Diagnosis of gout.
Topics: Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Synovial Fluid; Uric Acid | 2007 |
We can make gout management more successful now.
Topics: Evidence-Based Medicine; Gout; Humans; Patient Education as Topic; Practice Guidelines as Topic; Ris | 2008 |
Establishing outcome domains for evaluating treatment of acute and chronic gout.
Topics: Acute Disease; Chronic Disease; Clinical Trials as Topic; Endpoint Determination; Gout; Humans; Join | 2008 |
Control of renal uric acid excretion and gout.
Topics: Genetic Predisposition to Disease; Gout; Humans; Hyperuricemia; Kidney Tubules, Proximal; Organic An | 2008 |
Aspiration of normal or asymptomatic pathological joints for diagnosis and research: indications, technique and success rate.
Topics: Arthritis; Biopsy, Needle; Calcium Pyrophosphate; Case-Control Studies; Crystallization; Gout; Human | 2009 |
[Historical review of gout and hyperuricemia investigations].
Topics: Gout; History, 17th Century; History, 18th Century; History, 19th Century; History, 20th Century; Hu | 2008 |
[Physiology and dynamics of uric acid in hyperuricemia].
Topics: Gout; Humans; Hydrogen-Ion Concentration; Hyperuricemia; Solubility; Uric Acid | 2008 |
[Idiopathic hyperuricemia with overproduction of uric acid].
Topics: Antihypertensive Agents; Gout; Humans; Hypertension; Hyperuricemia; Hypoxanthine; Muscle, Skeletal; | 2008 |
[Increased activity of PRPP synthetase].
Topics: Chromosomes, Human, X; Genes, Dominant; Gout; Humans; Point Mutation; Ribose-Phosphate Pyrophosphoki | 2008 |
[Urolithiasis and nephropathy complicated with gout].
Topics: Gout; Humans; Hydrogen-Ion Concentration; Metabolic Syndrome; Renal Insufficiency; Uric Acid; Urolit | 2008 |
[Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; | 2008 |
[Uricosuric agent].
Topics: Allopurinol; Benzbromarone; Gout; Humans; Hyperuricemia; Kidney Tubules, Proximal; Organic Anion Tra | 2008 |
[Other antihyperuricemic agents].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout | 2008 |
Disorders associated with purine and pyrimidine metabolism.
Topics: 5'-Nucleotidase; Adenine Phosphoribosyltransferase; Adenosine Deaminase; AMP Deaminase; Gout; Guanin | 1984 |
[Kidneys in rheumatic diseases].
Topics: Animals; Anti-Inflammatory Agents; Antigen-Antibody Complex; Arteritis; Gout; Humans; Immune Complex | 1983 |
Heberden oration 1979: human aberrations of purine metabolism and their significance for rheumatology.
Topics: Adenosine Deaminase; Adult; Child; Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Imm | 1980 |
[Etiology and risks of hyperuricemia].
Topics: Alcoholism; Diuretics; Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney Calculi; | 1981 |
Human purine metabolism: some recent advances and relationships with immunodeficiency.
Topics: Adenine Phosphoribosyltransferase; Adenosine Deaminase; Glycogen Storage Disease Type I; Gout; Human | 1983 |
Gout and hyperuricemia associated with sickle-cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Arthritis; Female; Gout; Hemolysis; Humans; Male; Middle Age | 1983 |
Gout.
Topics: Acute Disease; Adult; Arthritis; Crystallization; Gout; Humans; Male; Uric Acid | 1983 |
Crystal deposition and inflammation.
Topics: Arthritis; Calcium Oxalate; Calcium Pyrophosphate; Cholesterol; Crystallization; Gout; Humans; Hydro | 1984 |
Urate nephropathy.
Topics: Allopurinol; Arthritis; Aspirin; Blood Urea Nitrogen; Glomerular Filtration Rate; Gout; Humans; Kidn | 1984 |
[Adverse effect of diuretics: hyperuricosuria].
Topics: Diuretics; Gout; Humans; Kidney; Kidney Diseases; Middle Aged; Uric Acid | 1984 |
Molecular mechanisms of gouty arthritis: new insights into an old disease.
Topics: Arthritis; Blood Proteins; Gout; Humans; Inflammation; Neutrophils; Phagocytosis; Protein Binding; U | 1984 |
[Animal model for gout].
Topics: Animals; Chickens; Disease Models, Animal; Female; Gout; Male; Mice; Oxonic Acid; Poultry Diseases; | 1982 |
[Various pathophysiological, clinical and therapeutic problems of disorders of purine metabolism].
Topics: Acute Kidney Injury; Allopurinol; Diuretics; Gout; Humans; Kidney Calculi; Uric Acid | 1982 |
Treatment of the gout and other forms of crystal-induced arthritis.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Benzbromarone; Colchicine; Gout; Go | 1982 |
Long-term management of gout and hyperuricaemia.
Topics: Allopurinol; Female; Gout; Humans; Long-Term Care; Male; Risk; Uric Acid; Uricosuric Agents | 1980 |
Complete destruction of both femoral heads following idiopathic necrosis of the femoral heads in a diabetic patient with hyperuricemia and hyperlipoproteinemia.
Topics: Aged; Angiography; Diabetes Complications; Femur Head Necrosis; Gout; Heel; Hip; Humans; Hyperlipopr | 1980 |
[Benzbromarone in the treatment of gout].
Topics: Benzbromarone; Benzofurans; Biological Availability; Chemical Phenomena; Chemistry; Gout; Half-Life; | 1980 |
[Hyperuricemia, gout and gout-induced nephropathy].
Topics: Allopurinol; Female; Gout; Humans; Kidney Calculi; Male; Nephritis, Interstitial; Purines; Uric Acid | 1980 |
[Current theories on the role of hyperuricemia as one of the risk factors in ischemic heart disease].
Topics: Carbohydrate Metabolism; Coronary Disease; Female; Gout; Humans; Hypercholesterolemia; Hypertension; | 1980 |
Gout and pseudogout: crystal-induced arthropathies.
Topics: Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Diuretics; Ethanol; Glycogen Storage Dise | 1981 |
[Urate nephropathy].
Topics: Allopurinol; Gout; Humans; Kidney Calculi; Kidney Diseases; Nephritis, Interstitial; Purines; Uric A | 1981 |
Hyperuricemia and gout.
Topics: Allopurinol; Arthritis; Aspirin; Colchicine; Diuretics; Gout; Gout Suppressants; Humans; Indomethaci | 1982 |
[Uric acid and arterial hypertension].
Topics: Carbohydrate Metabolism; Cardiovascular Diseases; Endocrine System Diseases; Female; Gout; Humans; H | 1981 |
[Double tunnel syndrome of the upper limb in tophaceous gout. Apropos of a case].
Topics: Aged; Carpal Tunnel Syndrome; Fingers; Gout; Hand; Humans; Male; Median Nerve; Nerve Compression Syn | 1994 |
Gout, uric acid metabolism, and crystal-induced inflammation.
Topics: Aged; Child; Female; Gout; Humans; Infant; Inflammation; Male; Uric Acid | 1995 |
[Obesity and the related diseases: gout].
Topics: Alcohol Drinking; Animals; Female; Gout; Humans; Hyperlipidemias; Male; Obesity; Uric Acid | 1995 |
Prevention and management of gout.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Gout; Gout Suppressants; Humans; Incidence; | 1993 |
Gout or 'pseudogout': how to differentiate crystal-induced arthropathies.
Topics: Adult; Arthritis, Gouty; Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Diagnosis, Di | 1995 |
Urate and calcium oxalate stones: from repute to rhetoric to reality.
Topics: Allopurinol; Calcium Oxalate; Glycosaminoglycans; Gout; Humans; Hydrogen-Ion Concentration; Hyperoxa | 1994 |
ABC of rheumatology. Gout, hyperuricaemia, and crystal arthritis.
Topics: Chondrocalcinosis; Gout; Humans; Kidney Diseases; Risk Factors; Uric Acid | 1995 |
[Gout and hyperuricemia].
Topics: Gout; Humans; Uric Acid | 1994 |
[Hyperuricemia].
Topics: Gout; Humans; Kidney Diseases; Uric Acid; Urinary Calculi | 1994 |
Clinical and biochemical aspects of uric acid overproduction.
Topics: Adenosine Triphosphate; Animals; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Nucleic Acids | 1994 |
Hyperuricemia and gout.
Topics: Arthritis, Gouty; Child; Child, Preschool; Crystallization; Gout; Humans; Inflammation; Kidney Trans | 1994 |
[What remains of gout in 1993?].
Topics: Acute Disease; Adult; Chronic Disease; Female; Gout; Humans; Male; Middle Aged; Radiography; Sex Fac | 1994 |
Optimal management of gout in older patients.
Topics: Aged; Gout; Humans; Uric Acid | 1994 |
Gout and 'pseudogout'. When are arthritic symptoms caused by crystal deposition?
Topics: Calcium Pyrophosphate; Chondrocalcinosis; Diagnosis, Differential; Gout; Humans; Uric Acid | 1994 |
Gout and mechanisms of crystal-induced inflammation.
Topics: Aged; Animals; Arthritis, Gouty; Female; Gout; Humans; Infant; Kidney; Male; Mice; Uric Acid | 1993 |
[Nutrition in gout].
Topics: Alcohol Drinking; Diet, Reducing; Food Analysis; Gout; Humans; Purines; Uric Acid | 1993 |
Gout, uric acid and purine metabolism in paediatric nephrology.
Topics: Adolescent; Animals; Child; Child, Preschool; Gout; Humans; Infant; Infant, Newborn; Kidney Diseases | 1993 |
[Osteo-articular complications of heart transplantation].
Topics: Bone Diseases; Bone Diseases, Metabolic; Gout; Heart Transplantation; Humans; Immunosuppressive Agen | 1995 |
The management of gout.
Topics: Acute Disease; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diet; | 1996 |
[Hyperuricemia].
Topics: Adult; Aged; Combined Modality Therapy; Diagnosis, Differential; Female; Gout; Humans; Male; Middle | 1995 |
[Hyperuricemia].
Topics: Adult; Aged; Arthritis, Gouty; Combined Modality Therapy; Cross-Sectional Studies; Female; Germany; | 1996 |
Rheumatoid arthritis preceding the onset of polyarticular tophaceous gout.
Topics: Arthritis, Rheumatoid; Female; Gout; Humans; Middle Aged; Uric Acid | 1996 |
The importance of uric acid examination.
Topics: Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney; Male; Purine-Pyrimidine Metabo | 1994 |
Uric acid stones.
Topics: Gout; Humans; Uric Acid; Urinary Calculi | 1996 |
Gout nodulosis: widespread subcutaneous deposits without gout.
Topics: Adult; Biopsy, Needle; Gout; Humans; Male; Uric Acid | 1996 |
[Metabolism of purine nucleotides and the production of uric acid].
Topics: Amidophosphoribosyltransferase; Gout; Humans; Purine Nucleotides; Ribose-Phosphate Pyrophosphokinase | 1996 |
[Mammalian phosphoribosylpyrophosphate synthetase].
Topics: Amino Acid Sequence; Animals; Catalysis; Gout; Humans; Molecular Sequence Data; Phosphoribosyl Pyrop | 1996 |
[Dynamics of uric acid metabolism in hyperuricemia].
Topics: Blood Proteins; Gout; Humans; Protein Binding; Uric Acid | 1996 |
[Hyperuricosuria and urolithiasis].
Topics: Calcium Oxalate; Gout; Humans; Uric Acid; Urinary Calculi | 1996 |
[Hyperuricemia and the kidney].
Topics: Acute Kidney Injury; Allopurinol; Gout; Humans; Hydrogen-Ion Concentration; Kidney; Renal Dialysis; | 1996 |
[Gout and atherosclerosis].
Topics: Alcohol Drinking; Coronary Artery Disease; Gout; Humans; Hyperlipidemias; Hypertension; Obesity; Pla | 1996 |
[PRPP synthetase superactivity].
Topics: Gout; Humans; Phosphoribosyl Pyrophosphate; Proteins; Purine Nucleotides; Purine-Pyrimidine Metaboli | 1996 |
[Pharmacological agents affecting uric acid metabolism].
Topics: Allopurinol; Diuretics; Fructose; Gout; Gout Suppressants; Humans; Inosine; Kidney Diseases; Niacin; | 1996 |
[Alcohol ingestion and hyperuricemia].
Topics: Adenosine Triphosphate; Alcohol Drinking; Aldehyde Dehydrogenase; Beer; Ethanol; Female; Genotype; G | 1996 |
[Gout and hyperuricemia].
Topics: Gout; Humans; Uric Acid | 1996 |
Gout and other crystal arthropathies.
Topics: Aged; Arthritis, Gouty; Calcium Pyrophosphate; Chronic Disease; Crystallization; Female; Gout; Human | 1997 |
[Uric acid and tubulointerstitial kidney diseases].
Topics: Gout; Humans; Kidney Function Tests; Nephritis, Interstitial; Renal Dialysis; Uric Acid | 1996 |
[Effects of alcohol on urate metabolism].
Topics: Alcohol Drinking; Ethanol; Gout; Humans; Kidney; Lactic Acid; Purine Nucleotides; Uric Acid | 1997 |
[Uric acid clearance].
Topics: Creatinine; Female; Gout; Humans; Male; Uric Acid | 1997 |
Crystal deposition disease.
Topics: Antirheumatic Agents; Azathioprine; Chondrocalcinosis; Colchicine; Cyclosporine; Gout; Gout Suppress | 1997 |
Gout and hyperuricemia.
Topics: Crystallization; Epidemiologic Methods; Forecasting; Gout; Humans; Inflammation; Kidney; Kidney Calc | 1997 |
Uric acid nephropathy and end-stage renal disease--review of a non-disease.
Topics: Gout; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Uric Acid | 1997 |
[Therapy of hyperuricemia and gout].
Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; C | 1997 |
[Gout due to disorder of urate binding proteins (the urate-binding alpha 1-2 globulin deficiency)].
Topics: Alpha-Globulins; Gout; Humans; Protein Binding; Uric Acid | 1998 |
[Familial juvenile gouty nephropathy].
Topics: Adult; Diagnosis, Differential; Family Health; Female; Gout; Humans; Hypertension; Kidney Diseases; | 1998 |
Gout: new questions for an ancient disease.
Topics: Adult; Female; Gout; Humans; Kidney Failure, Chronic; Male; Microvascular Angina; Purine-Pyrimidine | 1998 |
Broadsheet number 43: The role of the laboratory in the investigation and management of hyperuricemia.
Topics: Clinical Laboratory Techniques; Gout; Humans; Uric Acid | 1998 |
Kelley-Seegmiller syndrome: a case report and review of the literature.
Topics: Adult; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney Diseases; Male; Syndrome; Uric A | 1998 |
Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease.
Topics: Cardiovascular Diseases; Gout; Humans; Hypertension; Kidney Diseases; Risk Factors; Uric Acid | 1999 |
Gout and hyperuricemia.
Topics: Acute Disease; Algorithms; Female; Gout; Humans; Male; Sex Distribution; United States; Uric Acid | 1999 |
Diagnosis and management of gout.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Gout; Gout Suppressants; Humans; P | 1999 |
[Physiopathology and treatment of gout and hyperuricemia].
Topics: Adult; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Uric Acid | 1999 |
Regulation of oxidant production in acute lung injury.
Topics: Animals; Gout; Humans; Lung; NADPH Oxidases; Reactive Oxygen Species; Respiratory Distress Syndrome; | 1999 |
Gout.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Gout Suppressants; Humans; U | 1998 |
How well have diagnostic tests and therapies for gout been evaluated?
Topics: Gout; Humans; Uric Acid | 1999 |
Finger pad tophi.
Topics: Cyclosporine; Fingers; Follow-Up Studies; Gout; Gout Suppressants; Humans; Immunosuppressive Agents; | 1999 |
[Treatment of gout].
Topics: Acute Disease; Arthritis, Gouty; Gout; Humans; Uric Acid | 1999 |
[Insulin sensitizer and urate metabolism].
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Glucose; Gout; Humans; Hyperlipidemias; Hypertension; H | 2000 |
Renal transplant-associated hyperuricemia and gout.
Topics: Cyclosporine; Drug Interactions; Gout; Humans; Immunosuppressive Agents; Kidney Transplantation; Ris | 2000 |
Controlling hyperuricaemia in general practice.
Topics: Arthritis; Causality; Family Practice; Female; Gout; Humans; Male; Uric Acid | 1999 |
[Gout crisis].
Topics: Adult; Aged; Diagnosis, Differential; Gout; Humans; Male; Middle Aged; Nephritis, Interstitial; Uric | 2000 |
Gout update: from lab to the clinic and back.
Topics: Crystallization; Gout; Gout Suppressants; Humans; Organ Transplantation; Synovitis; Uric Acid | 2000 |
What is new about crystals other than monosodium urate?
Topics: Acute Disease; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Durapatite; Gout; Humans; | 2000 |
Clinical manifestations of gout and their management.
Topics: Adult; Aged; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Uric Acid | 2000 |
[Synovial fluid analysis in gout].
Topics: Arthritis, Gouty; Gout; Humans; Synovial Fluid; Uric Acid | 1998 |
Gout and other crystal-associated arthropathies.
Topics: Calcium; Calcium Phosphates; Calcium Pyrophosphate; Crystallization; Gout; Humans; Joint Diseases; U | 2000 |
The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases.
Topics: Amino Acid Substitution; Cells, Cultured; Codon; DNA Mutational Analysis; DNA, Complementary; Exons; | 2000 |
[Hyperuricemia in hypertension].
Topics: Adolescent; Child; Female; Gout; Humans; Hypertension; Male; Uric Acid | 2000 |
[Treatment of gout].
Topics: Acute Disease; Anti-Inflammatory Agents; Chronic Disease; Gout; Gout Suppressants; Humans; Patient S | 2000 |
Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient.
Topics: Allopurinol; Drug Hypersensitivity; Gout; Gout Suppressants; Humans; Kidney; Transplantation, Homolo | 2001 |
Pathogenesis of crystal-induced inflammation.
Topics: Arthritis; Crystallization; Gout; Humans; Macrophages; Monocytes; Neutrophils; Synovial Fluid; Uric | 2001 |
Gout: diagnosis, pathogenesis, and clinical manifestations.
Topics: Arthritis, Gouty; Gout; Humans; Joints; Risk Factors; Uric Acid | 2001 |
Gout: can management be improved?
Topics: Acute Disease; Causality; Cyclosporine; Gout; Gout Suppressants; Humans; Immunosuppressive Agents; U | 2001 |
[Hyperlipidemia in patients with hyperuricemia].
Topics: Diagnosis, Differential; Diet, Fat-Restricted; Dietary Fiber; Exercise Therapy; Gout; Humans; Hydrox | 2001 |
[Gout].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Glucocorticoids; Gout; Gout Suppressants; Humans; Incidence | 2000 |
When, why, and how should we quantify the excretion rate of urinary uric acid?
Topics: Chemistry, Clinical; Gout; Humans; Uric Acid | 2001 |
Dynamic videomicroscopy evaluation of synovial fluid in gout.
Topics: Crystallization; Gout; Humans; Microscopy, Video; Synovial Fluid; Uric Acid | 2001 |
Medullary cystic kidney disease: past and present.
Topics: Gout; Humans; Kidney Diseases, Cystic; Kidney Medulla; Uric Acid | 2001 |
Gout. A painful joint disorder.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Gout; Humans; Purines; Sex Factors; Uric Acid | 2001 |
[Gout and hyperuricemia].
Topics: Female; Gout; Humans; Male; Uric Acid | 2001 |
[Gout: current views. Stage oriented treatment].
Topics: Acute Disease; Adult; Arthritis; Female; Gout; Humans; Male; Middle Aged; Severity of Illness Index; | 2002 |
Gout and hyperuricemia.
Topics: Africa; Arthritis, Gouty; Asia; Cardiovascular Diseases; Diet Therapy; Gout; Humans; Prevalence; Uri | 2002 |
The value of synovial fluid assays in the diagnosis of joint disease: a literature survey.
Topics: Acute Disease; Arthritis; Arthritis, Infectious; Calcium Pyrophosphate; Crystallization; Gout; Gram- | 2002 |
Implications of disorders of purine metabolism for the kidney and the urinary tract.
Topics: Adenine Phosphoribosyltransferase; Allopurinol; Animals; Calcium; Gout; Humans; Hydrogen-Ion Concent | 1977 |
New knowledge of the pathogenesis of gout.
Topics: Aging; Complement System Proteins; Crystallization; Endotoxins; Factor XII; Gout; Humans; Hydrogen-I | 1978 |
[Hyperuricemia and arteriosclerosis].
Topics: Adult; Arteriosclerosis; Coronary Disease; Dehydroepiandrosterone; Female; Gout; Humans; Hyperlipide | 1978 |
[Theory of pathogenesis in primary hyperuricamia].
Topics: Adenosine Monophosphate; Adult; Child; Female; Glucosephosphates; Glycine; Gout; Humans; Kidney; Les | 1975 |
Uric acid metabolism in man.
Topics: Adenine Phosphoribosyltransferase; Adenosine; Adenosine Deaminase; Animals; Cells, Cultured; Gout; H | 1976 |
Metabolic effects of fructose in the liver.
Topics: Alcohols; AMP Deaminase; Animals; Child; Fructose; Fructose Intolerance; Fructosephosphates; Glucago | 1978 |
Hyperuricemia and gout. Classification, complications and management.
Topics: Acute Disease; Allopurinol; Arthritis; Aspirin; Colchicine; Coronary Disease; Diuretics; Gout; Human | 1979 |
The pathogenesis of podagra.
Topics: Adult; Age Factors; Aged; Crystallization; Gout; Humans; Middle Aged; Permeability; Radiography; Syn | 1977 |
Hyperuricemia and gout.
Topics: Adult; Allopurinol; Colchicine; Diagnosis, Differential; Female; Gout; Humans; Indomethacin; Male; M | 1977 |
Renal handling of uric acid.
Topics: Biological Transport; Glomerular Filtration Rate; Gout; Humans; Kidney; Kidney Tubules; Models, Biol | 1977 |
[Primary hyperparathyroidism. Clinical aspects, diagnosis and surgical treatment].
Topics: Adenoma; Aged; Bone Cysts; Female; Gout; Humans; Hypercalcemia; Hyperparathyroidism; Hypertension; K | 1977 |
[Therapy of gout].
Topics: Arteriosclerosis; Colchicine; Diabetes Mellitus; Diet; Gout; Humans; Hyperlipidemias; Kidney Calculi | 1977 |
[Associated and secondary chondrocalcinosis].
Topics: Arthritis, Rheumatoid; Chondrocalcinosis; Chondroma; Diabetes Complications; Female; Gout; Hemochrom | 1977 |
Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.
Topics: Aspirin; Benzbromarone; Benzofurans; Drug Interactions; Fasting; Gout; Humans; Kidney Diseases; Kine | 1977 |
[Gout. Diagnosis--pathogenesis--therapy].
Topics: Allopurinol; Balneology; Benzofurans; Crystallization; Diagnosis, Differential; Exercise Therapy; Gl | 1978 |
Drug control of gout and hyperuricaemia.
Topics: Allopurinol; Arthritis; Chronic Disease; Colchicine; Gout; Humans; Indomethacin; Naproxen; Phenylbut | 1978 |
[Etiology of arteriosclerosis].
Topics: Arteriosclerosis; Diabetes Complications; Gout; Humans; Hyperlipidemias; Hypertension; Risk; Smoking | 1978 |
Use of the uricase-inhibited rat as an animal model in toxicology.
Topics: Aggression; Animals; Diet; Disease Models, Animal; Dogs; Embryo, Mammalian; Female; Gout; Humans; Ki | 1978 |
Pathogenesis and clinical management of hyperuricemia and gout.
Topics: Allopurinol; Colchicine; Female; Gout; Humans; Kidney Calculi; Male; Uric Acid; Uricosuric Agents | 1979 |
[Uric acid metabolism, specifically the effect of diuretics on the process].
Topics: Allopurinol; Biological Transport; Diuretics; Glomerular Filtration Rate; Gout; Humans; Hypoxanthine | 1979 |
Gout, a multi-faceted disease: Jan Van Breemen lecture, presented to the Dutch Society of Rheumatologists.
Topics: Child, Preschool; Colchicine; Crystallization; Gout; Humans; Netherlands; Phagocytosis; Societies, M | 1979 |
Atherosclerosis and urate metabolism.
Topics: Arteriosclerosis; Coronary Disease; Gout; Humans; Hyperlipidemias; Hyperlipoproteinemia Type IV; Hyp | 1979 |
[Current aspects of pathogenesis of hyperuricemia and podagra].
Topics: Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney; Male; Middle Aged; Purines; Sy | 1979 |
Choice of treatment in gout.
Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Gout; Humans; Long-Term Care; U | 1977 |
[The kidney and uric acid].
Topics: Acute Kidney Injury; Female; Gout; Humans; Hypertension; Kidney; Kidney Calculi; Kidney Diseases; Ki | 1975 |
[Inborn errors of metabolism and their significance in urology and nephrology].
Topics: Acidosis, Renal Tubular; Alkaptonuria; Cystinuria; Diabetes Insipidus; Female; Glycine; Gout; Humans | 1976 |
Uric acid biosynthesis and its disorders.
Topics: Adult; Child, Preschool; Female; Gout; Humans; Immunologic Deficiency Syndromes; Infant; Kidney Calc | 1976 |
[Selected phsiopathological and clinical aspects of purine metabolism].
Topics: Alkalosis, Respiratory; Diabetes Mellitus; Diuresis; Female; Fructose Intolerance; Glomerular Filtra | 1976 |
[Arterial hypertension and hyperuricemia].
Topics: Female; Gout; Humans; Hypertension; Kidney; Male; Uric Acid | 1976 |
The radiology of gout. Review article.
Topics: Acute Disease; Aged; Alcoholism; BCG Vaccine; Bone Neoplasms; Chondrocalcinosis; Chronic Disease; Fe | 1975 |
Pharmacologic approach to the maintenance of urate homeostasis.
Topics: Allopurinol; Diuresis; Gout; Homeostasis; Humans; Kidney Tubules; Probenecid; Sulfinpyrazone; Uric A | 1975 |
Editorial: An evaluation of the pathogenesis of gouty kidney.
Topics: Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney; Kidney Diseases; Kidney Failure, Chron | 1975 |
Gout in Maoris.
Topics: Adult; Diabetes Complications; Europe; Female; Gout; Hemoglobins; History, 18th Century; History, 19 | 1975 |
[Early recognition and treatment of diet-dependent diseases--gout].
Topics: Gout; Humans; Purines; Uric Acid | 1992 |
[Hyperuricemia and gout].
Topics: Arthritis, Gouty; Energy Metabolism; Gout; Humans; Kidney Calculi; Myocardial Ischemia; Risk Factors | 1992 |
Gout and hyperuricemia.
Topics: Crystallization; Gout; Humans; Uric Acid | 1992 |
Tophi as the initial manifestation of gout. Report of six cases and review of the literature.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Female; Gout; Humans; Kidney Failure, Chronic; Male; Mi | 1992 |
Renal calculi: pathogenesis, diagnosis, and medical therapy.
Topics: Calcium; Citrates; Citric Acid; Combined Modality Therapy; Diagnosis, Differential; Diuretics; Gout; | 1992 |
Renal calculi: pathogenesis, diagnosis, and medical therapy.
Topics: Calcium; Citrates; Citric Acid; Combined Modality Therapy; Diagnosis, Differential; Diuretics; Gout; | 1992 |
Renal calculi: pathogenesis, diagnosis, and medical therapy.
Topics: Calcium; Citrates; Citric Acid; Combined Modality Therapy; Diagnosis, Differential; Diuretics; Gout; | 1992 |
Renal calculi: pathogenesis, diagnosis, and medical therapy.
Topics: Calcium; Citrates; Citric Acid; Combined Modality Therapy; Diagnosis, Differential; Diuretics; Gout; | 1992 |
[Neurological aspects of microcrystalline arthropathies].
Topics: Aged; Cervical Vertebrae; Chondrocalcinosis; Crystallization; Gout; Humans; Lumbar Vertebrae; Middle | 1991 |
Gout and hyperuricemia.
Topics: Adult; Animals; Female; Gout; Humans; Male; Purines; Uric Acid | 1991 |
Strategies and controversies in the treatment of gout and hyperuricaemia.
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Col | 1990 |
Gout and hyperuricemia.
Topics: Chronic Disease; Follow-Up Studies; Gout; Humans; Patient Compliance; Uric Acid | 1991 |
The clinical management of gout.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diet; Gout; Humans; Uric Acid | 1991 |
[New concept of the pathogenesis of gout and hyperuricemia].
Topics: Energy Metabolism; Gout; Purines; Uric Acid | 1991 |
[The genetic basis of hyperuricemia due to a decrease in renal urate secretion].
Topics: Adolescent; Adult; Female; Gout; Humans; Kidney; Male; Metabolic Clearance Rate; Uric Acid | 1991 |
[Clinical findings and pathogenesis of renal impairment in hyperuricemia].
Topics: Gout; Humans; Kidney Diseases; Uric Acid | 1991 |
[Advances in drugs used to normalize hyperuricemia].
Topics: Gout; Humans; Uric Acid; Uricosuric Agents | 1991 |
[Medical control of uric acid in patients with gout--desirable level of serum uric acid and the choice of drugs].
Topics: Allopurinol; Gout; Humans; Uric Acid | 1991 |
[Dietary guidance for hyperuricemia and gout: its principle and practice].
Topics: Gout; Humans; Uric Acid | 1991 |
[The prognosis of gout and hyperuricemia--the effect of the treatment on prognosis].
Topics: Gout; Humans; Prognosis; Uric Acid | 1991 |
[Therapy of the gouty patients with ischemic heart diseases or cerebral vascular diseases].
Topics: Cerebrovascular Disorders; Coronary Disease; Gout; Humans; Uric Acid | 1991 |
[Clinical management of obesity and diabetes with hyperuricemia].
Topics: Diabetes Complications; Diabetes Mellitus; Gout; Humans; Obesity; Uric Acid | 1991 |
[The management of hyperuricemic patients associated with hypertension].
Topics: Gout; Humans; Hypertension; Uric Acid | 1991 |
Drug-induced gout.
Topics: Cyclosporins; Cytotoxins; Diuretics; Drug-Related Side Effects and Adverse Reactions; Ethambutol; Et | 1991 |
[Hyperuricemia: a laboratory finding needing treatment?].
Topics: Diagnosis, Differential; Gout; Gout Suppressants; Humans; Uric Acid | 1990 |
Gout and hyperuricemia.
Topics: Gout; Humans; Prognosis; Risk Factors; Uric Acid | 1990 |
Gout and hyperuricemia.
Topics: Cyclosporins; Gout; Humans; Purines; Syndrome; Uric Acid | 1990 |
[Is asymptomatic hyperuricemia in kidney-failure patients in need of therapy?].
Topics: Allopurinol; Gout; Humans; Kidney; Kidney Failure, Chronic; Uric Acid | 1989 |
[Genetic metabolic defects in adults].
Topics: Arteriosclerosis; Gout; Humans; Hyperlipoproteinemias; Phenotype; Risk Factors; Uric Acid | 1989 |
Observations with Rabenid in patients with locomotor disease.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Gout; Human | 1989 |
Fungalbionics: a new concept of the etiology of gout, hyperuricemia and their related diseases.
Topics: Animals; Crystallization; Fungi; Gout; Humans; Purines; Uric Acid | 1989 |
[Paraparesis due to gout].
Topics: Adult; Arthritis, Gouty; Crystallization; Gout; Humans; Male; Paraparesis, Tropical Spastic; Radiogr | 1989 |
[Is gout correctly diagnosed?].
Topics: Gout; Humans; Synovial Fluid; Uric Acid | 1988 |
Crystal identification in human synovial fluids. Methods and interpretation.
Topics: Arthritis; Calcium Oxalate; Calcium Phosphates; Calcium Pyrophosphate; Crystallography; Gout; Humans | 1988 |
Pathology of crystal deposition diseases.
Topics: Apatites; Calcium Phosphates; Calcium Pyrophosphate; Cartilage, Articular; Crystallography; Gout; Hu | 1988 |
The inflammatory reaction to crystals.
Topics: Antibody Formation; Arthritis, Gouty; Cell Membrane; Crystallization; Crystallography; Gout; Humans; | 1988 |
Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout).
Topics: Adult; Child; Female; Gout; Humans; Kidney; Male; Uric Acid | 1988 |
Mixed crystal deposition.
Topics: Calcinosis; Calcium Pyrophosphate; Crystallization; Female; Gout; Humans; Joint Diseases; Middle Age | 1988 |
Therapy in gout.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calculi; Colchicine; Gout; Humans; Recurrence; Uric Acid | 1988 |
Gout: how presentation, diagnosis, and treatment differ in the elderly.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Female; Gout; Hu | 1988 |
Urate metabolism and gout--a perspective.
Topics: Gout; Humans; Kidney Diseases; Uric Acid | 1988 |
[Common sense and nonsense in diet therapy. Hyperuricemia and gout].
Topics: Gout; Humans; Purines; Uric Acid | 1988 |
Analytical reviews in clinical biochemistry: the measurement of urate.
Topics: Blood Chemical Analysis; Gout; Humans; Uric Acid | 1988 |
[Metabolism of uric acid and purines in leukocytes].
Topics: Adenosine Deaminase; Gout; Humans; Interleukin-1; Leukocytes; Purine-Nucleoside Phosphorylase; Purin | 1988 |
Tubulo-interstitial nephritis associated with systemic disease and electrolyte abnormalities.
Topics: Chronic Disease; Gout; Humans; Multiple Myeloma; Nephritis, Interstitial; Sarcoidosis; Sjogren's Syn | 1988 |
[Unusual clinical syndrome: rheumatoid arthritis and gouty arthritis].
Topics: Adult; Arthritis, Rheumatoid; Crystallization; Foot; Gout; Humans; Male; Metacarpus; Radiography; Rh | 1987 |
Gout.
Topics: Arthritis; Cardiovascular Diseases; Diabetes Complications; Environment; Gout; Humans; Hyperlipidemi | 1987 |
Hyperuricemia and gout.
Topics: Acute Disease; Adult; Allopurinol; Anti-Inflammatory Agents; Arthritis; Arthrography; Calcinosis; Ch | 1986 |
[Hyperuricemia and essential arterial hypertension].
Topics: Gout; Humans; Hypertension; Kidney; Renal Circulation; Uric Acid | 1985 |
[Current aspects of the etiology and pathogenesis of primary gout].
Topics: Adult; Aging; Anaerobiosis; Female; Glycolysis; Gout; Humans; Kidney; Lysosomes; Male; Nutritional P | 1985 |
Tophaceous gout of the spine in a patient with no peripheral tophi: case report and review of the literature.
Topics: Aged; Crystallization; Electromyography; Female; Gout; Humans; Laminectomy; Lumbar Vertebrae; Radiog | 1985 |
[Hyperuricemia: is treatment necessary or not?].
Topics: Cardiovascular Diseases; Diuretics; Gout; Humans; Kidney Calculi; Uric Acid | 1985 |
The 1968 interim scientific session of the American Rheumatism Association.
Topics: Amyloidosis; Arthritis, Rheumatoid; Collagen Diseases; Fibroblasts; gamma-Globulins; Gout; Humans; L | 1969 |
[Lipids and arteriosclerosis].
Topics: Adult; Age Factors; Aged; Animals; Arteriosclerosis; Cats; Cholesterol; Coronary Disease; Dogs; Gout | 1973 |
Hyperuricemia and gout.
Topics: Biological Transport; Carbohydrate Metabolism, Inborn Errors; Down Syndrome; Fructose; Glucosyltrans | 1969 |
[Hyperuricemia in childhood].
Topics: Anemia, Hemolytic; Child; Down Syndrome; Glycogen Storage Disease; Gout; Humans; Kidney Calculi; Kid | 1973 |
On the crystal deposition diseases.
Topics: Adult; Aged; Arthritis; Calcinosis; Diphosphates; Female; Gout; Humans; Joint Diseases; Male; Middle | 1970 |
Phosphoribosylpyrophosphate in man: biochemical and clinical significance.
Topics: Adenine; Adrenocorticotropic Hormone; Allopurinol; Animals; Glycogen; Gout; Humans; Lesch-Nyhan Synd | 1971 |
Pathophysiology of hyperuricemia in primary gout.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Culture Techniques; Diphosphates; Fibroblasts; Glut | 1970 |
Ethanol metabolism and uric acid.
Topics: Acetaldehyde; Alcoholism; Ethanol; Fasting; Gout; Humans; Hyperlipidemias; Ketone Bodies; Lactates; | 1972 |
Editorial: The kidney and uric acid excretion in man.
Topics: Angiotensin II; Animals; Biological Transport, Active; Blood Proteins; Diabetes Insipidus; Diet, Sod | 1972 |
Crystal deposition joint disease.
Topics: Aged; Arthritis, Rheumatoid; Chondrocalcinosis; Colchicine; Crystallization; Diphosphates; Female; G | 1974 |
Metabolic defects of primary hyperuricemia and gout.
Topics: Adenosine Monophosphate; Blood Proteins; Catalysis; Erythrocytes; Glutamine; Gout; Guanine; Guanine | 1974 |
Medical management of the patient with arthritis.
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Infectious; Arthritis, Rheumatoid; Aspirin; Chond | 1974 |
[Metabolic effects of diuretics].
Topics: Angiotensin II; Depression, Chemical; Diuretics; Glucose; Gout; Humans; Hypokalemia; Magnesium; Pota | 1974 |
Recent advances in rheumatic diseases: 1967 through 1969.
Topics: Arthritis; Arthritis, Infectious; Arthritis, Reactive; Arthritis, Rheumatoid; Behcet Syndrome; Colla | 1970 |
The physiologic approach to hyperuricemia.
Topics: Allopurinol; Gout; Humans; Kidney; Purine-Pyrimidine Metabolism, Inborn Errors; Purines; Uric Acid; | 1972 |
[Renal manifestations of hyperuricemia].
Topics: Acute Kidney Injury; Albuminuria; Cortisone; Gout; Hematuria; Humans; Kidney Calculi; Kidney Disease | 1972 |
Diabetes mellitus and gout.
Topics: Benzothiadiazines; Blood Glucose; Carbohydrate Metabolism; Diabetes Complications; Diabetes Mellitus | 1972 |
[Gout, archetype of diseases caused by deposits].
Topics: Gout; Humans; Kidney Calculi; Kinins; Lesch-Nyhan Syndrome; Metabolic Diseases; Nephritis, Interstit | 1972 |
Views on the pathogenesis and management of primary gout--1971.
Topics: Adenosine Triphosphate; Arthritis; Enzyme Precursors; Gout; Guanine Nucleotides; Humans; Hypoxanthin | 1972 |
Renal mechanisms for regulation of uric acid excretion, with special reference to normal and gouty man.
Topics: Allantoin; Animals; Birds; Dogs; Glomerular Filtration Rate; Gout; Guinea Pigs; Humans; Kidney; Kidn | 1972 |
Epidemiology of coronary heart disease.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol, Dietary; Coronary Disease; Diabetes Complications; Dieta | 1973 |
[Effect of allopurinol on the metabolism of uric acid].
Topics: Allopurinol; Chemical Phenomena; Chemistry; Depression, Chemical; Feedback; Gout; Humans; Kidney; Pu | 1973 |
Current concepts in the pathogenesis of hyperuricemia.
Topics: Gout; Humans; Metabolic Diseases; Purine Nucleotides; Purines; Uric Acid | 1973 |
[Coffee-drinking from the medical point of view].
Topics: Adult; Blood Pressure; Caffeine; Coffee; Diabetes Mellitus; Feeding Behavior; Female; Gout; Health S | 1973 |
Aetiology of gout.
Topics: Allopurinol; Creatinine; Diet Therapy; Erythrocytes; Gout; Humans; Hypoxanthines; Lesch-Nyhan Syndro | 1973 |
Drug induced gout.
Topics: Absorption; Allopurinol; Aspirin; Benzothiadiazines; Diuretics; Ethanol; Gout; Humans; Kidney Calcul | 1973 |
Crystals, lysosomes and gout.
Topics: Cell Survival; Crystallization; Endocytosis; Gonadal Steroid Hormones; Gout; Hemolysis; Humans; Hydr | 1974 |
Current management of polycythemia vera and related diseases.
Topics: Allopurinol; Bloodletting; Chlorambucil; Erythropoiesis; Gout; Humans; Melphalan; Phosphorus Radiois | 1974 |
Influence of the kidney upon urate homeostasis in health and disease.
Topics: Acute Kidney Injury; Female; Glomerular Filtration Rate; Gout; Homeostasis; Humans; Hypertension; Hy | 1974 |
[Renal insufficiency and uric acid metabolism: harmful effect of uric acid and new interpretation of uric acid metabolism].
Topics: Female; Gout; Homeostasis; Humans; Kidney; Kidney Failure, Chronic; Male; Renal Dialysis; Uric Acid | 1974 |
Genetic aspects of gout.
Topics: Adenine; Allopurinol; Carbon Radioisotopes; Erythrocytes; Fibroblasts; Glucosephosphate Dehydrogenas | 1974 |
Milestones in the treatment of gout.
Topics: Allopurinol; Colchicine; Gout; Humans; Indomethacin; Kidney Calculi; Probenecid; Sulfinpyrazone; Uri | 1974 |
[Threatening urate and gout].
Topics: Diet; Gout; Humans; Urate Oxidase; Uric Acid | 1974 |
Molecular variation in relation to purine metabolism.
Topics: Amidophosphoribosyltransferase; Chemical Phenomena; Chemistry; Glucosephosphate Dehydrogenase Defici | 1974 |
Invitation to the gout. A consideration of the role of various predisposing and provocative factors in the genesis of acute gouty arthritis.
Topics: Acute Disease; Alcoholic Beverages; Arthritis; Fasting; Food; Gout; Humans; Mercury; Organomercury C | 1967 |
Eighteenth rheumatism review. Review of American and English literature for the years 1965 and 1966.
Topics: Adult; Animals; Arthritis, Infectious; Arthritis, Rheumatoid; Autoimmune Diseases; Bone Diseases; Ca | 1968 |
Recent progress in the pathogenesis and treatment of gout.
Topics: Allopurinol; Gout; Humans; Uric Acid | 1969 |
[Effects and side-effects of hypotensive diuretics].
Topics: Antihypertensive Agents; Benzothiadiazines; Chlorothiazide; Diabetes Mellitus; Diuretics; Gout; Huma | 1968 |
Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout.
Topics: Adenine; Adolescent; Adult; Allopurinol; Azathioprine; Child; Child, Preschool; Female; Gout; Humans | 1969 |
[On the biochemistry and pathogenesis of gout].
Topics: Alcoholism; Glomerular Filtration Rate; Gout; Humans; Kidney Tubules; Obesity; Purines; Uric Acid | 1968 |
[The kidney in gout and gout of the kidney].
Topics: Arteriosclerosis Obliterans; Carbohydrate Metabolism; Cerebrovascular Disorders; Diabetes Complicati | 1968 |
Physiologic and biochemical basis for the treatment of gout and hyperuricemia.
Topics: Acute Disease; Adrenal Cortex Hormones; Arthritis; Chronic Disease; Colchicine; Glomerular Filtratio | 1969 |
Epidemiology of serum uric acid and gout: an example of the complexities of multifactorial causation.
Topics: ABO Blood-Group System; Adult; Aged; Altitude; Argentina; Brazil; Colombia; Female; Gout; Humans; Ma | 1970 |
[Present status of gout in Japan].
Topics: Diet Therapy; Gout; Health Education; Humans; Japan; Uric Acid | 1970 |
Crystal-induced inflammation of the joints.
Topics: Animals; Arthritis; Colchicine; Dogs; Gout; Humans; Inflammation; Leukocytes; Phagocytosis; Uric Aci | 1970 |
Uric acid excretion in the relatives of patients with gout.
Topics: Creatinine; Female; Gout; Humans; Male; Sex Factors; Uric Acid | 1970 |
Gout.
Topics: Allopurinol; Arthritis; Carbon Isotopes; Colchicine; Glutamine; Gout; Humans; Kidney; Orotic Acid; P | 1965 |
[Treatment of congenital purine-pyrimidine metabolism anomalies].
Topics: Athetosis; Chorea; Compulsive Behavior; Gout; Humans; Intellectual Disability; Orotic Acid; Purine-P | 1971 |
Control of uric acid excretion.
Topics: Animals; Dogs; Glycine; Gout; Humans; Kidney; Kidney Diseases; Kidney Tubules; Pyrazinamide; Uric Ac | 1971 |
[Gout. Clinical aspects, pathogenesis, current treatment].
Topics: Calcinosis; Colchicine; Diagnosis, Differential; Diet Therapy; Female; Gout; Humans; Joint Diseases; | 1971 |
[Drug therapy in gout].
Topics: Allopurinol; Chemical Phenomena; Chemistry; Colchicine; Gout; Humans; Phagocytosis; Probenecid; Puri | 1971 |
Treatment of gout.
Topics: Adrenal Cortex Hormones; Allopurinol; Colchicine; Gout; Humans; Indomethacin; Phenylbutazone; Proben | 1971 |
[What is certain in gout therapy?].
Topics: Acute Disease; Allopurinol; Chronic Disease; Colchicine; Gout; Humans; Hydrogen-Ion Concentration; K | 1971 |
Biochemical and genetic studies of an X-linked neurological disease (The Lesch-Nyhan syndrome).
Topics: Animals; Athetosis; Cells, Cultured; Cerebral Palsy; Child; Disease Models, Animal; Feedback; Female | 1971 |
[Gout].
Topics: Allopurinol; Chondrocalcinosis; Colchicine; Diagnosis, Differential; Diet Therapy; Gout; Humans; Ino | 1970 |
Allopurinol. A review.
Topics: Adult; Allopurinol; Child; Drug Hypersensitivity; Drug Interactions; Gout; Humans; Iron; Kidney Dise | 1971 |
Drug treatment of gout.
Topics: Acute Disease; Allopurinol; Arthritis; Colchicine; Gout; Humans; Orotic Acid; Probenecid; Structure- | 1971 |
Selected aspects of the aetiology, pathogenesis and treatment of disorders of purine metabolism.
Topics: Allopurinol; Colchicine; Glycogen Storage Disease Type I; Gout; Humans; Lesch-Nyhan Syndrome; Metabo | 1971 |
Drugs and uric acid.
Topics: Allopurinol; Chemical Phenomena; Chemistry; Gout; Humans; Purines; Uric Acid; Xanthines | 1969 |
[Hyperuricemia. IV. Theoretical mechanisms of hyperuricemia. Prinicipal causes of hyperuricemia: hereditary dyspurinia, overeating, renal insufficiency, blood diseases].
Topics: Gout; Humans; In Vitro Techniques; Uric Acid | 1966 |
Uric acid, gout, and the kidney.
Topics: Gout; Humans; Kidney Diseases; Uric Acid | 1966 |
The study of human intermediary purine metabolism and its regulation.
Topics: Gout; Humans; Purines; Uric Acid; Urine | 1966 |
[Hyperuricemias].
Topics: Gout; Humans; Uric Acid | 1966 |
Hyperuricemia, gout, and atherosclerosis.
Topics: Arteriosclerosis; Gout; Humans; Uric Acid | 1966 |
The biological significance of uric acid.
Topics: Gout; Humans; Uric Acid | 1966 |
[Gout and hyperuricemia].
Topics: Diagnosis, Differential; Gout; Humans; Uric Acid | 1966 |
Trials
229 trials available for uric acid and Gout
| Article | Year |
|---|---|
Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.
Topics: Aged; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2022 |
Effect of alkalized urine on renal calculi in patients with gout: a protocol for a placebo-controlled, double-blinded randomized controlled trial.
Topics: Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Kidney Calculi; Randomized Control | 2021 |
Denosumab did not improve computerized tomography erosion scores when added to intensive urate-lowering therapy in gout: Results from a pilot randomized controlled trial.
Topics: Denosumab; Gout; Gout Suppressants; Humans; Pilot Projects; Tomography, X-Ray Computed; Uric Acid | 2021 |
SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout.
Topics: Black or African American; Gout; Gout Suppressants; Humans; Male; Middle Aged; Quality of Life; Uric | 2021 |
SToRytelliing to Improve Disease outcomes in Gout (STRIDE-GO) in African American veterans with gout: a trial study protocol.
Topics: Black or African American; Ethnic and Racial Minorities; Gout; Gout Suppressants; Humans; Multicente | 2021 |
Intensive Serum Urate Lowering With Oral Urate-Lowering Therapy for Erosive Gout: A Randomized Double-Blind Controlled Trial.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Quality of Life; Treatment Outcome; Uric A | 2022 |
Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol.
Topics: Australia; Gout; Humans; Native Hawaiian or Other Pacific Islander; New Zealand; Symptom Flare Up; U | 2021 |
Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study.
Topics: Double-Blind Method; Gout; Healthy Volunteers; Humans; Hyperuricemia; Treatment Outcome; Uric Acid; | 2022 |
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcom | 2022 |
Zhengqing fengtongning sustained-release tablets prevents gout flares in the process of ULT: A randomized, positive control, double-blind, double-simulation, multicenter trial.
Topics: Arthritis, Gouty; Colchicine; Delayed-Action Preparations; Double-Blind Method; Drugs, Chinese Herba | 2022 |
Effects of vitamin C supplementation on gout risk: results from the Physicians' Health Study II trial.
Topics: Adult; Aged; Ascorbic Acid; Dietary Supplements; Double-Blind Method; Gout; Humans; Male; Middle Age | 2022 |
Urate-lowering effect of calcium supplementation: Analyses of a randomized controlled trial.
Topics: Adult; Calcium; Calcium Citrate; Calcium, Dietary; Dietary Supplements; Female; Gout; Humans; Uric A | 2022 |
Evaluation of the safety and efficacy of a Fuling-Zexie decoction for people with asymptomatic hyperuricemia: protocol for a prospective, double-blinded, randomized, placebo-controlled clinical trial.
Topics: Double-Blind Method; Gout; Humans; Hyperuricemia; Pilot Projects; Prospective Studies; Randomized Co | 2022 |
Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout.
Topics: Allopurinol; Follow-Up Studies; Gout; Gout Suppressants; Humans; Symptom Flare Up; Treatment Outcome | 2022 |
Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Prospe | 2022 |
The effects of aerobic exercise on body composition in overweight and obese patients with gout: a randomized, open-labeled, controlled trial.
Topics: Adolescent; Adult; Body Composition; Cholesterol, HDL; Exercise; Exercise Therapy; Gout; Humans; Mid | 2022 |
A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.
Topics: Adult; Anaphylaxis; Arthritis, Gouty; Double-Blind Method; Gout; Gout Suppressants; Humans; Methotre | 2023 |
A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia.
Topics: Drug Interactions; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Tr | 2023 |
Immersion in Water Between 20-30
Topics: Biomarkers; Gout; Humans; Immersion; Indonesia; Inflammasomes; Inflammation; Pain; Pain Management; | 2023 |
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
Topics: Aged; Allopurinol; Coronary Artery Disease; Female; Gout; Humans; Male; Myocardial Infarction; Myoca | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial.
Topics: Arthritis, Gouty; Chronic Disease; Colchicine; Gout; Gout Suppressants; Humans; Probenecid; Symptom | 2023 |
Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial.
Topics: Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up; T | 2023 |
Hmong microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C): A phase II clinical study protocol.
Topics: Adult; Ascorbic Acid; Clinical Trials, Phase II as Topic; COVID-19; Gout; Gout Suppressants; Humans; | 2023 |
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Topics: Aged; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment | 2023 |
Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
Topics: Gout; Gout Suppressants; Humans; Kidney; Multicenter Studies as Topic; Pragmatic Clinical Trials as | 2023 |
Pegloticase efficacy and safety in kidney transplant recipients; results of the phase IV, open-label PROTECT clinical trial.
Topics: Adult; COVID-19; Gout; Gout Suppressants; Humans; Kidney Transplantation; Middle Aged; Polyethylene | 2023 |
Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial.
Topics: Adult; Allopurinol; Colchicine; Gout; Gout Suppressants; Humans; Symptom Flare Up; Treatment Outcome | 2023 |
Efficacy and safety of tart cherry supplementary citrate mixture on gout patients: a prospective, randomized, controlled study.
Topics: C-Reactive Protein; Citrates; Citric Acid; Gout; Humans; Male; Metabolic Syndrome; Prospective Studi | 2023 |
Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial.
Topics: Adult; Dietary Approaches To Stop Hypertension; Female; Gout; Humans; Hypertension; Hyperuricemia; L | 2023 |
Efficacy of Aristolochia rotunda Linn in hyperuricemia: A randomised standard controlled study.
Topics: Aristolochia; Gout; Humans; Hyperuricemia; Single-Blind Method; Uric Acid | 2023 |
Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol.
Topics: Acupuncture Therapy; Gout; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Single-Blin | 2023 |
Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
Topics: Aged; Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; Body Mass Index; Creatin | 2020 |
Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
Topics: Benzbromarone; Biomarkers; China; Dose-Response Relationship, Drug; Febuxostat; Follow-Up Studies; G | 2019 |
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 stu
Topics: Adult; Benzothiazoles; Double-Blind Method; Gout; Humans; Hyperuricemia; Japan; Male; Middle Aged; O | 2020 |
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
Topics: Adult; Aged; Benzothiazoles; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gout; Hu | 2020 |
Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.
Topics: Adult; Benzothiazoles; Female; Gout; Humans; Hyperuricemia; Japan; Male; Middle Aged; Organic Anion | 2020 |
Lack of effect of tart cherry concentrate dose on serum urate in people with gout.
Topics: Adult; Aged; Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Phytotherapy; | 2020 |
A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
Topics: Adult; Aged; Benzothiazoles; Double-Blind Method; Febuxostat; Gout; Humans; Hyperuricemia; Japan; Ma | 2020 |
Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
Topics: Adult; Aged; Benzbromarone; Benzothiazoles; Double-Blind Method; Female; Gout; Humans; Hyperuricemia | 2020 |
Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial.
Topics: Curcumin; Female; Gout; Humans; Hyperuricemia; Male; Treatment Outcome; Uric Acid | 2021 |
Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR).
Topics: Adult; Gout; Gout Suppressants; Humans; Male; Methotrexate; Middle Aged; Polyethylene Glycols; Treat | 2021 |
UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis.
Topics: Aged; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Stu | 2020 |
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Denmark; Febuxostat; Female; Gout; Gout Suppressants; Ho | 2020 |
Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Febuxostat; Female; Gout; Gout Suppressa | 2021 |
Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study.
Topics: Adult; Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk | 2022 |
A Randomized Pilot Study of DASH Patterned Groceries on Serum Urate in Individuals with Gout.
Topics: Cross-Over Studies; Dietary Approaches To Stop Hypertension; Eating; Female; Follow-Up Studies; Frui | 2021 |
Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial.
Topics: Adolescent; Adult; Allopurinol; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Dilatation, | 2021 |
Detection of intracellular monosodium urate crystals in gout synovial fluid using optical diffraction tomography.
Topics: Cell Line; Gout; Humans; Imaging, Three-Dimensional; Macrophages; Refractometry; Synovial Fluid; Tom | 2021 |
Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial.
Topics: Allopurinol; Double-Blind Method; Gout; Gout Suppressants; Humans; Symptom Flare Up; Time-to-Treatme | 2022 |
A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Allopurinol; Aspartate Aminotransferases; Chemical | 2017 |
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
Topics: Creatinine; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressa | 2017 |
Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study.
Topics: Aged; Cross-Sectional Studies; Female; Gout; Humans; Image Interpretation, Computer-Assisted; Male; | 2017 |
Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Antihypertensive Agents; Biomarkers; Black or African | 2017 |
Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.
Topics: Aged; Allopurinol; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressants; Humans; Male; | 2017 |
Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Join | 2017 |
Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Internet; Patient Compliance; Prospective Studies; Qua | 2017 |
Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Dose-Response Relationship, Drug; Febuxo | 2018 |
The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressa | 2017 |
Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Gout; Humans; Hyperuricemia; Joints; Mal | 2018 |
Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans.
Topics: Carbon Radioisotopes; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Feces; Gastrointestinal Tract | 2018 |
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenofibrate; Gout; Humans; Hypolipidem | 2018 |
Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial.
Topics: Adult; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Dosage Calculations; | 2018 |
The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
Topics: Adult; Allopurinol; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 2018 |
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
Topics: Adolescent; Adult; Aged; Allopurinol; Area Under Curve; Drug Administration Schedule; Gout; Gout Sup | 2018 |
Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Topics: Administration, Oral; Adult; Aged; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Co | 2018 |
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Colchicine; Cough; Creatinine; Delay | 2019 |
Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial.
Topics: Allopurinol; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressants; Humans; Male; Middle | 2018 |
The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Therapy, Combination; Febuxos | 2018 |
Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Enzyme Inhibitors; Female; Gout; Go | 2018 |
Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Data Interpretation, Statistical; F | 2018 |
"Yellow-dragon Wonderful-seed Formula" for hyperuricemia in gout patients with dampness-heat pouring downward pattern: a pilot randomized controlled trial.
Topics: Adult; Biomarkers; China; Down-Regulation; Drugs, Chinese Herbal; Gout; Gout Suppressants; Humans; H | 2018 |
Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
Topics: Aged; Allopurinol; Cost-Benefit Analysis; Disease Management; England; Female; General Practice; Gou | 2018 |
Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care.
Topics: Allopurinol; Clinical Competence; Decision Making, Shared; Female; France; Gout; Gout Suppressants; | 2019 |
Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers.
Topics: Administration, Oral; Adult; Gout; Healthy Volunteers; HEK293 Cells; Humans; Kidney; Male; Microsome | 2019 |
How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Drug Delivery Systems; Femal | 2018 |
Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.
Topics: Adult; Aged; Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Middl | 2019 |
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
Topics: Adult; Aged; C-Reactive Protein; Double-Blind Method; Female; Follow-Up Studies; Gout; Gout Suppress | 2019 |
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
Topics: Administration, Oral; Adult; Asian People; Double-Blind Method; Gout; Healthy Volunteers; Humans; Hy | 2019 |
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
Topics: Administration, Oral; Adult; Asian People; Double-Blind Method; Gout; Healthy Volunteers; Humans; Hy | 2019 |
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
Topics: Administration, Oral; Adult; Asian People; Double-Blind Method; Gout; Healthy Volunteers; Humans; Hy | 2019 |
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
Topics: Administration, Oral; Adult; Asian People; Double-Blind Method; Gout; Healthy Volunteers; Humans; Hy | 2019 |
Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
Topics: Aged; Allopurinol; Bone Resorption; Dose-Response Relationship, Drug; Female; Foot Bones; Foot Joint | 2019 |
Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.
Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Urate Oxidase; Uric Acid | 2020 |
Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.
Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Urate Oxidase; Uric Acid | 2020 |
Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.
Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Urate Oxidase; Uric Acid | 2020 |
Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.
Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Urate Oxidase; Uric Acid | 2020 |
Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
Topics: Adult; Allopurinol; Double-Blind Method; Drug Therapy, Combination; Female; Gout; Gout Suppressants; | 2013 |
Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Ascorbic Acid; Creatinine; Dietary Supplements; Female; | 2013 |
Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout?
Topics: Adult; Aged; Aged, 80 and over; Cartilage, Articular; Case-Control Studies; Crystallization; Female; | 2014 |
As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
Topics: Aged; Allopurinol; Biomarkers; Chronic Disease; Enzyme Inhibitors; Febuxostat; Germany; Glomerular F | 2014 |
Serum urate levels are unchanged with continuous positive airway pressure therapy for obstructive sleep apnea: a randomized controlled trial.
Topics: Aged; Continuous Positive Airway Pressure; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; M | 2013 |
Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study.
Topics: Adult; Bariatric Surgery; Diabetes Mellitus, Type 2; Female; Gout; Humans; Longitudinal Studies; Mal | 2014 |
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
Topics: Adult; Aged; Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug R | 2013 |
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
Topics: Adult; Aged; Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug R | 2013 |
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
Topics: Adult; Aged; Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug R | 2013 |
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
Topics: Adult; Aged; Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug R | 2013 |
Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
Topics: Adiponectin; Aged; Albuminuria; Blood Pressure; Comorbidity; Creatinine; Double-Blind Method; Enzyme | 2014 |
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Topics: Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; G | 2014 |
Influence of the ABCG2 gout risk 141 K allele on urate metabolism during a fructose challenge.
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transp | 2014 |
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Topics: Adult; Aged; Colchicine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2014 |
Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Enzyme-Linked Immunosorbent Assay; Female; Gout; Gout S | 2014 |
Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Dose-Response Relationship, Drug; | 2014 |
Comprehensive dietary education in treated gout patients does not further improve serum urate.
Topics: Adult; Aged; Allopurinol; Australia; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pat | 2015 |
Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.
Topics: Adolescent; Adult; Aged; Calcium Channel Blockers; Computer Simulation; Dose-Response Relationship, | 2015 |
Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2015 |
Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Disease Progression; Dos | 2015 |
A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Topics: Administration, Oral; Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Febuxostat; Female | 2015 |
Combination Therapies of Diacerein and Febuxostat Inhibit IL-1β Responses and Improve Clinical Symptoms in Patients With Refractory Gout.
Topics: Adult; Anthraquinones; Anti-Inflammatory Agents; C-Reactive Protein; Case-Control Studies; Drug Ther | 2017 |
An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Female; Gout; Gout Su | 2015 |
Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
Topics: Administration, Oral; Adult; Alleles; Allopurinol; China; Febuxostat; Female; Gout; Gout Suppressant | 2016 |
The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression.
Topics: Adult; Amino Acid Substitution; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Mutation, Mi | 2016 |
Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hy | 2016 |
Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Gout; Gout Suppress | 2016 |
Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Double-Blind Method; Fe | 2016 |
Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Topics: Adult; Aged; Allopurinol; Double-Blind Method; Female; Follow-Up Studies; Gout; Gout Suppressants; H | 2016 |
Patients with gout differ from healthy subjects in renal response to changes in serum uric acid.
Topics: Adult; Aged; Female; Gout; Gout Suppressants; Healthy Volunteers; Humans; Hyperuricemia; Kidney; Mal | 2017 |
A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial.
Topics: Female; Gout; Humans; Male; Middle Aged; Patient Education as Topic; Pharmacists; Professional Role; | 2016 |
Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
Topics: Allopurinol; Ambulatory Care; Automation; Gout; Gout Suppressants; Humans; Patient Education as Topi | 2016 |
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
Topics: Cell Line; Gout; Humans; Kidney; Male; Organic Anion Transporters; Organic Cation Transport Proteins | 2016 |
Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Creatinine; Double | 2017 |
Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
Topics: Adult; Allopurinol; Double-Blind Method; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Jap | 2017 |
Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
Topics: Allopurinol; Benzbromarone; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration | 2017 |
Hypouricemic and arthritis relapse-reducing effects of compound tufuling oral-liquid in intercritical and chronic gout: A double-blind, placebo-controlled, multicenter randomized trial.
Topics: Adult; Aged; Arthritis, Gouty; Double-Blind Method; Drugs, Chinese Herbal; Female; Gout; Gout Suppre | 2017 |
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Topics: Aged; Allopurinol; Benzbromarone; Confidence Intervals; Dose-Response Relationship, Drug; Drug Admin | 2009 |
Clinical effect and action mechanism of Weicao Capsule in treating gout.
Topics: Adult; Aged; beta 2-Microglobulin; Capsules; Drugs, Chinese Herbal; Female; Gout; Hemoglobins; Human | 2008 |
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gout; Humans; I | 2008 |
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxos | 2008 |
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxos | 2008 |
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxos | 2008 |
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxos | 2008 |
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
Topics: Adult; Aged; Biomarkers; Clinical Trials, Phase II as Topic; Febuxostat; Female; Follow-Up Studies; | 2009 |
Serum urate during acute gout.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Cyclooxygenase Inhibitors; Etoricoxib; Female; Gout; | 2009 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Dr | 2010 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Dr | 2010 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Dr | 2010 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Dr | 2010 |
Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial.
Topics: Adult; Animals; Cross-Over Studies; Gout; Humans; Hypoxanthine; Male; Middle Aged; Milk; Purine Nucl | 2010 |
More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial.
Topics: Aged; Allopurinol; Benchmarking; Clinical Audit; Cultural Competency; Diagnosis, Differential; Gout; | 2009 |
[Antihypertensive therapy optimization and endothelial function in patients with gout and chronic urate tubulointerstitial nephritis].
Topics: Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2010 |
Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Drug Moni | 2011 |
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
Topics: Allopurinol; Drug Interactions; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Male; Mi | 2011 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
Topics: Adult; Aged; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle | 2011 |
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat | 2011 |
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Topics: Adult; Central Nervous System Diseases; Dental Enamel; Diabetes Mellitus, Type 2; Dose-Response Rela | 2011 |
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Fol | 2011 |
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat | 2011 |
Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Febuxostat; Female; Follow-Up Studies | 2011 |
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En | 2011 |
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En | 2011 |
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En | 2011 |
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En | 2011 |
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En | 2011 |
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En | 2011 |
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En | 2011 |
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En | 2011 |
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Topics: Allopurinol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Resistance; En | 2011 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Gout; Gout Suppressants; | 2011 |
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Topics: Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Double-Blind Method; Febuxostat; Female; Gout; | 2012 |
Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
Topics: Adult; Aged; Allopurinol; Area Under Curve; Case-Control Studies; Diuretics; Drug Interactions; Drug | 2012 |
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Gout; Gout Suppressants; Humans; Male; Midd | 2012 |
Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study.
Topics: Aged; Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Patient Compliance; P | 2013 |
Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Gout; Healthy Volunteers; Hu | 2012 |
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Drug Resistance; Enzymes, Immobilized; Female; Gout | 2013 |
Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney | 2013 |
Hyperuricemia and gout in renal transplant recipients.
Topics: Adult; Biomarkers; Causality; Creatinine; Cyclosporine; Dose-Response Relationship, Drug; Female; Fo | 2002 |
Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Cross-Over Studies; Dose-Response Relationship, Drug; Drug | 2002 |
Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Crystallization; Drug Therapy, Combination; Female; Gout; G | 2002 |
Environmental lead exposure and urate excretion in the general population.
Topics: Adult; Aged; Body Burden; Chelating Agents; Cross-Sectional Studies; Edetic Acid; Environmental Expo | 2002 |
Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
Topics: Acute Disease; Adult; Aged; Alkaline Phosphatase; Allopurinol; Arthritis, Gouty; Chronic Disease; Cr | 2003 |
Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy.
Topics: Allopurinol; Antioxidants; Autoantibodies; Body Weight; Case-Control Studies; Cholesterol, HDL; Chol | 2004 |
Clinical analysis for the acupuncture treatment in 42 cases of gouty renal damage.
Topics: Acupuncture Therapy; Adult; Aged; Arthritis, Gouty; Blood Urea Nitrogen; Creatinine; Female; Gout; H | 2004 |
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; | 2005 |
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; | 2005 |
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; | 2005 |
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; | 2005 |
Benzbromarone therapy in management of refractory gout.
Topics: Adult; Allopurinol; Benzbromarone; Creatinine; Female; Gout; Humans; Incidence; Male; Metabolic Clea | 2005 |
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Hu | 2005 |
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Hu | 2005 |
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Hu | 2005 |
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Hu | 2005 |
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Topics: Adult; Aged; Carbon Radioisotopes; Female; Gout; Humans; Hyperuricemia; Immunoglobulin G; Male; Midd | 2006 |
Clinicopathology of gout in growing layers induced by high calcium and high protein diets.
Topics: Animal Feed; Animals; Calcium; Calcium, Dietary; Chickens; Diet; Dietary Proteins; Female; Gout; Mag | 2005 |
[Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)].
Topics: Adult; Aged; Blood Glucose; Female; Follow-Up Studies; Gout; Humans; Hypoglycemic Agents; Insulin Re | 2005 |
Photobiomodulation of pain and inflammation in microcrystalline arthropathies: experimental and clinical results.
Topics: Animals; Arthralgia; Arthritis, Experimental; Biomarkers; Calcium Pyrophosphate; Diclofenac; Dinopro | 2006 |
Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese.
Topics: Asian People; Creatinine; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genoty | 2006 |
Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gou | 2007 |
Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Topics: Adult; Aged; Antibodies; Creatinine; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressan | 2007 |
Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH.
Topics: Bezafibrate; Biomarkers; Body Mass Index; Fenofibrate; Gout; Humans; Hydrogen-Ion Concentration; Hyp | 2007 |
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Topics: Aged; Allopurinol; Benzbromarone; Confidence Intervals; Dose-Response Relationship, Drug; Drug Admin | 2009 |
Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
Topics: Adult; Aged; Aged, 80 and over; Body Weight; Dose-Response Relationship, Drug; Drug Administration S | 2008 |
Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Topics: Adult; Aged; Allopurinol; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glomerular Filt | 2008 |
[Spa Treatment of increased uric acid and cholesterol levels].
Topics: Balneology; Diet Therapy; Female; Gout; Humans; Hypercholesterolemia; Male; Mineral Waters; Uric Aci | 1966 |
[Allopurinol in the treatment of gout and uric acid nephrolithiasis].
Topics: Allopurinol; Enzyme Therapy; Gout; Humans; Kidney Calculi; Uric Acid; Urinary Calculi; Xanthine Oxid | 1967 |
[Effect of benziodarone and benzbromarone on the uric acid level in the blood and urine and on the incidence of gout attacks].
Topics: Adult; Aged; Benzbromarone; Benzofurans; Clinical Trials as Topic; Gout; Humans; Male; Middle Aged; | 1980 |
A controlled study of the effect of long term allopurinol treatment on renal function in gout.
Topics: Allopurinol; Clinical Trials as Topic; Colchicine; Female; Follow-Up Studies; Gout; Humans; Kidney; | 1980 |
Benzbromarone as a long-term uricosuric agent.
Topics: Benzbromarone; Benzofurans; Clinical Trials as Topic; Follow-Up Studies; Gout; Humans; Uric Acid | 1980 |
The action of benzbromarone in relation to age, sex and accompanying diseases.
Topics: Benzbromarone; Benzofurans; Body Height; Body Weight; Clinical Trials as Topic; Female; Follow-Up St | 1980 |
[Mechanism of the action of allopurinol].
Topics: Adult; Aged; Allopurinol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind M | 1981 |
[The effect on uric acid and other laboratory parameters. A long-term study].
Topics: Allopurinol; Benzbromarone; Benzofurans; Clinical Trials as Topic; Gout; Humans; Uric Acid | 1982 |
Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia. A preliminary report.
Topics: Adult; Aged; Allopurinol; Apazone; Female; Gout; Humans; Kidney Function Tests; Male; Middle Aged; T | 1982 |
[Therapeutic efficacy of slow-release allopurinol in gout and hyperuricaemia (author's transl)].
Topics: Allopurinol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Gout; Humans; Uric Acid | 1981 |
Free oxypurines in plasma and urine of gout patients before and after a purine-free diet.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Creatinine; Diet Therapy; Female; Gout; Humans; H | 1994 |
The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Gout; Humans; Male; Middle Aged; Oxypurinol; Uric Acid | 1993 |
Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
Topics: Adult; Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Gout; Gout Suppressants; Humans | 1997 |
Determination of uric acid in scalp hair for non-invasive evaluation of uricemic controls in hyperuricemia.
Topics: Adult; Allopurinol; Gout; Gout Suppressants; Hair; Humans; Hydroxides; Middle Aged; Potassium Compou | 1998 |
Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Chronic Disease; Drug Administration Schedule; Gout; Gout S | 1998 |
Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.
Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Creatinine; Drug T | 2000 |
Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout.
Topics: Adult; Aged; Cluster Analysis; Creatinine; Eating; Gout; Humans; Insulin Resistance; Male; Middle Ag | 2001 |
Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
Topics: Allopurinol; Chronic Disease; Colchicine; Crystallization; Extracellular Space; Follow-Up Studies; G | 2001 |
Spot urine uric acid to creatinine ratio used in the estimation of uric acid excretion in primary gout.
Topics: Chemistry, Clinical; Circadian Rhythm; Creatinine; Eating; Gout; Humans; Male; Middle Aged; Sensitiv | 2001 |
Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout.
Topics: Adult; Aged; Body Burden; Chelating Agents; Cross-Sectional Studies; Edetic Acid; Female; Gout; Huma | 2001 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cross-Over Studies; Double-Blind | 2001 |
[Treatment of hyperuricemia using daily doses of 50 and 25mg of benzbromarone].
Topics: Benzbromarone; Clinical Trials as Topic; Drug Evaluation; Gout; Humans; Male; Uric Acid | 1977 |
Ticrynafen and probenecid in hyperuricemic, hypertensive men.
Topics: Blood Pressure; Blood Urea Nitrogen; Clinical Trials as Topic; Creatinine; Diuresis; Double-Blind Me | 1979 |
A new potent hypouricemic drug. A clinical trial of the drug in a group of gouty patients.
Topics: Benzofurans; Clinical Trials as Topic; Gout; Humans; Male; Middle Aged; Uric Acid | 1979 |
Urate kinetics in hypoxanthine-guanine phosphoribosyltransferase deficiency: their significance for the understanding of gout.
Topics: Adolescent; Adult; Arthritis; Clinical Trials as Topic; Creatinine; Female; Genetic Linkage; Glycine | 1976 |
[Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
Topics: Adult; Allopurinol; Benzbromarone; Benzofurans; Clinical Trials as Topic; Drug Combinations; Female; | 1976 |
[Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Calcium; Citrates; Creatinine; Glomerular Filt | 1977 |
Serum uric acid: its association with other risk factors and with mortality in coronary heart disease.
Topics: Adult; Aged; Diuretics; Follow-Up Studies; Gout; Humans; Male; Middle Aged; Myocardial Infarction; P | 1976 |
[Benzbromarone in the treatment of hyperuricemias].
Topics: Adult; Aged; Benzofurans; Clinical Trials as Topic; Drug Evaluation; Drug Tolerance; Ethacrynic Acid | 1975 |
[Uricolytic therapy. Value of urate oxidase in the treatment of hyperuricemias].
Topics: Acute Kidney Injury; Adult; Aged; Allantoin; Chemical Phenomena; Chemistry; Clinical Trials as Topic | 1975 |
Single daily dose of allopurinol.
Topics: Administration, Oral; Adult; Aged; Allopurinol; Clinical Trials as Topic; Gout; Humans; Middle Aged; | 1975 |
Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose.
Topics: Acute Disease; Adult; Aged; Allopurinol; Analysis of Variance; Chemical Phenomena; Chemistry; Gout; | 1975 |
[Pathogenesis and treatment of fast-induced hyperuricemia using benzbromarone].
Topics: Adolescent; Adult; Benzbromarone; Benzofurans; Fasting; Female; Gout; Humans; Male; Middle Aged; Sta | 1976 |
Hyperuricemia and gout in renal allograft recipients.
Topics: Adult; Azathioprine; Cyclosporine; Gout; Humans; Kidney Transplantation; Risk Factors; Transplantati | 1992 |
[Effectiveness and tolerance of long-term uricosuric treatment].
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug C | 1990 |
Gout and hyperuricemia.
Topics: Cyclosporins; Gout; Humans; Purines; Syndrome; Uric Acid | 1990 |
Intermittent control of hyperuricemia in the treatment of gout.
Topics: Allopurinol; Drug Administration Schedule; Gout; Humans; Male; Middle Aged; Randomized Controlled Tr | 1989 |
Observations with Rabenid in patients with locomotor disease.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Gout; Human | 1989 |
Hyperuricemia after renal transplantation.
Topics: Antilymphocyte Serum; Azathioprine; Clinical Trials as Topic; Cyclosporins; Drug Therapy, Combinatio | 1988 |
[The effect of allopurinol therapy on kidney processes concomitant with gout].
Topics: Allopurinol; Clinical Trials as Topic; Drug Evaluation; Gout; Humans; Kidney Diseases; Kidney Tubule | 1987 |
Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia.
Topics: Adult; Aged; Allopurinol; Apazone; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; D | 1987 |
Antihyperuricemic properties of amflutizole in gout.
Topics: Adult; Aged; Arthritis; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Tolerance; | 1985 |
Fructose-induced hyperuricaemia.
Topics: Fructose; Gout; Humans; Male; Uric Acid | 1971 |
[Treatment of hyperuricemic and gouty patients with derivatives of benzofuran].
Topics: Benzofurans; Bromine; Clinical Trials as Topic; Gout; Humans; Iodine; Uric Acid; Uricosuric Agents; | 1967 |
Renal excretion of ammonia and urate production: examination of Gutman-Yü hypothesis.
Topics: Adult; Aged; Ammonia; Ammonium Chloride; Bicarbonates; Clinical Trials as Topic; Glutamine; Gout; Hu | 1972 |
[Clinical trial of urate oxidase].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Diet, Reducing; Female; Gout; Humans; Kidney Fail | 1972 |
[Data on changes in blood and urinary uric acid induced by a urate oxidase].
Topics: Adult; Aged; Clinical Trials as Topic; Female; Gout; Humans; Injections, Intramuscular; Male; Middle | 1972 |
[Benziodarone in hyperuricemia due to renal insufficiency].
Topics: Acute Kidney Injury; Adult; Aged; Allopurinol; Benzofurans; Clinical Trials as Topic; Gout; Humans; | 1973 |
[First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
Topics: Cholesterol; Clinical Trials as Topic; Glycolates; Gout; Halofenate; Humans; Hyperlipidemias; Hypoli | 1973 |
Treatment of gout and hyperuricaemia by benzbromarone, ethyl 2 (dibromo-3,5 hydroxy-4 benzoyl)-3 benzofuran.
Topics: Benzoates; Bromine; Clinical Trials as Topic; Creatinine; Gout; Humans; Hypoxanthines; Probenecid; P | 1974 |
Uricosuric effect of glyceryl guaiacolate.
Topics: Clinical Trials as Topic; Gout; Guaifenesin; Humans; Male; Placebos; Uric Acid; Uricosuric Agents | 1974 |
Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects.
Topics: Adult; Allopurinol; Blood Pressure; Creatinine; Female; Follow-Up Studies; Glomerular Filtration Rat | 1974 |
Effect of allopurinol on urinary ammonia excretion in patients with gout.
Topics: Aged; Allopurinol; Ammonia; Ammonium Chloride; Clinical Trials as Topic; Computers; Female; Gout; Hu | 1969 |
Renal function in gout. 3. Estimation of tubular secretion and reabsorption of uric acid by use of pyrazinamide (pyrazinoic acid).
Topics: Adult; Allopurinol; Clinical Trials as Topic; Gout; Humans; Kidney Tubules; Metabolic Clearance Rate | 1969 |
A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents; Clinical Trials as Topic; Female; Flufenamic A | 1970 |
[Influence of aluminum nicotinate on serum lipids].
Topics: Adult; Alkaline Phosphatase; Aluminum; Arteriosclerosis; Blood Glucose; Cardiovascular Diseases; Cho | 1969 |
[New trend in gout treatment. Clinical and biological study of urate oxidase].
Topics: Adult; Aged; Clinical Trials as Topic; Female; Gout; Humans; Male; Middle Aged; Purines; Urate Oxida | 1971 |
Clinical efficacy and lack of toxicity of allopurinol (NSC-1390) given intravenously.
Topics: Administration, Oral; Adolescent; Adult; Alkaline Phosphatase; Allopurinol; Blood Urea Nitrogen; Chi | 1970 |
Comparison of allopurinol and probenecid.
Topics: Allopurinol; Clinical Trials as Topic; Colchicine; Enzyme Therapy; Follow-Up Studies; Gout; Humans; | 1966 |
Treatment of gout with allopurinol. A study of 106 cases.
Topics: Allopurinol; Clinical Trials as Topic; Colchicine; Diuresis; Enzymes; Gout; Humans; Purines; Uric Ac | 1966 |
Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone.
Topics: Acute Kidney Injury; Adult; Aged; Allopurinol; Arthritis, Rheumatoid; Clinical Trials as Topic; Duod | 1966 |
Effect of drugs on urate binding to plasma proteins.
Topics: Adult; Allopurinol; Arthritis; Aspirin; Blood Proteins; Chromatography, DEAE-Cellulose; Colchicine; | 1969 |
Allopurinol in treatment of gout.
Topics: Adult; Aged; Enzyme Therapy; Enzymes; Female; Gout; Humans; Liver Function Tests; Male; Middle Aged; | 1966 |
Other Studies
3422 other studies available for uric acid and Gout
| Article | Year |
|---|---|
Urate transport via human PAH transporter hOAT1 and its gene structure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Biological Transport; Blotting, Western; Car | 2003 |
High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies.
Topics: Animals; Gout; Humans; Mice; Polyethylene Glycols; Tissue Distribution; Urate Oxidase; Uric Acid | 2021 |
Using multiple Mendelian randomization approaches and genetic correlations to understand obesity, urate, and gout.
Topics: Causality; Genome-Wide Association Study; Gout; Humans; Linkage Disequilibrium; Lipoproteins, HDL; L | 2021 |
Incorporating gout guideline advice into urate reports is associated with reduced hospital admissions: results of an observational study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hospitals; Humans; Treatment Outcome; Uric Acid | 2022 |
Triterpenoid acids from medicinal mushroom Inonotus obliquus (Chaga) alleviate hyperuricemia and inflammation in hyperuricemic mice: Possible inhibitory effects on xanthine oxidase activity.
Topics: Agaricales; Animals; Gout; Hyperuricemia; Inflammation; Inonotus; Mice; Triterpenes; Uric Acid; Xant | 2022 |
X-ray dark-field radiography for in situ gout diagnosis by means of an ex vivo animal study.
Topics: Animals; Biomarkers; Crystallization; Gout; Joints; Lizards; Panthera; Radiography; Sensitivity and | 2021 |
Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.
Topics: Adult; Body Composition; Body Mass Index; China; Gout; Humans; Intra-Abdominal Fat; Male; Middle Age | 2021 |
Epidemiology of gout and hyperuricemia in New Caledonia.
Topics: Adolescent; Adult; Ethnicity; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; New Caledonia; | 2022 |
Gout, urate-lowering drugs, and risk of cardiovascular disease: can we clinically trust in the adjusted real-life data?
Topics: Cardiovascular Diseases; Gout; Humans; Pharmaceutical Preparations; Trust; Uric Acid | 2021 |
Guizhi-Shaoyao-Zhimu decoction attenuates monosodium urate crystal-induced inflammation through inactivation of NF-κB and NLRP3 inflammasome.
Topics: Animals; Caspase 1; Disease Models, Animal; Drugs, Chinese Herbal; Gout; Inflammasomes; Inflammation | 2022 |
CD38 activation by monosodium urate crystals contributes to inflammatory responses in human and murine macrophages.
Topics: ADP-ribosyl Cyclase 1; Animals; Crystallization; Female; Gene Expression Regulation; Gout; Humans; H | 2021 |
Pleiotropic Effects of Functional
Topics: Adult; Atherosclerosis; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Body Mass Index; DNA Met | 2021 |
Should we be more aware of gender aspects in hyperuricemia? Analysis of the population-based German health interview and examination survey for adults (DEGS1).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Cross-Sectional St | 2021 |
Pseudo-tumor of the patella due to gout tophi.
Topics: Arthritis, Gouty; Gout; Humans; Neoplasms; Patella; Uric Acid | 2022 |
Mechanosensitive TRPV4 is required for crystal-induced inflammation.
Topics: Adult; Animals; Arthralgia; Arthritis; Arthritis, Gouty; Crystal Arthropathies; Gout; Humans; Inflam | 2021 |
Gout-associated uric acid crystals induce tophi ulcerations and impair wound healing in a novel gouty ulcer model.
Topics: Animals; Arthritis, Gouty; Gout; Rats; Ulcer; Uric Acid; Wound Healing | 2022 |
Effect of integrated Traditional Chinese and Western Medicine on gout.
Topics: China; Drugs, Chinese Herbal; Gout; Humans; Medicine, Chinese Traditional; Uric Acid | 2021 |
Distribution of bony erosions in feet and performance of two bone erosion scores: A dual-energy computed tomography study of 61 patients with gout.
Topics: Gout; Humans; Middle Aged; Uric Acid | 2021 |
Comment on: Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank.
Topics: Biological Specimen Banks; Case-Control Studies; Gout; Humans; United Kingdom; Uric Acid | 2022 |
Comment on: Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank: reply.
Topics: Biological Specimen Banks; Case-Control Studies; Gout; Humans; United Kingdom; Uric Acid | 2022 |
Firm Nodule on the Ear.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Diagnosis, Differen | 2021 |
Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study.
Topics: Aged; Female; Gout; Gout Suppressants; Humans; Length of Stay; Male; Middle Aged; Native Hawaiian or | 2022 |
Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement.
Topics: Allopurinol; COVID-19; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pandemics; Prospective St | 2022 |
Gout Storm.
Topics: Colchicine; Gout; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Symptom Flare Up; Uric Acid | 2021 |
Effects of Washed Microbiota Transplantation on Serum Uric Acid Levels, Symptoms, and Intestinal Barrier Function in Patients with Acute and Recurrent Gout: A Pilot Study.
Topics: Endotoxins; Gout; Humans; Lactic Acid; Microbiota; Pilot Projects; Uric Acid | 2022 |
Epigenome-wide association study of serum urate reveals insights into urate co-regulation and the SLC2A9 locus.
Topics: Amino Acid Transport System y+; Cohort Studies; CpG Islands; DNA Methylation; Epigenome; Female; Gen | 2021 |
Assessing causality between osteoarthritis with urate levels and gout: a bidirectional Mendelian randomization study.
Topics: Genome-Wide Association Study; Gout; Humans; Mendelian Randomization Analysis; Osteoarthritis; Polym | 2022 |
Things We Do for No Reason™: Discontinuing urate-lowering therapy on admission.
Topics: Gout; Humans; Uric Acid | 2022 |
[Clinical characteristics of crystal deposits in joints and tendons in patients with gout].
Topics: Achilles Tendon; Gout; Humans; Knee Joint; Metatarsophalangeal Joint; Uric Acid | 2021 |
Factors associated with bone erosion in patients with gout: A dual-energy gemstone spectral imaging computed tomography study.
Topics: Arthritis, Gouty; Bone and Bones; Gout; Humans; Tomography, X-Ray Computed; Uric Acid | 2022 |
Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
Topics: Adolescent; Adult; Child; Cross-Sectional Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; I | 2021 |
Untreated Chronic Gout.
Topics: Aged; Arthrocentesis; Chronic Disease; Gout; Gout Suppressants; Hand; Humans; Male; Metatarsophalang | 2021 |
What Is Gout?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Gout Suppressants; Humans; Risk Factors; | 2021 |
Management of Gout.
Topics: Analgesics; Gout; Gout Suppressants; Humans; Practice Guidelines as Topic; Uric Acid; Uricosuric Age | 2021 |
A Case of Spinal Infectious Osteomyelitis Versus Gout: Advanced Imaging with Dual Energy CT.
Topics: Aged; Gout; Humans; Male; Osteomyelitis; Tomography, X-Ray Computed; Uric Acid | 2021 |
Patients with severe gout treated in mixed settings.
Topics: Aged; Female; Gout; Gout Suppressants; Humans; Male; Rheumatology; Treatment Outcome; Uric Acid | 2021 |
Comparison of Rates of Lower Extremity Amputation in Patients With and Without Gout in the US Department of Veterans Affairs Health System.
Topics: Aged; Amputation, Surgical; Cohort Studies; Female; Gout; Humans; Incidence; Lower Extremity; Male; | 2022 |
Recombinant Human Proteoglycan 4 Regulates Phagocytic Activation of Monocytes and Reduces IL-1β Secretion by Urate Crystal Stimulated Gout PBMCs.
Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents; Female; Free Radi | 2021 |
IL-37 blocks gouty inflammation by shaping macrophages into a non-inflammatory phagocytic phenotype.
Topics: Animals; Arthritis, Gouty; Glycogen Synthase Kinase 3 beta; Gout; Humans; Inflammation; Interleukin- | 2022 |
Vascular deposition of monosodium urate crystals in gout: analysis of cadaveric tissue by dual-energy computed tomography and compensated polarizing light microscopy.
Topics: Cadaver; Gout; Humans; Microscopy, Polarization; Tomography, X-Ray Computed; Uric Acid | 2022 |
Remission in Gout: Concepts From a Patient Perspective.
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 2022 |
Influence of Pinealectomy and Long-term Melatonin Administration on Inflammation and Oxidative Stress in Experimental Gouty Arthritis.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Gout; Inflammation; Melatonin; Ox | 2022 |
The Anti-Inflammatory and Uric Acid Lowering Effects of Si-Miao-San on Gout.
Topics: Animals; Anti-Inflammatory Agents; Chromones; Drugs, Chinese Herbal; Gout; Humans; Macrophages; Male | 2021 |
Association of acidic urine pH with impaired renal function in primary gout patients: a Chinese population-based cross-sectional study.
Topics: China; Cross-Sectional Studies; Gout; Humans; Hydrogen-Ion Concentration; Kidney; Kidney Calculi; Pr | 2022 |
Evolving Role of Dual-Energy CT in the Clinical Workup of Gout: A Retrospective Study.
Topics: Adult; Gout; Humans; Retrospective Studies; Tin; Tomography, X-Ray Computed; Uric Acid | 2022 |
Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.
Topics: Animals; Gout; Humans; Hyperuricemia; Mice; Organic Anion Transporters; Organic Cation Transport Pro | 2022 |
Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.
Topics: Anti-Inflammatory Agents; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Therapy, Combination; | 2022 |
Ocular manifestation in gout: an unusual presentation of gout.
Topics: Eye; Gout; Humans; Uric Acid | 2022 |
Is repeat serum urate testing superior to a single test to predict incident gout over time?
Topics: Adult; Area Under Curve; Female; Gout; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; R | 2022 |
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Cardiovascular Diseases; Gout; Heart Disease Risk Factors; Humans; Lupus | 2022 |
[Gout: an overview of diagnostics and treatment].
Topics: Gout; Humans; Hyperuricemia; Tomography, X-Ray Computed; Ultrasonography; Uric Acid | 2022 |
Colchicine use and the risk of CKD progression: a multicentre nested case-control study.
Topics: Case-Control Studies; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal | 2022 |
Green pixels on DECT: Is it gout?
Topics: Gout; Humans; Uric Acid | 2022 |
Why Do Patients With Gout Not Take Allopurinol?
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Male; Rheumatology; Treatment Outcome; Uric Acid | 2022 |
The shrinking toe sign in gout.
Topics: Gout; Humans; Metatarsophalangeal Joint; Retrospective Studies; Toes; Uric Acid | 2022 |
Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients.
Topics: Cognition; Decision Support Techniques; Gout; Gout Suppressants; Humans; Uric Acid | 2022 |
[Management of hyperuricemia in chronic kidney disease].
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2022 |
Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.
Topics: Arthritis, Gouty; Chronic Disease; Gout; Gout Suppressants; Humans; Pain; Polyethylene Glycols; Trea | 2022 |
Treating gout - can hypouricemia produced by moderate doses of combined oral treatment give early treatment success? Preliminary observations.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Male; Treatment Outcome; Uric Acid | 2022 |
What is the Place for Uricosuric Agents in Gout Management?
Topics: Gout; Humans; Uric Acid; Uricosuric Agents | 2022 |
A machine learning-assisted model for renal urate underexcretion with genetic and clinical variables among Chinese men with gout.
Topics: Asian People; Glucose Transport Proteins, Facilitative; Gout; Humans; Hyperuricemia; Machine Learnin | 2022 |
Assessing the Causal Effects of Adipokines on Uric Acid and Gout: A Two-Sample Mendelian Randomization Study.
Topics: Adipokines; Genome-Wide Association Study; Gout; Humans; Mendelian Randomization Analysis; Polymorph | 2022 |
Hospitalizations for Acute Gout: Process Mapping the Inpatient Journey and Identifying Predictors of Admission.
Topics: Aftercare; Arthritis, Gouty; Gout; Gout Suppressants; Hospitalization; Humans; Inpatients; Patient D | 2022 |
Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy.
Topics: Adult; Arthritis, Gouty; Gout; Humans; Male; Methotrexate; Middle Aged; Tomography, X-Ray Computed; | 2022 |
Natural antibodies and CRP drive anaphylatoxin production by urate crystals.
Topics: Anaphylatoxins; C-Reactive Protein; Gout; Humans; Immunoglobulin M; Receptors, Immunologic; Uric Aci | 2022 |
Retrospective longitudinal assessment of ultrasound gout lesions using the OMERACT semi-quantitative scoring system.
Topics: Arthritis, Gouty; Gout; Humans; Retrospective Studies; Ultrasonography; Uric Acid | 2022 |
The correlation of uric acid levels with biochemical parameters and dietary factors in individuals with asymptomatic hyperuricemia and gouty arthritis.
Topics: Arthritis, Gouty; Female; Gout; Humans; Hyperuricemia; Male; Triglycerides; Uric Acid; Vitamins | 2022 |
Comparison of ultrasound attenuation by calcium pyrophosphate, hydroxyapatite and monosodium urate crystals: a proof-of-concept study.
Topics: Calcium Pyrophosphate; Chondrocalcinosis; Durapatite; Gout; Humans; Uric Acid | 2022 |
Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients.
Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease | 2023 |
Association between serum uric acid and α-klotho protein levels in the middle-aged population.
Topics: Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Hyperuricemia; Klotho Proteins; Male; Middle A | 2022 |
Translation, internal consistency, reliability and validity of the Thai version of Gout Assessment Questionnaire version 2.0 (GAQ 2.0).
Topics: Gout; Humans; Psychometrics; Quality of Life; Reproducibility of Results; Surveys and Questionnaires | 2022 |
Kv1.5 channel mediates monosodium urate-induced activation of NLRP3 inflammasome in macrophages and arrhythmogenic effects of urate on cardiomyocytes.
Topics: Animals; Atrial Remodeling; Caspase 1; Gout; Humans; Inflammasomes; Interleukin-1beta; Kv1.5 Potassi | 2022 |
The Negative Association Between NAFLD Severity and CKD in a Non-Diabetic Gouty Population.
Topics: Cross-Sectional Studies; Female; Gout; Humans; Male; Non-alcoholic Fatty Liver Disease; Renal Insuff | 2022 |
A fly GWAS for purine metabolites identifies human FAM214 homolog medusa, which acts in a conserved manner to enhance hyperuricemia-driven pathologies by modulating purine metabolism and the inflammatory response.
Topics: Animals; Drosophila melanogaster; Drosophila Proteins; Genome-Wide Association Study; Gout; Humans; | 2022 |
Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout.
Topics: Gout; Gout Suppressants; Humans; Internet; Motivation; Uric Acid | 2022 |
Cardiovascular risk factors, ethnicity and infection stone are independent factors associated with reduced renal function in renal stone formers.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus; Ethnicity; Female; Gout; Heart | 2022 |
Probiotic Characterization of
Topics: Animals; Caco-2 Cells; Gout; Gout Suppressants; Humans; Hyperuricemia; Levilactobacillus brevis; Mic | 2022 |
One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study.
Topics: Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Symptom Flare Up; Uric Acid | 2022 |
[Gout attack].
Topics: Gout; Humans; Uric Acid | 2022 |
The Relationship between Alcohol Consumption and Gout: A Mendelian Randomization Study.
Topics: Alcohol Drinking; Gout; Humans; Hyperuricemia; Mendelian Randomization Analysis; Uric Acid | 2022 |
Assessing the Sensitivity of Dual-Energy Computed Tomography 3-Material Decomposition for the Detection of Gout.
Topics: Gout; Humans; Phantoms, Imaging; Tomography, X-Ray Computed; Uric Acid | 2022 |
Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing.
Topics: Gout; Humans; Hyperuricemia; Kidney; Uric Acid | 2022 |
Are we asking the right questions about urate-lowering therapy? Comment on the 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout.
Topics: Asia; Gout; Gout Suppressants; Humans; Rheumatology; Uric Acid | 2022 |
Risk of Parkinson's disease in a gout Mediterranean population: A case-control study.
Topics: Adult; Aged; Case-Control Studies; Cohort Studies; Female; Gout; Humans; Male; Neuroprotective Agent | 2022 |
Anti-inflammatory and Antioxidant Effect of Poly-gallic Acid (PGAL) in an In Vitro Model of Synovitis Induced by Monosodium Urate Crystals.
Topics: Anti-Inflammatory Agents; Antioxidants; Gallic Acid; Gout; Humans; Inflammation; Polyglutamic Acid; | 2022 |
Differential gene expression of ABCG2, SLC22A12, IL-1β, and ALPK1 in peripheral blood leukocytes of primary gout patients with hyperuricemia and their comorbidities: a case-control study.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Case-Control Studies; Gene Expression; Gout | 2022 |
Prediction of the Uric Acid Component in Nephrolithiasis Using Simple Clinical Information about Metabolic Disorder and Obesity: A Machine Learning-Based Model.
Topics: Female; Gout; Humans; Kidney Calculi; Machine Learning; Male; Obesity; Uric Acid | 2022 |
Urate-lowering therapy for patients with gout on hemodialysis.
Topics: Aged; Female; Gout; Gout Suppressants; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; Uric A | 2022 |
Altered Gut Microbiota in Children With Hyperuricemia.
Topics: Adult; Bacteria; Child; Gastrointestinal Microbiome; Gout; Humans; Hyperuricemia; RNA, Ribosomal, 16 | 2022 |
Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
Topics: Aged; Allopurinol; Austria; Cardiovascular Diseases; Cohort Studies; Febuxostat; Female; Gout; Gout | 2022 |
[Gout].
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Symptom Flare Up; Uric Acid | 2022 |
Distinct macrophage polarization in acute and chronic gout.
Topics: Animals; Arginase; Gout; Humans; Inflammation; Macrophages; Mice; Nitric Oxide Synthase Type II; RNA | 2022 |
What do we know about Toll-Like Receptors Involvement in Gout Arthritis?
Topics: Adaptor Proteins, Signal Transducing; Animals; Arthritis, Gouty; Gout; Humans; Mice; Toll-Like Recep | 2023 |
Genetically predicted physical activity is associated with lower serum urate concentrations.
Topics: Exercise; Genetic Predisposition to Disease; Genome-Wide Association Study; Gout; Humans; Mendelian | 2022 |
Are polymorphisms affecting serum urate, renal urate handling and alcohol intake associated with co-morbidities in gout cases? A case-control study using data from the UK Biobank.
Topics: Alcohol Drinking; Biological Specimen Banks; Case-Control Studies; Genetic Predisposition to Disease | 2022 |
Early hearing loss detection in gout using extended high frequency audiometry.
Topics: Audiometry; Audiometry, Pure-Tone; Auditory Threshold; Cross-Sectional Studies; Deafness; Gout; Hear | 2022 |
Investigation on monosodium urate deposition in the first metatarsophalangeal joint and ankle of primary gout patients using dual-energy computed tomography.
Topics: Ankle; Cross-Sectional Studies; Gout; Humans; Metatarsophalangeal Joint; Tomography, X-Ray Computed; | 2022 |
Phytochemicals in traditional Chinese medicine can treat gout by regulating intestinal flora through inactivating NLRP3 and inhibiting XOD activity.
Topics: Gastrointestinal Microbiome; Gout; Humans; Hyperuricemia; Inflammation; Lipopolysaccharides; Medicin | 2022 |
Natural Adrenocorticotropic Hormone (ACTH) Relieves Acute Inflammation in Gout Patients by Changing the Function of Macrophages.
Topics: Adrenocorticotropic Hormone; Animals; Arthritis, Gouty; Dexamethasone; Gout; Humans; Hydrocortisone; | 2022 |
The Inhibition of Osteoblast Viability by Monosodium Urate Crystal-Stimulated Neutrophil-Derived Exosomes.
Topics: Exosomes; Gout; Humans; MicroRNAs; Neutrophils; Osteoblasts; Uric Acid | 2022 |
Polysaccharide extract from Isatidis Radix inhibits multiple inflammasomes activation and alleviate gouty arthritis.
Topics: Animals; Arthritis, Gouty; Gout; Inflammasomes; Interleukin-1beta; Macrophages; Mice; NLR Family, Py | 2022 |
The disproportionately large contribution of the Māori and Pacific Islander community to the healthcare burden of gout in Western Sydney.
Topics: Cost of Illness; Delivery of Health Care; Gout; Humans; Maori People; New South Wales; Pacific Islan | 2023 |
Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions.
Topics: Allopurinol; Australia; Colchicine; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Pha | 2022 |
Association of the Quantity, Duration, and Type of Alcohol Consumption on the Development of Gouty Tophi.
Topics: Alcohol Drinking; Gout; Humans; Risk Factors; Uric Acid | 2023 |
Taxifolin blocks monosodium urate crystal-induced gouty inflammation by regulating phagocytosis and autophagy.
Topics: Arthritis, Gouty; Autophagy; Gout; Humans; Inflammation; Interleukin-1beta; Phagocytosis; Quercetin; | 2022 |
TET2-mutant clonal hematopoiesis and risk of gout.
Topics: Animals; Clonal Hematopoiesis; Dioxygenases; DNA-Binding Proteins; Gout; Humans; Inflammasomes; Inte | 2022 |
Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia.
Topics: Caspase 1; Ethanol; Gout; Humans; Hyperuricemia; Inflammasomes; Interleukin-1beta; NLR Family, Pyrin | 2022 |
Upregulated expression of FFAR2 and SOC3 genes is associated with gout.
Topics: Cytokines; Gout; Humans; Hyperuricemia; Symptom Flare Up; Uric Acid | 2023 |
Prevalence of Patients Receiving Urate-Lowering Medicine in Greenland and Denmark: A Cross-Sectional Case-Control Study.
Topics: Case-Control Studies; Cross-Sectional Studies; Female; Gout; Gout Suppressants; Greenland; Humans; H | 2022 |
Genetic contributions to female gout and hyperuricaemia using genome-wide association study and polygenic risk score analyses.
Topics: Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Glucose Transport Proteins | 2023 |
Determination of total purine and free purine content in milk, soymilk, and enteral nutritional supplements to assist nutritional therapy for hyperuricemia and gout.
Topics: Aged; Animals; Gout; Humans; Hyperuricemia; Milk; Purines; Uric Acid | 2022 |
Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the Clinical Practice Research Datalink.
Topics: Allopurinol; Cohort Studies; COVID-19; Gout; Gout Suppressants; Humans; Pandemics; Uric Acid | 2022 |
Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort.
Topics: China; Cohort Studies; Gout; Gout Suppressants; Humans; Male; Uric Acid | 2022 |
Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia.
Topics: Animals; Antioxidants; Cornus; Gout; Hyperuricemia; Mice; Oxonic Acid; Plant Extracts; Uric Acid; Xa | 2022 |
[X-Ray Dark-field radiography: Does this carry potential for diagnosing gout in exotic pets?]
Topics: Animals; Animals, Exotic; Gout; Radiography; Uric Acid; X-Rays | 2022 |
Monosodium urate deposition in the lumbosacral spine of patients with gout compared with non-gout controls: A dual-energy CT study.
Topics: Adult; Arthritis, Gouty; Case-Control Studies; Gout; Humans; Prevalence; Tomography, X-Ray Computed; | 2022 |
The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data.
Topics: Cohort Studies; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Insurance, Health; Jap | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topics: Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Observational Studies as To | 2022 |
Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study.
Topics: Genome-Wide Association Study; Glycated Hemoglobin; Gout; Humans; Polymorphism, Single Nucleotide; S | 2022 |
Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study.
Topics: Adult; Aged; Biomarkers; Carotid Arteries; Carotid Intima-Media Thickness; Cross-Sectional Studies; | 2022 |
Acute joint swelling in psoriatic arthritis: Flare or "psout"-A 10-year-monocentric study on synovial fluid.
Topics: Adult; Arthritis, Psoriatic; Female; Gout; Humans; Hyperuricemia; Male; Retrospective Studies; Synov | 2022 |
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes.
Topics: Adipocytes; Allopurinol; Colchicine; Enzyme Inhibitors; Fatty Acids, Nonesterified; Febuxostat; Gout | 2022 |
A rare presentation of a first gout flare.
Topics: Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid | 2023 |
Monosodium urate crystals with controlled shape and aspect ratio for elucidating the pathological progress of acute gout.
Topics: Arthritis, Gouty; Gout; Humans; Inflammasomes; Macrophages; Uric Acid | 2022 |
Protective effects of di-caffeoylquinic acids from Artemisia selengensis Turcz leaves against monosodium urate-induced inflammation via the modulation of NLRP3 inflammasome and Nrf2 signaling pathway in THP-1 macrophages.
Topics: Artemisia; Gout; Inflammasomes; Inflammation; Interleukin-1beta; Macrophages; NF-E2-Related Factor 2 | 2022 |
Study on the interaction mechanism between luteoloside and xanthine oxidase by multi-spectroscopic and molecular docking methods.
Topics: Enzyme Inhibitors; Gout; Humans; Molecular Docking Simulation; Spectrometry, Fluorescence; Uric Acid | 2022 |
Should Low Serum Urate Be Exonerated? Untangling the Influence of Sarcopenia in Observational Studies.
Topics: Cardiovascular Diseases; Gout; Humans; Sarcopenia; Uric Acid | 2023 |
Ultrasonography in the prediction of gout flares: a 12-month prospective observational study.
Topics: Gout; Humans; Inflammation; Prospective Studies; Symptom Flare Up; Ultrasonography; Uric Acid | 2023 |
Purine content of hospital meals and its effect on serum uric acid, urine pH, and urinary uric acid excretion.
Topics: Gout; Hospitals; Humans; Hydrogen-Ion Concentration; Hyperuricemia; Meals; Purines; Uric Acid | 2022 |
Anti-inflammatory potential of stevia residue extract against uric acid-associated renal injury in mice.
Topics: Allopurinol; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Colchicine; Creatinin | 2022 |
Predictors of disease activity in gout: a 12-month analysis of the ATTACk (Achieving improvement in the management of crystal-induced arthritis) multicentre cohort study.
Topics: Aged; Cohort Studies; Female; Gout; Gout Suppressants; Humans; Linear Models; Male; Middle Aged; Uri | 2023 |
Correlation of obesity, dietary patterns, and blood pressure with uric acid: data from the NHANES 2017-2018.
Topics: Blood Pressure; Cross-Sectional Studies; Gout; Humans; Hyperuricemia; Nutrition Surveys; Obesity; Ri | 2022 |
Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gout; Humans; Hyperuricemia; Neoplasm Prote | 2023 |
Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Aci | 2022 |
The Association of Serum Uric Acid Level, Gout, and Alzheimer's Disease: A Bidirectional Mendelian Randomization Study.
Topics: Alzheimer Disease; Genome-Wide Association Study; Gout; Humans; Mendelian Randomization Analysis; Po | 2022 |
The role of obesity, type 2 diabetes, and metabolic factors in gout: A Mendelian randomization study.
Topics: Diabetes Mellitus, Type 2; Genome-Wide Association Study; Gout; Humans; Hypertension; Mendelian Rand | 2022 |
A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an
Topics: Gout; Gout Suppressants; Humans; Male; Methotrexate; Polyethylene Glycols; Symptom Flare Up; Treatme | 2022 |
The paradoxical relation between serum uric acid and outcomes of hip fracture in older patients after surgery: A 1-year follow-up study.
Topics: Aged; Female; Follow-Up Studies; Gout; Hip Fractures; Humans; Hyperuricemia; Male; Risk Factors; Uri | 2022 |
Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long-Term Urate-Lowering Therapy in the American College of Rheumatology RISE Registry.
Topics: Aged; Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Registries; Rheumatol | 2023 |
Using Data-Driven Approaches to Classify and Predict Health Care Spending in Patients With Gout Using Urate-Lowering Therapy.
Topics: Aged; Aged, 80 and over; Female; Gout; Gout Suppressants; Health Expenditures; Humans; Male; Medicat | 2023 |
Living with gout. Experiences, impact and challenges of the disease. Qualitative study through focus groups.
Topics: Exercise; Female; Focus Groups; Gout; Humans; Male; Qualitative Research; Uric Acid | 2023 |
Clinical Effect of the Guizhi Shaoyao Zhimu Decoction in the Treatment of Hyperuricemia.
Topics: Gout; Humans; Hyperuricemia; Medicine, Chinese Traditional; Treatment Outcome; Uric Acid | 2022 |
Modelling and assessing one- and two-drug dose titrations.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospective Studies; Uric Acid | 2022 |
Isolation, identification, and pathogenicity of a goose astrovirus causing fatal gout in goslings.
Topics: Amino Acids; Animals; Astroviridae Infections; Avastrovirus; Biological Products; China; Geese; Gout | 2022 |
Type II collagen facilitates gouty arthritis by regulating MSU crystallisation and inflammatory cell recruitment.
Topics: Arthritis, Gouty; Collagen Type II; Cytokines; Gout; Humans; Inflammation; Matrilin Proteins; Uric A | 2023 |
Gout Flares and Intercritical Gout: Do they Play a Significant Role in Predicting Cardiovascular Events?
Topics: Cardiovascular Diseases; Chronic Disease; Gout; Humans; Symptom Flare Up; Uric Acid | 2022 |
Assessing the causal associations of obstructive sleep apnea with serum uric acid levels and gout: a bidirectional two-sample Mendelian randomization study.
Topics: Diabetes Mellitus, Type 2; Genome-Wide Association Study; Gout; Humans; Mendelian Randomization Anal | 2022 |
Gouty sacroiliitis: A case report of an often-overlooked cause of inflammatory back pain.
Topics: Arthritis, Gouty; Back Pain; Gout; Humans; Sacroiliac Joint; Sacroiliitis; Uric Acid | 2023 |
Outcomes of surgery for gouty tophi in the extremities.
Topics: Extremities; Female; Gout; Humans; Male; Middle Aged; Treatment Outcome; Uric Acid | 2022 |
Long-Term Adherence to Urate-Lowering Therapy in Gout: A Glass Half Empty or a Glass Half Full?
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 2022 |
Changes in purine and uric acid content in edible insects during culinary processing.
Topics: Animals; Edible Insects; Gout; Gryllidae; Humans; Insecta; Purines; Uric Acid; Xanthine | 2023 |
Surgical Treatment of Hand and Foot Gout Stone and Influence Factors on Prognosis.
Topics: Calcium Carbonate; Gout; Humans; Prognosis; Retrospective Studies; Uric Acid | 2022 |
Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors.
Topics: Animals; Gout; Humans; Hyperuricemia; Mice; Organic Anion Transporters; Organic Cation Transport Pro | 2022 |
Polygenic risk score trend and new variants on chromosome 1 are associated with male gout in genome-wide association study.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Chromosomes, Human, Pair 1; Female; Genetic | 2022 |
Letter to the editor regarding "urate-lowering therapy for patients with gout on hemodialysis".
Topics: Gout; Gout Suppressants; Humans; Renal Dialysis; Uric Acid | 2023 |
Predictors of Patient and Physician Assessments of Gout Control.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid | 2023 |
The Role of Ultrasound in Evaluating the Effect of Urate-lowering Drugs in Gout Patients.
Topics: Gout; Humans; Metatarsophalangeal Joint; Synovial Fluid; Ultrasonography; Uric Acid | 2022 |
Prevalence of motor neuron diseases in gout patients: a nationwide population-based cohort study.
Topics: Cohort Studies; Female; Gout; Humans; Motor Neuron Disease; Prevalence; Uric Acid | 2023 |
The ultrasonographic pseudo-double contour sign in calcium pyrophosphate deposition disease: an anatomic explanation and how to distinguish it from gout.
Topics: Chondrocalcinosis; Gout; Humans; Ultrasonography; Uric Acid | 2023 |
[Advantages of the use of metformin in patients with impaired uric acid metabolism].
Topics: Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Hypoglycemic Agent | 2021 |
Gout in Dalarna, Sweden - a population-based study of gout occurrence and compliance to treatment guidelines.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Sweden; Treatment Outcome; Uric Acid | 2023 |
Association between serum free fatty acid levels and tophus in patients with gout: a cross-sectional study.
Topics: Cross-Sectional Studies; Fatty Acids, Nonesterified; Gout; Humans; Uric Acid | 2023 |
Interplay between fat, muscle, bone mass, and oteophytes and risk for tophaceous gout.
Topics: Adipose Tissue; Aged; Bone Density; Case-Control Studies; Cross-Sectional Studies; Gout; Humans; Mal | 2023 |
Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study.
Topics: Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Surveys and Questio | 2022 |
Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Dise | 2023 |
A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout.
Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Febuxostat; Female; Gout; Gout Suppressants; Humans; Mal | 2023 |
Orthopaedic Management of Gout.
Topics: Cartilage; Gout; Humans; Knee Joint; Orthopedics; Uric Acid | 2022 |
Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
Topics: Cohort Studies; Colchicine; England; Gout; Gout Suppressants; Hospitalization; Humans; Uric Acid | 2023 |
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva | 2023 |
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva | 2023 |
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva | 2023 |
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva | 2023 |
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva | 2023 |
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva | 2023 |
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva | 2023 |
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva | 2023 |
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva | 2023 |
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org | 2023 |
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org | 2023 |
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org | 2023 |
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org | 2023 |
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org | 2023 |
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org | 2023 |
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org | 2023 |
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org | 2023 |
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
Topics: Allopurinol; Glucose Transport Proteins, Facilitative; Gout; Humans; Organic Anion Transporters; Org | 2023 |
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid | 2023 |
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid | 2023 |
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid | 2023 |
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid | 2023 |
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid | 2023 |
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid | 2023 |
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid | 2023 |
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid | 2023 |
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid | 2023 |
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi | 2023 |
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi | 2023 |
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi | 2023 |
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi | 2023 |
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi | 2023 |
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi | 2023 |
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi | 2023 |
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi | 2023 |
Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia.
Topics: beta 2-Microglobulin; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi | 2023 |
Characteristic alterations of gut microbiota in uncontrolled gout.
Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid | 2022 |
Characteristic alterations of gut microbiota in uncontrolled gout.
Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid | 2022 |
Characteristic alterations of gut microbiota in uncontrolled gout.
Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid | 2022 |
Characteristic alterations of gut microbiota in uncontrolled gout.
Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid | 2022 |
Characteristic alterations of gut microbiota in uncontrolled gout.
Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid | 2022 |
Characteristic alterations of gut microbiota in uncontrolled gout.
Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid | 2022 |
Characteristic alterations of gut microbiota in uncontrolled gout.
Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid | 2022 |
Characteristic alterations of gut microbiota in uncontrolled gout.
Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid | 2022 |
Characteristic alterations of gut microbiota in uncontrolled gout.
Topics: Bacteria; Feces; Gastrointestinal Microbiome; Gout; Humans; RNA, Ribosomal, 16S; Uric Acid | 2022 |
Increase in different peripheral effector T subsets in acute and chronic gout.
Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid | 2023 |
Increase in different peripheral effector T subsets in acute and chronic gout.
Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid | 2023 |
Increase in different peripheral effector T subsets in acute and chronic gout.
Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid | 2023 |
Increase in different peripheral effector T subsets in acute and chronic gout.
Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid | 2023 |
Increase in different peripheral effector T subsets in acute and chronic gout.
Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid | 2023 |
Increase in different peripheral effector T subsets in acute and chronic gout.
Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid | 2023 |
Increase in different peripheral effector T subsets in acute and chronic gout.
Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid | 2023 |
Increase in different peripheral effector T subsets in acute and chronic gout.
Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid | 2023 |
Increase in different peripheral effector T subsets in acute and chronic gout.
Topics: Gout; Humans; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Uric Acid | 2023 |
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk | 2023 |
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk | 2023 |
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk | 2023 |
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk | 2023 |
HQL6 serves as a novel P2Y
Topics: Animals; Arthritis, Gouty; Gout; Macrophages; Pyroptosis; Rats; Uric Acid | 2023 |
HQL6 serves as a novel P2Y
Topics: Animals; Arthritis, Gouty; Gout; Macrophages; Pyroptosis; Rats; Uric Acid | 2023 |
HQL6 serves as a novel P2Y
Topics: Animals; Arthritis, Gouty; Gout; Macrophages; Pyroptosis; Rats; Uric Acid | 2023 |
HQL6 serves as a novel P2Y
Topics: Animals; Arthritis, Gouty; Gout; Macrophages; Pyroptosis; Rats; Uric Acid | 2023 |
An interesting tophus in gingiva.
Topics: Arthritis, Gouty; Gingiva; Gout; Humans; Uric Acid | 2023 |
An interesting tophus in gingiva.
Topics: Arthritis, Gouty; Gingiva; Gout; Humans; Uric Acid | 2023 |
An interesting tophus in gingiva.
Topics: Arthritis, Gouty; Gingiva; Gout; Humans; Uric Acid | 2023 |
An interesting tophus in gingiva.
Topics: Arthritis, Gouty; Gingiva; Gout; Humans; Uric Acid | 2023 |
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Mice; Neutrophils; Ph | 2022 |
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Mice; Neutrophils; Ph | 2022 |
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Mice; Neutrophils; Ph | 2022 |
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Mice; Neutrophils; Ph | 2022 |
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl | 2022 |
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl | 2022 |
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl | 2022 |
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl | 2022 |
Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction.
Topics: Animals; Chalcone; Chalcones; Enzyme Inhibitors; Gout; Hyperuricemia; Rats; Structure-Activity Relat | 2023 |
Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction.
Topics: Animals; Chalcone; Chalcones; Enzyme Inhibitors; Gout; Hyperuricemia; Rats; Structure-Activity Relat | 2023 |
Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction.
Topics: Animals; Chalcone; Chalcones; Enzyme Inhibitors; Gout; Hyperuricemia; Rats; Structure-Activity Relat | 2023 |
Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction.
Topics: Animals; Chalcone; Chalcones; Enzyme Inhibitors; Gout; Hyperuricemia; Rats; Structure-Activity Relat | 2023 |
Associations of metal exposure with hyperuricemia and gout in general adults.
Topics: Cross-Sectional Studies; Gout; Humans; Hyperuricemia; Mercury; Nutrition Surveys; Selenium; Uric Aci | 2022 |
Response to "Urate lowering therapy for patients with gout on hemodialysis".
Topics: Gout; Gout Suppressants; Humans; Renal Dialysis; Uric Acid | 2023 |
Uricase-Deficient Larval Zebrafish with Elevated Urate Levels Demonstrate Suppressed Acute Inflammatory Response to Monosodium Urate Crystals and Prolonged Crystal Persistence.
Topics: Animals; Gout; Humans; Inflammation; Urate Oxidase; Uric Acid; Zebrafish | 2022 |
Assessing tophaceous spinal gout treatment response using dual-energy CT as a point-of-care imaging modality: case report.
Topics: Aged; Febuxostat; Gout; Humans; Male; Point-of-Care Systems; Tomography, X-Ray Computed; Uric Acid | 2023 |
Neutrophil extracellular traps induce the bone erosion of gout.
Topics: Animals; Extracellular Traps; Gout; Sodium; Uric Acid | 2022 |
Overnutrition-induced gout: An immune response to NLRP3 inflammasome dysregulation by XOD activity increased in quail.
Topics: Animals; Arthritis, Gouty; Enzyme Inhibitors; Gout; Hyperuricemia; Immunity; Inflammasomes; NLR Fami | 2022 |
Lipoxin A4 attenuates MSU-crystal-induced NLRP3 inflammasome activation through suppressing Nrf2 thereby increasing TXNRD2.
Topics: Animals; Gout; Inflammasomes; Inflammation; Macrophages; NF-E2-Related Factor 2; NLR Family, Pyrin D | 2022 |
Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
Topics: Adult; Gout; Gout Suppressants; Humans; Methotrexate; Polyethylene Glycols; Quality of Life; Treatme | 2022 |
Neutrophil Extracellular Trap-Borne Elastase Prevents Inflammatory Relapse in Intercritical Gout.
Topics: Animals; Chronic Disease; Extracellular Traps; Gout; Inflammation; Leukocyte Elastase; Mice; Uric Ac | 2023 |
Rutin ameliorates gout via reducing XOD activity, inhibiting ROS production and NLRP3 inflammasome activation in quail.
Topics: Animals; Gout; Inflammasomes; Inflammation; NLR Family, Pyrin Domain-Containing 3 Protein; Quail; Re | 2023 |
Associations between serum urate and telomere length and inflammation markers: Evidence from UK Biobank cohort.
Topics: Biological Specimen Banks; Biomarkers; Genome-Wide Association Study; Gout; Humans; Hyperuricemia; I | 2022 |
[Clinical and ultrasonic characteristics of male gout patients with normal serum uric acid].
Topics: Gout; Gout Suppressants; Humans; Male; Retrospective Studies; Ultrasonics; Uric Acid | 2023 |
Changes in Tophus Composition During Urate-Lowering Therapy: A Dual-Energy Computed Tomography Study.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Tomography, X-Ray Computed; Uric Acid | 2023 |
Gout Flare and Cardiovascular Events-Reply.
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid | 2023 |
Gout Flare and Cardiovascular Events.
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid | 2023 |
Optimizing adherence to allopurinol for gout: patients' perspectives.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Medication Adherence; Uric Acid | 2023 |
Cutting Edge: Negative Regulation of Inflammasome Activation by TRAF1 Can Limit Gout.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cytokines; Gout; Humans; Inflammasomes; Interleukin-1 | 2023 |
Evaluation of ABCG2-mediated extra-renal urate excretion in hemodialysis patients.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gout; Humans; Hyperuricemia; Kidney; Neopla | 2023 |
Nutrition Interventions for the Management of Gout.
Topics: Gout; Humans; Uric Acid | 2023 |
Global status and trends in gout research from 2012 to 2021: a bibliometric and visual analysis.
Topics: Bibliometrics; Gout; Humans; Inflammasomes; NLR Family, Pyrin Domain-Containing 3 Protein; Uric Acid | 2023 |
The risk of nonalcoholic fatty liver disease in gout patients with frequent flares: a retrospective cohort study.
Topics: Gout; Humans; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Risk Factors; Uric Acid | 2023 |
Acute gout attacks during the perioperative period and risk factors of recurrence after orthopedic surgery among untreated gout patients.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Orthopedic Procedures; Perioperative Period; Retrospe | 2023 |
P2X7R Mediates the Synergistic Effect of ATP and MSU Crystals to Induce Acute Gouty Arthritis.
Topics: Adenosine Triphosphate; Animals; Arthritis, Gouty; Gout; Inflammasomes; Leukocytes, Mononuclear; NLR | 2023 |
Gout of feet and ankles in different stages: The potentiality of a new semiquantitative DECT scoring system in monitoring urate deposition.
Topics: Ankle; Arthritis, Gouty; Foot; Gout; Humans; Uric Acid | 2023 |
Single-Cell Analysis in Blood Reveals Distinct Immune Cell Profiles in Gouty Arthritis.
Topics: Arthritis, Gouty; Gout; Humans; Monocytes; Single-Cell Analysis; Uric Acid | 2023 |
Inactivation of mitochondrial pyruvate carrier promotes NLRP3 inflammasome activation and gout development via metabolic reprogramming.
Topics: Animals; Diabetes Mellitus, Experimental; Gout; Hereditary Autoinflammatory Diseases; Inflammasomes; | 2023 |
Musculoskeletal Ultrasound in Monitoring the Efficacy of Gout: A Prospective Study Based on Tophus and Double Contour Sign
Topics: Gout; Humans; Prospective Studies; Ultrasonography; Uric Acid | 2023 |
Using human genetics to understand the epidemiological association between obesity, serum urate, and gout.
Topics: Genome-Wide Association Study; Gout; Human Genetics; Humans; Obesity; Polymorphism, Single Nucleotid | 2023 |
Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress.
Topics: Animals; Arthritis, Gouty; Caspases; Cytokines; Dimethyl Fumarate; Gout; Inflammasomes; Lipopolysacc | 2023 |
The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan.
Topics: Benzbromarone; Cerebrovascular Disorders; Gout; Gout Suppressants; Humans; Retrospective Studies; Ta | 2023 |
A metabonomic study to explore potential markers of asymptomatic hyperuricemia and acute gouty arthritis.
Topics: Arthritis, Gouty; Biomarkers; Gout; Humans; Hyperuricemia; Metabolomics; Uric Acid | 2023 |
Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross-sectional analysis.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Kidney Diseas | 2023 |
Scleroderma-like Disease Due to Diffuse Monosodium Urate Crystal Deposition.
Topics: Gout; Humans; Inflammation; Uric Acid | 2023 |
Diallyl trisulfide inhibits monosodium urate-induced NLRP3 inflammasome activation via NOX3/4-dependent mitochondrial oxidative stress in RAW 264.7 and bone marrow-derived macrophages.
Topics: Gout; Humans; Inflammasomes; Inflammation; Interleukin-1beta; Macrophages; NLR Family, Pyrin Domain- | 2023 |
Gender difference in the association between gout at diagnosis and metabolic syndrome in African population: a retrospective cohort study.
Topics: Aged; Cameroon; Female; Gout; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Obesity; | 2022 |
TGF-β is elevated in hyperuricemic individuals and mediates urate-induced hyperinflammatory phenotype in human mononuclear cells.
Topics: Gout; Humans; Hyperuricemia; Leukocytes; Leukocytes, Mononuclear; Transforming Growth Factor beta; U | 2023 |
Risk Factors for Hyperuricemia or Gout in Men and Women: The Circulatory Risk in Communities Study (CIRCS).
Topics: Diabetes Mellitus; Female; Gout; Humans; Hypercholesterolemia; Hypertension; Hypertriglyceridemia; H | 2023 |
Pattern of gout and its association with chronic kidney disease in Maiduguri, northeastern Nigeria.
Topics: Creatinine; Female; Glomerular Filtration Rate; Gout; Humans; Male; Nigeria; Renal Insufficiency, Ch | 2023 |
Superiority of low-dose benzbromarone to low-dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Ou | 2023 |
Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout.
Topics: Adult; Gout; Gout Suppressants; Hip Fractures; Humans; Hyperuricemia; Uric Acid | 2023 |
Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study.
Topics: Absenteeism; Efficiency; Female; Gout; Humans; Male; Middle Aged; Quality of Life; Surveys and Quest | 2023 |
Relationship between rs4349859 and rs116488202 polymorphisms close to MHC-I region and serum urate levels in patients with gout.
Topics: Genetic Predisposition to Disease; Genotype; Gout; Heterozygote; Humans; Polymorphism, Single Nucleo | 2023 |
Comparative Safety of Gout Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Clone-censor-weight Target Trial Emulation Approach.
Topics: Aged; Cardiovascular Diseases; Gout; Humans; Male; Medicare; United States; Uric Acid | 2023 |
Unusual Cause of Cord Compression in a Patient with Chronic Lymphocytic Leukemia.
Topics: Aged; Gout; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Spinal Cord Compression; Symptom F | 2023 |
Uric acid is independently associated with interleukin-1β levels in tear fluid of hyperuricemia and gout patients.
Topics: Gout; Humans; Hyperuricemia; Interleukin-1beta; Tumor Necrosis Factor-alpha; Uric Acid | 2023 |
Sex specific serum uric acid levels are associated with ischemic changes on ECG and with 20-year all-cause mortality among older adults.
Topics: Aged; Biomarkers; Electrocardiography; Female; Gout; Humans; Male; Prospective Studies; Risk Factors | 2023 |
Towards the Development of Dual Hypouricemic and Anti-inflammatory Candidates: Design, Synthesis, Stability Studies and Biological Evaluation of Some Mutual Ester Prodrugs of Febuxostat-NSAIDs.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Esters; Febuxostat; G | 2023 |
Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack.
Topics: Animals; Arthritis, Gouty; ATP-Binding Cassette Transporters; Caco-2 Cells; Gout; Humans; Hyperurice | 2023 |
Prediagnostic Glycoprotein Acetyl Levels and Incident and Recurrent Flare Risk Accounting for Serum Urate Levels: A Population-Based, Prospective Study and Mendelian Randomization Analysis.
Topics: Glycoproteins; Gout; Humans; Mendelian Randomization Analysis; Prospective Studies; Risk Factors; Ur | 2023 |
Prevalence and clinical association of hyperechoic crystal deposits on ultrasonography in patients with chronic kidney disease: a cross-sectional study from a single center.
Topics: Cross-Sectional Studies; Female; Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Male; Prev | 2023 |
Dissecting the causal effect between gut microbiota, DHA, and urate metabolism: A large-scale bidirectional Mendelian randomization.
Topics: Docosahexaenoic Acids; Gastrointestinal Microbiome; Gout; Humans; Mendelian Randomization Analysis; | 2023 |
Lowering serum urate level to a guideline-based target is associated with a lower risk of incident fracture in people with gout: comment on the article by Wei et al.
Topics: Fractures, Bone; Gout; Gout Suppressants; Humans; Risk; Treatment Outcome; Uric Acid | 2023 |
Topics: Gout; Humans; Uric Acid | 2023 |
Trends in Prevalence of Gout Among US Asian Adults, 2011-2018.
Topics: Adult; Aged; Asian; Cross-Sectional Studies; Female; Gout; Health Status Disparities; Humans; Male; | 2023 |
The risk of venous thromboembolism increases within one month of gout flare: comment on the article by Cipolletta et al.
Topics: Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid; Venous Thromboembolism | 2023 |
Exploring the mechanism underlying hyperuricemia using comprehensive research on multi-omics.
Topics: Animals; Caffeine; Gout; Humans; Hyperuricemia; Mice; Multiomics; Tandem Mass Spectrometry; Uric Aci | 2023 |
Detailed analysis of the association between urate deposition and bone erosion in gout: a dual-energy computed tomography study.
Topics: Gout; Humans; Tomography, X-Ray Computed; Uric Acid | 2023 |
Anaerobic purinolytic enzymes enable dietary purine clearance by engineered gut bacteria.
Topics: Anaerobiosis; Animals; Drosophila melanogaster; Escherichia coli; Gout; Humans; Hydrolases; Hyperuri | 2023 |
Effect of Dietary Counseling on Patients with Asymptomatic Hyperuricemia.
Topics: Female; Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Male; Obesity; Uric Acid | 2023 |
Development of a novel anti-inflammatory recombinant uricase with extended half-life for gout therapy.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Gout; Half-Life; Inflammasomes; Mice; Urate Oxi | 2023 |
Model Informed Development of SIM0295 in Patients with Gout and Hyperuricemia and Healthy Volunteers Using a Population Pharmacokinetics/ Pharmacodynamics Approach.
Topics: Gout; Gout Suppressants; Healthy Volunteers; Humans; Hyperuricemia; Uric Acid | 2023 |
A wild rice-derived peptide R14 ameliorates monosodium urate crystals-induced IL-1β secretion through inhibition of NF-κB signaling and NLRP3 inflammasome activation.
Topics: Gout; Humans; Inflammasomes; Inflammation; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein | 2023 |
Polydatin ameliorates inflammation and oxidative stress associated with MSU-induced gouty arthritis in mice by regulating PPAR-γ and ferritin activation.
Topics: Animals; Arthritis, Gouty; Cytokines; Gout; Humans; Inflammasomes; Inflammation; Mice; Mice, Inbred | 2023 |
[ANMCO statement: Uric acid and cardiovascular disease: evidence and therapeutic approach].
Topics: Allopurinol; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2023 |
Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Treatment O | 2023 |
Monosodium urate crystals alter the circadian clock in macrophages leading to loss of NLRP3 inflammasome repression: Implications for timing of the gout flare.
Topics: ARNTL Transcription Factors; Caspases; Circadian Clocks; Gout; Humans; Inflammasomes; Interleukin-1b | 2023 |
Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada.
Topics: Aged; Aged, 80 and over; Female; Gout; Gout Suppressants; Humans; Male; Ontario; Retrospective Studi | 2023 |
Tailored hydrogel composite membrane for the regulated crystallization of monosodium urate monohydrate within coffee's metabolites system.
Topics: Coffee; Crystallization; Gout; Humans; Hydrogels; Uric Acid | 2023 |
The aftermath of Urate-Lowering TheRApy in gout (ULTRA) registry: The first prospective observational multicenter cohort of Korean patients with gout.
Topics: Gout; Humans; Registries; Republic of Korea; Uric Acid | 2023 |
GLUT9 as a potential drug target for chronic kidney disease: Drug target validation by a Mendelian randomization study.
Topics: Glucose Transport Proteins, Facilitative; Gout; Humans; Mendelian Randomization Analysis; Organic An | 2023 |
[The influence of uric acid on the course of amyotrophic lateral sclerosis].
Topics: Amyotrophic Lateral Sclerosis; Antioxidants; Gout; Humans; Male; Neuroprotection; Uric Acid | 2023 |
Safety update: febuxostat and CVD.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome | 2023 |
Clec12a inhibits MSU-induced immune activation through lipid raft expulsion.
Topics: Gout; Humans; Immunity, Innate; Inflammation; Lipids; Uric Acid | 2023 |
Association between serum uric acid and muscle strength in older adults with or without gout diagnosis: NHANES 2011-2014.
Topics: Aged; Female; Gout; Hand Strength; Humans; Male; Muscle Strength; Nutrition Surveys; Uric Acid | 2023 |
Preparation of PEGylated uricase attached magnetic nanowires and application for uric acid oxidation.
Topics: Enzymes, Immobilized; Gout; Humans; Magnetic Phenomena; Nanowires; Polyethylene Glycols; Urate Oxida | 2023 |
DECT: A Novel Window in Gout Imaging.
Topics: Diagnostic Imaging; Gout; Humans; Uric Acid | 2023 |
Factors affecting serum urate monitoring among older adults with gout initiating urate-lowering therapy: comment on the article by Kwok et al.
Topics: Aged; Gout; Gout Suppressants; Humans; Uric Acid | 2023 |
Beliefs about medicines in gout patients: results from the NOR-Gout 2-year study.
Topics: Gout; Gout Suppressants; Health Knowledge, Attitudes, Practice; Humans; Longitudinal Studies; Medica | 2023 |
Efficient Synergistic Cooperation of an Arginine-Rich Peptide and Copper Ions in Sodium Urate Crystallization Inhibition.
Topics: Copper; Crystallization; Gout; Humans; Ions; Peptides; Uric Acid | 2023 |
14-3-3 η ETA protein as a potential marker of joint damage in gout.
Topics: 14-3-3 Proteins; Cross-Sectional Studies; Gout; Humans; ROC Curve; Uric Acid | 2023 |
Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database.
Topics: Adult; Allopurinol; Colchicine; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Insu | 2023 |
Potential clinical value of serum interleukin-41 levels in patients with acute gout.
Topics: Arthritis, Gouty; C-Reactive Protein; Gout; Humans; Interleukins; Uric Acid | 2023 |
Hyperuricemia and gout increased the risk of long-term mortality in patients with heart failure: insights from the National Health and Nutrition Examination Survey.
Topics: Gout; Heart Failure; Humans; Hyperuricemia; Nutrition Surveys; Uric Acid | 2023 |
Test characteristics of Raman spectroscopy integrated with polarized light microscopy for the diagnosis of acute gouty arthritis.
Topics: Arthritis, Gouty; Gout; Humans; Microscopy, Polarization; Prospective Studies; Sensitivity and Speci | 2023 |
Sirt3 improves monosodium urate crystal-induced inflammation by suppressing Acod1 expression.
Topics: Animals; Gout; Inflammation; Leukocytes, Mononuclear; Mice; Mice, Inbred C57BL; Sirtuin 3; Uric Acid | 2023 |
Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters.
Topics: Animals; Apigenin; Creatinine; Glucosides; Gout; Hyperuricemia; Kidney; Malondialdehyde; Mice; Molec | 2023 |
Purine-ifying uric acid by gut microbes.
Topics: Animals; Gastrointestinal Microbiome; Gout; Mammals; Purines; Uric Acid | 2023 |
[Association between metabolism-related chronic disease combination and prevalence of non-alcoholic fatty liver disease in community residents in Shanghai].
Topics: Adult; Body Mass Index; China; Chronic Disease; Diabetes Mellitus; Female; Gout; Humans; Hyperlipide | 2023 |
Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Gout; Hospit | 2023 |
Identification of tophi in ultrasound imaging based on transfer learning and clinical practice.
Topics: Arthritis, Gouty; Gout; Humans; Inflammation; Machine Learning; Reproducibility of Results; Tomograp | 2023 |
A widely distributed gene cluster compensates for uricase loss in hominids.
Topics: Adult; Animals; Evolution, Molecular; Gout; Hominidae; Humans; Hyperuricemia; Mammals; Mice; Urate O | 2023 |
Comparison of the different monosodium urate crystals in the preparation process and pro-inflammation.
Topics: Animals; Gout; Humans; Inflammation; Interleukin-18; Tumor Necrosis Factor-alpha; Uric Acid | 2023 |
Antihyperuricemic and Renal Protective Effect of Cordyceps chanhua (Ascomycetes) Fruiting Bodies in Acute Hyperuricemia and Chronic Gout Rodent Models.
Topics: Animals; Cordyceps; Fruiting Bodies, Fungal; Gout; Gout Suppressants; Hyperuricemia; Kidney; Mice; R | 2023 |
Asymptomatic hyperuricemia associated with increased risk of nephrolithiasis: a cross-sectional study.
Topics: China; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Male; Nephrolithiasis; Risk Fac | 2023 |
An interesting image of gout crystals with surrounding tophi.
Topics: Gout; Humans; Uric Acid | 2023 |
Validation of gout diagnosis in electronic primary care medical records: A population-based study.
Topics: Cross-Sectional Studies; Electronic Health Records; Electronics; Gout; Gout Suppressants; Humans; Pr | 2023 |
[Recommendations for the diagnosis and treatment of gout in China].
Topics: China; Gout; Humans; Practice Guidelines as Topic; Rheumatology; Uric Acid | 2023 |
Reliability and Validity of the Korean Version of the Gout Impact Scale.
Topics: Female; Gout; Humans; Male; Quality of Life; Reproducibility of Results; Republic of Korea; Uric Aci | 2023 |
Association between serum uric acid levels and peripheral artery disease in Chinese adults with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; East Asian People; Female; Gout; Humans; Hy | 2023 |
Uric Acid and Risk of Cardiovascular Disease and Mortality: A Longitudinal Cohort Study.
Topics: Adult; Cardiovascular Diseases; Cohort Studies; Gout; Humans; Longitudinal Studies; Uric Acid | 2023 |
MSU crystal deposition contributes to inflammation and immune responses in gout remission.
Topics: Chronic Disease; Gout; Humans; Inflammation; Leukocytes, Mononuclear; Monocytes; Uric Acid | 2023 |
Prediction of renal and cardiometabolic outcomes in gout during urate-lowering therapy by sonography.
Topics: Gout; Gout Suppressants; Humans; Hypertension; Kidney; Prospective Studies; Uric Acid | 2023 |
Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink.
Topics: Adult; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Colchicine; Diarrhea; G | 2023 |
Metabolomic analysis for asymptomatic hyperuricemia and gout based on a combination of dried blood spot sampling and mass spectrometry technology.
Topics: Biomarkers; Gout; Humans; Hyperuricemia; Mass Spectrometry; Metabolomics; Uric Acid | 2023 |
Interleukin-37: associations of plasma levels and genetic variants in gout.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Interleukin-1beta; Uric Acid | 2023 |
Molecular characteristic analysis of single-nucleotide polymorphisms in SLC16A9/hMCT9.
Topics: Animals; Creatine; Gout; Humans; Hyperuricemia; Oocytes; Polymorphism, Single Nucleotide; Uric Acid; | 2023 |
Diurnal Variations in Serum Uric Acid, Xanthine, and Xanthine Oxidoreductase Activity in Male Patients with Coronary Artery Disease.
Topics: Coronary Artery Disease; Gout; Humans; Male; Uric Acid; Xanthine; Xanthine Dehydrogenase | 2023 |
In patients with type 2 diabetes or HF, SGLT2 inhibitors reduce gout-related outcomes.
Topics: Diabetes Mellitus, Type 2; Gout; Humans; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2023 |
Factors influencing the kinetics of MSU crystal depletion measured with dual-energy CT in patients with gout.
Topics: Aged; Aged, 80 and over; Female; Foot; Gout; Humans; Male; Middle Aged; Tomography, X-Ray Computed; | 2023 |
New animal model of chronic gout reproduces pathological features of the disease in humans.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Gout Suppressants; Humans; Mice; Uric Acid | 2023 |
Peptide NCTX15 derived from spider toxin gland effectively relieves hyperuricemia in mice.
Topics: Animals; Gout; Hyperuricemia; Interleukin-6; Kidney; Mice; Uric Acid; Xanthine Oxidase | 2023 |
Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry.
Topics: Antihypertensive Agents; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Multivariate An | 2023 |
Cohort study investigating gout flares and management in UK general practice.
Topics: Cohort Studies; General Practice; Gout; Gout Suppressants; Humans; Male; Symptom Flare Up; United Ki | 2023 |
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Lipidomics; Uric Acid | 2023 |
Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study.
Topics: Cholesterol, LDL; Female; Gout; Humans; Life Style; Male; Middle Aged; Symptom Flare Up; Uric Acid | 2023 |
Role of immune system in development and progress of combined arterial hypertension and gout.
Topics: Arthritis, Gouty; Gout; Humans; Hypertension; Immune System; Male; Middle Aged; Uric Acid | 2019 |
Development and Pilot Testing of MyGoutCare: A Novel Web-Based Platform to Educate Patients With Gout.
Topics: Gout; Gout Suppressants; Humans; Internet; Middle Aged; Patient Education as Topic; Pilot Projects; | 2020 |
A conserved role of the insulin-like signaling pathway in diet-dependent uric acid pathologies in Drosophila melanogaster.
Topics: Animals; Animals, Genetically Modified; Cohort Studies; Disease Models, Animal; Drosophila melanogas | 2019 |
Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort.
Topics: Age Factors; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Female; Follow-Up Studies; Gout; Gou | 2020 |
Risk of gout flares after vaccination.
Topics: Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid; Vaccination | 2021 |
Evaluation of Treatment Success Rate Among Antihyperuricemic Using Real-World Data.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2019 |
Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of IκBα and blocking mitochondrial damage.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Curcumin; Cytokines; Disease Mo | 2019 |
Pegloticase and lowering blood pressure in refractory gout; is it uric acid or hydrogen peroxide?
Topics: Blood Pressure; Gout; Humans; Hydrogen Peroxide; Polyethylene Glycols; Urate Oxidase; Uric Acid | 2019 |
The target uric acid level in multimorbid patients with gout is difficult to achieve: data from a longitudinal Swiss single-centre cohort.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Female; Gout; Gout Suppressants; Humans; Longitudinal S | 2019 |
The challenges of managing gout in primary care: Results of a best-practice audit.
Topics: Aged; Allopurinol; Clinical Audit; Clinical Chemistry Tests; Clinical Protocols; Colchicine; Comorbi | 2019 |
Postoperative Recurrent Gout Flares: A Cross-sectional Study From China.
Topics: China; Cross-Sectional Studies; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid | 2020 |
Corneal Endothelial Morphology and Thickness Changes in Patients with Gout
Topics: Adult; Case-Control Studies; Cell Count; Endothelial Cells; Endothelium, Corneal; Female; Gout; Huma | 2019 |
The performance of dual-energy CT in the classification criteria of gout: a prospective study in subjects with unclassified arthritis.
Topics: Aged; Area Under Curve; Arthritis, Gouty; Female; Gout; Humans; Male; Microscopy, Polarization; Midd | 2020 |
Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cadaver; Cardiovascular Diseases; Coronary Vessels; Fema | 2019 |
Suppression of monosodium urate crystal-induced inflammation by inhibiting TGF-β-activated kinase 1-dependent signaling: role of the ubiquitin proteasome system.
Topics: Animals; Antioxidants; Fibroblasts; Gout; Humans; Inflammation; Lactones; Male; MAP Kinase Kinase Ki | 2021 |
Gout involved the cervical disc and adjacent vertebral endplates misdiagnosed infectious spondylodiscitis on imaging: case report and literature review.
Topics: C-Reactive Protein; Cervical Vertebrae; Colchicine; Diagnostic Errors; Discitis; Gout; Humans; Inter | 2019 |
Therapeutic potential of ethyl acetate fraction of Tephrosia purpurea Linn. leaves in a rat model of gout.
Topics: Acetates; Animals; Disease Models, Animal; Gout; Male; Plant Extracts; Plant Leaves; Rats; Rats, Spr | 2019 |
Clinical features and risk factors for gout attacks during anti-tuberculosis treatment: A case-control study in South Korea.
Topics: Aged; Antitubercular Agents; Biomarkers; Case-Control Studies; Disease Progression; Female; Follow-U | 2019 |
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Topics: Allopurinol; Benzbromarone; Disease Progression; Febuxostat; Female; Glomerular Filtration Rate; Gou | 2019 |
MSU crystals at-TAK!
Topics: Gout; Humans; Inflammation; MAP Kinase Kinase Kinases; Proteasome Endopeptidase Complex; Ubiquitin; | 2019 |
Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cardiovascular Diseases; Cohort Studies; Ge | 2019 |
Hyperuricemia and gout caused by missense mutation in d-lactate dehydrogenase.
Topics: Adult; Animals; Catalytic Domain; Child; DNA; Family Health; Female; Gout; HEK293 Cells; Heterozygot | 2019 |
Treat-to-target (T2T) of serum urate (SUA) in gout: a clinical audit in real-world gout patients.
Topics: Adult; Aged; Female; Gout; Humans; Male; Medical Audit; Middle Aged; Practice Guidelines as Topic; R | 2019 |
Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients.
Topics: Aged; Arthritis, Rheumatoid; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Necrosis; N | 2020 |
Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Comorbidity; Female; Follow-Up Studies; Gout; Humans; Hyp | 2019 |
Gout Management as Part of Secondary Cardiovascular Prevention: Comment on the Article by Stamp et al.
Topics: Cohort Studies; Coronary Disease; Gout; Gout Suppressants; Humans; Uric Acid | 2020 |
Population-specific factors associated with fractional excretion of uric acid.
Topics: Adult; Aged; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Native Hawaiian or Other Pacifi | 2019 |
Burden and management of gout in a multi-ethnic Asian cohort.
Topics: Adult; Aged; Allopurinol; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Em | 2020 |
A laser-engraved wearable sensor for sensitive detection of uric acid and tyrosine in sweat.
Topics: Adolescent; Adult; Aged; Equipment Design; Gout; Humans; Lasers; Microfluidics; Middle Aged; Reprodu | 2020 |
Dysfunctional missense variant of
Topics: Adult; Asian People; Case-Control Studies; Genetic Predisposition to Disease; Gout; Humans; Hyperuri | 2020 |
Chronic tophaceous gout presenting as nonhealing ulcers.
Topics: Adult; Allopurinol; Biopsy, Needle; Debridement; Foot Ulcer; Gout; Humans; Immunohistochemistry; Ind | 2019 |
Appraisal of anti-gout potential of colchicine-loaded chitosan nanoparticle gel in uric acid-induced gout animal model.
Topics: Animals; Chitosan; Colchicine; Disease Models, Animal; Gout; Nanoparticles; Uric Acid | 2022 |
Relationship between urate within tophus and bone erosion according to the anatomic location of urate deposition in gout: A quantitative analysis using dual-energy CT volume measurements.
Topics: Adult; Bone Diseases; Gout; Humans; Male; Middle Aged; Retrospective Studies; Tomography, X-Ray Comp | 2019 |
Serum urate goal attainment and associated factors in Chinese gout patients.
Topics: Adult; Aged; China; Cross-Sectional Studies; Female; Goals; Gout; Gout Suppressants; Humans; Male; M | 2020 |
Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis.
Topics: Animals; Eucalyptol; Gout; Humans; Inflammation; Macrophages; Mice; Pain; Quality of Life; Uric Acid | 2020 |
The prevalence of gout and hyperuricemia in middle-aged and elderly people in Tibet Autonomous Region, China: A preliminary study.
Topics: Adult; Aged; China; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; | 2020 |
Development of novel NLRP3-XOD dual inhibitors for the treatment of gout.
Topics: Animals; Benzimidazoles; Benzoxazoles; Cell Line; Disease Models, Animal; Gout; Humans; Hyperuricemi | 2020 |
Does normouricemic status in acute gouty arthritis really reflect a normal status? Consider confounders of serum levels of urate.
Topics: Arthritis, Gouty; Gout; Humans; Uric Acid | 2020 |
Review of gout clinic in a tertiary hospital setting.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Australia; Disease Management; Female; Gout; Gout Suppress | 2020 |
Genomic dissection of 43 serum urate-associated loci provides multiple insights into molecular mechanisms of urate control.
Topics: Case-Control Studies; Genetic Markers; Genetic Predisposition to Disease; Genome-Wide Association St | 2020 |
Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus.
Topics: Adult; Age of Onset; ATP Binding Cassette Transporter, Subfamily G, Member 2; Europe; Female; Geneti | 2020 |
Epistatic interaction between PKD2 and ABCG2 influences the pathogenesis of hyperuricemia and gout.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Body Mass Index; Epistasis, Genetic; Geneti | 2020 |
Contribution of Rare Variants of the
Topics: Animals; Female; Gene-Environment Interaction; Gout; Humans; Male; Middle Aged; Organic Anion Transp | 2020 |
Hyperuricemia as a potential plausible risk factor for periodontitis.
Topics: Animals; Gout; Humans; Hyperuricemia; Mice; Periodontitis; Risk Factors; Uric Acid | 2020 |
Do Serum Urate-associated Genetic Variants Influence Gout Risk in People Taking Diuretics? Analysis of the UK Biobank.
Topics: Biological Specimen Banks; Diuretics; Gout; Humans; United Kingdom; Uric Acid | 2020 |
Cytokine Production and NET Formation by Monosodium Urate-Activated Human Neutrophils Involves Early and Late Events, and Requires Upstream TAK1 and Syk.
Topics: Cytokines; Extracellular Traps; Gout; Humans; MAP Kinase Kinase Kinases; Neutrophil Activation; Neut | 2019 |
Study on the relationship between FFA and gout flare.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Biomarkers; Cholesterol, LDL; Fatty Acids, Noneste | 2020 |
Identification of Cardiovascular Monosodium Urate Crystal Deposition in Patients With Gout Using Dual-Energy Computed Tomography-Reply.
Topics: Cardiovascular System; Gout; Humans; Tomography, X-Ray Computed; Uric Acid | 2020 |
Identification of Cardiovascular Monosodium Urate Crystal Deposition in Patients With Gout Using Dual-Energy Computed Tomography.
Topics: Cardiovascular System; Gout; Humans; Tomography, X-Ray Computed; Uric Acid | 2020 |
Structured patient care pathway for gout.
Topics: Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Patient Care; Uric Acid | 2020 |
Efficacy and tolerability of febuxostat in gout patients on dialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Retrospecti | 2021 |
Risk factors of ultrasound-detected tophi in patients with gout.
Topics: Adult; Aged; Ankle Joint; Female; Glomerular Filtration Rate; Gout; Humans; Knee Joint; Logistic Mod | 2020 |
Gout in the Flexor Hallucis Longus Tendon Mimicking Cellulitis: A Case Report.
Topics: Aged; Ankle; Cellulitis; Diagnosis, Differential; Foot; Gout; Humans; Magnetic Resonance Imaging; Ma | 2020 |
A negative association between urinary iodine concentration and the prevalence of hyperuricemia and gout: a cross-sectional and population-based study in Mainland China.
Topics: Adult; China; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Iodine; Prevalence; Pros | 2020 |
Better outcomes for patients with gout.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Dose-Response Relationship, Drug; Drug Therapy, | 2020 |
A mouse model of MSU-induced acute inflammation
Topics: Acute Disease; Adjuvants, Immunologic; Administration, Topical; Animals; Antioxidants; Cytokines; Di | 2020 |
The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort.
Topics: Adolescent; Adult; Alleles; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; B | 2020 |
The role of annexin A1 in the modulation of the NLRP3 inflammasome.
Topics: Administration, Intranasal; Animals; Annexin A1; Cartilage, Articular; Caspase 1; Cells, Cultured; D | 2020 |
Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout.
Topics: Adult; Aged; Aged, 80 and over; Animals; Case-Control Studies; Female; Genetic Predisposition to Dis | 2020 |
Predictors of Success in Gout Treatment.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Uric Acid; Veterans | 2020 |
The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study.
Topics: Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Dyslipidemias; Female; Gout; Humans; Hy | 2020 |
Identification of the urine and serum metabolomics signature of gout.
Topics: Area Under Curve; Biomarkers; Carnitine; Case-Control Studies; Chromatography, High Pressure Liquid; | 2020 |
Australian tertiary institutions are failing people with gout.
Topics: Australia; Gout; Humans; Rheumatology; Uric Acid | 2020 |
Author reply.
Topics: Australia; Gout; Humans; Rheumatology; Uric Acid | 2020 |
Uric acid-mediated inflammasome activation in IL-6 primed innate immune cells is regulated by baricitinib.
Topics: Azetidines; Cells, Cultured; Gout; Humans; Immunity, Innate; Inflammasomes; Interleukin-6; Neutrophi | 2021 |
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Epistasis, Genetic; Eu | 2020 |
Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Community Pharmacy Services; Cultural Co | 2019 |
Effect of tart cherry juice on risk of gout attacks: protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Fruit and Vegetable Juices; Gout; Humans | 2020 |
The effect of reducing systemic inflammation on serum urate.
Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Blood Sedimentation; C-Rea | 2020 |
Clinical observation of Qushi Xiezhuo formula in reducing monosodium urate crystal deposition in patients with axial spondyloarthritis.
Topics: Adult; Cohort Studies; Drug Compounding; Drugs, Chinese Herbal; Female; Gout; Humans; Male; Prospect | 2019 |
IL-37 linked to gout pathogenesis and treatment.
Topics: Anti-Inflammatory Agents; Cytokines; Gout; Humans; Interleukins; Uric Acid | 2020 |
[Clinical study of staging operation for large gouty stone on the first metatarsophalangeal joint].
Topics: Aged; Arthrodesis; Gout; Humans; Male; Metatarsophalangeal Joint; Middle Aged; Treatment Outcome; Ur | 2020 |
Goose astrovirus infection affects uric acid production and excretion in goslings.
Topics: Animals; Astroviridae Infections; Avastrovirus; Avian Proteins; Carrier Proteins; Disease Models, An | 2020 |
The Utility of the Random Urine Uric Acid-to-Creatinine Ratio for Patients with Gout Who Need Uricosuric Agents: Retrospective Cross-Sectional Study.
Topics: Adult; Aged; Creatinine; Cross-Sectional Studies; Female; Gout; Humans; Male; Middle Aged; Retrospec | 2020 |
High-Protein Diet Induces Hyperuricemia in a New Animal Model for Studying Human Gout.
Topics: Allopurinol; Animal Structures; Animals; Chickens; Crystallization; Diet, High-Protein; Disease Mode | 2020 |
X-ray Dark-Field Radiography: Potential for Visualization of Monosodium Urate Deposition.
Topics: Animals; Disease Models, Animal; Gout; Humans; Mice; Photons; Radiography; Sensitivity and Specifici | 2020 |
Understanding and perceptions of gout: an interdisciplinary assessment among patients, physicians and pharmacists in Italy.
Topics: Clinical Competence; Cross-Sectional Studies; General Practitioners; Gout; Health Knowledge, Attitud | 2020 |
Gout management in Swiss primary care - a retrospective observational study.
Topics: Gout; Gout Suppressants; Humans; Primary Health Care; Switzerland; Uric Acid | 2020 |
Using electronic visits (E-visits) to achieve goal serum urate levels in patients with gout in a rheumatology practice: A pilot study.
Topics: Electronics; Goals; Gout; Gout Suppressants; Humans; Pilot Projects; Retrospective Studies; Rheumato | 2020 |
The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout.
Topics: Adult; Asian People; China; Cohort Studies; Double-Blind Method; Ethnicity; Febuxostat; Female; Gout | 2020 |
Urate-lowering therapy exerts protective effects against hypertension development in patients with gout.
Topics: Aged, 80 and over; Gout; Gout Suppressants; Humans; Hypertension; Retrospective Studies; Uric Acid | 2021 |
A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects.
Topics: Adult; Febuxostat; Female; Gout; Gout Suppressants; Healthy Volunteers; Humans; Kidney; Male; Renal | 2020 |
Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout.
Topics: Aged; Cause of Death; Comorbidity; Echocardiography; Female; Follow-Up Studies; Gout; Heart Failure; | 2020 |
Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy.
Topics: Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Joints; Male; Middle Aged; Musculoskeletal Sys | 2020 |
Treat-to-Target urate-lowering therapy in primary gout patients: A real-world retrospective study at a dedicated gout clinic in China.
Topics: China; Gout; Gout Suppressants; Humans; Retrospective Studies; Uric Acid | 2021 |
Management of gout by Moroccan rheumatologists: a Moroccan Society for Rheumatology National Survey.
Topics: Allopurinol; Colchicine; Cross-Sectional Studies; Drug Therapy, Combination; Female; Gout; Gout Supp | 2020 |
Patient Perceptions of Gout Management Goals: A Cross-sectional Internet Survey.
Topics: Attitude to Health; Cross-Sectional Studies; Disease Management; Drug Monitoring; Female; Gout; Gout | 2020 |
Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Middle Aged; Retrospective Studies; Uric A | 2020 |
In Vivo Transmigrated Human Neutrophils Are Highly Primed for Intracellular Radical Production Induced by Monosodium Urate Crystals.
Topics: Adult; Aged; Cells, Cultured; Extracellular Traps; Female; Gout; Humans; Middle Aged; Neutrophils; P | 2020 |
Mobile healthcare system based on the combination of a lateral flow pad and smartphone for rapid detection of uric acid in whole blood.
Topics: Biosensing Techniques; Delivery of Health Care; Gout; Humans; Smartphone; Uric Acid | 2020 |
A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
Topics: Adult; Aged; Allopurinol; Biomarkers; Down-Regulation; Female; Gout; Gout Suppressants; Humans; Male | 2020 |
Blood glucose fluctuations detected by continuous glucose monitoring system in gout patients with normal glucose tolerance and the effect of urate-lowering therapy.
Topics: Adult; Aged; Allopurinol; Biomarkers; Blood Glucose; Blood Glucose Self-Monitoring; Down-Regulation; | 2020 |
[Recommendations of diagnosis and treatment of gout in China].
Topics: China; Gout; Humans; Practice Guidelines as Topic; Uric Acid | 2020 |
The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion.
Topics: Alleles; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Models, Animal; E | 2020 |
Gout Treatment in the USA from 2009 to 2016: A Repeated Cross-sectional Analysis.
Topics: Cross-Sectional Studies; Gout; Humans; United States; Uric Acid | 2021 |
Cholesterol and Monosodium Urate Monohydrate Crystals in Synovial fluid From a Patient With Gout.
Topics: Aged; Cholesterol; Gout; Humans; Male; Synovial Fluid; Uric Acid | 2020 |
RDP3, A Novel Antigout Peptide Derived from Water Extract of Rice.
Topics: Animals; Anti-Inflammatory Agents; Edema; Gout; Gout Suppressants; Humans; Hyperuricemia; Mice; Mice | 2020 |
Spinal Urate Deposition in a Patient With Gout and Nonspecific Low Back Pain: Response to Initiation of Gout Therapy.
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Low Back Pain; Uric Acid | 2021 |
Serum Urate Levels of Hemodialyzed Renal Patients Revisited.
Topics: Aged; Aged, 80 and over; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; | 2021 |
Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
Topics: Adult; Aged; Allopurinol; Female; Gout; Gout Suppressants; Hospital Mortality; Hospitalization; Huma | 2020 |
Perfluoroalkyl acids, hyperuricemia and gout in adults: Analyses of NHANES 2009-2014.
Topics: Adult; Alkanesulfonic Acids; Caprylates; Cotinine; Cross-Sectional Studies; Decanoic Acids; Environm | 2020 |
EPS8 regulates an NLRP3 inflammasome-independent caspase-1 activation pathway in monosodium urate crystal-treated RAW264.7 macrophages.
Topics: Adaptor Proteins, Signal Transducing; Animals; Caspase 1; Enzyme Activation; Gout; Inflammasomes; In | 2020 |
[Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy].
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Prevalence; Ur | 2019 |
Development of a multivariable improvement measure for gout.
Topics: Arthritis, Gouty; Chronic Disease; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Treatment | 2020 |
Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
Topics: Allopurinol; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospecti | 2021 |
Sex Differences in the Clinical Profile Among Patients With Gout: Cross-sectional Analyses of an Observational Study.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Gout; Humans; Male; Middle Aged; Sex Cha | 2021 |
Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.
Topics: Adult; Enzyme Inhibitors; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Incidence; Japan; | 2020 |
A leg ulcer with hard, yellow projections.
Topics: Aged, 80 and over; Gout; Humans; Leg Ulcer; Male; Obesity; Uric Acid | 2020 |
Systemic Investigation of Promoter-wide Methylome and Genome Variations in Gout.
Topics: Adult; Aged; CpG Islands; DNA Methylation; Epigenesis, Genetic; Epigenome; Female; Gout; Humans; Hyp | 2020 |
Gradual reduction of tophaceous deposits during urate-lowering therapy.
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 2021 |
Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?
Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Uric Acid | 2021 |
Uric acid fluctuation had no effect on renal function among gout patients.
Topics: Adult; Aged; Biomarkers; Electronic Health Records; Female; Glomerular Filtration Rate; Gout; Humans | 2020 |
Associations of serum uric acid level and gout with cardiac structure, function and sex differences from large scale asymptomatic Asians.
Topics: Adult; Asian People; Asymptomatic Diseases; Echocardiography, Doppler; Female; Gout; Heart Atria; He | 2020 |
Ultrasound for the diagnosis of gout-the value of gout lesions as defined by the Outcome Measures in Rheumatology ultrasound group.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Gout; Humans; Joints; Logistic Mode | 2021 |
Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages.
Topics: Animals; Calcium Pyrophosphate; Glucose Transporter Type 1; Glycolysis; Gout; Humans; Interleukin-1b | 2020 |
Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Ph | 2021 |
Latent Class Growth Analysis of Gout Flare Trajectories: A Three-Year Prospective Cohort Study in Primary Care.
Topics: Aged; Allopurinol; Disease Progression; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; | 2020 |
Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study.
Topics: Aged; Comorbidity; Diabetes Mellitus, Type 2; Female; Gout; Gout Suppressants; Humans; Male; Middle | 2020 |
Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Evolution, Molecular; Genetic Pred | 2021 |
A Study of Metabolic Parameters in Patients with Gout: A Single Center Study from Nepal.
Topics: Adult; Cross-Sectional Studies; Female; Gout; Humans; Male; Metabolic Syndrome; Middle Aged; Nepal; | 2021 |
A novel mouse model of hyperuricemia and gouty nephropathy.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Hyperuricemia; Mice; Uric Acid | 2020 |
[INDICATORS OF GOUT INTERLAYKINS AND THERMOGRAPHY OF JOINTS ON THE BACKGROUND OF ENTEROSORBTION THERAPY].
Topics: Cytokines; Gout; Humans; Interleukin-1beta; Thermography; Tumor Necrosis Factor-alpha; Uric Acid | 2020 |
[ERRORS IN THE DIAGNOSTICS AND TREATMENT OF PATIENTS WITH GOUT AND THE ALGORITHM OF THERAPEUTIC TACTICS IN DIFFERENT PERIODS OF THE DISEASE (CLINICAL CASE)].
Topics: Algorithms; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Gout; Humans; Uric Acid | 2020 |
Inpatient gout flare is multifactorial: comment on "clinical characteristics and risk factors for gout flare during the postsurgical period".
Topics: Gout; Humans; Inpatients; Risk Factors; Symptom Flare Up; Uric Acid | 2020 |
[Consequences of Gout and Hyperuricemia].
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2020 |
[Large health benefits can be achieved by better treatment of gout].
Topics: Allopurinol; Colchicine; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2020 |
[Gout - a common and well known disease].
Topics: Gout; Humans; Hyperuricemia; Sweden; Ultrasonography; Uric Acid | 2020 |
Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study.
Topics: Aged; Aged, 80 and over; Allopurinol; Colchicine; Diabetes Mellitus, Type 2; Female; Follow-Up Studi | 2020 |
Association between hyperuricemia, gout, urate lowering therapy, and osteoarthritis: A protocol for a systematic review and meta-analysis.
Topics: Gout; Humans; Hyperuricemia; Meta-Analysis as Topic; Observational Studies as Topic; Osteoarthritis; | 2020 |
Gout of ankle and foot: DECT versus US for crystal detection.
Topics: Ankle; Arthritis, Gouty; Gout; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid | 2021 |
Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016.
Topics: Gout; Gout Suppressants; Hong Kong; Humans; Prevalence; Uric Acid | 2020 |
Repair of Bone Erosion With Effective Urate-Lowering Therapy in a Patient With Tophaceous Gout.
Topics: Benzbromarone; Bone Resorption; Enzyme Inhibitors; Gout; Humans; Male; Metatarsal Bones; Metatarsoph | 2021 |
A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout.
Topics: Cross-Sectional Studies; Gout; Humans; Hyperuricemia; Kidney Medulla; Uric Acid | 2021 |
Calcium Pyrophosphate Dihydrate Crystal Deposition in Gouty Tophi.
Topics: Adult; Age Factors; Aged; Calcium Pyrophosphate; Gout; Humans; Male; Microscopy, Electron, Scanning; | 2021 |
Dual-energy CT in gout patients: Do all colour-coded lesions actually represent monosodium urate crystals?
Topics: Color; Gout; Humans; Tendons; Tomography, X-Ray Computed; Uric Acid | 2020 |
Coexistence of gout and chondrocalcinosis instead? Comment on: "Monosodium urate deposition in the articular cartilage and meniscus can mimic chondrocalcinosis" by Bousson et al. Joint Bone Spine 2020, 87:95-96.
Topics: Cartilage, Articular; Chondrocalcinosis; Gout; Humans; Meniscus; Uric Acid | 2020 |
Allopurinol: Good for Gout But Not for Preventing Loss of Kidney Function.
Topics: Allopurinol; Diabetes Mellitus, Type 1; Gout; Gout Suppressants; Humans; Kidney; Uric Acid | 2021 |
Use of electronic recruitment methods in a clinical trial of adults with gout.
Topics: Adult; Cross-Over Studies; Dietary Approaches To Stop Hypertension; Electronics; Female; Gout; Human | 2021 |
Targeting uric acid levels in treating gout.
Topics: Gout; Humans; Uric Acid | 2020 |
Research in brief: Serum urate reduction and its effect on the progression of chronic kidney disease.
Topics: Allopurinol; Diabetes Mellitus, Type 1; Disease Progression; Gout; Humans; Kidney; Renal Insufficien | 2020 |
Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
Topics: Arthritis, Gouty; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Insurance, Health; Japan; | 2021 |
Volumetric reduction and dissolution prediction of monosodium urate crystal during urate-lowering therapy - a study using dual-energy computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Gout; Gout Suppressants; Humans; Male; Middle Aged; Polyethylene Gly | 2021 |
Urate in fingernail represents the deposition of urate burden in gout patients.
Topics: Adult; Chromatography, High Pressure Liquid; Female; Follow-Up Studies; Gout; Humans; Male; Middle A | 2020 |
Variability in Urate-lowering Therapy Prescribing: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Physicians; Uric Acid | 2021 |
Management of Gout-associated MSU crystals-induced NLRP3 inflammasome activation by procyanidin B2: targeting IL-1β and Cathepsin B in macrophages.
Topics: Animals; Anti-Inflammatory Agents; Biflavonoids; Catechin; Cathepsin B; Cytokines; Dinoprostone; Gou | 2020 |
Association of urate deposition shown by ultrasound and frequent gout attacks.
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Ultrasonography; Uric Acid | 2021 |
Pretreatment and Coadministration With Methotrexate Improved Durability of Pegloticase Response: An Observational, Proof-of-Concept Case Series.
Topics: Gout; Gout Suppressants; Humans; Methotrexate; Polyethylene Glycols; Treatment Outcome; Urate Oxidas | 2022 |
Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
Topics: Adolescent; Child; Child, Preschool; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; I | 2020 |
Rapid disappearance of gouty tophi of the foot by resection of massive gouty tophi of the opposite foot in a patient with hyperuricaemia: a case report.
Topics: Adult; Arthritis, Gouty; Female; Gout; Humans; Hyperuricemia; Uric Acid | 2020 |
Case with long-standing gout showing various ultrasonographic features caused by monosodium urate monohydrate crystal deposition.
Topics: Gout; Humans; Hyaline Cartilage; Liquid Crystals; Synovial Fluid; Ultrasonography; Uric Acid | 2020 |
Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis.
Topics: Age Factors; Causality; Cholesterol; Dyslipidemias; Genome-Wide Association Study; Gout; Humans; Hyp | 2021 |
External validation of Gout-calculator performance on a cohort of acute arthritis (SYNOLACTATE) sparing distal joints such as hallux and midfoot. A cross-sectional study of 170 patients.
Topics: Cross-Sectional Studies; Gout; Hallux; Humans; Male; Prospective Studies; Retrospective Studies; Syn | 2021 |
Combined effects of MSU crystals injection and high fat-diet feeding on the establishment of a gout model in C57BL/6 mice.
Topics: Animals; Cytokines; Diet, High-Fat; Disease Models, Animal; Edema; Gout; Inflammation; Mice; Mice, I | 2020 |
Discovery of a novel rice-derived peptide with significant anti-gout potency.
Topics: Animals; Edema; Female; Gout; Hyperuricemia; Inflammasomes; Inflammation; Interleukin-1beta; Kidney; | 2020 |
IL-33/ST2 induces neutrophil-dependent reactive oxygen species production and mediates gout pain.
Topics: Animals; Disease Models, Animal; Gout; Humans; Injections, Intra-Articular; Interleukin-1 Receptor-L | 2020 |
Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on
Topics: Adult; Cohort Studies; Female; Gout; Hep G2 Cells; Humans; Hyperlipidemias; Incidence; Kaplan-Meier | 2020 |
Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study.
Topics: Cohort Studies; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Polyethylene Glycols; Re | 2020 |
Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank.
Topics: Adult; Aged; Cardiovascular Diseases; Case-Control Studies; Comorbidity; Diabetes Mellitus; Female; | 2021 |
Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design.
Topics: Allopurinol; Bayes Theorem; Clinical Trials, Phase III as Topic; Computer Simulation; Decision Theor | 2021 |
What is remission in gout and how should we measure it?
Topics: Biomarkers; Gout; Gout Suppressants; Humans; Remission Induction; Uric Acid | 2021 |
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Topics: Allopurinol; Cardiovascular Diseases; Endothelial Cells; Febuxostat; Gout; Gout Suppressants; Humans | 2021 |
[Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout].
Topics: Allopurinol; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Hyperuricemia; Meloxicam; P | 2020 |
Improved ultra-high performance liquid chromatographic method for simultaneous determination of five gout-related metabolites in human serum.
Topics: Chromatography, High Pressure Liquid; Creatinine; Gout; Humans; Hypoxanthine; Inosine; Uric Acid; Xa | 2021 |
Non-alcoholic fatty kidney disease (NAFKD): A novel disease that explains the etiology of hyperuricemia and gout in metabolic syndrome.
Topics: Adult; Female; Gout; Humans; Hyperuricemia; Kidney Diseases; Male; Metabolic Syndrome; Uric Acid | 2021 |
Binding of Macrophage Receptor MARCO, LDL, and LDLR to Disease-Associated Crystalline Structures.
Topics: Animals; Biomarkers; Carrier Proteins; Case-Control Studies; Cytokines; Disease Models, Animal; Dise | 2020 |
A novel mouse model of hyperuricemia expressing a human functional ABCG2 variant.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gout; Humans; Hyperuricemia; Mice; Neoplasm | 2021 |
Does gouty nephropathy exist, and is it more common than we think?
Topics: Cross-Sectional Studies; Gout; Humans; Kidney Medulla; Ultrasonography; Uric Acid | 2021 |
Effects of bariatric surgery on serum uric acid in people with obesity with or without hyperuricaemia and gout: a retrospective analysis.
Topics: Adult; Bariatric Surgery; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Obesity; Retrospec | 2021 |
Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout.
Topics: Aged; Cardiovascular Diseases; Gout; Humans; Risk Factors; Tomography, X-Ray Computed; Uric Acid | 2021 |
Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study.
Topics: Aged; Aged, 80 and over; Biomarkers; Gout; Heart Failure; Humans; Hyperuricemia; Middle Aged; Natriu | 2021 |
HSP60 Regulates Monosodium Urate Crystal-Induced Inflammation by Activating the TLR4-NF-
Topics: Adult; Animals; Antioxidants; Arthritis, Experimental; Case-Control Studies; Chaperonin 60; Gout; Hu | 2020 |
How do dietary interventions affect serum urate and gout?
Topics: Diet; Gout; Gout Suppressants; Humans; Hypertension; Uric Acid | 2021 |
Expression, localization and metabolic function of "resurrected" human urate oxidase in human hepatocytes.
Topics: Cell Proliferation; Gene Expression; Gout; HEK293 Cells; Hepatocytes; Humans; Hyperuricemia; Microsc | 2021 |
Gout.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Gout; Gout Suppressants; Humans; Microscopy; P | 2021 |
Limitations of dual-energy CT in the detection of monosodium urate deposition in dense liquid tophi and calcified tophi.
Topics: Arthritis, Gouty; Gout; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid | 2021 |
Highly specific and label-free histological identification of microcrystals in fresh human gout tissues with stimulated Raman scattering.
Topics: Animals; China; Disease Models, Animal; Gout; Histological Techniques; Humans; Male; Middle Aged; Ra | 2021 |
Comorbidities and factors influencing frequent gout attacks in patients with gout: a cross-sectional study.
Topics: Adult; Comorbidity; Cross-Sectional Studies; Female; Gout; Gout Suppressants; Humans; Male; Middle A | 2021 |
Dual-Energy Computed Tomography for Detection and Characterization of Monosodium Urate, Calcium Pyrophosphate, and Hydroxyapatite: A Phantom Study on Diagnostic Performance.
Topics: Calcium Pyrophosphate; Durapatite; Gout; Humans; Tomography, X-Ray Computed; Uric Acid | 2021 |
How Are We Managing Patients with Hyperuricemia and Gout: A Cross Sectional Study Assessing Knowledge and Attitudes of Primary Care Physicians?
Topics: Attitude; Cross-Sectional Studies; Gout; Humans; Hyperuricemia; Physicians, Primary Care; Uric Acid | 2021 |
Synovial fluid analysis for the enhanced clinical diagnosis of crystal arthropathies in a tertiary care institution.
Topics: Calcium Pyrophosphate; Gout; Humans; Synovial Fluid; Tertiary Healthcare; Uric Acid | 2021 |
Genetic correlations between traits associated with hyperuricemia, gout, and comorbidities.
Topics: Bayes Theorem; Blood Pressure; Cardiometabolic Risk Factors; Comorbidity; Creatinine; Genome-Wide As | 2021 |
The comparative effect of exposure to various risk factors on the risk of hyperuricaemia: diet has a weak causal effect.
Topics: Diet; Glucose Transport Proteins, Facilitative; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk | 2021 |
Loganin Alleviates Gout Inflammation by Suppressing NLRP3 Inflammasome Activation and Mitochondrial Damage.
Topics: Administration, Oral; Animals; Cells, Cultured; Disease Models, Animal; DNA, Mitochondrial; Gout; In | 2021 |
Effects of fenofibrate therapy on renal function in primary gout patients.
Topics: Creatinine; Drug Monitoring; Electronic Health Records; Female; Fenofibrate; Gout; Humans; Hypolipid | 2021 |
Presence of tophi is associated with a rapid decline in the renal function in patients with gout.
Topics: Female; Follow-Up Studies; Glomerular Filtration Rate; Gout; Humans; Kidney; Kidney Function Tests; | 2021 |
[Gout].
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Symptom Flare Up; Uric Acid | 2021 |
Neutrophil extracellular trap clearance by synovial macrophages in gout.
Topics: Arthritis, Gouty; Extracellular Traps; Gout; Humans; Macrophages; Uric Acid | 2021 |
The URRAH study.
Topics: Diabetes Mellitus, Type 2; Gout; Heart Failure; Humans; Hypertension; Retrospective Studies; Stroke; | 2021 |
Genetic Predisposition to Type 2 Diabetes and Insulin Levels Is Positively Associated With Serum Urate Levels.
Topics: Adult; Blood Glucose; Causality; Diabetes Mellitus, Type 2; Fasting; Female; Genetic Predisposition | 2021 |
Drastic monosodium urate crystal dissolution with febuxostat and benzbromarone.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Solubility; Uric Acid | 2021 |
Urate Lowering for Blood Pressure Control in Adults: Another Nail in the Coffin?
Topics: Adult; Blood Pressure; Gout; Gout Suppressants; Humans; Uric Acid | 2021 |
12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target.
Topics: Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Symptom Flare Up; Treatment Outcome; Uri | 2021 |
Ultrasound Evaluation of Three Outcome Domains in the Follow-up of Urate-Lowering Therapy in Gout: An Observational Study.
Topics: Adult; Arthritis; Bone Diseases; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Hum | 2021 |
Genetically predicted serum urate levels have no causal role on depression or other psychiatric disorders.
Topics: Anxiety; Causality; Depression; Depressive Disorder, Major; Genome-Wide Association Study; Gout; Hum | 2021 |
Temporal trends in hyperuricaemia among adults in Wuhan city, China, from 2010 to 2019: a cross-sectional study.
Topics: Adult; China; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Male; Risk Factors; Uric | 2021 |
Influence of Short-Term Consumption of
Topics: Adult; Alkaline Phosphatase; Bacteria; Biomarkers; Creatinine; Fatty Acids, Volatile; Feces; Female; | 2021 |
Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12.
Topics: Adult; Case-Control Studies; Genetic Variation; Gout; HEK293 Cells; Humans; Male; Middle Aged; Organ | 2021 |
The inflammatory role of silent urate crystal deposition in intercritical gout.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Crystallization; Cytokines; Female; Gout; Huma | 2021 |
Association between Anti-inflammatory Drug and Dementia in Patients with Gout: A Nationwide, Population-Based Nested Case-Control Study.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Case-Control Studies; Dementia; Female; Glucocorticoi | 2021 |
Performance of Ultrasound in the Clinical Evaluation of Gout and Hyperuricemia.
Topics: Adolescent; Adult; Aged; Arthritis, Gouty; Asymptomatic Diseases; Female; Gout; Humans; Hyperuricemi | 2021 |
Polyarticular, ulcerated tophaceous gout.
Topics: Gout; Humans; Ulcer; Uric Acid | 2021 |
Real-world treatment of gout and asymptomatic hyperuricemia.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2022 |
Cold-inducible RNA-binding protein (CIRP) potentiates uric acid-induced IL-1β production.
Topics: Caspase 1; Gout; Humans; Inflammasomes; Interleukin-1beta; NLR Family, Pyrin Domain-Containing 3 Pro | 2021 |
Association of urate-lowering drugs with the risk of future urolithiasis in patients with gout: A population-based nested case-control study.
Topics: Case-Control Studies; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pharmaceutical Preparation | 2021 |
Gout-induced endothelial impairment: The role of SREBP2 transactivation of YAP.
Topics: Animals; Cell Cycle Proteins; Gout; Human Umbilical Vein Endothelial Cells; Humans; Hyperuricemia; M | 2021 |
Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization.
Topics: Adult; Aged; Female; Genetic Loci; Gout; Humans; Hyperuricemia; Insulin; Insulin Resistance; Male; M | 2021 |
CD300a contributes to the resolution of articular inflammation triggered by MSU crystals by controlling neutrophil apoptosis.
Topics: Animals; Antigens, CD; Apoptosis; Cells, Cultured; Gout; Humans; Inflammation; Interleukin-1beta; Jo | 2021 |
Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Drug Resistance; D | 2021 |
Explaining the natural course of gout to people living in the tropics.
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 2021 |
Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism.
Topics: Biodiversity; Computational Biology; Dysbiosis; Gastrointestinal Microbiome; Gout; Humans; Metagenom | 2021 |
Melatonin Alleviates Acute Gouty Inflammation In Vivo and In Vitro.
Topics: Acute Disease; Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Interl | 2021 |
Non-pharmacological treatment of gout.
Topics: Animals; Dairy Products; Diet; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2021 |
Urate levels and clearance in renal patients under peritoneal dialysis.
Topics: Gout; Humans; Middle Aged; Peritoneal Dialysis; Uric Acid | 2021 |
Tanshinones inhibit NLRP3 inflammasome activation by alleviating mitochondrial damage to protect against septic and gouty inflammation.
Topics: Abietanes; AMP-Activated Protein Kinases; Animals; Autophagy; Disease Models, Animal; Female; Furans | 2021 |
Response to: 'Correspondence on 'Variants in urate transporters, ADH1B, GCKR and MEPE genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data fro
Topics: Adaptor Proteins, Signal Transducing; Biological Specimen Banks; Extracellular Matrix Proteins; Geno | 2023 |
Correspondence on 'Variants in urate transporters,
Topics: Adaptor Proteins, Signal Transducing; Biological Specimen Banks; Extracellular Matrix Proteins; Geno | 2023 |
Highly permselective uric acid detection using kidney cell membrane-functionalized enzymatic biosensors.
Topics: Biosensing Techniques; Cell Membrane; Gout; Humans; Kidney; Uric Acid | 2021 |
Gout of feet and ankles in different disease durations: diagnostic value of single-source DECT and evaluation of urate deposition with a novel semi-quantitative DECT scoring system.
Topics: Ankle; Arthritis, Gouty; Gout; Humans; Tomography, X-Ray Computed; Uric Acid | 2021 |
Entheseal involvement of the lower extremities in gout: an ultrasonographic descriptive observational study.
Topics: Achilles Tendon; Aged; Enthesopathy; Gout; Humans; Lower Extremity; Severity of Illness Index; Ultra | 2021 |
Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
Topics: Adolescent; Adult; Aged; Asymptomatic Diseases; Cohort Studies; Female; Gout; Gout Suppressants; Hum | 2021 |
Cleroda-4(18),13-dien-15,16-olide as novel xanthine oxidase inhibitors: An integrated in silico and in vitro study.
Topics: Diterpenes, Clerodane; Enzyme Assays; Gout; Humans; Molecular Docking Simulation; Plant Extracts; Po | 2021 |
Identification and characterization of peripheral vascular color-coded DECT lesions in gout and non-gout patients: The VASCURATE study.
Topics: Arthritis, Gouty; Follow-Up Studies; Gout; Humans; Tomography, X-Ray Computed; Uric Acid | 2021 |
Quercetin decreases the antinociceptive effect of diclofenac in an arthritic gout-pain model in rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis; Diclofenac; Dis | 2021 |
Sonographic estimation of monosodium urate burden predicts the fulfillment of the 2016 remission criteria for gout: a 12-month study.
Topics: Gout; Humans; Metatarsophalangeal Joint; Prospective Studies; Ultrasonography; Uric Acid | 2021 |
Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Longitudinal Studies; Symptom Flare Up; Tomograph | 2022 |
Simple metabolic markers associated with tophaceous gout.
Topics: Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Uric Acid | 2021 |
The GOUT-36 prediction rule for inpatient gout flare in people with comorbid gout: derivation and external validation.
Topics: Gout; Gout Suppressants; Humans; Inpatients; Prospective Studies; Symptom Flare Up; Uric Acid | 2022 |
Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia.
Topics: Bariatric Surgery; Gout; Humans; Hyperuricemia; Obesity, Morbid; Symptom Flare Up; Uric Acid | 2021 |
Urate-induced epigenetic modifications in myeloid cells.
Topics: Animals; Epigenesis, Genetic; Gout; Humans; Leukocytes, Mononuclear; Membrane Proteins; Mice; Monocy | 2021 |
Factors Influencing the Serum Uric Acid in Gout with Cerebral Infarction.
Topics: Cerebral Infarction; Cross-Sectional Studies; Gout; Humans; Hypertension; Uric Acid | 2021 |
Increased Systolic Blood Pressure Mediates the Relationship Between Urate and Gout Risk in Indonesia: A Novel Application of a Partial Least Squares-Structural Equation Model.
Topics: Adult; Blood Pressure; Case-Control Studies; Gout; Humans; Hyperuricemia; Indonesia; Least-Squares A | 2022 |
Metagenomic analysis revealed the potential role of gut microbiome in gout.
Topics: Adolescent; Adult; Aged; Arthritis; Bacteria; Butyrates; Diabetes Mellitus, Type 2; Dysbiosis; Fatty | 2021 |
Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways.
Topics: Animals; Arthritis, Gouty; Gout; Inflammasomes; Interleukin-1beta; Mice; Necrosis; NLR Family, Pyrin | 2022 |
To Treat or Not to treat Asymptomatic Hyperuricemia.
Topics: Asymptomatic Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2021 |
Lower Temperatures Exacerbate NLRP3 Inflammasome Activation by Promoting Monosodium Urate Crystallization, Causing Gout.
Topics: Animals; Caspase 1; Crystallization; Gout; Inflammasomes; Interleukin-1beta; Macrophages; Mice; NLR | 2021 |
Acute Gout Following Dermofasciectomy in a Patient With Dupuytren Disease.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Dupuytren Contracture; Fasciotomy; Fingers; | 2017 |
EULAR gout treatment guidelines by Richette
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 2018 |
Performance of the 2015 American College of Rheumatology/European League Against Rheumatism gout classification criteria in Thai patients.
Topics: Aged; Aged, 80 and over; Female; Gout; Humans; Male; Middle Aged; Rheumatology; Sensitivity and Spec | 2017 |
Population-Specific Resequencing Associates the ATP-Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men.
Topics: Adult; Animals; Blotting, Western; Case-Control Studies; Female; Gout; Humans; Hyperuricemia; Logist | 2017 |
Grape seed-derived procyanidins alleviate gout pain via NLRP3 inflammasome suppression.
Topics: Animals; Ankle; Anti-Inflammatory Agents; Antioxidants; Colchicine; Cytokines; Gout; Grape Seed Extr | 2017 |
Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
Topics: Adult; Animals; Benzbromarone; Biological Transport; Dose-Response Relationship, Drug; Gout; HEK293 | 2017 |
GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations.
Topics: Allopurinol; Ambulatory Care; Colchicine; Female; France; Gout; Gout Suppressants; Health Behavior; | 2017 |
SUA levels should not be maintained <3 mg/dL for several years. Response to 'EULAR gout treatment guidelines by Richette
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 2018 |
The added value of synovial fluid centrifugation for monosodium urate and calcium pyrophosphate crystal detection.
Topics: Adult; Aged; Aged, 80 and over; Calcium Pyrophosphate; Centrifugation; Chondrocalcinosis; Female; Go | 2017 |
Performance of the 2015 ACR-EULAR classification criteria for gout in a primary care population presenting with monoarthritis.
Topics: Aged; Arthritis; Crystallization; Decision Support Techniques; Female; Gout; Humans; Male; Middle Ag | 2017 |
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Cause of Death; Female; Gout; Humans; Male; | 2017 |
Management of Gout and Hyperuricemia in CKD.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Diet Therapy; Disease Management; Febuxostat; | 2017 |
Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout; Gout Supp | 2017 |
Persistent clinical inertia in gout in 2014: An observational French longitudinal patient database study.
Topics: Age Factors; Aged; Comorbidity; Databases, Factual; Female; France; General Practice; Gout; Gout Sup | 2018 |
Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Autophagy; Disease Models, Animal; Gout; Granulomatou | 2017 |
Metabolic characteristics and renal dysfunction in 65 patients with tophi prior to gout.
Topics: Disease Progression; Female; Glomerular Filtration Rate; Gout; Humans; Kidney; Male; Middle Aged; Se | 2017 |
First validation of the gout activity score against gout impact scale in a primary care based gout cohort.
Topics: Adult; Age Factors; Aged; Cohort Studies; Cross-Sectional Studies; Female; Gout; Gout Suppressants; | 2018 |
Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization.
Topics: Cardiovascular Diseases; Female; Gout; Humans; Hyperuricemia; Logistic Models; Male; Middle Aged; Pa | 2017 |
A survey on the beliefs and knowledge of gout management in new medical graduates - New South Wales, Australia.
Topics: Attitude of Health Personnel; Biomarkers; Clinical Competence; Clinical Decision-Making; Education, | 2018 |
Response to: 'Is optimizing gout treatment the key to closing the mortality gap in gout patients?' by Brinck
Topics: Gout; Humans; Mortality, Premature; Research Design; Uric Acid | 2018 |
S100A9 potentiates the activation of neutrophils by the etiological agent of gout, monosodium urate crystals.
Topics: Adult; Calcium; Calcium Signaling; Calgranulin B; Female; Gout; Humans; Interleukin-1; Interleukin-8 | 2017 |
The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.
Topics: Adult; Aged; Asian People; Biomarkers; Chi-Square Distribution; China; Cross-Sectional Studies; Down | 2017 |
The Economic Value of Genetic Testing for Tolerance of Allopurinol in Gout.
Topics: Allopurinol; Genetic Testing; Gout; Gout Suppressants; Humans; Uric Acid | 2017 |
An optimal ultrasonographic diagnostic test for early gout: A prospective controlled study.
Topics: Adult; Aged; Ankle Joint; Case-Control Studies; Early Diagnosis; Female; Gout; Humans; Knee Joint; M | 2017 |
Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking.
Topics: Adult; Chronic Disease; Gout; Humans; Male; Physical Examination; Polyethylene Glycols; Quality of L | 2017 |
Replication of Gout/Urate Concentrations GWAS Susceptibility Loci Associated with Gout in a Han Chinese Population.
Topics: Alleles; Asian People; Biomarkers; China; Female; Genetic Loci; Genetic Predisposition to Disease; G | 2017 |
The Impact of Eid Al-Fitr on Serum Uric Acid and Arthritis among Patients with Gout.
Topics: Arthritis; Fasting; Gout; Humans; Islam; Uric Acid | 2017 |
Clinically-evident tophi are associated with reduced muscle force in the foot and ankle in people with gout: a cross-sectional study.
Topics: Achilles Tendon; Ankle Joint; Biomechanical Phenomena; Cross-Sectional Studies; Female; Foot; Gout; | 2017 |
Interaction of the GCKR and A1CF loci with alcohol consumption to influence the risk of gout.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Alcohol Drinking; Female; Gene-Environment Intera | 2017 |
In Reply to 'Detection of Urate Crystals in Kidney Tissue'.
Topics: Crystallization; Gout; Humans; Uric Acid | 2017 |
Tophaceous Gout of the Lumbar Spine Mimicking Malignancy on FDG PET/CT.
Topics: Diagnosis, Differential; Gout; Humans; Lumbar Vertebrae; Male; Middle Aged; Positron Emission Tomogr | 2017 |
Clinical significance of delta neutrophil index in the differential diagnosis between septic arthritis and acute gout attack within 24 hours after hospitalization.
Topics: Aged; Arthritis, Infectious; Biomarkers; Diagnosis, Differential; Female; Gout; Hospitalization; Hum | 2017 |
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
Topics: Aged; Aged, 80 and over; Biomarkers; Clinical Audit; Down-Regulation; Drug Therapy, Combination; Fem | 2017 |
Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Aging; Biomarkers; Brain; Cohort Studies; Dementia; Female; Follow-Up Studi | 2018 |
Management of Gout in a Hospital Setting: A Lost Opportunity.
Topics: Adult; Aged; Aged, 80 and over; Disease Management; Female; Gout; Gout Suppressants; Guideline Adher | 2017 |
My Treatment Approach to Gout.
Topics: Gout; Guideline Adherence; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid | 2017 |
Performance of gout definitions for genetic epidemiological studies: analysis of UK Biobank.
Topics: Adult; Aged; Biological Specimen Banks; Europe; Female; Genetic Predisposition to Disease; Gout; Gou | 2017 |
Calcium pyrophosphate deposition disease: a frequent finding in patients with long-standing erosive gout.
Topics: Aged; Aged, 80 and over; Calcium Pyrophosphate; Chondrocalcinosis; Female; Gout; Humans; Male; Middl | 2018 |
Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.
Topics: Aged; Allopurinol; Clinical Pharmacy Information Systems; Disease Management; Dose-Response Relation | 2017 |
Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
Topics: Allopurinol; Benzbromarone; Databases, Factual; Febuxostat; Gout; Gout Suppressants; Humans; Republi | 2018 |
Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
Topics: Aged; Alcohol Drinking; Comorbidity; Cross-Sectional Studies; Dyslipidemias; Female; France; Gout; G | 2018 |
Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.
Topics: Computer Simulation; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Male; M | 2018 |
Elevated UMOD methylation level in peripheral blood is associated with gout risk.
Topics: Adult; Aged; Blood Chemical Analysis; DNA Methylation; Gout; Humans; Male; Middle Aged; Real-Time Po | 2017 |
Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study.
Topics: Animals; Fermentation; Gout; Gout Suppressants; Hyperuricemia; Mice; Uric Acid; Xanthine Oxidase | 2017 |
Role of serum urate in neurocognitive function and dementia: new evidence contradicts old thinking.
Topics: Cohort Studies; Dementia; Gout; Humans; Research Design; Uric Acid | 2018 |
The problem of cardio-renal diseases in patients with gout.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Risk Factors; Ur | 2017 |
[Dual-energy CT: new diagnostic possibilities].
Topics: Absorptiometry, Photon; Gout; Humans; Sensitivity and Specificity; Tomography, X-Ray Computed; Uric | 2017 |
A common variant of MAF/c-MAF, transcriptional factor gene in the kidney, is associated with gout susceptibility.
Topics: Adult; Asian People; Cell Differentiation; Gene Frequency; Genetic Association Studies; Genetic Pred | 2018 |
Elderly Patients Exhibit Stronger Inflammatory Responses during Gout Attacks.
Topics: Adult; Age Factors; Aged; Blood Sedimentation; C-Reactive Protein; Female; Fever; Gout; Humans; Inte | 2017 |
Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
Topics: Allopurinol; Biomarkers; Drug Combinations; Gout; Gout Suppressants; Humans; Hyperuricemia; Thioglyc | 2017 |
Use of urate-lowering therapies is not associated with an increased risk of incident dementia in older adults.
Topics: Aged; Dementia; Gout; Humans; Uric Acid | 2018 |
Response to: 'Uric acid and incident dementia: a population-based cohort study' by Lee and Song.
Topics: Cohort Studies; Dementia; Gout; Humans; Research Design; Uric Acid | 2018 |
Adherence to gout management recommendations of Chinese patients.
Topics: Adult; Age Factors; China; Gout; Gout Suppressants; Humans; Logistic Models; Male; Medication Adhere | 2017 |
Response to: 'Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults' by Lee and Song.
Topics: Aged; Dementia; Gout; Humans; Hyperuricemia; Uric Acid | 2018 |
Growth patterns of monosodium urate monohydrate (gouty and urinary) crystals in gel: An in vitro study.
Topics: Crystallization; Gels; Gout; Humans; Kidney Calculi; Microscopy, Electron, Scanning; Silicates; Spec | 2017 |
Ultrasonographic detection of double contour sign and hyperechoic aggregates for diagnosis of gout: two sites examination is as good as six sites examination.
Topics: Adult; Ankle Joint; Biomarkers; Cartilage, Articular; Female; Gout; Humans; Knee Joint; Male; Metata | 2018 |
Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements.
Topics: Biomarkers; Clinical Trials as Topic; Gout; Humans; Observational Studies as Topic; Outcome Assessme | 2018 |
Treatment of gout: where are we now?
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 2018 |
Anorexia nervosa and uric acid beyond gout: An idea worth researching.
Topics: Anorexia Nervosa; Gout; Humans; Hyperuricemia; Research; Uric Acid | 2018 |
Joint nociceptor nerve activity and pain in an animal model of acute gout and its modulation by intra-articular hyaluronan.
Topics: Acute Pain; Adjuvants, Immunologic; Animals; Antioxidants; Disease Models, Animal; Flow Cytometry; G | 2018 |
Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation.
Topics: Acute Disease; Administration, Oral; Animals; Anticarcinogenic Agents; Cells, Cultured; Disease Mode | 2018 |
Clinical characteristics associated with subcutaneous tophi formation in Chinese gout patients: a retrospective study.
Topics: Adult; Age of Onset; Aged; Blood Pressure; China; Disease Progression; Female; Gout; Humans; Male; M | 2018 |
Monosodium Urate Crystals Generate Nuclease-Resistant Neutrophil Extracellular Traps via a Distinct Molecular Pathway.
Topics: Extracellular Traps; Gout; Humans; Leukocyte Elastase; Male; Neutrophils; Synovial Fluid; Uric Acid | 2018 |
Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis.
Topics: Adult; Aged; Arthritis, Gouty; Clinical Decision-Making; Female; Gout; Humans; Male; Middle Aged; Ne | 2018 |
Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease.
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Febuxostat; Foot Deformities, Acquired; Gout; Gou | 2018 |
Uric acid and cognitive decline: a double-edge sword?
Topics: Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Gout; Humans; Hyperuricemia; Oxidative Str | 2018 |
Response to: "Monosodium urate crystal deposition associated with the progress of radiographic grade at the sacroiliac joint in axial SpA: a dual-energy CT study".
Topics: Gout; Humans; Sacroiliac Joint; Sacroiliitis; Tomography, X-Ray Computed; Uric Acid | 2018 |
MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK Biobank.
Topics: Adult; Arthritis; Autoimmune Diseases; Biological Specimen Banks; Celiac Disease; Female; Genetic Pr | 2018 |
Ultrasound scans and dual energy CT identify tendons as preferred anatomical location of MSU crystal depositions in gouty joints.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ankle Joint; Crystallization; Female; Gout; Humans; Knee | 2018 |
Management of gout by UK rheumatologists: a British Society for Rheumatology national audit.
Topics: Clinical Audit; Disease Management; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Outp | 2018 |
The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring.
Topics: Australia; Cost-Benefit Analysis; Gout; Humans; Mass Screening; Quality-Adjusted Life Years; Uric Ac | 2018 |
Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein.
Topics: Adult; Aged; Brachial Artery; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; End | 2018 |
Levels of Cytokines and MicroRNAs in Individuals With Asymptomatic Hyperuricemia and Ultrasonographic Findings of Gout: A Bench-to-Bedside Approach.
Topics: Adult; Aged; Asymptomatic Diseases; Biomarkers; Case-Control Studies; Chronic Disease; Circulating M | 2018 |
Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis.
Topics: Adult; Age Distribution; Cohort Studies; Data Analysis; Disease Progression; Gout; Humans; Hyperuric | 2018 |
Topics: Cohort Studies; Gout; Humans; Immune System; Infections; Uric Acid | 2018 |
[Acid uric : key player in a recently recognized devastating nephropathy and in the development of chronic kidney disease.]
Topics: Central America; Disease Progression; Gout; Humans; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout.
Topics: Amines; Animals; Benzoin; Benzoxazoles; Cell Line; Dose-Response Relationship, Drug; Enzyme Inhibito | 2018 |
An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout.
Topics: Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Gout; Humans; Kidney; Longitudin | 2018 |
Coffee consumption and gout: a Mendelian randomisation study.
Topics: Adult; Coffee; Female; Gout; Humans; Male; Mendelian Randomization Analysis; Polymorphism, Single Nu | 2018 |
Genetic variants in two pathways influence serum urate levels and gout risk: a systematic pathway analysis.
Topics: Asian People; Case-Control Studies; China; Female; Genetic Loci; Genetic Predisposition to Disease; | 2018 |
Chronic Disease Approaches Needed to Curb Gout's Growing Burden.
Topics: Allopurinol; Chronic Disease; Diet; Drug Combinations; Febuxostat; Gout; Gout Suppressants; Healthy | 2018 |
Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study.
Topics: Adult; Allopurinol; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Kidney; Male; Mexico | 2018 |
Reference level of serum urate for clinically evident incident gout.
Topics: Data Analysis; Gout; Humans; Hyperuricemia; Uric Acid | 2019 |
Response to: 'The reference levels of serum urate for clinically evident incident gout' by Chen and Ding.
Topics: Data Analysis; Gout; Humans; Hyperuricemia; Uric Acid | 2019 |
Could corneal densitometry be used as a diagnostic and screening tool for ocular involvement in patients with gout?
Topics: Adult; Aged; Biomarkers; Cornea; Corneal Diseases; Corneal Topography; Densitometry; Female; Follow- | 2019 |
Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort.
Topics: Aged; Aged, 80 and over; Cohort Studies; Diuretics; Female; Follow-Up Studies; Gout; Gout Suppressan | 2018 |
Blocking fatty acid-fueled mROS production within macrophages alleviates acute gouty inflammation.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Fatty Acids; Gout; Humans; Inflammat | 2018 |
[Gout - a treatable condition].
Topics: Biomarkers; Gout; Gout Suppressants; Humans; Life Style; Practice Guidelines as Topic; Risk Factors; | 2018 |
4-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol is a potential agent for gout therapy as a dual inhibitor of XOD and NLRP3.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzene Derivatives; Enzyme Inhibitors; Gout; Huma | 2018 |
Monosodium urate crystals induced ICAM-1 expression and cell-cell adhesion in renal mesangial cells: Implications for the pathogenesis of gouty nephropathy.
Topics: Cell Adhesion; Cell Line; Gout; Humans; Intercellular Adhesion Molecule-1; Kidney; Kidney Diseases; | 2020 |
Crystal-proven Gout and Characteristic Gout Severity Factors Are Associated with Cardiovascular Disease.
Topics: Adult; Aged; Cardiovascular Diseases; Comorbidity; Cross-Sectional Studies; Female; Gout; Humans; Ma | 2018 |
Mediators of the Effects of Gender on Uric Acid Nephrolithiasis: A Novel Application of Structural Equation Modeling.
Topics: Adult; Aged; Female; Glomerular Filtration Rate; Gout; Humans; Likelihood Functions; Male; Middle Ag | 2018 |
The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals.
Topics: Gout; Humans; Hyperuricemia; Terminology as Topic; Uric Acid | 2018 |
Surprising safety outcomes of urate-lowering therapy.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid | 2018 |
Accuracy of the HumaSens
Topics: Blood Specimen Collection; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Point-of-Care Sys | 2018 |
Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities.
Topics: Adult; Aged; Black or African American; Comorbidity; Female; Gout; Humans; Hypertension; Incidence; | 2018 |
Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.
Topics: Consensus; Crystal Arthropathies; Delphi Technique; Gout; Humans; Hyperuricemia; Uric Acid | 2019 |
Pharmacophore modeling, molecular docking and molecular dynamics studies on natural products database to discover novel skeleton as non-purine xanthine oxidase inhibitors.
Topics: Biological Products; Enzyme Inhibitors; Gout; Humans; Ligands; Molecular Docking Simulation; Molecul | 2018 |
The lack of association between the burden of monosodium urate crystals assessed with dual-energy computed tomography or ultrasonography with cardiovascular risk in the commonly high-risk gout patient.
Topics: Adult; Aged; Cardiovascular Diseases; Cross-Sectional Studies; Female; Gout; Humans; Male; Middle Ag | 2018 |
Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Comorbidity; Dose-Response Relationship, Drug; Early | 2018 |
GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Topics: Adolescent; Adult; Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biomarkers; | 2018 |
Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Female; Follow-Up Studies; Gout; Gout Suppr | 2018 |
[Analysis of serum ferritin and high sensitive C reactive protein in patients with gout].
Topics: C-Reactive Protein; Ferritins; Gout; Humans; Hyperuricemia; Male; Uric Acid | 2017 |
From hyperuricaemia to gout: what are the missing links?
Topics: Data Analysis; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2018 |
Study on the expressions of NLRP3 gene transcript variants in peripheral blood monocytes of primary gout patients.
Topics: Adult; Case-Control Studies; China; Cross-Sectional Studies; Gene Expression; Gout; Humans; Interleu | 2018 |
Association of gout with osteoporotic fractures.
Topics: Aged; Aged, 80 and over; Bone Density; Cross-Sectional Studies; Female; Gout; Humans; Male; Middle A | 2018 |
Chronic gout: Barriers to effective management.
Topics: Australia; Disease Management; Gout; Gout Suppressants; Humans; Primary Health Care; Rheumatology; U | 2018 |
Mediation analysis to understand genetic relationships between habitual coffee intake and gout.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Alleles; ATP Binding Cassette Transporter, Subfam | 2018 |
Gouty arthritis: Can we avoid unnecessary dual-energy CT examinations using prior radiographs?
Topics: Adult; Aged; Algorithms; Arthritis, Gouty; False Negative Reactions; Female; Gout; Humans; Male; Mid | 2018 |
Editorial Commentary: Prevention and treatment of atrial fibrillation: Is hyperuricemia the next target?
Topics: Atrial Fibrillation; Gout; Humans; Hyperuricemia; Uric Acid | 2019 |
Urate-lowering treatment and risk of total joint replacement in patients with gout.
Topics: Aged; Arthroplasty, Replacement; Databases, Factual; Female; Gout; Gout Suppressants; Humans; Incide | 2018 |
Urate crystals induce macrophage PAF‑AH secretion which is differentially regulated by TGFβ1 and hydrocortisone.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Colchicine; Cytokines; Gout; Humans; Hydrocortisone; | 2018 |
Genetic Background of a Juvenile Onset Gout Patient.
Topics: Adult; Genetic Background; Gout; Humans; Hyperuricemia; Kidney Diseases; Male; Uric Acid; Young Adul | 2018 |
Genetic association between adiposity and gout: a Mendelian randomization study.
Topics: Adiposity; Adult; Body Mass Index; Female; Gout; Humans; Male; Mendelian Randomization Analysis; Mid | 2018 |
The relationship between ferritin and urate levels and risk of gout.
Topics: Black or African American; Female; Ferritins; Gout; Humans; Male; Middle Aged; Native Hawaiian or Ot | 2018 |
Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Clinical Trials, Phase III as T | 2019 |
Long-term Treatment of Gout: New Opportunities for Improved Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Curriculum; Education, Medical, Continuing; Female; Gout; Gout Suppr | 2018 |
Plasma D-dimer is a Promising Indicator for the Treatment of Acute Gouty Attack.
Topics: Acute Disease; Blood Sedimentation; C-Reactive Protein; Female; Fibrin Fibrinogen Degradation Produc | 2018 |
The benchmark dose estimation of reference levels of serum urate for gout.
Topics: Adult; Benchmarking; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Male | 2018 |
The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmö Preventive Project cohort in southern Sweden.
Topics: Adult; Cohort Studies; Female; Follow-Up Studies; Gout; Humans; Hyperuricemia; Male; Mass Screening; | 2018 |
Hyperuricemia and dementia - a case-control study.
Topics: Aged; Case-Control Studies; Dementia; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Odds R | 2018 |
Genetics of serum urate concentrations and gout in a high-risk population, patients with chronic kidney disease.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cohort Studies; Female; Genetic Predi | 2018 |
Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
Topics: Aged; Arthritis, Gouty; Creatinine; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middl | 2018 |
Monosodium urate crystals reduce osteocyte viability and indirectly promote a shift in osteocyte function towards a proinflammatory and proresorptive state.
Topics: Animals; Bone Resorption; Cell Survival; Gout; Humans; Inflammation Mediators; Male; Mice; Mice, Inb | 2018 |
Urate crystals and inflammation. Cardiovascular impact of gout.
Topics: Gout; Humans; Hyperuricemia; Inflammation; Uric Acid | 2018 |
Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study : MSU burden and risk of gout flare.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Cost of Illness; Female; Follow-Up Studies; Gout; H | 2018 |
Ultrasonographic Features of Lower-Limb Joints in Gout: Which Joints and Clinical Characteristics Would Provide More Information for Diagnosis?
Topics: Age Factors; Analysis of Variance; Ankle Joint; Cross-Sectional Studies; Female; Follow-Up Studies; | 2020 |
Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Calcium Channel Blockers; Cardiov | 2018 |
Coffee consumption and gout: a Mendelian randomisation study.
Topics: Coffee; Gout; Humans; Uric Acid | 2019 |
The role of diet in serum urate concentration.
Topics: Diet; Gout; Humans; Uric Acid | 2018 |
Hyperferritinaemia and hyperuricaemia - a causal connection?
Topics: Ferritins; Gout; Humans; Hyperuricemia; Uric Acid | 2018 |
Noninvasive diagnosis of liquefied gouty tophus: Reflectance confocal microscopy as an alternative to polarizing light microscopy analysis.
Topics: Female; Fingers; Gout; Granuloma; Humans; Microscopy, Confocal; Microscopy, Polarization; Middle Age | 2019 |
Cardiovascular Safety of Febuxostat.
Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid | 2018 |
Cardiovascular Safety of Febuxostat.
Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid | 2018 |
Cardiovascular Safety of Febuxostat.
Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid | 2018 |
Cardiovascular Safety of Febuxostat.
Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid | 2018 |
Patient education and engagement in treat-to-target gout care.
Topics: Gout; Gout Suppressants; Humans; Patient Education as Topic; Uric Acid | 2018 |
Renal excretion is a cause of decreased serum uric acid during acute gout.
Topics: Adult; Aged; Arthritis, Gouty; Biomarkers; Down-Regulation; Female; Gout; Humans; Hyperuricemia; Kid | 2018 |
White Powder Over Palm: An Unusual Presentation of Hyperuricemia in Polyarticular Gout.
Topics: Gout; Hand; Humans; Hyperuricemia; Uric Acid | 2018 |
Association of solute carrier family 2, member 9 (SLC2A9) genetic variant rs3733591 with gout in a Malay sample set.
Topics: Adolescent; Adult; Aged; Asian People; Case-Control Studies; Creatinine; Female; Genetic Association | 2018 |
Should our approach to diuretic using in patients with gout change?
Topics: Diuretics; Gout; Humans; Hypertension; Uric Acid | 2018 |
Urate-lowering therapy (ULT) reduces non-episodic foot pain in patients who fail to meet ACR/EULAR 2015 gout classification criteria: an effect predicted by ultrasound and potential rationale for reclassification.
Topics: Case-Control Studies; Female; Foot Joints; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pain; | 2019 |
Infection of a tophaceous nodule of the wirst and hand.
Topics: Adult; Anti-Bacterial Agents; Arthritis, Gouty; Fingers; Gout; Hand; Humans; Male; Treatment Outcome | 2018 |
Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
Topics: Adult; Aged; Cohort Studies; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Population | 2018 |
Kelley-Seegmiller Syndrome: Urolithiasis, Renal Uric Acid Deposits, and Gout: What is the Role of the Urologist?
Topics: Adult; Conservative Treatment; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney; Male; P | 2019 |
LncRNA-Jak3:Jak3 coexpressed pattern regulates monosodium urate crystal-induced osteoclast differentiation through Nfatc1/Ctsk expression.
Topics: Animals; Cathepsin K; Cell Differentiation; Gene Expression Regulation; Gout; HEK293 Cells; Humans; | 2019 |
Effect of fenofibrate on uric acid level in patients with gout.
Topics: Adult; Aged; Drug Interactions; Enzyme Inhibitors; Female; Fenofibrate; Gout; Humans; Kidney; Liver; | 2018 |
Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
Topics: Aged; Allopurinol; Cohort Studies; Cross-Sectional Studies; Female; Gout; Gout Suppressants; Humans; | 2019 |
Antioxidant properties of citric acid interfere with the uricase-based measurement of circulating uric acid.
Topics: Aged; Anticoagulants; Antioxidants; Biomarkers; Blood Specimen Collection; Citric Acid; Cohort Studi | 2019 |
Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?
Topics: Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency | 2018 |
Characteristics of gout patients according to the laterality of nephrolithiasis: A cross-sectional study using helical computed tomography.
Topics: Adult; Aged; Biomarkers; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Go | 2019 |
[A woman with a white skin lesion of her toe].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chronic Disease; Colchicine; Female | 2018 |
Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
Topics: Allopurinol; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceut | 2018 |
Resveratrol attenuates the MSU crystal-induced inflammatory response through the inhibition of TAK1 activity.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Crystal Arthropathies; Down-Regulation; Extracel | 2019 |
[A case of gout secondary to primary myelofibrosis].
Topics: Arthritis, Gouty; Febuxostat; Gout; Gout Suppressants; Humans; Male; Middle Aged; Primary Myelofibro | 2018 |
A Case Report of Immunosuppressant Medication‒Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol‒Conjugated Uricase Enzyme Pegloticase.
Topics: Adult; Female; Gout; Gout Suppressants; Heart Transplantation; Humans; Immunocompromised Host; Immun | 2018 |
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
Topics: Adult; Aged; Chronic Disease; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Polyethyle | 2018 |
Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Case-Control Studies; Diabe | 2019 |
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hy | 2019 |
Polymorphisms of
Topics: Adult; Aged; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; Blood Pressure; Case- | 2019 |
Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank.
Topics: Adult; Aged; Biological Specimen Banks; Female; Genetic Variation; Gout; Humans; Male; Middle Aged; | 2019 |
Achievement of Target Serum Uric Acid Levels and Factors Associated with Therapeutic Failure among Japanese Men Treated for Hyperuricemia/Gout.
Topics: Adult; Aged; Anthropometry; Body Mass Index; Cross-Sectional Studies; Drug Monitoring; Dyslipidemias | 2019 |
Evaluation of Turmeric Nanoparticles as Anti-Gout Agent: Modernization of a Traditional Drug.
Topics: Animals; Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Curcuma; Disease Models, Animal; Drug Del | 2019 |
Progress in Treatment of Gout Using Chinese and Western Medicine.
Topics: Drugs, Chinese Herbal; Gout; Humans; Medicine, Chinese Traditional; Uric Acid | 2020 |
Common variants in the
Topics: Adult; Aged; Asian People; Case-Control Studies; China; Gout; Humans; Hyperuricemia; Male; Membrane | 2019 |
Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Gout; G | 2019 |
Clinical features and recurrent attack in gout patients according to serum urate levels during an acute attack.
Topics: Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospective Studies; Uric Acid | 2020 |
Clinical Utility of Multi-Energy Spectral Photon-Counting Computed Tomography in Crystal Arthritis.
Topics: Calcium Pyrophosphate; Chondrocalcinosis; Crystal Arthropathies; Diagnosis, Differential; Durapatite | 2019 |
Secretion of IL-1β From Monocytes in Gout Is Redox Independent.
Topics: Acetylcysteine; Antioxidants; Cell Survival; Furans; Gene Expression; Gout; Heterocyclic Compounds, | 2019 |
Study on the diagnosis of gout with xanthine and hypoxanthine.
Topics: Blood Chemical Analysis; Chromatography, High Pressure Liquid; Gout; Humans; Hyperuricemia; Hypoxant | 2019 |
mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?
Topics: Cell Death; Cytokines; Gout; Humans; Inflammation; Metformin; Monocytes; Signal Transduction; TOR Se | 2019 |
Hyperuricemia and acute gout after laparoscopic sleeve gastrectomy.
Topics: Adult; Bariatric Surgery; Biomarkers; Body Composition; Body Water; Female; Gastrectomy; Gout; Greec | 2019 |
[Gout with tophi].
Topics: Gout; Humans; Uric Acid | 2018 |
Dual actions on gout flare and acute kidney injury along with enhanced renal transporter activities by Yokuininto, a Kampo medicine.
Topics: Acute Kidney Injury; Animals; Cell Line; Cells, Cultured; Gout; HEK293 Cells; Humans; Male; Medicine | 2019 |
Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update.
Topics: Aged; Allopurinol; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Uri | 2019 |
Urate Bulla: a Rare Manifestation of Gout.
Topics: Aged, 80 and over; Blister; Gout; Humans; Male; Uric Acid | 2019 |
Hyperuricaemia and vascular risk: the debate continues.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid; Xanthine Oxidase | 2019 |
Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Communicable Diseases; Female; Gout; Humans; Hyperuri | 2019 |
The Validity of Gout Diagnosis in Primary Care: Results from a Patient Survey.
Topics: Aged; Aged, 80 and over; Female; Gout; Humans; Inflammation; Male; Middle Aged; Primary Health Care; | 2019 |
Alpha2B-Adrenergic Receptor Regulates Neutrophil Recruitment in MSU-Induced Peritoneal Inflammation.
Topics: Animals; Disease Models, Animal; Gout; Inflammation; Interleukin-1beta; Macrophages; Male; Mice; Mic | 2019 |
Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Renal Insuf | 2020 |
Improving adherence to urate-lowering therapy in people living with gout.
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 2019 |
Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout.
Topics: Allopurinol; Computer Simulation; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Monitoring; E | 2019 |
Functional Characterization of Clinically-Relevant Rare Variants in
Topics: Adolescent; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; | 2019 |
Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice.
Topics: Animals; Antioxidants; Arthritis, Gouty; Disease Models, Animal; Drugs, Chinese Herbal; Edema; Flavo | 2019 |
Diagnostic challenges of spinal gout: A case series.
Topics: Aged; Female; Gout; Humans; Male; Middle Aged; Retrospective Studies; Spinal Diseases; Uric Acid; Yo | 2019 |
Chrysanthemum indicum extract inhibits NLRP3 and AIM2 inflammasome activation via regulating ASC phosphorylation.
Topics: Animals; Anti-Inflammatory Agents; CARD Signaling Adaptor Proteins; Chrysanthemum; DNA-Binding Prote | 2019 |
Are Target Urate and Remission Possible in Severe Gout? A Five-year Cohort Study.
Topics: Adult; Female; Follow-Up Studies; Gout; Gout Suppressants; Health Surveys; Humans; Longitudinal Stud | 2020 |
Partners and nurses' knowledge and representations of gout: A qualitative study.
Topics: Adult; Aged, 80 and over; Attitude to Health; Disease Progression; Female; France; Gout; Grounded Th | 2019 |
Point-of-care uric acid testing is useful in routine clinical care of gout.
Topics: Gout; Humans; Hyperuricemia; Point-of-Care Systems; Punctures; Uric Acid | 2019 |
Serum Urate, Uricase, and Blood Pressure Control in Gout.
Topics: Blood Pressure; Gout; Humans; Polyethylene Glycols; Urate Oxidase; Uric Acid | 2019 |
Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
Topics: Adult; Aged; Blood Pressure Determination; Chronic Disease; Dose-Response Relationship, Drug; Drug A | 2019 |
Sirt1 ameliorates monosodium urate crystal-induced inflammation by altering macrophage polarization via the PI3K/Akt/STAT6 pathway.
Topics: Acute Disease; Adult; Animals; Arthritis, Experimental; Arthritis, Gouty; Cell Polarity; Gout; Human | 2019 |
Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels.
Topics: Gout; Humans; Interleukin-1beta; Uric Acid | 2019 |
Level of Agreement with the Microscopic Analysis of Joint Aspirate for the Diagnosis of Gout in the Lower Extremity.
Topics: Gout; Humans; Lower Extremity; Reproducibility of Results; Retrospective Studies; Uric Acid | 2020 |
Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function.
Topics: Allopurinol; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gout; Gout Suppressants; Hum | 2019 |
Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
Topics: Adult; Aged; Biomarkers; Databases, Factual; Down-Regulation; Female; Gout; Gout Suppressants; Human | 2019 |
Comparative Study of Real-Life Management Strategies in Gout: Data From Two Protocolized Gout Clinics.
Topics: Aged; Allopurinol; Clinical Decision Rules; Clinical Protocols; Female; Follow-Up Studies; Gout; Gou | 2020 |
The Consequences of Untreated Gout: Is this a Tophus?
Topics: Aged, 80 and over; Fingers; Gout; Humans; Male; New Mexico; Uric Acid | 2019 |
Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy.
Topics: Aged; Case-Control Studies; Female; Gout; Gout Suppressants; Hospitalization; Humans; Length of Stay | 2019 |
Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Coronary Artery Disease; | 2019 |
2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout.
Topics: Gout; Humans; Hyperuricemia; Radiography; Risk Factors; Synovial Fluid; Tomography, X-Ray Computed; | 2020 |
Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis.
Topics: Animals; Caspase 1; Catechin; Disease Models, Animal; DNA, Mitochondrial; Gout; Humans; Inflammasome | 2019 |
Anti-hyperuricemic effect of Alpinia oxyphylla seed extract by enhancing uric acid excretion in the kidney.
Topics: Alpinia; Animals; China; Gout; Humans; Hyperuricemia; Kidney; Male; Organic Anion Transport Protein | 2019 |
Pilot study: asymptomatic hyperuricemia patients with obesity and nonalcoholic fatty liver disease have increased risk of double contour sign.
Topics: Gout; Humans; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Obesity; Pilot Projects; Ultrasonogr | 2020 |
The Pyroptotic Cell Death Effector Gasdermin D Is Activated by Gout-Associated Uric Acid Crystals but Is Dispensable for Cell Death and IL-1β Release.
Topics: Acrylamides; Animals; Caspase 1; Cathepsins; Female; Gout; Interleukin-1beta; Intracellular Signalin | 2019 |
DHA protects against monosodium urate-induced inflammation through modulation of oxidative stress.
Topics: Animals; Antioxidants; Catalase; Cell Survival; Cytokines; Docosahexaenoic Acids; Gout; Heme Oxygena | 2019 |
Palm-Sized Uric Acid Test Lab Powered by Smartphone for Proactive Gout Management.
Topics: Biosensing Techniques; Gout; Humans; Point-of-Care Systems; Smartphone; Uric Acid | 2019 |
Concurrent validity of provisional remission criteria for gout: a dual-energy CT study.
Topics: Biomarkers; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Joints; Male; Middle Aged; P | 2019 |
Downregulation of Transcription Factor T-Bet as a Protective Strategy in Monosodium Urate-Induced Gouty Inflammation.
Topics: Adult; Animals; Body Fluids; Cytokines; Disease Models, Animal; Down-Regulation; Edema; Female; Foot | 2019 |
[What is new on gout? : Report from ACR 2018].
Topics: Gout; Humans; Uric Acid | 2019 |
Human Cartilage Homogenates Influence the Crystallization of Monosodium Urate and Inflammatory Response to Monosodium Urate Crystals: A Potential Link Between Osteoarthritis and Gout.
Topics: Cartilage; Crystallization; Cytokines; Gout; Humans; Inflammation; Knee Joint; Osteoarthritis; Uric | 2019 |
Gout and hyperuricaemia: a worldwide health issue of joints and beyond.
Topics: Global Health; Gout; Humans; Hyperuricemia; Prevalence; United States; Uric Acid | 2019 |
Primary Care Diagnosis of Gout Compared to a Primary Care Diagnostic Rule for Gout and to Classification Criteria.
Topics: Gout; Humans; Primary Health Care; Surveys and Questionnaires; Uric Acid | 2019 |
Tophi reduction: ultrasound imaging and correlation with plasma levels of uric acid in patients undergoing treatment for tophaceous gout.
Topics: Adult; Aged; Correlation of Data; Gout; Humans; Male; Middle Aged; Prospective Studies; Uric Acid | 2019 |
Decreased Expression of CD14 in MSU-Mediated Inflammation May Be Associated with Spontaneous Remission of Acute Gout.
Topics: Adult; Aged; C-Reactive Protein; Female; Gout; Humans; Inflammation Mediators; Leukocytes, Mononucle | 2019 |
Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
Topics: Adult; Allopurinol; Benzbromarone; Biomarkers; Cholesterol; Febuxostat; Female; Gout; Gout Suppressa | 2019 |
Evaluation of the chemical composition of nephrolithiasis using dual-energy CT in Southern Chinese gout patients.
Topics: Adult; Aged; China; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Nephrolithiasis; Preval | 2019 |
Monosodium urate deposition in the articular cartilage and meniscus can mimic chondrocalcinosis.
Topics: Arthritis, Gouty; Cartilage, Articular; Chondrocalcinosis; Gout; Humans; Meniscus; Uric Acid | 2020 |
Clinical characteristics and risk factors for gout flare during the postsurgical period.
Topics: Allopurinol; Blood Loss, Surgical; Female; Foot Joints; Gout; Gout Suppressants; Humans; Knee Joint; | 2019 |
Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.
Topics: Aged; Alcohol Drinking; Allopurinol; Benzbromarone; Diet Therapy; Febuxostat; Female; Foot Joints; F | 2020 |
Risk factors for the formation of double-contour sign and tophi in gout.
Topics: Adult; Ankle Joint; Female; Gout; Humans; Knee Joint; Male; Metatarsophalangeal Joint; Middle Aged; | 2019 |
Defining remission in patients with gout.
Topics: Gout; Humans; Tomography, X-Ray Computed; Uric Acid | 2019 |
Radiologic evidence of symmetric and polyarticular monosodium urate crystal deposition in gout - A cluster pattern analysis of dual-energy CT.
Topics: Aged; Allopurinol; Female; Foot Joints; Gout; Gout Suppressants; Hand Joints; Humans; Knee Joint; Ma | 2020 |
Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia.
Topics: Allopurinol; Australia; Female; Gout; Gout Suppressants; Humans; Male; Rheumatology; Treatment Outco | 2020 |
What can asymptomatic hyperuricaemia and systemic inflammation in the absence of gout tell us?
Topics: Chemokine CCL2; Female; Gout; Humans; Hyperuricemia; Male; Monocytes; Uric Acid | 2013 |
Gout and the risk of Parkinson's disease in Denmark.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Denmark; Drug Prescriptions; Female; Gout; Gou | 2013 |
Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
Topics: Adult; Aged; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Male; Middle Aged; | 2013 |
Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, | 2013 |
Ultrasound learning curve in gout: a disease-oriented training program.
Topics: Gout; Humans; Joints; Learning Curve; Male; Middle Aged; Rheumatology; Ultrasonography; Uric Acid | 2013 |
Anti-nociceptive and anti-edematogenic effects of glibenclamide in a model of acute gouty attack in rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Dinoprostone; Disease Models, Animal; Glyburide; Gout | 2013 |
Italian Society of Rheumatology recommendations for the management of gout.
Topics: Adrenal Cortex Hormones; Advisory Committees; Alcoholic Beverages; Allopurinol; Anti-Inflammatory Ag | 2013 |
Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study.
Topics: Adult; Age Distribution; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Casset | 2013 |
Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality.
Topics: Adult; Age Factors; Biomarkers; Cardiovascular Diseases; Female; Gout; Humans; Hyperuricemia; Incide | 2013 |
ALPK1 genetic regulation and risk in relation to gout.
Topics: Adult; Alleles; Asian People; Case-Control Studies; Gene Expression Regulation; Genetic Predispositi | 2013 |
Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.
Topics: Aged; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Female; Gout; Humans; Hyperuricemia; K | 2013 |
Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire.
Topics: Female; Gout; Gout Suppressants; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; | 2013 |
The "gout of the Medici": making the modern diagnosis using paleopathology.
Topics: Arthritis, Rheumatoid; Diet; Family Health; Gout; History, 15th Century; History, 16th Century; Hist | 2013 |
Effect of bariatric surgery on the inflammatory response to monosodium urate crystals: a prospective study.
Topics: Adult; Bariatric Surgery; Body Weight; Cells, Cultured; Cytokines; Female; Gout; Humans; Inflammatio | 2013 |
Serum urate and incidence of kidney disease among veterans with gout.
Topics: Aged; Body Mass Index; Comorbidity; Gout; Humans; Hyperuricemia; Incidence; Kidney Diseases; Male; M | 2013 |
Cost-effectiveness of febuxostat in chronic gout.
Topics: Cost-Benefit Analysis; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans | 2014 |
Effect of genetic polymorphisms on development of gout.
Topics: Adult; Asian People; Case-Control Studies; Gene Frequency; Genetic Predisposition to Disease; Genome | 2013 |
Type of uromodulin mutation and allelic status influence onset and severity of uromodulin-associated kidney disease in mice.
Topics: Age of Onset; Alleles; Animals; Body Weight; Cystatins; Disease Models, Animal; Disease Progression; | 2013 |
Enzyme-entrapped mesoporous silica for treatment of uric acid disorders.
Topics: Administration, Cutaneous; Animals; Drug Delivery Systems; Enzyme Replacement Therapy; Enzymes, Immo | 2013 |
Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.
Topics: Aged; Aged, 80 and over; Crystallization; Disease Progression; Female; Foot Joints; Gout; Gout Suppr | 2014 |
Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications.
Topics: Blotting, Western; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gout; Humans; | 2013 |
Reversal of chronic refractory tophaceous gout with erosions with pegloticase.
Topics: Aged; Biomarkers; Chronic Disease; Disease Progression; Finger Joint; Gout; Gout Suppressants; Human | 2013 |
Common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility.
Topics: Aged; Female; Gene Expression; Gene Frequency; Genetic Predisposition to Disease; Genome-Wide Associ | 2013 |
Transient receptor potential melastatin 2: a novel target for treatment of gout.
Topics: Gout; Humans; Inflammation; TRPM Cation Channels; Uric Acid | 2013 |
Caspase-1 level in synovial fluid is high in patients with spondyloarthropathy but not in patients with gout.
Topics: Adult; Aged; Arthritis, Rheumatoid; Caspase 1; Female; Gout; Humans; Interleukin-18; Interleukin-1be | 2013 |
[<
Topics: Aged, 80 and over; Biopsy; Diagnosis, Differential; Discitis; Female; Gout; Humans; Lumbar Vertebrae | 2013 |
A common variant of organic anion transporter 4 (OAT4/SLC22A11) gene is associated with renal underexcretion type gout.
Topics: Asian People; Case-Control Studies; Chi-Square Distribution; Gene Frequency; Genetic Association Stu | 2014 |
Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Beverages; Case-Control Studies; Dietary Sucrose; Female | 2014 |
How to regulate neutrophils in gout.
Topics: Gout; Humans; Lectins, C-Type; Neutrophil Activation; Neutrophils; Receptors, Mitogen; Uric Acid | 2013 |
Experiences of gout-related disability from the patients' perspective: a mixed methods study.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Disability Eval | 2014 |
No association between gout and Alzheimer's disease: results of a case-control study in older people in Taiwan.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Comorbidity; Female; Gout; Humans; | 2013 |
Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease.
Topics: Animals; Embolism, Cholesterol; Gout; Humans; Inflammasomes; Kidney; Kidney Calculi; Nephritis; Uric | 2014 |
Workshop report: 4th European crystal network meeting.
Topics: Calcium; Calcium Phosphates; Crystallization; Gout; Humans; Hyperuricemia; Uric Acid | 2013 |
Participation of the TRPV1 receptor in the development of acute gout attacks.
Topics: Acute Disease; Anilides; Animals; Arthralgia; Cinnamates; Disease Models, Animal; Gout; Inflammation | 2014 |
The effects of monosodium urate monohydrate crystals on chondrocyte viability and function: implications for development of cartilage damage in gout.
Topics: Aged; Apoptosis; Cartilage; Cell Survival; Chondrocytes; Crystallization; Dose-Response Relationship | 2013 |
Crystal arthritis: Environment and genetics in gout: a maze for clinicians?
Topics: Arthritis; Carbonated Beverages; Dietary Sucrose; Gout; Humans; Male; Uric Acid | 2014 |
Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice.
Topics: Aged; Blood Glucose; Diet Therapy; Disease Management; Female; Glomerular Filtration Rate; Gout; Gou | 2013 |
Gout with auricular tophi following anti-tuberculosis treatment: a case report.
Topics: Antitubercular Agents; Biopsy; Carcinoma, Squamous Cell; Diagnosis, Differential; Ear Auricle; Epide | 2013 |
An audit of a therapeutic drug monitoring service for allopurinol therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Child; Child, Preschool; Creatinine; Drug M | 2013 |
CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
Topics: Allopurinol; Comorbidity; Disease Management; Drug Administration Schedule; Febuxostat; Gout; Gout S | 2014 |
Citric acid treatment of chronic nonhealing ulcerated tophaceous gout with bursitis.
Topics: Administration, Topical; Aged, 80 and over; Ankle Joint; Anti-Bacterial Agents; Anti-Infective Agent | 2013 |
Lack of change in urate deposition by dual-energy computed tomography among clinically stable patients with long-standing tophaceous gout: a prospective longitudinal study.
Topics: Aged; Allopurinol; Female; Foot; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Stu | 2013 |
Common variant of leucine-rich repeat-containing 16A (LRRC16A) gene is associated with gout susceptibility.
Topics: Actin Cytoskeleton; Actins; Carrier Proteins; Genetic Predisposition to Disease; Genetic Variation; | 2014 |
High-density lipoproteins inhibit urate crystal-induced inflammation in mice.
Topics: Animals; Back; Chemokine CCL2; Chemokine CXCL1; Disease Models, Animal; Gout; Inflammation; Interleu | 2015 |
Late diagnosis of Lesch-Nyhan disease variant.
Topics: Adult; Allopurinol; Diuretics; Genetic Counseling; Gout; Gout Suppressants; Humans; Hyperuricemia; H | 2013 |
Racial differences in gout incidence in a population-based cohort: Atherosclerosis Risk in Communities Study.
Topics: Black People; Female; Gout; Humans; Incidence; Male; Middle Aged; Proportional Hazards Models; Risk | 2014 |
Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study.
Topics: Aged; Allopurinol; Bone Density; Cohort Studies; Gout; Hip Fractures; Humans; Incidence; Male; Osteo | 2014 |
Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout.
Topics: Adult; Aged; Creatinine; Female; Foreign-Body Reaction; Gout; Humans; Logistic Models; Male; Middle | 2013 |
Evaluating appropriate use of prophylactic colchicine for gout flare prevention.
Topics: Adult; Aged; Aged, 80 and over; Colchicine; Electronic Health Records; Female; Gout; Gout Suppressan | 2014 |
The effects of gout on left atrial volume remodelling: a prospective echocardiographic study.
Topics: Adult; Aged; Arthritis, Gouty; Atrial Remodeling; Cardiac Volume; Case-Control Studies; Cross-Sectio | 2014 |
Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Ambulatory Care Facilities; Chronic Disease; Feasibilit | 2014 |
A customized Raman system for point-of-care detection of arthropathic crystals in the synovial fluid.
Topics: Calcium Pyrophosphate; Crystallization; Gout; Humans; Limit of Detection; Microscopy, Electron, Scan | 2014 |
Smilax riparia reduces hyperuricemia in mice as a potential treatment of gout.
Topics: Animals; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; Gout; Gout Suppressants; Hy | 2014 |
Arthritis of the first metatarsophalangeal joint is not always gout: a prospective cohort study in primary care patients.
Topics: Aged; Arthritis; Female; Gout; Humans; Male; Metatarsophalangeal Joint; Middle Aged; Primary Health | 2014 |
Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout.
Topics: Adult; Aged; Aged, 80 and over; Animals; Calgranulin A; Calgranulin B; Cells, Cultured; Crystallizat | 2014 |
Q: should patients with gout avoid thiazides for hypertension?
Topics: Contraindications; Gout; Gout Suppressants; Humans; Hypertension; Thiazides; Uric Acid | 2014 |
Additive value for ultrasonographic signal in a screening algorithm for patients presenting with acute mono-/oligoarthritis in whom gout is suspected.
Topics: Adult; Aged; Algorithms; Calcium Pyrophosphate; Chondrocalcinosis; Female; Finger Joint; Gout; Human | 2014 |
Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Ankylosis; Female; Foot Joints; | 2015 |
The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Asymptomatic Diseases; Cohort Studies; Female; Glo | 2014 |
MANAGEMENT of gout; new views on uric acid metabolism.
Topics: Disease Management; Gout; Humans; Uric Acid | 1951 |
Association and interaction effect between VEGF receptor-2 (VEGFR-2) gene polymorphisms and dietary pattern on blood uric acid in Malays and Indians.
Topics: Adult; Animals; Body Mass Index; Diet; Dietary Proteins; Fast Foods; Female; Food; Fruit; Genotype; | 2012 |
Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Elbow Joint; Female; Foot Joints; Gout; Hand Joints; | 2014 |
[A new application for well-known pharmaceutics--losartan and fenofibrate as potential remedies against gout?].
Topics: Angiotensin II Type 1 Receptor Blockers; Fenofibrate; Gout; Gout Suppressants; Humans; Hypolipidemic | 2014 |
Management of gout in a South Auckland general practice.
Topics: General Practice; Gout; Humans; Native Hawaiian or Other Pacific Islander; New Zealand; Practice Pat | 2014 |
Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study.
Topics: Absorptiometry, Photon; Adult; Aged; Arthritis; Case-Control Studies; Cohort Studies; Elbow Joint; F | 2015 |
Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study.
Topics: Absorptiometry, Photon; Adult; Aged; Arthritis; Case-Control Studies; Cohort Studies; Elbow Joint; F | 2015 |
Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study.
Topics: Absorptiometry, Photon; Adult; Aged; Arthritis; Case-Control Studies; Cohort Studies; Elbow Joint; F | 2015 |
Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study.
Topics: Absorptiometry, Photon; Adult; Aged; Arthritis; Case-Control Studies; Cohort Studies; Elbow Joint; F | 2015 |
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study.
Topics: Aged; Allopurinol; Black or African American; Evaluation Studies as Topic; Febuxostat; Female; Focus | 2014 |
Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Comparative Effectiveness Resea | 2014 |
Interactions between tenocytes and monosodium urate monohydrate crystals: implications for tendon involvement in gout.
Topics: Animals; Cell Survival; Cells, Cultured; Collagen; Crystallization; Dose-Response Relationship, Drug | 2014 |
Aging, not menopause, is associated with higher prevalence of hyperuricemia among older women.
Topics: Adult; Aged; Aging; Body Mass Index; Cross-Sectional Studies; Diuretics; Female; Glomerular Filtrati | 2014 |
An unusual case of gout.
Topics: Acute Coronary Syndrome; Aged; Chest Pain; Diagnosis, Differential; Gout; Humans; Knee Joint; Male; | 2014 |
Anakinra treatment in patients with gout and type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; | 2015 |
Cytospin preparations are superior to common smears in the detection of monosodium urate crystals in low-cellular synovial fluids.
Topics: Adult; Aged; C-Reactive Protein; Calcium Pyrophosphate; Crystallization; Female; Gout; Humans; Leuko | 2014 |
Crystal arthritis: Tendon damage in gout--a role for MSU crystals?
Topics: Animals; Gout; Humans; Tendons; Uric Acid | 2014 |
New gout test: enhanced ex vivo cytokine production from PBMCS in common gout patients and a gout patient with Kearns-Sayre syndrome.
Topics: Adult; Cytokines; Gout; Humans; Kearns-Sayre Syndrome; Leukocytes, Mononuclear; Male; Uric Acid | 2014 |
Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines.
Topics: Animals; Cell Aggregation; Chemokines; Cytokines; Gout; Humans; Inflammation; Mice; Neutrophils; Res | 2014 |
Drugs for gout.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Colchicine; Enzyme Inh | 2014 |
An MRI assessment of chronic synovial-based inflammation in gout and its correlation with serum urate levels.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Gout; Humans; Inflammation; Knee Joint; Magnetic Reson | 2015 |
In vitro xanthine oxidase inhibitory and in vivo hypouricemic activity of herbal coded formulation (Gouticin).
Topics: Allopurinol; Female; Gout; Humans; Male; Middle Aged; Phytotherapy; Plant Extracts; Plants, Medicina | 2014 |
The methanol extract of Euonymus laxiflorus, Rubia lanceolata and Gardenia jasminoides inhibits xanthine oxidase and reduce serum uric acid level in rats.
Topics: Animals; Disease Models, Animal; Euonymus; Formaldehyde; Gardenia; Gout; Hyperuricemia; Nociception; | 2014 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes M | 2014 |
Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors.
Topics: Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transpor | 2014 |
[A man with lung gout].
Topics: Bronchoscopy; Calculi; Crystallization; Gout; Humans; Lung Diseases; Male; Middle Aged; Uric Acid | 2014 |
Physician adherence to ACR gout treatment guidelines: perception versus practice.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Gout; Gout Suppress | 2014 |
Elevated serum homocysteine levels were not correlated with serum uric acid levels, but with decreased renal function in gouty patients.
Topics: Glomerular Filtration Rate; Gout; Homocysteine; Humans; Hyperhomocysteinemia; Male; Middle Aged; Ren | 2014 |
Methods of assessment of tophus and bone erosions in gout using dual-energy CT: reproducibility analysis.
Topics: Adult; Aged; Aged, 80 and over; Ankle; Arthritis, Gouty; Bone Diseases; C-Reactive Protein; Female; | 2015 |
Efficacy and safety of a urate lowering regimen in primary gout.
Topics: Adult; Aged; Aged, 80 and over; Female; Gout; Hospitals; Humans; Male; Middle Aged; Safety; Uric Aci | 2014 |
Miliarial gout: a rare clinical presentation.
Topics: Adult; Dermis; Gout; Humans; Male; Uric Acid | 2014 |
Detection of uric acid depositing in tophaceous gout using a new dual energy spectral CT technology.
Topics: Adult; Aged; Analysis of Variance; Female; Foot; Gout; Humans; Male; Middle Aged; Tomography, X-Ray | 2014 |
Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout.
Topics: Adolescent; Adult; Age of Onset; Child; Female; Gout; Humans; Hyperuricemia; Kidney; Male; Uric Acid | 2014 |
Monosodium urate crystals trigger Nrf2- and heme oxygenase-1-dependent inflammation in THP-1 cells.
Topics: Carrier Proteins; Cell Line, Tumor; Gout; Heme Oxygenase-1; Humans; Inflammation; Interleukin-1beta; | 2015 |
Development of a patient-reported outcome measure of tophus burden: the Tophus Impact Questionnaire (TIQ-20).
Topics: Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Male; Middle Aged; Patient Outcome Assessment; | 2015 |
Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion.
Topics: Aged; Alleles; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Organic Anion Transporters; P | 2014 |
A pilot study on dual-energy computed tomography for detection of urate deposits in renal transplant patients with asymptomatic hyperuricemia.
Topics: Adult; Arthrography; Female; Follow-Up Studies; Gout; Humans; Hyperuricemia; Joints; Kidney; Kidney | 2014 |
Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
Topics: Adult; Aged; Biomarkers; Disease Progression; Drug Administration Schedule; Female; Gout; Gout Suppr | 2017 |
Urate transporters: transforming the face of hyperuricemia and gout.
Topics: Female; Gout; Humans; Hyperuricemia; Male; Organic Anion Transporters; Polymorphism, Single Nucleoti | 2014 |
Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
Topics: Adult; Aged; Biomarkers; Cross-Sectional Studies; Female; Gout; Gout Suppressants; Humans; Male; Mid | 2015 |
Gout: a curable disease that often is undertreated. Long-term treatment is proven and available, but most patients and their physicians continue to take a short-term approach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diet; Gout; Gout Suppressants; Humans; Hyperuricemia; Patie | 2014 |
The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study.
Topics: Aged; Cardiovascular Diseases; Decision Support Techniques; Erythema; Female; Gout; Humans; Hyperten | 2015 |
The relationship between homocysteine and uric acid levels in gouty patients.
Topics: Gout; Homocysteine; Humans; Male; Uric Acid | 2014 |
Impact of gout on left atrial function: a prospective speckle-tracking echocardiographic study.
Topics: Adult; Aged; Atrial Function, Left; Echocardiography, Doppler; Female; Gout; Humans; Male; Middle Ag | 2014 |
NPT1/SLC17A1 is a renal urate exporter in humans and its common gain-of-function variant decreases the risk of renal underexcretion gout.
Topics: Amino Acid Sequence; Animals; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition t | 2015 |
Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis?
Topics: Cell Line; Chondroitin Sulfates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gou | 2014 |
A comparative study of serum and synovial fluid levels of uric acid between patients with gout and other arthritides.
Topics: Adult; Aged; Aged, 80 and over; Arthritis; Arthritis, Gouty; Arthritis, Infectious; Arthritis, Rheum | 2014 |
The impact of Ramadan fast on patients with gout.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Body Mass Index; Case-Control Studies; Colchicine; Crea | 2014 |
[Gouty tophus].
Topics: Aged; Diagnosis, Differential; Gout; Gout Suppressants; Humans; Male; Uric Acid | 2014 |
Detection and characterization of crystal suspensions using single-source dual-energy computed tomography: a phantom model of crystal arthropathies.
Topics: Calcium Pyrophosphate; Chondrocalcinosis; Feasibility Studies; Gout; Hand; Humans; Phantoms, Imaging | 2015 |
The role of kinin B1 receptor and the effect of angiotensin I-converting enzyme inhibition on acute gout attacks in rodents.
Topics: Acute Disease; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin B1 Receptor Antagonists | 2016 |
Performance of classification criteria for gout in early and established disease.
Topics: Adult; Aged; Biomarkers; Cross-Sectional Studies; Early Diagnosis; Female; Gout; Humans; Male; Middl | 2016 |
AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages.
Topics: AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Cells, Cultured; Colchicine; Enzyme Acti | 2016 |
The author response.
Topics: Gout; Homocysteine; Humans; Male; Uric Acid | 2014 |
Influence of urate-lowering therapies on renal handling of uric acid.
Topics: Adult; Antihypertensive Agents; Benzbromarone; Case-Control Studies; Creatinine; Glomerular Filtrati | 2016 |
Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation.
Topics: Animals; Chlorogenic Acid; Cytokines; Disease Models, Animal; Gout; Gout Suppressants; Hyperuricemia | 2014 |
Distinguishing gouty arthritis from calcium pyrophosphate disease and other arthritides.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Chondrocalcinosis; Female; Gout; Human | 2015 |
Adherence and persistence to urate-lowering therapies in the Irish setting.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Databases, Factual; Febuxostat | 2016 |
Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Chronic Disease; Comorbi | 2014 |
Uric acid crystals.
Topics: Crystallization; Gout; Humans; Microscopy, Polarization; Synovial Fluid; Uric Acid | 2014 |
Arsenic exposure, hyperuricemia, and gout in US adults.
Topics: Adult; Aged; Arsenic; Arsenicals; Cross-Sectional Studies; Environmental Exposure; Female; Gout; Hum | 2015 |
Health literacy in patients dealing with gout: a qualitative study.
Topics: Aged; Aged, 80 and over; Allopurinol; Female; Gout; Gout Suppressants; Health Literacy; Humans; Inte | 2015 |
Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
Topics: Aged; Allopurinol; Databases, Factual; Delivery of Health Care, Integrated; Female; Gout; Gout Suppr | 2015 |
Ultrasound in gout: a useful tool for following urate-lowering therapy.
Topics: Adult; Aged; Gout; Humans; Male; Middle Aged; Prospective Studies; Ultrasonography; Uric Acid | 2015 |
Allopurinol use and risk of non-fatal acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Case-Control Studies; Female; Free Radical Scavengers; | 2015 |
Patients with gout can be cured in primary care.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthrography; Colchicine; Disease Manage | 2014 |
Gout, tophi and the wonders of NETs.
Topics: Animals; Arthritis, Gouty; Extracellular Traps; Gout; Humans; Inflammation; Uric Acid | 2014 |
The molecular insight into the antihyperuricemic and renoprotective effect of Shuang Qi gout capsule in mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; | 2015 |
Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.
Topics: Allopurinol; Chronic Disease; Cost-Benefit Analysis; Febuxostat; Gout; Gout Suppressants; Humans; Ma | 2015 |
Images in clinical medicine. An unusual tophus.
Topics: Aged; Crystallization; Gout; Humans; Male; Nail Diseases; Nails; Uric Acid | 2015 |
Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study.
Topics: Absorptiometry, Photon; Aged; Asymptomatic Diseases; Cross-Sectional Studies; Female; Foot; Foot Joi | 2015 |
Role of miR-146a in regulation of the acute inflammatory response to monosodium urate crystals.
Topics: Animals; Antioxidants; Case-Control Studies; Cell Line; Disease Models, Animal; Female; Gene Express | 2015 |
Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Asian People; ATP Binding Cassette Transporter, S | 2016 |
Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Case-Control Studies; Cytokines; Enzyme-Linked Immunos | 2016 |
Urate crystal induced inflammation and joint pain are reduced in transient receptor potential ankyrin 1 deficient mice--potential role for transient receptor potential ankyrin 1 in gout.
Topics: Acetanilides; Animals; Cytokines; Disease Models, Animal; Gout; Inflammation; Mice; Mice, Knockout; | 2015 |
Smaller caliber renal arteries are a novel feature of uromodulin-associated kidney disease.
Topics: Adolescent; Adult; Aged; Angiography; Child; Chronic Disease; Female; Genotype; Glomerular Filtratio | 2015 |
Allopurinol adherence among patients with gout: an Italian general practice database study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Databases, Factual; Dose-Response Relations | 2015 |
Plasma Urate and Risk of a Hospital Stay with AKI: The Atherosclerosis Risk in Communities Study.
Topics: Acute Kidney Injury; Aged; Female; Follow-Up Studies; Glomerular Filtration Rate; Gout; Hospitalizat | 2015 |
Is the double contour sign specific for gout? Or only for crystal arthritis?
Topics: Arthritis, Gouty; Chondrocalcinosis; Female; Gout; Humans; Male; Uric Acid | 2015 |
Characteristics and management of gout patients in Europe: data from a large cohort of patients.
Topics: Adult; Allopurinol; Cohort Studies; Comorbidity; Cross-Sectional Studies; Europe; Febuxostat; Female | 2015 |
Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients.
Topics: Adult; Female; Gout; Humans; Hypertension; Hyperuricemia; Insulin Resistance; Kidney; Male; Middle A | 2015 |
Hyperuricemia starts at 360 micromoles (6 mg/dL).
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2015 |
Urate crystal degradation for treatment of gout: a nanoparticulate combination therapy approach.
Topics: Absorption, Physiological; Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroid | 2015 |
Ultrasound-guided dry-needle synovial tissue aspiration for diagnostic microscopy in gout patients presenting without synovial effusion or clinically detectable tophi.
Topics: Adult; Aged; Biopsy, Fine-Needle; Diagnostic Imaging; Gout; Humans; Male; Middle Aged; Synovial Memb | 2015 |
A network pharmacology approach to determine active ingredients and rationality of herb combinations of Modified-Simiaowan for treatment of gout.
Topics: Cells, Cultured; Drugs, Chinese Herbal; Gout; Human Umbilical Vein Endothelial Cells; Humans; Interc | 2015 |
Ungoutedly time for a change.
Topics: Female; Foot Joints; Gout; Humans; Hyperuricemia; Male; Radiography; Tendons; Uric Acid | 2015 |
Inpatient management of gout in a New Zealand hospital: a retrospective audit.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Drug Therapy, Combination; Drug Utilization Review; Fema | 2016 |
Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies.
Topics: Adult; Aged; Databases, Factual; England; Female; Gout; Hospitalization; Humans; Male; Middle Aged; | 2015 |
Clinicopathologic characterization of visceral gout of various internal organs--a study of 2 cases from a venom and toxin research center.
Topics: Animals; Animals, Laboratory; Autopsy; Biopsy; Cause of Death; Crystallization; Elapidae; Gout; Gran | 2015 |
Gout and sickle cell disease: not all pain is sickle cell pain.
Topics: Acute Disease; Adult; Age of Onset; Aged; Aged, 80 and over; Anemia, Sickle Cell; Female; Gout; Hemo | 2015 |
A brief history of uric acid: From gout to cardiovascular risk factor.
Topics: Cardiovascular Diseases; Gout; History, 18th Century; History, 19th Century; History, 20th Century; | 2015 |
A Role for Gut Microbiota and the Metabolite-Sensing Receptor GPR43 in a Murine Model of Gout.
Topics: Animals; Cell Movement; Chemokine CXCL1; Disease Models, Animal; Fatty Acids, Volatile; Gout; Hypera | 2015 |
The detection of monosodium urate crystals in synovial fluid after long-term and varying storage conditions.
Topics: Gout; Humans; Microscopy, Polarization; Specimen Handling; Synovial Fluid; Temperature; Time Factors | 2015 |
Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Topics: Aged; Allopurinol; Cohort Studies; Cost-Benefit Analysis; Creatinine; Dose-Response Relationship, Dr | 2015 |
Association of hormone therapy and incident gout: population-based case-control study.
Topics: Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Body Mass Index; Case-Control Studies; Estro | 2015 |
Cross-sectional analysis of nutrition and serum uric acid in two Caucasian cohorts: the AusDiab Study and the Tromsø study.
Topics: Adult; Aged; Aged, 80 and over; Animals; Australia; Body Mass Index; Choice Behavior; Cholesterol; C | 2015 |
Ticagrelor-related gout: An underestimated side effect.
Topics: Adenosine; Gout; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Ticagrelor; Uri | 2015 |
Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Topics: Aged; Biomarkers; California; Chi-Square Distribution; Delivery of Health Care, Integrated; Disease | 2015 |
Hyperuricemia and tissue monourate deposits: prospective therapeutic considerations.
Topics: Asymptomatic Diseases; Cardiovascular Diseases; Cartilage; Gout; Humans; Hyperuricemia; Kidney Disea | 2015 |
Gout: cartoonized and bagatellized and still left untreated. Time to change.
Topics: Allopurinol; Arthritis; Cartoons as Topic; Gout; History, 19th Century; History, 20th Century; Histo | 2015 |
Validity of gout diagnosis in Swedish primary and secondary care - a validation study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Crystallization; Female; Gout; Humans; Male; Medical Rec | 2015 |
[Disturbance of uric acid metabolism].
Topics: Gout; Humans; Hyperuricemia; Kidney Diseases; Metabolism, Inborn Errors; Nucleic Acids; Renal Tubula | 2015 |
Common Variants in LRP2 and COMT Genes Affect the Susceptibility of Gout in a Chinese Population.
Topics: Aged; Alleles; Asian People; Body Mass Index; Catechol O-Methyltransferase; China; Female; Gene Freq | 2015 |
A method for counting monosodium urate crystals in synovial fluid.
Topics: Antioxidants; Biomarkers; Crystallization; Disease Progression; Feasibility Studies; Gout; Humans; L | 2015 |
[Time course of changes in the clinical manifestations of gout in men: data of a 7-year retrospective follow-up].
Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Follow-Up Studies; Gout; Gout Suppressants; Humans; Midd | 2015 |
Treatment and prevention of gout.
Topics: Adult; Diagnosis, Differential; Diagnostic Tests, Routine; Diet; Gout; Humans; Male; Nursing Diagnos | 2015 |
Update on the diagnosis and management of gout.
Topics: Allopurinol; Anti-Inflammatory Agents; Diagnostic Imaging; Gout; Humans; Synovial Fluid; Uric Acid | 2015 |
Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Atrial Fibrillation; Cross-Sectional Studies; Diabetes Mellitu | 2016 |
The Positively Charged COOH-terminal Glycosaminoglycan-binding CXCL9(74-103) Peptide Inhibits CXCL8-induced Neutrophil Extravasation and Monosodium Urate Crystal-induced Gout in Mice.
Topics: Amino Acid Sequence; Animals; Anti-Inflammatory Agents; Cell Migration Inhibition; Chemokine CXCL9; | 2015 |
An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Australia; Electronic Health Records; Fema | 2015 |
Ulcerated tophaceous gout.
Topics: Anemia; Anti-Bacterial Agents; Calculi; Clostridium Infections; Gout; Honey; Humans; Hyperuricemia; | 2015 |
Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares.
Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Native Hawaiian or | 2015 |
Monosodium urate crystal-induced triggering receptor expressed on myeloid cells 1 is associated with acute gouty inflammation.
Topics: Acute Disease; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation; Gout; | 2016 |
[Dual-energy computer tomography can be used for gout diagnostics].
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Male; Middle Aged; Radiography, Dual-Energy Scanned Pr | 2015 |
Oral treatment with Bifidobacterium longum 51A reduced inflammation in a murine experimental model of gout.
Topics: Administration, Oral; Animals; Bifidobacterium; Cytokines; Disease Models, Animal; Gout; Gout Suppre | 2015 |
Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
Topics: Aged; Allopurinol; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Human | 2015 |
Gouty tophi in the bone marrow.
Topics: Biopsy; Bone Marrow; Bone Marrow Diseases; Gout; Granuloma, Giant Cell; Humans; Male; Uric Acid | 2016 |
Urate testing in gout: why, when and how.
Topics: Biomarkers; Gout; Humans; Hyperuricemia; New Zealand; Quality of Health Care; Risk Factors; Uric Aci | 2015 |
Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout.
Topics: Adult; Aged; Analysis of Variance; Beverages; Body Mass Index; Cross-Sectional Studies; Female; Fruc | 2015 |
Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises.
Topics: Consensus; Delphi Technique; Gout; Humans; Outcome Assessment, Health Care; Remission Induction; Sev | 2016 |
The role of uric acid in the development of cardiovascular disease.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2015 |
Serum urate gene associations with incident gout, measured in the Framingham Heart Study, are modified by renal disease and not by body mass index.
Topics: Age Factors; Aged; Aged, 80 and over; Biomarkers; Body Mass Index; Comorbidity; Female; Gene Frequen | 2016 |
WDR1 and CLNK gene polymorphisms correlate with serum glucose and high-density lipoprotein levels in Tibetan gout patients.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Asian People; Biomarkers; Blood Gluco | 2016 |
Transmembrane TNF-α is sufficient for articular inflammation and hypernociception in a mouse model of gout.
Topics: Animals; Disease Models, Animal; Gout; Hyperalgesia; Inflammation; Interleukin-1beta; Knee Joint; Ma | 2016 |
Predicting allopurinol response in patients with gout.
Topics: Allopurinol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Gout; Gout Suppress | 2016 |
Gout and foot drop.
Topics: Aged; Gait Disorders, Neurologic; Gout; Humans; Knee; Male; Peroneal Nerve; Peroneal Neuropathies; T | 2016 |
Rebamipide Suppresses Monosodium Urate Crystal-Induced Interleukin-1β Production Through Regulation of Oxidative Stress and Caspase-1 in THP-1 Cells.
Topics: Alanine; Ascorbic Acid; Caspase 1; Cell Line; Colchicine; Dexamethasone; Enzyme Activation; Gout; Hu | 2016 |
Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Topics: Adult; Allopurinol; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Recur | 2015 |
Development of a Dual-Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout.
Topics: Aged; Female; Gout; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Tomography, X-Ra | 2016 |
Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Denmark; Female; Gout; Gout Suppressants; | 2015 |
[Not Available].
Topics: Animals; Gout; Humans; Tendons; Uric Acid | 2015 |
Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study.
Topics: Cardiovascular Diseases; Cohort Studies; Crystallization; Denmark; Female; Gout; Humans; Hyperuricem | 2015 |
Febuxostat in the management of gout: a cost-effectiveness analysis.
Topics: Adult; Aged; Allopurinol; Cost-Benefit Analysis; Disease Management; Febuxostat; Female; Gout; Gout | 2016 |
Gout, not hyperuricemia alone, impairs left ventricular diastolic function.
Topics: Adult; Aged; Biomarkers; Cohort Studies; Diastole; Female; Gout; Humans; Hyperuricemia; Male; Middle | 2015 |
A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Clinical Audit; Female; Gout; Gout Suppressants; Guideli | 2016 |
A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.
Topics: Adult; Aged; Allopurinol; Comparative Effectiveness Research; Drug Monitoring; Drug Substitution; Fe | 2015 |
Management of gout in the real world: current practice versus guideline recommendations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Combined Modality Therapy; Cross-Sectional S | 2016 |
Psoriasis and uric acid: a population-based cross-sectional study.
Topics: Adult; Case-Control Studies; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Logistic | 2016 |
A Tincture of Time-Latent Crystal Formation and Clinical Decision-Making in Acute Gout: A Teachable Moment.
Topics: Arthritis, Infectious; Crystallization; Diagnosis, Differential; Gout; Humans; Male; Middle Aged; Sy | 2016 |
[Compliance in intercriticalgout patients and its related factors].
Topics: Case-Control Studies; Gout; Humans; Patient Compliance; Surveys and Questionnaires; Uric Acid | 2015 |
Gout in Older Adults: The Atherosclerosis Risk in Communities Study.
Topics: Age Factors; Aged; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bin | 2016 |
Low omega-3 fatty acid levels associate with frequent gout attacks: a case control study.
Topics: Aged; Case-Control Studies; Disease Progression; Fatty Acids, Omega-3; Gout; Gout Suppressants; Huma | 2016 |
rs3806268 of NLRP3 gene polymorphism is associated with the development of primary gout.
Topics: Adult; Alleles; Asian People; Biomarkers; Female; Gene Frequency; Genetic Predisposition to Disease; | 2015 |
Prevalence of monosodium urate deposits in a population of rheumatoid arthritis patients with hyperuricemia.
Topics: Age Distribution; Aged; Arthritis, Rheumatoid; Comorbidity; Female; Foot Joints; Gout; Hand Joints; | 2016 |
Dual-Energy CT in Patients with Suspected Gouty Arthritis: Effects on Treatment Regimen and Clinical Outcome.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ar | 2016 |
Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Case-Control Studies; Denmark; | 2016 |
Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study.
Topics: Adult; Age Distribution; Aged; Australia; Comorbidity; Female; Gout; Gout Suppressants; Humans; Hype | 2016 |
Effects of Pimenta pseudocaryophyllus extracts on gout: Anti-inflammatory activity and anti-hyperuricemic effect through xantine oxidase and uricosuric action.
Topics: Animals; Anti-Inflammatory Agents; Gout; Gout Suppressants; Hyperuricemia; Male; Mice; Phytotherapy; | 2016 |
Target Serum Urate: Do Gout Patients Know Their Goal?
Topics: Aged; Cross-Sectional Studies; Female; Gout; Health Knowledge, Attitudes, Practice; Humans; Male; Mi | 2016 |
ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2 | 2017 |
[Clinical value of toes periungual green-coloured voxels of dual-energy CT gout detecting technology].
Topics: Female; Gout; Humans; Male; Toes; Tomography, X-Ray Computed; Uric Acid | 2015 |
Development and First Validation of a Disease Activity Score for Gout.
Topics: Aged; Arthralgia; Disease Progression; Factor Analysis, Statistical; Female; Follow-Up Studies; Gout | 2016 |
Intestinal Microbiota Distinguish Gout Patients from Healthy Humans.
Topics: Adult; Aged; Area Under Curve; Bacteria; Bacteroides; Bifidobacterium pseudocatenulatum; Biomarkers; | 2016 |
Association of Serum Uric Acid and Disease Duration With Frequent Gout Attacks: A Case-Control Study.
Topics: Aged; Case-Control Studies; Comorbidity; Disease Progression; Female; Gout; Humans; Logistic Models; | 2016 |
Macrophage migration inhibitory factor drives neutrophil accumulation by facilitating IL-1β production in a murine model of acute gout.
Topics: Acute Disease; Animals; Disease Models, Animal; Female; Gout; Humans; Inflammation; Injections; Inte | 2016 |
Chronic tophaceous gout with unusual large tophi: case report.
Topics: Aged; Chronic Disease; Gout; Humans; Joints; Male; Uric Acid | 2015 |
Dual-energy computed tomography has limited sensitivity for non-tophaceous gout: a comparison study with tophaceous gout.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Male; Middle Aged; Tom | 2016 |
Knowledge, illness perceptions and stated clinical practice behaviour in management of gout: a mixed methods study in general practice.
Topics: Adult; Disease Management; Female; General Practice; General Practitioners; Gout; Health Knowledge, | 2016 |
PDK2 and ABCG2 genes polymorphisms are correlated with blood glucose levels and uric acid in Tibetan gout patients.
Topics: Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transpor | 2016 |
Diagnostic Tool for Gout Without Need for Joint Fluid Aspiration.
Topics: Female; Gout; Humans; Male; Synovial Fluid; Unnecessary Procedures; Uric Acid | 2016 |
A cross-sectional internet-based patient survey of the management strategies for gout.
Topics: Adult; Aged; Aged, 80 and over; Attitude to Health; Complementary Therapies; Consumer Behavior; Cros | 2016 |
Bone scintigraphy in tophaceous gout.
Topics: Aged; Bone and Bones; Gout; Humans; Male; Radionuclide Imaging; Uric Acid | 2016 |
Hypercrosslinked strong cation-exchange polymers for selective extraction of serum purine metabolites associated with gout.
Topics: Cation Exchange Resins; Chromatography, High Pressure Liquid; Cross-Linking Reagents; Gout; Humans; | 2016 |
Dual-Energy CT of Urate Deposits in Costal Cartilage and Intervertebral Disks of Patients With Tophaceous Gout and Age-Matched Controls.
Topics: Adult; Aged; Aged, 80 and over; Costal Cartilage; Female; Gout; Humans; Intervertebral Disc; Male; M | 2016 |
[Drug reduction of uric acid not just when symptoms appear].
Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Gout; Humans; Hyperuricemia; Uric Acid | 2016 |
Urate crystals deposition in the feet of overweight juveniles and those with symptomatic hyperuricemia: a dual-energy CT study.
Topics: Adolescent; Biomarkers; Child; Female; Follow-Up Studies; Gout; Humans; Hyperuricemia; Kidney Diseas | 2016 |
Clinical and genetic features of diuretic-associated gout: a case-control study.
Topics: Adult; Age of Onset; Aged; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biomark | 2016 |
[Uric acid and kidneys – Physiological and pathophysiological aspects].
Topics: Gout; Humans; Hyperuricemia; Kidney; Kidney Failure, Chronic; Kidney Tubules; Risk Factors; Uric Aci | 2016 |
Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard.
Topics: Colchicine; Diagnostic Self Evaluation; Epidemiologic Studies; Female; Gout; Gout Suppressants; Huma | 2016 |
Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Cost-Benefit Analysis; Febuxostat; Female; Gou | 2016 |
Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity.
Topics: Aged; Cross-Sectional Studies; Efficiency; Employment; Female; France; Germany; Gout; Gout Suppressa | 2016 |
SHEsisPlus, a toolset for genetic studies on polyploid species.
Topics: Algorithms; Arthritis, Gouty; China; Computer Simulation; Diploidy; Epistasis, Genetic; Genetic Mark | 2016 |
New therapeutic approach to hyperuricemia and gout in the light of recommendations.
Topics: Europe; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Monitoring, Physiologic; Pract | 2016 |
Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins C; Case-Control Studies; Female; Ge | 2016 |
Dual energy computed tomography: a novel technique for diagnosis of gout.
Topics: Adult; Aged; Biomarkers; Crystallization; Female; Foot Joints; Gout; Humans; Knee Joint; Male; Middl | 2016 |
Spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and asymptomatic hyperuricemia: comparison with healthy individuals with normal serum urate concentrations.
Topics: Adult; Aged; Body Mass Index; Case-Control Studies; Cross-Sectional Studies; Female; Foot; Gait; Gou | 2016 |
A survey of the assessment and management of gout in general practitioners and medical officers within the Illawarra Network, Australia.
Topics: Attitude of Health Personnel; Biomarkers; Colchicine; Creatinine; Drug Administration Schedule; Gene | 2017 |
ALPK1 phosphorylates myosin IIA modulating TNF-α trafficking in gout flares.
Topics: Amino Acid Sequence; Cell Line; Colchicine; Cytokines; Down-Regulation; Gene Knockdown Techniques; G | 2016 |
Synovial fluid proteins are required for the induction of interleukin-1β production by monosodium urate crystals.
Topics: Arthritis, Gouty; Case-Control Studies; Cell Line; Enzyme-Linked Immunosorbent Assay; Gout; Humans; | 2016 |
Monosodium urate crystals induce oxidative stress in human synoviocytes.
Topics: Apoptosis; Blotting, Western; Cell Survival; Cells, Cultured; Fibroblasts; Flow Cytometry; Fluoresce | 2016 |
Febuxostat for Asymptomatic Hyperuricemia in CKD.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; | 2016 |
Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; | 2016 |
In Reply to 'Febuxostat for Asymptomatic Hyperuricemia in CKD' and 'Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia'.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; | 2016 |
Gout Flare With a Draining Tophus.
Topics: Aged, 80 and over; Chronic Disease; Female; Gout; Humans; Metatarsophalangeal Joint; Radiography; Ur | 2016 |
Tendon involvement in patients with gout: an ultrasound study of prevalence.
Topics: Achilles Tendon; Adult; Aged; Case-Control Studies; Comorbidity; Cross-Sectional Studies; Female; Go | 2016 |
A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Cooperative Behavior; Female; Gout; Gout Suppressants; | 2016 |
The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
Topics: Adult; Aged; Allopurinol; Budgets; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Hea | 2016 |
Enhanced p62 Is Responsible for Mitochondrial Pathway-Dependent Apoptosis and Interleukin-1β Production at the Early Phase by Monosodium Urate Crystals in Murine Macrophage.
Topics: Animals; Apoptosis; Gout; Inflammation; Interleukin-1beta; Macrophages; Metabolic Networks and Pathw | 2016 |
Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2016 |
Genetic background of uric acid metabolism in a patient with severe chronic tophaceous gout.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Chronic Disease; Genetic Background; Gout; | 2016 |
Allopurinol Dose Reductions Based on Creatinine Alert Redesign System.
Topics: Allopurinol; Creatinine; Gout; Gout Suppressants; Humans; Uric Acid | 2016 |
[What do the guidelines say?].
Topics: Anti-Inflammatory Agents; Combined Modality Therapy; Drug Therapy, Combination; Evidence-Based Medic | 2016 |
Serum uric acid, gout, and venous thromboembolism: The atherosclerosis risk in communities study.
Topics: Atherosclerosis; Biomarkers; Female; Gout; Humans; Middle Aged; Prospective Studies; Risk Factors; U | 2016 |
Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.
Topics: Animals; Biological Evolution; Computer Simulation; Evolution, Molecular; Gout; HEK293 Cells; Homeos | 2016 |
Wide-field imaging of birefringent synovial fluid crystals using lens-free polarized microscopy for gout diagnosis.
Topics: Algorithms; Birefringence; Crystallization; Gout; Humans; Microscopy, Polarization; Point-of-Care Sy | 2016 |
Adequacy of Online Patient Information Resources on Gout and Potentially Curative Urate-Lowering Treatment.
Topics: Australia; Canada; Comprehension; Consumer Health Information; Gout; Gout Suppressants; Humans; Pati | 2017 |
The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
Topics: Aged; Allopurinol; Benzbromarone; Comorbidity; Exanthema; Female; Gout; Gout Suppressants; Humans; K | 2016 |
IMAGES IN CLINICAL MEDICINE. Milk of Urate Bulla.
Topics: Aged; Blister; Crystallization; Fingers; Gout; Humans; Kidney Transplantation; Male; Uric Acid | 2016 |
Tophaceous Gout in an Anorectic Patient Visualized by Dual Energy Computed Tomography (DECT).
Topics: Absorptiometry, Photon; Allopurinol; Anorexia Nervosa; Biomarkers; Biopsy; Colchicine; Drug Therapy, | 2016 |
[New diagnostics and treatments in gout].
Topics: Algorithms; Gout; Gout Suppressants; Humans; Life Style; Tomography, X-Ray Computed; Uric Acid | 2016 |
Clinical significance of SLC2A9/GLUT9 rs11722228 polymorphisms in gout.
Topics: Adult; Aged; Case-Control Studies; Chi-Square Distribution; Creatinine; Gene Frequency; Genetic Asso | 2018 |
Dual-energy computed tomography as a diagnostic tool for gout during intercritical periods.
Topics: Adult; Aged; Asymptomatic Diseases; Biomarkers; Female; Gout; Gout Suppressants; Humans; Joints; Mal | 2016 |
A qualitative study to explore health professionals' experience of treating gout: understanding perceived barriers to effective gout management.
Topics: Culture; Diet; Gout; Gout Suppressants; Health Knowledge, Attitudes, Practice; Health Personnel; Hum | 2016 |
Temporal evolution of urate crystal deposition over articular cartilage after successful urate-lowering therapy in patients with gout: An ultrasonographic perspective.
Topics: Adult; Aged; Cartilage, Articular; Gout; Gout Suppressants; Humans; Male; Metatarsophalangeal Joint; | 2017 |
Dietary fiber and the short-chain fatty acid acetate promote resolution of neutrophilic inflammation in a model of gout in mice.
Topics: Acetates; Animals; Apoptosis; Caspases; Crystallization; Diet, High-Fat; Dietary Fiber; Disease Mode | 2017 |
"From father to son": Early onset gout in Guidobaldo I da Montefeltro, Duke of Urbino (1472-1508).
Topics: Age of Onset; Conjunctiva; Erectile Dysfunction; Gout; History, 15th Century; History, 16th Century; | 2016 |
Usefulness of plain radiography for assessing hypouricemic treatment response in patients with tophaceous gout.
Topics: Aged; Arthrography; Biomarkers; Female; Gout; Gout Suppressants; Humans; Male; Metatarsophalangeal J | 2016 |
Sensitivity and specificity of ultrasonographic features of gout in intercritical and chronic phase.
Topics: Adult; Biomarkers; Case-Control Studies; Chronic Disease; Cross-Sectional Studies; Female; Gout; Hum | 2017 |
Gout and the Risk of Non-vertebral Fracture.
Topics: Cohort Studies; Female; Fractures, Bone; Gout; Humans; Male; Middle Aged; Risk Factors; Uric Acid | 2017 |
Poorly controlled gout: who is doing poorly?
Topics: Allopurinol; Arthritis; Comorbidity; Gout; Humans; Hyperuricemia; Inflammation; Medication Adherence | 2016 |
Genetic Association for P2X7R rs3751142 and CARD8 rs2043211 Polymorphisms for Susceptibility of Gout in Korean Men: Multi-Center Study.
Topics: Adult; Age of Onset; Asian People; Body Mass Index; CARD Signaling Adaptor Proteins; Case-Control St | 2016 |
Renal dosing of allopurinol results in suboptimal gout care.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Kidney; Uric Acid | 2017 |
Urate crystal deposition and bone erosion in gout: 'inside-out' or 'outside-in'? A dual-energy computed tomography study.
Topics: Adult; Aged; Bone and Bones; Female; Gout; Humans; Male; Middle Aged; Tomography, X-Ray Computed; Ur | 2016 |
Ultrasound Features of the First Metatarsophalangeal Joint in Gout and Asymptomatic Hyperuricemia: Comparison With Normouricemic Individuals.
Topics: Adult; Aged; Female; Gout; Humans; Hyperuricemia; Male; Metatarsophalangeal Joint; Middle Aged; Sing | 2017 |
Risk of acute gout among active smokers: data from nationwide inpatient sample.
Topics: Acute Disease; Adult; Aged; Arthritis, Gouty; Databases, Factual; Female; Gout; Hospitalization; Hum | 2016 |
Treat-to-target (T2T) recommendations for gout.
Topics: Chronic Disease; Gout; Guidelines as Topic; Humans; Kidney; Life Style; Medication Adherence; Patien | 2017 |
Serum uric acid levels and the risk of flares among gout patients in a US managed care setting.
Topics: Adult; Aged; Female; Gout; Humans; Male; Managed Care Programs; Middle Aged; Proportional Hazards Mo | 2017 |
Miliarial gout: a rare presentation of extensive cutaneous tophi.
Topics: Fatal Outcome; Gout; Humans; Hyperuricemia; Male; Middle Aged; Sepsis; Skin Diseases; Uric Acid | 2016 |
The management of gout in different clinical specialties in Turkey: a patient-based survey.
Topics: Adult; Aged; Allopurinol; Colchicine; Female; Gout; Gout Suppressants; Humans; Internal Medicine; Li | 2016 |
Metabolic syndrome: prevalence and risk factors in Korean gout patients.
Topics: Adult; Aged; Female; Gout; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Preval | 2018 |
Editorial: The Sound and the Fury: Musculoskeletal Ultrasound in the Diagnosis of Gout.
Topics: Gout; Humans; Ultrasonography; Uric Acid | 2017 |
Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard.
Topics: Cross-Sectional Studies; Crystallization; Female; Gout; Humans; Male; Middle Aged; Sensitivity and S | 2017 |
Decrystallization of Crystals Using Gold "Nano-Bullets" and the Metal-Assisted and Microwave-Accelerated Decrystallization Technique.
Topics: Alanine; Chemistry, Pharmaceutical; Crystallization; Gold; Gout; Humans; Metal Nanoparticles; Microw | 2016 |
Familial juvenile hyperuricemic nephropathy as rare cause of dialysis-dependent chronic kidney disease-a series of cases in two families.
Topics: Adolescent; Adult; Child; Child, Preschool; DNA Mutational Analysis; Female; Gout; Humans; Hyperuric | 2016 |
Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.
Topics: Acute Disease; Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Human | 2017 |
Diagnosis of Acute Gout: A Clinical Practice Guideline From the American College of Physicians.
Topics: Adult; Algorithms; Gout; Humans; Synovial Fluid; Uric Acid | 2017 |
Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Anti-Inflammatory Agents, Non-Steroidal | 2017 |
Relationship of bone erosion with the urate and soft tissue components of the tophus in gout: a dual energy computed tomography study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Resorption; Female; Foot Joints; Gout; Humans; Line | 2017 |
Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi et al.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Kidney; Uric Acid | 2017 |
Gout: will the "King of Diseases" be the first rheumatic disease to be cured?
Topics: Adult; Arthritis, Rheumatoid; Chronic Disease; Gout; Gout Suppressants; Humans; Inflammation; Pain; | 2016 |
Crystal identification of synovial fluid aspiration by polarized light microscopy. An online test suggesting that our traditional rheumatologic competence needs renewed attention and training.
Topics: Calcium Pyrophosphate; Clinical Competence; Gout; Humans; Microscopy, Polarization; Rheumatology; Sy | 2017 |
Macrophage-derived IL-1β enhances monosodium urate crystal-triggered NET formation.
Topics: Extracellular Traps; Gout; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Int | 2017 |
Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout.
Topics: Animals; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Flow | 2016 |
Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout.
Topics: Adult; Aged; C-Reactive Protein; Febuxostat; Female; Gout; Gout Suppressants; Humans; Insulin Resist | 2017 |
Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Drug Monitoring; Febuxostat; Fema | 2017 |
P2Y6 Receptor Antagonist MRS2578 Inhibits Neutrophil Activation and Aggregated Neutrophil Extracellular Trap Formation Induced by Gout-Associated Monosodium Urate Crystals.
Topics: Chemotaxis, Leukocyte; Enzyme-Linked Immunosorbent Assay; Extracellular Traps; Fluorescent Antibody | 2017 |
Ultrasonography in the diagnosis of asymptomatic hyperuricemia and gout.
Topics: Gout; Humans; Hyperuricemia; Ultrasonography; Uric Acid | 2016 |
Construct Validity of Radiographs of the Feet to Assess Joint Damage in Patients with Gout.
Topics: Age Factors; Aged; Disease Progression; Female; Foot; Foot Joints; Gout; Humans; Male; Middle Aged; | 2017 |
The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.
Topics: Allopurinol; Asian; Black or African American; Cost-Benefit Analysis; Female; Genetic Markers; Genet | 2017 |
Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: a novel strategy to treat acute gout.
Topics: Administration, Oral; Animals; Biomarkers; Caffeic Acids; CARD Signaling Adaptor Proteins; Disease M | 2016 |
A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Topics: Adult; Allopurinol; Asian People; Benzbromarone; Biomarkers; China; Drug Dosage Calculations; Febuxo | 2017 |
Emerging uricosurics for gout.
Topics: Drug Design; Gout; Humans; Hyperuricemia; Uric Acid; Uricosuric Agents | 2017 |
Predictors of Mortality in People with Recent-onset Gout: A Prospective Observational Study.
Topics: Aged; Aged, 80 and over; Creatinine; Female; Gout; Humans; Male; Middle Aged; Mortality; Prospective | 2017 |
Dietary Management of Gout: What is the Evidence?
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 2017 |
Annexin A1 promotes timely resolution of inflammation in murine gout.
Topics: Animals; Annexin A1; Anti-Inflammatory Agents; Antibodies, Blocking; Apoptosis; Cell Movement; Disea | 2017 |
AJKD Atlas of Renal Pathology: Gouty Nephropathy.
Topics: Diagnosis, Differential; Gout; Humans; Kidney; Kidney Diseases; Microscopy; Uric Acid | 2017 |
Chasing crystals out of the body: will treat to serum urate target for gout help us get there?
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 2017 |
URAT1 inhibition by ALPK1 is associated with uric acid homeostasis.
Topics: Animals; Case-Control Studies; Cells, Cultured; Crystallization; Gout; Homeostasis; Humans; Hyperuri | 2017 |
COX-2/mPGES-1/PGE2 cascade activation mediates uric acid-induced mesangial cell proliferation.
Topics: Aged; Animals; Case-Control Studies; Cell Line; Cell Proliferation; Cyclin A2; Cyclin D1; Cyclooxyge | 2017 |
Plasma oxypurinol as a measure of adherence in clinical trials.
Topics: Adult; Allopurinol; Clinical Trials as Topic; Female; Gout; Gout Suppressants; Humans; Male; Medicat | 2018 |
Oral delivery of allopurinol niosomes in treatment of gout in animal model.
Topics: Administration, Oral; Allopurinol; Animals; Disease Models, Animal; Drug Delivery Systems; Gout; Hex | 2017 |
Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial.
Topics: Adult; Bariatric Surgery; Body Mass Index; Case-Control Studies; Controlled Clinical Trials as Topic | 2017 |
Clinical Inquiry: How do clinical prediction rules compare with joint fluid analysis in diagnosing gout?
Topics: Decision Support Techniques; Diagnostic Techniques and Procedures; Gout; Humans; Netherlands; Practi | 2016 |
Delta neutrophil index contributes to the differential diagnosis between acute gout attack and cellulitis within 24 hours after hospitalization.
Topics: Acute Disease; Aged; Area Under Curve; Biomarkers; Cellulitis; Diagnosis, Differential; Female; Gout | 2017 |
Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Topics: Aged; Allopurinol; Biomarkers; Drug Substitution; Febuxostat; Female; Gout; Gout Suppressants; Human | 2017 |
A swollen red finger.
Topics: Aged, 80 and over; Diagnosis, Differential; Female; Finger Joint; Fingers; Gout; Humans; Uric Acid | 2017 |
Combining Hyperechoic Aggregates and the Double-Contour Sign Increases the Sensitivity of Sonography for Detection of Monosodium Urate Deposits in Gout.
Topics: Adult; Female; Gout; Humans; Joints; Male; Middle Aged; Sensitivity and Specificity; Ultrasonography | 2017 |
Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data.
Topics: Adult; Electronic Health Records; Female; Gout; Heart Failure; Humans; Kidney Diseases; Male; Middle | 2017 |
β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Animals; Diet, Ketogenic; Female; Gout; Humans; Infl | 2017 |
Effects of multiple genetic loci on the pathogenesis from serum urate to gout.
Topics: Alleles; Case-Control Studies; Disease Progression; Female; Gene Expression; Genetic Association Stu | 2017 |
What is your diagnosis? Joint and associated tissue aspirates from a Bearded Dragon (Pogona vitticeps).
Topics: Animals; Biopsy, Fine-Needle; Female; Gout; Joint Diseases; Lizards; Uric Acid | 2017 |
Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells.
Topics: Acid Phosphatase; Animals; Bone Resorption; Cell Differentiation; Cell Line; Cohort Studies; Fibrobl | 2008 |
Crystal-induced neutrophil activation: X. Proinflammatory role of the tyrosine kinase Tec.
Topics: Cells, Cultured; Gout; Gout Suppressants; Humans; Neutrophils; Protein-Tyrosine Kinases; Signal Tran | 2008 |
An initial presentation of polyarticular gout with spinal involvement.
Topics: Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents; Diffusion Magnetic Resonance Imaging; Fema | 2008 |
Fine needle aspiration of a subcutaneous gouty tophus.
Topics: Adult; Biopsy, Fine-Needle; Crystallization; Diagnosis, Differential; Female; Gout; Histological Tec | 2008 |
Gout in the spotlight.
Topics: Animals; Disease Models, Animal; Gout; Humans; Mice; Uric Acid | 2008 |
Re: Gout and risk of Parkinson disease: a prospective study.
Topics: Comorbidity; Databases as Topic; Diagnostic Errors; Epidemiologic Studies; Gout; Humans; Parkinson D | 2008 |
Re: Gout and risk of Parkinson disease: a prospective study.
Topics: Comorbidity; Dose-Response Relationship, Drug; Free Radical Scavengers; Gout; Gout Suppressants; Hum | 2008 |
An unusual patient with hypothyroidism, tophaceous gout, and marked joint destruction.
Topics: Aged; Gout; Humans; Hypothyroidism; Joints; Male; Uric Acid | 2008 |
A survey of the management of gout in primary care.
Topics: Gout; Health Care Surveys; Humans; Ireland; Physicians, Family; Prevalence; Primary Health Care; Ris | 2008 |
Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China.
Topics: Adult; Aged; China; Comorbidity; Feeding Behavior; Female; Gout; Humans; Hyperuricemia; Life Style; | 2008 |
Ultrasonography for diagnosing atypical gout. Two case reports.
Topics: Adult; Aged; Arthritis, Psoriatic; Cartilage, Articular; Colchicine; Diagnosis, Differential; Gout; | 2008 |
Opportunities for improving medication use and monitoring in gout.
Topics: Aged; Allopurinol; Biomarkers; Colchicine; Drug Administration Schedule; Drug Monitoring; Female; Go | 2009 |
Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography.
Topics: Adult; Aged; Biomarkers; C-Reactive Protein; Chronic Disease; Female; Gout; Hand Joints; Humans; Mal | 2009 |
Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile.
Topics: Adult; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Epidemiologic Meth | 2008 |
Febuxostat: a viewpoint by H. Ralph Schumacher Jr and Lan X. Chen.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Ac | 2008 |
Febuxostat : a viewpoint by Naomi Schlesinger.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Ac | 2008 |
Febuxostat : a viewpoint by N. Lawrence Edwards.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Ac | 2008 |
Hyperuricemia, gout, and lifestyle factors.
Topics: Adult; Aged; Aged, 80 and over; China; Comorbidity; Feeding Behavior; Gout; Humans; Hyperuricemia; L | 2008 |
A little citrus might go a long way!
Topics: Antioxidants; Ascorbic Acid; Citrus; Gout; Humans; Phytotherapy; Randomized Controlled Trials as Top | 2008 |
Confessions of a goutophile: Despite its treatability, gout remains a problem.
Topics: Diagnosis, Differential; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2008 |
How gout inhibits the development of cell-mediated autoimmune disease.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Gout; Humans; Immunity, Cellular; Uric Acid | 2009 |
How PCP education can impact gout management: the gout essentials.
Topics: Anti-Inflammatory Agents; Gout; Gout Suppressants; Humans; Hyperuricemia; Physicians, Family; Uric A | 2008 |
Understanding deficient elimination of uric acid.
Topics: Gout; Humans; Hyperuricemia; Kidney; Metabolic Clearance Rate; Uric Acid | 2008 |
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.
Topics: Alleles; Chromosomes, Human, 4-5; Chromosomes, Human, 6-12 and X; Cohort Studies; Female; Genetics, | 2008 |
An unusual "gouty" case of back pain and fever.
Topics: Anti-Inflammatory Agents; Back Pain; Colchicine; Female; Gout; Gout Suppressants; Humans; Knee Joint | 2008 |
Role of the adrenal cortex in urate metabolism and in gout.
Topics: Adrenal Cortex; Adrenal Glands; Adrenal Insufficiency; Cerebral Cortex; Gout; Humans; Uric Acid | 1948 |
Resolution of gouty tophi after twelve weeks of pegloticase treatment.
Topics: Aged; Gout; Humans; Male; Middle Aged; Polyethylene Glycols; Urate Oxidase; Uric Acid | 2008 |
Gout and the risk of Parkinson's disease: a cohort study.
Topics: Aged; Aged, 80 and over; Antioxidants; British Columbia; Case-Control Studies; Cohort Studies; Diure | 2008 |
Gout management: let's get it right this time.
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Drug Evaluation; Europe; Febuxo | 2008 |
Tophi as first clinical sign of gout.
Topics: Aged, 80 and over; Crystallization; Female; Fingers; Gout; Humans; Skin; Skin Diseases; Uric Acid | 2008 |
Persistent normalization of serum levels of uric acid in a gouty patient after administration of cyproterone acetate.
Topics: Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Dose-Response Relationship, Drug; Drug | 2009 |
Hyperuricemia and its related factors in an urban population, Izmir, Turkey.
Topics: Adult; Blood Glucose; Body Composition; Creatinine; Diabetes Mellitus; Female; Gout; Humans; Hyperte | 2009 |
Dual energy computed tomography in tophaceous gout.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Color; Female; Gout; Humans; Male; Middle Aged; Tissue D | 2009 |
Adherence to urate-lowering therapy.
Topics: Female; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Uric Acid | 2009 |
NALP3 inflammasome functional polymorphisms and gout susceptibility.
Topics: Carrier Proteins; Genetic Predisposition to Disease; Gout; Humans; Inflammation; Interleukin-1beta; | 2009 |
Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout.
Topics: Acute Disease; Animals; Crystallization; Disease Models, Animal; Gout; Interleukin-1beta; Interleuki | 2009 |
Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis.
Topics: Aged; Cohort Studies; Crystallization; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Predi | 2009 |
The role of diet in the management of gout: a comparison of knowledge and attitudes to current evidence.
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Attitude of Health Personnel; Cross-Sectional Studies; Di | 2009 |
A role of IgM antibodies in monosodium urate crystal formation and associated adjuvanticity.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal; B-Lymphocytes; Chromatography, High Pressur | 2009 |
[Uric acid. Biology, biochemistry, and diagnostic value in the role of an integral test (a lecture)].
Topics: Animals; Cardiovascular Diseases; Female; Gout; Humans; Male; Portraits as Topic; Uric Acid | 2009 |
Vitamin C intake and the risk of gout in men: a prospective study.
Topics: Adult; Aged; Ascorbic Acid; Gout; Humans; Incidence; Male; Middle Aged; Prospective Studies; Risk Fa | 2009 |
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hyperuricemia; Thiazoles; Treatment Outcome; Uric | 2009 |
New gout treatment approved.
Topics: Administration, Oral; Drug Approval; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; | 2009 |
High-resolution melting analysis for the rapid detection of an intronic single nucleotide polymorphism in SLC22A12 in male patients with primary gout in China.
Topics: Adult; Aged; Analysis of Variance; Case-Control Studies; China; DNA Mutational Analysis; Genetic Pre | 2009 |
Adherence with urate-lowering therapies for the treatment of gout.
Topics: Age Factors; Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Middl | 2009 |
Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gout; Homeostasis; Hyperuricemia; Hypogl | 2009 |
What rheumatologists should know about gout and cardiovascular disease.
Topics: Cardiovascular Diseases; Gout; Humans; Metabolic Syndrome; Physicians; Rheumatology; Uric Acid | 2009 |
Analysis of crystals leading to joint arthropathies by Raman spectroscopy: comparison with compensated polarized imaging.
Topics: Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Gout; Humans; Lasers; Microscopy, Polariz | 2009 |
Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?
Topics: Aged; Aging; Blood Chemical Analysis; Female; Gout; Gout Suppressants; Health Expenditures; Humans; | 2009 |
Fructose ingestion: dose-dependent responses in health research.
Topics: Blood Glucose; Body Weight; Coronary Disease; Diabetes Mellitus, Type 2; Diet; Dose-Response Relatio | 2009 |
Simple non-staining method to demonstrate urate crystals in formalin-fixed, paraffin-embedded skin biopsies.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Birefringence; Crystallization; Female; Formaldehyde; Gout; | 2009 |
Clinical images: Pseudorheumatoid gout.
Topics: Adult; Arthritis, Rheumatoid; Crystallization; Gout; Hand Joints; Humans; Male; Radiography; Uric Ac | 2009 |
Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Drug Therapy, Combination; Female; Gout; H | 2009 |
Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.
Topics: Amino Acid Sequence; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding C | 2009 |
Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved.
Topics: Aged; Aged, 80 and over; Allopurinol; Cartilage, Articular; Colchicine; Crystallization; Female; Gou | 2010 |
Unusual case of gouty tophous within oral-maxillofacial region. Case report.
Topics: Diagnosis, Differential; Female; Gout; Granuloma, Foreign-Body; Humans; Middle Aged; Paranasal Sinus | 2009 |
Gout Study Group: update on hyperuricemia and gout.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diet; Europe; Febuxostat; Gout; | 2009 |
Adherence to treatment guidelines in two primary care populations with gout.
Topics: Aged; Ambulatory Care Facilities; Biomarkers; Cohort Studies; Female; Gout; Guideline Adherence; Hum | 2010 |
Acute gouty arthropathy mimicking infection after total knee arthroplasty.
Topics: Adult; Arthroplasty, Replacement, Knee; Gout; Humans; Male; Reoperation; Synovial Fluid; Uric Acid | 2009 |
Lower back pain caused by tophaceous gout of the spine.
Topics: Aged; Biopsy; Cauda Equina; Gout; Humans; Low Back Pain; Lumbar Vertebrae; Magnetic Resonance Imagin | 2009 |
Gout: is a purine-restricted diet still recommended?
Topics: Alcohol Drinking; Evidence-Based Medicine; Gout; Humans; Purines; Treatment Outcome; Uric Acid | 2009 |
[Effect of metformin on the clinical course of gout and insulin resistance].
Topics: Adult; Female; Gout; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; | 2009 |
Identification of dairy fractions with anti-inflammatory properties in models of acute gout.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caseins; Crystallization; Dairy Pro | 2010 |
Identification of dairy fractions with anti-inflammatory properties in models of acute gout.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caseins; Crystallization; Dairy Pro | 2010 |
Identification of dairy fractions with anti-inflammatory properties in models of acute gout.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caseins; Crystallization; Dairy Pro | 2010 |
Identification of dairy fractions with anti-inflammatory properties in models of acute gout.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caseins; Crystallization; Dairy Pro | 2010 |
I've been diagnosed with gout and told that the elevated level of uric acid that brought it about may also increase my risk of heart attack. Is this true?
Topics: Gout; Humans; Male; Myocardial Infarction; Risk Factors; Uric Acid | 2009 |
A magic bullet for gout?
Topics: Gout; Gout Suppressants; Humans; Interleukin-1beta; Recombinant Fusion Proteins; Uric Acid | 2009 |
Calcium oxalate stone and gout.
Topics: Calcium; Calcium Oxalate; Case-Control Studies; Gout; Humans; Phosphorus; Uric Acid; Urinary Calculi | 2009 |
Pancreatic gout masquerading as pancreatic cancer in a heart transplant candidate.
Topics: Diagnosis, Differential; Gout; Heart Failure; Heart Transplantation; Humans; Male; Middle Aged; Panc | 2009 |
Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells.
Topics: Crystallization; Cytokines; Gout; Humans; Melanocortins; Monocytes; Neutrophil Activation; Neutrophi | 2009 |
Progress in measurement instruments for acute and chronic gout studies.
Topics: Acute Disease; Arthralgia; Chronic Disease; Consensus; Consensus Development Conferences as Topic; D | 2009 |
Outcome domains for studies of acute and chronic gout.
Topics: Acute Disease; Arthralgia; Chronic Disease; Consensus; Disability Evaluation; Gout; Humans; Outcome | 2009 |
[Crystal-induced activation of the inflammasome: gout and pseudogout].
Topics: Anti-Inflammatory Agents; Cytokines; Gout; Hereditary Autoinflammatory Diseases; Humans; Immunologic | 2009 |
Relationship between plasma uridine and urinary urea excretion.
Topics: Adult; Creatinine; Diet; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Gout; Homeostasis; H | 2010 |
[Dual energy CT--a new perspective in the diagnosis of gout].
Topics: Arthrography; Cervical Vertebrae; Extremities; Gout; Humans; Lumbar Vertebrae; Radiography, Dual-Ene | 2010 |
Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding | 2009 |
Monoamine oxidase A gene polymorphisms and enzyme activity associated with risk of gout in Taiwan aborigines.
Topics: Adult; Aged; Alleles; Asian People; Female; Gene Frequency; Genetic Predisposition to Disease; Genot | 2010 |
Images in clinical medicine. Gouty tophi.
Topics: Aged; Crystallization; Elbow Joint; Finger Joint; Gout; Humans; Male; Uric Acid | 2009 |
[The High Priest of gout - Sir Alfred Baring Garrod (1819-1907)].
Topics: Arthritis, Rheumatoid; Gout; History, 19th Century; History, 20th Century; Humans; United Kingdom; U | 2009 |
[Neutrophil bactericidal and absorptive function in gout].
Topics: Adult; Aged; Antioxidants; Blood Bactericidal Activity; Gout; Humans; Indicators and Reagents; Male; | 2009 |
Needle-shaped crystals are not always urate crystals: comment on the clinical image by Slobodin et al.
Topics: Adult; Arthritis, Rheumatoid; Birefringence; Cholesterol; Crystallization; Gout; Hand Joints; Humans | 2009 |
Medication trials in an imperfect world: gout and Parkinson's disease.
Topics: Antiparkinson Agents; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Drug-R | 2009 |
A case of isolated gouty tophus in a patient without a previous history of gouty arthritis.
Topics: Arthritis, Gouty; Diagnosis, Differential; Gout; Humans; Joint Diseases; Magnetic Resonance Imaging; | 2009 |
Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease.
Topics: Gout; Gout Suppressants; Hand Joints; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin | 2012 |
Sex and age interaction with genetic association of atherogenic uric acid concentrations.
Topics: Age Factors; Aged; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bin | 2010 |
Out with gout: opening the door on acute inflammation.
Topics: Acute Disease; Adaptive Immunity; Gout; Humans; Inflammation; Uric Acid | 2010 |
The dynamics of chronic gout treatment: medication gaps and return to therapy.
Topics: Age Factors; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Ch | 2010 |
Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort.
Topics: Adult; Alcohol Drinking; Blood Glucose; Cholesterol; Educational Status; Female; Follow-Up Studies; | 2010 |
Cellular characterization of the gouty tophus: a quantitative analysis.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, CD20; Antigens, Differentiation, Myelomonocy | 2010 |
High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals.
Topics: Cells, Cultured; Chemokine CCL2; Crystallization; Down-Regulation; Enzyme-Linked Immunosorbent Assay | 2010 |
The uptake by blood-borne phagocytes of monosodium urate is dependent on heat-labile serum factor(s) and divalent cations.
Topics: Cations, Divalent; Cytokines; Gout; Humans; Lupus Erythematosus, Systemic; Phagocytes; Uric Acid | 2010 |
Gout masquerading as a triquetral fracture.
Topics: Adrenal Cortex Hormones; Diagnosis, Differential; Fractures, Bone; Gout; Humans; Male; Middle Aged; | 2010 |
Gouty tophi presenting as medial patellar plica syndrome and patellofemoral disorder to limit knee range of motion.
Topics: Gout; Humans; Knee Joint; Male; Middle Aged; Patellofemoral Joint; Patellofemoral Pain Syndrome; Ran | 2010 |
Simiao pill ameliorates urate underexcretion and renal dysfunction in hyperuricemic mice.
Topics: Allopurinol; Animals; Biological Transport; Gout; Hyperuricemia; Kidney; Male; Mice; Mice, Inbred St | 2010 |
A survey on the management of gout in Malaysia.
Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colchicine; Cr | 2009 |
Differences in MSU-induced superoxide responses by neutrophils from gout subjects compared to healthy controls and a role for environmental inflammatory cytokines and hyperuricemia in neutrophil function and survival.
Topics: Aged; Antibodies, Blocking; Antioxidants; Apoptosis; Cell Survival; Crystallization; Culture Media, | 2010 |
The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people.
Topics: Adult; Aged; Aged, 80 and over; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member | 2010 |
Comment on: Gout: an independent risk factor for all-cause and cardiovascular mortality.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Iron; Risk Factors; Uric Acid | 2010 |
The importance of urgent cytological examination of synovial fluids in differentiation inflammatory and non-inflammatory joint diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis; Child; Crystallization; Diagnosis, Differenti | 2010 |
Treatment failure gout: failure to treat?
Topics: Allopurinol; Drug Hypersensitivity; General Practice; Gout; Gout Suppressants; Guideline Adherence; | 2010 |
On call. I've had gout for many years. I used to take Zyloprim without any problems, but I just had a severe allergic reaction, so my doctor switched me to Benemid. I'm doing okay, but the drug sometimes upsets my stomach. Do you have any suggestions?
Topics: Allopurinol; Drug Hypersensitivity; Gastritis; Gout; Gout Suppressants; Humans; Male; Middle Aged; P | 2010 |
Subconjunctival urate crystals: a case report.
Topics: Aged, 80 and over; Conjunctival Diseases; Crystallization; Female; Gout; Granuloma, Foreign-Body; Hu | 2010 |
Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
Topics: Allopurinol; Benzbromarone; Cohort Studies; Creatinine; Follow-Up Studies; Gout; Humans; Hyperuricem | 2010 |
Computed tomography in tophaceous gout.
Topics: Gout; Hand Joints; Humans; Male; Middle Aged; Tomography, X-Ray Computed; Uric Acid | 2010 |
An unusual soft tissue tumor.
Topics: Birefringence; Diagnosis, Differential; Foot; Gout; Humans; Male; Middle Aged; Soft Tissue Neoplasms | 2010 |
Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion.
Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Biopsy, Needle; Col | 2010 |
Metabolic syndrome characteristics in gout patients.
Topics: Aged; Blood Glucose; Blood Pressure; Female; Gout; Humans; Hyperuricemia; Male; Metabolic Syndrome; | 2010 |
Uric acid metabolism in patients with primary gout and the metabolic syndrome.
Topics: Female; Gout; Humans; Male; Metabolic Syndrome; Middle Aged; Uric Acid | 2010 |
Diagnosis of chronic gout: evaluating the american college of rheumatology proposal, European league against rheumatism recommendations, and clinical judgment.
Topics: Chronic Disease; Cohort Studies; Cross-Sectional Studies; Crystallization; European Union; Female; G | 2010 |
Gout and risk of non-alcoholic fatty liver disease.
Topics: Adult; Aged; Body Mass Index; Cross-Sectional Studies; Fatty Liver; Female; Glomerular Filtration Ra | 2010 |
Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter.
Topics: Amino Acid Substitution; Animals; Biological Transport; Chlorides; Electrophysiology; Gout; Humans; | 2010 |
Analyze multivariate phenotypes in genetic association studies by combining univariate association tests.
Topics: Analysis of Variance; Genetic Linkage; Genetic Variation; Genome-Wide Association Study; Genome, Hum | 2010 |
[Carbohydrate metabolic disorders in gout: incidence and clinical features].
Topics: Anthropometry; Blood Glucose; Carbohydrate Metabolism; Cardiovascular Diseases; Cholesterol; Diabete | 2010 |
Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.
Topics: Antioxidants; Cells, Cultured; Erythrocytes; F2-Isoprostanes; Gout; Humans; Hydrogen Peroxide; Oxida | 2010 |
Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases.
Topics: Age Factors; Case-Control Studies; Comorbidity; Creatinine; Genetic Variation; Genome-Wide Associati | 2010 |
Association of four genetic loci with uric acid levels and reduced renal function: the J-SHIPP Suita study.
Topics: Aged; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Tr | 2010 |
Panniculitis: another clinical expression of gout.
Topics: Adult; Allopurinol; Colchicine; Crystallization; Gout; Gout Suppressants; Humans; Hyperuricemia; Mal | 2011 |
Gout and coexisting pseudogout in the knee joint.
Topics: Arthroscopy; Calcium Pyrophosphate; Chondrocalcinosis; Debridement; Emergency Service, Hospital; Fol | 2011 |
The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial.
Topics: Body Weight; Cardiovascular Diseases; Cohort Studies; Follow-Up Studies; Gout; Humans; Hypertension; | 2010 |
Gout as an early warning of concomitant sleep apnea.
Topics: Gout; Humans; Hypoxia; Risk Factors; Sleep Apnea, Obstructive; Uric Acid | 2010 |
Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate.
Topics: Animals; Bumetanide; Diuretics; Furosemide; Genetic Predisposition to Disease; Glucose Transport Pro | 2010 |
Disabling gout.
Topics: Arthrodesis; Biomarkers; Foot; Gout; Hallux Valgus; Humans; Magnetic Resonance Imaging; Male; Metata | 2010 |
Dietary intake and the risk of hyperuricemia, gout and chronic kidney disease in elderly Taiwanese men.
Topics: Aged; Antihypertensive Agents; Chronic Disease; Comorbidity; Diet; Feeding Behavior; Glomerular Filt | 2011 |
Managing hypertensive patients with gout who take thiazide.
Topics: Adult; Aged; Diuretics; Female; Gout; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; | 2010 |
Coincidence of calcium pyrophosphate and monosodium urate crystals in the synovial fluid of patients with gout determined by the cytocentrifugation technique.
Topics: Adult; Aged; Aged, 80 and over; Calcium Pyrophosphate; Centrifugation; Crystallization; Female; Gout | 2011 |
Association of an intronic SNP of SLC2A9 gene with serum uric acid levels in the Chinese male Han population by high-resolution melting method.
Topics: Adult; Aged; China; Genotype; Glucose Transport Proteins, Facilitative; Gout; Homozygote; Humans; Hy | 2011 |
Genome-wide study of familial juvenile hyperuricaemic (gouty) nephropathy (FJHN) indicates a new locus, FJHN3, linked to chromosome 2p22.1-p21.
Topics: Chromosomes, Human, Pair 2; Female; Genetic Heterogeneity; Genetic Linkage; Genetic Loci; Genetic Pr | 2011 |
Uric acid is not the cause of gout.
Topics: Gout; Humans; Uric Acid | 1946 |
The current state of care in gout: Addressing the need for better understanding of an ancient disease.
Topics: Acute Disease; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthrit | 2010 |
Fructose-rich beverages and risk of gout in women.
Topics: Adult; Beverages; Female; Fructose; Gout; Humans; Incidence; Middle Aged; Prospective Studies; Risk; | 2010 |
Gout.
Topics: Acute Disease; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; | 2010 |
A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
Topics: Animals; Bacillus; Gout; Half-Life; Hyperuricemia; Male; Polyethylene Glycols; Rabbits; Rats; Rats, | 2010 |
Is metabolic syndrome related to uric acid metabolism in gout patients?
Topics: Gout; Humans; Metabolic Syndrome; Prevalence; Uric Acid | 2010 |
Gout: nonsteroidal anti-inflammatory drugs and colchicine to prevent painful flares during early urate-lowering therapy.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Gout Suppressants; Humans; Male; Pa | 2010 |
Nonsteroidal anti-inflammatory drugs and colchicine to prevent gout flare during early urate-lowering therapy: perspectives on alternative therapies and costs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Drug Costs; Gout; Gout Suppressants; Humans; Pr | 2010 |
Olea europaea leaf (Ph.Eur.) extract as well as several of its isolated phenolics inhibit the gout-related enzyme xanthine oxidase.
Topics: Allopurinol; Animals; Apigenin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Dr | 2011 |
Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout.
Topics: Aged; Chronic Disease; Cohort Studies; Colchicine; Disability Evaluation; Dose-Response Relationship | 2011 |
[Epidemiological study on hyperuricemia and gout in Foshan areas, Guangdong province].
Topics: Epidemiologic Studies; Gout; Humans; Hyperuricemia; Prevalence; Uric Acid | 2010 |
Did The Captain only have gout?
Topics: Cardiovascular Diseases; Cartoons as Topic; Fructose; Gout; History, 19th Century; History, 20th Cen | 2010 |
Large epidemiologic studies of gout: challenges in diagnosis and diagnostic criteria.
Topics: Biomarkers; Epidemiologic Studies; Gout; Humans; Reproducibility of Results; Synovial Fluid; Uric Ac | 2011 |
Non-invasive and transdermal measurement of blood uric acid level in human by electroporation and reverse iontophoresis.
Topics: Adult; Analysis of Variance; Diffusion; Electroporation; Female; Gout; Humans; Iontophoresis; Linear | 2010 |
Role of ultrasound and other advanced imaging in the diagnosis and management of gout.
Topics: Arthrography; Gout; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Microscopy, Pola | 2011 |
[Application of dual-energy computed tomography for detecting uric acid deposition in patients with gout].
Topics: Adult; Aged; Aged, 80 and over; Arthrography; Extremities; Female; Gout; Humans; Male; Middle Aged; | 2010 |
Treatment of gout.
Topics: Aged; Allopurinol; Australia; Colchicine; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 2011 |
Orange-colored diapers in infants from families with gout.
Topics: Color; Diagnostic Errors; Diapers, Infant; Family Health; Genetic Predisposition to Disease; Gout; H | 2011 |
Application of a new method for GWAS in a related case/control sample with known pedigree structure: identification of new loci for nephrolithiasis.
Topics: Carrier Proteins; Case-Control Studies; Cohort Studies; Data Interpretation, Statistical; Genetic Lo | 2011 |
Positive correlation between Beta-3-Adrenergic Receptor (ADRB3) gene and gout in a Chinese male population.
Topics: Asian People; Case-Control Studies; Gene Frequency; Genotype; Gout; Humans; Male; Polymorphism, Sing | 2011 |
A genome-wide association study of serum uric acid in African Americans.
Topics: Black or African American; Black People; Body Mass Index; Diabetes Mellitus, Type 2; Genome-Wide Ass | 2011 |
I've been told to avoid "purines" because I have gout. What are purines, and what foods contain them?
Topics: Diet; Gout; Humans; Purines; Uric Acid | 2011 |
Uric acid and gout.
Topics: Aged; Gout; Humans; Male; Nurse Practitioners; Physical Examination; Travel; Uric Acid | 2011 |
Gout and chronic kidney disease.
Topics: Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; Uric Acid | 2011 |
Impact of allopurinol use on urate concentration and cardiovascular outcome.
Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Cohort Studies; Female; Gout; Gout Su | 2011 |
Osteoblast retraction induced by adherent neutrophils promotes osteoclast bone resorption: implication for altered bone remodeling in chronic gout.
Topics: Analysis of Variance; Bone Remodeling; Bone Resorption; Cell Adhesion; Flow Cytometry; Gout; Humans; | 2011 |
The nail plate biopsy may pick up gout crystals and other crystals.
Topics: Aged, 80 and over; Biopsy; Crystallization; Gout; Humans; Male; Nail Diseases; Nails; Uric Acid | 2011 |
Monosodium urate monohydrate crystal-recruited noninflammatory monocytes differentiate into M1-like proinflammatory macrophages in a peritoneal murine model of gout.
Topics: Animals; Blotting, Western; Cell Differentiation; Disease Models, Animal; Flow Cytometry; Gout; Infl | 2011 |
Gout.
Topics: Allopurinol; Antihypertensive Agents; Gout; Gout Suppressants; Humans; Hydrochlorothiazide; Hyperten | 2011 |
Diagnosis of crystal-associated disease: where do we stand?
Topics: Calcium Phosphates; Calcium Pyrophosphate; Crystallization; Fluorescent Dyes; Gout; Humans; Light; S | 2011 |
Potential of vitamin C in the prevention and treatment of gout.
Topics: Antioxidants; Ascorbic Acid; Gout; Humans; Uric Acid | 2011 |
Febuxostat efficacy in allopurinol-resistant tophaceous gout.
Topics: Allopurinol; Dose-Response Relationship, Drug; Drug Resistance; Febuxostat; Female; Gout; Gout Suppr | 2011 |
Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout.
Topics: Animals; Apoptosis; Bone and Bones; Bone Resorption; Cell Death; Cell Differentiation; Cell Survival | 2011 |
Sonographic characterization of mixed crystal arthropathy due to monosodium urate and calcium pyrophosphate dihydrate: the triple-contour sign.
Topics: Aged, 80 and over; Calcium Pyrophosphate; Gout; Humans; Male; Ultrasonography; Uric Acid; Wrist Join | 2011 |
Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008.
Topics: Adult; Age Distribution; Aged; Beverages; Coffee; Dairy Products; Diet; Female; Fruit; Glycine max; | 2011 |
Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Crystallization; Gout; Hospitals, Veterans; Humans; | 2011 |
Gout and hyperuricaemia in adults with cystic fibrosis.
Topics: Adult; Cystic Fibrosis; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Prevalence; Uric Aci | 2011 |
Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
Topics: Aged; Aged, 80 and over; Allopurinol; Drug Monitoring; Febuxostat; Female; Gout; Gout Suppressants; | 2011 |
Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?
Topics: Biomarkers; Chronic Disease; Gout; Humans; Outcome Assessment, Health Care; Prognosis; Randomized Co | 2011 |
Gender-specific risk factors for incident gout: a prospective cohort study.
Topics: Adult; Comorbidity; Female; Follow-Up Studies; Gout; Humans; Hyperlipidemias; Hypertension; Incidenc | 2012 |
Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Arthritis, Gouty; Chronic Disease; Creatinine; Dose-Res | 2011 |
Chronic kidney disease in gout in a managed care setting.
Topics: Adult; Aged; Allopurinol; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Kidney Failure | 2011 |
Lymphocyte α-kinase is a gout-susceptible gene involved in monosodium urate monohydrate-induced inflammatory responses.
Topics: Cell Line, Tumor; Enzyme Induction; Gene Expression Profiling; Genetic Predisposition to Disease; Go | 2011 |
Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
Topics: Allopurinol; Arthritis, Gouty; Enzyme Inhibitors; Female; Gout; Gout Suppressants; Humans; Male; Oxy | 2011 |
Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations.
Topics: Adult; Belgium; Biomarkers; Central Nervous System Diseases; Chi-Square Distribution; Dental Enamel; | 2011 |
Crystal deposition at elbow hyaline cartilage: the sonographic perspective.
Topics: Aged; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Elbow Joint; Female; Gout; Humans; | 2011 |
A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Topics: Aged; Cohort Studies; Colchicine; Crystallization; Female; Fenofibrate; Follow-Up Studies; Gout; Gou | 2011 |
[Hyperuricemia in sickle cell disease in France].
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Female; France; Gout; Humans; Hyperuricemia; Male; Mid | 2012 |
Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study.
Topics: Acute Disease; Aged; Allopurinol; Arthritis, Gouty; Gout; Gout Suppressants; Humans; Male; Middle Ag | 2011 |
Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Female; Gout; Humans; Male; Middle Aged; Reproducibility | 2011 |
An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study.
Topics: Acute Disease; Adult; Aged; Cross-Sectional Studies; Europe; Female; Gout; Guideline Adherence; Huma | 2011 |
Catastrophic axial gout causing paraplegia in a patient with glycogen storage disease.
Topics: Adult; Catastrophic Illness; Drug Therapy, Combination; Febuxostat; Glycogen Storage Disease Type I; | 2011 |
Hyperuricaemia and gout.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diet; Gout; Gout Suppressants; Hum | 2011 |
NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout.
Topics: Animals; Carrier Proteins; Caspase 1; Cytokines; Gout; Hyperalgesia; Inflammasomes; Inflammation; In | 2012 |
Monosodium urate (gout) crystals, an uncommon finding in ThinPrep synovial fluid cytology.
Topics: Crystallization; Gout; Humans; Male; Middle Aged; Synovial Fluid; Uric Acid | 2013 |
Identification of low-frequency variants associated with gout and serum uric acid levels.
Topics: Gout; Humans; Iceland; Mutation, Missense; Polymorphism, Single Nucleotide; Uric Acid | 2011 |
Population heterogeneity in the genetic control of serum urate.
Topics: Glucose Transport Proteins, Facilitative; Gout; Humans; Hyperuricemia; Racial Groups; Uric Acid; Whi | 2011 |
Quantification of tissue uric acid levels in a Harris's hawk with visceral gout.
Topics: Animals; Bird Diseases; Gout; Hawks; Kidney; Louisiana; Muscle, Skeletal; Myocardium; Uric Acid | 2011 |
Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study.
Topics: Community Medicine; Comorbidity; Diuretics; Female; Gout; Humans; Hypertension; Male; Middle Aged; P | 2012 |
Giant gouty tophi of the hand and wrist.
Topics: Adult; Diet Therapy; Gout; Gout Suppressants; Hand Joints; Humans; Male; Plastic Surgery Procedures; | 2011 |
Pegloticase and chronic gout.
Topics: Enzymes, Immobilized; Female; Gout; Humans; Male; Polyethylene Glycols; Urate Oxidase; Uric Acid | 2011 |
[Exploration on the establishment of animal models for gouty nephropathy complicated with chronic renal failure].
Topics: Animals; Disease Models, Animal; Gout; Hyperuricemia; Kidney Failure, Chronic; Male; Rats; Rats, Wis | 2011 |
High prevalence of gout with sleep apnea.
Topics: Glomerular Filtration Rate; Gout; Humans; Hypoxia; Prevalence; Sleep Apnea Syndromes; Uric Acid | 2012 |
P2Y6 receptor signaling pathway mediates inflammatory responses induced by monosodium urate crystals.
Topics: Animals; Antioxidants; Cell Line; Cytokines; Disease Models, Animal; Gout; Humans; Hyperuricemia; In | 2012 |
ABCG2/BCRP dysfunction as a major cause of gout.
Topics: Amino Acid Sequence; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette T | 2011 |
Synthesis of [¹¹C]uric acid, using [¹¹C]phosgene, as a possible biomarker in PET imaging for diagnosis of gout.
Topics: Animals; Automation; Biomarkers; Carbon Isotopes; Chromatography, High Pressure Liquid; Disease Mode | 2012 |
Assessment of tophus size: a comparison between physical measurement methods and dual-energy computed tomography scanning.
Topics: Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Male; Middle Aged; Observer Variation; Physica | 2012 |
[Contribution of the CoLaus study to decipher the determinants of serum uric acid].
Topics: Biomarkers; Cardiovascular Diseases; Cohort Studies; Glucose Transport Proteins, Facilitative; Gout; | 2011 |
Neutrophil extracellular trap formation is associated with IL-1β and autophagy-related signaling in gout.
Topics: Acute Disease; Autophagy; Crystallization; DNA; Endosomes; Extracellular Space; Gout; HMGB1 Protein; | 2011 |
Interreader agreement in determining monosodium urate deposition using musculoskeletal ultrasound: comment on the article by Howard et al.
Topics: Gout; Humans; Hyperuricemia; Knee Joint; Male; Metatarsophalangeal Joint; Ultrasonography; Uric Acid | 2012 |
Unknown: Multiple painful nodules - what is the diagnosis? Chronic tophaceous gout.
Topics: Alcoholics; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Chronic Disease; Colch | 2011 |
Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Coronary Artery Disease; Co | 2012 |
Evaluation of health care costs and utilization patterns for patients with gout.
Topics: Cohort Studies; Drug Utilization; Female; Gout; Gout Suppressants; Health Care Costs; Health Service | 2012 |
Dual energy CT in gout: a prospective validation study.
Topics: Female; Gout; Humans; Male; Middle Aged; Observer Variation; Prospective Studies; Sensitivity and Sp | 2012 |
Association between gout and polymorphisms in GCKR in male Han Chinese.
Topics: Adaptor Proteins, Signal Transducing; Asian People; Blood Glucose; Case-Control Studies; China; Chol | 2012 |
Gender-dependent associations of uric acid levels with a polymorphism in SLC2A9 in Han Chinese patients.
Topics: Asian People; China; Female; Glucose Transport Proteins, Facilitative; Gout; Humans; Hyperuricemia; | 2012 |
False-negative dual-energy computed tomography in a patient with acute gout.
Topics: Allopurinol; Arthralgia; Biopsy; False Negative Reactions; Gout; Gout Suppressants; Humans; Magnetic | 2012 |
Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Allantoin; Benzbromarone; Biomarkers; Case-Control Studies; Crea | 2012 |
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Case-Control Studies; Dose-Response Relationship, Drug; | 2012 |
Genetic architecture for susceptibility to gout in the KARE cohort study.
Topics: Binding Sites; Cohort Studies; Genetic Loci; Genetic Predisposition to Disease; Gout; Humans; Polymo | 2012 |
Clinical study of ammonium acid urate urolithiasis.
Topics: Adult; Aged; Comorbidity; Female; Gout; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Renal I | 2012 |
Serum amyloid A triggers the mosodium urate -mediated mature interleukin-1β production from human synovial fibroblasts.
Topics: Antioxidants; Fibroblasts; Gout; Humans; Immunoblotting; Interleukin-1beta; Real-Time Polymerase Cha | 2012 |
[Clinical significance of insulin resistance syndrome in development of endothelial dysfunction in patients with primary gout].
Topics: Adult; Atherosclerosis; Blood Glucose; Brachial Artery; Carbohydrate Metabolism; Disease Progression | 2012 |
The gout pipeline crystallizes.
Topics: Allopurinol; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Drug Industry; Gout; Gou | 2012 |
Gout mimicking psoriatic arthritis flare.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Diagnosi | 2012 |
Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.
Topics: Aged; Aged, 80 and over; Allopurinol; C-Reactive Protein; Colchicine; Female; Gout; Gout Suppressant | 2012 |
The association of dietary intake of purine-rich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a cross-sectional study.
Topics: Beverages; Calcium; Cohort Studies; Cross-Sectional Studies; Dairy Products; Diet; Female; Fructose; | 2012 |
[Characteristics of carbohydrate metabolism changes in elderly patients with gout and metabolic syndrome].
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Carbohydrate Metabolism; Dyslipidemias; | 2012 |
Monosodium urate (MSU) crystals increase gout associated coronary heart disease (CHD) risk through the activation of NLRP3 inflammasome.
Topics: Carrier Proteins; Coronary Disease; Crystallization; Gout; Humans; Inflammasomes; NLR Family, Pyrin | 2012 |
A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study.
Topics: Databases, Factual; Diuretics; Drug Interactions; Female; Genotype; Glucose Transport Proteins, Faci | 2013 |
Enhanced interleukin-1β production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals.
Topics: Adult; Aged; Crystallization; Female; Gout; Humans; Interleukin-1beta; Leukocytes, Mononuclear; Liga | 2012 |
[Attack of gout].
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis, Gouty; Diagnosis, Diffe | 2012 |
Achieving treat to target in gout: a clinical practice improvement project.
Topics: Adult; Aged; Allopurinol; Diet; Evidence-Based Medicine; Female; Gout; Gout Suppressants; Humans; Li | 2012 |
Casebook consults: improving outcomes in gout (multimedia activity).
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxosta | 2012 |
Crystal arthritis: a new 'package of care' strategy for effective gout management.
Topics: Crystallization; Disease Management; Gout; Gout Suppressants; Humans; Nurse Clinicians; Rheumatology | 2012 |
Gout and osteoarthritis: a pathogenetic link?
Topics: Cartilage, Articular; Gout; Humans; Metatarsophalangeal Joint; Osteoarthritis; Uric Acid | 2012 |
Reducing effect of mangiferin on serum uric acid levels in mice.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gout; | 2012 |
Low-level lead exposure and the prevalence of gout: an observational study.
Topics: Adult; Age Factors; Aged; Cadmium; Creatinine; Cross-Sectional Studies; Diet; Environmental Exposure | 2012 |
Summaries for patients. Low levels of lead in the blood and the occurrence of gout.
Topics: Aged; Cadmium; Cross-Sectional Studies; Diet; Environmental Exposure; Female; Gout; Humans; Lead; Ma | 2012 |
Longan seed extract reduces hyperuricemia via modulating urate transporters and suppressing xanthine oxidase activity.
Topics: Allopurinol; Animals; Glucose Transporter Type 1; Gout; Gout Suppressants; Hyperuricemia; Hypoxanthi | 2012 |
Metabolite target analysis of human urine combined with pattern recognition techniques for the study of symptomatic gout.
Topics: Animals; Chromatography, High Pressure Liquid; Gout; Guanosine; Humans; Hypoxanthine; Male; Mice; Ri | 2012 |
Silkworms can be used as an animal model to screen and evaluate gouty therapeutic drugs.
Topics: Animals; Bombyx; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fat Body; Gout; Gou | 2012 |
Adherence to uric acid treatment guidelines in a rheumatology clinic.
Topics: Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Guideline Adherence; Humans; Male; M | 2012 |
[Therapy of gout. "Uric acid less than 6 mg/dl is the general consensus" (interview by Wiebke Kathmann)].
Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Colchicine; Consensus; Gout; Gout Suppressants; Guidelin | 2012 |
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Topics: Adult; Aged; Allopurinol; Biomarkers; Cross-Sectional Studies; Down-Regulation; Drug Dosage Calculat | 2012 |
Gout: the mechanism of urate crystal nucleation and growth. A hypothesis based in facts.
Topics: Calculi; Crystallization; Gout; Humans; Lithiasis; Ultrasonography; Uric Acid | 2013 |
DECT urate deposits: now you see them, now you don't.
Topics: Absorptiometry, Photon; Gout; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Sensitivity and | 2013 |
Uric Acid: a clearer focus.
Topics: Gout; Humans; Hyperuricemia; Uric Acid | 2012 |
Gout: a step forward.
Topics: Gout; Humans; Uric Acid | 2012 |
The experience and impact of gout in Māori and Pacific people: a prospective observational study.
Topics: Adult; Aged; Female; Follow-Up Studies; Gout; Health Status; Humans; Hyperuricemia; Male; Middle Age | 2013 |
Pegloticase and the patient with treatment-failure gout.
Topics: Allopurinol; Enzymes, Immobilized; Female; Gout; Gout Suppressants; Humans; Infusions, Intravenous; | 2012 |
Absence of the SLC22A12 gene mutation in Turkish population with primary gout disease.
Topics: Adult; Female; Genetic Predisposition to Disease; Gout; Humans; Hyperuricemia; Male; Middle Aged; Mu | 2013 |
Gout in women: differences in risk factors in young and older women.
Topics: Adult; Age Factors; Aged; Body Mass Index; Comorbidity; Diuretics; Ethnicity; Female; Gout; Gout Sup | 2012 |
Sack and sugar, and the aetiology of gout in England between 1650 and 1900.
Topics: Dietary Sucrose; England; Fructose; Gout; History, 17th Century; History, 18th Century; History, 19t | 2013 |
Management of gout: a 57-year-old man with a history of podagra, hyperuricemia, and mild renal insufficiency.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Gout | 2012 |
JAMA patient page. Gout.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Gout; Gout Suppressants; Humans; Uric Acid | 2012 |
Sonographic appearance of synovial crystal deposits in 2 patients with gout.
Topics: Arthroscopy; Crystallization; Gout; Humans; Male; Middle Aged; Synovial Fluid; Synovial Membrane; Ul | 2012 |
Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout.
Topics: Aged; Cell Movement; Chemokine CCL2; Female; Gout; Humans; Hyperuricemia; Lipopolysaccharide Recepto | 2013 |
Reduced glomerular function and prevalence of gout: NHANES 2009-10.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Glomerular | 2012 |
Potential interest of dual-energy computed tomography in gout: focus on anatomical distribution and clinical association.
Topics: Female; Foot Joints; Gout; Humans; Male; Retrospective Studies; Tomography, X-Ray Computed; Uric Aci | 2013 |
Assessment of arterial stiffness in female and male gout patients.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Case-Control Studies; Female; Gout; Humans; Male; Mi | 2013 |
Gouty panniculitis also involving the bone marrow.
Topics: Allopurinol; Biomarkers; Biopsy; Bone Marrow; Bone Marrow Examination; Colchicine; Crystallization; | 2013 |
Insulin resistance and metabolic syndrome in primary gout: relation to punched-out erosions.
Topics: Adult; Biomarkers; Case-Control Studies; Gout; Humans; Insulin; Insulin Resistance; Male; Metabolic | 2012 |
The effect of the systemic inflammatory response, as provoked by elective orthopaedic surgery, on serum uric acid in patients without gout: a prospective study.
Topics: Aged; Albuminuria; C-Reactive Protein; Creatinine; Elective Surgical Procedures; Female; Gout; Human | 2013 |
Neutrophil cannibalism triggers transforming growth factor β1 production and self regulation of neutrophil inflammatory function in monosodium urate monohydrate crystal-induced inflammation in mice.
Topics: Animals; Antioxidants; Apoptosis; Cells, Cultured; Crystallization; Cytophagocytosis; Disease Models | 2013 |
Allopurinol versus rilonacept for the prevention of gout flares: comment on the article by Schumacher et al.
Topics: Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Recombinant Fusion Proteins; Uric Acid | 2013 |
Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; | 2014 |
Unusual soft tissue mass of the left lower leg.
Topics: Biopsy, Fine-Needle; Gout; Gout Suppressants; Humans; Leg; Male; Middle Aged; Muscular Diseases; Rad | 2013 |
Gout treatment: should we aim for rapid crystal dissolution?
Topics: Crystallization; Gout; Gout Suppressants; Humans; Hyperuricemia; Solubility; Time Factors; Uric Acid | 2013 |
Tendon involvement in the feet of patients with gout: a dual-energy CT study.
Topics: Absorptiometry, Photon; Achilles Tendon; Crystallization; Female; Gout; Humans; Ligaments; Male; Mid | 2013 |
Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load.
Topics: Adolescent; Adult; Female; Fructose; Genotype; Glucose Transport Proteins, Facilitative; Gout; Human | 2013 |
Potential pitfalls in the diagnosis of crystal-induced arthritis and in the sonographic measurement of hyaline cartilage due to the presence of joint effusion.
Topics: Adult; Aged; Cartilage, Articular; Chondrocalcinosis; Diagnosis, Differential; Elbow Joint; Female; | 2013 |
Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events.
Topics: Animals; Cell Count; Crystallization; Disease Models, Animal; Exudates and Transudates; Fibroblasts; | 2002 |
[Gout].
Topics: Diet; Glucocorticoids; Gout; Gout Suppressants; Humans; Injections, Intra-Articular; Uric Acid | 2001 |
Hyperuricemia and gout: a reign of complacency.
Topics: Allopurinol; Colchicine; Coronary Disease; Gout; Gout Suppressants; Humans; Kidney Failure, Chronic; | 2002 |
The crystal, the gout, and the paradox.
Topics: Adult; Aged; Bursa, Synovial; Gout; Humans; Male; Uric Acid | 2002 |
A simple method of selecting gout patients for treatment with uricosuric agents, using spot urine and blood samples.
Topics: Adult; Analysis of Variance; Blood Chemical Analysis; Case-Control Studies; Chi-Square Distribution; | 2002 |
[Progress in the study of allergy and collagen disease in the last 100 years: Gout].
Topics: Gout; History, 19th Century; History, 20th Century; Humans; Uric Acid | 2002 |
Gout and diabetes in Polynesia.
Topics: Diabetes Mellitus; Dietary Sucrose; Gout; Humans; Native Hawaiian or Other Pacific Islander; New Zea | 1967 |
Tophaceous gout.
Topics: Aged; Arthralgia; Bone Neoplasms; Colonic Neoplasms; Diagnosis, Differential; Gout; Humans; Knee Joi | 2002 |
Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis.
Topics: Adult; Aged; Calcium; Calcium Oxalate; Diagnosis, Differential; Female; Gout; Humans; Hydrogen-Ion C | 2002 |
Clinical analysis of gouty patients with normouricaemia at diagnosis.
Topics: Aged; Blood Urea Nitrogen; Creatinine; Disease Progression; Female; Follow-Up Studies; Gout; Humans; | 2003 |
Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.
Topics: Adult; Allopurinol; Case-Control Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Middle Age | 2002 |
Gout related upper limb cellulitis: an ultrasound study.
Topics: Aged; Aged, 80 and over; Cellulitis; Exudates and Transudates; Female; Gout; Hand; Humans; Ultrasono | 2003 |
Long-term remission from gout associated with fenofibrate therapy.
Topics: Fenofibrate; Gout; Humans; Hyperlipidemias; Hyperuricemia; Hypolipidemic Agents; Lipids; Male; Middl | 2003 |
The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates.
Topics: Adult; Alleles; Apolipoprotein E2; Apolipoproteins E; Case-Control Studies; Genotype; Gout; Humans; | 2003 |
Biochemical profile of stone-forming patients with diabetes mellitus.
Topics: Adolescent; Adult; Age Factors; Aged; Blood Glucose; Calcium Oxalate; Comorbidity; Diabetes Mellitus | 2003 |
Acute gout precipitated by total parenteral nutrition.
Topics: Acute Disease; Adenocarcinoma; Esophagectomy; Gastrectomy; Gastrointestinal Neoplasms; Gout; Humans; | 2003 |
A comparison between pre- and posthibernation morphometry, hematology, and blood chemistry in viperid snakes.
Topics: Animals; Animals, Zoo; Bile Acids and Salts; Blood Chemical Analysis; Drinking; Female; Gout; Hemato | 2003 |
Clinical characterization of a family with a mutation in the uromodulin (Tamm-Horsfall glycoprotein) gene.
Topics: Adolescent; Alleles; Base Pairing; Chronic Disease; Creatinine; Female; Gene Deletion; Genes, Domina | 2003 |
Uric acid and urea in human sweat.
Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid | 2002 |
Uric acid and urea in human sweat.
Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid | 2002 |
Uric acid and urea in human sweat.
Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid | 2002 |
Uric acid and urea in human sweat.
Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid | 2002 |
Rush desensitization to allopurynol.
Topics: Adult; Allopurinol; Angioedema; Desensitization, Immunologic; Drug Administration Schedule; Drug Eru | 2003 |
Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman.
Topics: Adult; Female; Genes, Dominant; Gout; Humans; Hyperuricemia; Point Mutation; Ribose-Phosphate Pyroph | 2003 |
Predictive value of kidney stone composition in the detection of metabolic abnormalities.
Topics: Acidosis, Renal Tubular; Adolescent; Adult; Aged; Ambulatory Care; Apatites; Calcium; Calcium Oxalat | 2003 |
Limited knee joint range of motion due to invisible gouty tophi.
Topics: Adult; Follow-Up Studies; Gout; Humans; Knee Joint; Magnetic Resonance Imaging; Male; Middle Aged; R | 2004 |
[Diagnostic and therapeutic consequences from our knowledge of the uric acid metabolism to gout].
Topics: Gout; Humans; Knowledge; Uric Acid | 1952 |
Current concepts in gout.
Topics: Gout; Humans; Uric Acid | 1953 |
Uric acid production in normal and gouty subjects, determined by N15 labeled glycine.
Topics: Biochemical Phenomena; Body Fluids; Glycine; Gout; Humans; Uric Acid; Urine | 1953 |
A further study of the utilization of dietary glycine nitrogen for uric acid synthesis in gout.
Topics: Diet; Glycine; Gout; Nitrogen; Uric Acid | 1953 |
The relation of dietary nitrogen consumption to the rate of uric acid synthesis in normal and gouty man.
Topics: Diet; Gout; Humans; Male; Nitrogen; Uric Acid | 1953 |
Diagnosis and treatment of gouty arthritis.
Topics: Arthritis; Arthritis, Gouty; Colchicine; Gout; Humans; Hyperuricemia; Male; Middle Aged; Probenecid; | 1953 |
Effect of phenylbutazone on uric acid excretion in patients with gout and rheumatoid arthritis.
Topics: Analgesics; Arthritis; Arthritis, Rheumatoid; Body Fluids; Gout; Humans; Phenylbutazone; Uric Acid; | 1953 |
Ammonia, urea and uric acid content of toenails in renal insufficiency and gout.
Topics: Ammonia; Gout; Humans; Kidney Diseases; Nails; Renal Insufficiency; Urea; Uric Acid | 1953 |
[Relations between cortisone and uricosuria in uratic disease (acute and chronic gout)].
Topics: Arthritis, Gouty; Chronic Disease; Cortisone; Gout; Humans; Uric Acid | 1953 |
A simultaneous study of glycine-N15 incorporation into uric acid and heme, and of Fe59 utilization, in a case of gout associated with polycythemia secondary to congenital heart disease.
Topics: Blood; Cardiovascular Abnormalities; Cardiovascular System; Glycine; Gout; Heart Diseases; Heme; Hum | 1953 |
Uric acid production in a case of myeloid metaplasia associated with gouty arthritis, studied with N15 labeled glycine.
Topics: Arthritis, Gouty; Glycine; Gout; Humans; Metaplasia; Primary Myelofibrosis; Research; Uric Acid | 1953 |
Metabolism of uric acid and its relation to gout.
Topics: Gout; Humans; Probenecid; Uric Acid | 1954 |
Effect of phenylbutazone (3,5 dioxo-1,2-diphenyl-4-n-butylpyrazolidine) on renal clearance of urate and other discrete renal functions in gouty subjects.
Topics: Analgesics; Biphenyl Compounds; Gout; Humans; Kidney; Phenylbutazone; Uric Acid | 1953 |
Effect of ACTH and sodium salicylate on the urinary uric acid: creatinine ratio, and circulating eosinophils in man.
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Creatinine; Eosinophils; Gout; Humans | 1953 |
Effect of phenylbutazone on uric acid metabolism.
Topics: Analgesics; Gout; Humans; Phenylbutazone; Uric Acid | 1954 |
[Citrosalicylate of piperazine in therapy of uric acid diathesis].
Topics: Aged; Disease Susceptibility; Gout; Humans; Piperazine; Piperazines; Uric Acid | 1954 |
[Uric acid excretion after longacid administration in normal and in gouty persons].
Topics: Biological Transport; Body Fluids; Gout; Humans; Sulfanilamide; Sulfanilamides; Sulfonamides; Uric A | 1954 |
Urinary uric acid excretion after the ingestion of isotopic yeast nucleic acid in the normal and gouty human.
Topics: Eating; Gout; Humans; Nucleic Acids; Saccharomyces cerevisiae; Uric Acid; Urine | 1954 |
Sodium salicylate and probenecid in the treatment of chronic gout; assessment of their relative effects in lowering serum uric acid levels.
Topics: Arthritis, Gouty; Blood; Chronic Disease; Gout; Humans; Probenecid; Salicylates; Sodium Salicylate; | 1954 |
Further observation on the uricosuric effects of probenecid (benemid) in tophaceous gout.
Topics: Body Fluids; Gout; Humans; Probenecid; Uric Acid; Urine | 1954 |
The conversion of uric acid to allantoin in the normal and gouty human.
Topics: Allantoin; Gout; Humans; Hydantoins; Uric Acid | 1954 |
Failure of folic acid to affect uric acid metabolism in a case of gout.
Topics: Folic Acid; Gout; Humans; Uric Acid | 1955 |
[The metabolic problem of gout].
Topics: Biochemical Phenomena; Gout; Humans; Uric Acid | 1954 |
Non-keratin uric acid determinations in gout.
Topics: Gout; Humans; Keratins; Uric Acid; Urologic Diseases | 1955 |
Uricolysis in normal and gouty individuals.
Topics: Aged; Gout; Humans; Uric Acid | 1955 |
[Renal elimination of uric acid in gout patients with crystalluria or uric calculi].
Topics: Calculi; Gout; Humans; Renal Elimination; Uric Acid; Urinary Calculi; Urinary Tract; Urine; Urologic | 1955 |
Heredity in gout and hyperuricemia.
Topics: Blood; Gout; Heredity; Humans; Hyperuricemia; Uric Acid | 1955 |
[Crystalluria, uric lithiasis and gout; physiopathological study].
Topics: Calculi; Crystallization; Gout; Humans; Lithiasis; Uric Acid; Urine | 1955 |
Effect of a phenylbutazone analog (4-[phenylthioethyl]-1, 2-diphenyl 3, 5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects; evaluation as uricosuric agent.
Topics: Biphenyl Compounds; Gout; Humans; Kidney; Phenylbutazone; Pyrazoles; Uric Acid; Uricosuric Agents | 1956 |
[Effects of metacortandracin on clearance of urates].
Topics: Gout; Humans; Prednisone; Steroids; Uric Acid | 1956 |
[Studies on gout].
Topics: Aged; Gout; Humans; Uric Acid | 1956 |
[Studies on gout].
Topics: Aged; Gout; Humans; Uric Acid | 1956 |
[Studies on gout].
Topics: Aged; Gout; Humans; Uric Acid | 1956 |
[Studies on gout].
Topics: Aged; Gout; Humans; Uric Acid | 1956 |
Preliminary observation on the serum glutamic oxalacetic transaminase levels in gout and polycythemia vera.
Topics: Gout; Humans; Polycythemia Vera; Transaminases; Uric Acid | 1957 |
[Uric acid-eliminating drugs in gout].
Topics: Biological Transport; Gout; Humans; Uric Acid | 1957 |
Renal function in gout; with a commentary on the renal regulation of urate excretion, and the role of the kidney in the pathogenesis of gout.
Topics: Gout; Humans; Kidney; Uric Acid | 1957 |
Overproduction of uric acid as the cause of hyperuricemia in primary gout.
Topics: Gout; Humans; Hyperuricemia; Uric Acid | 1957 |
Uric acid and gout.
Topics: Gout; Humans; Uric Acid | 1956 |
[Hepatic polycordia, hyperuricemia and gout].
Topics: Child; Gout; Humans; Infant; Liver Diseases; Uric Acid | 1957 |
GOUT.
Topics: Body Fluids; Gout; Humans; Uric Acid; Urologic Diseases | 1958 |
[Origin of hyperuricemia and urate deposition in tissues due to alloxan action; studies in pigeons and ducks].
Topics: Alloxan; Animals; Columbidae; Ducks; Gout; Hyperuricemia; Uric Acid | 1957 |
Renal regulation of uric acid excretion in normal and gouty man; modification by uricosuric agents.
Topics: Biological Transport; Body Fluids; Gout; Humans; Kidney; Male; Uric Acid; Uricosuric Agents | 1958 |
Atypical manifestations of gout.
Topics: Female; Gout; Humans; Uric Acid | 1958 |
On the mechanism of overproduction of uric acid in patients with primary gout.
Topics: Gout; Humans; Hyperuricemia; Uric Acid | 1958 |
[Diuresis in gout: effects of Evian therapy on uric acid clearance].
Topics: Diuresis; Gout; Humans; Kidney; Kinetics; Mineral Waters; Uric Acid | 1958 |
Gout and metabolism.
Topics: Aged; Gout; Humans; Uric Acid | 1958 |
Normal glycine-C14-incorporation into uric acid in primary gout.
Topics: Glycine; Gout; Humans; Hyperuricemia; Uric Acid | 1958 |
Failure to detect consistent overincorporation of glycine-1-C14 into uric acid in primary gout.
Topics: Glycine; Gout; Humans; Hyperuricemia; Uric Acid | 1958 |
[Note on uraturia in gout patients during benemid therapy].
Topics: Body Fluids; Gout; Probenecid; Uric Acid | 1958 |
Chlorothiazide (diuril) as a hyperuricaci'emic agent.
Topics: Acetazolamide; Chlorothiazide; Gout; Uric Acid | 1958 |
The diagnosis of gout; significance of an elevated serum uric acid value.
Topics: Gout; Humans; Uric Acid | 1958 |
[Incorporation of C14 formate in urinary uric acid in subjects of gout].
Topics: Formates; Gout; Humans; Uric Acid | 1958 |
Incorporation of glycine-1-C14, glycine-2-C14 and glycine-N15 into uric acid in normal and gouty subjects.
Topics: Glycine; Gout; Humans; Uric Acid | 1958 |
Studies in sialolithiasis. II. Uric acid calculus of the parotid gland; report of a case.
Topics: Calculi; Gout; Humans; Medical Records; Parotid Gland; Salivary Gland Calculi; Uric Acid | 1958 |
Atypical gout and hyperuricemia.
Topics: Gout; Humans; Hyperuricemia; Uric Acid | 1959 |
[New data on the metabolism of gout].
Topics: Aged; Gout; Humans; Uric Acid | 1959 |
Dissolution of renal uric acid stones by oral alkalinization and large fluid intake in a patient suffering from gout.
Topics: Calculi; Gout; Humans; Kidney; Kidney Calculi; Solubility; Uric Acid | 1959 |
[Hyperuricemia in the entero-arthrotic syndrome and in the etiology of colitis].
Topics: Colitis; Gout; Humans; Hyperuricemia; Joint Diseases; Osteoarthritis; Syndrome; Uric Acid | 1961 |
Hyperuricemia and acute gouty arthritis precipitated by thiazide derivatives.
Topics: Antihypertensive Agents; Arthritis, Gouty; Chlorothiazide; Gout; Humans; Hyperuricemia; Uric Acid | 1961 |
[The problem of uricolysis: clinico-experimental studies, results of the same and possible new method for the treatment of certain aspects of gout].
Topics: Gout; Humans; Uric Acid | 1960 |
[Theoretical concepts and practical applications of liver catalase in the treatment of chronic gout].
Topics: Arthritis, Gouty; Catalase; Chronic Disease; Gout; Liver; Uric Acid | 1961 |
Gout and serum cholesterol.
Topics: Cholesterol; Gout; Humans; Uric Acid | 1960 |
Gout and the serum uric acid in diabetes mellitus.
Topics: Diabetes Complications; Diabetes Mellitus; Gout; Humans; Uric Acid | 1960 |
Chlorothiazide-induced hyperuricemia: report of two cases.
Topics: Chlorothiazide; Gout; Humans; Hyperuricemia; Uric Acid | 1960 |
Uric acid production in gout.
Topics: Aged; Gout; Humans; Uric Acid | 1961 |
[Effects of sulfinpyrazone on uricemia and excretion of uric acid in 50 gouty hyperuricemic patients during diuretic thermal treatment. Comparison of its action in simple gout patients and in tophaceous gout patients].
Topics: Biological Transport; Body Fluids; Diuretics; Gout; Humans; Hyperuricemia; Phenylbutazone; Sulfinpyr | 1961 |
Identification of urate crystals in gouty synovial fluid.
Topics: Gout; Humans; Synovial Fluid; Uric Acid | 1961 |
[Considerations on the pathogenesis of hyperuricemia in the gout patient].
Topics: Gout; Humans; Hyperuricemia; Uric Acid | 1961 |
On the dual etiology of hyperuricemia in primary gout.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Uric Acid | 1960 |
Suppression of uric acid synthesis in the gouty human by the use of 6-diazo-5-oxo-L-norleucine.
Topics: Diazooxonorleucine; Gout; Humans; Leucine; Uric Acid | 1960 |
Uricosuric agents in the treatment of gout.
Topics: Gout; Uric Acid; Uricosuric Agents | 1960 |
[A case of combined lipoid- and uric acid gout].
Topics: Gout; Humans; Lipid Metabolism; Lipids; Medical Records; Nucleoproteins; Uric Acid | 1959 |
[The renal regulation of urate excretion and its relationship to the etiology of gout].
Topics: Gout; Humans; Kidney; Uric Acid | 1962 |
Intramolecular distribution of uric acid-N15 after administration of glycine-N15 and ammonium-N15 chloride to goury and non-goury subjects.
Topics: Ammonia; Ammonium Chloride; Glycine; Gout; Humans; Uric Acid | 1962 |
[Hyperuricemia in Filipinos].
Topics: Gout; Humans; Hyperuricemia; Uric Acid | 1961 |
The effect of colchicine on purine metabolism in gout.
Topics: Biochemical Phenomena; Colchicine; Gout; Humans; Purines; Uric Acid | 1962 |
Long term uricosuric therapy in gout.
Topics: Gout; Phenylbutazone; Probenecid; Salicylates; Uric Acid; Zoxazolamine | 1962 |
[From uric lithiasis to gout].
Topics: Gout; Humans; Lithiasis; Medical Records; Uric Acid | 1960 |
Diagnosis of gouty arthritis. 18 months' experience with a pathognomonic test.
Topics: Arthritis, Gouty; Gout; Humans; Synovial Fluid; Uric Acid | 1963 |
Crystal-induced inflammation; syndromes of gout and pseudogout.
Topics: Chondrocalcinosis; Gout; Humans; Inflammation; Syndrome; Synovitis; Uric Acid | 1963 |
X-ray diffraction studies of the tophaceous deposits in gout.
Topics: Gout; Humans; Uric Acid; X-Ray Diffraction | 1963 |
Gout and hyperuricemia after adrenalectomy for hypertension.
Topics: Adrenalectomy; Gout; Humans; Hypertension; Hyperuricemia; Uric Acid | 1963 |
[Uricosuria therapy of chronic gout].
Topics: Arthritis; Chronic Disease; Gout; Humans; Probenecid; Uric Acid; Urologic Diseases | 1963 |
[The use of uricosuric agents].
Topics: Gout; Humans; Probenecid; Uric Acid; Uricosuric Agents | 1963 |
[The treatment of gout crises in patients with renal insufficiency].
Topics: Colchicine; Gout; Humans; Kidney Diseases; Phenylbutazone; Renal Insufficiency; Salicylates; Uric Ac | 1963 |
Current concepts of gout and its treatment.
Topics: Gout; Humans; Uric Acid | 1963 |
Arthritis after intrasynovial injection of sodium urate crystals.
Topics: Arthritis; Gout; Humans; Injections; Uric Acid | 1962 |
[The gouty kidney].
Topics: Gout; Humans; Kidney; Kidney Diseases; Uric Acid; Urinary Calculi | 1962 |
Biochemistry of uric acid and its relation to gout.
Topics: Gout; Humans; Uric Acid | 1963 |
Biochemistry of uric acid and its relation to gout.
Topics: Gout; Humans; Uric Acid | 1963 |
Biochemistry of uric acid and its relation to gout.
Topics: Gout; Humans; Uric Acid | 1963 |
The relationship between gout and the kidney.
Topics: Gout; Humans; Kidney; Kidney Diseases; Uric Acid | 1963 |
Renal function in gout. II. Effect of uric acid loading on renal excretion of uric acid.
Topics: Gout; Humans; Kidney Function Tests; Renal Elimination; Uric Acid | 1962 |
Significance of urate crystals in synovial fluids.
Topics: Gout; Humans; Synovial Fluid; Uric Acid | 1963 |
The effect of dietary fat on drug-induced uricosuria in gout.
Topics: Diet; Dietary Fats; Fats; Gout; Humans; Nutrition Assessment; Nutritional Status; Research; Uric Aci | 1962 |
[1st results of D10-1C in the treatment of gout].
Topics: Catalase; Gout; Humans; Uric Acid | 1963 |
[The treatment of gout].
Topics: Colchicine; Diet; Diet Therapy; Gout; Humans; Uric Acid | 1963 |
[Biological supervision of the gout patient treated with uric acid eliminators with the aid of a simple test: the mean clearance of urea and uric acid].
Topics: Gout; Humans; Kidney Function Tests; Kinetics; Urea; Uric Acid | 1961 |
[Preliminary note on the effect of a hepatocatalase on gout and hyperuricemia. (Apropos of 40 cases)].
Topics: Catalase; Gout; Humans; Hyperuricemia; Liver Extracts; Oxidoreductases; Uric Acid | 1962 |
[2-PHENYL-5-BROMO-1,3-INDANEDIONE IN THE URICOSURIC TREATMENT OF GOUT AND URIC ACID DIATHESIS].
Topics: Disease Susceptibility; Gout; Humans; Indans; Indenes; Phenindione; Uric Acid; Uricosuric Agents | 1963 |
RENAL LESIONS RESULTING FROM INDUCED HYPERURICEMIA IN ANIMALS.
Topics: Animals; Blood; Dogs; Gout; Hyperuricemia; Injections; Injections, Intravenous; Kidney; Kidney Disea | 1963 |
RENAL EXCRETION OF URATE IN PATIENTS WITH GOUT.
Topics: Blood; Gout; Humans; Kidney Function Tests; Metabolism; Renal Elimination; RNA; Uric Acid; Urine | 1964 |
[EFFECT ON URICEMIA, URICOSURIA AND URIC ACID CLEARANCE OF THE ADMINISTRATION OF 2-ACETYLAMINO-5-CHLOROBENZOXAZOLE TO 47 GOUTY PATIENTS].
Topics: Blood; Body Fluids; Gout; Humans; Oxazoles; Uric Acid; Uricosuric Agents; Urine; Urologic Diseases; | 1963 |
[APROPOS OF THE REPORT: ACETYLZOXAZOLAMINE IN THE TREATMENT OF GOUT: INITIAL RESULTS].
Topics: Blood; Geriatrics; Gout; Uric Acid; Uricosuric Agents; Zoxazolamine | 1963 |
GOUT AMONG FILIPINOS.
Topics: Asian People; Colorimetry; Epidemiology; Gout; Humans; Philippines; Uric Acid; Uricosuric Agents | 1963 |
[GOUT AND ARTERIOSCLEROSIS].
Topics: Arteriosclerosis; Biometry; Gout; Humans; Hypercholesterolemia; Statistics as Topic; Uric Acid | 1963 |
ANKYLOSING SPONDYLITIS, HYPERURICEMIA, AND ANOMALIES OF THE LUMBOSACRAL JUNCTION. A FAMILY STUDY.
Topics: Blood Chemical Analysis; Genetics, Medical; Gout; Hyperuricemia; Lumbosacral Region; Research; Spine | 1963 |
CHANGES IN SERUM AND URINARY URIC ACID WITH THE DEVELOPMENT OF SYMPTOMATIC GOUT.
Topics: Blood Chemical Analysis; Body Fluids; Gout; Humans; Uric Acid; Urine | 1963 |
BLOOD COAGULATION AND PLATELET ECONOMY IN SUBJECTS WITH PRIMARY GOUT.
Topics: Arteriosclerosis; Arthritis, Gouty; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Gou | 1963 |
[THE ACUTE INFLAMMATION OF GOUT].
Topics: Colchicine; Gout; Humans; Inflammation; Pathology; Uric Acid; Uricosuric Agents | 1963 |
[THE LIPIDS AND RHEUMATIC DISEASES. PRELIMINARY NOTE].
Topics: Arthritis, Rheumatoid; Cholesterol; Gout; Humans; Lipid Metabolism; Lipids; Obesity; Phospholipids; | 1963 |
A SURGERY OF RHEUMATISM IN A RURAL NEW ZEALAND MAORI COMMUNITY.
Topics: Adolescent; Arthritis; Arthritis, Rheumatoid; Blood; Geriatrics; Gout; Humans; Joint Diseases; Latex | 1963 |
AN ABNORMALITY OF GLUTAMINE METABOLISM IN PRIMARY GOUT.
Topics: Ammonia; Creatine; Creatinine; Glutamine; Glycine; Gout; Humans; Hyperuricemia; Kidney; Metabolism; | 1963 |
[TREATMENT OF GOUT WITH URACIL-6-CARBOXYLIC ACID AND ITS DERIVATIVES].
Topics: Blood; Body Fluids; Carboxylic Acids; Gout; Humans; Orotic Acid; Pharmacology; Toxicology; Uracil; U | 1963 |
[HYPOURICEMIC ACTION OF COLCHICINE. IMPORTANCE OF URICEMIA IN GOUT].
Topics: Acid-Base Imbalance; Blood; Colchicine; Gout; Purine-Pyrimidine Metabolism, Inborn Errors; Uric Acid | 1963 |
URIC ACID CALCULI.
Topics: Blood Chemical Analysis; Geriatrics; Gout; Humans; Infant; Ureteral Calculi; Uric Acid; Urinary Cath | 1963 |
MEDICAL GRAND ROUNDS FROM THE UNIVERSITY OF ALABAMA MEDICAL CENTER.
Topics: Arthritis; Colchicine; Gout; Humans; Phenylbutazone; Probenecid; Teaching Rounds; Uric Acid | 1964 |
[IS GRISEOFULVIN A URICO-ELIMINATOR?].
Topics: Gout; Griseofulvin; Metabolism; Uric Acid | 1963 |
[TREATMENT OF URIC LITHIASIS].
Topics: Bicarbonates; Calcium Metabolism Disorders; Citrates; Diet; Diet Therapy; Diuresis; Gout; Humans; Hy | 1963 |
ASSOCIATION OF HYPERURICAEMIA AND GOUT WITH HYPERPARATHYROIDISM.
Topics: Adenoma; Blood Chemical Analysis; Diagnosis; Gout; Humans; Hyperparathyroidism; Hyperuricemia; Nephr | 1964 |
METABOLIC MALADIES IN NEW ZEALAND MAORIS.
Topics: Adolescent; Anthropometry; Blood Chemical Analysis; Cholesterol; Coronary Disease; Epidemiology; Eth | 1964 |
POTENTIATION OF ANTICOAGULANTS CAUSED BY PYRAZOLE COMPOUNDS.
Topics: Anticoagulants; Blood Chemical Analysis; Chemical Phenomena; Chemistry; Coronary Disease; Gout; Hema | 1964 |
MEDICAL GRAND ROUNDS OF THE METHODIST HOSPITAL HOUSTON, TEXAS. SUBJECT: GOUTY NEPHRITIS.
Topics: Acetazolamide; Anuria; Blood Chemical Analysis; Body Fluids; Gout; Nephritis; Nephrosclerosis; Patho | 1964 |
GOUT IN INFANCY MANIFESTED BY RENAL FAILURE.
Topics: Acute Kidney Injury; Adolescent; Blood Cell Count; Child; Citrates; Genetics, Medical; Glycine; Gout | 1964 |
[CASE OF CHRONIC TOPHOCEOUS GOUT].
Topics: Arthritis, Gouty; Aspirin; Diet; Diet Therapy; Gout; Humans; Phenylbutazone; Prednisolone; Sulfinpyr | 1963 |
"STUDIES ON THE NATURE OF GOUTY TOPHI" BY MAX FREUDWEILER, 1899. (AN INFLAMMATORY RESPONSE TO INJECTED SODIUM URATE, 1899). AN ABRIDGED TRANSLATION, WITH COMMENTS.
Topics: Acid-Base Equilibrium; Animals; Calcium; Calcium, Dietary; Gout; History, 19th Century; History, 20t | 1964 |
THE EPIDEMIOLOGY OF RHEUMATIC DISEASES.
Topics: Arthritis; Arthritis, Rheumatoid; Blood; Colitis; Colitis, Ulcerative; Crohn Disease; Enteritis; Epi | 1964 |
JOINT COMPLAINTS IN POLYCYTHAEMIA VERA.
Topics: Arthritis; Arthritis, Rheumatoid; Blood; Blood Cell Count; Gout; Hemagglutination; Humans; Joints; L | 1964 |
GOUT, HYPERURICAEMIA AND CARBOHYDRATE METABOLISM.
Topics: Carbohydrate Metabolism; Cholesterol; Glucose Tolerance Test; Gout; Humans; Hypertension; Hyperurice | 1964 |
HYPERTRIGLYCERIDEMIA IN GOUT.
Topics: Arteriosclerosis; Black People; Blood Chemical Analysis; Cholesterol; Genetics, Medical; Geriatrics; | 1964 |
[THE KIDNEY IN CHRONIC LEAD POISONING].
Topics: Edetic Acid; Electrons; Gout; Humans; Hypertension; Kidney; Kidney Diseases; Kidney Function Tests; | 1964 |
CLINICAL TRIAL OF TRIAMTERENE IN HYPERTENSIVE PATIENTS.
Topics: Biomedical Research; Blood Chemical Analysis; Blood Pressure Determination; Diuretics; Gout; Hyperal | 1964 |
A FAMILIAL DISORDER OF URIC ACID METABOLISM AND CENTRAL NERVOUS SYSTEM FUNCTION.
Topics: Athetosis; Biomedical Research; Blood Chemical Analysis; Central Nervous System Diseases; Cerebral P | 1964 |
RECURRENT ACUTE (?GOUTY) ARTHRITIS IN CHRONIC RENAL FAILURE TREATED WITH PERIODIC HEMODIALYSIS.
Topics: Alkaline Phosphatase; Arthritis; Blood Chemical Analysis; Calcinosis; Calcium; Colchicine; Fingers; | 1964 |
[OUR EXPERIENCES WITH THE TREATMENT OF GOUT].
Topics: Blood Chemical Analysis; Body Fluids; Colchicine; Dietary Carbohydrates; Dietary Fats; Dietary Prote | 1964 |
[GOUT IN WOMEN].
Topics: Blood Chemical Analysis; Gout; Humans; Kidney Calculi; Kidney Diseases; Uric Acid; Women | 1964 |
[ON CASES OF GOUT AND FAMILIAL HYPERURICEMIA].
Topics: Blood; Genetics, Medical; Gout; Humans; Hyperuricemia; Pathology; Uric Acid | 1964 |
[URIC ACID METABOLISM AND SALIDIURETICS].
Topics: Aged; Chlorothiazide; Chlorthalidone; Diagnosis; Gout; Humans; Hydrochlorothiazide; Metabolism; Toxi | 1964 |
[ACUTE RECURRENT OLIGOARTICULAR GOUT. (STIMULATION OF RHEUMATOID ARTHRITIS)].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Classification; Clinica | 1964 |
HYPERURICEMIA, GOUT AND CEREBROVASCULAR DISEASE.
Topics: Black People; Blood Chemical Analysis; Cerebrovascular Disorders; Cholesterol; Geriatrics; Gout; Hum | 1964 |
[ON THE EFFECT OF ANTURAN AS A TREATMENT OF GOUT].
Topics: Biomedical Research; Geriatrics; Gout; Sulfinpyrazone; Toxicology; Uric Acid; Uricosuric Agents | 1964 |
MEASUREMENT OF SERUM URIC ACID IN GREAT BRITAIN IN 1963.
Topics: Blood Chemical Analysis; Colorimetry; Female; Freeze Drying; Gout; Humans; Menopause; Sex; Spectroph | 1964 |
POLYTHIAZIDE AND RESERPINE COMBINED IN THE OFFICE TREATMENT OF HYPERTENSION.
Topics: Antihypertensive Agents; Benzothiadiazines; Biomedical Research; Blood; Diuretics; Gastroenteritis; | 1964 |
[A STUDY ON THE INHERITABLE FACTORS OF GOUT AND HYPERURICEMIA].
Topics: Blood; Genetics, Medical; Gout; Humans; Hyperuricemia; Japan; Pathology; Physiology; Statistics as T | 1964 |
[ANEMIA AS A CONTRIBUTORY CAUSE OF URATIC ARTHRITIS].
Topics: Anemia; Arthritis; Blood Transfusion; Gout; Humans; Uric Acid | 1964 |
IN DEFENSE OF GOUT: THE IMPORTANCE OF URIC ACID IN DIAGNOSIS.
Topics: Black People; Blood Chemical Analysis; Colchicine; Diagnosis; Geriatrics; Gout; Humans; Synovial Flu | 1964 |
[LIVER CATALASE IN THE TREATMENT OF GOUT AND OTHER RHEUMATIC DISEASES].
Topics: Biomedical Research; Catalase; Cholesterol; Dermatomyositis; Drug Therapy; Gout; Liver; Porphyrias; | 1964 |
THE EFFECT OF GLUCOSE LOADS ON RENAL URIC ACID EXCRETION IN DIABETIC PATIENTS.
Topics: Blood Glucose; Carbohydrate Metabolism; Creatine; Creatinine; Diabetes Mellitus; Glucose; Gout; Huma | 1964 |
DIABETES MELLITUS IN PATIENTS WITH GOUTY ARTHRITIS.
Topics: Arthritis; Arthritis, Gouty; Blood; Diabetes Mellitus; Drug Therapy; Gout; Humans; Hyperglycemia; Ur | 1964 |
BLOOD LIPID AND URIC ACID INTERRELATIONSHIPS.
Topics: Biomedical Research; Blood; Glycerides; Gout; Humans; Hypercholesterolemia; Hyperlipidemias; Lipid M | 1964 |
[SECONDARY ASPECIFIC EFFECTS OF BENZOTHIAZINIC DIURETICS].
Topics: Agranulocytosis; Amylases; Blood Glucose; Chlorothiazide; Diabetes Mellitus; Diuretics; Drug Eruptio | 1964 |
ARTICULAR AND FIBROCARTILAGE CALCIFICATION IN HYPERPARATHYROIDISM: ASSOCIATED HYPERURICEMIA.
Topics: Acetabulum; Blood; Calcinosis; Cartilage; Cartilage, Articular; Fibrocartilage; Gout; Humans; Hyperp | 1964 |
NEW PROSPECTS IN THE TREATMENT OF GOUTY DYSPURINIA.
Topics: Azaserine; Blood; Drug Therapy; Enzyme Inhibitors; Gout; Leucine; Metabolism; Orotic Acid; Oxidoredu | 1964 |
THE TREATMENT OF GOUT.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Colchicine; Diet; Diet Therapy; Dr | 1964 |
SOLUBILITY OF SODIUM URATE IN THE PRESENCE OF CHONDROITIN-4-SULPHATE.
Topics: Chondroitin; Chondroitin Sulfates; Connective Tissue; Dialysis; Gout; Humans; Ions; Renal Dialysis; | 1964 |
THE PENDULUM OF PROGRESS IN GOUT: FROM CRYSTALS TO HYPERURICEMIA AND BACK.
Topics: Blood; Chemical Precipitation; Crystallization; Exudates and Transudates; Geriatrics; Gout; Humans; | 1964 |
GOUT.
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Colchicine; Diagnosis, Differential; Diet; Diet | 1964 |
[ON EXPERIMENTAL GOUT].
Topics: Animals; Arthritis, Experimental; Gout; Humans; Meat; Poultry; Research; Uric Acid | 1964 |
[CORTICOSTEROID THERAPY OF GOUT].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Drug Therapy; Gout; Humans; Indoles; Indometha | 1964 |
EFFECT OF SULFINPYRAZONE ON SERUM URIC ACID IN GOUT. A LONG-TERM STUDY.
Topics: Adolescent; Aging; Blood; Drug Therapy; Geriatrics; Gout; Longitudinal Studies; Metabolism; Phenylbu | 1964 |
4-HYDROXYPYRAZOLO (3,4-D) PYRIMIDINE (HPP) IN THE TREATMENT OF GOUT: PRELIMINARY OBSERVATIONS.
Topics: Blood; Colchicine; Diet; Diet Therapy; Drug Therapy; Enzyme Inhibitors; Geriatrics; Gout; Humans; Pr | 1964 |
[CLINICAL CONSIDERATIONS ON THE RELATIONS THAT SEEM TO EXIST BETWEEN CERVICAL PAINS AND HYPERURICEMIA].
Topics: Blood; Cervical Vertebrae; Gout; Humans; Hyperuricemia; Neck Pain; Neuralgia; Spinal Diseases; Torti | 1964 |
[SECONDARY GOUT IN CHRONIC NEPHROPATHIES].
Topics: Amyloidosis; Blood; Colchicine; Drug Therapy; Gout; Humans; Hypertension; Hypertension, Renal; Kidne | 1965 |
SIGNIFICANCE OF THE RENAL CLEARANCE OF URIC ACID IN NORMAL AND GOUTY MAN.
Topics: Animals; Dogs; Fluids and Secretions; Glomerular Filtration Rate; Gout; Humans; Kidney Function Test | 1964 |
OBSERVATIONS ON THE NATURAL HISTORY OF HYPERURICEMIA AND GOUT. I. AN EIGHTEEN YEAR FOLLOW-UP OF NINETEEN GOUTY FAMILIES.
Topics: Adolescent; Blood; Cerebrovascular Disorders; Colorimetry; Coronary Disease; Esophageal and Gastric | 1964 |
EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT.
Topics: Allopurinol; Arthritis; Blood; Bone Marrow Diseases; Drug Therapy; Enzyme Inhibitors; Fluids and Sec | 1964 |
HYPERURICAEMIA IN HYPERTENSION.
Topics: Blood; Body Weight; Cholesterol; Creatine; Creatinine; Dehydroepiandrosterone; Fluids and Secretions | 1965 |
STUDIES ON HYPERURICEMIA. II. A RECONSIDERATION OF THE DISTRIBUTION OF SERUM URIC ACID VALUES IN THE FAMILIES OF SMYTH, COTTERMAN, AND FREYBERG.
Topics: Blood; Genetics, Medical; Genetics, Population; Gout; Humans; Hyperuricemia; Metabolic Diseases; Mol | 1965 |
TREATMENT OF CONGESTIVE HEART FAILURE WITH TRIAMTERENE.
Topics: Blood; Diuresis; Diuretics; Drug Therapy; Gout; Heart Failure; Humans; Hydrochlorothiazide; Potassiu | 1965 |
TOXICITY OF DIURETICS.
Topics: Blood; Diuretics; Gastrointestinal Diseases; Gout; Hematologic Diseases; Humans; Hyperglycemia; Hype | 1965 |
URIC ACID IN HUMAN PLASMA. I. INVESTIGATIONS ON THE PRESENCE OF PURINES IN HUMAN BLOOD.
Topics: Blood; Colorimetry; Gout; Humans; Hypoxanthines; Leukemia; Liver Cirrhosis; Oxidoreductases; Purines | 1965 |
URIC ACID IN HUMAN PLASMA. II. INVESTIGATIONS ON THE POSSIBLE PRESENCE OF URIC ACID COVALENTLY LINKED TO PLASMA MACROMOLECULES.
Topics: Arthritis; Arthritis, Rheumatoid; Blood; Chromatography; Chromatography, Gel; Female; Gout; Humans; | 1965 |
URIC ACID, CALCIUM AND PHOSPHORUS CLEARANCES IN NORMAL SUBJECTS ON A LOW CALCIUM, LOW PHOSPHORUS DIET: URIC ACID, CALCIUM AND PHOSPHORUS CLEARANCES AFTER CLACIUM INFUSION IN NORMAL AND GOUTY PATIENTS.
Topics: Absorption; Biological Transport; Calcium; Calcium, Dietary; Diet; Fluids and Secretions; Gout; Huma | 1965 |
THE INFLAMMATORY PROCESS IN ACUTE GOUTY ARTHRITIS. I. ACTIVATION OF HAGEMAN FACTOR BY SODIUM URATE CRYSTALS.
Topics: Arthritis; Arthritis, Gouty; Blood Coagulation Factors; Factor XII; Gout; Humans; Inflammation; Phar | 1965 |
PATHOGENIC AND THERAPEUTIC CONSIDERATIONS ON CHRONIC GOUT.
Topics: Arthritis, Gouty; Drug Therapy; Gout; Physiology; Sulfinpyrazone; Toxicology; Uric Acid | 1964 |
URINARY PH IN GOUT.
Topics: Ammonia; Gout; Humans; Hydrogen-Ion Concentration; Kidney Diseases; Periodicity; Phosphorus; Phospho | 1965 |
THE EFFECTIVENESS OF THE XANTHINE OXIDASE INHIBITOR ALLOPURINOL IN THE TREATMENT OF GOUT.
Topics: Allopurinol; Blood Chemical Analysis; Drug Therapy; Enzyme Inhibitors; Gout; Humans; Metabolism; Pur | 1965 |
THE EFFECT OF PRETREATMENT WITH COLCHICINE ON THE INFLAMMATORY RESPONSE TO MICROCRYSTALLINE URATE: A MODEL FOR GOUTY INFLAMMATION.
Topics: Biomedical Research; Blood Chemical Analysis; Colchicine; Dosage Forms; Drug Therapy; Gout; Humans; | 1965 |
SERUM AND URINARY AMINO ACIDS IN NORMOURICEMIC AND HYPERURICEMIC SUBJECTS.
Topics: Amino Acids; Blood; Blood Proteins; Chromatography; Gout; Humans; Kidney Function Tests; Uric Acid; | 1965 |
THE RENAL LESION IN GOUT.
Topics: Blood Chemical Analysis; Gout; Histological Techniques; Humans; Kidney; Kidney Diseases; Nephroscler | 1965 |
EXPERIMENTAL INVESTIGATIONS INTO THE ORIGIN OF GOUTY TOPHI.
Topics: Animals; Gout; History; Humans; Inflammation; Necrosis; Pathology; Poultry; Rabbits; Research; Uric | 1965 |
THE INFLAMMATORY RESPONSE TO INJECTED MICROCRYSTALLINE MONOSODIUM URATE IN NORMAL, HYPERURICEMIC, GOUTY, AND UREMIC SUBJECTS.
Topics: Blood Chemical Analysis; Blood Urea Nitrogen; Erythema; Geriatrics; Gout; Humans; Hyperuricemia; Inf | 1965 |
SOME HAZARDS OF TOTAL FASTS IN THE CONTROL OF OBESITY AND DIABETES AND THEIR PREVENTION.
Topics: Anemia; Atrial Flutter; Blood; Diabetes Mellitus; Diet, Reducing; Fasting; Fatigue; Gout; Humans; Ne | 1964 |
[GOUT, DIAGNOSIS AND TREATMENT].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Colchicine; Diagnosis; Drug Therapy; Gout; Hum | 1965 |
ASSOCIATION OF HYPERURICEMIA AND POLYCYSTIC KIDNEY DISEASE.
Topics: Genetics, Medical; Gout; Humans; Hyperuricemia; Kidney; Polycystic Kidney Diseases; Uric Acid | 1965 |
CRYSTAL DEPOSITION DISEASES: SODIUM URATE (GOUT) AND CALCIUM PYROPHOSPHATE (CHONDROCALCINOSIS, PSEUDOGOUT).
Topics: Calcinosis; Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Crystallography; Diagnosis | 1965 |
[ON THE PATHOGENESIS AND THERAPY OF GOUT].
Topics: Drug Therapy; Gout; Humans; Metabolism; Uric Acid; Uricosuric Agents | 1965 |
SYNOVIAL FLUID IN GOUT.
Topics: Blood; Cartilage; Cartilage, Articular; Diagnosis, Differential; Gout; Humans; Hyperparathyroidism; | 1965 |
[ON URIC ACID CLEARANCE].
Topics: Gout; Humans; Kidney Function Tests; Kinetics; Uric Acid | 1964 |
URATE DIURETIC THERAPY IN CHRONIC GOUT; A COMPARATIVE STUDY OF PROBENECID AND SULFINPYRAZONE.
Topics: Arthritis, Gouty; Biomedical Research; Blood; Diuretics; Drug Therapy; Gout; Humans; Kidney Calculi; | 1965 |
THE DISTRIBUTION OF SERUM URIC ACID VALUES IN A POPULATION UNSELECTED AS TO GOUT OR HYPERURICEMIA: TECUMSEH, MICHIGAN 1959-1960.
Topics: Aging; Blood Chemical Analysis; Gout; Humans; Hyperuricemia; Mass Screening; Michigan; Sex; Uric Aci | 1965 |
[HYPERURICEMIA AND GOUT WITH DIURETICS].
Topics: Blood; Diuretics; Gout; Humans; Hyperuricemia; Toxicology; Uric Acid | 1965 |
METHODS OF MEASURING GLOMERULAR-FILTRATION RATE: A COMPARISON OF INULIN, VITAMIN-B 12 AND CREATININE CLEARANCES.
Topics: Cobalt Isotopes; Creatine; Creatinine; Diagnosis; Glomerular Filtration Rate; Gout; Humans; Hyperten | 1965 |
GOUT IN THE ELDERLY. MODERN MANAGEMENT IN HISTORICAL PERSPECTIVE.
Topics: Aged; Colchicine; Diagnosis; Diet; Diet Therapy; Drug Therapy; Geriatrics; Gout; History; Humans; Ph | 1965 |
[THE ROLE OF THE NORMAL KIDNEY AND THE PATHOLOGICAL KIDNEY IN THE GENESIS OF HYPERURICEMIA].
Topics: Blood; Diuresis; Gout; Humans; Hyperuricemia; Kidney; Kidney Diseases; Kidney Function Tests; Physio | 1965 |
Gout.
Topics: Blood; Gout; Humans; Uric Acid | 1955 |
Rate of conversion of isotopic glycine to uric acid in the normal and gouty human and how this is affected by vitamin E and folic acid.
Topics: Folic Acid; Glycine; Gout; Humans; Uric Acid; Vitamin E | 1955 |
Inhibition of the uricosuric action of benemid by salicylate.
Topics: Body Fluids; Gout; Probenecid; Salicylates; Uric Acid; Urine | 1955 |
Osteogenesis imperfecta tarda with hyperuricemia and gout; report of three cases.
Topics: Blood; Gout; Humans; Hyperuricemia; Osteogenesis Imperfecta; Uric Acid | 1955 |
The fate of uric acid in the normal and gouty human being.
Topics: Gout; Humans; Uric Acid | 1955 |
[The role of the kidney in hyperuricemia from the study of 390 clearances of uric acid].
Topics: Blood; Gout; Humans; Hyperuricemia; Kidney; Uric Acid | 1955 |
The renal excretion of uric acid in patients with gout and in nongouty subjects.
Topics: Gout; Humans; Kidney Function Tests; Renal Elimination; Uric Acid | 1959 |
The use of uricosuric agents in the management of gout.
Topics: Disease Management; Gout; Uric Acid; Uricosuric Agents | 1962 |
[The role of uric-elimination renal insufficiency in primary gout].
Topics: Gout; Humans; Hyperuricemia; Kidney; Renal Insufficiency; Uric Acid | 1962 |
[Influence of hydrochlorothiazide on the mechanism of excretion of uric acid. Clinico-experimental observations].
Topics: Biological Transport; Body Fluids; Chlorothiazide; Gout; Humans; Hydrochlorothiazide; Leadership; Ur | 1961 |
Uricosuric agents in the management of chronic tophaceous gout with renal impairment.
Topics: Arthritis, Gouty; Chronic Disease; Gout; Humans; Renal Insufficiency; Uric Acid; Uricosuric Agents | 1961 |
[Gout and sweating. The effect of sweating on the metabolism of uric acid in gout patients].
Topics: Gout; Humans; Sweating; Uric Acid | 1960 |
Renal excretion of uric acid in leukemia and gout.
Topics: Aged; Gout; Humans; Leukemia; Renal Elimination; Uric Acid | 1962 |
Gout and hyperuricaemia in rural and urban populations.
Topics: Gout; Humans; Hyperuricemia; Urban Population; Uric Acid | 1962 |
[Avoid purine-rich foods, drink a lot, reduce weight. The most important recipes against hyperuricemia].
Topics: Alcohol Drinking; Diet; Drinking; Exercise; Food; Gout; Humans; Hyperuricemia; Uric Acid; Weight Los | 2003 |
New standards for uric acid excretion and evidence for an inducible transporter.
Topics: Carrier Proteins; Gout; Humans; Hyperuricemia; Male; Reference Values; Uric Acid | 2003 |
[Urate transporter and renal hypouricemia].
Topics: Carrier Proteins; Gout; Humans; Kidney; Kidney Diseases; Mutation; Organic Anion Transporters; Organ | 2003 |
The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years.
Topics: Adult; Chronic Disease; Developing Countries; Gout; Humans; Indonesia; Joints; Malaysia; Male; Polyn | 2003 |
The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Colchici | 2003 |
Questions & answers. What's the difference between gout and pseudogout?
Topics: Age Factors; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Diagnosis, Differential; Fem | 2003 |
Substance P immunoreactive nerve fibres in the domestic chick ankle joint before and after acute urate arthritis.
Topics: Animals; Arthralgia; Arthritis; Chickens; Disease Models, Animal; Down-Regulation; Female; Gout; Imm | 2004 |
Association of biochemical values with morbidity in the elderly: a population-based Swedish study of persons aged 82 or more years.
Topics: Aged; Aged, 80 and over; Biomarkers; Blood Chemical Analysis; Body Mass Index; Cholesterol; Creatine | 2003 |
Diclofenac residues as the cause of vulture population decline in Pakistan.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autopsy; Bird Diseases; Cause of Death; Conservati | 2004 |
Gout.
Topics: Coronary Disease; Fenofibrate; Gout; Humans; Hypolipidemic Agents; Metabolic Syndrome; Risk Factors; | 2004 |
Impressions of gout.
Topics: Gout; Humans; Purines; Social Behavior; Uric Acid | 1950 |
URIC acid metabolism and gout.
Topics: Aged; Gout; Humans; Uric Acid | 1950 |
Some recent advances in the study of uric acid metabolism and gout.
Topics: Gout; Humans; Uric Acid | 1951 |
Some observations on the blood uric acid levels in gout.
Topics: Blood; Gout; Humans; Uric Acid | 1951 |
A study of labeled uric acid in gouty and non-gouty subjects.
Topics: Gout; Humans; Uric Acid | 1950 |
The effect of benemid (P-[DI-N-propylsulfamyl]-benzoic acid) on uric acid metabolism in one normal and one gouty subject.
Topics: Benzoic Acid; Gout; Humans; Probenecid; Uric Acid | 1951 |
Ultrafiltration of plasma uric acid.
Topics: Gout; Humans; Plasma; Ultrafiltration; Uric Acid | 1951 |
Gout; observations on the effects of drugs on plasma uric acid and urinary uric acid.
Topics: Gout; Humans; Uric Acid | 1951 |
Benemid (p-di-n-propylsulfamyl)-benzoic acid) as uricosuric agent in chronic gouty arthritis.
Topics: Arthritis, Gouty; Benzoic Acid; Body Fluids; Chronic Disease; Gout; Probenecid; Uric Acid; Uricosuri | 1951 |
The clinical and metabolic effects of benemid in patients with gout.
Topics: Body Fluids; Gout; Probenecid; Uric Acid | 1951 |
Incorporation of glycine nitrogen into uric acid in normal and gouty man.
Topics: Glycine; Gout; Humans; Male; Nitrogen; Uric Acid | 1952 |
Experimental observations in acute and chronic gout.
Topics: Arthritis, Gouty; Chronic Disease; Gout; Humans; Uric Acid | 1951 |
[Gout-hyperuricacidemia; their therapy].
Topics: Aged; Gout; Humans; Piperazines; Uric Acid | 1952 |
Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on urate clearance and other discrete renal functions in gouty subjects.
Topics: Benzoic Acid; Gout; Humans; Kinetics; Probenecid; Uric Acid | 1952 |
Uric acid and diet--insights into the epidemic of cardiovascular disease.
Topics: Dairy Products; Diet; Dietary Proteins; Female; Gout; History, 17th Century; History, 18th Century; | 2004 |
Synovial fluid from an African spur-thighed tortoise (Geochelone sulcata).
Topics: Animals; Crystallization; Fatal Outcome; Gout; Kidney; Liver; Male; Synovial Fluid; Turtles; Uric Ac | 2004 |
Drinking alcohol and gout.
Topics: Alcohol Drinking; Alcoholic Beverages; Gout; Humans; Risk Factors; Uric Acid | 2004 |
On call. I was recently diagnosed with gout. I'm feeling well with medication, but my doctor want me to take drugs for my cholesterol and blood pressure because gout will raise my risk of heart attack. I don't want to take more pills. What do you think?
Topics: Anticholesteremic Agents; Antihypertensive Agents; Attitude to Health; Gout; Humans; Uric Acid | 2004 |
Purine-rich foods and the risk of gout in men.
Topics: Diet; Follow-Up Studies; Gout; Humans; Male; Sensitivity and Specificity; Synovial Fluid; Uric Acid | 2004 |
Gout. Soothing a red-hot joint.
Topics: Benzothiadiazines; Diuretics; Female; Gout; Humans; Sodium Chloride Symporter Inhibitors; Uric Acid | 2004 |
[Insulin resistance syndrome in patients with gout and its influence on formation of clinical characteristics of the disease].
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Gout; Humans; | 2004 |
A (very) short history of diets for gout.
Topics: Gout; History, 20th Century; History, Ancient; History, Medieval; Hordeum; Humans; Social Class; Uri | 2004 |
Gout and alcohol.
Topics: Alcohol Drinking; Diet; Female; Gout; Humans; Risk Factors; Uric Acid | 2004 |
[Detection of sodium monourate crystals in biopsies of gastric mucosa in patients with gout].
Topics: Adult; Aged; Biopsy; Endoscopy, Digestive System; Gastric Mucosa; Gout; Humans; Microscopy, Polariza | 2004 |
Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis.
Topics: Animals; Complement C6; Complement Membrane Attack Complex; Crystallization; Gout; Interleukin-8; Kn | 2004 |
[Diagnosis at a glance: painful awakening].
Topics: Alcohol Drinking; Arthralgia; Gout; Humans; Male; Metabolic Clearance Rate; Middle Aged; Toe Joint; | 2004 |
The metabolism of uric acid in the normal and gouty human studied with the aid of isotopic uric acid.
Topics: Gout; Research; Uric Acid | 1949 |
Increased renal excretion of urate in young patients with gout.
Topics: Gout; Humans; Kidney; Renal Elimination; Urea; Uric Acid | 1950 |
The rôle of glutamine in metabolism, with special regard to the formation of uric acid in gout.
Topics: Blood; Glutamine; Gout; Humans; Uric Acid | 1950 |
The effect of salicylates and adrenocorticotropic hormone upon the miscible pool of uric acid in gout.
Topics: Adrenocorticotropic Hormone; Body Fluids; Gout; Humans; Salicylates; Uric Acid; Urine | 1950 |
Ecology. Circling in on a vulture killer.
Topics: Animals; Animals, Domestic; Anti-Inflammatory Agents, Non-Steroidal; Bird Diseases; Conservation of | 2004 |
[Uric acid, a neglected molecule--the value of imaging].
Topics: Arthritis, Gouty; Diagnosis, Differential; Diagnostic Imaging; Gout; Humans; Hyperuricemia; Joints; | 2004 |
[Gout and its differential diagnosis].
Topics: Arthritis, Gouty; Crystallization; Diagnosis, Differential; Gout; Humans; Joints; Microscopy, Polari | 2004 |
[Rasburicase (Fasturtec)].
Topics: Crystallization; Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; K | 2004 |
Peripheral involvement of the nitric oxide-cGMP pathway in the indomethacin-induced antinociception in rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Chronic Disease; Cyclic GMP; Disease Mod | 2004 |
The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug The | 2004 |
[Diagnosis at a glance? Nodule of the ear].
Topics: Ear Diseases; Ear, External; Gout; Humans; Male; Middle Aged; Uric Acid | 2004 |
Chyle and gout causing acute monoarthritis: some unusual findings.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents; Arthritis; Chyle; Diagnosis, Differential; Exudates a | 2005 |
Determination of uric acid in human saliva by capillary electrophoresis with electrochemical detection: potential application in fast diagnosis of gout.
Topics: Electrochemistry; Electrodes; Electrophoresis, Capillary; Gout; Humans; Hydrogen-Ion Concentration; | 2004 |
My big toe has been extremely painful for some time. I thought it was a bunion, but I've been told I have gout. I thought gout was something only overweight men developed. What is it?
Topics: Allopurinol; Drinking; Gout; Gout Suppressants; Humans; Male; Purines; Toes; Uric Acid | 2005 |
[Xanthine oxidase inhibitory activity and hypouricemia effect of propolis in rats].
Topics: Animals; Anti-Infective Agents; Brazil; Caffeic Acids; China; Coumaric Acids; Disease Models, Animal | 2005 |
Analysis for crystals in synovial fluid: training of the analysts results in high consistency.
Topics: Arthritis; Biomarkers; Calcium Pyrophosphate; Chondrocalcinosis; Clinical Competence; Crystallizatio | 2005 |
Intra-abdominal gout mimicking pelvic abscess.
Topics: Abdomen; Abdominal Pain; Abscess; Adult; Alcoholism; Biopsy, Needle; Contrast Media; Diagnosis, Diff | 2005 |
TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, Differentiation; Base Sequence; Calcium Pyr | 2005 |
Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis.
Topics: Adult; Aged; Calcium Oxalate; Chemical Phenomena; Chemistry, Physical; Disease Susceptibility; Femal | 2005 |
Inflammation and tissue damage in crystal deposition diseases.
Topics: Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Disease Progression; Gout; Humans; Inf | 2005 |
Cervical spine and crystal-associated diseases: imaging findings.
Topics: Adult; Calcinosis; Calcium Pyrophosphate; Cartilage, Articular; Cervical Vertebrae; Child; Chondroca | 2006 |
Gout induced by intoxication of sodium bicarbonate in Korean native broilers.
Topics: Animals; Chickens; Gout; Korea; Poultry Diseases; Sodium Bicarbonate; Uric Acid; Viscera | 2005 |
Unusual imaging manifestations of intraosseous tophaceous gout of the patella.
Topics: Gout; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Patella; Uric Acid | 2005 |
Spontaneous rupture of extensor pollicis longus tendon with tophaceous gout infiltration.
Topics: Aged; Crystallization; Gout; Humans; Male; Rupture, Spontaneous; Tendon Injuries; Tendons; Uric Acid | 2005 |
Ethnic background has minimal impact on the etiology of nephrolithiasis.
Topics: Adult; Aged; Calcium; Citric Acid; Cross-Sectional Studies; Ethnicity; Female; Gout; Humans; Hyperox | 2005 |
Confounders of uric acid levels.
Topics: Alcohol Drinking; Cardiovascular Diseases; Gout; Humans; Male; Middle Aged; Uric Acid | 2005 |
Optimal management of chronic gout: attempting to render the (t)issues crystal-clear.
Topics: Allopurinol; Anti-Inflammatory Agents; Benzbromarone; Chronic Disease; Colchicine; Drug Hypersensiti | 2005 |
A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout.
Topics: Adenine; Adult; Carrier Proteins; Case-Control Studies; Female; Gene Frequency; Genotype; Gout; Guan | 2005 |
[Hyperuricemia and disorders in content of amino acids-purine precursors in patients with autoimmune diseases and gout].
Topics: Amino Acids; Autoimmune Diseases; Gout; Humans; Hyperuricemia; Lipid Peroxides; Purines; Uric Acid; | 2005 |
I have gout, and my doctor told me not to take aspirin. Why?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraindications; Gout; Humans; Kidney; Uric Acid | 2005 |
Superficial collections of fluid tophaceous material as clinical presentation of anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Chronic Disease; Female; Gout; Hand Dermatoses; Humans; Uric Acid | 2005 |
Effects of long-term beer ingestion on plasma concentrations and urinary excretion of purine bases.
Topics: Adult; Alcohol Drinking; Beer; Ethanol; Gout; Humans; Hypoxanthine; Kidney Concentrating Ability; Ma | 2005 |
Tophaceous gout: quantitative evaluation by direct physical measurement.
Topics: Crystallization; Disease Progression; Extremities; Female; Gout; Humans; Joints; Male; Middle Aged; | 2005 |
Acute gouty inflammation of a cystic tophaceous lesion of a leg muscle associated with "urate milk".
Topics: Acute Disease; Adult; Crystallization; Cysts; Gout; Humans; Leg; Magnetic Resonance Imaging; Male; M | 2005 |
Febuxostat--treatment for hyperuricemia and gout?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric | 2005 |
Knee locking due to a single gouty tophus.
Topics: Gout; Granuloma, Foreign-Body; Humans; Joint Dislocations; Knee Joint; Male; Menisci, Tibial; Middle | 2006 |
Gout-associated uric acid crystals activate the NALP3 inflammasome.
Topics: Animals; Calcium Pyrophosphate; Carrier Proteins; Caspase 1; Cell Line; Cells, Cultured; Chondrocalc | 2006 |
New drugs for crystal deposition diseases.
Topics: Calcinosis; Calcium Compounds; Citrates; Gout; Gout Suppressants; Humans; Joints; Osteoarthritis; Ur | 2006 |
[Gout as an unusual cause of pelvic pain].
Topics: Aged, 80 and over; Allopurinol; Colchicine; Crystallization; Drug Therapy, Combination; Female; Gout | 2006 |
Clinical image: corneal tophus deposition in gout.
Topics: Cornea; Crystallization; Gout; Humans; Male; Middle Aged; Uric Acid | 2006 |
Urate deposition in the iris and anterior chamber.
Topics: Aged; Anterior Chamber; Crystallization; Female; Gonioscopy; Gout; Humans; Iris; Microscopy, Electro | 2006 |
[Diagnosis at a glance. This hand speaks volumes].
Topics: Arthritis, Gouty; Crystallization; Finger Joint; Gout; Hand Deformities, Acquired; Humans; Male; Per | 2006 |
Serum-synovial gradient data of normouricemic patients with history of gout and acute knee effusion.
Topics: Acute Disease; Aged; Crystallization; Gout; Humans; Hydrarthrosis; Knee Joint; Leukocytes; Male; Med | 2006 |
I've had a couple of painful gout attacks. My doctor says they're related to high levels of uric acid in my blood. My doctor also says that increased uric acid might mean a higher risk of heart problems. Are uric acid levels usually checked?
Topics: Biomarkers; Gout; Heart Diseases; Humans; Risk; Uric Acid | 2006 |
[Hyperuricemia and gout: diagnosis and therapy].
Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Diagnosis, Differential; Gout; Gout Suppressants; | 2006 |
Serum urate levels and gout flares: analysis from managed care data.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Databases as T | 2006 |
FNAC of gouty tophi--a case report.
Topics: Biopsy, Fine-Needle; Crystallization; Extremities; Giant Cells, Foreign-Body; Gout; Histocytochemist | 2006 |
Sex differences in gout epidemiology: evaluation and treatment.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Diuretics; Drug Monitoring; Drug Utilization; Epidemiol | 2006 |
Gout--new insights into a forgotten disease.
Topics: Carrier Proteins; Gout; Humans; Organic Anion Transporters; Organic Cation Transport Proteins; Uric | 2006 |
[Badly managed gout for decades. Only then do the hands look this way].
Topics: Aged, 80 and over; Colchicine; Creatinine; Gout; Hand Deformities, Acquired; Humans; Male; Treatment | 2006 |
Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Drug Moni | 2006 |
Gout's not just for the gluttonous.
Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Risk Factors; Sex Factors; S | 2006 |
The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China.
Topics: Adult; Aged; Alcohol Drinking; China; Cross-Sectional Studies; Female; Gout; Humans; Hypercholestero | 2006 |
The severe gout of Holy Roman Emperor Charles V.
Topics: Famous Persons; Finger Phalanges; Gout; Government; History, 16th Century; Humans; Male; Spain; Uric | 2006 |
MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals.
Topics: Adaptor Proteins, Signal Transducing; Animals; Gout; Inflammation; Mice; Mice, Inbred C57BL; Mice, K | 2006 |
Effect of fenofibrate in combination with urate lowering agents in patients with gout.
Topics: Adult; Aged; Fenofibrate; Gout; Humans; Lipids; Male; Middle Aged; Uric Acid; Uricosuric Agents | 2006 |
Fine needle aspiration of tophi in asymptomatic gout--a case report.
Topics: Ankle; Biopsy, Fine-Needle; Birefringence; Crystallization; Gout; Humans; Male; Middle Aged; Uric Ac | 2006 |
Hyperuricemia and gout following pediatric renal transplantation.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Gout; Humans; Hyperuricemia; Immunosuppressive A | 2006 |
Antihyperuricemic lignans from the leaves of Phyllanthus niruri.
Topics: Animals; Dose-Response Relationship, Drug; Gout; Lignans; Male; Phyllanthus; Phytotherapy; Plant Ext | 2006 |
Febuxostat for prevention of gout attacks.
Topics: Allopurinol; Canada; Clinical Trials, Phase III as Topic; Gout; Gout Suppressants; Humans; Hyperuric | 2006 |
Transglutaminase 2 limits murine peritoneal acute gout-like inflammation by regulating macrophage clearance of apoptotic neutrophils.
Topics: Animals; Apoptosis; Cells, Cultured; Female; Gene Expression Regulation; Gout; GTP-Binding Proteins; | 2006 |
The management of gout: it should be crystal clear.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anti-Inflammatory Agents, Non-Steroidal; China | 2006 |
The management of gout at an academic healthcare center in Beijing: a physician survey.
Topics: Academic Medical Centers; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; China; Colchi | 2006 |
A survey of current evaluation and treatment of gout.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anti-Inflammatory Agents, Non-Steroidal; Colch | 2006 |
Excellent response to the clinical treatment of tophaceous gout.
Topics: Aged; Allopurinol; Benzbromarone; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidne | 2007 |
Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals.
Topics: Animals; Caspase 1; Chemokines, CXC; CHO Cells; Cricetinae; Crystallization; Enzyme Activation; Gout | 2006 |
Case 5: treatment options for acute gout.
Topics: Acute Disease; Anti-Inflammatory Agents; Gout; Humans; Male; Middle Aged; Patient Compliance; Recurr | 2006 |
Gout: finally, diagnosis and treatment guidelines. A European task force offers the first recommendations on dealing with this painful arthritic condition.
Topics: Biomarkers; Colchicine; Gout; Gout Suppressants; Humans; Uric Acid | 2006 |
Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.
Topics: Adult; Aged; Benzbromarone; Chronic Disease; Crystallization; Follow-Up Studies; Gout; Gout Suppress | 2007 |
Does the presence of crystal arthritis rule out septic arthritis?
Topics: Age Distribution; Aged; Arthritis, Infectious; Calcium Pyrophosphate; Chondrocalcinosis; Comorbidity | 2007 |
[Gout and diuretics; still an issue].
Topics: Cardiovascular Diseases; Case-Control Studies; Diuretics; Gout; Humans; Hypertension; Incidence; Uri | 2007 |
[An unusual manifestation of osteo-articular, tendinous and nervous involvement secondary to tophaceous gout of the hand. A report of two cases].
Topics: Carpal Tunnel Syndrome; Contracture; Crystallization; Cubital Tunnel Syndrome; Electromyography; Fin | 2007 |
Diagnosis of gout by ultrasound.
Topics: Adult; Aged; Aged, 80 and over; Cartilage, Articular; Crystallization; Female; Gout; Humans; Joints; | 2007 |
Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.
Topics: Adult; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colchicine; Diuretics; | 2007 |
Quality of care for gout in the US needs improvement.
Topics: Aged; Allopurinol; Blood Cell Count; Colchicine; Comorbidity; Creatine Kinase; Evidence-Based Medici | 2007 |
Crystal-induced neutrophil activation. IX. Syk-dependent activation of class Ia phosphatidylinositol 3-kinase.
Topics: Adult; Blotting, Western; Cells, Cultured; Crystallization; Gout; Humans; Immunoprecipitation; Intra | 2007 |
Gout.
Topics: Bone and Bones; Gout; Humans; Male; Middle Aged; Radiography; Thumb; Uric Acid | 2007 |
New treatments for gout.
Topics: Allopurinol; Ascorbic Acid; Female; Fenofibrate; Gout; Gout Suppressants; Humans; Losartan; Male; Se | 2007 |
Gouty panniculitis in a healthy male.
Topics: Adipose Tissue; Adult; Gout; Humans; Male; Panniculitis; Uric Acid | 2007 |
Ultrasonographic measurement of tophi as an outcome measure for chronic gout.
Topics: Biopsy, Fine-Needle; Crystallization; Gout; Gout Suppressants; Humans; Joints; Sensitivity and Speci | 2007 |
Homozygous frameshift mutation in the SLC22A12 gene in a patient with primary gout and high levels of serum uric acid.
Topics: Adult; Arthritis, Gouty; Frameshift Mutation; Gout; Homozygote; Humans; Hyperuricemia; Male; Mutagen | 2007 |
Clinical image: Dual-energy computed tomographic molecular imaging of gout.
Topics: Colchicine; Contrast Media; Gout; Gout Suppressants; Humans; Iodine Compounds; Male; Middle Aged; To | 2007 |
Podagra, uric acid, and cardiovascular disease.
Topics: Cardiovascular Diseases; Gout; Humans; Prevalence; Uric Acid | 2007 |
[European League Against Rheumatism evidence-based recommendations for diagnosis and management of gout].
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Delphi Technique | 2007 |
Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study.
Topics: Aged; Aged, 80 and over; Allopurinol; Contraindications; Female; Gout; Gout Suppressants; Humans; Ma | 2007 |
Urate deposits.
Topics: Anterior Chamber; Crystallization; Gonioscopy; Gout; Humans; Iris; Microscopy, Electron; Suction; Ur | 2007 |
Information from your family doctor. Gout: what you should know.
Topics: Adult; Age Factors; Diagnosis, Differential; Diet; Exercise; Female; Gout; Gout Suppressants; Humans | 2007 |
Carpal bone involvement in gout.
Topics: Adult; Anti-Inflammatory Agents; Arthralgia; Carpal Bones; Gout; Humans; Male; Metatarsal Bones; Phy | 2007 |
Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.
Topics: Aged; Allopurinol; Drug Administration Schedule; Drug Monitoring; Epidemiologic Methods; Family Prac | 2008 |
Clinical features and risk factors of postsurgical gout.
Topics: Aged; Case-Control Studies; Colchicine; Female; Gout; Gout Suppressants; Humans; Lower Extremity; Ma | 2008 |
The genetics of gout and hyperuricaemia; an analysis of 19 families.
Topics: Blood; Gout; Humans; Hyperuricemia; Uric Acid | 1948 |
The transport and excretion of uric acid in man; a sex difference in urate metabolism; with a note on clinical and laboratory findings in gouty women.
Topics: Biological Transport; Body Fluids; Female; Gout; Humans; Male; Sex Characteristics; Uric Acid | 1949 |
Tophaceous gout in a patient with rheumatoid arthritis.
Topics: Anemia; Arthritis, Rheumatoid; Bone Diseases, Metabolic; Creatinine; Female; Fingers; Foot; Gout; Hu | 2007 |
Gout: joint pain and more.
Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Gout; Gout Suppressa | 2007 |
Urate crystals, inflammation, and colchicine.
Topics: Animals; Arthritis, Gouty; Colchicine; Disease Models, Animal; Gout; Gout Suppressants; History, 20t | 2008 |
Polymorphonuclear leukocyte motility in vitro: IV. Colchicine inhibition of chemotactic activity formation after phagocytosis of urate crystals.
Topics: Cell Movement; Cells, Cultured; Colchicine; Gout; Gout Suppressants; History, 20th Century; Humans; | 2008 |
Advanced gout.
Topics: Aged, 80 and over; Diagnosis, Differential; Female; Gout; Humans; Uric Acid | 2008 |
Management of recurrent gout: Professional guidelines differ.
Topics: Gout; Humans; Practice Guidelines as Topic; Recurrence; Uric Acid | 2008 |
Widespread arterial calcification in a patient with gout.
Topics: Adult; Anti-Inflammatory Agents; Arteries; Calcinosis; Gout; Humans; Male; Methylprednisolone; Pelvi | 2008 |
SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.
Topics: Adult; Aged; Aged, 80 and over; Austria; Biomarkers; Case-Control Studies; Computational Biology; Fe | 2008 |
SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Biological Transport, Active; Biomarkers; Case- | 2008 |
Disease-related and all-cause health care costs of elderly patients with gout.
Topics: Adolescent; Aged; Biomarkers; Female; Gout; Gout Suppressants; Health Expenditures; Health Services; | 2008 |
Uric acid: neuroprotective or neurotoxic?
Topics: Animals; Antioxidants; Brain Ischemia; Gout; Humans; Hyperuricemia; Lesch-Nyhan Syndrome; Neuroprote | 2008 |
Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey.
Topics: Adult; Biomarkers; Blood Glucose; C-Peptide; Diet; Fasting; Female; Glycated Hemoglobin; Gout; Healt | 2008 |
Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Coronary Artery Disease; Female; Genetic Predi | 2008 |
Gout.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Humans; Uric Acid | 2008 |
Vitamin C intake and serum uric acid concentration in men.
Topics: Adult; Aged; Antioxidants; Ascorbic Acid; Diet Surveys; Feeding Behavior; Gout; Humans; Hyperuricemi | 2008 |
Asymptomatic hyperuricemia: perhaps not so benign?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Kidney Diseases; Risk Factors; Uric Acid | 2008 |
Impact of childhood metabolic syndrome components on the risk of elevated uric acid in adulthood: the Bogalusa Heart Study.
Topics: Adolescent; Child; Child, Preschool; Cholesterol, HDL; Cross-Sectional Studies; Female; Gout; Humans | 2008 |
[Uric acid metabolism anomaly and its laboratory method--significance and limit of uric acid clearance].
Topics: Glomerular Filtration Rate; Gout; Humans; Uric Acid | 1966 |
[On gout].
Topics: Adult; Ankle Joint; Diet Therapy; Female; Gout; Humans; Male; Middle Aged; Phenylbutazone; Sulfinpyr | 1966 |
Epidemiology of gout and hyperuricemia. A long-term population study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Diabetes Mellitus; Female; Gout; Humans; Male; Middle Aged; Samp | 1967 |
Effect of food, fast and alcohol on serum uric acid and acute attacks of gout.
Topics: Adult; Aged; Butyrates; Dietary Proteins; Ethanol; Fasting; Female; Gout; Humans; Ketones; Lactates; | 1967 |
Use of allopurinol in gout, hyperuricemia and uric acid lithiasis.
Topics: Adult; Aged; Allopurinol; Blood Urea Nitrogen; Colchicine; Enzyme Therapy; Female; Gout; Humans; Ind | 1967 |
Gout and the pathogenesis of its attacks.
Topics: Adult; Aged; Diagnosis, Differential; Emotions; Female; Gout; Humans; Hypersensitivity; Kidney Disea | 1967 |
The presence of a kinin in inflammatory synovial effusion from arthritides of varying etiologies.
Topics: Adolescent; Adult; Animals; Arthritis; Arthritis, Rheumatoid; Bradykinin; Carboxypeptidases; Child; | 1967 |
Hyperuricemia in Filipinos: interaction of heredity and environment.
Topics: Adult; Aged; Diet; Ethnology; Genetics, Medical; Gout; Humans; Kidney Tubules; Male; Middle Aged; Ph | 1967 |
Regimen of indomethacin therapy in acute gouty arthritis.
Topics: Adult; Creatine; Female; Gout; Headache; Humans; Indomethacin; Male; Middle Aged; Nausea; Urea; Uric | 1967 |
Allopurinol in the treatment of uraemic patients with gout.
Topics: Allopurinol; Blood Urea Nitrogen; Enzyme Therapy; Gout; Humans; Purines; Uremia; Uric Acid; Xanthine | 1967 |
Studies of uric acid metabolism in glycogen storage disease associated with gouty arthritis.
Topics: Adolescent; Allopurinol; Body Height; Body Weight; Carbon Isotopes; Enzyme Therapy; Glucosephosphate | 1967 |
Correlations of serum uric acid and lipid concentrations in normal, gouty, and atherosclerotic men.
Topics: Adult; Arteriosclerosis; Black or African American; Blood Donors; Cholesterol; Ethnology; Female; Gl | 1967 |
Non-traumatic aseptic necrosis of the femoral head.
Topics: Adrenal Cortex Hormones; Adult; Alcoholism; Fats; Female; Femoral Fractures; Femur Head; Gout; Hip D | 1967 |
[Action of benziodarone on hyperuricemia in gout].
Topics: Adult; Aged; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Vasodilator Agents | 1967 |
[Place of hyperuricemia and gout in the etiology of retina vascular disorders].
Topics: Female; Gout; Humans; Male; Retinal Hemorrhage; Retinal Vessels; Thrombosis; Uric Acid | 1967 |
The effect of indomethacin on urate metabolism.
Topics: Adult; Arthritis, Rheumatoid; Creatine; Gout; Humans; Indomethacin; Kidney; Kidney Function Tests; M | 1967 |
Alcohol consumption and gout.
Topics: Adult; Alcoholic Beverages; Beer; Blood Pressure; Cardiovascular Diseases; Gout; Humans; Male; Middl | 1967 |
Biochemical evidence for a distinct type of primary gout.
Topics: Adolescent; Allopurinol; Azathioprine; Carbon; Carbon Isotopes; Enzymes; Glycine; Gout; Humans; Hypo | 1967 |
Treatment of gout.
Topics: Allopurinol; Enzyme Therapy; Gout; Humans; Uric Acid; Xanthine Oxidase | 1967 |
Changes in some serum and urine laboratory indices in idiopathic uric acid lithiasis after administration of Eisenberg solution.
Topics: Acid-Base Equilibrium; Adult; Ammonia; Androgens; Citrates; Creatine; Diagnosis, Differential; Diure | 1967 |
[Primary gout].
Topics: Gout; Humans; Purines; Uric Acid | 1967 |
Birth order in gout.
Topics: Adolescent; Adult; Aged; Birth Order; Black or African American; Female; Gout; Humans; Jews; Male; M | 1967 |
Methotrexate in psoriasis. Precipitation of gout.
Topics: Colchicine; Female; Gout; Humans; Injections, Intravenous; Male; Methotrexate; Middle Aged; Psoriasi | 1967 |
[Allopurinol treatment of hyperuricemia].
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Iron; Male; Middle Aged; Nitrogen; Purines; Uric Aci | 1967 |
The use of the xanthine oxidase inhibitor, allopurinol, in the control of hyperuricaemia, gout and uric acid calculi.
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Hypoxanthines; Male; Metabolic Diseases; Middle Aged | 1967 |
[Congenital hyperuricemia with neurologic, renal and blood disturbances].
Topics: Adolescent; Allopurinol; Anemia, Macrocytic; Athetosis; Chorea; Gout; Humans; Intellectual Disabilit | 1967 |
[The importance of the lithiasis factor in chronic renal insufficiency in uricemia].
Topics: Female; Gout; Humans; Kidney Calculi; Kidney Failure, Chronic; Male; Middle Aged; Uric Acid | 1967 |
Uric acid nephrolithiasis in gout. Predisposing factors.
Topics: Adolescent; Adult; Age Factors; Aged; Arthritis; Gout; Humans; Hydrogen-Ion Concentration; Kidney Ca | 1967 |
[Survey of patients with uric arthritis in the Trogir region (Central Dalmatia)].
Topics: Gout; Humans; Uric Acid; Yugoslavia | 1967 |
[On the simultaneous appearance of attacks of gout and coronary failure].
Topics: Coronary Disease; Gout; Humans; Uric Acid | 1967 |
[Gouty tophi in the renal medulla in chronic uremia. Study of 17 cases discovered from among 62 autopsies].
Topics: Adult; Aged; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Uremia; Uric Acid | 1967 |
[Gout and hyperuricemia].
Topics: Adult; Gout; Hematologic Diseases; Humans; Male; Uric Acid | 1967 |
Suppressive effects of indomethacin on crystal-induced inflammation in canine joints and on neutrophilic motility in vitro.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Arthritis; Blood Flow Velocity; Blood Pressure; Do | 1967 |
[The behavior of uricemia during treatment with spironolactone and with other diuretics].
Topics: Acetazolamide; Adolescent; Adult; Aged; Chlorthalidone; Clopamide; Diuretics; Ethacrynic Acid; Femal | 1967 |
[Data for the study of the gouty kidney].
Topics: Adolescent; Adult; Female; Glomerulonephritis; Gout; Humans; Kidney Calculi; Kidney Diseases, Cystic | 1967 |
[Study of the effects of benziodarone in 100 gouty patients during a diuresis cure: effects on uric acid and oxalic acid].
Topics: Allopurinol; Benzofurans; Colchicine; Diuretics; Gout; Humans; Mineral Waters; Oxalates; Tromethamin | 1967 |
The fever of gout: urate crystals activate endogenous pyrogen production from human and rabbit mononuclear phagocytes.
Topics: Animals; Colchicine; Crystallization; Cytochalasin B; Fever; Gout; Humans; Latex; Leukocytes; Monocy | 1983 |
Oxygen radical production by horse and pig neutrophils induced by a range of crystals.
Topics: Animals; Arthritis; Crystallization; Gout; Horses; In Vitro Techniques; Neutrophils; Oxygen Consumpt | 1984 |
[Pathogenetic mechanisms in joint diseases].
Topics: Arthritis; Arthritis, Infectious; Arthritis, Reactive; Autoimmune Diseases; Chondrocalcinosis; Cryst | 1981 |
Induction of collagenase and prostaglandin synthesis in synovial fibroblasts treated with monosodium urate crystals.
Topics: Animals; Cells, Cultured; Crystallization; Fibroblasts; Gout; Microbial Collagenase; Prostaglandins | 1981 |
Leukotriene B4, an inflammatory mediator in gout.
Topics: Acute Disease; Adult; Aged; Chemotactic Factors; Crystallization; Gout; Humans; Leukotriene B4; Male | 1982 |
[Clinical aspects and prognosis of hyperuricemia and gout].
Topics: Female; Gout; Humans; Male; Prognosis; Uric Acid | 1983 |
IMP dehydrogenase mutants: cell culture model for hyperuricemia.
Topics: Animals; Cell Line; Disease Models, Animal; Gout; Humans; IMP Dehydrogenase; Ketone Oxidoreductases; | 1984 |
Aspect of purine metabolic aberration associated with uric acid overproduction and gout.
Topics: Diphosphoglyceric Acids; Erythrocytes; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kinetic | 1980 |
Interpretation of synovial fluid data.
Topics: Arthritis; Arthritis, Rheumatoid; Calcium Pyrophosphate; Cholesterol; Crystallization; Diagnosis, Di | 1980 |
A hypothesis on the possible role of interferon in the initiation of acute gouty arthritis attack.
Topics: Acute Disease; Gout; Humans; Interferons; Macrophages; Models, Biological; Phagocytosis; Prostagland | 1980 |
[Hyperuricemia].
Topics: Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Male; Phosphoribosyl Pyrophosphate; Pu | 1980 |
Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate.
Topics: Adult; Aged; Erythrocytes; Female; Gout; Humans; Kinetics; Male; Pedigree; Phosphoribosyl Pyrophosph | 1982 |
Management of gout and hyperuricemia.
Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Gout; Humans; Indomethacin; Kidney; Patient Educa | 1984 |
Inherited disorders of purine metabolism--underlying molecular mechanisms.
Topics: Adenine Phosphoribosyltransferase; Adenosine Deaminase; Gout; Humans; Hypoxanthine Phosphoribosyltra | 1984 |
Hormonal aspects of human gout--excretion of adrenal hormone derivatives in gouty patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aging; Allopurinol; Androsterone; Dehydroepiandrosterone; Etio | 1983 |
Uric acid metabolism in two patients with coexistent Down's syndrome and gout.
Topics: Adult; Down Syndrome; Glomerular Filtration Rate; Gout; Humans; Male; Uric Acid | 1984 |
[The effect of water with medium mineral content on various biohumoral parameters of uric acid metabolism].
Topics: Bicarbonates; Diuresis; Gout; Humans; Mineral Waters; Uric Acid | 1984 |
The treatment of gout with azapropazone: clinical and experimental studies.
Topics: Animals; Apazone; Crystallization; Female; Gout; Humans; Male; Rats; Rats, Inbred Strains; Uric Acid | 1981 |
Image alterations in the teaching microscope. A source of error in synovial fluid crystal identification.
Topics: Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Diagnosis, Differential; Diphosphates; Go | 1980 |
Metabolic basis for disorders of purine nucleotide degradation.
Topics: Adenosine Deaminase; Adenosine Monophosphate; Adenosine Triphosphate; AMP Deaminase; Anemia; Animals | 1981 |
Stimulation of secretion of collagenase and prostaglandin E2 by synovial fibroblasts in response to crystals of monosodium urate monohydrate: a model for joint destruction in gout.
Topics: Animals; Crystallization; Dinoprostone; Disease Models, Animal; Fibroblasts; Gout; Microbial Collage | 1981 |
Crystal-induced arthritis.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Arthritis; Calcium Pyrophosphate; Crystalli | 1982 |
Stimulation of synovial fibroblasts by calcium oxalate and monosodium urate monohydrate. A mechanism of connective tissue degradation in oxalosis and gout.
Topics: Animals; Calcium Oxalate; Connective Tissue Diseases; Crystallization; Dinoprostone; Dose-Response R | 1982 |
Inflammatory responses to intradermal crystals in healthy volunteers and patients with rheumatic diseases.
Topics: Arthritis, Rheumatoid; Calcium Pyrophosphate; Diphosphates; Gout; Humans; Hydroxyapatites; Intraderm | 1982 |
Phosphoribosyl pyrophosphate synthetase and glutathione reductase in erythrocytes from hyperuricaemic and gout patients.
Topics: Erythrocytes; Female; Glutathione Reductase; Gout; Humans; Male; Phosphotransferases; Ribose-Phospha | 1982 |
Radiology of the crystal-associated arthritides.
Topics: Arthritis; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Durapatite; Gout; Humans; Hydr | 1983 |
An autopsy study of the prevalence of monosodium urate and calcium pyrophosphate dihydrate crystal deposition in first metatarsophalangeal joints.
Topics: Adolescent; Adult; Aged; Autopsy; Biopsy, Needle; Calcium Pyrophosphate; Crystallization; Diphosphat | 1983 |
Phagocytosis of sodium urate and calcium pyrophosphate crystals by leukocytes of gouty, pseudogouty and health donors.
Topics: Adult; Aged; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Diphosphates; Glucose; Gout; | 1983 |
Urinary cAMP excretion in gouty patients with and without nephrolithiasis.
Topics: Calcium; Cyclic AMP; Female; Gout; Humans; Kidney Calculi; Male; Phosphates; Uric Acid | 1984 |
Diagnostic evaluation of phosphoribosylpyrophosphate synthetase activities in hemolysates.
Topics: Adenine Phosphoribosyltransferase; Adenosine Diphosphate; Clinical Enzyme Tests; Dialysis; Enzyme Ac | 1984 |
Metabolic aspects in gout.
Topics: Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Purines; Ribose-Phosphate Pyrophosphokinase; U | 1984 |
Drug-induced rheumatic diseases.
Topics: Adrenal Cortex Hormones; Anticonvulsants; Antineoplastic Agents; Diuretics; Gout; Heparin; Humans; H | 1984 |
Gouty nephropathy: fact or fiction?
Topics: Gout; History, 16th Century; History, 19th Century; History, 20th Century; History, Ancient; Humans; | 1983 |
The first era of lithium in medicine. An historical note.
Topics: Chemistry; Depression; Gout; History, 19th Century; History, 20th Century; Humans; Lithium; Mineral | 1983 |
[Cutaneous bullous tophaceous gout].
Topics: Arthritis; Crystallization; Gout; Humans; Male; Middle Aged; Skin; Skin Diseases, Vesiculobullous; U | 1983 |
[Diet therapy of gout and urate nephrolithiasis].
Topics: Alcohol Drinking; Body Weight; Gout; Humans; Kidney Calculi; Purines; Uric Acid | 1984 |
[Increase in blood uric acid induced by indomethacin in hens or chickens].
Topics: Animals; Chickens; Dose-Response Relationship, Drug; Female; Gout; Indomethacin; Uric Acid | 1983 |
Purine metabolism in high- and low-uric acid lines of chickens: hypoxanthine/guanine phosphoribosyltransferase activities.
Topics: Animals; Chickens; Dietary Proteins; Female; Gout; Hypoxanthine Phosphoribosyltransferase; Hypoxanth | 1983 |
Food, drink, and gout.
Topics: Alcohol Drinking; Body Weight; Food; Gout; Humans; Purines; Uric Acid | 1983 |
Moonshine and lead. Relationship to the pathogenesis of hyperuricemia in gout.
Topics: Adult; Alcohol Drinking; Edetic Acid; Female; Gout; Humans; Kidney Diseases; Latex Fixation Tests; L | 1983 |
Molecular genetics of the HPRT-deficiency syndromes.
Topics: Amino Acid Sequence; Female; Genetic Carrier Screening; Gout; Humans; Hypoxanthine Phosphoribosyltra | 1984 |
Occult lead intoxication in patients with gout and kidney disease.
Topics: Adult; Aged; Alcohol Drinking; Creatinine; Edetic Acid; Female; Gout; Humans; Kidney Diseases; Lead; | 1984 |
Gas-chromatographic evaluation of urinary 17-ketosteroids, etiocholanolone, and dehydroepiandrosterone in primary gout and hyperuricemia.
Topics: 17-Ketosteroids; Adult; Aged; Chromatography, Gas; Dehydroepiandrosterone; Etiocholanolone; Female; | 1980 |
Musculoskeletal manifestations of Paget's disease of bone.
Topics: Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Back Pain; Female; Gout; Hip Joint; Humans; Knee | 1980 |
The differential diagnosis of septic arthritis in the elderly.
Topics: Aged; Arthritis; Arthritis, Infectious; Arthritis, Rheumatoid; Cellulitis; Diabetic Neuropathies; Di | 1984 |
[Gouty nephropathy (a review of the literature)].
Topics: Animals; Gout; Humans; Kidney; Kidney Calculi; Kidney Diseases; Nephritis, Interstitial; Purines; Ra | 1984 |
Juvenile gouty arthritis. Two cases associated with mild renal insufficiency.
Topics: Adolescent; Arthritis; Female; Gout; Humans; Kidney Diseases; Male; Recurrence; Synovial Fluid; Uric | 1984 |
A case-control study of alcohol consumption and drinking behaviour in patients with acute gout.
Topics: Acute Disease; Alcohol Drinking; Alcoholism; Diuretics; Female; Gout; Humans; Male; Middle Aged; Uri | 1984 |
Crystal deposition in the knee and great toe joints of asymptomatic gout patients.
Topics: Adult; Aged; Arthroscopy; Crystallization; Gout; Humans; Knee Joint; Male; Metatarsophalangeal Joint | 1984 |
A study of the potential interactions between azapropazone and frusemide in man.
Topics: Adult; Apazone; Drug Interactions; Female; Furosemide; Gout; Humans; Male; Potassium; Sodium; Triazi | 1984 |
Hyperuricaemia, gout and kidney function in New Zealand Maori men.
Topics: Adult; Alcohol Drinking; Ethnicity; Gout; Humans; Kidney; Male; Middle Aged; New Zealand; Obesity; S | 1984 |
An approach to hyperuricemia and gout.
Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Female; Gout; Humans; Male; Naproxen; Phenylbutaz | 1984 |
[Hyperuricemia in ischemic heart disease].
Topics: Adult; Body Weight; Coronary Disease; Diuretics; Gout; Humans; Hyperlipoproteinemias; Hypertension; | 1984 |
Prospective study of morphology and phagocytosis of synovial fluid monosodium urate crystals in gouty arthritis.
Topics: Arthritis; Crystallization; Gout; Humans; Leukocytes; Phagocytosis; Synovial Fluid; Uric Acid | 1984 |
[Urate spherulite crystals in gouty synovial fluid].
Topics: Gout; Humans; Synovial Fluid; Uric Acid | 1984 |
Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Creatinine; Drug Therapy, Combination; Glomeru | 1984 |
Podagra is more than gout.
Topics: Colchicine; Diagnosis, Differential; Gout; Humans; Metatarsophalangeal Joint; Toe Joint; Uric Acid | 1984 |
Hypouricemic action of diflunisal in gouty patients: in vitro and in vivo studies.
Topics: Adult; Aged; Creatinine; Diflunisal; Enzyme Inhibitors; Gout; Humans; In Vitro Techniques; Middle Ag | 1984 |
[Protein overload, hyperucemia, gout].
Topics: Adult; Diet; Female; Gout; Humans; Hyperlipoproteinemias; Male; Middle Aged; Uric Acid | 1983 |
The approach to the acute joint and synovial fluid examination.
Topics: Acute Disease; Adult; Arthritis; Arthritis, Infectious; Calcium Pyrophosphate; Chondrocalcinosis; Fe | 1984 |
[Hyperuricemia].
Topics: Gout; Humans; Uric Acid; Urinary Calculi | 1984 |
The role of the laboratory in rheumatology. Uric acid and the interpretation of hyperuricaemia.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Arthritis; Body Weight; Child; Female; Gout; Humans; Hype | 1983 |
Polarised light microscopy: principles and practice for the rheumatologist.
Topics: Aged; Birefringence; Calcium Pyrophosphate; Crystallization; Gout; Humans; Microscopy, Polarization; | 1983 |
T-cell leukaemia presenting with hyperuricaemia, acute renal failure and gout.
Topics: Acute Kidney Injury; Child; Gout; Humans; Leukemia, Lymphoid; Male; T-Lymphocytes; Uric Acid | 1983 |
[Problems with xeroradiography].
Topics: Adolescent; Adult; Arm; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Xeroradiography | 1983 |
Studies of urate crystallisation in relation to gout.
Topics: Chemical Phenomena; Chemistry; Crystallization; Gout; Humans; Macromolecular Substances; Neutral Red | 1983 |
[The spine and polytopic hyperostoses in gout and hyperuricemia].
Topics: Female; Gout; Humans; Male; Middle Aged; Spinal Osteophytosis; Uric Acid; Xeroradiography | 1983 |
The diagnosis and management of gouty arthritis.
Topics: Adult; Anti-Inflammatory Agents; Arthritis; Female; Gout; Gout Suppressants; Humans; Male; Middle Ag | 1983 |
[Hyperuricemia and gout. Physiopathology, diagnosis and therapy].
Topics: Gout; Humans; Metabolic Clearance Rate; Uric Acid | 1983 |
[The gouty kidney].
Topics: Gout; Humans; Kidney Diseases; Uric Acid | 1983 |
[Metabolic disorders in hyperuricemia].
Topics: Diabetes Mellitus; Glycerides; Gout; Humans; Metabolic Diseases; Obesity; Uric Acid | 1983 |
[Should asymptomatic hyperuricemia be treated?].
Topics: Gout; Humans; Metabolic Diseases; Uric Acid | 1983 |
Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury.
Topics: Blood Physiological Phenomena; Blood Platelets; Calcium Oxalate; Cell Adhesion; Cell Aggregation; Co | 1983 |
Oxipurinol therapy in allopurinol-allergic patients.
Topics: Aged; Allopurinol; Arthritis; Drug Hypersensitivity; Female; Gout; Humans; Oxypurinol; Pyrimidines; | 1983 |
[Secondary gut].
Topics: Adult; Age Factors; Aged; Female; Gout; Humans; Lead Poisoning; Male; Middle Aged; Polycythemia; Uri | 1983 |
Cutaneous gout in an Amazon dolphin.
Topics: Allopurinol; Animals; Animals, Zoo; Dolphins; Gout; Male; Skin; Skin Diseases; Uric Acid | 1983 |
[Features differentiating between gout and asymptomatic hyperuricemias (1). Clinical study].
Topics: Arthritis; Diagnosis, Differential; Female; Gout; Humans; Kidney Calculi; Male; Uric Acid | 1983 |
Cholesterol "tophus".
Topics: Ankle Joint; Biopsy, Needle; Cholesterol; Crystallization; Diagnosis, Differential; Gout; Granuloma; | 1983 |
[Hyperuricemia and gout; treatment of an acute attack of gout].
Topics: Adult; Colchicine; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Uricosuric Agents | 1983 |
[Features differentiating between gout and asymptomatic hyperuricemias. II. Laboratory data].
Topics: Blood Proteins; Diagnosis, Differential; Gout; Humans; Lipids; Uric Acid | 1983 |
[Features differentiating between gout and asymptomatic hyperuricemias. III. Correlations with metabolic parameters].
Topics: Blood Proteins; Diagnosis, Differential; Gout; Humans; Lipids; Uric Acid | 1983 |
[Therapy of gout and hyperuricemia].
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 1983 |
Preliminary studies with azapropazone in gout and hyperuricaemia.
Topics: Adult; Aged; Apazone; Drug Evaluation; Female; Gout; Humans; Male; Middle Aged; Triazines; Uric Acid | 1983 |
The behavior of oxypurines in human primary gout.
Topics: Adult; Aged; Female; Gout; Humans; Hypoxanthines; Male; Middle Aged; Purines; Sex Factors; Uric Acid | 1983 |
Effect of nonsteroidal anti-inflammatory drugs on the renal excretion of uric acid.
Topics: Anti-Inflammatory Agents; Arthritis; Gout; Humans; ortho-Aminobenzoates; Piroxicam; Quinazolines; Th | 1983 |
Gout and uric acid nephropathy: some new aspects in diagnosis and treatment.
Topics: Adult; Diet; Female; Gout; Humans; Hypolipidemic Agents; Kidney Diseases; Male; Uric Acid; Uricosuri | 1983 |
Azapropazone--a treatment for hyperuricaemia and gout?
Topics: Adult; Aged; Allopurinol; Apazone; Creatinine; Gout; Humans; Middle Aged; Osmolar Concentration; Tri | 1984 |
Does hyperuricemia protect from rheumatoid inflammation? A clinical study.
Topics: Arthritis, Rheumatoid; Gout; Humans; Inflammation; Uric Acid | 1984 |
[Urate gout in children].
Topics: Adolescent; Child; Finger Joint; Gout; Humans; Male; Metatarsophalangeal Joint; Toe Joint; Uric Acid | 1984 |
Clinical survey of 200 patients with gout.
Topics: Age Factors; Crystallization; Gout; Humans; Joints; Middle Aged; Retrospective Studies; Uric Acid | 1984 |
Incorporation of 15N from glycine into uric acid in gout: a follow-up study.
Topics: Adult; Follow-Up Studies; Glycine; Gout; Humans; Male; Nitrogen Isotopes; Uric Acid | 1984 |
Hyperuricaemia in young New Zealand Maori men.
Topics: Adult; Age Factors; Ethnicity; Gout; Humans; Male; Middle Aged; Native Hawaiian or Other Pacific Isl | 1984 |
Lean dry gout patients.
Topics: Body Weight; Cholesterol; Cholesterol, HDL; Gout; Humans; Lipoproteins; Lipoproteins, HDL; Triglycer | 1984 |
Urate deposits without gouty arthritis.
Topics: Aged; Arthritis; Arthritis, Rheumatoid; Gout; Humans; Male; Middle Aged; Osteoarthritis; Uric Acid | 1984 |
HDL-cholesterol levels in gouty patients.
Topics: Cholesterol; Cholesterol, HDL; Gout; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Middle Aged; Refe | 1984 |
Gout resistant to allopurinol: poor compliance or non-response.
Topics: Allopurinol; Arthritis; Gout; Humans; Male; Middle Aged; Patient Compliance; Uric Acid | 1984 |
Renal handling of uric acid in gout by means of the pyrazinamide and probenecid tests.
Topics: Adult; Gout; Humans; Kidney; Kidney Tubules; Probenecid; Pyrazinamide; Reference Values; Uric Acid | 1984 |
The effect of beer ingestion on plasma and urine uric acid in gout and normouricaemic subjects.
Topics: Alcohol Drinking; Beer; Gout; Humans; Reference Values; Uric Acid | 1984 |
Ethanol induced alterations of uric acid metabolism.
Topics: Alcohol Drinking; Creatinine; Ethanol; Gout; Humans; Uric Acid | 1984 |
The management of hyperuricaemia.
Topics: Adult; Aged; Follow-Up Studies; Gout; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Myoc | 1984 |
Diversity of clinical features in gouty arthritis.
Topics: Adolescent; Adult; Age Factors; Aged; Arthritis; Child; Female; Gout; Humans; Hyperlipidemias; Hyper | 1984 |
Mitral stenosis associated with valvular tophi.
Topics: Aged; Calcinosis; Female; Gout; Humans; Mitral Valve; Mitral Valve Stenosis; Uric Acid | 1984 |
[When should hyperuricemia be treated?].
Topics: Gout; Hematologic Diseases; Humans; Kidney Failure, Chronic; Uric Acid; Urinary Calculi | 1984 |
Therapeutics of hyperuricaemia and gout.
Topics: Acute Disease; Allopurinol; Colchicine; Gout; Humans; Indomethacin; Uric Acid; Uricosuric Agents | 1984 |
Gout in South African blacks.
Topics: Adult; Black People; Female; Gout; Humans; Male; Middle Aged; Retrospective Studies; South Africa; U | 1984 |
Beer drinking and its effect on uric acid.
Topics: Alcohol Drinking; Beer; Gout; Humans; Lactates; Male; Uric Acid | 1984 |
The rate of purine synthesis de nova in blood mononuclear cells in vitro from patients with familial hyperuricaemic nephropathy.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Erythrocytes; Female; Gout; Humans; Kidney Disease | 1984 |
Activation of the fifth component of human complement (C5) induced by monosodium urate crystals: C5 convertase assembly on the crystal surface.
Topics: Arthritis; Chemotactic Factors; Complement Activating Enzymes; Complement Activation; Complement C3- | 1982 |
The role of lead in gout nephropathy.
Topics: Adult; Aged; Creatinine; Edetic Acid; Gout; Humans; Kidney; Kidney Diseases; Kidney Function Tests; | 1981 |
[Urate-oxidase: a new therapy of cytotoxic-drug-induced hyperuricemia (author's transl)].
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Female; Gout; Humans; Kidney Diseases; Leukemia; Ma | 1981 |
Nonarticular gout: hyperuricemia and tophus formation without gouty arthritis.
Topics: Aged; Arthritis, Rheumatoid; Ear; Gout; Humans; Kidney; Male; Middle Aged; Osteoarthritis; Synovial | 1983 |
Tophaceous gout producing spinal cord compression. Case report.
Topics: Adult; Gout; Humans; Male; Paraplegia; Spinal Cord Compression; Uric Acid | 1983 |
Lead nephropathy and gout.
Topics: Adolescent; Adult; Aged; Child, Preschool; Creatinine; Female; Glomerular Filtration Rate; Gout; Hum | 1983 |
Calciuric effect of probenecid in gouty patients.
Topics: Adult; Aged; Calcium; Creatinine; Gout; Humans; Male; Middle Aged; Probenecid; Uric Acid | 1983 |
Familial nephropathy with hyperuricemia and gout.
Topics: Adult; Biopsy; Child; Female; Genes, Dominant; Glomerular Filtration Rate; Gout; Humans; Kidney; Kid | 1983 |
[Current therapy: combined drug therapy of hyperuricemia, gout and alcohol induced fatty liver].
Topics: Allopurinol; Benzbromarone; Benzofurans; Drug Therapy, Combination; Fatty Liver, Alcoholic; Gout; Hu | 1983 |
Activation of the alternative pathway of complement by monosodium urate crystals.
Topics: Complement Activation; Complement Pathway, Alternative; Crystallization; Gout; Humans; Uric Acid | 1983 |
[Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone].
Topics: Allopurinol; Benzbromarone; Benzofurans; Chemical Phenomena; Chemistry; Drug Therapy, Combination; G | 1983 |
[Should asymptomatic hyperuricemia be treated?].
Topics: Arthritis; Gout; Humans; Kidney Calculi; Risk; Uric Acid; Uricosuric Agents | 1983 |
Effect of IgG and C-reactive protein on complement depletion by monosodium urate crystals.
Topics: Acute Disease; Agammaglobulinemia; Arthritis; C-Reactive Protein; Complement Activation; Complement | 1983 |
Tophaceous aortic valve: a case report.
Topics: Aortic Valve; Aortic Valve Stenosis; Gout; Humans; Male; Middle Aged; Uric Acid | 1983 |
[Incidence of enthesopathic changes in gout and hyperuricemia].
Topics: Aged; Arthrography; Bone and Bones; Gout; Humans; Male; Periarthritis; Uric Acid | 1982 |
Failure of folic acid (pteroylglutamic acid) to affect hyperuricemia.
Topics: Adult; Dose-Response Relationship, Drug; Female; Folic Acid; Gout; Humans; Hypoxanthines; Liver; Mal | 1980 |
Clinical disorders of uric acid metabolism.
Topics: Amidophosphoribosyltransferase; Diet; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney; | 1981 |
Hyperuricemia and gout: an update.
Topics: Allopurinol; Female; Gout; Humans; Kidney; Kidney Diseases; Male; Metabolic Clearance Rate; Middle A | 1981 |
[Nursing of gout patient (author's transl)].
Topics: Gout; Gout Suppressants; Humans; Uric Acid | 1981 |
Purine oversecretion in cultured murine lymphoma cells deficient in adenylosuccinate synthetase: genetic model for inherited hyperuricemia and gout.
Topics: Adenylosuccinate Synthase; Animals; Cell Line; Gout; Ligases; Lymphoma; Mice; Neoplasms, Experimenta | 1982 |
Urate metabolism and renal calcium stone disease.
Topics: Acute Kidney Injury; Calcium Oxalate; Crystallization; Dietary Proteins; Feeding Behavior; Female; G | 1981 |
Epidemiology of Rheumatic disorders in the Pacific with particular emphasis on hyperuricaemia and gout.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Child, Preschool; Cross-Sectional Studies; Diabetes | 1981 |
Type III glycogenosis with deposition of urate and amyloid.
Topics: Adult; Amyloid; Fructose Intolerance; Glycogen Storage Disease; Glycogen Storage Disease Type IV; Go | 1980 |
[Serum urate and gout in a young male workforce (author's transl)].
Topics: Adult; Age Factors; Body Weight; Diet; Gout; Humans; Male; Risk; Uric Acid | 1980 |
Uric acid turnover in normals, in gout and in chronic renal failure using 14C-uric acid.
Topics: Carbon Radioisotopes; Gout; Humans; Kidney Failure, Chronic; Kinetics; Radioisotope Dilution Techniq | 1980 |
[100 years of gout: from quackery and hypothesis to directed therapy].
Topics: Europe; Gout; Gout Suppressants; History, 19th Century; History, 20th Century; Humans; Life Style; M | 1982 |
The appropriate processing of tophi for microscopy.
Topics: Ethanol; Fixatives; Gout; Histological Techniques; Humans; Microscopy; Uric Acid | 1982 |
[Asymptomatic hyperuricaemia: to treat or not to treat? (author's transl)].
Topics: Adult; Diagnosis, Differential; Female; Gout; Humans; Kidney Calculi; Male; Uric Acid; Uricosuric Ag | 1981 |
[Principles of treatment of gout and hyperuricemia].
Topics: Acute Disease; Adult; Gout; Humans; Male; Middle Aged; Uric Acid | 1982 |
Aspiration of the asymptomatic metatarsophalangeal joint in gout patients and hyperuricemic controls.
Topics: Arthritis; Biopsy, Needle; Gout; Humans; Kidney Failure, Chronic; Metatarsophalangeal Joint; Neutrop | 1982 |
Surgical management of tophaceous gout: a literature review and case report.
Topics: Aged; Female; Foot Dermatoses; Gout; Humans; Metatarsophalangeal Joint; Skin Ulcer; Toe Joint; Toes; | 1982 |
[Treatment of acute gout attacks with tolmetin (author's transl)].
Topics: Acute Disease; Adult; Aged; Analgesia; Gout; Humans; Male; Middle Aged; Pyrroles; Tolmetin; Uric Aci | 1982 |
[Uric acid load test. Proof of its value using the sequential probability ratio test].
Topics: Adenine; Adult; Female; Gout; Guanine; Humans; Male; Probability; Uric Acid | 1982 |
Plasterer's tophi.
Topics: Aged; Gout; Humans; Male; Occupational Diseases; Uric Acid | 1982 |
Psoriasis and normouricemic gout.
Topics: Acute Disease; Gout; Humans; Male; Middle Aged; Psoriasis; Triamcinolone Acetonide; Uric Acid | 1982 |
[Hallux rigidus arthrosis and gout].
Topics: Calcium; Gout; Hallux; Humans; Obesity; Osteoarthritis; Uric Acid | 1982 |
Tophaceous mitral value: Report of a case.
Topics: Gout; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve; Mitral Valve Prolapse; Uric Aci | 1982 |
[Treatment of cytostatic-induced hyperuricaemia with allopurinol (author's transl)].
Topics: Adenocarcinoma; Allopurinol; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Female; G | 1982 |
[Medico-social problems of alcoholism].
Topics: Alcoholism; Breath Tests; Female; Gout; Humans; Liver Diseases, Alcoholic; Male; Melanocyte-Stimulat | 1982 |
Gouty mammary tophus.
Topics: Adult; Breast; Breast Neoplasms; Crystallization; Diagnosis, Differential; Gout; Humans; Male; Uric | 1982 |
Family study of lipid and purine levels in gout patients.
Topics: Female; Gout; Humans; Hyperlipoproteinemia Type IV; Lipids; Male; Middle Aged; Uric Acid | 1982 |
Hyperuricemia.
Topics: Arthritis; Female; Gout; Humans; Hypertension; Kidney Calculi; Male; Uric Acid | 1982 |
Heberden Oration 1981: epidemiology and the arthritides.
Topics: Adolescent; Adult; Age Factors; Aged; Body Weight; Connecticut; Female; Gout; Hand; Humans; Male; Ma | 1982 |
Frequency of chondrocalcinosis of the knees in asymptomatic hyperuricaemia and rheumatoid arthritis: a controlled study.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Chondrocalcinosis; Female; Gout; Humans; Knee Joint | 1982 |
Purine synthesis de novo in lymphocytes from patients with gout.
Topics: Adult; Female; Gout; Humans; Lymphocytes; Male; Middle Aged; Purines; Uric Acid | 1982 |
A population study of hyperuricaemia and gout in Japan--analysis of sex, age and occupational differences in thirty-four thousand people living in Nagano Prefecture.
Topics: Adolescent; Adult; Age Factors; Aged; Agriculture; Female; Gout; Humans; Japan; Male; Middle Aged; O | 1982 |
Synovial fluid examination in hyperuricemic psoriatic patients.
Topics: Adult; Aged; Gout; Humans; Male; Middle Aged; Psoriasis; Synovial Fluid; Uric Acid | 1982 |
[Uric acid and arthritis in Australia. Purified plant extract from meadow saffron is a good preparation against acute gout attacks].
Topics: Arthritis; Australia; Colchicum; Gout; Humans; Plant Extracts; Plants, Medicinal; Uric Acid | 1982 |
Gout and its manifestations in the head and neck.
Topics: Allopurinol; Arthritis; Colchicine; Ear, External; Gout; Head; Humans; Indomethacin; Laryngeal Carti | 1982 |
[Microcrystal-induced joint diseases].
Topics: Chondrocalcinosis; Female; Gout; Humans; Hydroxyapatites; Male; Uric Acid | 1982 |
[Epidemiology of hyperuricemia and gout].
Topics: Body Weight; Chronic Disease; Female; Germany, East; Gout; Humans; Male; Purines; Sex Factors; Uric | 1982 |
[Extraarticular diseases and findings in gout].
Topics: Arteriosclerosis; Diabetes Complications; Female; Gout; Humans; Hyperlipoproteinemias; Hypertension; | 1982 |
[Synovial milieu in gouty arthritis].
Topics: Arthritis; Crystallization; Gout; Humans; Synovial Fluid; Uric Acid | 1982 |
[Pathogenesis of gouty arthritis].
Topics: Acute Disease; Arthritis; Demecolcine; Gout; Granulocytes; Humans; Lysosomes; Phagocytes; Uric Acid | 1982 |
[Prognosis for disorders of purine metabolism].
Topics: Age Factors; Arterial Occlusive Diseases; Diabetes Mellitus; Germany, East; Gout; Humans; Hyperlipop | 1982 |
[Prevention and therapy of disorders of purine metabolism].
Topics: Arteriosclerosis; Diabetes Mellitus; Gout; Gout Suppressants; Humans; Hyperlipoproteinemias; Metabol | 1982 |
Thiazide-induced hyperuricemia and gout.
Topics: Adult; Arthritis; Benzothiadiazines; Diuretics; Female; Gout; Humans; Male; Phenylbutazone; Sodium C | 1982 |
Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Administration, Oral; Adult; Aged; Alcoholic Beverages; | 1982 |
[Simultaneous incidence of systemic lupus erythematosus and gout].
Topics: Crystallization; Female; Gout; Humans; Lupus Erythematosus, Systemic; Middle Aged; Uric Acid | 1982 |
Idiopathic uric acid lithiasis: epidemiologic and metabolic aspects.
Topics: Age Factors; Alcohol Drinking; Calcium Oxalate; Calcium Phosphates; Female; Gout; Humans; Hydrogen-I | 1982 |
[Current treatment of hyperuricemia and gout].
Topics: Acute Disease; Anti-Inflammatory Agents; Arthritis; Gout; Gout Suppressants; Humans; Uric Acid | 1982 |
[Dyslipoproteinemia and hyperuricemia in podagra and urinary calculi].
Topics: Adult; Arteriosclerosis; Cholesterol; Foot Diseases; Gout; Humans; Hyperlipoproteinemias; Hypolipopr | 1982 |
[Asymptomatic hyperuricemia-when should it be treated?].
Topics: Arthritis; Cardiovascular Diseases; Gout; Humans; Kidney Calculi; Kidney Diseases; Patient Care Plan | 1982 |
[Hyperuricemia, gout and ischemic disease of the coronary arteries of the heart].
Topics: Coronary Disease; Gout; Humans; Hypertension; Lipids; Male; Middle Aged; Uric Acid | 1982 |
[Gout and the hyperuricemic syndrome - comments on the differential diagnosis and therapy].
Topics: Adult; Diagnosis, Differential; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1980 |
Urate spherulites in gouty synovia.
Topics: Acute Disease; Birefringence; Crystallization; Female; Gout; Humans; Leukocytes; Microscopy, Electro | 1981 |
Long-term follow-up of incorporation of 15N from glycine into uric acid in gout.
Topics: Adult; Aged; Aging; Follow-Up Studies; Glycine; Gout; Humans; Male; Middle Aged; Nitrogen; Nitrogen | 1981 |
Ten years' experience with benzbromarone in the management of gout and hyperuricaemia.
Topics: Adult; Aged; Benzbromarone; Benzofurans; Female; Follow-Up Studies; Gout; Humans; Male; Middle Aged; | 1981 |
[Effect of long-term base therapy on the clinical picture of gout].
Topics: Adult; Allopurinol; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Gout; Human | 1981 |
[Cardiovascular risk factors among African populations. Gout].
Topics: Africa; Black or African American; Black People; Cardiovascular Diseases; Female; Gout; Humans; Male | 1980 |
Treatment of gout.
Topics: Gout; Humans; Probenecid; Uric Acid; Uricosuric Agents | 1981 |
Effects of diuretics on urate and calcium excretion.
Topics: Adult; Aged; Calcium; Chlorides; Furosemide; Glycolates; Gout; Humans; Hydrochlorothiazide; Middle A | 1981 |
[Gout (author's transl)].
Topics: Gout; Humans; Purines; Uric Acid | 1981 |
[The relation between gout and diabetes mellitus].
Topics: Blood Glucose; Diabetes Complications; Diabetes Mellitus; Gout; Humans; Hyperlipoproteinemias; Metab | 1981 |
Calculus disease of upper urinary tract in San Francisco Chinese.
Topics: Adolescent; Adult; Aged; Calcium; California; Child; China; Diet; Female; Gout; Humans; Male; Middle | 1981 |
Diagnostic and therapeutic aids in gout and hyperuricemia.
Topics: Acute Disease; Allopurinol; Arthritis, Rheumatoid; Colchicine; Diagnosis, Differential; Gout; Humans | 1981 |
Effects of exercise performance on drugs used in musculoskeletal disorders.
Topics: Allopurinol; Analgesics; Anti-Inflammatory Agents; Bone Diseases; Colchicine; Gout; Humans; Muscle R | 1981 |
[Advances in the treatment of gout and hyperuricemia].
Topics: Anti-Inflammatory Agents; Female; Gout; Humans; Hypertension; Kidney Calculi; Kidney Diseases; Male; | 1981 |
[Comparative biochemical studies in asymptomatic hyperuricemia and manifest gout with special reference to renal change].
Topics: Adolescent; Adult; Creatinine; Electrophoresis, Polyacrylamide Gel; Gout; Humans; Hyperlipoproteinem | 1981 |
The diagnosis and management of acute and chronic gout.
Topics: Acute Disease; Arthritis; Chronic Disease; Diagnosis, Differential; Gout; Gout Suppressants; Humans; | 1981 |
Urolithiasis in hyperuricemia and gout.
Topics: Adult; Allopurinol; Child; Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Male; Myelo | 1981 |
Management of asymptomatic hyperuricemia.
Topics: Acute Disease; Cardiovascular Diseases; Decision Making; Gout; Humans; Kidney Calculi; Risk; Uric Ac | 1981 |
[Current methods of treating acute gouty arthritis].
Topics: Acute Disease; Administration, Topical; Adult; Aged; Arthritis; Dimethyl Sulfoxide; Female; Gout; Hu | 1981 |
Familial gout and renal failure.
Topics: Adult; Child; Creatinine; Female; Gout; Humans; Kidney Failure, Chronic; Male; Pedigree; Uric Acid | 1981 |
[The serum uric acid level in the Viennese population (author's transl)].
Topics: Adult; Age Factors; Austria; Blood Glucose; Body Weight; Diabetes Mellitus; Female; Gout; Health Sur | 1981 |
The effect of lead upon urate nucleation.
Topics: Chemical Phenomena; Chemistry; Crystallization; Gout; Humans; Lead; Lead Poisoning; Uric Acid | 1981 |
Uric acid crystal-induced nephropathy: evidence for a specific renal lesion in a gouty family.
Topics: Adenine; Adult; Animals; Child; Child, Preschool; Female; Gout; Humans; Kidney; Kidney Diseases; Swi | 1981 |
[Elevated serum uric acid in a normal population and in patients (author's transl)].
Topics: Adult; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1981 |
Uric acid, gout and the kidney.
Topics: Acute Kidney Injury; Adult; Animals; Female; Gout; Humans; Kidney; Kidney Diseases; Male; Middle Age | 1981 |
Urate deposits in the renal medulla. Prevalence and associations.
Topics: Female; Gout; Humans; Kidney Calculi; Kidney Medulla; Male; Uric Acid; Urodynamics | 1981 |
Rheumatoid factor and monosodium urate crystal-neutrophil interactions in gouty inflammation.
Topics: Adult; Cell Adhesion; Crystallization; Gout; Humans; Hydrolases; Inflammation; Kinetics; Lysosomes; | 1981 |
Avian gout caused by oosporein, a mycotoxin produced by Caetomium trilaterale.
Topics: Animals; Chickens; Gizzard, Avian; Gout; Kidney Tubules; Mycotoxins; Poultry; Poultry Diseases; Uric | 1981 |
[Acute, massive urate crystal deposition into the subcutaneous tissues of patients with gout (author's transl)].
Topics: Acute Disease; Aged; Connective Tissue; Crystallization; Female; Finger Joint; Gout; Humans; Male; U | 1981 |
[Diagnosis and therapy of gout and hyperuricemia].
Topics: Colchicine; Diet; Gout; Gout Suppressants; Humans; Kidney; Uric Acid; Uricosuric Agents | 1981 |
[Elements of risk of ischemic heart disease in patients with primary gout and its behavior as a function of the basic treatment].
Topics: Adult; Aged; Coronary Disease; Gout; Humans; Male; Middle Aged; Risk; Uric Acid | 1981 |
[Acute attack of gout].
Topics: Acute Disease; Allopurinol; Bed Rest; Breathing Exercises; Colchicine; Female; Gout; Humans; Indomet | 1981 |
Monosodium urate crystals in asymptomatic joints.
Topics: Crystallization; Gout; Humans; Male; Synovial Fluid; Uric Acid | 1980 |
High uric acid as an indicator of cardiovascular disease. Independence from obesity.
Topics: Aged; Body Weight; Cardiovascular Diseases; Coronary Disease; Female; Follow-Up Studies; Gout; Human | 1980 |
Coexistent rheumatoid arthritis and chronic tophaceous gout.
Topics: Aged; Arthritis, Rheumatoid; Chronic Disease; Foot; Gout; Hand; Humans; Immunosuppression Therapy; M | 1980 |
Gouty arthritis: a disease for all ages.
Topics: Aged; Arthritis; Colchicine; Female; Gout; Humans; Kidney; Male; Middle Aged; Synovial Fluid; Uric A | 1980 |
Current status of diagnosis and treatment of acute gouty arthritis.
Topics: Acute Disease; Adult; Arthritis; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Synovial | 1980 |
[The use of allopurinol in long-term treatments for optimal effect].
Topics: Allopurinol; Biological Availability; Dose-Response Relationship, Drug; Gout; Half-Life; Humans; Kin | 1980 |
[Uric acid-induced diseases. 1. Clinical picture, forms of manifestation].
Topics: Animals; Arteriosclerosis; Gout; Humans; Kidney Calculi; Kidney Diseases; Pruritus; Rats; Risk; Syno | 1980 |
[Uric acid-induced diseases. 2. Therapy].
Topics: Allopurinol; Benzbromarone; Benzothiadiazines; Diuretics; Gout; Humans; Purines; Sodium Chloride Sym | 1980 |
Studies on the nucleation of monosodium urate at 37 degrees c.
Topics: Connective Tissue; Crystallization; Gout; Humans; Hydrogen-Ion Concentration; Sodium; Solubility; Sy | 1980 |
Atraumatic avascular necrosis of the talus associated with hyperuricemia.
Topics: Black People; Female; Gout; Humans; Middle Aged; Osteonecrosis; Talus; Uric Acid | 1980 |
[Attempt at normalizing the uricemia in gout].
Topics: Adolescent; Adult; Aged; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Gout; | 1980 |
Renal handling of uric acid in normal and gouty subject: evidence for a 4-component system.
Topics: Absorption; Benzbromarone; Blood Proteins; Female; Gout; Humans; In Vitro Techniques; Kidney; Kidney | 1980 |
Determination of uric acid in serum using isotachophoresis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Electrophoresis; Female; Gout; Humans; Male; Microchemistry; Mid | 1980 |
[Hyperuricemia and gout].
Topics: Female; Gout; Humans; Male; Risk; Uric Acid; Urinary Calculi | 1980 |
[Efficacy and tolerance of a new benzbromarone preparation].
Topics: Benzbromarone; Benzofurans; Gout; Humans; Hydrogen-Ion Concentration; Uric Acid; Urine | 1980 |
Hereditary uricemia and articular gout in chickens.
Topics: Animals; Chickens; Diet; Female; Gout; Male; Poultry Diseases; Uric Acid | 1980 |
Primary overproduction of urate caused by a partial deficiency of hypoxanthine-guanine phosphoribosyl transferase.
Topics: Adult; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Male; Uric Acid | 1980 |
[Characteristics of the clinical course and diagnosis of gout under present-day conditions].
Topics: Adult; Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Gout; Humans; Male; Middle Aged; Synovi | 1980 |
[Clinical picture and management of gout and hyperuricemia].
Topics: Adult; Female; Gout; Humans; Japan; Male; Middle Aged; Uric Acid | 1980 |
[A case of primary hypouricosuric gout associated with mental retardation, self-mutilation and salt dependent hypertension (author's transl)].
Topics: Adolescent; Gout; Humans; Hypertension; Intellectual Disability; Male; Self Mutilation; Uric Acid | 1980 |
Psychosomatic aspects of gout.
Topics: Adult; Drive; Female; Gout; Humans; Male; Middle Aged; Psychophysiologic Disorders; Stress, Psycholo | 1980 |
Indomethacin-induced hyperkalemia in three patients with gouty arthritis.
Topics: Acute Disease; Acute Kidney Injury; Aged; Diabetes Mellitus; Female; Gout; Humans; Hyperkalemia; Ind | 1980 |
Changing trends of mortality in gout.
Topics: Aged; Arteriosclerosis; Coronary Disease; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; | 1980 |
Hyperuricemia in cyanotic congenital heart disease.
Topics: Adolescent; Adult; Allopurinol; Arthritis; Child; Child, Preschool; Gout; Heart Defects, Congenital; | 1980 |
The natural history of hyperuricemia among asymptomatic relatives of patients with gout.
Topics: Amino Acids; Blood; Female; Glutamates; Glutamine; Gout; Humans; Hydrogen-Ion Concentration; Male; R | 1980 |
Monosodium urate monohydrate as spherulites.
Topics: Birefringence; Crystallography; Gout; Humans; Microscopy, Electron, Scanning; Uric Acid | 1980 |
Hereditary and environmental factors influencing on the serum uric acid throughout ten years population study in Japan.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Environment; Female; Gout; Humans; In | 1980 |
Family study of lipid and purine levels in gout patients and analysis of mortality.
Topics: Cholesterol; Female; Gout; Humans; Hyperlipidemias; Lipoproteins; Male; Sex Factors; Triglycerides; | 1980 |
Tienilic acid in the treatment of gout and hypertension.
Topics: Adult; Blood Chemical Analysis; Blood Pressure; Creatinine; Glycolates; Gout; Humans; Hypertension; | 1980 |
Erythrocyte adenosine-deaminase activity in gout and hyperuricemia.
Topics: Adenosine Deaminase; Erythrocytes; Female; Fructose; Gout; Humans; Kidney Diseases; Male; Nucleoside | 1980 |
Clinical features of 4,000 gouty subjects in Japan.
Topics: Adult; Age Factors; Female; Gout; Humans; Hypertension; Japan; Kidney Failure, Chronic; Male; Middle | 1980 |
Determination of tubular secretion of urate in healthy and gouty men.
Topics: Adult; Benzbromarone; Female; Gout; Humans; Kidney Tubules; Male; Reference Values; Uric Acid | 1980 |
Familial gout and renal failure in young women.
Topics: Acute Kidney Injury; Adolescent; Adult; Allopurinol; Child; Female; Gout; Humans; Middle Aged; Uric | 1980 |
Gout and achievement.
Topics: Achievement; Gout; Humans; Uric Acid | 1980 |
[Case of uric acid gout].
Topics: Aged; Elbow Joint; Gout; Humans; Male; Uric Acid | 1980 |
[Epidemiology and clinical aspects of hyperuricemia and gout].
Topics: Aged; Alcohol Drinking; Blood Pressure; Body Weight; Diagnosis, Differential; Feeding Behavior; Gout | 1980 |
Controlled inpatient study of tienilic acid in treatment of gout and hypertension.
Topics: Blood Pressure; Drug Administration Schedule; Glycolates; Gout; Humans; Hypertension; Ticrynafen; Ur | 1980 |
Tienilic acid: a single treatment for hyperuricaemia and hypertension?
Topics: Adult; Aged; Blood Pressure; Glycolates; Gout; Humans; Hypertension; Male; Middle Aged; Ticrynafen; | 1980 |
Gout secondary to chronic renal disease: studies on urate metabolism.
Topics: Adult; Arthritis; Chronic Disease; Female; Gout; Humans; Kidney; Kidney Diseases; Male; Middle Aged; | 1980 |
[Gout as a joint disease and as a generalized disease. Incidence, diagnosis and therapy].
Topics: Allopurinol; Colchicine; Diabetes Complications; Gout; Humans; Hypertension; Indomethacin; Kidney Di | 1980 |
Chronic gouty nephropathy: a vanishing syndrome?
Topics: Animals; Gout; Humans; Kidney Diseases; Lead Poisoning; Lesch-Nyhan Syndrome; Lymphoproliferative Di | 1981 |
[Study of the binding between uric acid and plasma proteins (author's transl)].
Topics: Blood Proteins; Electrophoresis, Agar Gel; Electrophoresis, Cellulose Acetate; Gout; Humans; Hyperli | 1980 |
[Secondary hyperuricemia (author's transl)].
Topics: Female; Gout; Humans; Male; Metabolic Diseases; Uric Acid | 1980 |
Hyperuricaemia and gout in Western Samoans.
Topics: Adult; Aged; Epidemiologic Methods; Female; Gout; Humans; Independent State of Samoa; Life Style; Ma | 1981 |
Uricosuric diuretics.
Topics: Amiloride; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gout; Humans; Ind | 1980 |
[Value of uric acid clearance for the differential diagnosis and differential therapy of disorders of uric acid metabolism].
Topics: Arthritis; Female; Gout; Humans; Male; Uric Acid | 1980 |
Cyclosporine-induced hyperuricemia and gout in renal transplants.
Topics: Adult; Allopurinol; Azathioprine; Cyclosporine; Drug Interactions; Gout; Gout Suppressants; Humans; | 1995 |
Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis.
Topics: Calcium Pyrophosphate; Cells, Cultured; Chemokine CCL3; Chemokine CCL4; Chemokine CXCL1; Chemokines, | 1995 |
A quantitative study of the phagocytosis of urate crystals in the synovial fluid of asymptomatic joints of patients with gout.
Topics: Crystallization; Gout; Humans; Joints; Leukocyte Count; Monocytes; Neutrophils; Phagocytosis; Synovi | 1995 |
The effects of alcoholic beverages on urate metabolism in gout sufferers.
Topics: Alcohol Drinking; Alcoholic Beverages; Beer; Beverages; Citrus; Ethanol; Gout; Humans; Purines; Uric | 1995 |
Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation.
Topics: Adult; Age Distribution; Alkalies; Body Mass Index; Calcium; Chemical Phenomena; Chemistry, Physical | 1995 |
Gout in patients attending the rheumatology unit of Lomé Hospital.
Topics: Adult; Female; Gout; Hospital Departments; Hospitals; Humans; Male; Middle Aged; Retrospective Studi | 1995 |
Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases.
Topics: Adult; Aged; Female; Gout; Heart Transplantation; Humans; Male; Middle Aged; Postoperative Complicat | 1995 |
Renal urate hypoexcretion in Polynesian women is not as severe as in United Kingdom (UK) women with familial juvenile hyperuricaemic nephropathy (FJHN).
Topics: Adult; Analysis of Variance; Creatinine; Female; Gout; Humans; Kidney Diseases; Middle Aged; Polynes | 1994 |
Differential diagnosis of main rheumatic diseases in man.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Blood Glucose; Blood Sedimentation; Blood Urea Nitrogen | 1994 |
Analysis of the genotypes for aldehyde dehydrogenase 2 in Japanese patients with primary gout.
Topics: Alcohol Drinking; Aldehyde Dehydrogenase; Alleles; Genetic Carrier Screening; Gout; Homozygote; Huma | 1994 |
Purine metabolism in female patients with primary gout.
Topics: Adenine; Arthritis, Gouty; Creatinine; Female; Gout; Humans; Hypoxanthine; Hypoxanthines; Male; Puri | 1994 |
Familial juvenile hyperuricaemic nephropathy in adolescents.
Topics: Adolescent; Adult; Diagnosis, Differential; Erythrocytes; Female; Gout; Humans; Hypoxanthine Phospho | 1994 |
Serum concentration of Lp(a) in patients with primary gout.
Topics: Alanine Transaminase; Alcohol Drinking; Apolipoproteins; Aspartate Aminotransferases; Blood Glucose; | 1994 |
Study on lipoprotein lipase and hepatic triglyceride lipase activities in patients with gout.
Topics: Apolipoproteins B; Body Mass Index; Cholesterol; Cholesterol, HDL; Cohort Studies; Gout; Humans; Lip | 1994 |
Benzbromarone and fenofibrate are lipid lowering and uricosuric: a possible key to metabolic syndrome?
Topics: Benzbromarone; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Gout; Humans; Hyperlipi | 1994 |
Determination of plasma purine nucleoside phosphorylase activity by high-performance liquid chromatography.
Topics: Adult; Aged; Asthma; Calibration; Chromatography, High Pressure Liquid; Febuxostat; Female; Gout; Go | 1995 |
How much do we know about hyperuricemia and gout? The expectations and the results.
Topics: Clinical Competence; Educational Status; Gout; Humans; Internal Medicine; Uric Acid | 1993 |
Gout and the gullible.
Topics: Crystallization; Gout; Humans; Solubility; Uric Acid | 1994 |
Not water, but formalin, dissolves urate crystals in tophaceous tissue samples.
Topics: Crystallization; Ethanol; Formaldehyde; Gout; Humans; Solubility; Uric Acid; Water | 1994 |
Gout: questions that still need to be answered.
Topics: Animals; Crystallization; Disease Models, Animal; Gout; Humans; Mice; Mice, Mutant Strains; Synoviti | 1995 |
Missed opportunity following diagnosis of gout.
Topics: Adult; Allopurinol; Beer; Cardiovascular Diseases; Gout; Humans; Lipoproteins; Male; Risk Factors; U | 1995 |
Gout and hyperuricaemia.
Topics: Acute Disease; Africa; Asia, Southeastern; Chronic Disease; Female; Gout; Humans; Male; New Zealand; | 1995 |
[The frequency of gout and other disorders of uric acid metabolism in Dalmatia in comparison with these disorders in Croatia].
Topics: Croatia; Female; Gout; Humans; Male; Prevalence; Uric Acid; Urinary Calculi; Yugoslavia | 1993 |
Effect of glucose infusion on the renal transport of purine bases and oxypurinol.
Topics: Adult; Allopurinol; Biological Transport, Active; Diabetes Complications; Diabetes Mellitus; Glucose | 1995 |
Does renal impairment protect from gout?
Topics: Adult; Aged; Cohort Studies; Creatinine; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; R | 1995 |
Molecular recognition. Crystallographic antibodies.
Topics: Allopurinol; Animals; Antibodies; Catalysis; Crystallization; Gout; Humans; Immunoglobulin G; Rabbit | 1995 |
[Gout tophi and Heberden nodules in hyperuricemia].
Topics: Aged; Aged, 80 and over; Arthritis, Gouty; Female; Fingers; Gout; Hand Deformities, Acquired; Humans | 1994 |
Familial hyperuricemic nephropathy.
Topics: Adolescent; Adult; Child; Family Health; Female; Genes, Dominant; Gout; Humans; Hypertension; Kidney | 1995 |
Community-based epidemiological study on hyperuricemia in Pu-Li, Taiwan.
Topics: Adult; Cross-Sectional Studies; Diet; Female; Gout; Humans; Male; Middle Aged; Prevalence; Risk Fact | 1993 |
Polynesian women are also at risk for hyperuricaemia and gout because of a genetic defect in renal urate handling.
Topics: Adult; Erythrocytes; Family; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Pentosyltrans | 1994 |
Purine metabolism in women with primary gout.
Topics: Aged; Creatinine; Female; Gout; Humans; Hypoxanthine; Hypoxanthines; Male; Middle Aged; Prospective | 1994 |
Complexation of iron cation by sodium urate crystals and gouty inflammation.
Topics: Chemotaxis, Leukocyte; Chlorides; Complement Activation; Crystallization; Deferoxamine; Ferric Compo | 1994 |
Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.
Topics: Administration, Oral; Allopurinol; Animals; Dose-Response Relationship, Drug; Febuxostat; Female; Go | 1993 |
[Spectrophotometric determination of uric acid in serum using a titanium (IV)-porphyrin complex].
Topics: Gout; Humans; Porphyrins; Reagent Kits, Diagnostic; Spectrophotometry; Titanium; Urate Oxidase; Uric | 1994 |
[The clinical manifestations of a purine metabolic disorder in the practice of the internist].
Topics: Adult; Arthritis, Gouty; Glomerulonephritis; Gout; Humans; Liver Cirrhosis, Alcoholic; Middle Aged; | 1994 |
[The use of Allomaron in treating hyperuricemia].
Topics: Adult; Allopurinol; Arthritis, Gouty; Benzbromarone; Creatinine; Drug Combinations; Drug Evaluation; | 1994 |
Lesch-Nyhan syndrome presenting with renal insufficiency in infancy and transient neonatal hypothyroidism.
Topics: Acute Kidney Injury; Erythrocytes; Gout; Humans; Hypothyroidism; Hypoxanthine Phosphoribosyltransfer | 1994 |
[Hyperuricemia and gout: therapeutic indications].
Topics: Acute Disease; Gout; Gout Suppressants; Humans; Uric Acid | 1994 |
Thoracic myelopathy due to compression by the epidural tophus: a case report.
Topics: Constipation; Crystallization; Epidural Space; Gout; Humans; Laminectomy; Male; Middle Aged; Neuromu | 1994 |
Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model.
Topics: Aged; Animals; Apolipoproteins B; Crystallization; Gout; Humans; Immunoglobulin G; Immunohistochemis | 1993 |
Withdrawal of longterm antihyperuricemic therapy in tophaceous gout.
Topics: Adult; Allopurinol; Drug Administration Schedule; Gout; Humans; Middle Aged; Recurrence; Retrospecti | 1993 |
Tophaceous gout of patella partita.
Topics: Adult; Arthrography; Gout; Humans; Male; Patella; Uric Acid | 1993 |
Gout without hyperuricemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Crystallization; Gout; Humans; Male; Reference Values; Tempe | 1994 |
Gout: an experience from Zimbabwe.
Topics: Adult; Alcoholism; Comorbidity; Female; Follow-Up Studies; Gout; Humans; Male; Middle Aged; Risk Fac | 1993 |
[Female gout disclosing Bartter pseudo-syndrome caused by vomiting].
Topics: Adult; Bartter Syndrome; Diagnosis, Differential; Female; Gout; Humans; Uric Acid; Vomiting | 1993 |
[Hyperuricemia and atherosclerosis].
Topics: Aged; Arteriosclerosis; Diet, Atherogenic; Gout; Humans; Hyperinsulinism; Hyperlipidemias; Hypertens | 1993 |
Hereditary nephropathy associated with hyperuricemia and gout.
Topics: Adolescent; Adult; Child; Female; Follow-Up Studies; Gout; Humans; Kidney; Kidney Failure, Chronic; | 1993 |
[Hyperuricemia].
Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Japan; Male; Middle Aged; Prognosis; Uric Acid | 1993 |
Glycogenosis type V (McArdle's disease) with hyperuricemia. A case report and clinical investigation.
Topics: Adult; Biopsy; Enzymes; Exercise Test; Glycogen Storage Disease Type V; Gout; Humans; Male; Muscles; | 1993 |
Rapid development of a tophus following ipsilateral hemiparesis.
Topics: Acute Disease; Aged; Aged, 80 and over; Cerebrovascular Disorders; Foot Diseases; Gout; Hemiplegia; | 1993 |
Tophaceous gout in patients with renal transplants treated with cyclosporine A.
Topics: Adult; Cyclosporine; Female; Gout; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative | 1993 |
Tophaceous gout in young patients with systemic lupus erythematosus.
Topics: Adult; Female; Glomerulonephritis; Gout; Humans; Lupus Erythematosus, Systemic; Male; Uric Acid | 1993 |
Gout: modern management of an ancient malady.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Infectious; Gout; | 1993 |
[Contraindication of ATP related drugs for therapy of gout and uric acidemia].
Topics: Adenosine Triphosphate; Contraindications; Dipyridamole; Gout; Humans; Platelet Aggregation Inhibito | 1995 |
[An epidemiologic study on pathogenesis of uric acid urolithiasis].
Topics: Alcohol Drinking; Female; Gout; Humans; Male; Sex Factors; Time Factors; Uric Acid; Urinary Calculi | 1995 |
Management of gout.
Topics: Gout; Humans; Uric Acid | 1996 |
[Diagnosis and treatment of gout: not always simple].
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Arthritis, Rheumatoid; Biopsy; Colchicine; Diagnosis, D | 1996 |
[Gout: current aspects of etiology, diagnosis and therapy].
Topics: Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Female; Gout; Gou | 1996 |
Compressive ulnar neuropathy in the proximal forearm caused by a gouty tophus.
Topics: Carpal Tunnel Syndrome; Diagnosis, Differential; Elbow; Electrodiagnosis; Gout; Humans; Male; Middle | 1996 |
The diagnosis of gout and CPPD crystal arthropathy.
Topics: Calcium Pyrophosphate; Chondrocalcinosis; Gout; Humans; Synovial Fluid; Uric Acid | 1996 |
Characterization of E-selectin expression, leucocyte traffic and clinical sequelae in urate crystal-induced inflammation: an insight into gout.
Topics: Albumins; Animals; Cell Movement; Disease Models, Animal; E-Selectin; Gout; Leukocytes, Mononuclear; | 1996 |
Inhibition and prevention of monosodium urate monohydrate crystal-induced acute inflammation in vivo by transforming growth factor beta1.
Topics: Acute Disease; Animals; Antibodies, Anti-Idiotypic; Disease Models, Animal; Dose-Response Relationsh | 1996 |
[Kidney lesions in non-insulin dependent diabetes mellitus].
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; G | 1995 |
Finger pad tophi in gout.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Creatinine; Female; Fingers; Gout; Hand Dermatoses; | 1996 |
Gout in the cervical spine: MR pattern mimicking diskovertebral infection.
Topics: Arthritis, Gouty; Cervical Vertebrae; Diagnosis, Differential; Discitis; Gout; Humans; Intervertebra | 1996 |
[Microalbuminuria as one of the early diagnostic signs of kidney involvement in patients with a purine metabolic disorder].
Topics: Adult; Albuminuria; Female; Gout; Hematuria; Humans; Kidney Diseases; Male; Purines; Recurrence; Tim | 1996 |
Endogenous analgesia in the chicken.
Topics: Analgesia; Animals; Ankle Joint; Behavior, Animal; Chickens; Disease Models, Animal; Gout; Time Fact | 1995 |
Gout, uric acid, albumin, and aging.
Topics: Aging; Gout; Humans; Uric Acid | 1996 |
Determination of human plasma xanthine oxidase activity by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Ethanol; Glycogen Storage Disease Type I; Gout; Heparin; Hepat | 1996 |
Magnetic resonance imaging of tophaceous gout in the hands and wrists.
Topics: Aged; Gout; Hand; Humans; Magnetic Resonance Imaging; Male; Radiography; Sensitivity and Specificity | 1996 |
Unusual localisation of tophaceous gout. A report of four cases and review of the literature.
Topics: Adult; Aged; Foot Diseases; Gout; Humans; Knee Joint; Male; Toes; Uric Acid | 1996 |
Renal handling of urate in a patient with familial juvenile gouty nephropathy.
Topics: Adolescent; Benzbromarone; Female; Genes, Dominant; Gout; Gout Suppressants; Humans; Kidney; Kidney | 1996 |
Hyperuricemia among Kuwaitis.
Topics: Adult; Female; Gout; Hospitals, General; Humans; Kuwait; Life Style; Male; Middle Aged; Obesity; Pre | 1996 |
Gout is on the increase in New Zealand.
Topics: Adolescent; Adult; Age of Onset; Female; Gout; Humans; Male; Middle Aged; Native Hawaiian or Other P | 1997 |
Demonstration of urate in formalin fixative as support for the histopathological diagnosis of gout.
Topics: Crystallization; Elbow; Formaldehyde; Gout; Humans; Male; Middle Aged; Tissue Preservation; Uric Aci | 1997 |
Purine metabolism in patients with gout: the role of lead.
Topics: Aged; Arteriosclerosis; Chelating Agents; Creatinine; Edetic Acid; Female; Gout; Humans; Hypoxanthin | 1997 |
The perils of nontreatment of hyperuricemia.
Topics: Aged; Gout; Gout Suppressants; Humans; Male; Staphylococcal Skin Infections; Uric Acid | 1997 |
High prevalence of hyperuricaemia among Kuwaitis possibly without a proportionate increase in gout.
Topics: Adult; Female; Gout; Humans; Kuwait; Male; Middle Aged; Prevalence; Uric Acid | 1997 |
Gout: the last 50 years.
Topics: Arthritis, Gouty; Colchicine; Crystallization; Gout; Gout Suppressants; History, 20th Century; Human | 1996 |
Acute gout in a patient taking pefloxacin--a case report.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Gout; Humans; Male; Pefloxacin; Respiratory Tract In | 1996 |
Prepatellar bursitis: a unique presentation of tophaceous gout in an normouricemic patient.
Topics: Aged; Bursa, Synovial; Bursitis; Frail Elderly; Gout; Humans; Knee Joint; Magnetic Resonance Imaging | 1997 |
Altered arachidonic acid metabolism in urate crystal induced inflammation.
Topics: Animals; Arachidonic Acid; Arthritis, Gouty; Crystallization; Disease Models, Animal; Eicosanoids; F | 1997 |
Is the plasma uridine level a marker of the overproduction of uric acid?
Topics: Adult; Biomarkers; Gout; Humans; Male; Middle Aged; Osmolar Concentration; Purines; Triglycerides; U | 1997 |
High prevalence of gout and related risk factors in Taiwan's Aborigines.
Topics: Age Distribution; Aged; Female; Gout; Humans; Logistic Models; Male; Middle Aged; Native Hawaiian or | 1997 |
Thiazide diuretics and the initiation of anti-gout therapy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzothiadiazines; Diuretics; Female; Gout; Humans | 1997 |
Molecular determinants of monosodium urate crystal-induced murine peritonitis: a role for endogenous mast cells and a distinct requirement for endothelial-derived selectins.
Topics: Animals; Cell Movement; Crystallization; Endothelium, Vascular; Gout; Histamine; Macrophage-1 Antige | 1997 |
Gouty tophus simulating soft tissue tumor in a heart transplant recipient.
Topics: Adult; Diagnosis, Differential; Forearm; Gout; Heart Transplantation; Humans; Magnetic Resonance Ima | 1997 |
Gout due to xanthine derivatives.
Topics: Allopurinol; Aminophylline; Asthma; Benzbromarone; Bronchodilator Agents; Drug Therapy, Combination; | 1997 |
The contribution of the Rabin Medical Center to the field of rheumatology.
Topics: Gout; Humans; Israel; Publications; Rheumatic Diseases; Uric Acid | 1997 |
[Determination of uric acid in scalp hair for non-invasive estimation of uricemic control in hyperuricemia].
Topics: Biomarkers; Gout; Hair; Humans; Sensitivity and Specificity; Uric Acid | 1997 |
Analysis of abnormalities in purine metabolism leading to gout and to neurological dysfunctions in man.
Topics: Adenylosuccinate Lyase; Aminoimidazole Carboxamide; AMP Deaminase; Gout; Humans; Hypoxanthine Phosph | 1998 |
[Epidemiology, incidence and sex specific differences in primary gout].
Topics: Adult; Aged; Austria; Cross-Sectional Studies; Female; Gout; Health Behavior; Humans; Incidence; Lif | 1997 |
Serum uric acid in acute gout.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Biomarkers; Female; Gout; Humans; Male; Middle Aged; | 1997 |
Tophaceous gout of the navicular bone as a cause of medial inflammatory tumor of the foot.
Topics: Adult; Alcoholism; Anorexia Nervosa; Crystallization; Female; Foot Diseases; Gout; Granuloma, Foreig | 1998 |
[First-time standard setting for therapy of pulmonary tuberculosis after revision of the Medical Treatment Standard--special reference to results of questionnaire survey on reality of early stage short-term PZA therapy and occurrence of the adverse effect
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy; Gout; Humans; Japan; Li | 1997 |
[Treatment of asymptomatic hyperuricemia].
Topics: Allopurinol; Dose-Response Relationship, Drug; Drug Administration Schedule; Gout; Gout Suppressants | 1997 |
Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout.
Topics: Adult; Allopurinol; Benzbromarone; Calcifediol; Calcitriol; Calcium; Gout; Gout Suppressants; Humans | 1998 |
Disease-specific noncompliance with drug treatment as a cause of persistent hyperuricemia and gout in anorexia nervosa.
Topics: Allopurinol; Anorexia Nervosa; Female; Gout; Humans; Middle Aged; Patient Compliance; Treatment Fail | 1998 |
The epidemiology of hyperuricaemia and gout in Taiwan aborigines.
Topics: Adult; Age Distribution; Aged; Asian People; Body Mass Index; Cholesterol; Female; Gout; Humans; Mal | 1998 |
Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment.
Topics: Biomarkers; Confidence Intervals; Drug Monitoring; Gout; Gout Suppressants; Humans; Male; Purine-Pyr | 1998 |
How should we treat tophaceous gout in patients with allopurinol hypersensitivity?
Topics: Adolescent; Adult; Aged; Allopurinol; Benzbromarone; Creatinine; Drug Hypersensitivity; Gout; Gout S | 1998 |
Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout.
Topics: Allopurinol; Calcifediol; Calcitriol; Gout; Gout Suppressants; Humans; Male; Middle Aged; Parathyroi | 1998 |
De novo purine synthesis is increased in the fibroblasts of purine autism patients.
Topics: Autistic Disorder; Cells, Cultured; Fibroblasts; Gout; Humans; Lesch-Nyhan Syndrome; Purines; Refere | 1998 |
Effect of Tofu (bean curd) ingestion and on uric acid metabolism in healthy and gouty subjects.
Topics: Adult; Dietary Proteins; Food Handling; Glycine max; Gout; Humans; Male; Middle Aged; Reference Valu | 1998 |
Demonstration of urate crystals after formalin fixation.
Topics: Crystallization; Gout; Histological Techniques; Humans; Microscopy, Polarization; Specimen Handling; | 1998 |
Medullary cystic kidney disease with hyperuricemia and gout in a large Cypriot family: no allelism with nephronophthisis type 1.
Topics: Adult; Age of Onset; Aged; Cyprus; Female; Genes, Dominant; Genetic Linkage; Gout; Humans; Hypertens | 1998 |
Quality control of synovial fluid crystal identification.
Topics: Arthritis; Biomarkers; Crystallization; False Negative Reactions; False Positive Reactions; Gout; Hu | 1998 |
Treatment of gout after transplantation.
Topics: Allopurinol; Azathioprine; Cyclosporine; Diuretics; Drug Interactions; Furosemide; Gout; Gout Suppre | 1998 |
Salivary urate in gout, exercise, and diurnal variation.
Topics: Adult; Case-Control Studies; Circadian Rhythm; Exercise; Exercise Test; Female; Gout; Humans; Male; | 1998 |
Apoptosis of tubular epithelial cells in familial juvenile gouty nephropathy.
Topics: Adult; Apoptosis; Benzbromarone; Biopsy; Biotin; Deoxyuracil Nucleotides; DNA Fragmentation; Family | 1998 |
Presymptomatic detection of familial juvenile hyperuricaemic nephropathy in children.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Gout; Humans; Kidney Diseases; Kidney Failure, C | 1998 |
Serum uric acid in acute gout.
Topics: Acute Disease; Allopurinol; Gout; Gout Suppressants; Humans; Uric Acid | 1998 |
Restoration of the uricosuric effect of probenecid after triglycylvasopressine administration in a gouty patient.
Topics: Absorption; Acute Kidney Injury; Adult; Anti-Inflammatory Agents; Benzbromarone; Fludrocortisone; Go | 1998 |
Hyperlipidaemia in hyperuricaemia and gout.
Topics: Gout; Humans; Hyperinsulinism; Hypertriglyceridemia; Insulin Resistance; Uric Acid | 1998 |
Monosodium urate-crystal-stimulated phospholipase D in human neutrophils.
Topics: ADP-Ribosylation Factors; Adult; Biological Transport; Cell Compartmentation; Cytochalasin B; Cytoso | 1999 |
The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. 1956.
Topics: Adrenal Cortex Hormones; Androgens; Arteriosclerosis; Body Constitution; Cholelithiasis; Diabetes Me | 1999 |
Intradermal tophi in gout: a case-control study.
Topics: Adult; Aged; Case-Control Studies; Female; Glucocorticoids; Gout; Humans; Male; Middle Aged; Tissue | 1999 |
[Gout: physiopathology, diagnosis, course, treatment].
Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Benzbromarone; Diagnosis, Differential; Female; Gout; Go | 1998 |
[The central mechanisms regulating the blood circulation in hyperuricemia].
Topics: Adenosine; Animals; Blood Circulation; Brain; Brain Chemistry; Cyclic AMP; Cyclic GMP; Disease Model | 1999 |
Identification of crystals in synovial fluid.
Topics: Calcium Pyrophosphate; Crystallization; Gout; Humans; Microscopy, Polarization; Quality Control; Sen | 1999 |
Serum uric acid: correlation with biological, clinical and behavioral factors in Japanese men.
Topics: Adult; Alcohol Drinking; Cross-Sectional Studies; Diabetes Mellitus; Gout; Humans; Hypertension; Lif | 1999 |
Displaced pathological patella fracture due to gout.
Topics: Biopsy; Debridement; Fractures, Spontaneous; Gout; Humans; Male; Middle Aged; Patella; Radiography; | 1999 |
The epidemiology study of hyperuricemia and gout in a community population of Huangpu District in Shanghai.
Topics: Adolescent; Adult; Aged; China; Female; Gout; Humans; Male; Middle Aged; Prevalence; Risk Factors; S | 1998 |
Contribution of a missense mutation (Trp64Arg) in beta3-adrenergic receptor gene to multiple risk factors in Japanese men with hyperuricemia.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Gout; Humans; Insulin Resistance; Japan; Male; Mid | 1998 |
[Disseminated skin abnormalities due to gout].
Topics: Aged; Arthritis, Gouty; Biopsy; Crystallization; Gout; Humans; Male; Skin; Skin Diseases, Metabolic; | 1999 |
Gout.
Topics: Acute Disease; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Crystallizati | 1999 |
Synovial fluid analysis for diagnosis of intercritical gout.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Crystallization; Female; Gout; Humans; Knee | 1999 |
Kelley-Seegmiller syndrome due to a unique variant of hypoxanthine-guanine phosphoribosyltransferase: reduced affinity for 5-phosphoribosyl-1-pyrophosphate manifested only at low, physiological substrate concentrations.
Topics: Acute Kidney Injury; Adenine; Cells, Cultured; Child, Preschool; Culture Media, Conditioned; DNA Mut | 2000 |
Regulation of in vivo prostaglandin biosynthesis by glutathione.
Topics: Animals; Cyclooxygenase 1; Cyclooxygenase 2; Fatty Acids, Unsaturated; Glutathione; Glyceraldehyde-3 | 1999 |
Localization of a gene for familial juvenile hyperuricemic nephropathy causing underexcretion-type gout to 16p12 by genome-wide linkage analysis of a large family.
Topics: Chromosome Mapping; Chromosomes, Human, Pair 16; Family Health; Female; Genetic Linkage; Genotype; G | 2000 |
Familial juvenile hyperuricemic nephropathy: localization of the gene on chromosome 16p11.2-and evidence for genetic heterogeneity.
Topics: Adolescent; Adult; Age of Onset; Carrier Proteins; Child; Chromosome Mapping; Chromosomes, Human, Pa | 2000 |
Staining method to demonstrate urate crystals in formalin-fixed, paraffin-embedded tissue sections.
Topics: Birefringence; Crystallization; Formaldehyde; Gout; Histocytological Preparation Techniques; Humans; | 2000 |
Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen.
Topics: Adult; Age Distribution; Cholesterol; Female; Gout; Humans; Logistic Models; Male; Middle Aged; Pred | 2000 |
Clinical manifestations of Korean female gouty patients.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Cyclosporine; Diuretics; Female; Gout; Gra | 2000 |
Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients?
Topics: Adult; Aged; Aged, 80 and over; Crystallization; Cytokines; Cytological Techniques; Female; Gout; Hu | 2000 |
Effect of urine storage on urinary uric acid concentrations.
Topics: Gout; Humans; Male; Reference Values; Specimen Handling; Uric Acid | 2000 |
Diagnosis of intercritical gout.
Topics: Arthritis, Gouty; Crystallization; Gout; Humans; Synovial Fluid; Uric Acid | 2000 |
The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study.
Topics: Adult; Alcohol Drinking; Diuretics; Follow-Up Studies; Gout; Humans; Hypertension; Incidence; Logist | 2000 |
Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study.
Topics: Adult; Body Mass Index; Diet, Reducing; Dietary Fats, Unsaturated; Dietary Proteins; Follow-Up Studi | 2000 |
Effect of tea and coffee consumption on serum uric acid levels by liquid-chromatographic and uricase methods.
Topics: Chromatography, High Pressure Liquid; Coffee; Diet; Female; Gout; Humans; Male; Tea; Urate Oxidase; | 2000 |
Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study.
Topics: Age Factors; Aged; Alcohol Drinking; Blood Pressure; Body Mass Index; Bone Density; Cohort Studies; | 2000 |
Carpal tunnel syndrome caused by tophaceous gout: CT and MR imaging features in 20 patients.
Topics: Adult; Aged; Carpal Tunnel Syndrome; Female; Gout; Humans; Magnetic Resonance Imaging; Male; Middle | 2000 |
[Tophaceous gout].
Topics: Aged; Aged, 80 and over; Diuretics; Female; Fingers; Gout; Humans; Hypertension; Uric Acid | 2000 |
The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Drug Evaluation; Female; Gout; Gout Suppres | 2000 |
Flexor tendinitis and median nerve compression caused by gout in a patient with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Carpal Tunnel Syndrome; Female; Fingers; Giant Cells; Gout; Humans; Ten | 2000 |
Syndrome X and gout: benefits of altered diet.
Topics: Alcohol Drinking; Body Mass Index; Body Weight; Dietary Carbohydrates; Dietary Fats, Unsaturated; Di | 2001 |
Hyperuricemia in Saudi Arabia.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Female; Gout; Humans; Male; Middle Age | 2001 |
Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors.
Topics: Allopurinol; Animals; Area Under Curve; Gout; Gout Suppressants; Male; Metabolic Diseases; Models, A | 2001 |
Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
Topics: Animals; Body Water; Diabetes Insipidus; Disease Models, Animal; Gout; Humans; Kidney Concentrating | 2001 |
[Therapeutic criteria in hyperuricemia].
Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Colchicine; Gout; Go | 2001 |
How should hyperuricemia be treated in a patient with allopurinol hypersensitivity?
Topics: Antimetabolites; Desensitization, Immunologic; Drug Hypersensitivity; Gout; Gout Suppressants; Human | 2001 |
Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96).
Topics: Adolescent; Adult; Aged; Asian People; Child; Child, Preschool; Female; Gout; Humans; Male; Middle A | 2001 |
Biochemical profile of idiopathic uric acid nephrolithiasis.
Topics: Adult; Female; Gout; Humans; Hydrogen-Ion Concentration; Hypertriglyceridemia; Kidney Calculi; Male; | 2001 |
Laryngeal manifestation of gout: a case report of a subglottic gout tophus.
Topics: Arytenoid Cartilage; Gout; Humans; Larynx; Male; Respiratory Mucosa; Uric Acid; Voice Disorders | 2001 |
Evaluation of crystals in formalin-fixed, paraffin-embedded tissue sections for the differential diagnosis of pseudogout, gout, and tumoral calcinosis.
Topics: Calcinosis; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Diagnosis, Differential; Dura | 2001 |
[Familial gout and nephropathy in a young woman. Report of one case].
Topics: Adult; Allopurinol; Female; Genetic Counseling; Gout; Gout Suppressants; Humans; Kidney Diseases; Ur | 2001 |
Gout: diet and uric acid revisited.
Topics: Dietary Proteins; Gout; Humans; Uric Acid | 2001 |
[Urine fibrinolytic activity as an indicator of kidney damage in uric acid metabolic imbalance].
Topics: Adolescent; Adult; Creatinine; Female; Glomerular Filtration Rate; Gout; Humans; Kidney Diseases; Ma | 2001 |
[Interesting case no. 47. Gout tophus of the vocal cord].
Topics: Diagnosis, Differential; Gout; Humans; Laryngeal Diseases; Laryngoscopy; Male; Middle Aged; Uric Aci | 2001 |
Clinical features of familial gout and effects of probable genetic association between gout and its related disorders.
Topics: Age of Onset; Alcohol Drinking; Body Mass Index; Comorbidity; Creatinine; Cross-Sectional Studies; D | 2001 |
Crystal-induced neutrophil activation. VII. Involvement of Syk in the responses to monosodium urate crystals.
Topics: Adult; Antibodies; Cells, Cultured; Crystallization; Enzyme Inhibitors; Enzyme Precursors; Gout; Hum | 2001 |
[Upper limit value for uric acid much too high? Most frequent diagnostic error: arthritis instead if gout].
Topics: Arthritis, Rheumatoid; Diagnostic Errors; Gout; Humans; Uric Acid | 2001 |
Hyperuricemia, gout, and renal function after liver transplantation.
Topics: Adult; Aged; Allopurinol; Creatinine; Female; Gout; Humans; Kidney; Liver Transplantation; Male; Mid | 2001 |
Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature.
Topics: Adult; Cyclosporine; Female; Gout; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; M | 2001 |
Src family protein tyrosine kinase signaling mediates monosodium urate crystal-induced IL-8 expression by monocytic THP-1 cells.
Topics: Cell Line; Gout; Humans; I-kappa B Proteins; Interleukin-8; Monocytes; NF-kappa B; Ribosomal Protein | 2001 |
[Pleural effusion of gout].
Topics: Adult; Aged; Female; Fibrosis; Gout; Humans; Lung; Lung Diseases; Male; Middle Aged; Pleural Effusio | 2000 |
Increased visceral fat accumulation in patients with primary gout.
Topics: Fats; Gout; Humans; Incidence; Japan; Male; Obesity; Uric Acid | 2000 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout.
Topics: Antihypertensive Agents; Biphenyl Compounds; Gout; Humans; Hypertension; Irbesartan; Losartan; Tetra | 2002 |
[Hyperuricemia and gout. Case report].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diagnosis, Differential; Diclofenac; Follow-Up | 2002 |
[Hyperuricemia and gout--diagnosis].
Topics: Adenine; Adult; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Female; Go | 2002 |
[Hyperuricemia and gout--treatment].
Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Colchicine; Drug | 2002 |
[The Dutch College of General Practitioners' "Gout" Standard: a response from rheumatologists].
Topics: Attitude of Health Personnel; Family Practice; Gout; Humans; Netherlands; Practice Guidelines as Top | 2002 |
[How to treat hyperuricemia and gout attacks in compensated kidney failure?].
Topics: Aged; Aged, 80 and over; Allopurinol; Glucocorticoids; Gout; Gout Suppressants; Humans; Kidney Failu | 2002 |
[Gout tophus].
Topics: Aged; Aged, 80 and over; Arthritis, Gouty; Crystallization; Female; Gout; Humans; Uric Acid | 2001 |
Is it gout? Tap the joint!
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Glucocorticoids; Gout; Gout Suppre | 2002 |
High prevalence of hyperuricemia in adolescent Taiwan aborigines.
Topics: Adolescent; Asian People; Cholesterol; Creatinine; Female; Gout; Humans; Male; Native Hawaiian or Ot | 2002 |
Delayed examination of synovial fluid by ordinary and polarised light microscopy to detect and identify crystals.
Topics: Calcium Pyrophosphate; Case-Control Studies; Cryopreservation; Crystallization; Culture Media; Edeti | 2002 |
Pathologic quiz case: a soft tissue mass with bone destruction. Gouty tophus.
Topics: Aged; Biopsy; Elbow Joint; Gout; Humans; Male; Pain; Radiography; Uric Acid | 2002 |
Kidney function: gateway to a long life?
Topics: Animals; Antioxidants; Biological Transport; Carrier Proteins; Gout; Humans; Kidney; Longevity; Orga | 2002 |
Uric acid and the kidney.
Topics: Acute Kidney Injury; Ammonia; Animals; Glomerular Filtration Rate; Glutamine; Gout; Humans; Hydrogen | 1976 |
Dissolution of renal uric acid calculus with allopurinal and alkalization of urine: a case report.
Topics: Acetazolamide; Allopurinol; Bicarbonates; Citrates; Drug Combinations; Gout; Humans; Hydrogen-Ion Co | 1976 |
Physiological characteristics of various experimental models for the study of disorders in purine metabolism.
Topics: Acidosis; Alkalosis; Allopurinol; Animals; Cholesterol; Disease Models, Animal; Diuresis; Fructose; | 1977 |
The effect of acid loading on renal excretion of uric acid and ammonium in gout.
Topics: Adult; Aged; Ammonia; Ammonium Chloride; Circadian Rhythm; Diet; Female; Gout; Humans; Hydrogen-Ion | 1977 |
Urinary excretion of uricine.
Topics: Adult; Aged; Binding Sites; Calcium Phosphates; Female; Gout; Humans; Hydrogen-Ion Concentration; Ma | 1977 |
[Drug therapy and metaphylaxis of urolithiasis].
Topics: Alkalies; Citrates; Diuresis; Fluid Therapy; Gout; Humans; Hydrogen-Ion Concentration; Recurrence; U | 1978 |
Gout and cardiovascular disease.
Topics: Coronary Disease; Gout; Humans; Platelet Aggregation; Uric Acid | 1977 |
Enzyme defect in primary gout.
Topics: AMP Deaminase; Deamination; Gout; Humans; Inosine Monophosphate; Liver; Nucleotide Deaminases; Purin | 1979 |
The gout-calcium-stone connection.
Topics: Allopurinol; Calcium Oxalate; Gout; Humans; Kidney Calculi; Uric Acid | 1979 |
[Spinal complaints of hyperuricemic patients].
Topics: Back Pain; Female; Gout; Headache; Humans; Male; Neurologic Manifestations; Osteoarthritis; Pain; Sp | 1976 |
A case of gouty arthritis associated with Down's syndrome.
Topics: Adult; Down Syndrome; Gout; Humans; Karyotyping; Kidney Function Tests; Male; Metabolic Clearance Ra | 1976 |
[Gout in young subjects].
Topics: Adolescent; Adult; Age Factors; Angina Pectoris; Back Pain; Diabetes Complications; Fatty Liver; Fem | 1977 |
Stimulation of human purine synthesis de novo by fructose infusion.
Topics: Adolescent; Adult; Creatinine; Erythrocytes; Fructose; Glycine; Gout; Humans; Male; Middle Aged; Ost | 1975 |
An office technique for identifying crystal in synovial fluid.
Topics: Betamethasone; Calcium Phosphates; Cholesterol; Chondrocalcinosis; Color; Crystallography; Diphospha | 1975 |
[Frequency and distribution of types of hyperlipoproteinemia with life-shortening risk factors among ambulant patients (author's transl)].
Topics: Cholesterol; Diabetes Complications; Female; Germany, West; Gout; Humans; Hyperlipidemias; Hypertens | 1975 |
[Diet in hyperuricemia (author's transl)].
Topics: Adenosine Monophosphate; Diet Fads; Dietary Proteins; DNA; Ethanol; Fasting; Gout; Guanosine Monopho | 1975 |
Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Erythrocytes; Feedback; Female; Fibroblasts; Genes | 1975 |
Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction.
Topics: Adenine Phosphoribosyltransferase; Adolescent; Adult; Cells, Cultured; Erythrocytes; Female; Fibrobl | 1976 |
[Needle biopsy in gout and pseudogout (author's transl)].
Topics: Aged; Biopsy, Needle; Chondrocalcinosis; Diagnosis, Differential; Diphosphates; Female; Gout; Humans | 1976 |
[Therapy of hyperlipemia and hyperuricemia with a combination of clofibrate and an extractive mucopolysaccharide complex].
Topics: Adult; Aged; Arthritis, Rheumatoid; Cholesterol; Clofibrate; Drug Therapy, Combination; Female; Glyc | 1975 |
Evidence for X-linkage of phosphoribosylpyrophosphate synthetase in man. Studies with cultured fibroblasts from a gouty family with mutant feedback-resistant enzyme.
Topics: Adolescent; Adult; Aged; Cells, Cultured; Child; Child, Preschool; Female; Fibroblasts; Genetic Link | 1977 |
Fibroblast phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in gout with purine overproduction.
Topics: Cells, Cultured; Erythrocytes; Fibroblasts; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Pe | 1977 |
Familial distribution of increased erythrocyte PP-ribose-P levels.
Topics: Adult; Aged; Amidophosphoribosyltransferase; Erythrocytes; Gout; Humans; Hypoxanthine Phosphoribosyl | 1977 |
Superactivity of phosphoribosylpyrophosphate synthetase, due to feedback resistance, causing purine overproduction and gout.
Topics: Adolescent; Adult; Aged; Amidophosphoribosyltransferase; Child; Child, Preschool; Erythrocytes; Feed | 1977 |
Hyperuricemic nephropathy: pathologic features and factors influencing urate deposition.
Topics: Acute Kidney Injury; Animals; Binding Sites; Crystallization; Disease Models, Animal; Diuretics; Gou | 1975 |
[Automatic dosage of uric acid by urate oxydase. Comparison with Praetorius' methods].
Topics: Autoanalysis; Coronary Disease; Gout; Humans; Hydrogen Peroxide; Hydrogen-Ion Concentration; Oxidati | 1975 |
Nucleation of monosodium urate crystals.
Topics: Acid-Base Equilibrium; Calcium; Collagen; Copper; Crystallization; Ethanol; Gout; Hydrogen-Ion Conce | 1975 |
Acquired causes of hyperuricaemia.
Topics: Alcohol Drinking; Aspirin; Diet; Energy Intake; Gout; Humans; Kidney Diseases; Phenylbutazone; Uric | 1978 |
[Interrelationship between purine, carbohydrate, lipid and aminoacid metabolism, in hyperuricaemia and gout (author's transl)].
Topics: Alcoholic Intoxication; Alcoholism; Amino Acids; Carbohydrate Metabolism; Diabetes Mellitus; Fructos | 1978 |
Foibles and fallacies in the diagnosis of arthritis.
Topics: Antibodies, Antinuclear; Arthritis; Arthritis, Infectious; Arthritis, Rheumatoid; Chondrocalcinosis; | 1977 |
[Physiopathological bases for a rational therapy of gout].
Topics: Allopurinol; Benzofurans; Gout; Humans; Life Style; Phenylbutazone; Probenecid; Sulfinpyrazone; Uric | 1978 |
[The relationship of uric acid, triglycerides, and cholesterol].
Topics: Adult; Aged; Cholesterol; Gout; Humans; Middle Aged; Myocardial Infarction; Triglycerides; Uric Acid | 1978 |
Bullous tophi in gout.
Topics: Adrenal Cortex Hormones; Crystallization; Female; Gout; Humans; Male; Middle Aged; Skin Diseases, Ve | 1977 |
History of gout. Including comments from an illustrious timeless gathering.
Topics: Famous Persons; Gout; History, Ancient; History, Medieval; History, Modern 1601-; Terminology as Top | 1977 |
[Manifestation of gout. Observations concerning the combined effects of nutrition and biochemical individuality].
Topics: Diet; DNA; Gout; Humans; Purines; RNA; Uric Acid | 1977 |
Hyperuricemia and gout. A modern approach to diagnosis and treatment.
Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Gout; Humans; Uric Acid | 1979 |
Recessive X-linked hyperuricemia with gout and renal damage, normal activity of hypoxanthine phosphoribosyltransferase and resistance to azaguanine.
Topics: Adenine Phosphoribosyltransferase; Adolescent; Adult; Azaguanine; Azathioprine; Erythrocytes; Female | 1979 |
[Infantile familial hyperuricemia with gouty manifestations].
Topics: Autopsy; Gout; Humans; Infant; Kidney; Male; Uric Acid | 1979 |
Drug therapy reviews: pathogenesis and clinical management of hyperuricemia and gout.
Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents; Arthritis; Chronic Disease; Colchicine; Gout; | 1979 |
Management of gout.
Topics: Adrenal Cortex Hormones; Allopurinol; Colchicine; Female; Gout; Humans; Indomethacin; Patient Educat | 1979 |
Mechanism and treatment of hypertriglyceridaemia in gout.
Topics: Alcohol Drinking; Allopurinol; Cholesterol; Gout; Humans; Hyperlipidemias; Male; Middle Aged; Obesit | 1979 |
[Hyperuricemia].
Topics: Diagnosis, Differential; Gout; Humans; Models, Biological; Uric Acid | 1979 |
Definitive diagnosis of gout by identification of urate crystals in asymptomatic metatarsophalangeal joints.
Topics: Adult; Aged; Crystallization; Female; Gout; Humans; Male; Metatarsophalangeal Joint; Middle Aged; To | 1979 |
Management of gout.
Topics: Acute Disease; Allopurinol; Gout; Gout Suppressants; Humans; Methods; Uric Acid; Uricosuric Agents | 1979 |
Renal outcomes of gout and hyperuricemia.
Topics: Aged; Arthritis; California; Creatinine; Female; Follow-Up Studies; Gout; Humans; Kidney Calculi; Ki | 1979 |
Uric acid excretion: quantitative assessment from spot, midmorning serum and urine samples.
Topics: Gout; Humans; Male; Specimen Handling; Uric Acid | 1979 |
Urate crystals in asymptomatic metatarsophalangeal joints.
Topics: Crystallization; Gout; Humans; Male; Metatarsophalangeal Joint; Middle Aged; Synovial Fluid; Toe Joi | 1979 |
Re-examination of effect of paracetamol on serum uric acid measured by phosphotungstic acid reduction.
Topics: Acetaminophen; False Positive Reactions; Gout; Humans; Methods; Oxidation-Reduction; Phosphotungstic | 1979 |
Gout and crystal-related nephropathy.
Topics: Adenine Phosphoribosyltransferase; Female; Gout; Humans; Kidney; Kidney Calculi; Kidney Diseases; Le | 1979 |
Chronic gouty nephropathy treated by long-term hemodialysis and allopurinol.
Topics: Allopurinol; Gout; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Time Factors; | 1979 |
Synovial fluid leukocytosis. A study of extremes.
Topics: Aged; Arthritis, Infectious; Arthritis, Rheumatoid; Calcium Pyrophosphate; Chondrocalcinosis; Crysta | 1979 |
[Gout].
Topics: Gout; Humans; Uric Acid | 1979 |
[Therapy of gout].
Topics: Allopurinol; Arteriosclerosis; Benzbromarone; Colchicine; Gout; Humans; Immobilization; Indomethacin | 1979 |
[Uric acid clearance test].
Topics: Gout; Humans; Metabolic Clearance Rate; Methods; Uric Acid | 1979 |
Uric acid metabolism in normal subjects and in gouty patients by chromatographic measurement of 14C-uric acid in plasma and urine.
Topics: Adult; Carbon Radioisotopes; Gout; Humans; Kinetics; Male; Middle Aged; Reference Values; Uric Acid | 1979 |
Acute arthralgia (gout?) after tricrynafen.
Topics: Glycolates; Gout; Humans; Hypertension; Joint Diseases; Male; Middle Aged; Pain; Ticrynafen; Uric Ac | 1979 |
Genetics of hyperuricemia in families with gout.
Topics: Gene Frequency; Genetic Variation; Gout; Humans; Mathematics; Models, Genetic; Uric Acid | 1979 |
Acute gouty bursitis: report of 15 cases.
Topics: Acute Disease; Aged; Bursa, Synovial; Bursitis; Gout; Humans; Leukocyte Count; Male; Middle Aged; Sy | 1979 |
Treatment of hyperuricemia and gout.
Topics: Colchicine; Gout; Humans; Uric Acid | 1979 |
Treatment of hyperuricemia and gout.
Topics: Gout; Humans; Uric Acid | 1979 |
Hypertension, renal function and gout.
Topics: Adult; Glomerular Filtration Rate; Gout; Humans; Hypertension; Kidney; Kidney Diseases; Middle Aged; | 1979 |
Uricosuric therapy and urate solubility in blood and urine.
Topics: Gout; Humans; Solubility; Uric Acid; Uricosuric Agents | 1979 |
Tienilic acid in hypertension with hyperuricaemia.
Topics: Allopurinol; Bendroflumethiazide; Creatinine; Female; Glycolates; Gout; Humans; Hypertension; Male; | 1979 |
Allopurinol toxicity.
Topics: Allopurinol; Gout; Hematologic Diseases; Humans; Kidney Diseases; Uric Acid | 1979 |
[Diagnosis of gout: problems caused by crystallization "in vitro" of sodium urate].
Topics: Crystallization; Diagnosis, Differential; Gout; Humans; Specimen Handling; Synovial Fluid; Uric Acid | 1979 |
[Early diagnosis of gout].
Topics: Adult; Allopurinol; Efficiency; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Nephrocalc | 1979 |
Renal function in gout. V. Factors influencing the renal hemodynamics.
Topics: Adult; Aged; Glomerular Filtration Rate; Gout; Humans; Inulin; Kidney; Kidney Function Tests; Middle | 1979 |
[The effect of benzbromaron in gout patients with limited kidney function].
Topics: Adult; Aged; Benzbromarone; Benzofurans; Creatinine; Drug Evaluation; Gout; Humans; Kidney Diseases; | 1979 |
Evaluation of a new uricosuric diuretic--ticrynafen.
Topics: Diuretics; Drug Evaluation; Glycolates; Gout; Heart Failure; Humans; Hypertension; Ticrynafen; Uric | 1979 |
Piroxicam in the treatment of acute gout: a multicentre open study in general practice.
Topics: Acute Disease; Adult; Aged; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pyridines; T | 1979 |
[Allomaron in hyperuricemia and gout].
Topics: Adolescent; Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Drug Combinations; Drug Evaluation | 1979 |
[Clinical chemistry diagnosis of uric-acid metabolism disorders].
Topics: Circadian Rhythm; Female; Gout; Humans; Male; Methods; Uric Acid | 1978 |
Tophaceous gout. An unusual cause of bilateral carpal tunnel syndrome.
Topics: Adult; Carpal Tunnel Syndrome; Gout; Humans; Male; Paresthesia; Uric Acid | 1977 |
[On the dose-effect relation of allopurinol (author's transl)].
Topics: Adult; Aged; Allopurinol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Gout; Human | 1977 |
Acute gouty arthritis. The diagnostic importance of aspirating more than one involved joint.
Topics: Acute Disease; Adult; Ankle Joint; Crystallization; Gout; Humans; Knee Joint; Male; Synovial Fluid; | 1977 |
[Modern differential-therapeutic aspects of the drug therapy of chronic gout].
Topics: Allopurinol; Arteriosclerosis; Citrates; Gout; Humans; Hypertension; Kidney Diseases; Obesity; Pheny | 1979 |
Secondary gout in hemoglobinopathies: report of two cases and review of the literature.
Topics: Adolescent; Female; Gout; Hemoglobinopathies; Humans; Kidney; Middle Aged; Uric Acid | 1977 |
Gout and hyperuricaemia in Blacks.
Topics: Black or African American; Black People; Democratic Republic of the Congo; Female; Gout; Humans; Mal | 1977 |
Folic acid, xanthine oxidase, and uric acid.
Topics: Folic Acid; Gout; Humans; Uric Acid; Xanthine Oxidase | 1978 |
The workinghman's diet. II. Effect of weight reduction in obese patients with hypertension, diabetes, hyperuricemia and hyperlipidemia.
Topics: Body Weight; Diet, Diabetic; Diet, Reducing; Evaluation Studies as Topic; Female; Follow-Up Studies; | 1978 |
Gout without crystals on initial synovial fluid analysis.
Topics: Adult; Arthritis; Gout; Humans; Male; Middle Aged; Synovial Fluid; Uric Acid | 1978 |
[Uric acid diathesis in chickens].
Topics: Animals; Chickens; Disease Susceptibility; Gout; Kidney Calculi; Poultry Diseases; Uric Acid | 1978 |
The ultrastructure of urate crystals in gout.
Topics: Crystallization; Gout; Humans; Microscopy, Electron; Microscopy, Electron, Scanning; Synovial Fluid; | 1978 |
Distinguishing gout from other types of arthritis.
Topics: Acute Disease; Adult; Arthritis; Diagnosis, Differential; Female; Gout; Humans; Male; Synovial Fluid | 1978 |
Role of the kidneys in the pathogenesis of gout.
Topics: Absorption; Animals; Gout; Humans; Kidney; Kidney Tubules, Proximal; Models, Biological; Uric Acid | 1978 |
Nephrolithiasis in patients with gout.
Topics: Allopurinol; Gout; Humans; Kidney Calculi; Recurrence; Uric Acid | 1978 |
[Diagnostic value of renal urate excretion].
Topics: Adult; Female; Gout; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Time Factors; Uric Acid | 1978 |
Asymptomatic hyperuricemia: the case for conservative management.
Topics: Gout; Humans; Kidney Calculi; Risk; Uric Acid | 1978 |
Immunoglobulin in tophi and on the surface of monosodium urate crystals.
Topics: Agglutination; Blood; Gout; Humans; Immunoglobulin G; Immunoglobulin M; Immunoglobulins; Uric Acid | 1978 |
High prevalence of hyperuricaemia and gout in an urbanised Micronesian population.
Topics: Adult; Aged; Female; Gout; Humans; Life Style; Male; Micronesia; Middle Aged; Sex Factors; Urban Pop | 1978 |
Enhancement of urate solubility by connective tissue. I. Effect of proteoglycan aggregates and buffer cation.
Topics: Animals; Buffers; Connective Tissue; Gout; Humans; Hyaluronoglucosaminidase; In Vitro Techniques; La | 1978 |
Purine biosynthesis de novo by lymphocytes in gout.
Topics: Adult; Allopurinol; Female; Gout; Humans; In Vitro Techniques; Kidney Diseases; Lymphocytes; Male; M | 1978 |
[Juvenile gout with decreased activity of hypoxanthine-guanine-phosphoribosyl transferase and pheochromocytoma: partial persistence of tophi despite uric-acid reducing treatment for 12 years (author's transl)].
Topics: Adrenal Gland Neoplasms; Allopurinol; Gout; Humans; Hypertension, Malignant; Hypoxanthine Phosphorib | 1978 |
[Effects and side effects of benzbromaron in the initial treatment of hyperuricemia and gout. Results of a field study on 3899 patients].
Topics: Benzbromarone; Benzofurans; Diarrhea; Female; Gout; Humans; Kidney Calculi; Male; Nausea; Uric Acid | 1978 |
[Uptake of 2-C14 urate by erythrocytes in hyperuricemia and in gout (author's transl)].
Topics: Erythrocytes; Gout; Humans; Kinetics; Uric Acid | 1978 |
[Gastric xanthelasma (author's transl)].
Topics: Adult; Aged; Diabetes Mellitus; Female; Gastric Mucosa; Gastritis; Gastroscopy; Gout; Humans; Hypert | 1978 |
Hepatic purine enzyme profiles and uric acid overproduction in muscular dystrophy and in inherited tophaceous gout.
Topics: Animals; Chickens; Gout; Liver; Muscular Dystrophy, Animal; Purines; Uric Acid | 1978 |
[Xeroradiography in case of gout and hyperuricemic syndroms (author's transl)].
Topics: Adult; Female; Foot; Gout; Humans; Male; Middle Aged; Syndrome; Uric Acid; Xeroradiography | 1978 |
[Gout - a surgical problem].
Topics: Allopurinol; Benzbromarone; Female; Gout; Hand; Humans; Middle Aged; Patient Care Team; Uric Acid | 1978 |
Immobilized-enzyme nylon-tube reactor for routine determination of uric acid in serum.
Topics: Drug Stability; Enzymes, Immobilized; Gout; Humans; Urate Oxidase; Uric Acid | 1978 |
Normouricemic acute polyarticular gout.
Topics: Acute Disease; Aged; Gout; Humans; Male; Uric Acid | 1978 |
Gout and serum uric acid levels in the Cotswolds.
Topics: Adult; Aged; England; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1978 |
Treatment of gout with alternate-day hypo-uricaemic drugs.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Sulfi | 1978 |
[Various aspects of nephropathy in gout].
Topics: Adult; Age Factors; Aged; Amyloidosis; Glomerular Filtration Rate; Gout; Humans; Hypertension, Renal | 1978 |
Crystal induced arthritis: gout and pseudogout.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents; Apatites; Arthritis; Calcium Hydroxide; Calcium Pyrop | 1978 |
Hyperuricemia and gout: eminently treatable disorders.
Topics: Gout; Humans; Uric Acid | 1978 |
[Aseptic femoral head necrosis in patients with gouty arthritis].
Topics: Adult; Femur Head Necrosis; Gout; Humans; Male; Radionuclide Imaging; Synovial Fluid; Synovial Membr | 1978 |
A prospective study of gout in New Zealand Maoris.
Topics: Adolescent; Adult; Aged; Ethnicity; Female; Gout; Humans; Male; Middle Aged; New Zealand; Prospectiv | 1978 |
Familial occurrence of hyperuricemia, gout, and medullary cystic disease.
Topics: Adolescent; Adult; Aged; Benzothiadiazines; Diuretics; Female; Gout; Humans; Kidney Medulla; Kidney | 1978 |
Subclinical lead exposure: a possible cause of gout.
Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Lead; Male; Middle Aged; Uric Acid | 1978 |
Partial HGPRT deficiency: persistance of tophi after 12 years of therapeutic normouricemia and development of a pheochromocytoma.
Topics: Adult; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Male; Middle Aged; Pheochromocytoma; Pu | 1978 |
Nutritional aspects in the treatment of inborn errors.
Topics: Diet; Gout; Humans; Male; Metabolism, Inborn Errors; Nutritional Physiological Phenomena; Uric Acid | 1978 |
[Adenosine deaminase in hyperuricemic states].
Topics: Acute Kidney Injury; Adenosine Deaminase; Adolescent; Adult; Aged; Erythrocytes; Female; Gout; Human | 1978 |
Urate crystals in gout.
Topics: Crystallization; Gout; Humans; Synovial Fluid; Uric Acid | 1978 |
[Relationship between uric acid and lipids in primary gout].
Topics: Adult; Aged; Female; Gout; Humans; Lipids; Male; Middle Aged; Uric Acid | 1978 |
Uric acid excretion in patients with gout.
Topics: Gout; Humans; Kidney; Male; Uric Acid | 1979 |
[Hyperuricemia. Studies on the incidence of hyperuricemia and its therapeutic possibilities in general practice].
Topics: Diuretics; Family Practice; Female; Germany, West; Gout; Humans; Male; Uric Acid | 1979 |
Asymptomatic hyperuricemia: pathogenic or innocent bystander?
Topics: Gout; Humans; Kidney Diseases; Uric Acid | 1979 |
[Uric-acid reduction with high allopurinol dosages (author's transl)].
Topics: Aged; Allopurinol; Dose-Response Relationship, Drug; Female; Gout; Humans; Male; Middle Aged; Uric A | 1979 |
[Hyperuricemia. An introduction].
Topics: Animals; Austria; Female; Gout; History, Ancient; History, Medieval; History, Modern 1601-; Humans; | 1976 |
Gout.
Topics: Adult; Anti-Inflammatory Agents; Female; Gout; Humans; Long-Term Care; Male; Middle Aged; Uric Acid | 1975 |
[Chronic lead poisoning: Lead gout with giant tophi on the skin, nephrophathy and porphyrinopathy].
Topics: Aged; Book Industry; Chronic Disease; Edetic Acid; Gout; Humans; Kidney Diseases; Lead; Lead Poisoni | 1975 |
[Long-term therapy with benzbromarone in uric arthritis].
Topics: Adult; Aged; Benzbromarone; Benzofurans; Diarrhea; Female; Gout; Humans; Leukopenia; Long-Term Care; | 1975 |
[Hyperuricemia in Parkinson's syndrome--by chance or probable?].
Topics: Adult; Aged; Female; Gout; Humans; Hypertension; Levodopa; Male; Middle Aged; Obesity; Parkinson Dis | 1976 |
[Occurrence of hyperuricemia in atrioventricular block. (Results of a study of 158 patients with isotopic pacemaker implantations)].
Topics: Adolescent; Adult; Age Factors; Cardiac Surgical Procedures; Child; Female; Gout; Heart Block; Human | 1976 |
[Definition and treatment requirements of uricemia].
Topics: Adult; Aged; Chronic Disease; Diabetes Mellitus; Female; Gout; Humans; Hypertension, Renal; Liver Di | 1977 |
Some unusual features of gouty arthritis in females.
Topics: Adult; Age Factors; Aged; Black or African American; Female; Gout; Humans; Hypertension; Kidney Calc | 1977 |
The gouty toe - a multifactorial condition.
Topics: Calcium Pyrophosphate; Chemotaxis, Leukocyte; Gout; Humans; Immunoglobulin G; Leukocytes; Phagocytos | 1977 |
Gout with normal serum urate concentration.
Topics: Aged; Gout; Humans; Male; Middle Aged; Uric Acid | 1977 |
[Diagnosis of hyperuricemia].
Topics: Female; Gout; Humans; Pregnancy; Uric Acid | 1977 |
Purine enzyme abnormalities: a four year experience.
Topics: Adenine Phosphoribosyltransferase; Adolescent; Adult; Child; Erythrocytes; Female; Gout; Humans; Hyp | 1977 |
Xanthinuria, lithiasis and gout in the same family.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Creatinine; Female; Genes, Recessive; | 1977 |
Fatty acid composition of plasma lipid fractions in gout.
Topics: Cholesterol; Cholesterol Esters; Fatty Acids; Fatty Acids, Nonesterified; Fatty Acids, Unsaturated; | 1977 |
A relationship between free urate, protein-bound urate, hyperuricemia and gout in Caucasians and Maoris.
Topics: Asian People; Gout; Humans; New Zealand; Protein Binding; Serum Albumin; Uric Acid; White People | 1977 |
Protein binding to monosodium urate crystals and its effect on platelet degranulation. Influence of urate on connective tissue metabolism.
Topics: Acetylglucosaminidase; Benzbromarone; Connective Tissue; Glycosaminoglycans; Gout; Heparin; Hyaluron | 1977 |
Hyperuricemia as a risk factor in coronary heart disease.
Topics: Age Factors; Black People; Coronary Disease; Female; Gout; Humans; Male; Myocardial Infarction; Sex | 1977 |
Nutritional state and purine metabolism.
Topics: Adult; Age Factors; Aged; Alcohol Drinking; Body Weight; Coronary Disease; Diabetes Complications; D | 1977 |
The effect of weight loss on plasma and urinary uric acid and lipid levels.
Topics: Body Weight; Cholesterol; Female; Gout; Humans; Male; Obesity; Triglycerides; Uric Acid | 1977 |
Panel discussion: hyperuricemia as a risk factor.
Topics: Alcohol Drinking; Allopurinol; Blood Proteins; Body Weight; Coronary Disease; Diabetes Complications | 1977 |
Urate excretion in normal and gouty men.
Topics: Asian People; Glomerular Filtration Rate; Gout; Humans; Kidney; Male; Uric Acid; White People | 1977 |
Urinary excretion of uricine.
Topics: Bilirubin; Calcium; Chemical Precipitation; Gout; Humans; Kidney; Pigments, Biological; Pyrroles; Ur | 1977 |
Preliminary criteria for the classification of the acute arthritis of primary gout.
Topics: Acute Disease; Arthritis; Arthritis, Rheumatoid; Chondrocalcinosis; Diagnosis, Differential; Female; | 1977 |
Gout disease. Its natural history based on 1,000 observations.
Topics: Calculi; Diabetes Complications; Female; Gout; Humans; Hypertension; Male; Sex Factors; Uric Acid | 1977 |
Recurrent gouty phlebitis without articular gout.
Topics: Acute Disease; Colchicine; Gout; Humans; Male; Middle Aged; Phlebitis; Uric Acid | 1977 |
Panniculitis of the legs with urate crystal deposition.
Topics: Aged; Arthritis; Diagnosis, Differential; Female; Furosemide; Gout; Heart Failure; Humans; Lipase; S | 1977 |
[Allopurinol and gouty hyperuricemia : apropos of 30 cases treated by a single daily dose].
Topics: Allopurinol; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1977 |
Crystal deposition disease. Diagnosis by electron microscopy.
Topics: Aged; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Female; Gout; Humans; Male; Microsc | 1977 |
[Experiences with uricotest, a simple device for the demonstration of birefringent cristals in tissue (author's transl)].
Topics: Arthritis; Diagnosis, Differential; Gout; Humans; Synovial Fluid; Uric Acid | 1977 |
Rheumatic disorders in the South African Negro. Part IV. Gout and hyperuricaemia.
Topics: Adolescent; Adult; Age Factors; Aged; Black People; Ethnicity; Female; Gout; Humans; Male; Metabolic | 1977 |
Kidney in patients with abnormalities in uric acid metabolism.
Topics: Acute Disease; Aged; Animals; Dogs; Female; Gout; Humans; Kidney; Kidney Calculi; Kidney Diseases; R | 1977 |
[Isolated or combined drug therapy of hyperuricemia?].
Topics: Allopurinol; Benzbromarone; Drug Therapy, Combination; Gout; Humans; Uric Acid; Uricosuric Agents | 1977 |
[Comparison of effects of various therapeutic methods of the urinary system in patients with gout. Observations on 195 patients with gout].
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Male; Middle Aged; Probenecid; Uric Acid; Urinary Tr | 1977 |
[De novo purine biosynthesis. In vitro measurement in hyperuricemia (author's transl)].
Topics: Adult; Allopurinol; Azaserine; Carbon Radioisotopes; Female; Formates; Gout; Humans; In Vitro Techni | 1977 |
[Gouty attacks in hyperuricemic hypertensives. A follow-up study (author's transl)].
Topics: Adolescent; Adult; Aged; Female; Follow-Up Studies; Gout; Humans; Hypertension; Male; Middle Aged; U | 1977 |
[Enzymopathies as a cause of hyperuricemia].
Topics: Adenine Phosphoribosyltransferase; Carbohydrate Metabolism; Feedback; Gout; Humans; Hypoxanthine Pho | 1977 |
Uric acid, lean body weight, and creatinine interactions: results from regression analysis of 78 variables.
Topics: Adult; Aged; Alcohol Drinking; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Creatinine; | 1977 |
The gouty kidney.
Topics: Animals; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Gout; Humans; Kidney; Kidney C | 1977 |
[Diet therapy of hyperuricemia and gout].
Topics: Dietary Proteins; Ethanol; Fasting; Gout; Humans; Purines; Uric Acid | 1977 |
[Secondary gout in chronic kidney failure].
Topics: Aged; Chronic Disease; Female; Gout; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Pye | 1976 |
[Health maintenance despite health risks. III. 3 civilization diseases: hypertension, diabetes, and gout].
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus; Female; Gout | 1976 |
[Case of disabling form of gout with a 11-year follow-up].
Topics: Adult; Colchicine; Follow-Up Studies; Gout; Humans; Joints; Male; Uric Acid | 1976 |
[Urate nephrolithiasis. Cause of consequence?].
Topics: Calcium; Gout; Humans; Kidney Calculi; Oxalates; Uric Acid | 1976 |
[Hyperuricemia].
Topics: Arteriosclerosis; Cholelithiasis; Female; Gout; Humans; Male; Sex Factors; Uric Acid | 1976 |
Letter: Uric acid during phenylbutazone therapy.
Topics: Dose-Response Relationship, Drug; Gout; Humans; Phenylbutazone; Uric Acid | 1976 |
[Nutritional aspects in the treatment of hyperuricemia].
Topics: Body Weight; Dietary Carbohydrates; Gout; Humans; Uric Acid | 1976 |
[Clinical aspects of gout].
Topics: Adult; Age Factors; Aged; Female; Gout; Humans; Male; Middle Aged; Sex Factors; Uric Acid | 1976 |
Platelet aggregation in rats made hyperuricaemic with nucleic adid-rich diets containing oxonate, and inhibitor of uricase [proceedings].
Topics: Animals; Diet; Disease Models, Animal; Female; Fusarium; Gout; Nucleic Acids; Oxonic Acid; Platelet | 1976 |
[Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
Topics: Benzbromarone; Benzofurans; Gout; Humans; Uric Acid | 1976 |
Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone.
Topics: Adult; Aged; Arthritis; Benzbromarone; Benzofurans; Chemical Phenomena; Chemistry; Chronic Disease; | 1976 |
Hereditary variation in uric acid transport by avian kidney slices.
Topics: Animals; Biological Transport; Chickens; Gout; Kidney; Male; Ouabain; Potassium; Poultry Diseases; S | 1976 |
Paraparesis secondary to sodium urate deposits in the ligamentum flavum.
Topics: Aged; Gout; Humans; Ligaments; Male; Paraplegia; Spinal Cord Compression; Uric Acid | 1976 |
[Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
Topics: Allopurinol; Benzbromarone; Benzofurans; Drug Combinations; Gout; Humans; Time Factors; Uric Acid | 1976 |
[Monitoring of therapy in hyperuricemia and gout].
Topics: Adult; Child, Preschool; Female; Gout; Humans; Male; Middle Aged; Phenylbutazone; Salicylates; Uric | 1976 |
[Physiologic bases of the treatment of gout].
Topics: Gout; Humans; Kidney; Kidney Diseases; Uric Acid; Uricosuric Agents | 1976 |
[Diagnostic problems of gout].
Topics: Adolescent; Adult; Age Factors; Child; Female; Gout; Humans; Male; Methods; Sex Factors; Uric Acid | 1976 |
[Clinical effects of purine metabolism disorders in hematopoietic proliferative diseases].
Topics: Acute Disease; Calcium; Chronic Disease; Gout; Humans; Leukemia; Polycythemia Vera; Potassium; Progn | 1976 |
Sparing effect of hemiplegia on tophaceous gout.
Topics: Gout; Hemiplegia; Humans; Male; Middle Aged; Uric Acid | 1976 |
Levels and significance of erythrocyte purine enzymes in hyperuricemia.
Topics: Adenine Phosphoribosyltransferase; Adenosine Deaminase; Adenosine Kinase; Adolescent; Adult; Erythro | 1976 |
[Hyperuricemia and psoriasis].
Topics: Carbon Radioisotopes; Female; Glycine; Gout; Humans; Male; Metabolic Diseases; Psoriasis; Uric Acid | 1976 |
Current therapy of gout and hyperuricemia.
Topics: Allopurinol; Colchicine; Drug Interactions; Gout; Humans; Indomethacin; Phenylbutazone; Probenecid; | 1976 |
[Diet therapy in gout--experimental basis and practical application].
Topics: Gout; Humans; Male; Purines; RNA; Uric Acid | 1976 |
[Gout and hyperuricemia].
Topics: Gout; Humans; Uric Acid | 1975 |
[Diagnosis and therapy of gout].
Topics: Gout; Humans; Uric Acid | 1976 |
[Uric acid concentration in serum in different types of hyperlipoproteinemia, myocardial infarction and primary gout].
Topics: Adult; Blood Pressure; Body Weight; Cholesterol; Glucose Tolerance Test; Gout; Humans; Hyperlipidemi | 1975 |
[Type I glycogenosis. Description of 2 cases with hyperuricemia].
Topics: Biopsy; Child; Galactose; Glucagon; Glucose Tolerance Test; Glycogen Storage Disease Type I; Gout; H | 1975 |
Adenine phosphoribosyltransferase deficiency: its inheritance and occurrence in a female with gout and renal disease.
Topics: Adenine Phosphoribosyltransferase; Adolescent; Adult; Aged; Child; Child, Preschool; Erythrocytes; F | 1975 |
Etiopathogenesis of the gouty arthritis.
Topics: Arthritis; Gout; Humans; Obesity; Uric Acid | 1975 |
Hyperuricemia and renal failure-presenting manifestations of occult hematologic malignancies.
Topics: Adolescent; Anuria; Child; Gout; Humans; Kidney; Kidney Failure, Chronic; Leukemia; Leukemia, Monocy | 1976 |
Acute renal failure and gout as presenting features of acute lymphoblastic leukaemia.
Topics: Acute Kidney Injury; Allopurinol; Child, Preschool; Female; Gout; Humans; Leukemia, Lymphoid; Pancyt | 1976 |
A contribution to the interrelation of lipid and uric acid metabolism.
Topics: Adult; Aged; Arteriosclerosis; Gout; Humans; Hyperlipidemias; Lipids; Middle Aged; Uric Acid | 1976 |
[Clinical study of LC 75 (Ampliuril pH) in the states of hyperuricemia].
Topics: Benzofurans; Carbonates; Coronary Disease; Diabetes Complications; Gout; Humans; Hypertension; Kidne | 1975 |
Origin and extrarenal elimination of uric acid in man.
Topics: Amidophosphoribosyltransferase; Dietary Proteins; Glutamine; Gout; Humans; Hypoxanthine Phosphoribos | 1975 |
Intrinsic renal disease leading to abnormal urate excretion.
Topics: Acute Kidney Injury; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Kidney Tubules; Metabol | 1975 |
Gouty arthritis in the black race.
Topics: Adult; Aged; Anemia, Sickle Cell; Arthritis; Benzothiadiazines; Black People; Colchicine; Diuretics; | 1975 |
Hyperuricaemia--to treat or not?
Topics: Alcohol Drinking; Diet; Endocrine System Diseases; Gout; Hematologic Diseases; Humans; Hyperlipidemi | 1975 |
Letter: Gout.
Topics: Adult; Elbow Joint; Gout; Humans; Male; Tendinopathy; Uric Acid | 1975 |
[The interrelation between obesity, hyperinsulinism and hyperuricemia].
Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol; Diabetes Complications; Diabetes Mellitus; Fatt | 1975 |
The Filipino and gout.
Topics: Adolescent; Adult; Age Factors; Aged; Allopurinol; Cross-Cultural Comparison; Diet; Ethnicity; Femal | 1975 |
[Deviations in purine metabolism].
Topics: Gout; Humans; Purine-Pyrimidine Metabolism, Inborn Errors; Purines; Uric Acid | 1975 |
Proceedings: Single daily dose of allopurinol.
Topics: Allopurinol; Gout; Humans; Time Factors; Uric Acid | 1975 |
Letter: Fructose and hyperuricemia.
Topics: Dietary Carbohydrates; Fructose; Gout; Humans; Uric Acid | 1975 |
Long survival in sickle cell anemia.
Topics: Age Factors; Aged; Anemia, Aplastic; Anemia, Sickle Cell; Chronic Disease; Electrophoresis, Starch G | 1975 |
Hyperuricaemia in Sudanese.
Topics: Adult; Colorimetry; Female; Gout; Humans; Male; Middle Aged; Sex Factors; Sudan; Uric Acid; Urinary | 1975 |
Letter: Gout.
Topics: Crystallization; Gout; Humans; Solubility; Uric Acid | 1975 |
[25 years of arthritis treatment in the province of Groningen].
Topics: Adolescent; Adult; Aged; Arthritis; Arthritis, Rheumatoid; Child; Child, Preschool; Female; Gout; Hu | 1975 |
[On the hypouricemic action of an alkaline mineral water in the aged].
Topics: Aged; Alkalies; Gout; Humans; Mineral Waters; Purines; Uric Acid; Uricosuric Agents | 1975 |
Gout as a complication of Bartter's syndrome. A possible role for alkalosis in the decreased clearance of uric acid.
Topics: Acute Disease; Adolescent; Adult; Alkalosis; Bartter Syndrome; Bicarbonates; Child; Child, Preschool | 1975 |
[Letter: Gout and alcohol].
Topics: Alcohol Drinking; Ethanol; Gout; Humans; Uric Acid | 1975 |
Chronic experimental hyperuricemic nephropathy.
Topics: Animals; Disease Models, Animal; Gout; Kidney; Kidney Calculi; Nephritis, Interstitial; Oxonic Acid; | 1975 |
[Clinical picture of gout and gouty (hyperuricemic) kidney].
Topics: Adult; Gout; Hematuria; Humans; Kidney Diseases; Male; Proteinuria; Uric Acid | 1975 |
Gout: diagnosis and management.
Topics: Allopurinol; Anti-Inflammatory Agents; Gout; Humans; Probenecid; Uric Acid | 1975 |
[Choice between uricosurics and inhibitors of uric acid synthesis in the treatment of gout].
Topics: Depression, Chemical; Gout; Gout Suppressants; Humans; Kidney Diseases; Uric Acid; Uricosuric Agents | 1975 |
[Uric acid and gout].
Topics: Chemical Phenomena; Chemistry; Gout; Humans; Purine Nucleotides; Purines; Uric Acid | 1975 |
[Gout, hyperuricemia and femur head osteonecrosis (FHON)].
Topics: Adrenal Cortex Hormones; Adult; Female; Femur Head Necrosis; France; Gout; Humans; Hypercholesterole | 1975 |
Hypoxanthine-guanine phosphoribosyltransferase. Characterization of a mutant in a patient with gout.
Topics: Adult; Erythrocytes; Female; Fibroblasts; Genes; Gout; Humans; Hypoxanthine Phosphoribosyltransferas | 1975 |
[Hyperuricemia in the practice].
Topics: Gout; Humans; Paraproteinemias; Polycythemia; Uric Acid | 1975 |
Acute hyperuricemic nephropathy in rats. An electron microscopic study.
Topics: Animals; Disease Models, Animal; Gout; Kidney; Kidney Calculi; Kidney Diseases; Kidney Tubules; Male | 1975 |
Uric acid, joint morbidity, and streptococcal antibodies in Maori and European teenagers. Rotorua Lakes study 3.
Topics: Adolescent; Antibodies, Bacterial; Antistreptolysin; Female; Gout; Hemoglobins; Humans; Joint Diseas | 1975 |
Drug-induced gout.
Topics: Gout; Humans; Kidney; Nucleic Acids; Uric Acid | 1975 |
Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies.
Topics: Adult; Aged; Aging; Calculi; Follow-Up Studies; Glomerular Filtration Rate; Gout; Humans; Inulin; Ki | 1975 |
Avascular necrosis and its relation to lipid and purine metabolism.
Topics: Adrenal Cortex Hormones; Adult; Aged; Alcoholism; Cholesterol; Female; Femur Head Necrosis; Gout; Hu | 1975 |
The pharmacology of hypouricemic effect of benzbromarone.
Topics: Adult; Aspirin; Benzbromarone; Benzofurans; Blood Proteins; Creatinine; Female; Gout; Humans; Male; | 1975 |
[Proceedings: Normal values and samples of findings in kidney diseases].
Topics: Bacteriuria; Creatinine; Female; Glomerular Filtration Rate; Gout; Hematuria; Humans; Inulin; Kidney | 1975 |
[Clinical study of gout and hyperuricemia. (II) Physiopathology and diagnosis].
Topics: Adult; Aged; Gout; Humans; Middle Aged; Uric Acid | 1975 |
Localization of renal tubular uric acid transport defect in gouty chickens.
Topics: Aminohippuric Acids; Animals; Biological Transport; Chickens; Gout; Guanine; Kidney Tubules; Uric Ac | 1975 |
[The simultaneous occurrence of psoriasis, sarcoidosis and gout. Report of 3 cases].
Topics: Adult; Female; Gout; Humans; Male; Middle Aged; Psoriasis; Sarcoidosis; Uric Acid | 1975 |
[Hyperuricemia syndrome and blood coagulation disorder: effects of crenotherapy].
Topics: Blood Coagulation Disorders; Gout; Health Resorts; Humans; Mineral Waters; Syndrome; Uric Acid | 1975 |
[Effect of thiopurinol on renal uric acid and oxypurine excretion in man under modified formula diet with a constant purine content].
Topics: Allopurinol; Diet; Gout; Humans; Kidney; Purines; Uric Acid | 1975 |
[Uric acid and gout].
Topics: Chemical Phenomena; Chemistry; Gout; Humans; Uric Acid | 1975 |
Uricosuric activity of suxibuzone, a new phenylbutazone derivative.
Topics: Adolescent; Adult; Drug Evaluation; Gout; Humans; Phenylbutazone; Sulfinpyrazone; Uric Acid; Uricosu | 1975 |
[Behavior of 5-phosphoribosyl-1-pyrophosphate (PRPP) in erythrocytes, leukocytes and lymphocytes of normal and gouty subjects].
Topics: Adult; Aged; Allopurinol; Erythrocytes; Gout; Humans; Leukocytes; Lymphocytes; Middle Aged; Pentosep | 1975 |
Monosodium urate monohydrate, the gout culprit.
Topics: Adult; Aged; Chemical Phenomena; Chemistry; Crystallography; Female; Gout; Humans; Hydrogen Bonding; | 1976 |
[The hypoexcretors and hyperproducers of uric acid amomg juvenile gout patients].
Topics: Adolescent; Adult; Age Factors; Body Weight; Creatinine; Gout; Humans; Male; Uric Acid | 1976 |
[Which uric acid value is in need of treatment?].
Topics: Allopurinol; Benzbromarone; Citrates; Coronary Disease; Gout; Humans; Hyperlipidemias; Hypertension; | 1976 |
[Hyperuricemia].
Topics: Gout; Humans; Uric Acid | 1976 |
[Hyperuricemia and the kidney].
Topics: Gout; Humans; Kidney Diseases; Uric Acid; Uricosuric Agents | 1976 |
Gout, uric acid and renal disease.
Topics: Arthritis; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Metabolic Diseases; Uric Acid | 1976 |
[Uric acid balance in radiotherapy].
Topics: Adenocarcinoma; Gout; Hodgkin Disease; Humans; Kidney; Kidney Neoplasms; Male; Radiotherapy; Radioth | 1976 |
Clinical and family studies in Hungarian patients with gout.
Topics: Adult; Arthritis, Gouty; Female; Gout; HLA Antigens; Humans; Male; Uric Acid | 1992 |
[Hyperuricemia and its complications].
Topics: Gout; Humans; Uric Acid | 1992 |
[Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug The | 1992 |
Gout.
Topics: Adult; Aged; Arthritis, Gouty; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1992 |
[Hyperuricemia and gout].
Topics: Diagnosis, Differential; Education, Medical, Continuing; Gout; Humans; Spain; Uric Acid | 1992 |
Acute gout after carpal tunnel release.
Topics: Acute Disease; Carpal Tunnel Syndrome; Gout; Gout Suppressants; Humans; Male; Middle Aged; Postopera | 1992 |
Tophaceous gout as a fungating mass.
Topics: Adult; Gout; Humans; Male; Mycoses; Recurrence; Uric Acid | 1992 |
Gouty arthropathy and synovial uric acid.
Topics: Adult; Aged; Aged, 80 and over; Animals; Female; Gout; Humans; Joint Diseases; Male; Middle Aged; Sy | 1992 |
The epidemiology of gout and hyperuricemia in a rural population of Java.
Topics: Adolescent; Adult; Aged; Body Mass Index; Female; Gout; Humans; Indonesia; Life Expectancy; Male; Mi | 1992 |
Surgical management of chronic tophaceous gout. A case report.
Topics: Aged; Chronic Disease; Ciprofloxacin; Foot Deformities, Acquired; Gout; Humans; Male; Metatarsophala | 1992 |
[First indications of decrease in the incidence of hyperuricemia in North Germany].
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Feeding Behavior; Female; Germany; Gout; Hu | 1992 |
Relation between creatinine and uric acid excretion.
Topics: Adult; Creatinine; Gout; Humans; Male; Middle Aged; Time Factors; Uric Acid | 1992 |
Hyperuricemia and gout among heart transplant recipients receiving cyclosporine.
Topics: Arthritis, Gouty; Chi-Square Distribution; Cyclosporine; Female; Gout; Heart Transplantation; Heart- | 1992 |
Diuretic induced gout: a multifactorial condition.
Topics: Aged; Aged, 80 and over; Creatinine; Diuretics; Female; Glomerular Filtration Rate; Gout; Humans; Ki | 1992 |
[Secondary kidney diseases due to hyper-uric acidemia].
Topics: Gout; Humans; Kidney; Kidney Diseases; Prognosis; Ultrasonography; Uric Acid | 1992 |
What stops a gouty attack?
Topics: Anti-Inflammatory Agents; Crystallization; Cytokines; Gout; Humans; Joints; Neutrophils; Uric Acid | 1992 |
Accelerated purine nucleotide degradation by anaerobic but not by aerobic ergometer muscle exercise.
Topics: Adult; Aerobiosis; Anaerobiosis; Blood Pressure; Creatine Kinase; Gout; Heart Rate; Humans; Hypoxant | 1992 |
The incidence of gout in patients with Dupuytren's disease.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Dupuytren Contracture; Female; Gout; Humans; Incid | 1992 |
Antibodies against crystals.
Topics: Allopurinol; Animals; Antibody Formation; Arthritis, Rheumatoid; Crystallography; Electrophoresis, P | 1992 |
Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals.
Topics: Colchicine; Crystallization; Gout; Humans; Knee Joint; Leukocyte Count; Neutrophils; Synovial Fluid; | 1992 |
Subcutaneous pancreatic fat necrosis associated with acute arthritis.
Topics: Acute Disease; Aged; Arthritis; Crystallization; Diagnosis, Differential; Fat Necrosis; Gout; Humans | 1992 |
Identification of distinct PRS1 mutations in two patients with X-linked phosphoribosylpyrophosphate synthetase superactivity.
Topics: Amino Acid Sequence; Base Sequence; DNA; DNA Mutational Analysis; Genetic Linkage; Gout; Humans; Mut | 1991 |
Gout and uric acid excretion.
Topics: Gout; Humans; Uric Acid | 1992 |
Ultrastructural studies of the reaction of urate crystals with a cultured renal tubular cell line.
Topics: Animals; Binding Sites; Cell Line; Crystallization; Gout; Kidney Diseases; Kidney Tubules; Microscop | 1991 |
[Effects of alminoprofen on sodium urate crystal-induced inflammation].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemotaxis, Leukocyte; Depression, Chemical; Dinop | 1991 |
Renal urate hypoexcretion preceding renal disease in a new kindred with familial juvenile gouty nephropathy (FJGN).
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Gout; Humans; Kidney; Kidney Diseases; Male; Ped | 1991 |
Familial nephropathy and gout: which comes first?
Topics: Adult; Creatinine; Female; Gout; Humans; Hypoxanthine; Hypoxanthines; Kidney Diseases; Kidney Failur | 1991 |
Gout and main rheumatic diseases in man.
Topics: Adult; Arthritis; Arthritis, Psoriatic; Arthritis, Rheumatoid; Female; Gout; Humans; Male; Middle Ag | 1991 |
Organic distribution and interrelationships of lesions occurring in laying hens suffering from gout and urolithiasis.
Topics: Animals; Chickens; Female; Gout; Kidney; Liver; Lung; Myocardium; Poultry Diseases; Spleen; Uric Aci | 1991 |
A biochemical investigation on chicken gout observed in the Marmara region in Turkey.
Topics: Animals; Bicarbonates; Blood Proteins; Calcium; Chickens; Gout; Orotic Acid; Poultry Diseases; Refer | 1991 |
Crystal arthritis: a clinician's view.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, | 1991 |
Familial juvenile gouty nephropathy with renal urate hypoexcretion preceding renal disease.
Topics: Adolescent; Adult; Child; Creatinine; Female; Glomerular Filtration Rate; Gout; Humans; Kidney; Kidn | 1991 |
Evidence for a promoter of urate crystal formation in gouty synovial fluid.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Calcium Pyrophosphate; Crystallization; Femal | 1991 |
[Uric acid level in blood donors of southern Germany--almost constant since 1971].
Topics: Adult; Arthritis, Gouty; Benzbromarone; Benzimidazoles; Blood Donors; Cross-Sectional Studies; Femal | 1991 |
Precocious familial gout.
Topics: Adult; Child; Family Health; Female; Gout; Humans; Kidney Diseases; Male; Patient Compliance; Uric A | 1990 |
Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo.
Topics: Apolipoproteins E; Cartilage; Crystallization; Gout; Humans; Neutrophils; Synovial Fluid; Uric Acid | 1991 |
Dupuytren's contracture and gouty tophi in a black patient.
Topics: Dupuytren Contracture; Gout; Humans; Male; Middle Aged; Uric Acid | 1991 |
Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout.
Topics: Adult; Aged; Aged, 80 and over; Gout; Humans; Inflammation; Leukocyte Count; Middle Aged; Neutrophil | 1991 |
Urate and calcium stones--picking up a drop of mercury with one's fingers?
Topics: Allopurinol; Animals; Calcium Oxalate; Glycosaminoglycans; Gout; Humans; Kidney Calculi; Uric Acid | 1991 |
Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution.
Topics: Blotting, Northern; Cell Survival; Cells, Cultured; Crystallography; Dose-Response Relationship, Dru | 1991 |
Female gout. Clinical spectrum and uric acid metabolism.
Topics: Adult; Age Factors; Diuretics; Female; Gout; Humans; Hypertension; Kidney Failure, Chronic; Male; Me | 1991 |
Tophus-derived monosodium urate monohydrate crystals are biologically much more active than synthetic counterpart.
Topics: Blood Proteins; Crystallization; Gout; Hemolysis; Humans; Inflammation; Knee Joint; Luminescent Meas | 1991 |
[Epidemiology of hyperuricemia and gout: difference between Caucasians and Japanese].
Topics: Asian People; Gout; Humans; Japan; Uric Acid; White People | 1991 |
Underexcretory-type hyperuricemia, disproportionate to the reduced glomerular filtration rate, in two boys with mild proteinuria.
Topics: Child; Creatinine; Glomerular Filtration Rate; Gout; Humans; Kidney; Male; Nephritis, Interstitial; | 1990 |
[Changes in serum uric acid concentration after defined physical stress].
Topics: Adult; Energy Metabolism; Gout; Humans; Male; Physical Exertion; Pilot Projects; Risk Factors; Uric | 1990 |
An aberration of fructose metabolism in familial gout identified by 31P magnetic resonance spectroscopy of the liver.
Topics: Adult; Aged; Aged, 80 and over; Dietary Carbohydrates; Female; Fructose; Fructose-Bisphosphate Aldol | 1990 |
[Metabolism of purine nucleotides in the central nervous system in patients with phosphoribosylpyrophosphate synthetase hyperactivity and neurosensory deafness].
Topics: Adult; Brain; Child; Deafness; Female; Genetic Carrier Screening; Gout; Homozygote; Humans; Hypoxant | 1990 |
Acute uric acid nephropathy in two gouty patients with moderate hyperuricemia and high urine acidity.
Topics: Acute Kidney Injury; Benzbromarone; Glomerular Filtration Rate; Gout; Humans; Male; Middle Aged; Uri | 1990 |
[Gout without hyperuricemia?].
Topics: Diagnosis, Differential; Gout; Humans; Male; Middle Aged; Uric Acid | 1990 |
Monosodium urate crystals stimulate phospholipase A2 enzyme activities and the synthesis of a phospholipase A2-activating protein.
Topics: Cell Survival; Colchicine; Eicosanoids; Enzyme Activation; Gout; Humans; Phospholipases A; Phospholi | 1990 |
Fructose-induced aberration of metabolism in familial gout identified by 31P magnetic resonance spectroscopy.
Topics: Diet; Female; Fructose; Gout; Humans; Liver; Magnetic Resonance Spectroscopy; Male; Phosphates; Phos | 1990 |
[Clinical studies on hyperuricemia and gout after transplantation].
Topics: Adult; Allopurinol; Analgesics; Benzbromarone; Female; Gout; Humans; Immunosuppressive Agents; Kidne | 1990 |
Familial hyperuricemia and renal insufficiency.
Topics: Adolescent; Adult; Allopurinol; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Male; Pedigr | 1990 |
Serum uric acid correlates in elderly men and women with special reference to body composition and dietary intake (Dutch Nutrition Surveillance System).
Topics: Aged; Alcohol Drinking; Anthropometry; Antihypertensive Agents; Body Mass Index; Body Weight; Diet; | 1990 |
[Hyperuricemia--does modern therapy improve life expectancy?].
Topics: Cause of Death; Combined Modality Therapy; Gout; Humans; Life Expectancy; Uric Acid | 1990 |
[The effect of oral calcium loading on the serum concentrations and urinary excretion of uric acid in patients with recurrent calcium nephrolithiasis and hypercalciuria].
Topics: Administration, Oral; Adolescent; Adult; Aged; Autoanalysis; Calcium; Chronic Disease; Female; Gout; | 1990 |
Uric acid levels in southern Germany in 1989. A comparison with studies from 1962, 1971, and 1984.
Topics: Adult; Aged; Aging; Female; Germany; Gout; Humans; Kidney Calculi; Male; Middle Aged; Population Sur | 1990 |
Polyarticular symmetric tophaceous joint inflammation as the initial presentation of gout.
Topics: Aged; Female; Finger Joint; Gout; Hand Deformities, Acquired; Humans; Synovial Fluid; Uric Acid | 1990 |
Cyclosporine-induced hyperuricemia and gout.
Topics: Allopurinol; Azathioprine; Cyclosporins; Drug Interactions; Gout; Humans; Transplantation, Homologou | 1990 |
Is asteroid hyalosis ocular gout?
Topics: Age Factors; Aged; Aged, 80 and over; Black People; Eye Diseases; Female; Gout; Humans; Male; Medica | 1990 |
Cyclosporin induced hyperuricemia and gout.
Topics: Adult; Cyclosporins; Female; Gout; Humans; Kidney Transplantation; Male; Middle Aged; Uric Acid; Uve | 1990 |
Epidemiological study of urinary tract stones in a northern Italian city.
Topics: Adult; Calcium Oxalate; Colic; Diet; Drinking; Epidemiologic Methods; Female; Gout; Humans; Incidenc | 1990 |
Intraarticular noninflammatory free urate suspension (urate milk) in 3 patients with painful joints.
Topics: Aged; Alcoholism; Crystallization; Exudates and Transudates; Female; Gout; Humans; Knee Joint; Neutr | 1990 |
Quality control of the laboratory diagnosis of gout by synovial fluid microscopy.
Topics: Crystallization; False Positive Reactions; Gout; Humans; Quality Control; Synovial Fluid; Uric Acid | 1990 |
Substituted cyclic imides as potential anti-gout agents.
Topics: Allopurinol; Analysis of Variance; Animals; Dose-Response Relationship, Drug; Gout; Gout Suppressant | 1990 |
Tophaceous neck mass presenting as a thyroglossal duct cyst.
Topics: Diagnosis, Differential; Gout; Humans; Male; Middle Aged; Thyroglossal Cyst; Uric Acid | 1990 |
Precocious familial gout with reduced fractional urate clearance and normal purine enzymes.
Topics: Adolescent; Adult; Age Factors; Creatinine; Family; Female; Glomerular Filtration Rate; Gout; Humans | 1990 |
Alcohol and gout.
Topics: Alcohol Drinking; Alcoholic Intoxication; Gout; Humans; Uric Acid | 1989 |
[Infratemporal gout tophus--a rare differential diagnosis in primary parotid gland disease].
Topics: Aged; Diagnosis, Differential; Female; Gout; Humans; Ossification, Heterotopic; Parotid Diseases; Pa | 1989 |
Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes.
Topics: Calcium Pyrophosphate; Cell Survival; Cells, Cultured; Chondrocalcinosis; Crystallization; Durapatit | 1989 |
[Significance of uric acid analysis in clinical tests].
Topics: Energy Metabolism; Female; Gout; Humans; Male; Purines; Reference Values; Uric Acid | 1989 |
A model of gout nephropathy.
Topics: Animals; Cells, Cultured; Crystallization; Dogs; Gout; Kidney Diseases; Uric Acid | 1989 |
Hyperuricemia, gout and idiopathic aseptic necrosis of bone.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Female; Femur Head Necrosis; Gout; Humans; Ma | 1989 |
Is gout related to an alteration of the uric acid protein binding?
Topics: Arthritis, Gouty; Blood Proteins; Gout; Humans; Hypoxanthines; Kidney Diseases; Uric Acid | 1989 |
Should dietary restrictions always be prescribed in the treatment of gout?
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Diet; Female; Gout; Humans; Male; Middle Aged; Prevalen | 1989 |
Intermittent control of hyperuricaemia in the treatment of gout.
Topics: Allopurinol; Arthritis, Gouty; Gout; Humans; Middle Aged; Uric Acid | 1989 |
Impaired renal excretion of hypoxanthine and xanthine in primary gout.
Topics: Adult; Aged; Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Hypoxanthines; Kidney; Le | 1989 |
Hyperuricemia and gout in cyclosporin A-treated renal transplant recipients.
Topics: Cyclosporins; Female; Gout; Humans; Kidney Transplantation; Male; Metabolic Clearance Rate; Uric Aci | 1989 |
[Analysis of uric acid and oxypurines in normal subjects and in gout patients].
Topics: Adult; Gout; Humans; Hypoxanthine; Hypoxanthines; Middle Aged; Uric Acid; Xanthine; Xanthines | 1989 |
[Clearance of oxypurines in normal subjects and in gout patients subjected to a purine-free diet. Effects of allopurinol].
Topics: Adult; Allopurinol; Creatinine; Diet; Gout; Humans; Hypoxanthine; Hypoxanthines; Middle Aged; Uric A | 1989 |
Cyclosporine-induced hyperuricemia and gout.
Topics: Adult; Arthritis, Gouty; Azathioprine; Creatinine; Cyclosporins; Drug Therapy, Combination; Female; | 1989 |
A case of multiple urate deposition, without gouty attacks, in a patient with systemic lupus erythematosus.
Topics: Adult; Female; Gout; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Lupus Ne | 1989 |
[Differential indications for uricosuric drugs and allopurinol].
Topics: Allopurinol; Combined Modality Therapy; Dietary Proteins; Gout; Humans; Uric Acid; Uricosuric Agents | 1989 |
Relationship between hypertriglyceridemia and uric acid production in primary gout.
Topics: Alcohol Drinking; Cholesterol; Cholesterol, HDL; Gout; Humans; Hypertriglyceridemia; Male; Reference | 1989 |
[Changes in uric acid and blood lipids in patients with asymptomatic hyperuricemia treated with diet therapy in a rehabilitation procedure].
Topics: Adult; Aged; Combined Modality Therapy; Dietary Fats; Follow-Up Studies; Gout; Humans; Hyperlipidemi | 1989 |
[Kidney tubular transport disorders. Disorders of renal urate transport].
Topics: Acid-Base Imbalance; Biological Transport; Extracellular Space; Gout; Humans; Kidney; Kidney Disease | 1989 |
[Is it necessary to prescribe a diet for all patients with gout?].
Topics: Female; Gout; Humans; Male; Uric Acid | 1989 |
The "switch-off" mechanism of spontaneous resolution of acute gout attack.
Topics: Acute-Phase Reaction; Calorimetry; Crystallization; Gout; Humans; Inflammation; Lymphocytes; Microsc | 1988 |
Calcium pyrophosphate crystal deposition: the effect of monosodium urate and apatite crystals in a kinetic study using a gelatin matrix model.
Topics: Apatites; Calcium Pyrophosphate; Diphosphates; Gelatin; Gout; Humans; Microscopy, Electron, Scanning | 1988 |
Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness.
Topics: Adult; Child; Deafness; Female; Fibroblasts; Gout; Humans; Male; Phosphotransferases; Purine Nucleot | 1988 |
[Cyclic nucleotides in gout].
Topics: Adult; Cyclic AMP; Cyclic GMP; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1988 |
Gout and hyperuricaemia in patients on cyclosporin and diuretics.
Topics: Adult; Antilymphocyte Serum; Azathioprine; Cyclosporins; Diuretics; Female; Gout; Humans; Kidney Dis | 1985 |
[Gamma-glutamyltransferase and alcohol consumption in primary gout].
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; gamma-Glutamyltransferase; Gout; Humans; Middle Aged; Tri | 1986 |
Study of hereditary fructose intolerance by use of 31P magnetic resonance spectroscopy.
Topics: Carbohydrate Metabolism, Inborn Errors; Female; Fructose; Fructose Intolerance; Fructose-Bisphosphat | 1987 |
A structural approach to pathological crystallizations. Gout: the possible role of albumin in sodium urate crystallization.
Topics: Crystallization; Fluorescence; Gout; Humans; Microscopy, Electron, Scanning; Ovalbumin; Peptides; Po | 1988 |
Development of the gout tophus. An hypothesis.
Topics: Aged; Antibodies, Monoclonal; Crystallization; Gout; Humans; Macrophages; Male; Middle Aged; Models, | 1989 |
Hyperuricemia, gout, and autosomal dominant polycystic kidney disease.
Topics: Aged; Female; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney Failure, Chronic; Male; M | 1989 |
[Immune complex hyperuricemic nephritis: aspects of its morphology and pathogenesis].
Topics: Biopsy, Needle; Glomerular Mesangium; Glomerulonephritis; Gout; Humans; Immune Complex Diseases; Kid | 1986 |
Crystal-induced endogenous pyrogen production. A further look at gouty inflammation.
Topics: Calcium Pyrophosphate; Crystallization; Diphosphates; Durapatite; Gout; Humans; Hydroxyapatites; Int | 1985 |
[Hypothesis on the probable mechanism of auto-limitation of acute attacks of gout].
Topics: Calorimetry; Crystallization; Free Radicals; Gout; Humans; Microscopy, Electron, Scanning; Models, B | 1986 |
The "switch-off" mechanism of spontaneous resolution of acute gout attack.
Topics: Acute Disease; Allantoin; Crystallization; Durapatite; Gout; Humans; Hydroxyapatites; Kinetics; Lumi | 1986 |
Products of polymorphonuclear cell injury inhibit IgG enhancement of monosodium urate-induced superoxide production.
Topics: Animals; Crystallization; Gout; Humans; Immunoglobulin G; Microscopy, Electron; Neutrophils; Protein | 1986 |
Articular oxalate crystals and the taxonomy of gout.
Topics: Calcium Oxalate; Crystallization; Gout; History, 19th Century; History, 20th Century; History, Medie | 1988 |
Gout and hyperuricemia: diagnosis and management.
Topics: Adult; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Colchicine; Female; Gout; Hu | 1986 |
Intractable gouty arthritis.
Topics: Allopurinol; Arthritis; Colchicine; Duodenal Ulcer; Gout; Humans; Hypertension; Indomethacin; Male; | 1987 |
Migration and gout: the Tokelau Island migrant study.
Topics: Adolescent; Adult; Age Factors; Aged; Cholesterol; Female; Gout; Humans; Male; Middle Aged; New Zeal | 1987 |
Asymptomatic hyperuricaemia.
Topics: Gout; Humans; Kidney Diseases; Male; Risk Factors; Uric Acid | 1987 |
Studies on normal and abnormal excretion patterns of uric acid in Bahawalpur.
Topics: Adolescent; Adult; Aged; Aging; Female; Gout; Humans; Male; Middle Aged; Pakistan; Urban Population; | 1987 |
Altered fractional excretion of uric acid during total parenteral nutrition.
Topics: Adult; Aged; Amino Acids; Female; Gout; Humans; Male; Pancreatic Cyst; Pancreatic Pseudocyst; Parent | 1987 |
Allopurinol hypersensitivity in a patient with coexistent systemic lupus erythematosus and tophaceous gout.
Topics: Adult; Allopurinol; Arthrography; Drug Hypersensitivity; Fingers; Gout; Humans; Klinefelter Syndrome | 1988 |
[Dose response relations of allopurinol].
Topics: Allopurinol; Dose-Response Relationship, Drug; Gout; Humans; Uric Acid | 1988 |
Renal excretion of hypoxanthine and xanthine in primary gout.
Topics: Adult; Aged; Female; Gout; Humans; Hypoxanthine; Hypoxanthines; Kidney; Male; Middle Aged; Uric Acid | 1988 |
[Medications against gout].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Gout; Humans; Uric Acid; Uricosuric Agents; Xan | 1988 |
[A case of partial deficiency of hypoxanthine-guanine phosphoribosyltransferase].
Topics: Adolescent; Genes, Recessive; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Male; Purines; U | 1988 |
[Uric acid metabolism disorders associated with alcoholism].
Topics: Adenosine Triphosphate; Alcoholism; Gout; Humans; Kidney; Uric Acid | 1988 |
[Obesity as a risk factor in gout].
Topics: Diet; Female; Gout; Humans; Male; Middle Aged; Obesity; Risk Factors; Uric Acid | 1988 |
[Prevalence of excess blood uric acid and gout in a sample of a rural Castillian population 40-50 years of age].
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Gout; Humans; Lipids; Male; Middle Aged; Risk | 1988 |
Concomitant gout and rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Crystallization; Ear; Gout; HLA-DR Antigens; HLA-DR4 Antigen; Humans; | 1988 |
The incidence of gout in renal transplant recipients.
Topics: Azathioprine; Cyclosporins; Diuretics; Female; Gout; Humans; Kidney Transplantation; Male; Retrospec | 1987 |
[The effect of inhibitor of angiotensin-converting enzyme on uric acid metabolism].
Topics: Adult; Aged; Captopril; Female; Gout; Humans; Hypertension; Male; Middle Aged; Uric Acid | 1987 |
Ankle joint urate arthritis in rats provides a useful tool for the evaluation of analgesic and anti-arthritic agents.
Topics: Analgesics; Animals; Ankle Joint; Anti-Inflammatory Agents; Arthritis; Disease Models, Animal; Drug | 1988 |
[Hyperuricemia as a risk factor of nephropathy in gout].
Topics: Adult; Aged; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Risk Factors; Uric Acid | 1988 |
[A family of hereditary xanthinuria: two siblings with peptic ulcer and hypouricemia due to xanthine oxidase deficiency, and a heterozygote (father) with gout].
Topics: Adult; Gout; Heterozygote; Humans; Male; Peptic Ulcer; Purine-Pyrimidine Metabolism, Inborn Errors; | 1988 |
[Therapeutic nutrition in gout].
Topics: Female; Gout; Humans; Kidney; Male; Middle Aged; Uric Acid | 1988 |
[Uric acid concentrations of the kidney in primary gout].
Topics: Female; Gout; Humans; Kidney; Kidney Cortex; Kidney Failure, Chronic; Male; Middle Aged; Uric Acid | 1988 |
[Hyperlipoproteinemia in primary gout and asymptomatic hyperuricemia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cholesterol; Creatinine; Gout; Humans; Hyperlipoproteine | 1988 |
[Glomerular diseases secondary to gout].
Topics: Adult; Aged; Female; Glomerulonephritis; Gout; Humans; Kidney Glomerulus; Male; Middle Aged; Uric Ac | 1988 |
[Clinical aspects and diagnosis of urinary calculi in patients with gout].
Topics: Adult; Aged; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Uric Acid | 1988 |
[Intra-hospital acute arthritis. Prospective study of 50 cases].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Arthritis; Calcinosis; Calcium Pyrophosphate; Crystal | 1987 |
[The uric acid-lowering effect of diflunisal].
Topics: Adolescent; Adult; Aged; Arthritis; Diflunisal; Female; Gout; Humans; Male; Middle Aged; Salicylates | 1987 |
Primary hyperparathyroidism and hyperuricaemia are associated but not correlated with indicators of bone turnover.
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Regeneration; Female; Gout; Humans; Hydroxyp | 1987 |
[Total purine content in selected foods].
Topics: Food Analysis; Gout; Humans; Purines; Uric Acid | 1987 |
[Use of sorption for the correction of hyperuricemia in the combined treatment of gout].
Topics: Administration, Oral; Charcoal; Drug Therapy, Combination; Female; Gout; Humans; Male; Middle Aged; | 1987 |
[Substantiation and effectiveness of the use of purine antagonists in gouty nephropathy].
Topics: Adult; Azathioprine; Drug Therapy, Combination; Gout; Humans; Kidney Diseases; Mercaptopurine; Middl | 1987 |
[The clinical picture of acute gout without hyperuricemia].
Topics: Acute Disease; Adult; Aged; Female; Gout; Humans; Male; Middle Aged; Pedigree; Uric Acid | 1986 |
Gout and pseudogout of the temporomandibular joint.
Topics: Adult; Arthritis; Calcium Pyrophosphate; Diagnosis, Differential; Female; Gout; Humans; Male; Middle | 1987 |
[Uric acid levels of the serum of healthy persons and patients with various rheumatic diseases].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Gout; Humans; Male; Middle Aged; Osteoarthri | 1987 |
Gout and hyperuricaemia.
Topics: Allopurinol; Colchicine; Cross-Sectional Studies; Family Practice; Female; Gout; Humans; Indomethaci | 1987 |
[Evaluation of hyperuricemia caused by fructose in a status of altered uric acid metabolism].
Topics: Adult; Aged; Arthritis, Gouty; Diagnosis, Differential; Female; Fructose; Gout; Humans; Male; Metabo | 1987 |
[Beta 2-microglobulin in the blood serum and urine of patients with interstitial kidney lesions].
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; beta 2-Microglobulin; Chronic Disease; Female; Gout; Hu | 1986 |
Hyperuricemia and gout.
Topics: Adolescent; Age Factors; Arthritis; Arthrography; Bone Diseases; Child; Diagnosis, Differential; Fem | 1986 |
[Observations on the effect of PZA, EB and RFP on uric acid metabolism].
Topics: Adolescent; Adult; Arthritis; Drug Therapy, Combination; Ethambutol; Female; Gout; Humans; Male; Mid | 1986 |
Purine synthesis de novo in cultured lymphoblast cells derived from patients with gout.
Topics: Adult; Cells, Cultured; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Lymphocytes; Male; Mid | 1987 |
[Current clinical course of gout].
Topics: Adult; Age Factors; Aged; Arthritis; Female; Gout; Humans; Male; Middle Aged; Sex Factors; Uric Acid | 1987 |
[Epidemiology and pathogenesis of disorders of purine metabolism].
Topics: Adolescent; Adult; Alcohol Drinking; Arthritis; Diet; Female; Gout; Humans; Male; Meat; Middle Aged; | 1987 |
[Effect of decrease in hyperuricemia levels on joint, kidney and other symptoms in patients with gout].
Topics: Adult; Aged; Allopurinol; Arthritis; Colchicine; Coronary Disease; Gout; Humans; Hypertension; Middl | 1987 |
[Circadian rhythm of uric acid levels of the serum in gout].
Topics: Adult; Arthritis, Rheumatoid; Circadian Rhythm; Gout; Humans; Kidney; Metabolic Clearance Rate; Uric | 1987 |
[Rehabilitation of patients with gout during outpatient follow-up].
Topics: Adult; Aged; Arthritis; Female; Follow-Up Studies; Gout; Gout Suppressants; Health Resorts; Humans; | 1987 |
Comparison of the urate lowering effects of allopurinol and diflunisal.
Topics: Allopurinol; Diflunisal; Gout; Humans; Osmolar Concentration; Salicylates; Uric Acid; Xanthine; Xant | 1987 |
Hyperuricemia and uric acid nephropathy.
Topics: Aged; Allopurinol; Female; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Nephritis, Inters | 1987 |
Gout and hyperuricaemia in systemic lupus erythematosus.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Diagnosis, Differential; Diuretics; Female; | 1987 |
[Metabolic arthropathies with special reference to gout].
Topics: Arthritis; Chondrocalcinosis; Gout; Humans; Prognosis; Uric Acid | 1987 |
Evaluation of the renal mechanisms for urate homeostasis in uremic patients by probenecid and pyrazinamide test.
Topics: Absorption; Creatinine; Female; Glomerular Filtration Rate; Gout; Homeostasis; Humans; Kidney Failur | 1987 |
Significance of single serum urate estimations in acutely hospitalized elderly patients.
Topics: Aged; Aged, 80 and over; Arthritis; Diuretics; Female; Gout; Humans; Male; Middle Aged; Predictive V | 1987 |
[Diet therapy in gout].
Topics: Gout; Humans; Menu Planning; Uric Acid | 1986 |
Aseptic loosening of a total hip prosthesis secondary to tophaceous gout. A case report.
Topics: Aged; Female; Gout; Hip Joint; Hip Prosthesis; Humans; Prosthesis Failure; Radiography; Reoperation; | 1987 |
[Secondary gout and pseudo-Bartter syndrome in females with laxative abuse].
Topics: Adult; Anorexia Nervosa; Bartter Syndrome; Cathartics; Dose-Response Relationship, Drug; Female; Gou | 1987 |
Your CE topic this month (No. 26). Gout: medical management.
Topics: Diet, Reducing; Gout; Humans; Nursing, Practical; Uric Acid | 1987 |
[Molecular genetic mechanisms of the pathogenesis of gout and gouty nephropathy].
Topics: Adult; Aged; Creatine; DNA Repair; DNA Replication; Gout; Humans; Kidney Diseases; Male; Middle Aged | 1987 |
Plasma oxipurinol concentrations during allopurinol therapy.
Topics: Allopurinol; Creatine; Gout; Humans; Hypoxanthine; Hypoxanthines; Kidney Function Tests; Oxypurinol; | 1987 |
Tophaceous gout presenting with bilateral hand contractures and carpal tunnel syndrome.
Topics: Aged; Carpal Tunnel Syndrome; Contracture; Gout; Hand; Humans; Male; Uric Acid | 1986 |
[Clinical experience with a new uricolytic agent].
Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Kidney Failure, Chronic; Male; Middle Aged; Urate Oxi | 1986 |
Immunochemical and ultrastructural characterization of serum proteins associated with monosodium urate crystals (MSU) in synovial fluid cells from patients with gout.
Topics: Arthritis; Blood Proteins; Gout; Humans; Immunochemistry; Immunoglobulin G; Microscopy, Electron; Ph | 1986 |
Eye tophi deposition in gout.
Topics: Aged; Eye Diseases; Gout; Humans; Male; Sclera; Uric Acid | 1986 |
[Arthropathies and nutrition: gout].
Topics: Adolescent; Adult; Arthritis; Colchicine; Diet; Dietary Fats; Dietary Proteins; Female; Gout; Humans | 1986 |
[Hyperuricemia: explain, ignore or treat?].
Topics: Coronary Disease; Female; Gout; Humans; Hypertension; Kidney Calculi; Male; Purines; Risk; Uric Acid | 1986 |
Impact of associated medical conditions on clinical features of gout.
Topics: Adult; Gout; Humans; Kidney Calculi; Middle Aged; Proteinuria; United States; Uric Acid | 1986 |
Corrected clearance identifies underexcretion of uric acid in a gouty kindred.
Topics: Gout; Humans; Kidney; Kinetics; Models, Biological; Uric Acid | 1986 |
Diminished tubular secretion of urate in gout not dependent on serum urate levels.
Topics: Adult; Aged; Gout; Humans; Kidney Tubules; Kinetics; Male; Middle Aged; Nephrons; Probenecid; Refere | 1986 |
Study of the effect of hypouricaemic therapy on serum lipid levels in gout patients.
Topics: Allopurinol; Cholesterol; Cholesterol, HDL; Gout; Humans; Lipids; Probenecid; Triglycerides; Uric Ac | 1986 |
The sex steroids influence on uric acid binding to human plasma proteins.
Topics: Adolescent; Adult; Allopurinol; Blood Proteins; Child; Child, Preschool; Female; Gout; Humans; Male; | 1986 |
Hypouricemic action of diflunisal in gouty patients.
Topics: Adult; Aged; Diflunisal; Dose-Response Relationship, Drug; Female; Gout; Humans; Male; Middle Aged; | 1986 |
Prevalence of rheumatoid arthritis, osteoarthritis, chondrocalcinosis and gouty arthritis at age 79.
Topics: Aged; Aging; Arthritis; Arthritis, Rheumatoid; Chondrocalcinosis; Female; Finger Joint; Gout; Hip Jo | 1986 |
Carpal tunnel syndrome and gout: case report.
Topics: Aged; Carpal Tunnel Syndrome; Gout; Humans; Male; Uric Acid | 1986 |
Preliminary evidence for the presence of an inhibitor on the surface of natural monosodium urate crystals.
Topics: Gout; Humans; Uric Acid | 1986 |
[Ketazone hepatosis--a possibility for the development of secondary hypouricemia].
Topics: Adult; Arthritis; Chemical and Drug Induced Liver Injury; Gout; Humans; Liver Function Tests; Male; | 1986 |
Requiem for gouty nephropathy.
Topics: Acute Disease; Aged; Animals; Chronic Disease; Disease Models, Animal; Gout; Humans; Kidney; Kidney | 1986 |
[Arterial hypertension in gouty nephropathy].
Topics: Adult; Aged; Blood Pressure; Female; Gout; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; | 1986 |
Coexistence of rheumatoid nodulosis and gout.
Topics: Adult; Gout; Humans; Male; Rheumatoid Nodule; Synovial Fluid; Uric Acid | 1986 |
The clinical spectrum of gouty arthritis in women.
Topics: Adult; Age Factors; Aged; Arthritis; Diuretics; Female; Gout; Humans; Kidney Diseases; Male; Menopau | 1986 |
Paget's disease of bone in patients with gout.
Topics: Aged; Aged, 80 and over; Gout; Humans; Male; Middle Aged; Osteitis Deformans; Radionuclide Imaging; | 1986 |
Coexistent systemic lupus erythematosus and urate deposition.
Topics: Adult; Female; Gout; Humans; Lupus Erythematosus, Systemic; Uric Acid | 1986 |
Renal handling of uric acid in gout: impaired tubular transport of urate not dependent on serum urate levels.
Topics: Adult; Aged; Biological Transport, Active; Gout; Humans; Kidney Tubules; Kinetics; Male; Middle Aged | 1986 |
A comparison of gout in men and women. A 10-year experience.
Topics: Adult; Age Factors; Aged; Arthritis; Female; Gout; Humans; Male; Middle Aged; Retrospective Studies; | 1986 |
Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout.
Topics: Allopurinol; Crystallization; Female; Gout; Humans; Joints; Knee Joint; Male; Synovial Fluid; Uric A | 1986 |
[Hyperuricemic nephropathy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged | 1986 |
[Renal aspects of the pathogenesis of hyperuricemia].
Topics: Glomerular Filtration Rate; Gout; Humans; Kidney Tubules; Uric Acid | 1986 |
[Clinical picture and diagnosis of gout].
Topics: Adult; Aged; Diagnosis, Differential; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Uric | 1986 |
[Diet therapy of hyperuricemia--scientific principles and practical consequences].
Topics: Combined Modality Therapy; Gout; Humans; Purines; Uric Acid | 1986 |
[Drug therapy of hyperuricemia].
Topics: Allopurinol; Drug Therapy, Combination; Gout; Humans; Uric Acid; Uricosuric Agents | 1986 |
When to treat hyperuricaemia.
Topics: Female; Gout; Humans; Male; Risk; Uric Acid | 1986 |
Gout in the elderly, a separate entity?
Topics: Age Factors; Aged; Female; Gout; Humans; Male; Retrospective Studies; Sex Factors; Uric Acid | 1987 |
[Adenosine deaminase activity in the lymphocytes of patients with gouty arthritis].
Topics: Adenosine Deaminase; Arthritis; Clinical Enzyme Tests; Female; Gout; Humans; Lymphocytes; Male; Midd | 1986 |
[Hypouricemic effect of diflunisal in patients with gout].
Topics: Adult; Aged; Diflunisal; Female; Gout; Humans; Male; Middle Aged; Salicylates; Uric Acid | 1986 |
[Alkalit in the treatment of hyperuricemic syndrome].
Topics: Adult; Aged; Citrates; Citric Acid; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Uric | 1986 |
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.
Topics: Adult; Aged; Aged, 80 and over; Aging; Arthritis; Gout; Humans; Hypertension; Male; Massachusetts; M | 1987 |
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.
Topics: Adult; Aged; Aged, 80 and over; Aging; Arthritis; Gout; Humans; Hypertension; Male; Massachusetts; M | 1987 |
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.
Topics: Adult; Aged; Aged, 80 and over; Aging; Arthritis; Gout; Humans; Hypertension; Male; Massachusetts; M | 1987 |
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.
Topics: Adult; Aged; Aged, 80 and over; Aging; Arthritis; Gout; Humans; Hypertension; Male; Massachusetts; M | 1987 |
Tophaceous gout of the cervical spine without peripheral tophi.
Topics: Aged; Cervical Vertebrae; Creatinine; Female; Gout; Humans; Male; Spinal Diseases; Uric Acid | 1987 |
[A study on the prognosis of asymptomatic hyperuricemia--I].
Topics: Adult; Aged; Arthritis; Gout; Humans; Male; Middle Aged; Prognosis; Uric Acid; Urinary Calculi | 1985 |
Case report: intraosseous gouty tophus.
Topics: Aged; Clavicle; Female; Gout; Humans; Radiography; Uric Acid | 1985 |
Adenosine triphosphate degradation in specific disease.
Topics: Adenine; Adenosine Triphosphate; Biotransformation; Carnitine O-Palmitoyltransferase; Ethanol; Fruct | 1985 |
[Arresting an acute attack of gout. Open pilot study in 98 patients].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Drug Evaluation; Female; Gout; Humans; Male; | 1985 |
Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Chondrocalcinosis; Complement C3; Complement C3a; Complement C5; Complement C | 1985 |
The development of allopurinol.
Topics: Allopurinol; Animals; Chemistry; Coronary Disease; Gout; History, 20th Century; Humans; Hypertension | 1985 |
[Ultrasonography of the gouty kidney].
Topics: Adult; Aged; Female; Gout; Humans; Kidney; Male; Middle Aged; Ultrasonography; Uric Acid | 1985 |
Plasma follicle-stimulating hormone, luteinizing hormone, and sex hormones in patients with gout.
Topics: Adult; Aged; Clomiphene; Estradiol; Female; Follicle Stimulating Hormone; Gonadal Steroid Hormones; | 1985 |
Rational therapy for hyperuricaemia.
Topics: Gout; Gout Suppressants; Humans; Uric Acid; Uricosuric Agents | 1986 |
Hyperuricemia and gout.
Topics: Allopurinol; Anti-Inflammatory Agents; Arthritis; Colchicine; Female; Gout; Humans; Indomethacin; Ki | 1985 |
Gouty infiltration of a flexor tendon simulating rupture.
Topics: Adult; Fingers; Gout; Humans; Male; Rupture; Tendon Injuries; Tendons; Uric Acid | 1985 |
Gouty tenosynovitis in the hand.
Topics: Adult; Aged; Arthritis; Carpal Tunnel Syndrome; Female; Gout; Hand; Humans; Male; Middle Aged; Tenos | 1985 |
Asymptomatic hyperuricemia. The case for benign neglect.
Topics: Age Factors; Female; Gout; Humans; Kidney Calculi; Leukemia; Lymphoma; Male; Reference Values; Risk; | 1985 |
The treatment of hyperuricaemia and gout.
Topics: Arthritis; Gout; Gout Suppressants; Humans; Uric Acid | 1985 |
Diuretic-induced gout in elderly women.
Topics: Age Factors; Aged; Creatinine; Diuretics; Female; Gout; Humans; Sex Factors; Uric Acid | 1985 |
Juvenile gouty arthritis.
Topics: Arthritis, Juvenile; Child; Child, Preschool; Gout; Humans; Uric Acid | 1985 |
[Behavior of serum acid levels in children in comparison with adults and the incidence of purine metabolism disorders and concomitant diseases in children of families with gout].
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Female; Glomerular Filtration Rate; Gout; H | 1985 |
Studies on the interaction of rheumatoid factor with monosodium urate crystals and case report of coexistent tophaceous gout and rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Crystallization; Gout; Humans; Immunoglobulin G; Immunoglobulin M; In Vitro T | 1985 |
Hyperuricemia and hypertriglyceridemia: metabolic basis for the association.
Topics: Adult; Aged; Creatinine; Dietary Carbohydrates; Fat Emulsions, Intravenous; Female; Glucose; Gout; H | 1985 |
Multiple microcrystal deposition within a family.
Topics: Adult; Aged; Calcium Pyrophosphate; Chondrocalcinosis; Crystallization; Female; Gout; Humans; Joint | 1985 |
Aortic valvular tophus: identification by X-ray diffraction of urate and calcium phosphates.
Topics: Aged; Aortic Valve; Calcium Phosphates; Gout; Heart Valve Diseases; Humans; Hydroxyapatites; Male; U | 1985 |
Rapid development of gouty tophi after diuretic therapy.
Topics: Aged; Diuretics; Female; Furosemide; Gout; Heart Failure; Humans; Uric Acid | 1985 |
[Illusion and reality in gout].
Topics: Arthritis; Arthritis, Rheumatoid; Diagnosis, Differential; Gout; Hallux; Humans; Rheumatic Nodule; U | 1985 |
[Gout and urolithiasis].
Topics: Adult; Calcium Oxalate; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Urinary Calculi | 1985 |
[Lipoprotein patterns in gout and hyperuricemia].
Topics: Aged; Arteriosclerosis; Chylomicrons; Female; Gout; Humans; Lipoproteins, LDL; Lipoproteins, VLDL; M | 1985 |
Gout nephropathy and arterial hypertension.
Topics: Female; Glomerular Filtration Rate; Gout; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; | 1985 |
Role of alcohol in clinical nephrology.
Topics: Acute Kidney Injury; Alcoholism; Blood Glucose; Blood Proteins; Energy Metabolism; Female; Fetal Alc | 1985 |
[Gout with giant tophi: description of a case].
Topics: Aged; Gout; Humans; Male; Radiography; Uric Acid | 1985 |
Streptomycin induced acute hyperuricemia and podagra.
Topics: Acute Disease; Adult; Gout; Humans; Male; Streptomycin; Uric Acid | 1985 |
[Renal insufficiency and uric gout in a lead worker (clinicopathologic conference)].
Topics: Aged; Gout; Humans; Hypertension; Kidney; Kidney Failure, Chronic; Lead Poisoning; Male; Myocardium; | 1985 |
[Secondary hyperuricemia].
Topics: Cardiovascular Diseases; Diuretics; Endocrine System Diseases; Ethanol; Fructose; Gout; Hematologic | 1985 |
[Criteria for the selection and evaluation of diagnostic tests].
Topics: Blood Chemical Analysis; Clinical Laboratory Techniques; Creatinine; Diabetic Nephropathies; Glomeru | 1985 |
[Attacks of gout and thromboembolic disease: role of heparin therapy].
Topics: Acute Disease; Aged; Arthritis; Female; Gout; Heparin; Humans; Male; Middle Aged; Thromboembolism; U | 1985 |
Apatite-type crystal deposition in arthritic cartilage.
Topics: Apatites; Calcium Pyrophosphate; Cartilage, Articular; Electron Probe Microanalysis; Gout; Humans; M | 1985 |
[Uricosuria after administration of benethazone].
Topics: Adult; Aged; Gout; Humans; Middle Aged; Phenylbutazone; Uric Acid | 1985 |
Ambition and disease: the chicken or the egg?
Topics: Cholesterol; Coronary Disease; Disease; Gout; Humans; Personality; Research; Uric Acid | 1970 |
Fructose-induced hyperuricaemia.
Topics: Administration, Oral; Adult; Age Factors; Carbohydrate Metabolism, Inborn Errors; Child; Female; Fru | 1970 |
[The effect of animal protein and NaHCO3 on the occurrence of gout and on the protein content of the serum in chicks].
Topics: Animal Feed; Animals; Bicarbonates; Blood Proteins; Chickens; Cholinesterases; Dietary Proteins; gam | 1970 |
Presence of ornithine in the urate-binding alpha-alpha2 globulin.
Topics: Alpha-Globulins; Amino Acid Metabolism, Inborn Errors; Amino Acids; Arginase; Blood Protein Electrop | 1971 |
Automated computerized metabolic profiles and subclinical tubular and glomerular nephropathy.
Topics: Albumins; Alkaline Phosphatase; Amylases; Blood Glucose; Blood Urea Nitrogen; Calcium; Cholesterol; | 1968 |
Plasma concentrations of the urate-binding alpha 1-2 -globulin in patients with different types of primary gout as compared to healthy control subjects.
Topics: Adult; Alpha-Globulins; Female; Gout; Humans; Hypoproteinemia; Immunodiffusion; Male; Middle Aged; P | 1972 |
Laboratory investigations in connective tissue disease.
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Biopsy; Connective Tissue; Dermatomyositis; Diphosph | 1972 |
Differential diagnosis of gout.
Topics: Diagnosis, Differential; Fructose; Gout; Humans; Uric Acid | 1972 |
Effect of weight-loss on plasma and urinary levels of uric acid.
Topics: Adult; Aged; Body Weight; Diet Therapy; Dietary Carbohydrates; Female; Gout; Humans; Male; Middle Ag | 1972 |
Urate--plasma protein interactions.
Topics: Alpha-Globulins; Blood Proteins; Gout; Humans; Protein Binding; Uric Acid | 1972 |
[Arthritis uratica].
Topics: Autopsy; Cartilage, Articular; Gout; Humans; Macrophages; Microscopy, Electron; Staining and Labelin | 1973 |
[Discussion on gout].
Topics: Alpha-Globulins; Gout; Humans; Purines; Uric Acid | 1973 |
Local concentration of urate in the pathogenesis of gout.
Topics: Carbon Radioisotopes; Crystallization; Diffusion; Extracellular Space; Gout; Humans; Injections, Sub | 1973 |
[Glutamine synthetase activity in the liver in primary gout (author's transl)].
Topics: Adult; Aged; Creatinine; Female; Glutamate-Ammonia Ligase; Gout; Humans; Liver; Male; Middle Aged; U | 1974 |
Blood-uric-acid levels in familial hypercholesterolaemia.
Topics: Blood; Female; Gout; Hypercholesterolemia; Hyperlipidemias; Male; Statistics as Topic; Uric Acid | 1966 |
Hyperuricaemia, gout, and diabetic abnormality in Polynesian people.
Topics: Adult; Aged; Blood; Blood Pressure; Diabetes Mellitus; Ethnology; Female; Glucose Tolerance Test; Gl | 1966 |
Frequency-distribution curve of uric acid in the general population.
Topics: Blood Chemical Analysis; Female; Gout; Humans; In Vitro Techniques; Male; Statistics as Topic; Uric | 1966 |
Uric acid in human plasma. V. Isolation and identification of plasma proteins interacting with urate.
Topics: Adolescent; Adult; Aged; Alpha-Globulins; Blood Protein Electrophoresis; Chromatography, Gel; Chroma | 1966 |
Fructose-induced hyperuricaemia.
Topics: Adult; Aspartate Aminotransferases; Blood Glucose; Carbohydrate Metabolism, Inborn Errors; Child; Ch | 1967 |
Uric acid in bone-marrow.
Topics: Bone Marrow; Female; Gout; Humans; Middle Aged; Uric Acid | 1968 |
Gout and the kidney.
Topics: Allopurinol; Gout; Humans; Kidney Failure, Chronic; Uric Acid; Uricosuric Agents | 1968 |
Genetic studies in primary gout. Investigations on the plasma levels of the urate-binding alpha 1-alpha 2-globulin in individuals from two gouty kindreds.
Topics: Adult; Alpha-Globulins; Arthritis; Autoradiography; Chromatography, Gel; Epilepsy; Female; Gout; Het | 1968 |
Serum-uric-acid and coronary heart-disease.
Topics: Adult; Age Factors; Arteriosclerosis; Blood Glucose; Blood Pressure; Cholesterol; Coronary Disease; | 1969 |
[Ultrastructural observations on gout-tophi].
Topics: Capillaries; Connective Tissue; Gout; Histiocytes; Humans; Microscopy, Electron; Phagocytosis; Pinoc | 1969 |
Gout.
Topics: Allopurinol; Arthritis, Rheumatoid; Chondrocalcinosis; Colchicine; Diagnosis, Differential; Gout; Hu | 1973 |
[Homozygous inherited alpha1-antitrypsin deficiency with emphysema of the lung, cor pulmonale, and gout (author's transl)].
Topics: Adult; alpha 1-Antitrypsin; Gout; Homozygote; Humans; Immunodiffusion; Male; Metabolism, Inborn Erro | 1974 |
[Epidemiology and biochemistry of risk factors of gout (author's transl)].
Topics: Arteriosclerosis; Carbohydrate Metabolism; Fatty Acids; Germany, West; Gout; Humans; Proteins; Purin | 1974 |
[Nephrolithiasis within the framework of internal medicine (author's transl)].
Topics: Antineoplastic Agents; Cystine; Gout; Humans; Kidney Calculi; Lesch-Nyhan Syndrome; Myeloproliferati | 1974 |
[Fundamentals of gout research (author's transl)].
Topics: Arthritis; Chemical Phenomena; Chemistry; Diet Therapy; Gout; Humans; Kidney Calculi; Kidney Disease | 1974 |
[Incidence of primary hyperuricemia in ambulant patients (author's transl)].
Topics: Adult; Age Factors; Aged; Ambulatory Care; Blood Protein Disorders; Diabetes Mellitus; Female; Germa | 1974 |
[Simplification of allopurinol treatment].
Topics: Allopurinol; Dosage Forms; Drug Evaluation; Gout; Half-Life; Humans; Uric Acid | 1974 |
Drugs in the treatment of hyperuricemia.
Topics: Allopurinol; Gout; Humans; Oxypurinol; Probenecid; Sulfinpyrazone; Uric Acid; Uricosuric Agents | 1974 |
Hyperuricemia in children, with the exception of the Lesch-Nyhan syndrome.
Topics: Acidosis; Acute Disease; Acute Kidney Injury; Adult; Child; Child, Preschool; Chronic Disease; Femal | 1974 |
Studies in primary hyperuricaemia. I. Steroid and dehydroepiandrosterone excretion in primary hyperuricaemia and gout, renal clearances of uric acid and the incorporation of 14C from glycine-2-14C in urine uric acid.
Topics: 17-Ketosteroids; Carbon Isotopes; Dehydroepiandrosterone; Glucocorticoids; Gout; Humans; Uric Acid | 1968 |
The excretion of urinary dehydroepiandrosterone in gout.
Topics: 17-Ketosteroids; Adult; Aged; Allopurinol; Arthritis; Dehydroepiandrosterone; Gout; Humans; Joint Di | 1968 |
[Hyperuricemia and gout in childhood (Lesch-Nyhan syndrome)].
Topics: Adolescent; Athetosis; Brain; Child; Child, Preschool; Compulsive Behavior; Gout; Humans; Huntington | 1971 |
[Microscopic appearance and histogenesis of tophus in gout].
Topics: Acid-Base Equilibrium; Glycosaminoglycans; Gout; Histocytochemistry; Humans; Uric Acid | 1971 |
Excess of ampicillin rashes associated with allopurinol or hyperuricemia. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center.
Topics: Allopurinol; Ampicillin; Boston; Drug Eruptions; Drug Synergism; Female; Gout; Hospitalization; Huma | 1972 |
Dehydroepiandrosterone (3 -hydroxy-5-androsten-17-one) metabolism in gout.
Topics: 17-Ketosteroids; Administration, Oral; Androstanes; Androsterone; Carbon Isotopes; Chromatography, G | 1972 |
Microscopic appearance and histogenesis of gouty tophus.
Topics: Connective Tissue; Crystallization; Ear; Extremities; Glycosaminoglycans; Gout; Humans; Necrosis; Sk | 1972 |
[Organ findings in psoriasis].
Topics: Dehydroepiandrosterone; Erythrocytes; Female; Gout; Humans; Intestinal Diseases; Joint Diseases; Liv | 1973 |
[Juvenile gout of the hip-joints (author's transl)].
Topics: Adolescent; Age Factors; Child; Gout; Hip; Hip Joint; Humans; Male; Pain; Radiography; Uric Acid | 1973 |
[Gout and mongolism. Apropos of a case].
Topics: Adolescent; Down Syndrome; Gout; Humans; Male; Purine-Pyrimidine Metabolism, Inborn Errors; Trisomy; | 1974 |
[Multiple osteonecrosis with type IV hyperlipoproteinemia (author's transl)].
Topics: Adult; Blood Protein Disorders; Bone Diseases; Glucose Tolerance Test; Gout; Hip Joint; Humans; Hype | 1974 |
Etiologic varieties of hyperuricemia and gout.
Topics: Acute Kidney Injury; Diabetic Ketoacidosis; Down Syndrome; Female; Gout; Hematologic Diseases; Human | 1974 |
The use of certain immunosuppressive drugs in the clinical study of gout.
Topics: Azathioprine; Erythrocytes; Gout; Humans; Immune Adherence Reaction; Lymphocyte Culture Test, Mixed; | 1974 |
Dietary treatment of chronic renal failure. Experiences with a modified Giovannetti diet.
Topics: Acidosis; Acute Kidney Injury; Adolescent; Adult; Aged; Arteritis; Dietary Proteins; Edema; Female; | 1965 |
[The hypo-uricemic action of oral benziodarone].
Topics: Benzofurans; Gout; Humans; Uric Acid; Xanthines | 1967 |
A specific enzyme defect in gout associated with overproduction of uric acid.
Topics: Adult; Diphosphates; Erythrocytes; Glucosyltransferases; Gout; Guanine; Hot Temperature; Humans; Hyp | 1967 |
[Female gout. (Analysis of 40 cases)].
Topics: Adolescent; Adult; Aged; Child; Female; Gout; Humans; Kidney Failure, Chronic; Male; Middle Aged; Se | 1967 |
[Therapy of gout with allopurinol. (Study of 106 cases)].
Topics: Adult; Allopurinol; Gout; Humans; Male; Middle Aged; Uric Acid; Xanthine Oxidase | 1967 |
[The effects of allopurinol in gout patients with uric urinary lithiasis or hyperuraturia].
Topics: Aged; Allopurinol; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Urinary Calculi | 1967 |
[The action of ethanol in gout and on the metabolism of uric acid].
Topics: Ethanol; Gout; Humans; Purines; Uric Acid; Xanthines | 1967 |
[The level of oxypurines in the plasma and urine of control and gout patients. (Correlation with the level of uric acid)].
Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Hypoxanthines; Male; Middle Aged; Spectrophotometry; | 1967 |
[Value of the demonstration of crystalline formations in the synovial fluid: the morphologic and ultrastructural differentiation of the crystals].
Topics: Arthritis; Arthritis, Rheumatoid; Calcinosis; Calcium; Cytoplasmic Granules; Gout; Humans; Joint Dis | 1967 |
Recent developments in the therapy of gout.
Topics: Acute Disease; Adrenocorticotropic Hormone; Allopurinol; Analgesics; Colchicine; Gout; Humans; Oxyph | 1968 |
[Gout and myxedema].
Topics: Aged; Female; Gout; Humans; Male; Middle Aged; Myxedema; Thyroid Hormones; Uric Acid; Uricosuric Age | 1967 |
[Diet therapy in gout].
Topics: Diet Therapy; Diuresis; Gout; Humans; Hypersensitivity; Kidney Diseases; Obesity; Purines; Uric Acid | 1969 |
Depletion of erythrocyte phosphoribosylpyrophosphate in man.
Topics: Administration, Oral; Adult; Allopurinol; Diphosphates; Erythrocytes; Female; Gout; Hemolysis; Human | 1970 |
The purine revolution.
Topics: Allopurinol; Diphosphates; Erythrocytes; Gout; Humans; Purine-Pyrimidine Metabolism, Inborn Errors; | 1970 |
Corticosteroid crystals in synovial fluid.
Topics: Acetates; Arthritis; Arthritis, Rheumatoid; Betamethasone; Diagnosis, Differential; Diphosphates; Gl | 1970 |
Differential membranolytic effects of microcrystalline sodium urate and calcium pyrophosphate dihydrate.
Topics: Cell Membrane; Crystallization; Diphosphates; Erythrocytes; Gout; Hemolysis; Humans; Surface Propert | 1971 |
[Uric acid inhibitors in the treatment of gout. Apropos of 126 cases].
Topics: Adult; Aged; Allopurinol; Colchicine; Drug Synergism; Female; Gout; Humans; Kidney Calculi; Kidney F | 1970 |
Concentration and synthesis of phosphoribosylpyrophosphate in erythrocytes from normal, hyperuricemic, and gouty subjects.
Topics: Adenosine Diphosphate; Allopurinol; Diphosphates; Erythrocytes; Feedback; Female; Glycerophosphates; | 1971 |
[Differential diagnosis and therapy of gout and pseudo-gout].
Topics: Aged; Chondrocalcinosis; Crystallization; Diagnosis, Differential; Diphosphates; Female; Gout; Human | 1971 |
Management of chronic and recurrent gout.
Topics: Adrenocorticotropic Hormone; Allopurinol; Chronic Disease; Colchicine; Dexamethasone; Diet Therapy; | 1971 |
Medical Grand Rounds from the University of Alabama Medical Center. Lead poisoning.
Topics: Adult; Aged; Alcoholism; Amyotrophic Lateral Sclerosis; Anemia, Macrocytic; Brain Diseases; Diagnosi | 1972 |
Accelerated erythrocyte 5-phosphoribosyl-1-pyrophosphate synthesis. A familial abnormality associated with excessive uric acid production and gout.
Topics: Adult; Allopurinol; Diphosphates; Erythrocytes; Gout; Guanine; Humans; Hypoxanthines; Male; Nucleoti | 1972 |
A comparison of the toxicity of ergocalciferol and cholecalciferol in rhesus monkeys (Macaca mulatta).
Topics: Administration, Oral; Animals; Bone Diseases; Cholecalciferol; Diet; Ergocalciferols; Gout; Haplorhi | 1972 |
[Uricoeliminating or urico-inhibiting agents? Reasons for a choice].
Topics: Allopurinol; Colchicine; Diet Therapy; Glomerular Filtration Rate; Gout; Humans; Long-Term Care; Oro | 1972 |
Molecular basis of gouty inflammation: interaction of monosodium urate crystals with lysosomes and liposomes.
Topics: Acid Phosphatase; Animals; Cholesterol; Chromates; Erythrocytes; Estradiol; Female; Glucuronidase; G | 1972 |
Purine overproduction in man associated with increased phosphoribosylpyrophosphate synthetase activity.
Topics: Adenosine Triphosphate; Carbon Isotopes; Erythrocytes; Female; Fibroblasts; Glycine; Gout; Humans; M | 1973 |
Complement as a mediator of inflammation in acute gouty arthritis. I. Studies on the reaction between human serum complement and sodium urate crystals.
Topics: Animals; Calcium; Complement System Proteins; Diphosphates; Erythrocytes; Factor XII; Gout; Hemolysi | 1973 |
Gout.
Topics: Adrenocorticotropic Hormone; Allopurinol; Colchicine; Diet; Extracellular Space; Gout; Humans; Indom | 1973 |
Gout and pseudogout.
Topics: Adult; Aged; Arthritis; Calcium; Chondrocalcinosis; Crystallization; Diabetes Complications; Diet Th | 1973 |
Mechanisms of the crystal deposition diseases--gout and pseudogout.
Topics: Acid Phosphatase; Chondrocalcinosis; Diphosphates; Female; Gout; Hemolysis; Humans; Inflammation; Le | 1973 |
Chronic lead nephropathy.
Topics: Adult; Bone and Bones; Chelating Agents; Child; Child, Preschool; Edetic Acid; Environmental Exposur | 1973 |
Familial gouty malignant uric acid lithiasis due to mutant phosphoribosylpyrophosphate synthetase.
Topics: Adult; Allopurinol; Child; Child, Preschool; Diphosphates; Erythrocytes; Female; Gout; Humans; Infan | 1973 |
The kinetics of intramolecular distribution of 15N in uric acid after administration of (15N) glycine. A reappraisal of the significance of preferential labeling of N-(3+9) of uric acid in primary gout.
Topics: Adenosine Triphosphate; Adolescent; Adult; Carbon Isotopes; Glutamine; Glycine; Gout; Guanine; Hippu | 1973 |
Gout and its relation to lipid metabolism. I. Serum uric acid, lipid, and lipoprotein levels in gout.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Cholesterol; Fatty Acids, Nonesterified; Female; Gout; | 1973 |
Gout and its relation to lipid metabolism. II. Correlations between uric acid, lipid, and lipoprotein levels in gout.
Topics: Adolescent; Adult; Aged; Child; Cholesterol; Fatty Acids, Nonesterified; Female; Gout; Humans; Lipid | 1973 |
Pathology of gout.
Topics: Allopurinol; Arthritis; Calcium Phosphates; Cartilage, Articular; Chondrocalcinosis; Crystallization | 1973 |
[Investigations concerning the incidence of disorders of lipid and carbohydrate metabolism in primary gout and symptomless hyperuricaemia (author's transl)].
Topics: Carbohydrate Metabolism; Cholesterol; Coronary Disease; Diabetes Complications; Female; Gout; Humans | 1974 |
Increased PP-ribose-P synthetase activity: a genetic abnormality leading to excessive purine production and gout.
Topics: Adenine; Carbon Radioisotopes; Cellulose; Creatinine; Electrophoresis; Enzyme Activation; Erythrocyt | 1973 |
Observations of altered intracellular phosphoribosylpyrophosphate (PP-ribose-P) in human disease.
Topics: Adenine; Carbon Radioisotopes; Erythrocytes; Fibroblasts; Formates; Gout; Guanine Nucleotides; Heter | 1974 |
Evaluation of the role of 5-phosphoribosyl-alpha-1-pyrophosphate synthetase in congenital hyperuricemia and gout: a simple isotopic assay and an activity stain for the enzyme.
Topics: Cellulose; Chromatography, DEAE-Cellulose; Electrophoresis; Erythrocytes; Evaluation Studies as Topi | 1974 |
Pharmacologic effects of nicotinic acid on human purine metabolism.
Topics: Adult; Aspirin; Creatinine; Erythrocytes; Female; Gout; Humans; Iopanoic Acid; Kidney Tubules; Male; | 1974 |
Gout and pseudogout established by polarized light microscopy of synovial fluid. Methods and two case reports.
Topics: Aged; Arthritis, Rheumatoid; Calcium; Chondrocalcinosis; Crystallization; Diphosphates; Gout; Humans | 1970 |
Calcinosis.
Topics: Adult; Calcinosis; Collagen; Diagnosis, Differential; Diphosphates; Gout; Hand; Humans; Knee; Male; | 1974 |
[Microcrystalline arthropathies (gout and pseudo-gout)].
Topics: Calcium Phosphates; Chondrocalcinosis; Crystallization; Diphosphates; Gout; Humans; Joint Diseases; | 1974 |
Ultrastructural evidence for leakage of lysosomal contents after phagocytosis of monosodium urate crystals. A mechanism of gouty inflammation.
Topics: Acid Phosphatase; Animals; Carbon; Cell Membrane; Cell Separation; Colloids; Cytoplasm; Ferritins; G | 1974 |
["Articular and visceral gout" in armored lizards (Tomistoma schlegelii and Gavialis gangeticus) (reptilia, crocodylia)].
Topics: Animals; Gout; Histocytochemistry; Kidney; Liver; Lung; Myocardium; Pancreas; Reptiles; Spleen; Uric | 1965 |
[On the action of antihistamincs in some cases of hyperuricemia].
Topics: Adult; Aged; Female; Gout; Histamine; Histamine H1 Antagonists; Humans; Male; Middle Aged; Uric Acid | 1968 |
[A study of the value of Uralyt-U (Madaus) in the treatment of urinary calculi].
Topics: Adult; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Piperazines; Quinolines; Uric Acid | 1970 |
[Improvement of gout prognosis by suitable therapy].
Topics: Adult; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Prognosis; Uremia; Uric Acid | 1971 |
[Metabolic arthropathies (uric acid gout and diffuse articular chondrocalcinosis].
Topics: Chondrocalcinosis; Gout; Humans; Joint Diseases; Uric Acid | 1974 |
[Metabolism of uric acid and lactic acid in essential arterial hypertension].
Topics: Adolescent; Adult; Age Factors; Diuretics; Female; Gout; Humans; Hypertension; Lactates; Male; Middl | 1974 |
Factors affecting urate solubility in vitro.
Topics: Blood; Gout; Humans; Hydrogen-Ion Concentration; Protein Binding; Serum Albumin; Sodium Chloride; So | 1974 |
Gout and hyperlipidaemia.
Topics: Adult; Aged; Alcohol Drinking; Allopurinol; Aspartate Aminotransferases; Body Height; Body Weight; C | 1974 |
Proceedings: Metabolic studies of thiopurinol in man and pig.
Topics: Allantoin; Animals; Carbon Radioisotopes; Gout; Humans; Hypoxanthines; Intestinal Absorption; Pyrazo | 1974 |
Withdrawal of allopurinol in patients with gout.
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Male; Middle Aged; Recurrence; Substance Withdrawal | 1974 |
[Effects of coffee during good health and in disease from the medical standpoint].
Topics: Acute Disease; Aged; Blood Pressure; Caffeine; Cerebrovascular Disorders; Coffee; Diabetes Mellitus; | 1974 |
Letter: Drugs used in hyperuricaemia.
Topics: Allopurinol; Anti-Inflammatory Agents; Gout; Humans; Metabolic Diseases; Uric Acid | 1974 |
[Results obtained with long-term benzbromarone therapy (author's transl)].
Topics: Adult; Aged; Benzofurans; Cholesterol; Fatty Acids, Nonesterified; Gout; Humans; Lipids; Male; Middl | 1974 |
[Prevention of renal lithiasis].
Topics: Calcium; Cystinuria; Diet; Gout; Humans; Kidney; Kidney Calculi; Kidney Failure, Chronic; Metabolism | 1974 |
[Diabetes and hyperuricaemia (author's transl)].
Topics: Adult; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Diabetes Complications; Diabetes Mel | 1974 |
[Contribution to the study of hyperuricemia associated with essential hyperlipidemias. I].
Topics: Adolescent; Adult; Female; Glucose Tolerance Test; Gout; Humans; Hyperlipidemias; Male; Middle Aged; | 1974 |
Letter: A clinical impression of benzbromarone (Minuric).
Topics: Adult; Allopurinol; Benzoates; Benzofurans; Bromine; Gout; Gout Suppressants; Humans; Male; Metaboli | 1974 |
[Biochemistry and clinical features of fructose-induced hyperuricamia (author's transl)].
Topics: Adenosine Triphosphate; Aminohydrolases; Fructose; Gout; Humans; Infusions, Parenteral; Liver; Nucle | 1974 |
Abnormal regulation of carbohydrate metabolism in primary gout.
Topics: Adult; Aged; Blood Glucose; Body Weight; Carbohydrate Metabolism; Cholesterol; Fatty Acids, Nonester | 1974 |
Gout: new observations on an old disease.
Topics: Gout; Humans; Kidney; Uric Acid | 1974 |
[Editorial: Therapy of gout nowadays (author's transl)].
Topics: Allopurinol; Colchicine; Exercise Therapy; Gout; Humans; Uric Acid; Uricosuric Agents | 1974 |
[The effect of daily single doses of 300 mg allopurinol on serum uric acid concentration and urate excretion in gouty patients (author's transl)].
Topics: Allopurinol; Analysis of Variance; Gout; Humans; Metabolic Clearance Rate; Uric Acid | 1974 |
[Clinical study of gout and hyperuricemia. (1) Epidemiological study on the development of gout].
Topics: Adolescent; Adult; Aged; Child; Female; Gout; Humans; Japan; Male; Middle Aged; Uric Acid | 1974 |
[Incidence of partial deficiency of hypoxanthine-guanine phosphoribosyl-transferase in a gouty population. Study of the 1st affected Italian family].
Topics: Adult; Aged; Erythrocytes; Genes, Recessive; Gout; Heterozygote; Humans; Italy; Male; Metabolism, In | 1974 |
Renal excretion of urate in normal and gouty subjects at high, normal and low plasma urate levels.
Topics: Adult; Allantoin; Gout; Humans; Inulin; Kidney; Kidney Function Tests; Kidney Tubules; Male; Metabol | 1974 |
Urate binding: a clue to the pathogenesis of gout.
Topics: Binding, Competitive; Crystallization; Dialysis; Gout; Humans; Hydrogen-Ion Concentration; Jaundice; | 1974 |
[Prevention of arteriosclerosis].
Topics: Arteriosclerosis; Cholesterol; Diabetic Angiopathies; Diet Therapy; Female; Gout; Humans; Hyperglyce | 1974 |
Microangiopathy in hyperlipidemia and gout.
Topics: Adolescent; Adult; Age Factors; Aged; Basement Membrane; Biopsy, Needle; Blood Glucose; Body Weight; | 1974 |
Urate crystal induced inflammation in dog joints: sequence of synovial changes.
Topics: Acid Phosphatase; Acute Disease; Animals; Chronic Disease; Crystallization; Dogs; Glucuronidase; Gou | 1974 |
[Idiopathic necrosis of the femoral head and hyperuriciemia (author's transl)].
Topics: Crystallization; Femur Head Necrosis; Gout; Humans; Male; Middle Aged; Uric Acid | 1974 |
[Clearance of urates as a diagnostic tool in gout].
Topics: Adult; Age Factors; Aged; Blood Pressure; Creatine; Female; Gout; Humans; Kidney; Kidney Diseases; M | 1974 |
Effect of allopurinol in gouty patients given long term corticotherapy.
Topics: Adrenal Cortex Hormones; Allopurinol; Dose-Response Relationship, Drug; Gout; Humans; Purines; Uric | 1974 |
Effect of Milurit on decreasing hyperuricaemia in hypertensive patients.
Topics: Allopurinol; Glomerular Filtration Rate; Gout; Humans; Hypertension; Thiazines; Uric Acid | 1974 |
[The effect of fructose on uric acid metabolism].
Topics: Allopurinol; Animals; Diuresis; Fasting; Fructose; Gout; Humans; Male; Oxonic Acid; Rats; Urate Oxid | 1974 |
[Chronic nephritis and hyperuricemia].
Topics: Adolescent; Adult; Chronic Disease; Female; Glomerulonephritis; Gout; Humans; Male; Middle Aged; Uri | 1974 |
Current medical practice and the Food and Drug Administration. Some evidence for the existing gap.
Topics: Adult; Aged; Allopurinol; Angina Pectoris; Cephalexin; Child; Colchicine; Diuretics; Drug Labeling; | 1974 |
Understanding hyperuricemia: nursing implications.
Topics: Allopurinol; Diabetes Mellitus; Diet Therapy; Gout; Humans; Kidney Diseases; Metabolic Diseases; Uri | 1972 |
Metabolic implications of the Lesch-Nyhan syndrome.
Topics: Athetosis; Gout; Humans; Intellectual Disability; Lesch-Nyhan Syndrome; Mass Screening; Purine-Pyrim | 1972 |
The health of leaders and policy-makers.
Topics: Adult; Aged; Coronary Disease; Gout; Heart Diseases; Humans; Leadership; Longevity; Male; Middle Age | 1972 |
Problems of diagnostic failure in gouty arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Colchicine; Diagnosis, Differential; Diagnostic Errors; Female; | 1972 |
Coronary heart disease in young men: a study of seventy patients with a critical review of etiological factors.
Topics: Adult; Australia; Body Height; Body Weight; Cholesterol, Dietary; Coronary Disease; Diabetes Complic | 1973 |
Alteration of urate metabolism by weight reduction.
Topics: Gout; Humans; Hypertension; Male; Metabolic Clearance Rate; Middle Aged; Obesity; Uric Acid | 1973 |
Increasing excretion of urate with displacing agents in man.
Topics: Anti-Inflammatory Agents; Binding Sites; Dansyl Compounds; Dialysis; Fatty Acids; Gout; Humans; Kidn | 1973 |
Effects of alcohol on the kidney and blood electrolytes.
Topics: Acidosis; Alcoholism; Blood; Depression, Chemical; Diuresis; Ethanol; Gout; Humans; Lactates; Magnes | 1974 |
Cardiovascular epidemiology in New Zealand and the Pacific.
Topics: Adult; Aged; Anthropometry; Blood Pressure; Cardiovascular Diseases; Cholesterol; Coronary Disease; | 1974 |
Chondrocalcinosis articularis (pseudogout syndrome).
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Antinuclear; Arthritis, Rheumatoid; Aspirin; Blood | 1973 |
[Uric acid clearance related to the use of an antirheumatic non-steroid drug].
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Glomerular Filtration Rate; Go | 1973 |
[The prevalence of lipid metabolism disorders in rheumatological diseases].
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Blood Glucose; Body Weight; Cholesterol; Diabetes M | 1974 |
Some metabolic aspects of diseases of the locomotor system.
Topics: Body Weight; Calcinosis; Calcium Phosphates; Cartilage; Chondrocalcinosis; Female; Gout; Humans; Mal | 1973 |
[Gout and atherosclerosis].
Topics: Adult; Age Factors; Aged; Arteriosclerosis; Body Weight; Cholesterol; Female; Gout; Humans; Male; Mi | 1972 |
Cover story: Sir Alfred Baring Garrod, FRS.
Topics: Arthritis, Rheumatoid; England; Gout; History, 19th Century; History, 20th Century; Humans; Rheumati | 1973 |
The scientific development of clinical chemistry to 1948.
Topics: Albuminuria; Animals; Biochemistry; Blood; Blood Glucose; Chemistry, Clinical; Colorimetry; Edema; E | 1973 |
[Prevention of arteriosclerosis].
Topics: Adult; Arteriosclerosis; Clofibrate; Germany, West; Gout; Humans; Hyperlipidemias; Male; Middle Aged | 1973 |
Uric acid binding to serum proteins: differences among species.
Topics: Animals; Anura; Blood Proteins; Chickens; Dialysis; Dogs; Gout; Guinea Pigs; Haplorhini; Humans; Kid | 1972 |
[Regression of gout tophi under long-term therapy with allopurinol].
Topics: Aged; Allopurinol; Female; Fingers; Gout; Humans; Joint Diseases; Joints; Long-Term Care; Male; Midd | 1972 |
Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase.
Topics: Allantoin; Aspergillus flavus; Gout; Humans; Injections, Intramuscular; Injections, Intravenous; Met | 1972 |
[Urinary uric acid excretion in patients with gout].
Topics: Adult; Aged; Female; Gout; Humans; Kidney Tubules; Male; Middle Aged; Uric Acid | 1972 |
Plasma lipid levels in gout.
Topics: Cholesterol; Fatty Acids, Nonesterified; Female; Glycerides; Gout; Humans; Hyperlipidemias; Lipids; | 1972 |
[Localization of gout in the hip joint].
Topics: Aged; Female; Femur Head Necrosis; Gout; Hip; Hip Joint; Humans; Joint Prosthesis; Male; Middle Aged | 1972 |
[Clinical aspects of gout].
Topics: Adult; Age Factors; Aged; Body Weight; Diet Therapy; Female; Gout; Humans; Kidney Calculi; Male; Mid | 1972 |
Hyperuricemia: when does it signify gout?
Topics: Gout; Humans; Kidney Tubules; Uric Acid | 1972 |
Serum uric acid in 23,923 men and gout in a subsample of 4257 men in France.
Topics: Adult; Age Factors; France; Gout; Humans; Male; Middle Aged; Uric Acid | 1972 |
[Comparative radiologic studies in gout].
Topics: Adult; Aged; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Sex Factors; Uric Acid; Urogra | 1972 |
[Tophaceous gout and its surgical treatment].
Topics: Colchicine; Gout; Humans; Methods; Middle Aged; Phenylbutazone; Uric Acid | 1972 |
[The kidney and hyperuricemia].
Topics: Female; Glomerular Filtration Rate; Gout; Humans; Hypertension; Kidney Diseases; Kidney Function Tes | 1972 |
[Recognition of gout in a selected population pattern].
Topics: Adult; Age Factors; Ankle; C-Reactive Protein; Czechoslovakia; Elbow; Epidemiologic Methods; Female; | 1972 |
Some contributions to metabolic relationships of uric acid.
Topics: Cholesterol; Female; Gout; Humans; Hypothyroidism; Lactates; Male; Menopause; Sex Factors; Thyroid H | 1972 |
[Cytological and enzymatic studies of synovial fluid in the diagnosis of uric arthritis].
Topics: Acid Phosphatase; Alkaline Phosphatase; Aspartate Aminotransferases; Cytodiagnosis; Fructose-Bisphos | 1972 |
[Sodium urate crystals in the diagnosis of uric arthritis].
Topics: Crystallization; Female; Gout; Humans; Hydrarthrosis; Male; Sodium; Synovial Fluid; Uric Acid | 1972 |
[Urolithiasis in gout and hyperuricemic syndrome].
Topics: Allopurinol; Colchicine; Diabetes Complications; Diabetes Mellitus; Female; Gout; Humans; Male; Uric | 1972 |
[Kidney involvement in gout].
Topics: Adolescent; Adult; Aged; Allopurinol; Anti-Bacterial Agents; Antihypertensive Agents; Female; Gout; | 1972 |
[Reciprocal relationship between purine metabolism disorders and arteriosclerotic angioorganopathies].
Topics: Age Factors; Arm; Arterial Occlusive Diseases; Arteriosclerosis; Cholesterol; Diabetes Complications | 1972 |
[Hyperuricemia and myocardial infarct].
Topics: Arteriosclerosis; Coronary Disease; Diabetes Complications; Female; Gout; Humans; Hypercholesterolem | 1972 |
[Uric acid level and body weight].
Topics: Acidosis; Body Weight; Fasting; Female; Gout; Humans; Male; Obesity; Time Factors; Uric Acid | 1972 |
[Gout in women].
Topics: Adult; Age Factors; Female; Gout; Humans; Kidney Diseases; Male; Menopause; Middle Aged; Obesity; Se | 1972 |
[Prognosis and prevention of gout complications].
Topics: Adult; Aged; Arteriosclerosis; Diseases in Twins; Female; Gout; Humans; Kidney Calculi; Kidney Disea | 1972 |
[Experience with benziodarone therapy in gout and hyperuricemic syndrome].
Topics: Administration, Oral; Adult; Benzofurans; Gout; Humans; Joint Diseases; Male; Psoriasis; Uric Acid | 1972 |
[Current status of gout (physiopathological, morphological, clinical and therapeutic aspects)].
Topics: Anti-Inflammatory Agents; Colchicine; Diet Therapy; Gout; Humans; Joints; Purines; Urate Oxidase; Ur | 1972 |
Rheumatology.
Topics: Acute Disease; Aged; Analgesics; Arthritis, Rheumatoid; Chronic Disease; Diazepam; Female; Gout; Hum | 1972 |
Management of gout.
Topics: Anti-Inflammatory Agents; Arthritis; Diet; Gout; Humans; Kidney Diseases; Phagocytes; Synovial Fluid | 1972 |
[Aseptic, primary osteonecrosis of the femur head].
Topics: Alcoholism; Femur Head; Femur Head Necrosis; Gout; Humans; Hyperlipidemias; Ischemia; Obesity; Osteo | 1972 |
[Molecular bases of the treatment of Lesch-Nyhan syndrome, related syndromes and common gout].
Topics: Adenine Nucleotides; Allopurinol; Feedback; Gout; Guanosine; Humans; Hypoxanthines; Lesch-Nyhan Synd | 1972 |
Simultaneous measurement of plasma and erythrocyte oxypurines. II. Gouty patients with and without allopurinol medication.
Topics: Allopurinol; Erythrocytes; Gout; Humans; Hypoxanthines; Male; Purinones; Stimulation, Chemical; Uric | 1972 |
Effect of balneotherapy in Ciechocinek Spa on the occurrence of gouty attacks and the symptoms of chronic gouty arthropathy (observations of 112 cures).
Topics: Adult; Aged; Allopurinol; Balneology; Blood Sedimentation; Colchicine; Female; Gout; Humans; Male; M | 1972 |
[Lipid disorders in gout and in hyperuricemia with myalgia].
Topics: Adult; Aged; Cholesterol; Female; Gout; Humans; Hypercholesterolemia; Hyperlipidemias; Lipids; Lipop | 1972 |
[Diagnosis and therapy of gout (uricopathy). Guide lines for daily practice].
Topics: Allopurinol; Arthritis, Rheumatoid; Benzofurans; Diagnosis, Differential; Gout; Humans; Ketones; Pso | 1972 |
[Mode of renal elimination of uric acid in patients with gout and normal subjects with comparable blood levels. Preliminary results].
Topics: Adult; Glomerular Filtration Rate; Gout; Humans; Kidney; Kidney Concentrating Ability; Kidney Tubule | 1972 |
Urate crystal induced inflammation in the rat: evidence for the combined actions of kinins, histamine and components of complement.
Topics: Animals; Carboxypeptidases; Colchicine; Complement System Proteins; Cyproheptadine; Edema; Female; G | 1972 |
[Comparative studies on uric acid and phosphate levels in healthy subjects and patients with patent gout during several hours of intravenous fructose administration].
Topics: Adult; Fructose; Gout; Humans; Injections, Intravenous; Middle Aged; Phosphates; Time Factors; Uric | 1972 |
On the existence of a guanine nucleotide trap, the role of adenosine kinase and a possible cause of excessive purine production in mammalian cells.
Topics: Adenosine; Adenosine Monophosphate; Animals; Cell Line; Fibroblasts; Gout; Guanine; Guanine Nucleoti | 1972 |
[Hyperuricemia].
Topics: Gout; Humans; Kidney; Kidney Glomerulus; Kidney Tubules; Microscopy, Electron; Nephritis, Interstiti | 1972 |
[Possible clinical use of benziodarone].
Topics: Benzofurans; Fatty Acids; Gout; Humans; Uric Acid | 1972 |
[Relationship between metabolic diseases and the severity of coronary disease].
Topics: Angina Pectoris; Angiocardiography; Cholesterol; Diabetes Complications; Diabetic Angiopathies; Fema | 1972 |
[Clinico-roentgenologic parallels in gout].
Topics: Foot; Gout; Hand; Humans; Radiography; Uric Acid | 1972 |
Urate deposition disease. How is it regulated and how can it be modified?
Topics: Animals; Blood Proteins; Disease Models, Animal; Gout; Humans; Hydrogen-Ion Concentration; Kidney; K | 1973 |
[Changes between 1948 and 1970 in the epidemiology and clinical features of primary gout].
Topics: Adult; Age Factors; Aged; Alcohol Drinking; Blood Protein Disorders; Diabetes Complications; Fatty L | 1973 |
[Polycythemia, polyglobulia and gout].
Topics: Cyanosis; Erythropoiesis; Female; Gout; Heart Defects, Congenital; Humans; Leukemia; Male; Nucleic A | 1973 |
[The effect of spironolactone and thiabutazide on serum-uric acid and lipid levels in patients with gout and in healthy persons].
Topics: Adult; Allopurinol; Benzothiadiazines; Cholesterol; Female; Follow-Up Studies; Gout; Humans; Lipids; | 1973 |
[Current etiopathogenetic and therapeutic views concerning gout and hyperuremic syndromes].
Topics: Acute Disease; Aged; Antimetabolites; Chronic Disease; Colchicine; Female; Genetic Code; Gout; Human | 1973 |
[Hyperuricemia due to diuretics].
Topics: Acetazolamide; Aged; Chlorothiazide; Chlorthalidone; Diuretics; Ethacrynic Acid; Furosemide; Gout; H | 1973 |
[Arterial hypertension with convulsive seizures in a patient with right kidney hypoplasia and gout attacks and with a probable gouty kidney].
Topics: Electrocardiography; Gout; Headache; Heart; Humans; Hydronephrosis; Hypertension; Kidney; Kidney Dis | 1973 |
[Use of enzymatic uricolysis in the treatment of hyperuricemia of renal origin].
Topics: Gout; Humans; Injections, Intravenous; Kidney Failure, Chronic; Renal Dialysis; Urate Oxidase; Uric | 1973 |
[Arthritis urica and L-dopa therapy].
Topics: Dihydroxyphenylalanine; Gout; Humans; Parkinson Disease; Uric Acid | 1973 |
[Gout and hyperuricemia during fasting. Action of associated thyroid hormone therapy].
Topics: Adolescent; Adult; Fasting; Female; Gout; Humans; Male; Middle Aged; Obesity; Triiodothyronine; Uric | 1973 |
Complement as a mediator of inflammation in acute gouty arthritis. II. Biological activities generated from complement by the interaction of serum complement and sodium urate crystals.
Topics: Animals; Chemotaxis; Complement System Proteins; Gout; Hot Temperature; Humans; Immunoelectrophoresi | 1973 |
[Treatment with allopurinol in gout and hyperuricemic renal disease].
Topics: Adult; Aged; Allopurinol; Creatinine; Female; Glomerular Filtration Rate; Gout; Humans; Hypertension | 1973 |
Platelets and vascular disease in gout.
Topics: Allopurinol; Analgesics; Arteriosclerosis; Blood Platelets; Colchicine; Diabetes Complications; Gout | 1973 |
[Lipid disorders in gout and hyperuricemias].
Topics: Cholesterol; Female; Gout; Humans; Hyperlipidemias; Lipids; Male; Metabolic Diseases; Phospholipids; | 1973 |
Hyperglutamatemia in primary gout.
Topics: Adult; Aged; Alanine; Ammonia; Chromatography; Fasting; Glutamates; Glutamine; Glycine; Gout; Humans | 1973 |
[Long-term therapy of gout and hyperuricemia].
Topics: Allopurinol; Arteriosclerosis; Blood Protein Disorders; Citrates; Colchicine; Diabetes Mellitus; Die | 1973 |
Sarcroilaic joints in primary gout. Clinical and roentgenographic study of 143 patients.
Topics: Adolescent; Adult; Aged; Chronic Disease; Creatinine; Female; Gout; Humans; Male; Middle Aged; Osteo | 1973 |
[Laboratory diagnosis of gout].
Topics: Gout; Humans; Methods; Uric Acid | 1973 |
[Oxalate calculi formation in hyperuricemia].
Topics: Gout; Humans; Oxalates; Uric Acid; Urinary Calculi | 1973 |
Correlates and consequences of asymptomatic hyperuricemia.
Topics: ABO Blood-Group System; Adult; Aspartate Aminotransferases; Blood Glucose; Calcium; Cholesterol; Cre | 1973 |
[Gout treatment with a dibromine derivative of benzofuran].
Topics: Benzofurans; Bromine; Gout; Humans; Uric Acid; Uricosuric Agents | 1973 |
[Gout in an African university hospital].
Topics: Adult; Black People; Democratic Republic of the Congo; Gout; Humans; Male; Middle Aged; Rural Popula | 1973 |
Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity.
Topics: Adolescent; Adult; Carbon Isotopes; Child; Erythrocytes; Female; Fibroblasts; Glycine; Gout; Guanine | 1973 |
Serum uric acid concentrations in a rural Tswana community in Southern Africa.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Gout; Humans; Male; Middle Aged; Obesity; Sex Factors; | 1973 |
Comparison of indomethacin and phenylbutazone in acute gout.
Topics: Acute Disease; Adult; Aged; Blood Sedimentation; Edema; Female; Gout; Humans; Indomethacin; Leukocyt | 1973 |
A reappraisal of the concept of an abnormality of glutamine metabolism in primary gout.
Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Benzoates; Carbon Isotopes; Diet; Glutamine | 1973 |
[Hyperuricacidemia: abnormal metabolism in biosynthesis--on Lesch-Nyhan syndrome].
Topics: Child, Preschool; Gout; Humans; Lesch-Nyhan Syndrome; Male; Purines; Uric Acid | 1973 |
[Dynamics of uric acid metabolism in hyperuriacidemia].
Topics: Carbon Isotopes; Gout; Humans; Uric Acid | 1973 |
[Renal factor in the development of hyperuricacidemia].
Topics: Gout; Humans; Kidney; Kidney Diseases; Uric Acid | 1973 |
Hyperuricemia, gout, and the executive suite.
Topics: Achievement; Adolescent; Adult; Body Height; Body Weight; Drive; Feeding Behavior; Gout; Humans; Mal | 1973 |
Studies with some novel uricosuric agents and their metabolites: correlation between clinical activity and drug-induced displacement of urate from its albumin-binding sites.
Topics: Adult; Aged; Benzophenones; Binding Sites; Binding, Competitive; Creatinine; Dansyl Compounds; Fluor | 1973 |
Extradural spinal depositions of urates producing paraplegia. Case report.
Topics: Aged; Gout; Humans; Laminectomy; Ligaments; Male; Paraplegia; Radiography; Spinal Diseases; Spine; U | 1973 |
An atypical case of hypoxanthine-guanine phosphoribosyltransferase deficiency (Lesch-Nyhan syndrome). I. Clinical studies.
Topics: Adolescent; Adult; Bone Marrow Cells; Gout; Humans; Lesch-Nyhan Syndrome; Male; Neurologic Examinati | 1973 |
Letter: Gouty arthritis and polycystic kidney disease.
Topics: Gout; Humans; Polycystic Kidney Diseases; Uric Acid | 1973 |
[New, special preparations registered in Austria].
Topics: Austria; Benzofurans; Chemical Phenomena; Chemistry; Gout; Humans; Ketones; Kidney Failure, Chronic; | 1973 |
Hyperuricaemia and gout in Nigerians.
Topics: Adolescent; Adult; Body Height; Body Weight; Child; Child, Preschool; Female; Gout; Hospitals; Human | 1973 |
Editorial: Mechanism of gouty inflammation.
Topics: Gout; Humans; Inflammation; Leukocytes; Phagocytosis; Uric Acid | 1973 |
[Gout, ideas on acquisition and problems to be solved].
Topics: Gout; Humans; Kidney; Purines; Uric Acid | 1973 |
[Renal complications of gout].
Topics: Diet Therapy; Gout; Humans; Kidney Diseases; Uric Acid | 1973 |
Letter: Mechanism of gouty inflammation.
Topics: Animals; Chemotaxis; Complement System Proteins; Gout; Joint Diseases; Uric Acid | 1973 |
Familial hyperuricaemia and hypertriglyceridaemia.
Topics: Adolescent; Adult; Alcohol Drinking; Blood Pressure; Cholesterol; Female; Gout; Humans; Hyperlipidem | 1973 |
[The kidney and hyperuricemia].
Topics: Gout; Humans; Kidney; Kidney Calculi; Lesch-Nyhan Syndrome; Uric Acid | 1973 |
[Surgery of gout].
Topics: Blood Vessels; Foot; Gout; Hand; Humans; Male; Methods; Microscopy, Electron; Microscopy, Polarizati | 1973 |
Uric acid in alcoholics.
Topics: Age Factors; Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Female; Gout; Humans; Male; Middl | 1973 |
The treatment of gout.
Topics: Acute Disease; Allopurinol; Aspirin; Colchicine; Drug Therapy, Combination; Gout; Indomethacin; Phen | 1973 |
[When and how to treat hyperuricemia].
Topics: Gout; Humans; Uric Acid; Uricosuric Agents | 1973 |
[Evaluation and treatment of hyperuricemia].
Topics: Adult; Arthritis; Female; Gout; Humans; Joint Diseases; Male; Middle Aged; Uric Acid; Uricosuric Age | 1973 |
[The kidney and hyperuricemia].
Topics: Gout; Humans; Kidney; Kidney Function Tests; Uric Acid; Urinary Calculi | 1973 |
Urate metabolism in heterozygotes for HGPRTase deficiency.
Topics: Adult; Aged; Body Weight; Carbon Radioisotopes; Creatinine; Erythrocytes; Glycine; Gout; Guanine Nuc | 1973 |
Gout with adenine phosphoribosyl transferase deficiency.
Topics: Adenine; Allopurinol; Carbon Radioisotopes; Erythrocytes; Female; Glycine; Gout; Humans; Male; Pedig | 1973 |
Adenine phosphoribosyltransferase deficiency in a female with gout.
Topics: Adenine; Adult; Carbon Radioisotopes; Creatinine; Erythrocytes; Female; Glycine; Gout; Humans; Pento | 1973 |
[Studies on plasma protein binding of uric acid in gout].
Topics: Allopurinol; Blood Protein Electrophoresis; Blood Proteins; Carbon Radioisotopes; Chromatography, Ge | 1973 |
Urolithiasis and nephropathy in gout.
Topics: Adult; Aged; Albuminuria; Female; Gout; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Ur | 1973 |
[Diabetes mellitus, uricemia and gout].
Topics: Diabetes Complications; Diabetes Mellitus; Fructose; Glucose; Gout; Humans; Nucleoproteins; Nutritio | 1973 |
[Diabetes mellitus, serum urate and gout. A study in 314 patients (author's transl)].
Topics: Adult; Age Factors; Aged; Alloxan; Blood Urea Nitrogen; Diabetes Complications; Diabetes Mellitus; F | 1973 |
[Hyperuricemia. (Etiopathogenic and therapeutic concepts)].
Topics: Diuretics; Gout; Humans; Hypertension; Hypothyroidism; Kidney Diseases; Nicotinic Acids; Nucleoprote | 1973 |
[Dyspurinia and atherosclerosis].
Topics: Adult; Aged; Arteriosclerosis; Arteritis; Coronary Disease; Female; Gout; Humans; Intracranial Arter | 1973 |
[The kidney and hyperuricaemia (author's transl)].
Topics: Adult; Child; Female; Gout; Humans; Hydrogen-Ion Concentration; Kidney; Kidney Calculi; Male; Middle | 1973 |
[Anuria due to bilateral ureteral uric acid lithiasis during a treatment with Amplivix].
Topics: Anuria; Benzofurans; Gout; Humans; Male; Middle Aged; Ureteral Calculi; Uric Acid; Uricosuric Agents | 1973 |
Uric acid and the kidney.
Topics: Aged; Allopurinol; Animals; Diabetes Mellitus; Gout; Humans; Hydrogen-Ion Concentration; Hypercholes | 1973 |
[Treatment of uric acid disorders].
Topics: Acute Disease; Allopurinol; Colchicine; Female; Gout; Humans; Male; Uric Acid | 1973 |
[The action of allopurinol on uric acid transport].
Topics: Allopurinol; Biological Transport, Active; Gout; Humans; Male; Middle Aged; Uremia; Uric Acid | 1973 |
Use of Milurit in the treatment of gout.
Topics: Aged; Allopurinol; Drug Administration Schedule; Drug Evaluation; Female; Gout; Humans; Male; Middle | 1973 |
[Gout hazard as the price for development of intelligence?].
Topics: Achievement; Age Factors; Feeding Behavior; Female; Gout; Humans; Intelligence; Leadership; Male; Mo | 1974 |
Letter: Polycystic kidney disease and hyperuricemia.
Topics: Adult; Female; Gout; Humans; Male; Polycystic Kidney Diseases; Uric Acid | 1974 |
Erythrocytosis associated with chronic renal disease.
Topics: Adult; Biopsy; Blood Urea Nitrogen; Blood Volume Determination; Creatinine; Erythrocyte Count; Glome | 1974 |
Epidemiology of serum uric acid and gout in Frenchmen.
Topics: Adult; Age Factors; Body Constitution; Epidemiologic Methods; France; Gout; Humans; Male; Middle Age | 1974 |
Gout: presentation as a popliteal cyst.
Topics: Drainage; Gout; Humans; Knee; Knee Joint; Male; Middle Aged; Radiography; Synovial Cyst; Synovial Fl | 1974 |
[Diet in gout and hyperuricemia].
Topics: Diet Therapy; Gout; Humans; Obesity; Purines; Uric Acid | 1974 |
Gout.
Topics: Allopurinol; Blood Cell Count; Cell Movement; Colchicine; Diet; Drug Synergism; Gastrointestinal Dis | 1974 |
[Fructose-induced hyperuricemia in healthy subjects and in patients with gout and secondary hyperuricemia].
Topics: Fructose; Gout; Humans; Infusions, Parenteral; Stimulation, Chemical; Uric Acid | 1974 |
[Comparative study of uric acid renal elimination in the gout patients and normal patients in spontaneous or experimentally increased or decreased uricemia].
Topics: Adult; Aged; Allantoin; Glomerular Filtration Rate; Gout; Humans; Injections, Intravenous; Kidney Fu | 1974 |
The treatment of hyperuricemia in gout.
Topics: Allopurinol; Gout; Humans; Uric Acid; Uricosuric Agents | 1974 |
Proceedings: Gout, hypertriglyceridaemia, and alcohol consumption.
Topics: Alcohol Drinking; Fasting; Gout; Humans; Hyperlipidemias; Male; Obesity; Sulfobromophthalein; Trigly | 1974 |
[New drugs: allopurinol. Foligan, Urosin, Zyloric].
Topics: Allopurinol; Germany, West; Gout; Humans; Uric Acid; Uricosuric Agents | 1974 |
Rheumatic manifestations of Paget's disease of bone.
Topics: Adult; Aged; Alkaline Phosphatase; Arthritis; Arthritis, Rheumatoid; Female; Finger Joint; Gout; Hum | 1974 |
Diseases associated with calcium pyrophosphate dihydrate crystal deposition.
Topics: Adult; Aged; Calcium; Chondrocalcinosis; Creatinine; Diabetes Complications; Female; Gout; Hemochrom | 1974 |
Acute polyarticular gout.
Topics: Aged; Ankle Joint; Elbow Joint; Female; Finger Joint; Gout; Hip Joint; Humans; Knee Joint; Male; Mid | 1974 |
[Allopurinol treatment of gout with special reference to patients with gouty nephropathy].
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Uric Acid | 1974 |
The kinetics of intramolecular distribution of 15N in uric acid following administration of 15N-glycine: preferential labeling of N-(3+9) of uric acid in primary gout and a reappraisal of the "glutamine hypothesis".
Topics: Adolescent; Adult; Chromatography, Ion Exchange; Glutamine; Glycine; Gout; Guanine Nucleotides; Hipp | 1974 |
Hyperglutamatemia in primary gout.
Topics: Administration, Oral; Alanine; Erythrocytes; Glutamates; Glutamine; Glycine; Gout; Humans; Male; Pub | 1974 |
Effect of ribomononucleotides given orally on uric acid production in man.
Topics: Adult; Ammonia; Blood Urea Nitrogen; Creatinine; Gout; Humans; Hydrogen-Ion Concentration; Kidney Ca | 1974 |
The uptake of glycine-14C into the adenine and guanine of DNA and insoluble RNA of human leucocytes.
Topics: Adenine; Autoanalysis; Carbon Radioisotopes; Chromatography, Paper; DNA; Female; Glycine; Gout; Guan | 1974 |
On the problem of hyperuricemia in certain physiological stress conditions.
Topics: Adolescent; Adult; Autoanalysis; Creatinine; Fasting; Female; Gout; Humans; Labor, Obstetric; Menstr | 1974 |
The effect of weight reduction on urate metabolism.
Topics: Blood Pressure; Body Weight; Carbon Radioisotopes; Creatinine; Diet Therapy; Glycine; Gout; Humans; | 1974 |
Diet and gout.
Topics: Body Weight; Calorimetry; Diet; DNA; Female; Food Analysis; Gout; Humans; Male; Nitrogen; Purines; R | 1974 |
Relationship between gout and arterial hypertension.
Topics: Acute Disease; Adult; Aged; Blood Pressure; Chronic Disease; Diabetes Complications; Female; Gout; H | 1974 |
Observations concerning the incidence of disturbance of lipid and carbohydrate metabolism in gout.
Topics: Arteriosclerosis; Blood Glucose; Body Weight; Cholesterol; Coronary Disease; Diabetes Complications; | 1974 |
Gout and hyperlipidaemia.
Topics: Adult; Aged; Alcohol Drinking; Alkaline Phosphatase; Aspartate Aminotransferases; Beer; Bilirubin; B | 1974 |
An integrative hypothesis for the renal disease of urate overproduction.
Topics: Acute Kidney Injury; Adult; Diagnosis, Differential; Erythrocytes; Female; Glomerular Filtration Rat | 1974 |
Concentration of urate by differential diffusion: a hypothesis for initial urate deposition.
Topics: Carbon Radioisotopes; Connective Tissue; Diffusion; Gout; Hallux; Humans; Synovial Fluid; Time Facto | 1974 |
The binding of urate to plasma proteins.
Topics: Allopurinol; Aspirin; Binding Sites; Blood Proteins; Colchicine; Dialysis; Evaluation Studies as Top | 1974 |
Experimental hyperuricemia in rats.
Topics: Animals; Dialysis; Diet; Female; Gout; Kidney; Male; Rats; Time Factors; Uric Acid | 1974 |
Efficacy of single daily dose allopurinol in gouty hyperuricemia.
Topics: Allopurinol; Evaluation Studies as Topic; Gout; Half-Life; Humans; Male; Time Factors; Uric Acid | 1974 |
Withdrawal of allopurinol in patients with gout.
Topics: Allopurinol; Evaluation Studies as Topic; Follow-Up Studies; Gout; Humans; Male; Middle Aged; Recurr | 1974 |
Metabolic studies of thiopurinol in man and the pig.
Topics: Adult; Alcohol Drinking; Allopurinol; Animals; Carbon Radioisotopes; Duodenum; Gout; Humans; Hypoxan | 1974 |
Allopurinol and thiopurinol: effect in vivo on urinary oxypurine excretion and rate of synthesis of their ribonucleotides in different enzymatic deficiencies.
Topics: Adenine; Allopurinol; Erythrocytes; Female; Gout; Guanine; Humans; Hypoxanthines; Lesch-Nyhan Syndro | 1974 |
Influence of a uricosuric drug on connective tissue metabolism.
Topics: Benzoates; Benzofurans; Benzyl Compounds; Bromine; Cartilage; Chondroitin; Creatinine; Gout; Humans; | 1974 |
Uricosuric effect of an anticholinergic agent in hyperuricemic subjects.
Topics: Creatinine; Cyclohexanes; Glycopyrrolate; Gout; Humans; Parasympatholytics; Propanolamines; Purine-P | 1974 |
Hyperuricemia induced by ethambutol.
Topics: Allopurinol; Creatinine; Diuretics; Ethambutol; Ethanol; Gout; Humans; Isoniazid; Lactates; Pyrazina | 1974 |
A preliminary report of nephropathy in hyperuricemic rats.
Topics: Animals; Body Weight; Disease Models, Animal; Gout; Kidney; Kidney Calculi; Kidney Diseases; Kidney | 1974 |
[Hyperuricemia due to hypoxanthine-guanine-phosphoribosyltransferase deficiency].
Topics: Adult; Allopurinol; Anemia; Arthritis; Benzofurans; Gout; Humans; Hyperlipidemias; Hypothyroidism; H | 1974 |
[Articular exudate in a case of gout with exceptionally profuse mass of sodium urate crystals].
Topics: Aged; Gout; Humans; Male; Synovial Fluid; Uric Acid | 1974 |
[Renal tubular function in patients with gout].
Topics: Creatinine; Gout; Humans; Kidney Tubules; Uric Acid | 1974 |
Specificity of the renal transport impairment in chickens having hyperuricemia and articular gout.
Topics: Aminohippuric Acids; Animals; Arginine; Biological Transport; Chickens; Creatinine; Female; Glomerul | 1974 |
Pathophysiology of purine metabolism in man.
Topics: Adenosine; Alkaline Phosphatase; Amidinotransferases; Amidohydrolases; Glomerular Filtration Rate; G | 1974 |
[Mechanism of action and role of xanthine oxidoreductases (author's transl)].
Topics: Animals; Chemical Phenomena; Chemistry; Chickens; Electron Transport; Flavin-Adenine Dinucleotide; G | 1974 |
Editorial: Drugs used in hyperuricaemia.
Topics: Allopurinol; Gout; Humans; Metabolic Diseases; Uric Acid; Uricosuric Agents | 1974 |
Gout with adenine phosphoribosyl transferase deficiency.
Topics: Adenine; Adolescent; Adult; Aged; Allopurinol; Carbon Radioisotopes; Child; Child, Preschool; Chromo | 1974 |
The Jewish Hospital of St. Louis. Therapeutic grand rounds number 7. An approach to disorders of uric acid metabolism.
Topics: Allopurinol; Alloxan; Feedback; Gout; Guanine; Humans; Hypoxanthines; Kidney; Male; Metabolic Diseas | 1974 |
Gout in the temporomandibular joint. Report on a case.
Topics: Aged; Diagnosis, Differential; Gout; Humans; Male; Radiography; Temporomandibular Joint; Uric Acid | 1974 |
Genetics of hyperuricemia and achievement.
Topics: Achievement; Gout; History, 17th Century; History, 18th Century; History, 19th Century; History, 20t | 1967 |
[Comparative study of triglyceridemia, lipemia, glycemia and weight index in patients with high and normal serum uric acid].
Topics: Adult; Aged; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cholesterol; Gout; Humans; Hyperlipide | 1969 |
[Pathogenesis of gout].
Topics: Gout; Humans; Purines; Transferases; Uric Acid | 1969 |
Surgical management of tophaceous gout.
Topics: Calculi; Colchicine; Gout; Hand; Hand Deformities, Acquired; Humans; Methods; Postoperative Care; Ra | 1970 |
Diminished renal urate secretion per nephron as a basis for primary gout.
Topics: Adult; Allopurinol; Carbon Isotopes; Computers; Dietary Proteins; Gout; Humans; Inulin; Kidney Funct | 1970 |
[Clinical and biological aspects of dyspurinia with enzyme deficiency].
Topics: Adult; Allopurinol; Gout; Guanine; Humans; Hypoxanthines; Joint Diseases; Kidney Calculi; Metabolism | 1970 |
Tophectomy and bone-grafting for extensive tophi of the feet.
Topics: Ankle; Bone Transplantation; Foot Diseases; Gout; Humans; Male; Metatarsus; Middle Aged; Radiography | 1971 |
A study of familial aggregation of serum uric acid levels in the population of Tecumseh, Michigan, 1959-1960.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Child; Child, Preschool; Female; Gout; Humans; Male; | 1967 |
The chronicity of inflammation and its significance in rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Animals; Antibodies; Antigens; Arthritis, Rheumatoid; Autoimmune Diseases; C | 1968 |
[Retroaction effect of certain pyrazolopyrimidines on the metabolism of uric acid].
Topics: Adult; Aged; Allopurinol; Child; Gout; Humans; Pyrimidines; Uric Acid; Xanthine Oxidase; Xanthines | 1968 |
[Basic therapy of gout by benziodarone].
Topics: Blood Urea Nitrogen; Colchicine; Gout; Humans; Long-Term Care; Uric Acid; Uricosuric Agents | 1969 |
[Allopurinol in the prevention and treatment of urate complications in leukemia].
Topics: Adolescent; Allopurinol; Gout; Humans; Leukemia; Male; Middle Aged; Uric Acid | 1969 |
[Pathogenesis and therapy of gout].
Topics: Allopurinol; Androsterone; Colchicine; Gout; Gymnastics; Humans; Indomethacin; Kinins; Long-Term Car | 1971 |
Comparisons of serum lipid and uric acid content in white and Negro men.
Topics: ABO Blood-Group System; Adult; Black or African American; Cholesterol; Culture; Diet; Gout; Humans; | 1970 |
Treatment of hyperuricemia and gout.
Topics: Colchicine; Female; Gout; Humans; Pregnancy; Pregnancy Complications; Uric Acid | 1972 |
Juvenile gout.
Topics: Child; Female; Gout; Humans; Male; Uric Acid | 1972 |
Gout and levodopa.
Topics: Dihydroxyphenylalanine; Gout; Humans; Uric Acid | 1972 |
Rarity of X-linked partial hypoxanthine-guanine phosphoribosyltransferase deficiency in a large gouty population.
Topics: Adult; Aged; Erythrocytes; Female; Gout; Guanine; Humans; Hypoxanthines; Kidney Calculi; Male; Middl | 1972 |
[Gout attacks and serum uric acid].
Topics: Acute Disease; Gout; Humans; Uric Acid | 1972 |
[Introduction to the study of uric acid crystals in peripheral blood].
Topics: Crystallization; Gout; Humans; Uric Acid | 1972 |
The treatment of gout.
Topics: Acute Disease; Allopurinol; Colchicine; Diagnosis, Differential; Female; Gout; Humans; Indomethacin; | 1972 |
Comparison of urinary acidification and ammonium excretion in normal and gouty subjects.
Topics: Acidosis; Acids; Adult; Aged; Ammonia; Ammonium Chloride; Creatinine; Diet; Gout; Humans; Hydrogen-I | 1972 |
Organic acid excretion patterns in gout.
Topics: Acids; Adult; Aged; Carbon Dioxide; Chromatography, Gas; Citrates; Citric Acid Cycle; Fumarates; Glo | 1972 |
Azaguanine-resistance as a manifestation of a new form of metabolic overproduction of uric acid.
Topics: Adenine; Adolescent; Aminopterin; Azaguanine; Blood Urea Nitrogen; Carbon Isotopes; Cell Line; Creat | 1972 |
The management of gout.
Topics: Acute Disease; Allopurinol; Colchicine; Diet Therapy; Gout; Humans; Indomethacin; Phenylbutazone; Pu | 1972 |
Involvement of the spine in gout. A case report.
Topics: Arthritis, Rheumatoid; Biopsy; Cervical Vertebrae; Diagnosis, Differential; Gout; Humans; Interverte | 1972 |
Medical management of gout.
Topics: Adult; Allopurinol; Colchicine; Diet Therapy; Female; Gout; Humans; Kidney Diseases; Male; Middle Ag | 1972 |
[Significance of hyperuricacidemia in psoriasis vulgaris and some other dermatoses].
Topics: Adolescent; Adult; Aged; Autoimmune Diseases; Clinical Enzyme Tests; Female; Gout; Humans; Hypersens | 1972 |
Hyperuricemia--pathogenesis and treatment.
Topics: Diet Therapy; Gout; Humans; Kidney; Male; Middle Aged; Nucleotides; Purines; Uric Acid | 1972 |
Uric acid excretion and surgery.
Topics: Adult; Aged; Creatinine; Female; Gout; Humans; Kidney; Male; Metabolic Clearance Rate; Middle Aged; | 1972 |
Gout in a New England town. A prevalence study in Sudbury, Massachusetts.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Gout; Humans; Male; Massachusetts; Middle Aged; New Yo | 1972 |
Mechanism of allopurinol-mediated increase in enzyme activity in man.
Topics: Allopurinol; Analysis of Variance; Carbon Isotopes; Carboxy-Lyases; Depression, Chemical; Drug Toler | 1972 |
All hyperuricemia is not gout.
Topics: Colchicine; Gout; Humans; Uric Acid | 1972 |
Some genetical aspects of hyperuricaemia and xanthinuria.
Topics: Gout; Humans; Lesch-Nyhan Syndrome; Purine-Pyrimidine Metabolism, Inborn Errors; Sex Factors; Uric A | 1972 |
Acute gout in the soft tissues. A case report.
Topics: Acute Disease; Female; Gout; Humans; Middle Aged; Uric Acid | 1972 |
Studies on the mechanism of fructose-induced hyperuricemia in man.
Topics: Adenine; Adenosine Triphosphate; Aged; Allopurinol; Erythrocytes; Fasting; Fructose; Glucose; Gout; | 1972 |
Biochemistry of the X-linked uric aciduria--enzyme defect and its genetic variants.
Topics: Athetosis; Gout; Guanine; Humans; Hypoxanthines; Intellectual Disability; Lesch-Nyhan Syndrome; Phos | 1972 |
Clinical features of patients with the "partial" deficiency of the X-linked uricaciduria enzyme.
Topics: Adult; Athetosis; Female; Gout; Humans; Hypoxanthines; Intellectual Disability; Lesch-Nyhan Syndrome | 1972 |
[Current status of the problem of gout and hyperuricemic states (clinical case report)].
Topics: Aged; Foot; Gout; Hand; Humans; Male; Radiography; Uric Acid | 1972 |
Abnormal regulation of glucose and fatty acid metabolism in gout.
Topics: Dietary Carbohydrates; Fatty Acids; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Gly | 1972 |
Plasma lipoproteins, glucose tolerance and insulin response in primary gout.
Topics: Adult; Aged; Blood Protein Disorders; Body Weight; Carbohydrate Metabolism; Cholesterol; Electrophor | 1972 |
Impaired renal clearance of uric acid in chickens having hyperuricemia and articular gout.
Topics: Animals; Chickens; Female; Gout; Kidney; Kidney Tubules; Secretory Rate; Uric Acid | 1972 |
[Hyperuricemia].
Topics: Animals; Disease Models, Animal; Dogs; Gout; Mice; Uric Acid | 1972 |
Gout while receiving levodopa for Parkinsonism.
Topics: Aged; Dihydroxyphenylalanine; Gout; Humans; Male; Middle Aged; Parkinson Disease; Uric Acid | 1972 |
[Gout, diabetes mellitus and fatty liver].
Topics: Adult; Arteriosclerosis; Body Weight; Diabetes Complications; Fatty Liver; Female; Gout; Humans; Hyp | 1972 |
[Gout and pregnancy. An unusual case with severe hyperlipoproteinaemia].
Topics: Adult; Blood Protein Electrophoresis; Cholesterol; Female; Gout; Humans; Hyperlipidemias; Lipids; Li | 1972 |
[Missed gout].
Topics: Arteriosclerosis; Arthritis, Rheumatoid; Diagnosis, Differential; Gout; Humans; Hypertension; Kidney | 1972 |
Gouty tophus. (Analysis of 132 cases of gout).
Topics: Adult; Crystallization; Female; Gout; Granuloma; Humans; Male; Middle Aged; Tendons; Time Factors; U | 1972 |
[Gout].
Topics: Chronic Disease; Diet Therapy; Female; Gout; Humans; Male; Middle Aged; Radiography; Uric Acid; Uric | 1972 |
Hyperuricaemia and myocardial infarction.
Topics: Female; Gout; Humans; Male; Middle Aged; Myocardial Infarction; Uric Acid | 1972 |
Diagnosis of gout.
Topics: Diagnosis, Differential; Female; Gout; Humans; Male; Radiography; Synovial Fluid; Uric Acid | 1972 |
[Milky articular fluid in the course of gout].
Topics: Gout; Humans; Male; Middle Aged; Synovial Fluid; Uric Acid | 1972 |
[Benziodarone in the basic treatment of gout].
Topics: Adult; Aged; Benzofurans; Colchicine; Creatinine; Female; Gout; Humans; Kidney Function Tests; Male; | 1972 |
Gouty tophus of the true vocal cord.
Topics: Calculi; Gout; Hoarseness; Humans; Laryngeal Diseases; Male; Middle Aged; Uric Acid; Vocal Cords | 1972 |
Should asymptomatic hyperuricaemia be treated?
Topics: Allopurinol; Gout; Humans; Kidney Calculi; Metabolic Diseases; Multiphasic Screening; Uric Acid; Uri | 1972 |
Surgery of tophaceous gout.
Topics: Ankle Joint; Elbow Joint; Finger Joint; Gout; Hip Joint; Humans; Knee Joint; Radiography; Shoulder J | 1972 |
Hyperuricemia in health and disease.
Topics: Arteriosclerosis; Arthritis; Blood Group Antigens; Carbohydrate Metabolism; Diabetes Complications; | 1972 |
Serum urate levels and gout in Australian males.
Topics: Adult; Alcohol Drinking; Analysis of Variance; Australia; Blood Pressure; Body Height; Body Weight; | 1971 |
Notes on joint diseases. XI. Interpretation of the serum uric acid.
Topics: Female; Gout; Humans; Male; Uric Acid | 1971 |
[Clinical experience in long-term treatment of gout with benzofuran iodine and bromine derivatives].
Topics: Adult; Aged; Benzofurans; Bromine; Female; Gout; Humans; Iodine; Male; Middle Aged; Uric Acid; Urico | 1971 |
Juvenile gout.
Topics: Adolescent; Adult; Age Factors; Bacteriuria; Child; Child, Preschool; Creatinine; Female; Gout; Huma | 1971 |
Uric acid clearance in patients with gout and normal subjects.
Topics: Adult; Aged; Body Height; Body Weight; Creatinine; Female; Gout; Humans; Kidney; Male; Metabolic Cle | 1971 |
Microscopic studies on skeletal muscle in gout patients treated with allopurinol.
Topics: Adult; Aged; Allopurinol; Biopsy; Birefringence; Female; Freezing; Gout; Histocytochemistry; Humans; | 1971 |
[Is there a specific glomerulitis associated with gouty hyperuricemia? A case].
Topics: Glomerulonephritis; Gout; Humans; Kidney Failure, Chronic; Male; Middle Aged; Uric Acid | 1971 |
[Etiology of hyperuricemia].
Topics: Gout; Humans; Uric Acid | 1971 |
[Uninterrupted therapy of hyperuricemia and gout].
Topics: Gout; Humans; Kidney Diseases; Uric Acid; Uricosuric Agents | 1971 |
Renal handling of uric acid in homozygous haemoglobin C disease.
Topics: Africa, Western; Age Factors; Creatinine; Electrophoresis, Paper; Female; Genotype; Glomerular Filtr | 1971 |
[Various types of arthritis associated with psoriasis].
Topics: Adult; Arthritis; Female; Gout; Hand; Humans; Knee Joint; Male; Middle Aged; Psoriasis; Radiography; | 1971 |
[Clinical symptoms and progress of gout complicated by urolithiasis].
Topics: Adult; Aged; Diabetes Complications; Female; Gout; Humans; Hypertension; Male; Middle Aged; Obesity; | 1971 |
[Uric acid abnormalities in juveniles. Peculiarities of the clinical picture].
Topics: Adolescent; Adult; Diabetes Complications; Diagnosis, Differential; Fatty Liver; Gout; Humans; Hyper | 1971 |
Plasma lipid levels and platelet adhesiveness in gout.
Topics: Blood Group Antigens; Cholesterol; Fatty Acids, Nonesterified; Glycerides; Gout; Hemoglobinometry; H | 1971 |
[Podagric arthropathy].
Topics: Adolescent; Adult; Albuminuria; Algeria; Cardiovascular Diseases; Child; Child, Preschool; Cholester | 1971 |
[Serum uric acid levels and the occurrence of hyperuricemia].
Topics: Adolescent; Adult; Age Factors; Aged; Blood Pressure Determination; Body Weight; Cerebrovascular Dis | 1971 |
["Gout" and angioorganopathies].
Topics: Arteriosclerosis Obliterans; Female; Germany, East; Gout; Humans; Male; Uric Acid; Vascular Diseases | 1971 |
[Severious azotemia and secondary gout in acute leukosis].
Topics: Adolescent; Gout; Humans; Leukemia; Male; Nitrogen; Uremia; Uric Acid | 1971 |
Hyperuricemia and levodopa.
Topics: Dihydroxyphenylalanine; Gout; Humans; Parkinson Disease; Uric Acid | 1971 |
Determination of volatile constituents of human blood and tissue specimens by quantitative high resolution mass spectrometry.
Topics: Allopurinol; Gout; Humans; Hypoxanthines; Mass Spectrometry; Methods; Muscles; Purines; Pyrazoles; P | 1971 |
[Xanthinoxidase inhibitors in hyperuricemia and gout].
Topics: Allopurinol; Female; Gout; Humans; Male; Phenylbutazone; Uric Acid | 1971 |
Hyperuricemia and gout in an employee population.
Topics: Adult; Age Factors; Alcoholism; Coronary Disease; Diabetes Complications; Diuretics; Gout; Humans; H | 1971 |
[Clinico-statistical studies on coronary insufficiency and heart rhythm changes in an aged patient with gout].
Topics: Adult; Aged; Arrhythmias, Cardiac; Arteriosclerosis; Coronary Disease; Gout; Humans; Middle Aged; Ur | 1971 |
[Diet and pharmacologic therapy of hyperuricemias in the aged].
Topics: Aged; Allopurinol; Benzofurans; Diet Therapy; Gout; Humans; Uric Acid | 1971 |
Results of surgical therapy in chronic gouty arthritis.
Topics: Arthritis, Rheumatoid; Chronic Disease; Gout; Humans; Uric Acid | 1971 |
[Physiopathology and treatment of hyperuricemia and gout].
Topics: Acidosis; Acute Disease; Gout; Humans; Kidney Failure, Chronic; Orotic Acid; Purines; Urate Oxidase; | 1971 |
[Determination of uric acid in blood. Experimental determination; critical studies of the technics and results].
Topics: Adolescent; Adult; Aspirin; Autoanalysis; Female; Gout; Humans; Indicators and Reagents; Kidney Dise | 1971 |
[Gouty arthropathy (presentation of 2 cases of exceptional seriousness)].
Topics: Ear, External; Gout; Humans; Joints; Kidney; Male; Middle Aged; Time Factors; Uric Acid | 1971 |
[Possibilities of the differential diagnosis of effusions from joints].
Topics: Acid Phosphatase; Arthritis, Rheumatoid; C-Reactive Protein; Diagnosis, Differential; Gout; Histiocy | 1971 |
Alterations in the activity of hypoxanthine and adenine phosphoribosyltransferase in patients with hyperuricaemia and gout.
Topics: Adenine; Adult; Erythrocytes; Gout; Humans; Hypoxanthines; Lesch-Nyhan Syndrome; Pentosyltransferase | 1971 |
[Current trends in gouty arthropathy (clinical correlations and possibilities of surgical treatment)].
Topics: Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Exercise Therapy; Gout; Humans; Joints; Lipid | 1971 |
[Studies on uric acid metabolism in man. 2. Studies on uric acid metabolism in patients with hyperuricemia].
Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Male; Metabolic Diseases; Middle Aged; Nephritis; Uri | 1971 |
[Gout].
Topics: Adolescent; Adult; Aged; Arthritis; Colchicine; Diet Therapy; Female; Gout; Griseofulvin; Humans; Ja | 1971 |
[Coagulation factors in inflammation].
Topics: Blood Coagulation; Blood Coagulation Factors; Factor XII; Fibrin; Gout; Humans; Inflammation; Phagoc | 1971 |
[Endocrine components in pathogenesis and clinico-metabolic evolution of dyspurinia in primary gout and its therapy].
Topics: Anti-Inflammatory Agents; Diet Therapy; Endocrine Glands; Gout; Humans; Purines; Uric Acid; Uricosur | 1971 |
[Hand in uric arthritis].
Topics: Aged; Gout; Hand; Humans; Male; Middle Aged; Radiography; Uric Acid | 1969 |
[Uric arthritis and pseudo-uric syndrome. Diagnostic and pathogenetic significance in the study of crystals in synovial fluid].
Topics: Calcium; Crystallization; Gout; Humans; Synovial Fluid; Uric Acid | 1969 |
Uric acid in human plasma. IV. Investigations on the interactions between urate and the macromolecular fraction in plasma from healthy individuals and patients with diseases associated with hyperuricemia.
Topics: Adolescent; Adult; Aged; Blood; Chemical Phenomena; Chemistry; Female; Gout; Hodgkin Disease; Humans | 1965 |
Secondary gout associated with myeloproliferative diseases.
Topics: Anemia, Hemolytic; Female; Gaucher Disease; Gout; Humans; Kidney Calculi; Leukemia, Myeloid; Male; N | 1965 |
The interrelationship of glycogen storage disease and gout.
Topics: Adult; Child; Glycogen Storage Disease Type I; Gout; Humans; Kidney Function Tests; Lactates; Uric A | 1965 |
Contraindications and therapeutic results of fasting in obese patients.
Topics: Anemia; Anuria; Atrial Flutter; Blood; Diabetes Mellitus; Diet, Sodium-Restricted; Fasting; Female; | 1965 |
Uric acid, gout and public health in the South Pacific.
Topics: Adult; Ethnology; Female; Gout; Humans; Male; Mass Screening; Middle Aged; Pacific Islands; Public H | 1966 |
Suppression of the shunt pathway in primary gout by azathioprine.
Topics: Adenine Nucleotides; Azathioprine; Blood; Enzyme Repression; Glycine; Gout; Guanine Nucleotides; Hum | 1966 |
Lactic acid and hyperuricemia of faulty renal urate transport.
Topics: Female; Glycogen Storage Disease; Gout; Humans; Hypertension; Kidney Diseases; Lactates; Pre-Eclamps | 1967 |
Relationships between glycogen storage disease and tophaceous gout.
Topics: Adult; Female; Glucose Tolerance Test; Glycogen Storage Disease Type I; Gout; Humans; Inulin; Lactat | 1967 |
Metabolic effects of allopurinol and allo-xanthine.
Topics: Adult; Allopurinol; Drug Tolerance; Enzyme Therapy; Female; Gout; Humans; Leukemia, Myeloid, Acute; | 1966 |
Biochemical considerations of the renal damage of gout.
Topics: Allopurinol; Gout; Humans; Hypoxanthines; Kidney Calculi; Leukemia, Lymphoid; Uric Acid; X-Ray Diffr | 1966 |
Two rare causes of secondary gouty arthritis.
Topics: Adult; Glomerulonephritis; Glycogen Storage Disease; Gout; Humans; Male; Phosphates; Radiography; Re | 1967 |
The clinical significance of hyperuricemia.
Topics: Arthritis; Gout; Humans; Uric Acid; Uricosuric Agents | 1967 |
Allopurinol in treatment of patients with gout and chronic renal failure.
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Hypoxanthines; Kidney Failure, Chronic; Kidney Funct | 1967 |
[Hyperuricemia with arthritis symptoms in the course of acute myeloid leukemia].
Topics: Gout; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Uric Acid | 1967 |
Gout of the temporomandibular joint. Report of three cases.
Topics: Colchicine; Diagnosis, Differential; Gout; Humans; Male; Middle Aged; Probenecid; Temporomandibular | 1969 |
[Gout in the evolution of Von Gierke's disease].
Topics: Adolescent; Adult; Allopurinol; Child; Female; Glycogen Storage Disease; Glycogen Storage Disease Ty | 1969 |
[Gout as a complication of adult glycogen storage disease].
Topics: Adolescent; Adult; Blood Glucose; Female; Glycogen Storage Disease Type I; Gout; Humans; Lactates; M | 1969 |
Allopurinol in the treatment of gout.
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Male; Sulfinpyrazone; Uric Acid | 1969 |
[Diagnostic value of hyperuricemia].
Topics: Adult; Allopurinol; Child; Diabetes Mellitus; Female; Glycogen Storage Disease; Gout; Humans; Hypert | 1968 |
Roentgenographic skeletal changes in the glycogen storage diseases.
Topics: Adolescent; Adult; Age Factors; Body Height; Bone and Bones; Child; Child, Preschool; Female; Glycog | 1969 |
Metabolic aberrations in gout.
Topics: Female; Glycogen Storage Disease Type I; Gout; Humans; Kidney; Kidney Calculi; Kidney Diseases; Male | 1970 |
Gout in Chinese patients.
Topics: Adult; Aged; Asian People; China; Gout; Humans; Male; Middle Aged; Uric Acid | 1970 |
Drug-induced hyperuricemia prevented by probenecid.
Topics: Adult; Aged; Female; Gout; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Probenecid; | 1971 |
[Serum and urine uric acid content in hemoblastoses and gout as well as its modification by allopurinol].
Topics: Allopurinol; Bone Marrow Diseases; Gout; Hodgkin Disease; Humans; Leukemia; Leukemia, Myeloid; Plasm | 1971 |
The relative contributions of tubular reabsorption and secretion to urate excretion in lead nephropathy.
Topics: Absorption; Adult; Female; Glomerular Filtration Rate; Gout; Humans; Insulin; Kidney Failure, Chroni | 1971 |
[Deposition of crystalline uric acid in the kidneys].
Topics: Aged; Gout; Humans; Hydronephrosis; Kidney Diseases, Cystic; Male; Pyelonephritis; Uremia; Uric Acid | 1966 |
[Treatment of gout and of certain rheumatisms with hyperuricemia caused by benziodarone].
Topics: Adult; Arthritis, Rheumatoid; Benzofurans; Female; Gout; Humans; Male; Rheumatic Diseases; Sulfinpyr | 1968 |
[Comparative examinations of concrements of the human kidney by scanning electron microscopy].
Topics: Adult; Calcinosis; Crystallography; Gout; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infarc | 1969 |
[Early diagnosis of gout].
Topics: Feeding Behavior; Gout; Humans; Uric Acid | 1969 |
[Gout. Clinical analysis of 300 cases of urate gout].
Topics: Adult; Age Factors; Biopsy; Colchicine; Creatinine; Diagnosis, Differential; Diet; Diuretics; Female | 1968 |
[Effects of benziodarone on hyperuricemia].
Topics: Adult; Aged; Arthritis; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1969 |
[Basic concepts of physics for the interpretation of the curative effect of radioactive mineral waters].
Topics: Female; Genital Diseases, Female; Gout; Humans; Hypertension; Infertility, Female; Joint Diseases; M | 1969 |
[Gout from the view of a special hospital for rheumatic patients].
Topics: Acute Disease; Adolescent; Adult; Aged; Austria; Child; Cholesterol; Colchicine; Colic; Diabetes Com | 1971 |
Nephrotoxic effect of MSG (monosodium glutamate) in the chicken.
Topics: Acute Kidney Injury; Animals; Atrophy; Body Weight; Chickens; Edema; Extremities; Gallbladder; Gluta | 1971 |
The inflammatory reaction to microcrystalline sodium urate.
Topics: Animals; Calcinosis; Crystallization; Dogs; Gout; History of Medicine; Humans; Inflammation; Leukocy | 1965 |
Ultrastructural study of leucocytes and urates in gouty arthritis.
Topics: Adult; Aged; Cytoplasm; Female; Gout; Humans; Leukocytes; Male; Microscopy, Electron; Microscopy, Fl | 1967 |
[Orotic acid and hyperuricemia caused by fructose].
Topics: Adult; Female; Fructose; Gout; Humans; Male; Orotic Acid; Uric Acid | 1969 |
[Allpurinol in the treatment of hyperuricemia and chronic gout].
Topics: Adult; Aged; Allopurinol; Arthritis; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Xanthine Ox | 1969 |
Nail changes in gout.
Topics: Adult; Aged; Gout; Humans; Middle Aged; Nails; Uric Acid | 1969 |
Gout.
Topics: Anti-Inflammatory Agents; Gout; Humans; Uric Acid; Uricosuric Agents | 1969 |
What to do about an elevated uric acid level.
Topics: Gout; Metabolic Diseases; Uric Acid | 1969 |
Medical conference from the University of New Mexico School of Medicine. About gout.
Topics: Aged; Arthritis; Gout; Humans; Joints; Male; Metabolism, Inborn Errors; Uric Acid | 1969 |
Gout and hyperuricemia in a Finnish rural population.
Topics: Adolescent; Adult; Age Factors; Aged; Colchicine; Female; Finland; Gout; Humans; Male; Middle Aged; | 1969 |
[Juvenile hyperuricemia, gout and cerebral palsy (Lesch-Nyhan syndrome)].
Topics: Adolescent; Allopurinol; Athetosis; Cerebral Palsy; Chorea; Gout; Humans; Male; Uric Acid | 1969 |
[Apparently primary kidney disease revealing latent error of purine metabolism in 2 adolescents].
Topics: Adolescent; Adult; Allopurinol; Diet Therapy; Diet, Sodium-Restricted; Diuretics; Gout; Humans; Kidn | 1969 |
[Clinical findings and therapy of gout with special reference to the metabolic effects of sulfinpyrazone (Anturan) and allopurinol (Zyloric)].
Topics: Allopurinol; Diabetes Mellitus; Gout; Humans; Hypertension; Kidney Diseases; Male; Sulfinpyrazone; U | 1969 |
[The daily rhythm of renal uric acid excretion in patients with gout].
Topics: Adult; Calcium; Chlorides; Circadian Rhythm; Creatinine; Gout; Humans; Middle Aged; Natriuresis; Pho | 1969 |
[Articular manifestations in hyperlipidemia].
Topics: Adolescent; Adult; Aged; Arthritis; Arthritis, Rheumatoid; Child; Child, Preschool; Female; Gout; Hu | 1969 |
[The hypouricemic effect of benziodarone].
Topics: Adult; Aged; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1969 |
[Uricemia in chronic arteriopathies of limbs].
Topics: Arteries; Arteriosclerosis; Arteritis; Chronic Disease; Extremities; Female; Gout; Humans; Leg; Male | 1969 |
Allopurinol and urolithiasis.
Topics: Allopurinol; Female; Gout; Humans; Male; Uric Acid; Urinary Calculi | 1969 |
[Xanthine oxidase activity in the jejunal mucosa of patients with gout].
Topics: Gout; Humans; Intestinal Mucosa; Jejunum; Uric Acid; Xanthine Oxidase | 1969 |
[Familial encephalopathy with hyperuricemia. A study of purine metabolism and therapeutic attempts].
Topics: Brain Diseases; Child, Preschool; Electroencephalography; Follow-Up Studies; Gout; Humans; Infant; K | 1969 |
Total heart block as a complication of gout.
Topics: Electrocardiography; Gout; Heart Block; Heart Conduction System; Humans; Male; Middle Aged; Uric Aci | 1969 |
[Proliferative synovitis after intra-articular injections of micro-crystals of sodium urate in rabbits. Preliminary note].
Topics: Animals; Arthritis, Rheumatoid; Freund's Adjuvant; Gout; Injections, Intra-Articular; Male; Rabbits; | 1969 |
[Renal scintiscanning and curves of urinary and hematic activity in the renal, peripheral and hepatic areas in presenile and senile gout].
Topics: Aged; Blood Circulation; Diuresis; Female; Gout; Humans; Kidney; Kidney Diseases; Kidney Function Te | 1969 |
[Gout and trauma].
Topics: Adult; Athletic Injuries; Diagnosis, Differential; Female; Gout; Humans; Male; Middle Aged; Occupati | 1969 |
[The uric acid contents of surgically excised gout nodes and bursae with gouty changes].
Topics: Aged; Bursa, Synovial; Bursitis; Elbow; Fingers; Gout; Humans; Male; Spectrophotometry; Toes; Uric A | 1969 |
[Inhibition of endogenous synthesis of uric acid with allopurinol in patients with gout and urate diathesis].
Topics: Adult; Aged; Allopurinol; Disease Susceptibility; Gout; Humans; Kidney Calculi; Kidney Diseases; Kid | 1969 |
[Clinical biochemistry of gout].
Topics: Adenine Nucleotides; Benzofurans; Fatty Acids; Gout; Guanine; Humans; Hypoxanthines; Pentosephosphat | 1969 |
Hyperuricaemia in northern Finland. An epidemiological study of serum uric acid in rural, urban and hospital populations.
Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Body Weight; Cerebrovascular Disorders; Cholesterol; C | 1969 |
[Gout and hyperuricemia associated with lead poisoning].
Topics: Adult; Glomerular Filtration Rate; Gout; Humans; Kidney Failure, Chronic; Kidney Tubules; Lead Poiso | 1969 |
[Clinical trial of L2214 in the treatment of gout or of rheumatologic syndromes associated with hyperuricemia].
Topics: Adult; Aged; Arthritis, Rheumatoid; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Uric Acid; | 1969 |
[Blood uric acid in chronic arteriopathies of the limbs. 3. Statistics on a continuous series of 200 personal cases. IV. Prospects of research].
Topics: Adult; Age Factors; Aged; Arteriosclerosis; Arteritis; Body Weight; Cholesterol; Chronic Disease; Go | 1969 |
[Clinical and biological effects of a new uric acid lowering substance (benziodaronum) in gout. Results of a 2-year-long study].
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents; Benzofurans; Chronic Disease; Gout; Humans; Ma | 1969 |
[Uricemia in chronic arteriopathy of the extremities. 3. Statistical data on a continuous series of 200 personal cases. 4. Research perspectives].
Topics: Adolescent; Adult; Aged; Arteritis; Gout; Humans; Leg; Male; Middle Aged; Uric Acid; Vascular Diseas | 1969 |
[Recent progress in the knowledge of the mechanism of hyperuricemia and gout].
Topics: Gout; Humans; Uric Acid | 1969 |
Effects of allopurinol on hyperuricemia secondary to fasting.
Topics: Allopurinol; Drug Tolerance; Fasting; Gout; Humans; Kidney; Uric Acid | 1970 |
Reduction of serum uric acid in young men during physical training.
Topics: Adolescent; Adult; Age Factors; Body Height; Body Surface Area; Body Weight; Coronary Disease; Gout; | 1970 |
Notes on joint diseases. I. Gout is not hyperuricemia.
Topics: Diagnosis, Differential; Gout; Humans; Uric Acid | 1970 |
Long-term use of allopurinol in the treatment of gout.
Topics: Adolescent; Aged; Allopurinol; Colic; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; Sulf | 1970 |
Disorder of purine metabolism due to partial deficiency of hypoxanthine-guanine phosphoribosyltransferase. A study of a family.
Topics: Adolescent; Adult; Carbon Isotopes; Child; Child, Preschool; Female; Glucosyltransferases; Glutamina | 1970 |
Benign symmetric lipomatosis (Launois-Bensaude adenolipomatosis) with gout and hyperlipoproteinemia.
Topics: Adult; Azathioprine; Blood Protein Electrophoresis; Carbon Isotopes; Female; Glucose Tolerance Test; | 1970 |
The binding of urate to plasma proteins determined by means of equilibrium dialysis.
Topics: Aspirin; Blood Proteins; Dialysis; Gout; Humans; Hydrogen-Ion Concentration; Hypoxanthines; Kidney D | 1970 |
[Benziodarone in the treatment of hyperuricemia].
Topics: Benzofurans; Gout; Humans; Purines; Uric Acid | 1970 |
[Treatment of uric lithiasis].
Topics: Bicarbonates; Diet Therapy; Gout; Humans; Lactates; Uric Acid; Urinary Calculi | 1970 |
[Dietetics in gout].
Topics: Diet Therapy; Gout; Humans; Uric Acid | 1970 |
[Gout].
Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Female; Gout; Humans; Male; Middle Aged | 1970 |
[At the borders of gout: procedure to follow in the case of isolated hyperuricemia].
Topics: Gout; Humans; Uric Acid | 1970 |
[Indications of basic treatment of gout].
Topics: Gout; Uric Acid; Uricosuric Agents | 1970 |
Uric acid lithiasis--a study of six hundred and twenty-two patients.
Topics: Adult; Ethnicity; Female; Gout; Humans; Hyperparathyroidism; Israel; Male; Myeloproliferative Disord | 1970 |
[Gout].
Topics: Colchicine; Gout; Humans; Uric Acid; Uricosuric Agents | 1970 |
Diagnosis of gout.
Topics: Albuminuria; Arthritis; Arthritis, Rheumatoid; Colchicine; Colic; Diagnosis, Differential; Gout; Hum | 1970 |
Pathogenesis and treatment of the acute attack of gout.
Topics: Acute Disease; Animals; Calculi; Colchicine; Crystallization; Dogs; Gout; Humans; Inflammation; Leuk | 1970 |
Pathogenesis and medical management of chronic gouty arthritis.
Topics: Allopurinol; Chronic Disease; Colchicine; Gout; Humans; Joints; Kidney; Probenecid; Sulfinpyrazone; | 1970 |
Visceral (nonarticular) manifestations associated with gout.
Topics: Acute Kidney Injury; Arteriosclerosis; Gout; Humans; Hypertension; Kidney Calculi; Radiography; Uric | 1970 |
Gouty arthritis of the spine.
Topics: Autopsy; Biopsy; Calculi; Cervical Vertebrae; Colchicine; Female; Gout; Humans; Lumbar Vertebrae; Ma | 1970 |
[Renal excretion of uric acid in various conditions inducing hyperuricemia].
Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Hydrochlorothiazide; Hypertension, Renal; Kidney Fail | 1970 |
Non-traumatic necrosis of the femoral head. I. Relation of altered hemostasis to etiology.
Topics: Alcohol Drinking; Blood Coagulation Disorders; Blood Coagulation Tests; Blood Platelet Disorders; Fe | 1970 |
Chlorthalidone in the long term therapy of patients with hypertension.
Topics: Adult; Aged; Blood Chemical Analysis; Blood Glucose; Blood Pressure; Carbohydrate Metabolism, Inborn | 1970 |
Effects of colchicine in rats with urate crystal-induced inflammation.
Topics: Adrenal Glands; Animals; Body Weight; Colchicine; Crystallization; Edema; Gout; Inflammation; Male; | 1970 |
[Biological manifestations of gout].
Topics: Blood Sedimentation; Female; Fibrinogen; Gout; Humans; Male; Uric Acid | 1970 |
Mechanism of excessive purine biosynthesis in hypoxanthine-guanine phosphoribosyltransferase deficiency.
Topics: Adult; Allopurinol; Athetosis; Carbon Isotopes; Child; Chorea; Compulsive Behavior; Deficiency Disea | 1970 |
Diuretics and hyperuricemia.
Topics: Allopurinol; Diuretics; Gout; Humans; Hypertension; Uric Acid; Uricosuric Agents | 1970 |
[On the hypouricemic and uricuric action of benziodarone].
Topics: Benzofurans; Gout; Humans; Middle Aged; Uric Acid | 1970 |
[Enzymopathic gout. Dyspurinia due to hypoxanthine-guanine-phosphoribosyl-transferase deficiency. Occurrence and clinical characteristics of enzyme repression].
Topics: Adenine; Adult; Age Factors; Allopurinol; Enzyme Repression; Female; Gout; Guanine; Humans; Hypoxant | 1970 |
Allopurinol: alteration in pyrimidine metabolism in man.
Topics: Allopurinol; Carboxy-Lyases; Depression, Chemical; Erythrocytes; Gout; Humans; Hypoxanthines; Kineti | 1970 |
[Circadian rhythm in uricemia].
Topics: Circadian Rhythm; Female; Gout; Humans; Male; Sex Factors; Uric Acid | 1970 |
[Gout and the excretion of uric acid in sweat].
Topics: Gout; Hot Temperature; Humans; Sports; Sweat; Sweating; Uric Acid | 1970 |
Effect of glycine loading on plasma and urinary uric acid and amino acids in normal and gouty subjects.
Topics: Adult; Aged; Amino Acids; Glycine; Gout; Humans; Hydrogen-Ion Concentration; Kidney; Male; Middle Ag | 1970 |
The interaction of monosodium urate with connective tissue components.
Topics: Animals; Binding Sites; Buffers; Cartilage; Cattle; Chondroitin; Crystallization; Dialysis; Gout; Hy | 1970 |
Pitfalls in the diagnosis of hyperuricemic arthritis.
Topics: Arthritis; Foot Diseases; Gout; Humans; Uric Acid | 1970 |
[Symptomless hyperuricemia].
Topics: Gout; Humans; Metabolic Diseases; Uric Acid | 1970 |
Clinical significance of hyperuricemia in routinely screened hospitalized men.
Topics: Acidosis; Adult; Aged; Autoanalysis; Diuretics; Gout; Heart Failure; Hospitalization; Humans; Kidney | 1970 |
[Biochemistry of gout, with special reference to the etiology of hyperuricemia].
Topics: Gout; Humans; Nucleotides; Purines; Uric Acid | 1970 |
[Determination of uric acid in gout].
Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Female; Gout; Humans; Male; Methods; | 1970 |
[Heredity of gout and experimental gout].
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Birds; Child; Child, Preschool; Female; Gout; Humans; | 1970 |
[Clinical studies of gout. Problems in the areas outside the cities].
Topics: Adult; Diagnosis, Differential; Gout; Humans; Japan; Male; Rural Health; Uric Acid | 1970 |
[Diagnosis of gout].
Topics: Colchicine; Diagnosis, Differential; Gout; Humans; Joint Diseases; Uric Acid | 1970 |
[Treatment of gout].
Topics: Allopurinol; Analgesics; Gout; Humans; Uric Acid; Uricosuric Agents | 1970 |
[Therapeutic agents for gout effecting the kidney].
Topics: Allopurinol; Gout; Humans; Kidney; Phenylbutazone; Uric Acid; Uricosuric Agents | 1970 |
[Physiopathology of articular manifestations of gout].
Topics: Gout; Humans; Joint Diseases; Uric Acid | 1970 |
[Treatment of hyperuricemia with benziodarone].
Topics: Benzofurans; Gout; Humans; Male; Uric Acid; Uricosuric Agents | 1970 |
[Crenotherapy of gout and hyperuricemia].
Topics: Balneology; Diuresis; Gout; Humans; Mineral Waters; Uric Acid | 1970 |
[Will the gout be eliminated?].
Topics: Allopurinol; Gout; Humans; Uric Acid; Uricosuric Agents | 1970 |
Serum uric acid and achievement--an explanation.
Topics: Achievement; Gout; Humans; Male; Personality; Social Class; Uric Acid | 1970 |
The influence of allopurinol on the course of gout. A study of 28 cases.
Topics: Age Factors; Allopurinol; Colchicine; Drug Synergism; Gout; Humans; Probenecid; Uric Acid | 1970 |
The epidemiology of hyperuricemia.
Topics: Age Factors; Body Weight; Ethnicity; Female; Gout; Humans; Indians, North American; Male; Sex Factor | 1970 |
[Diagnosis and therapy of uric arthritis].
Topics: Acute Disease; Adult; Allopurinol; Anti-Inflammatory Agents; Chronic Disease; Diagnosis, Differentia | 1970 |
Preliminary results from high-resolution analyses of ultraviolet-absorbing and carbohydrate constituents in several pathologic body fluids.
Topics: Adolescent; Adult; Alkaptonuria; Allopurinol; Amniotic Fluid; Athetosis; Carbohydrates; Chorea; Chro | 1970 |
Diuretics and hyperuricemia.
Topics: Diuretics; Gout; Humans; Uric Acid | 1970 |
[Further studies on the use of orotic acid in the treatment of gout].
Topics: Gout; Humans; Orotic Acid; Uric Acid | 1970 |
Clinical survey of 354 patients with gout.
Topics: Adolescent; Adult; Age Factors; Aged; Alcohol Drinking; Blood Urea Nitrogen; Body Weight; Child; Com | 1970 |
Uric acid metabolism in starvation.
Topics: Allopurinol; Female; Gout; Humans; Male; Obesity; Starvation; Uric Acid | 1970 |
A new assay method for hypoxanthine-guanine phosphoribosyltransferase.
Topics: Adenine; Adenine Nucleotides; Athetosis; Carbon Isotopes; Chorea; Chromatography; Compulsive Behavio | 1970 |
[Effect of benzbromarone on serum uric acid level and uric acid excretion of patients with gout].
Topics: Adult; Aged; Benzofurans; Creatinine; Female; Glomerular Filtration Rate; Gout; Humans; Kidney Funct | 1970 |
Uricaemic pleurisy.
Topics: Adult; Aged; Analysis of Variance; Asthma; Gout; Humans; Male; Middle Aged; Pleurisy; Uric Acid | 1970 |
[Role of carbohydrates in the diet of gout patients].
Topics: Adult; Dietary Carbohydrates; Fructose; Glucose; Gout; Humans; Male; Sucrose; Uric Acid | 1970 |
[Glucose and hyperuricemia caused by fructose].
Topics: Adult; Fructose; Glucose; Gout; Humans; Male; Sucrose; Uric Acid | 1970 |
Partial deficiency of hypoxanthine-guanine phosphoribosyltransferase associated with gout and uric acid lithiasis.
Topics: Adult; Aged; Allopurinol; Calculi; Erythrocytes; Genes, Recessive; Gout; Guanine; Heterozygote; Huma | 1970 |
[Dynamics of metabolism in gout].
Topics: Adult; Aged; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus; Fasting; Fatty Acids; Female | 1970 |
[Uric acid in the diagnosis of gout].
Topics: Colorimetry; Gout; Humans; Methods; Uric Acid | 1970 |
[Allopurinol in the treatment of gout].
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Male; Middle Aged; Probenecid; Uric Acid | 1970 |
[Metabolism relations between psoriasis vulgaris and secondary gout].
Topics: Blood Glucose; Gout; Humans; Phosphates; Psoriasis; Uric Acid | 1970 |
[Effect of allopurinol (Zyloric) on uric acid, creatinine, fasting blood sugar and plasma lipids in patients with gout].
Topics: Adult; Allopurinol; Blood Glucose; Cholesterol; Creatinine; Fasting; Fatty Acids, Nonesterified; Gou | 1970 |
[Pre-senile and senile gout].
Topics: Age Factors; Aged; Female; Gout; Humans; Kidney; Male; Uric Acid | 1970 |
[Benziodarone therapy in hyperuricemia in the aged].
Topics: Age Factors; Aged; Cardiovascular Diseases; Gout; Humans; Kidney Failure, Chronic; Respiratory Insuf | 1970 |
[Current problems of gout].
Topics: Blood Glucose; Cholesterol; Coronary Disease; Diabetes Complications; Female; Gout; Humans; Hypercho | 1970 |
[Clinical experiences with the citrate granulate Blemaren in the prevention and therapy of uric acid lithiasis].
Topics: Bicarbonates; Calcium; Citrates; Female; Gout; Humans; Kidney Pelvis; Magnesium; Male; Middle Aged; | 1970 |
[Treatment of gout by inhibitors of uric acid synthesis].
Topics: Drug Synergism; Gout; Humans; Pyrazoles; Pyrimidines; Uric Acid; Uricosuric Agents | 1970 |
[Etiopathogenesis of gout].
Topics: Female; Gout; Humans; Male; Uric Acid | 1970 |
[Clinical, radiological and diagnostic study of articular gout].
Topics: Diagnosis, Differential; Female; Gout; Humans; Male; Uric Acid | 1970 |
[Inhibition of endogenous uric acid synthesis with allopurinol in gout and urate diathesis. Remarks on E. Holländer and P. Schwarczmann, Münch. Med. Wschr. 3 (1969) 32, 1623-1626].
Topics: Allopurinol; Gout; Humans; Purine-Pyrimidine Metabolism, Inborn Errors; Urate Oxidase; Uric Acid | 1970 |
[Diabetes mellitus, hyperlipemia, fatty liver, hypertension in primary gout and their influencing by benzbromaronum].
Topics: Adult; Benzofurans; Blood Glucose; Blood Sedimentation; Colchicine; Creatinine; Diabetes Mellitus; E | 1970 |
Executive hyperuricemia.
Topics: Administrative Personnel; Arthritis; Gout; Humans; Male; Uric Acid; Urinary Calculi | 1971 |
[Ocular findings in gout and hyperuricemia].
Topics: Adult; Eye Diseases; Gout; Humans; Hypertension; Male; Middle Aged; Uric Acid | 1971 |
[Alterations of lipid metabolism in primary gout and hyperuircemia].
Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus; Fatty Acids; Fatty Acids, Nonesterified; | 1971 |
[The kidneys and hyperuricemia. Therapeutic problems].
Topics: Gout; Humans; Hypertension; Kidney Diseases; Uric Acid | 1971 |
[Uricosuric effect of a phenylbutazone derivative, cetophenylbutazone].
Topics: Female; Glomerular Filtration Rate; Gout; Humans; Male; Middle Aged; Phenylbutazone; Uric Acid; Uric | 1971 |
[Microcrystalline arthritis: the gout crisis].
Topics: Acute Disease; Gout; Humans; Leukocytes; Synovial Fluid; Uric Acid | 1971 |
[Ultrastructural study of intraleukocyte urates in the gout crisis].
Topics: Acute Disease; Gout; Humans; Leukocytes; Microscopy, Electron; Synovial Fluid; Uric Acid | 1971 |
Phosphoribosyl transferase activity in normal subjects, gout patients, and children with mental retardation.
Topics: Adenine; Adolescent; Adult; Child; Child, Preschool; Creatinine; Erythrocytes; Female; Gout; Guanine | 1971 |
Hyperuricemia, a concomitant of congenital vasopressin-resistant diabetes insipidus in the adult.
Topics: Adult; Aminohippuric Acids; Arginine; Child; Child, Preschool; Creatinine; Diabetes Insipidus; Diet; | 1971 |
[Acute kidney failure and hyperuricemia].
Topics: Acidosis, Respiratory; Acute Kidney Injury; Allopurinol; Animals; Anuria; Dogs; Gout; Humans; Hypoxa | 1971 |
An unusual form of renal disease associated with gout and hypertension.
Topics: Adolescent; Adult; Aged; Biopsy; Cerebrovascular Disorders; Chromosome Aberrations; Chromosome Disor | 1971 |
Hyperuricemia and chronic renal disease.
Topics: Adult; Aged; Alcohol Drinking; Chronic Disease; Creatinine; Diabetes Mellitus; Diuretics; Female; Go | 1971 |
[Genetic problems concerning gout].
Topics: Adult; Aged; Female; Gout; Humans; Male; Metabolism, Inborn Errors; Middle Aged; Uric Acid | 1971 |
Hyperuricaemia and gout.
Topics: Acute Disease; Adult; Arthritis; Chronic Disease; Diagnosis, Differential; Female; Gout; Humans; Mal | 1971 |
[Gout in young patients].
Topics: Adolescent; Adult; Age Factors; Diabetes Complications; Fatty Liver; Gout; Humans; Hyperlipidemias; | 1971 |
A quantitative study of skeletal-muscle purines and pyrazolo(3,4-d)pyrimidines in gout patients treated with allopurinol.
Topics: Allopurinol; Biopsy; Gout; Humans; Hypoxanthines; Mass Spectrometry; Muscles; Purines; Pyrazoles; Py | 1971 |
[Gout].
Topics: Dietary Fats; Gout; Humans; Indomethacin; Radiography; Uric Acid; Uricosuric Agents; Urinary Calculi | 1971 |
The causes of nonazotemic hyperuricemia.
Topics: Adult; Age Factors; Animals; Arteriosclerosis; Blood Urea Nitrogen; Computers; Coronary Disease; Dia | 1971 |
Triglyceride concentrations in primary gout and gout of chronic lead nephropathy.
Topics: Adult; Aged; Alcoholic Beverages; Cholesterol; Gout; Humans; Kidney Failure, Chronic; Lead Poisoning | 1971 |
[Renal manifestations of hyperuricemia].
Topics: Gout; Humans; Kidney Diseases; Uric Acid | 1971 |
Hyperlipoproteinaemia in gout.
Topics: Adult; Aged; Allopurinol; Blood Protein Disorders; Blood Protein Electrophoresis; Cholesterol; Gout; | 1971 |
[Too much and too little uric acid].
Topics: Gout; Humans; Uric Acid | 1971 |
Hyperuricemia and levodopa.
Topics: Aged; Dihydroxyphenylalanine; Female; Gout; Humans; Male; Parkinson Disease; Uric Acid | 1971 |
[The kidney and hyperuricemia].
Topics: Diuretics; Gout; Humans; Kidney Calculi; Kidney Diseases; Kidney Failure, Chronic; Kidney Function T | 1971 |
[X-ray morphology of uric arthritis].
Topics: Adult; Aged; Chronic Disease; Female; Gout; Humans; Male; Middle Aged; Radiography; Uric Acid | 1971 |
[Simple determination of purines by preparative thin-layer chromatography].
Topics: Athetosis; Chorea; Chromatography, Thin Layer; Compulsive Behavior; Diagnosis, Differential; Gout; H | 1971 |
[Liver pathology in gout].
Topics: Adult; Biopsy; Blood Glucose; Blood Protein Electrophoresis; Body Weight; Cholesterol; Diabetes Comp | 1971 |
High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure.
Topics: Adolescent; Adult; Creatine; Creatinine; Diuresis; Female; Furosemide; Gout; Humans; Hypertension, R | 1971 |
Rheumatoid arthritis and gout in Hiroshima and Nagasaki, Japan. A prevalence and incidence study.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Blood Pressure; Educational Status; Environment; Fa | 1971 |
[Synovial fluid in arthritis urica. Sodium urate crystals as a key to the diagnosis and pathogenesis].
Topics: Diagnosis, Differential; Female; Gout; Humans; Inflammation; Male; Synovial Fluid; Synovitis; Uric A | 1971 |
[Gout and hyperlipemia].
Topics: Body Height; Body Weight; Cholesterol; Fatty Acids, Nonesterified; Gout; Humans; Hyperlipidemias; Ma | 1967 |
[Secondary gout in skin diseases].
Topics: Aged; Gout; Humans; Male; Middle Aged; Mycosis Fungoides; Nucleoproteins; Psoriasis; Uric Acid | 1967 |
[The mechanism of urinary calculus formation from the internist's point of view].
Topics: Gout; Humans; Kidney Tubules; Leukemia; Uric Acid; Urinary Calculi | 1967 |
Prophylaxis of idiopathic and gouty uric acid lithiasis by allopurinol.
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Hyperparathyroidism; Kidney Tubules; Male; Middle Ag | 1967 |
[Urate phagocytosis of granulocytes and its influencing by colchicine. Simultaneously a methodical contribution on the determination of their phagocytosis activity in vitro].
Topics: Arthritis; Colchicine; Gout; Humans; In Vitro Techniques; Leukocytes; Neutrophils; Phagocytosis; Uri | 1967 |
[Hints to the recognition of gout].
Topics: Age Factors; Arthritis; Diagnosis, Differential; Gout; Humans; Radiography; Sex Factors; Uric Acid | 1967 |
[Allopurinol].
Topics: Allopurinol; Gout; Humans; Kidney Diseases; Uric Acid; Xanthine Oxidase | 1967 |
[Hyperuricemia. IX. Complications of hyperuricemia. On the treatment of hyperuricemia].
Topics: Allopurinol; Gout; Humans; Joint Diseases; Kidney Calculi; Orotic Acid; Time Factors; Uric Acid; Uri | 1967 |
[Allopurinol in hyperuricemia].
Topics: Allopurinol; Gout; Humans; Male; Methods; Uric Acid | 1967 |
[Ethamide--a drug for the therapy of gout and other conditions associated with accumulation of uric acid in the body].
Topics: Adult; Aged; Female; Gout; Humans; Male; Probenecid; Toe Joint; Uric Acid | 1967 |
[Treatment of the gouty diathesis with a xanthine oxidase inhibitor. A clinical trial of allopurinol].
Topics: Aged; Allopurinol; Drug Synergism; Gout; Humans; Male; Middle Aged; Phenylbutazone; Sulfinpyrazone; | 1967 |
[Renal function in uric gout. Analysis of 270 cases].
Topics: Gout; Humans; Kidney; Uric Acid | 1967 |
[Effects of allopurinol on plasma lipid fractions in gout patients].
Topics: Adult; Aged; Allopurinol; Gout; Humans; Lipids; Male; Middle Aged; Uric Acid | 1967 |
[Hypouricemizing effect of benzbromarone. Study of 24 cases (preliminary results)].
Topics: Adult; Aged; Allopurinol; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1967 |
[Treatment of hyperuricemia].
Topics: Allopurinol; Gout; Humans; Male; Middle Aged; Uric Acid | 1967 |
[Influence of Schroth's cure on the metabolism of uric acid].
Topics: Czechoslovakia; Diet Therapy; Folklore; Gout; History, 18th Century; History, 19th Century; Humans; | 1967 |
[Acute kidney failure during drug-induced litholysis in urate calculi formation and in gout].
Topics: Acute Kidney Injury; Citrates; Drug Prescriptions; Gout; Humans; Male; Middle Aged; Solutions; Uric | 1967 |
[Laboratory problems in gout].
Topics: Gout; Humans; Methods; Uric Acid | 1967 |
Effects of azathiprine in a disorder of uric acid metabolism and cerebral function.
Topics: Adult; Azathioprine; Blood Platelets; Brain Diseases; Child; Gout; Hematocrit; Hemoglobinometry; Hum | 1968 |
Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin.
Topics: Allantoin; Aspergillus; Gout; Humans; Urate Oxidase; Uric Acid | 1968 |
An enzymatic basis for variation in response to allopurinol. Hypoxanthine-guanine phosphoribosyltransferase deficiency.
Topics: Adenine; Adolescent; Adult; Aged; Allopurinol; Child; Creatinine; Glucosyltransferases; Gout; Guanin | 1968 |
Regulation of uric acid formation.
Topics: Allopurinol; Glucosyltransferases; Gout; Humans; Hypoxanthines; Purines; Uric Acid; Xanthine Oxidase | 1968 |
Hyperlipidemia in primary gout.
Topics: Adult; Age Factors; Aged; Arteriosclerosis; Cholesterol; Fatty Acids; Female; Gout; Humans; Hyperlip | 1968 |
Sulphobromophthalein retention in gout and asymptomatic hyperuricaemia.
Topics: Adolescent; Adult; Age Factors; Aged; Alcoholic Beverages; Female; Gout; Humans; Liver; Liver Diseas | 1968 |
An enzyme defect in metabolic gout.
Topics: Feedback; Glucosyltransferases; Gout; Humans; Hypoxanthines; Purines; Uric Acid | 1968 |
Chondrocalcinosis.
Topics: Calcinosis; Calcium Phosphates; Cartilage, Articular; Diagnosis, Differential; Female; Gout; Humans; | 1968 |
Ultrastructural studies in hypertension. 3. Gouty nephropathy.
Topics: Adult; Aged; Animals; Biopsy; Gout; Humans; Hypertension; Kidney; Kidney Glomerulus; Kidney Tubules; | 1968 |
Comparison of uric acid levels in some Oriental and Caucasian groups unselected as to gout or hyperuricemia.
Topics: Adolescent; Adult; Age Factors; Asian People; Colorimetry; Ethnicity; Female; Gout; Humans; Malaysia | 1968 |
Suppression of glycine-15N incorporation into urinary uric acid by adenine-8-13C in normal and gouty subjects.
Topics: Adenine Nucleotides; Carbon Isotopes; Glycine; Gout; Humans; Nitrogen; Purines; Uric Acid | 1968 |
[Secondary gout, 6-years after acute renal failure].
Topics: Accidents, Traffic; Acute Kidney Injury; Adult; Blood Pressure; Creatinine; Electrolytes; Erythrocyt | 1968 |
Hypoglycemic and uricosuric properties of acetohexamide and hydroxyhexamide.
Topics: Acetohexamide; Adolescent; Adult; Age Factors; Aged; Blood Glucose; Cyclohexanes; Diabetes Complicat | 1968 |
Renal excretion of hydrogen in primarygout.
Topics: Acidosis; Acids; Adult; Ammonia; Ammonium Chloride; Bicarbonates; Diet; Dietary Proteins; Gout; Huma | 1968 |
Basic sciences in medicine: the example of gout.
Topics: Allopurinol; Colchicine; Female; Gout; Humans; Male; Metabolism, Inborn Errors; Purines; Sex Factors | 1968 |
Studies in primary hyperuricaemia. II. Glucose tolerance before and after prednisolone sensitization. IV. Tolbutamide response and fasting serum cholesterol and triglycerides.
Topics: Adult; Aged; Cholesterol; Fatty Acids, Nonesterified; Glucose Tolerance Test; Gout; Humans; Middle A | 1968 |
Long-term treatment of gout with "allopurinol".
Topics: Allopurinol; Chronic Disease; Colchicine; Colorimetry; Female; Gout; Humans; Male; Purines; Sulfinpy | 1968 |
Studies in primary hyperuricaemia. 3. The conversion of 14C to breath 14CO2 from glucose-1-14C and glucose-6-14C in hyperuricaemia and gout.
Topics: Adult; Blood Glucose; Carbon Dioxide; Carbon Isotopes; Chromatography, Thin Layer; Diabetes Mellitus | 1968 |
Defects in purine metabolism and neurologic disease.
Topics: Brain; Cerebellum; Child; Glucosyltransferases; Gout; Hemorrhage; Humans; Male; Necrosis; Nervous Sy | 1968 |
Renal urate deposits in chronic renal insufficiency.
Topics: Adult; Aged; Gout; Humans; Kidney; Kidney Failure, Chronic; Male; Uric Acid | 1968 |
[Secondary gout, 6 years after acute renal failure].
Topics: Accidents, Traffic; Acute Kidney Injury; Adult; Blood Pressure; Creatinine; Electrolytes; Erythrocyt | 1968 |
Variations in purine metabolism of cultured skin fibroblasts from patients with gout.
Topics: Adenine Nucleotides; Adolescent; Adult; Culture Techniques; Feedback; Fibroblasts; Gout; Humans; Pur | 1968 |
Renal clearance of oxipurinol, the chief metabolite of allopurinol.
Topics: Allopurinol; Animals; Dogs; Gout; Humans; Kidney; Kidney Function Tests; Probenecid; Spectrophotomet | 1968 |
Congenital hyperuricosuria. Associated radiologic features.
Topics: Cerebral Palsy; Child; Finger Injuries; Gout; Hip Dislocation; Humans; Intellectual Disability; Male | 1968 |
[Early diagnosis and early treatment of gout].
Topics: Adult; Allopurinol; Colchicine; Diagnosis, Differential; Female; Gout; Humans; Male; Middle Aged; Ur | 1968 |
[Primary uratic gout in identical twins in the pathologic-anatomical picture].
Topics: Diseases in Twins; Gout; Humans; Male; Middle Aged; Uric Acid | 1968 |
[Gout in women].
Topics: Adolescent; Adult; Age Factors; Aged; Blood Pressure; Calculi; Female; Germany, West; Gout; Humans; | 1968 |
Intranuclear urate crystals in corneal epithelium.
Topics: Aged; Body Temperature; Cell Nucleus; Cornea; Crystallization; Epithelium; Gout; Histocytochemistry; | 1968 |
Asymptomatic hyperuricemia in flight personnel.
Topics: Adult; Aerospace Medicine; Arthritis; Gout; Humans; Male; Middle Aged; Preventive Medicine; United S | 1968 |
Etiology and treatment of gout--modern concepts.
Topics: Allopurinol; Colchicine; Crystallization; Diagnosis, Differential; Diet Therapy; Gout; Humans; Indom | 1968 |
Allopurinol and iron metabolism in man.
Topics: Alkaline Phosphatase; Allopurinol; Arthritis, Rheumatoid; Blood Cell Count; Blood Protein Electropho | 1968 |
C14 studies of uric acid turnover.
Topics: Acute Kidney Injury; Allopurinol; Carbon Isotopes; Gout; Humans; Mathematics; Uric Acid | 1968 |
Urine uric acid to creatinine rtio--a screening test for inherited disorders of purine metabolism. Phosphoribosyltransferase (PRT) deficiency in X-linked cerebral palsy and in a variant of gout.
Topics: Adolescent; Adult; Age Factors; Aged; Cerebral Palsy; Child; Child, Preschool; Creatinine; Diet; Fem | 1968 |
The relationship of serum uric acid to risk factors in coronary heart disease.
Topics: Age Factors; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cholesterol; Coronary Dis | 1968 |
Management of gouty arthritis and hyperuricemia.
Topics: Anti-Infective Agents, Urinary; Gout; Humans; Male; Middle Aged; Uric Acid; Uricosuric Agents | 1968 |
The clinical differentiation of lead gout from primary gout.
Topics: Alcohol Drinking; Body Height; Body Weight; Child Behavior Disorders; Diagnosis, Differential; Envir | 1968 |
A short trial assessment of uricosuric therapy in gout.
Topics: Adult; Aged; Allopurinol; Female; Glomerular Filtration Rate; Gout; Humans; Male; Middle Aged; Probe | 1968 |
Estimation of uricosuric activity of sulfinpyrazone in healthy adults.
Topics: Adult; Creatinine; Gout; Humans; Sulfinpyrazone; Uric Acid | 1968 |
[On the influence of Anturan on ric acid and plasma lipids in patients with gout].
Topics: Adult; Age Factors; Aged; Animals; Body Weight; Cholesterol; Diet Therapy; Fatty Acids, Nonesterifie | 1968 |
Avascular necrosis of the femoral head in a patient with gout.
Topics: Adult; Amputation, Surgical; Bone Diseases; Femur Head; Gout; Hip Joint; Humans; Male; Necrosis; Rad | 1968 |
Compensated polarized light microscopy. Identification of crystals in synovial fluids from gout and pseudogout.
Topics: Calcinosis; Calcium Phosphates; Cholesterol; Diagnosis, Differential; Gout; Humans; Joint Diseases; | 1968 |
Sickle cell anemia and hyperuricemia.
Topics: Anemia, Sickle Cell; Erythropoiesis; Female; Gout; Humans; Middle Aged; Uric Acid | 1968 |
Determination of uric acid levels in uraemia by enzymatic and colorimetric techniques.
Topics: Acute Kidney Injury; Colorimetry; Gout; Humans; Kidney Failure, Chronic; Methods; Phosphotungstic Ac | 1968 |
[Gout and diabetes. II. Diabetes and its relation to saluretic-induced diabetes and hyperuricemia].
Topics: Aged; Carbohydrate Metabolism; Chlorothiazide; Cholesterol; Diabetes Mellitus; Female; Gout; Humans; | 1968 |
[Allopurinol in the treatment of gout: initial results].
Topics: Adult; Aged; Allopurinol; Female; Gastrointestinal Diseases; Gout; Humans; Kidney Failure, Chronic; | 1968 |
[Gout and development of urate calculi in the urinary tract].
Topics: Allopurinol; Citrus; Flavonoids; Gout; Humans; Male; Middle Aged; Piperazines; Purines; Uric Acid; U | 1968 |
[Primary skin gout. Observations and contribution on the clinical course of gout].
Topics: Acrodermatitis; Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Erysipelas; Gout; Humans; Male | 1968 |
[On clinical experiences with 2-ethyl-3(4-hydroxy-3,5-dibrombenzoyl)-benzofuran ("Benzbromaron") in the therapy of gout and hyperuricemia].
Topics: Adult; Aged; Benzofurans; Colchicine; Female; Gout; Humans; Male; Metabolism, Inborn Errors; Middle | 1968 |
[Allopurinol in the treatment of gout].
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1968 |
[On the therapy of gout].
Topics: Creatinine; Female; Gout; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Piperazines; Uric A | 1968 |
[Gout and plasma lipid values].
Topics: Adult; Age Factors; Aged; Blood Sedimentation; Cholesterol; Fatty Acids, Nonesterified; Gout; Humans | 1968 |
[Positive rheumatic serology in gouty arthritis].
Topics: Agglutination Tests; Arthritis, Rheumatoid; Gout; Humans; Latex Fixation Tests; Male; Methods; Middl | 1968 |
[Allopurinol in the treatment of gout].
Topics: Adult; Allopurinol; Gout; Humans; Indomethacin; Male; Middle Aged; Probenecid; Uric Acid | 1968 |
[Therapy of gout in surgical patients].
Topics: Achilles Tendon; Allopurinol; Cortisone; Diagnosis, Differential; Gout; Humans; Joint Diseases; Male | 1968 |
[Study of amplivix in gout patients and nongouty arthrosic hyperuricemics].
Topics: Adult; Aged; Benzofurans; Female; Gout; Humans; Joint Diseases; Male; Middle Aged; Uric Acid | 1968 |
[On pyelogram changes in gout].
Topics: Adult; Female; Gout; Humans; Kidney Pelvis; Male; Sex Factors; Uric Acid; Urography | 1968 |
Gout in India. (A study of clinical features).
Topics: Adolescent; Adult; Female; Gout; Humans; Hypertension; India; Male; Middle Aged; Uremia; Uric Acid | 1968 |
Development of urate crystals in tophus.
Topics: Animals; Cattle; Crystallization; Gallbladder; Gelatin; Gout; Guinea Pigs; Humans; Hydrogen-Ion Conc | 1968 |
[The inhibition of uric acid synthesis with Allopurinol].
Topics: Adult; Aged; Allopurinol; Arthritis, Rheumatoid; Female; Gout; Humans; Kidney Calculi; Male; Middle | 1968 |
[Benziodarone in the treatment of primary hyperuricemias].
Topics: Adult; Aged; Benzofurans; Gout; Humans; Middle Aged; Uric Acid; Uricosuric Agents | 1968 |
The interpretation of radioactive uric acid turnover data.
Topics: Arthritis, Rheumatoid; Biological Assay; Carbon Isotopes; Gout; Humans; Hypertension; Myocardial Inf | 1968 |
A comparative study of the xanthine oxidase inhibitors allopurinol and oxipurinol in man.
Topics: Adult; Aged; Allopurinol; Gout; Humans; Hypoxanthines; Male; Middle Aged; Purines; Pyrazoles; Pyrimi | 1968 |
Nyhan-Lesch syndrome and juvenile gout (2 cases).
Topics: Adult; Child, Preschool; Deficiency Diseases; Gout; Guanine; Humans; Hypoxanthines; Kidney Failure, | 1968 |
[Purine metabolism and the possible pathogenesis of hyperuricemia and gout].
Topics: Alanine Transaminase; Gout; Humans; Purines; Uric Acid | 1968 |
[Kidneys, uric acid secretion and hyperuricemia].
Topics: Glutaminase; Gout; Humans; Kidney; Pyelonephritis; Uric Acid | 1968 |
[Therapy of hyperuricemia with allopurinol].
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Kidney Diseases; Kidney Function Tests; Male; Method | 1968 |
Gout and uveitis. Report of a case.
Topics: Adult; Colchicine; Gout; Humans; Male; Probenecid; Steroids; Uric Acid; Uveitis | 1968 |
The pathophysiology of hyperuricemia and gout.
Topics: Gout; Humans; Purines; Uric Acid | 1968 |
[Subacute rheumatoid arthritis in old age. II. Diseases under diagnostic exclusions].
Topics: Aged; Antistreptolysin; Arthritis, Infectious; Arthritis, Reactive; Arthritis, Rheumatoid; Auscultat | 1968 |
Idiopathic hyperlipemia and gout.
Topics: Cholesterol; Colorimetry; Diet Therapy; Dietary Carbohydrates; Dietary Fats; Fatty Acids, Nonesterif | 1968 |
Juvenile hyperuricemia with neurological manifestations. ACRH-29.
Topics: Adolescent; Carbon Isotopes; Child; Gout; Humans; Male; Neurologic Manifestations; Uric Acid | 1968 |
Psoriasis and factors affecting the level of uricaemia.
Topics: Female; Follow-Up Studies; Gout; Humans; Male; Obesity; Psoriasis; Respiratory Tract Infections; Sex | 1968 |
[Allopurinol: its clinical use].
Topics: Adult; Aged; Allopurinol; Child; Diuretics; Female; Gout; Humans; Kidney Diseases; Kidney Failure, C | 1968 |
[Curve of uricemia].
Topics: Acetylcholinesterase; Gout; Humans; Uric Acid | 1968 |
[Allopurinol in the treatment of hyperuricemia and chronic gout].
Topics: Adult; Aged; Allopurinol; Arthritis; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Xanthine Ox | 1968 |
[Uric acid and its metabolism].
Topics: Allopurinol; Female; Glomerular Filtration Rate; Glutamine; Gout; Humans; Kidney Tubules; Male; Puri | 1968 |
[Gout and pseudogout].
Topics: Bradykinin; Calcinosis; Calcium; Female; Gout; Humans; Joint Diseases; Lysosomes; Male; Methods; Pep | 1968 |
[Modalities of purine excretion during enzyme treatment of gout and other hyperuricemic conditions with urate oxidase].
Topics: Aged; Allantoin; Antigen-Antibody Reactions; Complement Fixation Tests; Female; Gout; Humans; Immuni | 1968 |
[Treatment of gouty purine metabolism disorder with mercapto-pyrazolo-pyrimidine (thiopurinol)].
Topics: Allopurinol; Calculi; Drug Tolerance; Female; Gout; Guanine Nucleotides; Humans; Male; Purine-Pyrimi | 1968 |
[Uricemia and uric acid excretion in normal patients].
Topics: Adolescent; Adult; Creatine; Female; Gout; Humans; Male; Periodicity; Uric Acid | 1968 |
[Preliminary note on the hypourecemic effect of benzofuran (benziodarone)].
Topics: Benzofurans; Gout; Humans; Uric Acid | 1968 |
[Study of pH, of titrable acidity, and urinary buffer system in oxalate lithiasis, in gout and urate lithiasis].
Topics: Gout; Humans; Hydrogen-Ion Concentration; Oxalates; Phosphorus; Urea; Uric Acid; Urinary Calculi | 1968 |
[Variations of uricemia during fasting by the obese].
Topics: Fasting; Gout; Humans; Male; Middle Aged; Obesity; Uric Acid | 1968 |
[Gout (pathogenesis and therapy)].
Topics: Allopurinol; Colchicine; Diet Therapy; Gout; Humans; Indomethacin; Phenylbutazone; Uric Acid; Uricos | 1968 |
[Polycythemia vera and secondary gout].
Topics: Gout; Humans; Kidney; Male; Middle Aged; Polycythemia Vera; Uric Acid | 1968 |
[New findings in the pathology and therapy of gout].
Topics: Colchicine; Diet Therapy; Gout; Humans; Hydrogen-Ion Concentration; Physical Exertion; Purines; Uric | 1968 |
[Formation of a gout nodule].
Topics: Crystallization; Gelatin; Gout; Proteins; Uric Acid | 1968 |
[Gout in advanced age].
Topics: Age Factors; Aged; Allopurinol; Bone and Bones; Cardiovascular Diseases; Colchicine; Female; Gout; H | 1968 |
Treatment of gout and urate calculi with allopurinol.
Topics: Allopurinol; Colchicine; Follow-Up Studies; Gout; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; | 1968 |
[Experimental studies of fructose overloading in normal subjects and in patients with gout].
Topics: Adult; Fructose; Gout; Humans; Liver; Male; Nucleoproteins; Proteins; Purines; Uric Acid; Xanthine O | 1968 |
Bilateral ureteral obstruction after the administration of allopurinol to a patient with renal pelvic urate calculi.
Topics: Allopurinol; Colchicine; Creatinine; Gout; Humans; Kidney Calculi; Male; Middle Aged; Phenylbutazone | 1969 |
Liver xanthine oxidase in gouty patients.
Topics: Adult; Aged; Biopsy; Female; Gout; Humans; Liver; Liver Function Tests; Male; Middle Aged; Uric Acid | 1969 |
Pathogenesis of hyperuricemia in saturnine gout.
Topics: Adult; Alcoholic Beverages; Alcoholism; Carbon Isotopes; Creatinine; Diet; Food Contamination; Glyci | 1969 |
Saturnine gout--a moonshine malady.
Topics: Alcoholic Beverages; Alcoholism; Gout; Humans; Kidney Diseases; Lead Poisoning; Uric Acid | 1969 |
Medical memorandum: a case of pseudogout accompanying gout.
Topics: Aged; Calcium Metabolism Disorders; Female; Finger Joint; Gout; Hallux; Humans; Joint Diseases; Knee | 1969 |
Glycine-C-14 incorporation into nucleic acid purine by leucocytes obtained from normal and gouty subjects.
Topics: Adenine; Carbon Isotopes; Cyanides; Depression, Chemical; DNA; Female; Glycine; Gout; Guanine; Human | 1969 |
Deposition of urate crystals in man.
Topics: Cartilage; Crystallization; Gout; Humans; Polysaccharides; Uric Acid | 1969 |
Current concepts of hyperuricemia and gout.
Topics: Chemical Phenomena; Chemistry; Gout; Humans; Uric Acid | 1969 |
The use of allopurinol in controlling hyperuricemia.
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1969 |
Uric acid renal lithiasis: management by allopurinol.
Topics: Adult; Allopurinol; Gout; Humans; Kidney Calculi; Male; Middle Aged; Uric Acid | 1969 |
A new disorder of purine metabolism with behavioral manifestations.
Topics: Adenine; Allopurinol; Autistic Disorder; Carbon Isotopes; Child Behavior Disorders; Child, Preschool | 1969 |
[Treatment of acute gouty attack with local infiltration of Kenacort-A and the study of gout and hyperuricemia at the Tanabe National Hospital during 1967].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Female; Gout; Humans; Injections; Japan; Male; Mid | 1969 |
Polymorphonuclear leukocyte motility in vitro. II. Stimulatory effect of monosodium urate crystals and urate in solution; partial inhibition by colchicine and indomethacin.
Topics: Anti-Inflammatory Agents; Cell Movement; Colchicine; Gout; Humans; In Vitro Techniques; Indomethacin | 1969 |
Polymorphonuclear leukocyte motility in vitro. 3. Possible release of a chemotactic substance after phagocytosis of urate crystals by polymorphonuclear leukocytes.
Topics: Cell Movement; Chemotaxis; Gout; Humans; In Vitro Techniques; Methods; Neutrophils; Phagocytosis; Se | 1969 |
Studies of uric acid pool size and turnover rate.
Topics: Adolescent; Adult; Aged; Allopurinol; Carbon Isotopes; Female; Gout; Humans; Hypertension; Male; Mat | 1969 |
Dietes mellitus and gout. Blood sugar and plasma insulin responses to oral glucose in normal weight, overweight, and gouty patients.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mellitus; Dietary Carbohyd | 1969 |
Gouty tenosynovitis and the carpal tunnel syndrome.
Topics: Carpal Tunnel Syndrome; Diagnosis, Differential; Gout; Humans; Male; Median Nerve; Middle Aged; Radi | 1969 |
[Benziodarone (Amplivix) in the treatment of hyperuricemia].
Topics: Benzofurans; Female; Gout; Humans; Male; Middle Aged; Phenylbutazone; Purine-Pyrimidine Metabolism, | 1969 |
[Hyperuricemia in therapy with saluretics].
Topics: Diuretics; Gout; Humans; Kidney Diseases; Uric Acid | 1969 |
[Are there characteristic x-ray findings in gout?].
Topics: Arthritis, Rheumatoid; Chronic Disease; Gout; Humans; Radiography; Uric Acid | 1969 |
Elevation of plasma glutamate in gout. Its possible role in the pathogenesis of hyperuricemia.
Topics: Amino Acids; Caseins; Fasting; Glutamates; Glutamine; Gout; Humans; Male; Middle Aged; Nitrogen; Pur | 1969 |
Causes of hyperuricaemia.
Topics: Diet; Female; Gout; Hematopoiesis; Humans; Intellectual Disability; Male; Metabolic Diseases; Purine | 1969 |
Management of gout.
Topics: Acute Disease; Allopurinol; Chronic Disease; Colchicine; Gout; Humans; Indomethacin; Metabolic Disea | 1969 |
[Clinical findings and therapy of gout].
Topics: Adult; Age Factors; Aged; Diabetes Complications; Diet Therapy; Female; Gout; Humans; Hypertension; | 1969 |
[Hyperuricemia in internal diseases].
Topics: Anemia; Cardiovascular Diseases; Gout; Hematologic Diseases; Humans; Hydrochlorothiazide; Kidney Dis | 1969 |
[Is there in gout a more frequent incidence of an astragalus spur?].
Topics: Adolescent; Adult; Aged; Female; Foot; Gout; Humans; Male; Middle Aged; Radiography; Talus; Uric Aci | 1969 |
Plasma uric acid concentrations among Edinburgh business executives.
Topics: Achievement; Adult; Alcohol Drinking; Diet; Dietary Proteins; Gout; Humans; Male; Middle Aged; Occup | 1969 |
Uric acid and the psyche.
Topics: Achievement; Gout; Humans; Male; Occupations; Personality; Uric Acid | 1969 |
[Changes in the serum concentration of uric acid under the effect of benzbromaronum].
Topics: Adult; Allopurinol; Benzofurans; Depression, Chemical; Female; Gout; Humans; Male; Middle Aged; Uric | 1969 |
[Fracture healing in hyperuricemia].
Topics: Adolescent; Adult; Aged; Female; Fractures, Bone; Gout; Humans; Male; Middle Aged; Uric Acid; Wound | 1969 |
Total fasting, hyperuricaemia and gout.
Topics: Fasting; Female; Gout; Humans; Male; Middle Aged; Obesity; Uric Acid | 1969 |
[Blood uric acid].
Topics: Age Factors; Female; Gout; Humans; Male; Uric Acid | 1969 |
Social class gradients and serum uric acid in males and females.
Topics: Adult; Age Factors; Connecticut; England; Female; Gout; Humans; Male; Middle Aged; Sex Factors; Soci | 1969 |
Grand rounds at William Beaumont General Hospital. Gout and hyperuricemia.
Topics: Diagnosis, Differential; Gout; Humans; Uric Acid | 1965 |
Acute gouty arthritis provoked by cerebrovascular disease.
Topics: Aged; Anticoagulants; Blood; Electroencephalography; Gout; Hemiplegia; Humans; Intracranial Arterios | 1965 |
Juvenile gout with brain involvement.
Topics: Blood; Brain; Cerebral Palsy; Child; Demyelinating Diseases; Gout; Humans; Intellectual Disability; | 1965 |
[Hyperuricemia. Apropos of a study dealing with 130 cases of articular gout and 1370 cases of various diseases].
Topics: Female; Gout; Humans; Male; Uric Acid | 1965 |
Significance of joint fluid uric acid levels in gout.
Topics: Gout; Humans; Knee Joint; Synovial Fluid; Uric Acid | 1965 |
Effect of atromid and its components on uric acid excretion and on gout.
Topics: Adult; Androsterone; Butyrates; Female; Gout; Humans; Male; Uric Acid; Uricosuric Agents; Urine | 1965 |
[New method for the determination of uric acid in the blood].
Topics: Blood Chemical Analysis; Gout; Humans; Uric Acid | 1965 |
Heredity of gout and hyperuricemia.
Topics: Blood; Ethnology; Gout; Humans; Purine-Pyrimidine Metabolism, Inborn Errors; Uric Acid | 1965 |
The overproduction of uric acid in primary gout.
Topics: Carbon Isotopes; Glycine; Gout; Humans; Nitrogen; Radioisotopes; Uric Acid | 1965 |
Renal excretion of uric acid in normal and gouty man.
Topics: Gout; Humans; Kidney; Uric Acid; Urine | 1965 |
Renal urate excretion in gout studied by feeding ribonucleic acid.
Topics: Blood; Gout; Humans; Kidney; RNA; Uric Acid; Urine | 1965 |
Role of the intestinal tract in the elimination of uric acid.
Topics: Allantoin; Ammonia; Carbon Dioxide; Carbon Isotopes; Digestive System Physiological Phenomena; Feces | 1965 |
Pathology of gout.
Topics: Arteriosclerosis; Gout; Humans; Kidney; Uric Acid | 1965 |
Activation of Hageman factor by sodium urate crystals.
Topics: Factor XII; Gout; In Vitro Techniques; Inflammation; Kinins; Leukocytes; Uric Acid | 1965 |
The acute attack of gouty arthritis.
Topics: Animals; Crystallization; Dogs; Gout; Humans; Kinins; Uric Acid | 1965 |
Hyperuricemia induced by alcohol.
Topics: Alcoholic Intoxication; Blood; Ethanol; Gout; Humans; Lactates; Uric Acid; Urine | 1965 |
Hyperuricemia induced by high fat diets and starvation.
Topics: Arthritis, Rheumatoid; Blood; Dietary Fats; Fasting; Gout; Humans; Ketone Bodies; Osteoarthritis; Ur | 1965 |
Correlations among hyperuricemia, hypercholesterolemia, coronary disease and hypertension.
Topics: Blood; Coronary Disease; Epidemiologic Methods; Gout; Humans; Hypercholesterolemia; Hypertension; Ur | 1965 |
Hyperuricemia associated with uremia.
Topics: Apatites; Blood; Calcinosis; Gout; Humans; Hydroxyapatites; Kidneys, Artificial; Uremia; Uric Acid | 1965 |
The possible association of hyperuricemia and/or gout with diabetes mellitus.
Topics: Blood; Diabetes Complications; Gout; Humans; Statistics as Topic; Uric Acid | 1965 |
The renal excretion of urate in chronic lead nephropathy.
Topics: Adult; Creatine; Female; Gout; Humans; In Vitro Techniques; Kidney Diseases; Kidney Function Tests; | 1965 |
Hyperuricemia, acute gout, renal insufficiency and urate nephrolithiasis due to starvation.
Topics: Blood; Colchicine; Diet, Reducing; Fasting; Gout; Humans; Kidney Calculi; Kidney Diseases; Obesity; | 1965 |
[Hyperuricemia and gout in retinal vascular accidents. New etiological and therapeutic data].
Topics: Adult; Aged; Female; Gout; Humans; Male; Middle Aged; Retinal Hemorrhage; Retinal Vessels; Thromboph | 1963 |
Suppression of metabolic accompaniments of phagocytosis by colchicine.
Topics: Carbon Isotopes; Colchicine; Gout; Humans; In Vitro Techniques; Leukocytes; Phagocytosis; Uric Acid | 1965 |
Inhibition of monosodium urate needle crystal growth.
Topics: Coloring Agents; Crystallization; Gout; In Vitro Techniques; Ions; Methylene Blue; Sodium; Solubilit | 1965 |
[Recent views on gout].
Topics: Gout; Humans; Uric Acid | 1965 |
[Secondary gout in renal insufficiency].
Topics: Adult; Blood; Glomerulonephritis; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Kidney Fun | 1965 |
Gout in orthopaedic practice: review of 232 cases.
Topics: Acute Disease; Adolescent; Aged; Bone Diseases; Chlorothiazide; Colchicine; Diagnosis, Differential; | 1963 |
[On a family of persons with severe gout].
Topics: Blood; Female; Gout; Hip Dislocation, Congenital; Humans; Male; Middle Aged; Nephritis, Interstitial | 1965 |
Significance of uric acid as a nitrogenous waste in vertebrate evolution.
Topics: Animals; Biological Evolution; Gout; Humans; Physiology, Comparative; Purines; Uric Acid; Vertebrate | 1965 |
Gout: clinical and underwriting aspects.
Topics: Female; Gout; Humans; Insurance, Life; Male; United States; Uric Acid | 1965 |
[The kidneys in gout. Study of their interaction].
Topics: Adult; Gout; Humans; Kidney Diseases; Male; Uric Acid | 1965 |
[Surgical treatment of hands severely deformed by gout].
Topics: Aged; Blood Vessels; Colchicine; Gout; Hand; Hand Deformities, Acquired; Humans; Male; Preoperative | 1965 |
[Experiences with potassium orotate in hyperuricemic subjects].
Topics: Adult; Aged; Blood; Gout; Humans; Middle Aged; Orotic Acid; Potassium; Uric Acid; Urine | 1965 |
Selected aspects of gout and gouty arthritis.
Topics: Adult; Aged; Gout; Humans; Middle Aged; Uric Acid; Uricosuric Agents | 1966 |
Investigation of renal excretion of phosphate and urate.
Topics: Adult; Gout; Humans; Middle Aged; Phosphates; Primary Myelofibrosis; Uric Acid; Urinary Calculi | 1966 |
[Blood uric acid levels in gout patients].
Topics: Gout; Humans; Male; Uric Acid | 1966 |
Serum uric acid in relation to body weight.
Topics: Adolescent; Adult; Aged; Body Weight; Female; Gout; Humans; Male; Middle Aged; Obesity; Uric Acid | 1966 |
[Uric acid gout. Pathogenetic considerations].
Topics: Gout; Humans; Hydrogen-Ion Concentration; Immunoelectrophoresis; Lipoproteins; Serum Albumin; Serum | 1966 |
Allopurinol in the management of gout.
Topics: Adult; Enzyme Therapy; Female; Gout; Humans; Male; Middle Aged; Uric Acid; Xanthine Oxidase | 1966 |
Effect of anti-inflammatory agents on acute experimental synovitis in dogs.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Chlorpromazine; Codeine; Dogs; Gout; Hydrocortisone; Ind | 1966 |
The treatment of gout and disorders of uric acid metabolism with allopurinol.
Topics: Aged; Colchicine; Diet; Enzyme Therapy; Female; Gout; Humans; Male; Middle Aged; Sulfinpyrazone; Uri | 1966 |
Use of allopurinol in preventing hyperuricemia in leukemia and lymphoma.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Enzyme Therapy; Female; Gout; Humans; Kidney Disea | 1966 |
[On the combination of gouty arthritis and adenoma of the parathyroid gland].
Topics: Adenoma; Angioedema; Diabetes Mellitus; Gout; Humans; Hyperparathyroidism; Male; Middle Aged; Parath | 1966 |
Allopurinol in the treatment of hyperuricemia and gout.
Topics: Adult; Blood; Child; Child, Preschool; Enzyme Therapy; Gout; Humans; Male; Middle Aged; Uric Acid; X | 1966 |
Hyperuricaemia and gout in the Mariana Islands.
Topics: Blood; Ethnology; Gout; Humans; In Vitro Techniques; Pacific Islands; Uric Acid | 1966 |
[Action of ethanol in gout and on the metabolism of uric acid].
Topics: Ethanol; Female; Gout; Humans; In Vitro Techniques; Middle Aged; Uric Acid | 1966 |
Uric acid excretion in gouty and nongouty subjects.
Topics: Gout; Humans; Kidney Function Tests; Uric Acid; Urine | 1966 |
Acute gout apparently precipitated by furosemide.
Topics: Blood; Diuretics; Furosemide; Gout; Humans; Male; Middle Aged; Pulmonary Edema; Uric Acid; Urine | 1966 |
Uric acid production with particular reference to the role of xanthine oxidase and its inhibition.
Topics: Enzymes; Gout; Humans; Pyrimidines; Uric Acid; Xanthine Oxidase | 1966 |
Urates and kinin formation in synovial fluid.
Topics: Gout; Humans; Kinins; Phagocytosis; Proteins; Synovial Fluid; Uric Acid | 1966 |
Urate excretion.
Topics: Blood; Gout; Humans; Kidney; Kidney Tubules; Uric Acid; Urine | 1966 |
Factors inhibiting the excretion of uric acid.
Topics: Blood; Gout; Humans; Uric Acid; Urine | 1966 |
Population studies of serum uric acid.
Topics: Black or African American; Blood; Ethnology; Gout; Humans; Obesity; Statistics as Topic; Uric Acid; | 1966 |
Lipid metabolism in gout.
Topics: Arteriosclerosis; Blood; Cholesterol; Gout; Humans; Lipid Metabolism; Lipids; Triglycerides; Uric Ac | 1966 |
The pharmaceutical treatment of gout.
Topics: Enzyme Therapy; Gout; Humans; Indomethacin; Phenylbutazone; Sulfinpyrazone; Uric Acid; Xanthine Oxid | 1966 |
Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout.
Topics: Aged; Blood; Drug Synergism; Enzyme Therapy; Gout; Humans; Middle Aged; Pyrimidines; Sulfinpyrazone; | 1966 |
[Trial treatments of hyperuricemia in patients with chronic renal failure. I. Action of benziodarone].
Topics: Blood; Furans; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Uremia; Uric Acid; Vasodilato | 1966 |
The effects of allopurinol on serum and urinary uric acid.
Topics: Adult; Aged; Blood; Enzymes; Female; Gout; Humans; Male; Probenecid; Uric Acid; Urinary Calculi; Uri | 1966 |
Treatment of gout by reduction of uric acid production.
Topics: Catalase; Drug Synergism; Enzyme Therapy; Gout; Humans; Kidney Calculi; Sulfinpyrazone; Uracil; Uric | 1966 |
Serum urate concentrations among university professors; relation to drive, achievement, and leadership.
Topics: Achievement; Blood; Drive; Gout; Humans; Leadership; Motivation; Occupational Diseases; Psychology; | 1966 |
Diabetes mellitus in patients with gout.
Topics: Adult; Aged; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Female; Glu | 1966 |
Coexistent rheumatoid arthritis and chronic tophaceous gout.
Topics: Arthritis, Rheumatoid; Colchicine; Foot; Gout; Hand Deformities, Acquired; Histocytochemistry; Human | 1966 |
Allopurinol (xanthine oxidase inhibitor) in the treatment of resistant gout.
Topics: Adult; Aged; Colchicine; Enzyme Therapy; Enzymes; Female; Gout; Humans; Male; Middle Aged; Probeneci | 1966 |
Allopurinol in primary gout with and after the administration of uricosuric agents.
Topics: Allopurinol; Drug Synergism; Enzyme Therapy; Female; Gout; Humans; Male; Sulfinpyrazone; Uric Acid; | 1966 |
Effects of allopurinol on gouty and non-gouty uric acid nephropathy.
Topics: Allopurinol; Blood Urea Nitrogen; Enzyme Therapy; Female; Gout; Humans; Kidney Calculi; Kidney Disea | 1966 |
Allopurinol in thiazide-induced hyperuricaemia.
Topics: Allopurinol; Clopamide; Enzyme Therapy; Gout; Hematologic Diseases; Humans; Hypertension; Kidney Fai | 1966 |
Allopurinol in patients with impaired renal function.
Topics: Adolescent; Adult; Aged; Allopurinol; Child; Creatine; Enzyme Therapy; Female; Gout; Humans; Hydroge | 1966 |
Allopurinol therapy of gout with renal complications.
Topics: Adult; Allopurinol; Calcium; Creatine; Enzyme Therapy; Gout; Humans; Kidney Failure, Chronic; Male; | 1966 |
Allopurinol in the prophylaxis of uric acid stones.
Topics: Allopurinol; Enzyme Therapy; Female; Gout; Humans; Hydrogen-Ion Concentration; Kidney Calculi; Male; | 1966 |
Lysosomes and gout.
Topics: Cell Membrane; Colchicine; Cytoplasmic Granules; Gout; Hydrolases; In Vitro Techniques; Leukocytes; | 1966 |
The effects of estradiol-17 beta and/or progesterone on nitrogen balance values in studies on the castrated rooster.
Topics: Animals; Animals, Newborn; Blood Glucose; Blood Urea Nitrogen; Body Weight; Castration; Eating; Estr | 1966 |
Gout and gouty arthritis. Current concepts and management.
Topics: Arthritis; Gout; Humans; Uric Acid | 1966 |
[Clinical aspects of chronic gout].
Topics: Adult; Aged; Allopurinol; Anemia; Arthritis; Bicarbonates; Blood Sedimentation; Chronic Disease; Fem | 1966 |
[The kidney in gout].
Topics: Aged; Arteriosclerosis; Gout; Humans; Kidney; Kidney Glomerulus; Male; Middle Aged; Uric Acid | 1966 |
[Uricemia in the senile age].
Topics: Aged; Aging; Female; Gout; Humans; Male; Uric Acid | 1966 |
[Contributions on the formation and dissolution of urinary calculi].
Topics: Carbohydrates; Carbonates; Citrates; Female; Gout; Humans; Male; Middle Aged; Potassium; Sodium; Sol | 1966 |
[A rare form of podagra and its surgical treatment].
Topics: Crystallization; Foot; Gout; Humans; Male; Middle Aged; Rheumatic Nodule; Uric Acid | 1966 |
[Our experience in the treatment of hyperuricemia with a xanthine oxidase inhibitor (HPP), Allopurinol].
Topics: Allopurinol; Gout; Humans; Uric Acid; Xanthine Oxidase | 1966 |